
<html lang="en"     class="pb-page"  data-request-id="de51f335-fc90-4585-9d28-c01324ed9aa8"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;article:article:10.1021/acs.jmedchem.9b01617;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2020.63.issue-11"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Acetylene Group, Friend or Foe in Medicinal Chemistry" /></meta><meta name="dc.Creator" content="Tanaji T.  Talele" /></meta><meta name="dc.Description" content="The use of an acetylene (ethynyl) group in medicinal chemistry coincides with the launch of the Journal of Medicinal Chemistry in 1959. Since then, the acetylene group has been broadly exploited in..." /></meta><meta name="Description" content="The use of an acetylene (ethynyl) group in medicinal chemistry coincides with the launch of the Journal of Medicinal Chemistry in 1959. Since then, the acetylene group has been broadly exploited in..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="February 7, 2020" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b01617" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b01617" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b01617" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b01617" /></link>
        
    
    

<title>Acetylene Group, Friend or Foe in Medicinal Chemistry | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b01617" /></meta><meta property="og:title" content="Acetylene Group, Friend or Foe in Medicinal Chemistry" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0084.jpeg" /></meta><meta property="og:description" content="The use of an acetylene (ethynyl) group in medicinal chemistry coincides with the launch of the Journal of Medicinal Chemistry in 1959. Since then, the acetylene group has been broadly exploited in drug discovery and development. As a result, it has become recognized as a privileged structural feature for targeting a wide range of therapeutic target proteins, including MAO, tyrosine kinases, BACE1, steroid receptors, mGlu5 receptors, FFA1/GPR40, and HIV-1 RT. Furthermore, a terminal alkyne functionality is frequently introduced in chemical biology probes as a click handle to identify molecular targets and to assess target engagement. This Perspective is divided into three parts encompassing: (1) the physicochemical properties of the ethynyl group, (2) the advantages and disadvantages of the ethynyl group in medicinal chemistry, and (3) the impact of the ethynyl group on chemical biology approaches." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b01617"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01617">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b01617&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b01617&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b01617&amp;href=/doi/10.1021/acs.jmedchem.9b01617" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 11</span><span class="cit-fg-pageRange">, 5625-5663</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/11" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.9b01738" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Acetylene Group, Friend or Foe in Medicinal Chemistry</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Tanaji T. Talele</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tanaji T. Talele</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John’s University, Queens, New York 11439, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Phone: (718)990-5405. Fax: (718)990-1877. Email: <a href="/cdn-cgi/l/email-protection#d0a4b1bcb5bcb5a490a3a4babfb8bea3feb5b4a5"><span class="__cf_email__" data-cfemail="ff8b9e939a939a8bbf8c8b959097918cd19a9b8a">[email protected]</span></a></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tanaji+T.++Talele">Tanaji T. Talele</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5938-6505" title="Orcid link">http://orcid.org/0000-0002-5938-6505</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b01617&amp;href=/doi/10.1021%2Facs.jmedchem.9b01617" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 11</span><span class="cit-pageRange">, 5625–5663</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">February 7, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>29 September 2019</li><li><span class="item_label"><b>Published</b> online</span>7 February 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 11 June 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b01617" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01617</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D5625%26pageCount%3D39%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DTanaji%2BT.%2BTalele%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D11%26contentID%3Dacs.jmedchem.9b01617%26title%3DAcetylene%2BGroup%252C%2BFriend%2Bor%2BFoe%2Bin%2BMedicinal%2BChemistry%26numPages%3D39%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D5663%26publicationDate%3DJune%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b01617"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">5945</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">15</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b01617" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Acetylene Group, Friend or Foe in Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Tanaji&quot;,&quot;last_name&quot;:&quot;T. Talele&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;02&quot;,&quot;day&quot;:&quot;07&quot;,&quot;issue&quot;:&quot;11&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;5625-5663&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b01617&quot;},&quot;abstract&quot;:&quot;The use of an acetylene (ethynyl) group in medicinal chemistry coincides with the launch of the Journal of Medicinal Chemistry in 1959. Since then, the acetylene group has been broadly exploited in drug discovery and development. As a result, it has become recognized as a privileged structural feature for targeting a wide range of therapeutic target proteins, including MAO, tyrosine kinases, BACE1, steroid receptors, mGlu5 receptors, FFA1/GPR40, and HIV-1 RT. Furthermore, a terminal alkyne functionality is frequently introduced in chemical biology probes as a click handle to identify molecular targets and to assess target engagement. This Perspective is divided into three parts encompassing: (1) the physicochemical properties of the ethynyl group, (2) the advantages and disadvantages of the ethynyl group in medicinal chemistry, and (3) the impact of the ethynyl group on chemical biology approaches.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01617&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01617" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01617&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01617" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01617&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01617" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b01617&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01617&amp;href=/doi/10.1021/acs.jmedchem.9b01617" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b01617" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b01617" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (6 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01617&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b01617%26sid%3Dliteratum%253Aachs%26pmid%3D32031378%26genre%3Darticle%26aulast%3DTalele%26date%3D2020%26atitle%3DAcetylene%2BGroup%252C%2BFriend%2Bor%2BFoe%2Bin%2BMedicinal%2BChemistry%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D11%26spage%3D5625%26epage%3D5663%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291445" title="Chemical structure">Chemical structure</a>,</li><li><a href="/action/doSearch?ConceptID=291456" title="Hydrocarbons">Hydrocarbons</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292589" title="Agonists">Agonists</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/11" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/jmcmar.2020.63.issue-11/20200611/jmcmar.2020.63.issue-11.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0084.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0084.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The use of an acetylene (ethynyl) group in medicinal chemistry coincides with the launch of the <i>Journal of Medicinal Chemistry</i> in 1959. Since then, the acetylene group has been broadly exploited in drug discovery and development. As a result, it has become recognized as a privileged structural feature for targeting a wide range of therapeutic target proteins, including MAO, tyrosine kinases, BACE1, steroid receptors, mGlu5 receptors, FFA1/GPR40, and HIV-1 RT. Furthermore, a terminal alkyne functionality is frequently introduced in chemical biology probes as a click handle to identify molecular targets and to assess target engagement. This Perspective is divided into three parts encompassing: (1) the physicochemical properties of the ethynyl group, (2) the advantages and disadvantages of the ethynyl group in medicinal chemistry, and (3) the impact of the ethynyl group on chemical biology approaches.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Physicochemical Properties of the Ethynyl Group</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_07047" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_07047" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Acetylene, discovered in 1836 by Edmund Davy, is a colorless and odorless gas. It is comprised of a carbon–carbon triple bond that features one σ- and two π-bonds. The triple bond of an acetylene is shorter (1.21 Å) and stronger than a carbon–carbon (C–C) double (1.34 Å) or single (1.53 Å) bond. For example, 318 kJ/mol is required to break a π bond of acetylene as compared to the ethylene bond, which requires 268 kJ/mol.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1,2)</a> Because of its increased S character, the acetylene −C–H bond is shorter (1.06 Å) than that of either ethene (1.08 Å) or ethane (1.09 Å), respectively.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> The acetylene group is stabilized via hyperconjugation (π bonds overlap with neighboring C–H bonds) when it carries an alkyl substituent. Therefore, internal alkynes are more stable than terminal ones. A terminal alkyne is a stronger Brönsted acid (p<i>K</i><sub>a</sub> ∼ 25) compared to the corresponding alkene (p<i>K</i><sub>a</sub> ∼ 44) or alkane (p<i>K</i><sub>a</sub> ∼ 50). Moreover, the acetylene serves as a proton donor because it is a weak electron-withdrawing group.<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3,4)</a> The H–C–C angle in an acetylene group is linear (i.e., 180°), thus, it can serve as a rigid spacer that places any appendage in the plane of the acetylene group. An acetylene group π-system provides donor–acceptor interactions similar to those observed with the phenyl ring,<a onclick="showRef(event, 'ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref5 ref6">(5,6)</a> and thus, it can also function as an effective isostere of the phenyl moiety.</div><div class="NLM_p">Although an acetylene is a hydrocarbon, it is considered a functional group because its −C–H can be deprotonated under basic conditions to produce a conjugate base (acetylide ion). Similarly, it can undergo nucleophilic addition at the electrophilic π bonds. Consequently, an acetylene group has a prominent place in the synthesis of many groups, including alkanes, alkenes, aldehydes, halides, heterocycles, and in ring-closing metathesis.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> A copper-catalyzed azide–alkyne [3 + 2] cycloaddition (CuAAC), the so-called “click reaction”, rapidly produces 1,4-disubstituted 1,2,3-triazoles. This reaction has been broadly explored for efficient lead optimization in medicinal chemistry.<a onclick="showRef(event, 'ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref8 ref9">(8,9)</a> CuAAC click chemistry has also positively influenced peptide-based drug design.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> The acetylene also serves as a notable building block for chemical biology research (therapeutic target identification/validation) due to its efficient conversion to the 1,2,3-triazole ring via a 1,3-dipolar CuAAC click reaction with azide reagents.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a></div><div class="NLM_p">It is evident that the acetylene group has been important in medicinal chemistry by the fact that it was utilized in pharmacologically active compounds as early as the launch of the <i>Journal of Medicinal Chemistry</i> in 1959.<a onclick="showRef(event, 'ref12 ref13 ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref12 ref13 ref14 ref15">(12−15)</a> The continued widespread popularity of this functional group in medicinal chemistry is also apparent from the number of examples of approved drugs or those in clinical/preclinical evaluation that containing a terminal or an internal acetylene group. There are many roles that this structural feature can play in drug activity, which include potency enhancement (by a complementary fit into a receptor binding pocket), reactive warhead (for irreversible inhibition of a target protein), nonpolar linear rigid spacer (to direct pharmacophore appendages in a favorable geometry), bioisostere to a wide range of functionalities (i.e., cyano, chloro, iodo, carboxamide, ethene, carbonyl, ethyl, phenyl, and cyclopropyl groups), and modulation of drug metabolism pharmacokinetic (DMPK) profile.</div><div class="NLM_p">An ethyne group also can be considered a privileged structural pharmacophore, for example, in the development of free fatty acid receptor 1 agonists<a onclick="showRef(event, 'ref16 ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref16 ref17 ref18">(16−18)</a> and mGlu5 receptor allosteric modulators.<a onclick="showRef(event, 'ref19 ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref19 ref20 ref21">(19−21)</a> However, it should be noted that a terminal acetylene group possesses certain inherent context-dependent liabilities such as irreversible inhibition of drug metabolizing enzymes (CYP450s,<a onclick="showRef(event, 'ref22 ref23 ref24 ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref22 ref23 ref24 ref25 ref26">(22−26)</a> glutathione (GSH)/glutathione-S-transferases (GSTs),<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> and UDP-glucuronyl transferases (UDPGTs)).<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a></div><div class="NLM_p last">Where possible, matched molecular pairs (MMPs) with succinct discussion will be provided for the reader with references to the original scientific literature for a more detailed information. In this Perspective, an acetylene group will be presented with context-dependent bilateral features, playing as a friend or a foe depending on the molecular or biological circumstances. It is hoped that this Perspective will also demonstrate that the positive contributions of an acetylene group outweigh its potential liabilities in the medicinal chemistry research to reinforce its utility for medicinal chemists.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">The Good Sides of the Ethynyl Group in Medicinal Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_55235" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_55235" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> The Ethynyl Group is a Versatile Isostere of a Wide Range of Groups (i.e., Chloro, Cyano, Iodo, Ethyl, Ethene, Carbonyl, Carboxamide, Phenyl, and Cyclopropyl)</h3><div class="NLM_p">The ethynyl group is a nonclassical bioisostere based on its versatility. For example, its π cloud effectively mimics aromatic rings and its polarized −CH motif acts as a weak hydrogen bond donor and thus can be isosterically replaced with the iodine atom. Furthermore, molecular electrostatic potentials for the chloro-, bromo-, and iodo-benzenes are similar to those observed for the phenylacetylene. The ethynyl group is a bioisostere of the iodine atom based on their comparable length. Further, the weak hydrogen bonding capacity of an acetylene is parallel in strength to that of a halogen bond. A prominent use of this isosteric replacement is facilitated by the fact that the iodine atom on an aromatic ring can be conveniently displaced using Sonogashira coupling chemistry.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> The presence of similar π system and donor–acceptor interactions in an acetylene, ethene, and phenyl allows them to serve as isosteres of each other.</div><div class="NLM_p">Both the cyano and the acetylene groups share structural similarity as evidenced from the presence of a sterically less demanding (suitable for exploiting sterically congested target protein active site environments) short and polarized linear triple bonds due to the presence of sp-hybridized centers. Further sp-hybridized terminal carbon in an acetylene has an electronegativity of 3.29, whereas sp-hybridized nitrogen in cyano group has an electronegativity of 5.07, suggesting that both are electron-withdrawing groups although the cyano is more powerful electron-withdrawing compared to an acetylene.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Therefore, an acetylene and the cyano groups are isosterically interchanged in bioactive compounds. Functional mimicry of an acetylene group extends to the <i>trans</i>-carboxamide, carbonyl, ethyl, and cyclopropyl groups as evidenced through examples provided in this Perspective.</div><div id="sec2_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i5" class="anchor-spacer"></div><h4 class="article-section__title" id="_i5"> Mtb PknA/PknB Dual Inhibitors <b>1</b> and <b>2</b></h4><div class="NLM_p">Protein kinase A (PknA) and protein kinase B (PknB) of <i>Mycobacterium tuberculosis</i> (Mtb) are attractive drug targets due to their essential role in the bacterial cell growth.<a onclick="showRef(event, 'ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref31 ref32">(31,32)</a> Wang and colleagues decided to develop novel inhibitors that target both kinases to obtain potent inhibitors with a possibility of lowering frequency of drug resistance.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Toward this goal, they developed an early lead compound <b>1</b> that demonstrated single-digit micromolar minimum inhibitory concentration (MIC) against Mtb and also showed single-digit nanomolar potency against both kinases (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). However, <b>1</b> suffered from poor selectivity over mammalian kinase CDK2. In the meanwhile, they obtained the X-ray crystal structure of <b>1</b> bound to PknA and PknB. These structural studies revealed the presence of a pocket due to flipped glycine residues (Gly100 in PknA and Gly97 in PknB), which could be exploited to achieve selectivity toward Mtb kinases over mammalian kinase CDK2. Accordingly, they replaced a 5-chloro group with a 5-ethynyl group as in compound <b>2</b>, a change that resulted in retention of potency against Mtb kinases as well as in antibacterial activity against Mtb and, most importantly, improved selectivity toward Mtb kinases over CDK2.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures and in vitro potency of Mtb PknA/PknB inhibitors <b>1</b> and <b>2</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i6" class="anchor-spacer"></div><h4 class="article-section__title" id="_i6"> Epidermal Growth Factor Receptor 2 (EGFR2) Inhibitors Gefitinib (<b>3</b>) and Erlotinib (<b>4</b>)</h4><div class="NLM_p">The chlorine atom in <b>3</b> forms a weak halogen bonding interaction<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> with the backbone carbonyl oxygen atom of Leu788 within the active site of EGFR2.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Both the aromatic C–Cl and aryl-C≡CH show a positive charge at the tip of these groups.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Because an acetylene group presents a polarized −CH moiety that can serve as a weak hydrogen bond donor, it successfully imitates the chlorine atom of <b>3</b> to obtain <b>4</b> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>) as substantiated from its cocrystal structure with EGFR2.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structures and EGFR2 kinase inhibitory activity of <b>3</b> and <b>4</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i7" class="anchor-spacer"></div><h4 class="article-section__title" id="_i7"> Fast Skeletal Muscle Troponin Activators <b>5</b>–<b>8</b></h4><div class="NLM_p">Myosin and troponin are the two major components of fast skeletal muscle fibers. The troponin complex localized in the thin filament along with actin and tropomyosin play a key role in calcium sensing.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> Patients with compromised muscle function are expected to benefit from the troponin activators.<a onclick="showRef(event, 'ref39 ref40'); return false;" href="javascript:void(0);" class="ref ref39 ref40">(39,40)</a> Consequently, Collibee and colleagues decided to develop small-molecule troponin activators.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> Structure–activity relationship (SAR) studies around the imidazopyrazine scaffold at the R-position led to a chloro derivative <b>5</b> with a submicromolar potency. Replacement of the compact electron-withdrawing chlorine atom with the cyano group resulted in compound <b>6</b> with a substantial loss of potency. While replacement with a vinyl substituent gave the potent compound <b>7</b>, one with an alkyne substituent as in <b>8</b> (tirasemtiv, CK-2017357)<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> led to the most potent compound (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). Compared to <b>5</b>, compound <b>8</b> showed improved clearance and unbound fraction in rat PK studies. Compound <b>8</b> is currently undergoing phase 3 clinical trial to evaluate its effect on respiratory function in patients with amyotrophic lateral sclerosis (NCT02496767).<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a></div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Structures, in vitro potency, and in vivo PK properties of troponin activators <b>5</b>–<b>8</b>. AC, concentration that increases native ATPas function by 40%; <i>F</i><sub>u</sub>, fraction unbound; ND, not determined.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i8" class="anchor-spacer"></div><h4 class="article-section__title" id="_i8"> Cyanoenone Michael Acceptors as Anti-inflammatory Agents <b>9</b>–<b>12</b></h4><div class="NLM_p">Zheng and colleagues converted the complex tricyclic cyanoenone <b>9</b> into simplified Michael acceptors in the form of monocyclic cyanoenones <b>10</b>–<b>12</b> possessing anti-inflammatory action (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>).<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> The study indicated a progressive increase in potency when going from a cyano to an ethene to an ethyne substitution at the C3-position. These compounds target cysteine residues of the target proteins such as Keap1 in a reversible manner.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Structures and in vitro potency of cyanoenone Michael acceptors <b>9</b>–<b>12</b>. <sup><i>a</i></sup>Average of three independent experiments. <sup><i>b</i></sup>Concentration required to double the specificity of NAD(P)H quinone dehydrogenase 1 (NQ01).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i9" class="anchor-spacer"></div><h4 class="article-section__title" id="_i9"> Pan-Serotype Dengue Virus NS5 RNA-Dependent RNA Polymerase Inhibitors <b>13</b>–<b>16</b></h4><div class="NLM_p">Functional activity of the dengue virus (DENV) NS5 RNA-dependent RNA polymerase (RdRp) is essential for the replication of dengue virus. It has no mammalian counterpart, thus making it an attractive target for the development of novel agents to treat dengue viral infections. Yokokawa and colleagues decided to optimize fragment-based early leads to obtain compound <b>13</b> that showed good potency (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>).<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> The X-ray crystal structure of <b>13</b> bound to the NS5 RdRp domain revealed that the C2-position of a thiophene ring offered the desired vector to extend the compound into the narrow cavity. The same structural data also indicated the presence of a water molecule in the narrow cavity forming hydrogen bonding interactions with His800 and Gln802. Therefore, they introduced a cyano group at the C2-position of the thiophene ring (compound <b>14</b>) to form an interaction network with the bound water molecule, but unfortunately with a considerable loss of potency. Next, they opted to displace the bound water molecule by installing a propargyl alcohol group. These efforts led to the identification of compound <b>15</b> showing a greater potency than <b>14</b>. The X-ray crystal structure of <b>15</b> bound to the NS5 RdRp domain confirmed the binding of a propargyl alcohol moiety in the narrow cavity where it has successfully displaced the water molecule while forming hydrogen bonds, with the backbone of His800 and the side chain of Gln802. Compound <b>15</b> showed pan-serotype (DENV1–4) activity, with IC<sub>50</sub> values ranging from 0.3–2.2 μM. Further optimization of <b>15</b> ultimately led to compound <b>16</b>, showing enhanced potency in biochemical and cell-based assays.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Structures and DENV-4 NS5 polymerase inhibitory activity of <b>13</b>–<b>16</b>. ITC, isothermal calorimetry; SPR, surface plasmon resonance.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i10" class="anchor-spacer"></div><h4 class="article-section__title" id="_i10"> Phosphoinositide-3-Kinase (PI3K)-γ Inhibitors <b>17</b>–<b>19</b></h4><div class="NLM_p">Because PI3K-γ signaling is critical for the function of myeloid cells, it serves as an important immuno-oncology target.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> To obtain potent and selective PI3K-γ inhibitors, Evans and co-workers introduced a cyano group at the C8-position of the isoquinolinone scaffold to obtain <b>17</b>, showing a moderate potency and a greater selectivity toward PI3K-γ than toward PI3K-δ (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>).<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> Isosteric replacement of the cyano group with an acetylene gave <b>18</b> with improved potency and selectivity. Because the acetylene CH pointed toward a nonconserved pocket, it was substituted with an <i>N</i>-methylpyrazol-4-yl moiety to obtain clinical candidate <b>19</b> (IPI-549)<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> with considerable selectivity toward PI3K-γ over PI3K-δ.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Structures and PI3K inhibitory potency of <b>17</b>–<b>19</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i11" class="anchor-spacer"></div><h4 class="article-section__title" id="_i11"> HIV-1 Reverse Transcriptase Inhibitor (4′-Ethynylstavudine/<b>22</b>)</h4><div class="NLM_p">Because the C4′-position tolerates an sp-hybridized carbon atom for binding to the active site of HIV-1 reverse transcriptase (HIV-1 RT), Tanaka and co-workers decided to replace the C4′-H of <b>20</b> with a cyano group (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>).<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> This modification led to <b>21</b> with no improvement in anti-HIV activity compared to <b>20</b>. However, introduction of an alternate sp-hybridized group such as ethynyl gave <b>22</b> with submicromolar anti-HIV activity and lower toxicity toward mammalian cells. Because compound <b>22</b> must undergo phosphorylation by thymidine kinase to form an active triphosphate metabolite, the <i>K</i><sub>m</sub> value was determined. The <i>K</i><sub>m</sub> value of <b>22</b> toward human thymidine kinase was lower than that of the parent molecule <b>20</b>, thus undergoing a faster conversion than <b>20</b>.</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Structures and anti-HIV activity of <b>20</b>–<b>22</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i12" class="anchor-spacer"></div><h4 class="article-section__title" id="_i12"> First-in-Class Nucleoside Reverse Transcriptase Translocation Inhibitor (NRTTI) (<b>23</b>, MK8591, EFdA/Islatravir)</h4><div class="NLM_p">EFdA is a highly potent nucleoside HIV-1 reverse transcriptase translocation inhibitor, also known as 4′-ethynyl-2-fluoro-2′-deoxyadenosine (<b>23</b>, <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>).<a onclick="showRef(event, 'ref48 ref49'); return false;" href="javascript:void(0);" class="ref ref48 ref49">(48,49)</a> Compound <b>23</b> showed anti-HIV efficacy in primary cells at subnanomolar concentrations.<a onclick="showRef(event, 'ref48 ref50'); return false;" href="javascript:void(0);" class="ref ref48 ref50">(48,50)</a> It has been shown to maintain activity against both wild-type and various drug-resistant HIV-1 RT mutants.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> The 4′-ethynyl and 2-fluoro groups in <b>23</b> contributed toward increased selectivity (CC<sub>50</sub>/IC<sub>50</sub> > 60000) in early stage antiviral investigation.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> The X-ray crystal structure of <b>23</b> with HIV-1 RT revealed strong van der Waals interactions of the 4′-ethynyl moiety with a preformed hydrophobic pocket comprised of residues Ala114, Tyr115, Phe160, and Met184 and the methylene portion of Asp185.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> These strong interactions allows <b>23</b> to sit tightly at the pretranslocation binding mode (N-site) and thus prevent binding of an incoming dNTP, which ultimately leads to a termination of DNA polymerization.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> Compound <b>23</b> is currently being investigated in a phase 2 clinical trial for the treatment of HIV-1 infection (NCT03272347).</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Structure and anti-HIV activity of <b>23</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i13" class="anchor-spacer"></div><h4 class="article-section__title" id="_i13"> GPR40 Agonists <b>24</b> and <b>25</b></h4><div class="NLM_p">GPR40 (free fatty acid reporter 1, FFA1) activation has shown the ability to stimulate the secretion of insulin only when glucose levels are elevated.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> Thus, it can serve as antidiabetic drug target. Li and colleagues began the development of GPR40 agonists based on an arylpropanoic acid scaffold.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> Among the many analogues synthesized, analogues <b>24</b> and <b>25</b> demonstrated isosterism between the propyne and cyano groups (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>). From a comparison of agonistic potency, the propynyl moiety is interchangeable with the cyano group. Although the cyano derivative was marginally more potent than the propynyl analogue, it was chemically unstable; therefore, further structure optimization efforts retained the propynyl moiety at the β-position of the thienylpropanoic acid scaffold.</div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Structures and GPR40 agonist activity of <b>24</b> and <b>25</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i14" class="anchor-spacer"></div><h4 class="article-section__title" id="_i14"> Quinazolinones as Anti-MRSA Agents</h4><div class="NLM_p">Replacement of the cyano group in compound <b>26</b> with an acetylene as in <b>27</b> led to a 67-fold enhanced potency against MRSA strain and an acceptable elimination half-life in mice (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>).<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a></div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Structures, in vitro potency, and PK property of anti-MRSA agents <b>26</b> and <b>27</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i15" class="anchor-spacer"></div><h4 class="article-section__title" id="_i15"> Thienopyrimidinones as Anti-<i>Clostridium difficile</i> Agents</h4><div class="NLM_p">We have recently conducted screening of in-house compounds against two pathogenic strains of <i>Clostridium difficile</i> and identified a screening hit, which was optimized to obtain the cyano derivative <b>28</b> with a moderate potency. Replacing the cyano group with an acetylene group resulted in <b>29</b> with a 16–32-fold increased potency (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>).<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a></div><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Structures and anti-<i>C. difficile</i> activity of <b>28</b> and <b>29</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i16" class="anchor-spacer"></div><h4 class="article-section__title" id="_i16"> Propargyl-Containing β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitors <b>30</b>–<b>36</b></h4><div class="NLM_p">BACE1 emerged as a promising target for the discovery of disease-modifying anti-Alzheimer’s therapeutics. Consequently, several BACE1 inhibitors were designed by inserting a privileged propargyl moiety. Fragment-based lead generation and subsequent scaffold hopping led to the 5-cyano-3-pyridinyl-containing aminoisoindole derivative <b>30</b> as an early lead compound. Although <b>30</b> was a potent inhibitor of BACE1 in the FRET and cell-based assays, it exhibited a very high efflux ratio and a poor permeability in Caco-2 cells. To address these liabilities, the cyano group of <b>30</b> was isosterically replaced with a propargyl moiety and thus yielded <b>31</b> with increased potency and Caco-2 permeability and reduced efflux ratio (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>). Further the propargyl moiety extends toward the S<sub>3</sub> subpocket of the enzyme and displaced a bound water molecule to gain binding affinity.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a></div><figure id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Structures and in vitro profile of BACE1 inhibitors <b>30</b>–<b>36</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Cumming and colleagues<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> synthesized an iminohydantoin scaffold to obtain the S<sub>3</sub> pocket binding chlorophenyl substituted iminohydantoin analogue <b>32</b> with appreciable biochemical and cell-based potency. To exploit the available space within the S<sub>3</sub> subpocket of BACE1, the distal chlorophenyl ring was replaced with the propynylpyridinyl ring to obtain <b>33</b> with improved BACE1 and cell Aβ40-based inhibitory potencies (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>).</div><div class="NLM_p last">Stamford and co-workers<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> optimized a six-membered iminopyrimidinone core, which resulted in the cyanophenyl derivative <b>34</b> with nanomolar biochemical and cell-based potency. On the basis of the above principle, they replaced the S<sub>3</sub> subpocket-binding 3-cyanophenyl moiety with the 3-propynylpyridinyl moiety to obtain <b>35</b> with improved potencies compared to <b>34</b>. Further gain in potency was achieved by replacing the thiophene ring attachment sites and by the addition of a chlorine atom as evidenced from compound <b>36</b> (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>).</div></div><div id="sec2_1_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i17" class="anchor-spacer"></div><h4 class="article-section__title" id="_i17"> Cytotoxic Compounds <b>37</b>–<b>39</b> for Myeloid Malignancies</h4><div class="NLM_p">Amdouni and co-workers<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> began optimization of their early lead compound <b>37</b> (acadesine)<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> that showed poor cytotoxic effect on the chronic myeloid leukemia (CML) K562 cell line, but interestingly, it showed an autophagic mechanism of cell death. Therefore, they replaced the imidazole ring of <b>37</b> with a synthetically accessible 1,2,3-triazole ring and obtained compound <b>38</b> with moderate inhibitory activity toward K562 cell line. Replacement of the iodine atom in <b>38</b> with an isosteric alkynyl substituent capped with an ethyl ester led to <b>39</b> with substantially increased cytotoxic effect on K562 cell line (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>). Further compound <b>39</b> was able to kill resistant as well as sensitive K562 cells with equal efficiency as evidenced from an IC<sub>50</sub> of 0.37 μM.</div><figure id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0013.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Structures and cytotoxic data of compounds <b>37</b>–<b>39</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_1_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18"> HDM2–p53 Interaction Antagonists <b>40</b> and <b>41</b></h4><div class="NLM_p">The disruption of interactions between p53 and HDM2 has long been considered a strategy for the development of cancer therapeutics.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> Parks and co-workers developed a new series of 1,4-benzodiazepine-2,5-diones (BDPs) as antagonists of the p53–HDM2 interaction.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> Early lead compound <b>40</b> featuring the iodine atom at the C7-position of the BDP showed submicromolar activity (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>). Replacement of the iodine atom with an acetylene group led to compound <b>41</b> with retention of submicromolar activity. Although acetylene group is smaller in volume compared to the iodine atom, the vector of the acetylene moiety allowed it to fill a hydrophobic region created by binding site residue Phe19 similar to that occupied by the iodine atom.</div><figure id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0014.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Structures and in vitro potency of p53–HDM2 interaction disruptors <b>40</b> and <b>41</b>. <sup><i>a</i></sup>ThermoFluor screening assay; <sup><i>b</i></sup>fluorescence polarization peptide displacement assay.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_1_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> D<sub>2</sub>/D<sub>3</sub> Full Agonist <b>42</b> to D<sub>2</sub> Partial Agonist <b>43</b></h4><div class="NLM_p">Because progressive loss of dopaminergic neurons in the substantia nigra pars compacta is the hallmark of Parkinson’s disease, the development of D<sub>2</sub>/D<sub>3</sub> receptor agonists serves as a useful approach to treat Parkinson’s disease. Consequently, Das and co-workers chose to develop a set of D<sub>2</sub>/D<sub>3</sub> full agonists and D<sub>2</sub>/D<sub>3</sub> partial agonists.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> A full D<sub>2</sub>/D<sub>3</sub> receptor agonist <b>42</b> was transformed into a new analogue <b>43</b> with partial agonist activity toward D<sub>2</sub> but full agonist activity toward D<sub>3</sub> by replacing the <i>N</i>-propyl substituent with the <i>N</i>-propargyl group (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>).</div><figure id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0015.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Structures and in vitro activity of D<sub>2</sub>/D<sub>3</sub> full agonist <b>42</b> and D<sub>2</sub> partial/D<sub>3</sub> full agonist <b>43</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_1_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> MDR in Cancer Treatment</h4><div class="NLM_p">Multidrug resistance (MDR) is a common occurrence among all malignancies. Therefore, new agents that can evade MDR are necessary to attain optimal treatment. Toward this objective, Aridoss and co-workers synthesized chromene-based compounds against MDR in cancers.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> For example, diethyl ester analogue <b>44</b> showed micromolar inhibition of HL60 cell growth. Replacing one of the ethyl ester groups with a propargyl ester led to <b>45</b> with a >2-fold increased potency. Finally, dipropargyl ester derivative <b>46</b> was identified as a submicromolar inhibitor of HL60 cells (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>).</div><figure id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0016.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Structures and cytotoxic data of compounds <b>44</b>–<b>46</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_1_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> Discovery of Cysteinyl Leukotriene (CysLT<sub>1</sub> and CysLT<sub>2</sub>) Receptor Antagonist <b>49</b> (Gemilukast)</h4><div class="NLM_p">The cysteinyl leukotriene (CysLT<sub>1</sub> and CysLT<sub>2</sub>) receptors are expressed on airway smooth muscle and inflammatory cells, and thus antagonizing these receptors is an attractive strategy for treating asthma.<a onclick="showRef(event, 'ref65 ref66'); return false;" href="javascript:void(0);" class="ref ref65 ref66">(65,66)</a> Itadani and co-workers began optimization of the 2-methylindole-1-acetic acid lead compound <b>47</b> that exhibited low permeability (<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>).<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> They postulated poor permeability of <b>47</b> is a result of conformational flexibility and acidic property. This prompted them to replace the <i>trans</i>-double bond with a more linear triple bond, leading to <b>48</b> with a retention of dual antagonist activity of <b>47</b>. Having established successful replacement of the <i>trans</i>-double bond with a linear triple bond, they conducted further modifications (i.e., the indole-<i>N</i>-acetic acid to indole-<i>N</i>-butanoic acid, chloro to fluoro exchange, and insertion of a fluorine at C4 of the indole ring) in <b>48</b>, which led to the discovery of <b>49</b> (gemilukast).</div><figure id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0017.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Structures of CysLT<sub>1</sub> and CysLT<sub>2</sub> receptor antagonists <b>47</b>–<b>49</b> and their in vitro potency and permeability data.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_1_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> Bis-Michael Acceptors <b>50</b>–<b>52</b> as Chemical Probes for Keap1/Nrf2/ARE Pathways</h4><div class="NLM_p">Kelch-like ECH-associated protein 1 (Keap1)/nuclear factor erythroid 2-related factor 2 (Nrf2)/antioxidant response element (ARE) pathway is important in the cellular response to oxidative/electrophilic stress (OES) because the cellular antioxidant defense component ARE is under the transcriptional control of Nrf2.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> Because Keap1 regulates Nrf2-mediated transcription, it serves as a therapeutic target for oxidative stress-associated disorders. Deny and colleagues developed moderately reactive dual cysteine trapping Keap1 agonists with a potentially increased target residence time.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> The three analogues shown in <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">18</a></a> produced greater induction of ARE when tether group rigidity was high, as evidenced from flexible butane (<b>50</b>) to rigid butene (<b>51</b>) and butyne (<b>52</b>) tethers. On the basis of these results, the authors concluded that optimal distance and favorable conformational arrangement of both Michael acceptors are necessary for effective interaction with the Keap1.</div><figure id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0018.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Structures of bis-Michael acceptors <b>50</b>–<b>52</b> and their in vitro potency.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_1_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> <i>Mycobacterium</i> Protein Tyrosine Phosphatase B (mPTPB) Inhibitors <b>53</b> and <b>54</b></h4><div class="NLM_p"><i>Mycobacterium tuberculosis</i> secretes an essential virulence mPTPB phosphatase into the host macrophage.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> It has been shown that mPTPB inhibition by small molecules will increase intrinsic host signaling pathways to tackle TB infection.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> Therefore, He and co-workers decided to develop potent and selective benzofuran salicylic acid scaffold-based mPTPB inhibitors.<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> Reduction of an unsaturated rigid alkyne spacer in <b>54</b> to an ethyl bridge led to <b>53</b> with a substantial suppression of mPTPB inhibitory potency, thus highlighting favorable contribution of a directionally rigid pendant C3-substituent of the benzofuran salicylic acid scaffold to effectively interact with the mPTPB enzyme (<a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>).</div><figure id="fig19" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0019.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Structures and the mPTPB inhibitory activity of <b>53</b> and <b>54</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_1_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> Calcium Sensing Receptor Antagonists <b>55</b> and <b>56</b></h4><div class="NLM_p">Parathyroid hormone secretion is regulated by the calcium-sensing receptor (CaSR) that is expressed on the surface of parathyroid cells.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> CaSR antagonists imitate a state of hypocalcaemia, which leads to enhanced release of parathyroid hormone.<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> Consequently, Widler and colleagues developed CaSR antagonists based on the quinazolinone scaffold.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> One optimized lead, <b>55</b>, with the C6-allyloxy substituent, showed potent inhibition of CaSR. Further improvement in CaSR antagonist activity was realized by replacing the C6-allyloxy substituent in <b>55</b> with the C6-propargyloxy group as in <b>56</b> (<a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>).</div><figure id="fig20" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0020.jpeg" id="gr20" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. Structures and in vitro potency of CaSR antagonists <b>55</b> and <b>56</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_1_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> Histone Deacetylase 8 (HDAC8) Inhibitors <b>57</b>–<b>59</b></h4><div class="NLM_p">The majority of the HDAC inhibitors are pan-HDAC inhibitors. Thus, there is an urgent need for isoform-specific HDAC inhibitors to not only understand biological functions of individual HDAC isoforms but also to develop tolerable clinical candidates. Toward this goal, Ingham and colleagues described the synthesis of highly potent and selective HDAC8 inhibitors.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> Among 70 compounds synthesized, <b>57</b> showed inhibition of HDAC8 at a subnanomolar concentration. Sequential reduction of the alkyne moiety to ethene (<b>58</b>) or ethyl (<b>59</b>) resulted in loss of HDAC8 inhibitory activity, thus substantiating favorable contribution of an alkyne linker between the 1,2,3-triazole ring and the cyclopropyl moiety (<a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">21</a></a>).</div><figure id="fig21" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0021.jpeg" id="gr21" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21. Structures of compounds <b>57</b>–<b>59</b> and HDAC8-inhibitory activity of <b>57</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig21"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_1_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> Discovery of Metabotropic Glutamate Receptor 5 (MGluR5) Antagonist <b>64</b> (Mavoglurant)</h4><div class="NLM_p">mGluR5 subtype is involved in a number of pathologies, including anxiety and Parkinson’s disease.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> Therefore, Vranesic and co-workers developed clinically effective mGluR5 antagonists.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> These efforts resulted in acetylene-containing early lead compound <b>60</b>, with a submicromolar potency in fluorescent imaging plate reader (FLIPR) and 2-methyl-6-(3-methoxyphenyl)ethynylpyridine (M-MPEP) displacement assays. To establish the importance of an acetylene linker between the phenyl ring and the octahydroindole ring, they synthesized <i>cis</i>- (<b>61</b>) and <i>trans</i>-double-bond (<b>62</b>) and single-bond (<b>63</b>) analogues, which led to noticeable loss of potency compared to <b>60</b>. Having established the key role of an acetylene group, they retained an acetylene group and conducted molecular modifications at the pendant phenyl ring and the carbamate ester, leading to the discovery of <b>64</b> (AFQ056)<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> as a clinical candidate (<a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">22</a></a>).</div><figure id="fig22" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0022.jpeg" id="gr22" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22. Structures and activity of mGluR5 antagonists <b>60</b>–<b>64</b>. <sup><i>a</i></sup>[<sup>3</sup>H]-M-MPEP binding displacement in rat membranes.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig22"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_1_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> Targeting DCN1–UBE2M Interaction by Inhibitors <b>65</b>–<b>68</b></h4><div class="NLM_p">Defective in cullin neddylation 1 (DCN1) is overexpressed in squamous cell carcinomas.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> Blocking the interaction of DCN1 and ubiquitin conjugating enzyme E2M (UBE2M) has been shown to reduce cullin3 neddylation.<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> Therefore, disrupting the interaction of DCN1 with UBE2M is considered a strategy to develop anticancer drugs. Consequently, Zhou and colleagues designed small molecules that targets a pocket on DCN1 that binds to UBE2M.<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> To determine robust binding affinities, they used two competitive binding assays such as fluorescence polarization (FP) and homogeneous time-resolved fluorescence (HTRF). Compound <b>65</b> demonstrated a low nanomolar potency in both the assays. To elucidate the importance of a propargyl substituent in <b>65</b> for potent inhibition of DCN1–UBE2M interaction, they synthesized and tested compounds <b>66</b> and <b>67</b> (featuring sequential reduction of a C≡C triple bond) with a dramatic loss of potency (<a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">23</a></a>). While retaining the required propargyl group, they replaced the chlorine atom with an isosteric/isolipophilic methyl to obtain the most potent inhibitor <b>68</b>. Predicted binding model of <b>68</b> within the binding pocket of DCN1 revealed favorable hydrophobic interactions of a terminal alkyne group at the sterically compact pocket surrounded by Ile83 and Ile86.</div><figure id="fig23" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Figure 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0023.jpeg" id="gr23" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 23. Structures of DCN1–UBE2M interaction inhibitors <b>65</b>–<b>68</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig23"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_1_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> Discovery of Dipeptidyl Peptidase-4 (DPP-4) Inhibitor <b>71</b> (Linagliptin)</h4><div class="NLM_p">DPP-4 is a well-established target of drugs to treat type 2 diabetes. Eckhardt and co-workers began DPP-4 inhibitor development program using one of the early lead compounds <b>69</b> that feature a dimethylallyl group at <i>N</i>7-position of the dihydropurine scaffold.<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> Although <b>69</b> exhibited potent inhibition of DPP-4, it had unacceptably high inhibition of human ether-a-go-go (hERG) channel and high affinity for the muscarinic M<sub>1</sub> receptor. Therefore, the dimethylallyl group was replaced with 2-butynyl group, leading to <b>70</b> with improved DPP-4 inhibition and eliminated unfavorable interaction with hERG channel and M<sub>1</sub> receptor (<a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">24</a></a>). Finally, phenacyl <i>N</i>1-substituent was replaced with 4-methylquinazolin-2-yl-methyl moiety to obtain linagliptin (<b>71</b>, BI 1356).<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> The X-ray crystal structure of <b>71</b> bound to DPP-4 concluded favorable binding of the 2-butynyl group in S<sub>1</sub> hydrophobic pocket that not only contributed toward improved potency but also to the long residence time of the inhibitor.</div><figure id="fig24" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Figure 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0024.jpeg" id="gr24" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 24. Structures and DPP-4 inhibitory activity of <b>69</b>–<b>71</b>. <sup><i>a</i></sup>hERG current remaining at tested concentration of 1 μM.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig24"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_1_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> B-Raf Inhibitors <b>72</b> (Vemurafenib) and <b>73</b></h4><div class="NLM_p">B-Raf serine/threonine kinase is a key component of mitogen-activated protein kinase (MAPK) signaling pathway.<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> B-Raf mutations such as V600E are frequently detected in human cancers.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> Therefore, selective inhibition of B-Raf<sup>V600E</sup> mutant-driven human cancers is an attractive strategy. Although <b>72</b> (vemurafenib) is approved for the treatment of metastatic and unresectable melanoma harboring B-Raf mutations,<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> it suffers from intrinsic or acquired resistance.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> Therefore, Li and co-workers began structural optimization of <b>72</b>.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> They replaced the carbonyl group with a conformation- and distance-favorable ethynyl linker to correctly position the hinge binding bicyclic core 1<i>H</i>-7-azaindazole and a back pocket binding difluorophenyl moiety to obtain <b>73</b> with superior in vitro and in vivo profile (<a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">25</a></a>).</div><figure id="fig25" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Figure 25</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0025.jpeg" id="gr25" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 25. Structures of <b>72</b> and <b>73</b> with B-Raf inhibitory activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig25"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_1_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> CRTH2 Receptor Antagonists <b>74</b>–<b>76</b></h4><div class="NLM_p">Chemoattractant receptor-homologous expressed in Th2 lymphocytes (CRTH2) is largely expressed by Th2 cells, eosinophils, and basophils, and thus it is involved in allergic diseases.<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> Consequently, Crosignani and co-workers decided to develop potent, selective, and orally active CRTH2 antagonists as a possible treatment of allergic and inflammatory diseases.<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> A focused screening of 8500 compound library identified <b>74</b> as a potent CRTH2 inhibitor. Replacement of the amide linker between the two aromatic rings by a rigid acetylene linker produced <b>75</b>, with retention of affinity toward CRTH2 receptor. It was observed that the two aromatic rings in <b>75</b> assumed similar orientation as seen in the more active <i>trans</i>-amide analogue <b>74</b>. However, both <b>74</b> and <b>75</b> suffer from very high serum protein binding due to their lipophilic acidic property. To address this concern, further polarity-enhancing modifications were made involving an isosteric replacement of the chloro with a fluoro and insertion of an <i>n</i>-propylsulfone moiety <i>para</i> to the fluoro to obtain orally active compound <b>76</b> with enhanced potency compared to <b>74</b> and <b>75</b> (<a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">26</a></a>).</div><figure id="fig26" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Figure 26</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0026.jpeg" id="gr26" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 26. Structures, in vitro potency (<b>74</b> and <b>75</b>), serum protein binding, and clearance data of CRTH2 receptor antagonist <b>76</b>. KHSA, human serum albumin binding constant.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig26"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_1_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> Tumor Necrosis Factor-α (TNFα) Converting Enzyme (TACE) Inhibitors <b>77</b> and <b>78</b></h4><div class="NLM_p">TNFα is a major proinflammatory cytokine that is implicated in the pathogenesis of rheumatoid arthritis.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> A soluble form of TNFα (17 kDa) is cleaved from the membrane bound TNFα (26 kDa) by the action of metalloproteinase TACE. Therefore, the development of TACE inhibitors is an attractive approach for the treatment of rheumatoid arthritis. The X-ray crystal structure of TACE inhibitor <b>77</b> bound to the active site of TACE indicated the binding of the phenyl–pyridyl (biaryl) system in a shallow hydrophobic S<sub>1</sub> pocket surrounded by residues Val314 and Leu350.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> Although <b>77</b> showed potent inhibition of TACE, it exhibited poor activity in the presence of human whole blood. Therefore, Girijavallabhan and colleagues optimized this lead further with the assumption that internal aryl ring can be replaced with an isosteric acetylene while still projecting the terminal aryl ring in a similar orientation as observed in biaryl series.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> These efforts culminated in the discovery of <b>78</b> with comparable TACE inhibitory activity and improved activity in a human whole blood assay (hWBA) (<a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">27</a></a>).</div><figure id="fig27" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Figure 27</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0027.jpeg" id="gr27" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 27. Structures of <b>77</b> and <b>78</b> with TACE inhibitory activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig27"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_1_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> Histone Lysine Specific Demethylase 1 (LSD1) Inhibitors <b>79</b> and <b>80</b></h4><div class="NLM_p">LSD1 is overexpressed in a number of human cancers, and thus LSD1 is a broadly explored anticancer drug target.<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a> Therefore, Ma and co-workers synthesized LSD1-specific inhibitors to elucidate detailed biological functions of the enzyme.<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> These efforts led to the discovery of a propargyl-containing aminothiourea-pyrimidine derivative <b>79</b> with submicromolar potency against LSD1 (<a data-tab="pane-pcw-Figures" href="#fig28" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig28" id="" class=" internalNav">28</a></a>). The importance of the propargyl group in <b>79</b> was assessed by replacing it with a 3,4-dichlorobenzyl moiety, leading to <b>80</b> with a substantial loss of potency. This data ascertained the importance of a propargyl group toward LSD1 inhibition. It has been shown that <i>N</i>5 of the flavin adenine dinucleotide (FAD) cofactor initiates nucleophilic attack at the propargyl group to produce covalent inactivation of LSD1.<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a></div><figure id="fig28" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Figure 28</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0028.jpeg" id="gr28" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 28. Structures and LSD1 inhibitory potency of <b>79</b> and <b>80</b>. A covalent complex of <b>79</b> with LSD1 cofactor FAD is also shown.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig28"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_1_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> Diacylglycerol Lipase α (DAGLα) Inhibitors <b>81</b> and <b>82</b></h4><div class="NLM_p">A 120 kDa DAGLα contains a serine hydrolase-like catalytic triad (Ser-His-Asp) that catalyzes the hydrolysis of an ester bond of diacylglycerol (DAG) in a nucleophilic substitution 1 (S<sub>N</sub>1) specific manner to release 2-arachidonoylglycerol (2-AG).<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> 2-AG, in turn, activates the cannabinoid CB1 receptor. DAGLα is primarily expressed in the brain.<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a> To understand the molecular functions of DAGLα in a temporal and dynamic fashion, Deng and co-workers designed a CNS-active chemical probe based on the most active C5-back diastereoisomer <b>81</b> with picomolar potency.<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a> To visualize the target engagement, they replaced a cyclopropyl ring with an acetylene group, leading to an alkyne-containing chemical probe <b>82</b> with retention of potency and selectivity against DAGLα over α,β-hydrolase domain 6 (ABHD6) (<a data-tab="pane-pcw-Figures" href="#fig29" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig29" id="" class=" internalNav">29</a></a>). The terminal acetylene present in in vivo active probe <b>82</b> will function as a ligation handle to introduce fluorescently labeled reporter groups via copper-catalyzed azide–alkyne [3 + 2] cycloaddition to assess target engagement events.</div><figure id="fig29" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Figure 29</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0029.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0029.jpeg" id="gr29" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 29. Structures of <b>81</b> and <b>82</b> with DAGLα and ABHD6 inhibitory activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig29"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> Modulation of Drug Metabolism Pharmacokinetic (DMPK) Profile Using the Ethyne Group</h3><div id="sec2_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> Isosteric Replacement of the Benzyl with a Propargyl to Improve Metabolic Stability</h4><div class="NLM_p">Dragovich and co-workers reported pharmacokinetic optimization of 2-pyridone class of human rhinovirus 3C protease inhibitors.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> For example, the 3,4-difluorobenzyl P<sub>2</sub> moiety present in <b>83</b> was replaced with a propargyl moiety to obtain <b>84</b> with a marginal loss of potency. Interestingly, compound <b>84</b> is manifested with a number of attractive properties such as increased polarity, aqueous solubility, metabolic stability, and plasma half-life (<a data-tab="pane-pcw-Figures" href="#fig30" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig30" id="" class=" internalNav">30</a></a>).</div><figure id="fig30" data-index="30" class="article__inlineFigure"><h2 class="fig-label">Figure 30</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0030.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0030.jpeg" id="gr30" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 30. Structures of human rhinovirus 3C protease inhibitors <b>83</b> and <b>84</b> and their in vitro potency and DMPK profile.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0030.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig30"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> Methylvinyl to Vinylacetylene Modification to Enhance Oral Bioavailability</h4><div class="NLM_p">Replacement of metabolically labile methylvinyl substituent in antirhinovirus enviroxime analogue <b>85</b> by a vinylacetylene moiety led to <b>86</b>, with a 3-fold improved inhibitory activity in poliovirus plaque reduction assay and increased blood levels in rhesus monkeys after oral administration (<a data-tab="pane-pcw-Figures" href="#fig31" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig31" id="" class=" internalNav">31</a></a>).<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a></div><figure id="fig31" data-index="31" class="article__inlineFigure"><h2 class="fig-label">Figure 31</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0031.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0031.jpeg" id="gr31" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 31. Structures, in vitro potency and <i>C</i><sub>max</sub> data of poliovirus plaque inhibitors <b>85</b> and <b>86</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0031.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig31"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> Improvement of Pharmacokinetic Profile of <b>87</b> (Zileuton)</h4><div class="NLM_p">Compound <b>87</b>, a 5-lipoxygenase inhibitor, has a very short half-life as a result of fast glucuronide conjugation at <i>N</i>-hydroxyurea pharmacophore. Because <i>N</i>-hydroxyurea moiety is essential for the activity, Bouska and colleagues modified the template and linker regions of <b>87</b>.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Replacement of the benzothiophene template with a fluorophenoxyphenyl and insertion of an ethylene linker led to <b>88</b> with a decrease in UDPGT rate and plasma clearance and increase in plasma half-life. Further improvement in UDPGT rate, plasma clearance, and plasma half-life was accomplished when ethylene linker was replaced with an acetylene moiety as in <b>89</b>. Isosteric replacement of the 4-fluorophenoxyphenyl moiety in <b>89</b> with a 4-fluorobenzylthiophene moiety led to <b>90</b> with desirable UDPGT rate, plasma clearance, and plasma half-life (<a data-tab="pane-pcw-Figures" href="#fig32" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig32" id="" class=" internalNav">32</a></a>).</div><figure id="fig32" data-index="32" class="article__inlineFigure"><h2 class="fig-label">Figure 32</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0032.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0032.jpeg" id="gr32" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 32. Structures, in vitro UDPGT rate, and PK profile of 5-lipoxygenase inhibitors <b>87</b>–<b>90</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0032.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig32"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> Increased Metabolic Stability of Steroidal Drugs <b>91</b>–<b>96</b></h4><div class="NLM_p">Among several alkyne-containing steroidal drugs, a representative set of them (<b>91</b>–<b>96</b>) are presented in <a data-tab="pane-pcw-Figures" href="#fig33" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig33" id="" class=" internalNav">33</a></a>. Because the C17β-OH group in steroidal drugs was shown to undergo 17β-hydroxysteroid dehydrogenase-mediated oxidation to the much less active C17-keto metabolite,<a onclick="showRef(event, 'ref100 ref101'); return false;" href="javascript:void(0);" class="ref ref100 ref101">(100,101)</a> C17α-ethynyl or -propargyl group was introduced to prevent this oxidation and thus render them orally active. In addition, the propargyl alcohol moiety in these steroids ensure reduced androgenic activity.</div><figure id="fig33" data-index="33" class="article__inlineFigure"><h2 class="fig-label">Figure 33</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0033.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0033.jpeg" id="gr33" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 33. Structures of the alkyne-containing steroidal drugs <b>91</b>–<b>96</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0033.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig33"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> CYP1B1 Selective Inhibitors <b>97</b> and <b>98</b></h4><div class="NLM_p">CYP1B1 is responsible for metabolic inactivation of anticancer drugs such as docetaxel, paclitaxel, and cisplatin.<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a> Additionally, it is involved in the bioactivation of a wide range of procarcinogens. Further overexpression of CYP1B1 is observed in several types of human cancers.<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> Therefore, CYP1B1 serves as a target to achieve multiple therapeutic goals. Dutour and colleagues reported greater selectivity of estrogens toward CYP1B1 over CYP1A1 when the C17α-ethynyl group was inserted as evidenced from compounds <b>97</b> and <b>98</b> (<a data-tab="pane-pcw-Figures" href="#fig34" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig34" id="" class=" internalNav">34</a></a>).<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a> An additional reason for installation of the C17α-ethynyl group was to protect the C17β-hydroxy group from undergoing metabolic oxidation.<a onclick="showRef(event, 'ref100 ref101'); return false;" href="javascript:void(0);" class="ref ref100 ref101">(100,101)</a></div><figure id="fig34" data-index="34" class="article__inlineFigure"><h2 class="fig-label">Figure 34</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0034.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0034.jpeg" id="gr34" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 34. Structures and CYP1B1/CYP1A1 inhibitory activity of <b>97</b> and <b>98</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0034.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig34"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> Disrupters of the Glucokinase–Glucokinase Regulatory Protein (GK-GKRP) Interaction</h4><div class="NLM_p">Glucokinase activators are antidiabetic agents; however, they suffer from hypoglycemia.<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a> Therefore, St. Jean and colleagues synthesized novel compounds with a potential to disrupt GK–GKRP interaction with a concomitant mitigation of the hypoglycemia.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> Although initial lead compound <b>99</b> was potent in biochemical assays, it lacked metabolic stability (<a data-tab="pane-pcw-Figures" href="#fig35" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig35" id="" class=" internalNav">35</a></a>). The lack of metabolic stability was attributed to the presence of a methyl-substituted morpholine ring. Further, it was observed that the thiophene binding site contained a pair of hydrogen bond acceptor groups. Therefore, the thiophene ring was replaced with hydrogen bond donating moiety such as aminopyridine and the methyl substituted morpholinylmethyl moiety was replaced with the hydrogen to obtain <b>100</b> with a drastic improvement in metabolic stability. Addition of a propargyl substituent onto the piperazine ring led to the discovery of <b>101</b> (AMG-3969) with a >20-fold increased potency and desirable metabolic stability.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a></div><figure id="fig35" data-index="35" class="article__inlineFigure"><h2 class="fig-label">Figure 35</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0035.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0035.jpeg" id="gr35" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 35. Structures, in vitro activity, and microsomal stability profile of GK-GKRP disrupters <b>99</b>–<b>101</b>. <sup><i>a</i></sup>AS, hGK-hGKRP AlphaScreen. <sup><i>b</i></sup>mGK, mouse GK translation assay. <sup><i>c</i></sup>In vitro microsomal stability measurements.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0035.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig35"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> Ghrelin Inverse Agonists <b>102</b>–<b>105</b></h4><div class="NLM_p">Ghrelin is a 28-amino acid long “hunger hormone”, which upon octanoylation becomes effective endogenous agonist for the growth hormone secretagogue receptor (GHSR). Activation of GHSR leads to increased food intake and thus plays a key role in obesity-related metabolic diseases.<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a> Therefore, the development of GHSR inverse agonist would reduce food intake. Consequently, Daina and colleagues began structure-based design and development of GHSR inverse agonists.<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a> The <i>para</i>-cyclopropyl analogue <b>102</b> gave a moderate potency, whereas <i>para</i>-ethynyl analogue <b>103</b> showed a substantial improvement in potency. However, <b>103</b> suffered from poor metabolic stability. To increase metabolic stability, ethynyl and cyclopropyl substituents were combined, leading to a <i>para</i>-cyclopropylethynyl analogue <b>104</b> with good potency and increased metabolic stability. Chiral separation of <b>104</b> revealed the (<i>R</i>)-isomer to be the more potent diastereomer (<b>105</b>) (<a data-tab="pane-pcw-Figures" href="#fig36" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig36" id="" class=" internalNav">36</a></a>).</div><figure id="fig36" data-index="36" class="article__inlineFigure"><h2 class="fig-label">Figure 36</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0036.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0036.jpeg" id="gr36" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 36. Structures, in vitro activity, and microsomal stability profile of ghrelin inverse agonists <b>102</b>–<b>105</b>. <sup><i>a</i></sup>Inositol phosphate accumulation assay.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0036.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig36"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> Enhanced Target Selectivity with an Acetylene</h3><div class="NLM_p">The development of inhibitors with a defined selectivity profile has been a priority for drug discovery scientists to limit off-target effects. Toward this objective, the acetylene group has contributed to the development of isoform-selective ligands as supported by following examples.</div><div id="sec2_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> Insertion of an Acetylene Group in DPP-4 Inhibitor Enhanced Target Selectivity</h4><div class="NLM_p">Madar and colleagues developed DPP-4 specific inhibitors over closely related isoforms DPP-8 and DPP-9.<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a> They installed an acetylene group at the C5-position of 2-cyanopyrrolidine moiety in <b>106</b> to obtain <b>107</b> with a considerable improvement in DPP-4 selectivity over DPP-8 and DPP-9 compared to <b>106</b>. While retaining the cyano and acetylene substituted pyrrolidine ring, they replaced the cyclohexyloxy linker by C4-methylpiperidine and cyanopyridine ring by the isonicotinic acid to obtain compound <b>108</b> (ABT-279),<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a> with further improvement in potency and selectivity (<a data-tab="pane-pcw-Figures" href="#fig37" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig37" id="" class=" internalNav">37</a></a>).</div><figure id="fig37" data-index="37" class="article__inlineFigure"><h2 class="fig-label">Figure 37</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0037.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0037.jpeg" id="gr37" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 37. Structures of DPP-4 inhibitors <b>106</b>–<b>108</b> and in vitro potency.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0037.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig37"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> Propargyl Derivative (<b>110</b>) of Retigabine (<b>109</b>) as Potent KCNQ4 and KCNQ5 Channel Agonist</h4><div class="NLM_p">KCNQ is a subfamily of voltage-gated potassium ion channels comprising five members (KCNQ1–5). Among these subtypes, KCNQ4 and KCNQ5 channels are involved in visceral smooth muscle-related diseases such as overactive bladder syndrome and irritable bowel syndrome.<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a> Therefore, Wang and colleagues synthesized KCNQ4 and KCNQ5 channel selective agonists.<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a> Insertion of the <i>N</i>1-propargyl and <i>N</i>3-Boc groups in nonselective <b>109</b> (retigabine) led to <b>110</b>, with improved KCNQ4/5 subtype specificity (<a data-tab="pane-pcw-Figures" href="#fig38" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig38" id="" class=" internalNav">38</a></a>).</div><figure id="fig38" data-index="38" class="article__inlineFigure"><h2 class="fig-label">Figure 38</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0038.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0038.jpeg" id="gr38" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 38. Structures of <b>109</b> and <b>110</b> with KCNQ channel agonist activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0038.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig38"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> Structural Role of an Acetylene Group</h3><div class="NLM_p">The alkyne group has been widely used as a structural motif due to its narrow, rod-like configuration to traverse sterically restricted channels within the target protein. Being electron-rich, it was further used to establish potency enhancing π–π interactions with the active site aromatic residues. Moreover, it serves as an effective sterically less demanding linker to create symmetric dimeric compounds directed at the two adjacent binding sites on the target macromolecule. Additionally, it can be used as a connecting bridge to sterically restrict the bioactive conformation and enhancing target selectivity.</div><div id="sec2_4_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> Phosphinic Pseudotripeptide Inhibitors (<b>111</b> and <b>112</b>) of Aminopeptidases</h4><div class="NLM_p">The three major aminopeptidases, including endoplasmic reticulum aminopeptidase 1 (ERAP1), ERAP2, and insulin-regulated aminopeptidase (IRAP), are involved in pruning antigenic peptides.<a onclick="showRef(event, 'ref112 ref113 ref114'); return false;" href="javascript:void(0);" class="ref ref112 ref113 ref114">(112−114)</a> Therefore, these enzymes serves as drug targets for the regulation of immune responses.<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a> Replacement of the P<sub>1′</sub> Ile side chain in <b>111</b> with a propargyl group led to <b>112</b> with increased inhibition of three aminopeptidases (<a data-tab="pane-pcw-Figures" href="#fig39" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig39" id="" class=" internalNav">39</a></a>).<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a> Kokkala and co-workers speculated that the potency increase was a result of favorable interactions between the electron-rich propargyl group and the catalytic Zn<sup>2+</sup> atom. However, an X-ray crystal structure was unavailable to confirm this hypothesis.<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a> Recently, Giastas and colleagues<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a> determined a high-resolution (1.60 Å) structure of ERAP1 bound to <b>112</b> (DG046). The X-ray structure showed localization of a propargyl group into the S<sub>1′</sub> pocket of the ERAP1 active site, where it forms potency enhancing π–π interactions with the aromatic cloud of the zinc<sup>2+</sup>-coordinating His353.</div><figure id="fig39" data-index="39" class="article__inlineFigure"><h2 class="fig-label">Figure 39</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0039.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0039.jpeg" id="gr39" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 39. Structures of ERAP1/ERAP2/IRAP inhibitors <b>111</b> and <b>112</b> with in vitro potency data.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0039.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig39"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> Discovery of Bcr-Abl Kinase Inhibitor <b>115</b></h4><div class="NLM_p">Bcr-Abl kinase play a key role in chronic myelogenous leukemia (CML), and thus it serves as oncology drug target.<a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(118)</a> Clinical use of compound <b>113</b> (imatinib) in CML patients is associated with drug resistance as a result of mutation at the gatekeeper residue (Thr315Ile).<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a> Bulky side chain of Ile315 produces a steric clash with <b>113</b> and a concomitant >400-fold loss of binding affinity (<a data-tab="pane-pcw-Figures" href="#fig40" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig40" id="" class=" internalNav">40</a></a>).<a onclick="showRef(event, 'ref119 ref120'); return false;" href="javascript:void(0);" class="ref ref119 ref120">(119,120)</a> Compound <b>114</b> (ponatinib) was designed to contain an alkyne linker between the adenine-binding moiety and allosteric pocket-binding moiety to avoid steric clash with the bulky side chain of Ile315 as evidenced from potent inhibition of both wild-type and mutant Bcr-Abl kinase.<a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(121)</a> Although <b>114</b> was useful for targeting both wild-type and resistant Bcr-Abl kinases, it suffered from side effects such as blood clots and narrowing of blood vessels. Therefore, Liu and co-workers developed new generation Bcr-Abl kinase inhibitors wherein a novel adenine-binding moiety and allosteric pocket-binding moiety was linked via an alkyne group.<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a> These efforts culminated in compound <b>115</b> with a balanced subnanomolar inhibition of wild-type as well as Thr315Ile mutant Bcr-Abl kinase.</div><figure id="fig40" data-index="40" class="article__inlineFigure"><h2 class="fig-label">Figure 40</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0040.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0040.jpeg" id="gr40" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 40. Structures of <b>113</b>–<b>115</b> with Bcr-Abl kinase inhibitory activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0040.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig40"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> Stem Cell Factor Receptor KIT Inhibitor <b>116</b></h4><div class="NLM_p">The tyrosine kinase mast/stem cell growth factor receptor KIT is a validated target for the development of cancer therapeutics to treat gastrointestinal stromal tumors and CML. However, this strategy failed due to acquired resistance mutations in the catalytic domain of KIT. Consequently, Kaitsiotou and colleagues developed a novel KIT inhibitor <b>116</b> that addresses this problem.<a onclick="showRef(event, 'ref122'); return false;" href="javascript:void(0);" class="ref ref122">(122)</a> To do so, they connected hinge binding element to the back pocket moiety via an acetylene linker which allowed maximum affinity toward the gatekeeper Thr670Ile mutation (<a data-tab="pane-pcw-Figures" href="#fig41" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig41" id="" class=" internalNav">41</a></a>).</div><figure id="fig41" data-index="41" class="article__inlineFigure"><h2 class="fig-label">Figure 41</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0041.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0041.jpeg" id="gr41" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 41. Structure and KIT inhibitory activity of <b>116</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0041.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig41"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> Type II Inhibitor (<b>117</b>) of Maternal Embryonic Leucine Zipper Kinase (MELK)</h4><div class="NLM_p">MELK is a target for cancer therapeutics development.<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a> Johnson and co-workers designed and synthesized compound <b>117</b> as a type II inhibitor of MELK (<a data-tab="pane-pcw-Figures" href="#fig42" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig42" id="" class=" internalNav">42</a></a>).<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a> The propargyloxy linker having a low steric demand traverses a narrow connecting tunnel lined by gatekeeper residue Leu86 and the DFG motif residue Phe151, allowing the aminoisoquinoline moiety to effectively interact with the hinge residues.</div><figure id="fig42" data-index="42" class="article__inlineFigure"><h2 class="fig-label">Figure 42</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0042.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0042.jpeg" id="gr42" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 42. Structure and MELK inhibitory activity of <b>117</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0042.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig42"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> Hsp90 Inhibitors <b>118</b> and <b>119</b></h4><div class="NLM_p">Heat shock protein 90 (Hsp90) is a well-established target for anticancer drug development.<a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a> Hsp90 inhibitors are primarily indicated for HER-2 positive breast cancers. Shi and colleagues began optimization of <b>118</b>,<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a> which required higher doses (100 mg twice daily) in the phase 2 clinical study.<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a> The X-ray crystal structure of <b>118</b> with Hsp90 showed that the <i>N</i>7 lone pair of <b>118</b> were facing the solvent-exposed region. Thus, the <i>N</i>7 was considered to be the desired vector for installation of various substituents. To achieve this goal, the <i>N</i>7 needed to be replaced with a carbon atom and subsequent addition of substituents such as 2-methylpent-4-yn-2-ol, which led to the more potent analogue <b>119</b> (EC144) (<a data-tab="pane-pcw-Figures" href="#fig43" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig43" id="" class=" internalNav">43</a></a>).<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a> Further <b>119</b> demonstrated improved efficacy in mice compared to <b>118</b>. The X-ray cocrystal structure of <b>119</b>-Hsp90 revealed hydrophobic interaction between the alkyne moiety and the side chain of Met98 and Leu107.</div><figure id="fig43" data-index="43" class="article__inlineFigure"><h2 class="fig-label">Figure 43</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0043.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0043.jpeg" id="gr43" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 43. Structures and activity of Hsp90 inhibitors <b>118</b> and <b>119</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0043.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig43"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> <i>Pseudomonas aeruginosa</i> Deacetylase LpxC Inhibitor <b>120</b></h4><div class="NLM_p">The zinc metallo enzyme LpxC (UDP-3-O(-acyl)-<i>N</i>-acetylglucosamine deacetylase) is necessary for the growth of several Gram-negative bacteria, including <i>P. aeruginosa</i>.<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a> Compound <b>120</b>, a potent inhibitor of LpxC, showed substantial antipseudomonal activity in both in vitro and in vivo studies (<a data-tab="pane-pcw-Figures" href="#fig44" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig44" id="" class=" internalNav">44</a></a>).<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a> The X-ray crystal structure of <i>P. aeruginosa</i> LpxC bound to <b>120</b> confirmed favorable binding of the butynyl ether tail moiety into a hydrophobic tunnel by engaging with Ile197.</div><figure id="fig44" data-index="44" class="article__inlineFigure"><h2 class="fig-label">Figure 44</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0044.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0044.jpeg" id="gr44" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 44. Structure and in vitro potency of LpxC inhibitor <b>120</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0044.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig44"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> <i>Pseudomonas aeruginosa</i> Deacetylase LpxC Inhibitors <b>121</b>−<b>123</b></h4><div class="NLM_p">Lee and colleagues described development of a novel LpxC inhibitor <b>121</b> with picomolar <i>K</i><sub>d</sub> value against <i>P. aeruginosa</i>.<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> Importance of an alkyne moiety in <b>121</b> and <b>123</b> is evidenced from the less potent analogue <b>122</b> that lacks an alkyne motif (<a data-tab="pane-pcw-Figures" href="#fig45" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig45" id="" class=" internalNav">45</a></a>). The X-ray cocrystal structure of <b>121</b>-<i>P. aeruginosa</i> LpxC enzyme showed that the cyclopropylalkyne moiety forms hydrophobic interactions with the nonpolar residues of the lipophilic tunnel such that the cyclopropyl moiety extends into the solvent-exposed region of <i>P. aeruginosa</i> LpxC enzyme.</div><figure id="fig45" data-index="45" class="article__inlineFigure"><h2 class="fig-label">Figure 45</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0045.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0045.jpeg" id="gr45" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 45. Structures of LpxC inhibitors <b>121</b>–<b>123</b> and in vitro potency.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0045.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig45"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> The Design of Dimeric Smac Mimetics Through a 1,3-Bisacetylene Spacer</h4><div class="NLM_p">Second mitochondrial activator of caspases (Smac) is the endogenous inhibitor of a family of inhibitor of apoptosis proteins (IAPs). Because Smac protein is known to interact with the IAPs as a dimer,<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a> Hennessy and co-workers decided to dimerize two monomeric Smac mimetic tetrapeptide components through a sterically less demanding linear 1,3-bisacetylene spacer to obtain a clinical candidate <b>124</b> (AZD5582) (<a data-tab="pane-pcw-Figures" href="#fig46" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig46" id="" class=" internalNav">46</a></a>).<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a> Compound <b>124</b> simultaneously binds to both baculovirus IAP repeat (BIR2 and BIR3) domains of X chromosome-linked inhibitor of apoptosis (XIAP) and thus disrupt the interactions between XIAP and caspases, which leads to apoptosis.</div><figure id="fig46" data-index="46" class="article__inlineFigure"><h2 class="fig-label">Figure 46</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0046.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0046.jpeg" id="gr46" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 46. Structure and in vitro potency of Smac mimetic dimer <b>124</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0046.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig46"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> Tazarotene (<b>126</b>)</h4><div class="NLM_p">Compound <b>126</b> belong to a conformationally constrained nonisomerizable topical retinoids. All-<i>trans</i>-retinoic acid (<b>125</b>/tretinoin) is nonselective toward retinoid receptors due to its relatively flexible conformation. Consequently, tazarotene (<b>126</b>) structure featuring the thiocroman and pyridine rings and a connecting acetylene bridge offer restricted conformation and thus demonstrate receptor selectivity toward RARβ and RARγ (<a data-tab="pane-pcw-Figures" href="#fig47" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig47" id="" class=" internalNav">47</a></a>).<a onclick="showRef(event, 'ref133 ref134'); return false;" href="javascript:void(0);" class="ref ref133 ref134">(133,134)</a></div><figure id="fig47" data-index="47" class="article__inlineFigure"><h2 class="fig-label">Figure 47</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0047.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0047.jpeg" id="gr47" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 47. Structures of tretinoin (<b>125</b>) and tazarotene (<b>126</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0047.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig47"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> Ethyne as a Latent Electrophile for Irreversible Inhibitor Design</h3><div class="NLM_p">The development of covalent inhibitors with high selectivity toward a desired target has increasingly becoming popular in the clinic due to (1) enhanced biochemical efficiency, (2) beneficial PK profile, (3) longer duration of action because recovery of target protein activity is only possible through de novo synthesis, which allows for low treatment doses, and (4) efficient approach in situations where a complete loss of target function is desired.<a onclick="showRef(event, 'ref135'); return false;" href="javascript:void(0);" class="ref ref135">(135)</a> However, the use of highly reactive electrophilic warheads can potentially lead to indiscriminate covalent modification of off-target proteins and concurrent idiosyncratic toxicity. Therefore, the use of less reactive electrophilic warhead groups such as alkyne functionality is of particular interest as evident from the following selected examples.</div><div id="sec2_5_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> Covalent Inhibitors of Bruton Tyrosine Kinase (<b>127</b>–<b>129</b>)</h4><div class="NLM_p">Acalabrutinib (<b>127</b>),<a onclick="showRef(event, 'ref136'); return false;" href="javascript:void(0);" class="ref ref136">(136)</a> tirabrutinib (<b>128</b>),<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a> and branebrutinib (<b>129</b>)<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a> featuring butynamide warhead group are small-molecule irreversible inhibitors of anticancer target, bruton tyrosine kinase (BTK). As an example, the reactive butynamide warhead in <b>127</b> covalently reacts with the thiol of Cys481 at the rim of the BTK active site (<a data-tab="pane-pcw-Figures" href="#fig48" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig48" id="" class=" internalNav">48</a></a>).<a onclick="showRef(event, 'ref136'); return false;" href="javascript:void(0);" class="ref ref136">(136)</a> Compared to the more reactive warheads known to target Cys residues of various kinases, butynamides appear to exhibit reduced reactivity and as a result limit inhibition of off-target kinases having analogous cysteine residues.</div><figure id="fig48" data-index="48" class="article__inlineFigure"><h2 class="fig-label">Figure 48</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0048.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0048.jpeg" id="gr48" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 48. Structures of BTK inhibitors <b>127</b>–<b>129</b> and covalent mechanism of action.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0048.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig48"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> Covalent Nek2 Inhibitor <b>130</b></h4><div class="NLM_p">Overexpression of Nek2 has been linked with a number of cancers, including primary breast tumors<a onclick="showRef(event, 'ref139'); return false;" href="javascript:void(0);" class="ref ref139">(139)</a> and diffuse large B-cell lymphoma.<a onclick="showRef(event, 'ref140'); return false;" href="javascript:void(0);" class="ref ref140">(140)</a> Thus, Nek2 inhibitors are potentially useful as anticancer agents. Henise and co-workers developed the first cell-active irreversible propynamide-based Nek2 inhibitor <b>130</b> (<a data-tab="pane-pcw-Figures" href="#fig49" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig49" id="" class=" internalNav">49</a></a>).<a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(141)</a> Compound <b>130</b> has been shown to label Cys22 within the active site of Nek2 as evidenced from the mass spectrometry analysis. Further, it failed to label C22V mutant Nek2, which suggest its site-specific labeling ability.</div><figure id="fig49" data-index="49" class="article__inlineFigure"><h2 class="fig-label">Figure 49</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0049.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0049.jpeg" id="gr49" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 49. Structure and covalent mechanism of Nek2 kinase inhibitor <b>130</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0049.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig49"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> Irreversible p97 Inhibitor <b>131</b></h4><div class="NLM_p">Adenosine triphosphatase p97 has been actively pursued as an anticancer target.<a onclick="showRef(event, 'ref142 ref143'); return false;" href="javascript:void(0);" class="ref ref142 ref143">(142,143)</a> Ding and co-workers<a onclick="showRef(event, 'ref144'); return false;" href="javascript:void(0);" class="ref ref144">(144)</a> developed butynamide warhead-containing compound <b>131</b> as a Cys522 targeted irreversible inhibitor of p97 (<a data-tab="pane-pcw-Figures" href="#fig50" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig50" id="" class=" internalNav">50</a></a>). Proposed binding models and site-directed mutagenesis experiments validated labeling of Cys522 by compound <b>131</b>.</div><figure id="fig50" data-index="50" class="article__inlineFigure"><h2 class="fig-label">Figure 50</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0050.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0050.jpeg" id="gr50" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 50. Structure and covalent mechanism of p97 inhibitor <b>131</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0050.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig50"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> EGFR Cys797 Targeted Inhibitor <b>132</b></h4><div class="NLM_p">Wood and colleagues designed a thienopyrimidine derivative <b>132</b> featuring an ethynyl pyrrolidine warhead as a Cys797 targeted covalent inhibitor of anticancer target EGFR.<a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">(145)</a> The covalent complex shown in <a data-tab="pane-pcw-Figures" href="#fig51" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig51" id="" class=" internalNav">51</a></a> was deduced based on the mass spectrometry analysis.</div><figure id="fig51" data-index="51" class="article__inlineFigure"><h2 class="fig-label">Figure 51</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0051.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0051.jpeg" id="gr51" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 51. Structure and covalent mechanism of EGFR kinase inhibitor <b>132</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0051.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig51"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> <i>N</i>-Propargyl Amides as Covalent Inhibitors of Cysteinyl Proteases</h4><div class="NLM_p">Arkona and co-workers investigated the suitability of <i>N</i>-propargylamides as active site cysteine targeted irreversible inhibitors of cysteinyl proteases.<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a> For example, the C-terminal propargylamide derivative of ubiquitin irreversibly inhibited deubiquitinating enzyme (DUB) isopeptidase in a stoichiometric manner (<a data-tab="pane-pcw-Figures" href="#fig52" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig52" id="" class=" internalNav">52</a></a>A and <a data-tab="pane-pcw-Figures" href="#fig52" id="" class=" internalNav">52</a>B). Addition of a terminal methyl group or a <i>gem</i>-dimethyl moiety on a propargyl unit prevented the thiol addition reaction as shown in <a data-tab="pane-pcw-Figures" href="#fig52" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig52" id="" class=" internalNav">52</a></a>C.<a onclick="showRef(event, 'ref147'); return false;" href="javascript:void(0);" class="ref ref147">(147)</a> This underscores the context-dependent change in the reactivity of an alkyne group toward the active site cysteine residue.</div><figure id="fig52" data-index="52" class="article__inlineFigure"><h2 class="fig-label">Figure 52</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0052.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0052.jpeg" id="gr52" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 52. (A) DUB-mediated cleavage of the ubiquitin isopeptide bond. Isopeptide amide carbon activated by oxyanion hole residues is nucleophilically attacked by the thiolate anion. (B) Active site-directed covalent inhibitor undergoes similar type of reaction to inhibit DUB in an irreversible manner. (C) Increasing steric bulk at the propargyl unit leads to decreased reactivity toward cysteine.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0052.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig52"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> Transforming Reversible Cathepsin K (CatK) Inhibitor <b>133</b> to Latent Electrophile-Containing Irreversible Inhibitor <b>134</b></h4><div class="NLM_p">Cysteinyl protease CatK overexpressed in osteoclasts is involved in bone degradation.<a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(148)</a> Therefore, small-molecule inhibitors of CatK are useful for the treatment of osteoporosis. To offset idiosyncratic toxicity associated with highly reactive electrophilic groups in irreversible inhibitors, Mons and co-workers developed CatK inhibitors, containing less reactive warheads such as <i>N</i>-propargylamide.<a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(149)</a> Compound <b>133</b> (odanacatib) is a highly selective reversible covalent inhibitor of CatK due to the presence of a cysteine reactive nitrile group. These investigators conveniently replaced the nitrile group in <b>133</b> with an alkyne isostere, however, they noticed decreased aqueous solubility. This problem was resolved by removing hydrophobic spirocyclopropyl moiety, leading to <b>134</b> that exhibited less electrophilic <i>N</i>-propargyl amide warhead compared to widely known acrylamide warheads. Compound <b>134</b> was able to form irreversible thioether bond by in situ thiol-alkyne addition. The X-ray crystal structure studies confirmed the formation of a covalent thiol adduct at Cys25 (<a data-tab="pane-pcw-Figures" href="#fig53" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig53" id="" class=" internalNav">53</a></a>).</div><figure id="fig53" data-index="53" class="article__inlineFigure"><h2 class="fig-label">Figure 53</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0053.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0053.jpeg" id="gr53" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 53. Structures of reversible covalent inhibitor <b>133</b> and irreversible inhibitor <b>134</b> and its covalent mechanism of action.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0053.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig53"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> Dihydropyrimidine Dehydrogenase (DHPDHase) Inactivating Compound <b>135</b></h4><div class="NLM_p">DHPDHase catalyzes reversible reduction of pyrimidines to 5,6-dihydropyrimidines as the first step to generate β-amino acids. Therefore, DHPDHase has been considered as a key target for modulation of 5-fluorouracil chemotherapy. Porter and colleagues reported mechanism-based inactivation of DHPDHase by a novel 5-ethynyluracil analogue (<b>135</b>) (<a data-tab="pane-pcw-Figures" href="#fig54" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig54" id="" class=" internalNav">54</a></a>).<a onclick="showRef(event, 'ref150'); return false;" href="javascript:void(0);" class="ref ref150">(150)</a> Among various C5-substituents such as ethynyl (<i>k</i><sub>inact,app</sub>/min = 5.64), diazo (<i>k</i><sub>inact,app</sub>/min = 1.68), cyano (<i>k</i><sub>inact,app</sub>/min = 0.78), bromovinyl (<i>k</i><sub>inact,app</sub>/min = 0.60), propynyl (<i>k</i><sub>inact,app</sub>/min = 0.46), bromo (<i>k</i><sub>inact,app</sub>/min = 0.42), and trifluoromethyl (<i>k</i><sub>inact,app</sub>/min = 0.23), ethynyl substituent produced the fastest rate of inactivation of DHPDHase. By comparing the rate of inactivation by ethyne versus propyne analogues, one would conclude that C≡C triple bond demonstrate context-dependent reactivity toward endogenous nucleophiles.</div><figure id="fig54" data-index="54" class="article__inlineFigure"><h2 class="fig-label">Figure 54</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0054.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0054.jpeg" id="gr54" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 54. Structure and the covalent mechanism of DHPDHase inhibitor <b>135</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0054.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig54"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> LSD1 Inhibitor <b>136</b></h4><div class="NLM_p">The lysine specific demethylase 1 (LSD1) play a key role in androgen dependent gene expression and has been shown to become overexpressed in prostate cancers.<a onclick="showRef(event, 'ref151'); return false;" href="javascript:void(0);" class="ref ref151">(151)</a> Therefore, LSD1 inhibitors are useful for the treatment of hormone-dependent cancers. Consequently, Schmitt and co-workers began development of covalent LSD1 inhibitors using MAO inhibitory propargylamine as an initial structural core.<a onclick="showRef(event, 'ref152'); return false;" href="javascript:void(0);" class="ref ref152">(152)</a> Compound <b>136</b> showed dual inhibition of LSD1 and MAO-B enzymes (<a data-tab="pane-pcw-Figures" href="#fig55" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig55" id="" class=" internalNav">55</a></a>). Computational docking of <b>136</b> within the active site of LSD1 indicated the proximity of <i>N</i>-propargylamine group to the reactive <i>N</i>5 of the FAD cofactor. Preincubation of <b>136</b> with LSD1 and subsequent dilution resulted in loss of enzyme activity, thus confirming the irreversible mechanism of inhibition.</div><figure id="fig55" data-index="55" class="article__inlineFigure"><h2 class="fig-label">Figure 55</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0055.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0055.jpeg" id="gr55" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 55. Structure and covalent mechanism of LSD1 inhibitor <b>136</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0055.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig55"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> Covalent Inhibitors (<b>137</b>–<b>139</b>) of Monoamine Oxidase B (MAO-B)</h4><div class="NLM_p">MAO-B inhibitors are useful in the treatment of depression and Parkinson’s disease. Clinically useful propargyl-containing MAO-B inhibitors such as <b>137</b> (selegiline), <b>138</b> (rasagiline), and <b>139</b> (pargyline) irreversibly inhibits MAO-B by forming adduct between its terminal acetylene CH and the <i>N</i>5 of FAD cofactor (<a data-tab="pane-pcw-Figures" href="#fig56" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig56" id="" class=" internalNav">56</a></a>).<a onclick="showRef(event, 'ref153'); return false;" href="javascript:void(0);" class="ref ref153">(153)</a> This covalent binding mechanism was further supported by X-ray crystal structure studies.<a onclick="showRef(event, 'ref154'); return false;" href="javascript:void(0);" class="ref ref154">(154)</a></div><figure id="fig56" data-index="56" class="article__inlineFigure"><h2 class="fig-label">Figure 56</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0056.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0056.jpeg" id="gr56" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 56. Structures and covalent mechanism of MAO-B inhibitors <b>137</b>–<b>139</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0056.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig56"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> Propargylamine-Derived Multitarget-Directed Ligands (MTDLs) in the Treatment of Neurodegenerative Diseases</h4><div class="NLM_p">Single-target-directed drugs exert less than desirable therapeutic effect in patients with Alzheimer’s disease (AD).<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a> This is not surprising because progress and development of AD involves an interplay of multiple biochemical targets, including acetylcholinesterase (AChE),<a onclick="showRef(event, 'ref156'); return false;" href="javascript:void(0);" class="ref ref156">(156)</a> monoamine oxidase (MAO),<a onclick="showRef(event, 'ref157'); return false;" href="javascript:void(0);" class="ref ref157">(157)</a> biometal ions (iron, copper and zinc),<a onclick="showRef(event, 'ref158'); return false;" href="javascript:void(0);" class="ref ref158">(158)</a> oxidative stress,<a onclick="showRef(event, 'ref159'); return false;" href="javascript:void(0);" class="ref ref159">(159)</a> amyloid β aggregation and plaque formation,<a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(160)</a> apoptosis,<a onclick="showRef(event, 'ref161'); return false;" href="javascript:void(0);" class="ref ref161">(161)</a> inflammatory cytokines,<a onclick="showRef(event, 'ref162'); return false;" href="javascript:void(0);" class="ref ref162">(162)</a> and adenosine receptors.<a onclick="showRef(event, 'ref163'); return false;" href="javascript:void(0);" class="ref ref163">(163)</a> Consequently, the design strategy for MTDLs has gained increasing acceptance for the discovery of novel therapies to treat multifactorial AD. The MTDLs design strategy involves molecular hybridization of different pharmacophoric moieties of different drugs in the same structure with the assumption that individual pharmacophore will engage intended target site. The propargylamine-containing MAO inhibitors produce neuroprotective effect through biochemical mechanisms, such as antioxidant,<a onclick="showRef(event, 'ref164'); return false;" href="javascript:void(0);" class="ref ref164">(164)</a> antiapoptotic activity, anti-inflammatory, and promoting nonamyloidogenic pathway,<a onclick="showRef(event, 'ref165'); return false;" href="javascript:void(0);" class="ref ref165">(165)</a> besides their potential to increase amine neurotransmission. Therefore, all of the MTDLs discovered so far possess one common MAO-inhibitory pharmacophore, i.e., propargylamine moiety (<a data-tab="pane-pcw-Figures" href="#fig57" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig57" id="" class=" internalNav">57</a></a>).</div><figure id="fig57" data-index="57" class="article__inlineFigure"><h2 class="fig-label">Figure 57</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0057.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0057.jpeg" id="gr57" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 57. Structures of multifunctional anti-AD compounds <b>140</b>–<b>148</b>. ee, <i>Electrophorus electricus</i>; eq, equine; hr, human recombinant.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0057.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig57"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Compound <b>140</b> is synthesized and evaluated as a potent and selective inhibitor of MAO-B that also exhibited neuroprotective effect in animal models.<a onclick="showRef(event, 'ref166'); return false;" href="javascript:void(0);" class="ref ref166">(166)</a> Compound <b>141</b> was designed as a potent dual MAO and AChE inhibitor by combining the MAO inhibitory and neuroprotective activities of <b>140</b> and AChE inhibitory pharmacophore <i>N</i>-benzylpiperidine.<a onclick="showRef(event, 'ref167'); return false;" href="javascript:void(0);" class="ref ref167">(167)</a> Compound <b>142</b> (ladostigil), failed in phase 2b clinical trials, was developed as a dual inhibitor by combining MAO inhibitory propargylamine moiety and cholinesterase inhibitory carbamate moiety.<a onclick="showRef(event, 'ref168'); return false;" href="javascript:void(0);" class="ref ref168">(168)</a> Apart from MAO and cholinesterase inhibitory properties, <b>142</b> showed antiapoptotic and neuroprotective activity that is unrelated to its MAO inhibitory activity.<a onclick="showRef(event, 'ref169'); return false;" href="javascript:void(0);" class="ref ref169">(169)</a> Compound <b>142</b> contain a chiral center, and its activity resides in the (<i>R</i>)-enantiomer. Further, its carbamate group is known to undergo hydrolytic degradation to a metabolite that possess neuroprotective activity but lack cholinesterase inhibitory activity. To circumvent these problems, Denya and colleagues<a onclick="showRef(event, 'ref170'); return false;" href="javascript:void(0);" class="ref ref170">(170)</a> designed a structurally similar analogue <b>143</b> that replaces the indane ring with the indole ring to eliminate chiral center and the carbamate group with a stable diethylurea group. Compound <b>143</b> demonstrated superior dual inhibitory activity toward cholinesterase and MAO enzymes compared to <b>142</b>. Cholinesterase inhibitory tacrine ring amino substituent was hybridized with MAO inhibitory propargylamine-containing motif to obtain dual inhibitor <b>144</b>. Compound <b>144</b> demonstrated nanomolar potency against cholinesterase and MAO.<a onclick="showRef(event, 'ref171'); return false;" href="javascript:void(0);" class="ref ref171">(171)</a> Wang and colleagues<a onclick="showRef(event, 'ref172'); return false;" href="javascript:void(0);" class="ref ref172">(172)</a> synthesized and evaluated a novel class of multifunctional anti-AD agents by combining <i>N</i>-benzylpiperidine, <i>N</i>-propargylamine, and 8-hydroxyquinoline structural features that target cholinesterase, MAO, and neuroprotective biometal chelation, respectively. These efforts led to the identification of compound <b>145</b>, with potent inhibition of cholinesterase and MAO and efficient biometal ion chelation. Further continuation of this design strategy led to compound <b>146</b> with improved cholinesterase inhibitory potency and selectivity toward MAO-A over MAO-B and retention of biometal chelation property.<a onclick="showRef(event, 'ref173'); return false;" href="javascript:void(0);" class="ref ref173">(173)</a> Bautista-Aguilera and co-workers<a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(174)</a> synthesized a dual inhibitor <b>147</b> by molecular hybridization of AChE and MAO inhibitory pharmacophores. Because adenosine receptor antagonism contribute to neuroprotective action, Koch and colleagues<a onclick="showRef(event, 'ref175'); return false;" href="javascript:void(0);" class="ref ref175">(175)</a> synthesized a bifunctional compound <b>148</b> that has adenosine receptor targeting tetrahydropyrimidopurinedione pharmacophore and MAO-targeting <i>N</i>-propargyl moiety (<a data-tab="pane-pcw-Figures" href="#fig57" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig57" id="" class=" internalNav">57</a></a>).</div></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i66">Acetylene-Containing Natural Products</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_84088" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_84088" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">More than 1000 alkyne-containing natural products or natural product derived compounds have been reported.<a onclick="showRef(event, 'ref176'); return false;" href="javascript:void(0);" class="ref ref176">(176)</a> Herein, a representative set of natural products or their semisynthetic counterparts are described to reflect upon alkyne presence in nature.</div><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> Discovery of Ironomycin (<b>150</b>)</h3><div class="NLM_p">Salinomycin (<b>149</b>) is a monocarboxylic acid-containing polyether with cell membrane ionophore activity.<a onclick="showRef(event, 'ref177'); return false;" href="javascript:void(0);" class="ref ref177">(177)</a> Ironomycin (<b>150</b>), a semisynthetic analogue, is derived from <b>149</b> by substituting a hydroxyl group with a propargylamine moiety (<a data-tab="pane-pcw-Figures" href="#fig58" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig58" id="" class=" internalNav">58</a></a>). This molecular modification led to an order of magnitude higher potency than <b>149</b> for killing breast cancer stem cells in vitro and in vivo.<a onclick="showRef(event, 'ref178'); return false;" href="javascript:void(0);" class="ref ref178">(178)</a> The ability of compound <b>150</b> to kill cancer stem cells is derived from the accumulation and sequestration of iron in lysosomes and from the subsequent production of reactive oxygen species and lysosomal membrane permeabilization.<a onclick="showRef(event, 'ref178'); return false;" href="javascript:void(0);" class="ref ref178">(178)</a></div><figure id="fig58" data-index="58" class="article__inlineFigure"><h2 class="fig-label">Figure 58</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0058.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0058.jpeg" id="gr58" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 58. Structures of natural product <b>149</b> and its semisynthetic derivative <b>150</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0058.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig58"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Hitora and colleagues reported six cytotoxic durynes isolated from the marine sponge <i>Petrosia</i> sp.<a onclick="showRef(event, 'ref179'); return false;" href="javascript:void(0);" class="ref ref179">(179)</a> The most potent cytotoxic homologue duryne E (<b>151</b>) is shown <a data-tab="pane-pcw-Figures" href="#fig59" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig59" id="" class=" internalNav">59</a></a>. Sanchez and co-workers isolated the cyanobacterial natural product almiramide B (<b>152</b>) with antiparasitic activity against <i>Leishmania donovani</i> (<a data-tab="pane-pcw-Figures" href="#fig59" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig59" id="" class=" internalNav">59</a></a>).<a onclick="showRef(event, 'ref180'); return false;" href="javascript:void(0);" class="ref ref180">(180)</a> Kurahyne (<b>153</b>), an acetylene-containing lipopeptide isolated from the cyanobacteria has shown growth inhibitory activity toward human cancer cells and an ability to induce apoptosis in HeLa cells (<a data-tab="pane-pcw-Figures" href="#fig59" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig59" id="" class=" internalNav">59</a></a>).<a onclick="showRef(event, 'ref181'); return false;" href="javascript:void(0);" class="ref ref181">(181)</a> Viridamide A (<b>154</b>), isolated from the marine cyanobacterium <i>Oscillatoria nigro-viridis</i>, has shown antileishmanial and antitrypanosomal activity in low micromolar concentrations (<a data-tab="pane-pcw-Figures" href="#fig59" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig59" id="" class=" internalNav">59</a></a>).<a onclick="showRef(event, 'ref182'); return false;" href="javascript:void(0);" class="ref ref182">(182)</a> Companeramide A (<b>155</b>), isolated from a Panamanian marine cyanobacterium, has demonstrated inhibitory activity against <i>Plasmodium falciparum</i> Dd2 strain in nanomolar range (<a data-tab="pane-pcw-Figures" href="#fig59" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig59" id="" class=" internalNav">59</a></a>).<a onclick="showRef(event, 'ref183'); return false;" href="javascript:void(0);" class="ref ref183">(183)</a></div><figure id="fig59" data-index="59" class="article__inlineFigure"><h2 class="fig-label">Figure 59</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0059.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0059.jpeg" id="gr59" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 59. Examples of natural products <b>151</b>–<b>155</b> and associated in vitro potency.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0059.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig59"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Chai and co-workers have recently reviewed a number of alkyne-containing peptides of natural origin.<a onclick="showRef(event, 'ref184'); return false;" href="javascript:void(0);" class="ref ref184">(184)</a></div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68"> Enediyne-Based Natural Products</h3><div class="NLM_p">The enediyne unit is a structural element of several clinically useful natural products as described below. The potent anticancer effect of these natural products is derived from their highly reactive enediyne unit, which either cleaves or cross-links genomic DNA by a novel molecular mechanism.</div><div id="sec3_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> Calicheamicin (<b>156</b>)</h4><div class="NLM_p">Compound <b>156</b> is a group of enediyne-containing antibiotics derived from microbial cultures. The enediyne chromophore is an essential component of a strained 10-membered ring that also present a methyl trisulfide moiety.<a onclick="showRef(event, 'ref185 ref186'); return false;" href="javascript:void(0);" class="ref ref185 ref186">(185,186)</a> This class of naturally occurring compounds has been extensively investigated as anticancer agents. Compound <b>156</b> contains three components: (1) a polysaccharide unit that facilitates the enediyne docking into the minor groove of DNA, (2) a trigger devise containing a methyl trisulfide group next to the conjugated cyclohexenone, and (3) a DNA targeting enediyne reactive antitumor warhead (<a data-tab="pane-pcw-Figures" href="#fig60" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig60" id="" class=" internalNav">60</a></a>). GSH initiates nucleophilic attack on the trisulfide moiety to produce an intramolecular Michael addition intermediate, which, in turn, leads to contraction of the enediyne ring system and subsequent Bergman cyclization<a onclick="showRef(event, 'ref187'); return false;" href="javascript:void(0);" class="ref ref187">(187)</a> of the enediyne component. A reactive <i>para</i>-didehydrobenzene diradical is generated and subsequently positioned to abstract two proximal hydrogens from the deoxyribose sugars on each strand of DNA and thus cause the cleavage of the double-stranded DNA and cell death while forming a stable arene byproduct (<a data-tab="pane-pcw-Figures" href="#fig60" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig60" id="" class=" internalNav">60</a></a>).<a onclick="showRef(event, 'ref188'); return false;" href="javascript:void(0);" class="ref ref188">(188)</a></div><figure id="fig60" data-index="60" class="article__inlineFigure"><h2 class="fig-label">Figure 60</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0060.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0060.jpeg" id="gr60" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 60. Structure and covalent mechanism of <b>156</b> (calicheamicin).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0060.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig60"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> Dynemicin A (<b>157</b>)</h4><div class="NLM_p">Compound <b>157</b> is a member of enediyne warhead-containing antitumor antibiotics. It is comprised of a highly strained 10-membered carbocycle fused to a highly oxidized planar anthraquinone chromophore. It was originally obtained from the cultures of <i>Micromonospora chersina</i>.<a onclick="showRef(event, 'ref189'); return false;" href="javascript:void(0);" class="ref ref189">(189)</a> Opening of the reactive epoxide group of the anthraquinone chromophore by bioreductive GSH or NADPH cofactors<a onclick="showRef(event, 'ref190'); return false;" href="javascript:void(0);" class="ref ref190">(190)</a> serves as a device that triggers Bergman cycloaromatization.<a onclick="showRef(event, 'ref187'); return false;" href="javascript:void(0);" class="ref ref187">(187)</a> The enediyne bridge has been shown to position toward the minor groove of the double-stranded DNA. Therefore, <b>157</b> is an example of a naturally occurring prodrug equipped with a triggering device that undergoes activation under physiological conditions. Dynemicin A frequently cut the 3′-ends of purine (adenine and guanine), which is markedly different from the cutting sites of calicheamicin. Initially, the anthraquinone ring intercalates between the adjacent bases of a DNA helix and, subsequently, phenyl diradical generated from the enediyne warhead attacks the DNA strands and triggers their cleavage. Compound <b>157</b> appears to cleave DNA strands via both alkylation and hydrogen atom abstraction (<a data-tab="pane-pcw-Figures" href="#fig61" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig61" id="" class=" internalNav">61</a></a>).</div><figure id="fig61" data-index="61" class="article__inlineFigure"><h2 class="fig-label">Figure 61</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0061.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0061.jpeg" id="gr61" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 61. Structure and covalent mechanism of dynemicin A (<b>157</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0061.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig61"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> Inotuzumab Ozogamicin (<b>158</b>)</h4><div class="NLM_p">It is a CD22-targeted antibody–drug conjugate (ADC) that includes three elements: (1) inotuzumab, a human CD22-specific IgG4 κ antibody, (2) <i>N</i>-acetyl-γ-calicheamicin that is responsible for initiating double-stranded DNA breaks similar to that described for calicheamicin, and (3) an acid-cleavable linker, which itself is a condensation product of 4-(4′-acetylphenoxy)-butanoic acid and 3-methyl-3-mercaptobutane hydrazide, facilitates covalent attachment of the <i>N</i>-acetyl-γ-calicheamicin to inotuzumab (<a data-tab="pane-pcw-Figures" href="#fig62" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig62" id="" class=" internalNav">62</a></a>).<a onclick="showRef(event, 'ref191'); return false;" href="javascript:void(0);" class="ref ref191">(191)</a> It is approved for the treatment of CD22-positive relapsed or refractory B-cell precursor acute lymphoblastic leukemia.</div><figure id="fig62" data-index="62" class="article__inlineFigure"><h2 class="fig-label">Figure 62</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0062.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0062.jpeg" id="gr62" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 62. Structures of <b>158</b> (inotuzumab ozogamicin) and <b>159</b> (gemtuzumab ozogamicin).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0062.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig62"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> Gemtuzumab Ozogamicin (<b>159</b>)</h4><div class="NLM_p last">It is an ADC comprised of CD33-directed monoclonal antibody that is covalently linked to a highly cytotoxic DNA strand breaking <i>N</i>-acetyl-γ-calicheamicin (<a data-tab="pane-pcw-Figures" href="#fig62" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig62" id="" class=" internalNav">62</a></a>). The molecular mechanism of activation of this ADC is akin to that of calicheamicin. It contains an average of 2–3 moles of calicheamicin derivatives per mole of gemtuzumab.<a onclick="showRef(event, 'ref191'); return false;" href="javascript:void(0);" class="ref ref191">(191)</a> It is approved for the treatment of CD33-positive acute myeloid leukemia.</div></div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i73">The Downsides of the Ethynyl Group in Medicinal Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_62624" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_62624" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The liver plays a key role in the metabolism and clearance of drugs through conversion to hydrophilic metabolites that are easier to excrete. This role is enabled by an abundance of drug metabolizing enzymes with which the liver is equipped and among which the cytochrome P450 (CYP450) plays a key role. It is recognized that CYP450-catalyzed reactions oftentimes produce metabolites that are more reactive than the original drug. Drug-induced liver injury results in ∼2700 deaths each year in the U.S. alone.<a onclick="showRef(event, 'ref192'); return false;" href="javascript:void(0);" class="ref ref192">(192)</a> A representative group of acetylene-containing FDA approved drugs are presented here to demonstrate the mechanism-based inactivation of CYP450 enzymes (<a data-tab="pane-pcw-Figures" href="#fig63" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig63" id="" class=" internalNav">63</a></a>). A terminal acetylene group can alkylate the prosthetic heme chromophore or an active site nucleophilic amino acid residues of CYP450 to cause irreversible inhibition of this metabolizing system (<a data-tab="pane-pcw-Figures" href="#fig63" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig63" id="" class=" internalNav">63</a></a>). Such an effect can occur through two potential pathways: (1) the oxidation of an internal acetylenic carbon that leads to the degradation of heme and (2) the oxidation of the terminal acetylenic carbon that covalently attaches to the nucleophilic residue at the active site while sparing heme (<a data-tab="pane-pcw-Figures" href="#fig63" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig63" id="" class=" internalNav">63</a></a>). The acetylene-containing steroidal drugs, 17α-ethynylestradiol (<b>93</b>),<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> norethindrone (<b>160</b>), and danazole (<b>91</b>)<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> inactivated hepatic CYP450 enzymes by a mechanism-based alkylation of heme pyrrole nitrogen. Time-dependent inhibition of CYP450 enzymes can produce pharmacokinetic changes in simultaneously administered drugs, thus leading to a potential risk of drug–drug interactions. Activation of an acetylene group in selegiline (<b>137</b>) was shown to selectively inactivate CYP2B1 with a <i>K</i><sub>i</sub> of 1 μM and <i>k</i><sub>inact</sub> of 0.23/min.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Mifepristone (<b>96</b>), a methyl substituted internal alkyne, potently and selectively inactivated CYP3A4 with <i>K</i><sub>i</sub> and <i>k</i><sub>inact</sub> values of 4.7 μM and 0.089/min.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a></div><figure id="fig63" data-index="63" class="article__inlineFigure"><h2 class="fig-label">Figure 63</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0063.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0063.jpeg" id="gr63" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 63. Structures and mechanism of inactivation of CYP450 by acetylene-containing steroids <b>91</b>, <b>93</b>, <b>96</b>, and <b>160</b> and MAO-B inhibitor <b>137</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0063.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig63"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Many factors were shown to influence the potency, selectivity, and heme versus protein inactivation of CYP450 enzymes, and these include size and shape of the molecule, anchoring of an acetylene group, the length of an alkyne-containing side chain, and/or the presence of a terminal hydrogen or a methyl group.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Mechanism-based inactivation of CYP450 is the most common toxicity associated with the alkyne-containing drugs. Consequently, preclinical evaluation of metabolic routes across major CYP450 isoforms and screening for reactive metabolites becomes a requirement for chemists developing alkyne-bearing compounds for eventual use as drugs.</div><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i74" class="anchor-spacer"></div><h3 class="article-section__title" id="_i74"> Glutathione (GSH) Conjugates of Positive Allosteric Modulators (PAMs) of Metabotropic Glutamate Receptor Subtype 5 (mGluR5)</h3><div class="NLM_p">Several mGluR5 PAMs that contain an acetylene group are susceptible toward the formation of GSH conjugates. However, it was observed that the presence of a substituent near an acetylene group controls their reactivity toward thiols.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> An acetylene group adjacent to an electron-withdrawing <i>N</i>-containing heteroaromatic ring as in <b>161</b> was substantially conjugated with GSH because of its increased electrophilic character. In contrast, the cyclohexyl substituted acetylene derivative <b>162</b> did not undergo any GSH conjugation due to the diminished electrophilicity of its acetylene group. These observations highlight the importance of the electronic property of an acetylene group toward its reactivity with the thiols (<a data-tab="pane-pcw-Figures" href="#fig64" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig64" id="" class=" internalNav">64</a></a>).</div><figure id="fig64" data-index="64" class="article__inlineFigure"><h2 class="fig-label">Figure 64</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0064.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0064.jpeg" id="gr64" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 64. Structures of mGluR5 PAMs <b>161</b> and <b>162</b> and the mechanism of conjugation of <b>161</b> with GSH.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0064.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig64"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i75" class="anchor-spacer"></div><h3 class="article-section__title" id="_i75"> HIV-1 Reverse Transcriptase Inhibitor <b>163</b> (Efavirenz)</h3><div class="NLM_p">Compound <b>163</b> contains an acetylene group as a key pharmacophore element. After hydroxylation on the carbon next to the triple bond, <b>163</b> was shown in rats to undergo reaction with GSH to form conjugate at an internal acetylene group (<a data-tab="pane-pcw-Figures" href="#fig65" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig65" id="" class=" internalNav">65</a></a>).<a onclick="showRef(event, 'ref193'); return false;" href="javascript:void(0);" class="ref ref193">(193)</a> The GSH conjugate has been reported to produce nephrotoxicity in rats.<a onclick="showRef(event, 'ref194'); return false;" href="javascript:void(0);" class="ref ref194">(194)</a></div><figure id="fig65" data-index="65" class="article__inlineFigure"><h2 class="fig-label">Figure 65</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0065.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0065.jpeg" id="gr65" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 65. Structure and rat-specific mechanism of inactivation of GSH by <b>163</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0065.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig65"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i76" class="anchor-spacer"></div><h3 class="article-section__title" id="_i76"> Time-Dependent Inactivation of CYP3A4 by <b>4</b> (Erlotinib)</h3><div class="NLM_p">Compound <b>4</b>, featuring a terminal alkyne, undergoes CYP3A4-mediated metabolism to produce two reactive metabolites (oxirene and ketene) that cause time-dependent inhibition of CYP3A4.<a onclick="showRef(event, 'ref195 ref196'); return false;" href="javascript:void(0);" class="ref ref195 ref196">(195,196)</a> These reactive metabolites eventually give rise to the stable acetic acid metabolite (<a data-tab="pane-pcw-Figures" href="#fig66" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig66" id="" class=" internalNav">66</a></a>).</div><figure id="fig66" data-index="66" class="article__inlineFigure"><h2 class="fig-label">Figure 66</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0066.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0066.jpeg" id="gr66" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 66. Structure and mechanism of time-dependent inhibition of CYP3A4 by <b>4</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0066.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig66"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i77">Acetylene as a Probe in Chemical Biology Research</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_45357" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_45357" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Determination of macromolecular level mechanism of a ligand molecule, which involves identification of target binding partners and off-target binding events, has become a critical area of research in chemical biology. Insertion of a molecular handle such as alkyne or azide allows for detection of target binding proteins in a cellular proteome via fluorescence read out or affinity purification and subsequent mass spectrometric analysis. Consequently, copper-(I)-catalyzed 1,2,3-triazole ring formation plays a key role in numerous chemical biology studies, including activity-based protein profiling (ABPP), labeling of DNA, tagging living organisms, in vivo imaging, and labeling of live cells. Copper-(I)-catalyzed azide–alkyne [3 + 2] cycloaddition (CuAAC) reaction has also played a key role in generation of new chemical libraries. CuAAC reaction with polymers contributed to the field of drug delivery. Further, the CuAAC reaction has allowed generation of cyclic peptides and the development of antibody-based therapeutics.</div><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i78" class="anchor-spacer"></div><h3 class="article-section__title" id="_i78"> Activity-Based Protein Profiling (ABPP)</h3><div class="NLM_p">An elegant use of CuAAC chemistry between an acetylene handle and electrophilic reactive groups allows the identification of target proteins. ABPP is a well established chemocentric method comprising three components: (1) an electrophilic group to react covalently with nucleophiles at the active site, (2) a binding group that directs the chemical probe toward a desired protein target, and (3) a pendant secondary handle such as terminal acetylene group to monitor the expression levels and function in complex protein mixtures via click chemistry (<a data-tab="pane-pcw-Figures" href="#fig67" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig67" id="" class=" internalNav">67</a></a>).</div><figure id="fig67" data-index="67" class="article__inlineFigure"><h2 class="fig-label">Figure 67</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0067.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0067.jpeg" id="gr67" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 67. Schematic representation of the concept of ABPP. ABP reacts with target proteins and tagged with fluorescent azides via CuAAC and subsequent trypsinization and detection by LC-MS/MS.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0067.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig67"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i79" class="anchor-spacer"></div><h3 class="article-section__title" id="_i79"> Alkyne-Containing Probes Track Vancomycin-Induced Cell Wall Changes</h3><div class="NLM_p">Vancomycin-resistant enterococci (VRE) is a significant public health burden. The antimicrobial mechanism of action of vancomycin involves inhibition of peptidoglycan (PG) biosynthesis. PG contains monomeric units of disaccharides that are capped with pentapeptide chains. The pentapeptide features a terminal <span class="smallcaps smallerCapital">d</span>-Ala-<span class="smallcaps smallerCapital">d</span>-Ala dipeptide sequence. VRE bacterial cells develop resistance to vancomycin by synthesizing alternate <span class="smallcaps smallerCapital">d</span>-Ala-<span class="smallcaps smallerCapital">d</span>-lactate capped PG precursors.<a onclick="showRef(event, 'ref197 ref198'); return false;" href="javascript:void(0);" class="ref ref197 ref198">(197,198)</a> As a result, VRE bacterial cells can grow and proliferate under the pressure of vancomycin. To understand the PG structural plasticity associated with VRE cells, Pidgeon and colleagues designed and investigated the chemical probe <b>164</b>, an alkyne-containing analogue of the VRE-linked VanB ligase substrate <span class="smallcaps smallerCapital">d</span>-lactate.<a onclick="showRef(event, 'ref199'); return false;" href="javascript:void(0);" class="ref ref199">(199)</a> This probe feature an alkyne handle suitable for CuAAC click chemistry. It was anticipated that the VanB ligases will use this modified substrate to produce the <span class="smallcaps smallerCapital">d</span>-Ala-<span class="smallcaps smallerCapital">d</span>-laclick PG anchor, which was subsequently subjected to CuAAC click chemistry with an azido-fluorophore such as 6-carboxyfluorescein azide (6-FAM-azide). The development of vancomycin resistance was indicated by observing increases in the fluorescence levels (<a data-tab="pane-pcw-Figures" href="#fig68" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig68" id="" class=" internalNav">68</a></a>).</div><figure id="fig68" data-index="68" class="article__inlineFigure"><h2 class="fig-label">Figure 68</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0068.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0068.jpeg" id="gr68" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 68. Structures of <b>164</b> (<span class="smallcaps smallerCapital">d</span>-lactate) and <b>165</b> (dipeptide) probes and the corresponding click products with 6-FAM-azide. THPTA, Tris(3-hydroxypropyltriazolylmethyl)amine.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0068.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig68"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Pidgeon and colleagues hypothesized that a synthetic mimic of <span class="smallcaps smallerCapital">d</span>-Ala-<span class="smallcaps smallerCapital">d</span>-Ala terminal dipeptide unit such as probe <b>165</b> as the <span class="smallcaps smallerCapital">d</span>,<span class="smallcaps smallerCapital">d</span>-dipeptidase (VanX) substrate would allow for in vivo interrogation of VanX activity in VRE bacterial cells.<a onclick="showRef(event, 'ref200'); return false;" href="javascript:void(0);" class="ref ref200">(200)</a> Consequently, a clickable dipeptide <b>165</b> featuring an alkyne group for conducting click chemistry was designed using 6-FAM-azide (<a data-tab="pane-pcw-Figures" href="#fig68" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig68" id="" class=" internalNav">68</a></a>). A decrease in the fluorescence of this chemical probe was associated with the development of drug resistance.</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i80" class="anchor-spacer"></div><h3 class="article-section__title" id="_i80"> Alkyne-Azido-Containing Chemical Probe for Labeling Target Proteins Involved in Ebola Virus Infection</h3><div class="NLM_p">Compound <b>166</b> is a potent inhibitor of Ebola virus infection (IC<sub>50</sub> = 20 nM). It features an aromatic azide for UV-mediated photolabeling of the target proteins and a terminal acetylene handle for azide–alkyne [3 + 2] cycloaddition reaction with Alexa-fluor 488-azide. Incubation of the Niemann–Pick C1 (NPC1) protein expressing CHO cells with <b>166</b> and subsequent exposure to UV light led to <b>166</b> cross-linked proteins (<a data-tab="pane-pcw-Figures" href="#fig69" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig69" id="" class=" internalNav">69</a></a>). The cross-linked product was then subjected to click chemistry using Alexa-fluor 488-azide and analyzed by immunoblot probed with Alexa-fluor 488 antibody. This analysis led to the identification of NPC1 as the host molecular target for compound <b>166</b>.<a onclick="showRef(event, 'ref201'); return false;" href="javascript:void(0);" class="ref ref201">(201)</a></div><figure id="fig69" data-index="69" class="article__inlineFigure"><h2 class="fig-label">Figure 69</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0069.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0069.jpeg" id="gr69" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 69. Structure of NPC1-targeted compound <b>166</b> and its covalent bonding to the target protein. The covalent complexes are tagged via CuAAC using Alexa-fluor 488-azide for in gel detection.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0069.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig69"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i81" class="anchor-spacer"></div><h3 class="article-section__title" id="_i81"> Artemisinin-Derived Alkyne Chemical Probe</h3><div class="NLM_p">Reactive endoperoxide-containing artemisinins (ART, <b>167</b>) are a class of important antimalarial agents whose mechanism of action remains poorly understood. To attain this goal, Ismail and co-workers developed the ART activity-based chemical probe <b>168</b> for in situ identification of malarial parasite protein drug targets (<a data-tab="pane-pcw-Figures" href="#fig70" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig70" id="" class=" internalNav">70</a></a>).<a onclick="showRef(event, 'ref202'); return false;" href="javascript:void(0);" class="ref ref202">(202)</a> Chemical probe <b>168</b> demonstrated comparable in vitro potency and ability to alkylate target proteins of <i>Plasmodium falciparum</i> 3D7 parasites to that observed for the parent ART. Target proteins covalently tagged with ART probe were isolated via click chemistry with a trifunctional rhodamine-biotin azide in the form of conjugated 1,2,3-triazoles. These functionalized target proteins were subjected to streptavidin affinity purification, trypsin digestion on beads, and LC-MS/MS analysis, which revealed alkylated target proteins belonging to the antioxidant defense, hemoglobin degradation, glycolytic, and protein synthesis pathways. All of these pathways are critical for the survival of malarial parasites.</div><figure id="fig70" data-index="70" class="article__inlineFigure"><h2 class="fig-label">Figure 70</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0070.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0070.jpeg" id="gr70" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 70. Structures of <b>167</b> and <b>167</b>-derived ABP (<b>168</b>) and elucidation of alkylated target proteins by CuAAC click chemistry with a trifunctional tag. TCEP, Tris(2-carboxyethyl)phosphine; TBTA, Tris[(1-benzyl-1<i>H</i>-1,2,3-triazol-4-yl)methyl]amine.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0070.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig70"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i82" class="anchor-spacer"></div><h3 class="article-section__title" id="_i82"> SAHA (<b>169</b>)-Derived Activity-Based Photo-Cross-linking Chemical Probe for Histone Deacetylases</h3><div class="NLM_p">The FDA approved reversible HDAC inhibitor <b>169</b> (SAHA/vorinostat) was converted to the activity-based probe <b>170</b> by inserting a photoactivatable benzophenone moiety and an acetylene handle (<a data-tab="pane-pcw-Figures" href="#fig71" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig71" id="" class=" internalNav">71</a></a>).<a onclick="showRef(event, 'ref203 ref204'); return false;" href="javascript:void(0);" class="ref ref203 ref204">(203,204)</a></div><figure id="fig71" data-index="71" class="article__inlineFigure"><h2 class="fig-label">Figure 71</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0071.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0071.jpeg" id="gr71" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 71. Structures of HDAC inhibitor (<b>169</b>) and <b>169</b>-derived alkyne-containing photo-cross-linking probe (<b>170</b>). Alkylated proteins are tagged via CuAAC with a trifunctional rhodamine-biotin-azide for subsequent detection.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0071.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig71"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i83" class="anchor-spacer"></div><h3 class="article-section__title" id="_i83"> Clickable Transglutaminase 2 (TG2) Inhibitor (<b>171</b>)</h3><div class="NLM_p">Dafik and colleagues developed 3-bromodihydroisoxazole (DHI)-based chemical probes such as <b>171</b> for the labeling and subsequent visualization of the catalytically active transglutaminase 2 (<a data-tab="pane-pcw-Figures" href="#fig72" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig72" id="" class=" internalNav">72</a></a>).<a onclick="showRef(event, 'ref205'); return false;" href="javascript:void(0);" class="ref ref205">(205)</a> The DHI moiety functions as a warhead to covalently inhibit TG2 via thioether bond formation. A terminal aromatic acetylene handle participates in the azide–alkyne [3 + 2] cycloaddition reaction with a biotin-conjugated azide to produce triazole as a reporter group. These compounds were selective for TG2 proteins and allowed visualization of the location of active TG2 in cells using the streptavidin-conjugated form of biotin.<a onclick="showRef(event, 'ref205'); return false;" href="javascript:void(0);" class="ref ref205">(205)</a></div><figure id="fig72" data-index="72" class="article__inlineFigure"><h2 class="fig-label">Figure 72</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0072.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0072.jpeg" id="gr72" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 72. Structure of clickable TG2 inhibitor <b>171</b> and labeling and visualization of catalytically active TG2.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0072.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig72"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i84" class="anchor-spacer"></div><h3 class="article-section__title" id="_i84"> Alkyne-Containing Probes for a Covalent Labeling of CYP450s in an Activity-Dependent Manner</h3><div class="NLM_p">Wright and co-workers synthesized and functionally characterized a series of alkyne-containing probes to profile CYP450s in native biological systems.<a onclick="showRef(event, 'ref206'); return false;" href="javascript:void(0);" class="ref ref206">(206)</a> These probe molecules (<b>172</b>) represent three structural features: (1) a reactive group that covalently binds to the enzyme active site, (2) a binding group that specifically direct the probe to a desired enzyme family, and (3) a latent clickable alkyne handle to attach a reporter group for visualizing labeling events. The labeling events were detected by linking the fluorescent rhodamine-azide reporter via azide–alkyne click chemistry onto the probe–CYP450 covalent adducts (<a data-tab="pane-pcw-Figures" href="#fig73" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig73" id="" class=" internalNav">73</a></a>).</div><figure id="fig73" data-index="73" class="article__inlineFigure"><h2 class="fig-label">Figure 73</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0073.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0073.jpeg" id="gr73" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 73. Structure of the alkyne probe (<b>172</b>) and detection of alkylated CYP450s via CuAAC reaction with rhodamine-azide.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0073.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig73"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i85" class="anchor-spacer"></div><h3 class="article-section__title" id="_i85"> Natural Product Hypothemycin (<b>173</b>) Derivatized to an Alkyne for the Identification of Therapeutic Target</h3><div class="NLM_p">Hypothemycin (<b>173</b>), a polyketide natural product, covalently inhibits various human kinases.<a onclick="showRef(event, 'ref207'); return false;" href="javascript:void(0);" class="ref ref207">(207)</a> Compound <b>174</b>, a semisynthetic derivative of hypothemycin containing a terminal alkyne handle, was developed for use as a chemical probe. Because <b>173</b> showed potent trypanocidal activity, a propargyl-containing affinity probe <b>174</b> with activity equipotent to <b>173</b> was synthesized for click conjugation to rhodamine-azide or biotin-azide (<a data-tab="pane-pcw-Figures" href="#fig74" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig74" id="" class=" internalNav">74</a></a>). These chemical biology studies led to the identification of <i>Trypanosoma brucei</i> cdc2-like kinase 1 (TbCLK1) as the preferential target for hypothemycin.<a onclick="showRef(event, 'ref208'); return false;" href="javascript:void(0);" class="ref ref208">(208)</a></div><figure id="fig74" data-index="74" class="article__inlineFigure"><h2 class="fig-label">Figure 74</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0074.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0074.jpeg" id="gr74" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 74. Structures of <b>173</b> and <b>173</b>-derived alkyne affinity probe (<b>174</b>) and subsequent in gel visualization of bound target proteins by CuAAC reaction with rhodamine-azide or biotin-azide. TAMRA-azide, tetramethylrhodamine-azide.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0074.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig74"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i86" class="anchor-spacer"></div><h3 class="article-section__title" id="_i86"> Salinomycin-Derived Chemical Probe to Detect Subcellular Localization of Small Molecules</h3><div class="NLM_p">Incubation of cells with an alkyne chemical probe <b>150</b> (ironomycin) and subsequent intracellular labeling of ironomycin using in situ click chemistry conditions and Alexa-Fluor 488-azide revealed the accumulation of the compound in lysosomal compartments (<a data-tab="pane-pcw-Figures" href="#fig75" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig75" id="" class=" internalNav">75</a></a>). This result concluded that the target for ironomycin probe-precursor <b>149</b> (salinomycin) is lysosomes.<a onclick="showRef(event, 'ref178'); return false;" href="javascript:void(0);" class="ref ref178">(178)</a></div><figure id="fig75" data-index="75" class="article__inlineFigure"><h2 class="fig-label">Figure 75</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0075.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0075.jpeg" id="gr75" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 75. Structure of the alkyne probe <b>150</b> and subsequent detection of labeling events using CuAAC reaction with Alexa-Fluor 488-azide.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0075.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig75"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i87" class="anchor-spacer"></div><h3 class="article-section__title" id="_i87"> An Acetylene-Containing Natural Product Callysponginic Acid as a Chemical Probe for the Characterization of Potential Intracellular Targets</h3><div class="NLM_p">Cell lysates isolated from <b>175</b>-treated HeLa cells were subjected to a click reaction by the addition of the capture reagent terbium-azide (Tb-azide) and copper sulfate. The resulting click adduct was detected by in gel fluorescence using Imager (<a data-tab="pane-pcw-Figures" href="#fig76" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig76" id="" class=" internalNav">76</a></a>). For proteomic analysis, the tagged protein targets were trypsinized and subjected to LC-MS/MS analysis. These tagging experiments confirmed that <b>175</b> binds primarily to the membrane confined protein targets. About 60% of the identified protein targets are enzymes that are involved in the metabolism of lipids and fatty acids.<a onclick="showRef(event, 'ref209'); return false;" href="javascript:void(0);" class="ref ref209">(209)</a></div><figure id="fig76" data-index="76" class="article__inlineFigure"><h2 class="fig-label">Figure 76</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0076.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0076.jpeg" id="gr76" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 76. Structure of a polyalkyne probe <b>175</b> and subsequent in gel and proteome LC-MS/MS analyses via CuAAC reaction with Tb-azide.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0076.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig76"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i88" class="anchor-spacer"></div><h3 class="article-section__title" id="_i88"> Compound <b>176</b>-Derived Chemical Probe <b>177</b> for Fatty Acid Amide Hydrolase (FAAH)</h3><div class="NLM_p">Replacement of a trifluoromethyl group in <b>176</b> (PF-3845) with nonclassical isosteric acetylene group resulted in an alkyne chemical probe <b>177</b> (PF3845yne).<a onclick="showRef(event, 'ref210'); return false;" href="javascript:void(0);" class="ref ref210">(210)</a> Protein targets of <b>177</b> were directly analyzed in vivo through click chemistry (<a data-tab="pane-pcw-Figures" href="#fig77" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig77" id="" class=" internalNav">77</a></a>). Brain and liver proteomes after treatment with <b>177</b> were reacted with a rhodamine-azide tag under azide–alkyne [3 + 2] cycloaddition conditions, and subsequent analysis was performed using in gel fluorescence scanning. This labeling experiment revealed that <b>177</b> successfully labeled FAAH in both brain and liver tissues.<a onclick="showRef(event, 'ref210'); return false;" href="javascript:void(0);" class="ref ref210">(210)</a></div><figure id="fig77" data-index="77" class="article__inlineFigure"><h2 class="fig-label">Figure 77</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0077.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0077.jpeg" id="gr77" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 77. Structures of FAAH inhibitor <b>176</b> and <b>176</b>-derived alkyne probe (<b>177</b>). <b>177</b> allowed for in gel analysis of the target proteins using CuAAC reaction with rhodamine-azide.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0077.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig77"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i89" class="anchor-spacer"></div><h3 class="article-section__title" id="_i89"> Hypoxia-Induced Factor-1α (HIF-1α)/Malate Dehydrogenase 2 (MDH2) Inhibitor as a Photoaffinity Probe</h3><div class="NLM_p">Naik and co-workers synthesized compound <b>178</b> as an inhibitor of both HIF-1α and MDH2.<a onclick="showRef(event, 'ref211'); return false;" href="javascript:void(0);" class="ref ref211">(211)</a> Because compound <b>178</b> contains a photoactivatable diazirine probe and the terminal alkyne handle for click chemistry with the fluorescent azides, it was used for the target identification. Chemical probe <b>178</b> was incubated with a recombinant human MDH2 and subsequently exposed to UV light (360 nm) for photoaffinity labeling of MDH2 via highly reactive carbene intermediate. The resulting photolabeled conjugate was subjected to click reaction conditions using an azide-containing fluorescent dye (Cy3-azide) to visualize the probe–MDH2 binding event (<a data-tab="pane-pcw-Figures" href="#fig78" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig78" id="" class=" internalNav">78</a></a>).</div><figure id="fig78" data-index="78" class="article__inlineFigure"><h2 class="fig-label">Figure 78</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0078.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0078.jpeg" id="gr78" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 78. Structure of <b>178</b> featuring photoactivatable diazirine probe and a terminal alkyne handle. Alkylated target proteins were subsequently detected using CuAAC reaction with Cy3-azide.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0078.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig78"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i90" class="anchor-spacer"></div><h3 class="article-section__title" id="_i90"> Clickable Disaccharide Unit of Bleomycin <b>179</b> for in Vivo PET Imaging</h3><div class="NLM_p">Positron emission tomography (PET) imaging allows for detection of disease-related biochemical changes and can be used to monitor target engagement by installing a radionuclide such as <sup>18</sup>F. Bleomycins are antitumor antibiotics comprising tumoricidal and tumor targeting structural domains. Because the disaccharide unit of bleomycin (<b>179</b>) contributes to the tumor cell selectivity and internalization, the development of clickable disaccharide unit is expected to shed light on tumor imaging. Toward this goal, Maity and co-workers synthesized an alkyne-containing bleomycin disaccharide devoid of peptide domain that will be click conjugated with <sup>18</sup>F-labeled radiotracer to obtain and study PET imaging of <b>180</b> in vivo in a breast cancer xenograft mouse model (<a data-tab="pane-pcw-Figures" href="#fig79" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig79" id="" class=" internalNav">79</a></a>).<a onclick="showRef(event, 'ref212'); return false;" href="javascript:void(0);" class="ref ref212">(212)</a> The results, however, indicated poor uptake of <b>180</b> into the tumor but high uptake in the kidneys, thus suggesting the role of a peptide domain of bleomycin toward overall uptake profile.</div><figure id="fig79" data-index="79" class="article__inlineFigure"><h2 class="fig-label">Figure 79</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0079.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0079.jpeg" id="gr79" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 79. Structures of clickable <b>179</b> and clicked PET imaging agent <b>180</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0079.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig79"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i91" class="anchor-spacer"></div><h3 class="article-section__title" id="_i91"> Clickable Antihuman PD-L1 Adnectin for in Vivo PET Imaging</h3><div class="NLM_p">Inhibition of the interaction between programmed death ligand-1 (PD-L1) and PD1 appears as a promising antitumor strategy. Therefore, antibodies that are designed to disrupt this interaction have been approved for the treatment of a wide range of cancers.<a onclick="showRef(event, 'ref213 ref214'); return false;" href="javascript:void(0);" class="ref ref213 ref214">(213,214)</a> The development of noninvasive imaging agents for detecting the expression of tumor drivers such as PD-L1 is an attractive strategy. Consequently, Donnelly and colleagues<a onclick="showRef(event, 'ref215'); return false;" href="javascript:void(0);" class="ref ref215">(215)</a> developed <sup>18</sup>F-labeled radioligand for imaging PD-L1 expression in tumors. Adnectin (BMS-986192), exhibiting high affinity and specificity toward human PD-L1, was transformed into picomolar affinity radioligand [<sup>18</sup>F]BMS-986192 (<b>181</b>) for use as a PET imaging agent to detect PD-L1 expression in vivo (<a data-tab="pane-pcw-Figures" href="#fig80" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig80" id="" class=" internalNav">80</a></a>).<a onclick="showRef(event, 'ref215'); return false;" href="javascript:void(0);" class="ref ref215">(215)</a> Radioligand <b>181</b> was prepared in two steps: (1) maleimide facilitated incorporation of highly strained dibenzocyclooctyne (DBCO) moiety on to adnectin via cysteine residue and (2) insertion of <sup>18</sup>F azido prosthetic group using copper-free azide–alkyne click chemistry. In vivo, <b>181</b> demonstrated a rapid uptake into PD-L1-expressing tumors and a rapid clearance from tumors lacking PD-L1 expression.</div><figure id="fig80" data-index="80" class="article__inlineFigure"><h2 class="fig-label">Figure 80</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0080.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0080.jpeg" id="gr80" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 80. Structure and synthesis of clicked PET imaging agent <b>181</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0080.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig80"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i92" class="anchor-spacer"></div><h3 class="article-section__title" id="_i92"> Imaging Protein Synthesis in Cells via CuAAC Click Chemistry on Alkyne-Functionalized Puromycin</h3><div class="NLM_p">Liu and co-workers introduced a propargyl handle on puromycin (<b>182</b>) to obtain <i>O</i>-propargyl puromycin (<b>183</b>).<a onclick="showRef(event, 'ref216'); return false;" href="javascript:void(0);" class="ref ref216">(216)</a> Incubation of cells with <b>183</b> leads to the formation of prematurely terminated peptides, which upon in situ CuAAC click reaction with Alexa568 azide fluorophore allows for detection of the intensity of fluorescent signal (<a data-tab="pane-pcw-Figures" href="#fig81" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig81" id="" class=" internalNav">81</a></a>).</div><figure id="fig81" data-index="81" class="article__inlineFigure"><h2 class="fig-label">Figure 81</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0081.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0081.jpeg" id="gr81" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 81. Structures of puromycin <b>182</b> and its clickable handle <b>183</b> and mechanism of formation of fluorescently labeled click product.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0081.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig81"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i93">Acetylene as a Clickable Handle for Kinetic Target-Guided Syntheses (KTGS)</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_33081" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_33081" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">KTGS utilizes therapeutically important macromolecules (protein and DNA) and in situ click chemistry and offers a promising strategy for identification and optimization of novel leads.<a onclick="showRef(event, 'ref217'); return false;" href="javascript:void(0);" class="ref ref217">(217)</a> In KTGS, the target receptor itself assemble a set of high affinity fragments from the pool carrying complementary reactive functional groups and enables irreversible reaction between a pair of reactive fragments by stabilizing a productive conformation of a ternary complex. In KTGS, target macromolecule help formation of its own inhibitors by allowing covalent linking of high affinity fragments (<a data-tab="pane-pcw-Figures" href="#fig82" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig82" id="" class=" internalNav">82</a></a>A). To illustrate the concept, a representative example is depicted in <a data-tab="pane-pcw-Figures" href="#fig82" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig82" id="" class=" internalNav">82</a></a>B. Antti and colleagues<a onclick="showRef(event, 'ref218'); return false;" href="javascript:void(0);" class="ref ref218">(218)</a> conducted a cell-based KTGS of carbonic anhydrase II inhibitor. For example, azide <b>184</b> and alkyne <b>185</b> were incubated with bovine blood RBCs endowed with abundant carbonic anhydrase II to achieve target-guided synthesis of <b>186</b>. Further details on KTGS concept are furnished in recent reviews.<a onclick="showRef(event, 'ref217 ref219 ref220'); return false;" href="javascript:void(0);" class="ref ref217 ref219 ref220">(217,219,220)</a></div><figure id="fig82" data-index="82" class="article__inlineFigure"><h2 class="fig-label">Figure 82</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0082.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0082.jpeg" id="gr82" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 82. (A) Schematic representation of target-guided synthesis of lead compounds. (B) Example of cell-based KTGS.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0082.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig82"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec7" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i94">Acetylene as a Clickable Handle for Antibody–Drug Conjugate (ADC) Development</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_72087" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_72087" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Gregson and colleagues reported the design of pyrrolobenzodiazepine drug linkers for the development of ADCs using the key intermediate <b>187</b>.<a onclick="showRef(event, 'ref221'); return false;" href="javascript:void(0);" class="ref ref221">(221)</a> These ADCs were comprised of a maleimide moiety for conjugation to a cysteine of anti-HER2/anti-CD22 antibodies, a hydrophilic spacer, and either an alkyne (<b>188)</b> or a 1,4-disubstituted 1,2,3-triazole (<b>189</b>) linked to the pyrrolobenzodiazepine (<a data-tab="pane-pcw-Figures" href="#fig83" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig83" id="" class=" internalNav">83</a></a>).</div><figure id="fig83" data-index="83" class="article__inlineFigure"><h2 class="fig-label">Figure 83</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0083.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0083.jpeg" id="gr83" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 83. Structure of the pyrrolobenzodiazepine dimer <b>187</b> and the corresponding alkyne-/triazole-based anti-HER2 or anti-CD22 cysteine-containing antibodies <b>188</b> and <b>189</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0083.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig83"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Readers may refer to additional examples of ADCs that take advantage of an alkyne functionality.<a onclick="showRef(event, 'ref222 ref223 ref224 ref225'); return false;" href="javascript:void(0);" class="ref ref222 ref223 ref224 ref225">(222−225)</a></div></div><div id="sec8" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i95">Summary</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_72322" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_72322" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">A number of alkyne-containing clinically useful molecules is on the rise due in part to their application in covalent inhibitor design and chemical biology research. Despite occasional propensity of an internal and terminal acetylenes for bioactivation and CYP inhibition, they have given rise to many meaningful contributions in medicinal chemistry. Owing to the many commercially available building blocks, the facile methods for their construction, and their utility in chemical biology, it is anticipated that their use will only grow.</div><div class="NLM_p">An acetylene group has been successfully employed to emulate structural and functional properties of a wide range of groups, including chloro, iodo, cyano, carbonyl, carboxamide, ethene, cyclopropyl, and phenyl. Occasionally, insertion of an acetylene group in lead compounds, such as human rhinovirus 3C protease inhibitors, 5-lipoxygenase inhibitors, and steroid-based drugs, demonstrated improved metabolic stability. An acetylene group has been successfully employed to increase target selectivity for DPP-4 inhibitors and voltage-gated potassium ion channel agonists. An acetylene group also manifested a key structural role in a wide range of lead optimization programs, including ERAP/IRAP, Bcr-Abl kinase, KIT, MELK, Hsp90, <i>Pseudomonas aeruginosa</i> LpxC inhibitors, retinoids, and as a dimeric Smac mimetic. Because of its rod-like geometrical feature, it was effectively used to displace the structural water molecule and enhance binding affinity through increased entropic component (examples include inhibitors of DENV NS5 RdRp and BACE1). Because the acetylene group serves as a latent electrophilic warhead, it was widely used for the development of covalent inhibitors of BTKs, Nek2, p97, EGFR, cysteine proteases, DHPDHase, LSD1, and MAO-B with reduced potential for indiscriminate covalent modification of off-target proteins. Occasionally, acetylene group, particularly the terminal one, forms a covalent bond with the drug-metabolizing CYP450s prosthetic heme or protein component, which leads to covalent inhibition and potential concerns over drug–drug interactions. An acetylene group serves as a privileged moiety for the development of MTDLs to treat Alzheimer’s disease. A structural simplicity and reactivity of an acetylene group makes it a versatile building block for organic synthesis and medicinal chemistry optimizations. For example, irreversible conversion of azide and alkyne to 1,2,3-triazoles is highly exothermic and can be efficiently used to optimize either azide- or alkyne-containing ligands. A 1,2,3-triazole linker in such compounds functions as a pure linker or it may contribute to the biological activity as well. In situ azide–alkyne [3 + 2] cycloaddition is also applied for target-driven synthesis (within the active site), which minimizes the number of inactive compounds. An acetylene group is also a key structural component of clinically useful natural products or natural product-derived compounds, including ironomycin, duryne, almiramide, viridamide, companeramide, calicheamicin, and dynemicin.</div><div class="NLM_p last">Because acetylene can take part in CuAAC and strain-promoted azide–alkyne [3 + 2] cycloaddition (SPAAC) click chemistry, it finds application in the development of bioconjugates, biosensors, and for probing target proteins, nucleotides, or in situ whole organism. Because of the increasing awareness of the importance of measuring target engagement in vivo, a number of alkyne-containing bioactive chemical probes is on the rise. Because of its clickable property, acetylene group has been widely used for the development of PET imaging agents. The design strategy for the development of antibody drug conjugates is further expanded by the use of an acetylene handle. Incorporation of an acetylene group in screening libraries, biological probes, and therapeutic agents is increasingly prevalent due to the relative ease of its insertion into complex molecules through cross-coupling chemistry, participation in bioorthogonal azide–alkyne [3 + 2] cycloaddition, distinct topological features, and functional mimicry with a broad range of groups/moieties.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.9b01617" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_37237" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_37237" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tanaji T. Talele</span> - <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical
Sciences, College of Pharmacy and Health Sciences, St. John’s University, Queens, New York 11439, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5938-6505" title="Orcid link">http://orcid.org/0000-0002-5938-6505</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#04706568616861704477706e6b6c6a772a616071"><span class="__cf_email__" data-cfemail="d2a6b3beb7beb7a692a1a6b8bdbabca1fcb7b6a7">[email protected]</span></a></span></div></li></ul></li><li><ul></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The author declares the following competing financial interest(s): Tanaji T. Talele co-founded Hysplex LLC that focuses on PARP-inhibitor development.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i96">Biography</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_73886" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_73886" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="84" class="article__inlineFigure"><h2 class="fig-label">Tanaji T. Talele</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=BIO-d7e4299-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Tanaji T. Talele</b> received his Ph.D. (1998) in Medicinal Chemistry from the University of Mumbai, India. He completed a postdoctoral training at New Jersey Medical School, Louisiana State University, and Moffitt Cancer Center (1999–2005). He joined the St. John’s University in 2005, where he is currently a Full Professor. He has authored/coauthored over 95 scientific publications including two book chapters. Since 2016, he has been serving as an editorial advisory board member of the <i>European Journal of Medicinal Chemistry</i>. In 2018, he was appointed as an Editor of <i>Bioorganic Chemistry</i>. In 2019, he cofounded start-up company Hysplex LLC. His current research efforts are directed toward the development of small-molecule inhibitors of PARP/HDAC/RAD51.</p></figure></div><div class="ack" id="ACK-d7e4296-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i97">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_55064" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_55064" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">I am thankful to Drs. Cesar A. Lau-Cam (St. John’s University) and Vijay M. Gokhale (The University of Arizona) for reading and commenting on the manuscript. I also acknowledge Prof. Robert J. DeVita, Ph.D. (Icahn School of Medicine at Mount Sinai), for his review of the manuscript.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">ABHD6</td><td class="NLM_def"><p class="first last">α,β-hydrolase domain 6</p></td></tr><tr><td class="NLM_term">ABPP</td><td class="NLM_def"><p class="first last">activity-based protein profiling</p></td></tr><tr><td class="NLM_term">AChE</td><td class="NLM_def"><p class="first last">acetylcholinesterase</p></td></tr><tr><td class="NLM_term">AD</td><td class="NLM_def"><p class="first last">Alzheimer’s disease</p></td></tr><tr><td class="NLM_term">ARE</td><td class="NLM_def"><p class="first last">antioxidant response element</p></td></tr><tr><td class="NLM_term">ART</td><td class="NLM_def"><p class="first last">artemisinins</p></td></tr><tr><td class="NLM_term">BACE1</td><td class="NLM_def"><p class="first last">β-site amyloid precursor protein cleaving enzyme</p></td></tr><tr><td class="NLM_term">BuChE</td><td class="NLM_def"><p class="first last">butyrylcholinesterase</p></td></tr><tr><td class="NLM_term">CaSR</td><td class="NLM_def"><p class="first last">calcium-sensing receptor</p></td></tr><tr><td class="NLM_term">Cdk</td><td class="NLM_def"><p class="first last">cyclin-dependent kinase</p></td></tr><tr><td class="NLM_term">CRTH2</td><td class="NLM_def"><p class="first last">chemoattractant receptor-homologous expressed in Th2 lymphocytes</p></td></tr><tr><td class="NLM_term">CuAAC</td><td class="NLM_def"><p class="first last">copper-catalyzed azide–alkyne cycloaddition</p></td></tr><tr><td class="NLM_term">CYP</td><td class="NLM_def"><p class="first last">cytochrome P enzyme</p></td></tr><tr><td class="NLM_term">CysLT</td><td class="NLM_def"><p class="first last">cysteinyl leukotriene</p></td></tr><tr><td class="NLM_term">DAG</td><td class="NLM_def"><p class="first last">diacylglycerol</p></td></tr><tr><td class="NLM_term">DAGLα</td><td class="NLM_def"><p class="first last">diacylglycerol lipase α</p></td></tr><tr><td class="NLM_term">DENV</td><td class="NLM_def"><p class="first last">dengue virus</p></td></tr><tr><td class="NLM_term">DHI</td><td class="NLM_def"><p class="first last">3-bromodihydroisoxazole</p></td></tr><tr><td class="NLM_term">DPP-4</td><td class="NLM_def"><p class="first last">dipeptidyl peptidase-4</p></td></tr><tr><td class="NLM_term">DUB</td><td class="NLM_def"><p class="first last">deubiquitinating enzyme</p></td></tr><tr><td class="NLM_term">EFdA</td><td class="NLM_def"><p class="first last">4′-ethynyl-2-fluoro-2′-deoxyadenosine</p></td></tr><tr><td class="NLM_term">EGFR2</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor 2</p></td></tr><tr><td class="NLM_term">ERAP1</td><td class="NLM_def"><p class="first last">endoplasmic reticulum aminopeptidase 1</p></td></tr><tr><td class="NLM_term">FAAH</td><td class="NLM_def"><p class="first last">fatty acid amide hydrolase</p></td></tr><tr><td class="NLM_term">FFA1</td><td class="NLM_def"><p class="first last">free fatty acid reporter 1</p></td></tr><tr><td class="NLM_term">FLIPR</td><td class="NLM_def"><p class="first last">fluorescent imaging plate reader</p></td></tr><tr><td class="NLM_term">GHSR</td><td class="NLM_def"><p class="first last">growth hormone secretagogue receptor</p></td></tr><tr><td class="NLM_term">GSH</td><td class="NLM_def"><p class="first last">glutathione</p></td></tr><tr><td class="NLM_term">GST</td><td class="NLM_def"><p class="first last">glutathione-S-transferase</p></td></tr><tr><td class="NLM_term">HDAC</td><td class="NLM_def"><p class="first last">histone deacetylase</p></td></tr><tr><td class="NLM_term">hERG</td><td class="NLM_def"><p class="first last">human ether-a-go-go</p></td></tr><tr><td class="NLM_term">HIF-1α</td><td class="NLM_def"><p class="first last">hypoxia induced factor-1α</p></td></tr><tr><td class="NLM_term">hWBA</td><td class="NLM_def"><p class="first last">human whole blood assay</p></td></tr><tr><td class="NLM_term">IRAP</td><td class="NLM_def"><p class="first last">insulin-regulated aminopeptidase</p></td></tr><tr><td class="NLM_term">Keap1</td><td class="NLM_def"><p class="first last">Kelch-like ECH-associated protein 1</p></td></tr><tr><td class="NLM_term">LSD1</td><td class="NLM_def"><p class="first last">histone lysine specific demethylase 1</p></td></tr><tr><td class="NLM_term">MAO-B</td><td class="NLM_def"><p class="first last">monoamine oxidase B</p></td></tr><tr><td class="NLM_term">MAPK</td><td class="NLM_def"><p class="first last">mitogen-activated protein kinase</p></td></tr><tr><td class="NLM_term">MDH2</td><td class="NLM_def"><p class="first last">malate dehydrogenase 2</p></td></tr><tr><td class="NLM_term">MGluR5</td><td class="NLM_def"><p class="first last">metabotropic glutamate receptor 5</p></td></tr><tr><td class="NLM_term">M-MPEP</td><td class="NLM_def"><p class="first last">2-methyl-6-(3-methoxyphenyl)ethynylpyridine</p></td></tr><tr><td class="NLM_term">mPTPB</td><td class="NLM_def"><p class="first last">Mycobacterium protein tyrosine phosphatase B</p></td></tr><tr><td class="NLM_term">MTDLs</td><td class="NLM_def"><p class="first last">multitarget directed ligands</p></td></tr><tr><td class="NLM_term">NPC1</td><td class="NLM_def"><p class="first last">Niemann–Pick C1</p></td></tr><tr><td class="NLM_term">Nrf2</td><td class="NLM_def"><p class="first last">nuclear factor erythroid 2-related factor 2</p></td></tr><tr><td class="NLM_term">OES</td><td class="NLM_def"><p class="first last">oxidative/electrophilic stress</p></td></tr><tr><td class="NLM_term">PAM</td><td class="NLM_def"><p class="first last">positive allosteric modulators</p></td></tr><tr><td class="NLM_term">PD-L1</td><td class="NLM_def"><p class="first last">programmed death ligand-1</p></td></tr><tr><td class="NLM_term">PG</td><td class="NLM_def"><p class="first last">peptidoglycan</p></td></tr><tr><td class="NLM_term">PET</td><td class="NLM_def"><p class="first last">positron-emission tomography</p></td></tr><tr><td class="NLM_term">PI3K</td><td class="NLM_def"><p class="first last">phosphoinositide-3-kinase</p></td></tr><tr><td class="NLM_term">PknA</td><td class="NLM_def"><p class="first last">protein kinase A</p></td></tr><tr><td class="NLM_term">PknB</td><td class="NLM_def"><p class="first last">protein kinase B</p></td></tr><tr><td class="NLM_term">RdRp</td><td class="NLM_def"><p class="first last">RNA-dependent RNA polymerase</p></td></tr><tr><td class="NLM_term">SPAAC</td><td class="NLM_def"><p class="first last">strain-promoted azide–alkyne cycloaddition</p></td></tr><tr><td class="NLM_term">TACE</td><td class="NLM_def"><p class="first last">TNFα converting enzyme</p></td></tr><tr><td class="NLM_term">TG2</td><td class="NLM_def"><p class="first last">transglutaminase 2</p></td></tr><tr><td class="NLM_term">TNFα</td><td class="NLM_def"><p class="first last">tumor necrosis factor-α</p></td></tr><tr><td class="NLM_term">UBE2M</td><td class="NLM_def"><p class="first last">ubiquitin conjugating enzyme E2M</p></td></tr><tr><td class="NLM_term">UDPGT</td><td class="NLM_def"><p class="first last">UDP-glucuronyl transferase</p></td></tr><tr><td class="NLM_term">VRE</td><td class="NLM_def"><p class="first last">vancomycin-resistant enterococci</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i99">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_55415" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_55415" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 225 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ervin, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gronert, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barlow, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilles, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bierbaum, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DePuy, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lineberger, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellison, G. B.</span></span> <span> </span><span class="NLM_article-title">Bond strengths of ethylene and acetylene</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>112</i></span>,  <span class="NLM_fpage">5750</span>– <span class="NLM_lpage">5759</span>, <span class="refDoi"> DOI: 10.1021/ja00171a013</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja00171a013" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADyaK3cXkslOls7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=1990&pages=5750-5759&author=K.+M.+Ervinauthor=S.+Gronertauthor=S.+E.+Barlowauthor=M.+K.+Gillesauthor=A.+G.+Harrisonauthor=V.+M.+Bierbaumauthor=C.+H.+DePuyauthor=W.+C.+Linebergerauthor=G.+B.+Ellison&title=Bond+strengths+of+ethylene+and+acetylene&doi=10.1021%2Fja00171a013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Bond strengths of ethylene and acetylene</span></div><div class="casAuthors">Ervin, Kent M.; Gronert, Scott; Barlow, S. E.; Gilles, Mary K.; Harrison, Alex G.; Bierbaum, Veronica M.; DePuy, Charles H.; Lineberger, W. C.; Ellison, G. Barney</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5750-9</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    </div><div class="casAbstract">Neg. ion photoelectron spectroscopy and gas-phase proton transfer kinetics were employed to det. the CH bond dissocn. energies of acetylene, ethylene, and vinyl radical: D0(HCC-H) = 131.3 ± 0.7 kcal mol-1, D0(CH2CH-H) = 109.7 ± 0.8 kcal mol-1, and D0(CH2C-H) = 81.0 ± 3.5 kcal mol-1.  The strengths of each of the other CH and CC bonds in acetylene and ethylene and their fragments were derived.  The energy required to isomerize acetylene to vinylidene was also detd.  Proton transfer kinetics in a flowing after glow/selected-ion flow tube app. were used to refine the acidities of ethylene, acetylene, and vinyl.  The gas-phase acidity of acetylene was tied to values for HF.  The electron affinities of ethynyl, vinyl, and vinylidene radicals were detd. by photoelectron spectroscopy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9WztXNlowjbVg90H21EOLACvtfcHk0liR-dbSuO_BIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXkslOls7Y%253D&md5=7fedf13049014cd6bb88bfc7eb0667ed</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1021%2Fja00171a013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja00171a013%26sid%3Dliteratum%253Aachs%26aulast%3DErvin%26aufirst%3DK.%2BM.%26aulast%3DGronert%26aufirst%3DS.%26aulast%3DBarlow%26aufirst%3DS.%2BE.%26aulast%3DGilles%26aufirst%3DM.%2BK.%26aulast%3DHarrison%26aufirst%3DA.%2BG.%26aulast%3DBierbaum%26aufirst%3DV.%2BM.%26aulast%3DDePuy%26aufirst%3DC.%2BH.%26aulast%3DLineberger%26aufirst%3DW.%2BC.%26aulast%3DEllison%26aufirst%3DG.%2BB.%26atitle%3DBond%2520strengths%2520of%2520ethylene%2520and%2520acetylene%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1990%26volume%3D112%26spage%3D5750%26epage%3D5759%26doi%3D10.1021%2Fja00171a013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blanksby, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellison, G. B.</span></span> <span> </span><span class="NLM_article-title">Bond dissociation energies of organic molecules</span>. <i>Acc. Chem. Res.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">255</span>– <span class="NLM_lpage">263</span>, <span class="refDoi"> DOI: 10.1021/ar020230d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ar020230d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmt1OqsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2003&pages=255-263&author=S.+J.+Blanksbyauthor=G.+B.+Ellison&title=Bond+dissociation+energies+of+organic+molecules&doi=10.1021%2Far020230d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Bond Dissociation Energies of Organic Molecules</span></div><div class="casAuthors">Blanksby, Stephen J.; Ellison, G. Barney</div><div class="citationInfo"><span class="NLM_cas:title">Accounts of Chemical Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">255-263</span>CODEN:
                <span class="NLM_cas:coden">ACHRE4</span>;
        ISSN:<span class="NLM_cas:issn">0001-4842</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  In this Account the authors have compiled a list of reliable bond energies that are based on a set of critically evaluated expts.  A brief description of the three most important exptl. techniques for measuring bond energies is provided.  The authors demonstrate how these exptl. data can be applied to yield the heats of formation of org. radicals and the bond enthalpies of more than 100 representative org. mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1Gd4XRKVyrbVg90H21EOLACvtfcHk0liR-dbSuO_BIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmt1OqsA%253D%253D&md5=e313bd3c3a7809b70baa32c83e70d135</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1021%2Far020230d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Far020230d%26sid%3Dliteratum%253Aachs%26aulast%3DBlanksby%26aufirst%3DS.%2BJ.%26aulast%3DEllison%26aufirst%3DG.%2BB.%26atitle%3DBond%2520dissociation%2520energies%2520of%2520organic%2520molecules%26jtitle%3DAcc.%2520Chem.%2520Res.%26date%3D2003%26volume%3D36%26spage%3D255%26epage%3D263%26doi%3D10.1021%2Far020230d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bent, H. A.</span></span> <span> </span><span class="NLM_article-title">Distribution of atomic s character in molecules and its chemical implications</span>. <i>J. Chem. Educ.</i> <span class="NLM_year" style="font-weight: bold;">1960</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">616</span>, <span class="refDoi"> DOI: 10.1021/ed037p616</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ed037p616" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADyaF3MXhtVeitLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1960&pages=616&author=H.+A.+Bent&title=Distribution+of+atomic+s+character+in+molecules+and+its+chemical+implications&doi=10.1021%2Fed037p616"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Distribution of atomic s character in molecules and its chemical implication</span></div><div class="casAuthors">Bent, Henry A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Education</span>
        (<span class="NLM_cas:date">1960</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">616-24</span>CODEN:
                <span class="NLM_cas:coden">JCEDA8</span>;
        ISSN:<span class="NLM_cas:issn">0021-9584</span>.
    </div><div class="casAbstract">Classification of s character in mols. according to sp, sp2, and sp3 bonding permits prediction of bond lengths, bond angles, relative electronegativity, and basicity of valence.  Deviation from these simple hybrid bonds is explained by use of a quantum-mech. model, which also explains a mechanism for the inductive effect, carbonium ion rearrangements, energetics of addn. to multiple bonds, interaction within the CO group, and the structure of CO2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqC5PcB2Z1JeLVg90H21EOLACvtfcHk0liR-dbSuO_BIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF3MXhtVeitLw%253D&md5=771fd607741b33ac004c8ab5af17eda5</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1021%2Fed037p616&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fed037p616%26sid%3Dliteratum%253Aachs%26aulast%3DBent%26aufirst%3DH.%2BA.%26atitle%3DDistribution%2520of%2520atomic%2520s%2520character%2520in%2520molecules%2520and%2520its%2520chemical%2520implications%26jtitle%3DJ.%2520Chem.%2520Educ.%26date%3D1960%26volume%3D37%26spage%3D616%26doi%3D10.1021%2Fed037p616" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W. G.</span></span> <span> </span><span class="NLM_article-title">The vinyl carbanion1</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">1959</span>,  <span class="NLM_volume"><i>81</i></span>,  <span class="NLM_fpage">6313</span>– <span class="NLM_lpage">6319</span>, <span class="refDoi"> DOI: 10.1021/ja01532a050</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja01532a050" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADyaF3MXht12gug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=1959&pages=6313-6319&author=S.+I.+Millerauthor=W.+G.+Lee&title=The+vinyl+carbanion1&doi=10.1021%2Fja01532a050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">The vinyl carbanion</span></div><div class="casAuthors">Miller, Sidney I.; Lee, Warren G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">1959</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">6313-19</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    </div><div class="casAbstract">A kinetic and mechanistic study of H-D exchange and elimination reactions of 1,2-dihalo-ethenes was made in order to est. pK values and cis-trans isomerization energy barriers.  (CDBr2)2 (I), b0.04 56°, n25D 1.6331 (prepd. by bromination of DC:CD), was debrominated with Zn to a cis-trans mixt. of BrDC:CDBr (II), which was fractionated to yield pure cis-II, n25D 1.5365 (CA 45, 9984d).  The rates of dehydrobromination of cis-II and cis-HBrC: CBrH (III) in various concns. of halides and MeONa in MeOH at 24.8-35.4° were measured and no isotope effect was observed, kH/kD = 1.03.  The rates of MeO-catalyzed exchange of II with MeOH were followed by infrared analysis by using the C-D band at 45 μ.  If extinction coeffs. for C-D and C-H bands were equal, k = 3.3 × 10-3 l./mole sec. at 26° (mean).  Several alkenes, which were treated with basic D2O, with no exchange taking place at 210° during 2-6 days in the presence of tert-BuOK, were Me acrylate, maleic anhydride, Et cinnamate, Me chloromaleate, cis- and trans-stilbene, 1,1-diphenylethylene, and triphenylethylene.  For alkenes which exchanged with D2O, approx. 1-2M in NaOMe, resp., were given compd., temp., time in hrs., CC-D/CC-H, energy of activation for the dehydrobromination reaction in kcal./mole: trans-III, 25, 65, 0.24, 33.4; cis-III, 25, 45, 0.26, 28.1; trans-HCCl:CHCl (trans-IV), 3, 48, 0.03, 29.0; cis-IV, 70, 20, 1, 35.1; trans-CHI:CHI (V), 55, 20, 1, 35.8; cis-CHI: CHI, 25, 88, <0.05, 2.47; BrHC:CBr, 25, 2, 0.13, -; PhCH:CHBr, 110, 144, 0.06, -.  Exchange rates of 5 dihaloethers decreased in the order cis-IV ∼ cis-III > trans-IV > trans-II > trans-V.  Bromides isomerized during the exchange reaction to a greater extent than chlorides.  Yield of V was >95% in a single equilibration run.  A mechanism involving a vinyl anion intermediate in the key steps for both elimination and exchange reaction was suggested.  By use of the abs. rate theory the acidity of the alkenes was estd., thus the pKa of cis-III and cis-IV were, resp., 33.6 and ∼34 at most, whereas the pKa of the resp. trans isomers were 1-2 units higher.  Stability of vinyl anions was discussed in terms of the cistrans isomerization energy barrier.  A kinetic analysis of the elimination was proposed, assuming a steady state vinyl ion concn., with H-D exchange, H-H exchange, isomerization, and HX elimination as competing reactions.  Apparently similar systems eliminate by different paths and 1-, 2-, or 3-step mechanisms must be considered for each specific case.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoW6JzVz6DMzrVg90H21EOLACvtfcHk0liR-dbSuO_BIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF3MXht12gug%253D%253D&md5=43a7c615b70403a419e5e2335404f0aa</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1021%2Fja01532a050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja01532a050%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DS.%2BI.%26aulast%3DLee%26aufirst%3DW.%2BG.%26atitle%3DThe%2520vinyl%2520carbanion1%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1959%26volume%3D81%26spage%3D6313%26epage%3D6319%26doi%3D10.1021%2Fja01532a050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lenz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boeckler, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gmeiner, P.</span></span> <span> </span><span class="NLM_article-title">Fancy bioisosteres: Synthesis, SAR, and pharmacological investigations of novel nonaromatic dopamine D<sub>3</sub> receptor ligands</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">4434</span>– <span class="NLM_lpage">4442</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2005.04.047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1016%2Fj.bmc.2005.04.047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=15908220" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlt1Sktbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2005&pages=4434-4442&author=C.+Lenzauthor=F.+Boecklerauthor=H.+Hubnerauthor=P.+Gmeiner&title=Fancy+bioisosteres%3A+Synthesis%2C+SAR%2C+and+pharmacological+investigations+of+novel+nonaromatic+dopamine+D3+receptor+ligands&doi=10.1016%2Fj.bmc.2005.04.047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Fancy bioisosteres: Synthesis, SAR, and pharmacological investigations of novel nonaromatic dopamine D3 receptor ligands</span></div><div class="casAuthors">Lenz, Carola; Boeckler, Frank; Huebner, Harald; Gmeiner, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4434-4442</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Structural variations of the lead compd. FAUC 88 led to dopaminergic enynes with an extended π-system when Pd-catalyzed cross coupling reactions were employed for the key reaction steps.  The dienyne (I) displayed substantial affinity for the dopamine receptor subtype D3 and remarkable selectivity over D4.  Compared to FAUC 88, the novel fancy bioisostere I displayed reduced ligand efficacy.  DFT-based conformational anal. of the test compd. I, including the calcn. of diagnostic magnetic shielding properties and their comparison with exptl. derived NMR data, indicated a clear energetic preference for the s-trans geometry of the diene substructure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqu1n-sAJR8QbVg90H21EOLACvtfcHk0lgoIUb0lvZ-Og"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlt1Sktbs%253D&md5=24f78ad6908b4c927206cf6efa150afb</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2005.04.047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2005.04.047%26sid%3Dliteratum%253Aachs%26aulast%3DLenz%26aufirst%3DC.%26aulast%3DBoeckler%26aufirst%3DF.%26aulast%3DHubner%26aufirst%3DH.%26aulast%3DGmeiner%26aufirst%3DP.%26atitle%3DFancy%2520bioisosteres%253A%2520Synthesis%252C%2520SAR%252C%2520and%2520pharmacological%2520investigations%2520of%2520novel%2520nonaromatic%2520dopamine%2520D3%2520receptor%2520ligands%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2005%26volume%3D13%26spage%3D4434%26epage%3D4442%26doi%3D10.1016%2Fj.bmc.2005.04.047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lenz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haubmann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boeckler, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gmeiner, P.</span></span> <span> </span><span class="NLM_article-title">Fancy bioisosteres: Synthesis and dopaminergic properties of the endiyne FAUC 88 as a novel non-aromatic D<sub>3</sub> agonist</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">185</span>– <span class="NLM_lpage">191</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2004.09.044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1016%2Fj.bmc.2004.09.044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=15582463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A280%3ADC%252BD2M%252FitFKrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2005&pages=185-191&author=C.+Lenzauthor=C.+Haubmannauthor=H.+Hubnerauthor=F.+Boecklerauthor=P.+Gmeiner&title=Fancy+bioisosteres%3A+Synthesis+and+dopaminergic+properties+of+the+endiyne+FAUC+88+as+a+novel+non-aromatic+D3+agonist&doi=10.1016%2Fj.bmc.2004.09.044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Fancy bioisosteres: synthesis and dopaminergic properties of the endiyne FAUC 88 as a novel non-aromatic D3 agonist</span></div><div class="casAuthors">Lenz Carola; Haubmann Christian; Hubner Harald; Boeckler Frank; Gmeiner Peter</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & medicinal chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">185-91</span>
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    </div><div class="casAbstract">Enlargement of the pi-electronic system of the non-aromatic D3 agonist FAUC 73 led to dopaminergic endiynes of type 1 being synthesized via the bromovinyl triflate 7a as a key intermediate when palladium catalyzed coupling reactions were exploited for the introduction of the (aza)alkyne substituents.  As the first neuroreceptor active endiyne, FAUC 88 (1c) displayed high and selective dopamine D3 receptor affinity (K(ihigh) = 3.2 nM) and substantial ligand efficacy (72%, EC(50) = 2.5 nM).  Similarities between molecular electrostatic potentials induced by the catechol subunit of the genuine neurotransmitter and those of its non-aromatic endiyne bioisostere are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRyHvFP5rn5GbHHuJhbyicZfW6udTcc2ebUg2X14WEGrLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2M%252FitFKrtg%253D%253D&md5=107537fb22eec1736c001d91b7041d9a</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2004.09.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2004.09.044%26sid%3Dliteratum%253Aachs%26aulast%3DLenz%26aufirst%3DC.%26aulast%3DHaubmann%26aufirst%3DC.%26aulast%3DHubner%26aufirst%3DH.%26aulast%3DBoeckler%26aufirst%3DF.%26aulast%3DGmeiner%26aufirst%3DP.%26atitle%3DFancy%2520bioisosteres%253A%2520Synthesis%2520and%2520dopaminergic%2520properties%2520of%2520the%2520endiyne%2520FAUC%252088%2520as%2520a%2520novel%2520non-aromatic%2520D3%2520agonist%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2005%26volume%3D13%26spage%3D185%26epage%3D191%26doi%3D10.1016%2Fj.bmc.2004.09.044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Voronin, V. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ledovskaya, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogachenkov, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodygin, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ananikov, V. P.</span></span> <span> </span><span class="NLM_article-title">Acetylene in organic synthesis: Recent progress and new uses</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">2442</span>, <span class="refDoi"> DOI: 10.3390/molecules23102442</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.3390%2Fmolecules23102442" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2018&pages=2442&author=V.+V.+Voroninauthor=M.+S.+Ledovskayaauthor=A.+S.+Bogachenkovauthor=K.+S.+Rodyginauthor=V.+P.+Ananikov&title=Acetylene+in+organic+synthesis%3A+Recent+progress+and+new+uses&doi=10.3390%2Fmolecules23102442"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.3390%2Fmolecules23102442&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules23102442%26sid%3Dliteratum%253Aachs%26aulast%3DVoronin%26aufirst%3DV.%2BV.%26aulast%3DLedovskaya%26aufirst%3DM.%2BS.%26aulast%3DBogachenkov%26aufirst%3DA.%2BS.%26aulast%3DRodygin%26aufirst%3DK.%2BS.%26aulast%3DAnanikov%26aufirst%3DV.%2BP.%26atitle%3DAcetylene%2520in%2520organic%2520synthesis%253A%2520Recent%2520progress%2520and%2520new%2520uses%26jtitle%3DMolecules%26date%3D2018%26volume%3D23%26spage%3D2442%26doi%3D10.3390%2Fmolecules23102442" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kolb, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharpless, K. B.</span></span> <span> </span><span class="NLM_article-title">The growing impact of click chemistry on drug discovery</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1128</span>– <span class="NLM_lpage">1137</span>, <span class="refDoi"> DOI: 10.1016/S1359-6446(03)02933-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1016%2FS1359-6446%2803%2902933-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=14678739" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpvVWkuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2003&pages=1128-1137&author=H.+C.+Kolbauthor=K.+B.+Sharpless&title=The+growing+impact+of+click+chemistry+on+drug+discovery&doi=10.1016%2FS1359-6446%2803%2902933-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">The growing impact of click chemistry on drug discovery</span></div><div class="casAuthors">Kolb, Hartmuth C.; Sharpless, K. Barry</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">1128-1137</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Click chem. is a modular approach that uses only the most practical and reliable chem. transformations.  Its applications are increasingly found in all aspects of drug discovery, ranging from lead finding through combinatorial chem. and target-templated in situ chem., to proteomics and DNA research, using bioconjugation reactions.  The copper-(I)-catalyzed 1,2,3-triazole formation from azides and terminal acetylenes is a particularly powerful linking reaction, due to its high degree of dependability, complete specificity, and the bio-compatibility of the reactants.  The triazole products are more than just passive linkers; they readily assoc. with biol. targets, through hydrogen bonding and dipole interactions.  Click chem., a modular approach based on highly reliable chem. transformations, is being applied in all aspects of drug discovery, ranging from lead finding to proteomics and DNA research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqEB1hjIBNhbVg90H21EOLACvtfcHk0lgoIUb0lvZ-Og"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpvVWkuro%253D&md5=f0042f3a8f153d1c1192533d90699d19</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2803%2902933-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252803%252902933-7%26sid%3Dliteratum%253Aachs%26aulast%3DKolb%26aufirst%3DH.%2BC.%26aulast%3DSharpless%26aufirst%3DK.%2BB.%26atitle%3DThe%2520growing%2520impact%2520of%2520click%2520chemistry%2520on%2520drug%2520discovery%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2003%26volume%3D8%26spage%3D1128%26epage%3D1137%26doi%3D10.1016%2FS1359-6446%2803%2902933-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tron, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirali, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billington, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canonico, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorba, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genazzani, A. A.</span></span> <span> </span><span class="NLM_article-title">Click chemistry reactions in medicinal chemistry: applications of the 1,3-dipolar cycloaddition between azides and alkynes</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">278</span>– <span class="NLM_lpage">308</span>, <span class="refDoi"> DOI: 10.1002/med.20107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1002%2Fmed.20107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=17763363" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjsVerurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2008&pages=278-308&author=G.+C.+Tronauthor=T.+Piraliauthor=R.+A.+Billingtonauthor=P.+L.+Canonicoauthor=G.+Sorbaauthor=A.+A.+Genazzani&title=Click+chemistry+reactions+in+medicinal+chemistry%3A+applications+of+the+1%2C3-dipolar+cycloaddition+between+azides+and+alkynes&doi=10.1002%2Fmed.20107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Click chemistry reactions in medicinal chemistry: applications of the 1,3-dipolar cycloaddition between azides and alkynes</span></div><div class="casAuthors">Tron, Gian Cesare; Pirali, Tracey; Billington, Richard A.; Canonico, Pier Luigi; Sorba, Giovanni; Genazzani, Armando A.</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">278-308</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  In recent years, there has been an ever-increasing need for rapid reactions that meet the three main criteria of an ideal synthesis: efficiency, versatility, and selectivity.  Such reactions would allow medicinal chem. to keep pace with the multitude of information derived from modern biol. screening techniques.  The present review describes one of these reactions, the 1,3-dipolar cycloaddn. ("click-reaction") between azides and alkynes catalyzed by copper (I) salts.  The simplicity of this reaction and the ease of purifn. of the resulting products have opened new opportunities in generating vast arrays of compds. with biol. potential.  The present review will outline the accomplishments of this strategy achieved so far and outline some of medicinal chem. applications in which click-chem. might be relevant in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbqDBrdkhYXrVg90H21EOLACvtfcHk0liP1oBX0aO8-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjsVerurg%253D&md5=ef565fc46c50047a6181e85711cb5c37</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1002%2Fmed.20107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.20107%26sid%3Dliteratum%253Aachs%26aulast%3DTron%26aufirst%3DG.%2BC.%26aulast%3DPirali%26aufirst%3DT.%26aulast%3DBillington%26aufirst%3DR.%2BA.%26aulast%3DCanonico%26aufirst%3DP.%2BL.%26aulast%3DSorba%26aufirst%3DG.%26aulast%3DGenazzani%26aufirst%3DA.%2BA.%26atitle%3DClick%2520chemistry%2520reactions%2520in%2520medicinal%2520chemistry%253A%2520applications%2520of%2520the%25201%252C3-dipolar%2520cycloaddition%2520between%2520azides%2520and%2520alkynes%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2008%26volume%3D28%26spage%3D278%26epage%3D308%26doi%3D10.1002%2Fmed.20107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aneja, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaiken, I.</span></span> <span> </span><span class="NLM_article-title">Click chemistry in peptide-based drug design</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">9797</span>– <span class="NLM_lpage">9817</span>, <span class="refDoi"> DOI: 10.3390/molecules18089797</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.3390%2Fmolecules18089797" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=23959192" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlKlsrbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2013&pages=9797-9817&author=H.+Liauthor=R.+Anejaauthor=I.+Chaiken&title=Click+chemistry+in+peptide-based+drug+design&doi=10.3390%2Fmolecules18089797"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Click chemistry in peptide-based drug design</span></div><div class="casAuthors">Li, Huiyuan; Aneja, Rachna; Chaiken, Irwin</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">9797-9817</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Click chem. is an efficient and chemoselective synthetic method for coupling mol. fragments under mild reaction conditions.  Since the advent in 2001 of methods to improve stereochem. conservation, the click chem. approach has been broadly used to construct diverse chemotypes in both chem. and biol. fields.  In this review, we discuss the application of click chem. in peptide-based drug design.  We highlight how triazoles formed by click reactions have been used for mimicking peptide and disulfide bonds, building secondary structural components of peptides, linking functional groups together, and bioconjugation.  The progress made in this field opens the way for synthetic approaches to convert peptides with promising functional leads into structure-minimized and more stable forms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoo3QhPT6JMbrVg90H21EOLACvtfcHk0liP1oBX0aO8-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlKlsrbN&md5=cc7cfed7b6249b9ce98a7051def886ee</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.3390%2Fmolecules18089797&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules18089797%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DH.%26aulast%3DAneja%26aufirst%3DR.%26aulast%3DChaiken%26aufirst%3DI.%26atitle%3DClick%2520chemistry%2520in%2520peptide-based%2520drug%2520design%26jtitle%3DMolecules%26date%3D2013%26volume%3D18%26spage%3D9797%26epage%3D9817%26doi%3D10.3390%2Fmolecules18089797" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kolb, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finn, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharpless, K. B.</span></span> <span> </span><span class="NLM_article-title">Click chemistry: Diverse chemical function from a few good reactions</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">2004</span>– <span class="NLM_lpage">2021</span>, <span class="refDoi"> DOI: 10.1002/1521-3773(20010601)40:11<2004::AID-ANIE2004>3.0.CO;2-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1002%2F1521-3773%2820010601%2940%3A11%3C2004%3A%3AAID-ANIE2004%3E3.0.CO%3B2-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=11433435" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD3MXksVOis78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2001&pages=2004-2021&author=H.+C.+Kolbauthor=M.+G.+Finnauthor=K.+B.+Sharpless&title=Click+chemistry%3A+Diverse+chemical+function+from+a+few+good+reactions&doi=10.1002%2F1521-3773%2820010601%2940%3A11%3C2004%3A%3AAID-ANIE2004%3E3.0.CO%3B2-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Click chemistry: diverse chemical function from a few good reactions</span></div><div class="casAuthors">Kolb, Hartmuth C.; Finn, M. G.; Sharpless, K. Barry</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2004-2021</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH</span>)
        </div><div class="casAbstract">Review with > 88 refs.  Examn. of nature's favorite mols. reveals a striking preference for making carbon-heteroatom bonds over carbon-carbon bonds - surely no surprise given that carbon dioxide is nature's starting material and that most reactions are performed in water.  Nucleic acids, proteins, and polysaccharides are condensation polymers of small subunits stitched together by carbon-heteroatom bonds.  Even the 35 or so building blocks from which these crucial mols. are made each contain, at most, six contiguous C-C bonds, except for the three arom. amino acids.  Taking a cue from nature's approach, the development of a set of powerful, highly reliable, and selective reactions for the rapid synthesis of useful new compds. and combinatorial libraries through heteroatom links (C-X-C), an approach called "click chem." is addressed.  Click chem. is at once defined, enabled, and constrained by a handful of nearly perfect "spring-loaded" reactions.  The stringent criteria for a process to earn click chem. status are described along with examples of the mol. frameworks that are easily made using this spartan, but powerful, synthetic strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptrjo9nxXNRrVg90H21EOLACvtfcHk0liP1oBX0aO8-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXksVOis78%253D&md5=61c28b416c42c87821bc8a5bc2fdec36</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1002%2F1521-3773%2820010601%2940%3A11%3C2004%3A%3AAID-ANIE2004%3E3.0.CO%3B2-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F1521-3773%252820010601%252940%253A11%253C2004%253A%253AAID-ANIE2004%253E3.0.CO%253B2-5%26sid%3Dliteratum%253Aachs%26aulast%3DKolb%26aufirst%3DH.%2BC.%26aulast%3DFinn%26aufirst%3DM.%2BG.%26aulast%3DSharpless%26aufirst%3DK.%2BB.%26atitle%3DClick%2520chemistry%253A%2520Diverse%2520chemical%2520function%2520from%2520a%2520few%2520good%2520reactions%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2001%26volume%3D40%26spage%3D2004%26epage%3D2021%26doi%3D10.1002%2F1521-3773%2820010601%2940%3A11%3C2004%3A%3AAID-ANIE2004%3E3.0.CO%3B2-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harper, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fullerton, S. E.</span></span> <span> </span><span class="NLM_article-title">Ethynyl and styryl compounds of the prodine type</span>. <i>J. Med. Pharm. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1961</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">297</span>– <span class="NLM_lpage">316</span>, <span class="refDoi"> DOI: 10.1021/jm50018a005</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm50018a005" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADyaF38XitlWk" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=1961&pages=297-316&author=N.+J.+Harperauthor=S.+E.+Fullerton&title=Ethynyl+and+styryl+compounds+of+the+prodine+type&doi=10.1021%2Fjm50018a005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Ethynyl and styryl compounds of the prodine type</span></div><div class="casAuthors">Harper, N. J.; Fullerton, S. E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal & Pharmaceutical Chemistry</span>
        (<span class="NLM_cas:date">1961</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">297-316</span>CODEN:
                <span class="NLM_cas:coden">JMPCAS</span>;
        ISSN:<span class="NLM_cas:issn">0095-9065</span>.
    </div><div class="casAbstract">N-Substituted 4-acetylenic-4-piperidinols and their acyloxy esters were synthesized.  N-Phenethyl-4-phenylethynyl-4-piperidinol was reduced to the 4-styryland 4-phenethyl analogs.  The compds. were assessed for analgesic activity to evaluate the effect of replacing the 4phenyl group in analgesics of the prodine type by an ethynyl or substituted ethynyl group.  The compds. were tested by the hot-plate and tail-pinch methods on mice, and although some of the compds. showed central nervous system activity, it was unlikely that they were true morphine-like analgesics.  Me2CO-free acetylene was bubbled through a suspension of sodamide (from 4.1 g. Na) in 750 ml. liquid NH3 contg. a trace of Fe(NO3)3 4 hrs. at -25°.  A soln. of 30.3 g.  N-phenethyl-4-piperidone in 150 ml. Et2O was added dropwise over 1 hr., the passage of acetylene through the soln. continued 6 hrs. more (with 25 ml. Et2C being added every 2 hrs.), 7.5 g. NH4Cl was added in small portions, followed by 50 ml. concd. NH4OH and 100 g. crushed ice.  The mixt. allowed to stand at room temp. overnight, extd. with 3 150-ml. portions CHCl3, the exts. extd. with 3 100- ml. portions dil. HCl, the acid soln. washed with Et2O, made alk. with NH4OH, extd. with 3 100-ml. portions CHCl3, the combined exts. evapd. to dryness, and the residue recrystd. from C6H6-petr. ether (40:60) gave N-phenethyl-4-ethynyl-4-piperidinol, m. 96.5-7.5°.  Also prepd. were:  N-phenethyl-3-methyl-4-phenylethynyl-4-piperidinol, m. 144.5°; N-methyl-3-methyl-4-phenylethynyl-4-piperidinol, m. 144.5°; N-phenethyl-3-methyl-4-chloro-4-phenylethynylpiperidone-HCl, m. 199°.  A soln. of 3.5 g. N-phenethyl- 4-phenylethynyl-4-piperidinol in 50 ml. tetrahydrofuran was added to a suspension of 0.4 g. LiAlH4 in 77 ml. tetrahydrofuran during 0.5 hr., the mixt. refluxed 3 hrs., cooled, the product decompd. with damp tetrahydrofuran, filtered, evapd., and crystd. from C6H6 to give trans-N-phenethyl-4styryl-4-piperidinol, isomer A, m. 127.5°.  Also prepd. were:  N-phenethyl-3-methyl-4-phenylethynyl-4-piperidinol, m. 111-2°; N-methyl-3-methyl-4-phenylethynyl-4piperidinol, isomer A, m. 159.5°; isomer B, m. 130.5°; N-phenethyl-4-acetoxy-4-phenethylpiperidine-HCl, m. 241°; N-phenethyl-4-styryl-1,2,5,6-tetrahydropyridineHCl, m. 252-4° (decompn.); trans-N-phenethyl-4-acetoxy-4-styrylpiperidine-HCl, isomer A, m. 247.5-9.5°; cis-N-phenethyl-4-acetoxy-4-styrylpiperidine-HCl, isomer B, m. 190.5-1.5°; N-phenethyl-3-methyl-4-piperidone, m. 111-12°; N-phenethyl-4-bromoethynyl-4-piperidinol-HCl, m. 192.5-5.5° (decompn.); N-phenethyl-4-cyano-4-piperidinol, m. 93°; N-phenethyl-4-acetoxy-4-cyanopiperidine-HCl, m. 258.5°; N-phenethyl-4-cyano-4-propionyloxypiperidine-HCl, m. 245°; N-phenethyl-4-carboxy-4-piperidinol-HCl, m. 176.5°.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2x4wtLUaPy7Vg90H21EOLACvtfcHk0lhHJPlXXGcA2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF38XitlWk&md5=0537af38e9d24425eb6b6eb502b3f953</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fjm50018a005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm50018a005%26sid%3Dliteratum%253Aachs%26aulast%3DHarper%26aufirst%3DN.%2BJ.%26aulast%3DFullerton%26aufirst%3DS.%2BE.%26atitle%3DEthynyl%2520and%2520styryl%2520compounds%2520of%2520the%2520prodine%2520type%26jtitle%3DJ.%2520Med.%2520Pharm.%2520Chem.%26date%3D1961%26volume%3D4%26spage%3D297%26epage%3D316%26doi%3D10.1021%2Fjm50018a005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Easton, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dillard, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henderson, F. G.</span></span> <span> </span><span class="NLM_article-title">Acetylenic amines. III. The haloethynyl derivatives</span>. <i>J. Med. Pharm. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1962</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">780</span>– <span class="NLM_lpage">784</span>, <span class="refDoi"> DOI: 10.1021/jm01239a011</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm01239a011" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADyaF38Xks1ylu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1962&pages=780-784&author=C.+W.+Ryanauthor=N.+R.+Eastonauthor=R.+D.+Dillardauthor=F.+G.+Henderson&title=Acetylenic+amines.+III.+The+haloethynyl+derivatives&doi=10.1021%2Fjm01239a011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Acetylenic amines. III. The haloethynyl derivatives</span></div><div class="casAuthors">Ryan, C. W.; Easton, Nelson E.; Dillard, Robert D.; Henderson, Francis G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal & Pharmaceutical Chemistry</span>
        (<span class="NLM_cas:date">1962</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">780-4</span>CODEN:
                <span class="NLM_cas:coden">JMPCAS</span>;
        ISSN:<span class="NLM_cas:issn">0095-9065</span>.
    </div><div class="casAbstract">A series of 15 haloethynyl analogs of acetylenic amines were prepd.  The bromo compds. were more potent than the chloro compds., and the most potent compd., 3-tert-butylamino-3-methyl-1-bromo-1-butyne-HCl, was about as potent as the nonhalogenated analog in tests on hypertensive rats.  Na (2.5 g.) was added to 300 ml. liquid NH3 contg. a trace of Fe(NO3)3, 13.9 g. 3-(tert-butylamino)-3-methyl-1-butyne was added dropwise, the soln. stirred 1 hr. 250 ml. dry Et2O added, the mixt. warmed to release the NH3, then refluxed 1 hr.  The soln. was cooled, 20 g. p-toluenesulfonyl chloride in 150 ml. dry Et2O added over 5 min., the mixt. refluxed with stirring 2 hrs., allowed to stand overnight, 200 ml. H2O added cautiously, the org. layer sepd., dried, and concd. in vacuo, the residue distd. at 45-50° and 9 mm., and then redistd. to give 7 g. oil, b10 55°, n25D 1.4510.  This oil was mixed with excess HCl-EtOH, and the salt recrystd. from EtOAc to give 3.5 g. 3-(tert-butylamino)-1-chloro-3-methyl1-butyne-HCl.  A soln. of 30 g. 3-ethylamino-3-methyl-1-butyne, 15 g. ethylene oxide, and 500 ml. EtOH was stirred 14 hrs. at room temp., then refluxed 2 hrs., cooled, 10% HCl-EtOH added until acidic to litmus, the solvent removed in vacuo, the residue dissolved in H2O, made alk. to litmus with 50% NaOH, extd. with Et2O, the org. layer sepd., dried and distd. to give 9.5 g. 3-(2-hydroxydiethylamino)-3-methyl-1-butyne, bl0 89-90°, n25D 1.4529.  3-(2-Hydroxydiethylamino)-3-methyl-1-butyne-HCl (38.1 g.) in 100 ml. CHCl3 was mixed with 40 ml. dihydropyran and 5 drops H2SO4, stirred 4 hrs., 100 ml. 20% NaOH added, the org. layer sepd., dried, concd. on a steam bath, and the residue distd. to give 44.2 g. 3-methyl-3-[2-(2-tetrahydropyranoxy)diethylamino]-1-butyne, b1 82°, n25D 1.4652.  Prepd. similarly were: 1-chloro-3-(2-hydroxydiethylamino)3-methyl-1-butyne, b1 73-5°, n25D 1.4793-1.4800; 3-tert-butylamino-3-methyl-1-bromo-1-butyne, m. 41-2°; 1-bromoethynyl-1-(tert-butylamino)cyclohexane-HCl,in. 232-4°.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkm5tOzbQkibVg90H21EOLACvtfcHk0lhHJPlXXGcA2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF38Xks1ylu7o%253D&md5=9994c910f1e1e9441d0610699e070af7</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Fjm01239a011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm01239a011%26sid%3Dliteratum%253Aachs%26aulast%3DRyan%26aufirst%3DC.%2BW.%26aulast%3DEaston%26aufirst%3DN.%2BR.%26aulast%3DDillard%26aufirst%3DR.%2BD.%26aulast%3DHenderson%26aufirst%3DF.%2BG.%26atitle%3DAcetylenic%2520amines.%2520III.%2520The%2520haloethynyl%2520derivatives%26jtitle%3DJ.%2520Med.%2520Pharm.%2520Chem.%26date%3D1962%26volume%3D5%26spage%3D780%26epage%3D784%26doi%3D10.1021%2Fjm01239a011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neumeyer, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cannon, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckley, J. P.</span></span> <span> </span><span class="NLM_article-title">Synthesis and hypotensive activity of unsymmetrically substituted acetylenic bis-quaternary ammonium compounds and certain of their reduction products</span>. <i>J. Med. Pharm. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1962</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">784</span>– <span class="NLM_lpage">792</span>, <span class="refDoi"> DOI: 10.1021/jm01239a012</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm01239a012" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADyaF38XkslaitLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1962&pages=784-792&author=J.+L.+Neumeyerauthor=J.+G.+Cannonauthor=J.+P.+Buckley&title=Synthesis+and+hypotensive+activity+of+unsymmetrically+substituted+acetylenic+bis-quaternary+ammonium+compounds+and+certain+of+their+reduction+products&doi=10.1021%2Fjm01239a012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and hypotensive activity of unsymmetrically substituted acetylenic bisquaternary ammonium compounds and certain of their reduction products</span></div><div class="casAuthors">Neumeyer, John L.; Cannon, Joseph G.; Buckley, Joseph P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal & Pharmaceutical Chemistry</span>
        (<span class="NLM_cas:date">1962</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">784-92</span>CODEN:
                <span class="NLM_cas:coden">JMPCAS</span>;
        ISSN:<span class="NLM_cas:issn">0095-9065</span>.
    </div><div class="casAbstract">Twelve acetylenic bisquaternary compds. derived from quinoline were prepd. as a part of a structure-activity study of steric requirements for ganglionic blockade.  The compds. were screened for hypotensive activity in anesthetized normotensive rats and dogs, and the results were consistent with Gill's concept of the significance of interquaternary distance in ganglionic blockade (CA 53, 15347c).  Several of the compds. were reduced stereospecifically to the cis- and trans-olefins, and further to alkanes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNDhSydYROMbVg90H21EOLACvtfcHk0lhHJPlXXGcA2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF38XkslaitLo%253D&md5=dc147ca2244a39a2d711cb12bcabb058</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Fjm01239a012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm01239a012%26sid%3Dliteratum%253Aachs%26aulast%3DNeumeyer%26aufirst%3DJ.%2BL.%26aulast%3DCannon%26aufirst%3DJ.%2BG.%26aulast%3DBuckley%26aufirst%3DJ.%2BP.%26atitle%3DSynthesis%2520and%2520hypotensive%2520activity%2520of%2520unsymmetrically%2520substituted%2520acetylenic%2520bis-quaternary%2520ammonium%2520compounds%2520and%2520certain%2520of%2520their%2520reduction%2520products%26jtitle%3DJ.%2520Med.%2520Pharm.%2520Chem.%26date%3D1962%26volume%3D5%26spage%3D784%26epage%3D792%26doi%3D10.1021%2Fjm01239a012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerman, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ariëns, E. J.</span></span> <span> </span><span class="NLM_article-title">1-Ethynylphenethylamine1</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1966</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">469</span>– <span class="NLM_lpage">470</span>, <span class="refDoi"> DOI: 10.1021/jm00322a004</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00322a004" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADyaF28Xkt1Snu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1966&pages=469-470&author=A.+Burgerauthor=S.+E.+Zimmermanauthor=E.+J.+Ari%C3%ABns&title=1-Ethynylphenethylamine1&doi=10.1021%2Fjm00322a004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">1-Ethynylphenethylamine</span></div><div class="casAuthors">Burger, Alfred; Zimmerman, Stuart E.; Ariens, E. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1966</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">469-70</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">The synthesis of 1-ethynylphenethylamine (I) is described.  I appears to protect phenethylamine from biol. deamination and reveals its central nervous system activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxFHzvdMquErVg90H21EOLACvtfcHk0lhHJPlXXGcA2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF28Xkt1Snu7s%253D&md5=8537b90608dcf466d933145671a4cb31</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fjm00322a004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00322a004%26sid%3Dliteratum%253Aachs%26aulast%3DBurger%26aufirst%3DA.%26aulast%3DZimmerman%26aufirst%3DS.%2BE.%26aulast%3DAri%25C3%25ABns%26aufirst%3DE.%2BJ.%26atitle%3D1-Ethynylphenethylamine1%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1966%26volume%3D9%26spage%3D469%26epage%3D470%26doi%3D10.1021%2Fjm00322a004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Christiansen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urban, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merten, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liebscher, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlsen, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamacher, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spinrath, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bond, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewke, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ullrich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kassack, M. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kostenis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulven, T.</span></span> <span> </span><span class="NLM_article-title">Discovery of potent and selective agonists for the free fatty acid receptor 1 (FFA(1)/GPR40), a potential target for the treatment of type II diabetes</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">7061</span>– <span class="NLM_lpage">7064</span>, <span class="refDoi"> DOI: 10.1021/jm8010178</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm8010178" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht12qt73J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=7061-7064&author=E.+Christiansenauthor=C.+Urbanauthor=N.+Mertenauthor=K.+Liebscherauthor=K.+K.+Karlsenauthor=A.+Hamacherauthor=A.+Spinrathauthor=A.+D.+Bondauthor=C.+Drewkeauthor=S.+Ullrichauthor=M.+U.+Kassackauthor=E.+Kostenisauthor=T.+Ulven&title=Discovery+of+potent+and+selective+agonists+for+the+free+fatty+acid+receptor+1+%28FFA%281%29%2FGPR40%29%2C+a+potential+target+for+the+treatment+of+type+II+diabetes&doi=10.1021%2Fjm8010178"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Potent and Selective Agonists for the Free Fatty Acid Receptor 1 (FFA1/GPR40), a Potential Target for the Treatment of Type II Diabetes</span></div><div class="casAuthors">Christiansen, Elisabeth; Urban, Christian; Merten, Nicole; Liebscher, Kathrin; Karlsen, Kasper K.; Hamacher, Alexandra; Spinrath, Andreas; Bond, Andrew D.; Drewke, Christel; Ullrich, Susanne; Kassack, Matthias U.; Kostenis, Evi; Ulven, Trond</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">7061-7064</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of 4-phenethynyldihydrocinnamic acid agonists of the free fatty acid receptor 1 (FFA1) has been discovered and explored.  The preferred compd. 20 (TUG-424, EC50 = 32 nM) significantly increased glucose-stimulated insulin secretion at 100 nM and may serve to explore the role of FFA1 in metabolic diseases such as diabetes or obesity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBq5qOnlccv7Vg90H21EOLACvtfcHk0liEQLbgHwM0bA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht12qt73J&md5=b097bb659bc0b5adbbd6c8757f820214</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fjm8010178&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8010178%26sid%3Dliteratum%253Aachs%26aulast%3DChristiansen%26aufirst%3DE.%26aulast%3DUrban%26aufirst%3DC.%26aulast%3DMerten%26aufirst%3DN.%26aulast%3DLiebscher%26aufirst%3DK.%26aulast%3DKarlsen%26aufirst%3DK.%2BK.%26aulast%3DHamacher%26aufirst%3DA.%26aulast%3DSpinrath%26aufirst%3DA.%26aulast%3DBond%26aufirst%3DA.%2BD.%26aulast%3DDrewke%26aufirst%3DC.%26aulast%3DUllrich%26aufirst%3DS.%26aulast%3DKassack%26aufirst%3DM.%2BU.%26aulast%3DKostenis%26aufirst%3DE.%26aulast%3DUlven%26aufirst%3DT.%26atitle%3DDiscovery%2520of%2520potent%2520and%2520selective%2520agonists%2520for%2520the%2520free%2520fatty%2520acid%2520receptor%25201%2520%2528FFA%25281%2529%252FGPR40%2529%252C%2520a%2520potential%2520target%2520for%2520the%2520treatment%2520of%2520type%2520II%2520diabetes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D7061%26epage%3D7064%26doi%3D10.1021%2Fjm8010178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Christiansen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urban, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grundmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Due-Hansen, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagesaether, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ullrich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kostenis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kassack, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulven, T.</span></span> <span> </span><span class="NLM_article-title">Identification of a potent and selective free fatty acid receptor 1 (FFA1/GPR40) agonist with favorable physicochemical and in vitro ADME properties</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">6691</span>– <span class="NLM_lpage">6703</span>, <span class="refDoi"> DOI: 10.1021/jm2005699</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2005699" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFKrs7%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6691-6703&author=E.+Christiansenauthor=C.+Urbanauthor=M.+Grundmannauthor=M.+E.+Due-Hansenauthor=E.+Hagesaetherauthor=J.+Schmidtauthor=L.+Pardoauthor=S.+Ullrichauthor=E.+Kostenisauthor=M.+Kassackauthor=T.+Ulven&title=Identification+of+a+potent+and+selective+free+fatty+acid+receptor+1+%28FFA1%2FGPR40%29+agonist+with+favorable+physicochemical+and+in+vitro+ADME+properties&doi=10.1021%2Fjm2005699"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a Potent and Selective Free Fatty Acid Receptor 1 (FFA1/GPR40) Agonist with Favorable Physicochemical and in Vitro ADME Properties</span></div><div class="casAuthors">Christiansen, Elisabeth; Urban, Christian; Grundmann, Manuel; Due-Hansen, Maria E.; Hagesaether, Ellen; Schmidt, Johannes; Pardo, Leonardo; Ullrich, Susanne; Kostenis, Evi; Kassack, Matthias; Ulven, Trond</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">6691-6703</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The free fatty acid receptor 1 (FFA1, also known as GPR40) enhances glucose-stimulated insulin secretion from pancreatic β-cells and is recognized as an interesting new target for treatment of type 2 diabetes.  Several series of selective FFA1 agonists are already known.  Most of these are derived from free fatty acids (FFAs) or glitazones and are relatively lipophilic.  Aiming for the development of potent, selective, and less lipophilic FFA1 agonists, the terminal Ph of a known compd. series was replaced by nitrogen contg. heterocycles.  This resulted in the identification of 37, a selective FFA1 agonist with potent activity on recombinant human FFA1 receptors and on the rat insulinoma cell line INS-1E, optimal lipophilicity, and excellent in vitro permeability and metabolic stability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojEP11kF9rsLVg90H21EOLACvtfcHk0liEQLbgHwM0bA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFKrs7%252FE&md5=e21df7c246c56e61708c3937c272350e</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm2005699&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2005699%26sid%3Dliteratum%253Aachs%26aulast%3DChristiansen%26aufirst%3DE.%26aulast%3DUrban%26aufirst%3DC.%26aulast%3DGrundmann%26aufirst%3DM.%26aulast%3DDue-Hansen%26aufirst%3DM.%2BE.%26aulast%3DHagesaether%26aufirst%3DE.%26aulast%3DSchmidt%26aufirst%3DJ.%26aulast%3DPardo%26aufirst%3DL.%26aulast%3DUllrich%26aufirst%3DS.%26aulast%3DKostenis%26aufirst%3DE.%26aulast%3DKassack%26aufirst%3DM.%26aulast%3DUlven%26aufirst%3DT.%26atitle%3DIdentification%2520of%2520a%2520potent%2520and%2520selective%2520free%2520fatty%2520acid%2520receptor%25201%2520%2528FFA1%252FGPR40%2529%2520agonist%2520with%2520favorable%2520physicochemical%2520and%2520in%2520vitro%2520ADME%2520properties%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6691%26epage%3D6703%26doi%3D10.1021%2Fjm2005699" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christiansen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urban, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudson, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stocker, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Due-Hansen, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wargent, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimpukade, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almeida, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ejsing, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cawthorne, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kassack, M. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milligan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulven, T.</span></span> <span> </span><span class="NLM_article-title">Discovery of a potent free fatty acid 1 receptor agonist with low lipophilicity, low polar surface area, and robust in vivo efficacy</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">2841</span>– <span class="NLM_lpage">2846</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01962</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01962" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC28XjsFaqsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=2841-2846&author=S.+V.+Hansenauthor=E.+Christiansenauthor=C.+Urbanauthor=B.+D.+Hudsonauthor=C.+J.+Stockerauthor=M.+E.+Due-Hansenauthor=E.+T.+Wargentauthor=B.+Shimpukadeauthor=R.+Almeidaauthor=C.+S.+Ejsingauthor=M.+A.+Cawthorneauthor=M.+U.+Kassackauthor=G.+Milliganauthor=T.+Ulven&title=Discovery+of+a+potent+free+fatty+acid+1+receptor+agonist+with+low+lipophilicity%2C+low+polar+surface+area%2C+and+robust+in+vivo+efficacy&doi=10.1021%2Facs.jmedchem.5b01962"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent Free Fatty Acid 1 Receptor Agonist with Low Lipophilicity, Low Polar Surface Area, and Robust in Vivo Efficacy</span></div><div class="casAuthors">Hansen, Steffen V. F.; Christiansen, Elisabeth; Urban, Christian; Hudson, Brian D.; Stocker, Claire J.; Due-Hansen, Maria E.; Wargent, Ed T.; Shimpukade, Bharat; Almeida, Reinaldo; Ejsing, Christer S.; Cawthorne, Michael A.; Kassack, Matthias U.; Milligan, Graeme; Ulven, Trond</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2841-2846</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The free fatty acid receptor 1 (FFA1 or GPR40) is established as an interesting potential target for treatment of type 2 diabetes.  However, to obtain optimal ligands, it may be necessary to limit both lipophilicity and polar surface area, translating to a need for small compds.  We here describe the identification of 24, a potent FFA1 agonist with low lipophilicity and very high ligand efficiency that exhibit robust glucose lowering effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzSC_3c__9I7Vg90H21EOLACvtfcHk0lizm1rS77PSwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjsFaqsLg%253D&md5=fd45247c6b2bb272cc23b84cb97391d9</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01962&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01962%26sid%3Dliteratum%253Aachs%26aulast%3DHansen%26aufirst%3DS.%2BV.%26aulast%3DChristiansen%26aufirst%3DE.%26aulast%3DUrban%26aufirst%3DC.%26aulast%3DHudson%26aufirst%3DB.%2BD.%26aulast%3DStocker%26aufirst%3DC.%2BJ.%26aulast%3DDue-Hansen%26aufirst%3DM.%2BE.%26aulast%3DWargent%26aufirst%3DE.%2BT.%26aulast%3DShimpukade%26aufirst%3DB.%26aulast%3DAlmeida%26aufirst%3DR.%26aulast%3DEjsing%26aufirst%3DC.%2BS.%26aulast%3DCawthorne%26aufirst%3DM.%2BA.%26aulast%3DKassack%26aufirst%3DM.%2BU.%26aulast%3DMilligan%26aufirst%3DG.%26aulast%3DUlven%26aufirst%3DT.%26atitle%3DDiscovery%2520of%2520a%2520potent%2520free%2520fatty%2520acid%25201%2520receptor%2520agonist%2520with%2520low%2520lipophilicity%252C%2520low%2520polar%2520surface%2520area%252C%2520and%2520robust%2520in%2520vivo%2520efficacy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D2841%26epage%3D2846%26doi%3D10.1021%2Facs.jmedchem.5b01962" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vranesic, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ofner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flor, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bilbe, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouhelal, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desrayaud, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McAllister, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhn, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasparini, F.</span></span> <span> </span><span class="NLM_article-title">AFQ056/mavoglurant, a novel clinically effective mGluR5 antagonist: identification, SAR and pharmacological characterization</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">5790</span>– <span class="NLM_lpage">5803</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2014.09.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1016%2Fj.bmc.2014.09.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=25316499" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslGns7bJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=5790-5803&author=I.+Vranesicauthor=S.+Ofnerauthor=P.+J.+Florauthor=G.+Bilbeauthor=R.+Bouhelalauthor=A.+Enzauthor=S.+Desrayaudauthor=K.+McAllisterauthor=R.+Kuhnauthor=F.+Gasparini&title=AFQ056%2Fmavoglurant%2C+a+novel+clinically+effective+mGluR5+antagonist%3A+identification%2C+SAR+and+pharmacological+characterization&doi=10.1016%2Fj.bmc.2014.09.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">AFQ056/mavoglurant, a novel clinically effective mGluR5 antagonist: Identification, SAR and pharmacological characterization</span></div><div class="casAuthors">Vranesic, Ivo; Ofner, Silvio; Flor, Peter Josef; Bilbe, Graeme; Bouhelal, Rochdi; Enz, Albert; Desrayaud, Sandrine; McAllister, Kevin; Kuhn, Rainer; Gasparini, Fabrizio</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5790-5803</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Here we describe the identification, structure-activity relation and the initial pharmacol. characterization of AFQ056/mavoglurant, a structurally novel, non-competitive mGlu5 receptor antagonist.  AFQ056/mavoglurant was identified by chem. derivatization of a lead compd. discovered in a HTS campaign.  In vitro, AFQ056/mavoglurant had an IC50 of 30 nM in a functional assay with human mGluR5 and was selective over the other mGluR subtypes, iGluRs and a panel of 238 CNS relevant receptors, transporter or enzymes.  In vivo, AFQ056/mavoglurant showed an improved pharmacokinetic profile in rat and efficacy in the stress-induced hyperthermia test in mice as compared to the prototypic mGluR5 antagonist MPEP.  The efficacy of AFQ056/mavoglurant in humans has been assessed in L-dopa induced dyskinesia in Parkinson's disease and Fragile X syndrome in proof of principle clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomfnTAWNW_RbVg90H21EOLACvtfcHk0lizm1rS77PSwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslGns7bJ&md5=a34ab6585a186730f2fbf09d8c97180c</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2014.09.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2014.09.033%26sid%3Dliteratum%253Aachs%26aulast%3DVranesic%26aufirst%3DI.%26aulast%3DOfner%26aufirst%3DS.%26aulast%3DFlor%26aufirst%3DP.%2BJ.%26aulast%3DBilbe%26aufirst%3DG.%26aulast%3DBouhelal%26aufirst%3DR.%26aulast%3DEnz%26aufirst%3DA.%26aulast%3DDesrayaud%26aufirst%3DS.%26aulast%3DMcAllister%26aufirst%3DK.%26aulast%3DKuhn%26aufirst%3DR.%26aulast%3DGasparini%26aufirst%3DF.%26atitle%3DAFQ056%252Fmavoglurant%252C%2520a%2520novel%2520clinically%2520effective%2520mGluR5%2520antagonist%253A%2520identification%252C%2520SAR%2520and%2520pharmacological%2520characterization%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2014%26volume%3D22%26spage%3D5790%26epage%3D5803%26doi%3D10.1016%2Fj.bmc.2014.09.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balakrishnan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sivarao, D. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Easton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulianello, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanumegowda, U. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matchett, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattson, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santone, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senapati, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shields, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simutis, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westphal, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whiterock, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bronson, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macor, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degnan, A. P.</span></span> <span> </span><span class="NLM_article-title">Discovery and preclinical evaluation of BMS-955829, a potent positive allosteric modulator of mGluR5</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">289</span>– <span class="NLM_lpage">293</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00450</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00450" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVaqsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=289-293&author=F.+Yangauthor=L.+B.+Snyderauthor=A.+Balakrishnanauthor=J.+M.+Brownauthor=D.+V.+Sivaraoauthor=A.+Eastonauthor=A.+Fernandesauthor=M.+Gulianelloauthor=U.+M.+Hanumegowdaauthor=H.+Huangauthor=Y.+Huangauthor=K.+M.+Jonesauthor=Y.+W.+Liauthor=M.+Matchettauthor=G.+Mattsonauthor=R.+Millerauthor=K.+S.+Santoneauthor=A.+Senapatiauthor=E.+E.+Shieldsauthor=F.+J.+Simutisauthor=R.+Westphalauthor=V.+J.+Whiterockauthor=J.+J.+Bronsonauthor=J.+E.+Macorauthor=A.+P.+Degnan&title=Discovery+and+preclinical+evaluation+of+BMS-955829%2C+a+potent+positive+allosteric+modulator+of+mGluR5&doi=10.1021%2Facsmedchemlett.5b00450"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Preclinical Evaluation of BMS-955829, a Potent Positive Allosteric Modulator of mGluR5</span></div><div class="casAuthors">Yang, Fukang; Snyder, Lawrence B.; Balakrishnan, Anand; Brown, Jeffrey M.; Sivarao, Digavalli V.; Easton, Amy; Fernandes, Alda; Gulianello, Michael; Hanumegowda, Umesh M.; Huang, Hong; Huang, Yanling; Jones, Kelli M.; Li, Yu-Wen; Matchett, Michele; Mattson, Gail; Miller, Regina; Santone, Kenneth S.; Senapati, Arun; Shields, Eric E.; Simutis, Frank J.; Westphal, Ryan; Whiterock, Valerie J.; Bronson, Joanne J.; Macor, John E.; Degnan, Andrew P.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">289-293</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Pos. allosteric modulators (PAMs) of the metabotropic glutamate receptor subtype 5 (mGluR5) are of interest due to their potential therapeutic utility in schizophrenia and other cognitive disorders.  Herein we describe the discovery and optimization of a novel oxazolidinone-based chemotype to identify BMS-955829 (4), a compd. with high functional PAM potency, excellent mGluR5 binding affinity, low glutamate fold shift, and high selectivity for the mGluR5 subtype.  The low fold shift and absence of agonist activity proved crit. in the identification of a mol. with an acceptable preclin. safety profile.  Despite its low fold shift, 4 retained efficacy in set shifting and novel object recognition models in rodents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeCsDWyDOvK7Vg90H21EOLACvtfcHk0lizm1rS77PSwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVaqsA%253D%253D&md5=07f54ebf4e79aa16bd51823b81897975</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00450&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00450%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DF.%26aulast%3DSnyder%26aufirst%3DL.%2BB.%26aulast%3DBalakrishnan%26aufirst%3DA.%26aulast%3DBrown%26aufirst%3DJ.%2BM.%26aulast%3DSivarao%26aufirst%3DD.%2BV.%26aulast%3DEaston%26aufirst%3DA.%26aulast%3DFernandes%26aufirst%3DA.%26aulast%3DGulianello%26aufirst%3DM.%26aulast%3DHanumegowda%26aufirst%3DU.%2BM.%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DJones%26aufirst%3DK.%2BM.%26aulast%3DLi%26aufirst%3DY.%2BW.%26aulast%3DMatchett%26aufirst%3DM.%26aulast%3DMattson%26aufirst%3DG.%26aulast%3DMiller%26aufirst%3DR.%26aulast%3DSantone%26aufirst%3DK.%2BS.%26aulast%3DSenapati%26aufirst%3DA.%26aulast%3DShields%26aufirst%3DE.%2BE.%26aulast%3DSimutis%26aufirst%3DF.%2BJ.%26aulast%3DWestphal%26aufirst%3DR.%26aulast%3DWhiterock%26aufirst%3DV.%2BJ.%26aulast%3DBronson%26aufirst%3DJ.%2BJ.%26aulast%3DMacor%26aufirst%3DJ.%2BE.%26aulast%3DDegnan%26aufirst%3DA.%2BP.%26atitle%3DDiscovery%2520and%2520preclinical%2520evaluation%2520of%2520BMS-955829%252C%2520a%2520potent%2520positive%2520allosteric%2520modulator%2520of%2520mGluR5%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D289%26epage%3D293%26doi%3D10.1021%2Facsmedchemlett.5b00450" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Turlington, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noetzel, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chun, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gogliotti, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregory, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinson, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rook, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gogi, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bridges, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniels, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niswender, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meiler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conn, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindsley, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stauffer, S. R.</span></span> <span> </span><span class="NLM_article-title">Exploration of allosteric agonism structure-activity relationships within an acetylene series of metabotropic glutamate receptor 5 (mGlu5) positive allosteric modulators (PAMs): discovery of 5-((3-fluorophenyl)ethynyl)-N-(3-methyloxetan-3-yl)picolinamide (ML254)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">7976</span>– <span class="NLM_lpage">7996</span>, <span class="refDoi"> DOI: 10.1021/jm401028t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401028t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVynsr7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=7976-7996&author=M.+Turlingtonauthor=M.+J.+Noetzelauthor=A.+Chunauthor=Y.+Zhouauthor=R.+D.+Gogliottiauthor=E.+D.+Nguyenauthor=K.+J.+Gregoryauthor=P.+N.+Vinsonauthor=J.+M.+Rookauthor=K.+K.+Gogiauthor=Z.+Xiangauthor=T.+M.+Bridgesauthor=J.+S.+Danielsauthor=C.+Jonesauthor=C.+M.+Niswenderauthor=J.+Meilerauthor=P.+J.+Connauthor=C.+W.+Lindsleyauthor=S.+R.+Stauffer&title=Exploration+of+allosteric+agonism+structure-activity+relationships+within+an+acetylene+series+of+metabotropic+glutamate+receptor+5+%28mGlu5%29+positive+allosteric+modulators+%28PAMs%29%3A+discovery+of+5-%28%283-fluorophenyl%29ethynyl%29-N-%283-methyloxetan-3-yl%29picolinamide+%28ML254%29&doi=10.1021%2Fjm401028t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Exploration of Allosteric Agonism Structure-Activity Relationships within an Acetylene Series of Metabotropic Glutamate Receptor 5 (mGlu5) Positive Allosteric Modulators (PAMs): Discovery of 5((3-Fluorophenyl)ethynyl)N(3-methyloxetan-3-yl)picolinamide (ML254)</span></div><div class="casAuthors">Turlington, Mark; Noetzel, Meredith J.; Chun, Aspen; Zhou, Ya; Gogliotti, Rocco D.; Nguyen, Elizabeth D.; Gregory, Karen J.; Vinson, Paige N.; Rook, Jerri M.; Gogi, Kiran K.; Xiang, Zixiu; Bridges, Thomas M.; Daniels, J. Scott; Jones, Carrie; Niswender, Colleen M.; Meiler, Jens; Conn, P. Jeffrey; Lindsley, Craig W.; Stauffer, Shaun R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7976-7996</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Pos. allosteric modulators (PAMs) of metabotropic glutamate receptor 5 (mGlu5) represent a promising therapeutic strategy for the treatment of schizophrenia.  Both allosteric agonism and high glutamate fold-shift have been implicated in the neurotoxic profile of some mGlu5 PAMs; however, these hypotheses remain to be adequately addressed.  To develop tool compds. to probe these hypotheses, the structure-activity relationship of allosteric agonism was examd. within an acetylenic series of mGlu5 PAMs exhibiting allosteric agonism in addn. to pos. allosteric modulation (ago-PAMs).  PAM 38t, a low glutamate fold-shift allosteric ligand (max. fold-shift ∼3.0), was selected as a potent PAM with no agonism in the in vitro system used for compd. characterization and in two native electrophysiol. systems using rat hippocampal slices.  PAM 38t (ML254) will be useful to probe the relative contribution of cooperativity and allosteric agonism to the adverse effect liability and neurotoxicity assocd. with this class of mGlu5 PAMs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnDUnm1DOpl7Vg90H21EOLACvtfcHk0lgg0X26F1wFvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVynsr7K&md5=6cde52e3bce520515109ee638054230a</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjm401028t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401028t%26sid%3Dliteratum%253Aachs%26aulast%3DTurlington%26aufirst%3DM.%26aulast%3DNoetzel%26aufirst%3DM.%2BJ.%26aulast%3DChun%26aufirst%3DA.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DGogliotti%26aufirst%3DR.%2BD.%26aulast%3DNguyen%26aufirst%3DE.%2BD.%26aulast%3DGregory%26aufirst%3DK.%2BJ.%26aulast%3DVinson%26aufirst%3DP.%2BN.%26aulast%3DRook%26aufirst%3DJ.%2BM.%26aulast%3DGogi%26aufirst%3DK.%2BK.%26aulast%3DXiang%26aufirst%3DZ.%26aulast%3DBridges%26aufirst%3DT.%2BM.%26aulast%3DDaniels%26aufirst%3DJ.%2BS.%26aulast%3DJones%26aufirst%3DC.%26aulast%3DNiswender%26aufirst%3DC.%2BM.%26aulast%3DMeiler%26aufirst%3DJ.%26aulast%3DConn%26aufirst%3DP.%2BJ.%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26aulast%3DStauffer%26aufirst%3DS.%2BR.%26atitle%3DExploration%2520of%2520allosteric%2520agonism%2520structure-activity%2520relationships%2520within%2520an%2520acetylene%2520series%2520of%2520metabotropic%2520glutamate%2520receptor%25205%2520%2528mGlu5%2529%2520positive%2520allosteric%2520modulators%2520%2528PAMs%2529%253A%2520discovery%2520of%25205-%2528%25283-fluorophenyl%2529ethynyl%2529-N-%25283-methyloxetan-3-yl%2529picolinamide%2520%2528ML254%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D7976%26epage%3D7996%26doi%3D10.1021%2Fjm401028t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guengerich, F. P.</span></span> <span> </span><span class="NLM_article-title">Oxidation of 17 alpha-ethynylestradiol by human liver cytochrome P-450</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">500</span>– <span class="NLM_lpage">508</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=3285175" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADyaL1cXktFOitLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=1988&pages=500-508&author=F.+P.+Guengerich&title=Oxidation+of+17+alpha-ethynylestradiol+by+human+liver+cytochrome+P-450"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Oxidation of 17α-ethynylestradiol by human liver cytochrome P-450</span></div><div class="casAuthors">Guengerich, F. Peter</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">500-8</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    </div><div class="casAbstract">Previous work had demonstrated increased metab. (2-hydroxylation) of 17α-ethynylestradiol in individuals using rifampicin.  Evidence is presented for the involvement of a specific form of human cytochrome P 450, termed P-450NF, in this phenomenon.  Although purified P-450NF has only relatively low catalytic 17α-ethynylestradiol 2-hydroxylase activity, antibodies raised to P-450NF specifically inhibited >90% of the activity in liver microsomes which had either high or low catalytic activity.  When different liver samples were compared, rates of microsomal 17α-ethynylestradiol 2-hydroxylation were highly correlated with amts. of immunochem. measured P-450NF or rates of nifedipine oxidn., a characteristic activity of P-450NF.  Prior incubation of human liver microsomes with NADPH and troleandomycin resulted in decreased 17α-ethynylestradiol 2-hydroxylation.  In addn., 17α-ethynylestradiol appears to be a mechanism-based inhibitor in human liver microsomes, as shown by the loss of both spectrally detectable cytochrome P 450 and 17α-ethynylestradiol 2-hydroxylase activity during incubation in the presence of NADPH.  Addnl. expts. did not show any evidence for the involvement of a no. of other human cytochrome P 450 enzymes in 17α-ethynylestradiol 2-hydroxylation (i.e., P-450DB, P-450PA, P-450MP, P-450j).  Apparently, P-450NF is the major enzyme involved in 17α-ethynylestradiol oxidn. and drugs and hormones which influence the expression and activity of this enzyme can influence the efficacy and side effects of this compd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLHe0Mmm83l7Vg90H21EOLACvtfcHk0lgg0X26F1wFvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXktFOitLY%253D&md5=f46c7608ed02490b5779a0bfbd0669a1</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGuengerich%26aufirst%3DF.%2BP.%26atitle%3DOxidation%2520of%252017%2520alpha-ethynylestradiol%2520by%2520human%2520liver%2520cytochrome%2520P-450%26jtitle%3DMol.%2520Pharmacol.%26date%3D1988%26volume%3D33%26spage%3D500%26epage%3D508" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">White, I. N.</span></span> <span> </span><span class="NLM_article-title">Metabolic activation of acetylenic substituents to derivatives in the rat causing the loss of hepatic cytochrome P-450 and haem</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">1978</span>,  <span class="NLM_volume"><i>174</i></span>,  <span class="NLM_fpage">853</span>– <span class="NLM_lpage">861</span>, <span class="refDoi"> DOI: 10.1042/bj1740853</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1042%2Fbj1740853" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=728091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADyaE1MXhvVSlsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=174&publication_year=1978&pages=853-861&author=I.+N.+White&title=Metabolic+activation+of+acetylenic+substituents+to+derivatives+in+the+rat+causing+the+loss+of+hepatic+cytochrome+P-450+and+haem&doi=10.1042%2Fbj1740853"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic activation of acetylenic substituents to derivatives in the rat causing the loss of hepatic cytochrome P-450 and heme</span></div><div class="casAuthors">White, Ian N. H.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">1978</span>),
    <span class="NLM_cas:volume">174</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">853-61</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    </div><div class="casAbstract">2,2-Dipropargylacetamide  [69977-32-8], danazol  [17230-88-5] in doses of 3.0 μg, and acetylene  [74-86-2] in a 4:1 vol. acetylene/O mixt. when administered to rats in vivo caused decreased concns. of the hepatic microsomal cytochrome P 450  [9035-51-2] and heme  [14875-96-8].  The enzyme responsible for the activation of the acetylenic substituent, and hence loss of P-450 showed characteristics typical of microsomal mixed-function oxidases.  When rats were dosed with 17α-ethynyl-17β-hydroxyandrost-4-en-3-one  [434-03-7] (1 mmol/kg) the pattern of green pigments extd. from the liver 4 h after dosing was different from that in rats given vinyltestosterone  [1235-98-9].  The green pigments extd. from livers of rats 4 h after administration of acetylene-substituted compds. (1 mmol/kg) had variable Rf values on thin-layer chromatog. on silica gel.  The no. and distribution of green pigments was characteristic of each compd. given.  After incubation of acetylene-14C in vitro with microsomal prepns. from phenobarbitone-pretreated rats, and a NADPH-generating system, no significant covalent binding to microsomal protein was detected over 30 min incubation, although under similar conditions, there was significant loss of P 450.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGSWdIZrqzjrVg90H21EOLACvtfcHk0lgg0X26F1wFvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE1MXhvVSlsrY%253D&md5=e87cb97e88b470440b5bb3b74983f946</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1042%2Fbj1740853&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252Fbj1740853%26sid%3Dliteratum%253Aachs%26aulast%3DWhite%26aufirst%3DI.%2BN.%26atitle%3DMetabolic%2520activation%2520of%2520acetylenic%2520substituents%2520to%2520derivatives%2520in%2520the%2520rat%2520causing%2520the%2520loss%2520of%2520hepatic%2520cytochrome%2520P-450%2520and%2520haem%26jtitle%3DBiochem.%2520J.%26date%3D1978%26volume%3D174%26spage%3D853%26epage%3D861%26doi%3D10.1042%2Fbj1740853" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollenberg, P. F.</span></span> <span> </span><span class="NLM_article-title">Inactivation of cytochrome P4502B1 by the monoamine oxidase inhibitors R-(−)-deprenyl and clorgyline</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">669</span>– <span class="NLM_lpage">675</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=8781784" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADyaK28Xjs1Crt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=1996&pages=669-675&author=U.+Sharmaauthor=E.+S.+Robertsauthor=P.+F.+Hollenberg&title=Inactivation+of+cytochrome+P4502B1+by+the+monoamine+oxidase+inhibitors+R-%28%E2%88%92%29-deprenyl+and+clorgyline"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Inactivation of cytochrome P4502B1 by the monoamine oxidase inhibitors R-(-)-deprenyl and clorgyline</span></div><div class="casAuthors">Sharma, Uma; Roberts, Elizabeth S.; Hollenberg, Paul F.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">669-675</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">The monoamine oxidase inhibitors R-(-)-deprenyl and clorgyline inactivated the 7-ethoxy-4-trifluoromethylcoumarin O-deethylase activity of purified cytochrome P 4502B1 in a reconstituted system contg. P 4502B1, NADPH-cytochrome P 450 oxidoreductase, and L-α-phosphatidylcholine dilauroyl as the lipid.  The inactivation was time- and concn.-dependent.  The inactivation required NADPH, demonstrated satn. kinetics, and no lag time for inactivation was obsd.  The inactivation was not affected by the presence of an excess exogenous nucleophile, such as glutathione.  Deprenyl exhibited a KI (concn. of inactivator required for half-maximal inactivation) of 1.05 μM, and clorgyline had a KI of 1.5 μM.  The max. rate of inactivation of the enzyme at satg. levels of inactivator was 0.23 min-1 for deprenyl and 0.28 min-1 for clorgyline.  The partition ratio for deprenyl and clorgyline was between 2 and 3.  Studies on the isoenzyme specificity of these compds. in microsomes from rats pretreated with specific inducers demonstrate that the inactivation was relatively specific for the major phenobarbital-inducible isoenzyme, P 4502B1, because significant inactivation of P 4501A1 and P 4502E1 was not obsd.  When the purified P 4502B1 in the reconstituted system was incubated with either inactivator in the presence of NADPH, there was approx. a 60-70% loss in spectrally detectable P 450 over 5 min at a 1:21 ratio of P 450 to inactivator.  However, at this ratio of enzyme to inactivator, there was >90% loss of the O-deethylase activity.  This loss in enzyme activity was irreversible, and the protein did not regain activity after dialysis or extensive washing to remove excess inactivator.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYr8hu-oz-C7Vg90H21EOLACvtfcHk0ljocXidvIL0pA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xjs1Crt7Y%253D&md5=e401e911e5e29cbfdf531e6bdb07776e</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DU.%26aulast%3DRoberts%26aufirst%3DE.%2BS.%26aulast%3DHollenberg%26aufirst%3DP.%2BF.%26atitle%3DInactivation%2520of%2520cytochrome%2520P4502B1%2520by%2520the%2520monoamine%2520oxidase%2520inhibitors%2520R-%2528%25E2%2588%2592%2529-deprenyl%2520and%2520clorgyline%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D1996%26volume%3D24%26spage%3D669%26epage%3D675" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woolf, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollenberg, P. F.</span></span> <span> </span><span class="NLM_article-title">Mechanism-based inactivation of cytochrome P-450–3A4 by mifepristone (RU486)</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>288</i></span>,  <span class="NLM_fpage">791</span>– <span class="NLM_lpage">797</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=9918590" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADyaK1MXpvFOlsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=288&publication_year=1999&pages=791-797&author=K.+Heauthor=T.+F.+Woolfauthor=P.+F.+Hollenberg&title=Mechanism-based+inactivation+of+cytochrome+P-450%E2%80%933A4+by+mifepristone+%28RU486%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism-based inactivation of cytochrome P-450-3A4 by mifepristone (RU486)</span></div><div class="casAuthors">He, Kan; Woolf, Thomas F.; Hollenberg, Paul F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">288</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">791-797</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Mifepristone (RU486), an 11β-substituted nor-steroid contg. a 17α-1-propynyl group used clin. as an antiprogestin agent for medical abortions, was demonstrated to be a selective mechanism-based inactivator of human cytochrome P 450-3A4 (CYP-3A4).  The loss of testosterone 6β-hydroxylation activity was time- and concn.-dependent as well as requiring metab. of mifepristone in a purified CYP-3A4 reconstituted system.  The inactivation exhibited pseudofirst-order kinetics.  The values for KI and kinactivation were 4.7 μM and 0.089 min-1, resp.  The reduced-CO spectrum of CYP-3A4 was decreased by 76%, whereas approx. 81% of the activity was lost following incubation with mifepristone in the reconstituted system in the presence of NADPH.  However, the Soret peak of the inactivated CYP-3A4 was slightly increased.  High-performance liq. chromatog. anal. of the incubation mixt. showed that the peak contg. the heme dissocd. from the inactivated CYP3A4 was almost identical with that seen for the -NADPH control.  Covalent binding of [3H]mifepristone to apoCYP3A4 was demonstrated by SDS-PAGE and high-pressure liq. chromatog. analyses of the reconstituted system contg. CYP-3A4, NADPH-CYP reductase, cytochrome b5 and lipids in the presence of NADPH.  The stoichiometry was detd. to be approx. 1 mol of mifepristone bound per 1 mol of CYP-3A4 inactivated.  Therefore, the mechanism of inactivation of CYP-34A by mifepristone involves irreversible modification of the apoprotein at the enzyme active site instead of being the result of heme adduct formation or heme fragmentation.  Mifepristone exhibits selectivity for CYP-3A4 as evidenced by the fact that it did not show mechanism-based inactivation of CYPs 1A, 2B, 2D6, and 2E1, although a competitive inhibition of CYP 2B1 and 2D6 was obsd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1tJZHJLfOOLVg90H21EOLACvtfcHk0ljocXidvIL0pA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXpvFOlsA%253D%253D&md5=b445578c15b3828b36da08f32b9fe46c</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DK.%26aulast%3DWoolf%26aufirst%3DT.%2BF.%26aulast%3DHollenberg%26aufirst%3DP.%2BF.%26atitle%3DMechanism-based%2520inactivation%2520of%2520cytochrome%2520P-450%25E2%2580%25933A4%2520by%2520mifepristone%2520%2528RU486%2529%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1999%26volume%3D288%26spage%3D791%26epage%3D797" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chan, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sui, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortiz de Montellano, P. R.</span></span> <span> </span><span class="NLM_article-title">Determinants of protein modification versus heme alkylation: inactivation of cytochrome P450 1A1 by 1-ethynylpyrene and phenylacetylene</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">38</span>– <span class="NLM_lpage">45</span>, <span class="refDoi"> DOI: 10.1021/tx00031a006</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx00031a006" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADyaK3sXltlOhtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1993&pages=38-45&author=W.+K.+Chanauthor=Z.+Suiauthor=P.+R.+Ortiz+de+Montellano&title=Determinants+of+protein+modification+versus+heme+alkylation%3A+inactivation+of+cytochrome+P450+1A1+by+1-ethynylpyrene+and+phenylacetylene&doi=10.1021%2Ftx00031a006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Determinants of protein modification versus heme alkylation:  inactivation of cytochrome P450 1A1 by 1-ethynylpyrene and phenylacetylene</span></div><div class="casAuthors">Chan, William K.; Sui, Zhihua; Ortiz de Montellano, Paul R.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">38-45</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    </div><div class="casAbstract">The authors have investigated the cytochrome P 4501A1-catalyzed oxidn. of 1-ethynylpyrene (1-EP) (I) and phenylacetylene (PA).  Cytochrome P 4501A1 in microsomes from β-naphthoflavone-induced rats is inactivated in a time- and NADPH-dependent manner by 1-EP and PA.  Parallel loss of the heme chromophore is obsd. with PA but not with 1-EP, although partial heme chromophore loss is obsd. when the purified, reconstituted enzyme is inactivated by either agent.  Product anal. shows that 1-EP and PA are oxidized to, resp., (1'-pyrenyl)acetic and phenylacetic acids.  In contrast to the inactivation of cytochrome P 4502B1 by PA, no isotope effect is obsd. on enzyme inactivation or metabolite formation when the acetylenic hydrogen is replaced by deuterium in either 1-EP or PA.  Inactivation of cytochrome P 4501A1 by 1-EP results in covalent binding of 0.8-0.9 equiv (relative to total cytochrome P 450 content) of the inhibitor to the microsomal protein.  The results demonstrate that a single isoenzyme can be inactivated, depending on the structure of the arylacetylene, by heme or protein alkylation.  Spectroscopic binding consts. (Ks) show that 1-EP binds to the enzyme with >2000 times greater affinity that PA.  This large difference in binding affinity is a probable factor in the heme vs. protein specificity of the inactivation reaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwxYo06ht8UbVg90H21EOLACvtfcHk0ljocXidvIL0pA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXltlOhtw%253D%253D&md5=31bdb5ab23048a75b7feaadb0c03a196</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Ftx00031a006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx00031a006%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DW.%2BK.%26aulast%3DSui%26aufirst%3DZ.%26aulast%3DOrtiz%2Bde%2BMontellano%26aufirst%3DP.%2BR.%26atitle%3DDeterminants%2520of%2520protein%2520modification%2520versus%2520heme%2520alkylation%253A%2520inactivation%2520of%2520cytochrome%2520P450%25201A1%2520by%25201-ethynylpyrene%2520and%2520phenylacetylene%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D1993%26volume%3D6%26spage%3D38%26epage%3D45%26doi%3D10.1021%2Ftx00031a006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhuo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degnan, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shu, Y. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, B. M.</span></span> <span> </span><span class="NLM_article-title">Identification of glutathione conjugates of acetylene-containing positive allosteric modulators of metabotropic glutamate receptor subtype 5</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">578</span>– <span class="NLM_lpage">589</span>, <span class="refDoi"> DOI: 10.1124/dmd.114.061879</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1124%2Fdmd.114.061879" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=25633841" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC2MXkvFSjsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2015&pages=578-589&author=X.+Zhuoauthor=X.+S.+Huangauthor=A.+P.+Degnanauthor=L.+B.+Snyderauthor=F.+Yangauthor=H.+Huangauthor=Y.+Z.+Shuauthor=B.+M.+Johnson&title=Identification+of+glutathione+conjugates+of+acetylene-containing+positive+allosteric+modulators+of+metabotropic+glutamate+receptor+subtype+5&doi=10.1124%2Fdmd.114.061879"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of glutathione conjugates of acetylene-containing positive allosteric modulators of metabotropic glutamate receptor subtype 5</span></div><div class="casAuthors">Zhuo, Xiaoliang; Huang, Xiaohua Stella; Degnan, Andrew P.; Snyder, Lawrence B.; Yang, Fukang; Huang, Hong; Shu, Yue-Zhong; Johnson, Benjamin M.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">578-589</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A recent medicinal chem. campaign to identify pos. allosteric modulators (PAMs) of metabotropic glutamate receptor subtype 5 (mGluR5) led to the discovery of potent compds. featuring an oxazolidinone structural core flanked by biaryl acetylene and haloaryl moieties.  However, biotransformation studies of some of these mGluR5 PAMs demonstrated the formation of glutathione (GSH) conjugates.  The conjugates in question were formed independently of NADPH as the main products in liver microsomes and liver cytosol (rat and human) and exhibited masses that were 307 u greater than their resp. substrates, indicating the involvement of a reductive step in the formation of these metabolites.  To further characterize the relevant metabolic sequences, GSH conjugates of (4R,5R)-5-(3-fluorophenyl)-4-(5-(pyrazin-2-ylethynyl)pyridin-3-yl)oxazolidin-2-one and (4R,5R)-5-(4-fluorophenyl)-4-(6-((3-fluoropyridin-2-yl)ethynyl) pyridin-2-yl)oxazolidin-2-one were biosynthesized and isolated.  Subsequent anal. by NMR showed that GSH had reacted with the acetylene carbon atoms of these mGluR5 PAMs, suggesting a conjugate addn. mechanism and implicating cytosolic and microsomal GSH S-transferases (GSTs) in catalysis.  Interestingly, five closely related mGluR5 PAMs were not similarly prone to the formation of GSH conjugates in vitro.  These compds. also featured acetylenes, but were flanked by either Ph or cyclohexyl rings, which indicated that the formation of GSH conjugates was influenced by proximal functional groups that modulated the electron d. of the triple bond and/or differences in enzyme-substrate specificity.  These results informed an ongoing drug-discovery effort to identify mGluR5 PAMs with drug-like properties and a low risk of reactivity with endogenous thiols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIHBHWhrex97Vg90H21EOLACvtfcHk0ljhHtUH_lY_wQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXkvFSjsbY%253D&md5=fca55e910eac73eebdf2e67242b13718</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1124%2Fdmd.114.061879&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.114.061879%26sid%3Dliteratum%253Aachs%26aulast%3DZhuo%26aufirst%3DX.%26aulast%3DHuang%26aufirst%3DX.%2BS.%26aulast%3DDegnan%26aufirst%3DA.%2BP.%26aulast%3DSnyder%26aufirst%3DL.%2BB.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DShu%26aufirst%3DY.%2BZ.%26aulast%3DJohnson%26aufirst%3DB.%2BM.%26atitle%3DIdentification%2520of%2520glutathione%2520conjugates%2520of%2520acetylene-containing%2520positive%2520allosteric%2520modulators%2520of%2520metabotropic%2520glutamate%2520receptor%2520subtype%25205%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2015%26volume%3D43%26spage%3D578%26epage%3D589%26doi%3D10.1124%2Fdmd.114.061879" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bouska, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodfellow, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, G. W.</span></span> <span> </span><span class="NLM_article-title">Improving the in vivo duration of 5-lipoxygenase inhibitors: application of an in vitro glucuronosyltransferase assay</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1032</span>– <span class="NLM_lpage">1038</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=9311617" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADyaK2sXmt1Wqsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=1997&pages=1032-1038&author=J.+J.+Bouskaauthor=R.+L.+Bellauthor=C.+L.+Goodfellowauthor=A.+O.+Stewartauthor=C.+D.+Brooksauthor=G.+W.+Carter&title=Improving+the+in+vivo+duration+of+5-lipoxygenase+inhibitors%3A+application+of+an+in+vitro+glucuronosyltransferase+assay"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Improving the in vivo duration of 5-lipoxygenase inhibitors: application of an in vitro glucuronosyltransferase assay</span></div><div class="casAuthors">Bouska, Jennifer J.; Bell, Randy L.; Goodfellow, Carole L.; Stewart, Andrew O.; Brooks, Clint D. W.; Carter, George W.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1032-1038</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">An in vitro glucuronidation assay was used to optimize a series of N-hydroxyurea-contg. 5-lipoxygenase inhibitors for metabolic stability.  The glucuronidation of these compds. in cynomolgus monkey microsomes followed Michaelis-Menten kinetics allowing calcn. of Vmax and KM.  The Vmax values ranged from 0.02 to 7.9 nmol/min/mg microsomal protein, a 400-fold difference, whereas KM ranged from 204 to 2500 μM, only a 12-fold difference.  In vitro intrinsic clearance values (CLint) were calcd. for 18 compds. tested in the kinetic assay and compared with the in vivo plasma clearance (CLp) calcd. from i.v. studies done in cynomolgus monkeys.  These initial results suggested a relation between the in vitro CLint and in vivo duration as defined by CLp.  A more rapid in vitro assay was developed in a 96-well format using a single concn. of substrate (100 μM) from which a glucuronidation rate was calcd.  The results from this assay for 40 compds. correlated with in vivo plasma clearance (r = 0.57).  This more efficient assay was used to test more than 100 compds. and develop structure-metab. relationships based on metabolic stability and improved duration.  The culmination of this effort contributed to the discovery of ABT-761, a 5-lipoxygenase inhibitor with in vivo duration in monkey improved 40-fold over the first generation inhibitor.  Further studies performed in human liver microsomes demonstrated a similar trend that was corroborated by the 8-fold increase in duration after oral dosing in humans obsd. with ABT-761.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKusP0a0dCmbVg90H21EOLACvtfcHk0ljhHtUH_lY_wQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXmt1Wqsbg%253D&md5=1779014c9842d5927a96e5ea3e4503fb</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBouska%26aufirst%3DJ.%2BJ.%26aulast%3DBell%26aufirst%3DR.%2BL.%26aulast%3DGoodfellow%26aufirst%3DC.%2BL.%26aulast%3DStewart%26aufirst%3DA.%2BO.%26aulast%3DBrooks%26aufirst%3DC.%2BD.%26aulast%3DCarter%26aufirst%3DG.%2BW.%26atitle%3DImproving%2520the%2520in%2520vivo%2520duration%2520of%25205-lipoxygenase%2520inhibitors%253A%2520application%2520of%2520an%2520in%2520vitro%2520glucuronosyltransferase%2520assay%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D1997%26volume%3D25%26spage%3D1032%26epage%3D1038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sonogashira, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tohda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagihara, N.</span></span> <span> </span><span class="NLM_article-title">A convenient synthesis of acetylenes: catalytic substitutions of acetylenic hydrogen with bromoalkenes, iodoarenes and bromopyridines</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">1975</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">4467</span>– <span class="NLM_lpage">4470</span>, <span class="refDoi"> DOI: 10.1016/S0040-4039(00)91094-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1016%2FS0040-4039%2800%2991094-3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1975&pages=4467-4470&author=K.+Sonogashiraauthor=Y.+Tohdaauthor=N.+Hagihara&title=A+convenient+synthesis+of+acetylenes%3A+catalytic+substitutions+of+acetylenic+hydrogen+with+bromoalkenes%2C+iodoarenes+and+bromopyridines&doi=10.1016%2FS0040-4039%2800%2991094-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2FS0040-4039%2800%2991094-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4039%252800%252991094-3%26sid%3Dliteratum%253Aachs%26aulast%3DSonogashira%26aufirst%3DK.%26aulast%3DTohda%26aufirst%3DY.%26aulast%3DHagihara%26aufirst%3DN.%26atitle%3DA%2520convenient%2520synthesis%2520of%2520acetylenes%253A%2520catalytic%2520substitutions%2520of%2520acetylenic%2520hydrogen%2520with%2520bromoalkenes%252C%2520iodoarenes%2520and%2520bromopyridines%26jtitle%3DTetrahedron%2520Lett.%26date%3D1975%26volume%3D16%26spage%3D4467%26epage%3D4470%26doi%3D10.1016%2FS0040-4039%2800%2991094-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hinze, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaffe, H. H.</span></span> <span> </span><span class="NLM_article-title">Electronegativity. I. Orbital electronegativity of neutral atoms</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">1962</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">540</span>– <span class="NLM_lpage">546</span>, <span class="refDoi"> DOI: 10.1021/ja00863a008</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja00863a008" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADyaF38XktF2qtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=1962&pages=540-546&author=J.+Hinzeauthor=H.+H.+Jaffe&title=Electronegativity.+I.+Orbital+electronegativity+of+neutral+atoms&doi=10.1021%2Fja00863a008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Electronegativity. I. Orbital electronegativity of neutral atoms</span></div><div class="casAuthors">Hinze, Juergen; Jaffe, H. H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">1962</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">540-6</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    </div><div class="casAbstract">The electronegativity of atoms is considered to change with the electron configuration found in the mol. environment.  The energy difference (P) between the ground state and various valence stages of atoms in the first 2 periods of the periodic table are calcd. by using a variation of Slater's treatment.  Combination of these energies with the ionization potentials (Ig) and electron affinities (Eg) of the ground state gives the electronegativities of the valence state (v), according to Mulliken's definition X = Iv + Ev, where Iv = Ig + P+ + P0 and Ev = Eg  = P0 - P-.  Both the promotion energies and electronegativities (X) are tabulated and compared with Pauling's electronegativities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQilfyJSUQhLVg90H21EOLACvtfcHk0ljhHtUH_lY_wQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF38XktF2qtbo%253D&md5=c46b83f7910959d390c0d49d225b61e6</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fja00863a008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja00863a008%26sid%3Dliteratum%253Aachs%26aulast%3DHinze%26aufirst%3DJ.%26aulast%3DJaffe%26aufirst%3DH.%2BH.%26atitle%3DElectronegativity.%2520I.%2520Orbital%2520electronegativity%2520of%2520neutral%2520atoms%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1962%26volume%3D84%26spage%3D540%26epage%3D546%26doi%3D10.1021%2Fja00863a008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Av-Gay, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Everett, M.</span></span> <span> </span><span class="NLM_article-title">The eukaryotic-like Ser/Thr protein kinases of <i>Mycobacterium tuberculosis</i></span>. <i>Trends Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">238</span>– <span class="NLM_lpage">244</span>, <span class="refDoi"> DOI: 10.1016/S0966-842X(00)01734-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1016%2FS0966-842X%2800%2901734-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10785641" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A280%3ADC%252BD3czpt1aitw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2000&pages=238-244&author=Y.+Av-Gayauthor=M.+Everett&title=The+eukaryotic-like+Ser%2FThr+protein+kinases+of+Mycobacterium+tuberculosis&doi=10.1016%2FS0966-842X%2800%2901734-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">The eukaryotic-like Ser/Thr protein kinases of Mycobacterium tuberculosis</span></div><div class="casAuthors">Av-Gay Y; Everett M</div><div class="citationInfo"><span class="NLM_cas:title">Trends in microbiology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">238-44</span>
        ISSN:<span class="NLM_cas:issn">0966-842X</span>.
    </div><div class="casAbstract">In bacteria, extracellular signals are generally transduced into cellular responses via a two-component system.  However, genome sequence data have now revealed the presence of 'eukaryotic-like' protein kinases and phosphatases.  Mycobacterium tuberculosis appears to be unique among bacteria in that its genome contains 11 members of a newly identified protein kinase family.  These M. tuberculosis eukaryotic-like protein kinases could be key regulators of metabolic processes, including transcription, cell development and interactions with host cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTm1x1DQVChQZPlX7E30qdzfW6udTcc2ebaBO7PGmRjbrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3czpt1aitw%253D%253D&md5=9b872125492821512af6d68cc7c3e56b</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2FS0966-842X%2800%2901734-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0966-842X%252800%252901734-0%26sid%3Dliteratum%253Aachs%26aulast%3DAv-Gay%26aufirst%3DY.%26aulast%3DEverett%26aufirst%3DM.%26atitle%3DThe%2520eukaryotic-like%2520Ser%252FThr%2520protein%2520kinases%2520of%2520Mycobacterium%2520tuberculosis%26jtitle%3DTrends%2520Microbiol.%26date%3D2000%26volume%3D8%26spage%3D238%26epage%3D244%26doi%3D10.1016%2FS0966-842X%2800%2901734-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saint-Joanis, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barilone, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gicquel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alzari, P. M.</span></span> <span> </span><span class="NLM_article-title">The Ser/Thr protein kinase PknB is essential for sustaining mycobacterial growth</span>. <i>J. Bacteriol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>188</i></span>,  <span class="NLM_fpage">7778</span>– <span class="NLM_lpage">7784</span>, <span class="refDoi"> DOI: 10.1128/JB.00963-06</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1128%2FJB.00963-06" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=16980473" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1ahsb%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=188&publication_year=2006&pages=7778-7784&author=P.+Fernandezauthor=B.+Saint-Joanisauthor=N.+Bariloneauthor=M.+Jacksonauthor=B.+Gicquelauthor=S.+T.+Coleauthor=P.+M.+Alzari&title=The+Ser%2FThr+protein+kinase+PknB+is+essential+for+sustaining+mycobacterial+growth&doi=10.1128%2FJB.00963-06"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">The Ser/Thr protein kinase PknB is essential for sustaining mycobacterial growth</span></div><div class="casAuthors">Fernandez, Pablo; Saint-Joanis, Brigitte; Barilone, Nathalie; Jackson, Mary; Gicquel, Brigitte; Cole, Stewart T.; Alzari, Pedro M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Bacteriology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">188</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">7778-7784</span>CODEN:
                <span class="NLM_cas:coden">JOBAAY</span>;
        ISSN:<span class="NLM_cas:issn">0021-9193</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The receptor-like protein kinase PknB from Mycobacterium tuberculosis is encoded by the distal gene in a highly conserved operon, present in all actinobacteria, that may control cell shape and cell division.  Genes coding for a PknB-like protein kinase are also found in many more distantly related gram-pos. bacteria.  Here, we report that the pknB gene can be disrupted by allelic replacement in M. tuberculosis and the saprophyte Mycobacterium smegmatis only in the presence of a second functional copy of the gene.  We also demonstrate that eukaryotic Ser/Thr protein kinase inhibitors, which inactivate PknB in vitro with a 50% inhibitory concn. in the submicromolar range, are able to kill M. tuberculosis H37Rv, M. smegmatis Mc2155, and Mycobacterium aurum A+ with MICs in the micromolar range.  Furthermore, significantly higher concns. of these compds. are required to inhibit growth of M. smegmatis strains overexpressing PknB, suggesting that this protein kinase is the mol. target.  These findings demonstrate that the Ser/Thr protein kinase PknB is essential for sustaining mycobacterial growth and support the development of protein kinase inhibitors as new potential antituberculosis drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpe6ARQk75TCLVg90H21EOLACvtfcHk0lgUyxvagU1wUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1ahsb%252FM&md5=83cfb5336c75a7708be9f12420d9ede6</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1128%2FJB.00963-06&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJB.00963-06%26sid%3Dliteratum%253Aachs%26aulast%3DFernandez%26aufirst%3DP.%26aulast%3DSaint-Joanis%26aufirst%3DB.%26aulast%3DBarilone%26aufirst%3DN.%26aulast%3DJackson%26aufirst%3DM.%26aulast%3DGicquel%26aufirst%3DB.%26aulast%3DCole%26aufirst%3DS.%2BT.%26aulast%3DAlzari%26aufirst%3DP.%2BM.%26atitle%3DThe%2520Ser%252FThr%2520protein%2520kinase%2520PknB%2520is%2520essential%2520for%2520sustaining%2520mycobacterial%2520growth%26jtitle%3DJ.%2520Bacteriol.%26date%3D2006%26volume%3D188%26spage%3D7778%26epage%3D7784%26doi%3D10.1128%2FJB.00963-06" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bemis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanzelka, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuccola, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wynn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moody, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locher, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennani, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomson, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muh, U.</span></span> <span> </span><span class="NLM_article-title">Mtb PKNA/PKNB dual inhibition provides selectivity advantages for inhibitor design to minimize host kinase interactions</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1224</span>– <span class="NLM_lpage">1229</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00239</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00239" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVOit7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1224-1229&author=T.+Wangauthor=G.+Bemisauthor=B.+Hanzelkaauthor=H.+Zuccolaauthor=M.+Wynnauthor=C.+S.+Moodyauthor=J.+Greenauthor=C.+Locherauthor=A.+Liuauthor=H.+Gaoauthor=Y.+Xuauthor=S.+Wangauthor=J.+Wangauthor=Y.+L.+Bennaniauthor=J.+A.+Thomsonauthor=U.+Muh&title=Mtb+PKNA%2FPKNB+dual+inhibition+provides+selectivity+advantages+for+inhibitor+design+to+minimize+host+kinase+interactions&doi=10.1021%2Facsmedchemlett.7b00239"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Mtb PKNA/PKNB Dual Inhibition Provides Selectivity Advantages for Inhibitor Design To Minimize Host Kinase Interactions</span></div><div class="casAuthors">Wang, Tiansheng; Bemis, Guy; Hanzelka, Brian; Zuccola, Harmon; Wynn, Michael; Moody, Cameron Stuver; Green, Jeremy; Locher, Christopher; Liu, Aixiang; Gao, Hongwu; Xu, Yuzhou; Wang, Shaohui; Wang, Jie; Bennani, Youssef L.; Thomson, John A.; Muh, Ute</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1224-1229</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Drug resistant tuberculosis (TB) infections are on the rise and antibiotics that inhibit Mycobacterium tuberculosis through a novel mechanism could be an important component of evolving TB therapy.  Protein kinase A (PknA) and protein kinase B (PknB) are both essential serine-threonine kinases in M. tuberculosis.  Given the extensive knowledge base in kinase inhibition, these enzymes present an interesting opportunity for antimycobacterial drug discovery.  This study focused on targeting both PknA and PknB while improving the selectivity window over related mammalian kinases.  Compds. achieved potent inhibition (Ki ≈ 5 nM) of both PknA and PknB.  A binding pocket unique to mycobacterial kinases was identified.  Substitutions that filled this pocket resulted in a 100-fold differential against a broad selection of mammalian kinases.  Reducing lipophilicity improved antimycobacterial activity with the most potent compds. achieving min. inhibitory concns. ranging from 3 to 5 μM (1-2 μg/mL) against the H37Ra isolate of M. tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo14ZnkMwzQ0LVg90H21EOLACvtfcHk0lgUyxvagU1wUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVOit7%252FM&md5=aebc570badb168bf80d5b3a921a48847</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00239&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00239%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DT.%26aulast%3DBemis%26aufirst%3DG.%26aulast%3DHanzelka%26aufirst%3DB.%26aulast%3DZuccola%26aufirst%3DH.%26aulast%3DWynn%26aufirst%3DM.%26aulast%3DMoody%26aufirst%3DC.%2BS.%26aulast%3DGreen%26aufirst%3DJ.%26aulast%3DLocher%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DA.%26aulast%3DGao%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DBennani%26aufirst%3DY.%2BL.%26aulast%3DThomson%26aufirst%3DJ.%2BA.%26aulast%3DMuh%26aufirst%3DU.%26atitle%3DMtb%2520PKNA%252FPKNB%2520dual%2520inhibition%2520provides%2520selectivity%2520advantages%2520for%2520inhibitor%2520design%2520to%2520minimize%2520host%2520kinase%2520interactions%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26spage%3D1224%26epage%3D1229%26doi%3D10.1021%2Facsmedchemlett.7b00239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wilcken, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lange, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joerger, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boeckler, F. M.</span></span> <span> </span><span class="NLM_article-title">Principles and applications of halogen bonding in medicinal chemistry and chemical biology</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">1363</span>– <span class="NLM_lpage">1388</span>, <span class="refDoi"> DOI: 10.1021/jm3012068</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3012068" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1GrurfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=1363-1388&author=R.+Wilckenauthor=M.+O.+Zimmermannauthor=A.+Langeauthor=A.+C.+Joergerauthor=F.+M.+Boeckler&title=Principles+and+applications+of+halogen+bonding+in+medicinal+chemistry+and+chemical+biology&doi=10.1021%2Fjm3012068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Principles and Applications of Halogen Bonding in Medicinal Chemistry and Chemical Biology</span></div><div class="casAuthors">Wilcken, Rainer; Zimmermann, Markus O.; Lange, Andreas; Joerger, Andreas C.; Boeckler, Frank M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1363-1388</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Halogen bonding has been known in material science for decades, but until recently, halogen bonds in protein-ligand interactions were largely the result of serendipitous discovery rather than rational design.  In this Perspective, we provide insights into the phenomenon of halogen bonding, with special focus on its role in drug discovery.  We summarize the theor. background defining its strength and directionality, provide a systematic anal. of its occurrence and interaction geometries in protein-ligand complexes, and give recent examples where halogen bonding has been successfully harnessed for lead identification and optimization.  In light of these data, we discuss the potential and limitations of exploiting halogen bonds for mol. recognition and rational drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjholHfNZ9kbVg90H21EOLACvtfcHk0lh8PIeVua0i5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1GrurfJ&md5=81ba024e4427fac3e7af0a4cd330909c</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fjm3012068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3012068%26sid%3Dliteratum%253Aachs%26aulast%3DWilcken%26aufirst%3DR.%26aulast%3DZimmermann%26aufirst%3DM.%2BO.%26aulast%3DLange%26aufirst%3DA.%26aulast%3DJoerger%26aufirst%3DA.%2BC.%26aulast%3DBoeckler%26aufirst%3DF.%2BM.%26atitle%3DPrinciples%2520and%2520applications%2520of%2520halogen%2520bonding%2520in%2520medicinal%2520chemistry%2520and%2520chemical%2520biology%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D1363%26epage%3D1388%26doi%3D10.1021%2Fjm3012068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boggon, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greulich, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span> <span> </span><span class="NLM_article-title">Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">217</span>– <span class="NLM_lpage">227</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2006.12.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1016%2Fj.ccr.2006.12.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=17349580" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjsVymtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2007&pages=217-227&author=C.+H.+Yunauthor=T.+J.+Boggonauthor=Y.+Liauthor=M.+S.+Wooauthor=H.+Greulichauthor=M.+Meyersonauthor=M.+J.+Eck&title=Structures+of+lung+cancer-derived+EGFR+mutants+and+inhibitor+complexes%3A+mechanism+of+activation+and+insights+into+differential+inhibitor+sensitivity&doi=10.1016%2Fj.ccr.2006.12.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity</span></div><div class="casAuthors">Yun, Cai-Hong; Boggon, Titus J.; Li, Yiqun; Woo, Michele S.; Greulich, Heidi; Meyerson, Matthew; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">217-227</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Mutations in the EGFR kinase are a cause of non-small-cell lung cancer.  To understand their mechanism of activation and effects on drug binding, we studied the kinetics of the L858R and G719S mutants and detd. their crystal structures with inhibitors including gefitinib, AEE788, and a staurosporine.  We find that the mutations activate the kinase by disrupting autoinhibitory interactions, and that they accelerate catalysis as much as 50-fold in vitro.  Structures of inhibitors in complex with both wild-type and mutant kinases reveal similar binding modes for gefitinib and AEE788, but a marked rotation of the staurosporine in the G719S mutant.  Strikingly, direct binding measurements show that gefitinib binds 20-fold more tightly to the L858R mutant than to the wild-type enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoogeLQ1CuEnLVg90H21EOLACvtfcHk0lh8PIeVua0i5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjsVymtL4%253D&md5=6bc3223df84d829d9cb2bb00fd88ca29</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2006.12.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2006.12.017%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWoo%26aufirst%3DM.%2BS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DStructures%2520of%2520lung%2520cancer-derived%2520EGFR%2520mutants%2520and%2520inhibitor%2520complexes%253A%2520mechanism%2520of%2520activation%2520and%2520insights%2520into%2520differential%2520inhibitor%2520sensitivity%26jtitle%3DCancer%2520Cell%26date%3D2007%26volume%3D11%26spage%3D217%26epage%3D227%26doi%3D10.1016%2Fj.ccr.2006.12.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wilcken, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutherford, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fersht, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joerger, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boeckler, F. M.</span></span> <span> </span><span class="NLM_article-title">Experimental and theoretical evaluation of the ethynyl moiety as a halogen bioisostere</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">2725</span>– <span class="NLM_lpage">2732</span>, <span class="refDoi"> DOI: 10.1021/acschembio.5b00515</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.5b00515" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFWns7zF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=2725-2732&author=R.+Wilckenauthor=M.+O.+Zimmermannauthor=M.+R.+Bauerauthor=T.+J.+Rutherfordauthor=A.+R.+Fershtauthor=A.+C.+Joergerauthor=F.+M.+Boeckler&title=Experimental+and+theoretical+evaluation+of+the+ethynyl+moiety+as+a+halogen+bioisostere&doi=10.1021%2Facschembio.5b00515"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Experimental and Theoretical Evaluation of the Ethynyl Moiety as a Halogen Bioisostere</span></div><div class="casAuthors">Wilcken, Rainer; Zimmermann, Markus O.; Bauer, Matthias R.; Rutherford, Trevor J.; Fersht, Alan R.; Joerger, Andreas C.; Boeckler, Frank M.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2725-2732</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bioisosteric replacements are widely used in medicinal chem. to improve physicochem. and ADME properties of mols. while retaining or improving affinity.  Here, using the p53 cancer mutant Y220C as a test case, we investigate both computationally and exptl. whether an ethynyl moiety is a suitable bioisostere to replace iodine in ligands that form halogen bonds with the protein backbone.  This bioisosteric transformation is synthetically feasible via Sonogashira cross-coupling.  In our test case of a particularly strong halogen bond, replacement of the iodine with an ethynyl group resulted in a 13-fold affinity loss.  High-resoln. crystal structures of the two analogs in complex with the p53-Y220C mutant enabled us to correlate the different affinities with particular features of the binding site and subtle changes in ligand binding mode.  In addn., using QM calcns. and analyzing the PDB, we provide general guidelines for identifying cases where such a transformation is likely to improve ligand recognition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoK-zRhwdTYQbVg90H21EOLACvtfcHk0lh8PIeVua0i5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFWns7zF&md5=7525e863f79e26f7dbe18ad45fde39e6</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Facschembio.5b00515&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.5b00515%26sid%3Dliteratum%253Aachs%26aulast%3DWilcken%26aufirst%3DR.%26aulast%3DZimmermann%26aufirst%3DM.%2BO.%26aulast%3DBauer%26aufirst%3DM.%2BR.%26aulast%3DRutherford%26aufirst%3DT.%2BJ.%26aulast%3DFersht%26aufirst%3DA.%2BR.%26aulast%3DJoerger%26aufirst%3DA.%2BC.%26aulast%3DBoeckler%26aufirst%3DF.%2BM.%26atitle%3DExperimental%2520and%2520theoretical%2520evaluation%2520of%2520the%2520ethynyl%2520moiety%2520as%2520a%2520halogen%2520bioisostere%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2015%26volume%3D10%26spage%3D2725%26epage%3D2732%26doi%3D10.1021%2Facschembio.5b00515" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemmon, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radhakrishnan, R.</span></span> <span> </span><span class="NLM_article-title">Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>448</i></span>,  <span class="NLM_fpage">417</span>– <span class="NLM_lpage">423</span>, <span class="refDoi"> DOI: 10.1042/BJ20121513</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1042%2FBJ20121513" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=23101586" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhslelt7zK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=448&publication_year=2012&pages=417-423&author=J.+H.+Parkauthor=Y.+Liuauthor=M.+A.+Lemmonauthor=R.+Radhakrishnan&title=Erlotinib+binds+both+inactive+and+active+conformations+of+the+EGFR+tyrosine+kinase+domain&doi=10.1042%2FBJ20121513"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain</span></div><div class="casAuthors">Park, Jin H.; Liu, Yingting; Lemmon, Mark A.; Radhakrishnan, Ravi</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">448</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">417-423</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">Erlotinib and gefitinib, tyrosine kinase inhibitors used to block EGFR (epidermal growth factor receptor) signalling in cancer, are thought to bind only the active conformation of the EGFR-TKD (tyrosine kinase domain).  Through parallel computational and crystallog. studies, we show in the present study that erlotinib also binds the inactive EGFR-TKD conformation, which may have significant implications for its use in EGFR-mutated cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprbzRYtaWcm7Vg90H21EOLACvtfcHk0lgS4x-TOkET2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhslelt7zK&md5=170e0fe51a413edfbc15d4357ba6877b</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1042%2FBJ20121513&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20121513%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DJ.%2BH.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLemmon%26aufirst%3DM.%2BA.%26aulast%3DRadhakrishnan%26aufirst%3DR.%26atitle%3DErlotinib%2520binds%2520both%2520inactive%2520and%2520active%2520conformations%2520of%2520the%2520EGFR%2520tyrosine%2520kinase%2520domain%26jtitle%3DBiochem.%2520J.%26date%3D2012%26volume%3D448%26spage%3D417%26epage%3D423%26doi%3D10.1042%2FBJ20121513" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gomes, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potter, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szczesna-Cordary, D.</span></span> <span> </span><span class="NLM_article-title">The role of troponins in muscle contraction</span>. <i>IUBMB Life</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">323</span>– <span class="NLM_lpage">333</span>, <span class="refDoi"> DOI: 10.1080/15216540216037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1080%2F15216540216037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=12665242" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD3sXitVagsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2002&pages=323-333&author=A.+V.+Gomesauthor=J.+D.+Potterauthor=D.+Szczesna-Cordary&title=The+role+of+troponins+in+muscle+contraction&doi=10.1080%2F15216540216037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">The Role of Troponins in Muscle Contraction</span></div><div class="casAuthors">Gomes, Aldrin V.; Potter, James D.; Szczesna-Cordary, Danuta</div><div class="citationInfo"><span class="NLM_cas:title">IUBMB Life</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">323-333</span>CODEN:
                <span class="NLM_cas:coden">IULIF8</span>;
        ISSN:<span class="NLM_cas:issn">1521-6543</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis, Inc.</span>)
        </div><div class="casAbstract">A review.  Troponin (Tn) is the sarcomeric Ca2+ regulator for striated (skeletal and cardiac) muscle contraction.  On binding Ca2+ Tn transmits information via structural changes throughout the actin-tropomyosin filaments, activating myosin ATPase activity and muscle contraction.  Although the Tn-mediated regulation of striated muscle contraction is now well understood, the role of different Tn isoforms in these processes is the subject of intensive investigations.  This review addresses the physiol. significance of the multiple Tn isoforms in skeletal and cardiac muscles as well as their role in the regulation of contraction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosVGCwqDg7ibVg90H21EOLACvtfcHk0lgS4x-TOkET2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXitVagsLk%253D&md5=aa86ee82bce082c9fe20b9b31a16bbda</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1080%2F15216540216037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F15216540216037%26sid%3Dliteratum%253Aachs%26aulast%3DGomes%26aufirst%3DA.%2BV.%26aulast%3DPotter%26aufirst%3DJ.%2BD.%26aulast%3DSzczesna-Cordary%26aufirst%3DD.%26atitle%3DThe%2520role%2520of%2520troponins%2520in%2520muscle%2520contraction%26jtitle%3DIUBMB%2520Life%26date%3D2002%26volume%3D54%26spage%3D323%26epage%3D333%26doi%3D10.1080%2F15216540216037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rowland, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shneider, N. A.</span></span> <span> </span><span class="NLM_article-title">Amyotrophic lateral sclerosis</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>344</i></span>,  <span class="NLM_fpage">1688</span>– <span class="NLM_lpage">1700</span>, <span class="refDoi"> DOI: 10.1056/NEJM200105313442207</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1056%2FNEJM200105313442207" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=11386269" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD3MXkslWjtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=344&publication_year=2001&pages=1688-1700&author=L.+P.+Rowlandauthor=N.+A.+Shneider&title=Amyotrophic+lateral+sclerosis&doi=10.1056%2FNEJM200105313442207"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Amyotrophic lateral sclerosis</span></div><div class="casAuthors">Rowland, Lewis P.; Shneider, Neil A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">344</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">1688-1700</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review, with 148 refs., discusses the definition and the diagnosis of amyotrophic lateral sclerosis.  It also covers the environmental causes, pathogenesis, and therapy of the disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJH5K1VPSzK7Vg90H21EOLACvtfcHk0lgS4x-TOkET2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXkslWjtbo%253D&md5=085da8625919cb55acaf8834d3450fed</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1056%2FNEJM200105313442207&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM200105313442207%26sid%3Dliteratum%253Aachs%26aulast%3DRowland%26aufirst%3DL.%2BP.%26aulast%3DShneider%26aufirst%3DN.%2BA.%26atitle%3DAmyotrophic%2520lateral%2520sclerosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2001%26volume%3D344%26spage%3D1688%26epage%3D1700%26doi%3D10.1056%2FNEJM200105313442207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kolb, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kissel, J. T.</span></span> <span> </span><span class="NLM_article-title">Spinal muscular atrophy: a timely review</span>. <i>Arch. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">979</span>– <span class="NLM_lpage">984</span>, <span class="refDoi"> DOI: 10.1001/archneurol.2011.74</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1001%2Farchneurol.2011.74" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=21482919" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A280%3ADC%252BC3MjksVKjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2011&pages=979-984&author=S.+J.+Kolbauthor=J.+T.+Kissel&title=Spinal+muscular+atrophy%3A+a+timely+review&doi=10.1001%2Farchneurol.2011.74"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Spinal muscular atrophy: a timely review</span></div><div class="casAuthors">Kolb Stephen J; Kissel John T</div><div class="citationInfo"><span class="NLM_cas:title">Archives of neurology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">979-84</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Spinal muscular atrophy (SMA) is a neurodegenerative disease characterized by loss of motor neurons in the anterior horn of the spinal cord and resultant weakness.  The most common form of SMA, accounting for 95% of cases, is autosomal recessive proximal SMA associated with mutations in the survival of motor neurons (SMN1) gene.  Relentless progress during the past 15 years in the understanding of the molecular genetics and pathophysiology of SMA has resulted in a unique opportunity for rational, effective therapeutic trials.  The goal of SMA therapy is to increase the expression levels of the SMN protein in the correct cells at the right time.  With this target in sight, investigators can now effectively screen potential therapies in vitro, test them in accurate, reliable animal models, move promising agents forward to clinical trials, and accurately diagnose patients at an early or presymptomatic stage of disease.  A major challenge for the SMA community will be to prioritize and develop the most promising therapies in an efficient, timely, and safe manner with the guidance of the appropriate regulatory agencies.  This review will take a historical perspective to highlight important milestones on the road to developing effective therapies for SMA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQy90kBbekgJf69nzq6467DfW6udTcc2eZPRco_ke41fLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MjksVKjsA%253D%253D&md5=0dca2120de923052563b6d2f3905a87d</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1001%2Farchneurol.2011.74&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Farchneurol.2011.74%26sid%3Dliteratum%253Aachs%26aulast%3DKolb%26aufirst%3DS.%2BJ.%26aulast%3DKissel%26aufirst%3DJ.%2BT.%26atitle%3DSpinal%2520muscular%2520atrophy%253A%2520a%2520timely%2520review%26jtitle%3DArch.%2520Neurol.%26date%3D2011%26volume%3D68%26spage%3D979%26epage%3D984%26doi%3D10.1001%2Farchneurol.2011.74" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Collibee, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergnes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muci, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Browne, W. F. t.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinken, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suehiro, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawas, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marquez, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomlinson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwee, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaletzky, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malik, F. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgans, D. J.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, B. P.</span></span> <span> </span><span class="NLM_article-title">Discovery of tirasemtiv, the first direct fast skeletal muscle troponin activator</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">354</span>– <span class="NLM_lpage">358</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00546</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00546" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC1cXis1Kqurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=354-358&author=S.+E.+Collibeeauthor=G.+Bergnesauthor=A.+Muciauthor=W.+F.+t.+Browneauthor=M.+Garardauthor=A.+C.+Hinkenauthor=A.+J.+Russellauthor=I.+Suehiroauthor=J.+Hartmanauthor=R.+Kawasauthor=P.+P.+Luauthor=K.+H.+Leeauthor=D.+Marquezauthor=M.+Tomlinsonauthor=D.+Xuauthor=A.+Kennedyauthor=D.+Hweeauthor=J.+Schaletzkyauthor=K.+Leungauthor=F.+I.+Malikauthor=D.+J.+Morgansauthor=B.+P.+Morgan&title=Discovery+of+tirasemtiv%2C+the+first+direct+fast+skeletal+muscle+troponin+activator&doi=10.1021%2Facsmedchemlett.7b00546"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Tirasemtiv, the First Direct Fast Skeletal Muscle Troponin Activator</span></div><div class="casAuthors">Collibee, Scott E.; Bergnes, Gustave; Muci, Alexander; Browne, William F.; Garard, Marc; Hinken, Aaron C.; Russell, Alan J.; Suehiro, Ion; Hartman, James; Kawas, Raja; Lu, Pu-Ping; Lee, Kenneth H.; Marquez, David; Tomlinson, Matthew; Xu, Donghong; Kennedy, Adam; Hwee, Darren; Schaletzky, Julia; Leung, Kwan; Malik, Fady I.; Morgans, David J.; Morgan, Bradley P.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">354-358</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The identification and optimization of the first activators of fast skeletal muscle are reported.  Compd. I was identified from high-throughput screening (HTS) and subsequently found to improve muscle function via interaction with the troponin complex.  Optimization of I for potency, metabolic stability and phys. properties led to the discovery of tirasemtiv (25), which has been extensively characterized in clin. trials for the treatment of ALS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOmgscBIzySrVg90H21EOLACvtfcHk0liCmHPEAM_KsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXis1Kqurg%253D&md5=33b2fba4224554b6a4c7309aaaa67c25</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00546&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00546%26sid%3Dliteratum%253Aachs%26aulast%3DCollibee%26aufirst%3DS.%2BE.%26aulast%3DBergnes%26aufirst%3DG.%26aulast%3DMuci%26aufirst%3DA.%26aulast%3DBrowne%26aufirst%3DW.%2BF.%2Bt.%26aulast%3DGarard%26aufirst%3DM.%26aulast%3DHinken%26aufirst%3DA.%2BC.%26aulast%3DRussell%26aufirst%3DA.%2BJ.%26aulast%3DSuehiro%26aufirst%3DI.%26aulast%3DHartman%26aufirst%3DJ.%26aulast%3DKawas%26aufirst%3DR.%26aulast%3DLu%26aufirst%3DP.%2BP.%26aulast%3DLee%26aufirst%3DK.%2BH.%26aulast%3DMarquez%26aufirst%3DD.%26aulast%3DTomlinson%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DD.%26aulast%3DKennedy%26aufirst%3DA.%26aulast%3DHwee%26aufirst%3DD.%26aulast%3DSchaletzky%26aufirst%3DJ.%26aulast%3DLeung%26aufirst%3DK.%26aulast%3DMalik%26aufirst%3DF.%2BI.%26aulast%3DMorgans%26aufirst%3DD.%2BJ.%26aulast%3DMorgan%26aufirst%3DB.%2BP.%26atitle%3DDiscovery%2520of%2520tirasemtiv%252C%2520the%2520first%2520direct%2520fast%2520skeletal%2520muscle%2520troponin%2520activator%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D9%26spage%3D354%26epage%3D358%26doi%3D10.1021%2Facsmedchemlett.7b00546" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vijayakumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoltz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolff, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malik, F. I.</span></span> <span> </span><span class="NLM_article-title">CK-2127107 amplifies skeletal muscle response to nerve activation in humans</span>. <i>Muscle Nerve</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">729</span>– <span class="NLM_lpage">734</span>, <span class="refDoi"> DOI: 10.1002/mus.26017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1002%2Fmus.26017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=29150952" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotlyhsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2018&pages=729-734&author=J.+A.+Andrewsauthor=T.+M.+Millerauthor=V.+Vijayakumarauthor=R.+Stoltzauthor=J.+K.+Jamesauthor=L.+Mengauthor=A.+A.+Wolffauthor=F.+I.+Malik&title=CK-2127107+amplifies+skeletal+muscle+response+to+nerve+activation+in+humans&doi=10.1002%2Fmus.26017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">CK-2127107 amplifies skeletal muscle response to nerve activation in humans</span></div><div class="casAuthors">Andrews, Jinsy A.; Miller, Timothy M.; Vijayakumar, Vipin; Stoltz, Randall; James, Joyce K.; Meng, Lisa; Wolff, Andrew A.; Malik, Fady I.</div><div class="citationInfo"><span class="NLM_cas:title">Muscle & Nerve</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">729-734</span>CODEN:
                <span class="NLM_cas:coden">MUNEDE</span>;
        ISSN:<span class="NLM_cas:issn">0148-639X</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Three studies evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics of CK-2127107 (CK-107), a next-generation fast skeletal muscle troponin activator (FSTA), in healthy participants.  We tested the hypothesis that CK-107 would amplify the force-frequency response of muscle in humans.  To assess the force-frequency response, participants received single doses of CK-107 and placebo in a randomized, double-blind, 4-period, crossover study.  The force-frequency response of foot dorsiflexion following stimulation of the deep fibular nerve to activate the tibialis anterior muscle was assessed.  CK-107 significantly increased tibialis anterior muscle response with increasing dose and plasma concn. in a frequency-dependent manner; the largest increase in peak force was ∼60% at 10 Hz.  CK-107 appears more potent and produced larger increases in force than tirasemtiv-a first-generation FSTA-in a similar pharmacodynamic study, thereby supporting its development for improvement of muscle function of patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqH8rDODhoS47Vg90H21EOLACvtfcHk0liCmHPEAM_KsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotlyhsrc%253D&md5=cceb7e42894750c3a2657a0381076417</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1002%2Fmus.26017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmus.26017%26sid%3Dliteratum%253Aachs%26aulast%3DAndrews%26aufirst%3DJ.%2BA.%26aulast%3DMiller%26aufirst%3DT.%2BM.%26aulast%3DVijayakumar%26aufirst%3DV.%26aulast%3DStoltz%26aufirst%3DR.%26aulast%3DJames%26aufirst%3DJ.%2BK.%26aulast%3DMeng%26aufirst%3DL.%26aulast%3DWolff%26aufirst%3DA.%2BA.%26aulast%3DMalik%26aufirst%3DF.%2BI.%26atitle%3DCK-2127107%2520amplifies%2520skeletal%2520muscle%2520response%2520to%2520nerve%2520activation%2520in%2520humans%26jtitle%3DMuscle%2520Nerve%26date%3D2018%26volume%3D57%26spage%3D729%26epage%3D734%26doi%3D10.1002%2Fmus.26017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santosh Laxmi, Y. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">David, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinkova-Kostova, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiavoni, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trevino, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bumeister, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ojima, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wigley, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bliska, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mierke, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honda, T.</span></span> <span> </span><span class="NLM_article-title">Synthesis, chemical reactivity as Michael acceptors, and biological potency of monocyclic cyanoenones, novel and highly potent anti-inflammatory and cytoprotective agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">4837</span>– <span class="NLM_lpage">4846</span>, <span class="refDoi"> DOI: 10.1021/jm3003922</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3003922" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC38XmtFWju78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=4837-4846&author=S.+Zhengauthor=Y.+R.+Santosh+Laxmiauthor=E.+Davidauthor=A.+T.+Dinkova-Kostovaauthor=K.+H.+Shiavoniauthor=Y.+Renauthor=Y.+Zhengauthor=I.+Trevinoauthor=R.+Bumeisterauthor=I.+Ojimaauthor=W.+C.+Wigleyauthor=J.+B.+Bliskaauthor=D.+F.+Mierkeauthor=T.+Honda&title=Synthesis%2C+chemical+reactivity+as+Michael+acceptors%2C+and+biological+potency+of+monocyclic+cyanoenones%2C+novel+and+highly+potent+anti-inflammatory+and+cytoprotective+agents&doi=10.1021%2Fjm3003922"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, Chemical Reactivity as Michael Acceptors, and Biological Potency of Monocyclic Cyanoenones, Novel and Highly Potent Anti-inflammatory and Cytoprotective Agents</span></div><div class="casAuthors">Zheng, Suqing; Santosh Laxmi, Y. R.; David, Emilie; Dinkova-Kostova, Albena T.; Shiavoni, Katherine H.; Ren, Yanqing; Zheng, Ying; Trevino, Isaac; Bumeister, Ronald; Ojima, Iwao; Wigley, W. Christian; Bliska, James B.; Mierke, Dale F.; Honda, Tadashi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4837-4846</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Novel monocyclic cyanoenones examd. to date display unique features regarding chem. reactivity as Michael acceptors and biol. potency.  Remarkably, in some biol. assays, the simple structure is more potent than pentacyclic triterpenoids (e.g., CDDO and bardoxolone methyl) and tricycles (e.g., TBE-31).  Among monocyclic cyanoenones, 1 (I) is a highly reactive Michael acceptor with thiol nucleophiles.  Furthermore, an important feature of 1 is that its Michael addn. is reversible.  For the inhibition of NO prodn., 1 shows the highest potency.  Notably, its potency is about three times higher than CDDO, whose Me ester (bardoxolone methyl) is presently in phase III clin. trials.  For the induction of NQO1, 1 also demonstrated the highest potency.  These results suggest that the reactivity of these Michael acceptors is closely related to their biol. potency.  Interestingly, in LPS-stimulated macrophages, 1 causes apoptosis and inhibits secretion of TNF-α and IL-1β with potencies that are higher than those of bardoxolone Me and TBE-31.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9JECzJnGhn7Vg90H21EOLACvtfcHk0liCmHPEAM_KsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmtFWju78%253D&md5=c821917bc8e0da1143c02c58cbc6dae6</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Fjm3003922&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3003922%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DS.%26aulast%3DSantosh%2BLaxmi%26aufirst%3DY.%2BR.%26aulast%3DDavid%26aufirst%3DE.%26aulast%3DDinkova-Kostova%26aufirst%3DA.%2BT.%26aulast%3DShiavoni%26aufirst%3DK.%2BH.%26aulast%3DRen%26aufirst%3DY.%26aulast%3DZheng%26aufirst%3DY.%26aulast%3DTrevino%26aufirst%3DI.%26aulast%3DBumeister%26aufirst%3DR.%26aulast%3DOjima%26aufirst%3DI.%26aulast%3DWigley%26aufirst%3DW.%2BC.%26aulast%3DBliska%26aufirst%3DJ.%2BB.%26aulast%3DMierke%26aufirst%3DD.%2BF.%26aulast%3DHonda%26aufirst%3DT.%26atitle%3DSynthesis%252C%2520chemical%2520reactivity%2520as%2520Michael%2520acceptors%252C%2520and%2520biological%2520potency%2520of%2520monocyclic%2520cyanoenones%252C%2520novel%2520and%2520highly%2520potent%2520anti-inflammatory%2520and%2520cytoprotective%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D4837%26epage%3D4846%26doi%3D10.1021%2Fjm3003922" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yokokawa, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noble, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tania, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunziker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karuna, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manjunatha, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P. W.</span></span> <span> </span><span class="NLM_article-title">Discovery of potent non-nucleoside inhibitors of Dengue viral RNA-dependent RNA polymerase from a fragment hit using structure-based drug design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">3935</span>– <span class="NLM_lpage">3952</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00143</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00143" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC28Xkt1Cmsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=3935-3952&author=F.+Yokokawaauthor=S.+Nilarauthor=C.+G.+Nobleauthor=S.+P.+Limauthor=R.+Raoauthor=S.+Taniaauthor=G.+Wangauthor=G.+Leeauthor=J.+Hunzikerauthor=R.+Karunaauthor=U.+Manjunathaauthor=P.+Y.+Shiauthor=P.+W.+Smith&title=Discovery+of+potent+non-nucleoside+inhibitors+of+Dengue+viral+RNA-dependent+RNA+polymerase+from+a+fragment+hit+using+structure-based+drug+design&doi=10.1021%2Facs.jmedchem.6b00143"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Potent Non-Nucleoside Inhibitors of Dengue Viral RNA-Dependent RNA Polymerase from a Fragment Hit Using Structure-Based Drug Design</span></div><div class="casAuthors">Yokokawa, Fumiaki; Nilar, Shahul; Noble, Christian G.; Lim, Siew Pheng; Rao, Ranga; Tania, Stefani; Wang, Gang; Lee, Gladys; Hunziker, Jurg; Karuna, Ratna; Manjunatha, Ujjini; Shi, Pei-Yong; Smith, Paul W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3935-3952</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery and optimization of non-nucleoside dengue viral RNA-dependent-RNA polymerase (RdRp) inhibitors are described.  An X-ray-based fragment screen of Novartis' fragment collection resulted in the identification of a biphenyl acetic acid fragment 3, which bound in the palm subdomain of RdRp.  Subsequent optimization of the fragment hit 3, relying on structure-based design, resulted in a >1000-fold improvement in potency in vitro and acquired antidengue activity against all four serotypes with low micromolar EC50 in cell-based assays.  The lead candidate 27 interacts with a novel binding pocket in the palm subdomain of the RdRp and exerts a promising activity against all clin. relevant dengue serotypes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpRKw1WHPPP7Vg90H21EOLACvtfcHk0lgw5na3w0PW6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xkt1Cmsb4%253D&md5=93c41f9b5b01dc1ea8c91b6e0a6ef2ea</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00143&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00143%26sid%3Dliteratum%253Aachs%26aulast%3DYokokawa%26aufirst%3DF.%26aulast%3DNilar%26aufirst%3DS.%26aulast%3DNoble%26aufirst%3DC.%2BG.%26aulast%3DLim%26aufirst%3DS.%2BP.%26aulast%3DRao%26aufirst%3DR.%26aulast%3DTania%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DLee%26aufirst%3DG.%26aulast%3DHunziker%26aufirst%3DJ.%26aulast%3DKaruna%26aufirst%3DR.%26aulast%3DManjunatha%26aufirst%3DU.%26aulast%3DShi%26aufirst%3DP.%2BY.%26aulast%3DSmith%26aufirst%3DP.%2BW.%26atitle%3DDiscovery%2520of%2520potent%2520non-nucleoside%2520inhibitors%2520of%2520Dengue%2520viral%2520RNA-dependent%2520RNA%2520polymerase%2520from%2520a%2520fragment%2520hit%2520using%2520structure-based%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D3935%26epage%3D3952%26doi%3D10.1021%2Facs.jmedchem.6b00143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Irie-Sasaki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliveira-dos-Santos, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanford, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolon, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakeham, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Itie, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouchard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozieradzki, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joza, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mak, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohashi, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penninger, J. M.</span></span> <span> </span><span class="NLM_article-title">Function of PI3Kgamma in thymocyte development, T cell activation, and neutrophil migration</span>. <i>Science (Washington, DC, U. S.)</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>287</i></span>,  <span class="NLM_fpage">1040</span>– <span class="NLM_lpage">1046</span>, <span class="refDoi"> DOI: 10.1126/science.287.5455.1040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1126%2Fscience.287.5455.1040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10669416" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhtFyqtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=287&publication_year=2000&pages=1040-1046&author=T.+Sasakiauthor=J.+Irie-Sasakiauthor=R.+G.+Jonesauthor=A.+J.+Oliveira-dos-Santosauthor=W.+L.+Stanfordauthor=B.+Bolonauthor=A.+Wakehamauthor=A.+Itieauthor=D.+Bouchardauthor=I.+Kozieradzkiauthor=N.+Jozaauthor=T.+W.+Makauthor=P.+S.+Ohashiauthor=A.+Suzukiauthor=J.+M.+Penninger&title=Function+of+PI3Kgamma+in+thymocyte+development%2C+T+cell+activation%2C+and+neutrophil+migration&doi=10.1126%2Fscience.287.5455.1040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Function of PI3Kγ in thymocyte development, T cell activation, and neutrophil migration</span></div><div class="casAuthors">Sasaki, Takehiko; Irie-Sasaki, Unko; Jones, Russell G.; Oliveira-do-Santos, Antonio J.; Stanford, William L.; Bolon, Brad; Wakeham, Andrew; Itie, Annick; Bouchard, Dennis; Kozieradzki, Ivona; Joza, Nicholas; Mak, Tak W.; Ohashi, Pamela S.; Suzuki, Akira; Penninger, Josef M.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">287</span>
        (<span class="NLM_cas:issue">5455</span>),
    <span class="NLM_cas:pages">1040-1046</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Phosphoinositide 3-kinases (PI3Ks) regulate fundamental cellular responses such as proliferation, apoptosis, cell motility, and adhesion.  Viable gene-targeted mice lacking the p110 catalytic subunit of PI3Kγ were generated.  The authors show that PI3Kγ controls thymocyte survival and activation of mature T cells but has no role in the development or function of B cells.  PI3Kγ-deficient neutrophils exhibited severe defects in migration and respiratory burst in response to heterotrimeric GTP-binding protein (G protein)-coupled receptor (GPCR) agonists and chemotactic agents.  P13Kγ links GPCR stimulation to the formation of phosphatidylinositol 3,4,5-triphosphate and the activation of protein kinase B, ribosomal protein S6 kinase, and extracellular signal-regulated kinases 1 and 2.  Thus, P13Kγ regulates thymocyte development, T cell activation, neutrophil migration, and the oxidative burst.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6G1gpy-GhpbVg90H21EOLACvtfcHk0lgw5na3w0PW6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhtFyqtb4%253D&md5=53c44ac104f8eb423a727eb3d09364a5</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1126%2Fscience.287.5455.1040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.287.5455.1040%26sid%3Dliteratum%253Aachs%26aulast%3DSasaki%26aufirst%3DT.%26aulast%3DIrie-Sasaki%26aufirst%3DJ.%26aulast%3DJones%26aufirst%3DR.%2BG.%26aulast%3DOliveira-dos-Santos%26aufirst%3DA.%2BJ.%26aulast%3DStanford%26aufirst%3DW.%2BL.%26aulast%3DBolon%26aufirst%3DB.%26aulast%3DWakeham%26aufirst%3DA.%26aulast%3DItie%26aufirst%3DA.%26aulast%3DBouchard%26aufirst%3DD.%26aulast%3DKozieradzki%26aufirst%3DI.%26aulast%3DJoza%26aufirst%3DN.%26aulast%3DMak%26aufirst%3DT.%2BW.%26aulast%3DOhashi%26aufirst%3DP.%2BS.%26aulast%3DSuzuki%26aufirst%3DA.%26aulast%3DPenninger%26aufirst%3DJ.%2BM.%26atitle%3DFunction%2520of%2520PI3Kgamma%2520in%2520thymocyte%2520development%252C%2520T%2520cell%2520activation%252C%2520and%2520neutrophil%2520migration%26jtitle%3DScience%2520%2528Washington%252C%2520DC%252C%2520U.%2520S.%2529%26date%3D2000%26volume%3D287%26spage%3D1040%26epage%3D1046%26doi%3D10.1126%2Fscience.287.5455.1040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Evans, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lescarbeau, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nair, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grenier, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pradeilles, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glenadel, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tibbitts, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowley, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiNitto, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brophy, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Hearn, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkler, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Hearn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoyt, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soglia, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pink, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proctor, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palombella, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tremblay, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castro, A. C.</span></span> <span> </span><span class="NLM_article-title">Discovery of a selective phosphoinositide-3-kinase (PI3K)-gamma inhibitor (IPI-549) as an immuno-oncology clinical candidate</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">862</span>– <span class="NLM_lpage">867</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.6b00238</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00238" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1aju7vO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=862-867&author=C.+A.+Evansauthor=T.+Liuauthor=A.+Lescarbeauauthor=S.+J.+Nairauthor=L.+Grenierauthor=J.+A.+Pradeillesauthor=Q.+Glenadelauthor=T.+Tibbittsauthor=A.+M.+Rowleyauthor=J.+P.+DiNittoauthor=E.+E.+Brophyauthor=E.+L.+O%E2%80%99Hearnauthor=J.+A.+Aliauthor=D.+G.+Winklerauthor=S.+I.+Goldsteinauthor=P.+O%E2%80%99Hearnauthor=C.+M.+Martinauthor=J.+G.+Hoytauthor=J.+R.+Sogliaauthor=C.+Cheungauthor=M.+M.+Pinkauthor=J.+L.+Proctorauthor=V.+J.+Palombellaauthor=M.+R.+Tremblayauthor=A.+C.+Castro&title=Discovery+of+a+selective+phosphoinositide-3-kinase+%28PI3K%29-gamma+inhibitor+%28IPI-549%29+as+an+immuno-oncology+clinical+candidate&doi=10.1021%2Facsmedchemlett.6b00238"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Selective Phosphoinositide-3-Kinase (PI3K)-γ Inhibitor (IPI-549) as an Immuno-Oncology Clinical Candidate</span></div><div class="casAuthors">Evans, Catherine A.; Liu, Tao; Lescarbeau, Andre; Nair, Somarajan J.; Grenier, Louis; Pradeilles, Johan A.; Glenadel, Quentin; Tibbitts, Thomas; Rowley, Ann M.; DiNitto, Jonathan P.; Brophy, Erin E.; OHearn, Erin L.; Ali, Janid A.; Winkler, David G.; Goldstein, Stanley I.; OHearn, Patrick; Martin, Christian M.; Hoyt, Jennifer G.; Soglia, John R.; Cheung, Culver; Pink, Melissa M.; Proctor, Jennifer L.; Palombella, Vito J.; Tremblay, Martin R.; Castro, Alfredo C.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">862-867</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Optimization of isoquinolinone PI3K inhibitors led to the discovery of a potent inhibitor of PI3K-γ (IPI-549) with >100-fold selectivity over other lipid and protein kinases.  IPI-549 demonstrates favorable pharmacokinetic properties and robust inhibition of PI3K-γ mediated neutrophil migration in vivo and is currently in Phase 1 clin. evaluation in subjects with advanced solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrc4njNatEdTbVg90H21EOLACvtfcHk0liZmS2cqo2r3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1aju7vO&md5=9850bb40b0727512d0ca844264c2ec8a</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00238%26sid%3Dliteratum%253Aachs%26aulast%3DEvans%26aufirst%3DC.%2BA.%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DLescarbeau%26aufirst%3DA.%26aulast%3DNair%26aufirst%3DS.%2BJ.%26aulast%3DGrenier%26aufirst%3DL.%26aulast%3DPradeilles%26aufirst%3DJ.%2BA.%26aulast%3DGlenadel%26aufirst%3DQ.%26aulast%3DTibbitts%26aufirst%3DT.%26aulast%3DRowley%26aufirst%3DA.%2BM.%26aulast%3DDiNitto%26aufirst%3DJ.%2BP.%26aulast%3DBrophy%26aufirst%3DE.%2BE.%26aulast%3DO%25E2%2580%2599Hearn%26aufirst%3DE.%2BL.%26aulast%3DAli%26aufirst%3DJ.%2BA.%26aulast%3DWinkler%26aufirst%3DD.%2BG.%26aulast%3DGoldstein%26aufirst%3DS.%2BI.%26aulast%3DO%25E2%2580%2599Hearn%26aufirst%3DP.%26aulast%3DMartin%26aufirst%3DC.%2BM.%26aulast%3DHoyt%26aufirst%3DJ.%2BG.%26aulast%3DSoglia%26aufirst%3DJ.%2BR.%26aulast%3DCheung%26aufirst%3DC.%26aulast%3DPink%26aufirst%3DM.%2BM.%26aulast%3DProctor%26aufirst%3DJ.%2BL.%26aulast%3DPalombella%26aufirst%3DV.%2BJ.%26aulast%3DTremblay%26aufirst%3DM.%2BR.%26aulast%3DCastro%26aufirst%3DA.%2BC.%26atitle%3DDiscovery%2520of%2520a%2520selective%2520phosphoinositide-3-kinase%2520%2528PI3K%2529-gamma%2520inhibitor%2520%2528IPI-549%2529%2520as%2520an%2520immuno-oncology%2520clinical%2520candidate%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D862%26epage%3D867%26doi%3D10.1021%2Facsmedchemlett.6b00238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haraguchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumamoto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baba, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y. C.</span></span> <span> </span><span class="NLM_article-title">4′-Ethynylstavudine (4′-Ed4T) has potent anti-HIV-1 activity with reduced toxicity and shows a unique activity profile against drug-resistant mutants</span>. <i>Antiviral Chem. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">217</span>– <span class="NLM_lpage">221</span>, <span class="refDoi"> DOI: 10.1177/095632020501600402</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1177%2F095632020501600402" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=16130520" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpvVKnsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2005&pages=217-221&author=H.+Tanakaauthor=K.+Haraguchiauthor=H.+Kumamotoauthor=M.+Babaauthor=Y.+C.+Cheng&title=4%E2%80%B2-Ethynylstavudine+%284%E2%80%B2-Ed4T%29+has+potent+anti-HIV-1+activity+with+reduced+toxicity+and+shows+a+unique+activity+profile+against+drug-resistant+mutants&doi=10.1177%2F095632020501600402"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">4'-Ethynylstavudine (4'-Ed4T) has potent anti-HIV-1 activity with reduced toxicity and shows a unique activity profile against drug-resistant mutants</span></div><div class="casAuthors">Tanaka, Hiromichi; Haraguchi, Kazuhiro; Kumamoto, Hiroki; Baba, Masanori; Cheng, Yung-Chi</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Chemistry & Chemotherapy</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">217-221</span>CODEN:
                <span class="NLM_cas:coden">ACCHEH</span>;
        ISSN:<span class="NLM_cas:issn">0956-3202</span>.
    
            (<span class="NLM_cas:orgname">International Medical Press</span>)
        </div><div class="casAbstract">A nucleoside analog 4'-ethynylstavudine (4'-Ed4T) was recently synthesized during chem. studies directed towards the development of a new route to 4'-carbon-substituted nucleosides.  This compd. was more anti-HIV-1 active than the parent compd. stavudine (d4T) and much less toxic to various cells and also to mitochondrial DNA synthesis.  It became apparent that 4'-Ed4T is a better substrate for human thymidine kinase than d4t, and very much more resistant to catabolism by thymidine phosphorylase.  The study of 4'-Ed4T against various drug-resistant HIV-1 mutants has disclosed its unique activity profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolQCaaea0lurVg90H21EOLACvtfcHk0liZmS2cqo2r3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpvVKnsLk%253D&md5=0d0ff69b964bc0d1cc1876020ce295ad</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1177%2F095632020501600402&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F095632020501600402%26sid%3Dliteratum%253Aachs%26aulast%3DTanaka%26aufirst%3DH.%26aulast%3DHaraguchi%26aufirst%3DK.%26aulast%3DKumamoto%26aufirst%3DH.%26aulast%3DBaba%26aufirst%3DM.%26aulast%3DCheng%26aufirst%3DY.%2BC.%26atitle%3D4%25E2%2580%25B2-Ethynylstavudine%2520%25284%25E2%2580%25B2-Ed4T%2529%2520has%2520potent%2520anti-HIV-1%2520activity%2520with%2520reduced%2520toxicity%2520and%2520shows%2520a%2520unique%2520activity%2520profile%2520against%2520drug-resistant%2520mutants%26jtitle%3DAntiviral%2520Chem.%2520Chemother.%26date%3D2005%26volume%3D16%26spage%3D217%26epage%3D221%26doi%3D10.1177%2F095632020501600402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kawamoto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kodama, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarafianos, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakagami, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohgo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitano, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashida, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayakawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakata, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsuya, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuoka, M.</span></span> <span> </span><span class="NLM_article-title">2′-Deoxy-4′-C-ethynyl-2-halo-adenosines active against drug-resistant human immunodeficiency virus type 1 variants</span>. <i>Int. J. Biochem. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">2410</span>– <span class="NLM_lpage">2420</span>, <span class="refDoi"> DOI: 10.1016/j.biocel.2008.04.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1016%2Fj.biocel.2008.04.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=18487070" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpsVaguro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2008&pages=2410-2420&author=A.+Kawamotoauthor=E.+Kodamaauthor=S.+G.+Sarafianosauthor=Y.+Sakagamiauthor=S.+Kohgoauthor=K.+Kitanoauthor=N.+Ashidaauthor=Y.+Iwaiauthor=H.+Hayakawaauthor=H.+Nakataauthor=H.+Mitsuyaauthor=E.+Arnoldauthor=M.+Matsuoka&title=2%E2%80%B2-Deoxy-4%E2%80%B2-C-ethynyl-2-halo-adenosines+active+against+drug-resistant+human+immunodeficiency+virus+type+1+variants&doi=10.1016%2Fj.biocel.2008.04.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">2'-Deoxy-4'-C-ethynyl-2-halo-adenosines active against drug-resistant human immunodeficiency virus type 1 variants</span></div><div class="casAuthors">Kawamoto, Atsushi; Kodama, Eiichi; Sarafianos, Stefan G.; Sakagami, Yasuko; Kohgo, Satoru; Kitano, Kenji; Ashida, Noriyuki; Iwai, Yuko; Hayakawa, Hiroyuki; Nakata, Hirotomo; Mitsuya, Hiroaki; Arnold, Eddy; Matsuoka, Masao</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Biochemistry & Cell Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2410-2420</span>CODEN:
                <span class="NLM_cas:coden">IJBBFU</span>;
        ISSN:<span class="NLM_cas:issn">1357-2725</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">One of the formidable challenges in therapy of infections by human immunodeficiency virus (HIV) is the emergence of drug-resistant variants that attenuate the efficacy of highly active antiretroviral therapy (HAART).  We have recently introduced 4'-ethynyl-nucleoside analogs as nucleoside reverse transcriptase inhibitors (NRTIs) that could be developed as therapeutics for treatment of HIV infections.  In this study, we present 2'-deoxy-4'-C-ethynyl-2-fluoroadenosine (EFdA), a second generation 4'-ethynyl inhibitor that exerted highly potent activity against wild-type HIV-1 (EC50 ∼ 0.07 nM).  EFdA retains potency toward many HIV-1 resistant strains, including the multi-drug resistant clone HIV-1A62V/V75I/F77L/F116Y/q151M.  The selectivity index of EFdA (cytotoxicity/inhibitory activity) is more favorable than all approved NRTIs used in HIV therapy.  Furthermore, EFdA efficiently inhibited clin. isolates from patients heavily treated with multiple anti-HIV-1 drugs.  EFdA appears to be primarily phosphorylated by the cellular 2'-deoxycytidine kinase (dCK) because: (a) the antiviral activity of EFdA was reduced by the addn. of dC, which competes nucleosides phosphorylated by the dCK pathway, (b) the antiviral activity of EFdA was significantly reduced in dCK-deficient HT-1080/Ara-Cr cells, but restored after dCK transduction.  Further, unlike other dA analogs, EFdA is completely resistant to degrdn. by adenosine deaminase.  Moderate decrease in susceptibility to EFdA is conferred by a combination of three RT mutations (I142V, T165R, and M184V) that result in a significant decrease of viral fitness.  Mol. modeling anal. suggests that the M184V/I substitutions may reduce anti-HIV activity of EFdA through steric hindrance between its 4'-ethynyl moiety and the V/I184 β-branched side chains.  The present data suggest that EFdA, is a promising candidate for developing as a therapeutic agent for the treatment of individuals harboring multi-drug resistant HIV variants.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1x9Q0xUpKX7Vg90H21EOLACvtfcHk0liZmS2cqo2r3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpsVaguro%253D&md5=69039c735ae8e2f42c73c085f5ba87a3</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2Fj.biocel.2008.04.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biocel.2008.04.007%26sid%3Dliteratum%253Aachs%26aulast%3DKawamoto%26aufirst%3DA.%26aulast%3DKodama%26aufirst%3DE.%26aulast%3DSarafianos%26aufirst%3DS.%2BG.%26aulast%3DSakagami%26aufirst%3DY.%26aulast%3DKohgo%26aufirst%3DS.%26aulast%3DKitano%26aufirst%3DK.%26aulast%3DAshida%26aufirst%3DN.%26aulast%3DIwai%26aufirst%3DY.%26aulast%3DHayakawa%26aufirst%3DH.%26aulast%3DNakata%26aufirst%3DH.%26aulast%3DMitsuya%26aufirst%3DH.%26aulast%3DArnold%26aufirst%3DE.%26aulast%3DMatsuoka%26aufirst%3DM.%26atitle%3D2%25E2%2580%25B2-Deoxy-4%25E2%2580%25B2-C-ethynyl-2-halo-adenosines%2520active%2520against%2520drug-resistant%2520human%2520immunodeficiency%2520virus%2520type%25201%2520variants%26jtitle%3DInt.%2520J.%2520Biochem.%2520Cell%2520Biol.%26date%3D2008%26volume%3D40%26spage%3D2410%26epage%3D2420%26doi%3D10.1016%2Fj.biocel.2008.04.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Michailidis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchand, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kodama, E. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuoka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirby, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawani, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagy, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashida, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsuya, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parniak, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarafianos, S. G.</span></span> <span> </span><span class="NLM_article-title">Mechanism of inhibition of HIV-1 reverse transcriptase by 4′-Ethynyl-2-fluoro-2′-deoxyadenosine triphosphate, a translocation-defective reverse transcriptase inhibitor</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>284</i></span>,  <span class="NLM_fpage">35681</span>– <span class="NLM_lpage">35691</span>, <span class="refDoi"> DOI: 10.1074/jbc.M109.036616</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1074%2Fjbc.M109.036616" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=19837673" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFCqurfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=284&publication_year=2009&pages=35681-35691&author=E.+Michailidisauthor=B.+Marchandauthor=E.+N.+Kodamaauthor=K.+Singhauthor=M.+Matsuokaauthor=K.+A.+Kirbyauthor=E.+M.+Ryanauthor=A.+M.+Sawaniauthor=E.+Nagyauthor=N.+Ashidaauthor=H.+Mitsuyaauthor=M.+A.+Parniakauthor=S.+G.+Sarafianos&title=Mechanism+of+inhibition+of+HIV-1+reverse+transcriptase+by+4%E2%80%B2-Ethynyl-2-fluoro-2%E2%80%B2-deoxyadenosine+triphosphate%2C+a+translocation-defective+reverse+transcriptase+inhibitor&doi=10.1074%2Fjbc.M109.036616"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of Inhibition of HIV-1 Reverse Transcriptase by 4'-Ethynyl-2-fluoro-2'-deoxyadenosine Triphosphate, a Translocation-defective Reverse Transcriptase Inhibitor</span></div><div class="casAuthors">Michailidis, Eleftherios; Marchand, Bruno; Kodama, Eiichi N.; Singh, Kamlendra; Matsuoka, Masao; Kirby, Karen A.; Ryan, Emily M.; Sawani, Ali M.; Nagy, Eva; Ashida, Noriyuki; Mitsuya, Hiroaki; Parniak, Michael A.; Sarafianos, Stefan G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">284</span>
        (<span class="NLM_cas:issue">51</span>),
    <span class="NLM_cas:pages">35681-35691</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Nucleoside reverse transcriptase inhibitors (NRTIs) are employed in first line therapies for the treatment of human immunodeficiency virus (HIV) infection.  They generally lack a 3'-hydroxyl group, and thus when incorporated into the nascent DNA they prevent further elongation.  The authors show that 4'-ethynyl-2-fluoro-2'-deoxyadenosine (EFdA), a nucleoside analog that retains a 3'-hydroxyl moiety, inhibited HIV-1 replication in activated peripheral blood mononuclear cells with an EC50 of 0.05 nM, a potency several orders of magnitude better than any of the current clin. used NRTIs.  This exceptional antiviral activity stems in part from a mechanism of action that is different from approved NRTIs.  Reverse transcriptase (RT) can use EFdA-5'-triphosphate (EFdA-TP) as a substrate more efficiently than the natural substrate, dATP.  Importantly, despite the presence of a 3'-hydroxyl, the incorporated EFdA monophosphate (EFdA-MP) acted mainly as a de facto terminator of further RT-catalyzed DNA synthesis because of the difficulty of RT translocation on the nucleic acid primer possessing 3'-terminal EFdA-MP.  EFdA-TP is thus a translocation-defective RT inhibitor (TDRTI).  This diminished translocation kept the primer 3'-terminal EFdA-MP ideally located to undergo phosphorolytic excision.  However, net phosphorolysis was not substantially increased, because of the apparently facile reincorporation of the newly excised EFdA-TP.  The authors' mol. modeling studies suggest that the 4'-ethynyl fits into a hydrophobic pocket defined by RT residues Ala 114, Tyr-115, Phe 160, and Met 184 and the aliph. chain of Asp 185.  These interactions, which contribute to both enhanced RT utilization of EFdA-TP and difficulty in the translocation of 3'-terminal EFdA-MP primers, underlie the mechanism of action of this potent antiviral nucleoside.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSzybzRvJFz7Vg90H21EOLACvtfcHk0lik0oRWbxqq7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFCqurfI&md5=af4d7c768df0bc42d8a058bd7fd7e993</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M109.036616&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M109.036616%26sid%3Dliteratum%253Aachs%26aulast%3DMichailidis%26aufirst%3DE.%26aulast%3DMarchand%26aufirst%3DB.%26aulast%3DKodama%26aufirst%3DE.%2BN.%26aulast%3DSingh%26aufirst%3DK.%26aulast%3DMatsuoka%26aufirst%3DM.%26aulast%3DKirby%26aufirst%3DK.%2BA.%26aulast%3DRyan%26aufirst%3DE.%2BM.%26aulast%3DSawani%26aufirst%3DA.%2BM.%26aulast%3DNagy%26aufirst%3DE.%26aulast%3DAshida%26aufirst%3DN.%26aulast%3DMitsuya%26aufirst%3DH.%26aulast%3DParniak%26aufirst%3DM.%2BA.%26aulast%3DSarafianos%26aufirst%3DS.%2BG.%26atitle%3DMechanism%2520of%2520inhibition%2520of%2520HIV-1%2520reverse%2520transcriptase%2520by%25204%25E2%2580%25B2-Ethynyl-2-fluoro-2%25E2%2580%25B2-deoxyadenosine%2520triphosphate%252C%2520a%2520translocation-defective%2520reverse%2520transcriptase%2520inhibitor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2009%26volume%3D284%26spage%3D35681%26epage%3D35691%26doi%3D10.1074%2Fjbc.M109.036616" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ohrui, H.</span></span> <span> </span><span class="NLM_article-title">2′-Deoxy-4′-C-ethynyl-2-fluoroadenosine, a nucleoside reverse transcriptase inhibitor, is highly potent against all human immunodeficiency viruses type 1 and has low toxicity</span>. <i>Chem. Rec.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">133</span>– <span class="NLM_lpage">143</span>, <span class="refDoi"> DOI: 10.1002/tcr.20078</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1002%2Ftcr.20078" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=16795005" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD28XntVChsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=133-143&author=H.+Ohrui&title=2%E2%80%B2-Deoxy-4%E2%80%B2-C-ethynyl-2-fluoroadenosine%2C+a+nucleoside+reverse+transcriptase+inhibitor%2C+is+highly+potent+against+all+human+immunodeficiency+viruses+type+1+and+has+low+toxicity&doi=10.1002%2Ftcr.20078"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">2'-deoxy-4'-C-ethynyl-2-fluoroadenosine, a nucleoside reverse transcriptase inhibitor, is highly potent against all human immunodeficiency viruses type 1 and has low toxicity</span></div><div class="casAuthors">Ohrui, Hiroshi</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Record</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">133-143</span>CODEN:
                <span class="NLM_cas:coden">CRHEAK</span>;
        ISSN:<span class="NLM_cas:issn">1527-8999</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">This review presents an idea to use 4'-C-substituted-2'-deoxynucleoside derivs. based on a working hypothesis to solve the problems of existing acquired immune deficiency syndrome chemotherapy (highly active antiretroviral therapy).  Subsequent studies have successfully proved the validity of the idea and resulted in the development of 2'-deoxy-4'-C-ethynyl-2-fluoroadenosine, a nucleoside reverse transcriptase inhibitor, which is highly potent to all human immunodeficiency viruses type 1 (HIV-1s) including multidrug-resistant HIV-1 and has a low toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdvdl4XojO6bVg90H21EOLACvtfcHk0lik0oRWbxqq7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XntVChsL0%253D&md5=088b34c005c70f95a5b72eb5f6cdba69</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1002%2Ftcr.20078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Ftcr.20078%26sid%3Dliteratum%253Aachs%26aulast%3DOhrui%26aufirst%3DH.%26atitle%3D2%25E2%2580%25B2-Deoxy-4%25E2%2580%25B2-C-ethynyl-2-fluoroadenosine%252C%2520a%2520nucleoside%2520reverse%2520transcriptase%2520inhibitor%252C%2520is%2520highly%2520potent%2520against%2520all%2520human%2520immunodeficiency%2520viruses%2520type%25201%2520and%2520has%2520low%2520toxicity%26jtitle%3DChem.%2520Rec.%26date%3D2006%26volume%3D6%26spage%3D133%26epage%3D143%26doi%3D10.1002%2Ftcr.20078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Salie, Z. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirby, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michailidis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchand, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rohan, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kodama, E. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsuya, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parniak, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarafianos, S. G.</span></span> <span> </span><span class="NLM_article-title">Structural basis of HIV inhibition by translocation-defective RT inhibitor 4′-ethynyl-2-fluoro-2′-deoxyadenosine (EFdA)</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">9274</span>– <span class="NLM_lpage">9279</span>, <span class="refDoi"> DOI: 10.1073/pnas.1605223113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1073%2Fpnas.1605223113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=27489345" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1ygt73K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2016&pages=9274-9279&author=Z.+L.+Salieauthor=K.+A.+Kirbyauthor=E.+Michailidisauthor=B.+Marchandauthor=K.+Singhauthor=L.+C.+Rohanauthor=E.+N.+Kodamaauthor=H.+Mitsuyaauthor=M.+A.+Parniakauthor=S.+G.+Sarafianos&title=Structural+basis+of+HIV+inhibition+by+translocation-defective+RT+inhibitor+4%E2%80%B2-ethynyl-2-fluoro-2%E2%80%B2-deoxyadenosine+%28EFdA%29&doi=10.1073%2Fpnas.1605223113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis of HIV inhibition by translocation-defective RT inhibitor 4'-ethynyl-2-fluoro-2'-deoxyadenosine (EFdA)</span></div><div class="casAuthors">Salie, Zhe Li; Kirby, Karen A.; Michailidis, Eleftherios; Marchand, Bruno; Singh, Kamalendra; Rohan, Lisa C.; Kodama, Eiichi N.; Mitsuya, Hiroaki; Parniak, Michael A.; Sarafianos, Stefan G.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">9274-9279</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">4'-Ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) is the most potent nucleoside analog inhibitor of HIV reverse transcriptase (RT).  It retains a 3'-OH yet acts as a chain-terminating agent by diminishing translocation from the pretranslocation nucleotide-binding site (N site) to the posttranslocation primer-binding site (P site).  Also, facile misincorporation of EFdA-monophosphate (MP) results in difficult-to-extend mismatched primers.  To understand the high potency and unusual inhibition mechanism of EFdA, we solved RT crystal structures (resolns. from 2.4 to 2.9 Å) that include inhibition intermediates (i) before inhibitor incorporation (catalytic complex, RT/DNA/EFdA-triphosphate), (ii) after incorporation of EFdA-MP followed by dT-MP (RT/DNAEFdA-MPSUP°P/SUP°buldT-MPSUP°N/SUP°), or (iii) after incorporation of two EFdA-MPs (RT/DNAEFdA-MPSUP°P/SUP°bulEFdA-MPSUP°N/SUP°); (iv) the latter was also solved with EFdA-MP mismatched at the N site (RT/DNAEFdA-MPSUP°P/SUP°bulEFdA-MPtSUP°N/SUP°).  We report that the inhibition mechanism and potency of EFdA stem from interactions of its 4'-ethynyl at a previously unexploited conserved hydrophobic pocket in the polymerase active site.  The high resoln. of the catalytic complex structure revealed a network of ordered water mols. at the polymerase active site that stabilize enzyme interactions with nucleotide and DNA substrates.  Finally, decreased translocation results from favorable interactions of primer-terminating EFdA-MP at the pretranslocation site and unfavorable posttranslocation interactions that lead to obsd. localized primer distortions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-6y_9SBl-hbVg90H21EOLACvtfcHk0liJTZsphqxLrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1ygt73K&md5=f3668fe0d312877907006a44549d1520</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1605223113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1605223113%26sid%3Dliteratum%253Aachs%26aulast%3DSalie%26aufirst%3DZ.%2BL.%26aulast%3DKirby%26aufirst%3DK.%2BA.%26aulast%3DMichailidis%26aufirst%3DE.%26aulast%3DMarchand%26aufirst%3DB.%26aulast%3DSingh%26aufirst%3DK.%26aulast%3DRohan%26aufirst%3DL.%2BC.%26aulast%3DKodama%26aufirst%3DE.%2BN.%26aulast%3DMitsuya%26aufirst%3DH.%26aulast%3DParniak%26aufirst%3DM.%2BA.%26aulast%3DSarafianos%26aufirst%3DS.%2BG.%26atitle%3DStructural%2520basis%2520of%2520HIV%2520inhibition%2520by%2520translocation-defective%2520RT%2520inhibitor%25204%25E2%2580%25B2-ethynyl-2-fluoro-2%25E2%2580%25B2-deoxyadenosine%2520%2528EFdA%2529%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2016%26volume%3D113%26spage%3D9274%26epage%3D9279%26doi%3D10.1073%2Fpnas.1605223113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Itoh, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawamata, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujii, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukusumi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosoya, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uejima, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maruyama, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satoh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okubo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kizawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komatsu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumura, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noguchi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinohara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinuma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujisawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujino, M.</span></span> <span> </span><span class="NLM_article-title">Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>422</i></span>,  <span class="NLM_fpage">173</span>– <span class="NLM_lpage">176</span>, <span class="refDoi"> DOI: 10.1038/nature01478</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1038%2Fnature01478" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=12629551" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhvFKgs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=422&publication_year=2003&pages=173-176&author=Y.+Itohauthor=Y.+Kawamataauthor=M.+Haradaauthor=M.+Kobayashiauthor=R.+Fujiiauthor=S.+Fukusumiauthor=K.+Ogiauthor=M.+Hosoyaauthor=Y.+Tanakaauthor=H.+Uejimaauthor=H.+Tanakaauthor=M.+Maruyamaauthor=R.+Satohauthor=S.+Okuboauthor=H.+Kizawaauthor=H.+Komatsuauthor=F.+Matsumuraauthor=Y.+Noguchiauthor=T.+Shinoharaauthor=S.+Hinumaauthor=Y.+Fujisawaauthor=M.+Fujino&title=Free+fatty+acids+regulate+insulin+secretion+from+pancreatic+beta+cells+through+GPR40&doi=10.1038%2Fnature01478"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Free fatty acids regulate insulin secretion from pancreatic β cells through GPR40</span></div><div class="casAuthors">Itoh, Yasuaki; Kawamata, Yuji; Harada, Masataka; Kobayashi, Makoto; Fujii, Ryo; Fukusumi, Shoji; Ogi, Kazuhiro; Hosoya, Masaki; Tanaka, Yasuhiro; Uejima, Hiroshi; Tanaka, Hideyuki; Maruyama, Minoru; Satoh, Rie; Okubo, Shoichi; Kizawa, Hideki; Komatsu, Hidetoshi; Matsumura, Fumika; Noguchi, Yuko; Shinohara, Tokuyuki; Hinuma, Shuji; Fujisawa, Yukio; Fujino, Masahiko</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">422</span>
        (<span class="NLM_cas:issue">6928</span>),
    <span class="NLM_cas:pages">173-176</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Diabetes, a disease in which carbohydrate and lipid metab. are regulated improperly by insulin, is a serious worldwide health issue.  Insulin is secreted from pancreatic β cells in response to elevated plasma glucose, with various factors modifying its secretion.  Free fatty acids (FFAs) provide an important energy source as nutrients, and they also act as signaling mols. in various cellular processes, including insulin secretion.  Although FFAs are thought to promote insulin secretion in an acute phase, this mechanism is not clearly understood.  A G-protein-coupled receptor, GPR40, which is abundantly expressed in the pancreas, functions as a receptor for long-chain FFAs.  Furthermore, the authors show that long-chain FFAs amplify glucose-stimulated insulin secretion from pancreatic β cells by activating GPR40.  The authors' results indicate that GPR40 agonists and/or antagonists show potential for the development of new anti-diabetic drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5Y9oes-9VG7Vg90H21EOLACvtfcHk0liJTZsphqxLrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhvFKgs7w%253D&md5=96af869fb87b235a482ad6c0c42db5e3</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1038%2Fnature01478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature01478%26sid%3Dliteratum%253Aachs%26aulast%3DItoh%26aufirst%3DY.%26aulast%3DKawamata%26aufirst%3DY.%26aulast%3DHarada%26aufirst%3DM.%26aulast%3DKobayashi%26aufirst%3DM.%26aulast%3DFujii%26aufirst%3DR.%26aulast%3DFukusumi%26aufirst%3DS.%26aulast%3DOgi%26aufirst%3DK.%26aulast%3DHosoya%26aufirst%3DM.%26aulast%3DTanaka%26aufirst%3DY.%26aulast%3DUejima%26aufirst%3DH.%26aulast%3DTanaka%26aufirst%3DH.%26aulast%3DMaruyama%26aufirst%3DM.%26aulast%3DSatoh%26aufirst%3DR.%26aulast%3DOkubo%26aufirst%3DS.%26aulast%3DKizawa%26aufirst%3DH.%26aulast%3DKomatsu%26aufirst%3DH.%26aulast%3DMatsumura%26aufirst%3DF.%26aulast%3DNoguchi%26aufirst%3DY.%26aulast%3DShinohara%26aufirst%3DT.%26aulast%3DHinuma%26aufirst%3DS.%26aulast%3DFujisawa%26aufirst%3DY.%26aulast%3DFujino%26aufirst%3DM.%26atitle%3DFree%2520fatty%2520acids%2520regulate%2520insulin%2520secretion%2520from%2520pancreatic%2520beta%2520cells%2520through%2520GPR40%26jtitle%3DNature%26date%3D2003%26volume%3D422%26spage%3D173%26epage%3D176%26doi%3D10.1038%2Fnature01478" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, Y. Q.</span></span> <span> </span><span class="NLM_article-title">Discovery of potent and orally bioavailable GPR40 full agonists bearing thiophen-2-ylpropanoic acid scaffold</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">2697</span>– <span class="NLM_lpage">2717</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01357</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01357" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC2sXktVagu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=2697-2717&author=H.+Liauthor=Q.+Huangauthor=C.+Chenauthor=B.+Xuauthor=H.+Y.+Wangauthor=Y.+Q.+Long&title=Discovery+of+potent+and+orally+bioavailable+GPR40+full+agonists+bearing+thiophen-2-ylpropanoic+acid+scaffold&doi=10.1021%2Facs.jmedchem.6b01357"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Potent and Orally Bioavailable GPR40 Full Agonists Bearing Thiophen-2-ylpropanoic Acid Scaffold</span></div><div class="casAuthors">Li, He; Huang, Qi; Chen, Cheng; Xu, Bin; Wang, He-Yao; Long, Ya-Qiu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2697-2717</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The free fatty acid receptor GPR40 is predominantly expressed in pancreatic β-cells and enhances insulin secretion in a glucose dependent manner.  Therefore, GPR40 agonists are possible novel insulin secretagogues with reduced or no risk of hypoglycemia for the treatment of type 2 diabetes mellitus (T2DM).  Chem. and structurally diverse GPR40 agonists with high safety are pursued for the clin. development of GPR40-based pharmacotherapeutics.  Herein we report our design and discovery of a new chemotype of GPR40 agonists free of the typical phenylpropanoic acid scaffold.  The thiophen-2-ylpropanoic acid contg. GPR40 modulators functioned as full agonists with high-efficacy response (Emax) and reduced lipophilicity.  Significantly, the lead compd. in this series, (R)-7k, exhibited more potent in vitro glucose-stimulated insulin secretion and in vivo glucose-lowering effects (10 mg/kg, po) than the GPR40 partial agonist TAK-875, which was once in phase III clin. trials, and high selectivity over the relevant receptors GPR120 and PPARγ.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqsvYiEpKif7Vg90H21EOLACvtfcHk0liJTZsphqxLrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXktVagu7w%253D&md5=d766a3a56c2a5b22a2b48591ecb7d27e</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01357&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01357%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DXu%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DH.%2BY.%26aulast%3DLong%26aufirst%3DY.%2BQ.%26atitle%3DDiscovery%2520of%2520potent%2520and%2520orally%2520bioavailable%2520GPR40%2520full%2520agonists%2520bearing%2520thiophen-2-ylpropanoic%2520acid%2520scaffold%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D2697%26epage%3D2717%26doi%3D10.1021%2Facs.jmedchem.6b01357" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bouley, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bastian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lastochkin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suckow, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroeder, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolter, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mobashery, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, M.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationship for the 4(3<i>H</i>)-quinazolinone antibacterials</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">5011</span>– <span class="NLM_lpage">5021</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00372</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00372" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC28XmtF2lsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=5011-5021&author=R.+Bouleyauthor=D.+Dingauthor=Z.+Pengauthor=M.+Bastianauthor=E.+Lastochkinauthor=W.+Songauthor=M.+A.+Suckowauthor=V.+A.+Schroederauthor=W.+R.+Wolterauthor=S.+Mobasheryauthor=M.+Chang&title=Structure-activity+relationship+for+the+4%283H%29-quinazolinone+antibacterials&doi=10.1021%2Facs.jmedchem.6b00372"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity Relationship for the 4(3H)-Quinazolinone Antibacterials</span></div><div class="casAuthors">Bouley, Renee; Ding, Derong; Peng, Zhihong; Bastian, Maria; Lastochkin, Elena; Song, Wei; Suckow, Mark A.; Schroeder, Valerie A.; Wolter, William R.; Mobashery, Shahriar; Chang, Mayland</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">5011-5021</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We recently reported on the discovery of a novel antibacterial (2) with a 4(3H)-quinazolinone core.  This discovery was made by in silico screening of 1.2 million compds. for binding to a penicillin-binding protein and the subsequent demonstration of antibacterial activity against Staphylococcus aureus.  The first structure-activity relationship for this antibacterial scaffold is explored in this report with evaluation of 77 variants of the structural class.  Eleven promising compds. were further evaluated for in vitro toxicity, pharmacokinetics, and efficacy in a mouse peritonitis model of infection, which led to the discovery of compd. 27.  This new quinazolinone has potent activity against methicillin-resistant (MRSA) strains, low clearance, oral bioavailability and shows efficacy in a mouse neutropenic thigh infection model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoES54kEeDf6bVg90H21EOLACvtfcHk0lj0wbT9rcSpPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmtF2lsr4%253D&md5=9287f7924141b19a517b3ec04d723eff</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00372&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00372%26sid%3Dliteratum%253Aachs%26aulast%3DBouley%26aufirst%3DR.%26aulast%3DDing%26aufirst%3DD.%26aulast%3DPeng%26aufirst%3DZ.%26aulast%3DBastian%26aufirst%3DM.%26aulast%3DLastochkin%26aufirst%3DE.%26aulast%3DSong%26aufirst%3DW.%26aulast%3DSuckow%26aufirst%3DM.%2BA.%26aulast%3DSchroeder%26aufirst%3DV.%2BA.%26aulast%3DWolter%26aufirst%3DW.%2BR.%26aulast%3DMobashery%26aufirst%3DS.%26aulast%3DChang%26aufirst%3DM.%26atitle%3DStructure-activity%2520relationship%2520for%2520the%25204%25283H%2529-quinazolinone%2520antibacterials%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D5011%26epage%3D5021%26doi%3D10.1021%2Facs.jmedchem.6b00372" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">AbdelKhalek, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abutaleb, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velagapudi, U. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoganathan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seleem, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talele, T. T.</span></span> <span> </span><span class="NLM_article-title">Chemical space exploration around thieno[3,2-d]pyrimidin-4(3<i>H</i>)-one scaffold led to a novel class of highly active <i>Clostridium difficile</i> inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">9772</span>– <span class="NLM_lpage">9791</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01198</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01198" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFSru7fJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=9772-9791&author=X.+Shaoauthor=A.+AbdelKhalekauthor=N.+S.+Abutalebauthor=U.+K.+Velagapudiauthor=S.+Yoganathanauthor=M.+N.+Seleemauthor=T.+T.+Talele&title=Chemical+space+exploration+around+thieno%5B3%2C2-d%5Dpyrimidin-4%283H%29-one+scaffold+led+to+a+novel+class+of+highly+active+Clostridium+difficile+inhibitors&doi=10.1021%2Facs.jmedchem.9b01198"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical Space Exploration around Thieno[3,2-d]pyrimidin-4(3H)-one Scaffold Led to a Novel Class of Highly Active Clostridium difficile Inhibitors</span></div><div class="casAuthors">Shao, Xuwei; AbdelKhalek, Ahmed; Abutaleb, Nader S.; Velagapudi, Uday Kiran; Yoganathan, Sabesan; Seleem, Mohamed N.; Talele, Tanaji T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">9772-9791</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Clostridium difficile infection (CDI) is the leading cause of health care-assocd. infection in the United States.  Therefore, development of novel treatments for CDI is a high priority.  Toward this goal, the authors began in vitro screening of a structurally diverse inhouse library of 67 compds. against two pathogenic C. difficile strains (ATCC BAA 1870 and ATCC 43255), which yielded a hit compd., 2-methyl-8-nitroquinazolin-4(3H)-one with moderate potency (MIC = 312/156 μM).  Optimization of the hit compd. gave lead compd. 2-methyl-7-nitrothieno[3,2-d]pyrimidin-4(3H)-one with improved potency (MIC = 19/38 μM), selectivity over normal gut microflora, CC50s >606 μM against mammalian cell lines, and acceptable stability in simulated gastric and intestinal fluid.  Further optimization of the lead compd. at C2-, N3-, C4- and C7-positions resulted in a library of >50 compds. with MICs ranging from 3-800 μM against clin. isolates of C. difficile.  Compd. 8f, (E)-2-(4-fluorostyryl)-7-nitrothieno(3,2-d)pyrimidin-4(3H)-one [2380003-26-7] (MIC = 3/6 μM) was identified as a promising lead for further optimization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZXT-bOec4IbVg90H21EOLACvtfcHk0lj0wbT9rcSpPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFSru7fJ&md5=7f6b5ef5fdc67ec804c24018a6e7bd9c</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01198&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01198%26sid%3Dliteratum%253Aachs%26aulast%3DShao%26aufirst%3DX.%26aulast%3DAbdelKhalek%26aufirst%3DA.%26aulast%3DAbutaleb%26aufirst%3DN.%2BS.%26aulast%3DVelagapudi%26aufirst%3DU.%2BK.%26aulast%3DYoganathan%26aufirst%3DS.%26aulast%3DSeleem%26aufirst%3DM.%2BN.%26aulast%3DTalele%26aufirst%3DT.%2BT.%26atitle%3DChemical%2520space%2520exploration%2520around%2520thieno%255B3%252C2-d%255Dpyrimidin-4%25283H%2529-one%2520scaffold%2520led%2520to%2520a%2520novel%2520class%2520of%2520highly%2520active%2520Clostridium%2520difficile%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D9772%26epage%3D9791%26doi%3D10.1021%2Facs.jmedchem.9b01198" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Swahn, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolmodin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlstrom, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Berg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soderman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holenz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindstrom, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sundstrom, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turek, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kihlstrom, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slivo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pyring, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rotticci, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohberg, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kers, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Kieseritzky, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsson, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eketjall, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Georgievska, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeppsson, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falting, J.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of beta-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors with in vivo brain reduction of beta-amyloid peptides</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">9346</span>– <span class="NLM_lpage">9361</span>, <span class="refDoi"> DOI: 10.1021/jm3009025</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3009025" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1OmtL%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=9346-9361&author=B.+M.+Swahnauthor=K.+Kolmodinauthor=S.+Karlstromauthor=S.+von+Bergauthor=P.+Sodermanauthor=J.+Holenzauthor=S.+Bergauthor=J.+Lindstromauthor=M.+Sundstromauthor=D.+Turekauthor=J.+Kihlstromauthor=C.+Slivoauthor=L.+Anderssonauthor=D.+Pyringauthor=D.+Rotticciauthor=L.+Ohbergauthor=A.+Kersauthor=K.+Bogarauthor=F.+von+Kieseritzkyauthor=M.+Berghauthor=L.+L.+Olssonauthor=J.+Jansonauthor=S.+Eketjallauthor=B.+Georgievskaauthor=F.+Jeppssonauthor=J.+Falting&title=Design+and+synthesis+of+beta-site+amyloid+precursor+protein+cleaving+enzyme+%28BACE1%29+inhibitors+with+in+vivo+brain+reduction+of+beta-amyloid+peptides&doi=10.1021%2Fjm3009025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of β-Site Amyloid Precursor Protein Cleaving Enzyme (BACE1) Inhibitors with in Vivo Brain Reduction of β-Amyloid Peptides</span></div><div class="casAuthors">Swahn, Britt-Marie; Kolmodin, Karin; Karlstroem, Sofia; von Berg, Stefan; Soederman, Peter; Holenz, Joerg; Berg, Stefan; Lindstroem, Johan; Sundstroem, Marie; Turek, Dominika; Kihlstroem, Jacob; Slivo, Can; Andersson, Lars; Pyring, David; Rotticci, Didier; Oehberg, Liselotte; Kers, Annika; Bogar, Krisztian; Bergh, Margareta; Olsson, Lise-Lotte; Janson, Juliette; Eketjaell, Susanna; Georgievska, Biljana; Jeppsson, Fredrik; Faelting, Johanna</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">9346-9361</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The evaluation of a series of aminoisoindoles as β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors and the discovery of a clin. candidate drug for Alzheimer's disease, (S)-32 (I, AZD3839), are described.  The improvement in permeability properties by the introduction of fluorine adjacent to the amidine moiety, resulting in in vivo brain redn. of Aβ40, is discussed.  Due to the basic nature of these compds., they displayed affinity for the human ether-a-go-go related gene (hERG) ion channel.  Different ways to reduce hERG inhibition and increase hERG margins for this series are described, culminating in (S)-16 (II) and (R)-41 (III) showing large in vitro margins with BACE1 cell IC50 values of 8.6 and 0.16 nM, resp., and hERG IC50 values of 16 and 2.8 μM, resp.  Several compds. were advanced into pharmacodynamic studies and demonstrated significant redn. of β-amyloid peptides in mouse brain following oral dosing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGox062OT8a6ubVg90H21EOLACvtfcHk0lj0wbT9rcSpPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1OmtL%252FM&md5=da7685d90f56449caa77b6e6393e0a7d</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1021%2Fjm3009025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3009025%26sid%3Dliteratum%253Aachs%26aulast%3DSwahn%26aufirst%3DB.%2BM.%26aulast%3DKolmodin%26aufirst%3DK.%26aulast%3DKarlstrom%26aufirst%3DS.%26aulast%3Dvon%2BBerg%26aufirst%3DS.%26aulast%3DSoderman%26aufirst%3DP.%26aulast%3DHolenz%26aufirst%3DJ.%26aulast%3DBerg%26aufirst%3DS.%26aulast%3DLindstrom%26aufirst%3DJ.%26aulast%3DSundstrom%26aufirst%3DM.%26aulast%3DTurek%26aufirst%3DD.%26aulast%3DKihlstrom%26aufirst%3DJ.%26aulast%3DSlivo%26aufirst%3DC.%26aulast%3DAndersson%26aufirst%3DL.%26aulast%3DPyring%26aufirst%3DD.%26aulast%3DRotticci%26aufirst%3DD.%26aulast%3DOhberg%26aufirst%3DL.%26aulast%3DKers%26aufirst%3DA.%26aulast%3DBogar%26aufirst%3DK.%26aulast%3Dvon%2BKieseritzky%26aufirst%3DF.%26aulast%3DBergh%26aufirst%3DM.%26aulast%3DOlsson%26aufirst%3DL.%2BL.%26aulast%3DJanson%26aufirst%3DJ.%26aulast%3DEketjall%26aufirst%3DS.%26aulast%3DGeorgievska%26aufirst%3DB.%26aulast%3DJeppsson%26aufirst%3DF.%26aulast%3DFalting%26aufirst%3DJ.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520beta-site%2520amyloid%2520precursor%2520protein%2520cleaving%2520enzyme%2520%2528BACE1%2529%2520inhibitors%2520with%2520in%2520vivo%2520brain%2520reduction%2520of%2520beta-amyloid%2520peptides%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D9346%26epage%3D9361%26doi%3D10.1021%2Fjm3009025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cumming, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misiaszek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durkin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iserloh, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strickland, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voigt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuvelkar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyde, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Favreau, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czarniecki, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenlee, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKittrick, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stamford, A. W.</span></span> <span> </span><span class="NLM_article-title">Structure based design of iminohydantoin BACE1 inhibitors: identification of an orally available, centrally active BACE1 inhibitor</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">2444</span>– <span class="NLM_lpage">2449</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.02.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1016%2Fj.bmcl.2012.02.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=22390835" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjt1ektbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=2444-2449&author=J.+N.+Cummingauthor=E.+M.+Smithauthor=L.+Wangauthor=J.+Misiaszekauthor=J.+Durkinauthor=J.+Panauthor=U.+Iserlohauthor=Y.+Wuauthor=Z.+Zhuauthor=C.+Stricklandauthor=J.+Voigtauthor=X.+Chenauthor=M.+E.+Kennedyauthor=R.+Kuvelkarauthor=L.+A.+Hydeauthor=K.+Coxauthor=L.+Favreauauthor=M.+F.+Czarnieckiauthor=W.+J.+Greenleeauthor=B.+A.+McKittrickauthor=E.+M.+Parkerauthor=A.+W.+Stamford&title=Structure+based+design+of+iminohydantoin+BACE1+inhibitors%3A+identification+of+an+orally+available%2C+centrally+active+BACE1+inhibitor&doi=10.1016%2Fj.bmcl.2012.02.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Structure based design of iminohydantoin BACE1 inhibitors: Identification of an orally available, centrally active BACE1 inhibitor</span></div><div class="casAuthors">Cumming, Jared N.; Smith, Elizabeth M.; Wang, Lingyan; Misiaszek, Jeffrey; Durkin, James; Pan, Jianping; Iserloh, Ulrich; Wu, Yusheng; Zhu, Zhaoning; Strickland, Corey; Voigt, Johannes; Chen, Xia; Kennedy, Matthew E.; Kuvelkar, Reshma; Hyde, Lynn A.; Cox, Kathleen; Favreau, Leonard; Czarniecki, Michael F.; Greenlee, William J.; McKittrick, Brian A.; Parker, Eric M.; Stamford, Andrew W.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2444-2449</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">From an initial lead 2-imino-1-methyl-4,4-diphenyl-5-imidazolidinone, a structure-based design approach led to identification of the novel, high-affinity iminohydantoin BACE1 inhibitor I that lowers CNS-derived Aβ following oral administration to rats.  SAR development in the S3 and F' subsites of BACE1 for this series, the synthetic approaches employed in this effort, and in vivo data for I are reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3tWBE09QKNLVg90H21EOLACvtfcHk0limVznpxB1tEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjt1ektbY%253D&md5=783b6cb9a6d9608ff5e9dc4f5d634397</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.02.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.02.013%26sid%3Dliteratum%253Aachs%26aulast%3DCumming%26aufirst%3DJ.%2BN.%26aulast%3DSmith%26aufirst%3DE.%2BM.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DMisiaszek%26aufirst%3DJ.%26aulast%3DDurkin%26aufirst%3DJ.%26aulast%3DPan%26aufirst%3DJ.%26aulast%3DIserloh%26aufirst%3DU.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DStrickland%26aufirst%3DC.%26aulast%3DVoigt%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DKennedy%26aufirst%3DM.%2BE.%26aulast%3DKuvelkar%26aufirst%3DR.%26aulast%3DHyde%26aufirst%3DL.%2BA.%26aulast%3DCox%26aufirst%3DK.%26aulast%3DFavreau%26aufirst%3DL.%26aulast%3DCzarniecki%26aufirst%3DM.%2BF.%26aulast%3DGreenlee%26aufirst%3DW.%2BJ.%26aulast%3DMcKittrick%26aufirst%3DB.%2BA.%26aulast%3DParker%26aufirst%3DE.%2BM.%26aulast%3DStamford%26aufirst%3DA.%2BW.%26atitle%3DStructure%2520based%2520design%2520of%2520iminohydantoin%2520BACE1%2520inhibitors%253A%2520identification%2520of%2520an%2520orally%2520available%252C%2520centrally%2520active%2520BACE1%2520inhibitor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D2444%26epage%3D2449%26doi%3D10.1016%2Fj.bmcl.2012.02.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stamford, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tadesse, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misiaszek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cumming, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKittrick, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strickland, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orth, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voigt, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuvelkar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodgson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyde, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Favreau, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenlee, W. J.</span></span> <span> </span><span class="NLM_article-title">Discovery of an orally available, brain penetrant BACE1 inhibitor that affords robust CNS Abeta reduction</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">897</span>– <span class="NLM_lpage">902</span>, <span class="refDoi"> DOI: 10.1021/ml3001165</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml3001165" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVWhtLvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=897-902&author=A.+W.+Stamfordauthor=J.+D.+Scottauthor=S.+W.+Liauthor=S.+Babuauthor=D.+Tadesseauthor=R.+Hunterauthor=Y.+Wuauthor=J.+Misiaszekauthor=J.+N.+Cummingauthor=E.+J.+Gilbertauthor=C.+Huangauthor=B.+A.+McKittrickauthor=L.+Hongauthor=T.+Guoauthor=Z.+Zhuauthor=C.+Stricklandauthor=P.+Orthauthor=J.+H.+Voigtauthor=M.+E.+Kennedyauthor=X.+Chenauthor=R.+Kuvelkarauthor=R.+Hodgsonauthor=L.+A.+Hydeauthor=K.+Coxauthor=L.+Favreauauthor=E.+M.+Parkerauthor=W.+J.+Greenlee&title=Discovery+of+an+orally+available%2C+brain+penetrant+BACE1+inhibitor+that+affords+robust+CNS+Abeta+reduction&doi=10.1021%2Fml3001165"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of an Orally Available, Brain Penetrant BACE1 Inhibitor That Affords Robust CNS Aβ Reduction</span></div><div class="casAuthors">Stamford, Andrew W.; Scott, Jack D.; Li, Sarah W.; Babu, Suresh; Tadesse, Dawit; Hunter, Rachael; Wu, Yusheng; Misiaszek, Jeffrey; Cumming, Jared N.; Gilbert, Eric J.; Huang, Chunli; McKittrick, Brian A.; Hong, Liwu; Guo, Tao; Zhu, Zhaoning; Strickland, Corey; Orth, Peter; Voigt, Johannes H.; Kennedy, Matthew E.; Chen, Xia; Kuvelkar, Reshma; Hodgson, Robert; Hyde, Lynn A.; Cox, Kathleen; Favreau, Leonard; Parker, Eric M.; Greenlee, William J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">897-902</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of BACE1 to prevent brain Aβ peptide formation is a potential disease-modifying approach to the treatment of Alzheimer's disease.  Despite over a decade of drug discovery efforts, the identification of brain-penetrant BACE1 inhibitors that substantially lower CNS Aβ levels following systemic administration remains challenging.  In this report we describe structure-based optimization of a series of brain-penetrant BACE1 inhibitors derived from an iminopyrimidinone scaffold.  Application of structure-based design in tandem with control of physicochem. properties culminated in the discovery of compd. 16, which potently reduced cortex and CSF Aβ40 levels when administered orally to rats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplHonEJedFZbVg90H21EOLACvtfcHk0limVznpxB1tEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVWhtLvL&md5=8f743636119e48ed25d0f8c97d963440</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1021%2Fml3001165&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml3001165%26sid%3Dliteratum%253Aachs%26aulast%3DStamford%26aufirst%3DA.%2BW.%26aulast%3DScott%26aufirst%3DJ.%2BD.%26aulast%3DLi%26aufirst%3DS.%2BW.%26aulast%3DBabu%26aufirst%3DS.%26aulast%3DTadesse%26aufirst%3DD.%26aulast%3DHunter%26aufirst%3DR.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DMisiaszek%26aufirst%3DJ.%26aulast%3DCumming%26aufirst%3DJ.%2BN.%26aulast%3DGilbert%26aufirst%3DE.%2BJ.%26aulast%3DHuang%26aufirst%3DC.%26aulast%3DMcKittrick%26aufirst%3DB.%2BA.%26aulast%3DHong%26aufirst%3DL.%26aulast%3DGuo%26aufirst%3DT.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DStrickland%26aufirst%3DC.%26aulast%3DOrth%26aufirst%3DP.%26aulast%3DVoigt%26aufirst%3DJ.%2BH.%26aulast%3DKennedy%26aufirst%3DM.%2BE.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DKuvelkar%26aufirst%3DR.%26aulast%3DHodgson%26aufirst%3DR.%26aulast%3DHyde%26aufirst%3DL.%2BA.%26aulast%3DCox%26aufirst%3DK.%26aulast%3DFavreau%26aufirst%3DL.%26aulast%3DParker%26aufirst%3DE.%2BM.%26aulast%3DGreenlee%26aufirst%3DW.%2BJ.%26atitle%3DDiscovery%2520of%2520an%2520orally%2520available%252C%2520brain%2520penetrant%2520BACE1%2520inhibitor%2520that%2520affords%2520robust%2520CNS%2520Abeta%2520reduction%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D3%26spage%3D897%26epage%3D902%26doi%3D10.1021%2Fml3001165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Amdouni, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Driowya, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furstoss, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubois, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dufies, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zerhouni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orange, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacas-Gervais, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bougrin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auberger, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benhida, R.</span></span> <span> </span><span class="NLM_article-title">In vitro and in vivo evaluation of fully substituted (5-(3-ethoxy-3-oxopropynyl)-4-(ethoxycarbonyl)-1,2,3-triazolyl-glycosides as original nucleoside analogues to circumvent resistance in myeloid malignancies</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1523</span>– <span class="NLM_lpage">1533</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01803</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01803" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1Wis7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=1523-1533&author=H.+Amdouniauthor=G.+Robertauthor=M.+Driowyaauthor=N.+Furstossauthor=C.+Metierauthor=A.+Duboisauthor=M.+Dufiesauthor=M.+Zerhouniauthor=F.+Orangeauthor=S.+Lacas-Gervaisauthor=K.+Bougrinauthor=A.+R.+Martinauthor=P.+Aubergerauthor=R.+Benhida&title=In+vitro+and+in+vivo+evaluation+of+fully+substituted+%285-%283-ethoxy-3-oxopropynyl%29-4-%28ethoxycarbonyl%29-1%2C2%2C3-triazolyl-glycosides+as+original+nucleoside+analogues+to+circumvent+resistance+in+myeloid+malignancies&doi=10.1021%2Facs.jmedchem.6b01803"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">In Vitro and in Vivo Evaluation of Fully Substituted (5-(3-Ethoxy-3-oxopropynyl)-4-(ethoxycarbonyl)-1,2,3-triazolyl-glycosides as Original Nucleoside Analogues to Circumvent Resistance in Myeloid Malignancies</span></div><div class="casAuthors">Amdouni, Hella; Robert, Guillaume; Driowya, Mohsine; Furstoss, Nathan; Metier, Camille; Dubois, Alix; Dufies, Maeva; Zerhouni, Marwa; Orange, Francois; Lacas-Gervais, Sandra; Bougrin, Khalid; Martin, Anthony R.; Auberger, Patrick; Benhida, Rachid</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1523-1533</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of nucleoside analogs, e.g. I, bearing a 1,4,5-tri-substituted-1,2,3-triazole aglycon was synthesized using a straightforward click/electrophilic addn. or click/oxidative coupling tandem procedures.  SAR anal., using cell culture assays, led to the discovery of a series of compds. belonging to the 5-alkynyl-1,2,3-triazole family that exhibits potent antileukemic effects on several hematol. malignancies including chronic myeloid leukemia (CML) and myelodysplastic syndromes (MDS) either sensitive or resistant to their resp. therapy.  Compd. I also proved efficient in vivo on mice xenografted with SKM1-R MDS cell line.  Addnl., some insights in its mode of action revealed that this compd. can induce cell death by caspase and autophagy induction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTyWFgIEL5lbVg90H21EOLACvtfcHk0lgy7NVxKnKnUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1Wis7Y%253D&md5=ff14c875c43a6f56897d356d48c4a6e9</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01803&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01803%26sid%3Dliteratum%253Aachs%26aulast%3DAmdouni%26aufirst%3DH.%26aulast%3DRobert%26aufirst%3DG.%26aulast%3DDriowya%26aufirst%3DM.%26aulast%3DFurstoss%26aufirst%3DN.%26aulast%3DMetier%26aufirst%3DC.%26aulast%3DDubois%26aufirst%3DA.%26aulast%3DDufies%26aufirst%3DM.%26aulast%3DZerhouni%26aufirst%3DM.%26aulast%3DOrange%26aufirst%3DF.%26aulast%3DLacas-Gervais%26aufirst%3DS.%26aulast%3DBougrin%26aufirst%3DK.%26aulast%3DMartin%26aufirst%3DA.%2BR.%26aulast%3DAuberger%26aufirst%3DP.%26aulast%3DBenhida%26aufirst%3DR.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520evaluation%2520of%2520fully%2520substituted%2520%25285-%25283-ethoxy-3-oxopropynyl%2529-4-%2528ethoxycarbonyl%2529-1%252C2%252C3-triazolyl-glycosides%2520as%2520original%2520nucleoside%2520analogues%2520to%2520circumvent%2520resistance%2520in%2520myeloid%2520malignancies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D1523%26epage%3D1533%26doi%3D10.1021%2Facs.jmedchem.6b01803" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robert, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ben Sahra, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puissant, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colosetti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belhacene, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gounon, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bost, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassuto, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auberger, P.</span></span> <span> </span><span class="NLM_article-title">Acadesine kills chronic myelogenous leukemia (CML) cells through PKC-dependent induction of autophagic cell death</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">e7889</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0007889</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1371%2Fjournal.pone.0007889" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=19924252" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2009&pages=e7889&author=G.+Robertauthor=I.+Ben+Sahraauthor=A.+Puissantauthor=P.+Colosettiauthor=N.+Belhaceneauthor=P.+Gounonauthor=P.+Hofmanauthor=F.+Bostauthor=J.+P.+Cassutoauthor=P.+Auberger&title=Acadesine+kills+chronic+myelogenous+leukemia+%28CML%29+cells+through+PKC-dependent+induction+of+autophagic+cell+death&doi=10.1371%2Fjournal.pone.0007889"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0007889&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0007889%26sid%3Dliteratum%253Aachs%26aulast%3DRobert%26aufirst%3DG.%26aulast%3DBen%2BSahra%26aufirst%3DI.%26aulast%3DPuissant%26aufirst%3DA.%26aulast%3DColosetti%26aufirst%3DP.%26aulast%3DBelhacene%26aufirst%3DN.%26aulast%3DGounon%26aufirst%3DP.%26aulast%3DHofman%26aufirst%3DP.%26aulast%3DBost%26aufirst%3DF.%26aulast%3DCassuto%26aufirst%3DJ.%2BP.%26aulast%3DAuberger%26aufirst%3DP.%26atitle%3DAcadesine%2520kills%2520chronic%2520myelogenous%2520leukemia%2520%2528CML%2529%2520cells%2520through%2520PKC-dependent%2520induction%2520of%2520autophagic%2520cell%2520death%26jtitle%3DPLoS%2520One%26date%3D2009%26volume%3D4%26spage%3De7889%26doi%3D10.1371%2Fjournal.pone.0007889" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Echeverria, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chene, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blommers, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furet, P.</span></span> <span> </span><span class="NLM_article-title">Discovery of potent antagonists of the interaction between human double minute 2 and tumor suppressor p53</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">3205</span>– <span class="NLM_lpage">3208</span>, <span class="refDoi"> DOI: 10.1021/jm990966p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm990966p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD3cXltlOruro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=3205-3208&author=C.+Garcia-Echeverriaauthor=P.+Cheneauthor=M.+J.+Blommersauthor=P.+Furet&title=Discovery+of+potent+antagonists+of+the+interaction+between+human+double+minute+2+and+tumor+suppressor+p53&doi=10.1021%2Fjm990966p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Potent Antagonists of the Interaction between Human Double Minute 2 and Tumor Suppressor p53</span></div><div class="casAuthors">Garcia-Echeverria, Carlos; Chene, Patrick; Blommers, Marcel J. J.; Furet, Pascal</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">3205-3208</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">As part of a drug discovery program to identify antagonists of the p53/hdm2 (human double minute 2) protein-protein interaction, the authors have attempted to det. the amino acid specificities of hdm2's binding pockets to establish a pharmacophore model for this protein-protein interaction.  This work has resulted in the identification of highly potent peptide antagonists.  Structural information has been exploited to increase the hdm2-binding affinity of short peptide motifs derived from the N-terminal domain of the human wild-type p53 protein.  Combining conformational constraints as selected by mol. modeling with functional groups that are able to establish addnl. electrostatic and van der Waals interactions with the hdm2 protein, the authors have been able to increase the hdm2-binding affinity of the authors initial peptide 1700-fold.  Particularly interesting is the increase in binding affinity obtained by replacing tryptophan with 6-chlorotryptophan (IC50 = 314 nM vs. IC50 = 5 nM, 63-fold).  The new interactions identified and exptl. confirmed in this work could be directly applied to the optimization of nonpeptidic leads or incorporated into the "de novo" design of antagonists of the p53/hdm2 protein-protein interaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpOq3ikfGqz7Vg90H21EOLACvtfcHk0lgy7NVxKnKnUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXltlOruro%253D&md5=b921adfdd6a5c85510276a6446e600a8</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1021%2Fjm990966p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm990966p%26sid%3Dliteratum%253Aachs%26aulast%3DGarcia-Echeverria%26aufirst%3DC.%26aulast%3DChene%26aufirst%3DP.%26aulast%3DBlommers%26aufirst%3DM.%2BJ.%26aulast%3DFuret%26aufirst%3DP.%26atitle%3DDiscovery%2520of%2520potent%2520antagonists%2520of%2520the%2520interaction%2520between%2520human%2520double%2520minute%25202%2520and%2520tumor%2520suppressor%2520p53%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D3205%26epage%3D3208%26doi%3D10.1021%2Fjm990966p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parks, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lafrance, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calvo, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milkiewicz, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lattanze, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramachandren, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carver, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrella, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cummings, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maguire, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grasberger, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, T.</span></span> <span> </span><span class="NLM_article-title">1,4-Benzodiazepine-2,5-diones as small molecule antagonists of the HDM2-p53 interaction: discovery and SAR</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">765</span>– <span class="NLM_lpage">770</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2004.11.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1016%2Fj.bmcl.2004.11.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=15664854" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD2MXnsVOjsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=765-770&author=D.+J.+Parksauthor=L.+V.+Lafranceauthor=R.+R.+Calvoauthor=K.+L.+Milkiewiczauthor=V.+Guptaauthor=J.+Lattanzeauthor=K.+Ramachandrenauthor=T.+E.+Carverauthor=E.+C.+Petrellaauthor=M.+D.+Cummingsauthor=D.+Maguireauthor=B.+L.+Grasbergerauthor=T.+Lu&title=1%2C4-Benzodiazepine-2%2C5-diones+as+small+molecule+antagonists+of+the+HDM2-p53+interaction%3A+discovery+and+SAR&doi=10.1016%2Fj.bmcl.2004.11.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">1,4-Benzodiazepine-2,5-diones as small molecule antagonists of the HDM2-p53 interaction: discovery and SAR</span></div><div class="casAuthors">Parks, Daniel J.; LaFrance, Louis V.; Calvo, Raul R.; Milkiewicz, Karen L.; Gupta, Varsha; Lattanze, Jennifer; Ramachandren, Kannan; Carver, Theodore E.; Petrella, Eugene C.; Cummings, Maxwell D.; Maguire, Diane; Grasberger, Bruce L.; Lu, Tianbao</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">765-770</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A library of 1,4-benzodiazepine-2,5-diones, e.g., I, was screened for binding to the p53-binding domain of HDM2 using Thermofluor, a miniaturized thermal denaturation assay.  The hits obtained were shown to bind to HDM2 in the p53-binding pocket using a fluorescence polarization (FP) peptide displacement assay.  The potency of the series was optimized, leading to sub-micromolar antagonists of the p53-HDM2 interaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_zZ37DwJB07Vg90H21EOLACvtfcHk0lgy7NVxKnKnUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXnsVOjsg%253D%253D&md5=2c6cbe6faecdf2313130f4c6a868be7c</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2004.11.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2004.11.009%26sid%3Dliteratum%253Aachs%26aulast%3DParks%26aufirst%3DD.%2BJ.%26aulast%3DLafrance%26aufirst%3DL.%2BV.%26aulast%3DCalvo%26aufirst%3DR.%2BR.%26aulast%3DMilkiewicz%26aufirst%3DK.%2BL.%26aulast%3DGupta%26aufirst%3DV.%26aulast%3DLattanze%26aufirst%3DJ.%26aulast%3DRamachandren%26aufirst%3DK.%26aulast%3DCarver%26aufirst%3DT.%2BE.%26aulast%3DPetrella%26aufirst%3DE.%2BC.%26aulast%3DCummings%26aufirst%3DM.%2BD.%26aulast%3DMaguire%26aufirst%3DD.%26aulast%3DGrasberger%26aufirst%3DB.%2BL.%26aulast%3DLu%26aufirst%3DT.%26atitle%3D1%252C4-Benzodiazepine-2%252C5-diones%2520as%2520small%2520molecule%2520antagonists%2520of%2520the%2520HDM2-p53%2520interaction%253A%2520discovery%2520and%2520SAR%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2005%26volume%3D15%26spage%3D765%26epage%3D770%26doi%3D10.1016%2Fj.bmcl.2004.11.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Das, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vedachalam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonio, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reith, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutta, A. K.</span></span> <span> </span><span class="NLM_article-title">Development of a highly potent D<sub>2</sub>/D<sub>3</sub> agonist and a partial agonist from structure-activity relationship study of <i>N</i>(6)-(2-(4-(1<i>H</i>-indol-5-yl)piperazin-1-yl)ethyl)-<i>N</i>(6)-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine analogues: Implication in the treatment of Parkinson’s disease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">9179</span>– <span class="NLM_lpage">9195</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01031</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01031" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVWnsb3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=9179-9195&author=B.+Dasauthor=S.+Vedachalamauthor=D.+Luoauthor=T.+Antonioauthor=M.+E.+Reithauthor=A.+K.+Dutta&title=Development+of+a+highly+potent+D2%2FD3+agonist+and+a+partial+agonist+from+structure-activity+relationship+study+of+N%286%29-%282-%284-%281H-indol-5-yl%29piperazin-1-yl%29ethyl%29-N%286%29-propyl-4%2C5%2C6%2C7-tetrahydrobenzo%5Bd%5Dthiazole-2%2C6-diamine+analogues%3A+Implication+in+the+treatment+of+Parkinson%E2%80%99s+disease&doi=10.1021%2Facs.jmedchem.5b01031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a Highly Potent D2/D3 Agonist and a Partial Agonist from Structure-Activity Relationship Study of N6-(2-(4-(1H-Indol-5-yl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine Analogues: Implication in the Treatment of Parkinson's Disease</span></div><div class="casAuthors">Das, Banibrata; Vedachalam, Seenuvasan; Luo, Dan; Antonio, Tamara; Reith, Maarten E. A.; Dutta, Aloke K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">9179-9195</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The structure-activity relationship studies with N6-(2-(4-(1H-indol-5-yl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine derivs. led to development of a lead compd. I which exhibited very high affinity (Ki, D2 = 16.4 nM, D3 = 1.15 nM) and full agonist activity (EC50 (GTPγS); D2 = 3.23 and D3 = 1.41 nM) at both D2 and D3 receptors.  A partial agonist mol. II (EC50 (GTPγS); D2 = 21.6 (Emax = 27%) and D3 = 10.9 nM) was also identified.  In a Parkinson's disease (PD) animal model, I was highly efficacious in reversing hypolocomotion in reserpinized rats with a long duration of action, indicating its potential as an anti-PD drug.  Compd. II was also able to elevate locomotor activity in the above PD animal model significantly, implying its potential application in PD therapy.  Furthermore, I was shown to be neuroprotective in protecting neuronal PC12 from toxicity of 6-OHDA.  This report, therefore, underpins the notion that a multifunctional drug like I might have the potential not only to ameliorate motor dysfunction in PD patients but also to modify disease progression by protecting DA neurons from progressive degeneration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3VvEVudaNt7Vg90H21EOLACvtfcHk0lgdmLC7F1-TtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVWnsb3F&md5=a9f9d11a85cb0fb0150899403dba4fd7</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01031%26sid%3Dliteratum%253Aachs%26aulast%3DDas%26aufirst%3DB.%26aulast%3DVedachalam%26aufirst%3DS.%26aulast%3DLuo%26aufirst%3DD.%26aulast%3DAntonio%26aufirst%3DT.%26aulast%3DReith%26aufirst%3DM.%2BE.%26aulast%3DDutta%26aufirst%3DA.%2BK.%26atitle%3DDevelopment%2520of%2520a%2520highly%2520potent%2520D2%252FD3%2520agonist%2520and%2520a%2520partial%2520agonist%2520from%2520structure-activity%2520relationship%2520study%2520of%2520N%25286%2529-%25282-%25284-%25281H-indol-5-yl%2529piperazin-1-yl%2529ethyl%2529-N%25286%2529-propyl-4%252C5%252C6%252C7-tetrahydrobenzo%255Bd%255Dthiazole-2%252C6-diamine%2520analogues%253A%2520Implication%2520in%2520the%2520treatment%2520of%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D9179%26epage%3D9195%26doi%3D10.1021%2Facs.jmedchem.5b01031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aridoss, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hermanson, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bleeker, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, C.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationship (SAR) study of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4<i>H</i>-chromene-3-carboxylate (CXL017) and the potential of the lead against multidrug resistance in cancer treatment</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">5566</span>– <span class="NLM_lpage">5581</span>, <span class="refDoi"> DOI: 10.1021/jm300515q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300515q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC38XmvFWrurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=5566-5581&author=G.+Aridossauthor=B.+Zhouauthor=D.+L.+Hermansonauthor=N.+P.+Bleekerauthor=C.+Xing&title=Structure-activity+relationship+%28SAR%29+study+of+ethyl+2-amino-6-%283%2C5-dimethoxyphenyl%29-4-%282-ethoxy-2-oxoethyl%29-4H-chromene-3-carboxylate+%28CXL017%29+and+the+potential+of+the+lead+against+multidrug+resistance+in+cancer+treatment&doi=10.1021%2Fjm300515q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-activity relationship (SAR) study of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and the potential of the lead against multidrug resistance in cancer treatment</span></div><div class="casAuthors">Aridoss, Gopalakrishnan; Zhou, Bo; Hermanson, David L.; Bleeker, Nicholas P.; Xing, Chengguo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5566-5581</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Multidrug resistance (MDR) against std. therapies poses a serious challenge in cancer treatment, and there is a clin. need for new anticancer agents that would selectively target MDR malignancies.  Our previous studies have identified a 4H-chromene system, CXL017 as an example, that can preferentially kill MDR cancer cells.  To further improve its potency, we have performed detailed structure-activity relationship (SAR) studies at the 3, 4, and 6 positions of the 4H-chromene system.  The results reveal that the 3 and 4 positions prefer rigid and hydrophobic functional groups while the 6 position prefers a meta or para-substituted aryl functional group and the substituent should be small and hydrophilic.  We have also identified and characterized nine MDR cancer cells that acquire MDR through different mechanisms and demonstrated the scope of our new lead, (I), to selectively target different MDR cancers, which holds promise to help manage MDR in cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUJiRF64HIhrVg90H21EOLACvtfcHk0lgdmLC7F1-TtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmvFWrurs%253D&md5=d3de8ff2f8decb159a3872d076c84920</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1021%2Fjm300515q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300515q%26sid%3Dliteratum%253Aachs%26aulast%3DAridoss%26aufirst%3DG.%26aulast%3DZhou%26aufirst%3DB.%26aulast%3DHermanson%26aufirst%3DD.%2BL.%26aulast%3DBleeker%26aufirst%3DN.%2BP.%26aulast%3DXing%26aufirst%3DC.%26atitle%3DStructure-activity%2520relationship%2520%2528SAR%2529%2520study%2520of%2520ethyl%25202-amino-6-%25283%252C5-dimethoxyphenyl%2529-4-%25282-ethoxy-2-oxoethyl%2529-4H-chromene-3-carboxylate%2520%2528CXL017%2529%2520and%2520the%2520potential%2520of%2520the%2520lead%2520against%2520multidrug%2520resistance%2520in%2520cancer%2520treatment%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D5566%26epage%3D5581%26doi%3D10.1021%2Fjm300515q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heise, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Dowd, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figueroa, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawyer, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Im, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stocco, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellefeuille, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abramovitz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, D. L.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clements, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coulombe, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neill, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metters, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, J. F.</span></span> <span> </span><span class="NLM_article-title">Characterization of the human cysteinyl leukotriene 2 receptor</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>275</i></span>,  <span class="NLM_fpage">30531</span>– <span class="NLM_lpage">30536</span>, <span class="refDoi"> DOI: 10.1074/jbc.M003490200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1074%2Fjbc.M003490200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10851239" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD3cXnt1agt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=275&publication_year=2000&pages=30531-30536&author=C.+E.+Heiseauthor=B.+F.+O%E2%80%99Dowdauthor=D.+J.+Figueroaauthor=N.+Sawyerauthor=T.+Nguyenauthor=D.+S.+Imauthor=R.+Stoccoauthor=J.+N.+Bellefeuilleauthor=M.+Abramovitzauthor=R.+Chengauthor=D.+L.+Williamsauthor=Z.+Zengauthor=Q.+Liuauthor=L.+Maauthor=M.+K.+Clementsauthor=N.+Coulombeauthor=Y.+Liuauthor=C.+P.+Austinauthor=S.+R.+Georgeauthor=G.+P.+O%E2%80%99Neillauthor=K.+M.+Mettersauthor=K.+R.+Lynchauthor=J.+F.+Evans&title=Characterization+of+the+human+cysteinyl+leukotriene+2+receptor&doi=10.1074%2Fjbc.M003490200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of the human cysteinyl leukotriene 2 receptor</span></div><div class="casAuthors">Heise, Christopher E.; O'Dowd, Brian F.; Figueroa, David J.; Sawyer, Nicole; Nguyen, Tuan; Im, Dong-Soon; Stocco, Rino; Bellefeuille, Julie N.; Abramovitz, Mark; Cheng, Regina; Williams, David L., Jr.; Zeng, Zhizhen; Liu, Qingyun; Ma, Lei; Clements, Michelle K.; Coulombe, Nathalie; Liu, Yuan; Austin, Christopher P.; George, Susan R.; O'Neill, Gary P.; Metters, Kathleen M.; Lynch, Kevin R.; Evans, Jilly F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">275</span>
        (<span class="NLM_cas:issue">39</span>),
    <span class="NLM_cas:pages">30531-30536</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The contractile and inflammatory actions of the cysteinyl leukotrienes (CysLTs), LTC4, LTD4, and LTE4, are thought to be mediated through at least two distinct but related CysLT G protein-coupled receptors.  The human CysLT1 receptor has been recently cloned and characterized.  We describe here the cloning and characterization of the second cysteinyl leukotriene receptor, CysLT2, a 346-amino acid protein with 38% amino acid identity to the CysLT1 receptor.  The recombinant human CysLT2 receptor was expressed in Xenopus oocytes and HEK293T cells and shown to couple to elevation of intracellular calcium when activated by LTC4, LTD4, or LTE4.  Analyses of radiolabeled LTD4 binding to the recombinant CysLT2 receptor demonstrated high affinity binding and a rank order of potency for competition of LTC4 = LTD4 » LTE4.  In contrast to the dual CysLT1/CysLT2 antagonist, BAY u9773, the CysLT1 receptor-selective antagonists MK-571, montelukast, zafirlukast, and pranlukast exhibited low potency in competition for LTD4 binding and as antagonists of CysLT2 receptor signaling.  CysLT2 receptor mRNA was detected in lung macrophages and airway smooth muscle, cardiac Purkinje cells, adrenal medulla cells, peripheral blood leukocytes, and brain, and the receptor gene was mapped to chromosome 13q14, a region linked to atopic asthma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNARzHAjs1wLVg90H21EOLACvtfcHk0lhXm5QI5aLqGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXnt1agt74%253D&md5=a3c128d90e193664c2180e3029d8b96d</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M003490200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M003490200%26sid%3Dliteratum%253Aachs%26aulast%3DHeise%26aufirst%3DC.%2BE.%26aulast%3DO%25E2%2580%2599Dowd%26aufirst%3DB.%2BF.%26aulast%3DFigueroa%26aufirst%3DD.%2BJ.%26aulast%3DSawyer%26aufirst%3DN.%26aulast%3DNguyen%26aufirst%3DT.%26aulast%3DIm%26aufirst%3DD.%2BS.%26aulast%3DStocco%26aufirst%3DR.%26aulast%3DBellefeuille%26aufirst%3DJ.%2BN.%26aulast%3DAbramovitz%26aufirst%3DM.%26aulast%3DCheng%26aufirst%3DR.%26aulast%3DWilliams%26aufirst%3DD.%2BL.%26aulast%3DZeng%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DMa%26aufirst%3DL.%26aulast%3DClements%26aufirst%3DM.%2BK.%26aulast%3DCoulombe%26aufirst%3DN.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DAustin%26aufirst%3DC.%2BP.%26aulast%3DGeorge%26aufirst%3DS.%2BR.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DG.%2BP.%26aulast%3DMetters%26aufirst%3DK.%2BM.%26aulast%3DLynch%26aufirst%3DK.%2BR.%26aulast%3DEvans%26aufirst%3DJ.%2BF.%26atitle%3DCharacterization%2520of%2520the%2520human%2520cysteinyl%2520leukotriene%25202%2520receptor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2000%26volume%3D275%26spage%3D30531%26epage%3D30536%26doi%3D10.1074%2Fjbc.M003490200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Figueroa, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borish, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baramki, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philip, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, J. F.</span></span> <span> </span><span class="NLM_article-title">Expression of cysteinyl leukotriene synthetic and signalling proteins in inflammatory cells in active seasonal allergic rhinitis</span>. <i>Clin. Exp. Allergy</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">1380</span>– <span class="NLM_lpage">1388</span>, <span class="refDoi"> DOI: 10.1046/j.1365-2222.2003.01786.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1046%2Fj.1365-2222.2003.01786.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=14519144" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD3sXptVCjt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2003&pages=1380-1388&author=D.+J.+Figueroaauthor=L.+Borishauthor=D.+Baramkiauthor=G.+Philipauthor=C.+P.+Austinauthor=J.+F.+Evans&title=Expression+of+cysteinyl+leukotriene+synthetic+and+signalling+proteins+in+inflammatory+cells+in+active+seasonal+allergic+rhinitis&doi=10.1046%2Fj.1365-2222.2003.01786.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of cysteinyl leukotriene synthetic and signalling proteins in inflammatory cells in active seasonal allergic rhinitis</span></div><div class="casAuthors">Figueroa, D. J.; Borish, L.; Baramki, D.; Philip, G.; Austin, C. P.; Evans, J. F.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and Experimental Allergy</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1380-1388</span>CODEN:
                <span class="NLM_cas:coden">CLEAEN</span>;
        ISSN:<span class="NLM_cas:issn">0954-7894</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Cysteinyl leukotrienes (CysLTs) are bioactive lipids that have been shown to contribute to allergic and inflammatory diseases.  Eosinophils and mast cells have the capacity to produce large amts. of CysLTs after allergic or non-allergic stimulation.  Mol. identification of both the synthetic and signaling proteins in the CysLT pathway allows the investigation of expression of the CysLT enzymes and receptors in active allergic rhinitis.  The authors examd. the expression of the proteins involved in the synthesis of CysLTs and the cysteinyl leukotriene-1 (CysLT1) and cysteinyl leukotriene-2 (CysLT2) receptors in inflammatory cells from patients with active seasonal allergic rhinitis.  Nasal lavage samples were obtained from patients during active seasonal allergic rhinitis.  Specific cellular immunocytochem. techniques were used to detect the cysteinyl leukotriene synthetic proteins, namely 5-lipoxygenase (5-LO), 5-lipoxygenase-activating protein (FLAP), and leukotriene C4 synthase (LTC4S).  In situ hybridization and immunocytochem. techniques were used to identify the mRNA and proteins for the CysLT1 and CysLT2 receptors.  5-LO, FLAP, and LTC4S, and the CysLT1 and CysLT2 receptors were expressed in the majority of eosinophils and in subsets of mast cells and mononuclear cells.  5-LO, FLAP, and the CysLT1 receptor, but not LTC4S or the CysLT2 receptor, were expressed in a subset of nasal neutrophils.  The study thus demonstrates the presence of CysLT pathway proteins in key allergic and inflammatory cells from the upper airway of patients with active seasonal allergic rhinitis.  These data highlight the potential of CysLT-modifying agents to treat both upper and lower airway symptoms in patients suffering from allergic rhinitis and asthma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpm-YdA-xBKwbVg90H21EOLACvtfcHk0lhXm5QI5aLqGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXptVCjt7w%253D&md5=d0957d7e8082e022542f234ed7e77f3c</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1046%2Fj.1365-2222.2003.01786.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1365-2222.2003.01786.x%26sid%3Dliteratum%253Aachs%26aulast%3DFigueroa%26aufirst%3DD.%2BJ.%26aulast%3DBorish%26aufirst%3DL.%26aulast%3DBaramki%26aufirst%3DD.%26aulast%3DPhilip%26aufirst%3DG.%26aulast%3DAustin%26aufirst%3DC.%2BP.%26aulast%3DEvans%26aufirst%3DJ.%2BF.%26atitle%3DExpression%2520of%2520cysteinyl%2520leukotriene%2520synthetic%2520and%2520signalling%2520proteins%2520in%2520inflammatory%2520cells%2520in%2520active%2520seasonal%2520allergic%2520rhinitis%26jtitle%3DClin.%2520Exp.%2520Allergy%26date%3D2003%26volume%3D33%26spage%3D1380%26epage%3D1388%26doi%3D10.1046%2Fj.1365-2222.2003.01786.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Itadani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yashiro, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aratani, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekiguchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinoshita, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriguchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohta, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishida, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tajima, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hisaichi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ima, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueda, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egashira, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekioka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadode, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yonetomi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakao, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nomura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitamine, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nabe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imagawa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakayama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeuchi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohmoto, K.</span></span> <span> </span><span class="NLM_article-title">Discovery of gemilukast (ONO-6950), a dual CysLT1 and CysLT2 antagonist as a therapeutic agent for asthma</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">6093</span>– <span class="NLM_lpage">6113</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00741</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00741" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFejt7fO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=6093-6113&author=S.+Itadaniauthor=K.+Yashiroauthor=Y.+Arataniauthor=T.+Sekiguchiauthor=A.+Kinoshitaauthor=H.+Moriguchiauthor=N.+Ohtaauthor=S.+Takahashiauthor=A.+Ishidaauthor=Y.+Tajimaauthor=K.+Hisaichiauthor=M.+Imaauthor=J.+Uedaauthor=H.+Egashiraauthor=T.+Sekiokaauthor=M.+Kadodeauthor=Y.+Yonetomiauthor=T.+Nakaoauthor=A.+Inoueauthor=H.+Nomuraauthor=T.+Kitamineauthor=M.+Fujitaauthor=T.+Nabeauthor=Y.+Yamauraauthor=N.+Matsumuraauthor=A.+Imagawaauthor=Y.+Nakayamaauthor=J.+Takeuchiauthor=K.+Ohmoto&title=Discovery+of+gemilukast+%28ONO-6950%29%2C+a+dual+CysLT1+and+CysLT2+antagonist+as+a+therapeutic+agent+for+asthma&doi=10.1021%2Facs.jmedchem.5b00741"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Gemilukast (ONO-6950), a Dual CysLT1 and CysLT2 Antagonist As a Therapeutic Agent for Asthma</span></div><div class="casAuthors">Itadani, Satoshi; Yashiro, Kentaro; Aratani, Yoshiyuki; Sekiguchi, Tetsuya; Kinoshita, Atsushi; Moriguchi, Hideki; Ohta, Nobukazu; Takahashi, Shinya; Ishida, Akiharu; Tajima, Yohei; Hisaichi, Katsuya; Ima, Masaki; Ueda, Junya; Egashira, Hiromu; Sekioka, Tomohiko; Kadode, Michiaki; Yonetomi, Yasuo; Nakao, Takafumi; Inoue, Atsuto; Nomura, Hiroaki; Kitamine, Tetsuya; Fujita, Manabu; Nabe, Takeshi; Yamaura, Yoshiyuki; Matsumura, Naoya; Imagawa, Akira; Nakayama, Yoshisuke; Takeuchi, Jun; Ohmoto, Kazuyuki</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6093-6113</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">An orally active dual CysLT1 and CysLT2 antagonist possessing a distinctive structure which consists of triple bond and dicarboxylic acid moieties is described.  Gemilukast I (ONO-6950) was generated via isomerization of the core indole and the incorporation of a triple bond into a lead compd.  Gemilukast exhibited antagonist activities with IC50 values of 1.7 and 25 nM against human CysLT1 and human CysLT2, resp., and potent efficacy at an oral dose of 0.1 mg/kg given 24 h before LTD4 challenge in a CysLT1-dependent guinea pig asthmatic model.  In addn., gemilukast dose-dependently reduced LTC4-induced bronchoconstriction in both CysLT1- and CysLT2-dependent guinea pig asthmatic models, and it reduced antigen-induced constriction of isolated human bronchi.  Gemilukast is currently being evaluated in phase II trials for the treatment of asthma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFLZ2Xl1uTMLVg90H21EOLACvtfcHk0lhXm5QI5aLqGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFejt7fO&md5=038a9b0d067394f1398b57f6bf440afe</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00741&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00741%26sid%3Dliteratum%253Aachs%26aulast%3DItadani%26aufirst%3DS.%26aulast%3DYashiro%26aufirst%3DK.%26aulast%3DAratani%26aufirst%3DY.%26aulast%3DSekiguchi%26aufirst%3DT.%26aulast%3DKinoshita%26aufirst%3DA.%26aulast%3DMoriguchi%26aufirst%3DH.%26aulast%3DOhta%26aufirst%3DN.%26aulast%3DTakahashi%26aufirst%3DS.%26aulast%3DIshida%26aufirst%3DA.%26aulast%3DTajima%26aufirst%3DY.%26aulast%3DHisaichi%26aufirst%3DK.%26aulast%3DIma%26aufirst%3DM.%26aulast%3DUeda%26aufirst%3DJ.%26aulast%3DEgashira%26aufirst%3DH.%26aulast%3DSekioka%26aufirst%3DT.%26aulast%3DKadode%26aufirst%3DM.%26aulast%3DYonetomi%26aufirst%3DY.%26aulast%3DNakao%26aufirst%3DT.%26aulast%3DInoue%26aufirst%3DA.%26aulast%3DNomura%26aufirst%3DH.%26aulast%3DKitamine%26aufirst%3DT.%26aulast%3DFujita%26aufirst%3DM.%26aulast%3DNabe%26aufirst%3DT.%26aulast%3DYamaura%26aufirst%3DY.%26aulast%3DMatsumura%26aufirst%3DN.%26aulast%3DImagawa%26aufirst%3DA.%26aulast%3DNakayama%26aufirst%3DY.%26aulast%3DTakeuchi%26aufirst%3DJ.%26aulast%3DOhmoto%26aufirst%3DK.%26atitle%3DDiscovery%2520of%2520gemilukast%2520%2528ONO-6950%2529%252C%2520a%2520dual%2520CysLT1%2520and%2520CysLT2%2520antagonist%2520as%2520a%2520therapeutic%2520agent%2520for%2520asthma%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D6093%26epage%3D6113%26doi%3D10.1021%2Facs.jmedchem.5b00741" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Motohashi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, M.</span></span> <span> </span><span class="NLM_article-title">Toward clinical application of the Keap1-Nrf2 pathway</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">340</span>– <span class="NLM_lpage">346</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2013.04.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1016%2Fj.tips.2013.04.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=23664668" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnsVylu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2013&pages=340-346&author=T.+Suzukiauthor=H.+Motohashiauthor=M.+Yamamoto&title=Toward+clinical+application+of+the+Keap1-Nrf2+pathway&doi=10.1016%2Fj.tips.2013.04.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Toward clinical application of the Keap1-Nrf2 pathway</span></div><div class="casAuthors">Suzuki, Takafumi; Motohashi, Hozumi; Yamamoto, Masayuki</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">340-346</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The Keap1-Nrf2 pathway plays a crucial role in detg. the sensitivity of cells to chem. and/or oxidative insults by regulating the basal and inducible expression of detoxification and antioxidant enzymes, ABC transporters, and other stress response enzymes and/or proteins.  Increasing attention has been focused on the roles that the Keap1-Nrf2 pathway plays in the protection of our body against drug toxicity and stress-induced diseases.  Simultaneously, Nrf2 has been recognized to promote oncogenesis and resistance to chemotherapeutic drugs.  Cancer cells hijack Nrf2 activity to support their malignant growth and thus Nrf2 has emerged as a therapeutic target.  Translational studies of the Keap1-Nrf2 system, from mechanistic understanding to clin. applications, are now important to improve human health.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3LyyVFE7CB7Vg90H21EOLACvtfcHk0ljCR_r2wUByGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnsVylu7s%253D&md5=5834bbcb887101cbd4231e384e0580b6</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2013.04.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2013.04.005%26sid%3Dliteratum%253Aachs%26aulast%3DSuzuki%26aufirst%3DT.%26aulast%3DMotohashi%26aufirst%3DH.%26aulast%3DYamamoto%26aufirst%3DM.%26atitle%3DToward%2520clinical%2520application%2520of%2520the%2520Keap1-Nrf2%2520pathway%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2013%26volume%3D34%26spage%3D340%26epage%3D346%26doi%3D10.1016%2Fj.tips.2013.04.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deny, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traboulsi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantin, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsault, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richter, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belanger, G.</span></span> <span> </span><span class="NLM_article-title">Bis-Michael acceptors as novel probes to study the Keap1/Nrf2/ARE pathway</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">9431</span>– <span class="NLM_lpage">9442</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01132</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01132" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFyntrbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=9431-9442&author=L.+J.+Denyauthor=H.+Traboulsiauthor=A.+M.+Cantinauthor=E.+Marsaultauthor=M.+V.+Richterauthor=G.+Belanger&title=Bis-Michael+acceptors+as+novel+probes+to+study+the+Keap1%2FNrf2%2FARE+pathway&doi=10.1021%2Facs.jmedchem.6b01132"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Bis-Michael Acceptors as Novel Probes to Study the Keap1/Nrf2/ARE Pathway</span></div><div class="casAuthors">Deny, Ludovic J.; Traboulsi, Hussein; Cantin, Andre M.; Marsault, Eric; Richter, Martin V.; Belanger, Guillaume</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">9431-9442</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Nuclear factor erythroid 2-related factor 2 (Nrf2) is a master regulator that promotes the transcription of cytoprotective genes in response to oxidative/electrophilic stress.  Various Michael-type compds. were designed and synthesized and their potency to activate the Keap1/Nrf2/ARE pathway was evaluated.  Compds. bearing two Michael-type acceptors proved to be the most active.  Tether length and rigidity between the acceptors was crucial.  This study will help to understand how this feature disrupts the interaction between Keap1 and Nrf2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9W1p2xZ8QDLVg90H21EOLACvtfcHk0ljCR_r2wUByGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFyntrbK&md5=f70adbe3ebaef7bac1d9ed91778bd723</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01132&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01132%26sid%3Dliteratum%253Aachs%26aulast%3DDeny%26aufirst%3DL.%2BJ.%26aulast%3DTraboulsi%26aufirst%3DH.%26aulast%3DCantin%26aufirst%3DA.%2BM.%26aulast%3DMarsault%26aufirst%3DE.%26aulast%3DRichter%26aufirst%3DM.%2BV.%26aulast%3DBelanger%26aufirst%3DG.%26atitle%3DBis-Michael%2520acceptors%2520as%2520novel%2520probes%2520to%2520study%2520the%2520Keap1%252FNrf2%252FARE%2520pathway%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D9431%26epage%3D9442%26doi%3D10.1021%2Facs.jmedchem.6b01132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shakila, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khera, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koul, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naseema, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayanan, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paramasivan, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramanathan, V. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyagi, A. K.</span></span> <span> </span><span class="NLM_article-title">Disruption of mptpB impairs the ability of <i>Mycobacterium tuberculosis</i> to survive in guinea pigs</span>. <i>Mol. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">751</span>– <span class="NLM_lpage">762</span>, <span class="refDoi"> DOI: 10.1046/j.1365-2958.2003.03712.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1046%2Fj.1365-2958.2003.03712.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=14617138" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD3sXptVyrsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2003&pages=751-762&author=R.+Singhauthor=V.+Raoauthor=H.+Shakilaauthor=R.+Guptaauthor=A.+Kheraauthor=N.+Dharauthor=A.+Singhauthor=A.+Koulauthor=Y.+Singhauthor=M.+Naseemaauthor=P.+R.+Narayananauthor=C.+N.+Paramasivanauthor=V.+D.+Ramanathanauthor=A.+K.+Tyagi&title=Disruption+of+mptpB+impairs+the+ability+of+Mycobacterium+tuberculosis+to+survive+in+guinea+pigs&doi=10.1046%2Fj.1365-2958.2003.03712.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Disruption of mptpB impairs the ability of Mycobacterium tuberculosis to survive in guinea pigs</span></div><div class="casAuthors">Singh, Ramandeep; Rao, Vivek; Shakila, H.; Gupta, Radhika; Khera, Aparna; Dhar, Neeraj; Singh, Amit; Koul, Anil; Singh, Yogendra; Naseema, M.; Narayanan, P. R.; Paramasivan, C. N.; Ramanathan, V. D.; Tyagi, Anil K.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Microbiology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">751-762</span>CODEN:
                <span class="NLM_cas:coden">MOMIEE</span>;
        ISSN:<span class="NLM_cas:issn">0950-382X</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Protein tyrosine kinases and tyrosine phosphatases from several bacterial pathogens have been shown to act as virulence factors by modulating the phosphorylation and dephosphorylation of host proteins.  The identification and characterization of two tyrosine phosphatases, namely MptpA and MptpB, from M. tuberculosis has been reported earlier.  MptpB is secreted by M. tuberculosis into extracellular milieu and exhibits a pH optimum of 5.6, similar to the pH of the lysosomal compartment of the cell.  To det. the role of MptpB in the pathogenesis of M. tuberculosis, we constructed a mptpB mutant strain by homologous recombination and compared the ability of parent and the mutant strain to survive intracellularly.  We show that disruption of the mptpB gene impairs the ability of the mutant strain to survive in activated macrophages and guinea pigs but not in resting macrophages, suggesting the importance of its role in the host-pathogen interaction.  Infection of guinea pigs with the mutant strain resulted in a 70-fold redn. in the bacillary load of spleens in infected animals as compared with the bacillary load in animals infected with the parental strain.  Upon reintroduction of the mptpB gene into the mutant strain, the complemented strain was able to establish infection and survive in guinea pigs at rates comparable to the parental strain.  These observations demonstrate a role of MptpB in the pathogenesis of M. tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqna7lf5deGyLVg90H21EOLACvtfcHk0ljCR_r2wUByGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXptVyrsbg%253D&md5=88d8f01f758712bb90bf974bf7bf0662</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1046%2Fj.1365-2958.2003.03712.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1365-2958.2003.03712.x%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DR.%26aulast%3DRao%26aufirst%3DV.%26aulast%3DShakila%26aufirst%3DH.%26aulast%3DGupta%26aufirst%3DR.%26aulast%3DKhera%26aufirst%3DA.%26aulast%3DDhar%26aufirst%3DN.%26aulast%3DSingh%26aufirst%3DA.%26aulast%3DKoul%26aufirst%3DA.%26aulast%3DSingh%26aufirst%3DY.%26aulast%3DNaseema%26aufirst%3DM.%26aulast%3DNarayanan%26aufirst%3DP.%2BR.%26aulast%3DParamasivan%26aufirst%3DC.%2BN.%26aulast%3DRamanathan%26aufirst%3DV.%2BD.%26aulast%3DTyagi%26aufirst%3DA.%2BK.%26atitle%3DDisruption%2520of%2520mptpB%2520impairs%2520the%2520ability%2520of%2520Mycobacterium%2520tuberculosis%2520to%2520survive%2520in%2520guinea%2520pigs%26jtitle%3DMol.%2520Microbiol.%26date%3D2003%26volume%3D50%26spage%3D751%26epage%3D762%26doi%3D10.1046%2Fj.1365-2958.2003.03712.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franzblau, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z. Y.</span></span> <span> </span><span class="NLM_article-title">Targeting mycobacterium protein tyrosine phosphatase B for antituberculosis agents</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">4573</span>– <span class="NLM_lpage">4578</span>, <span class="refDoi"> DOI: 10.1073/pnas.0909133107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1073%2Fpnas.0909133107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=20167798" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjs1emur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=4573-4578&author=B.+Zhouauthor=Y.+Heauthor=X.+Zhangauthor=J.+Xuauthor=Y.+Luoauthor=Y.+Wangauthor=S.+G.+Franzblauauthor=Z.+Yangauthor=R.+J.+Chanauthor=Y.+Liuauthor=J.+Zhengauthor=Z.+Y.+Zhang&title=Targeting+mycobacterium+protein+tyrosine+phosphatase+B+for+antituberculosis+agents&doi=10.1073%2Fpnas.0909133107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting mycobacterium protein tyrosine phosphatase B for antituberculosis agents</span></div><div class="casAuthors">Zhou, Bo; He, Yantao; Zhang, Xian; Xu, Jie; Luo, Yong; Wang, Yuehong; Franzblau, Scott G.; Yang, Zhenyun; Chan, Rebecca J.; Liu, Yan; Zheng, Jianyu; Zhang, Zhong-Yin</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4573-4578, S4573/1-S4573/27</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Protein tyrosine phosphatases are often exploited and subverted by pathogenic bacteria to cause human diseases.  The tyrosine phosphatase mPTPB from Mycobacterium tuberculosis is an essential virulence factor that is secreted by the bacterium into the cytoplasm of macrophages, where it mediates mycobacterial survival in the host.  Consequently, there is considerable interest in understanding the mechanism by which mPTPB evades the host immune responses, and in developing potent and selective mPTPB inhibitors as unique antituberculosis (antiTB) agents.  We uncovered that mPTPB subverts the innate immune responses by blocking the ERK1/2 and p38 mediated IL-6 prodn. and promoting host cell survival by activating the Akt pathway.  We identified a potent and selective mPTPB inhibitor I-A09 with highly efficacious cellular activity, from a combinatorial library of bidentate benzofuran salicylic acid derivs. assembled by click chem.  We demonstrated that inhibition of mPTPB with I-A09 in macrophages reverses the altered host immune responses induced by the bacterial phosphatase and prevents TB growth in host cells.  The results provide the necessary proof-of-principle data to support the notion that specific inhibitors of the mPTPB may serve as effective antiTB therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqm8ZG4dVudgrVg90H21EOLACvtfcHk0ljnfKuL9VE1zA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjs1emur4%253D&md5=2d4d319b03d7a7268d8b348e0f7eaf7c</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0909133107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0909133107%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DB.%26aulast%3DHe%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DFranzblau%26aufirst%3DS.%2BG.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DChan%26aufirst%3DR.%2BJ.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DZheng%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DZ.%2BY.%26atitle%3DTargeting%2520mycobacterium%2520protein%2520tyrosine%2520phosphatase%2520B%2520for%2520antituberculosis%2520agents%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2010%26volume%3D107%26spage%3D4573%26epage%3D4578%26doi%3D10.1073%2Fpnas.0909133107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Z. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunawan, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z. Y.</span></span> <span> </span><span class="NLM_article-title">Discovery and evaluation of novel inhibitors of mycobacterium protein tyrosine phosphatase B from the 6-Hydroxy-benzofuran-5-carboxylic acid scaffold</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">832</span>– <span class="NLM_lpage">842</span>, <span class="refDoi"> DOI: 10.1021/jm301781p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301781p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC3sXms1Oguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=832-842&author=Y.+Heauthor=J.+Xuauthor=Z.+H.+Yuauthor=A.+M.+Gunawanauthor=L.+Wuauthor=L.+Wangauthor=Z.+Y.+Zhang&title=Discovery+and+evaluation+of+novel+inhibitors+of+mycobacterium+protein+tyrosine+phosphatase+B+from+the+6-Hydroxy-benzofuran-5-carboxylic+acid+scaffold&doi=10.1021%2Fjm301781p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Evaluation of Novel Inhibitors of Mycobacterium Protein Tyrosine Phosphatase B from the 6-Hydroxy-benzofuran-5-carboxylic Acid Scaffold</span></div><div class="casAuthors">He, Yantao; Xu, Jie; Yu, Zhi-Hong; Gunawan, Andrea M.; Wu, Li; Wang, Lina; Zhang, Zhong-Yin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">832-842</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Mycobacterium tuberculosis (Mtb) protein tyrosine phosphatase B (mPTPB) is a virulence factor secreted by the pathogen and mediates mycobacterial survival in macrophages by targeting host cell immune responses.  Consequently, mPTPB represents an exciting new target to combat tuberculosis (TB) infection.  We describe a medicinal chem. oriented approach that transforms a benzofuran salicylic acid scaffold into a highly potent (IC50 = 38 nM) and selective mPTPB inhibitor (>50 fold against a large panel of PTPs).  Importantly, the inhibitor is capable of reversing the altered host immune responses induced by the bacterial phosphatase and restoring the macrophage's full capacity to secrete IL-6 and undergo apoptosis in response to interferon-γ stimulation, validating the concept that chem. inhibition of mPTPB may be therapeutically useful for novel TB treatment.  The study further demonstrates that bicyclic salicylic acid pharmacophores can be used to deliver PTP inhibitors with high potency, selectivity, and cellular efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPqxb8o40oqrVg90H21EOLACvtfcHk0ljnfKuL9VE1zA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXms1Oguw%253D%253D&md5=c9492d72c21adb7be4e74eb2f5d5860a</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1021%2Fjm301781p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301781p%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DZ.%2BH.%26aulast%3DGunawan%26aufirst%3DA.%2BM.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DZ.%2BY.%26atitle%3DDiscovery%2520and%2520evaluation%2520of%2520novel%2520inhibitors%2520of%2520mycobacterium%2520protein%2520tyrosine%2520phosphatase%2520B%2520from%2520the%25206-Hydroxy-benzofuran-5-carboxylic%2520acid%2520scaffold%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D832%26epage%3D842%26doi%3D10.1021%2Fjm301781p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, E. M.</span></span> <span> </span><span class="NLM_article-title">The calcium-sensing receptor: physiology, pathophysiology and CaR-based therapeutics</span>. <i>Subcell. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">139</span>– <span class="NLM_lpage">167</span>, <span class="refDoi"> DOI: 10.1007/978-1-4020-6191-2_6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1007%2F978-1-4020-6191-2_6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=18193637" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A280%3ADC%252BD1c%252FktVahtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2007&pages=139-167&author=E.+M.+Brown&title=The+calcium-sensing+receptor%3A+physiology%2C+pathophysiology+and+CaR-based+therapeutics&doi=10.1007%2F978-1-4020-6191-2_6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">The calcium-sensing receptor: physiology, pathophysiology and CaR-based therapeutics</span></div><div class="casAuthors">Brown E M</div><div class="citationInfo"><span class="NLM_cas:title">Sub-cellular biochemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">139-67</span>
        ISSN:<span class="NLM_cas:issn">0306-0225</span>.
    </div><div class="casAbstract">The extracellular calcium (Ca(o)2+)-sensing receptor (CaR) enables the parathyroid glands and other CaR-expressing cells to sense alterations in the level of Ca(o)2+ and to respond with changes in function that are directed at normalizing the blood calcium concentration.  In addition to the parathyroid gland, the kidney is a key site for Ca(o)2(+)-sensing that enables it to make physiologically relevant alterations in divalent cation and water metabolism.  Several disorders of Ca(o)2(+)-sensing arise from inherited or acquired abnormalities that "reset" the serum calcium concentration upward or downward.  Inactivating mutations produce a benign form of hypercalcemia when present in the heterozygous state, termed Familial Hypocalciuric Hypercalcemia (FHH), while homozygous mutations produce a much more severe hypercalcemic disorder resulting from marked hyperparathyroidism, called Neonatal Severe Hyperparathyroidism (NSHPT).  Activating mutations cause a hypocalcemic syndrome of varying severity, termed autosomal dominant hypocalcemia or hypoparathyroidism.  Inactivating or activating antibodies directed at the CaR produce the expected hyper- or hypocalcemic syndromes, respectively. "Calcimimetic" CaR activators and "calcilytic" CaR antagonists have been developed.  The calcimimetics are currently in use for controlling severe hyperparathyroidism in patients receiving dialysis treatment for end stage renal disease or with parathyroid cancer.  Calcilytics are being evaluated as a means of inducing a "pulse" in the circulating parathyroid hormone (PTH) concentration, which would mimic that resulting from injection of PTH, an established anabolic form of treatment for osteoporosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR8IqdjdhC4Am52AMpI4GK2fW6udTcc2eaUmEeXJuZld7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c%252FktVahtQ%253D%253D&md5=efb4412b5755168f5433ee1f034cd934</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1007%2F978-1-4020-6191-2_6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-4020-6191-2_6%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DE.%2BM.%26atitle%3DThe%2520calcium-sensing%2520receptor%253A%2520physiology%252C%2520pathophysiology%2520and%2520CaR-based%2520therapeutics%26jtitle%3DSubcell.%2520Biochem.%26date%3D2007%26volume%3D45%26spage%3D139%26epage%3D167%26doi%3D10.1007%2F978-1-4020-6191-2_6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Steddon, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, J.</span></span> <span> </span><span class="NLM_article-title">Calcimimetics and calcilytics--fooling the calcium receptor</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>365</i></span>,  <span class="NLM_fpage">2237</span>– <span class="NLM_lpage">2239</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(05)66782-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1016%2FS0140-6736%2805%2966782-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=15978932" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlsFCrsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=365&publication_year=2005&pages=2237-2239&author=S.+J.+Steddonauthor=J.+Cunningham&title=Calcimimetics+and+calcilytics%2D%2Dfooling+the+calcium+receptor&doi=10.1016%2FS0140-6736%2805%2966782-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Calcimimetics and calcilytics-fooling the calcium receptor</span></div><div class="casAuthors">Steddon, Simon J.; Cunningham, John</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">365</span>
        (<span class="NLM_cas:issue">9478</span>),
    <span class="NLM_cas:pages">2237-2239</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Context: Just a decade after the the calcium-sensing receptor (CaR) was identified, pharmacol. manipulation of the CaR is about to enter routine practice.  For hyperparathyroid states, calcimimetics, which increase activation of the CaR, have been licensed in Europe and the USA.  Calcilytics, which decrease CaR function and increase secretion of parathyroid hormone (PTH), might allow the anabolic effects of PTH on bone to be harnessed for the prevention and treatment of osteoporosis.  Starting point: In a multicentre randomised double-blind placebo-controlled study, Munro Peacock and colleagues recently confirmed the efficacy of the oral calcimimetic cinacalcet for achieving long-term redns. in serum calcium and PTH concns. in primary hyperparathyroidism (J Clin Endocrinol Metab 2005; 90:135-41).  The arrival of a non-surgical option for this common disorder is important.  What next: Study in primary and uremic secondary hyperparathyroidism will indicate whether the efficacy of calcimimetic agents extends into the longer term.  The extracellular relation between the CaR and its ligands and the intracellular signalling cascades that modify PTH gene transcription and secretion need further study.  Drugs acting on the CaR might treat other disorders of bone remodelling, including osteoporosis.  CaR expression in tissues beyond those involved in mineral ion homoeostasis should remain an important focus of research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrK4dlbwzx3XLVg90H21EOLACvtfcHk0lgj-zmGlpD0ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlsFCrsrY%253D&md5=2fbb8130dc410d3f438037e09c5e22cd</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2805%2966782-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252805%252966782-7%26sid%3Dliteratum%253Aachs%26aulast%3DSteddon%26aufirst%3DS.%2BJ.%26aulast%3DCunningham%26aufirst%3DJ.%26atitle%3DCalcimimetics%2520and%2520calcilytics--fooling%2520the%2520calcium%2520receptor%26jtitle%3DLancet%26date%3D2005%26volume%3D365%26spage%3D2237%26epage%3D2239%26doi%3D10.1016%2FS0140-6736%2805%2966782-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Widler, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altmann, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beerli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breitenstein, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouhelal, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buhl, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamse, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerspacher, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halleux, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">John, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehmann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalb, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kneissel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Missbach, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, I. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reidemeister, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renaud, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taillardat, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tommasi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiler, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seuwen, K.</span></span> <span> </span><span class="NLM_article-title">1-Alkyl-4-phenyl-6-alkoxy-1<i>H</i>-quinazolin-2-ones: A novel series of potent calcium-sensing receptor antagonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">2250</span>– <span class="NLM_lpage">2263</span>, <span class="refDoi"> DOI: 10.1021/jm901811v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901811v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhvF2ksrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2250-2263&author=L.+Widlerauthor=E.+Altmannauthor=R.+Beerliauthor=W.+Breitensteinauthor=R.+Bouhelalauthor=T.+Buhlauthor=R.+Gamseauthor=M.+Gerspacherauthor=C.+Halleuxauthor=M.+R.+Johnauthor=H.+Lehmannauthor=O.+Kalbauthor=M.+Kneisselauthor=M.+Missbachauthor=I.+R.+Mullerauthor=S.+Reidemeisterauthor=J.+Renaudauthor=A.+Taillardatauthor=R.+Tommasiauthor=S.+Weilerauthor=R.+M.+Wolfauthor=K.+Seuwen&title=1-Alkyl-4-phenyl-6-alkoxy-1H-quinazolin-2-ones%3A+A+novel+series+of+potent+calcium-sensing+receptor+antagonists&doi=10.1021%2Fjm901811v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">1-Alkyl-4-phenyl-6-alkoxy-1H-quinazolin-2-ones: A Novel Series of Potent Calcium-Sensing Receptor Antagonists</span></div><div class="casAuthors">Widler, Leo; Altmann, Eva; Beerli, Rene; Breitenstein, Werner; Bouhelal, Rochdi; Buhl, Thomas; Gamse, Rainer; Gerspacher, Marc; Halleux, Christine; John, Markus R.; Lehmann, Hansjoerg; Kalb, Oskar; Kneissel, Michaela; Missbach, Martin; Muller, Irene R.; Reidemeister, Sibylle; Renaud, Johanne; Taillardat, Agnes; Tommasi, Ruben; Weiler, Sven; Wolf, Romain M.; Seuwen, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2250-2263</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Parathyroid hormone (PTH) is an effective bone anabolic agent.  However, only when administered by daily s.c. injections exposure of short duration is achieved, a prerequisite for an anabolic response.  Instead of applying exogenous PTH, mobilization of endogenous stores of the hormone can be envisaged.  The secretion of PTH stored in the parathyroid glands is mediated by a calcium sensing receptor (CaSR) a GPCR localized at the cell surface.  Antagonists of CaSR (calcilytics) mimic a state of hypocalcemia and stimulate PTH release to the bloodstream.  Screening of the internal compd. collection for inhibition of CaSR signaling function afforded 2a (I).  In vitro potency could be improved > 1000 fold by optimization of its chem. structure.  The binding mode of our compds. was predicted based on mol. modeling and confirmed by testing with mutated receptors.  While the compds. readily induced PTH release after iv application a special formulation was needed for oral activity.  The required profile was achieved by using microemulsions.  Excellent PK/PD correlation was found in rats and dogs.  High levels of PTH were reached in plasma within minutes which reverted to baseline in about 1-2 h in both species.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodQxVma9P28LVg90H21EOLACvtfcHk0lgj-zmGlpD0ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhvF2ksrY%253D&md5=5828ea47ee9160c5b1a63221f95dae1d</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1021%2Fjm901811v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901811v%26sid%3Dliteratum%253Aachs%26aulast%3DWidler%26aufirst%3DL.%26aulast%3DAltmann%26aufirst%3DE.%26aulast%3DBeerli%26aufirst%3DR.%26aulast%3DBreitenstein%26aufirst%3DW.%26aulast%3DBouhelal%26aufirst%3DR.%26aulast%3DBuhl%26aufirst%3DT.%26aulast%3DGamse%26aufirst%3DR.%26aulast%3DGerspacher%26aufirst%3DM.%26aulast%3DHalleux%26aufirst%3DC.%26aulast%3DJohn%26aufirst%3DM.%2BR.%26aulast%3DLehmann%26aufirst%3DH.%26aulast%3DKalb%26aufirst%3DO.%26aulast%3DKneissel%26aufirst%3DM.%26aulast%3DMissbach%26aufirst%3DM.%26aulast%3DMuller%26aufirst%3DI.%2BR.%26aulast%3DReidemeister%26aufirst%3DS.%26aulast%3DRenaud%26aufirst%3DJ.%26aulast%3DTaillardat%26aufirst%3DA.%26aulast%3DTommasi%26aufirst%3DR.%26aulast%3DWeiler%26aufirst%3DS.%26aulast%3DWolf%26aufirst%3DR.%2BM.%26aulast%3DSeuwen%26aufirst%3DK.%26atitle%3D1-Alkyl-4-phenyl-6-alkoxy-1H-quinazolin-2-ones%253A%2520A%2520novel%2520series%2520of%2520potent%2520calcium-sensing%2520receptor%2520antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2250%26epage%3D2263%26doi%3D10.1021%2Fjm901811v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ingham, O. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paranal, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Escobar, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yueh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porco, J. A.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beeler, A. B.</span></span> <span> </span><span class="NLM_article-title">Development of a potent and selective HDAC8 inhibitor</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">929</span>– <span class="NLM_lpage">932</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.6b00239</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00239" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVeksbbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=929-932&author=O.+J.+Inghamauthor=R.+M.+Paranalauthor=W.+B.+Smithauthor=R.+A.+Escobarauthor=H.+Yuehauthor=T.+Snyderauthor=J.+A.+Porcoauthor=J.+E.+Bradnerauthor=A.+B.+Beeler&title=Development+of+a+potent+and+selective+HDAC8+inhibitor&doi=10.1021%2Facsmedchemlett.6b00239"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a Potent and Selective HDAC8 Inhibitor</span></div><div class="casAuthors">Ingham, Oscar J.; Paranal, Ronald M.; Smith, William B.; Escobar, Randolph A.; Yueh, Han; Snyder, Tracy; Porco, John A.; Bradner, James E.; Beeler, Aaron B.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">929-932</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel, isoform-selective inhibitor of histone deacetylase 8 (HDAC8) has been discovered by the repurposing of a diverse compd. collection.  Medicinal chem. optimization led to the identification of a highly potent (0.8 nM) and selective inhibitor I of HDAC8.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKF0r_7S2dWLVg90H21EOLACvtfcHk0lgj-zmGlpD0ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVeksbbP&md5=69ab76f942dfc6a6b7801b90f48aa619</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00239&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00239%26sid%3Dliteratum%253Aachs%26aulast%3DIngham%26aufirst%3DO.%2BJ.%26aulast%3DParanal%26aufirst%3DR.%2BM.%26aulast%3DSmith%26aufirst%3DW.%2BB.%26aulast%3DEscobar%26aufirst%3DR.%2BA.%26aulast%3DYueh%26aufirst%3DH.%26aulast%3DSnyder%26aufirst%3DT.%26aulast%3DPorco%26aufirst%3DJ.%2BA.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DBeeler%26aufirst%3DA.%2BB.%26atitle%3DDevelopment%2520of%2520a%2520potent%2520and%2520selective%2520HDAC8%2520inhibitor%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D929%26epage%3D932%26doi%3D10.1021%2Facsmedchemlett.6b00239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gasparini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bilbe, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez-Mancilla, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spooren, W.</span></span> <span> </span><span class="NLM_article-title">mGluR5 antagonists: discovery, characterization and drug development</span>. <i>Curr. Opin. Drug Discovery Dev.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">655</span>– <span class="NLM_lpage">665</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=18729017" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtV2rt7nO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2008&pages=655-665&author=F.+Gaspariniauthor=G.+Bilbeauthor=B.+Gomez-Mancillaauthor=W.+Spooren&title=mGluR5+antagonists%3A+discovery%2C+characterization+and+drug+development"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">mGluR5 antagonists: discovery, characterization and drug development</span></div><div class="casAuthors">Gasparini, Fabrizio; Bilbe, Graeme; Gomez-Mancilla, Baltazar; Spooren, Will</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Drug Discovery & Development</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">655-665</span>CODEN:
                <span class="NLM_cas:coden">CODDFF</span>;
        ISSN:<span class="NLM_cas:issn">1367-6733</span>.
    
            (<span class="NLM_cas:orgname">Thomson Scientific</span>)
        </div><div class="casAbstract">A review.  Disturbances of glutamate-mediated neurotransmission have been implicated in a broad range of nervous system disorders.  Numerous attempts to correct nervous system dysfunction by pharmacol. intervention at glutamate receptors have been made, and some of the approaches have achieved a high level of preclin. validation.  However, in a no. of cases involving agents acting as blockers of the ionotropic glutamate receptors, clin. success could not be achieved, mostly because of the lack of a therapeutic window.  The identification of the metabotropic glutamate receptor (mGluR) family and their modulatory role in the control of neurotransmission provided a new means to alter glutamatergic transmission.  Furthermore, selective agents acting as allosteric antagonists at the mGluR5 subtype have demonstrated therapeutic potential.  The identification and characterization of mGluR5 antagonists and recent progress in clin. development are summarized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGox2OH93uxCzbVg90H21EOLACvtfcHk0lihXBusGu9UMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtV2rt7nO&md5=cce30e9f299498315c4d2799f43bf4e3</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGasparini%26aufirst%3DF.%26aulast%3DBilbe%26aufirst%3DG.%26aulast%3DGomez-Mancilla%26aufirst%3DB.%26aulast%3DSpooren%26aufirst%3DW.%26atitle%3DmGluR5%2520antagonists%253A%2520discovery%252C%2520characterization%2520and%2520drug%2520development%26jtitle%3DCurr.%2520Opin.%2520Drug%2520Discovery%2520Dev.%26date%3D2008%26volume%3D11%26spage%3D655%26epage%3D665" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sarkaria, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O-Charoenrat, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talbot, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ngai, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maghami, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yonekawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghossein, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoffel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramanathan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, B.</span></span> <span> </span><span class="NLM_article-title">Squamous cell carcinoma related oncogene/DCUN1D1 is highly conserved and activated by amplification in squamous cell carcinomas</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">9437</span>– <span class="NLM_lpage">9444</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-06-2074</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1158%2F0008-5472.CAN-06-2074" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=17018598" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVamsrjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=9437-9444&author=I.+Sarkariaauthor=P.+O-Charoenratauthor=S.+G.+Talbotauthor=P.+G.+Reddyauthor=I.+Ngaiauthor=E.+Maghamiauthor=K.+N.+Patelauthor=B.+Leeauthor=Y.+Yonekawaauthor=M.+Dudasauthor=A.+Kaufmanauthor=R.+Ryanauthor=R.+Ghosseinauthor=P.+H.+Raoauthor=A.+Stoffelauthor=Y.+Ramanathanauthor=B.+Singh&title=Squamous+cell+carcinoma+related+oncogene%2FDCUN1D1+is+highly+conserved+and+activated+by+amplification+in+squamous+cell+carcinomas&doi=10.1158%2F0008-5472.CAN-06-2074"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Squamous Cell Carcinoma Related Oncogene/DCUN1D1 Is Highly Conserved and Activated by Amplification in Squamous Cell Carcinomas</span></div><div class="casAuthors">Sarkaria, Inderpal; O-charoenrat, Pornchai; Talbot, Simon G.; Reddy, Pabbathi G.; Ngai, Ivan; Maghami, Ellie; Patel, Kepal N.; Lee, Benjamin; Yonekawa, Yoshihiro; Dudas, Maria; Kaufman, Andrew; Ryan, Russell; Ghossein, Ronald; Rao, Pulivarthi H.; Stoffel, Archontoula; Ramanathan, Y.; Singh, Bhuvanesh</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">9437-9444</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Chromosomal amplification at 3q is common to multiple human cancers, but has a specific predilection for squamous cell carcinomas (SCC) of mucosal origin.  We identified and characterized a novel oncogene, SCC-related oncogene (SCCRO), which is amplified along the 3q26.3 region in human SCC.  Amplification and overexpression of SCCRO in these tumors correlate with poor clin. outcome.  The importance of SCCRO amplification in malignant transformation is established by the apoptotic response to short hairpin RNA against SCCRO, exclusively in cancer cell lines carrying SCCRO amplification.  The oncogenic potential of SCCRO is underscored by its ability to transform fibroblasts (NIH-3T3 cells) in vitro and in vivo.  We show that SCCRO regulates Gli1-a key regulator of the hedgehog (HH) pathway.  Collectively, these data suggest that SCCRO is a novel component of the HH signaling pathway involved in the malignant transformation of squamous cell lineage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzTIFIhphYXrVg90H21EOLACvtfcHk0lihXBusGu9UMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVamsrjE&md5=359faefb6b6305279f3df1ec54a544f7</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-06-2074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-06-2074%26sid%3Dliteratum%253Aachs%26aulast%3DSarkaria%26aufirst%3DI.%26aulast%3DO-Charoenrat%26aufirst%3DP.%26aulast%3DTalbot%26aufirst%3DS.%2BG.%26aulast%3DReddy%26aufirst%3DP.%2BG.%26aulast%3DNgai%26aufirst%3DI.%26aulast%3DMaghami%26aufirst%3DE.%26aulast%3DPatel%26aufirst%3DK.%2BN.%26aulast%3DLee%26aufirst%3DB.%26aulast%3DYonekawa%26aufirst%3DY.%26aulast%3DDudas%26aufirst%3DM.%26aulast%3DKaufman%26aufirst%3DA.%26aulast%3DRyan%26aufirst%3DR.%26aulast%3DGhossein%26aufirst%3DR.%26aulast%3DRao%26aufirst%3DP.%2BH.%26aulast%3DStoffel%26aufirst%3DA.%26aulast%3DRamanathan%26aufirst%3DY.%26aulast%3DSingh%26aufirst%3DB.%26atitle%3DSquamous%2520cell%2520carcinoma%2520related%2520oncogene%252FDCUN1D1%2520is%2520highly%2520conserved%2520and%2520activated%2520by%2520amplification%2520in%2520squamous%2520cell%2520carcinomas%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D9437%26epage%3D9444%26doi%3D10.1158%2F0008-5472.CAN-06-2074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Salas, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chinnaswamy, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Layton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuckey, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">A potent small-molecule inhibitor of the DCN1-UBC12 interaction that selectively blocks cullin 3 neddylation</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1150</span>, <span class="refDoi"> DOI: 10.1038/s41467-017-01243-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1038%2Fs41467-017-01243-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=29074978" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A280%3ADC%252BC1M7kvFOquw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1150&author=H.+Zhouauthor=J.+Luauthor=L.+Liuauthor=D.+Bernardauthor=C.+Y.+Yangauthor=E.+Fernandez-Salasauthor=K.+Chinnaswamyauthor=S.+Laytonauthor=J.+Stuckeyauthor=Q.+Yuauthor=W.+Zhouauthor=Z.+Panauthor=Y.+Sunauthor=S.+Wang&title=A+potent+small-molecule+inhibitor+of+the+DCN1-UBC12+interaction+that+selectively+blocks+cullin+3+neddylation&doi=10.1038%2Fs41467-017-01243-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">A potent small-molecule inhibitor of the DCN1-UBC12 interaction that selectively blocks cullin 3 neddylation</span></div><div class="casAuthors">Zhou Haibin; Lu Jianfeng; Liu Liu; Bernard Denzil; Yang Chao-Yie; Wang Shaomeng; Fernandez-Salas Ester; Chinnaswamy Krishnapriya; Layton Stephanie; Stuckey Jeanne; Yu Qing; Sun Yi; Zhou Weihua; Sun Yi; Pan Zhenqiang; Wang Shaomeng; Wang Shaomeng</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1150</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The Cullin-RING E3 ubiquitin ligases (CRLs) regulate homeostasis of ~20% of cellular proteins and their activation require neddylation of their cullin subunit.  Cullin neddylation is modulated by a scaffolding DCN protein through interactions with both the cullin protein and an E2 enzyme such as UBC12.  Here we report the development of DI-591 as a high-affinity, cell-permeable small-molecule inhibitor of the DCN1-UBC12 interaction.  DI-591 binds to purified recombinant human DCN1 and DCN2 proteins with K i values of 10-12 nM, and disrupts the DCN1-UBC12 interaction in cells.  Treatment with DI-591 selectively converts cellular cullin 3 into an un-neddylated inactive form with no or minimum effect on other cullin members.  Our data firmly establish a previously unrecognized specific role of the DCN1-UBC12 interaction for cellular neddylation of cullin 3.  DI-591 is an excellent probe compound to investigate the role of the cullin 3 CRL ligase in biological processes and human diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTn87oIyDIsYOxsqfvU0ziafW6udTcc2eZ4moCnY57tO7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M7kvFOquw%253D%253D&md5=47a713f31bcad6e0b45196cb3f1c8766</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1038%2Fs41467-017-01243-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-017-01243-7%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DBernard%26aufirst%3DD.%26aulast%3DYang%26aufirst%3DC.%2BY.%26aulast%3DFernandez-Salas%26aufirst%3DE.%26aulast%3DChinnaswamy%26aufirst%3DK.%26aulast%3DLayton%26aufirst%3DS.%26aulast%3DStuckey%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DQ.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DPan%26aufirst%3DZ.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DA%2520potent%2520small-molecule%2520inhibitor%2520of%2520the%2520DCN1-UBC12%2520interaction%2520that%2520selectively%2520blocks%2520cullin%25203%2520neddylation%26jtitle%3DNat.%2520Commun.%26date%3D2017%26volume%3D8%26spage%3D1150%26doi%3D10.1038%2Fs41467-017-01243-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span> <span> </span><span class="NLM_article-title">Potent 5-cyano-6-phenyl-pyrimidin-based derivatives targeting DCN1–UBE2M interaction</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">5382</span>– <span class="NLM_lpage">5403</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00003</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00003" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVOntrzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=5382-5403&author=W.+Zhouauthor=L.+Maauthor=L.+Dingauthor=Q.+Guoauthor=Z.+Heauthor=J.+Yangauthor=H.+Qiaoauthor=L.+Liauthor=J.+Yangauthor=S.+Yuauthor=L.+Zhaoauthor=S.+Wangauthor=H.-M.+Liuauthor=Z.+Suoauthor=W.+Zhao&title=Potent+5-cyano-6-phenyl-pyrimidin-based+derivatives+targeting+DCN1%E2%80%93UBE2M+interaction&doi=10.1021%2Facs.jmedchem.9b00003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Potent 5-Cyano-6-phenyl-pyrimidin-Based Derivatives Targeting DCN1-UBE2M Interaction</span></div><div class="casAuthors">Zhou, Wenjuan; Ma, Liying; Ding, Lina; Guo, Qian; He, Zhangxu; Yang, Jing; Qiao, Hui; Li, Lingyu; Yang, Jie; Yu, Shimin; Zhao, Lili; Wang, Shaomeng; Liu, Hong-Min; Suo, Zhenhe; Zhao, Wen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5382-5403</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Neddylation of the Cullin-RING E3 ligases (CRLs) regulates the homeostasis of approx. 20% of cellular proteins.  Defective in cullin neddylation 1 (DCN1), as a co-E3 ligase, interacts with UBE2M to enhance the activation of CRLs, and this interaction is emerging as a therapeutic target for human diseases.  Here, we present a series of pyrimidin-based small mol. inhibitors targeting DCN1-UBE2M interaction.  After finding a novel inhibitor DC-1 with IC50 = 1.2 μM, we performed a series of chem. optimizations, which finally led to the discovery of a potent thiazole contg. 5-cyano-6-phenylpyrimidin-based inhibitor DC-2 (IC50 = 15 nM).  Next, using protein and cellular thermal shift assays, coimmunopptn., mol. docking, and site-specific mutation expts., we further proved that DC-2 specifically inhibited the interaction of UBE2M and DCN1 at mol. and cellular levels, resulting in the decrease of cullin3 neddylation and accumulation of its substrate, NRF2.  Our findings indicate that DC-2 may serve as a novel lead compd. for specific derivs. targeting DCN1-UBE2M interaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqFJ-HvcKxn7Vg90H21EOLACvtfcHk0lhOp_hMwGBv2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVOntrzI&md5=b0b7b00a80e377905d1532b4e2c5992b</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00003%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DMa%26aufirst%3DL.%26aulast%3DDing%26aufirst%3DL.%26aulast%3DGuo%26aufirst%3DQ.%26aulast%3DHe%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DQiao%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DH.-M.%26aulast%3DSuo%26aufirst%3DZ.%26aulast%3DZhao%26aufirst%3DW.%26atitle%3DPotent%25205-cyano-6-phenyl-pyrimidin-based%2520derivatives%2520targeting%2520DCN1%25E2%2580%2593UBE2M%2520interaction%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D5382%26epage%3D5403%26doi%3D10.1021%2Facs.jmedchem.9b00003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eckhardt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langkopf, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mark, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tadayyon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nar, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfrengle, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guth, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lotz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sieger, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuchs, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Himmelsbach, F.</span></span> <span> </span><span class="NLM_article-title">8-(3-(<i>R</i>)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-yl-methyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">6450</span>– <span class="NLM_lpage">6453</span>, <span class="refDoi"> DOI: 10.1021/jm701280z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm701280z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlyqs7vJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=6450-6453&author=M.+Eckhardtauthor=E.+Langkopfauthor=M.+Markauthor=M.+Tadayyonauthor=L.+Thomasauthor=H.+Narauthor=W.+Pfrengleauthor=B.+Guthauthor=R.+Lotzauthor=P.+Siegerauthor=H.+Fuchsauthor=F.+Himmelsbach&title=8-%283-%28R%29-aminopiperidin-1-yl%29-7-but-2-ynyl-3-methyl-1-%284-methyl-quinazolin-2-yl-methyl%29-3%2C7-dihydropurine-2%2C6-dione+%28BI+1356%29%2C+a+highly+potent%2C+selective%2C+long-acting%2C+and+orally+bioavailable+DPP-4+inhibitor+for+the+treatment+of+type+2+diabetes&doi=10.1021%2Fjm701280z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">8-(3-(R)-Aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a Highly Potent, Selective, Long-Acting, and Orally Bioavailable DPP-4 Inhibitor for the Treatment of Type 2 Diabetes</span></div><div class="casAuthors">Eckhardt, Matthias; Langkopf, Elke; Mark, Michael; Tadayyon, Moh; Thomas, Leo; Nar, Herbert; Pfrengle, Waldemar; Guth, Brian; Lotz, Ralf; Sieger, Peter; Fuchs, Holger; Himmelsbach, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">6450-6453</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new chem. class of potent DPP-4 inhibitors structurally derived from the xanthine scaffold for the treatment of type 2 diabetes has been discovered and evaluated.  Systematic structural variations have led to 1 (BI 1356, I), a highly potent, selective, long-acting, and orally active DPP-4 inhibitor that shows considerable blood glucose lowering in different animal species.  1 Is currently undergoing clin. phase IIb trials and holds the potential for once-daily treatment of type 2 diabetics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVyDZtAZGjgLVg90H21EOLACvtfcHk0lhOp_hMwGBv2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlyqs7vJ&md5=442ec88b800d899cc7a1f1528e1af4fa</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1021%2Fjm701280z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701280z%26sid%3Dliteratum%253Aachs%26aulast%3DEckhardt%26aufirst%3DM.%26aulast%3DLangkopf%26aufirst%3DE.%26aulast%3DMark%26aufirst%3DM.%26aulast%3DTadayyon%26aufirst%3DM.%26aulast%3DThomas%26aufirst%3DL.%26aulast%3DNar%26aufirst%3DH.%26aulast%3DPfrengle%26aufirst%3DW.%26aulast%3DGuth%26aufirst%3DB.%26aulast%3DLotz%26aufirst%3DR.%26aulast%3DSieger%26aufirst%3DP.%26aulast%3DFuchs%26aufirst%3DH.%26aulast%3DHimmelsbach%26aufirst%3DF.%26atitle%3D8-%25283-%2528R%2529-aminopiperidin-1-yl%2529-7-but-2-ynyl-3-methyl-1-%25284-methyl-quinazolin-2-yl-methyl%2529-3%252C7-dihydropurine-2%252C6-dione%2520%2528BI%25201356%2529%252C%2520a%2520highly%2520potent%252C%2520selective%252C%2520long-acting%252C%2520and%2520orally%2520bioavailable%2520DPP-4%2520inhibitor%2520for%2520the%2520treatment%2520of%2520type%25202%2520diabetes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D6450%26epage%3D6453%26doi%3D10.1021%2Fjm701280z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dhillon, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rath, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolch, W.</span></span> <span> </span><span class="NLM_article-title">MAP kinase signalling pathways in cancer</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">3279</span>– <span class="NLM_lpage">3290</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1210421</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1038%2Fsj.onc.1210421" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=17496922" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlt1WktLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=3279-3290&author=A.+S.+Dhillonauthor=S.+Haganauthor=O.+Rathauthor=W.+Kolch&title=MAP+kinase+signalling+pathways+in+cancer&doi=10.1038%2Fsj.onc.1210421"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">MAP kinase signaling pathways in cancer</span></div><div class="casAuthors">Dhillon, A. S.; Hagan, S.; Rath, O.; Kolch, W.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">3279-3290</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Cancer can be perceived as a disease of communication between and within cells.  The aberrations are pleiotropic, but mitogen-activated protein kinase (MAPK) pathways feature prominently.  Here, we discuss recent findings and hypotheses on the role of MAPK pathways in cancer.  Cancerous mutations in MAPK pathways are frequently mostly affecting Ras and B-Raf in the extracellular signal-regulated kinase pathway.  Stress-activated pathways, such as Jun N-terminal kinase and p38, largely seem to counteract malignant transformation.  The balance and integration between these signals may widely vary in different tumors, but are important for the outcome and the sensitivity to drug therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2AJjwZsw0PbVg90H21EOLACvtfcHk0lhOp_hMwGBv2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlt1WktLc%253D&md5=510709dcee2bbe62c7d48dbd8f270130</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1210421&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1210421%26sid%3Dliteratum%253Aachs%26aulast%3DDhillon%26aufirst%3DA.%2BS.%26aulast%3DHagan%26aufirst%3DS.%26aulast%3DRath%26aufirst%3DO.%26aulast%3DKolch%26aufirst%3DW.%26atitle%3DMAP%2520kinase%2520signalling%2520pathways%2520in%2520cancer%26jtitle%3DOncogene%26date%3D2007%26volume%3D26%26spage%3D3279%26epage%3D3290%26doi%3D10.1038%2Fsj.onc.1210421" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarkowski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baccarini, M.</span></span> <span> </span><span class="NLM_article-title">Raf kinases in cancer-roles and therapeutic opportunities</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">3477</span>– <span class="NLM_lpage">3488</span>, <span class="refDoi"> DOI: 10.1038/onc.2011.160</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1038%2Fonc.2011.160" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=21577205" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtV2hsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2011&pages=3477-3488&author=G.+Maurerauthor=B.+Tarkowskiauthor=M.+Baccarini&title=Raf+kinases+in+cancer-roles+and+therapeutic+opportunities&doi=10.1038%2Fonc.2011.160"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Raf kinases in cancer - roles and therapeutic opportunities</span></div><div class="casAuthors">Maurer, G.; Tarkowski, B.; Baccarini, M.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">3477-3488</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Raf are conserved, ubiquitous serine/protein kinases discovered as the cellular elements hijacked by transforming retroviruses.  The 3 mammalian RAF proteins (A, B and CRAF) can be activated by the human oncogene RAS, downstream from which they exert both kinase-dependent and kinase-independent, tumor-promoting functions.  The kinase-dependent functions are mediated chiefly by the MEK/ERK pathway, whose activation is assocd. with proliferation in a broad range of human tumors.  Almost 10 years ago, activating BRAF mutations were discovered in a subset of human tumors, and in the past year treatment with small-mol. RAF inhibitors has yielded unprecedented response rates in melanoma patients.  Thus, Raf qualifies as an excellent mol. target for anticancer therapy.  This review focuses on the role of BRAF and CRAF in different aspects of carcinogenesis, on the success of mol. therapies targeting Raf and the challenges they present.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnwcV59PKy5bVg90H21EOLACvtfcHk0lhOp_hMwGBv2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtV2hsrk%253D&md5=b2e37c1cd3a97d3dceedf5ec3e965f2e</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1038%2Fonc.2011.160&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2011.160%26sid%3Dliteratum%253Aachs%26aulast%3DMaurer%26aufirst%3DG.%26aulast%3DTarkowski%26aufirst%3DB.%26aulast%3DBaccarini%26aufirst%3DM.%26atitle%3DRaf%2520kinases%2520in%2520cancer-roles%2520and%2520therapeutic%2520opportunities%26jtitle%3DOncogene%26date%3D2011%26volume%3D30%26spage%3D3477%26epage%3D3488%26doi%3D10.1038%2Fonc.2011.160" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bollag, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirth, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spevak, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habets, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burton, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shellooe, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marimuthu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artis, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higgins, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Andrea, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koehler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stumm, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grippo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puzanov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McArthur, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaherty, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nathanson, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolop, K.</span></span> <span> </span><span class="NLM_article-title">Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>467</i></span>,  <span class="NLM_fpage">596</span>– <span class="NLM_lpage">599</span>, <span class="refDoi"> DOI: 10.1038/nature09454</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1038%2Fnature09454" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=20823850" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1ajtbfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=467&publication_year=2010&pages=596-599&author=G.+Bollagauthor=P.+Hirthauthor=J.+Tsaiauthor=J.+Zhangauthor=P.+N.+Ibrahimauthor=H.+Choauthor=W.+Spevakauthor=C.+Zhangauthor=Y.+Zhangauthor=G.+Habetsauthor=E.+A.+Burtonauthor=B.+Wongauthor=G.+Tsangauthor=B.+L.+Westauthor=B.+Powellauthor=R.+Shellooeauthor=A.+Marimuthuauthor=H.+Nguyenauthor=K.+Y.+Zhangauthor=D.+R.+Artisauthor=J.+Schlessingerauthor=F.+Suauthor=B.+Higginsauthor=R.+Iyerauthor=K.+D%E2%80%99Andreaauthor=A.+Koehlerauthor=M.+Stummauthor=P.+S.+Linauthor=R.+J.+Leeauthor=J.+Grippoauthor=I.+Puzanovauthor=K.+B.+Kimauthor=A.+Ribasauthor=G.+A.+McArthurauthor=J.+A.+Sosmanauthor=P.+B.+Chapmanauthor=K.+T.+Flahertyauthor=X.+Xuauthor=K.+L.+Nathansonauthor=K.+Nolop&title=Clinical+efficacy+of+a+RAF+inhibitor+needs+broad+target+blockade+in+BRAF-mutant+melanoma&doi=10.1038%2Fnature09454"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma</span></div><div class="casAuthors">Bollag, Gideon; Hirth, Peter; Tsai, James; Zhang, Jiazhong; Ibrahim, Prabha N.; Cho, Hanna; Spevak, Wayne; Zhang, Chao; Zhang, Ying; Habets, Gaston; Burton, Elizabeth A.; Wong, Bernice; Tsang, Garson; West, Brian L.; Powell, Ben; Shellooe, Rafe; Marimuthu, Adhirai; Nguyen, Hoa; Zhang, Kam Y. J.; Artis, Dean R.; Schlessinger, Joseph; Su, Fei; Higgins, Brian; Iyer, Raman; D'Andrea, Kurt; Koehler, Astrid; Stumm, Michael; Lin, Paul S.; Lee, Richard J.; Grippo, Joseph; Puzanov, Igor; Kim, Kevin B.; Ribas, Antoni; McArthur, Grant A.; Sosman, Jeffrey A.; Chapman, Paul B.; Flaherty, Keith T.; Xu, Xiaowei; Nathanson, Katherine L.; Nolop, Keith</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">467</span>
        (<span class="NLM_cas:issue">7315</span>),
    <span class="NLM_cas:pages">596-599</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">B-RAF is the most frequently mutated protein kinase in human cancers.  The finding that oncogenic mutations in BRAF are common in melanoma, followed by the demonstration that these tumors are dependent on the RAF/MEK/ERK pathway, offered hope that inhibition of B-RAF kinase activity could benefit melanoma patients.  Herein, we describe the structure-guided discovery of PLX4032 (RG7204), a potent inhibitor of oncogenic B-RAF kinase activity.  Preclin. expts. demonstrated that PLX4032 selectively blocked the RAF/MEK/ERK pathway in BRAF mutant cells and caused regression of BRAF mutant xenografts.  Toxicol. studies confirmed a wide safety margin consistent with the high degree of selectivity, enabling Phase 1 clin. trials using a cryst. formulation of PLX4032 (ref. 5).  In a subset of melanoma patients, pathway inhibition was monitored in paired biopsy specimens collected before treatment initiation and following 2 wk of treatment.  This anal. revealed substantial inhibition of ERK phosphorylation, yet clin. evaluation did not show tumor regressions.  At higher drug exposures afforded by a new amorphous drug formulation, greater than 80% inhibition of ERK phosphorylation in the tumors of patients correlated with clin. response.  Indeed, the Phase 1 clin. data revealed a remarkably high 81% response rate in metastatic melanoma patients treated at an oral dose of 960 mg twice daily.  These data demonstrate that BRAF-mutant melanomas are highly dependent on B-RAF kinase activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpYwlns1EfcLVg90H21EOLACvtfcHk0liYKxnwcN1iNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1ajtbfK&md5=8a26d0ab41970f39a109ddafff2f17b4</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1038%2Fnature09454&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature09454%26sid%3Dliteratum%253Aachs%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DHirth%26aufirst%3DP.%26aulast%3DTsai%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DIbrahim%26aufirst%3DP.%2BN.%26aulast%3DCho%26aufirst%3DH.%26aulast%3DSpevak%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHabets%26aufirst%3DG.%26aulast%3DBurton%26aufirst%3DE.%2BA.%26aulast%3DWong%26aufirst%3DB.%26aulast%3DTsang%26aufirst%3DG.%26aulast%3DWest%26aufirst%3DB.%2BL.%26aulast%3DPowell%26aufirst%3DB.%26aulast%3DShellooe%26aufirst%3DR.%26aulast%3DMarimuthu%26aufirst%3DA.%26aulast%3DNguyen%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DK.%2BY.%26aulast%3DArtis%26aufirst%3DD.%2BR.%26aulast%3DSchlessinger%26aufirst%3DJ.%26aulast%3DSu%26aufirst%3DF.%26aulast%3DHiggins%26aufirst%3DB.%26aulast%3DIyer%26aufirst%3DR.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DK.%26aulast%3DKoehler%26aufirst%3DA.%26aulast%3DStumm%26aufirst%3DM.%26aulast%3DLin%26aufirst%3DP.%2BS.%26aulast%3DLee%26aufirst%3DR.%2BJ.%26aulast%3DGrippo%26aufirst%3DJ.%26aulast%3DPuzanov%26aufirst%3DI.%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DChapman%26aufirst%3DP.%2BB.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DNathanson%26aufirst%3DK.%2BL.%26aulast%3DNolop%26aufirst%3DK.%26atitle%3DClinical%2520efficacy%2520of%2520a%2520RAF%2520inhibitor%2520needs%2520broad%2520target%2520blockade%2520in%2520BRAF-mutant%2520melanoma%26jtitle%3DNature%26date%3D2010%26volume%3D467%26spage%3D596%26epage%3D599%26doi%3D10.1038%2Fnature09454" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lito, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solit, D. B.</span></span> <span> </span><span class="NLM_article-title">Tumor adaptation and resistance to RAF inhibitors</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1401</span>– <span class="NLM_lpage">1409</span>, <span class="refDoi"> DOI: 10.1038/nm.3392</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1038%2Fnm.3392" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=24202393" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslCntbvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=1401-1409&author=P.+Litoauthor=N.+Rosenauthor=D.+B.+Solit&title=Tumor+adaptation+and+resistance+to+RAF+inhibitors&doi=10.1038%2Fnm.3392"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Tumor adaptation and resistance to RAF inhibitors</span></div><div class="casAuthors">Lito, Piro; Rosen, Neal; Solit, David B.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1401-1409</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  RAF kinase inhibitors have substantial therapeutic effects in patients with BRAF-mutant melanoma.  However, only rarely do tumors regress completely, and the therapeutic effects are often temporary.  Several mechanisms of resistance to RAF inhibitors have been proposed.  The majority of these cause ERK signaling to become insensitive to treatment with RAF inhibitors by increasing the amt. of RAF dimers in cells, whereas others bypass the dependence of the tumor on mutant RAF.  One motivation for studying mechanisms of drug resistance is that such efforts may suggest new therapeutic targets or rational combination strategies that delay or prevent the emergence of drug-resistant clones.  Here, we review the current model of RAF inhibitor resistance with a focus on the implications of this model on ongoing lab. and clin. efforts to develop more effective therapeutic strategies for patients with BRAF-mutant tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpApldbPW5lXLVg90H21EOLACvtfcHk0liYKxnwcN1iNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslCntbvN&md5=32718ee0a8ea50be5d6412ce0086cf3d</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1038%2Fnm.3392&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3392%26sid%3Dliteratum%253Aachs%26aulast%3DLito%26aufirst%3DP.%26aulast%3DRosen%26aufirst%3DN.%26aulast%3DSolit%26aufirst%3DD.%2BB.%26atitle%3DTumor%2520adaptation%2520and%2520resistance%2520to%2520RAF%2520inhibitors%26jtitle%3DNat.%2520Med.%26date%3D2013%26volume%3D19%26spage%3D1401%26epage%3D1409%26doi%3D10.1038%2Fnm.3392" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhuang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taghipouran, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smaill, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span> <span> </span><span class="NLM_article-title"><i>N</i>-(3-Ethynyl-2,4-difluorophenyl)sulfonamide derivatives as selective Raf inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">543</span>– <span class="NLM_lpage">547</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00039</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00039" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC2MXksl2hsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=543-547&author=Y.+Liauthor=H.+Chengauthor=Z.+Zhangauthor=X.+Zhuangauthor=J.+Luoauthor=H.+Longauthor=Y.+Zhouauthor=Y.+Xuauthor=R.+Taghipouranauthor=D.+Liauthor=A.+Pattersonauthor=J.+Smaillauthor=Z.+Tuauthor=D.+Wuauthor=X.+Renauthor=K.+Ding&title=N-%283-Ethynyl-2%2C4-difluorophenyl%29sulfonamide+derivatives+as+selective+Raf+inhibitors&doi=10.1021%2Facsmedchemlett.5b00039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">N-(3-Ethynyl-2,4-difluorophenyl)sulfonamide Derivatives as Selective Raf Inhibitors</span></div><div class="casAuthors">Li, Yingjun; Cheng, Huimin; Zhang, Zhang; Zhuang, Xiaoxi; Luo, Jinfeng; Long, Huoyou; Zhou, Yang; Xu, Yong; Taghipouran, Rana; Li, Dan; Patterson, Adam; Smaill, Jeff; Tu, Zhengchao; Wu, Donghai; Ren, Xiaomei; Ding, Ke</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">543-547</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of N-(3-ethynyl-2,4-difluorophenyl)sulfonamides were identified as new selective Raf inhibitors.  The compds. potently inhibit B-RafV600E with low nanomolar IC50 values and exhibit excellent target specificity in a selectivity profiling investigation against 468 kinases.  They strongly suppress proliferation of a panel of human cancer cell lines and patient-derived melanoma cells with B-RafV600E mutation while being significantly less potent to the cells with B-RafWT.  The compds. also display favorable pharmacokinetic properties with a preferred example (3s) demonstrating significant in vivo antitumor efficacy in a xenograft mouse model of B-RafV600E mutated Colo205 human colorectal cancer cells, supporting it as a promising lead compd. for further anticancer drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4y5H_m-zXlLVg90H21EOLACvtfcHk0ljS_Su8KmsmtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXksl2hsbc%253D&md5=ea0fd2bf798161ff95853daf9518ae31</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00039%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DZhuang%26aufirst%3DX.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DLong%26aufirst%3DH.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DTaghipouran%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DPatterson%26aufirst%3DA.%26aulast%3DSmaill%26aufirst%3DJ.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DD.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DN-%25283-Ethynyl-2%252C4-difluorophenyl%2529sulfonamide%2520derivatives%2520as%2520selective%2520Raf%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26spage%3D543%26epage%3D547%26doi%3D10.1021%2Facsmedchemlett.5b00039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pettipher, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansel, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armer, R.</span></span> <span> </span><span class="NLM_article-title">Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">313</span>– <span class="NLM_lpage">325</span>, <span class="refDoi"> DOI: 10.1038/nrd2266</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1038%2Fnrd2266" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=17396136" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjs1SisL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=313-325&author=R.+Pettipherauthor=T.+T.+Hanselauthor=R.+Armer&title=Antagonism+of+the+prostaglandin+D2+receptors+DP1+and+CRTH2+as+an+approach+to+treat+allergic+diseases&doi=10.1038%2Fnrd2266"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases</span></div><div class="casAuthors">Pettipher, Roy; Hansel, Trevor T.; Armer, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">313-325</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Immunol. activation of mast cells is an important trigger in the cascade of inflammatory events leading to the manifestation of allergic diseases.  Pharmacol. studies using the recently discovered DP1 and CRTH2 antagonists combined with genetic anal. support the view that these receptors have a pivotal role in mediating aspects of allergic diseases that are resistant to current therapy.  This Review focuses on the emerging roles that DP1 and CRTH2 (also known as DP2) have in acute and chronic aspects of allergic diseases and proposes that, rather than having opposing actions, these receptors have complementary roles in the initiation and maintenance of the allergy state.  We also discuss recent progress in the discovery and development of selective antagonists of these receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBjHJH6cAZgbVg90H21EOLACvtfcHk0ljS_Su8KmsmtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjs1SisL0%253D&md5=270421c9fa796738b0a27331ef448ea0</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1038%2Fnrd2266&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2266%26sid%3Dliteratum%253Aachs%26aulast%3DPettipher%26aufirst%3DR.%26aulast%3DHansel%26aufirst%3DT.%2BT.%26aulast%3DArmer%26aufirst%3DR.%26atitle%3DAntagonism%2520of%2520the%2520prostaglandin%2520D2%2520receptors%2520DP1%2520and%2520CRTH2%2520as%2520an%2520approach%2520to%2520treat%2520allergic%2520diseases%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26spage%3D313%26epage%3D325%26doi%3D10.1038%2Fnrd2266" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crosignani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pretre, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorand-Lebrun, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraboulet, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seenisamy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Augustine, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Missotten, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humbert, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cleva, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abla, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daff, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schott, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgat-Charvillon, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivron, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamernig, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arrighi, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaudet, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerli, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juillard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, Z.</span></span> <span> </span><span class="NLM_article-title">Discovery of potent, selective, and orally bioavailable alkynylphenoxyacetic acid CRTH2 (DP2) receptor antagonists for the treatment of allergic inflammatory diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">7299</span>– <span class="NLM_lpage">7317</span>, <span class="refDoi"> DOI: 10.1021/jm200866y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200866y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1GitLrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7299-7317&author=S.+Crosignaniauthor=A.+Pretreauthor=C.+Jorand-Lebrunauthor=G.+Frabouletauthor=J.+Seenisamyauthor=J.+K.+Augustineauthor=M.+Missottenauthor=Y.+Humbertauthor=C.+Clevaauthor=N.+Ablaauthor=H.+Daffauthor=O.+Schottauthor=M.+Schneiderauthor=F.+Burgat-Charvillonauthor=D.+Rivronauthor=I.+Hamernigauthor=J.+F.+Arrighiauthor=M.+Gaudetauthor=S.+C.+Zimmerliauthor=P.+Juillardauthor=Z.+Johnson&title=Discovery+of+potent%2C+selective%2C+and+orally+bioavailable+alkynylphenoxyacetic+acid+CRTH2+%28DP2%29+receptor+antagonists+for+the+treatment+of+allergic+inflammatory+diseases&doi=10.1021%2Fjm200866y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Potent, Selective, and Orally Bioavailable Alkynylphenoxyacetic Acid CRTH2 (DP2) Receptor Antagonists for the Treatment of Allergic Inflammatory Diseases</span></div><div class="casAuthors">Crosignani, Stefano; Pretre, Adeline; Jorand-Lebrun, Catherine; Fraboulet, Gaele; Seenisamy, Jeyaprakashnarayanan; Augustine, John Kallikat; Missotten, Marc; Humbert, Yves; Cleva, Christophe; Abla, Nada; Daff, Hamina; Schott, Olivier; Schneider, Manfred; Burgat-Charvillon, Fabienne; Rivron, Delphine; Hamernig, Ingrid; Arrighi, Jean-Francois; Gaudet, Marilene; Zimmerli, Simone C.; Juillard, Pierre; Johnson, Zoe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7299-7317</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">New phenoxyacetic acid antagonists of CRTH2 are described.  Following the discovery of a hit compd., I, by a focused screening, high protein binding was identified as its main weakness.  Optimization aimed at reducing serum protein binding led to the identification of several compds. that showed not only excellent affinities for the receptor (41 compds. with Ki < 10 nM) but also excellent potencies in a human whole blood assay (IC50 < 100 nM; PGD2-induced eosinophil shape change).  Addnl. optimization of the pharmacokinetic characteristics led to the identification of several compds. suitable for in vivo testing.  Of these, II (R1 = n-Pr, R2 = Me; R1 = n-Pr, R2 = F) were tested in two different pharmacol. models (acute FITC-mediated contact hypersensitivity and ovalbumin-induced eosinophilia models) and found to be active after oral dosing (10 and 30 mg/kg).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryieXI4i54w7Vg90H21EOLACvtfcHk0ljS_Su8KmsmtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1GitLrK&md5=348d6859d00f830d881599aab91e48bd</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1021%2Fjm200866y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200866y%26sid%3Dliteratum%253Aachs%26aulast%3DCrosignani%26aufirst%3DS.%26aulast%3DPretre%26aufirst%3DA.%26aulast%3DJorand-Lebrun%26aufirst%3DC.%26aulast%3DFraboulet%26aufirst%3DG.%26aulast%3DSeenisamy%26aufirst%3DJ.%26aulast%3DAugustine%26aufirst%3DJ.%2BK.%26aulast%3DMissotten%26aufirst%3DM.%26aulast%3DHumbert%26aufirst%3DY.%26aulast%3DCleva%26aufirst%3DC.%26aulast%3DAbla%26aufirst%3DN.%26aulast%3DDaff%26aufirst%3DH.%26aulast%3DSchott%26aufirst%3DO.%26aulast%3DSchneider%26aufirst%3DM.%26aulast%3DBurgat-Charvillon%26aufirst%3DF.%26aulast%3DRivron%26aufirst%3DD.%26aulast%3DHamernig%26aufirst%3DI.%26aulast%3DArrighi%26aufirst%3DJ.%2BF.%26aulast%3DGaudet%26aufirst%3DM.%26aulast%3DZimmerli%26aufirst%3DS.%2BC.%26aulast%3DJuillard%26aufirst%3DP.%26aulast%3DJohnson%26aufirst%3DZ.%26atitle%3DDiscovery%2520of%2520potent%252C%2520selective%252C%2520and%2520orally%2520bioavailable%2520alkynylphenoxyacetic%2520acid%2520CRTH2%2520%2528DP2%2529%2520receptor%2520antagonists%2520for%2520the%2520treatment%2520of%2520allergic%2520inflammatory%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D7299%26epage%3D7317%26doi%3D10.1021%2Fjm200866y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cerretti, D. P.</span></span> <span> </span><span class="NLM_article-title">Characterization of the tumour necrosis factor alpha-converting enzyme, TACE/ADAM17</span>. <i>Biochem. Soc. Trans.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">219</span>– <span class="NLM_lpage">223</span>, <span class="refDoi"> DOI: 10.1042/bst0270219</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1042%2Fbst0270219" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10093737" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADyaK1MXhsValurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1999&pages=219-223&author=D.+P.+Cerretti&title=Characterization+of+the+tumour+necrosis+factor+alpha-converting+enzyme%2C+TACE%2FADAM17&doi=10.1042%2Fbst0270219"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of the tumor necrosis factor α-converting enzyme, TACE/ADAM17</span></div><div class="casAuthors">Cerretti, D. P.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Society Transactions</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">219-223</span>CODEN:
                <span class="NLM_cas:coden">BCSTB5</span>;
        ISSN:<span class="NLM_cas:issn">0300-5127</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">TNF-α is a trimeric type II transmembrane protein with its N-terminus inside the cell and its C-terminus outside the cell.  A specific proteinase or TNF-α-converting enzyme (TACE) is responsible for the cleavage or shedding of the precursor protein (pro-TNF-α) from the membrane surface.  To characterize TACE we searched for cells that produced large quantities of shed TNF-α.  We found that the human monocytic cell line THP-1 met this criterion.  Our findings have demonstrated that a single proteinase TACE/ADAM17 is required for the shedding of TNF-α from T cells and myeloid cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVWiKYnfWkzLVg90H21EOLACvtfcHk0lh0BDSgCLouUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXhsValurw%253D&md5=4e7f18bc489a082ae2de77d8e9be3131</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1042%2Fbst0270219&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252Fbst0270219%26sid%3Dliteratum%253Aachs%26aulast%3DCerretti%26aufirst%3DD.%2BP.%26atitle%3DCharacterization%2520of%2520the%2520tumour%2520necrosis%2520factor%2520alpha-converting%2520enzyme%252C%2520TACE%252FADAM17%26jtitle%3DBiochem.%2520Soc.%2520Trans.%26date%3D1999%26volume%3D27%26spage%3D219%26epage%3D223%26doi%3D10.1042%2Fbst0270219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shankar, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavey, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosinski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizvi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feltz, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piwinski, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosner, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shih, N. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siddiqui, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orth, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Umland, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundell, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozlowski, J. A.</span></span> <span> </span><span class="NLM_article-title">Biaryl substituted hydantoin compounds as TACE inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">5286</span>– <span class="NLM_lpage">5289</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.06.134</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1016%2Fj.bmcl.2010.06.134" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=20663669" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVehtr3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=5286-5289&author=W.+Yuauthor=L.+Tongauthor=S.+H.+Kimauthor=M.+K.+Wongauthor=L.+Chenauthor=D.+Y.+Yangauthor=B.+B.+Shankarauthor=B.+J.+Laveyauthor=G.+Zhouauthor=A.+Kosinskiauthor=R.+Rizviauthor=D.+Liauthor=R.+J.+Feltzauthor=J.+J.+Piwinskiauthor=K.+E.+Rosnerauthor=N.+Y.+Shihauthor=M.+A.+Siddiquiauthor=Z.+Guoauthor=P.+Orthauthor=H.+Shahauthor=J.+Sunauthor=S.+Umlandauthor=D.+J.+Lundellauthor=X.+Niuauthor=J.+A.+Kozlowski&title=Biaryl+substituted+hydantoin+compounds+as+TACE+inhibitors&doi=10.1016%2Fj.bmcl.2010.06.134"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Biaryl substituted hydantoin compounds as TACE inhibitors</span></div><div class="casAuthors">Yu, Wensheng; Tong, Ling; Kim, Seong Heon; Wong, Michael K. C.; Chen, Lei; Yang, De-Yi; Shankar, Bandarpalle B.; Lavey, Brian J.; Zhou, Guowei; Kosinski, Aneta; Rizvi, Razia; Li, Dansu; Feltz, Robert J.; Piwinski, John J.; Rosner, Kristin E.; Shih, Neng-Yang; Siddiqui, M. Arshad; Guo, Zhuyan; Orth, Peter; Shah, Himanshu; Sun, Jing; Umland, Shelby; Lundell, Daniel J.; Niu, Xiaoda; Kozlowski, Joseph A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5286-5289</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We disclose further optimization of hydantoin TNF-α convertase enzyme (TACE) inhibitors.  SAR with respect to the non-prime region of TACE active site was explored.  A series of biaryl substituted hydantoin compds. was shown to have sub-nanomolar K i, good rat PK, and good selectivity vs. MMP-1, -2, -3, -7, -9, and -13.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMqDvlftR2sbVg90H21EOLACvtfcHk0lh0BDSgCLouUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVehtr3I&md5=085e9aeb4fb958b2c91d7cf3ffa7cbe7</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.06.134&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.06.134%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DW.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DWong%26aufirst%3DM.%2BK.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DD.%2BY.%26aulast%3DShankar%26aufirst%3DB.%2BB.%26aulast%3DLavey%26aufirst%3DB.%2BJ.%26aulast%3DZhou%26aufirst%3DG.%26aulast%3DKosinski%26aufirst%3DA.%26aulast%3DRizvi%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DFeltz%26aufirst%3DR.%2BJ.%26aulast%3DPiwinski%26aufirst%3DJ.%2BJ.%26aulast%3DRosner%26aufirst%3DK.%2BE.%26aulast%3DShih%26aufirst%3DN.%2BY.%26aulast%3DSiddiqui%26aufirst%3DM.%2BA.%26aulast%3DGuo%26aufirst%3DZ.%26aulast%3DOrth%26aufirst%3DP.%26aulast%3DShah%26aufirst%3DH.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DUmland%26aufirst%3DS.%26aulast%3DLundell%26aufirst%3DD.%2BJ.%26aulast%3DNiu%26aufirst%3DX.%26aulast%3DKozlowski%26aufirst%3DJ.%2BA.%26atitle%3DBiaryl%2520substituted%2520hydantoin%2520compounds%2520as%2520TACE%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D5286%26epage%3D5289%26doi%3D10.1016%2Fj.bmcl.2010.06.134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Girijavallabhan, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feltz, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Firmansjah, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozlowski, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavey, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosinski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piwinski, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popovici-Muller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizvi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosner, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shankar, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shih, N. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siddiqui, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orth, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madison, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundell, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Umland, S.</span></span> <span> </span><span class="NLM_article-title">Novel TNF-alpha converting enzyme (TACE) inhibitors as potential treatment for inflammatory diseases</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">7283</span>– <span class="NLM_lpage">7287</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.10.081</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1016%2Fj.bmcl.2010.10.081" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=21106451" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVKjtb7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=7283-7287&author=V.+M.+Girijavallabhanauthor=L.+Chenauthor=C.+Daiauthor=R.+J.+Feltzauthor=L.+Firmansjahauthor=D.+Liauthor=S.+H.+Kimauthor=J.+A.+Kozlowskiauthor=B.+J.+Laveyauthor=A.+Kosinskiauthor=J.+J.+Piwinskiauthor=J.+Popovici-Mullerauthor=R.+Rizviauthor=K.+E.+Rosnerauthor=B.+B.+Shankarauthor=N.+Y.+Shihauthor=M.+A.+Siddiquiauthor=L.+Tongauthor=M.+K.+Wongauthor=D.+Y.+Yangauthor=L.+Yangauthor=W.+Yuauthor=G.+Zhouauthor=Z.+Guoauthor=P.+Orthauthor=V.+Madisonauthor=H.+Bianauthor=D.+Lundellauthor=X.+Niuauthor=H.+Shahauthor=J.+Sunauthor=S.+Umland&title=Novel+TNF-alpha+converting+enzyme+%28TACE%29+inhibitors+as+potential+treatment+for+inflammatory+diseases&doi=10.1016%2Fj.bmcl.2010.10.081"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Novel TNF-α converting enzyme (TACE) inhibitors as potential treatment for inflammatory diseases</span></div><div class="casAuthors">Girijavallabhan, Vinay M.; Chen, Lei; Dai, Chaoyang; Feltz, Robert J.; Firmansjah, Luke; Li, Dansu; Kim, Seong Heon; Kozlowski, Joseph A.; Lavey, Brian J.; Kosinski, Aneta; Piwinski, John J.; Popovici-Muller, Janeta; Rizvi, Razia; Rosner, Kristin E.; Shankar, Banderpalle B.; Shih, Neng-Yang; Siddiqui, M. Arshad; Tong, Ling; Wong, Michael K. C.; Yang, De-yi; Yang, Liping; Yu, Wensheng; Zhou, Guowei; Guo, Zhuyan; Orth, Peter; Madison, Vincent; Bian, Hong; Lundell, Daniel; Niu, Xiaoda; Shah, Himanshu; Sun, Jing; Umland, Shelby</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7283-7287</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Our research on hydantoin based TNF-α converting enzyme (TACE) inhibitors has led to an acetylene contg. series that demonstrates sub-nanomolar potency (K i) as well as excellent activity in human whole blood.  These studies led to the discovery of highly potent TACE inhibitors such as 37 (I) with good DMPK profiles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZMVt5qIgU-7Vg90H21EOLACvtfcHk0lh0BDSgCLouUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVKjtb7P&md5=f885b195abe9ce531bf1f5dde1f8b89f</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.10.081&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.10.081%26sid%3Dliteratum%253Aachs%26aulast%3DGirijavallabhan%26aufirst%3DV.%2BM.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DDai%26aufirst%3DC.%26aulast%3DFeltz%26aufirst%3DR.%2BJ.%26aulast%3DFirmansjah%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DKozlowski%26aufirst%3DJ.%2BA.%26aulast%3DLavey%26aufirst%3DB.%2BJ.%26aulast%3DKosinski%26aufirst%3DA.%26aulast%3DPiwinski%26aufirst%3DJ.%2BJ.%26aulast%3DPopovici-Muller%26aufirst%3DJ.%26aulast%3DRizvi%26aufirst%3DR.%26aulast%3DRosner%26aufirst%3DK.%2BE.%26aulast%3DShankar%26aufirst%3DB.%2BB.%26aulast%3DShih%26aufirst%3DN.%2BY.%26aulast%3DSiddiqui%26aufirst%3DM.%2BA.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DWong%26aufirst%3DM.%2BK.%26aulast%3DYang%26aufirst%3DD.%2BY.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DYu%26aufirst%3DW.%26aulast%3DZhou%26aufirst%3DG.%26aulast%3DGuo%26aufirst%3DZ.%26aulast%3DOrth%26aufirst%3DP.%26aulast%3DMadison%26aufirst%3DV.%26aulast%3DBian%26aufirst%3DH.%26aulast%3DLundell%26aufirst%3DD.%26aulast%3DNiu%26aufirst%3DX.%26aulast%3DShah%26aufirst%3DH.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DUmland%26aufirst%3DS.%26atitle%3DNovel%2520TNF-alpha%2520converting%2520enzyme%2520%2528TACE%2529%2520inhibitors%2520as%2520potential%2520treatment%2520for%2520inflammatory%2520diseases%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D7283%26epage%3D7287%26doi%3D10.1016%2Fj.bmcl.2010.10.081" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyata, N.</span></span> <span> </span><span class="NLM_article-title">Lysine demethylases inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">8236</span>– <span class="NLM_lpage">8250</span>, <span class="refDoi"> DOI: 10.1021/jm201048w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201048w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1OrtrnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=8236-8250&author=T.+Suzukiauthor=N.+Miyata&title=Lysine+demethylases+inhibitors&doi=10.1021%2Fjm201048w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Lysine Demethylases Inhibitors</span></div><div class="casAuthors">Suzuki, Takayoshi; Miyata, Naoki</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8236-8250</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review, on the use of lysine demethylases inhibitors in therapy of various diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplp9MjSdvnn7Vg90H21EOLACvtfcHk0lgpOzlTbEaumA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1OrtrnF&md5=194d4bbc2e52672f5d5f019de0bb760c</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1021%2Fjm201048w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201048w%26sid%3Dliteratum%253Aachs%26aulast%3DSuzuki%26aufirst%3DT.%26aulast%3DMiyata%26aufirst%3DN.%26atitle%3DLysine%2520demethylases%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D8236%26epage%3D8250%26doi%3D10.1021%2Fjm201048w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, L. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H. M.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and structure-activity relationship of novel LSD1 inhibitors based on pyrimidine-thiourea hybrids as potent, orally active antitumor agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">1705</span>– <span class="NLM_lpage">1716</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00037</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00037" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlyksbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=1705-1716&author=L.+Y.+Maauthor=Y.+C.+Zhengauthor=S.+Q.+Wangauthor=B.+Wangauthor=Z.+R.+Wangauthor=L.+P.+Pangauthor=M.+Zhangauthor=J.+W.+Wangauthor=L.+Dingauthor=J.+Liauthor=C.+Wangauthor=B.+Huauthor=Y.+Liuauthor=X.+D.+Zhangauthor=J.+J.+Wangauthor=Z.+J.+Wangauthor=W.+Zhaoauthor=H.+M.+Liu&title=Design%2C+synthesis%2C+and+structure-activity+relationship+of+novel+LSD1+inhibitors+based+on+pyrimidine-thiourea+hybrids+as+potent%2C+orally+active+antitumor+agents&doi=10.1021%2Facs.jmedchem.5b00037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Structure-Activity Relationship of Novel LSD1 Inhibitors Based on Pyrimidine-Thiourea Hybrids As Potent, Orally Active Antitumor Agents</span></div><div class="casAuthors">Ma, Li-Ying; Zheng, Yi-Chao; Wang, Sai-Qi; Wang, Bo; Wang, Zhi-Ru; Pang, Lu-Ping; Zhang, Miao; Wang, Jun-Wei; Ding, Lina; Li, Juan; Wang, Cong; Hu, Biao; Liu, Ying; Zhang, Xiao-Dan; Wang, Jia-Jia; Wang, Zhi-Jian; Zhao, Wen; Liu, Hong-Min</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1705-1716</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Histone lysine specific demethylase 1 (LSD1) was reported to be overexpressed in several human cancers and recognized as a promising anticancer drug target.  In the current study, we designed and synthesized a novel series of pyrimidine-thiourea hybrids and evaluated their potential LSD1 inhibitory effect.  One of the compds., 6b, contg. a terminal alkyne appendage, was shown to be the most potent and selective LSD1 inhibitor in vitro and exhibited strong cytotoxicity against LSD1 overexpressed gastric cancer cells.  Compd. 6b also showed marked inhibition of cell migration and invasion as well as significant in vivo tumor suppressing and antimetastasis role, without significant side effects by oral administration.  Our findings indicate that the pyrimidine-thiourea-based LSD1 inactivator may serve as a leading compd. targeting LSD1 overexpressed cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpy8SIAhdqGGbVg90H21EOLACvtfcHk0lgpOzlTbEaumA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlyksbw%253D&md5=7256792e23b75e5f26bac47dfa773b11</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00037%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DL.%2BY.%26aulast%3DZheng%26aufirst%3DY.%2BC.%26aulast%3DWang%26aufirst%3DS.%2BQ.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DZ.%2BR.%26aulast%3DPang%26aufirst%3DL.%2BP.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DJ.%2BW.%26aulast%3DDing%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DHu%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DX.%2BD.%26aulast%3DWang%26aufirst%3DJ.%2BJ.%26aulast%3DWang%26aufirst%3DZ.%2BJ.%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DH.%2BM.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520structure-activity%2520relationship%2520of%2520novel%2520LSD1%2520inhibitors%2520based%2520on%2520pyrimidine-thiourea%2520hybrids%2520as%2520potent%252C%2520orally%2520active%2520antitumor%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D1705%26epage%3D1716%26doi%3D10.1021%2Facs.jmedchem.5b00037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Szewczuk, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Culhane, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majumdar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, P. A.</span></span> <span> </span><span class="NLM_article-title">Mechanistic analysis of a suicide inactivator of histone demethylase LSD1</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">6892</span>– <span class="NLM_lpage">6902</span>, <span class="refDoi"> DOI: 10.1021/bi700414b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi700414b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlsVSgt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2007&pages=6892-6902&author=L.+M.+Szewczukauthor=J.+C.+Culhaneauthor=M.+Yangauthor=A.+Majumdarauthor=H.+Yuauthor=P.+A.+Cole&title=Mechanistic+analysis+of+a+suicide+inactivator+of+histone+demethylase+LSD1&doi=10.1021%2Fbi700414b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanistic Analysis of a Suicide Inactivator of Histone Demethylase LSD1</span></div><div class="casAuthors">Szewczuk, Lawrence M.; Culhane, Jeffrey C.; Yang, Maojun; Majumdar, Ananya; Yu, Hongtao; Cole, Philip A.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">6892-6902</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Lysine-specific demethylase 1 (LSD1) is a transcriptional repressor and a flavin-dependent amine oxidase that is responsible for the removal of Me from lysine 4 of histone H3.  In this study, we characterize the mechanism and scope of LSD1 inhibition by a propargylamine-derivatized histone H3 substrate (1).  Unlike aziridinyl and cyclopropylamine-derivatized histone H3 peptide substrate analogs, compd. 1 appears to covalently modify and irreversibly inactivate LSD1 with high potency.  Accompanying this inactivation is a spectroscopic change, which shifts the absorbance max. to 392 nm.  Spectral changes assocd. with the 1-LSD1 complex and reactivity to decreased pH and sodium borohydride treatment were suggestive of a structure involving a flavin-linked inhibitor conjugate between N5 of the flavin and the terminal carbon of the inhibitor.  Using a 13C-labeled inhibitor, NMR anal. of the 1-flavin conjugate was consistent with this structural assignment.  Kinetic anal. of the spectroscopic shift induced by 1 showed that the flavin adduct formed in a reaction with kinetic consts. similar to those of the LSD1 inactivation process.  Taken together, these data support a mechanism of LSD1 inactivation by 1 involving amine oxidn. followed by Michael addn. to the propargylic imine.  We further examd. the potential for a biotinylated analog of 1 (1-Btn) to be used as a tool in affinity pulldown expts.  Using 1-Btn, it was feasible to selectively pull down spiked and endogenous LSD1 from HeLa cell nuclear exts., setting the stage for activity-based demethylase proteomics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2nUlBCS3LG7Vg90H21EOLACvtfcHk0lgpOzlTbEaumA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlsVSgt7Y%253D&md5=97eaa358443717b9f5b1214b4aebe807</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1021%2Fbi700414b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi700414b%26sid%3Dliteratum%253Aachs%26aulast%3DSzewczuk%26aufirst%3DL.%2BM.%26aulast%3DCulhane%26aufirst%3DJ.%2BC.%26aulast%3DYang%26aufirst%3DM.%26aulast%3DMajumdar%26aufirst%3DA.%26aulast%3DYu%26aufirst%3DH.%26aulast%3DCole%26aufirst%3DP.%2BA.%26atitle%3DMechanistic%2520analysis%2520of%2520a%2520suicide%2520inactivator%2520of%2520histone%2520demethylase%2520LSD1%26jtitle%3DBiochemistry%26date%3D2007%26volume%3D46%26spage%3D6892%26epage%3D6902%26doi%3D10.1021%2Fbi700414b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bisogno, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howell, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minassi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cascio, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ligresti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matias, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiano-Moriello, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paul, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gangadharan, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hobbs, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Marzo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doherty, P.</span></span> <span> </span><span class="NLM_article-title">Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain</span>. <i>J. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>163</i></span>,  <span class="NLM_fpage">463</span>– <span class="NLM_lpage">468</span>, <span class="refDoi"> DOI: 10.1083/jcb.200305129</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1083%2Fjcb.200305129" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=14610053" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD3sXovFCnur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2003&pages=463-468&author=T.+Bisognoauthor=F.+Howellauthor=G.+Williamsauthor=A.+Minassiauthor=M.+G.+Cascioauthor=A.+Ligrestiauthor=I.+Matiasauthor=A.+Schiano-Morielloauthor=P.+Paulauthor=E.+J.+Williamsauthor=U.+Gangadharanauthor=C.+Hobbsauthor=V.+Di+Marzoauthor=P.+Doherty&title=Cloning+of+the+first+sn1-DAG+lipases+points+to+the+spatial+and+temporal+regulation+of+endocannabinoid+signaling+in+the+brain&doi=10.1083%2Fjcb.200305129"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain</span></div><div class="casAuthors">Bisogno, Tiziana; Howell, Fiona; Williams, Gareth; Minassi, Alberto; Grazia Cascio, Maria; Ligresti, Alessia; Matias, Isabel; Schiano-Moriello, Aniello; Paul, Praveen; Williams, Emma-Jane; Gangadharan, Uma; Hobbs, Carl; Di Marzo, Vincenzo; Doherty, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Biology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">463-468</span>CODEN:
                <span class="NLM_cas:coden">JCLBA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9525</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Diacylglycerol (DAG) lipase activity is required for axonal growth during development and for retrograde synaptic signaling at mature synapses.  This enzyme synthesizes the endocannabinoid 2-arachidonoyl-glycerol (2-AG), and the CB1 cannabinoid receptor is also required for the above responses.  We now report on the cloning and enzymic characterization of the first specific sn-1 DAG lipases.  Two closely related genes have been identified and their expression in cells correlated with 2-AG biosynthesis and release.  The expression of both enzymes changes from axonal tracts in the embryo to dendritic fields in the adult, and this correlates with the developmental change in requirement for 2-AG synthesis from the pre- to the postsynaptic compartment.  This switch provides a possible explanation for a fundamental change in endocannabinoid function during brain development.  Identification of these enzymes may offer new therapeutic opportunities for a wide range of disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolsTG3YamCQ7Vg90H21EOLACvtfcHk0lhvQwfu1IMvFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXovFCnur8%253D&md5=37bfbb4e29da593151e155d4c9d22cfa</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1083%2Fjcb.200305129&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.200305129%26sid%3Dliteratum%253Aachs%26aulast%3DBisogno%26aufirst%3DT.%26aulast%3DHowell%26aufirst%3DF.%26aulast%3DWilliams%26aufirst%3DG.%26aulast%3DMinassi%26aufirst%3DA.%26aulast%3DCascio%26aufirst%3DM.%2BG.%26aulast%3DLigresti%26aufirst%3DA.%26aulast%3DMatias%26aufirst%3DI.%26aulast%3DSchiano-Moriello%26aufirst%3DA.%26aulast%3DPaul%26aufirst%3DP.%26aulast%3DWilliams%26aufirst%3DE.%2BJ.%26aulast%3DGangadharan%26aufirst%3DU.%26aulast%3DHobbs%26aufirst%3DC.%26aulast%3DDi%2BMarzo%26aufirst%3DV.%26aulast%3DDoherty%26aufirst%3DP.%26atitle%3DCloning%2520of%2520the%2520first%2520sn1-DAG%2520lipases%2520points%2520to%2520the%2520spatial%2520and%2520temporal%2520regulation%2520of%2520endocannabinoid%2520signaling%2520in%2520the%2520brain%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D2003%26volume%3D163%26spage%3D463%26epage%3D468%26doi%3D10.1083%2Fjcb.200305129" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sugiura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sukagawa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakane, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinoda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Itoh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waku, K.</span></span> <span> </span><span class="NLM_article-title">2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>215</i></span>,  <span class="NLM_fpage">89</span>– <span class="NLM_lpage">97</span>, <span class="refDoi"> DOI: 10.1006/bbrc.1995.2437</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1006%2Fbbrc.1995.2437" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=7575630" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADyaK2MXosVyqtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=215&publication_year=1995&pages=89-97&author=T.+Sugiuraauthor=S.+Kondoauthor=A.+Sukagawaauthor=S.+Nakaneauthor=A.+Shinodaauthor=K.+Itohauthor=A.+Yamashitaauthor=K.+Waku&title=2-Arachidonoylglycerol%3A+a+possible+endogenous+cannabinoid+receptor+ligand+in+brain&doi=10.1006%2Fbbrc.1995.2437"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain</span></div><div class="casAuthors">Sugiura, Takayuki; Kondo, Sachiko; Sukagawa, Akihiro; Nakane, Shinji; Shinoda, Akira; Itoh, Koyoko; Yamashita, Atsushi; Waku, Keizo</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">215</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">89-97</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Academic</span>)
        </div><div class="casAbstract">The effects of anandamide, 2-arachidonoylglycerol and related compds. on the specific binding of a radiolabeled cannabinoid receptor ligand, [3H]CP55940, to synaptosomal membranes were examines.  Anandamide, an endogenous cannabinoid receptor ligand, reduced the specific binding of [3H]CP55940 to synaptosomal membranes in a dose-dependent manner: the Ki value was 89 nM.  2-Arachidonoylglycerol was also shown to bind appreciably to the cannabinoid receptor in competitive inhibition expts.  The apparent binding affinity was markedly increased when the binding assay was carried out in the presence of the esterase inhibitor DFP or at 0°C.  Free arachidonic acid and N-palmitoylethanolamine were almost inactive in terms of binding to the cannabinoid receptor in synaptosomal membranes.  2-Arachidonoylglycerol may be an endogenous cannabinoid receptor ligand in the brain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGob2R5xY8ybgbVg90H21EOLACvtfcHk0lhvQwfu1IMvFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXosVyqtLk%253D&md5=faac2eccf862d0e27808349932440009</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1006%2Fbbrc.1995.2437&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fbbrc.1995.2437%26sid%3Dliteratum%253Aachs%26aulast%3DSugiura%26aufirst%3DT.%26aulast%3DKondo%26aufirst%3DS.%26aulast%3DSukagawa%26aufirst%3DA.%26aulast%3DNakane%26aufirst%3DS.%26aulast%3DShinoda%26aufirst%3DA.%26aulast%3DItoh%26aufirst%3DK.%26aulast%3DYamashita%26aufirst%3DA.%26aulast%3DWaku%26aufirst%3DK.%26atitle%3D2-Arachidonoylglycerol%253A%2520a%2520possible%2520endogenous%2520cannabinoid%2520receptor%2520ligand%2520in%2520brain%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D1995%26volume%3D215%26spage%3D89%26epage%3D97%26doi%3D10.1006%2Fbbrc.1995.2437" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kooijman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van den
Nieuwendijk, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogasawara, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Wel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Dalen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baggelaar, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janssen, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van den Berg, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">den Dulk, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overkleeft, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rensen, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Stelt, M.</span></span> <span> </span><span class="NLM_article-title">Triazole ureas act as diacylglycerol lipase inhibitors and prevent fasting-induced refeeding</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">428</span>– <span class="NLM_lpage">440</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01482</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01482" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVGitbrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=428-440&author=H.+Dengauthor=S.+Kooijmanauthor=A.+M.+van+den%0ANieuwendijkauthor=D.+Ogasawaraauthor=T.+van+der+Welauthor=F.+van+Dalenauthor=M.+P.+Baggelaarauthor=F.+J.+Janssenauthor=R.+J.+van+den+Bergauthor=H.+den+Dulkauthor=B.+F.+Cravattauthor=H.+S.+Overkleeftauthor=P.+C.+Rensenauthor=M.+van+der+Stelt&title=Triazole+ureas+act+as+diacylglycerol+lipase+inhibitors+and+prevent+fasting-induced+refeeding&doi=10.1021%2Facs.jmedchem.6b01482"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Triazole Ureas Act as Diacylglycerol Lipase Inhibitors and Prevent Fasting-Induced Refeeding</span></div><div class="casAuthors">Deng, Hui; Kooijman, Sander; van den Nieuwendijk, Adrianus M. C. H.; Ogasawara, Daisuke; van der Wel, Tom; van Dalen, Floris; Baggelaar, Marc P.; Janssen, Freek J.; van den Berg, Richard J. B. H. N.; den Dulk, Hans; Cravatt, Benjamin F.; Overkleeft, Herman S.; Rensen, Patrick C. N.; van der Stelt, Mario</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">428-440</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Triazole ureas constitute a versatile class of irreversible inhibitors that target serine hydrolases in both cells and animal models.  We have previously reported that triazole ureas can act as selective and CNS-active inhibitors for diacylglycerol lipases (DAGLs), enzymes responsible for the biosynthesis of 2-arachidonoyl glycerol (2-AG) that activates cannabinoid CB1 receptor.  Here, we report the enantio- and diastereoselective synthesis and structure-activity relationship studies.  We found that 2,4-substituted triazole ureas with a biphenylmethanol group provided the most optimal scaffold.  Introduction of a chiral ether substituent on the 5-position of the piperidine ring provided ultrapotent inhibitor I (DH376) with picomolar activity.  Compd. I temporarily reduces fasting-induced refeeding of mice, thereby emulating the effect of cannabinoid CB1-receptor inverse agonists.  This was mirrored by II (DO34) but also by the neg. control compd. III (DO53) (which does not inhibit DAGL), which indicates the triazole ureas may affect the energy balance in mice through multiple mol. targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp70FEOiinaZrVg90H21EOLACvtfcHk0lhvQwfu1IMvFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVGitbrF&md5=94d1ccb26a0d76fbc5c2e5d59b579c0c</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01482&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01482%26sid%3Dliteratum%253Aachs%26aulast%3DDeng%26aufirst%3DH.%26aulast%3DKooijman%26aufirst%3DS.%26aulast%3Dvan%2Bden%2BNieuwendijk%26aufirst%3DA.%2BM.%26aulast%3DOgasawara%26aufirst%3DD.%26aulast%3Dvan%2Bder%2BWel%26aufirst%3DT.%26aulast%3Dvan%2BDalen%26aufirst%3DF.%26aulast%3DBaggelaar%26aufirst%3DM.%2BP.%26aulast%3DJanssen%26aufirst%3DF.%2BJ.%26aulast%3Dvan%2Bden%2BBerg%26aufirst%3DR.%2BJ.%26aulast%3Dden%2BDulk%26aufirst%3DH.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26aulast%3DOverkleeft%26aufirst%3DH.%2BS.%26aulast%3DRensen%26aufirst%3DP.%2BC.%26aulast%3Dvan%2Bder%2BStelt%26aufirst%3DM.%26atitle%3DTriazole%2520ureas%2520act%2520as%2520diacylglycerol%2520lipase%2520inhibitors%2520and%2520prevent%2520fasting-induced%2520refeeding%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D428%26epage%3D440%26doi%3D10.1021%2Facs.jmedchem.6b01482" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dragovich, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prins, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hua, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luu, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakata, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maldonado, F. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuntland, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuhrman, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zalman, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patick, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, E. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borer, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nayyar, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moran, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rejto, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guzman, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dovalsantos, E. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohajeri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liese, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosa, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batugo, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gleeson, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meador, J. W.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferre, R. A.</span></span> <span> </span><span class="NLM_article-title">Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 8. Pharmacological optimization of orally bioavailable 2-pyridone-containing peptidomimetics</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">4572</span>– <span class="NLM_lpage">4285</span>, <span class="refDoi"> DOI: 10.1021/jm030166l</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm030166l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD3sXot1Ojs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=4572-4285&author=P.+S.+Dragovichauthor=T.+J.+Prinsauthor=R.+Zhouauthor=T.+O.+Johnsonauthor=Y.+Huaauthor=H.+T.+Luuauthor=S.+K.+Sakataauthor=E.+L.+Brownauthor=F.+C.+Maldonadoauthor=T.+Tuntlandauthor=C.+A.+Leeauthor=S.+A.+Fuhrmanauthor=L.+S.+Zalmanauthor=A.+K.+Patickauthor=D.+A.+Matthewsauthor=E.+Y.+Wuauthor=M.+Guoauthor=B.+C.+Borerauthor=N.+K.+Nayyarauthor=T.+Moranauthor=L.+Chenauthor=P.+A.+Rejtoauthor=P.+W.+Roseauthor=M.+C.+Guzmanauthor=E.+Z.+Dovalsantosauthor=S.+Leeauthor=K.+McGeeauthor=M.+Mohajeriauthor=A.+Lieseauthor=J.+Taoauthor=M.+B.+Kosaauthor=B.+Liuauthor=M.+R.+Batugoauthor=J.+P.+Gleesonauthor=Z.+P.+Wuauthor=J.+Liuauthor=J.+W.+Meadorauthor=R.+A.+Ferre&title=Structure-based+design%2C+synthesis%2C+and+biological+evaluation+of+irreversible+human+rhinovirus+3C+protease+inhibitors.+8.+Pharmacological+optimization+of+orally+bioavailable+2-pyridone-containing+peptidomimetics&doi=10.1021%2Fjm030166l"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 8. Pharmacological optimization of orally bioavailable 2-pyridone-containing peptidomimetics</span></div><div class="casAuthors">Dragovich, Peter S.; Prins, Thomas J.; Zhou, Ru; Johnson, Theodore O.; Hua, Ye; Luu, Hiep T.; Sakata, Sylvie K.; Brown, Edward L.; Maldonado, Fausto C.; Tuntland, Tove; Lee, Caroline A.; Fuhrman, Shella A.; Zalman, Leora S.; Patick, Amy K.; Matthews, David A.; Wu, Ellen Y.; Guo, Ming; Borer, Bennett C.; Nayyar, Naresh K.; Moran, Terence; Chen, Lijian; Rejto, Paul A.; Rose, Peter W.; Guzman, Mark C.; Dovalsantos, Elena Z.; Lee, Steven; McGee, Kevin; Mohajeri, Michael; Liese, Andreas; Tao, Junhua; Kosa, Maha B.; Liu, Bo; Batugo, Minerva R.; Gleeson, Jean-Paul R.; Wu, Zhen Ping; Liu, Jia; Meador, James W., III; Ferre, Rose Ann</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">4572-4585</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The optimization of the pharmacokinetic performance of various 2-pyridone-contg. human rhinovirus (HRV) 3C protease (3CP) inhibitors following oral administration to either beagle dogs or CM-monkeys is described.  The mols. described in this work are composed of a 2-pyridone-contg. peptidomimetic binding determinant and an α,β-unsatd. ester Michael acceptor moiety which forms an irreversible covalent adduct with the active site cysteine residue of the 3C enzyme.  Modification of the ester contained within these compds. is detailed along with alteration of the P2 substituent present in the peptidomimetic portion of the inhibitors.  The pharmacokinetics of several inhibitors in both dogs and monkeys are described (7 h plasma concns. after oral administration) along with their human plasma stabilities, stabilities in incubations with human, dog, and monkey microsomes and hepatocytes, Caco-2 permeabilities, and aq. solubilities.  Compds. contg. an α,β-unsatd. Et ester fragment and either an Et or propargyl P2 moiety displayed the most promising combination of 3C enzyme inhibition (kobs/[I] 170 000-223 000 M-1 s-1), antiviral activity (EC50 = 0.047-0.058 μM, mean vs. seven HRV serotypes), and pharmacokinetics following oral administration (7 h dog plasma levels = 0.248-0.682 μM; 7 h CM-monkey plasma levels = 0.057-0.896 μM).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGom7ef81WRYlrVg90H21EOLACvtfcHk0lgPdjBeuvCoiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXot1Ojs78%253D&md5=c4b964698cce3c97c107076f24692056</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1021%2Fjm030166l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030166l%26sid%3Dliteratum%253Aachs%26aulast%3DDragovich%26aufirst%3DP.%2BS.%26aulast%3DPrins%26aufirst%3DT.%2BJ.%26aulast%3DZhou%26aufirst%3DR.%26aulast%3DJohnson%26aufirst%3DT.%2BO.%26aulast%3DHua%26aufirst%3DY.%26aulast%3DLuu%26aufirst%3DH.%2BT.%26aulast%3DSakata%26aufirst%3DS.%2BK.%26aulast%3DBrown%26aufirst%3DE.%2BL.%26aulast%3DMaldonado%26aufirst%3DF.%2BC.%26aulast%3DTuntland%26aufirst%3DT.%26aulast%3DLee%26aufirst%3DC.%2BA.%26aulast%3DFuhrman%26aufirst%3DS.%2BA.%26aulast%3DZalman%26aufirst%3DL.%2BS.%26aulast%3DPatick%26aufirst%3DA.%2BK.%26aulast%3DMatthews%26aufirst%3DD.%2BA.%26aulast%3DWu%26aufirst%3DE.%2BY.%26aulast%3DGuo%26aufirst%3DM.%26aulast%3DBorer%26aufirst%3DB.%2BC.%26aulast%3DNayyar%26aufirst%3DN.%2BK.%26aulast%3DMoran%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DRejto%26aufirst%3DP.%2BA.%26aulast%3DRose%26aufirst%3DP.%2BW.%26aulast%3DGuzman%26aufirst%3DM.%2BC.%26aulast%3DDovalsantos%26aufirst%3DE.%2BZ.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DMcGee%26aufirst%3DK.%26aulast%3DMohajeri%26aufirst%3DM.%26aulast%3DLiese%26aufirst%3DA.%26aulast%3DTao%26aufirst%3DJ.%26aulast%3DKosa%26aufirst%3DM.%2BB.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DBatugo%26aufirst%3DM.%2BR.%26aulast%3DGleeson%26aufirst%3DJ.%2BP.%26aulast%3DWu%26aufirst%3DZ.%2BP.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DMeador%26aufirst%3DJ.%2BW.%26aulast%3DFerre%26aufirst%3DR.%2BA.%26atitle%3DStructure-based%2520design%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520irreversible%2520human%2520rhinovirus%25203C%2520protease%2520inhibitors.%25208.%2520Pharmacological%2520optimization%2520of%2520orally%2520bioavailable%25202-pyridone-containing%2520peptidomimetics%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D4572%26epage%3D4285%26doi%3D10.1021%2Fjm030166l" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Victor, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campanale, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinz, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shipley, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vance, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spitzer, W. A.</span></span> <span> </span><span class="NLM_article-title">Synthesis, antiviral activity, and biological properties of vinylacetylene analogs of enviroxime</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">1511</span>– <span class="NLM_lpage">1518</span>, <span class="refDoi"> DOI: 10.1021/jm960718i</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm960718i" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADyaK2sXis1ahtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1997&pages=1511-1518&author=F.+Victorauthor=T.+J.+Brownauthor=K.+Campanaleauthor=B.+A.+Heinzauthor=L.+A.+Shipleyauthor=K.+S.+Suauthor=J.+Tangauthor=L.+M.+Vanceauthor=W.+A.+Spitzer&title=Synthesis%2C+antiviral+activity%2C+and+biological+properties+of+vinylacetylene+analogs+of+enviroxime&doi=10.1021%2Fjm960718i"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, Antiviral Activity, and Biological Properties of Vinylacetylene Analogs of Enviroxime</span></div><div class="casAuthors">Victor, Frantz; Brown, Thomas J.; Campanale, Kristina; Heinz, Beverly A.; Shipley, Lisa A.; Su, Kenneth S.; Tang, Joseph; Vance, Lori M.; Spitzer, Wayne A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1511-1518</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of vinylacetylene analogs of Enviroxime was synthesized.  The new compds. are potent inhibitors of poliovirus in tissue culture.  Cross-sensitivity with enviroxime-derived mutants shows that the new compds. have the same mechanism of action as enviroxime, which involves the viral 3A protein.  In studies with Rhesus monkeys, the p-fluoro deriv. was unique in providing oral bioavailability.  Metab. studies using hepatic microsomes suggest that this procedure would be a useful in vitro method for selecting the appropriate animal model for testing oral absorption.  The p-fluoro deriv. was efficacious by oral administration in treating a Coxsackie A21 infection in CD-1 mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpk0XGBilSt-rVg90H21EOLACvtfcHk0lgPdjBeuvCoiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXis1ahtbw%253D&md5=0dec8942b9a94455e1c79fa41acc5b59</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1021%2Fjm960718i&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm960718i%26sid%3Dliteratum%253Aachs%26aulast%3DVictor%26aufirst%3DF.%26aulast%3DBrown%26aufirst%3DT.%2BJ.%26aulast%3DCampanale%26aufirst%3DK.%26aulast%3DHeinz%26aufirst%3DB.%2BA.%26aulast%3DShipley%26aufirst%3DL.%2BA.%26aulast%3DSu%26aufirst%3DK.%2BS.%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DVance%26aufirst%3DL.%2BM.%26aulast%3DSpitzer%26aufirst%3DW.%2BA.%26atitle%3DSynthesis%252C%2520antiviral%2520activity%252C%2520and%2520biological%2520properties%2520of%2520vinylacetylene%2520analogs%2520of%2520enviroxime%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1997%26volume%3D40%26spage%3D1511%26epage%3D1518%26doi%3D10.1021%2Fjm960718i" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, M. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conney, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, B. T.</span></span> <span> </span><span class="NLM_article-title">Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome P450 isoforms</span>. <i>Endocrinology</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>144</i></span>,  <span class="NLM_fpage">3382</span>– <span class="NLM_lpage">3398</span>, <span class="refDoi"> DOI: 10.1210/en.2003-0192</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1210%2Fen.2003-0192" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=12865317" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD3sXlslGjsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=2003&pages=3382-3398&author=A.+J.+Leeauthor=M.+X.+Caiauthor=P.+E.+Thomasauthor=A.+H.+Conneyauthor=B.+T.+Zhu&title=Characterization+of+the+oxidative+metabolites+of+17beta-estradiol+and+estrone+formed+by+15+selectively+expressed+human+cytochrome+P450+isoforms&doi=10.1210%2Fen.2003-0192"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of the oxidative metabolites of 17β-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms</span></div><div class="casAuthors">Lee, Anthony J.; Cai, May Xiaoxin; Thomas, Paul E.; Conney, Allan H.; Zhu, Bao Ting</div><div class="citationInfo"><span class="NLM_cas:title">Endocrinology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">144</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3382-3398</span>CODEN:
                <span class="NLM_cas:coden">ENDOAO</span>;
        ISSN:<span class="NLM_cas:issn">0013-7227</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">We systematically characterized the oxidative metabolites of 17β-estradiol and estrone formed by 15 human cytochrome P 450 (CYP) isoforms.  CYP1A1 had high activity for 17β-estradiol 2-hydroxylation, followed by 15α-, 6α-, 4-, and 7α-hydroxylation.  However, when estrone was the substrate, CYP1A1 formed more 4-hydroxyestrone than 15α- or 6α-hydroxyestrone, with 2-hydroxyestrone as the major metabolite.  CYP1A2 had the highest activity for the 2-hydroxylation of both 17β-estradiol and estrone, although it also had considerable activity for their 4-hydroxylation (9-13% of 2-hydroxylation).  CYP1B1 mainly catalyzed the formation of catechol estrogens, with 4-hydroxyestrogens predominant.  CYP2A6, 2B6, 2C8, 2C9, 2C19, and 2D6 each showed a varying degree of low catalytic activity for estrogen 2-hydroxylation, whereas CYP2C18 and CYP2E1 did not show any detectable estrogen-hydroxylating activity.  CYP3A4 had strong activity for the formation of 2-hydroxyestradiol, followed by 4-hydroxyestradiol and an unknown polar metabolite, and small amts. of 16α- and 16β-hydroxyestrogens were also formed.  The ratio of 4- to 2-hydroxylation of 17β-estradiol or estrone with CYP3A4 was 0.22 or 0.51, resp.  CYP3A5 had similar catalytic activity for the formation of 2- and 4-hydroxyestrogens.  Notably, CYP3A5 had an unusually high ratio of 4- to 2-hydroxylation of 17β-estradiol or estrone (0.53 or 1.26, resp.).  CYP3A4 and 3A5 also catalyzed the formation of nonpolar estrogen metabolite peaks (chromatog. less polar than estrone).  CYP3A7 had a distinct catalytic activity for the 16α-hydroxylation of estrone, but not 17β-estradiol.  CYP4A11 had little catalytic activity for the metab. of 17β-estradiol and estrone.  In conclusion, many human CYP isoforms are involved in the oxidative metab. of 17β-estradiol and estrone, with a varying degree of catalytic activity and distinct regioselectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5q2Y1i5eYsrVg90H21EOLACvtfcHk0lgPdjBeuvCoiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXlslGjsb0%253D&md5=dc77411de262647d6fcf0c28c27d66e7</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1210%2Fen.2003-0192&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fen.2003-0192%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DA.%2BJ.%26aulast%3DCai%26aufirst%3DM.%2BX.%26aulast%3DThomas%26aufirst%3DP.%2BE.%26aulast%3DConney%26aufirst%3DA.%2BH.%26aulast%3DZhu%26aufirst%3DB.%2BT.%26atitle%3DCharacterization%2520of%2520the%2520oxidative%2520metabolites%2520of%252017beta-estradiol%2520and%2520estrone%2520formed%2520by%252015%2520selectively%2520expressed%2520human%2520cytochrome%2520P450%2520isoforms%26jtitle%3DEndocrinology%26date%3D2003%26volume%3D144%26spage%3D3382%26epage%3D3398%26doi%3D10.1210%2Fen.2003-0192" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McKinney, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cawley, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerwick, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunnington, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambrus, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willis, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLeod, M. D.</span></span> <span> </span><span class="NLM_article-title">The metabolism of anabolic-androgenic steroids in the greyhound</span>. <i>Bioanalysis</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">769</span>– <span class="NLM_lpage">781</span>, <span class="refDoi"> DOI: 10.4155/bio.13.40</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.4155%2Fbio.13.40" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=23534422" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC3sXks1Gitrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&pages=769-781&author=A.+R.+McKinneyauthor=A.+T.+Cawleyauthor=E.+B.+Youngauthor=C.+M.+Kerwickauthor=K.+Cunningtonauthor=R.+T.+Stewartauthor=J.+I.+Ambrusauthor=A.+C.+Willisauthor=M.+D.+McLeod&title=The+metabolism+of+anabolic-androgenic+steroids+in+the+greyhound&doi=10.4155%2Fbio.13.40"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">The metabolism of anabolic-androgenic steroids in the greyhound</span></div><div class="casAuthors">McKinney, Andrew R.; Cawley, Adam T.; Young, E. Bruce; Kerwick, Carmel M.; Cunnington, Karen; Stewart, Rhiannon T.; Ambrus, Joseph I.; Willis, Anthony C.; McLeod, Malcolm D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioanalysis</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">769-781</span>CODEN:
                <span class="NLM_cas:coden">BIOAB4</span>;
        ISSN:<span class="NLM_cas:issn">1757-6180</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">Background: Effective control of the use of anabolic-androgenic steroids (AASs) in animal sports is essential in order to ensure both animal welfare and integrity.  In order to better police their use in Australian and New Zealand greyhound racing, thorough metabolic studies have been carried out on a range of registered human and veterinary AASs available in the region.  Results: Canine metabolic data are presented for the AASs boldenone, danazol, ethylestrenol, mesterolone, methandriol, nandrolone and norethandrolone.  The principal Phase I metabolic processes obsd. were the redn. of A-ring unsaturations and/or 3-ketones with either 3α,5β- or 3β,5α-stereochem., the oxidn. of secondary 17β-hydroxyl groups and 16α-hydroxylation.  The Phase II β-glucuronylation of sterol metabolites was extensive.  Conclusion: The presented data have enabled the effective anal. of AASs and their metabolites in competition greyhound urine samples.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrL0M_uDTI-iLVg90H21EOLACvtfcHk0liRWNqVH_zOCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXks1Gitrc%253D&md5=b6d3508a2074b8e928491aeb73910075</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.4155%2Fbio.13.40&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Fbio.13.40%26sid%3Dliteratum%253Aachs%26aulast%3DMcKinney%26aufirst%3DA.%2BR.%26aulast%3DCawley%26aufirst%3DA.%2BT.%26aulast%3DYoung%26aufirst%3DE.%2BB.%26aulast%3DKerwick%26aufirst%3DC.%2BM.%26aulast%3DCunnington%26aufirst%3DK.%26aulast%3DStewart%26aufirst%3DR.%2BT.%26aulast%3DAmbrus%26aufirst%3DJ.%2BI.%26aulast%3DWillis%26aufirst%3DA.%2BC.%26aulast%3DMcLeod%26aufirst%3DM.%2BD.%26atitle%3DThe%2520metabolism%2520of%2520anabolic-androgenic%2520steroids%2520in%2520the%2520greyhound%26jtitle%3DBioanalysis%26date%3D2013%26volume%3D5%26spage%3D769%26epage%3D781%26doi%3D10.4155%2Fbio.13.40" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rochat, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morsman, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, G. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figg, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLeod, H. L.</span></span> <span> </span><span class="NLM_article-title">Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation?</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>296</i></span>,  <span class="NLM_fpage">537</span>– <span class="NLM_lpage">541</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=11160641" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD3MXoslejtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=296&publication_year=2001&pages=537-541&author=B.+Rochatauthor=J.+M.+Morsmanauthor=G.+I.+Murrayauthor=W.+D.+Figgauthor=H.+L.+McLeod&title=Human+CYP1B1+and+anticancer+agent+metabolism%3A+mechanism+for+tumor-specific+drug+inactivation%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation?</span></div><div class="casAuthors">Rochat, Bertrand; Morsman, Janine M.; Murray, Graeme I.; Figg, William D.; Mcleod, Howard L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">296</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">537-541</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The cytochrome P 450 1B1 (CYP1B1) is involved in the metab. of procarcinogens and xenobiotics.  Human CYP1B1 protein has been detected in a variety of tumors but is not detected in adjacent normal tissues or in liver.  This suggests that CYP1B1 could biotransform anticancer agents specifically in the target cells.  The interaction between CYP1B1 and 12 commonly used anticancer drugs was screened using an ethoxyresorufin deethylase assay.  Four agents were competitive inhibitors of CYP1B1 activity: flutamide (Ki = 1.0 μM), paclitaxel (Ki = 31.6 μM), mitoxantrone (Ki = 11.6 μM), and docetaxel (Ki = 28.0 μM).  Doxorubicin (Ki = 2.6 μM) and daunomycin (Ki = 2.1 μM) were mixed inhibitors, while tamoxifen was a noncompetitive inhibitor (Ki = 5.0 μM).  Vinblastine, vincristine, 5-fluorouracil, etoposide, and cyclophosphamide did not inhibit CYP1B1 activity.  In vitro incubations with flutamide and CYP1B1 produced a metabolite consistent with 2-hydroxyflutamide.  Comparison of kinetic parameters (Km, Ki, Vmax) for flutamide 2-hydroxylation by CYP1B1, CYP1A1, and CYP1A2 indicate that CYP1B1 could play a major role for flutamide biotransformation in tumors.  The results obtained indicate that several anticancer agents inhibit CYP1B1 activity.  Drug inactivation by CYP1B1 may represent a novel mechanism of resistance, influencing the clin. outcome of chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbcNluZYN4frVg90H21EOLACvtfcHk0liRWNqVH_zOCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXoslejtQ%253D%253D&md5=868705be020cddfc48ca2577ecf66265</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRochat%26aufirst%3DB.%26aulast%3DMorsman%26aufirst%3DJ.%2BM.%26aulast%3DMurray%26aufirst%3DG.%2BI.%26aulast%3DFigg%26aufirst%3DW.%2BD.%26aulast%3DMcLeod%26aufirst%3DH.%2BL.%26atitle%3DHuman%2520CYP1B1%2520and%2520anticancer%2520agent%2520metabolism%253A%2520mechanism%2520for%2520tumor-specific%2520drug%2520inactivation%253F%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2001%26volume%3D296%26spage%3D537%26epage%3D541" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murray, G. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McFadyen, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKay, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenlee, W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melvin, W. T.</span></span> <span> </span><span class="NLM_article-title">Tumor-specific expression of cytochrome P450 CYP1B1</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">3026</span>– <span class="NLM_lpage">3031</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=9230218" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADyaK2sXkslOkurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=1997&pages=3026-3031&author=G.+I.+Murrayauthor=M.+C.+Taylorauthor=M.+C.+McFadyenauthor=J.+A.+McKayauthor=W.+F.+Greenleeauthor=M.+D.+Burkeauthor=W.+T.+Melvin&title=Tumor-specific+expression+of+cytochrome+P450+CYP1B1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Tumor-specific expression of cytochrome P450 CYP1B1</span></div><div class="casAuthors">Murray, Graeme I.; Taylor, Martin C.; Mcfadyen, Morag C. E.; Mckay, Judith A.; Greenlee, William F.; Burke, M. Danny; Melvin, William T.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">3026-3031</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Cytochrome P 450 CYP1B1 is a recently cloned dioxin-inducible form of the cytochrome P 450 family of xenobiotic metabolizing enzymes.  An antibody raised against a peptide specific for CYP1B1 was found to recognize CYP1B1 expressed in human lymphoblastoid cells but not to recognize other forms of cytochrome P 450, particularly CYP1A1 and CYP1A2.  Using this antibody, the cellular distribution and localization of CYP1B1 were investigated by immunohistochem. in a range of malignant tumors and corresponding normal tissues.  CYP1B1 was found to be expressed at a high frequency in a wide range of human cancers of different histogenetic types, including cancers of the breast, colon, lung, esophagus, skin, lymph node, brain, and testis.  There was no detectable immunostaining for CYP1B1 in normal tissues.  These results provide the basis for the development of novel methods of cancer diagnosis based on the identification of CYP1B1 in tumor cells and the development of anticancer drugs that are selectively activated in tumors by CYP1B1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlIpk-3D25VLVg90H21EOLACvtfcHk0liRWNqVH_zOCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXkslOkurg%253D&md5=bf8fe72b748a4e920d71ad37d91e6a22</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMurray%26aufirst%3DG.%2BI.%26aulast%3DTaylor%26aufirst%3DM.%2BC.%26aulast%3DMcFadyen%26aufirst%3DM.%2BC.%26aulast%3DMcKay%26aufirst%3DJ.%2BA.%26aulast%3DGreenlee%26aufirst%3DW.%2BF.%26aulast%3DBurke%26aufirst%3DM.%2BD.%26aulast%3DMelvin%26aufirst%3DW.%2BT.%26atitle%3DTumor-specific%2520expression%2520of%2520cytochrome%2520P450%2520CYP1B1%26jtitle%3DCancer%2520Res.%26date%3D1997%26volume%3D57%26spage%3D3026%26epage%3D3031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dutour, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes-Benitez, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maltais, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poirier, D.</span></span> <span> </span><span class="NLM_article-title">Targeting cytochrome P450 (CYP) 1B1 enzyme with four series of A-ring substituted estrane derivatives: Design, synthesis, inhibitory activity, and selectivity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">9229</span>– <span class="NLM_lpage">9245</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00907</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00907" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslaitLrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=9229-9245&author=R.+Dutourauthor=J.+Royauthor=F.+Cortes-Benitezauthor=R.+Maltaisauthor=D.+Poirier&title=Targeting+cytochrome+P450+%28CYP%29+1B1+enzyme+with+four+series+of+A-ring+substituted+estrane+derivatives%3A+Design%2C+synthesis%2C+inhibitory+activity%2C+and+selectivity&doi=10.1021%2Facs.jmedchem.8b00907"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Cytochrome P450 (CYP) 1B1 Enzyme with Four Series of A-Ring Substituted Estrane Derivatives: Design, Synthesis, Inhibitory Activity, and Selectivity</span></div><div class="casAuthors">Dutour, Raphael; Roy, Jenny; Cortes-Benitez, Francisco; Maltais, Rene; Poirier, Donald</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">9229-9245</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cytochrome P 450 (CYP) 1B1 is involved in the bioactivation of procarcinogens and drug resistance.  To obtain selective CYP1B1 inhibitors over CYP1A1, we synthesized four series of estrane derivs.: (1) 12 estrone (E1)- and 17β-estradiol (E2)-derivs. bearing a 3- or a 4-pyridinyl core at C2, C3, or C4, (2) eight estrane derivs. with different sulfur groups at C3, (3) 19 E1- and E2-derivs. bearing distinct aryls at C2, and (4) five D-ring derivs.  E2-derivs. were more active than oxidized E1-analogs, thus highlighting the key role of 17β-OH for interaction with CYP1B1.  2-(4-Fluorophenyl)-E2 was the best CYP1B1 inhibitor (IC50 = 0.24 μM), with a selectivity index (SI) of 20 over CYP1A1.  Furthermore, the addn. of a C17α-ethynyl group as D-ring modification improved the selectivity index to 25 with only a slight loss of activity (IC50 = 0.37 μM).  Our docking results showed that these compds. fit better into the CYP1B1 binding site than that of CYP1A1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeOdA_fcjr77Vg90H21EOLACvtfcHk0lgFEJwkbJRLEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslaitLrP&md5=3b962485950d1a34001e34a45aa37c8d</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00907&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00907%26sid%3Dliteratum%253Aachs%26aulast%3DDutour%26aufirst%3DR.%26aulast%3DRoy%26aufirst%3DJ.%26aulast%3DCortes-Benitez%26aufirst%3DF.%26aulast%3DMaltais%26aufirst%3DR.%26aulast%3DPoirier%26aufirst%3DD.%26atitle%3DTargeting%2520cytochrome%2520P450%2520%2528CYP%2529%25201B1%2520enzyme%2520with%2520four%2520series%2520of%2520A-ring%2520substituted%2520estrane%2520derivatives%253A%2520Design%252C%2520synthesis%252C%2520inhibitory%2520activity%252C%2520and%2520selectivity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D9229%26epage%3D9245%26doi%3D10.1021%2Facs.jmedchem.8b00907" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matschinsky, F. M.</span></span> <span> </span><span class="NLM_article-title">GKAs for diabetes therapy: why no clinically useful drug after two decades of trying?</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">90</span>– <span class="NLM_lpage">99</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2012.11.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1016%2Fj.tips.2012.11.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=23305809" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC3sXltVCguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2013&pages=90-99&author=F.+M.+Matschinsky&title=GKAs+for+diabetes+therapy%3A+why+no+clinically+useful+drug+after+two+decades+of+trying%3F&doi=10.1016%2Fj.tips.2012.11.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">GKAs for diabetes therapy: why no clinically useful drug after two decades of trying?</span></div><div class="casAuthors">Matschinsky, Franz M.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">90-99</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Results of basic biochem. and physiol. research, strongly endorsed by findings in human pathophysiol. and genetics, had characterized the glucose phosphorylating enzyme glucokinase as a crit. player in normal glucose homeostasis, diabetes mellitus, and hyperinsulinemic hypoglycemia, and identified the enzyme as a promising new drug target.  R&D initiated in the early 1990s and directed at this target discovered glucokinase activators (GKAs) as a new class of potentially antidiabetic drugs.  GKAs were characterized as nonessential allosteric activators that increase glucose affinity and Vmax of the enzyme, thus stimulating glucose metab. in glucokinase expressing tissue, of foremost functional significance in the insulin producing pancreatic beta cells and the liver.  The results of preclin. testing of GKAs by many pharmaceutical companies demonstrated uniformly high hypoglycemic efficacy in normal and diabetic animals.  GKAs were also highly effective in Phase I trials in patients with type 2 diabetes mellitus (T2DM).  However, results of a recent Phase II trial were less encouraging because patients developed hyperlipidemia and vascular hypertension, and the drug lost efficacy within several months.  This outcome is prompting a reappraisal of the GKA strategy.  In this opinion article, the 'pros and cons' of the strategy to use these compds. in diabetes management are critically reexamd. and suggestions are made that might facilitate progress of GKA R&D that could still result in a novel antidiabetic medicine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5MvSwP_8RcLVg90H21EOLACvtfcHk0lgFEJwkbJRLEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXltVCguw%253D%253D&md5=d118756d0cdb6de4478e18862ba71c20</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2012.11.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2012.11.007%26sid%3Dliteratum%253Aachs%26aulast%3DMatschinsky%26aufirst%3DF.%2BM.%26atitle%3DGKAs%2520for%2520diabetes%2520therapy%253A%2520why%2520no%2520clinically%2520useful%2520drug%2520after%2520two%2520decades%2520of%2520trying%253F%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2013%26volume%3D34%26spage%3D90%26epage%3D99%26doi%3D10.1016%2Fj.tips.2012.11.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">St. Jean, D. J.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashton, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartberger, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chmait, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cupples, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galbreath, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helmering, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, F. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunz, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michelsen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pennington, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poon, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reid, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sivits, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stec, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tadesse, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamayo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fotsch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lloyd, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hale, C.</span></span> <span> </span><span class="NLM_article-title">Small molecule disruptors of the glucokinase-glucokinase regulatory protein interaction: 2. Leveraging structure-based drug design to identify analogues with improved pharmacokinetic profiles</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">325</span>– <span class="NLM_lpage">338</span>, <span class="refDoi"> DOI: 10.1021/jm4016747</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4016747" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkvFKitw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=325-338&author=D.+J.+St.+Jeanauthor=K.+S.+Ashtonauthor=M.+D.+Bartbergerauthor=J.+Chenauthor=S.+Chmaitauthor=R.+Cupplesauthor=E.+Galbreathauthor=J.+Helmeringauthor=F.+T.+Hongauthor=S.+R.+Jordanauthor=L.+Liuauthor=R.+K.+Kunzauthor=K.+Michelsenauthor=N.+Nishimuraauthor=L.+D.+Penningtonauthor=S.+F.+Poonauthor=D.+Reidauthor=G.+Sivitsauthor=M.+M.+Stecauthor=S.+Tadesseauthor=N.+Tamayoauthor=G.+Vanauthor=K.+C.+Yangauthor=J.+Zhangauthor=M.+H.+Normanauthor=C.+Fotschauthor=D.+J.+Lloydauthor=C.+Hale&title=Small+molecule+disruptors+of+the+glucokinase-glucokinase+regulatory+protein+interaction%3A+2.+Leveraging+structure-based+drug+design+to+identify+analogues+with+improved+pharmacokinetic+profiles&doi=10.1021%2Fjm4016747"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Disruptors of the Glucokinase-Glucokinase Regulatory Protein Interaction: 2. Leveraging Structure-Based Drug Design to Identify Analogues with Improved Pharmacokinetic Profiles</span></div><div class="casAuthors">St. Jean, David J., Jr.; Ashton, Kate S.; Bartberger, Michael D.; Chen, Jie; Chmait, Samer; Cupples, Rod; Galbreath, Elizabeth; Helmering, Joan; Hong, Fang-Tsao; Jordan, Steven R.; Liu, Longbin; Kunz, Roxanne K.; Michelsen, Klaus; Nishimura, Nobuko; Pennington, Lewis D.; Poon, Steve F.; Reid, Darren; Sivits, Glenn; Stec, Markian M.; Tadesse, Seifu; Tamayo, Nuria; Van, Gwyneth; Yang, Kevin C.; Zhang, Jiandong; Norman, Mark H.; Fotsch, Christopher; Lloyd, David J.; Hale, Clarence</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">325-338</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In the previous report, we described the discovery and optimization of novel small mol. disruptors of the GK-GKRP interaction culminating in the identification of I (AMG-1694).  Although this analog possessed excellent in vitro potency and was a useful tool compd. in initial proof-of-concept expts., high metabolic turnover limited its advancement.  Guided by a combination of metabolite identification and structure-based design, we have successfully discovered a potent and metabolically stable GK-GKRP disruptor, II (AMG-3969).  When administered to db/db mice, this compd. demonstrated a robust pharmacodynamic response (GK translocation) as well as statistically significant dose-dependent redns. in fed blood glucose levels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPdKFACRrkebVg90H21EOLACvtfcHk0lgFEJwkbJRLEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkvFKitw%253D%253D&md5=aebfcbc169a9fbd443badcff47b2b90f</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1021%2Fjm4016747&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4016747%26sid%3Dliteratum%253Aachs%26aulast%3DSt.%2BJean%26aufirst%3DD.%2BJ.%26aulast%3DAshton%26aufirst%3DK.%2BS.%26aulast%3DBartberger%26aufirst%3DM.%2BD.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DChmait%26aufirst%3DS.%26aulast%3DCupples%26aufirst%3DR.%26aulast%3DGalbreath%26aufirst%3DE.%26aulast%3DHelmering%26aufirst%3DJ.%26aulast%3DHong%26aufirst%3DF.%2BT.%26aulast%3DJordan%26aufirst%3DS.%2BR.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DKunz%26aufirst%3DR.%2BK.%26aulast%3DMichelsen%26aufirst%3DK.%26aulast%3DNishimura%26aufirst%3DN.%26aulast%3DPennington%26aufirst%3DL.%2BD.%26aulast%3DPoon%26aufirst%3DS.%2BF.%26aulast%3DReid%26aufirst%3DD.%26aulast%3DSivits%26aufirst%3DG.%26aulast%3DStec%26aufirst%3DM.%2BM.%26aulast%3DTadesse%26aufirst%3DS.%26aulast%3DTamayo%26aufirst%3DN.%26aulast%3DVan%26aufirst%3DG.%26aulast%3DYang%26aufirst%3DK.%2BC.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DNorman%26aufirst%3DM.%2BH.%26aulast%3DFotsch%26aufirst%3DC.%26aulast%3DLloyd%26aufirst%3DD.%2BJ.%26aulast%3DHale%26aufirst%3DC.%26atitle%3DSmall%2520molecule%2520disruptors%2520of%2520the%2520glucokinase-glucokinase%2520regulatory%2520protein%2520interaction%253A%25202.%2520Leveraging%2520structure-based%2520drug%2520design%2520to%2520identify%2520analogues%2520with%2520improved%2520pharmacokinetic%2520profiles%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D325%26epage%3D338%26doi%3D10.1021%2Fjm4016747" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, K. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhattacharya, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loomis, A. K.</span></span> <span> </span><span class="NLM_article-title">Small molecule ghrelin receptor inverse agonists and antagonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">8671</span>– <span class="NLM_lpage">8691</span>, <span class="refDoi"> DOI: 10.1021/jm5003183</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5003183" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFyiur3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=8671-8691&author=K.+O.+Cameronauthor=S.+K.+Bhattacharyaauthor=A.+K.+Loomis&title=Small+molecule+ghrelin+receptor+inverse+agonists+and+antagonists&doi=10.1021%2Fjm5003183"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Ghrelin Receptor Inverse Agonists and Antagonists</span></div><div class="casAuthors">Cameron, Kimberly O.; Bhattacharya, Samit K.; Loomis, A. Katrina</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">8671-8691</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Ghrelin is an endogenous peptide hormone secreted primarily by the stomach and is involved in a no. of physiol. processes including growth hormone secretion, food intake, as well as energy and glucose homeostasis.  The physiol. actions of ghrelin are mediated through the growth hormone secretagogue receptor 1a (ghrelin receptor), a peptidic G-protein-coupled receptor.  This target has attracted much interest, as agents that block ghrelin's actions on its receptor are anticipated to be pharmaceutical interventions for a no. of diseases.  This review provides an overview of ghrelin biol. with a focus on metabolic diseases and summarizes recent medicinal chem. programs aimed at delivering small mol. ghrelin receptor antagonists and inverse agonists to the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohKCJaGbnZerVg90H21EOLACvtfcHk0lhGj1u8FtcHNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFyiur3P&md5=06ce0cd0c75db752aaa984fd2723aaed</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1021%2Fjm5003183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5003183%26sid%3Dliteratum%253Aachs%26aulast%3DCameron%26aufirst%3DK.%2BO.%26aulast%3DBhattacharya%26aufirst%3DS.%2BK.%26aulast%3DLoomis%26aufirst%3DA.%2BK.%26atitle%3DSmall%2520molecule%2520ghrelin%2520receptor%2520inverse%2520agonists%2520and%2520antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D8671%26epage%3D8691%26doi%3D10.1021%2Fjm5003183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Daina, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giuliano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pietra, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guainazzi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia Rubio, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoete, V.</span></span> <span> </span><span class="NLM_article-title">Rational design, synthesis, and pharmacological characterization of novel Ghrelin receptor inverse agonists as potential treatment against obesity-related metabolic diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">11039</span>– <span class="NLM_lpage">11060</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00794</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00794" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVantLfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=11039-11060&author=A.+Dainaauthor=C.+Giulianoauthor=C.+Pietraauthor=J.+Wangauthor=Y.+Chiauthor=Z.+Zouauthor=F.+Liauthor=Z.+Yanauthor=Y.+Zhouauthor=A.+Guainazziauthor=S.+Garcia+Rubioauthor=V.+Zoete&title=Rational+design%2C+synthesis%2C+and+pharmacological+characterization+of+novel+Ghrelin+receptor+inverse+agonists+as+potential+treatment+against+obesity-related+metabolic+diseases&doi=10.1021%2Facs.jmedchem.8b00794"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Design, Synthesis, and Pharmacological Characterization of Novel Ghrelin Receptor Inverse Agonists as Potential Treatment against Obesity-Related Metabolic Diseases</span></div><div class="casAuthors">Daina, Antoine; Giuliano, Claudio; Pietra, Claudio; Wang, Junbo; Chi, Yushi; Zou, Zack; Li, Fugang; Yan, Zhonghua; Zhou, Yifan; Guainazzi, Angelo; Garcia Rubio, Silvina; Zoete, Vincent</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">11039-11060</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new chemotype of ghrelin inverse agonists was discovered through chimeric design based on mol. scaffolds known as growth-hormone secretagogue receptor (GHSR) modulators but with divergent pharmacodynamic and pharmacokinetic properties.  The structure-activities/properties exploration led to compd. I, which displayed potent human GHSR antagonism and inverse agonism in cellular assays (IC50 = 68 nM, EC50 = 29 nM), moderate oral bioavailability, and notable brain penetration in rat (F = 27%, B/P ratio = 1.9).  First in vivo studies demonstrated effective redn. of food intake after oral or parenteral administration to mouse (78% at 1 h and 38% at 8 h, resp.).  Further preclin. studies are needed to evaluate the most suited mode of administration with the aim of promoting a first central-acting ghrelin inverse agonist mol. to development, which would represent a significant step toward therapeutic agents to treat metabolic disorders related to obesity, such as type 2 diabetes mellitus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQ1xJll3Qu0LVg90H21EOLACvtfcHk0lhGj1u8FtcHNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVantLfI&md5=83f3dd140db3f999eeed0158a5dcc9f6</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00794&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00794%26sid%3Dliteratum%253Aachs%26aulast%3DDaina%26aufirst%3DA.%26aulast%3DGiuliano%26aufirst%3DC.%26aulast%3DPietra%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DChi%26aufirst%3DY.%26aulast%3DZou%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DYan%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DGuainazzi%26aufirst%3DA.%26aulast%3DGarcia%2BRubio%26aufirst%3DS.%26aulast%3DZoete%26aufirst%3DV.%26atitle%3DRational%2520design%252C%2520synthesis%252C%2520and%2520pharmacological%2520characterization%2520of%2520novel%2520Ghrelin%2520receptor%2520inverse%2520agonists%2520as%2520potential%2520treatment%2520against%2520obesity-related%2520metabolic%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D11039%26epage%3D11060%26doi%3D10.1021%2Facs.jmedchem.8b00794" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Madar, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopecka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pireh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiedeman, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Djuric, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Von Geldern, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fickes, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhagavatula, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittenberger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richards, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longenecker, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubben, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballaron, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stashko, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zinker, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mika, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beno, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kempf-Grote, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polakowski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segreti, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinhart, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fryer, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sham, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trevillyan, J. M.</span></span> <span> </span><span class="NLM_article-title">Discovery of 2-[4-{{2-(2<i>S</i>,5<i>R</i>)-2-cyano-5-ethynyl-1-pyrrolidinyl]-2-oxoethyl]amino]- 4-methyl-1-piperidinyl]-4-pyridinecarboxylic acid (ABT-279): A very potent, selective, effective, and well-tolerated inhibitor of dipeptidyl peptidase-IV, useful for the treatment of diabetes</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">6416</span>– <span class="NLM_lpage">6420</span>, <span class="refDoi"> DOI: 10.1021/jm060777o</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060777o" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD28XpvVGmurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=6416-6420&author=D.+J.+Madarauthor=H.+Kopeckaauthor=D.+Pirehauthor=H.+Yongauthor=Z.+Peiauthor=X.+Liauthor=P.+E.+Wiedemanauthor=S.+W.+Djuricauthor=T.+W.+Von+Geldernauthor=M.+G.+Fickesauthor=L.+Bhagavatulaauthor=T.+McDermottauthor=S.+Wittenbergerauthor=S.+J.+Richardsauthor=K.+L.+Longeneckerauthor=K.+D.+Stewartauthor=T.+H.+Lubbenauthor=S.+J.+Ballaronauthor=M.+A.+Stashkoauthor=M.+A.+Longauthor=H.+Wellsauthor=B.+A.+Zinkerauthor=A.+K.+Mikaauthor=D.+W.+Benoauthor=A.+J.+Kempf-Groteauthor=J.+Polakowskiauthor=J.+Segretiauthor=G.+A.+Reinhartauthor=R.+M.+Fryerauthor=H.+L.+Shamauthor=J.+M.+Trevillyan&title=Discovery+of+2-%5B4-%7B%7B2-%282S%2C5R%29-2-cyano-5-ethynyl-1-pyrrolidinyl%5D-2-oxoethyl%5Damino%5D-+4-methyl-1-piperidinyl%5D-4-pyridinecarboxylic+acid+%28ABT-279%29%3A+A+very+potent%2C+selective%2C+effective%2C+and+well-tolerated+inhibitor+of+dipeptidyl+peptidase-IV%2C+useful+for+the+treatment+of+diabetes&doi=10.1021%2Fjm060777o"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 2-[4-{{2-(2S,5R)-2-Cyano-5-ethynyl-1-pyrrolidinyl]-2-oxoethyl]amino]- 4-methyl-1-piperidinyl]-4-pyridinecarboxylic Acid (ABT-279): A Very Potent, Selective, Effective, and Well-Tolerated Inhibitor of Dipeptidyl Peptidase-IV, Useful for the Treatment of Diabetes</span></div><div class="casAuthors">Madar, David J.; Kopecka, Hana; Pireh, Daisy; Yong, Hong; Pei, Zhonghua; Li, Xiaofeng; Wiedeman, Paul E.; Djuric, Stevan W.; Von Geldern, Thomas W.; Fickes, Michael G.; Bhagavatula, Lakshmi; McDermott, Todd; Wittenberger, Steven; Richards, Steven J.; Longenecker, Kenton L.; Stewart, Kent D.; Lubben, Thomas H.; Ballaron, Stephen J.; Stashko, Michael A.; Long, Michelle A.; Wells, Heidi; Zinker, Bradley A.; Mika, Amanda K.; Beno, David W. A.; Kempf-Grote, Anita J.; Polakowski, James; Segreti, Jason; Reinhart, Glenn A.; Fryer, Ryan M.; Sham, Hing L.; Trevillyan, James M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6416-6420</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dipeptidyl peptidase-IV (DPP-IV) inhibitors are poised to be the next major drug class for the treatment of type 2 diabetes.  Structure-activity studies of substitutions at the C5 position of the 2-cyanopyrrolidide warhead led to the discovery of potent inhibitors of DPP-IV that lack activity against DPP8 and DPP9.  Further modification led to an extremely potent (KiDPP-IV = 1.0 nM) and selective (KiDPP8 > 30 μM; KiDPP9 > 30 μM) clin. candidate, ABT-279 (I), that is orally available, efficacious, and remarkably safe in preclin. safety studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqpkr5QItgArVg90H21EOLACvtfcHk0lhGj1u8FtcHNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XpvVGmurc%253D&md5=e4b070b39f0be7367cb8949b8e85c40b</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1021%2Fjm060777o&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060777o%26sid%3Dliteratum%253Aachs%26aulast%3DMadar%26aufirst%3DD.%2BJ.%26aulast%3DKopecka%26aufirst%3DH.%26aulast%3DPireh%26aufirst%3DD.%26aulast%3DYong%26aufirst%3DH.%26aulast%3DPei%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DWiedeman%26aufirst%3DP.%2BE.%26aulast%3DDjuric%26aufirst%3DS.%2BW.%26aulast%3DVon%2BGeldern%26aufirst%3DT.%2BW.%26aulast%3DFickes%26aufirst%3DM.%2BG.%26aulast%3DBhagavatula%26aufirst%3DL.%26aulast%3DMcDermott%26aufirst%3DT.%26aulast%3DWittenberger%26aufirst%3DS.%26aulast%3DRichards%26aufirst%3DS.%2BJ.%26aulast%3DLongenecker%26aufirst%3DK.%2BL.%26aulast%3DStewart%26aufirst%3DK.%2BD.%26aulast%3DLubben%26aufirst%3DT.%2BH.%26aulast%3DBallaron%26aufirst%3DS.%2BJ.%26aulast%3DStashko%26aufirst%3DM.%2BA.%26aulast%3DLong%26aufirst%3DM.%2BA.%26aulast%3DWells%26aufirst%3DH.%26aulast%3DZinker%26aufirst%3DB.%2BA.%26aulast%3DMika%26aufirst%3DA.%2BK.%26aulast%3DBeno%26aufirst%3DD.%2BW.%26aulast%3DKempf-Grote%26aufirst%3DA.%2BJ.%26aulast%3DPolakowski%26aufirst%3DJ.%26aulast%3DSegreti%26aufirst%3DJ.%26aulast%3DReinhart%26aufirst%3DG.%2BA.%26aulast%3DFryer%26aufirst%3DR.%2BM.%26aulast%3DSham%26aufirst%3DH.%2BL.%26aulast%3DTrevillyan%26aufirst%3DJ.%2BM.%26atitle%3DDiscovery%2520of%25202-%255B4-%257B%257B2-%25282S%252C5R%2529-2-cyano-5-ethynyl-1-pyrrolidinyl%255D-2-oxoethyl%255Damino%255D-%25204-methyl-1-piperidinyl%255D-4-pyridinecarboxylic%2520acid%2520%2528ABT-279%2529%253A%2520A%2520very%2520potent%252C%2520selective%252C%2520effective%252C%2520and%2520well-tolerated%2520inhibitor%2520of%2520dipeptidyl%2520peptidase-IV%252C%2520useful%2520for%2520the%2520treatment%2520of%2520diabetes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D6416%26epage%3D6420%26doi%3D10.1021%2Fjm060777o" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haick, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byron, K. L.</span></span> <span> </span><span class="NLM_article-title">Novel treatment strategies for smooth muscle disorders: Targeting Kv7 potassium channels</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>165</i></span>,  <span class="NLM_fpage">14</span>– <span class="NLM_lpage">25</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2016.05.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1016%2Fj.pharmthera.2016.05.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=27179745" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC28XnvFOisLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=165&publication_year=2016&pages=14-25&author=J.+M.+Haickauthor=K.+L.+Byron&title=Novel+treatment+strategies+for+smooth+muscle+disorders%3A+Targeting+Kv7+potassium+channels&doi=10.1016%2Fj.pharmthera.2016.05.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Novel treatment strategies for smooth muscle disorders: Targeting Kv7 potassium channels</span></div><div class="casAuthors">Haick, Jennifer M.; Byron, Kenneth L.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">165</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">14-25</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Smooth muscle cells provide crucial contractile functions in visceral, vascular, and lung tissues.  The contractile state of smooth muscle is largely detd. by their elec. excitability, which is in turn influenced by the activity of potassium channels.  The activity of potassium channels sustains smooth muscle cell membrane hyperpolarization, reducing cellular excitability and thereby promoting smooth muscle relaxation.  Research over the past decade has indicated an important role for Kv7 (KCNQ) voltage-gated potassium channels in the regulation of the excitability of smooth muscle cells.  Expression of multiple Kv7 channel subtypes has been demonstrated in smooth muscle cells from viscera (gastrointestinal, bladder, myometrial), from the systemic and pulmonary vasculature, and from the airways of the lung, from multiple species, including humans.  A no. of clin. used drugs, some of which were developed to target Kv7 channels in other tissues, have been found to exert robust effects on smooth muscle Kv7 channels.  Functional studies have indicated that Kv7 channel activators and inhibitors have the ability to relax and contact smooth muscle prepns., resp., suggesting a wide range of novel applications for the pharmacol. tool set.  This review summarizes recent findings regarding the physiol. functions of Kv7 channels in smooth muscle, and highlights potential therapeutic applications based on pharmacol. targeting of smooth muscle Kv7 channels throughout the body.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxEjwlNnlcTbVg90H21EOLACvtfcHk0libAgHqsehsAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnvFOisLw%253D&md5=d85c0b5cd6f22a65fb9c10a41fef579e</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2016.05.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2016.05.002%26sid%3Dliteratum%253Aachs%26aulast%3DHaick%26aufirst%3DJ.%2BM.%26aulast%3DByron%26aufirst%3DK.%2BL.%26atitle%3DNovel%2520treatment%2520strategies%2520for%2520smooth%2520muscle%2520disorders%253A%2520Targeting%2520Kv7%2520potassium%2520channels%26jtitle%3DPharmacol.%2520Ther.%26date%3D2016%26volume%3D165%26spage%3D14%26epage%3D25%26doi%3D10.1016%2Fj.pharmthera.2016.05.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiao, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, H. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Z. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nan, F. J.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel retigabine derivatives as potent KCNQ4 and KCNQ5 channel agonists with improved specificity</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">27</span>– <span class="NLM_lpage">33</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.8b00315</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.8b00315" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFKiurvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=27-33&author=L.+Wangauthor=G.+H.+Qiaoauthor=H.+N.+Huauthor=Z.+B.+Gaoauthor=F.+J.+Nan&title=Discovery+of+novel+retigabine+derivatives+as+potent+KCNQ4+and+KCNQ5+channel+agonists+with+improved+specificity&doi=10.1021%2Facsmedchemlett.8b00315"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel Retigabine Derivatives as Potent KCNQ4 and KCNQ5 Channel Agonists with Improved Specificity</span></div><div class="casAuthors">Wang, Lei; Qiao, Guan-Hua; Hu, Hai-Ning; Gao, Zhao-Bing; Nan, Fa-Jun</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-33</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Recent research suggests that KCNQ isoforms, particularly the KCNQ4 and KCNQ5 subtypes expressed in smooth muscle cells, are involved in both establishing and maintaining resting membrane potentials and regulating smooth muscle contractility.  Retigabine (RTG) is a first-in-class antiepileptic drug that potentiates neuronal KCNQ potassium channels, but poor subtype selectivity limits its further application as a pharmacol. tool.  In this study, we improved the subtype specificity of retigabine by altering the N-1/3 substituents and discovered several compds. that show better selectivity for KCNQ4 and KCNQ5 channels.  Among these compds., 10g is highly selective for KCNQ4 and KCNQ5 channels without potentiating KCNQ1 and KCNQ2 channels.  These results are an advance in the exploration of small mol. modifiers that selectively activate different KCNQ isoforms.  The developed compds. could also serve as new pharmacol. tools for elucidating the function of KCNQ channels natively expressed in various tissues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrv-ER_THotFbVg90H21EOLACvtfcHk0libAgHqsehsAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFKiurvJ&md5=ae805b9756783970a0e721a3c232c1fd</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.8b00315&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.8b00315%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DL.%26aulast%3DQiao%26aufirst%3DG.%2BH.%26aulast%3DHu%26aufirst%3DH.%2BN.%26aulast%3DGao%26aufirst%3DZ.%2BB.%26aulast%3DNan%26aufirst%3DF.%2BJ.%26atitle%3DDiscovery%2520of%2520novel%2520retigabine%2520derivatives%2520as%2520potent%2520KCNQ4%2520and%2520KCNQ5%2520channel%2520agonists%2520with%2520improved%2520specificity%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26spage%3D27%26epage%3D33%26doi%3D10.1021%2Facsmedchemlett.8b00315" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tsujimoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hattori, A.</span></span> <span> </span><span class="NLM_article-title">The oxytocinase subfamily of M1 aminopeptidases</span>. <i>Biochim. Biophys. Acta, Proteins Proteomics</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>1751</i></span>,  <span class="NLM_fpage">9</span>– <span class="NLM_lpage">18</span>, <span class="refDoi"> DOI: 10.1016/j.bbapap.2004.09.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1016%2Fj.bbapap.2004.09.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=16054015" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmvVWlsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1751&publication_year=2005&pages=9-18&author=M.+Tsujimotoauthor=A.+Hattori&title=The+oxytocinase+subfamily+of+M1+aminopeptidases&doi=10.1016%2Fj.bbapap.2004.09.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">The oxytocinase subfamily of M1 aminopeptidases</span></div><div class="casAuthors">Tsujimoto, Masafumi; Hattori, Akira</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Proteins and Proteomics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">1751</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">9-18</span>CODEN:
                <span class="NLM_cas:coden">BBAPBW</span>;
        ISSN:<span class="NLM_cas:issn">1570-9639</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Placental leucine aminopeptidase (P-LAP), adipocyte-derived leucine aminopeptidase (A-LAP) and leukocyte-derived aminopeptidase (L-RAP) belong to one distinct group of the M1 family of aminopeptidases, which has been termed the "oxytocinase subfamily".  They share HEXXH(X)18E Zn-binding and GAMEN motifs essential for the enzymic activities.  Intracellular localization is the characteristic feature of the subfamily members.  While P-LAP is translocated from intracellular vesicles to plasma membrane in a stimulus-dependent manner, both A-LAP and L-RAP are retained in the endoplasmic reticulum.  They contain sequences necessary for the specific localization in the cell.  It has become evident that the subfamily members play important roles in the maintenance of homeostasis including maintenance of normal pregnancy, memory retention, blood pressure regulation, and antigen presentation.  Here, the current situation of this newly identified subfamily is summarized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrghl94CnfL-LVg90H21EOLACvtfcHk0libAgHqsehsAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmvVWlsro%253D&md5=26ccab0ed3f952b827d8ab956100e121</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1016%2Fj.bbapap.2004.09.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbapap.2004.09.011%26sid%3Dliteratum%253Aachs%26aulast%3DTsujimoto%26aufirst%3DM.%26aulast%3DHattori%26aufirst%3DA.%26atitle%3DThe%2520oxytocinase%2520subfamily%2520of%2520M1%2520aminopeptidases%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Proteins%2520Proteomics%26date%3D2005%26volume%3D1751%26spage%3D9%26epage%3D18%26doi%3D10.1016%2Fj.bbapap.2004.09.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weimershaus, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evnouchidou, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saveanu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Endert, P.</span></span> <span> </span><span class="NLM_article-title">Peptidases trimming MHC class I ligands</span>. <i>Curr. Opin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">90</span>– <span class="NLM_lpage">96</span>, <span class="refDoi"> DOI: 10.1016/j.coi.2012.10.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1016%2Fj.coi.2012.10.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=23089230" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFCksLzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2013&pages=90-96&author=M.+Weimershausauthor=I.+Evnouchidouauthor=L.+Saveanuauthor=P.+van+Endert&title=Peptidases+trimming+MHC+class+I+ligands&doi=10.1016%2Fj.coi.2012.10.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Peptidases trimming MHC class I ligands</span></div><div class="casAuthors">Weimershaus, Mirjana; Evnouchidou, Irini; Saveanu, Loredana; van Endert, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Immunology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">90-96</span>CODEN:
                <span class="NLM_cas:coden">COPIEL</span>;
        ISSN:<span class="NLM_cas:issn">0952-7915</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Peptides presented by MHC class I mols. are typically produced through antigen degrdn. by the proteasome followed by trimming by exopeptidases.  According to recent results, these include both aminopeptidases and carboxypeptidases in the cytosol and the endoplasmic reticulum.  While cytosolic peptidases have a net neutral or destructive effect on MHC ligands, endoplasmic reticulum aminopeptidases are required for efficient class I loading and have a strong effect on the repertoire of peptide/MHC complexes.  Cells lacking these enzymes can be eliminated both by NK cells and by CD8+ T cells recognizing complexes formed between an MHC class Ib mol. and a conserved peptide.  Cross-presented peptides derived from internalized antigens can be processed by insulin-regulated aminopeptidase, the only endosomal trimming peptidase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTTuHIi5zkQrVg90H21EOLACvtfcHk0lhZ-fZhgqN_dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFCksLzL&md5=dbed24e460af7509ad6a8c9ac453de5b</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1016%2Fj.coi.2012.10.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coi.2012.10.001%26sid%3Dliteratum%253Aachs%26aulast%3DWeimershaus%26aufirst%3DM.%26aulast%3DEvnouchidou%26aufirst%3DI.%26aulast%3DSaveanu%26aufirst%3DL.%26aulast%3Dvan%2BEndert%26aufirst%3DP.%26atitle%3DPeptidases%2520trimming%2520MHC%2520class%2520I%2520ligands%26jtitle%3DCurr.%2520Opin.%2520Immunol.%26date%3D2013%26volume%3D25%26spage%3D90%26epage%3D96%26doi%3D10.1016%2Fj.coi.2012.10.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saveanu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weimershaus, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guermonprez, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Firat, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davoust, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kratzer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niedermann, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Endert, P.</span></span> <span> </span><span class="NLM_article-title">IRAP identifies an endosomal compartment required for MHC class I cross-presentation</span>. <i>Science (Washington, DC, U. S.)</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>325</i></span>,  <span class="NLM_fpage">213</span>– <span class="NLM_lpage">217</span>, <span class="refDoi"> DOI: 10.1126/science.1172845</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1126%2Fscience.1172845" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=19498108" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD1MXos1Srtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=325&publication_year=2009&pages=213-217&author=L.+Saveanuauthor=O.+Carrollauthor=M.+Weimershausauthor=P.+Guermonprezauthor=E.+Firatauthor=V.+Lindoauthor=F.+Greerauthor=J.+Davoustauthor=R.+Kratzerauthor=S.+R.+Kellerauthor=G.+Niedermannauthor=P.+van+Endert&title=IRAP+identifies+an+endosomal+compartment+required+for+MHC+class+I+cross-presentation&doi=10.1126%2Fscience.1172845"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">IRAP Identifies an Endosomal Compartment Required for MHC Class I Cross-Presentation</span></div><div class="casAuthors">Saveanu, Loredana; Carroll, Oliver; Weimershaus, Mirjana; Guermonprez, Pierre; Firat, Elke; Lindo, Vivian; Greer, Fiona; Davoust, Jean; Kratzer, Roland; Keller, Susanna R.; Niedermann, Gabriele; van Endert, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">325</span>
        (<span class="NLM_cas:issue">5937</span>),
    <span class="NLM_cas:pages">213-217</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Major histocompatibility complex (MHC) class I mols. present peptides, produced through cytosolic proteasomal degrdn. of cellular proteins, to cytotoxic T lymphocytes.  In dendritic cells, the peptides can also be derived from internalized antigens through a process known as cross-presentation.  The cellular compartments involved in cross-presentation remain poorly defined.  The authors found a role for peptide trimming by insulin-regulated aminopeptidase (IRAP) in cross-presentation.  In human dendritic cells, IRAP was localized to a Rab14+ endosomal storage compartment in which it interacted with MHC class I mols.  IRAP deficiency compromised cross-presentation in vitro and in vivo but did not affect endogenous presentation.  The authors propose the existence of two pathways for proteasome-dependent cross-presentation in which final peptide trimming involves IRAP in endosomes and involves the related aminopeptidases in the endoplasmic reticulum.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGot6ZHOya1cBrVg90H21EOLACvtfcHk0lhZ-fZhgqN_dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXos1Srtbo%253D&md5=563afe447cf31123b55c9da2d5c8b12f</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1126%2Fscience.1172845&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1172845%26sid%3Dliteratum%253Aachs%26aulast%3DSaveanu%26aufirst%3DL.%26aulast%3DCarroll%26aufirst%3DO.%26aulast%3DWeimershaus%26aufirst%3DM.%26aulast%3DGuermonprez%26aufirst%3DP.%26aulast%3DFirat%26aufirst%3DE.%26aulast%3DLindo%26aufirst%3DV.%26aulast%3DGreer%26aufirst%3DF.%26aulast%3DDavoust%26aufirst%3DJ.%26aulast%3DKratzer%26aufirst%3DR.%26aulast%3DKeller%26aufirst%3DS.%2BR.%26aulast%3DNiedermann%26aufirst%3DG.%26aulast%3Dvan%2BEndert%26aufirst%3DP.%26atitle%3DIRAP%2520identifies%2520an%2520endosomal%2520compartment%2520required%2520for%2520MHC%2520class%2520I%2520cross-presentation%26jtitle%3DScience%2520%2528Washington%252C%2520DC%252C%2520U.%2520S.%2529%26date%3D2009%26volume%3D325%26spage%3D213%26epage%3D217%26doi%3D10.1126%2Fscience.1172845" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stratikos, E.</span></span> <span> </span><span class="NLM_article-title">Regulating adaptive immune responses using small molecule modulators of aminopeptidases that process antigenic peptides</span>. <i>Curr. Opin. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">7</span>, <span class="refDoi"> DOI: 10.1016/j.cbpa.2014.08.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1016%2Fj.cbpa.2014.08.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=25173825" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVOmtr%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2014&pages=1-7&author=E.+Stratikos&title=Regulating+adaptive+immune+responses+using+small+molecule+modulators+of+aminopeptidases+that+process+antigenic+peptides&doi=10.1016%2Fj.cbpa.2014.08.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Regulating adaptive immune responses using small molecule modulators of aminopeptidases that process antigenic peptides</span></div><div class="casAuthors">Stratikos, Efstratios</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-7</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Antigenic peptide processing by intracellular aminopeptidases has emerged recently as an important pathway that regulates adaptive immune responses.  Pathogens and cancer can manipulate the activity of key enzymes of this pathway to promote immune evasion.  Furthermore, the activity of these enzymes is naturally variable due to polymorphic variation, contributing to predisposition to disease, most notably autoimmunity.  Here, we review recent findings that suggest that the pharmacol. regulation of the activity of these aminopeptidases constitutes a valid approach for regulating human immune responses.  We furthermore review the state of the art in chem. tools for inhibiting these enzymes and how these tools can be useful for the development of innovative therapeutic approaches for a variety of diseases including cancer, viral infections and autoimmunity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmdJYdWyF8GLVg90H21EOLACvtfcHk0lhZ-fZhgqN_dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVOmtr%252FM&md5=7b375d25108c1620a29380cc2b6c41f2</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2014.08.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2014.08.007%26sid%3Dliteratum%253Aachs%26aulast%3DStratikos%26aufirst%3DE.%26atitle%3DRegulating%2520adaptive%2520immune%2520responses%2520using%2520small%2520molecule%2520modulators%2520of%2520aminopeptidases%2520that%2520process%2520antigenic%2520peptides%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2014%26volume%3D23%26spage%3D1%26epage%3D7%26doi%3D10.1016%2Fj.cbpa.2014.08.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kokkala, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mpakali, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mauvais, F. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papakyriakou, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daskalaki, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petropoulou, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kavvalou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papathanasopoulou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agrotis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fonsou, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Endert, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stratikos, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Georgiadis, D.</span></span> <span> </span><span class="NLM_article-title">Optimization and structure-activity relationships of phosphinic pseudotripeptide inhibitors of aminopeptidases that generate antigenic peptides</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">9107</span>– <span class="NLM_lpage">9123</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01031</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01031" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVyqtbzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=9107-9123&author=P.+Kokkalaauthor=A.+Mpakaliauthor=F.+X.+Mauvaisauthor=A.+Papakyriakouauthor=I.+Daskalakiauthor=I.+Petropoulouauthor=S.+Kavvalouauthor=M.+Papathanasopoulouauthor=S.+Agrotisauthor=T.+M.+Fonsouauthor=P.+van+Endertauthor=E.+Stratikosauthor=D.+Georgiadis&title=Optimization+and+structure-activity+relationships+of+phosphinic+pseudotripeptide+inhibitors+of+aminopeptidases+that+generate+antigenic+peptides&doi=10.1021%2Facs.jmedchem.6b01031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization and Structure-Activity Relationships of Phosphinic Pseudotripeptide Inhibitors of Aminopeptidases That Generate Antigenic Peptides</span></div><div class="casAuthors">Kokkala, Paraskevi; Mpakali, Anastasia; Mauvais, Francois-Xavier; Papakyriakou, Athanasios; Daskalaki, Ira; Petropoulou, Ioanna; Kavvalou, Sofia; Papathanasopoulou, Mirto; Agrotis, Stefanos; Fonsou, Theodora-Markisia; van Endert, Peter; Stratikos, Efstratios; Georgiadis, Dimitris</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">9107-9123</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The oxytocinase subfamily of M1 aminopeptidases, consisting of ER aminopeptidase 1 (ERAP1), ER aminopeptidase 2 (ERAP2) and insulin-regulated aminopeptidase (IRAP), plays crit. roles in the generation of antigenic peptides and indirectly regulates human adaptive immune responses.  The authors have previously demonstrated that phosphinic pseudotripeptides can constitute potent inhibitors of this group of enzymes.  In this study, the authors used synthetic methodologies able to furnish a series of stereochem. defined phosphinic pseudotripeptides and demonstrate that side-chains at P1 and P2 positions are crit. determinants in driving potency and selectivity.  The authors identified low nanomolar inhibitors of ERAP2 and IRAP that display selectivity of more than 2 and 3 orders of magnitude, resp.  Cellular anal. demonstrated that one of the compds. that is a selective IRAP inhibitor can reduce IRAP-dependent but not ERAP1-dependent cross-presentation by dendritic cells with nanomolar efficacy.  The results encourage further preclin. development of phosphinic pseudotripeptides as regulators of adaptive immune responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0t6PN8VuuXrVg90H21EOLACvtfcHk0ljhN3Le8xB3DA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVyqtbzF&md5=6353903037762758d64a48c5b1529f20</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01031%26sid%3Dliteratum%253Aachs%26aulast%3DKokkala%26aufirst%3DP.%26aulast%3DMpakali%26aufirst%3DA.%26aulast%3DMauvais%26aufirst%3DF.%2BX.%26aulast%3DPapakyriakou%26aufirst%3DA.%26aulast%3DDaskalaki%26aufirst%3DI.%26aulast%3DPetropoulou%26aufirst%3DI.%26aulast%3DKavvalou%26aufirst%3DS.%26aulast%3DPapathanasopoulou%26aufirst%3DM.%26aulast%3DAgrotis%26aufirst%3DS.%26aulast%3DFonsou%26aufirst%3DT.%2BM.%26aulast%3Dvan%2BEndert%26aufirst%3DP.%26aulast%3DStratikos%26aufirst%3DE.%26aulast%3DGeorgiadis%26aufirst%3DD.%26atitle%3DOptimization%2520and%2520structure-activity%2520relationships%2520of%2520phosphinic%2520pseudotripeptide%2520inhibitors%2520of%2520aminopeptidases%2520that%2520generate%2520antigenic%2520peptides%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D9107%26epage%3D9123%26doi%3D10.1021%2Facs.jmedchem.6b01031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Giastas, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowland, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stratikos, E.</span></span> <span> </span><span class="NLM_article-title">High-resolution crystal structure of endoplasmic reticulum aminopeptidase 1 with bound phosphinic transition-state analogue inhibitor</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">708</span>– <span class="NLM_lpage">713</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00002</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00002" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjtVGmsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=708-713&author=P.+Giastasauthor=M.+Neuauthor=P.+Rowlandauthor=E.+Stratikos&title=High-resolution+crystal+structure+of+endoplasmic+reticulum+aminopeptidase+1+with+bound+phosphinic+transition-state+analogue+inhibitor&doi=10.1021%2Facsmedchemlett.9b00002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">High-resolution crystal structure of endoplasmic reticulum aminopeptidase 1 with bound phosphinic transition-state analogue inhibitor</span></div><div class="casAuthors">Giastas, Petros; Neu, Margarete; Rowland, Paul; Stratikos, Efstratios</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">708-713</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Endoplasmic reticulum aminopeptidase 1 (ERAP1) is an intracellular enzyme that helps generate peptides presented by Major Histocompatibility Complex Class I (MHC class I) mols. and is an emerging target for immunotherapy applications.  Despite almost two decades of research on ERAP1, lack of high-resoln. crystal structures has hampered drug-development efforts.  By optimizing the protein construct, we obtained a high-resoln. (1.60 Å) crystal structure of the closed-conformation of ERAP1 with a potent phosphinic pseudopeptide inhibitor bound in its active site.  The structure provides key insight on the mechanism of inhibition as well as selectivity toward homologous enzymes and allows detailed mapping of the internal cavity of the enzyme that accommodates peptide-substrates.  Bis-tris propane and malic acid mols., found bound in pockets in the internal cavity, reveal potential druggable secondary binding sites.  The ability to obtain high-resoln. crystal structures of ERAP1 removes a major bottleneck in the development of compds. that regulate its activity and will greatly accelerate drug-discovery efforts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTY0rTge63ZLVg90H21EOLACvtfcHk0ljhN3Le8xB3DA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjtVGmsLo%253D&md5=b6e4b207eb7723944f709389e9ff4bed</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00002%26sid%3Dliteratum%253Aachs%26aulast%3DGiastas%26aufirst%3DP.%26aulast%3DNeu%26aufirst%3DM.%26aulast%3DRowland%26aufirst%3DP.%26aulast%3DStratikos%26aufirst%3DE.%26atitle%3DHigh-resolution%2520crystal%2520structure%2520of%2520endoplasmic%2520reticulum%2520aminopeptidase%25201%2520with%2520bound%2520phosphinic%2520transition-state%2520analogue%2520inhibitor%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26spage%3D708%26epage%3D713%26doi%3D10.1021%2Facsmedchemlett.9b00002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kurzrock, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Druker, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talpaz, M.</span></span> <span> </span><span class="NLM_article-title">Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics</span>. <i>Ann. Intern. Med.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>138</i></span>,  <span class="NLM_fpage">819</span>– <span class="NLM_lpage">830</span>, <span class="refDoi"> DOI: 10.7326/0003-4819-138-10-200305200-00010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.7326%2F0003-4819-138-10-200305200-00010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=12755554" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD3sXktl2ht70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=2003&pages=819-830&author=R.+Kurzrockauthor=H.+M.+Kantarjianauthor=B.+J.+Drukerauthor=M.+Talpaz&title=Philadelphia+chromosome-positive+leukemias%3A+from+basic+mechanisms+to+molecular+therapeutics&doi=10.7326%2F0003-4819-138-10-200305200-00010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Philadelphia chromosome-positive leukemias: From basic mechanisms to molecular therapeutics</span></div><div class="casAuthors">Kurzrock, Razelle; Kantarjian, Hagop M.; Druker, Brian J.; Talpaz, Moshe</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Internal Medicine</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">138</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">819-830</span>CODEN:
                <span class="NLM_cas:coden">AIMEAS</span>;
        ISSN:<span class="NLM_cas:issn">0003-4819</span>.
    
            (<span class="NLM_cas:orgname">American College of Physicians-American Society of Internal Medicine</span>)
        </div><div class="casAbstract">A review.  The Philadelphia chromosome translocation (t(9;22)) results in the mol. juxtaposition of 2 genes, BCR and ABL, to form an aberrant BCR-ABL gene on chromosome 22.  BCR-ABL is crit. to the pathogenesis of chronic myelogenous leukemia and a subset of acute leukemias.  The chimeric Bcr-Abl protein has constitutively elevated tyrosine phosphokinase activity.  This abnormal enzymic activation is crit. to the oncogenic potential of Bcr-Abl.  Initially, protein kinases were thought to be poor therapeutic targets because of their ubiquitous nature and crucial role in many normal physiol. processes.  However, the advent of imatinib mesylate (Gleevec, Novartis Pharmaceuticals, Basel, Switzerland), formerly known as ST1571 and CGP57148B, demonstrated that designer kinase inhibitors could be specific.  This agent has shown striking activity in chronic myelogenous leukemia.  It also inhibits phosphorylation of Kit (stem-cell factor receptor) and platelet-derived growth factor receptor.  In addn., it has shown similar impressive responses, with little host toxicity, in gastrointestinal stromal tumors, which harbor activating Kit mutations, and in tumors with activated platelet-derived growth factor receptor.  The studies of imatinib mesylate provide proof-of-principle for using aberrant kinases as a therapeutic target and are a model for the promise of mol. therapeutics.  This paper reviews the current knowledge on the function of Bcr-Abl and its normal counterparts (Bcr and Abl), as well as the impact of this knowledge on the development of a remarkably successful targeted therapy approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3h7VvjEn5vrVg90H21EOLACvtfcHk0ljhN3Le8xB3DA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXktl2ht70%253D&md5=ac97d62f6cfcc51f268d6cea1dcf1d22</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.7326%2F0003-4819-138-10-200305200-00010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7326%252F0003-4819-138-10-200305200-00010%26sid%3Dliteratum%253Aachs%26aulast%3DKurzrock%26aufirst%3DR.%26aulast%3DKantarjian%26aufirst%3DH.%2BM.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DTalpaz%26aufirst%3DM.%26atitle%3DPhiladelphia%2520chromosome-positive%2520leukemias%253A%2520from%2520basic%2520mechanisms%2520to%2520molecular%2520therapeutics%26jtitle%3DAnn.%2520Intern.%2520Med.%26date%3D2003%26volume%3D138%26spage%3D819%26epage%3D830%26doi%3D10.7326%2F0003-4819-138-10-200305200-00010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Capdeville, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchdunger, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matter, A.</span></span> <span> </span><span class="NLM_article-title">Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">493</span>– <span class="NLM_lpage">502</span>, <span class="refDoi"> DOI: 10.1038/nrd839</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1038%2Fnrd839" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=12120256" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD38XkvFKlurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=493-502&author=R.+Capdevilleauthor=E.+Buchdungerauthor=J.+Zimmermannauthor=A.+Matter&title=Glivec+%28STI571%2C+imatinib%29%2C+a+rationally+developed%2C+targeted+anticancer+drug&doi=10.1038%2Fnrd839"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug</span></div><div class="casAuthors">Capdeville, Renaud; Buchdunger, Elisabeth; Zimmermann, Juerg; Matter, Alex</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">493-502</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In the early 1980s, it became apparent that the work of pioneers such as Robert Weinberg, Mariano Barbacid and many others in identifying cancer-causing genes in humans was opening the door to a new era in anticancer research.  Motivated by this, and by dissatisfaction with the limited efficacy and tolerability of available anticancer modalities, a drug discovery program was initiated with the aim of rationally developing targeted anticancer therapies.  Here, we describe how this program led to the discovery and continuing development of Glivec (Gleevec in the United States), the first selective tyrosine-kinase inhibitor to be approved for the treatment of a cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeI0HV4de6ObVg90H21EOLACvtfcHk0ljhN3Le8xB3DA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkvFKlurY%253D&md5=c8f6b7a66f74b64f0dedb5e641097acc</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1038%2Fnrd839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd839%26sid%3Dliteratum%253Aachs%26aulast%3DCapdeville%26aufirst%3DR.%26aulast%3DBuchdunger%26aufirst%3DE.%26aulast%3DZimmermann%26aufirst%3DJ.%26aulast%3DMatter%26aufirst%3DA.%26atitle%3DGlivec%2520%2528STI571%252C%2520imatinib%2529%252C%2520a%2520rationally%2520developed%252C%2520targeted%2520anticancer%2520drug%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2002%26volume%3D1%26spage%3D493%26epage%3D502%26doi%3D10.1038%2Fnrd839" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malinoski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prakash, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span> <span> </span><span class="NLM_article-title">Development of alkyne-containing pyrazolopyrimidines to overcome drug resistance of Bcr-Abl kinase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">9228</span>– <span class="NLM_lpage">9237</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01125</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01125" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVaht7vL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=9228-9237&author=X.+Liuauthor=A.+Kungauthor=B.+Malinoskiauthor=G.+K.+Prakashauthor=C.+Zhang&title=Development+of+alkyne-containing+pyrazolopyrimidines+to+overcome+drug+resistance+of+Bcr-Abl+kinase&doi=10.1021%2Facs.jmedchem.5b01125"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Alkyne-Containing Pyrazolopyrimidines To Overcome Drug Resistance of Bcr-Abl Kinase</span></div><div class="casAuthors">Liu, Xu; Kung, Alvin; Malinoski, Brock; Prakash, G. K. Surya; Zhang, Chao</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">9228-9237</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Despite the success of imatinib at inhibiting Bcr-Abl and treating chronic myelogenous leukemia (CML), resistance to the therapy occurs over time in patients.  In particular, the resistance to imatinib caused by the gatekeeper mutation T315I in Bcr-Abl remains a challenge in the clinic.  Inspired by the successful development of ponatinib to curb drug resistance, we hypothesize that the incorporation of an alkyne linker in other heterocyclic scaffolds can also achieve potent inhibition of Bcr-AblT315I by allowing for simultaneous occupancy of both the active site and the allosteric pocket in the Abl kinase domain.  Herein, we describe the design, synthesis, and characterization of a series of alkyne-contg. pyrazolopyrimidines as Bcr-Abl inhibitors.  Our results demonstrate that some alkyne-contg. pyrazolopyrimidines potently inhibit not only AblT315I in vitro but also Bcr-AblT315I in cells.  These pyrazolopyrimidines can serve as lead compds. for future development of novel targeted therapy to overcome drug resistance of CML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvCwLSMJhHxLVg90H21EOLACvtfcHk0liA9kE5fPGMBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVaht7vL&md5=adfdddc095b76175f04f8ace9f51b847</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01125%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DKung%26aufirst%3DA.%26aulast%3DMalinoski%26aufirst%3DB.%26aulast%3DPrakash%26aufirst%3DG.%2BK.%26aulast%3DZhang%26aufirst%3DC.%26atitle%3DDevelopment%2520of%2520alkyne-containing%2520pyrazolopyrimidines%2520to%2520overcome%2520drug%2520resistance%2520of%2520Bcr-Abl%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D9228%26epage%3D9237%26doi%3D10.1021%2Facs.jmedchem.5b01125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metcalf, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sundaramoorthi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banda, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lentini, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keats, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wardwell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ning, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snodgrass, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broudy, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russian, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Commodore, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narasimhan, N. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohemmad, Q. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iuliucci, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivera, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalgarno, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawyer, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clackson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shakespeare, W. C.</span></span> <span> </span><span class="NLM_article-title">Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-<i>N</i>-{4-[(4-methylpiperazin-1-y l)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">4701</span>– <span class="NLM_lpage">4719</span>, <span class="refDoi"> DOI: 10.1021/jm100395q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100395q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmslels7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=4701-4719&author=W.+S.+Huangauthor=C.+A.+Metcalfauthor=R.+Sundaramoorthiauthor=Y.+Wangauthor=D.+Zouauthor=R.+M.+Thomasauthor=X.+Zhuauthor=L.+Caiauthor=D.+Wenauthor=S.+Liuauthor=J.+Romeroauthor=J.+Qiauthor=I.+Chenauthor=G.+Bandaauthor=S.+P.+Lentiniauthor=S.+Dasauthor=Q.+Xuauthor=J.+Keatsauthor=F.+Wangauthor=S.+Wardwellauthor=Y.+Ningauthor=J.+T.+Snodgrassauthor=M.+I.+Broudyauthor=K.+Russianauthor=T.+Zhouauthor=L.+Commodoreauthor=N.+I.+Narasimhanauthor=Q.+K.+Mohemmadauthor=J.+Iuliucciauthor=V.+M.+Riveraauthor=D.+C.+Dalgarnoauthor=T.+K.+Sawyerauthor=T.+Clacksonauthor=W.+C.+Shakespeare&title=Discovery+of+3-%5B2-%28imidazo%5B1%2C2-b%5Dpyridazin-3-yl%29ethynyl%5D-4-methyl-N-%7B4-%5B%284-methylpiperazin-1-y+l%29methyl%5D-3-%28trifluoromethyl%29phenyl%7Dbenzamide+%28AP24534%29%2C+a+potent%2C+orally+active+pan-inhibitor+of+breakpoint+cluster+region-abelson+%28BCR-ABL%29+kinase+including+the+T315I+gatekeeper+mutant&doi=10.1021%2Fjm100395q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 3-[2-(Imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-[4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl]benzamide (AP24534), a Potent, Orally Active Pan-Inhibitor of Breakpoint Cluster Region-Abelson (BCR-ABL) Kinase Including the T315I Gatekeeper Mutant</span></div><div class="casAuthors">Huang, Wei-Sheng; Metcalf, Chester A.; Sundaramoorthi, Raji; Wang, Yihan; Zou, Dong; Thomas, R. Mathew; Zhu, Xiaotian; Cai, Lisi; Wen, David; Liu, Shuangying; Romero, Jan; Qi, Jiwei; Chen, Ingrid; Banda, Geetha; Lentini, Scott P.; Das, Sasmita; Xu, Qihong; Keats, Jeff; Wang, Frank; Wardwell, Scott; Ning, Yaoyu; Snodgrass, Joseph T.; Broudy, Marc I.; Russian, Karin; Zhou, Tianjun; Commodore, Lois; Narasimhan, Narayana I.; Mohemmad, Qurish K.; Iuliucci, John; Rivera, Victor M.; Dalgarno, David C.; Sawyer, Tomi K.; Clackson, Tim; Shakespeare, William C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4701-4719</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In the treatment of chronic myeloid leukemia (CML) with BCR-ABL kinase inhibitors, the T315I gatekeeper mutant has emerged as resistant to all currently approved agents.  This report describes the structure-guided design of a novel series of potent pan-inhibitors of BCR-ABL, including the T315I mutation.  A key structural feature is the carbon-carbon triple bond linker which skirts the increased bulk of Ile315 side chain.  Extensive SAR studies led to the discovery of development candidate benzamide I (AP24534), which inhibited the kinase activity of both native BCR-ABL and the T315I mutant with low nM IC50s, and potently inhibited proliferation of corresponding Ba/F3-derived cell lines.  Daily oral administration of I significantly prolonged survival of mice injected i.v. with BCR-ABLT315I expressing Ba/F3 cells.  These data, coupled with a favorable ADME profile, support the potential of I to be an effective treatment for CML, including patients refractory to all currently approved therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoci2zVFUazgLVg90H21EOLACvtfcHk0liA9kE5fPGMBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmslels7s%253D&md5=0dcd7b4ff31164b1d9883e897b7058ff</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1021%2Fjm100395q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100395q%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DW.%2BS.%26aulast%3DMetcalf%26aufirst%3DC.%2BA.%26aulast%3DSundaramoorthi%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZou%26aufirst%3DD.%26aulast%3DThomas%26aufirst%3DR.%2BM.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DCai%26aufirst%3DL.%26aulast%3DWen%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DRomero%26aufirst%3DJ.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DI.%26aulast%3DBanda%26aufirst%3DG.%26aulast%3DLentini%26aufirst%3DS.%2BP.%26aulast%3DDas%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DKeats%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DWardwell%26aufirst%3DS.%26aulast%3DNing%26aufirst%3DY.%26aulast%3DSnodgrass%26aufirst%3DJ.%2BT.%26aulast%3DBroudy%26aufirst%3DM.%2BI.%26aulast%3DRussian%26aufirst%3DK.%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DCommodore%26aufirst%3DL.%26aulast%3DNarasimhan%26aufirst%3DN.%2BI.%26aulast%3DMohemmad%26aufirst%3DQ.%2BK.%26aulast%3DIuliucci%26aufirst%3DJ.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26aulast%3DDalgarno%26aufirst%3DD.%2BC.%26aulast%3DSawyer%26aufirst%3DT.%2BK.%26aulast%3DClackson%26aufirst%3DT.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26atitle%3DDiscovery%2520of%25203-%255B2-%2528imidazo%255B1%252C2-b%255Dpyridazin-3-yl%2529ethynyl%255D-4-methyl-N-%257B4-%255B%25284-methylpiperazin-1-y%2520l%2529methyl%255D-3-%2528trifluoromethyl%2529phenyl%257Dbenzamide%2520%2528AP24534%2529%252C%2520a%2520potent%252C%2520orally%2520active%2520pan-inhibitor%2520of%2520breakpoint%2520cluster%2520region-abelson%2520%2528BCR-ABL%2529%2520kinase%2520including%2520the%2520T315I%2520gatekeeper%2520mutant%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D4701%26epage%3D4719%26doi%3D10.1021%2Fjm100395q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kaitsiotou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keul, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardick, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muhlenberg, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ketzer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehrt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krull, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medda, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giordanetto, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauh, D.</span></span> <span> </span><span class="NLM_article-title">Inhibitors to overcome secondary mutations in the stem cell factor receptor KIT</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">8801</span>– <span class="NLM_lpage">8815</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00841</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00841" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1amtLrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=8801-8815&author=H.+Kaitsiotouauthor=M.+Keulauthor=J.+Hardickauthor=T.+Muhlenbergauthor=J.+Ketzerauthor=C.+Ehrtauthor=J.+Krullauthor=F.+Meddaauthor=O.+Kochauthor=F.+Giordanettoauthor=S.+Bauerauthor=D.+Rauh&title=Inhibitors+to+overcome+secondary+mutations+in+the+stem+cell+factor+receptor+KIT&doi=10.1021%2Facs.jmedchem.7b00841"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors to Overcome Secondary Mutations in the Stem Cell Factor Receptor KIT</span></div><div class="casAuthors">Kaitsiotou, Helena; Keul, Marina; Hardick, Julia; Muehlenberg, Thomas; Ketzer, Julia; Ehrt, Christiane; Kruell, Jasmin; Medda, Federico; Koch, Oliver; Giordanetto, Fabrizio; Bauer, Sebastian; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">8801-8815</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In modern cancer therapy, the use of small org. mols. against receptor tyrosine kinases (RTKs) has been shown to be a valuable strategy.  The assocn. of cancer cells with dysregulated signaling pathways linked to RTKs represents a key element in targeted cancer therapies.  The tyrosine kinase mast/stem cell growth factor receptor KIT is an example of a clin. relevant RTK.  KIT is targeted for cancer therapy in gastrointestinal stromal tumors (GISTs) and chronic myelogenous leukemia (CML).  However, acquired resistance mutations within the catalytic domain decrease the efficacy of this strategy and are the most common cause of failed therapy.  Here, we present the structure-based design and synthesis of novel type II kinase inhibitors to overcome these mutations in KIT.  Biochem. and cellular studies revealed promising mols. for the inhibition of mutated KIT.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-lJTbHOMKKbVg90H21EOLACvtfcHk0lhk9CFno50IDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1amtLrE&md5=27459cff0dbf5dad390dea330458c201</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00841%26sid%3Dliteratum%253Aachs%26aulast%3DKaitsiotou%26aufirst%3DH.%26aulast%3DKeul%26aufirst%3DM.%26aulast%3DHardick%26aufirst%3DJ.%26aulast%3DMuhlenberg%26aufirst%3DT.%26aulast%3DKetzer%26aufirst%3DJ.%26aulast%3DEhrt%26aufirst%3DC.%26aulast%3DKrull%26aufirst%3DJ.%26aulast%3DMedda%26aufirst%3DF.%26aulast%3DKoch%26aufirst%3DO.%26aulast%3DGiordanetto%26aufirst%3DF.%26aulast%3DBauer%26aufirst%3DS.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DInhibitors%2520to%2520overcome%2520secondary%2520mutations%2520in%2520the%2520stem%2520cell%2520factor%2520receptor%2520KIT%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D8801%26epage%3D8815%26doi%3D10.1021%2Facs.jmedchem.7b00841" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gray, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jubb, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hogue, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowd, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kljavin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frantz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koeppen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Sauvage, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, D. P.</span></span> <span> </span><span class="NLM_article-title">Maternal embryonic leucine zipper kinase/murine protein serine-threonine kinase 38 is a promising therapeutic target for multiple cancers</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">9751</span>– <span class="NLM_lpage">9761</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-04-4531</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1158%2F0008-5472.CAN-04-4531" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=16266996" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFKktL7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=9751-9761&author=D.+Grayauthor=A.+M.+Jubbauthor=D.+Hogueauthor=P.+Dowdauthor=N.+Kljavinauthor=S.+Yiauthor=W.+Baiauthor=G.+Frantzauthor=Z.+Zhangauthor=H.+Koeppenauthor=F.+J.+de+Sauvageauthor=D.+P.+Davis&title=Maternal+embryonic+leucine+zipper+kinase%2Fmurine+protein+serine-threonine+kinase+38+is+a+promising+therapeutic+target+for+multiple+cancers&doi=10.1158%2F0008-5472.CAN-04-4531"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Maternal embryonic leucine zipper kinase/murine protein serine-threonine kinase 38 is a promising therapeutic target for multiple cancers</span></div><div class="casAuthors">Gray, Daniel; Jubb, Adrian M.; Hogue, Deborah; Dowd, Patrick; Kljavin, Noelyn; Yi, Sothy; Bai, Wei; Frantz, Gretchen; Zhang, Zemin; Koeppen, Hartmut; de Sauvage, Frederic J.; Davis, David P.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">9751-9761</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">To identify genes that could serve as targets for novel cancer therapeutics, we used a bioinformatic anal. of microarray data comparing gene expression between normal and tumor-derived primary human tissues.  From this approach, we have found that maternal embryonic leucine zipper kinase (Melk), a member of the AMP serine/threonine kinase family, exhibits multiple features consistent with the potential utility of this gene as an anticancer target.  An oligonucleotide microarray anal. of multiple human tumor samples and cell lines suggests that Melk expression is frequently elevated in cancer relative to normal tissues, a pattern confirmed by quant. reverse transcription-PCR and Western blotting of selected primary tumor samples.  In situ hybridization localized Melk expression to malignant epithelial cells in 96%, 23%, and 13% of colorectal, lung, and ovarian tissue tumor samples, resp.  Expression of this gene is also elevated in spontaneous tumors derived from the ApcMin and Apc1638N murine models of intestinal tumorigenesis.  To begin addressing whether Melk is relevant for tumorigenesis, RNA interference-mediated silencing within human and murine tumor cell lines was done.  We show that Melk knockdown decreases proliferation and anchorage-independent growth in vitro as well as tumor growth in a xenograft model.  Together, these results suggest that Melk may provide a growth advantage for neoplastic cells and, therefore, inactivation may be therapeutically beneficial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_9K-J3ofrbrVg90H21EOLACvtfcHk0lhk9CFno50IDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFKktL7F&md5=9d923595fbdf3b522d22c1329ba634c9</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-04-4531&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-04-4531%26sid%3Dliteratum%253Aachs%26aulast%3DGray%26aufirst%3DD.%26aulast%3DJubb%26aufirst%3DA.%2BM.%26aulast%3DHogue%26aufirst%3DD.%26aulast%3DDowd%26aufirst%3DP.%26aulast%3DKljavin%26aufirst%3DN.%26aulast%3DYi%26aufirst%3DS.%26aulast%3DBai%26aufirst%3DW.%26aulast%3DFrantz%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DKoeppen%26aufirst%3DH.%26aulast%3Dde%2BSauvage%26aufirst%3DF.%2BJ.%26aulast%3DDavis%26aufirst%3DD.%2BP.%26atitle%3DMaternal%2520embryonic%2520leucine%2520zipper%2520kinase%252Fmurine%2520protein%2520serine-threonine%2520kinase%252038%2520is%2520a%2520promising%2520therapeutic%2520target%2520for%2520multiple%2520cancers%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26spage%3D9751%26epage%3D9761%26doi%3D10.1158%2F0008-5472.CAN-04-4531" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adelinet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berdini, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beke, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brehmer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coyle, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frederickson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freyne, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilissen, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamlett, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meerpoel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mevellec, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMenamin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasquier, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rees, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linders, J. T.</span></span> <span> </span><span class="NLM_article-title">Structure-based design of type II inhibitors applied to maternal embryonic leucine zipper kinase</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">36</span>, <span class="refDoi"> DOI: 10.1021/ml5001273</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml5001273" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC2cXos1WltL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=31-36&author=C.+N.+Johnsonauthor=C.+Adelinetauthor=V.+Berdiniauthor=L.+Bekeauthor=P.+Bonnetauthor=D.+Brehmerauthor=F.+Caloauthor=J.+E.+Coyleauthor=P.+J.+Dayauthor=M.+Fredericksonauthor=E.+J.+Freyneauthor=R.+A.+Gilissenauthor=C.+C.+Hamlettauthor=S.+Howardauthor=L.+Meerpoelauthor=L.+Mevellecauthor=R.+McMenaminauthor=E.+Pasquierauthor=S.+Patelauthor=D.+C.+Reesauthor=J.+T.+Linders&title=Structure-based+design+of+type+II+inhibitors+applied+to+maternal+embryonic+leucine+zipper+kinase&doi=10.1021%2Fml5001273"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Design of Type II Inhibitors Applied to Maternal Embryonic Leucine Zipper Kinase</span></div><div class="casAuthors">Johnson, Christopher N.; Adelinet, Christophe; Berdini, Valerio; Beke, Lijs; Bonnet, Pascal; Brehmer, Dirk; Calo, Frederick; Coyle, Joseph E.; Day, Phillip J.; Frederickson, Martyn; Freyne, Eddy J. E.; Gilissen, Ron A. H. J.; Hamlett, Christopher C. F.; Howard, Steven; Meerpoel, Lieven; Mevellec, Laurence; McMenamin, Rachel; Pasquier, Elisabeth; Patel, Sahil; Rees, David C.; Linders, Joannes T. M.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">31-36</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel Type II kinase inhibitor chemotype has been identified for maternal embryonic leucine zipper kinase (MELK) using structure-based ligand design.  The strategy involved structural characterization of an induced DFG-out pocket by protein-ligand X-ray crystallog. and incorporation of a slender linkage capable of bypassing a large gate-keeper residue, thus enabling design of mols. accessing both hinge and induced pocket regions.  Optimization of an initial hit led to the identification of a low-nanomolar, cell-penetrant Type II inhibitor suitable for use as a chem. probe for MELK.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWmY300FJpQ7Vg90H21EOLACvtfcHk0lhk9CFno50IDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXos1WltL8%253D&md5=35e87bcfe134c8373da3dc57c3c4e6c5</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1021%2Fml5001273&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml5001273%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DC.%2BN.%26aulast%3DAdelinet%26aufirst%3DC.%26aulast%3DBerdini%26aufirst%3DV.%26aulast%3DBeke%26aufirst%3DL.%26aulast%3DBonnet%26aufirst%3DP.%26aulast%3DBrehmer%26aufirst%3DD.%26aulast%3DCalo%26aufirst%3DF.%26aulast%3DCoyle%26aufirst%3DJ.%2BE.%26aulast%3DDay%26aufirst%3DP.%2BJ.%26aulast%3DFrederickson%26aufirst%3DM.%26aulast%3DFreyne%26aufirst%3DE.%2BJ.%26aulast%3DGilissen%26aufirst%3DR.%2BA.%26aulast%3DHamlett%26aufirst%3DC.%2BC.%26aulast%3DHoward%26aufirst%3DS.%26aulast%3DMeerpoel%26aufirst%3DL.%26aulast%3DMevellec%26aufirst%3DL.%26aulast%3DMcMenamin%26aufirst%3DR.%26aulast%3DPasquier%26aufirst%3DE.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DRees%26aufirst%3DD.%2BC.%26aulast%3DLinders%26aufirst%3DJ.%2BT.%26atitle%3DStructure-based%2520design%2520of%2520type%2520II%2520inhibitors%2520applied%2520to%2520maternal%2520embryonic%2520leucine%2520zipper%2520kinase%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26spage%3D31%26epage%3D36%26doi%3D10.1021%2Fml5001273" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neckers, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Workman, P.</span></span> <span> </span><span class="NLM_article-title">Hsp90 molecular chaperone inhibitors: are we there yet?</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">64</span>– <span class="NLM_lpage">76</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-11-1000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1158%2F1078-0432.CCR-11-1000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=22215907" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvFWmsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=64-76&author=L.+Neckersauthor=P.+Workman&title=Hsp90+molecular+chaperone+inhibitors%3A+are+we+there+yet%3F&doi=10.1158%2F1078-0432.CCR-11-1000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Hsp90 Molecular Chaperone Inhibitors: Are We There Yet?</span></div><div class="casAuthors">Neckers, Len; Workman, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">64-76</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Heat shock protein (Hsp) 90 is an ATP-dependent mol. chaperone that is exploited by malignant cells to support activated oncoproteins, including many cancer-assocd. kinases and transcription factors, and it is essential for oncogenic transformation.  Originally viewed with skepticism, Hsp90 inhibitors are now being actively pursued by the pharmaceutical industry, with 17 agents having entered clin. trials.  Investigators established Hsp90's druggability using the natural products geldanamycin and radicicol, which mimic the unusual ATP structure adopted in the chaperone's N-terminal nucleotide-binding pocket and cause potent and selective blockade of ATP binding/hydrolysis, inhibit chaperone function, deplete oncogenic clients, and show antitumor activity.  Preclin. data obtained with these natural products have heightened interest in Hsp90 as a drug target, and 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) has shown clin. activity (as defined by Response Evaluation Criteria in Solid Tumors) in HER2+ breast cancer.  Many optimized synthetic, small-mol. Hsp90 inhibitors from diverse chemotypes are now in clin. trials.  Here, we review the discovery and development of Hsp90 inhibitors and assess their potential.  There has been significant learning from studies of the basic biol. of Hsp90, as well as translational drug development involving this chaperone, enhanced by the use of Hsp90 inhibitors as chem. probes.  Success will likely lie in treating cancers that are addicted to particular driver oncogene products (e.g., HER2, ALK, EGFR, and BRAF) that are sensitive Hsp90 clients, as well as malignancies (esp. multiple myeloma) in which buffering of proteotoxic stress is crit. for survival.  We discuss approaches for enhancing the effectiveness of Hsp90 inhibitors and highlight new chaperone and stress-response pathway targets, including HSF1 and Hsp70.  Clin Cancer Res; 18(1); 64-76.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfICmNu1IWFbVg90H21EOLACvtfcHk0lgX67VR57O8TQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvFWmsw%253D%253D&md5=f67c3c11b5847e3866c91af2a16a63b8</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-1000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-1000%26sid%3Dliteratum%253Aachs%26aulast%3DNeckers%26aufirst%3DL.%26aulast%3DWorkman%26aufirst%3DP.%26atitle%3DHsp90%2520molecular%2520chaperone%2520inhibitors%253A%2520are%2520we%2520there%2520yet%253F%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D64%26epage%3D76%26doi%3D10.1158%2F1078-0432.CCR-11-1000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kasibhatla, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biamonte, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Busch, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karjian, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sensintaffar, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lough, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brekken, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundgren, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grecko, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timony, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ran, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansfield, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fritz, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulm, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boehm, M. F.</span></span> <span> </span><span class="NLM_article-title">Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">2767</span>– <span class="NLM_lpage">2778</span>, <span class="refDoi"> DOI: 10.1021/jm050752+</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm050752%2B" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltVWqtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=2767-2778&author=S.+R.+Kasibhatlaauthor=K.+Hongauthor=M.+A.+Biamonteauthor=D.+J.+Buschauthor=P.+L.+Karjianauthor=J.+L.+Sensintaffarauthor=A.+Kamalauthor=R.+E.+Loughauthor=J.+Brekkenauthor=K.+Lundgrenauthor=R.+Greckoauthor=G.+A.+Timonyauthor=Y.+Ranauthor=R.+Mansfieldauthor=L.+C.+Fritzauthor=E.+Ulmauthor=F.+J.+Burrowsauthor=M.+F.+Boehm&title=Rationally+designed+high-affinity+2-amino-6-halopurine+heat+shock+protein+90+inhibitors+that+exhibit+potent+antitumor+activity&doi=10.1021%2Fjm050752%2B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Rationally Designed High-Affinity 2-Amino-6-halopurine Heat Shock Protein 90 Inhibitors That Exhibit Potent Antitumor Activity</span></div><div class="casAuthors">Kasibhatla, Srinivas R.; Hong, Kevin; Biamonte, Marco A.; Busch, David J.; Karjian, Patricia L.; Sensintaffar, John L.; Kamal, Adeela; Lough, Rachel E.; Brekken, John; Lundgren, Karen; Grecko, Roy; Timony, Gregg A.; Ran, Yingqing; Mansfield, Robert; Fritz, Lawrence C.; Ulm, Edgar; Burrows, Francis J.; Boehm, Marcus F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2767-2778</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Heat shock protein 90 (Hsp90) is a mol. chaperone protein implicated in stabilizing the conformation and maintaining the function of many cell-signaling proteins.  Many oncogenic proteins are more dependent on Hsp90 in maintaining their conformation, stability, and maturation than their normal counterparts.  Furthermore, recent data show that Hsp90 exists in an activated form in malignant cells but in a latent inactive form in normal tissues, suggesting that inhibitors selective for the activated form could provide a high therapeutic index.  Hence, Hsp90 is emerging as an exciting new target for the treatment of cancer.  We now report on a novel series of 2-amino-6-halopurine Hsp90 inhibitors exemplified by 2-amino-6-chloro-9-(4-iodo-3,5-dimethylpyridin-2-ylmethyl)purine (30).  These highly potent inhibitors (IC50 of 30 = 0.009 μM in a HER-2 degrdn. assay) also display excellent antiproliferative activity against various tumor cell lines (IC50 of 30 = 0.03 μM in MCF7 cells).  Moreover, this class of inhibitors shows higher affinity for the activated form of Hsp90 compared to our earlier 8-sulfanylpurine Hsp90 inhibitor series.  When administered orally to mice, these compds. exhibited potent tumor growth inhibition (>80%) in an N87 xenograft model, similar to that obsd. with 17-allylamino-17-desmethoxygeldanamycin (17-AAG), which is a compd. currently in phase I/II clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiBDUeN7k4z7Vg90H21EOLACvtfcHk0lgX67VR57O8TQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltVWqtLY%253D&md5=4d339610f0865ba089df631decae91f4</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1021%2Fjm050752%2B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050752%252B%26sid%3Dliteratum%253Aachs%26aulast%3DKasibhatla%26aufirst%3DS.%2BR.%26aulast%3DHong%26aufirst%3DK.%26aulast%3DBiamonte%26aufirst%3DM.%2BA.%26aulast%3DBusch%26aufirst%3DD.%2BJ.%26aulast%3DKarjian%26aufirst%3DP.%2BL.%26aulast%3DSensintaffar%26aufirst%3DJ.%2BL.%26aulast%3DKamal%26aufirst%3DA.%26aulast%3DLough%26aufirst%3DR.%2BE.%26aulast%3DBrekken%26aufirst%3DJ.%26aulast%3DLundgren%26aufirst%3DK.%26aulast%3DGrecko%26aufirst%3DR.%26aulast%3DTimony%26aufirst%3DG.%2BA.%26aulast%3DRan%26aufirst%3DY.%26aulast%3DMansfield%26aufirst%3DR.%26aulast%3DFritz%26aufirst%3DL.%2BC.%26aulast%3DUlm%26aufirst%3DE.%26aulast%3DBurrows%26aufirst%3DF.%2BJ.%26aulast%3DBoehm%26aufirst%3DM.%2BF.%26atitle%3DRationally%2520designed%2520high-affinity%25202-amino-6-halopurine%2520heat%2520shock%2520protein%252090%2520inhibitors%2520that%2520exhibit%2520potent%2520antitumor%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D2767%26epage%3D2778%26doi%3D10.1021%2Fjm050752%2B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van de Water, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamer, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weichert, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandoval, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasibhatla, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boehm, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundgren, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timple, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lough, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibanez, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boykin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kehry, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harning, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambrose, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bixler, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunah, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snodgrass-Belt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arndt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enyedy, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKenzie, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biamonte, M. A.</span></span> <span> </span><span class="NLM_article-title">EC144 is a potent inhibitor of the heat shock protein 90</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">7786</span>– <span class="NLM_lpage">7795</span>, <span class="refDoi"> DOI: 10.1021/jm300810x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300810x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht12it7%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=7786-7795&author=J.+Shiauthor=R.+Van+de+Waterauthor=K.+Hongauthor=R.+B.+Lamerauthor=K.+W.+Weichertauthor=C.+M.+Sandovalauthor=S.+R.+Kasibhatlaauthor=M.+F.+Boehmauthor=J.+Chaoauthor=K.+Lundgrenauthor=N.+Timpleauthor=R.+Loughauthor=G.+Ibanezauthor=C.+Boykinauthor=F.+J.+Burrowsauthor=M.+R.+Kehryauthor=T.+J.+Yunauthor=E.+K.+Harningauthor=C.+Ambroseauthor=J.+Thompsonauthor=S.+A.+Bixlerauthor=A.+Dunahauthor=P.+Snodgrass-Beltauthor=J.+Arndtauthor=I.+J.+Enyedyauthor=P.+Liauthor=V.+S.+Hongauthor=A.+McKenzieauthor=M.+A.+Biamonte&title=EC144+is+a+potent+inhibitor+of+the+heat+shock+protein+90&doi=10.1021%2Fjm300810x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">EC144 Is a Potent Inhibitor of the Heat Shock Protein 90</span></div><div class="casAuthors">Shi, Jiandong; Van de Water, Ryan; Hong, Kevin; Lamer, Ryan B.; Weichert, Kenneth W.; Sandoval, Cristina M.; Kasibhatla, Srinivas R.; Boehm, Marcus F.; Chao, Jianhua; Lundgren, Karen; Timple, Noelito; Lough, Rachel; Ibanez, Gerardo; Boykin, Christina; Burrows, Francis J.; Kehry, Marilyn R.; Yun, Theodore J.; Harning, Erin K.; Ambrose, Christine; Thompson, Jeffrey; Bixler, Sarah A.; Dunah, Anthone; Snodgrass-Belt, Pamela; Arndt, Joseph; Enyedy, Istvan J.; Li, Ping; Hong, Victor S.; McKenzie, Andres; Biamonte, Marco A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7786-7795</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Alkyne 5-(2-amino-4-chloro-7-((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methylpent-4-yn-2-ol (EC144), is a second generation inhibitor of heat shock protein 90 (Hsp90) and is substantially more potent in vitro and in vivo than the first generation inhibitor (BIIB021) that completed phase II clin. trials.  Alkyne (EC144) is more potent than (BIIB021) in an Hsp90α binding assay (IC50 = 1.1 vs. 5.1 nM) as well as in its ability to degrade Her-2 in MCF-7 cells (EC50 = 14 vs. 38 nM).  In a mouse model of gastric tumors (N87), (EC144) stops tumor growth at 5 mg/kg and causes partial tumor regressions at 10 mg/kg (po, qd×5).  Under the same conditions, (BIIB021) stops tumor growth only at 120 mg/kg, and does not induce partial regressions.  Thus, alkyne (EC144) is approx. 20-fold more efficacious than (BIIB021) in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLRtKyDCD2OLVg90H21EOLACvtfcHk0liG-chEFRxQ3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht12it7%252FE&md5=201153ad61f71af267f1e1ba2ca7c2e7</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1021%2Fjm300810x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300810x%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DVan%2Bde%2BWater%26aufirst%3DR.%26aulast%3DHong%26aufirst%3DK.%26aulast%3DLamer%26aufirst%3DR.%2BB.%26aulast%3DWeichert%26aufirst%3DK.%2BW.%26aulast%3DSandoval%26aufirst%3DC.%2BM.%26aulast%3DKasibhatla%26aufirst%3DS.%2BR.%26aulast%3DBoehm%26aufirst%3DM.%2BF.%26aulast%3DChao%26aufirst%3DJ.%26aulast%3DLundgren%26aufirst%3DK.%26aulast%3DTimple%26aufirst%3DN.%26aulast%3DLough%26aufirst%3DR.%26aulast%3DIbanez%26aufirst%3DG.%26aulast%3DBoykin%26aufirst%3DC.%26aulast%3DBurrows%26aufirst%3DF.%2BJ.%26aulast%3DKehry%26aufirst%3DM.%2BR.%26aulast%3DYun%26aufirst%3DT.%2BJ.%26aulast%3DHarning%26aufirst%3DE.%2BK.%26aulast%3DAmbrose%26aufirst%3DC.%26aulast%3DThompson%26aufirst%3DJ.%26aulast%3DBixler%26aufirst%3DS.%2BA.%26aulast%3DDunah%26aufirst%3DA.%26aulast%3DSnodgrass-Belt%26aufirst%3DP.%26aulast%3DArndt%26aufirst%3DJ.%26aulast%3DEnyedy%26aufirst%3DI.%2BJ.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DHong%26aufirst%3DV.%2BS.%26aulast%3DMcKenzie%26aufirst%3DA.%26aulast%3DBiamonte%26aufirst%3DM.%2BA.%26atitle%3DEC144%2520is%2520a%2520potent%2520inhibitor%2520of%2520the%2520heat%2520shock%2520protein%252090%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D7786%26epage%3D7795%26doi%3D10.1021%2Fjm300810x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mdluli, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witte, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kline, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barb, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erwin, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansfield, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McClerren, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirrung, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tumey, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warrener, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raetz, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stover, C. K.</span></span> <span> </span><span class="NLM_article-title">Molecular validation of LpxC as an antibacterial drug target in <i>Pseudomonas aeruginosa</i></span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">2178</span>– <span class="NLM_lpage">2184</span>, <span class="refDoi"> DOI: 10.1128/AAC.00140-06</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1128%2FAAC.00140-06" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=16723580" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD28XlsVOiu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2006&pages=2178-2184&author=K.+E.+Mdluliauthor=P.+R.+Witteauthor=T.+Klineauthor=A.+W.+Barbauthor=A.+L.+Erwinauthor=B.+E.+Mansfieldauthor=A.+L.+McClerrenauthor=M.+C.+Pirrungauthor=L.+N.+Tumeyauthor=P.+Warrenerauthor=C.+R.+Raetzauthor=C.+K.+Stover&title=Molecular+validation+of+LpxC+as+an+antibacterial+drug+target+in+Pseudomonas+aeruginosa&doi=10.1128%2FAAC.00140-06"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular validation of LpxC as an antibacterial drug target in Pseudomonas aeruginosa</span></div><div class="casAuthors">Mdluli, Khisimuzi E.; Witte, Pamela R.; Kline, Toni; Barb, Adam W.; Erwin, Alice L.; Mansfield, Bryce E.; McClerren, Amanda L.; Pirrung, Michael C.; Tumey, L. Nathan; Warrener, Paul; Raetz, Christian R. H.; Stover, C. Kendall</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2178-2184</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">LpxC [UDP-3-O-(R-3-hydroxymyristoyl)-GlcNAc deacetylase] is a metalloamidase that catalyzes the first committed step in the biosynthesis of the lipid A component of lipopolysaccharide.  A previous study identified a series of synthetic LpxC-inhibitory mols. that were bactericidal for Escherichia coli.  These mols. did not inhibit the growth of Pseudomonas aeruginosa and were therefore not developed further as antibacterial drugs.  The inactivity of the LpxC inhibitors for P. aeruginosa raised the possibility that LpxC activity might not be essential for all gram-neg. bacteria.  By placing the lpxC gene of P. aeruginosa under tight control of an arabinose-inducible promoter, we demonstrated the essentiality of LpxC activity for P. aeruginosa.  It was found that compd. L-161,240, the most potent inhibitor from the previous study, was active against a P. aeruginosa construct in which the endogenous lpxC gene was inactivated and in which LpxC activity was supplied by the lpxC gene from E. coli.  Conversely, an E. coli construct in which growth was dependent on the P. aeruginosa lpxC gene was resistant to the compd.  The differential activities of L-161,240 against the two bacterial species are thus the result primarily of greater potency toward the E. coli enzyme rather than of differences in the intrinsic resistance of the bacteria toward antibacterial compds. due to permeability or efflux.  These data validate P. aeruginosa LpxC as a target for novel antibiotic drugs and should help direct the design of inhibitors against clin. important gram-neg. bacteria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr72k931w5vjbVg90H21EOLACvtfcHk0liG-chEFRxQ3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlsVOiu74%253D&md5=2fa9711c5bcbea239092f23d3c70e87b</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1128%2FAAC.00140-06&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00140-06%26sid%3Dliteratum%253Aachs%26aulast%3DMdluli%26aufirst%3DK.%2BE.%26aulast%3DWitte%26aufirst%3DP.%2BR.%26aulast%3DKline%26aufirst%3DT.%26aulast%3DBarb%26aufirst%3DA.%2BW.%26aulast%3DErwin%26aufirst%3DA.%2BL.%26aulast%3DMansfield%26aufirst%3DB.%2BE.%26aulast%3DMcClerren%26aufirst%3DA.%2BL.%26aulast%3DPirrung%26aufirst%3DM.%2BC.%26aulast%3DTumey%26aufirst%3DL.%2BN.%26aulast%3DWarrener%26aufirst%3DP.%26aulast%3DRaetz%26aufirst%3DC.%2BR.%26aulast%3DStover%26aufirst%3DC.%2BK.%26atitle%3DMolecular%2520validation%2520of%2520LpxC%2520as%2520an%2520antibacterial%2520drug%2520target%2520in%2520Pseudomonas%2520aeruginosa%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2006%26volume%3D50%26spage%3D2178%26epage%3D2184%26doi%3D10.1128%2FAAC.00140-06" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Piizzi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patnaik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wattanasin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenoir, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nunez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerrigan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKenney, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osborne, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanieri, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bojkovic, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dzink-Fox, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lilly, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sprague, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranjitkar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glick, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamann, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tommasi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dean, C. R.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and properties of a potent inhibitor of <i>Pseudomonas aeruginosa</i> deacetylase LpxC</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">5002</span>– <span class="NLM_lpage">5014</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00377</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00377" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC2sXos1SgsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=5002-5014&author=G.+Piizziauthor=D.+T.+Parkerauthor=Y.+Pengauthor=M.+Doblerauthor=A.+Patnaikauthor=S.+Wattanasinauthor=E.+Liuauthor=F.+Lenoirauthor=J.+Nunezauthor=J.+Kerriganauthor=D.+McKenneyauthor=C.+Osborneauthor=D.+Yuauthor=L.+Lanieriauthor=J.+Bojkovicauthor=J.+Dzink-Foxauthor=M.+D.+Lillyauthor=E.+R.+Spragueauthor=Y.+Luauthor=H.+Wangauthor=S.+Ranjitkarauthor=L.+Xieauthor=B.+Wangauthor=M.+Glickauthor=L.+G.+Hamannauthor=R.+Tommasiauthor=X.+Yangauthor=C.+R.+Dean&title=Design%2C+synthesis%2C+and+properties+of+a+potent+inhibitor+of+Pseudomonas+aeruginosa+deacetylase+LpxC&doi=10.1021%2Facs.jmedchem.7b00377"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Properties of a Potent Inhibitor of Pseudomonas aeruginosa Deacetylase LpxC</span></div><div class="casAuthors">Piizzi, Grazia; Parker, David T.; Peng, Yunshan; Dobler, Markus; Patnaik, Anup; Wattanasin, Som; Liu, Eugene; Lenoir, Francois; Nunez, Jill; Kerrigan, John; McKenney, David; Osborne, Colin; Yu, Donghui; Lanieri, Leanne; Bojkovic, Jade; Dzink-Fox, JoAnn; Lilly, Maria-Dawn; Sprague, Elizabeth R.; Lu, Yipin; Wang, Hongming; Ranjitkar, Srijan; Xie, Lili; Wang, Bing; Glick, Meir; Hamann, Lawrence G.; Tommasi, Ruben; Yang, Xia; Dean, Charles R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5002-5014</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Over the past several decades, the frequency of antibacterial resistance in hospitals, including multidrug resistance (MDR) and its assocn. with serious infectious diseases, has increased at alarming rates.  Pseudomonas aeruginosa is a leading cause of nosocomial infections, and resistance to virtually all approved antibacterial agents is emerging in this pathogen.  To address the need for new agents to treat MDR P. aeruginosa, we focused on inhibiting the first committed step in the biosynthesis of lipid A, the deacetylation of uridyldiphospho-3-O-(R-hydroxydecanoyl)-N-acetylglucosamine by the enzyme LpxC.  We approached this through the design, synthesis, and biol. evaluation of novel hydroxamic acid LpxC inhibitors, exemplified by I, where cytotoxicity against mammalian cell lines was reduced, soly. and plasma-protein binding were improved while retaining potent anti-pseudomonal activity in vitro and in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodbG9H5F_ITrVg90H21EOLACvtfcHk0ljLrXNVIZDWBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXos1SgsLk%253D&md5=ea3fc92a1b15ffed9edd3702395a2b35</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00377&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00377%26sid%3Dliteratum%253Aachs%26aulast%3DPiizzi%26aufirst%3DG.%26aulast%3DParker%26aufirst%3DD.%2BT.%26aulast%3DPeng%26aufirst%3DY.%26aulast%3DDobler%26aufirst%3DM.%26aulast%3DPatnaik%26aufirst%3DA.%26aulast%3DWattanasin%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DE.%26aulast%3DLenoir%26aufirst%3DF.%26aulast%3DNunez%26aufirst%3DJ.%26aulast%3DKerrigan%26aufirst%3DJ.%26aulast%3DMcKenney%26aufirst%3DD.%26aulast%3DOsborne%26aufirst%3DC.%26aulast%3DYu%26aufirst%3DD.%26aulast%3DLanieri%26aufirst%3DL.%26aulast%3DBojkovic%26aufirst%3DJ.%26aulast%3DDzink-Fox%26aufirst%3DJ.%26aulast%3DLilly%26aufirst%3DM.%2BD.%26aulast%3DSprague%26aufirst%3DE.%2BR.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DRanjitkar%26aufirst%3DS.%26aulast%3DXie%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DGlick%26aufirst%3DM.%26aulast%3DHamann%26aufirst%3DL.%2BG.%26aulast%3DTommasi%26aufirst%3DR.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DDean%26aufirst%3DC.%2BR.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520properties%2520of%2520a%2520potent%2520inhibitor%2520of%2520Pseudomonas%2520aeruginosa%2520deacetylase%2520LpxC%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D5002%26epage%3D5014%26doi%3D10.1021%2Facs.jmedchem.7b00377" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lapointe, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madera, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simmons, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yifru, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tjandra, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karur, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rico, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bojkovic, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uehara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellamacina, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKenney, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonn, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osborne, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benton, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDowell, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, Z. K.</span></span> <span> </span><span class="NLM_article-title">Application of virtual screening to the identification of new LpxC inhibitor chemotypes, oxazolidinone and isoxazoline</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">9360</span>– <span class="NLM_lpage">9370</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01287</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01287" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslaqtrvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=9360-9370&author=P.+S.+Leeauthor=G.+Lapointeauthor=A.+M.+Maderaauthor=R.+L.+Simmonsauthor=W.+Xuauthor=A.+Yifruauthor=M.+Tjandraauthor=S.+Karurauthor=A.+Ricoauthor=K.+Thompsonauthor=J.+Bojkovicauthor=L.+Xieauthor=K.+Ueharaauthor=A.+Liuauthor=W.+Shuauthor=C.+Bellamacinaauthor=D.+McKenneyauthor=L.+Morrisauthor=G.+R.+Tonnauthor=C.+Osborneauthor=B.+M.+Bentonauthor=L.+McDowellauthor=J.+Fuauthor=Z.+K.+Sweeney&title=Application+of+virtual+screening+to+the+identification+of+new+LpxC+inhibitor+chemotypes%2C+oxazolidinone+and+isoxazoline&doi=10.1021%2Facs.jmedchem.8b01287"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Application of Virtual Screening to the Identification of New LpxC Inhibitor Chemotypes, Oxazolidinone and Isoxazoline</span></div><div class="casAuthors">Lee, Patrick S.; Lapointe, Guillaume; Madera, Ann Marie; Simmons, Robert L.; Xu, Wenjian; Yifru, Aregahegn; Tjandra, Meiliana; Karur, Subramanian; Rico, Alice; Thompson, Katherine; Bojkovic, Jade; Xie, Lili; Uehara, Kyoko; Liu, Amy; Shu, Wei; Bellamacina, Cornelia; McKenney, David; Morris, Laura; Tonn, George R.; Osborne, Colin; Benton, Bret M.; McDowell, Laura; Fu, Jiping; Sweeney, Zachary K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">9360-9370</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This report summarizes the identification and synthesis of novel LpxC inhibitors aided by computational methods that leveraged numerous crystal structures.  This effort led to the identification of oxazolidinone and isoxazoline inhibitors with potent in vitro activity against P. aeruginosa and other Gram-neg. bacteria.  Representative compd. 13f demonstrated efficacy against P. aeruginosa in a mouse neutropenic thigh infection model.  The antibacterial activity against K. pneumoniae could be potentiated by Gram-pos. antibiotics rifampicin (RIF) and vancomycin (VAN) in both in vitro and in vivo models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphGwLR2DR7VrVg90H21EOLACvtfcHk0ljLrXNVIZDWBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslaqtrvF&md5=73c59bf77a4a9ea5c993d7f935955307</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01287&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01287%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DP.%2BS.%26aulast%3DLapointe%26aufirst%3DG.%26aulast%3DMadera%26aufirst%3DA.%2BM.%26aulast%3DSimmons%26aufirst%3DR.%2BL.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DYifru%26aufirst%3DA.%26aulast%3DTjandra%26aufirst%3DM.%26aulast%3DKarur%26aufirst%3DS.%26aulast%3DRico%26aufirst%3DA.%26aulast%3DThompson%26aufirst%3DK.%26aulast%3DBojkovic%26aufirst%3DJ.%26aulast%3DXie%26aufirst%3DL.%26aulast%3DUehara%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DA.%26aulast%3DShu%26aufirst%3DW.%26aulast%3DBellamacina%26aufirst%3DC.%26aulast%3DMcKenney%26aufirst%3DD.%26aulast%3DMorris%26aufirst%3DL.%26aulast%3DTonn%26aufirst%3DG.%2BR.%26aulast%3DOsborne%26aufirst%3DC.%26aulast%3DBenton%26aufirst%3DB.%2BM.%26aulast%3DMcDowell%26aufirst%3DL.%26aulast%3DFu%26aufirst%3DJ.%26aulast%3DSweeney%26aufirst%3DZ.%2BK.%26atitle%3DApplication%2520of%2520virtual%2520screening%2520to%2520the%2520identification%2520of%2520new%2520LpxC%2520inhibitor%2520chemotypes%252C%2520oxazolidinone%2520and%2520isoxazoline%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D9360%26epage%3D9370%26doi%3D10.1021%2Facs.jmedchem.8b01287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kyin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span> <span> </span><span class="NLM_article-title">Structural and biochemical basis of apoptotic activation by Smac/DIABLO</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>406</i></span>,  <span class="NLM_fpage">855</span>– <span class="NLM_lpage">862</span>, <span class="refDoi"> DOI: 10.1038/35022514</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1038%2F35022514" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10972280" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmsVCrsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=406&publication_year=2000&pages=855-862&author=J.+Chaiauthor=C.+Duauthor=J.+W.+Wuauthor=S.+Kyinauthor=X.+Wangauthor=Y.+Shi&title=Structural+and+biochemical+basis+of+apoptotic+activation+by+Smac%2FDIABLO&doi=10.1038%2F35022514"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and biochemical basis of apoptotic activation by Smac/DIABLO</span></div><div class="casAuthors">Chai, Jijie; Du, Chunying; Wu, Jia-Wei; Kyin, Saw; Wang, Xiaodong; Shi, Yigong</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">406</span>
        (<span class="NLM_cas:issue">6798</span>),
    <span class="NLM_cas:pages">855-862</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Apoptosis (programmed cell death), an essential process in the development and homeostasis of metazoans, is carried out by caspases.  The mitochondrial protein Smac/DIABLO performs a crit. function in apoptosis by eliminating the inhibitory effect of IAPs (inhibitor of apoptosis proteins) on caspases.  Here we show that Smac/DIABLO promotes not only the proteolytic activation of procaspase-3 but also the enzymic activity of mature caspase-3, both of which depend upon its ability to interact phys. with IAPs.  The crystal structure of Smac/DIABLO at 2.2Å resoln. reveals that it homodimerizes through an extensive hydrophobic interface.  Missense mutations inactivating this dimeric interface significantly compromise the function of Smac/DIABLO.  As in the Drosophila proteins Reaper, Grim and Hid, the amino-terminal amino acids of Smac/DIABLO are indispensable for its function, and a seven-residue peptide derived from the amino terminus promotes procaspase-3 activation in vitro.  These results establish an evolutionarily conserved structural and biochem. basis for the activation of apoptosis by Smac/DIABLO.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQ4zPSamJORbVg90H21EOLACvtfcHk0ljLrXNVIZDWBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmsVCrsLk%253D&md5=e3e65405a679b11556fa875b7c5dc9fa</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1038%2F35022514&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35022514%26sid%3Dliteratum%253Aachs%26aulast%3DChai%26aufirst%3DJ.%26aulast%3DDu%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DJ.%2BW.%26aulast%3DKyin%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DShi%26aufirst%3DY.%26atitle%3DStructural%2520and%2520biochemical%2520basis%2520of%2520apoptotic%2520activation%2520by%2520Smac%252FDIABLO%26jtitle%3DNature%26date%3D2000%26volume%3D406%26spage%3D855%26epage%3D862%26doi%3D10.1038%2F35022514" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hennessy, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adam, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aquila, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castriotta, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hattersley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hird, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huntington, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamhi, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laing, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacIntyre, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omer, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oza, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Repik, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rooney, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saeh, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sha, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasbinder, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitston, D.</span></span> <span> </span><span class="NLM_article-title">Discovery of a novel class of dimeric Smac mimetics as potent IAP antagonists resulting in a clinical candidate for the treatment of cancer (AZD5582)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">9897</span>– <span class="NLM_lpage">9919</span>, <span class="refDoi"> DOI: 10.1021/jm401075x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401075x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFWltrjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=9897-9919&author=E.+J.+Hennessyauthor=A.+Adamauthor=B.+M.+Aquilaauthor=L.+M.+Castriottaauthor=D.+Cookauthor=M.+Hattersleyauthor=A.+W.+Hirdauthor=C.+Huntingtonauthor=V.+M.+Kamhiauthor=N.+M.+Laingauthor=D.+Liauthor=T.+MacIntyreauthor=C.+A.+Omerauthor=V.+Ozaauthor=T.+Pattersonauthor=G.+Repikauthor=M.+T.+Rooneyauthor=J.+C.+Saehauthor=L.+Shaauthor=M.+M.+Vasbinderauthor=H.+Wangauthor=D.+Whitston&title=Discovery+of+a+novel+class+of+dimeric+Smac+mimetics+as+potent+IAP+antagonists+resulting+in+a+clinical+candidate+for+the+treatment+of+cancer+%28AZD5582%29&doi=10.1021%2Fjm401075x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Novel Class of Dimeric Smac Mimetics as Potent IAP Antagonists Resulting in a Clinical Candidate for the Treatment of Cancer (AZD5582)</span></div><div class="casAuthors">Hennessy, Edward J.; Adam, Ammar; Aquila, Brian M.; Castriotta, Lillian M.; Cook, Donald; Hattersley, Maureen; Hird, Alexander W.; Huntington, Christopher; Kamhi, Victor M.; Laing, Naomi M.; Li, Danyang; MacIntyre, Terry; Omer, Charles A.; Oza, Vibha; Patterson, Troy; Repik, Galina; Rooney, Michael T.; Saeh, Jamal C.; Sha, Li; Vasbinder, Melissa M.; Wang, Haiyun; Whitston, David</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">9897-9919</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of dimeric compds. based on the AVPI motif of Smac (second mitochondrial activator of caspases) were designed and prepd. as antagonists of the inhibitor of apoptosis proteins (IAPs).  Optimization of cellular potency, phys. properties, and pharmacokinetic parameters led to the identification of compd. 14 (AZD5582), which binds potently to the BIR3 domains of cIAP1, cIAP2, and XIAP (IC50 = 15, 21, and 15 nM, resp.).  This compd. causes cIAP1 degrdn. and induces apoptosis in the MDA-MB-231 breast cancer cell line at subnanomolar concns. in vitro.  When administered i.v. to MDA-MB-231 xenograft-bearing mice, 14 results in cIAP1 degrdn. and caspase-3 cleavage within tumor cells and causes substantial tumor regressions following two weekly doses of 3.0 mg/kg.  Antiproliferative effects are obsd. with 14 in only a small subset of the over 200 cancer cell lines examd., consistent with other published IAP inhibitors.  As a result of its in vitro and in vivo profile, 14 was nominated as a candidate for clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppmeDH06Y5lLVg90H21EOLACvtfcHk0liFyHcd7L-e2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFWltrjM&md5=9b4a5f7b89ebf74737d86c86acdf9c77</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1021%2Fjm401075x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401075x%26sid%3Dliteratum%253Aachs%26aulast%3DHennessy%26aufirst%3DE.%2BJ.%26aulast%3DAdam%26aufirst%3DA.%26aulast%3DAquila%26aufirst%3DB.%2BM.%26aulast%3DCastriotta%26aufirst%3DL.%2BM.%26aulast%3DCook%26aufirst%3DD.%26aulast%3DHattersley%26aufirst%3DM.%26aulast%3DHird%26aufirst%3DA.%2BW.%26aulast%3DHuntington%26aufirst%3DC.%26aulast%3DKamhi%26aufirst%3DV.%2BM.%26aulast%3DLaing%26aufirst%3DN.%2BM.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DMacIntyre%26aufirst%3DT.%26aulast%3DOmer%26aufirst%3DC.%2BA.%26aulast%3DOza%26aufirst%3DV.%26aulast%3DPatterson%26aufirst%3DT.%26aulast%3DRepik%26aufirst%3DG.%26aulast%3DRooney%26aufirst%3DM.%2BT.%26aulast%3DSaeh%26aufirst%3DJ.%2BC.%26aulast%3DSha%26aufirst%3DL.%26aulast%3DVasbinder%26aufirst%3DM.%2BM.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DWhitston%26aufirst%3DD.%26atitle%3DDiscovery%2520of%2520a%2520novel%2520class%2520of%2520dimeric%2520Smac%2520mimetics%2520as%2520potent%2520IAP%2520antagonists%2520resulting%2520in%2520a%2520clinical%2520candidate%2520for%2520the%2520treatment%2520of%2520cancer%2520%2528AZD5582%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D9897%26epage%3D9919%26doi%3D10.1021%2Fjm401075x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chandraratna, R. A.</span></span> <span> </span><span class="NLM_article-title">Tazarotene: the first receptor-selective topical retinoid for the treatment of psoriasis</span>. <i>J. Am. Acad. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">S12</span>– <span class="NLM_lpage">17</span>, <span class="refDoi"> DOI: 10.1016/S0190-9622(97)80395-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1016%2FS0190-9622%2897%2980395-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=9270551" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1997&pages=S12-17&author=R.+A.+Chandraratna&title=Tazarotene%3A+the+first+receptor-selective+topical+retinoid+for+the+treatment+of+psoriasis&doi=10.1016%2FS0190-9622%2897%2980395-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1016%2FS0190-9622%2897%2980395-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0190-9622%252897%252980395-7%26sid%3Dliteratum%253Aachs%26aulast%3DChandraratna%26aufirst%3DR.%2BA.%26atitle%3DTazarotene%253A%2520the%2520first%2520receptor-selective%2520topical%2520retinoid%2520for%2520the%2520treatment%2520of%2520psoriasis%26jtitle%3DJ.%2520Am.%2520Acad.%2520Dermatol.%26date%3D1997%26volume%3D37%26spage%3DS12%26epage%3D17%26doi%3D10.1016%2FS0190-9622%2897%2980395-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Talele, T. T.</span></span> <span> </span><span class="NLM_article-title">Natural-products-inspired use of the <i>gem</i>-dimethyl group in medicinal chemistry</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">2166</span>– <span class="NLM_lpage">2210</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00315</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00315" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtl2lsLjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=2166-2210&author=T.+T.+Talele&title=Natural-products-inspired+use+of+the+gem-dimethyl+group+in+medicinal+chemistry&doi=10.1021%2Facs.jmedchem.7b00315"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Natural-Products-Inspired Use of the gem-Dimethyl Group in Medicinal Chemistry</span></div><div class="casAuthors">Talele, Tanaji T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2166-2210</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The gem-di-Me moiety is a structural feature frequently found in many natural products of clin. interest, including, but not limited to, taxanes, epothilones, statins, retinoids, di-/triterpenes, noviose deoxysugar, and antibiotics derived from β-lactams, macrolides, and aminocoumarins.  Inspired by this time-tested moiety, medicinal chemists have widely explored its use in developing bioactive mols. because of the possibility to (1) increase target engagement, potency, and selectivity through van der Waals interactions and entropically favorable restriction to a bioactive conformation, (2) mitigate toxicity, (3) obtain superior DMPK profile, (4) modulate the pKa of nearby functionality, (5) induce symmetry into a monomethyl substituted chiral center, and (6) apply the Thorpe-Ingold conformational effect in an o-hydroxydihydrocinnamic acid based prodrug design.  The aim of this Perspective is to illustrate how medicinal chemists have elegantly employed the gem-di-Me group to obtain clin. useful drugs and to provide synthetic methods to install a gem-di-Me group.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdrXsWHYSwO7Vg90H21EOLACvtfcHk0liFyHcd7L-e2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtl2lsLjE&md5=dcb844c4655081b8a38f75696ea2723d</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00315&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00315%26sid%3Dliteratum%253Aachs%26aulast%3DTalele%26aufirst%3DT.%2BT.%26atitle%3DNatural-products-inspired%2520use%2520of%2520the%2520gem-dimethyl%2520group%2520in%2520medicinal%2520chemistry%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D2166%26epage%3D2210%26doi%3D10.1021%2Facs.jmedchem.7b00315" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gehringer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, S. A.</span></span> <span> </span><span class="NLM_article-title">Emerging and re-emerging warheads for targeted covalent inhibitors: Applications in medicinal chemistry and chemical biology</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">5673</span>– <span class="NLM_lpage">5724</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01153</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01153" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFKiur%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=5673-5724&author=M.+Gehringerauthor=S.+A.+Laufer&title=Emerging+and+re-emerging+warheads+for+targeted+covalent+inhibitors%3A+Applications+in+medicinal+chemistry+and+chemical+biology&doi=10.1021%2Facs.jmedchem.8b01153"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging and Re-Emerging Warheads for Targeted Covalent Inhibitors: Applications in Medicinal Chemistry and Chemical Biology</span></div><div class="casAuthors">Gehringer, Matthias; Laufer, Stefan A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5673-5724</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Targeted covalent inhibitors (TCIs) are designed to bind poorly conserved amino acids by means of reactive groups, the so-called warheads.  Currently, targeting noncatalytic cysteine residues with acrylamides and other α,β-unsatd. carbonyl compds. is the predominant strategy in TCI development.  The recent ascent of covalent drugs has stimulated considerable efforts to characterize alternative warheads for the covalent-reversible and irreversible engagement of noncatalytic cysteine residues as well as other amino acids.  This Perspective article provides an overview of warheads-beyond α,β-unsatd. amides-recently used in the design of targeted covalent ligands.  Promising reactive groups that have not yet demonstrated their utility in TCI development are also highlighted.  Special emphasis is placed on the discussion of reactivity and of case studies illustrating applications in medicinal chem. and chem. biol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDhc4PWV293LVg90H21EOLACvtfcHk0lgRyYG5CpiIKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFKiur%252FL&md5=4623733558ff99aadebfc13950b816ad</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01153%26sid%3Dliteratum%253Aachs%26aulast%3DGehringer%26aufirst%3DM.%26aulast%3DLaufer%26aufirst%3DS.%2BA.%26atitle%3DEmerging%2520and%2520re-emerging%2520warheads%2520for%2520targeted%2520covalent%2520inhibitors%253A%2520Applications%2520in%2520medicinal%2520chemistry%2520and%2520chemical%2520biology%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D5673%26epage%3D5724%26doi%3D10.1021%2Facs.jmedchem.8b01153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barf, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Covey, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izumi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van de Kar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulrajani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Lith, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Hoek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Zwart, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mittag, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demont, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verkaik, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krantz, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulrich, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaptein, A.</span></span> <span> </span><span class="NLM_article-title">Acalabrutinib (ACP-196): A covalent Bruton Tyrosine Kinase inhibitor with a differentiated selectivity and in vivo potency profile</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>363</i></span>,  <span class="NLM_fpage">240</span>– <span class="NLM_lpage">252</span>, <span class="refDoi"> DOI: 10.1124/jpet.117.242909</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1124%2Fjpet.117.242909" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=28882879" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtleltrnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2017&pages=240-252&author=T.+Barfauthor=T.+Coveyauthor=R.+Izumiauthor=B.+van+de+Karauthor=M.+Gulrajaniauthor=B.+van+Lithauthor=M.+van+Hoekauthor=E.+de+Zwartauthor=D.+Mittagauthor=D.+Demontauthor=S.+Verkaikauthor=F.+Krantzauthor=P.+G.+Pearsonauthor=R.+Ulrichauthor=A.+Kaptein&title=Acalabrutinib+%28ACP-196%29%3A+A+covalent+Bruton+Tyrosine+Kinase+inhibitor+with+a+differentiated+selectivity+and+in+vivo+potency+profile&doi=10.1124%2Fjpet.117.242909"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Acalabrutinib (ACP-196): a covalent Bruton tyrosine kinase inhibitor with a differentiated selectivity and in vivo potency profile</span></div><div class="casAuthors">Barf, Tjeerd; Covey, Todd; Izumi, Raquel; van de Kar, Bas; Gulrajani, Michael; van Lith, Bart; van Hoek, Maaike; de Zwart, Edwin; Mittag, Diana; Demont, Dennis; Verkaik, Saskia; Krantz, Fanny; Pearson, Paul G.; Ulrich, Roger; Kaptein, Allard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">240-252</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Several small-mol. Bruton tyrosine kinase (BTK) inhibitors are in development for B cell malignancies and autoimmune disorders, each characterized by distinct potency and selectivity patterns.  Herein we describe the pharmacol. characterization of BTK inhibitor acalabrutinib [compd. 1, ACP-196 (4-[8- amino-3-[(2S)-1-but-2-ynoylpyrrolidin-2-yl]imidazo[1,5-a]pyrazin1-yl]-N-(2-pyridyl)benzamide)].  Acalabrutinib possesses a reactive butynamide group that binds covalently to Cys481 in BTK.  Relative to the other BTK inhibitors described here, the reduced intrinsic reactivity of acalabrutinib helps to limit inhibition of off-target kinases having cysteine-mediated covalent binding potential.  Acalabrutinib demonstrated higher biochem. and cellular selectivity than ibrutinib and spebrutinib (compds. 2 and 3, resp.).  Importantly, off-target kinases, such as epidermal growth factor receptor (EGFR) and interleukin 2-inducible T cell kinase (ITK), were not inhibited.  Detn. of the inhibitory potential of anti-IgM-induced CD69 expression in human peripheral blood mononuclear cells and whole blood demonstrated that acalabrutinib is a potent functional BTK inhibitor.  In vivo evaluation in mice revealed that acalabrutinib is more potent than ibrutinib and spebrutinib.  Preclin. and clin. studies showed that the level and duration of BTK occupancy correlates with in vivo efficacy.  Evaluation of the pharmacokinetic properties of acalabrutinib in healthy adult volunteers demonstrated rapid absorption and fast elimination.  In these healthy individuals, a single oral dose of 100 mg showed approx. 99% median target coverage at 3 and 12 h and around 90% at 24 h in peripheral B cells.  In conclusion, acalabrutinib is a BTK inhibitor with key pharmacol. differentiators vs. ibrutinib and spebrutinib and is currently being evaluated in clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGol9xhDmwvup7Vg90H21EOLACvtfcHk0lgRyYG5CpiIKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtleltrnO&md5=73cbd3a87396abbf8cb20e4361f96f64</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1124%2Fjpet.117.242909&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.117.242909%26sid%3Dliteratum%253Aachs%26aulast%3DBarf%26aufirst%3DT.%26aulast%3DCovey%26aufirst%3DT.%26aulast%3DIzumi%26aufirst%3DR.%26aulast%3Dvan%2Bde%2BKar%26aufirst%3DB.%26aulast%3DGulrajani%26aufirst%3DM.%26aulast%3Dvan%2BLith%26aufirst%3DB.%26aulast%3Dvan%2BHoek%26aufirst%3DM.%26aulast%3Dde%2BZwart%26aufirst%3DE.%26aulast%3DMittag%26aufirst%3DD.%26aulast%3DDemont%26aufirst%3DD.%26aulast%3DVerkaik%26aufirst%3DS.%26aulast%3DKrantz%26aufirst%3DF.%26aulast%3DPearson%26aufirst%3DP.%2BG.%26aulast%3DUlrich%26aufirst%3DR.%26aulast%3DKaptein%26aufirst%3DA.%26atitle%3DAcalabrutinib%2520%2528ACP-196%2529%253A%2520A%2520covalent%2520Bruton%2520Tyrosine%2520Kinase%2520inhibitor%2520with%2520a%2520differentiated%2520selectivity%2520and%2520in%2520vivo%2520potency%2520profile%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2017%26volume%3D363%26spage%3D240%26epage%3D252%26doi%3D10.1124%2Fjpet.117.242909" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walter, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rule, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyer, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cazin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quittet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchinson, C. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffy, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birkett, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamieson, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Courtenay-Luck, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshizawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharpe, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohno, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cartron, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morschhauser, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fegan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salles, G.</span></span> <span> </span><span class="NLM_article-title">A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">411</span>– <span class="NLM_lpage">419</span>, <span class="refDoi"> DOI: 10.1182/blood-2015-08-664086</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1182%2Fblood-2015-08-664086" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=26542378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Cis7zO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2016&pages=411-419&author=H.+S.+Walterauthor=S.+A.+Ruleauthor=M.+J.+Dyerauthor=L.+Karlinauthor=C.+Jonesauthor=B.+Cazinauthor=P.+Quittetauthor=N.+Shahauthor=C.+V.+Hutchinsonauthor=H.+Hondaauthor=K.+Duffyauthor=J.+Birkettauthor=V.+Jamiesonauthor=N.+Courtenay-Luckauthor=T.+Yoshizawaauthor=J.+Sharpeauthor=T.+Ohnoauthor=S.+Abeauthor=A.+Nishimuraauthor=G.+Cartronauthor=F.+Morschhauserauthor=C.+Feganauthor=G.+Salles&title=A+phase+1+clinical+trial+of+the+selective+BTK+inhibitor+ONO%2FGS-4059+in+relapsed+and+refractory+mature+B-cell+malignancies&doi=10.1182%2Fblood-2015-08-664086"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies</span></div><div class="casAuthors">Walter, Harriet S.; Rule, Simon A.; Dyer, Martin J. S.; Karlin, Lionel; Jones, Ceri; Cazin, Bruno; Quittet, Philippe; Shah, Nimish; Hutchinson, Claire V.; Honda, Hideyuki; Duffy, Kevin; Birkett, Joseph; Jamieson, Virginia; Courtenay-Luck, Nigel; Yoshizawa, Toshio; Sharpe, John; Ohno, Tomoya; Abe, Shinichiro; Nishimura, Akihisa; Cartron, Guillaume; Morschhauser, Franck; Fegan, Christopher; Salles, Gilles</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">411-419</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">We report the results of a multicenter phase 1 dose-escalation study of the selective Bruton tyrosine kinase (BTK) inhibitor ONO/GS-4059 in 90 patients with relapsed/refractory B-cell malignancies.  There were 9 dose-escalation cohorts ranging from 20 mg to 600 mg once daily with twice-daily regimens of 240 mg and 300 mg.  Twenty-four of 25 evaluable chronic lymphocytic leukemia (CLL) patients (96%) responded to ONO/GS-4059, with a median treatment duration of 80 wk; 21 CLL patients remain on treatment.  Lymph node responses were rapid and assocd. with a concurrent lymphocytosis.  Eleven of 12 evaluable patients with mantle cell lymphoma (92%) responded (median treatment duration, 40 wk).  Eleven of 31 non-germinal center B-cell diffuse large B-cell lymphoma patients (35%) responded but median treatment duration was 12 wk due to development of progressive disease.  ONO/GS-4059 was very well tolerated with 75% of adverse events (AEs) being Common Toxicity Criteria for Adverse Events version 4.0 grade 1 or grade 2.  Grade 3/4 AEs were mainly hematol. and recovered spontaneously during therapy.  One CLL patient experienced a grade 3 treatment-related bleeding event (spontaneous muscle hematoma) but no clin. significant diarrhea, cardiac dysrhythmias, or arthralgia were obsd.  No maximal tolerated dose (MTD) was reached in the CLL cohort.  In the non-Hodgkin lymphoma cohort, 4 patients developed a dose-limiting toxicity, yielding an MTD of 480 mg once daily.  ONO/GS-4059 has significant activity in relapsed/refractory B-cell malignancies without major drug-related toxicity.  The selectivity of ONO/GS-4059 should confer advantages in combination therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZFfZyaWsIdbVg90H21EOLACvtfcHk0litY8lMX5IlZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Cis7zO&md5=f12cd01520c82ddd2067f2b329bd38a9</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1182%2Fblood-2015-08-664086&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2015-08-664086%26sid%3Dliteratum%253Aachs%26aulast%3DWalter%26aufirst%3DH.%2BS.%26aulast%3DRule%26aufirst%3DS.%2BA.%26aulast%3DDyer%26aufirst%3DM.%2BJ.%26aulast%3DKarlin%26aufirst%3DL.%26aulast%3DJones%26aufirst%3DC.%26aulast%3DCazin%26aufirst%3DB.%26aulast%3DQuittet%26aufirst%3DP.%26aulast%3DShah%26aufirst%3DN.%26aulast%3DHutchinson%26aufirst%3DC.%2BV.%26aulast%3DHonda%26aufirst%3DH.%26aulast%3DDuffy%26aufirst%3DK.%26aulast%3DBirkett%26aufirst%3DJ.%26aulast%3DJamieson%26aufirst%3DV.%26aulast%3DCourtenay-Luck%26aufirst%3DN.%26aulast%3DYoshizawa%26aufirst%3DT.%26aulast%3DSharpe%26aufirst%3DJ.%26aulast%3DOhno%26aufirst%3DT.%26aulast%3DAbe%26aufirst%3DS.%26aulast%3DNishimura%26aufirst%3DA.%26aulast%3DCartron%26aufirst%3DG.%26aulast%3DMorschhauser%26aufirst%3DF.%26aulast%3DFegan%26aufirst%3DC.%26aulast%3DSalles%26aufirst%3DG.%26atitle%3DA%2520phase%25201%2520clinical%2520trial%2520of%2520the%2520selective%2520BTK%2520inhibitor%2520ONO%252FGS-4059%2520in%2520relapsed%2520and%2520refractory%2520mature%2520B-cell%2520malignancies%26jtitle%3DBlood%26date%3D2016%26volume%3D127%26spage%3D411%26epage%3D419%26doi%3D10.1182%2Fblood-2015-08-664086" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watterson, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaudoin
Bertrand, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batt, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pattoli, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skala, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obermeier, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vickery, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elzinga, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Discenza, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Arienzo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillooly, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulicicchio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heimrich, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruan, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westhouse, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catlett, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhry, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galella, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tebben, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pokross, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rampulla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allentoff, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallace, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salter-Cid, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macor, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tino, J. A.</span></span> <span> </span><span class="NLM_article-title">Discovery of branebrutinib (BMS-986195): A strategy for identifying a highly potent and selective covalent inhibitor providing rapid in vivo inactivation of Bruton’s tyrosine kinase (BTK)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">3228</span>– <span class="NLM_lpage">3250</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00167</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00167" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC1MXls1aks7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=3228-3250&author=S.+H.+Wattersonauthor=Q.+Liuauthor=M.+Beaudoin%0ABertrandauthor=D.+G.+Battauthor=L.+Liauthor=M.+A.+Pattoliauthor=S.+Skalaauthor=L.+Chengauthor=M.+T.+Obermeierauthor=R.+Mooreauthor=Z.+Yangauthor=R.+Vickeryauthor=P.+A.+Elzingaauthor=L.+Discenzaauthor=C.+D%E2%80%99Arienzoauthor=K.+M.+Gilloolyauthor=T.+L.+Taylorauthor=C.+Pulicicchioauthor=Y.+Zhangauthor=E.+Heimrichauthor=K.+W.+McIntyreauthor=Q.+Ruanauthor=R.+A.+Westhouseauthor=I.+M.+Catlettauthor=N.+Zhengauthor=C.+Chaudhryauthor=J.+Daiauthor=M.+A.+Galellaauthor=A.+J.+Tebbenauthor=M.+Pokrossauthor=J.+Liauthor=R.+Zhaoauthor=D.+Smithauthor=R.+Rampullaauthor=A.+Allentoffauthor=M.+A.+Wallaceauthor=A.+Mathurauthor=L.+Salter-Cidauthor=J.+E.+Macorauthor=P.+H.+Carterauthor=A.+Furaauthor=J.+R.+Burkeauthor=J.+A.+Tino&title=Discovery+of+branebrutinib+%28BMS-986195%29%3A+A+strategy+for+identifying+a+highly+potent+and+selective+covalent+inhibitor+providing+rapid+in+vivo+inactivation+of+Bruton%E2%80%99s+tyrosine+kinase+%28BTK%29&doi=10.1021%2Facs.jmedchem.9b00167"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton's Tyrosine Kinase (BTK)</span></div><div class="casAuthors">Watterson, Scott H.; Liu, Qingjie; Beaudoin Bertrand, Myra; Batt, Douglas G.; Li, Ling; Pattoli, Mark A.; Skala, Stacey; Cheng, Lihong; Obermeier, Mary T.; Moore, Robin; Yang, Zheng; Vickery, Rodney; Elzinga, Paul A.; Discenza, Lorell; D'Arienzo, Celia; Gillooly, Kathleen M.; Taylor, Tracy L.; Pulicicchio, Claudine; Zhang, Yifan; Heimrich, Elizabeth; McIntyre, Kim W.; Ruan, Qian; Westhouse, Richard A.; Catlett, Ian M.; Zheng, Naiyu; Chaudhry, Charu; Dai, Jun; Galella, Michael A.; Tebben, Andrew J.; Pokross, Matt; Li, Jianqing; Zhao, Rulin; Smith, Daniel; Rampulla, Richard; Allentoff, Alban; Wallace, Michael A.; Mathur, Arvind; Salter-Cid, Luisa; Macor, John E.; Carter, Percy H.; Fura, Aberra; Burke, James R.; Tino, Joseph A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3228-3250</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (BTK), a non-receptor tyrosine kinase, is a member of the Tec family of kinases and is essential for B cell receptor (BCR) mediated signaling.  BTK also plays a crit. role in the downstream signaling pathways for the Fcγ receptor in monocytes, the Fcε receptor in granulocytes, and the RANK receptor in osteoclasts.  As a result, pharmacol. inhibition of BTK is anticipated to provide an effective strategy for the clin. treatment of autoimmune diseases such as rheumatoid arthritis and lupus.  This article will outline the evolution of our strategy to identify a covalent, irreversible inhibitor of BTK that has the intrinsic potency, selectivity, and pharmacokinetic properties necessary to provide a rapid rate of inactivation systemically following a very low dose.  With excellent in vivo efficacy and a very desirable tolerability profile, 5a (branebrutinib, BMS-986195) has advanced into clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGr5oQEoebirVg90H21EOLACvtfcHk0lj-duVaUbAbDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXls1aks7w%253D&md5=2d521ec7c06d503f940cb44d381af58d</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00167%26sid%3Dliteratum%253Aachs%26aulast%3DWatterson%26aufirst%3DS.%2BH.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DBeaudoin%2BBertrand%26aufirst%3DM.%26aulast%3DBatt%26aufirst%3DD.%2BG.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DPattoli%26aufirst%3DM.%2BA.%26aulast%3DSkala%26aufirst%3DS.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DObermeier%26aufirst%3DM.%2BT.%26aulast%3DMoore%26aufirst%3DR.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DVickery%26aufirst%3DR.%26aulast%3DElzinga%26aufirst%3DP.%2BA.%26aulast%3DDiscenza%26aufirst%3DL.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%26aulast%3DGillooly%26aufirst%3DK.%2BM.%26aulast%3DTaylor%26aufirst%3DT.%2BL.%26aulast%3DPulicicchio%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHeimrich%26aufirst%3DE.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DRuan%26aufirst%3DQ.%26aulast%3DWesthouse%26aufirst%3DR.%2BA.%26aulast%3DCatlett%26aufirst%3DI.%2BM.%26aulast%3DZheng%26aufirst%3DN.%26aulast%3DChaudhry%26aufirst%3DC.%26aulast%3DDai%26aufirst%3DJ.%26aulast%3DGalella%26aufirst%3DM.%2BA.%26aulast%3DTebben%26aufirst%3DA.%2BJ.%26aulast%3DPokross%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DR.%26aulast%3DSmith%26aufirst%3DD.%26aulast%3DRampulla%26aufirst%3DR.%26aulast%3DAllentoff%26aufirst%3DA.%26aulast%3DWallace%26aufirst%3DM.%2BA.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DSalter-Cid%26aufirst%3DL.%26aulast%3DMacor%26aufirst%3DJ.%2BE.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DFura%26aufirst%3DA.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26aulast%3DTino%26aufirst%3DJ.%2BA.%26atitle%3DDiscovery%2520of%2520branebrutinib%2520%2528BMS-986195%2529%253A%2520A%2520strategy%2520for%2520identifying%2520a%2520highly%2520potent%2520and%2520selective%2520covalent%2520inhibitor%2520providing%2520rapid%2520in%2520vivo%2520inactivation%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528BTK%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D3228%26epage%3D3250%26doi%3D10.1021%2Facs.jmedchem.9b00167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hayward, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faragher, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pillai, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagan, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fry, A. M.</span></span> <span> </span><span class="NLM_article-title">The centrosomal kinase Nek2 displays elevated levels of protein expression in human breast cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">7370</span>– <span class="NLM_lpage">7376</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-04-0960</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1158%2F0008-5472.CAN-04-0960" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=15492258" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD2cXosFyntLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=7370-7376&author=D.+G.+Haywardauthor=R.+B.+Clarkeauthor=A.+J.+Faragherauthor=M.+R.+Pillaiauthor=I.+M.+Haganauthor=A.+M.+Fry&title=The+centrosomal+kinase+Nek2+displays+elevated+levels+of+protein+expression+in+human+breast+cancer&doi=10.1158%2F0008-5472.CAN-04-0960"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">The Centrosomal Kinase Nek2 Displays Elevated Levels of Protein Expression in Human Breast Cancer</span></div><div class="casAuthors">Hayward, Daniel G.; Clarke, Robert B.; Faragher, Alison J.; Pillai, Meenu R.; Hagan, Iain M.; Fry, Andrew M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7370-7376</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Aneuploidy and chromosome instability are common abnormalities in human cancer.  Loss of control over mitotic progression, multipolar spindle formation, and cytokinesis defects are all likely to contribute to these phenotypes.  Nek2 is a cell cycle-regulated protein kinase with maximal activity at the onset of mitosis that localizes to the centrosome.  Functional studies have implicated Nek2 in regulation of centrosome sepn. and spindle formation.  Here, the authors present the first study of the protein expression levels of the Nek2 kinase in human cancer cell lines and primary tumors.  Nek2 protein is elevated 2- to 5-fold in cell lines derived from a range of human tumors including those of cervical, ovarian, breast, prostate, and leukemic origin.  Most importantly, by immunohistochem., the authors find that Nek2 protein is significantly up-regulated in preinvasive in situ ductal carcinomas of the breast as well as in invasive breast carcinomas.  Finally, by ectopic expression of Nek2A in immortalized HBL100 breast epithelial cells, the authors show that increased Nek2 protein leads to accumulation of multinucleated cells with supernumerary centrosomes.  These data highlight the Nek2 kinase as novel potential target for chemotherapeutic intervention in breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4ko1rEDu8fbVg90H21EOLACvtfcHk0lj-duVaUbAbDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXosFyntLc%253D&md5=10b8d50fa1025dd8013fced43532e4c2</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-04-0960&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-04-0960%26sid%3Dliteratum%253Aachs%26aulast%3DHayward%26aufirst%3DD.%2BG.%26aulast%3DClarke%26aufirst%3DR.%2BB.%26aulast%3DFaragher%26aufirst%3DA.%2BJ.%26aulast%3DPillai%26aufirst%3DM.%2BR.%26aulast%3DHagan%26aufirst%3DI.%2BM.%26aulast%3DFry%26aufirst%3DA.%2BM.%26atitle%3DThe%2520centrosomal%2520kinase%2520Nek2%2520displays%2520elevated%2520levels%2520of%2520protein%2520expression%2520in%2520human%2520breast%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26spage%3D7370%26epage%3D7376%26doi%3D10.1158%2F0008-5472.CAN-04-0960" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andreasson, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dictor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jerkeman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berglund, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sundstrom, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linderoth, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenquist, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borrebaeck, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ek, S.</span></span> <span> </span><span class="NLM_article-title">Identification of molecular targets associated with transformed diffuse large B cell lymphoma using highly purified tumor cells</span>. <i>Am. J. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">803</span>– <span class="NLM_lpage">808</span>, <span class="refDoi"> DOI: 10.1002/ajh.21549</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1002%2Fajh.21549" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=19844990" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjslOmsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2009&pages=803-808&author=U.+Andreassonauthor=M.+Dictorauthor=M.+Jerkemanauthor=M.+Berglundauthor=C.+Sundstromauthor=J.+Linderothauthor=R.+Rosenquistauthor=C.+A.+Borrebaeckauthor=S.+Ek&title=Identification+of+molecular+targets+associated+with+transformed+diffuse+large+B+cell+lymphoma+using+highly+purified+tumor+cells&doi=10.1002%2Fajh.21549"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of molecular targets associated with transformed diffuse large B cell lymphoma using highly purified tumor cells</span></div><div class="casAuthors">Andreasson, Ulrika; Dictor, Michael; Jerkeman, Mats; Berglund, Mattias; Sundstroem, Christer; Linderoth, Johan; Rosenquist, Richard; Borrebaeck, Carl A. K.; Ek, Sara</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Hematology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">803-808</span>CODEN:
                <span class="NLM_cas:coden">AJHEDD</span>;
        ISSN:<span class="NLM_cas:issn">0361-8609</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Follicular lymphoma (FL) frequently transforms into the more aggressive diffuse large B cell lymphoma (DLBCL-tr), but no protein biomarkers have been identified for predictive or early diagnosis.  Gene expression analyses have identified genes changing on transformation but have failed to be reproducible in different studies, reflecting the heterogeneity within the tumor tissue and between tumor samples.  Gene expression analyses on Affymetrix Human Genome U133 Plus 2.0 arrays were performed, using flow cytometry sorted tumor cells derived from FL and transformed DLBCL.  To identify mol. targets assocd. with the transformation, subsequent immunohistochem. (IHC) analyses of the corresponding proteins were performed.  Using highly purified cells, this study identified 163 genes, which were significantly deregulated during the transformation in a majority of cases.  Among the upregulated transcripts, 13 genes were selected for validation using IHC, based on the availability of com. antibodies, and galectin-3 and NEK2 proteins specifically identify DLBCL-tr, when compared with FL.  We demonstrate that by purifying tumor cells through cell sorting, thereby reducing the heterogeneity due to infiltrating cells, it was possible to identify distinct differences between tumor entities rather than variations due to cellular compn.  Galectin-3 and NEK2 both identified a subgroup of DLBCL-tr, and the function of these protein markers also suggests a biol. role in the transformation process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpprkSM8SoOcrVg90H21EOLACvtfcHk0lj-duVaUbAbDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjslOmsA%253D%253D&md5=8e1a1cb183a5a11a28efdf011c8bb52f</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1002%2Fajh.21549&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fajh.21549%26sid%3Dliteratum%253Aachs%26aulast%3DAndreasson%26aufirst%3DU.%26aulast%3DDictor%26aufirst%3DM.%26aulast%3DJerkeman%26aufirst%3DM.%26aulast%3DBerglund%26aufirst%3DM.%26aulast%3DSundstrom%26aufirst%3DC.%26aulast%3DLinderoth%26aufirst%3DJ.%26aulast%3DRosenquist%26aufirst%3DR.%26aulast%3DBorrebaeck%26aufirst%3DC.%2BA.%26aulast%3DEk%26aufirst%3DS.%26atitle%3DIdentification%2520of%2520molecular%2520targets%2520associated%2520with%2520transformed%2520diffuse%2520large%2520B%2520cell%2520lymphoma%2520using%2520highly%2520purified%2520tumor%2520cells%26jtitle%3DAm.%2520J.%2520Hematol.%26date%3D2009%26volume%3D84%26spage%3D803%26epage%3D808%26doi%3D10.1002%2Fajh.21549" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Henise, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taunton, J.</span></span> <span> </span><span class="NLM_article-title">Irreversible Nek2 kinase inhibitors with cellular activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">4133</span>– <span class="NLM_lpage">4146</span>, <span class="refDoi"> DOI: 10.1021/jm200222m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200222m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmslGlsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=4133-4146&author=J.+C.+Heniseauthor=J.+Taunton&title=Irreversible+Nek2+kinase+inhibitors+with+cellular+activity&doi=10.1021%2Fjm200222m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Irreversible Nek2 Kinase Inhibitors with Cellular Activity</span></div><div class="casAuthors">Henise, Jeffrey C.; Taunton, Jack</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4133-4146</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A structure-based approach was used to design irreversible, cysteine-targeted inhibitors of the human centrosomal kinase, Nek2.  Potent inhibition of Nek2 kinase activity in biochem. and cell-based assays required a noncatalytic cysteine residue (Cys22), located near the glycine-rich loop in a subset of human kinases.  Elaboration of an oxindole scaffold led to our most selective compd., oxindole propynamide 16 (JH295).  Propynamide 16 irreversibly inhibited cellular Nek2 without affecting the mitotic kinases, Cdk1, Aurora B, or Plk1.  Moreover, 16 did not perturb bipolar spindle assembly or the spindle assembly checkpoint.  To our knowledge, 16 is the first small mol. shown to inactivate Nek2 kinase activity in cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpq8mOvaT5BPbVg90H21EOLACvtfcHk0liGuEU6hxCkNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmslGlsb4%253D&md5=35277e74fc346501e4847bba6586f9d0</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1021%2Fjm200222m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200222m%26sid%3Dliteratum%253Aachs%26aulast%3DHenise%26aufirst%3DJ.%2BC.%26aulast%3DTaunton%26aufirst%3DJ.%26atitle%3DIrreversible%2520Nek2%2520kinase%2520inhibitors%2520with%2520cellular%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D4133%26epage%3D4146%26doi%3D10.1021%2Fjm200222m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Moigne, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Djakovic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valle, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiss von
Soly, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madriaga, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soriano, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menon, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kampmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weissman, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aftab, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yakes, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shawver, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wustrow, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolfe, M.</span></span> <span> </span><span class="NLM_article-title">Targeting the AAA ATPase p97 as an approach to treat cancer through disruption of protein homeostasis</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">653</span>– <span class="NLM_lpage">665</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2015.10.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1016%2Fj.ccell.2015.10.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=26555175" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVSksr%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2015&pages=653-665&author=D.+J.+Andersonauthor=R.+Le+Moigneauthor=S.+Djakovicauthor=B.+Kumarauthor=J.+Riceauthor=S.+Wongauthor=J.+Wangauthor=B.+Yaoauthor=E.+Valleauthor=S.+Kiss+von%0ASolyauthor=A.+Madriagaauthor=F.+Sorianoauthor=M.+K.+Menonauthor=Z.+Y.+Wuauthor=M.+Kampmannauthor=Y.+Chenauthor=J.+S.+Weissmanauthor=B.+T.+Aftabauthor=F.+M.+Yakesauthor=L.+Shawverauthor=H.+J.+Zhouauthor=D.+Wustrowauthor=M.+Rolfe&title=Targeting+the+AAA+ATPase+p97+as+an+approach+to+treat+cancer+through+disruption+of+protein+homeostasis&doi=10.1016%2Fj.ccell.2015.10.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the AAA ATPase p97 as an Approach to Treat Cancer through Disruption of Protein Homeostasis</span></div><div class="casAuthors">Anderson, Daniel J.; Le Moigne, Ronan; Djakovic, Stevan; Kumar, Brajesh; Rice, Julie; Wong, Steve; Wang, Jinhai; Yao, Bing; Valle, Eduardo; Kiss von Soly, Szerenke; Madriaga, Antonett; Soriano, Ferdie; Menon, Mary-Kamala; Wu, Zhi Yong; Kampmann, Martin; Chen, Yuwen; Weissman, Jonathan S.; Aftab, Blake T.; Yakes, F. Michael; Shawver, Laura; Zhou, Han-Jie; Wustrow, David; Rolfe, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">653-665</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">P97 is a AAA-ATPase with multiple cellular functions, one of which is crit. regulation of protein homeostasis pathways.  We describe the characterization of CB-5083, a potent, selective, and orally bioavailable inhibitor of p97.  Treatment of tumor cells with CB-5083 leads to accumulation of poly-ubiquitinated proteins, retention of endoplasmic reticulum-assocd. degrdn. (ERAD) substrates, and generation of irresolvable proteotoxic stress, leading to activation of the apoptotic arm of the unfolded protein response.  In xenograft models, CB-5083 causes modulation of key p97-related pathways, induces apoptosis, and has antitumor activity in a broad range of both hematol. and solid tumor models.  Mol. determinants of CB-5083 activity include expression of genes in the ERAD pathway, providing a potential strategy for patient selection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7c4WXhvOlYLVg90H21EOLACvtfcHk0liGuEU6hxCkNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVSksr%252FN&md5=662df92598397deba1586e8993f2bb7a</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2015.10.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2015.10.002%26sid%3Dliteratum%253Aachs%26aulast%3DAnderson%26aufirst%3DD.%2BJ.%26aulast%3DLe%2BMoigne%26aufirst%3DR.%26aulast%3DDjakovic%26aufirst%3DS.%26aulast%3DKumar%26aufirst%3DB.%26aulast%3DRice%26aufirst%3DJ.%26aulast%3DWong%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DYao%26aufirst%3DB.%26aulast%3DValle%26aufirst%3DE.%26aulast%3DKiss%2Bvon%2BSoly%26aufirst%3DS.%26aulast%3DMadriaga%26aufirst%3DA.%26aulast%3DSoriano%26aufirst%3DF.%26aulast%3DMenon%26aufirst%3DM.%2BK.%26aulast%3DWu%26aufirst%3DZ.%2BY.%26aulast%3DKampmann%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DWeissman%26aufirst%3DJ.%2BS.%26aulast%3DAftab%26aufirst%3DB.%2BT.%26aulast%3DYakes%26aufirst%3DF.%2BM.%26aulast%3DShawver%26aufirst%3DL.%26aulast%3DZhou%26aufirst%3DH.%2BJ.%26aulast%3DWustrow%26aufirst%3DD.%26aulast%3DRolfe%26aufirst%3DM.%26atitle%3DTargeting%2520the%2520AAA%2520ATPase%2520p97%2520as%2520an%2520approach%2520to%2520treat%2520cancer%2520through%2520disruption%2520of%2520protein%2520homeostasis%26jtitle%3DCancer%2520Cell%26date%3D2015%26volume%3D28%26spage%3D653%26epage%3D665%26doi%3D10.1016%2Fj.ccell.2015.10.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Djakovic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valle, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soriano, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menon, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madriaga, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiss von
Soly, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parlati, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yakes, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shawver, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Moigne, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolfe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wustrow, D.</span></span> <span> </span><span class="NLM_article-title">Discovery of a first-in-class, potent, selective, and orally bioavailable inhibitor of the p97 AAA ATPase (CB-5083)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">9480</span>– <span class="NLM_lpage">9497</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01346</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01346" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVahtL3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=9480-9497&author=H.+J.+Zhouauthor=J.+Wangauthor=B.+Yaoauthor=S.+Wongauthor=S.+Djakovicauthor=B.+Kumarauthor=J.+Riceauthor=E.+Valleauthor=F.+Sorianoauthor=M.+K.+Menonauthor=A.+Madriagaauthor=S.+Kiss+von%0ASolyauthor=A.+Kumarauthor=F.+Parlatiauthor=F.+M.+Yakesauthor=L.+Shawverauthor=R.+Le+Moigneauthor=D.+J.+Andersonauthor=M.+Rolfeauthor=D.+Wustrow&title=Discovery+of+a+first-in-class%2C+potent%2C+selective%2C+and+orally+bioavailable+inhibitor+of+the+p97+AAA+ATPase+%28CB-5083%29&doi=10.1021%2Facs.jmedchem.5b01346"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a First-in-Class, Potent, Selective, and Orally Bioavailable Inhibitor of the p97 AAA ATPase (CB-5083)</span></div><div class="casAuthors">Zhou, Han-Jie; Wang, Jinhai; Yao, Bing; Wong, Steve; Djakovic, Stevan; Kumar, Brajesh; Rice, Julie; Valle, Eduardo; Soriano, Ferdie; Menon, Mary-Kamala; Madriaga, Antonett; Kiss von Soly, Szerenke; Kumar, Abhinav; Parlati, Francesco; Yakes, F. Michael; Shawver, Laura; Le Moigne, Ronan; Anderson, Daniel J.; Rolfe, Mark; Wustrow, David</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">9480-9497</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The AAA-ATPase p97 plays vital roles in mechanisms of protein homeostasis, including ubiquitin-proteasome system (UPS) mediated protein degrdn., endoplasmic reticulum-assocd. degrdn. (ERAD), and autophagy.  Herein we describe our lead optimization efforts focused on in vitro potency, ADME, and pharmaceutical properties that led to the discovery of a potent, ATP-competitive, D2-selective, and orally bioavailable p97 inhibitor 71, CB-5083 (I).  Treatment of tumor cells with 71 leads to significant accumulation of markers assocd. with inhibition of UPS and ERAD functions, which induces irresolvable proteotoxic stress and cell death.  In tumor bearing mice, oral administration of 71 causes rapid accumulation of markers of the unfolded protein response (UPR) and subsequently induces apoptosis leading to sustained antitumor activity in in vivo xenograft models of both solid and hematol. tumors. 71 has been taken into phase 1 clin. trials in patients with multiple myeloma and solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGok_KA_ARhOyLVg90H21EOLACvtfcHk0liGuEU6hxCkNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVahtL3K&md5=9e124f8653d0b9ea7f0eba5f4b2a4412</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01346&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01346%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DH.%2BJ.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DYao%26aufirst%3DB.%26aulast%3DWong%26aufirst%3DS.%26aulast%3DDjakovic%26aufirst%3DS.%26aulast%3DKumar%26aufirst%3DB.%26aulast%3DRice%26aufirst%3DJ.%26aulast%3DValle%26aufirst%3DE.%26aulast%3DSoriano%26aufirst%3DF.%26aulast%3DMenon%26aufirst%3DM.%2BK.%26aulast%3DMadriaga%26aufirst%3DA.%26aulast%3DKiss%2Bvon%2BSoly%26aufirst%3DS.%26aulast%3DKumar%26aufirst%3DA.%26aulast%3DParlati%26aufirst%3DF.%26aulast%3DYakes%26aufirst%3DF.%2BM.%26aulast%3DShawver%26aufirst%3DL.%26aulast%3DLe%2BMoigne%26aufirst%3DR.%26aulast%3DAnderson%26aufirst%3DD.%2BJ.%26aulast%3DRolfe%26aufirst%3DM.%26aulast%3DWustrow%26aufirst%3DD.%26atitle%3DDiscovery%2520of%2520a%2520first-in-class%252C%2520potent%252C%2520selective%252C%2520and%2520orally%2520bioavailable%2520inhibitor%2520of%2520the%2520p97%2520AAA%2520ATPase%2520%2528CB-5083%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D9480%26epage%3D9497%26doi%3D10.1021%2Facs.jmedchem.5b01346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ding, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span> <span> </span><span class="NLM_article-title">Discovery of irreversible p97 inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">2814</span>– <span class="NLM_lpage">2829</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00144</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00144" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjvFyjs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=2814-2829&author=R.+Dingauthor=T.+Zhangauthor=D.+J.+Wilsonauthor=J.+Xieauthor=J.+Williamsauthor=Y.+Xuauthor=Y.+Yeauthor=L.+Chen&title=Discovery+of+irreversible+p97+inhibitors&doi=10.1021%2Facs.jmedchem.9b00144"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Irreversible p97 Inhibitors</span></div><div class="casAuthors">Ding, Rui; Zhang, Ting; Wilson, Daniel J.; Xie, Jiashu; Williams, Jessica; Xu, Yue; Ye, Yihong; Chen, Liqiang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2814-2829</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibitors of human p97 (also known as valosin-contg. protein) have been actively pursued because of their potential therapeutic applications in cancer and other diseases.  However, covalent and irreversible p97 inhibitors have not been well explored.  Herein, we report our design, synthesis, and biol. evaluation of covalent and irreversible inhibitors of p97.  Among an amide and a reverse amide series we synthesized, we have identified a p97 inhibitor whose functional irreversibility has been established both in vitro and in cells.  Also importantly, mass spectrometry reveals three potential cysteine residues labeled by this compd., and mutagenesis together with computer modeling suggests Cys522 as a major site, which when modified, could compromise the function of p97.  Taken together, this new inhibitor may provide a template for designing more potent p97 inhibitors with covalent and irreversible characteristics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrL1fyf_-hDOLVg90H21EOLACvtfcHk0lhjg15oQE-DMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjvFyjs74%253D&md5=313f9befff986d93967d4c1e9d631517</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00144&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00144%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DWilson%26aufirst%3DD.%2BJ.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DWilliams%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DYe%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DL.%26atitle%3DDiscovery%2520of%2520irreversible%2520p97%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D2814%26epage%3D2829%26doi%3D10.1021%2Facs.jmedchem.9b00144" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wood, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shewchuk, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brignola, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brashear, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caferro, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickerson, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickson, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donaldson, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaul, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassell, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keith, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrov, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reno, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusnak, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tadepalli, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulrich, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanderwall, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waterson, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uehling, D. E.</span></span> <span> </span><span class="NLM_article-title">6-Ethynylthieno[3,2-d]- and 6-ethynylthieno[2,3-d]pyrimidin-4-anilines as tunable covalent modifiers of ErbB kinases</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">2773</span>– <span class="NLM_lpage">2778</span>, <span class="refDoi"> DOI: 10.1073/pnas.0708281105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1073%2Fpnas.0708281105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=18287036" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjtVSjtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=2773-2778&author=E.+R.+Woodauthor=L.+M.+Shewchukauthor=B.+Ellisauthor=P.+Brignolaauthor=R.+L.+Brashearauthor=T.+R.+Caferroauthor=S.+H.+Dickersonauthor=H.+D.+Dicksonauthor=K.+H.+Donaldsonauthor=M.+Gaulauthor=R.+J.+Griffinauthor=A.+M.+Hassellauthor=B.+Keithauthor=R.+Mullinauthor=K.+G.+Petrovauthor=M.+J.+Renoauthor=D.+W.+Rusnakauthor=S.+M.+Tadepalliauthor=J.+C.+Ulrichauthor=C.+D.+Wagnerauthor=D.+E.+Vanderwallauthor=A.+G.+Watersonauthor=J.+D.+Williamsauthor=W.+L.+Whiteauthor=D.+E.+Uehling&title=6-Ethynylthieno%5B3%2C2-d%5D-+and+6-ethynylthieno%5B2%2C3-d%5Dpyrimidin-4-anilines+as+tunable+covalent+modifiers+of+ErbB+kinases&doi=10.1073%2Fpnas.0708281105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">6-Ethynylthieno[3,2-d]- and 6-ethynylthieno[2,3-d]pyrimidin-4-anilines as tunable covalent modifiers of ErbB kinases</span></div><div class="casAuthors">Wood, Edgar R.; Shewchuk, Lisa M.; Ellis, Byron; Brignola, Perry; Brashear, Ronald L.; Caferro, Thomas R.; Dickerson, Scott H.; Dickson, Hamilton D.; Donaldson, Kelly H.; Gaule, Michael; Griffin, Robert J.; Hassell, Anne M.; Keith, Barry; Mullin, Robert; Petrov, Kimberly G.; Reno, Michael J.; Rusnak, David W.; Tadepalli, Sarva M.; Ulrich, John C.; Wagner, Craig D.; Vanderwall, Dana E.; Waterson, Alex G.; Williams, Jon D.; White, Wendy L.; Uehling, David E.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2773-2778</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Anal. of the x-ray crystal structure of mono-substituted acetylenic thienopyrimidine 6 complexed with the ErbB family enzyme ErbB-4 revealed a covalent bond between the terminal carbon of the acetylene moiety and the sulfhydryl group of Cys-803 at the solvent interface.  The identification of this covalent adduct suggested that acetylenic thienopyrimidine 6 and related analogs might also be capable of forming an analogous covalent adduct with EGFR, which has a conserved cysteine (797) near the ATP binding pocket.  To test this hypothesis, we treated a truncated, catalytically competent form of EGFR (678-1020) with a structurally related propargylic amine (8).  An investigation of the resulting complex by mass spectrometry revealed the formation of a covalent complex of thienopyrimidine 8 with Cys-797 of EGFR.  This finding enabled us to readily assess the irreversibility of various inhibitors and also facilitated a structure-activity relation understanding of the covalent modifying potential and biol. activity of a series of acetylenic thienopyrimidine compds. with potent antitumor activity.  Several ErbB family enzyme and cell potent 6-ethynyl thienopyrimidine kinase inhibitors were found to form covalent adducts with EGFR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNoM38Ky48ELVg90H21EOLACvtfcHk0lhjg15oQE-DMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjtVSjtbw%253D&md5=fbfeeff1f03e8f7fb2c9e228231ff92e</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0708281105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0708281105%26sid%3Dliteratum%253Aachs%26aulast%3DWood%26aufirst%3DE.%2BR.%26aulast%3DShewchuk%26aufirst%3DL.%2BM.%26aulast%3DEllis%26aufirst%3DB.%26aulast%3DBrignola%26aufirst%3DP.%26aulast%3DBrashear%26aufirst%3DR.%2BL.%26aulast%3DCaferro%26aufirst%3DT.%2BR.%26aulast%3DDickerson%26aufirst%3DS.%2BH.%26aulast%3DDickson%26aufirst%3DH.%2BD.%26aulast%3DDonaldson%26aufirst%3DK.%2BH.%26aulast%3DGaul%26aufirst%3DM.%26aulast%3DGriffin%26aufirst%3DR.%2BJ.%26aulast%3DHassell%26aufirst%3DA.%2BM.%26aulast%3DKeith%26aufirst%3DB.%26aulast%3DMullin%26aufirst%3DR.%26aulast%3DPetrov%26aufirst%3DK.%2BG.%26aulast%3DReno%26aufirst%3DM.%2BJ.%26aulast%3DRusnak%26aufirst%3DD.%2BW.%26aulast%3DTadepalli%26aufirst%3DS.%2BM.%26aulast%3DUlrich%26aufirst%3DJ.%2BC.%26aulast%3DWagner%26aufirst%3DC.%2BD.%26aulast%3DVanderwall%26aufirst%3DD.%2BE.%26aulast%3DWaterson%26aufirst%3DA.%2BG.%26aulast%3DWilliams%26aufirst%3DJ.%2BD.%26aulast%3DWhite%26aufirst%3DW.%2BL.%26aulast%3DUehling%26aufirst%3DD.%2BE.%26atitle%3D6-Ethynylthieno%255B3%252C2-d%255D-%2520and%25206-ethynylthieno%255B2%252C3-d%255Dpyrimidin-4-anilines%2520as%2520tunable%2520covalent%2520modifiers%2520of%2520ErbB%2520kinases%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26spage%3D2773%26epage%3D2778%26doi%3D10.1073%2Fpnas.0708281105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arkona, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rademann, J.</span></span> <span> </span><span class="NLM_article-title">Propargyl amides as irreversible inhibitors of cysteine proteases--a lesson on the biological reactivity of alkynes</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">8210</span>– <span class="NLM_lpage">8212</span>, <span class="refDoi"> DOI: 10.1002/anie.201303544</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1002%2Fanie.201303544" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpvVeqtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2013&pages=8210-8212&author=C.+Arkonaauthor=J.+Rademann&title=Propargyl+amides+as+irreversible+inhibitors+of+cysteine+proteases%2D%2Da+lesson+on+the+biological+reactivity+of+alkynes&doi=10.1002%2Fanie.201303544"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Propargyl Amides as Irreversible Inhibitors of Cysteine Proteases-A Lesson on the Biological Reactivity of Alkynes</span></div><div class="casAuthors">Arkona, Christoph; Rademann, Joerg</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">8210-8212</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Ubiquitin like proteins are transferred to target proteins and bound by means of isopeptide bonds in an ATP driven enzymic transfer reaction with thioester intermediates.  Modified target proteins are often driven towards degrdn.  De-ubiquitinating enzymes (DUB) are capable of hydrolyzing the isopeptide bonds thereby reliberating ubiquitin-like proteins and target proteins.  This review discusses the role of DUBs in health and disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppalwwtDnPW7Vg90H21EOLACvtfcHk0lhjg15oQE-DMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpvVeqtb0%253D&md5=18ee2b226627f5bf11f4ac54ff365884</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1002%2Fanie.201303544&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201303544%26sid%3Dliteratum%253Aachs%26aulast%3DArkona%26aufirst%3DC.%26aulast%3DRademann%26aufirst%3DJ.%26atitle%3DPropargyl%2520amides%2520as%2520irreversible%2520inhibitors%2520of%2520cysteine%2520proteases--a%2520lesson%2520on%2520the%2520biological%2520reactivity%2520of%2520alkynes%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2013%26volume%3D52%26spage%3D8210%26epage%3D8212%26doi%3D10.1002%2Fanie.201303544" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ekkebus, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Kasteren, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulathu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scholten, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berlin, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geurink, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Jong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goerdayal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neefjes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heck, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komander, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ovaa, H.</span></span> <span> </span><span class="NLM_article-title">On terminal alkynes that can react with active-site cysteine nucleophiles in proteases</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>135</i></span>,  <span class="NLM_fpage">2867</span>– <span class="NLM_lpage">2870</span>, <span class="refDoi"> DOI: 10.1021/ja309802n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja309802n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC3sXit1Sqtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=135&publication_year=2013&pages=2867-2870&author=R.+Ekkebusauthor=S.+I.+van+Kasterenauthor=Y.+Kulathuauthor=A.+Scholtenauthor=I.+Berlinauthor=P.+P.+Geurinkauthor=A.+de+Jongauthor=S.+Goerdayalauthor=J.+Neefjesauthor=A.+J.+Heckauthor=D.+Komanderauthor=H.+Ovaa&title=On+terminal+alkynes+that+can+react+with+active-site+cysteine+nucleophiles+in+proteases&doi=10.1021%2Fja309802n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">On Terminal Alkynes That Can React with Active-Site Cysteine Nucleophiles in Proteases</span></div><div class="casAuthors">Ekkebus, Reggy; van Kasteren, Sander I.; Kulathu, Yogesh; Scholten, Arjen; Berlin, Ilana; Geurink, Paul P.; de Jong, Annemieke; Goerdayal, Soenita; Neefjes, Jacques; Heck, Albert J. R.; Komander, David; Ovaa, Huib</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">135</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2867-2870</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Active-site directed probes are powerful in studies of enzymic function.  We report an active-site directed probe based on a warhead so far considered unreactive.  By replacing the C-terminal carboxylate of ubiquitin (Ub) with an alkyne functionality, a selective reaction with the active-site cysteine residue of deubiquitinating enzymes (DUBs) was obsd.  The resulting product was shown to be a quaternary vinyl thioether, as detd. by X-ray crystallog.  Proteomic anal. of proteins bound to an immobilized Ub alkyne probe confirmed the selectivity toward deubiquitinating enzymes.  The obsd. reactivity is not just restricted to propargylated Ub, as highlighted by the selective reaction between caspase-1 (interleukin converting enzyme) and a propargylated peptide derived from IL-1β, a caspase-1 substrate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtg0tt7PzZcbVg90H21EOLACvtfcHk0ljM17j5O4KSKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXit1Sqtbc%253D&md5=d0f813975b6dae3de723facd0b78e47f</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1021%2Fja309802n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja309802n%26sid%3Dliteratum%253Aachs%26aulast%3DEkkebus%26aufirst%3DR.%26aulast%3Dvan%2BKasteren%26aufirst%3DS.%2BI.%26aulast%3DKulathu%26aufirst%3DY.%26aulast%3DScholten%26aufirst%3DA.%26aulast%3DBerlin%26aufirst%3DI.%26aulast%3DGeurink%26aufirst%3DP.%2BP.%26aulast%3Dde%2BJong%26aufirst%3DA.%26aulast%3DGoerdayal%26aufirst%3DS.%26aulast%3DNeefjes%26aufirst%3DJ.%26aulast%3DHeck%26aufirst%3DA.%2BJ.%26aulast%3DKomander%26aufirst%3DD.%26aulast%3DOvaa%26aufirst%3DH.%26atitle%3DOn%2520terminal%2520alkynes%2520that%2520can%2520react%2520with%2520active-site%2520cysteine%2520nucleophiles%2520in%2520proteases%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2013%26volume%3D135%26spage%3D2867%26epage%3D2870%26doi%3D10.1021%2Fja309802n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Turk, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoka, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasiljeva, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renko, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turk, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turk, D.</span></span> <span> </span><span class="NLM_article-title">Cysteine cathepsins: from structure, function and regulation to new frontiers</span>. <i>Biochim. Biophys. Acta, Proteins Proteomics</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>1824</i></span>,  <span class="NLM_fpage">68</span>– <span class="NLM_lpage">88</span>, <span class="refDoi"> DOI: 10.1016/j.bbapap.2011.10.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1016%2Fj.bbapap.2011.10.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=22024571" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFOns7rI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1824&publication_year=2012&pages=68-88&author=V.+Turkauthor=V.+Stokaauthor=O.+Vasiljevaauthor=M.+Renkoauthor=T.+Sunauthor=B.+Turkauthor=D.+Turk&title=Cysteine+cathepsins%3A+from+structure%2C+function+and+regulation+to+new+frontiers&doi=10.1016%2Fj.bbapap.2011.10.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Cysteine cathepsins: From structure, function and regulation to new frontiers</span></div><div class="casAuthors">Turk, Vito; Stoka, Veronika; Vasiljeva, Olga; Renko, Miha; Sun, Tao; Turk, Boris; Turk, Dusan</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Proteins and Proteomics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">1824</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">68-88</span>CODEN:
                <span class="NLM_cas:coden">BBAPBW</span>;
        ISSN:<span class="NLM_cas:issn">1570-9639</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B. V.</span>)
        </div><div class="casAbstract">A review.  It is more than 50 years since the lysosome was discovered.  Since then its hydrolytic machinery, including proteases and other hydrolases, has been fairly well identified and characterized.  Among these are the cysteine cathepsins, members of the family of papain-like cysteine proteases.  They have unique reactive-site properties and an uneven tissue-specific expression pattern.  In living organisms, their activity is a delicate balance of expression, targeting, zymogen activation, inhibition by protein inhibitors and degrdn.  The specificity of their substrate binding sites, small-mol. inhibitor repertoire and crystal structures are providing new tools for research and development.  Their unique reactive-site properties have made it possible to confine the targets simply by the use of appropriate reactive groups.  The epoxysuccinyls still dominate the field, but now nitriles seem to be the most appropriate "warhead".  The view of cysteine cathepsins as lysosomal proteases is changing as there is now clear evidence of their localization in other cellular compartments.  Besides being involved in protein turnover, they build an important part of endosomal antigen presentation.  Together with the growing no. of non-endosomal roles of cysteine cathepsins is growing also the knowledge of their involvement in diseases such as cancer and rheumatoid arthritis, among others.  Finally, cysteine cathepsins are important regulators and signaling mols. of an unimaginable no. of biol. processes.  The current challenge is to identify their endogenous substrates, in order to gain an insight into the mechanisms of substrate degrdn. and processing.  In this review, some of the remarkable advances that have taken place in the past decade are presented.  This article is part of a Special Issue entitled: Proteolysis 50 years after the discovery of lysosome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUEZ0u2P21D7Vg90H21EOLACvtfcHk0ljM17j5O4KSKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFOns7rI&md5=8615c1f0205d66b0fad932d6ff874390</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1016%2Fj.bbapap.2011.10.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbapap.2011.10.002%26sid%3Dliteratum%253Aachs%26aulast%3DTurk%26aufirst%3DV.%26aulast%3DStoka%26aufirst%3DV.%26aulast%3DVasiljeva%26aufirst%3DO.%26aulast%3DRenko%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DT.%26aulast%3DTurk%26aufirst%3DB.%26aulast%3DTurk%26aufirst%3DD.%26atitle%3DCysteine%2520cathepsins%253A%2520from%2520structure%252C%2520function%2520and%2520regulation%2520to%2520new%2520frontiers%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Proteins%2520Proteomics%26date%3D2012%26volume%3D1824%26spage%3D68%26epage%3D88%26doi%3D10.1016%2Fj.bbapap.2011.10.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mons, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansen, I. D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loboda, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Doodewaerd, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hermans, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verdoes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Boeckel, C. A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Veelen, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turk, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turk, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ovaa, H.</span></span> <span> </span><span class="NLM_article-title">The alkyne moiety as a latent electrophile in irreversible covalent small molecule inhibitors of cathepsin K</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>141</i></span>,  <span class="NLM_fpage">3507</span>– <span class="NLM_lpage">3514</span>, <span class="refDoi"> DOI: 10.1021/jacs.8b11027</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.8b11027" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFKjtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2019&pages=3507-3514&author=E.+Monsauthor=I.+D.+C.+Jansenauthor=J.+Lobodaauthor=B.+R.+van+Doodewaerdauthor=J.+Hermansauthor=M.+Verdoesauthor=C.+A.+A.+van+Boeckelauthor=P.+A.+van+Veelenauthor=B.+Turkauthor=D.+Turkauthor=H.+Ovaa&title=The+alkyne+moiety+as+a+latent+electrophile+in+irreversible+covalent+small+molecule+inhibitors+of+cathepsin+K&doi=10.1021%2Fjacs.8b11027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">The Alkyne Moiety as a Latent Electrophile in Irreversible Covalent Small Molecule Inhibitors of Cathepsin K</span></div><div class="casAuthors">Mons, Elma; Jansen, Ineke D. C.; Loboda, Jure; van Doodewaerd, Bjorn R.; Hermans, Jill; Verdoes, Martijn; van Boeckel, Constant A. A.; van Veelen, Peter A.; Turk, Boris; Turk, Dusan; Ovaa, Huib</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3507-3514</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Irreversible covalent inhibitors can have a beneficial pharmacokinetic/pharmacodynamics profile but are still often avoided due to the risk of indiscriminate covalent reactivity and the resulting adverse effects.  To overcome this potential liability, we introduced an alkyne moiety as a latent electrophile into small mol. inhibitors of cathepsin K (CatK).  Alkyne-based inhibitors do not show indiscriminate thiol reactivity but potently inhibit CatK protease activity by formation of an irreversible covalent bond with the catalytic cysteine residue, confirmed by crystal structure anal.  The rate of covalent bond formation (kinact) does not correlate with electrophilicity of the alkyne moiety, indicative of a proximity-driven reactivity.  Inhibition of CatK-mediated bone resorption is validated in human osteoclasts.  Together, this work illustrates the potential of alkynes as latent electrophiles in small mol. inhibitors, enabling the development of irreversible covalent inhibitors with an improved safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzdP4Hy1PKPrVg90H21EOLACvtfcHk0lhFBN_8zYpklQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFKjtbY%253D&md5=3a18718aa722a8d46c5be1cf07dd077b</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1021%2Fjacs.8b11027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.8b11027%26sid%3Dliteratum%253Aachs%26aulast%3DMons%26aufirst%3DE.%26aulast%3DJansen%26aufirst%3DI.%2BD.%2BC.%26aulast%3DLoboda%26aufirst%3DJ.%26aulast%3Dvan%2BDoodewaerd%26aufirst%3DB.%2BR.%26aulast%3DHermans%26aufirst%3DJ.%26aulast%3DVerdoes%26aufirst%3DM.%26aulast%3Dvan%2BBoeckel%26aufirst%3DC.%2BA.%2BA.%26aulast%3Dvan%2BVeelen%26aufirst%3DP.%2BA.%26aulast%3DTurk%26aufirst%3DB.%26aulast%3DTurk%26aufirst%3DD.%26aulast%3DOvaa%26aufirst%3DH.%26atitle%3DThe%2520alkyne%2520moiety%2520as%2520a%2520latent%2520electrophile%2520in%2520irreversible%2520covalent%2520small%2520molecule%2520inhibitors%2520of%2520cathepsin%2520K%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2019%26volume%3D141%26spage%3D3507%26epage%3D3514%26doi%3D10.1021%2Fjacs.8b11027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Porter, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chestnut, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merrill, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spector, T.</span></span> <span> </span><span class="NLM_article-title">Mechanism-based inactivation of dihydropyrimidine dehydrogenase by 5-ethynyluracil</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>267</i></span>,  <span class="NLM_fpage">5236</span>– <span class="NLM_lpage">5242</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1544906" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADyaK38XitFSju7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=267&publication_year=1992&pages=5236-5242&author=D.+J.+Porterauthor=W.+G.+Chestnutauthor=B.+M.+Merrillauthor=T.+Spector&title=Mechanism-based+inactivation+of+dihydropyrimidine+dehydrogenase+by+5-ethynyluracil"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism-based inactivation of dihydropyrimidine dehydrogenase by 5-ethynyluracil</span></div><div class="casAuthors">Porter, David J. T.; Chestnut, William G.; Merrill, Barbara M.; Spector, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">267</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">5236-42</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">Uracil analogs with appropriate substituents at the 5-position inactivated dihydropyrimidine dehydrogenase (I).  The efficiency of these inactivators was highly dependent on the size of the 5-substituent.  For example, 5-ethynyluracil (II) inactivated I with an efficiency (kinact/Ki) that was 500-fold greater than that for 5-propynyluracil.  II inactivated I by initially forming a reversible complex with a Ki of 1.6 μM.  This initial complex yielded inactivated enzyme with a rate const. of 20 min-1 (kinact).  Thymine competitively decreased the apparent rate const. for inactivation of I by II.  The absorbance spectrum of II-inactivated I was different from that of reduced enzyme.  These optical changes were correlated with the loss of enzymic activity.  II inactivated I with a stoichiometry of 0.9 mol of inactivator per mol of active site.  I inactivated with [2-14C]II retained all of the radiolabel after denaturation in 8M urea, but lost radiolabel under acidic conditions.  These results suggested that inactivation was due to covalent modification of an amino acid residue and not due to modification of a noncovalently bound prosthetic group.  A radiolabeled peptide was isolated from a tryptic digest of the enzyme inactivated with [2-14C]II.  The sequence of this peptide was Lys-Ala-Glu-Ala-Ser-Gly-Ala-Y-Ala-Leu-Glu-Leu-Asn-Leu-Ser-X-Pro-His-Gly-Met-Gly-Glu-Arg, where X and Y were unidentified amino acids.  Since the radiolabel was lost from the peptide during the 1st cycle on the amino acid sequenator, the position of the radiolabeled amino acid was not detd.  The amino acid residue designated by X was identified as Cys from previous work with I inactivated with 5-iodouracil.  In contrast to II, 5-cyanouracil was a reversible inactivator of I.  5-Cyanouracil-inactivated I slowly regained activity (t1/2 = 1.8 min) after diln. into the std. assay.  I isolated from rat, mouse, and human liver had similar sensitivities to inactivation by 5-alkynyluracils.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7Yb9-u9vspbVg90H21EOLACvtfcHk0lhFBN_8zYpklQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XitFSju7c%253D&md5=993e74947279ca25da52d60149ff8473</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPorter%26aufirst%3DD.%2BJ.%26aulast%3DChestnut%26aufirst%3DW.%2BG.%26aulast%3DMerrill%26aufirst%3DB.%2BM.%26aulast%3DSpector%26aufirst%3DT.%26atitle%3DMechanism-based%2520inactivation%2520of%2520dihydropyrimidine%2520dehydrogenase%2520by%25205-ethynyluracil%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1992%26volume%3D267%26spage%3D5236%26epage%3D5242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Metzger, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wissmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunther, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buettner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schule, R.</span></span> <span> </span><span class="NLM_article-title">LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>437</i></span>,  <span class="NLM_fpage">436</span>– <span class="NLM_lpage">439</span>, <span class="refDoi"> DOI: 10.1038/nature04020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1038%2Fnature04020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=16079795" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpvFOrtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=437&publication_year=2005&pages=436-439&author=E.+Metzgerauthor=M.+Wissmannauthor=N.+Yinauthor=J.+M.+Mullerauthor=R.+Schneiderauthor=A.+H.+Petersauthor=T.+Guntherauthor=R.+Buettnerauthor=R.+Schule&title=LSD1+demethylates+repressive+histone+marks+to+promote+androgen-receptor-dependent+transcription&doi=10.1038%2Fnature04020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription</span></div><div class="casAuthors">Metzger, Eric; Wissmann, Melanie; Yin, Na; Mueller, Judith M.; Schneider, Robert; Peters, Antoine H. F. M.; Guenther, Thomas; Buettner, Reinhard; Schuele, Roland</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">437</span>
        (<span class="NLM_cas:issue">7057</span>),
    <span class="NLM_cas:pages">436-439</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Gene regulation in eukaryotes requires the coordinate interaction of chromatin-modulating proteins with specific transcription factors such as the androgen receptor.  Gene activation and repression is specifically regulated by histone methylation status at distinct lysine residues.  Here the authors show that lysine-specific demethylase 1 (LSD1; also known as BHC110) co-localizes with the androgen receptor in normal human prostate and prostate tumor.  LSD1 interacts with androgen receptor in vitro and in vivo, and stimulates androgen-receptor-dependent transcription.  Conversely, knockdown of LSD1 protein levels abrogates androgen-induced transcriptional activation and cell proliferation.  Chromatin immunopptn. analyses demonstrate that androgen receptor and LSD1 form chromatin-assocd. complexes in a ligand-dependent manner.  LSD1 relieves repressive histone marks by demethylation of histone H3 at lysine 9 (H3-K9), thereby leading to de-repression of androgen receptor target genes.  Furthermore, the authors identify pargyline as an inhibitor of LSD1.  Pargyline blocks demethylation of H3-K9 by LSD1 and consequently androgen-receptor-dependent transcription.  Thus, modulation of LSD1 activity offers a new strategy to regulate androgen receptor functions.  Here, the authors link demethylation of a repressive histone mark with androgen-receptor-dependent gene activation, thus providing a mechanism by which demethylases control specific gene expression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgFgaYIdjiFbVg90H21EOLACvtfcHk0lhFBN_8zYpklQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpvFOrtL4%253D&md5=6cac1e6f6c21a80f59de27796cc9ee22</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1038%2Fnature04020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature04020%26sid%3Dliteratum%253Aachs%26aulast%3DMetzger%26aufirst%3DE.%26aulast%3DWissmann%26aufirst%3DM.%26aulast%3DYin%26aufirst%3DN.%26aulast%3DMuller%26aufirst%3DJ.%2BM.%26aulast%3DSchneider%26aufirst%3DR.%26aulast%3DPeters%26aufirst%3DA.%2BH.%26aulast%3DGunther%26aufirst%3DT.%26aulast%3DBuettner%26aufirst%3DR.%26aulast%3DSchule%26aufirst%3DR.%26atitle%3DLSD1%2520demethylates%2520repressive%2520histone%2520marks%2520to%2520promote%2520androgen-receptor-dependent%2520transcription%26jtitle%3DNature%26date%3D2005%26volume%3D437%26spage%3D436%26epage%3D439%26doi%3D10.1038%2Fnature04020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref152"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref152'); return false;" data-citation="" class="refNumLink">152</a></strong><div class="NLM_citation" id="cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hauser, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlino, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pippel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulz-Fincke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metzger, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yiu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schule, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sippl, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, M.</span></span> <span> </span><span class="NLM_article-title">Nonpeptidic propargylamines as inhibitors of lysine specific demethylase 1 (LSD1) with cellular activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">7334</span>– <span class="NLM_lpage">7342</span>, <span class="refDoi"> DOI: 10.1021/jm400792m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400792m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlSjurnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=7334-7342&author=M.+L.+Schmittauthor=A.+T.+Hauserauthor=L.+Carlinoauthor=M.+Pippelauthor=J.+Schulz-Finckeauthor=E.+Metzgerauthor=D.+Willmannauthor=T.+Yiuauthor=M.+Bartonauthor=R.+Schuleauthor=W.+Sipplauthor=M.+Jung&title=Nonpeptidic+propargylamines+as+inhibitors+of+lysine+specific+demethylase+1+%28LSD1%29+with+cellular+activity&doi=10.1021%2Fjm400792m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Nonpeptidic Propargylamines as Inhibitors of Lysine Specific Demethylase 1 (LSD1) with Cellular Activity</span></div><div class="casAuthors">Schmitt, Martin L.; Hauser, Alexander-Thomas; Carlino, Luca; Pippel, Martin; Schulz-Fincke, Johannes; Metzger, Eric; Willmann, Dominica; Yiu, Teresa; Barton, Michelle; Schuele, Roland; Sippl, Wolfgang; Jung, Manfred</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">7334-7342</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Lysine demethylases play an important role in epigenetic regulation and thus in the development of diseases like cancer or neurodegenerative disorders.  As the lysine specific demethylase 1 (LSD1/KDM1) has been strongly connected to androgen and estrogen dependent gene expression, it serves as a promising target for the therapy of hormone dependent cancer.  Here, we report on the discovery of new small mol. inhibitors of LSD1 contg. a propargylamine warhead, starting out from lysine contg. substrate analogs.  On the basis of these substrate mimicking inhibitors, we were able to increase potency by a combination of similarity-based virtual screening and subsequent synthetic optimization resulting in more druglike LSD1 inhibitors that led to histone hypermethylation in breast cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRGRr4rUPfsLVg90H21EOLACvtfcHk0lgIb7zUjmFrLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlSjurnO&md5=d4de914dec37f011a7b9488ec539a395</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1021%2Fjm400792m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400792m%26sid%3Dliteratum%253Aachs%26aulast%3DSchmitt%26aufirst%3DM.%2BL.%26aulast%3DHauser%26aufirst%3DA.%2BT.%26aulast%3DCarlino%26aufirst%3DL.%26aulast%3DPippel%26aufirst%3DM.%26aulast%3DSchulz-Fincke%26aufirst%3DJ.%26aulast%3DMetzger%26aufirst%3DE.%26aulast%3DWillmann%26aufirst%3DD.%26aulast%3DYiu%26aufirst%3DT.%26aulast%3DBarton%26aufirst%3DM.%26aulast%3DSchule%26aufirst%3DR.%26aulast%3DSippl%26aufirst%3DW.%26aulast%3DJung%26aufirst%3DM.%26atitle%3DNonpeptidic%2520propargylamines%2520as%2520inhibitors%2520of%2520lysine%2520specific%2520demethylase%25201%2520%2528LSD1%2529%2520with%2520cellular%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D7334%26epage%3D7342%26doi%3D10.1021%2Fjm400792m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref153"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref153'); return false;" data-citation="" class="refNumLink">153</a></strong><div class="NLM_citation" id="cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Potashman, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duggan, M. E.</span></span> <span> </span><span class="NLM_article-title">Covalent modifiers: an orthogonal approach to drug design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">1231</span>– <span class="NLM_lpage">1246</span>, <span class="refDoi"> DOI: 10.1021/jm8008597</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm8008597" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1Sltbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=1231-1246&author=M.+H.+Potashmanauthor=M.+E.+Duggan&title=Covalent+modifiers%3A+an+orthogonal+approach+to+drug+design&doi=10.1021%2Fjm8008597"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent Modifiers: An Orthogonal Approach to Drug Design</span></div><div class="casAuthors">Potashman, Michele H.; Duggan, Mark E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1231-1246</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  In this article we review a variety of examples in which therapeutic targets are covalently bound by small-mol. drugs or by compds. in advanced clin. development.  The covalent interactions can be either reversible or irreversible, depending on the reaction partners.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6BO6g9_F717Vg90H21EOLACvtfcHk0lgIb7zUjmFrLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1Sltbw%253D&md5=f8380d5a1cdd8638ad2a1e0405d25267</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1021%2Fjm8008597&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8008597%26sid%3Dliteratum%253Aachs%26aulast%3DPotashman%26aufirst%3DM.%2BH.%26aulast%3DDuggan%26aufirst%3DM.%2BE.%26atitle%3DCovalent%2520modifiers%253A%2520an%2520orthogonal%2520approach%2520to%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D1231%26epage%3D1246%26doi%3D10.1021%2Fjm8008597" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref154"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref154'); return false;" data-citation="" class="refNumLink">154</a></strong><div class="NLM_citation" id="cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gaweska, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzpatrick, P. F.</span></span> <span> </span><span class="NLM_article-title">Structures and mechanism of the monoamine oxidase family</span>. <i>Biomol. Concepts</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">365</span>– <span class="NLM_lpage">377</span>, <span class="refDoi"> DOI: 10.1515/BMC.2011.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1515%2FBMC.2011.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=22022344" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFejtrrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=365-377&author=H.+Gaweskaauthor=P.+F.+Fitzpatrick&title=Structures+and+mechanism+of+the+monoamine+oxidase+family&doi=10.1515%2FBMC.2011.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Structures and mechanism of the monoamine oxidase family</span></div><div class="casAuthors">Gaweska, Helena; Fitzpatrick, Paul F.</div><div class="citationInfo"><span class="NLM_cas:title">Biomolecular Concepts</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">365-377</span>CODEN:
                <span class="NLM_cas:coden">BCIOB8</span>;
        ISSN:<span class="NLM_cas:issn">1868-5021</span>.
    
            (<span class="NLM_cas:orgname">Walter de Gruyter GmbH & Co. KG</span>)
        </div><div class="casAbstract">A review.  Members of the monoamine oxidase family of flavoproteins catalyze the oxidn. of primary and secondary amines, polyamines, amino acids, and methylated lysine side chains in proteins.  The enzymes have similar overall structures, with conserved FAD (FAD)-binding domains and varied substrate-binding sites.  Multiple mechanisms have been proposed for the catalytic reactions of these enzymes.  The present review compares the structures of different members of the family and the various mechanistic proposals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoI1ElkC8rKEbVg90H21EOLACvtfcHk0lgIb7zUjmFrLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFejtrrM&md5=8674c4f01d7ad790037ee46d2e39dfd1</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1515%2FBMC.2011.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1515%252FBMC.2011.030%26sid%3Dliteratum%253Aachs%26aulast%3DGaweska%26aufirst%3DH.%26aulast%3DFitzpatrick%26aufirst%3DP.%2BF.%26atitle%3DStructures%2520and%2520mechanism%2520of%2520the%2520monoamine%2520oxidase%2520family%26jtitle%3DBiomol.%2520Concepts%26date%3D2011%26volume%3D2%26spage%3D365%26epage%3D377%26doi%3D10.1515%2FBMC.2011.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref155"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref155'); return false;" data-citation="" class="refNumLink">155</a></strong><div class="NLM_citation" id="cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pisani, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonetti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolotti, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefanachi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campagna, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carotti, A.</span></span> <span> </span><span class="NLM_article-title">Targeting monoamine oxidases with multipotent ligands: an emerging strategy in the search of new drugs against neurodegenerative diseases</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">4568</span>– <span class="NLM_lpage">4587</span>, <span class="refDoi"> DOI: 10.2174/092986711797379302</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.2174%2F092986711797379302" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=21864289" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlyitb7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=4568-4587&author=L.+Pisaniauthor=M.+Cattoauthor=F.+Leonettiauthor=O.+Nicolottiauthor=A.+Stefanachiauthor=F.+Campagnaauthor=A.+Carotti&title=Targeting+monoamine+oxidases+with+multipotent+ligands%3A+an+emerging+strategy+in+the+search+of+new+drugs+against+neurodegenerative+diseases&doi=10.2174%2F092986711797379302"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting monoamine oxidases with multipotent ligands: an emerging strategy in the search of new drugs against neurodegenerative diseases</span></div><div class="casAuthors">Pisani, L.; Catto, M.; Leonetti, F.; Nicolotti, O.; Stefanachi, A.; Campagna, F.; Carotti, A.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">4568-4587</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The socioeconomic burden of multi-factorial pathologies, such as neurodegenerative diseases (NDs), is enormous worldwide.  Unfortunately, no proven disease-modifying therapy is available yet and in most cases (e.g., Alzheimer's and Parkinson's disease) the approved drugs exert only palliative and symptomatic effects.  Nowadays, an emerging strategy for the discovery of disease-modifying drugs is based on the multi-target directed ligand (MTDL) design, an innovative shift from the traditional approach one-drug-one-target to the more ambitious one-drug-more-targets goal.  Herein, we review the discovery strategy, the mechanism of action and the biopharmacol. evaluation of multipotent ligands exhibiting monoamine oxidase (MAO) inhibition as the core activity with a potential for the treatment of NDs.  In particular, MAO inhibitors exhibiting addnl. acetylcholinesterase (AChE) or nitric oxide synthase (NOS) inhibition, or ion chelation/antioxidant-radical scavenging/anti-inflammatory/A2A receptor antagonist/APP processing modulating activities have been thoroughly examd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4N8fMdFNcwrVg90H21EOLACvtfcHk0lgIb7zUjmFrLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlyitb7O&md5=2463da84a1da0142e353ff9d3a354fe6</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.2174%2F092986711797379302&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986711797379302%26sid%3Dliteratum%253Aachs%26aulast%3DPisani%26aufirst%3DL.%26aulast%3DCatto%26aufirst%3DM.%26aulast%3DLeonetti%26aufirst%3DF.%26aulast%3DNicolotti%26aufirst%3DO.%26aulast%3DStefanachi%26aufirst%3DA.%26aulast%3DCampagna%26aufirst%3DF.%26aulast%3DCarotti%26aufirst%3DA.%26atitle%3DTargeting%2520monoamine%2520oxidases%2520with%2520multipotent%2520ligands%253A%2520an%2520emerging%2520strategy%2520in%2520the%2520search%2520of%2520new%2520drugs%2520against%2520neurodegenerative%2520diseases%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2011%26volume%3D18%26spage%3D4568%26epage%3D4587%26doi%3D10.2174%2F092986711797379302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref156"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref156'); return false;" data-citation="" class="refNumLink">156</a></strong><div class="NLM_citation" id="cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Querfurth, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaFerla, F. M.</span></span> <span> </span><span class="NLM_article-title">Alzheimer’s disease</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>362</i></span>,  <span class="NLM_fpage">329</span>– <span class="NLM_lpage">344</span>, <span class="refDoi"> DOI: 10.1056/NEJMra0909142</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1056%2FNEJMra0909142" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=20107219" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1aqt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=362&publication_year=2010&pages=329-344&author=H.+W.+Querfurthauthor=F.+M.+LaFerla&title=Alzheimer%E2%80%99s+disease&doi=10.1056%2FNEJMra0909142"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Alzheimer's disease</span></div><div class="casAuthors">Querfurth, Henry W.; LaFerla, Frank M.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">362</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">329-344</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review.  The role of β-amyloid peptide in spontaneous self-aggregation in brain in Alzheimer's disease is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPeniV_Jn6orVg90H21EOLACvtfcHk0ljuBj837BfRyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1aqt7s%253D&md5=c116f6a6b8fed9af9f5282cc4b755c70</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1056%2FNEJMra0909142&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra0909142%26sid%3Dliteratum%253Aachs%26aulast%3DQuerfurth%26aufirst%3DH.%2BW.%26aulast%3DLaFerla%26aufirst%3DF.%2BM.%26atitle%3DAlzheimer%25E2%2580%2599s%2520disease%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D362%26spage%3D329%26epage%3D344%26doi%3D10.1056%2FNEJMra0909142" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref157"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref157'); return false;" data-citation="" class="refNumLink">157</a></strong><div class="NLM_citation" id="cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Finberg, J. P.</span></span> <span> </span><span class="NLM_article-title">Update on the pharmacology of selective inhibitors of MAO-A and MAO-B: focus on modulation of CNS monoamine neurotransmitter release</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>143</i></span>,  <span class="NLM_fpage">133</span>– <span class="NLM_lpage">152</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2014.02.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1016%2Fj.pharmthera.2014.02.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=24607445" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkslGht7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=143&publication_year=2014&pages=133-152&author=J.+P.+Finberg&title=Update+on+the+pharmacology+of+selective+inhibitors+of+MAO-A+and+MAO-B%3A+focus+on+modulation+of+CNS+monoamine+neurotransmitter+release&doi=10.1016%2Fj.pharmthera.2014.02.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Update on the pharmacology of selective inhibitors of MAO-A and MAO-B: Focus on modulation of CNS monoamine neurotransmitter release</span></div><div class="casAuthors">Finberg, John P. M.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">143</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">133-152</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Inhibitors of monoamine oxidase (MAO) were initially used in medicine following the discovery of their antidepressant action.  Subsequently their ability to potentiate the effects of an indirectly-acting sympathomimetic amine such as tyramine was discovered, leading to their limitation in clin. use, except for cases of treatment-resistant depression.  More recently, the understanding that: a) potentiation of indirectly-acting sympathomimetic amines is caused by inhibitors of MAO-A but not by inhibitors of MAO-B, and b) that reversible inhibitors of MAO-A cause minimal tyramine potentiation, has led to their re-introduction to clin. use for treatment of depression (reversible MAO-A inhibitors and new dose form MAO-B inhibitor) and treatment of Parkinson's disease (MAO-B inhibitors).  The profound neuroprotective properties of propargyl-based inhibitors of MAO-B in preclin. expts. have drawn attention to the possibility of employing these drugs for their neuroprotective effect in neurodegenerative diseases, and have raised the question of the involvement of the MAO-mediated reaction as a source of reactive free radicals.  Despite the long-standing history of MAO inhibitors in medicine, the way in which they affect neuronal release of monoamine neurotransmitters is still poorly understood.  In recent years, the detailed chem. structure of MAO-B and MAO-A has become available, providing new possibilities for synthesis of mechanism-based inhibitors.  This review describes the latest advances in understanding the way in which MAO inhibitors affect the release of the monoamine neurotransmitters dopamine, noradrenaline and serotonin (5-HT) in the CNS, with an accent on the importance of these effects for the clin. actions of the drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSGMvtQ1Ca5bVg90H21EOLACvtfcHk0ljuBj837BfRyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkslGht7o%253D&md5=0f31959bad34842d4aaaba7b8162e5b8</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2014.02.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2014.02.010%26sid%3Dliteratum%253Aachs%26aulast%3DFinberg%26aufirst%3DJ.%2BP.%26atitle%3DUpdate%2520on%2520the%2520pharmacology%2520of%2520selective%2520inhibitors%2520of%2520MAO-A%2520and%2520MAO-B%253A%2520focus%2520on%2520modulation%2520of%2520CNS%2520monoamine%2520neurotransmitter%2520release%26jtitle%3DPharmacol.%2520Ther.%26date%3D2014%26volume%3D143%26spage%3D133%26epage%3D152%26doi%3D10.1016%2Fj.pharmthera.2014.02.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref158"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref158'); return false;" data-citation="" class="refNumLink">158</a></strong><div class="NLM_citation" id="cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Storr, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orvig, C.</span></span> <span> </span><span class="NLM_article-title">Design of targeting ligands in medicinal inorganic chemistry</span>. <i>Chem. Soc. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">534</span>– <span class="NLM_lpage">544</span>, <span class="refDoi"> DOI: 10.1039/b514859f</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1039%2Fb514859f" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=16729147" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD28XkvFOitLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2006&pages=534-544&author=T.+Storrauthor=K.+H.+Thompsonauthor=C.+Orvig&title=Design+of+targeting+ligands+in+medicinal+inorganic+chemistry&doi=10.1039%2Fb514859f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Design of targeting ligands in medicinal inorganic chemistry</span></div><div class="casAuthors">Storr, Tim; Thompson, Katherine H.; Orvig, Chris</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Society Reviews</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">534-544</span>CODEN:
                <span class="NLM_cas:coden">CSRVBR</span>;
        ISSN:<span class="NLM_cas:issn">0306-0012</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  This tutorial review will highlight recent advances in medicinal inorg. chem. pertaining to the use of multifunctional ligands for enhanced effect.  Ligands that adequately bind metal ions and also include specific targeting features are gaining in popularity due to their ability to enhance the efficacy of less complicated metal-based agents.  Moving beyond the traditional view of ligands modifying reactivity, stabilizing specific oxidn. states, and contributing to substitution inertness, the authors will discuss recent work involving metal complexes with multifunctional ligands that target specific tissues, membrane receptors, or endogenous mols., including enzymes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRgMqYlFgDWLVg90H21EOLACvtfcHk0ljuBj837BfRyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XkvFOitLs%253D&md5=71fdda23c9be3857c8415114c7c12b50</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1039%2Fb514859f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fb514859f%26sid%3Dliteratum%253Aachs%26aulast%3DStorr%26aufirst%3DT.%26aulast%3DThompson%26aufirst%3DK.%2BH.%26aulast%3DOrvig%26aufirst%3DC.%26atitle%3DDesign%2520of%2520targeting%2520ligands%2520in%2520medicinal%2520inorganic%2520chemistry%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2006%26volume%3D35%26spage%3D534%26epage%3D544%26doi%3D10.1039%2Fb514859f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref159"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref159'); return false;" data-citation="" class="refNumLink">159</a></strong><div class="NLM_citation" id="cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gella, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durany, N.</span></span> <span> </span><span class="NLM_article-title">Oxidative stress in Alzheimer disease</span>. <i>Cell Adh. Migr.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">88</span>– <span class="NLM_lpage">93</span>, <span class="refDoi"> DOI: 10.4161/cam.3.1.7402</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.4161%2Fcam.3.1.7402" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=19372765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A280%3ADC%252BC3cvps1ajsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2009&pages=88-93&author=A.+Gellaauthor=N.+Durany&title=Oxidative+stress+in+Alzheimer+disease&doi=10.4161%2Fcam.3.1.7402"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">Oxidative stress in Alzheimer disease</span></div><div class="casAuthors">Gella Alejandro; Durany Nuria</div><div class="citationInfo"><span class="NLM_cas:title">Cell adhesion & migration</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">88-93</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Alzheimer disease (AD) is a progressive dementia affecting a large proportion of the aging population.  The histopathological changes in AD include neuronal cell death, formation of amyloid plaques and neurofibrillary tangles.  There is also evidence that brain tissue in patients with AD is exposed to oxidative stress (e.g., protein oxidation, lipid oxidation, DNA oxidation and glycoxidation) during the course of the disease.  Advanced glycation endproducts (AGEs) are present in amyloid plaques in AD, and its extracellular accumulation may be caused by an accelerated oxidation of glycated proteins.  AGEs participate in neuronal death causing direct (chemical) and indirect (cellular) free radical production and consequently increase oxidative stress.  The development of drugs for the treatment of AD that breaks the vicious cycles of oxidative stress and neurodegeneration offer new opportunities.  These approaches include AGE-inhibitors, antioxidants and anti-inflammatory substances, which prevent free radical production.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTWN_iAi3-0DO3MPKNEWB5RfW6udTcc2eY1w0Fn0WV1kLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cvps1ajsw%253D%253D&md5=13d55d79537d8763d44759703e13e023</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.4161%2Fcam.3.1.7402&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcam.3.1.7402%26sid%3Dliteratum%253Aachs%26aulast%3DGella%26aufirst%3DA.%26aulast%3DDurany%26aufirst%3DN.%26atitle%3DOxidative%2520stress%2520in%2520Alzheimer%2520disease%26jtitle%3DCell%2520Adh.%2520Migr.%26date%3D2009%26volume%3D3%26spage%3D88%26epage%3D93%26doi%3D10.4161%2Fcam.3.1.7402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref160"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref160'); return false;" data-citation="" class="refNumLink">160</a></strong><div class="NLM_citation" id="cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hardy, J.</span></span> <span> </span><span class="NLM_article-title">The amyloid hypothesis for Alzheimer’s disease: a critical reappraisal</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">1129</span>– <span class="NLM_lpage">1134</span>, <span class="refDoi"> DOI: 10.1111/j.1471-4159.2009.06181.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1111%2Fj.1471-4159.2009.06181.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=19457065" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpsFOmu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2009&pages=1129-1134&author=J.+Hardy&title=The+amyloid+hypothesis+for+Alzheimer%E2%80%99s+disease%3A+a+critical+reappraisal&doi=10.1111%2Fj.1471-4159.2009.06181.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">The amyloid hypothesis for Alzheimer's disease: a critical reappraisal</span></div><div class="casAuthors">Hardy, John</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1129-1134</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  The amyloid hypothesis has been the basis for most work on the pathogenesis of Alzheimer's disease.  Recent clin. trials based on this hypothesis have been inconclusive.  In this article I review the current status of the hypothesis and suggest that a major scientific need is to understand the normal function of amyloid-β precursor protein (APP) and think how this may relate to the cell death in the disease process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvUSGTA_5CwbVg90H21EOLACvtfcHk0lg0CWtGCYcmyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpsFOmu70%253D&md5=b33ac5bdb5b02548736b5d7cbc83325c</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1111%2Fj.1471-4159.2009.06181.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1471-4159.2009.06181.x%26sid%3Dliteratum%253Aachs%26aulast%3DHardy%26aufirst%3DJ.%26atitle%3DThe%2520amyloid%2520hypothesis%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%253A%2520a%2520critical%2520reappraisal%26jtitle%3DJ.%2520Neurochem.%26date%3D2009%26volume%3D110%26spage%3D1129%26epage%3D1134%26doi%3D10.1111%2Fj.1471-4159.2009.06181.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref161"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref161'); return false;" data-citation="" class="refNumLink">161</a></strong><div class="NLM_citation" id="cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Calissano, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matrone, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amadoro, G.</span></span> <span> </span><span class="NLM_article-title">Apoptosis and in vitro Alzheimer disease neuronal models</span>. <i>Commun. Integr. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">163</span>– <span class="NLM_lpage">169</span>, <span class="refDoi"> DOI: 10.4161/cib.7704</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.4161%2Fcib.7704" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=19513272" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1Ojs7zK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2009&pages=163-169&author=P.+Calissanoauthor=C.+Matroneauthor=G.+Amadoro&title=Apoptosis+and+in+vitro+Alzheimer+disease+neuronal+models&doi=10.4161%2Fcib.7704"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Apoptosis and in vitro Alzheimer's disease neuronal models</span></div><div class="casAuthors">Calissano, P.; Matrone, C.; Amadoro, G.</div><div class="citationInfo"><span class="NLM_cas:title">Communicative & Integrative Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">163-169</span>CODEN:
                <span class="NLM_cas:coden">CIBOBQ</span>;
        ISSN:<span class="NLM_cas:issn">1942-0889</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">A review.  Alzheimer disease (AD) is a human neurodegenerative disease characterized by co-existence of extracellular senile plaques (SP) and neurofibrillary tangles (NFT) assocd. with an extensive neuronal loss, primarily in the cerebral cortex and hippocampus.  Several studies suggest that caspase(s)-mediated neuronal death occurs in cellular and animal AD models as well as in human brains of affected patients, although an etiol. role of apoptosis in such neurodegenerative disorder is still debated.  This review summarizes the exptl. evidences corroborating the possible involvement of apoptosis in AD pathogenesis and discusses the usefulness of ad hoc devised in vitro approaches to study how caspase(s), amyloidogenic processing and tau metab. might reciprocally interact leading to neuronal death.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsZQ_pSt_Hc7Vg90H21EOLACvtfcHk0lg0CWtGCYcmyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1Ojs7zK&md5=90cbf25854989a8908b49c0faeee1cf0</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.4161%2Fcib.7704&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcib.7704%26sid%3Dliteratum%253Aachs%26aulast%3DCalissano%26aufirst%3DP.%26aulast%3DMatrone%26aufirst%3DC.%26aulast%3DAmadoro%26aufirst%3DG.%26atitle%3DApoptosis%2520and%2520in%2520vitro%2520Alzheimer%2520disease%2520neuronal%2520models%26jtitle%3DCommun.%2520Integr.%2520Biol.%26date%3D2009%26volume%3D2%26spage%3D163%26epage%3D169%26doi%3D10.4161%2Fcib.7704" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref162"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref162'); return false;" data-citation="" class="refNumLink">162</a></strong><div class="NLM_citation" id="cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Domingues, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">da Cruz, E. S. O. A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henriques, A. G.</span></span> <span> </span><span class="NLM_article-title">Impact of cytokines and chemokines on Alzheimer’s disease neuropathological hallmarks</span>. <i>Curr. Alzheimer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">870</span>– <span class="NLM_lpage">882</span>, <span class="refDoi"> DOI: 10.2174/1567205014666170317113606</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.2174%2F1567205014666170317113606" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=28317487" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1Okur7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2017&pages=870-882&author=C.+Dominguesauthor=E.+S.+O.+A.+B.+da+Cruzauthor=A.+G.+Henriques&title=Impact+of+cytokines+and+chemokines+on+Alzheimer%E2%80%99s+disease+neuropathological+hallmarks&doi=10.2174%2F1567205014666170317113606"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of Cytokines and Chemokines on Alzheimer's Disease Neuropathological Hallmarks</span></div><div class="casAuthors">Domingues, Catarina; da Cruz e Silva, Odete A. B.; Henriques, Ana Gabriela</div><div class="citationInfo"><span class="NLM_cas:title">Current Alzheimer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">870-882</span>CODEN:
                <span class="NLM_cas:coden">CARUBY</span>;
        ISSN:<span class="NLM_cas:issn">1567-2050</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Alzheimer's disease (AD) is the most common neurodegenerative disorder, neuropathol. characterized by aggregates of β-amyloid peptides, which deposit as senile plaques, and of TAU protein, which forms neurofibrillary tangles.  It is now widely accepted that neuroinflammation is implicated in AD pathogenesis.  Indeed, inflammatory mediators, such as cytokines and chemokines (chemotactic cytokines) can impact on the Alzheimer's amyloid precursor protein by affecting its expression levels and amyloidogenic processing and/or β -amyloid aggregation.  Addnl., cytokines and chemokines can influence kinases' activities, leading to abnormal TAU phosphorylation.  To date there is no cure for AD, but several therapeutic strategies have been directed to prevent neuroinflammation.  Anti-inflammatory, but also anti-amyloidogenic compds., such as flavonoids were shown to favorably modulate some pathol. events assocd. with neurodegeneration.  This review focuses on the role of cytokines and chemokines in AD-assocd. pathologies, and summarizes the potential anti-inflammatory therapeutic approaches aimed at preventing or slowing down disease progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWGEmdgXfysLVg90H21EOLACvtfcHk0ljIf9eWtIRH1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1Okur7M&md5=860ab9a2701a805b519aaf4ee802e48f</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.2174%2F1567205014666170317113606&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1567205014666170317113606%26sid%3Dliteratum%253Aachs%26aulast%3DDomingues%26aufirst%3DC.%26aulast%3Dda%2BCruz%26aufirst%3DE.%2BS.%2BO.%2BA.%2BB.%26aulast%3DHenriques%26aufirst%3DA.%2BG.%26atitle%3DImpact%2520of%2520cytokines%2520and%2520chemokines%2520on%2520Alzheimer%25E2%2580%2599s%2520disease%2520neuropathological%2520hallmarks%26jtitle%3DCurr.%2520Alzheimer%2520Res.%26date%3D2017%26volume%3D14%26spage%3D870%26epage%3D882%26doi%3D10.2174%2F1567205014666170317113606" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref163"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref163'); return false;" data-citation="" class="refNumLink">163</a></strong><div class="NLM_citation" id="cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rahman, A.</span></span> <span> </span><span class="NLM_article-title">The role of adenosine in Alzheimer’s disease</span>. <i>Curr. Neuropharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">207</span>– <span class="NLM_lpage">216</span>, <span class="refDoi"> DOI: 10.2174/157015909789152119</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.2174%2F157015909789152119" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=20190962" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVSksrnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2009&pages=207-216&author=A.+Rahman&title=The+role+of+adenosine+in+Alzheimer%E2%80%99s+disease&doi=10.2174%2F157015909789152119"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">The role of adenosine in Alzheimer's disease</span></div><div class="casAuthors">Rahman, Anisur</div><div class="citationInfo"><span class="NLM_cas:title">Current Neuropharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">207-216</span>CODEN:
                <span class="NLM_cas:coden">CNUEAN</span>;
        ISSN:<span class="NLM_cas:issn">1875-6190</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Alzheimer's disease (AD) is a neurodegenerative disorder of the central nervous system manifested by cognitive and memory deterioration, a variety of neuropsychiatric symptoms, behavioral disturbances, and progressive impairment of daily life activities.  Current pharmacotherapies are restricted to symptomatic interventions but do not prevent progressive neuronal degeneration.  Therefore, new therapeutic strategies are needed to intervene with these progressive pathol. processes.  In the past several years adenosine, a ubiquitously released purine ribonucleoside, has become important for its neuromodulating capability and its emerging pos. exptl. effects in neurodegenerative diseases.  Recent research suggests that adenosine receptors play important roles in the modulation of cognitive function.  The present paper attempts to review published reports and data from different studies showing the evidence of a relationship between adenosinergic function and AD-related cognitive deficits.  Epidemiol. studies have found an assocn. between coffee (a nonselective adenosine receptor antagonist) consumption and improved cognitive function in AD patients and in the elderly.  Long-term administration of caffeine in transgenic animal models showed a reduced amyloid burden in brain with better cognitive performance.  Antagonists of adenosine A2A receptors mimic these beneficial effects of caffeine on cognitive function.  Neuronal cell cultures with amyloid beta in the presence of an A2A receptor antagonist completely prevented amyloid beta-induced neurotoxicity.  These findings suggest that the adenosinergic system constitutes a new therapeutic target for AD, and caffeine and A2A receptor antagonists may have promise to manage cognitive dysfunction in AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrV5y-6o7HJKbVg90H21EOLACvtfcHk0ljIf9eWtIRH1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVSksrnP&md5=91646b591f011f244b07654acea2741c</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.2174%2F157015909789152119&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F157015909789152119%26sid%3Dliteratum%253Aachs%26aulast%3DRahman%26aufirst%3DA.%26atitle%3DThe%2520role%2520of%2520adenosine%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DCurr.%2520Neuropharmacol.%26date%3D2009%26volume%3D7%26spage%3D207%26epage%3D216%26doi%3D10.2174%2F157015909789152119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref164"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref164'); return false;" data-citation="" class="refNumLink">164</a></strong><div class="NLM_citation" id="cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carrillo, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minami, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitani, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maruyama, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naoi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Youdim, M. B.</span></span> <span> </span><span class="NLM_article-title">Enhancing effect of rasagiline on superoxide dismutase and catalase activities in the dopaminergic system in the rat</span>. <i>Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">577</span>– <span class="NLM_lpage">585</span>, <span class="refDoi"> DOI: 10.1016/S0024-3205(00)00643-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1016%2FS0024-3205%2800%2900643-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10993123" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD3cXksVKjurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2000&pages=577-585&author=M.+C.+Carrilloauthor=C.+Minamiauthor=K.+Kitaniauthor=W.+Maruyamaauthor=K.+Ohashiauthor=T.+Yamamotoauthor=M.+Naoiauthor=S.+Kanaiauthor=M.+B.+Youdim&title=Enhancing+effect+of+rasagiline+on+superoxide+dismutase+and+catalase+activities+in+the+dopaminergic+system+in+the+rat&doi=10.1016%2FS0024-3205%2800%2900643-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">Enhancing effect of rasagiline on superoxide dismutase and catalase activities in the dopaminergic system in the rat</span></div><div class="casAuthors">Carrillo, M. C.; Minami, C.; Kitani, K.; Maruyama, W.; Ohashi, K.; Yamamoto, T.; Naoi, M.; Kanai, S.; Youdim, M. B. H.</div><div class="citationInfo"><span class="NLM_cas:title">Life Sciences</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">577-585</span>CODEN:
                <span class="NLM_cas:coden">LIFSAK</span>;
        ISSN:<span class="NLM_cas:issn">0024-3205</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">Rasagiline [N-propargyl-1(R)-aminoindan] is a selective irreversible MAO-B inhibitor as is (-)deprenyl.  The effect of the drug on antioxidant enzyme activities on dopaminergic tissue was examd. in male F-344 rats (8.5-mo-old).  Two exptl. groups were infused s.c. with rasagiline saline solns. by means of osmotic mini pumpus implanted s.c. in the back of the rats.  Control animals were also similarly implanted with saline filled mini-pumps.  Three-and-one-half weeks later, animals were sacrificed and selected tissue samples removed from brain, kidney and heart.  Two doses of rasagiline (0.5 mg/kg/day, 1.0 mg/kg/day, both for 3.5 wk) significantly increased catalase activities about 2-fold in substantia nigra and striatum but not in hippocampus.  Interestingly, in both renal cortex and medulla, catalase (CAT) activities were significantly increased.  Both Mn- and Cu,Zn-superoxide dismutase (SOD) activities were increased 2 to 4 fold in substantia nigra, striatum and renal cortex and heart.  Several groups, including our own have reported an extension of survival of deprenyl-treated animals of different species.  Although the mechanism(s) of the life extension by deprenyl remains unresolved, it would be interesting to investigate the effect of rasagiline on the survival of animals, since deprenyl also was shown to increase antioxidant enzyme activities in brain dopaminergic regions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3sp8TlppOL7Vg90H21EOLACvtfcHk0ljIf9eWtIRH1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXksVKjurg%253D&md5=8e0b602a42ddf81f039b732fbf1d76b1</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1016%2FS0024-3205%2800%2900643-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0024-3205%252800%252900643-3%26sid%3Dliteratum%253Aachs%26aulast%3DCarrillo%26aufirst%3DM.%2BC.%26aulast%3DMinami%26aufirst%3DC.%26aulast%3DKitani%26aufirst%3DK.%26aulast%3DMaruyama%26aufirst%3DW.%26aulast%3DOhashi%26aufirst%3DK.%26aulast%3DYamamoto%26aufirst%3DT.%26aulast%3DNaoi%26aufirst%3DM.%26aulast%3DKanai%26aufirst%3DS.%26aulast%3DYoudim%26aufirst%3DM.%2BB.%26atitle%3DEnhancing%2520effect%2520of%2520rasagiline%2520on%2520superoxide%2520dismutase%2520and%2520catalase%2520activities%2520in%2520the%2520dopaminergic%2520system%2520in%2520the%2520rat%26jtitle%3DLife%2520Sci.%26date%3D2000%26volume%3D67%26spage%3D577%26epage%3D585%26doi%3D10.1016%2FS0024-3205%2800%2900643-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref165"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref165'); return false;" data-citation="" class="refNumLink">165</a></strong><div class="NLM_citation" id="cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Youdim, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstock, M.</span></span> <span> </span><span class="NLM_article-title">Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(<i>N</i>-propargyl-(3<i>R</i>)aminoindan-5-yl)-ethyl methyl carbamate]</span>. <i>Cell. Mol. Neurobiol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">555</span>– <span class="NLM_lpage">573</span>, <span class="refDoi"> DOI: 10.1023/A:1015131516649</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1023%2FA%3A1015131516649" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=12043833" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A280%3ADC%252BD38zgt12ksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2001&pages=555-573&author=M.+B.+Youdimauthor=M.+Weinstock&title=Molecular+basis+of+neuroprotective+activities+of+rasagiline+and+the+anti-Alzheimer+drug+TV3326+%5B%28N-propargyl-%283R%29aminoindan-5-yl%29-ethyl+methyl+carbamate%5D&doi=10.1023%2FA%3A1015131516649"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate]</span></div><div class="casAuthors">Youdim M B; Weinstock M</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and molecular neurobiology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">555-73</span>
        ISSN:<span class="NLM_cas:issn">0272-4340</span>.
    </div><div class="casAbstract">Rasagiline (N-propargyl-1-(R)-aminoindan) is a selective, irreversible monoamine oxidase B (MAO B) inhibitor which has been developed as an anti-Parkinson drug.  In controlled monotherapy and as adjunct to L-dopa it has shown anti-Parkinson activity.  In cell culture (PC-12 and neuroblastoma SH-SY5Y cells) it exhibits neuroprotective and anti-apoptotic activity against several neurotoxins (SIN-1, MPTP, 6-hydroxydopamine and N-methyl-(R)-salsolinol) and ischemia.  In vivo, it reduces the sequelae of traumatic brain injury in mice and speeds their recovery.  The neuroprotective activity of rasagaline does not result from MAO B inhibition, since its S-enantiomer, TVP1022, which has 1000-fold weaker MAO inhibitory activity, exhibits similar neuroprotective properties.  Introduction of a carbamate moiety into the rasagiline molecule to confer cholinesterase inhibitory activity for the treatment of Alzheimer's disease, resulted in compounds TV3326 [(N-Propargyl-(3R)Aminoindan-5-YL)-Ethyl Methyl Carbamate] and its S-enantiomer TV3279 [(N-Propargyl-(3S)Aminoindan-5-YL)-Ethyl Methyl Carbamate], which retain the neuroprotective activities of rasagiline and TVP1022.  They also antagonize scopolamine-induced impairments in spatial memory.  In addition, TV3326 exhibits brain-selective MAO A and B inhibitory activity after chronic administration and has antidepressant-like activity in the forced swim test.  This is associated with an increase in brain levels of serotonin.  The anti-apoptotic activity of these propargylamine-containing derivatives may be related to their ability to delay the opening of voltage-dependent anion channels (VDAC), which are part of the mitochondrial permeability transition pore.  The propargylamine moiety is responsible for the increase in the mitochondrial family of Bcl-2 proteins, prevention in the fall in mitochondrial membrane potential, prevention of the activation of caspase 3, and of translocation of glyceraldehyde-3-phosphate dehydrogenase from the cytoplasm to the nucleus.  The latter processes are closely associated with neurotoxin-induced apoptosis.  Rasagiline interacts with and prevents the binding of PKI 1195 to the pro-apoptotic peripheral benzodiazepine receptor, which together with Bcl-2, hexokinase, porin, and adenine nucleotide translocator constitutes part of the VDAC.  Furthermore, rasagiline, TV3326 and TV3279 are able to influence the processing of amyloid precursor protein by activation of alpha-secretase and increasing the release of soluble alpha APP in rat PC-12 and human neuroblastoma SH-SY5Y cells and in rat and mice cortex and hippocampus.  This process has been shown to involve the upregulation of PKC and MAP kinase.  It is quite likely that the induction of Bcl-2 and activation of PKC by rasagiline and TV3326 is closely linked to the anti-apoptotic action of these drugs and their ability to process APP by activation of alpha-secretase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQR3CdWC5jGOz0SWnHPWbmmfW6udTcc2eYhKEExWWRZZrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD38zgt12ksQ%253D%253D&md5=0909d8e1af5f7cbdcd55ad7d48ebfc15</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1023%2FA%3A1015131516649&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1015131516649%26sid%3Dliteratum%253Aachs%26aulast%3DYoudim%26aufirst%3DM.%2BB.%26aulast%3DWeinstock%26aufirst%3DM.%26atitle%3DMolecular%2520basis%2520of%2520neuroprotective%2520activities%2520of%2520rasagiline%2520and%2520the%2520anti-Alzheimer%2520drug%2520TV3326%2520%255B%2528N-propargyl-%25283R%2529aminoindan-5-yl%2529-ethyl%2520methyl%2520carbamate%255D%26jtitle%3DCell.%2520Mol.%2520Neurobiol.%26date%3D2001%26volume%3D21%26spage%3D555%26epage%3D573%26doi%3D10.1023%2FA%3A1015131516649" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref166"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref166'); return false;" data-citation="" class="refNumLink">166</a></strong><div class="NLM_citation" id="cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perez, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marco, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Alvarez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unzeta, M.</span></span> <span> </span><span class="NLM_article-title">Relevance of benzyloxy group in 2-indolyl methylamines in the selective MAO-B inhibition</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">869</span>– <span class="NLM_lpage">876</span>, <span class="refDoi"> DOI: 10.1038/sj.bjp.0702600</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1038%2Fsj.bjp.0702600" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10433493" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADyaK1MXktlOmsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=1999&pages=869-876&author=V.+Perezauthor=J.+L.+Marcoauthor=E.+Fernandez-Alvarezauthor=M.+Unzeta&title=Relevance+of+benzyloxy+group+in+2-indolyl+methylamines+in+the+selective+MAO-B+inhibition&doi=10.1038%2Fsj.bjp.0702600"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">Relevance of benzyloxy group in 2-indolyl methylamines in the selective MAO-B inhibition</span></div><div class="casAuthors">Perez, Virgili; Marco, Jose Luis; Fernandez-Alvarez, Eldiberto; Unzeta, Mercedes</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">869-876</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Stockton Press</span>)
        </div><div class="casAbstract">Previous studies with indolyl derivs. as monoamine oxidase (MAO) inhibitors have shown the relevance of the indole structure for recognition by the active site of this enzyme.  We now report a new series of mols. with structural features which det. the selectivity of MAO inhibition.  A benzyloxy group attached at position 5 of the indole ring is crit. for this selective behavior.  Amongst all of these benzyloxy-indolyl methylamines, N-(2-propynyl)-2-(5-benzyloxyindol)methylamine FA-73 was the most potent MAO-B "suicide" inhibitor studied.  The Ki values for MAO-A and MAO-B were 800±60 and 0.75±0.15 nM, resp.  These data represent a selectivity value of 1066 for MAO-B, being 48 times more selective than L-deprenyl (Ki values of 376±0.032 and 16.8±0.1 nM for MAO A and MAO-B, resp.).  The IC50 values for dopamine uptake in striatal synaptosomal fractions from rats were 150±8 μM for FA-73 and 68±10 μM for L-deprenyl whereas in human caudate tissue the IC50 values were 0.36±0.015 μM for FA-73 and 0.10±0.007 μM for L-deprenyl.  Moreover, mouse brain MAO-B activity was 90% ex vivo inhibited by both compds. 1 h after 4 mg kg-1 administration, MAO-A activity was not affected.  These novel mols. should provide a better understanding of the active site of monoamine oxidase and could be the starting point for the design of further selective, non-amphetamine-like MAO-B inhibitors with therapeutic potential for the treatment of neurol. disorders, such as parkinsonism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoynmDOjiKQgbVg90H21EOLACvtfcHk0ljz9bkYujvLbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXktlOmsrw%253D&md5=756c3b6564fe28ee128fdcf06b730f6c</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0702600&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0702600%26sid%3Dliteratum%253Aachs%26aulast%3DPerez%26aufirst%3DV.%26aulast%3DMarco%26aufirst%3DJ.%2BL.%26aulast%3DFernandez-Alvarez%26aufirst%3DE.%26aulast%3DUnzeta%26aufirst%3DM.%26atitle%3DRelevance%2520of%2520benzyloxy%2520group%2520in%25202-indolyl%2520methylamines%2520in%2520the%2520selective%2520MAO-B%2520inhibition%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D1999%26volume%3D127%26spage%3D869%26epage%3D876%26doi%3D10.1038%2Fsj.bjp.0702600" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref167"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref167'); return false;" data-citation="" class="refNumLink">167</a></strong><div class="NLM_citation" id="cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bolea, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juarez-Jimenez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Los Rios, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chioua, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pouplana, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luque, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unzeta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marco-Contelles, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samadi, A.</span></span> <span> </span><span class="NLM_article-title">Synthesis, biological evaluation, and molecular modeling of donepezil and <i>N</i>-[(5-(benzyloxy)-1-methyl-1<i>H</i>-indol-2-yl)methyl]-<i>N</i>-methylprop-2-yn-1-amine hybrids as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer’s disease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">8251</span>– <span class="NLM_lpage">8270</span>, <span class="refDoi"> DOI: 10.1021/jm200853t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200853t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlGktrrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=8251-8270&author=I.+Boleaauthor=J.+Juarez-Jimenezauthor=C.+de+Los+Riosauthor=M.+Chiouaauthor=R.+Pouplanaauthor=F.+J.+Luqueauthor=M.+Unzetaauthor=J.+Marco-Contellesauthor=A.+Samadi&title=Synthesis%2C+biological+evaluation%2C+and+molecular+modeling+of+donepezil+and+N-%5B%285-%28benzyloxy%29-1-methyl-1H-indol-2-yl%29methyl%5D-N-methylprop-2-yn-1-amine+hybrids+as+new+multipotent+cholinesterase%2Fmonoamine+oxidase+inhibitors+for+the+treatment+of+Alzheimer%E2%80%99s+disease&doi=10.1021%2Fjm200853t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, biological evaluation, and molecular modeling of donepezil and N-[(5-(benzyloxy)-1-methyl-1H-indol-2-yl)methyl]-N-methylprop-2-yn-1-amine hybrids as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease</span></div><div class="casAuthors">Bolea, Irene; Juarez-Jimenez, Jordi; de los Rios, Cristobal; Chioua, Mourad; Pouplana, Ramon; Luque, F. Javier; Unzeta, Mercedes; Marco-Contelles, Jose; Samadi, Abdelouahid</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8251-8270</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new family of multitarget mols. able to interact with acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), as well as with monoamino oxidase (MAO) A and B, has been synthesized.  Novel compds. (3-9) (I) (X = N, Y = CH, n = 0, 1, 2, 3; X = CH, Y = N, n = 1, 2; X = Y = N, n = 2) have been designed using a conjunctive approach that combines the benzylpiperidine moiety of the AChE inhibitor donepezil (II) and the indolyl propargylamino moiety of the MAO inhibitor N-[(5-benzyloxy-1-methyl-1H-indol-2-yl)methyl]-N-methylprop-2-yn-1-amine (III), connected through an oligomethylene linker.  The most promising hybrid I ( X =N, Y = CH, n =2) is a potent inhibitor of both MAO-A (IC50 = 5.2 ± 1.1 nM) and MAO-B (IC50 = 43 ± 8.0 nM) and is a moderately potent inhibitor of AChE (IC50 = 0.35 ± 0.01 μM) and BuChE (IC50 = 0.46 ± 0.06 μM).  Moreover, mol. modeling and kinetic studies support the dual binding site to AChE, which explains the inhibitory effect exerted on Aβ aggregation.  Overall, the results suggest that the new compds. are promising multitarget drug candidates with potential impact for Alzheimer's disease therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHRdbLgOyA0LVg90H21EOLACvtfcHk0ljz9bkYujvLbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlGktrrP&md5=c82c849b5db4315744c4b9b9554b6b30</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1021%2Fjm200853t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200853t%26sid%3Dliteratum%253Aachs%26aulast%3DBolea%26aufirst%3DI.%26aulast%3DJuarez-Jimenez%26aufirst%3DJ.%26aulast%3Dde%2BLos%2BRios%26aufirst%3DC.%26aulast%3DChioua%26aufirst%3DM.%26aulast%3DPouplana%26aufirst%3DR.%26aulast%3DLuque%26aufirst%3DF.%2BJ.%26aulast%3DUnzeta%26aufirst%3DM.%26aulast%3DMarco-Contelles%26aufirst%3DJ.%26aulast%3DSamadi%26aufirst%3DA.%26atitle%3DSynthesis%252C%2520biological%2520evaluation%252C%2520and%2520molecular%2520modeling%2520of%2520donepezil%2520and%2520N-%255B%25285-%2528benzyloxy%2529-1-methyl-1H-indol-2-yl%2529methyl%255D-N-methylprop-2-yn-1-amine%2520hybrids%2520as%2520new%2520multipotent%2520cholinesterase%252Fmonoamine%2520oxidase%2520inhibitors%2520for%2520the%2520treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D8251%26epage%3D8270%26doi%3D10.1021%2Fjm200853t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref168"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref168'); return false;" data-citation="" class="refNumLink">168</a></strong><div class="NLM_citation" id="cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sterling, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herzig, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goren, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finkelstein, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lerner, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldenberg, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miskolczi, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molnar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rantal, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamas, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toth, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zagyva, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zekany, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavian, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gross, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Razin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krais, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chorev, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Youdim, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstock, M.</span></span> <span> </span><span class="NLM_article-title">Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer’s disease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">5260</span>– <span class="NLM_lpage">5279</span>, <span class="refDoi"> DOI: 10.1021/jm020120c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm020120c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD38XotVymsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=5260-5279&author=J.+Sterlingauthor=Y.+Herzigauthor=T.+Gorenauthor=N.+Finkelsteinauthor=D.+Lernerauthor=W.+Goldenbergauthor=I.+Miskolcziauthor=S.+Molnarauthor=F.+Rantalauthor=T.+Tamasauthor=G.+Tothauthor=A.+Zagyvaauthor=A.+Zekanyauthor=G.+Lavianauthor=A.+Grossauthor=R.+Friedmanauthor=M.+Razinauthor=W.+Huangauthor=B.+Kraisauthor=M.+Chorevauthor=M.+B.+Youdimauthor=M.+Weinstock&title=Novel+dual+inhibitors+of+AChE+and+MAO+derived+from+hydroxy+aminoindan+and+phenethylamine+as+potential+treatment+for+Alzheimer%E2%80%99s+disease&doi=10.1021%2Fjm020120c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Dual Inhibitors of AChE and MAO Derived from Hydroxy Aminoindan and Phenethylamine as Potential Treatment for Alzheimer's Disease</span></div><div class="casAuthors">Sterling, Jeffrey; Herzig, Yaacov; Goren, Tamar; Finkelstein, Nina; Lerner, David; Goldenberg, Willy; Miskolczi, Istvan; Molnar, Sandor; Rantal, Ferenc; Tamas, Tivadar; Toth, Gyorgy; Zagyva, Adela; Zekany, Andras; Lavian, Gila; Gross, Aviva; Friedman, Rachel; Razin, Michal; Huang, Wei; Krais, Boris; Chorev, Michael; Youdim, Moussa B.; Weinstock, Marta</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">5260-5279</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Carbamate derivs. of N-propargylaminoindanes (Series I) and N-propargylphenethylamines (Series II) were synthesized via multistep procedures from the corresponding hydroxy precursors.  The resp. rasagiline- and selegiline-related series were designed to combine inhibitory activities of both acetylcholine esterase (AChE) and monoamine oxidase (MAO) by virtue of their carbamoyl and propargylamine pharmacophores.  Each compd. was tested for these activities in vitro in order to find mols. with similar potencies against each enzyme.  Compds. with such dual AChE and MAO inhibitory activities are expected to have potential for the treatment of Alzheimer's disease.  The obsd. SAR also offers insight into the requirements of the active sites on these enzymes.  A carbamate moiety was found to be essential for AChE inhibition, which was absent in the corresponding hydroxy precursors.  The propargyl group caused 2-70-fold decrease in AChE inhibitory activity (depending on the position of the carbamoyl group) of Series I, but had little or no effect in Series II.  Thus, the 6- and 7-carbamyloxyphenyls in Series I were either equipotent to, or slightly (2- to 5-fold) less active as AChE inhibitors than, the corresponding compds. in Series II, while the 4-carbamyloxyphenyls were more potent.  The presence of the carbamate moiety in 6- and 7-carbamyloxyphenyls of Series I, considerably decreased MAO-A and -B inhibitory activity, compared to that of the parent hydroxy analogs, while the opposite was true for Series II.  Thus, the 6- and 7-carbamyloxyphenyls in Series I were 2-3 orders of magnitude weaker MAO inhibitors while the 4- carbamyloxyphenyls were equipotent with the corresponding compds. in Series II.  In both series, N-methylation of the propargylamine enhanced the MAO (A and B equally) inhibitory activities and decreased the AChE inhibitory activity.  Two candidates belonging to the indan and tetralin ring systems (HCl salts of I and II) and one phenethylamine (mesylate salt of III) were identified as possible leads for further development based on the following criteria: (a) comparable AChE and MAO-B inhibitory activities, (b) good to moderate AChE inhibitory activity, and (c) lack of strong MAO-A selectivity.  However, it is likely that these compds. will be metabolized to the corresponding phenols, with inhibitory activities against AChE and/or MAO-A or -B, different from those of the parent carbamates.  Thus, the apparent enzyme inhibition will be a result of the combined inhibition of all of these individual metabolites.  The results of our ongoing in vivo screening programs will be published elsewhere.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0RScteajUEbVg90H21EOLACvtfcHk0ljz9bkYujvLbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XotVymsLg%253D&md5=62136a48889ce0fe28a76aa70e577eb9</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1021%2Fjm020120c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020120c%26sid%3Dliteratum%253Aachs%26aulast%3DSterling%26aufirst%3DJ.%26aulast%3DHerzig%26aufirst%3DY.%26aulast%3DGoren%26aufirst%3DT.%26aulast%3DFinkelstein%26aufirst%3DN.%26aulast%3DLerner%26aufirst%3DD.%26aulast%3DGoldenberg%26aufirst%3DW.%26aulast%3DMiskolczi%26aufirst%3DI.%26aulast%3DMolnar%26aufirst%3DS.%26aulast%3DRantal%26aufirst%3DF.%26aulast%3DTamas%26aufirst%3DT.%26aulast%3DToth%26aufirst%3DG.%26aulast%3DZagyva%26aufirst%3DA.%26aulast%3DZekany%26aufirst%3DA.%26aulast%3DLavian%26aufirst%3DG.%26aulast%3DGross%26aufirst%3DA.%26aulast%3DFriedman%26aufirst%3DR.%26aulast%3DRazin%26aufirst%3DM.%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DKrais%26aufirst%3DB.%26aulast%3DChorev%26aufirst%3DM.%26aulast%3DYoudim%26aufirst%3DM.%2BB.%26aulast%3DWeinstock%26aufirst%3DM.%26atitle%3DNovel%2520dual%2520inhibitors%2520of%2520AChE%2520and%2520MAO%2520derived%2520from%2520hydroxy%2520aminoindan%2520and%2520phenethylamine%2520as%2520potential%2520treatment%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D5260%26epage%3D5279%26doi%3D10.1021%2Fjm020120c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref169"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref169'); return false;" data-citation="" class="refNumLink">169</a></strong><div class="NLM_citation" id="cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yogev-Falach, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bar-Am, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amit, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinreb, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Youdim, M. B.</span></span> <span> </span><span class="NLM_article-title">A multifunctional, neuroprotective drug, ladostigil (TV3326), regulates holo-APP translation and processing</span>. <i>FASEB J.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">2177</span>– <span class="NLM_lpage">2179</span>, <span class="refDoi"> DOI: 10.1096/fj.05-4910fje</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1096%2Ffj.05-4910fje" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=16935943" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVyrurvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2006&pages=2177-2179&author=M.+Yogev-Falachauthor=O.+Bar-Amauthor=T.+Amitauthor=O.+Weinrebauthor=M.+B.+Youdim&title=A+multifunctional%2C+neuroprotective+drug%2C+ladostigil+%28TV3326%29%2C+regulates+holo-APP+translation+and+processing&doi=10.1096%2Ffj.05-4910fje"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">A multifunctional, neuroprotective drug, ladostigil (TV3326), regulates holo-APP translation and processing</span></div><div class="casAuthors">Yogev-Falach, Merav; Bar-Am, Orit; Amit, Tamar; Weinreb, Orly; Youdim, Moussa B. H.</div><div class="citationInfo"><span class="NLM_cas:title">FASEB Journal</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2177-2179</span>CODEN:
                <span class="NLM_cas:coden">FAJOEC</span>;
        ISSN:<span class="NLM_cas:issn">0892-6638</span>.
    
            (<span class="NLM_cas:orgname">Federation of American Societies for Experimental Biology</span>)
        </div><div class="casAbstract">The recent therapeutic approach in which drug candidates are designed to possess diverse pharmacol. properties and act on multiple targets has stimulated the development of the bifunctional drug ladostigil (TV3326) [(N-propargyl-(3R) aminoindan-5-yl)-Et Me carbamate].  Ladostigil combines the neuroprotective effects of the antiparkinson drug rasagiline, a selective monoamine oxidase (MAO)-B inhibitor, with the cholinesterase (ChE) inhibitory activity of rivastigmine in a single mol., as a potential treatment for Alzheimer's disease (AD) and Lewy Body disease.  Here, we assessed the dual effects of lodostigil in terms of the mol. mechanism of neuroprotection and amyloid precursor protein (APP) regulation/processing by using an apoptotic model of neuroblastoma SK-N-SH cells.  Ladostigil dose-dependently decreased cell death via inhibition of the cleavage and prevention of caspase-3 activation (IC50=1.05 μM) through a mechanism related to regulation of the Bcl-2 family proteins, which resulted in reduced levels of Bad and Bax and induced levels of Bcl-2 gene and protein expression.  We have also followed APP regulation/processing and found that ladostigil markedly decreased apoptotic-induced levels of holo-APP protein without altering APP mRNA levels, suggesting a posttranscriptional mechanism.  In addn., the drug-elevated phosphorylated protein kinase C (pPKC) levels and stimulated the release of the nonamyloidogenic ot-secretase proteolytic pathway.  Similar to ladostigil, its S-isomer, TV3279, which is a ChE inhibitor but lacks MAO inhibitory activity, exerted neuroprotective properties and regulated APP processing, indicating that these effects are independent of MAO inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEeVwmkmV5FrVg90H21EOLACvtfcHk0lgA3ygVBSlsZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVyrurvJ&md5=98af5388c49c4d1a4cf7b56752367fc6</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1096%2Ffj.05-4910fje&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1096%252Ffj.05-4910fje%26sid%3Dliteratum%253Aachs%26aulast%3DYogev-Falach%26aufirst%3DM.%26aulast%3DBar-Am%26aufirst%3DO.%26aulast%3DAmit%26aufirst%3DT.%26aulast%3DWeinreb%26aufirst%3DO.%26aulast%3DYoudim%26aufirst%3DM.%2BB.%26atitle%3DA%2520multifunctional%252C%2520neuroprotective%2520drug%252C%2520ladostigil%2520%2528TV3326%2529%252C%2520regulates%2520holo-APP%2520translation%2520and%2520processing%26jtitle%3DFASEB%2520J.%26date%3D2006%26volume%3D20%26spage%3D2177%26epage%3D2179%26doi%3D10.1096%2Ffj.05-4910fje" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref170"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref170'); return false;" data-citation="" class="refNumLink">170</a></strong><div class="NLM_citation" id="cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Denya, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malan, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enogieru, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omoruyi, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekpo, O. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapp, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zindo, F. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joubert, J.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and evaluation of indole derivatives as multifunctional agents against Alzheimer’s disease</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">357</span>– <span class="NLM_lpage">370</span>, <span class="refDoi"> DOI: 10.1039/C7MD00569E</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1039%2FC7MD00569E" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=30108930" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC1cXovFSnuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=357-370&author=I.+Denyaauthor=S.+F.+Malanauthor=A.+B.+Enogieruauthor=S.+I.+Omoruyiauthor=O.+E.+Ekpoauthor=E.+Kappauthor=F.+T.+Zindoauthor=J.+Joubert&title=Design%2C+synthesis+and+evaluation+of+indole+derivatives+as+multifunctional+agents+against+Alzheimer%E2%80%99s+disease&doi=10.1039%2FC7MD00569E"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit170R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and evaluation of indole derivatives as multifunctional agents against Alzheimer's disease</span></div><div class="casAuthors">Denya, Ireen; Malan, Sarel F.; Enogieru, Adaze B.; Omoruyi, Sylvester I.; Ekpo, Okobi E.; Kapp, Erika; Zindo, Frank T.; Joubert, Jacques</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">357-370</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A series of indole derivs. was designed and synthesized to improve on activity and circumvent pharmacokinetic limitations experienced with the structurally related compd., ladostigil.  The compds. consisted of a propargylamine moiety (a known MAO inhibitor and neuroprotector) at the N1 position and a ChE inhibiting diethyl-carbamate/urea moiety at the 5 or 6 position of the indole ring.  In order to prevent or slow down the in vivo hydrolysis and deactivation assocd. with the carbamate function of ladostigil, a urea moeity was incorporated into selected compds. to obtain more metabolically stable structures.  The majority of the synthesized compds. showed improved MAO-A inhibitory activity compared to ladostigil.  The compds. possessing the propargylamine moiety showed good MAO-B inhibitory activity with 6 and 8 portraying IC50 values between 14-20 fold better than ladostigil.  The ChE assay results indicated that the compds. have non-selective inhibitory activities on eeAChE and eqBuChE regardless of the type or position of substitution (IC50: 2-5 μM).  MAO-A and MAO-B docking results showed that the propargylamine moiety was positioned in close proximity to the FAD cofactor suggesting that the good inhibitory activity may be attributed to the propargylamine moiety and irreversible inhibition as confirmed in the reversibility studies.  Docking results also indicated that the compds. have interactions with important amino acids in the AChE and BuChE catalytic sites.  Compd. 6 was the most potent multifunctional agent showing better inhibitory activity than ladostigil in vitro on all enzymes tested (hMAO-A IC50 = 4.31 μM, hMAO-B IC50 = 2.62 μM, eeAChE IC50 = 3.70 μM, eqBuChE IC50 = 2.82 μM).  Chem. stability tests confirmed the diethyl-urea contg. compd. 6 to be more stable than its diethyl-carbamate contg. counterpart compd. 8.  Compd. 6 also exerted significant neuroprotection (52.62% at 1 μM) against MPP+ insult to SH-SY5Y neural cells and has good in silico predicted ADMET properties.  The favorable neuronal enzyme inhibitory activity, likely improved pharmacokinetic properties in vivo and the potent neuroprotective ability of compd. 6 make it a promising compd. for further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJKcedPibrbbVg90H21EOLACvtfcHk0lgA3ygVBSlsZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXovFSnuw%253D%253D&md5=81fd9574c036f0ad3923170e5a7c206c</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1039%2FC7MD00569E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC7MD00569E%26sid%3Dliteratum%253Aachs%26aulast%3DDenya%26aufirst%3DI.%26aulast%3DMalan%26aufirst%3DS.%2BF.%26aulast%3DEnogieru%26aufirst%3DA.%2BB.%26aulast%3DOmoruyi%26aufirst%3DS.%2BI.%26aulast%3DEkpo%26aufirst%3DO.%2BE.%26aulast%3DKapp%26aufirst%3DE.%26aulast%3DZindo%26aufirst%3DF.%2BT.%26aulast%3DJoubert%26aufirst%3DJ.%26atitle%3DDesign%252C%2520synthesis%2520and%2520evaluation%2520of%2520indole%2520derivatives%2520as%2520multifunctional%2520agents%2520against%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DMedChemComm%26date%3D2018%26volume%3D9%26spage%3D357%26epage%3D370%26doi%3D10.1039%2FC7MD00569E" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref171"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref171'); return false;" data-citation="" class="refNumLink">171</a></strong><div class="NLM_citation" id="cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span> <span> </span><span class="NLM_article-title">A novel series of tacrine-selegiline hybrids with cholinesterase and monoamine oxidase inhibition activities for the treatment of Alzheimer’s disease</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">745</span>– <span class="NLM_lpage">753</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2013.01.039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1016%2Fj.ejmech.2013.01.039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=23454517" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlslWgu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2013&pages=745-753&author=C.+Luauthor=Q.+Zhouauthor=J.+Yanauthor=Z.+Duauthor=L.+Huangauthor=X.+Li&title=A+novel+series+of+tacrine-selegiline+hybrids+with+cholinesterase+and+monoamine+oxidase+inhibition+activities+for+the+treatment+of+Alzheimer%E2%80%99s+disease&doi=10.1016%2Fj.ejmech.2013.01.039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">A novel series of tacrine-selegiline hybrids with cholinesterase and monoamine oxidase inhibition activities for the treatment of Alzheimer's disease</span></div><div class="casAuthors">Lu, Chuanjun; Zhou, Qi; Yan, Jun; Du, Zhiyun; Huang, Ling; Li, Xingshu</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">745-753</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A novel series of tacrine-selegiline hybrids was synthesized and evaluated for application as inhibitors of cholinesterase (AChE/BuChE) and monoamine oxidase (MAO-A/B).  The results demonstrate that most of the synthesized compds. exhibit high inhibitory activity.  Among these compds., compd. I provided a good balance of activity towards all targets (with IC50 values of 22.6 nM, 9.37 nM, 0.3724 μM, and 0.1810 μM for AChE, BuChE, MAO-A and MAO-B, resp.).  These results indicated that I has the potential to be a multi-functional candidate for Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB-OnHqpBtBrVg90H21EOLACvtfcHk0lgA3ygVBSlsZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlslWgu7g%253D&md5=9e0cfdecbe4e8a2890482f8b32cbf4a4</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2013.01.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2013.01.039%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DC.%26aulast%3DZhou%26aufirst%3DQ.%26aulast%3DYan%26aufirst%3DJ.%26aulast%3DDu%26aufirst%3DZ.%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DX.%26atitle%3DA%2520novel%2520series%2520of%2520tacrine-selegiline%2520hybrids%2520with%2520cholinesterase%2520and%2520monoamine%2520oxidase%2520inhibition%2520activities%2520for%2520the%2520treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2013%26volume%3D62%26spage%3D745%26epage%3D753%26doi%3D10.1016%2Fj.ejmech.2013.01.039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref172"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref172'); return false;" data-citation="" class="refNumLink">172</a></strong><div class="NLM_citation" id="cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esteban, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ojima, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bautista-Aguilera, O. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inokuchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moraleda, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iriepa, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samadi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Youdim, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soriano, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrero, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez Fernandez, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Murillo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marco-Contelles, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unzeta, M.</span></span> <span> </span><span class="NLM_article-title">Donepezil + propargylamine + 8-hydroxyquinoline hybrids as new multifunctional metal-chelators, ChE and MAO inhibitors for the potential treatment of Alzheimer’s disease</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">543</span>– <span class="NLM_lpage">561</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2014.04.078</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1016%2Fj.ejmech.2014.04.078" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=24813882" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC2cXovVensL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2014&pages=543-561&author=L.+Wangauthor=G.+Estebanauthor=M.+Ojimaauthor=O.+M.+Bautista-Aguileraauthor=T.+Inokuchiauthor=I.+Moraledaauthor=I.+Iriepaauthor=A.+Samadiauthor=M.+B.+Youdimauthor=A.+Romeroauthor=E.+Sorianoauthor=R.+Herreroauthor=A.+P.+Fernandez+Fernandezauthor=R.+Martinez-Murilloauthor=J.+Marco-Contellesauthor=M.+Unzeta&title=Donepezil+%2B+propargylamine+%2B+8-hydroxyquinoline+hybrids+as+new+multifunctional+metal-chelators%2C+ChE+and+MAO+inhibitors+for+the+potential+treatment+of+Alzheimer%E2%80%99s+disease&doi=10.1016%2Fj.ejmech.2014.04.078"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Donepezil + propargylamine + 8-hydroxyquinoline hybrids as new multifunctional metal-chelators, ChE and MAO inhibitors for the potential treatment of Alzheimer's disease</span></div><div class="casAuthors">Wang, Li; Esteban, Gerard; Ojima, Masaki; Bautista-Aguilera, Oscar M.; Inokuchi, Tsutomu; Moraleda, Ignacio; Iriepa, Isabel; Samadi, Abdelouahid; Youdim, Moussa B. H.; Romero, Alejandro; Soriano, Elena; Herrero, Raquel; Fernandez Fernandez, Ana Patricia; Ricardo-Martinez-Murillo; Marco-Contelles, Jose; Unzeta, Mercedes</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">543-561</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The synthesis, biochem. evaluation, ADMET, toxicity and mol. modeling of novel multi-target-directed Donepezil + Propargylamine + 8-Hydroxyquinoline (DPH) hybrids for the potential prevention and treatment of Alzheimer's disease is described.  The most interesting deriv. was racemic α-aminotrile4-(1-benzylpiperidin-4-yl)-2-(((8-hydroxyquinolin-5-yl)methyl)(prop-2-yn-1-yl)amino) butanenitrile (DPH6) [MAO A (IC50 = 6.2±0.7 μM); MAO B (IC50 = 10.2±0.9 μM); AChE (IC50 = 1.8±0.1 μM); BuChE (IC50 = 1.6±0.25 μM)], an irreversible MAO A/B inhibitor and mixed-type AChE inhibitor with metal-chelating properties.  According to docking studies, both DPH6 enantiomers interact simultaneously with the catalytic and peripheral site of EeAChE through a linker of appropriate length, supporting the obsd. mixed-type AChE inhibition.  Both enantiomers exhibited a relatively similar position of both hydroxyquinoline and benzyl moieties with the rest of the mol. easily accommodated in the relatively large cavity of MAO A.  For MAO B, the quinoline system was hosted at the cavity entrance, whereas for MAO A this system occupied the substrate cavity.  In this disposition the quinoline moiety interacted directly with the FAD arom. ring.  Very similar binding affinity values were also obsd. for both enantiomers with ChE and MAO enzymes.  DPH derivs. exhibited moderate to good ADMET properties and brain penetration capacity for CNS activity.  DPH6 was less toxic than donepezil at high concns.; while at low concns. both displayed a similar cell viability profile.  Finally, in a passive avoidance task, the antiamnesic effect of DPH6 was tested on mice with exptl. induced amnesia.  DPH6 was capable to significantly decrease scopolamine-induced learning deficits in healthy adult mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphrIxeM4RW2rVg90H21EOLACvtfcHk0lgAWCzWAkI3VQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXovVensL8%253D&md5=2e1f262b4002653cbac7a6dafabe3548</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.04.078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.04.078%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DL.%26aulast%3DEsteban%26aufirst%3DG.%26aulast%3DOjima%26aufirst%3DM.%26aulast%3DBautista-Aguilera%26aufirst%3DO.%2BM.%26aulast%3DInokuchi%26aufirst%3DT.%26aulast%3DMoraleda%26aufirst%3DI.%26aulast%3DIriepa%26aufirst%3DI.%26aulast%3DSamadi%26aufirst%3DA.%26aulast%3DYoudim%26aufirst%3DM.%2BB.%26aulast%3DRomero%26aufirst%3DA.%26aulast%3DSoriano%26aufirst%3DE.%26aulast%3DHerrero%26aufirst%3DR.%26aulast%3DFernandez%2BFernandez%26aufirst%3DA.%2BP.%26aulast%3DMartinez-Murillo%26aufirst%3DR.%26aulast%3DMarco-Contelles%26aufirst%3DJ.%26aulast%3DUnzeta%26aufirst%3DM.%26atitle%3DDonepezil%2520%252B%2520propargylamine%2520%252B%25208-hydroxyquinoline%2520hybrids%2520as%2520new%2520multifunctional%2520metal-chelators%252C%2520ChE%2520and%2520MAO%2520inhibitors%2520for%2520the%2520potential%2520treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2014%26volume%3D80%26spage%3D543%26epage%3D561%26doi%3D10.1016%2Fj.ejmech.2014.04.078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref173"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref173'); return false;" data-citation="" class="refNumLink">173</a></strong><div class="NLM_citation" id="cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esteban, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brogi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shionoya, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campiani, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unzeta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inokuchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marco-Contelles, J.</span></span> <span> </span><span class="NLM_article-title">Donepezil-like multifunctional agents: Design, synthesis, molecular modeling and biological evaluation</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>121</i></span>,  <span class="NLM_fpage">864</span>– <span class="NLM_lpage">879</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2015.10.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1016%2Fj.ejmech.2015.10.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=26471320" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1GktL%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2016&pages=864-879&author=M.+Y.+Wuauthor=G.+Estebanauthor=S.+Brogiauthor=M.+Shionoyaauthor=L.+Wangauthor=G.+Campianiauthor=M.+Unzetaauthor=T.+Inokuchiauthor=S.+Butiniauthor=J.+Marco-Contelles&title=Donepezil-like+multifunctional+agents%3A+Design%2C+synthesis%2C+molecular+modeling+and+biological+evaluation&doi=10.1016%2Fj.ejmech.2015.10.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">Donepezil-like multifunctional agents: Design, synthesis, molecular modeling and biological evaluation</span></div><div class="casAuthors">Wu, Ming-Yu; Esteban, Gerard; Brogi, Simone; Shionoya, Masahi; Wang, Li; Campiani, Giuseppe; Unzeta, Mercedes; Inokuchi, Tsutomu; Butini, Stefania; Marco-Contelles, Jose</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">864-879</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Currently available drugs against Alzheimer's disease (AD) are only able to ameliorate the disease symptoms resulting in a moderate improvement in memory and cognitive function without any efficacy in preventing and inhibiting the progression of the pathol.  In an effort to obtain disease-modifying anti-Alzheimer's drugs (DMAADs) following the multifactorial nature of AD, we have recently developed multifunctional compds.  We herein describe the design, synthesis, mol. modeling and biol. evaluation of a new series of donepezil-related compds. possessing metal chelating properties, and being capable of targeting different enzymic systems related to AD (cholinesterases, ChEs, and monoamine oxidase A, MAO-A).  Among this set of analogs compd. I showed excellent ChEs inhibition potency and a selective MAO-A inhibition (vs MAO-B) coupled to strong complexing properties for zinc and copper ions, both known to be involved in the progression of AD.  Moreover, I exhibited moderate antioxidant properties as found by in vitro assessment.  This compd. represents a novel donepezil-hydroxyquinoline hybrid with DMAAD profile paving the way to the development of a novel class of drugs potentially able to treat AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCOvmO6AroXrVg90H21EOLACvtfcHk0lgAWCzWAkI3VQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1GktL%252FM&md5=7bf3ba2586578a39287a0aacbbe3f672</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.10.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.10.001%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DM.%2BY.%26aulast%3DEsteban%26aufirst%3DG.%26aulast%3DBrogi%26aufirst%3DS.%26aulast%3DShionoya%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DCampiani%26aufirst%3DG.%26aulast%3DUnzeta%26aufirst%3DM.%26aulast%3DInokuchi%26aufirst%3DT.%26aulast%3DButini%26aufirst%3DS.%26aulast%3DMarco-Contelles%26aufirst%3DJ.%26atitle%3DDonepezil-like%2520multifunctional%2520agents%253A%2520Design%252C%2520synthesis%252C%2520molecular%2520modeling%2520and%2520biological%2520evaluation%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D121%26spage%3D864%26epage%3D879%26doi%3D10.1016%2Fj.ejmech.2015.10.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref174"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref174'); return false;" data-citation="" class="refNumLink">174</a></strong><div class="NLM_citation" id="cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bautista-Aguilera, O. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esteban, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chioua, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolic, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agbaba, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moraleda, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iriepa, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soriano, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samadi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unzeta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marco-Contelles, J.</span></span> <span> </span><span class="NLM_article-title">Multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer’s disease: design, synthesis, biochemical evaluation, ADMET, molecular modeling, and QSAR analysis of novel donepezil-pyridyl hybrids</span>. <i>Drug Des., Dev. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1893</span>– <span class="NLM_lpage">1910</span>, <span class="refDoi"> DOI: 10.2147/DDDT.S69258</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.2147%2FDDDT.S69258" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=25378907" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A280%3ADC%252BC2M3ms1alug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2014&pages=1893-1910&author=O.+M.+Bautista-Aguileraauthor=G.+Estebanauthor=M.+Chiouaauthor=K.+Nikolicauthor=D.+Agbabaauthor=I.+Moraledaauthor=I.+Iriepaauthor=E.+Sorianoauthor=A.+Samadiauthor=M.+Unzetaauthor=J.+Marco-Contelles&title=Multipotent+cholinesterase%2Fmonoamine+oxidase+inhibitors+for+the+treatment+of+Alzheimer%E2%80%99s+disease%3A+design%2C+synthesis%2C+biochemical+evaluation%2C+ADMET%2C+molecular+modeling%2C+and+QSAR+analysis+of+novel+donepezil-pyridyl+hybrids&doi=10.2147%2FDDDT.S69258"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">Multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease: design, synthesis, biochemical evaluation, ADMET, molecular modeling, and QSAR analysis of novel donepezil-pyridyl hybrids</span></div><div class="casAuthors">Bautista-Aguilera Oscar M; Chioua Mourad; Samadi Abdelouahid; Marco-Contelles Jose; Esteban Gerard; Unzeta Mercedes; Nikolic Katarina; Agbaba Danica; Moraleda Ignacio; Iriepa Isabel; Soriano Elena</div><div class="citationInfo"><span class="NLM_cas:title">Drug design, development and therapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1893-910</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The design, synthesis, and biochemical evaluation of donepezil-pyridyl hybrids (DPHs) as multipotent cholinesterase (ChE) and monoamine oxidase (MAO) inhibitors for the potential treatment of Alzheimer's disease (AD) is reported.  The 3D-quantitative structure-activity relationship study was used to define 3D-pharmacophores for inhibition of MAO A/B, acetylcholinesterase (AChE), and butyrylcholinesterase (BuChE) enzymes and to design DPHs as novel multi-target drug candidates with potential impact in the therapy of AD.  DPH14 (Electrophorus electricus AChE [EeAChE]: half maximal inhibitory concentration [IC50] =1.1±0.3 nM; equine butyrylcholinesterase [eqBuChE]: IC50 =600±80 nM) was 318-fold more potent for the inhibition of AChE, and 1.3-fold less potent for the inhibition of BuChE than the reference compound ASS234.  DPH14 is a potent human recombinant BuChE (hBuChE) inhibitor, in the same range as DPH12 or DPH16, but 13.1-fold less potent than DPH15 for the inhibition of human recombinant AChE (hAChE).  Compared with donepezil, DPH14 is almost equipotent for the inhibition of hAChE, and 8.8-fold more potent for hBuChE.  Concerning human monoamine oxidase (hMAO) A inhibition, only DPH9 and 5 proved active, compound DPH9 being the most potent (IC50 [MAO A] =5,700±2,100 nM).  For hMAO B, only DPHs 13 and 14 were moderate inhibitors, and compound DPH14 was the most potent (IC50 [MAO B] =3,950±940 nM).  Molecular modeling of inhibitor DPH14 within EeAChE showed a binding mode with an extended conformation, interacting simultaneously with both catalytic and peripheral sites of EeAChE thanks to a linker of appropriate length.  Absortion, distribution, metabolism, excretion and toxicity analysis showed that structures lacking phenyl-substituent show better druglikeness profiles; in particular, DPHs13-15 showed the most suitable absortion, distribution, metabolism, excretion and toxicity properties.  Novel donepezil-pyridyl hybrid DPH14 is a potent, moderately selective hAChE and selective irreversible hMAO B inhibitor which might be considered as a promising compound for further development for the treatment of AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSpLMbTfemCUrFU0A1HOshhfW6udTcc2eY9ZkVtaZBQRrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M3ms1alug%253D%253D&md5=3b3ba418a994f9a5aa796dc3710260a0</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S69258&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S69258%26sid%3Dliteratum%253Aachs%26aulast%3DBautista-Aguilera%26aufirst%3DO.%2BM.%26aulast%3DEsteban%26aufirst%3DG.%26aulast%3DChioua%26aufirst%3DM.%26aulast%3DNikolic%26aufirst%3DK.%26aulast%3DAgbaba%26aufirst%3DD.%26aulast%3DMoraleda%26aufirst%3DI.%26aulast%3DIriepa%26aufirst%3DI.%26aulast%3DSoriano%26aufirst%3DE.%26aulast%3DSamadi%26aufirst%3DA.%26aulast%3DUnzeta%26aufirst%3DM.%26aulast%3DMarco-Contelles%26aufirst%3DJ.%26atitle%3DMultipotent%2520cholinesterase%252Fmonoamine%2520oxidase%2520inhibitors%2520for%2520the%2520treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%253A%2520design%252C%2520synthesis%252C%2520biochemical%2520evaluation%252C%2520ADMET%252C%2520molecular%2520modeling%252C%2520and%2520QSAR%2520analysis%2520of%2520novel%2520donepezil-pyridyl%2520hybrids%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2014%26volume%3D8%26spage%3D1893%26epage%3D1910%26doi%3D10.2147%2FDDDT.S69258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref175"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref175'); return false;" data-citation="" class="refNumLink">175</a></strong><div class="NLM_citation" id="cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koch, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akkari, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunschweiger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borrmann, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlenk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuppers, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kose, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radjainia, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hockemeyer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drabczynska, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiec-Kononowicz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, C. E.</span></span> <span> </span><span class="NLM_article-title">1,3-Dialkyl-substituted tetrahydropyrimido[1,2-f]purine-2,4-diones as multiple target drugs for the potential treatment of neurodegenerative diseases</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">7435</span>– <span class="NLM_lpage">7452</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2013.09.044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1016%2Fj.bmc.2013.09.044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=24139167" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1CrsbfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=7435-7452&author=P.+Kochauthor=R.+Akkariauthor=A.+Brunschweigerauthor=T.+Borrmannauthor=M.+Schlenkauthor=P.+Kuppersauthor=M.+Koseauthor=H.+Radjainiaauthor=J.+Hockemeyerauthor=A.+Drabczynskaauthor=K.+Kiec-Kononowiczauthor=C.+E.+Muller&title=1%2C3-Dialkyl-substituted+tetrahydropyrimido%5B1%2C2-f%5Dpurine-2%2C4-diones+as+multiple+target+drugs+for+the+potential+treatment+of+neurodegenerative+diseases&doi=10.1016%2Fj.bmc.2013.09.044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">1,3-Dialkyl-substituted tetrahydropyrimido[1,2-f]purine-2,4-diones as multiple target drugs for the potential treatment of neurodegenerative diseases</span></div><div class="casAuthors">Koch, Pierre; Akkari, Rhalid; Brunschweiger, Andreas; Borrmann, Thomas; Schlenk, Miriam; Kueppers, Petra; Koese, Meryem; Radjainia, Hamid; Hockemeyer, Joerg; Drabczynska, Anna; Kiec-Kononowicz, Katarzyna; Mueller, Christa E.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">7435-7452</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Adenosine receptors and monoamine oxidases are drug targets for neurodegenerative diseases such as Parkinson's and Alzheimer's disease.  In the present study the authors prepd. a library of 55 mostly novel tetrahydropyrimido[2,1-f]purinediones I [R1 = Me, Et, n-Pr, CH≡CCH2; R2 = Me, Et, n-Pr; R3 = PhCH2, 4-FC6H4, 2-thienyl, etc.].  A synthetic strategy to obtain 3-propargyl-substituted tetrahydropyrimido[2,1-f]purinedione derivs. was developed.  The new compds. were evaluated for their interaction with all four adenosine receptor subtypes and for their ability to inhibit monoamine oxidases (MAO).  Introduction of mono- or di-chloro-substituted Ph, benzyl or phenethyl residues at N9 of the 1,3-di-Me series led to the discovery of a novel class of potent MAO-B inhibitors, the most potent compd. being I [R1 = Me; R2 = Me; R3 = 3,4-Cl2C6H3CH2] 9-(3,4-dichlorobenzyl)-1,3-dimethyl-6,7,8,9-tetrahydropyrimido[1,2-f]purine-2,4(1H,3H)-dione (IC50 human MAO-B: 0.0629 μM), which displayed high selectivity vs. the other investigated targets.  Potent dually active A1/A2A adenosine receptor antagonists were identified, for example, 9-benzyl-1-methyl-3-propargyl-6,7,8,9-tetrahydropyrimido[1,2-f]purine-2,4(1H,3H)dione I [R1 = CH≡CCH2; R2 = Me; R3 = PhCH2] (Ki, human receptors, A1: 0.249 μM, A2A: 0.253 μM).  Several compds. showed triple-target inhibition, the best compd. being I [R1 = CH≡CCH2; R2 = Me; R3 = 3-MeOC6H4CH2] (KiA1: 0.605 μM, KiA2A: 0.417 μM, IC50 MAO-B: 1.80 μM).  Compds. inhibiting several different targets involved in neurodegeneration may exhibit additive or even synergistic effects in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPERWbTreIyLVg90H21EOLACvtfcHk0ljcsETD7NnRyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1CrsbfK&md5=27b1f8581d9f8c96d80d93a1117e6008</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2013.09.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2013.09.044%26sid%3Dliteratum%253Aachs%26aulast%3DKoch%26aufirst%3DP.%26aulast%3DAkkari%26aufirst%3DR.%26aulast%3DBrunschweiger%26aufirst%3DA.%26aulast%3DBorrmann%26aufirst%3DT.%26aulast%3DSchlenk%26aufirst%3DM.%26aulast%3DKuppers%26aufirst%3DP.%26aulast%3DKose%26aufirst%3DM.%26aulast%3DRadjainia%26aufirst%3DH.%26aulast%3DHockemeyer%26aufirst%3DJ.%26aulast%3DDrabczynska%26aufirst%3DA.%26aulast%3DKiec-Kononowicz%26aufirst%3DK.%26aulast%3DMuller%26aufirst%3DC.%2BE.%26atitle%3D1%252C3-Dialkyl-substituted%2520tetrahydropyrimido%255B1%252C2-f%255Dpurine-2%252C4-diones%2520as%2520multiple%2520target%2520drugs%2520for%2520the%2520potential%2520treatment%2520of%2520neurodegenerative%2520diseases%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2013%26volume%3D21%26spage%3D7435%26epage%3D7452%26doi%3D10.1016%2Fj.bmc.2013.09.044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref176"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref176'); return false;" data-citation="" class="refNumLink">176</a></strong><div class="NLM_citation" id="cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Siddiq, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dembitsky, V.</span></span> <span> </span><span class="NLM_article-title">Acetylenic anticancer agents</span>. <i>Anti-Cancer Agents Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">132</span>– <span class="NLM_lpage">170</span>, <span class="refDoi"> DOI: 10.2174/187152008783497073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.2174%2F187152008783497073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=18288919" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsFOmsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=132-170&author=A.+Siddiqauthor=V.+Dembitsky&title=Acetylenic+anticancer+agents&doi=10.2174%2F187152008783497073"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">Acetylenic anticancer agents</span></div><div class="casAuthors">Siddiq, A.; Dembitsky, V.</div><div class="citationInfo"><span class="NLM_cas:title">Anti-Cancer Agents in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">132-170</span>CODEN:
                <span class="NLM_cas:coden">AAMCE4</span>;
        ISSN:<span class="NLM_cas:issn">1871-5206</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  This review is a comprehensive survey of acetylenic anticancer agents obtained from living organisms.  Acetylenic metabolites belong to a class of mols. contg. triple bond(s).  They are found in plants, fungi, microorganisms, and marine invertebrates.  Although acetylenes are common as components of terrestrial plants, fungi, and bacteria, it is only within the last 30 years that biol. active polyacetylenes having unusual structural features have been reported from plants, cyanobacteria, algae, invertebrates, and other sources.  Naturally occurring aquatic acetylenes are of particular interest since many of them display important biol. activities and possess antitumor, antibacterial, antimicrobial, antifungal, phototoxic, HIV inhibitory, and immunosuppressive properties.  There is no doubt that they are of great interest, esp. for the medicinal chem., and/or pharmaceutical industries.  This review presents structures and describes cytotoxic activities of more than 300 acetylenic metabolites isolated from living organisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrw4lcEs6Xy9bVg90H21EOLACvtfcHk0ljcsETD7NnRyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsFOmsb4%253D&md5=6bbede7c9a964ff699d1b560411b19cf</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.2174%2F187152008783497073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F187152008783497073%26sid%3Dliteratum%253Aachs%26aulast%3DSiddiq%26aufirst%3DA.%26aulast%3DDembitsky%26aufirst%3DV.%26atitle%3DAcetylenic%2520anticancer%2520agents%26jtitle%3DAnti-Cancer%2520Agents%2520Med.%2520Chem.%26date%3D2008%26volume%3D8%26spage%3D132%26epage%3D170%26doi%3D10.2174%2F187152008783497073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref177"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref177'); return false;" data-citation="" class="refNumLink">177</a></strong><div class="NLM_citation" id="cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kinashi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O̅take, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yonehara, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, Y.</span></span> <span> </span><span class="NLM_article-title">The structure of salinomycin, a new member of the polyether antibiotics</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">1973</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">4955</span>– <span class="NLM_lpage">4958</span>, <span class="refDoi"> DOI: 10.1016/S0040-4039(01)87382-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1016%2FS0040-4039%2801%2987382-2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1973&pages=4955-4958&author=H.+Kinashiauthor=N.+O%CC%85takeauthor=H.+Yoneharaauthor=S.+Satoauthor=Y.+Saito&title=The+structure+of+salinomycin%2C+a+new+member+of+the+polyether+antibiotics&doi=10.1016%2FS0040-4039%2801%2987382-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1016%2FS0040-4039%2801%2987382-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4039%252801%252987382-2%26sid%3Dliteratum%253Aachs%26aulast%3DKinashi%26aufirst%3DH.%26aulast%3DO%25CC%2585take%26aufirst%3DN.%26aulast%3DYonehara%26aufirst%3DH.%26aulast%3DSato%26aufirst%3DS.%26aulast%3DSaito%26aufirst%3DY.%26atitle%3DThe%2520structure%2520of%2520salinomycin%252C%2520a%2520new%2520member%2520of%2520the%2520polyether%2520antibiotics%26jtitle%3DTetrahedron%2520Lett.%26date%3D1973%26volume%3D14%26spage%3D4955%26epage%3D4958%26doi%3D10.1016%2FS0040-4039%2801%2987382-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref178"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref178'); return false;" data-citation="" class="refNumLink">178</a></strong><div class="NLM_citation" id="cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mai, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hienzsch, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caneque, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wicinski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cabaud, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leroy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">David, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acevedo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ginestier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birnbaum, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charafe-Jauffret, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Codogno, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehrpour, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, R.</span></span> <span> </span><span class="NLM_article-title">Salinomycin kills cancer stem cells by sequestering iron in lysosomes</span>. <i>Nat. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1025</span>– <span class="NLM_lpage">1033</span>, <span class="refDoi"> DOI: 10.1038/nchem.2778</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1038%2Fnchem.2778" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=28937680" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnslKku7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2017&pages=1025-1033&author=T.+T.+Maiauthor=A.+Hamaiauthor=A.+Hienzschauthor=T.+Canequeauthor=S.+Mullerauthor=J.+Wicinskiauthor=O.+Cabaudauthor=C.+Leroyauthor=A.+Davidauthor=V.+Acevedoauthor=A.+Ryoauthor=C.+Ginestierauthor=D.+Birnbaumauthor=E.+Charafe-Jauffretauthor=P.+Codognoauthor=M.+Mehrpourauthor=R.+Rodriguez&title=Salinomycin+kills+cancer+stem+cells+by+sequestering+iron+in+lysosomes&doi=10.1038%2Fnchem.2778"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">Salinomycin kills cancer stem cells by sequestering iron in lysosomes</span></div><div class="casAuthors">Mai, Trang Thi; Hamai, Ahmed; Hienzsch, Antje; Caneque, Tatiana; Muller, Sebastian; Wicinski, Julien; Cabaud, Olivier; Leroy, Christine; David, Amandine; Acevedo, Veronica; Ryo, Akihide; Ginestier, Christophe; Birnbaum, Daniel; Charafe-Jauffret, Emmanuelle; Codogno, Patrice; Mehrpour, Maryam; Rodriguez, Raphael</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1025-1033</span>CODEN:
                <span class="NLM_cas:coden">NCAHBB</span>;
        ISSN:<span class="NLM_cas:issn">1755-4330</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Cancer stem cells (CSCs) represent a subset of cells within tumors that exhibit self-renewal properties and the capacity to seed tumors.  CSCs are typically refractory to conventional treatments and have been assocd. to metastasis and relapse.  Salinomycin operates as a selective agent against CSCs through mechanisms that remain elusive.  Here, the authors provide evidence that a synthetic deriv. of salinomycin, which the authors named ironomycin (AM5), exhibits a more potent and selective activity against breast CSCs in vitro and in vivo, by accumulating and sequestering iron in lysosomes.  In response to the ensuing cytoplasmic depletion of iron, cells triggered the degrdn. of ferritin in lysosomes, leading to further iron loading in this organelle.  Iron-mediated prodn. of reactive oxygen species promoted lysosomal membrane permeabilization, activating a cell death pathway consistent with ferroptosis.  These findings reveal the prevalence of iron homeostasis in breast CSCs, pointing towards iron and iron-mediated processes as potential targets against these cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHPwn6HNYghLVg90H21EOLACvtfcHk0liIkOQ1YTKzRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnslKku7Y%253D&md5=41218199375748b92d4b2478f0cb6086</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1038%2Fnchem.2778&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchem.2778%26sid%3Dliteratum%253Aachs%26aulast%3DMai%26aufirst%3DT.%2BT.%26aulast%3DHamai%26aufirst%3DA.%26aulast%3DHienzsch%26aufirst%3DA.%26aulast%3DCaneque%26aufirst%3DT.%26aulast%3DMuller%26aufirst%3DS.%26aulast%3DWicinski%26aufirst%3DJ.%26aulast%3DCabaud%26aufirst%3DO.%26aulast%3DLeroy%26aufirst%3DC.%26aulast%3DDavid%26aufirst%3DA.%26aulast%3DAcevedo%26aufirst%3DV.%26aulast%3DRyo%26aufirst%3DA.%26aulast%3DGinestier%26aufirst%3DC.%26aulast%3DBirnbaum%26aufirst%3DD.%26aulast%3DCharafe-Jauffret%26aufirst%3DE.%26aulast%3DCodogno%26aufirst%3DP.%26aulast%3DMehrpour%26aufirst%3DM.%26aulast%3DRodriguez%26aufirst%3DR.%26atitle%3DSalinomycin%2520kills%2520cancer%2520stem%2520cells%2520by%2520sequestering%2520iron%2520in%2520lysosomes%26jtitle%3DNat.%2520Chem.%26date%3D2017%26volume%3D9%26spage%3D1025%26epage%3D1033%26doi%3D10.1038%2Fnchem.2778" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref179"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref179'); return false;" data-citation="" class="refNumLink">179</a></strong><div class="NLM_citation" id="cit179"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hitora, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takada, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okada, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ise, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsunaga, S.</span></span> <span> </span><span class="NLM_article-title">(−)-Duryne and its homologues, cytotoxic acetylenes from a marine sponge Petrosia sp</span>. <i>J. Nat. Prod.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">1262</span>– <span class="NLM_lpage">1267</span>, <span class="refDoi"> DOI: 10.1021/np200271n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/np200271n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlsVyhs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2011&pages=1262-1267&author=Y.+Hitoraauthor=K.+Takadaauthor=S.+Okadaauthor=Y.+Iseauthor=S.+Matsunaga&title=%28%E2%88%92%29-Duryne+and+its+homologues%2C+cytotoxic+acetylenes+from+a+marine+sponge+Petrosia+sp&doi=10.1021%2Fnp200271n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">(-)-Duryne and Its Homologues, Cytotoxic Acetylenes from a Marine Sponge Petrosia sp.</span></div><div class="casAuthors">Hitora, Yuki; Takada, Kentaro; Okada, Shigeru; Ise, Yuji; Matsunaga, Shigeki</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Natural Products</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1262-1267</span>CODEN:
                <span class="NLM_cas:coden">JNPRDF</span>;
        ISSN:<span class="NLM_cas:issn">0163-3864</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society-American Society of Pharmacognosy</span>)
        </div><div class="casAbstract">Six linear acetylenes, (-)-duryne (I) and (-)-durynes B-F, were isolated from the marine sponge Petrosia sp.  Their structures were elucidated by NMR and tandem FABMS analyses.  The positions of the olefinic bonds were confirmed by ozonolysis expts., and the abs. configurations were detd. by the modified Mosher's method.  I was found to be the enantiomer of duryne, a previously reported sponge metabolite.  All 6 compds. show cytotoxicity against HeLa cells with IC50 values between 0.08 and 0.50 μM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_M5WONe43lrVg90H21EOLACvtfcHk0liIkOQ1YTKzRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlsVyhs74%253D&md5=6b28fe2cede33296d5f15cb822280fd0</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1021%2Fnp200271n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fnp200271n%26sid%3Dliteratum%253Aachs%26aulast%3DHitora%26aufirst%3DY.%26aulast%3DTakada%26aufirst%3DK.%26aulast%3DOkada%26aufirst%3DS.%26aulast%3DIse%26aufirst%3DY.%26aulast%3DMatsunaga%26aufirst%3DS.%26atitle%3D%2528%25E2%2588%2592%2529-Duryne%2520and%2520its%2520homologues%252C%2520cytotoxic%2520acetylenes%2520from%2520a%2520marine%2520sponge%2520Petrosia%2520sp%26jtitle%3DJ.%2520Nat.%2520Prod.%26date%3D2011%26volume%3D74%26spage%3D1262%26epage%3D1267%26doi%3D10.1021%2Fnp200271n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref180"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref180'); return false;" data-citation="" class="refNumLink">180</a></strong><div class="NLM_citation" id="cit180"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vesely, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Della
Togna, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerwick, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kyle, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linington, R. G.</span></span> <span> </span><span class="NLM_article-title">Almiramides A-C: Discovery and development of a new class of leishmaniasis lead compounds</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">4187</span>– <span class="NLM_lpage">4197</span>, <span class="refDoi"> DOI: 10.1021/jm100265s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100265s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlsFeqtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=4187-4197&author=L.+M.+Sanchezauthor=D.+Lopezauthor=B.+A.+Veselyauthor=G.+Della%0ATognaauthor=W.+H.+Gerwickauthor=D.+E.+Kyleauthor=R.+G.+Linington&title=Almiramides+A-C%3A+Discovery+and+development+of+a+new+class+of+leishmaniasis+lead+compounds&doi=10.1021%2Fjm100265s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">Almiramides A-C: Discovery and development of a new class of Leishmaniasis lead compounds</span></div><div class="casAuthors">Sanchez, Laura M.; Lopez, Dioxelis; Vesely, Brian A.; Della Togna, Gina; Gerwick, William H.; Kyle, Dennis E.; Linington, Roger G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4187-4197</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Leishmaniasis is a debilitating disease caused by protozoan parasites of the genus Leishmania, which affects an estd. 12 million people worldwide.  The discovery of new lead compds. for leishmaniasis is therefore a pressing concern for global health programs.  The org. ext. of a Panamanian collection of the marine cyanobacterium Lyngbya majuscula showed strong in vitro activity in two complementary screens against the tropical parasite Leishmania donovani, the causative agent of visceral leishmaniasis.  Chromatog. sepn. of this complex mixt. led to the isolation of the highly N-methylated linear lipopeptides, almiramides A-C.  Comparison with the biol. activities of a no. of related metabolites and semisynthetic derivs. revealed key features required for activity and afforded one new compd. (I) with superior in vitro activity.  Subsequent synthesis of a library of simplified analogs led to the discovery of several compds. with improved therapeutic indexes to the natural products.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonVhootp7ISLVg90H21EOLACvtfcHk0liIkOQ1YTKzRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlsFeqtr8%253D&md5=ea573cd8d849d3418b46a7641b7bb381</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1021%2Fjm100265s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100265s%26sid%3Dliteratum%253Aachs%26aulast%3DSanchez%26aufirst%3DL.%2BM.%26aulast%3DLopez%26aufirst%3DD.%26aulast%3DVesely%26aufirst%3DB.%2BA.%26aulast%3DDella%2BTogna%26aufirst%3DG.%26aulast%3DGerwick%26aufirst%3DW.%2BH.%26aulast%3DKyle%26aufirst%3DD.%2BE.%26aulast%3DLinington%26aufirst%3DR.%2BG.%26atitle%3DAlmiramides%2520A-C%253A%2520Discovery%2520and%2520development%2520of%2520a%2520new%2520class%2520of%2520leishmaniasis%2520lead%2520compounds%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D4187%26epage%3D4197%26doi%3D10.1021%2Fjm100265s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref181"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref181'); return false;" data-citation="" class="refNumLink">181</a></strong><div class="NLM_citation" id="cit181"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iwasaki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohno, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sumimoto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suenaga, K.</span></span> <span> </span><span class="NLM_article-title">Kurahyne, an acetylene-containing lipopeptide from a marine cyanobacterial assemblage of Lyngbya sp</span>. <i>RSC Adv.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">12840</span>– <span class="NLM_lpage">12843</span>, <span class="refDoi"> DOI: 10.1039/C4RA00132J</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1039%2FC4RA00132J" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjslGgsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=12840-12843&author=A.+Iwasakiauthor=O.+Ohnoauthor=S.+Sumimotoauthor=S.+Sudaauthor=K.+Suenaga&title=Kurahyne%2C+an+acetylene-containing+lipopeptide+from+a+marine+cyanobacterial+assemblage+of+Lyngbya+sp&doi=10.1039%2FC4RA00132J"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit181R"><div class="casContent"><span class="casTitleNuber">181</span><div class="casTitle"><span class="NLM_cas:atitle">Kurahyne, an acetylene-containing lipopeptide from a marine cyanobacterial assemblage of Lyngbya sp.</span></div><div class="casAuthors">Iwasaki, Arihiro; Ohno, Osamu; Sumimoto, Shinpei; Suda, Shoichiro; Suenaga, Kiyotake</div><div class="citationInfo"><span class="NLM_cas:title">RSC Advances</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">12840-12843</span>CODEN:
                <span class="NLM_cas:coden">RSCACL</span>;
        ISSN:<span class="NLM_cas:issn">2046-2069</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Kurahyne, a new acetylene-contg. lipopeptide, was isolated from a cyanobacterial assemblage that mostly consisted of Lyngbya sp.  Its structure was elucidated by spectroscopic analyses and chiral HPLC analyses of hydrolysis products.  Kurahyne inhibited the growth of human cancer cells and induced apoptosis in HeLa cells, and it seemed to localize in mitochondria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolH4kEzvcjR7Vg90H21EOLACvtfcHk0liIkOQ1YTKzRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjslGgsb8%253D&md5=d474abf9e6d5063a088ee5de94a504c6</span></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.1039%2FC4RA00132J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC4RA00132J%26sid%3Dliteratum%253Aachs%26aulast%3DIwasaki%26aufirst%3DA.%26aulast%3DOhno%26aufirst%3DO.%26aulast%3DSumimoto%26aufirst%3DS.%26aulast%3DSuda%26aufirst%3DS.%26aulast%3DSuenaga%26aufirst%3DK.%26atitle%3DKurahyne%252C%2520an%2520acetylene-containing%2520lipopeptide%2520from%2520a%2520marine%2520cyanobacterial%2520assemblage%2520of%2520Lyngbya%2520sp%26jtitle%3DRSC%2520Adv.%26date%3D2014%26volume%3D4%26spage%3D12840%26epage%3D12843%26doi%3D10.1039%2FC4RA00132J" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref182"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref182'); return false;" data-citation="" class="refNumLink">182</a></strong><div class="NLM_citation" id="cit182"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Simmons, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engene, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urena, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, L. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortega-Barria, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerwick, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerwick, W. H.</span></span> <span> </span><span class="NLM_article-title">Viridamides A and B, lipodepsipeptides with antiprotozoal activity from the marine cyanobacterium <i>Oscillatoria nigro-viridis</i></span>. <i>J. Nat. Prod.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">1544</span>– <span class="NLM_lpage">1550</span>, <span class="refDoi"> DOI: 10.1021/np800110e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/np800110e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A280%3ADC%252BD1cnivFChsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2008&pages=1544-1550&author=T.+L.+Simmonsauthor=N.+Engeneauthor=L.+D.+Urenaauthor=L.+I.+Romeroauthor=E.+Ortega-Barriaauthor=L.+Gerwickauthor=W.+H.+Gerwick&title=Viridamides+A+and+B%2C+lipodepsipeptides+with+antiprotozoal+activity+from+the+marine+cyanobacterium+Oscillatoria+nigro-viridis&doi=10.1021%2Fnp800110e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit182R"><div class="casContent"><span class="casTitleNuber">182</span><div class="casTitle"><span class="NLM_cas:atitle">Viridamides A and B, lipodepsipeptides with antiprotozoal activity from the marine cyanobacterium Oscillatoria nigro-viridis</span></div><div class="casAuthors">Simmons T Luke; Engene Niclas; Urena Luis David; Romero Luz I; Ortega-Barria Eduardo; Gerwick Lena; Gerwick William H</div><div class="citationInfo"><span class="NLM_cas:title">Journal of natural products</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1544-50</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Parallel chemical and phylogenetic investigation of a marine cyanobacterium from Panama led to the isolation of two new PKS-NRPS-derived compounds, viridamides A and B.  Their structures were determined by NMR and mass spectroscopic methods, and the absolute configurations assigned by Marfey's method and chiral HPLC analysis.  In addition to six standard, N-methylated amino and hydroxy acids, these metabolites contained the structurally novel 5-methoxydec-9-ynoic acid moiety and an unusual proline methyl ester terminus.  Morphologically, this cyanobacterium was identified as Oscillatoria nigro-viridis, and its 16S rDNA sequence is reported here for the first time.  Phylogenetic analysis of these sequence data has identified O. nigro-viridis strain OSC3L to be closely related to two other marine cyanobacterial genera, Trichodesmium and Blennothrix.  Viridamide A showed antitrypanosomal activity with an IC50 of 1.1 microM and antileishmanial activity with an IC50 of 1.5 microM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQDGAOZde4J9iCEBeYuoi7AfW6udTcc2eaazf9R9PgpnLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cnivFChsw%253D%253D&md5=dcddca72c89105ce99fa0abc73c17bf7</span></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.1021%2Fnp800110e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fnp800110e%26sid%3Dliteratum%253Aachs%26aulast%3DSimmons%26aufirst%3DT.%2BL.%26aulast%3DEngene%26aufirst%3DN.%26aulast%3DUrena%26aufirst%3DL.%2BD.%26aulast%3DRomero%26aufirst%3DL.%2BI.%26aulast%3DOrtega-Barria%26aufirst%3DE.%26aulast%3DGerwick%26aufirst%3DL.%26aulast%3DGerwick%26aufirst%3DW.%2BH.%26atitle%3DViridamides%2520A%2520and%2520B%252C%2520lipodepsipeptides%2520with%2520antiprotozoal%2520activity%2520from%2520the%2520marine%2520cyanobacterium%2520Oscillatoria%2520nigro-viridis%26jtitle%3DJ.%2520Nat.%2520Prod.%26date%3D2008%26volume%3D71%26spage%3D1544%26epage%3D1550%26doi%3D10.1021%2Fnp800110e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref183"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref183'); return false;" data-citation="" class="refNumLink">183</a></strong><div class="NLM_citation" id="cit183"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vining, O. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Videau, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serrill, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, J. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerwick, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proteau, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishmael, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McPhail, K. L.</span></span> <span> </span><span class="NLM_article-title">Depsipeptide companeramides from a Panamanian marine cyanobacterium associated with the coibamide producer</span>. <i>J. Nat. Prod.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">413</span>– <span class="NLM_lpage">420</span>, <span class="refDoi"> DOI: 10.1021/np5007907</span> </span><div class="citationLinks">[<a href="/doi/10.1021/np5007907" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC2MXltVWktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2015&pages=413-420&author=O.+B.+Viningauthor=R.+A.+Medinaauthor=E.+A.+Mitchellauthor=P.+Videauauthor=D.+Liauthor=J.+D.+Serrillauthor=J.+X.+Kellyauthor=W.+H.+Gerwickauthor=P.+J.+Proteauauthor=J.+E.+Ishmaelauthor=K.+L.+McPhail&title=Depsipeptide+companeramides+from+a+Panamanian+marine+cyanobacterium+associated+with+the+coibamide+producer&doi=10.1021%2Fnp5007907"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit183R"><div class="casContent"><span class="casTitleNuber">183</span><div class="casTitle"><span class="NLM_cas:atitle">Depsipeptide companeramides from a Panamanian marine cyanobacterium associated with the coibamide producer</span></div><div class="casAuthors">Vining, Oliver B.; Medina, Rebecca A.; Mitchell, Edward A.; Videau, Patrick; Li, Dong; Serrill, Jeffrey D.; Kelly, Jane X.; Gerwick, William H.; Proteau, Philip J.; Ishmael, Jane E.; McPhail, Kerry L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Natural Products</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">413-420</span>CODEN:
                <span class="NLM_cas:coden">JNPRDF</span>;
        ISSN:<span class="NLM_cas:issn">0163-3864</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society-American Society of Pharmacognosy</span>)
        </div><div class="casAbstract">Two new cyclic depsipeptides, companeramides A (I) and B (II), have been isolated from the phylogenetically characterized cyanobacterial collection that yielded the previously reported cancer cell toxin coibamide A (collected from Coiba Island, Panama).  The planar structures of the companeramides, which contain 3-amino-2-methyl-7-octynoic acid (Amoya), hydroxy isovaleric acid (Hiva), and eight α-amino acid units, were established by NMR spectroscopy and mass spectrometry.  The abs. configuration of each companeramide was assigned using a combination of Marfey's methodol. and chiral-phase HPLC anal. of complete and partial hydrolysis products compared to com. and synthesized stds.  Companeramides A (1) and B (2) showed high nanomolar in vitro antiplasmodial activity but were not overtly cytotoxic to four human cancer cell lines at the doses tested.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocYIfQRHhNFbVg90H21EOLACvtfcHk0lgKw6_RTrylQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXltVWktg%253D%253D&md5=10073c7ff72892615a5f6340adc936eb</span></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.1021%2Fnp5007907&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fnp5007907%26sid%3Dliteratum%253Aachs%26aulast%3DVining%26aufirst%3DO.%2BB.%26aulast%3DMedina%26aufirst%3DR.%2BA.%26aulast%3DMitchell%26aufirst%3DE.%2BA.%26aulast%3DVideau%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DSerrill%26aufirst%3DJ.%2BD.%26aulast%3DKelly%26aufirst%3DJ.%2BX.%26aulast%3DGerwick%26aufirst%3DW.%2BH.%26aulast%3DProteau%26aufirst%3DP.%2BJ.%26aulast%3DIshmael%26aufirst%3DJ.%2BE.%26aulast%3DMcPhail%26aufirst%3DK.%2BL.%26atitle%3DDepsipeptide%2520companeramides%2520from%2520a%2520Panamanian%2520marine%2520cyanobacterium%2520associated%2520with%2520the%2520coibamide%2520producer%26jtitle%3DJ.%2520Nat.%2520Prod.%26date%3D2015%26volume%3D78%26spage%3D413%26epage%3D420%26doi%3D10.1021%2Fnp5007907" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref184"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref184'); return false;" data-citation="" class="refNumLink">184</a></strong><div class="NLM_citation" id="cit184"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chai, Q. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, B. N.</span></span> <span> </span><span class="NLM_article-title">Alkynyl-containing peptides of marine origin: A review</span>. <i>Mar. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">216</span>, <span class="refDoi"> DOI: 10.3390/md14110216</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.3390%2Fmd14110216" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC1cXptVagtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2016&pages=216&author=Q.+Y.+Chaiauthor=Z.+Yangauthor=H.+W.+Linauthor=B.+N.+Han&title=Alkynyl-containing+peptides+of+marine+origin%3A+A+review&doi=10.3390%2Fmd14110216"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit184R"><div class="casContent"><span class="casTitleNuber">184</span><div class="casTitle"><span class="NLM_cas:atitle">Alkynyl-containing peptides of marine origin: A review</span></div><div class="casAuthors">Chai, Qiu-Ye; Yang, Zhen; Lin, Hou-Wen; Han, Bing-Nan</div><div class="citationInfo"><span class="NLM_cas:title">Marine Drugs</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">216/1-216/18</span>CODEN:
                <span class="NLM_cas:coden">MDARE6</span>;
        ISSN:<span class="NLM_cas:issn">1660-3397</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Since the 1990s, a no. of terminal alkynyl residue-contg. cyclic/acyclic peptides have been identified from marine organisms, esp. cyanobacteria and marine mollusks.  This review has presented 66 peptides, which covers over 90% marine peptides with terminal alkynyl fatty acyl units.  In fact, more than 90% of these peptides described in the literature are of cyanobacterial origin.  Interestingly, all the linear peptides featured with terminal alkyne were solely discovered from marine cyanobacteria.  The objective of this article is to provide an overview on the types, structural characterization of these unusual terminal alkynyl fatty acyl units, as well as the sources and biol. functions of their composed peptides.  Many of these peptides have a variety of biol. activities, including antitumor, antibacterial, antimalarial, etc.  Further, we have also discussed the evident biosynthetic origin responsible for formation of terminal alkynes of natural PKS (polyketide synthase)/NRPS (nonribosome peptide synthetase) hybrids.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJ4rgRFnei-7Vg90H21EOLACvtfcHk0lgAsSDV7KG_Jw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXptVagtg%253D%253D&md5=cca7c110ea5e062ed565580f016df27c</span></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.3390%2Fmd14110216&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmd14110216%26sid%3Dliteratum%253Aachs%26aulast%3DChai%26aufirst%3DQ.%2BY.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DLin%26aufirst%3DH.%2BW.%26aulast%3DHan%26aufirst%3DB.%2BN.%26atitle%3DAlkynyl-containing%2520peptides%2520of%2520marine%2520origin%253A%2520A%2520review%26jtitle%3DMar.%2520Drugs%26date%3D2016%26volume%3D14%26spage%3D216%26doi%3D10.3390%2Fmd14110216" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref185"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref185'); return false;" data-citation="" class="refNumLink">185</a></strong><div class="NLM_citation" id="cit185"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunne, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morton, G. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borders, D. B.</span></span> <span> </span><span class="NLM_article-title">Calichemicins, a novel family of antitumor antibiotics. 1. Chemistry and partial structure of calichemicin.gamma.1I</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">3464</span>– <span class="NLM_lpage">3466</span>, <span class="refDoi"> DOI: 10.1021/ja00245a050</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja00245a050" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADyaL2sXkt1elsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=1987&pages=3464-3466&author=M.+D.+Leeauthor=T.+S.+Dunneauthor=M.+M.+Siegelauthor=C.+C.+Changauthor=G.+O.+Mortonauthor=D.+B.+Borders&title=Calichemicins%2C+a+novel+family+of+antitumor+antibiotics.+1.+Chemistry+and+partial+structure+of+calichemicin.gamma.1I&doi=10.1021%2Fja00245a050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit185R"><div class="casContent"><span class="casTitleNuber">185</span><div class="casTitle"><span class="NLM_cas:atitle">Calichemicins, a novel family of antitumor antibiotics.  1.  Chemistry and partial structure of calichemicin γ1I</span></div><div class="casAuthors">Lee, May D.; Dunne, Theresa S.; Siegel, Marshall M.; Chang, Conway C.; Morton, George O.; Borders, Donald B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3464-6</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    </div><div class="casAbstract">The calichemicins, produced by Micromonospora echinospora ssp.. calichensis, represent a novel class of extremely potent antitumor antibiotics.  Degrdn. and derivatization studies were carried out on calichemicin γ1I (I; C55H74IN3O21S4), the major component of the calichemicin complex, and provided information for a partial structure proposal.  These studies showed calichemicin γ1I to contain 3-O-methyl-α-L-rhamnopyranoside, a pentasubstituted benzoate, a novel thioglycoside, an unusual hydroxyaminoglycoside, an ethylaminoglycoside, and an aglycon (C18H17NO5S3).  The connectivity and the substitution patterns of these structural units were elucidated by two-dimensional NMR techniques, high-resoln. FABMS (fast-atom-bombardment mass spectra), and x-ray crystallog. of degrdn. products.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlVcIXyoXokbVg90H21EOLACvtfcHk0lgAsSDV7KG_Jw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXkt1elsb0%253D&md5=dc21e6bfd8f6bef5774439d7c3e93c0f</span></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=10.1021%2Fja00245a050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja00245a050%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DM.%2BD.%26aulast%3DDunne%26aufirst%3DT.%2BS.%26aulast%3DSiegel%26aufirst%3DM.%2BM.%26aulast%3DChang%26aufirst%3DC.%2BC.%26aulast%3DMorton%26aufirst%3DG.%2BO.%26aulast%3DBorders%26aufirst%3DD.%2BB.%26atitle%3DCalichemicins%252C%2520a%2520novel%2520family%2520of%2520antitumor%2520antibiotics.%25201.%2520Chemistry%2520and%2520partial%2520structure%2520of%2520calichemicin.gamma.1I%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1987%26volume%3D109%26spage%3D3464%26epage%3D3466%26doi%3D10.1021%2Fja00245a050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref186"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref186'); return false;" data-citation="" class="refNumLink">186</a></strong><div class="NLM_citation" id="cit186"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nicolaou, K. C.</span></span> <span> </span><span class="NLM_article-title">The battle of calicheamicin γ</span>. <i>Angew. Chem., Int. Ed. Engl.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">1377</span>– <span class="NLM_lpage">1385</span>, <span class="refDoi"> DOI: 10.1002/anie.199313773</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1002%2Fanie.199313773" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=1993&pages=1377-1385&author=K.+C.+Nicolaou&title=The+battle+of+calicheamicin+%CE%B3&doi=10.1002%2Fanie.199313773"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=10.1002%2Fanie.199313773&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.199313773%26sid%3Dliteratum%253Aachs%26aulast%3DNicolaou%26aufirst%3DK.%2BC.%26atitle%3DThe%2520battle%2520of%2520calicheamicin%2520%25CE%25B3%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%2520Engl.%26date%3D1993%26volume%3D32%26spage%3D1377%26epage%3D1385%26doi%3D10.1002%2Fanie.199313773" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref187"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref187'); return false;" data-citation="" class="refNumLink">187</a></strong><div class="NLM_citation" id="cit187"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bergman, R. G.</span></span> <span> </span><span class="NLM_article-title">Reactive 1,4-dehydroaromatics</span>. <i>Acc. Chem. Res.</i> <span class="NLM_year" style="font-weight: bold;">1973</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">25</span>– <span class="NLM_lpage">31</span>, <span class="refDoi"> DOI: 10.1021/ar50061a004</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ar50061a004" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADyaE3sXntFWktw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1973&pages=25-31&author=R.+G.+Bergman&title=Reactive+1%2C4-dehydroaromatics&doi=10.1021%2Far50061a004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit187R"><div class="casContent"><span class="casTitleNuber">187</span><div class="casTitle"><span class="NLM_cas:atitle">Reactive 1,4-dehydroaromatics</span></div><div class="casAuthors">Bergman, Robert G.</div><div class="citationInfo"><span class="NLM_cas:title">Accounts of Chemical Research</span>
        (<span class="NLM_cas:date">1973</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">25-31</span>CODEN:
                <span class="NLM_cas:coden">ACHRE4</span>;
        ISSN:<span class="NLM_cas:issn">0001-4842</span>.
    </div><div class="casAbstract">A review with 44 ref. and some new data.  The synthesis and chemistry of dehydroarom. mols. is discussed.  Evidence is presented for the generation of 1,4-dehydrobenzene as a transient intermediate in the thermal rearrangement of cis-1,5-hexadiyn-3-ene.  Pyrolysis of the diacetylene labeled with D in the acetylenic positions results in scrambling of D between the vinyl and acetylenic positions.  Trapping experiments provide evidence that this rearrangement proceeds through 1,4-dehydrobenzene, which apparently has a 1,4-benzenediyl structure:  pyrolysis of cis-1,5-hexadiyne-3-ene in hydrocarbon soln. gives benzene, in CCl4 gives p-C6H4Cl2, and in MeOH leads to PhCH2OH but no anisole.  1,4-Dehydroaromatics having 7 rather than 6 carbons are discussed.  Pyrolysis of cis- and trans-1,2-diethynylcyclopropane leads to bicyclo[3.2.0]hepta-1,4,6-triene.  The mechanism of this reaction is discussed and evidence for the formation of the bicycloheptatrienyl anion on treatment of the triene with strong base is presented.  Finally, the synthesis and some chemistry of 3,6-dehydrooxepin (3-oxabicyclo[3.2.0]hepta-1,4,6-triene) is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpW-wcqQofoSLVg90H21EOLACvtfcHk0lgAsSDV7KG_Jw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE3sXntFWktw%253D%253D&md5=8fe8a9163b905b76db270de291b3ebe1</span></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=10.1021%2Far50061a004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Far50061a004%26sid%3Dliteratum%253Aachs%26aulast%3DBergman%26aufirst%3DR.%2BG.%26atitle%3DReactive%25201%252C4-dehydroaromatics%26jtitle%3DAcc.%2520Chem.%2520Res.%26date%3D1973%26volume%3D6%26spage%3D25%26epage%3D31%26doi%3D10.1021%2Far50061a004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref188"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref188'); return false;" data-citation="" class="refNumLink">188</a></strong><div class="NLM_citation" id="cit188"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kraka, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cremer, D.</span></span> <span> </span><span class="NLM_article-title">Computer design of anticancer drugs. A new enediyne warhead</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>122</i></span>,  <span class="NLM_fpage">8245</span>– <span class="NLM_lpage">8264</span>, <span class="refDoi"> DOI: 10.1021/ja001017k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja001017k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD3cXls1OktrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2000&pages=8245-8264&author=E.+Krakaauthor=D.+Cremer&title=Computer+design+of+anticancer+drugs.+A+new+enediyne+warhead&doi=10.1021%2Fja001017k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit188R"><div class="casContent"><span class="casTitleNuber">188</span><div class="casTitle"><span class="NLM_cas:atitle">Computer design of anticancer drugs. a new enediyne warhead</span></div><div class="casAuthors">Kraka, Elfi; Cremer, Dieter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">8245-8264</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Seven criteria are developed and discussed that lead to the design of a new enediyne anticancer drug, which should have low toxicity but high biol. selectivity and activity when attacking the DNA of tumor cells.  These criteria concern (among others) the thermodn. and kinetic stability of the species involved in the reaction of an enediyne, the biradical character and H-abstraction ability of the intermediate biradical generated in a Bergman reaction of the enediyne, and the basicity of the enediyne and its assocd. biradical.  Thirteen different heteroenediynes were investigated with the help of B3LYP/6-31G(d,p) calcns. to find a suitable candidate for a new enediyne anticancer drug, which fulfills the seven criteria.  These calcns. included the detn. of reaction profiles for Bergman and retro-Bergman reactions, the calcn. of singlet-triplet splittings of biradicals formed from enediynes, and the prediction of pKa values.  Results were tested by using a larger basis set (6-311+G(3df,3pd)), another functional (BLYP), and coupled cluster methods such as CCSD(T) and the Brueckner orbitals-based BD(T) method.  The best candidate for a new enediyne anticancer drug is an N,C-dialkynyl aldimine incorporated into a cyclodecaene ring.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvrqtsKh3_DLVg90H21EOLACvtfcHk0lhnFFUqusuCjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXls1OktrY%253D&md5=c93596dcf27b7f50554d436268405996</span></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=10.1021%2Fja001017k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja001017k%26sid%3Dliteratum%253Aachs%26aulast%3DKraka%26aufirst%3DE.%26aulast%3DCremer%26aufirst%3DD.%26atitle%3DComputer%2520design%2520of%2520anticancer%2520drugs.%2520A%2520new%2520enediyne%2520warhead%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2000%26volume%3D122%26spage%3D8245%26epage%3D8264%26doi%3D10.1021%2Fja001017k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref189"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref189'); return false;" data-citation="" class="refNumLink">189</a></strong><div class="NLM_citation" id="cit189"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Konishi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohkuma, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuno, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamei, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawaguchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">VanDuyne, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clardy, J.</span></span> <span> </span><span class="NLM_article-title">Dynemicin A, a novel antibiotic with the anthraquinone and 1,5-diyn-3-ene subunit</span>. <i>J. Antibiot.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">1449</span>– <span class="NLM_lpage">1452</span>, <span class="refDoi"> DOI: 10.7164/antibiotics.42.1449</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.7164%2Fantibiotics.42.1449" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=2793600" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADyaK3cXjtlSgsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1989&pages=1449-1452&author=M.+Konishiauthor=H.+Ohkumaauthor=K.+Matsumotoauthor=T.+Tsunoauthor=H.+Kameiauthor=T.+Miyakiauthor=T.+Okiauthor=H.+Kawaguchiauthor=G.+D.+VanDuyneauthor=J.+Clardy&title=Dynemicin+A%2C+a+novel+antibiotic+with+the+anthraquinone+and+1%2C5-diyn-3-ene+subunit&doi=10.7164%2Fantibiotics.42.1449"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit189R"><div class="casContent"><span class="casTitleNuber">189</span><div class="casTitle"><span class="NLM_cas:atitle">Dynemicin A, a novel antibiotic with the anthraquinone and 1,5-diyn-3-ene subunit</span></div><div class="casAuthors">Konishi, Masataka; Ohkuma, Hiroaki; Matsumoto, Kiyoshi; Tsuno, Takashi; Kamei, Hideo; Miyaki, Takeo; Oki, Toshikazu; Kawaguchi, Hiroshi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antibiotics</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1449-52</span>CODEN:
                <span class="NLM_cas:coden">JANTAJ</span>;
        ISSN:<span class="NLM_cas:issn">0021-8820</span>.
    </div><div class="casAbstract">Dynemicin A (I) was isolated from the culture broth of Micromonospora species and its structure was detd.  It was esp. active against gram-pos. bacteria and prolonged the life span of mice inoculated with P388 leukemia.  Treating I with acetic acid anhydride yielded a triacetyl deriv. of I which was 2-5-fold as potent as I against all microbes tested.  In addn. both compds. displayed significant activity against P388 leukemia and 316 melanoma in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6sU283EH0HbVg90H21EOLACvtfcHk0lhnFFUqusuCjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXjtlSgsw%253D%253D&md5=48845123f3f9273cb43fb87bb3f55604</span></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=10.7164%2Fantibiotics.42.1449&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7164%252Fantibiotics.42.1449%26sid%3Dliteratum%253Aachs%26aulast%3DKonishi%26aufirst%3DM.%26aulast%3DOhkuma%26aufirst%3DH.%26aulast%3DMatsumoto%26aufirst%3DK.%26aulast%3DTsuno%26aufirst%3DT.%26aulast%3DKamei%26aufirst%3DH.%26aulast%3DMiyaki%26aufirst%3DT.%26aulast%3DOki%26aufirst%3DT.%26aulast%3DKawaguchi%26aufirst%3DH.%26aulast%3DVanDuyne%26aufirst%3DG.%2BD.%26aulast%3DClardy%26aufirst%3DJ.%26atitle%3DDynemicin%2520A%252C%2520a%2520novel%2520antibiotic%2520with%2520the%2520anthraquinone%2520and%25201%252C5-diyn-3-ene%2520subunit%26jtitle%3DJ.%2520Antibiot.%26date%3D1989%26volume%3D42%26spage%3D1449%26epage%3D1452%26doi%3D10.7164%2Fantibiotics.42.1449" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref190"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref190'); return false;" data-citation="" class="refNumLink">190</a></strong><div class="NLM_citation" id="cit190"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sugiura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiraki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konishi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oki, T.</span></span> <span> </span><span class="NLM_article-title">DNA intercalation and cleavage of an antitumor antibiotic dynemicin that contains anthracycline and enediyne cores</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">3831</span>– <span class="NLM_lpage">3835</span>, <span class="refDoi"> DOI: 10.1073/pnas.87.10.3831</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1073%2Fpnas.87.10.3831" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=2339123" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADyaK3cXksFaitbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=1990&pages=3831-3835&author=Y.+Sugiuraauthor=T.+Shirakiauthor=M.+Konishiauthor=T.+Oki&title=DNA+intercalation+and+cleavage+of+an+antitumor+antibiotic+dynemicin+that+contains+anthracycline+and+enediyne+cores&doi=10.1073%2Fpnas.87.10.3831"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit190R"><div class="casContent"><span class="casTitleNuber">190</span><div class="casTitle"><span class="NLM_cas:atitle">DNA intercalation and cleavage of an antitumor antibiotic dynemicin that contains anthracycline and enediyne cores</span></div><div class="casAuthors">Sugiura, Yukio; Shiraki, Takashi; Konishi, Masataka; Oki, Toshikazu</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3831-5</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">Dynemicin is a hybrid contg. anthraquinone and enediyne cores, which contribute to binding and cleavage of DNA, resp.  DNA strand scission by the antitumor antibiotic is enhanced by the addn. of NADPH or thiol compds.  The preferential cutting site of dynemicin is on the 3' side of purine bases (i.e., 5'-GC, -GT, and -AG) and is clearly different from the cutting sites of esperamicin and calicheamicin.  The double-stranded and the stem regions of single-stranded DNAs are preferentially cleaved by dynemicin.  Therefore, dynemicin may be a useful reagent for probing secondary structures of DNA.  Pretreatment of DNA with Adriamycin and actinomycin D alters the cutting mode of dynemicin.  Dynemicin-mediated DNA breakage is strongly inhibited by pretreatment of the DNA with distamycin A and anthramycin, suggesting that dynemicin interacts with the minor groove of the DNA helix.  Intercalation of the anthraquinone core into the DNA followed by the attack of the Ph diradical formed from the enediyne core is considered as a possible mechanism of action of dynemicin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIbvMr4_V1SrVg90H21EOLACvtfcHk0lhnFFUqusuCjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXksFaitbw%253D&md5=5fb86c3df813ba5d8f33944000458106</span></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=10.1073%2Fpnas.87.10.3831&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.87.10.3831%26sid%3Dliteratum%253Aachs%26aulast%3DSugiura%26aufirst%3DY.%26aulast%3DShiraki%26aufirst%3DT.%26aulast%3DKonishi%26aufirst%3DM.%26aulast%3DOki%26aufirst%3DT.%26atitle%3DDNA%2520intercalation%2520and%2520cleavage%2520of%2520an%2520antitumor%2520antibiotic%2520dynemicin%2520that%2520contains%2520anthracycline%2520and%2520enediyne%2520cores%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1990%26volume%3D87%26spage%3D3831%26epage%3D3835%26doi%3D10.1073%2Fpnas.87.10.3831" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref191"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref191'); return false;" data-citation="" class="refNumLink">191</a></strong><div class="NLM_citation" id="cit191"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chari, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widdison, W. C.</span></span> <span> </span><span class="NLM_article-title">Antibody-drug conjugates: an emerging concept in cancer therapy</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">3796</span>– <span class="NLM_lpage">3827</span>, <span class="refDoi"> DOI: 10.1002/anie.201307628</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1002%2Fanie.201307628" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtVGmsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2014&pages=3796-3827&author=R.+V.+Chariauthor=M.+L.+Millerauthor=W.+C.+Widdison&title=Antibody-drug+conjugates%3A+an+emerging+concept+in+cancer+therapy&doi=10.1002%2Fanie.201307628"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit191R"><div class="casContent"><span class="casTitleNuber">191</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody-Drug Conjugates: An Emerging Concept in Cancer Therapy</span></div><div class="casAuthors">Chari, Ravi V. J.; Miller, Michael L.; Widdison, Wayne C.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3796-3827</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Traditional cancer chemotherapy is often accompanied by systemic toxicity to the patient.  Monoclonal antibodies against antigens on cancer cells offer an alternative tumor-selective treatment approach.  However, most monoclonal antibodies are not sufficiently potent to be therapeutically active on their own.  Antibody-drug conjugates (ADCs) use antibodies to deliver a potent cytotoxic compd. selectively to tumor cells, thus improving the therapeutic index of chemotherapeutic agents.  The recent approval of two ADCs, brentuximab vedotin and ado-trastuzumab emtansine, for cancer treatment has spurred tremendous research interest in this field.  This Review touches upon the early efforts in the field, and describes how the lessons learned from the first-generation ADCs have led to improvements in every aspect of this technol., i.e., the antibody, the cytotoxic compd., and the linker connecting them, leading to the current successes.  The design of ADCs currently in clin. development, and results from mechanistic studies and preclin. and clin. evaluation are discussed.  Emerging technologies that seek to further advance this exciting area of research are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4T2rhmji6DLVg90H21EOLACvtfcHk0lhnFFUqusuCjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtVGmsr0%253D&md5=fbfb2f843f516654ea7c0eb98949604c</span></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=10.1002%2Fanie.201307628&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201307628%26sid%3Dliteratum%253Aachs%26aulast%3DChari%26aufirst%3DR.%2BV.%26aulast%3DMiller%26aufirst%3DM.%2BL.%26aulast%3DWiddison%26aufirst%3DW.%2BC.%26atitle%3DAntibody-drug%2520conjugates%253A%2520an%2520emerging%2520concept%2520in%2520cancer%2520therapy%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2014%26volume%3D53%26spage%3D3796%26epage%3D3827%26doi%3D10.1002%2Fanie.201307628" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref192"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref192'); return false;" data-citation="" class="refNumLink">192</a></strong><div class="NLM_citation" id="cit192"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fontana, R. J.</span></span> <span> </span><span class="NLM_article-title">Acute liver failure due to drugs</span>. <i>Semin. Liver Dis.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">175</span>– <span class="NLM_lpage">187</span>, <span class="refDoi"> DOI: 10.1055/s-2008-1073117</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1055%2Fs-2008-1073117" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=18452117" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmsV2mu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2008&pages=175-187&author=R.+J.+Fontana&title=Acute+liver+failure+due+to+drugs&doi=10.1055%2Fs-2008-1073117"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit192R"><div class="casContent"><span class="casTitleNuber">192</span><div class="casTitle"><span class="NLM_cas:atitle">Acute liver failure due to drugs</span></div><div class="casAuthors">Fontana, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Liver Disease</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">175-187</span>CODEN:
                <span class="NLM_cas:coden">SLDIEE</span>;
        ISSN:<span class="NLM_cas:issn">0272-8087</span>.
    
            (<span class="NLM_cas:orgname">Thieme Medical Publishers, Inc.</span>)
        </div><div class="casAbstract">A review.  Acetaminophen overdose and idiosyncratic drug-induced liver injury (DILI) are the most commonly identified causes of acute liver failure (ALF) in the United States.  Suspected acetaminophen hepatotoxicity can be effectively treated with N-acetylcysteine but still an estd. 500 patients die each year.  Product labeling changes, dispensing restrictions, and reformulation of acetaminophen contg. narcotic analgesics have been proposed to reduce the rising incidence of this preventable form of dose-dependent liver injury.  In contrast, idiosyncratic DILI is not preventable due to our lack of understanding of host susceptibility and outcome factors.  Patients with ALF due to DILI are difficult to diagnose and have a low likelihood of spontaneous recovery.  Patients with severe idiosyncratic DILI should be urgently referred to a transplant center as there are no established medical treatments beyond drug discontinuation.  Investigation of host variability in metabolic, regeneration, and immunol. pathways may provide insights into the mol. basis of DILI as well as improved diagnostic and prognostic biomarkers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq51HyI4BlEa7Vg90H21EOLACvtfcHk0lgZSTxwnurAug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmsV2mu7Y%253D&md5=fc960892169cc9aed8be5f062982abab</span></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=10.1055%2Fs-2008-1073117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-2008-1073117%26sid%3Dliteratum%253Aachs%26aulast%3DFontana%26aufirst%3DR.%2BJ.%26atitle%3DAcute%2520liver%2520failure%2520due%2520to%2520drugs%26jtitle%3DSemin.%2520Liver%2520Dis.%26date%3D2008%26volume%3D28%26spage%3D175%26epage%3D187%26doi%3D10.1055%2Fs-2008-1073117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref193"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref193'); return false;" data-citation="" class="refNumLink">193</a></strong><div class="NLM_citation" id="cit193"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mutlib, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nemeth, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gan, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christ, D. D.</span></span> <span> </span><span class="NLM_article-title">Liquid chromatography/mass spectrometry and high-field nuclear magnetic resonance characterization of novel mixed diconjugates of the non-nucleoside human immunodeficiency virus-1 reverse transcriptase inhibitor, efavirenz</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">1045</span>– <span class="NLM_lpage">1056</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10460805" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADyaK1MXlslCqsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1999&pages=1045-1056&author=A.+E.+Mutlibauthor=H.+Chenauthor=G.+Nemethauthor=L.+S.+Ganauthor=D.+D.+Christ&title=Liquid+chromatography%2Fmass+spectrometry+and+high-field+nuclear+magnetic+resonance+characterization+of+novel+mixed+diconjugates+of+the+non-nucleoside+human+immunodeficiency+virus-1+reverse+transcriptase+inhibitor%2C+efavirenz"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit193R"><div class="casContent"><span class="casTitleNuber">193</span><div class="casTitle"><span class="NLM_cas:atitle">Liquid chromatography/mass spectrometry and high-field nuclear magnetic resonance characterization of novel mixed diconjugates of the non-nucleoside human immunodeficiency virus-1 reverse transcriptase inhibitor, efavirenz</span></div><div class="casAuthors">Mutlib, A. E.; Chen, H.; Nemeth, G.; Gan, L.-S.; Christ, D. D.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1045-1056</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Efavirenz (Sustiva) is a potent and specific inhibitor of the HIV-1 reverse transcriptase and is approved for the treatment of HIV infection.  The metab. of efavirenz in different species has been described previously.  Efavirenz is primarily metabolized in rats to the glucuronide conjugate of 8-OH efavirenz.  Electrospray ionization-liq. chromatog./mass spectrometry analyses of bile samples from rats dosed with either efavirenz or with 8-OH efavirenz revealed three polar metabolites, M9, M12, and M13, with pseudomol. ions [M-H]- at m/z 733, 602, and 749, resp.  The characteristic mass spectral fragmentation patterns obtained for metabolites M9 and M13 suggested that these were glutathione-sulfate diconjugates, and the presence of a glutathione moiety in metabolite M9 was confirmed by liq. chromatog./NMR (NMR) anal. of bile exts.  Metabolite M12 was characterized by liq. chromatog./mass spectrometry as a glucuronide-sulfate diconjugate.  Unambiguous structures of M9, M12, and M13 were obtained from one-dimensional proton and carbon NMR as well as proton-proton (correlated spectroscopy, two-dimensional shift correlation), proton-carbon heteronuclear multiple quantum correlation, and long-range proton-carbon (heteronuclear multiple bond correlation) correlated two-dimensional NMR analyses of metabolites isolated from rat bile.  The mass spectral and NMR analyses of M10, which was isolated from rat urine, suggested a cysteinylglycine-sulfate diconjugate.  The isolation of these polar metabolites for further characterization by NMR was aided by mass spectral analyses of HPLC fractions and solid phase extn. exts. during the isolation steps.  The complete characterization of these novel diconjugates demonstrates that further phase II metab. of polar conjugates such as sulfates could take place in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3NZjMK6OUK7Vg90H21EOLACvtfcHk0lgZSTxwnurAug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXlslCqsrs%253D&md5=0d71b01f85990a6222ccae185aa848e0</span></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMutlib%26aufirst%3DA.%2BE.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DNemeth%26aufirst%3DG.%26aulast%3DGan%26aufirst%3DL.%2BS.%26aulast%3DChrist%26aufirst%3DD.%2BD.%26atitle%3DLiquid%2520chromatography%252Fmass%2520spectrometry%2520and%2520high-field%2520nuclear%2520magnetic%2520resonance%2520characterization%2520of%2520novel%2520mixed%2520diconjugates%2520of%2520the%2520non-nucleoside%2520human%2520immunodeficiency%2520virus-1%2520reverse%2520transcriptase%2520inhibitor%252C%2520efavirenz%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D1999%26volume%3D27%26spage%3D1045%26epage%3D1056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref194"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref194'); return false;" data-citation="" class="refNumLink">194</a></strong><div class="NLM_citation" id="cit194"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mutlib, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerson, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meunier, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haley, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gan, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gemzik, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christ, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krahn, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markwalder, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seitz, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miwa, G. T.</span></span> <span> </span><span class="NLM_article-title">The species-dependent metabolism of efavirenz produces a nephrotoxic glutathione conjugate in rats</span>. <i>Toxicol. Appl. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>169</i></span>,  <span class="NLM_fpage">102</span>– <span class="NLM_lpage">113</span>, <span class="refDoi"> DOI: 10.1006/taap.2000.9055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1006%2Ftaap.2000.9055" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=11076702" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD3cXnvFyrt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=169&publication_year=2000&pages=102-113&author=A.+E.+Mutlibauthor=R.+J.+Gersonauthor=P.+C.+Meunierauthor=P.+J.+Haleyauthor=H.+Chenauthor=L.+S.+Ganauthor=M.+H.+Daviesauthor=B.+Gemzikauthor=D.+D.+Christauthor=D.+F.+Krahnauthor=J.+A.+Markwalderauthor=S.+P.+Seitzauthor=R.+T.+Robertsonauthor=G.+T.+Miwa&title=The+species-dependent+metabolism+of+efavirenz+produces+a+nephrotoxic+glutathione+conjugate+in+rats&doi=10.1006%2Ftaap.2000.9055"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit194R"><div class="casContent"><span class="casTitleNuber">194</span><div class="casTitle"><span class="NLM_cas:atitle">The Species-Dependent Metabolism of Efavirenz Produces a Nephrotoxic Glutathione Conjugate in Rats</span></div><div class="casAuthors">Mutlib, Abdul E.; Gerson, Ronald J.; Meunier, Paul C.; Haley, Patrick J.; Chen, Hao; Gan, Lawrence S.; Davies, Marc H.; Gemzik, Brian; Christ, David D.; Krahn, David F.; Markwalder, Jay A.; Seitz, Steven P.; Robertson, Richard T.; Miwa, Gerald T.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology and Applied Pharmacology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">169</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">102-113</span>CODEN:
                <span class="NLM_cas:coden">TXAPA9</span>;
        ISSN:<span class="NLM_cas:issn">0041-008X</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">Efavirenz, a potent nonnucleoside reverse transcriptase inhibitor widely prescribed for the treatment of HIV infection, produces renal tubular epithelial cell necrosis in rats but not in cynomolgus monkeys or humans.  This species selectivity in nephrotoxicity could result from differences in the prodn. or processing of reactive metabolites, or both.  A detailed comparison of the metabolites produced by rats, monkeys, and humans revealed that rats produce a unique glutathione adduct.  The mechanism of formation and role of this glutathione adduct in the renal toxicity were investigated using both chem. and biochem. probes.  Efavirenz was labeled at the methine position on the cyclopropyl ring with the stable isotope deuterium, effectively reducing the formation of the cyclopropanol metabolite, an obligate precursor to the glutathione adduct.  This substitution markedly reduced both the incidence and severity of nephrotoxicity as measured histol.  Further processing of this glutathione adduct was also important in producing the lesion and was demonstrated by inhibiting γ-glutamyltranspeptidase with acivicin pretreatment (10 mg/kg, IV) prior to dosing with efavirenz.  Again, both the incidence and severity of the nephrotoxicity were reduced, such that four of nine rats given acivicin were without detectable lesions.  These studies provide compelling evidence that a species-specific formation of glutathione conjugate(s) from efavirenz is involved in producing nephrotoxicity in rats.  Mechanisms are proposed for the formation of reactive metabolites that could be responsible for the renal toxicity obsd. in rats.  (c) 2000 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtZ2yUYxMePrVg90H21EOLACvtfcHk0lgZSTxwnurAug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXnvFyrt7Y%253D&md5=13f8d2f66902fef25d827b2f492f88ce</span></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=10.1006%2Ftaap.2000.9055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Ftaap.2000.9055%26sid%3Dliteratum%253Aachs%26aulast%3DMutlib%26aufirst%3DA.%2BE.%26aulast%3DGerson%26aufirst%3DR.%2BJ.%26aulast%3DMeunier%26aufirst%3DP.%2BC.%26aulast%3DHaley%26aufirst%3DP.%2BJ.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DGan%26aufirst%3DL.%2BS.%26aulast%3DDavies%26aufirst%3DM.%2BH.%26aulast%3DGemzik%26aufirst%3DB.%26aulast%3DChrist%26aufirst%3DD.%2BD.%26aulast%3DKrahn%26aufirst%3DD.%2BF.%26aulast%3DMarkwalder%26aufirst%3DJ.%2BA.%26aulast%3DSeitz%26aufirst%3DS.%2BP.%26aulast%3DRobertson%26aufirst%3DR.%2BT.%26aulast%3DMiwa%26aufirst%3DG.%2BT.%26atitle%3DThe%2520species-dependent%2520metabolism%2520of%2520efavirenz%2520produces%2520a%2520nephrotoxic%2520glutathione%2520conjugate%2520in%2520rats%26jtitle%3DToxicol.%2520Appl.%2520Pharmacol.%26date%3D2000%26volume%3D169%26spage%3D102%26epage%3D113%26doi%3D10.1006%2Ftaap.2000.9055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref195"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref195'); return false;" data-citation="" class="refNumLink">195</a></strong><div class="NLM_citation" id="cit195"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamenecka, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, M. D.</span></span> <span> </span><span class="NLM_article-title">Cytochrome P450-mediated bioactivation of the epidermal growth factor receptor inhibitor erlotinib to a reactive electrophile</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">1238</span>– <span class="NLM_lpage">1245</span>, <span class="refDoi"> DOI: 10.1124/dmd.109.030361</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1124%2Fdmd.109.030361" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=20382753" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC3cXos1Kltr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2010&pages=1238-1245&author=X.+Liauthor=T.+M.+Kameneckaauthor=M.+D.+Cameron&title=Cytochrome+P450-mediated+bioactivation+of+the+epidermal+growth+factor+receptor+inhibitor+erlotinib+to+a+reactive+electrophile&doi=10.1124%2Fdmd.109.030361"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit195R"><div class="casContent"><span class="casTitleNuber">195</span><div class="casTitle"><span class="NLM_cas:atitle">Cytochrome P450-mediated bioactivation of the epidermal growth factor receptor inhibitor erlotinib to a reactive electrophile</span></div><div class="casAuthors">Li, Xiaohai; Kamenecka, Theodore M.; Cameron, Michael D.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1238-1245</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (ERL) is approved for treatment of non-small-cell lung cancer.  Numerous reports of ERL-assocd. toxicities are consistent with immune-mediated toxicity, including drug-induced hepatitis, interstitial lung disease, Stevens-Johnson syndrome, and toxic epidermal necrolysis.  Although the mechanism of toxicity has not been established, we present evidence that reactive intermediates are formed during the metab. of ERL, which can covalently conjugate to the cysteine group of the peptide-mimetic GSH.  Seven ERL-GSH conjugates were identified in incubations with hepatic microsomes.  Cytochrome P 450-dependent adducts are proposed to be formed via reactive epoxide and electrophilic quinone-imine intermediates.  In incubations of human liver microsomes, intestinal microsomes, pulmonary microsomes, and recombinant P450s, CYP3A4 was the primary enzyme responsible for the bioactivation of ERL; however, CYP1A1, CYP1A2, CYP3A5, and CYP2D6 were capable of catalyzing the bioactivation as well.  During the metab. of ERL, CYP3A4 and CYP3A5 are irreversibly inactivated by ERL in a time- and concn.-dependent manner.  Inactivation was not dependent on oxidn. of the ERL alkyne group to form a reactive oxirene or ketene, as shown by synthesizing analogs where the alkyne was replaced with a cyano group.  CYP1A1, CYP1A2, and CYP2D6 were not inactivated despite catalyzing the formation of ERL-GSH adducts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-JZKcu0DZAbVg90H21EOLACvtfcHk0lhQvQ4Ic5TbCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXos1Kltr8%253D&md5=281dd1ded9b88b66451f03532fafc6e7</span></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=10.1124%2Fdmd.109.030361&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.109.030361%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%26aulast%3DKamenecka%26aufirst%3DT.%2BM.%26aulast%3DCameron%26aufirst%3DM.%2BD.%26atitle%3DCytochrome%2520P450-mediated%2520bioactivation%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520inhibitor%2520erlotinib%2520to%2520a%2520reactive%2520electrophile%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2010%26volume%3D38%26spage%3D1238%26epage%3D1245%26doi%3D10.1124%2Fdmd.109.030361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref196"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref196'); return false;" data-citation="" class="refNumLink">196</a></strong><div class="NLM_citation" id="cit196"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, J.</span></span> <span> </span><span class="NLM_article-title">Identification of ketene-reactive intermediate of erlotinib possibly responsible for inactivation of P450 enzymes</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">442</span>– <span class="NLM_lpage">450</span>, <span class="refDoi"> DOI: 10.1124/dmd.117.079327</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1124%2Fdmd.117.079327" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=29352069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpsV2kt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2018&pages=442-450&author=H.+Zhaoauthor=S.+Liauthor=Z.+Yangauthor=Y.+Pengauthor=X.+Chenauthor=J.+Zheng&title=Identification+of+ketene-reactive+intermediate+of+erlotinib+possibly+responsible+for+inactivation+of+P450+enzymes&doi=10.1124%2Fdmd.117.079327"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit196R"><div class="casContent"><span class="casTitleNuber">196</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of ketene-reactive intermediate of erlotinib possibly responsible for inactivation of P450 enzymes</span></div><div class="casAuthors">Zhao, Huimin; Li, Siyuan; Yang, Zixin; Peng, Ying; Chen, Xiaohui; Zheng, Jiang</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">442-450</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Erlotinib (ELT), a tyrosine kinase inhibitor, is widely used for the treatment of nonsmall cell lung cancer in clinic.  Unfortunately, severe drug-induced liver injury and other adverse effects occurred during the treatment.  Meanwhile, ELT has been reported to be a mechanism-based inactivator of cytochrome P 450(CYPs) 3A4 and 3A5.  The objectives of this study were to identify ketene intermediate of ELT and investigate the assocn. of the acetylenic bioactivation with the enzyme inactivation caused by ELT.  A ketene intermediate was detected in human microsomal incubations of ELT, using 4-bromobenzylamine as a trapping agent.  CYPs 3A4 and 3A5 mainly contributed to the bioactivation of ELT.  Microsomal incubation study showed that the ketene intermediate covalently modified the enzyme protein at lysine residues and destroyed the structure of heme.  The vinyl and Et analogs of ELT showed minor enzyme inhibitory effect (less than 20%), whereas ELT inactivated more than 60% of the enzyme.  The present study provided a novel bioactivation pathway of ELT and facilitated the understanding of the mechanisms of ELT-induced mechanism-based enzyme inactivation and liver injury.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrK0gSOxk31P7Vg90H21EOLACvtfcHk0lhQvQ4Ic5TbCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpsV2kt7k%253D&md5=8baff6e76338898db2e01114265d4f95</span></div><a href="/servlet/linkout?suffix=cit196&amp;dbid=16384&amp;doi=10.1124%2Fdmd.117.079327&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.117.079327%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DPeng%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DZheng%26aufirst%3DJ.%26atitle%3DIdentification%2520of%2520ketene-reactive%2520intermediate%2520of%2520erlotinib%2520possibly%2520responsible%2520for%2520inactivation%2520of%2520P450%2520enzymes%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2018%26volume%3D46%26spage%3D442%26epage%3D450%26doi%3D10.1124%2Fdmd.117.079327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref197"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref197'); return false;" data-citation="" class="refNumLink">197</a></strong><div class="NLM_citation" id="cit197"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bugg, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutka-Malen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arthur, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Courvalin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walsh, C. T.</span></span> <span> </span><span class="NLM_article-title">Identification of vancomycin resistance protein VanA as a D-alanine:D-alanine ligase of altered substrate specificity</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">2017</span>– <span class="NLM_lpage">2021</span>, <span class="refDoi"> DOI: 10.1021/bi00222a002</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi00222a002" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADyaK3MXpslWlug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=1991&pages=2017-2021&author=T.+D.+Buggauthor=S.+Dutka-Malenauthor=M.+Arthurauthor=P.+Courvalinauthor=C.+T.+Walsh&title=Identification+of+vancomycin+resistance+protein+VanA+as+a+D-alanine%3AD-alanine+ligase+of+altered+substrate+specificity&doi=10.1021%2Fbi00222a002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit197R"><div class="casContent"><span class="casTitleNuber">197</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of vancomycin resistance protein VanA as a D-alanine:D-alanine ligase of altered substrate specificity</span></div><div class="casAuthors">Bugg, Timothy D. H.; Dutka-Malen, Sylvie; Arthur, Michel; Courvalin, Patrice; Walsh, Christopher T.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2017-21</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    </div><div class="casAbstract">High-level glycopeptide resistance in Enterococcus faecium BM4147 is mediated by a 38-kDa protein VanA, whose amino acid sequence is related to Gram-neg. D-alanyl-D-alanine synthetase (I).  The purifn. of VanA is reported and it is demonstrated that it has I activity but has substantially modified substrate specificity, compared with I from Gram-neg. bacteria.  VanA preferentially condenses D-alanine with D-methionine or D-phenylalanine, raising the possibility that its cellular role is to synthesize a modified cell-wall component, which is subsequently not recognized by vancomycin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoE6W_5B3bKILVg90H21EOLACvtfcHk0lhQvQ4Ic5TbCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXpslWlug%253D%253D&md5=c4266c9c43d4aa5d3c983e3c95ee8529</span></div><a href="/servlet/linkout?suffix=cit197&amp;dbid=16384&amp;doi=10.1021%2Fbi00222a002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi00222a002%26sid%3Dliteratum%253Aachs%26aulast%3DBugg%26aufirst%3DT.%2BD.%26aulast%3DDutka-Malen%26aufirst%3DS.%26aulast%3DArthur%26aufirst%3DM.%26aulast%3DCourvalin%26aufirst%3DP.%26aulast%3DWalsh%26aufirst%3DC.%2BT.%26atitle%3DIdentification%2520of%2520vancomycin%2520resistance%2520protein%2520VanA%2520as%2520a%2520D-alanine%253AD-alanine%2520ligase%2520of%2520altered%2520substrate%2520specificity%26jtitle%3DBiochemistry%26date%3D1991%26volume%3D30%26spage%3D2017%26epage%3D2021%26doi%3D10.1021%2Fbi00222a002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref198"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref198'); return false;" data-citation="" class="refNumLink">198</a></strong><div class="NLM_citation" id="cit198"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arthur, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molinas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bugg, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walsh, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Courvalin, P.</span></span> <span> </span><span class="NLM_article-title">Evidence for in vivo incorporation of D-lactate into peptidoglycan precursors of vancomycin-resistant enterococci</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">867</span>– <span class="NLM_lpage">869</span>, <span class="refDoi"> DOI: 10.1128/AAC.36.4.867</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1128%2FAAC.36.4.867" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1503450" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADyaK38XitFWjtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1992&pages=867-869&author=M.+Arthurauthor=C.+Molinasauthor=T.+D.+Buggauthor=G.+D.+Wrightauthor=C.+T.+Walshauthor=P.+Courvalin&title=Evidence+for+in+vivo+incorporation+of+D-lactate+into+peptidoglycan+precursors+of+vancomycin-resistant+enterococci&doi=10.1128%2FAAC.36.4.867"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit198R"><div class="casContent"><span class="casTitleNuber">198</span><div class="casTitle"><span class="NLM_cas:atitle">Evidence for in vivo incorporation of D-lactate into peptidoglycan precursors of vancomycin-resistant enterococci</span></div><div class="casAuthors">Arthur, Michel; Molinas, Catherine; Bugg, Timothy D. H.; Wright, Gerard D.; Walsh, Christopher T.; Courvalin, Patrice</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">867-9</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    </div><div class="casAbstract">The VanA ligase encoded by the vancomycin resistance plasmid pIP816 of Enterococcus faecium BM4147 condenses D-alanine with various D-2-hydroxy and D-2-amino acids in vitro.  D-Lactate added to the culture medium restored the vancomycin resistance of a strain that does not produce the VanH dehydrogenase and therefore appears to be a substrate of VanA in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPd65bkEY0p7Vg90H21EOLACvtfcHk0liacYXv6kx0OQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XitFWjtrk%253D&md5=5c71e639085a7265af95f0eccc42fdc0</span></div><a href="/servlet/linkout?suffix=cit198&amp;dbid=16384&amp;doi=10.1128%2FAAC.36.4.867&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.36.4.867%26sid%3Dliteratum%253Aachs%26aulast%3DArthur%26aufirst%3DM.%26aulast%3DMolinas%26aufirst%3DC.%26aulast%3DBugg%26aufirst%3DT.%2BD.%26aulast%3DWright%26aufirst%3DG.%2BD.%26aulast%3DWalsh%26aufirst%3DC.%2BT.%26aulast%3DCourvalin%26aufirst%3DP.%26atitle%3DEvidence%2520for%2520in%2520vivo%2520incorporation%2520of%2520D-lactate%2520into%2520peptidoglycan%2520precursors%2520of%2520vancomycin-resistant%2520enterococci%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1992%26volume%3D36%26spage%3D867%26epage%3D869%26doi%3D10.1128%2FAAC.36.4.867" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref199"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref199'); return false;" data-citation="" class="refNumLink">199</a></strong><div class="NLM_citation" id="cit199"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pidgeon, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pires, M. M.</span></span> <span> </span><span class="NLM_article-title">Cell wall remodeling by a synthetic analog reveals metabolic adaptation in vancomycin resistant Enterococci</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1913</span>– <span class="NLM_lpage">1918</span>, <span class="refDoi"> DOI: 10.1021/acschembio.7b00412</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.7b00412" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC2sXptFels7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=1913-1918&author=S.+E.+Pidgeonauthor=M.+M.+Pires&title=Cell+wall+remodeling+by+a+synthetic+analog+reveals+metabolic+adaptation+in+vancomycin+resistant+Enterococci&doi=10.1021%2Facschembio.7b00412"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit199R"><div class="casContent"><span class="casTitleNuber">199</span><div class="casTitle"><span class="NLM_cas:atitle">Cell Wall Remodeling by a Synthetic Analog Reveals Metabolic Adaptation in Vancomycin Resistant Enterococci</span></div><div class="casAuthors">Pidgeon, Sean E.; Pires, Marcos M.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1913-1918</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Drug-resistant bacterial infections threaten to overburden our healthcare system and disrupt modern medicine.  A large class of potent antibiotics, including vancomycin, operate by interfering with bacterial cell wall biosynthesis.  Vancomycin-resistant Enterococci (VRE) evade the blockage of cell wall biosynthesis by altering cell wall precursors, rendering them drug insensitive.  Herein, we reveal the phenotypic plasticity and cell wall remodeling of VRE in response to vancomycin in live bacterial cells via a metabolic probe.  A synthetic cell wall analog was designed and constructed to monitor cell wall structural alterations.  Our results demonstrate that the biosynthetic pathway for vancomycin-resistant precursors can be hijacked by synthetic analogs to track the kinetics of phenotype induction.  In addn., we leveraged this probe to interrogate the response of VRE cells to vancomycin analogs and a series of cell wall-targeted antibiotics.  Finally, we describe a proof-of-principle strategy to visually inspect drug resistance induction.  Based on our findings, we anticipate that our metabolic probe will play an important role in further elucidating the interplay among the enzymes involved in the VRE biosynthetic rewiring.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrupp-jjQmcB7Vg90H21EOLACvtfcHk0liacYXv6kx0OQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXptFels7c%253D&md5=21a7864cf48856ac03af543d25dec50a</span></div><a href="/servlet/linkout?suffix=cit199&amp;dbid=16384&amp;doi=10.1021%2Facschembio.7b00412&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.7b00412%26sid%3Dliteratum%253Aachs%26aulast%3DPidgeon%26aufirst%3DS.%2BE.%26aulast%3DPires%26aufirst%3DM.%2BM.%26atitle%3DCell%2520wall%2520remodeling%2520by%2520a%2520synthetic%2520analog%2520reveals%2520metabolic%2520adaptation%2520in%2520vancomycin%2520resistant%2520Enterococci%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2017%26volume%3D12%26spage%3D1913%26epage%3D1918%26doi%3D10.1021%2Facschembio.7b00412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref200"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref200'); return false;" data-citation="" class="refNumLink">200</a></strong><div class="NLM_citation" id="cit200"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pidgeon, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pires, M. M.</span></span> <span> </span><span class="NLM_article-title">Vancomycin-dependent response in live drug-resistant bacteria by metabolic labeling</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">8839</span>– <span class="NLM_lpage">8843</span>, <span class="refDoi"> DOI: 10.1002/anie.201704851</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1002%2Fanie.201704851" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVCrtrfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2017&pages=8839-8843&author=S.+E.+Pidgeonauthor=M.+M.+Pires&title=Vancomycin-dependent+response+in+live+drug-resistant+bacteria+by+metabolic+labeling&doi=10.1002%2Fanie.201704851"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit200R"><div class="casContent"><span class="casTitleNuber">200</span><div class="casTitle"><span class="NLM_cas:atitle">Vancomycin-Dependent Response in Live Drug-Resistant Bacteria by Metabolic Labeling</span></div><div class="casAuthors">Pidgeon, Sean E.; Pires, Marcos M.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">8839-8843</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The surge in drug-resistant bacterial infections threatens to overburden healthcare systems worldwide.  Bacterial cell walls are essential to bacteria, thus making them unique targets for the development of antibiotics.  We describe a cellular reporter to directly monitor the phenotypic switch in drug-resistant bacteria with temporal resoln.  Vancomycin-resistant enterococci (VRE) escape the bactericidal action of vancomycin by chem. modifying their cell-wall precursors.  A synthetic cell-wall analog was developed to hijack the biosynthetic rewiring of drug-resistant cells in response to antibiotics.  Our study provides the first in vivo VanX reporter agent that responds to cell-wall alteration in drug-resistant bacteria.  Cellular reporters that reveal mechanisms related to antibiotic resistance can potentially have a significant impact on the fundamental understanding of cellular adaptation to antibiotics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobKUDAIhEpObVg90H21EOLACvtfcHk0liacYXv6kx0OQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVCrtrfF&md5=d11b3fbcb2e2df1ecf5e4db6436984ee</span></div><a href="/servlet/linkout?suffix=cit200&amp;dbid=16384&amp;doi=10.1002%2Fanie.201704851&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201704851%26sid%3Dliteratum%253Aachs%26aulast%3DPidgeon%26aufirst%3DS.%2BE.%26aulast%3DPires%26aufirst%3DM.%2BM.%26atitle%3DVancomycin-dependent%2520response%2520in%2520live%2520drug-resistant%2520bacteria%2520by%2520metabolic%2520labeling%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2017%26volume%3D56%26spage%3D8839%26epage%3D8843%26doi%3D10.1002%2Fanie.201704851" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref201"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref201'); return false;" data-citation="" class="refNumLink">201</a></strong><div class="NLM_citation" id="cit201"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cote, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gholamreza, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misasi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruchez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, J.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Ebola virus infection: Identification of niemann-pick C1 as the target by optimization of a chemical probe</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">239</span>– <span class="NLM_lpage">243</span>, <span class="refDoi"> DOI: 10.1021/ml300370k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml300370k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVCjurfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=239-243&author=K.+Leeauthor=T.+Renauthor=M.+Coteauthor=B.+Gholamrezaauthor=J.+Misasiauthor=A.+Bruchezauthor=J.+Cunningham&title=Inhibition+of+Ebola+virus+infection%3A+Identification+of+niemann-pick+C1+as+the+target+by+optimization+of+a+chemical+probe&doi=10.1021%2Fml300370k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit201R"><div class="casContent"><span class="casTitleNuber">201</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Ebola Virus Infection: Identification of Niemann-Pick C1 as the Target by Optimization of a Chemical Probe</span></div><div class="casAuthors">Lee, Kyungae; Ren, Tao; Cote, Marceline; Gholamreza, Berahman; Misasi, John; Bruchez, Anna; Cunningham, James</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">239-243</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A high-throughput screen identified adamantane dipeptide 1 as an inhibitor of Ebola virus (EboV) infection.  Hit-to-lead optimization to det. the structure-activity relationship (SAR) identified the more potent EboV inhibitor (I) and a photoaffinity labeling agent (II).  These antiviral compds. were employed to identify the target as Niemann-Pick C1 (NPC1), a host protein that binds the EboV glycoprotein and is essential for infection.  These studies establish NPC1 as a promising target for antiviral therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSQ3UVP3tK47Vg90H21EOLACvtfcHk0liacYXv6kx0OQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVCjurfO&md5=b4d0829f290d3d785f3595f335ad6609</span></div><a href="/servlet/linkout?suffix=cit201&amp;dbid=16384&amp;doi=10.1021%2Fml300370k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml300370k%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DK.%26aulast%3DRen%26aufirst%3DT.%26aulast%3DCote%26aufirst%3DM.%26aulast%3DGholamreza%26aufirst%3DB.%26aulast%3DMisasi%26aufirst%3DJ.%26aulast%3DBruchez%26aufirst%3DA.%26aulast%3DCunningham%26aufirst%3DJ.%26atitle%3DInhibition%2520of%2520Ebola%2520virus%2520infection%253A%2520Identification%2520of%2520niemann-pick%2520C1%2520as%2520the%2520target%2520by%2520optimization%2520of%2520a%2520chemical%2520probe%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26spage%3D239%26epage%3D243%26doi%3D10.1021%2Fml300370k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref202"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref202'); return false;" data-citation="" class="refNumLink">202</a></strong><div class="NLM_citation" id="cit202"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ismail, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barton, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phanchana, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charoensutthivarakul, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemingway, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biagini, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neill, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, S. A.</span></span> <span> </span><span class="NLM_article-title">Artemisinin activity-based probes identify multiple molecular targets within the asexual stage of the malaria parasites Plasmodium falciparum 3D7</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">2080</span>– <span class="NLM_lpage">2085</span>, <span class="refDoi"> DOI: 10.1073/pnas.1600459113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1073%2Fpnas.1600459113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=26858419" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC28Xit12ktb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2016&pages=2080-2085&author=H.+M.+Ismailauthor=V.+Bartonauthor=M.+Phanchanaauthor=S.+Charoensutthivarakulauthor=M.+H.+Wongauthor=J.+Hemingwayauthor=G.+A.+Biaginiauthor=P.+M.+O%E2%80%99Neillauthor=S.+A.+Ward&title=Artemisinin+activity-based+probes+identify+multiple+molecular+targets+within+the+asexual+stage+of+the+malaria+parasites+Plasmodium+falciparum+3D7&doi=10.1073%2Fpnas.1600459113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit202R"><div class="casContent"><span class="casTitleNuber">202</span><div class="casTitle"><span class="NLM_cas:atitle">Artemisinin activity-based probes identify multiple molecular targets within the asexual stage of the malaria parasites Plasmodium falciparum 3D7</span></div><div class="casAuthors">Ismail, Hanafy M.; Barton, Victoria; Phanchana, Matthew; Charoensutthivarakul, Sitthivut; Wong, Michael H. L.; Hemingway, Janet; Biagini, Giancarlo A.; O'Neill, Paul M.; Ward, Stephen A.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2080-2085</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The artemisinin (ART)-based antimalarials have contributed significantly to reducing global malaria deaths over the past decade, but the authors still do not know how they kill parasites.  To gain greater insight into the potential mechanisms of ART drug action, the authors developed a suite of ART activity-based protein profiling probes to identify parasite protein drug targets in situ.  Probes were designed to retain biol. activity and alkylate the mol. target(s) of Plasmodium falciparum 3D7 parasites in situ.  Proteins tagged with the ART probe can then be isolated using click chem. before identification by liq. chromatog.-MS/MS.  Using these probes, the authors define an ART proteome that shows alkylated targets in the glycolytic, Hb degrdn., antioxidant defense, and protein synthesis pathways, processes essential for parasite survival.  This work reveals the pleiotropic nature of the biol. functions targeted by this important class of antimalarial drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqe38he4JorxrVg90H21EOLACvtfcHk0lihUEFfuCOoTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xit12ktb8%253D&md5=50a46614e45c5e2e7c819675679ec4a1</span></div><a href="/servlet/linkout?suffix=cit202&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1600459113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1600459113%26sid%3Dliteratum%253Aachs%26aulast%3DIsmail%26aufirst%3DH.%2BM.%26aulast%3DBarton%26aufirst%3DV.%26aulast%3DPhanchana%26aufirst%3DM.%26aulast%3DCharoensutthivarakul%26aufirst%3DS.%26aulast%3DWong%26aufirst%3DM.%2BH.%26aulast%3DHemingway%26aufirst%3DJ.%26aulast%3DBiagini%26aufirst%3DG.%2BA.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DP.%2BM.%26aulast%3DWard%26aufirst%3DS.%2BA.%26atitle%3DArtemisinin%2520activity-based%2520probes%2520identify%2520multiple%2520molecular%2520targets%2520within%2520the%2520asexual%2520stage%2520of%2520the%2520malaria%2520parasites%2520Plasmodium%2520falciparum%25203D7%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2016%26volume%3D113%26spage%3D2080%26epage%3D2085%26doi%3D10.1073%2Fpnas.1600459113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref203"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref203'); return false;" data-citation="" class="refNumLink">203</a></strong><div class="NLM_citation" id="cit203"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Salisbury, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span> <span> </span><span class="NLM_article-title">Optimization of activity-based probes for proteomic profiling of histone deacetylase complexes</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>130</i></span>,  <span class="NLM_fpage">2184</span>– <span class="NLM_lpage">2194</span>, <span class="refDoi"> DOI: 10.1021/ja074138u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja074138u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD1cXps1KksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2008&pages=2184-2194&author=C.+M.+Salisburyauthor=B.+F.+Cravatt&title=Optimization+of+activity-based+probes+for+proteomic+profiling+of+histone+deacetylase+complexes&doi=10.1021%2Fja074138u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit203R"><div class="casContent"><span class="casTitleNuber">203</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of Activity-Based Probes for Proteomic Profiling of Histone Deacetylase Complexes</span></div><div class="casAuthors">Salisbury, Cleo M.; Cravatt, Benjamin F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2184-2194</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) are key enzymic regulators of the epigenome and serve as promising targets for anticancer therapeutics.  Recently, we developed a photoreactive "clickable" probe, SAHA-BPyne, to report on HDAC activity and complex formation in native biol. systems.  Here, we investigate the selectivity, sensitivity, and inhibitory properties of SAHA-BPyne and related potential activity-based probes for HDACs.  While we identified several probes that are potent HDAC inhibitors and label HDAC complex components in native proteomic prepns., SAHA-BPyne was markedly superior for profiling HDAC activities in live cells.  Interestingly, the enhanced performance of SAHA-BPyne as an in situ activity-based probe could not be solely ascribed to potency in HDAC binding, implying that other features of the mol. were key to efficient active site-directed labeling in living systems.  Finally, we demonstrate the value of in situ profiling of HDACs by comparing the activity and expression of HDAC1 in cancer cells treated with the cytotoxic agent parthenolide.  These results underscore the utility of activity-based protein profiling for studying HDAC function and may provide insight for the future development of click chem.-based photoreactive probes for the in situ anal. of addnl. enzyme activities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqq74n9E1na_LVg90H21EOLACvtfcHk0lihUEFfuCOoTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXps1KksQ%253D%253D&md5=19155ee3a2771bab4c9b16a5de68c7ad</span></div><a href="/servlet/linkout?suffix=cit203&amp;dbid=16384&amp;doi=10.1021%2Fja074138u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja074138u%26sid%3Dliteratum%253Aachs%26aulast%3DSalisbury%26aufirst%3DC.%2BM.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26atitle%3DOptimization%2520of%2520activity-based%2520probes%2520for%2520proteomic%2520profiling%2520of%2520histone%2520deacetylase%2520complexes%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2008%26volume%3D130%26spage%3D2184%26epage%3D2194%26doi%3D10.1021%2Fja074138u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref204"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref204'); return false;" data-citation="" class="refNumLink">204</a></strong><div class="NLM_citation" id="cit204"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weerapana, E.</span></span> <span> </span><span class="NLM_article-title">Applications of copper-catalyzed click chemistry in activity-based protein profiling</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1378</span>– <span class="NLM_lpage">1393</span>, <span class="refDoi"> DOI: 10.3390/molecules19021378</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.3390%2Fmolecules19021378" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=24473203" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkvVClsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2014&pages=1378-1393&author=J.+Martellauthor=E.+Weerapana&title=Applications+of+copper-catalyzed+click+chemistry+in+activity-based+protein+profiling&doi=10.3390%2Fmolecules19021378"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit204R"><div class="casContent"><span class="casTitleNuber">204</span><div class="casTitle"><span class="NLM_cas:atitle">Applications of copper-catalyzed click chemistry in activity-based protein profiling</span></div><div class="casAuthors">Martell, Julianne; Weerapana, Eranthie</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">1378-1393, 16 pp.</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Activity-based protein profiling (ABPP) is a chem. proteomic technique that enables the interrogation of protein activity directly within complex proteomes.  Given the dominant role of posttranslational modifications in regulating protein function in vivo, ABPP provides a direct readout of activity that is not attained through traditional proteomic methods.  ABPP relies on the design of covalent binding probes that either target a specific enzyme or a class of enzymes with related function.  These covalent warheads are coupled to either fluorophores or biotin groups for visualization and enrichment of these active proteins.  The advent of bioorthogonal chemistries, in particular, the copper (I)-catalyzed azide-alkyne cycloaddn. (CuAAC), has benefitted the field of ABPP by achieving the following: (1) replacing bulky reporter groups with smaller alkyne or azide groups to promote cell permeability; (2) adding modularity to the system such that a single probe can be diversified with a variety of reporter groups without the need to develop new synthetic routes; and (3) enabling the conjugation of complex linkers to facilitate quant. proteomic analyses.  Here, we summarize recent examples of CuAAC in ABPP that serve to illustrate the contribution of bioorthogonal chem. to advancing discoveries in this field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqH5hQZJXhe7bVg90H21EOLACvtfcHk0lihUEFfuCOoTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkvVClsbY%253D&md5=1f306b2cb93635295832e63b555a6df0</span></div><a href="/servlet/linkout?suffix=cit204&amp;dbid=16384&amp;doi=10.3390%2Fmolecules19021378&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules19021378%26sid%3Dliteratum%253Aachs%26aulast%3DMartell%26aufirst%3DJ.%26aulast%3DWeerapana%26aufirst%3DE.%26atitle%3DApplications%2520of%2520copper-catalyzed%2520click%2520chemistry%2520in%2520activity-based%2520protein%2520profiling%26jtitle%3DMolecules%26date%3D2014%26volume%3D19%26spage%3D1378%26epage%3D1393%26doi%3D10.3390%2Fmolecules19021378" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref205"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref205'); return false;" data-citation="" class="refNumLink">205</a></strong><div class="NLM_citation" id="cit205"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dafik, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khosla, C.</span></span> <span> </span><span class="NLM_article-title">Dihydroisoxazole analogs for labeling and visualization of catalytically active transglutaminase 2</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">58</span>– <span class="NLM_lpage">66</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2010.11.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1016%2Fj.chembiol.2010.11.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=21276939" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlars7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=58-66&author=L.+Dafikauthor=C.+Khosla&title=Dihydroisoxazole+analogs+for+labeling+and+visualization+of+catalytically+active+transglutaminase+2&doi=10.1016%2Fj.chembiol.2010.11.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit205R"><div class="casContent"><span class="casTitleNuber">205</span><div class="casTitle"><span class="NLM_cas:atitle">Dihydroisoxazole Analogs for Labeling and Visualization of Catalytically Active Transglutaminase 2</span></div><div class="casAuthors">Dafik, Laila; Khosla, Chaitan</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">58-66</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">We report the synthesis and preliminary characterization of "clickable" inhibitors of human transglutaminase 2 (TG2).  These inhibitors possess the 3-halo-4,5-dihydroisoxazole warhead along with bioorthogonal groups such as azide or alkyne moieties that enable subsequent covalent modification with fluorophores.  Their mechanism for inhibition of TG2 is based on halide displacement, resulting in the formation of a stable imino thioether.  Inhibition assays against recombinant human TG2 revealed that some of the clickable inhibitors prepd. in this study have comparable specificity as benchmark dihydroisoxazole inhibitors reported earlier.  At low micromolar concns. they completely inhibited transiently activated TG2 in a WI-38 fibroblast scratch assay and could subsequently be used to visualize the active enzyme in situ.  The potential use of these inhibitors to probe the role of TG2 in celiac sprue as well as other diseases is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpa5iAwD6WvG7Vg90H21EOLACvtfcHk0lhFWCg0t71FtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlars7c%253D&md5=686bfe203bff64029fc001c48ef83e8a</span></div><a href="/servlet/linkout?suffix=cit205&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2010.11.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2010.11.004%26sid%3Dliteratum%253Aachs%26aulast%3DDafik%26aufirst%3DL.%26aulast%3DKhosla%26aufirst%3DC.%26atitle%3DDihydroisoxazole%2520analogs%2520for%2520labeling%2520and%2520visualization%2520of%2520catalytically%2520active%2520transglutaminase%25202%26jtitle%3DChem.%2520Biol.%26date%3D2011%26volume%3D18%26spage%3D58%26epage%3D66%26doi%3D10.1016%2Fj.chembiol.2010.11.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref206"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref206'); return false;" data-citation="" class="refNumLink">206</a></strong><div class="NLM_citation" id="cit206"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wright, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span> <span> </span><span class="NLM_article-title">A suite of activity-based probes for human cytochrome P450 enzymes</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">10692</span>– <span class="NLM_lpage">10700</span>, <span class="refDoi"> DOI: 10.1021/ja9037609</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja9037609" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD1MXot1ejsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2009&pages=10692-10700&author=A.+T.+Wrightauthor=J.+D.+Songauthor=B.+F.+Cravatt&title=A+suite+of+activity-based+probes+for+human+cytochrome+P450+enzymes&doi=10.1021%2Fja9037609"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit206R"><div class="casContent"><span class="casTitleNuber">206</span><div class="casTitle"><span class="NLM_cas:atitle">A Suite of Activity-Based Probes for Human Cytochrome P450 Enzymes</span></div><div class="casAuthors">Wright, Aaron T.; Song, Joongyu D.; Cravatt, Benjamin F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">10692-10700</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cytochrome P 450 enzymes regulate a variety of endogenous signaling mols. and play central roles in the metab. of xenobiotics and drugs.  We recently showed that an aryl alkyne serves as an effective activity-based probe for profiling mouse liver microsomal P450s in vitro and in vivo.  However, individual P450s display distinct substrate and inhibitor specificities, indicating that multiple probe structures may be required to achieve comprehensive coverage of this large and diverse enzyme family.  Here, we have synthesized a suite of P 450-directed, activity-based protein profiling (ABPP) probes that contain: (1) varied chem. architectures validated as mechanism-based inhibitors of the P 450 enzyme family, and (2) terminal alkyne groups for click chem. conjugation of reporter tags.  This set of probes was screened against a wide cross-section of human P450s, leading to the discovery of an optimal set of probes that provide broad coverage of this enzyme family.  We used these probes to profile the effects on P 450 activity of aromatase inhibitors in current clin. use for the treatment of breast cancer.  We describe the surprising discovery that one of these aromatase inhibitors, anastrozole, significantly increases probe-labeling of P 450 1A2, indicative of a heterotypic cooperativity effect on a central P 450 isoenzyme involved in metabolizing numerous drugs and xenobiotics.  The results presented herein greatly expand the suite of ABPP probes for profiling P450s and illuminate new applications for these tools to understand P 450-drug interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPSCo5wcvBLrVg90H21EOLACvtfcHk0lhFWCg0t71FtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXot1ejsbY%253D&md5=73f0ebac489c8df2ad9cc184819f2e43</span></div><a href="/servlet/linkout?suffix=cit206&amp;dbid=16384&amp;doi=10.1021%2Fja9037609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja9037609%26sid%3Dliteratum%253Aachs%26aulast%3DWright%26aufirst%3DA.%2BT.%26aulast%3DSong%26aufirst%3DJ.%2BD.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26atitle%3DA%2520suite%2520of%2520activity-based%2520probes%2520for%2520human%2520cytochrome%2520P450%2520enzymes%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2009%26volume%3D131%26spage%3D10692%26epage%3D10700%26doi%3D10.1021%2Fja9037609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref207"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref207'); return false;" data-citation="" class="refNumLink">207</a></strong><div class="NLM_citation" id="cit207"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schirmer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reid, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santi, D. V.</span></span> <span> </span><span class="NLM_article-title">Targeted covalent inactivation of protein kinases by resorcylic acid lactone polyketides</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">4234</span>– <span class="NLM_lpage">4239</span>, <span class="refDoi"> DOI: 10.1073/pnas.0600445103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1073%2Fpnas.0600445103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=16537514" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD28XivFWhsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2006&pages=4234-4239&author=A.+Schirmerauthor=J.+Kennedyauthor=S.+Murliauthor=R.+Reidauthor=D.+V.+Santi&title=Targeted+covalent+inactivation+of+protein+kinases+by+resorcylic+acid+lactone+polyketides&doi=10.1073%2Fpnas.0600445103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit207R"><div class="casContent"><span class="casTitleNuber">207</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted covalent inactivation of protein kinases by resorcylic acid lactone polyketides</span></div><div class="casAuthors">Schirmer, Andreas; Kennedy, Jonathan; Murli, Sumati; Reid, Ralph; Santi, Daniel V.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4234-4239</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Resorcylic acid lactones contg. a cis-enone are susceptible to Michael addn. reactions and are potent inhibitors of several protein kinases.  A structural-bioinformatics anal. identified a conserved Cys residue in the ATP-binding site of the kinases reported to be inhibited by cis-enone resorcylic acid lactones but absent in those that are not.  Mining of the kinome database revealed that a subset of some 46 kinases contained this Cys residue.  Screening a panel of 124 kinases with the resorcylic acid lactone hypothemycin showed that 18 of 19 targets contg. the conserved Cys were inhibited.  Kinetic analyses showed time-dependent inhibition, a hallmark of covalent inactivation, and biochem. studies of the interaction of extracellular signal-regulated kinase (ERK)2 with hypothemycin confirmed covalent adduct formation.  Resorcylic acid lactones are unique among kinase inhibitors in that they target mitogen-activated protein (MAP) kinase pathways at four levels: mitogen receptors, MAP kinase kinase (MEK)1/2 and ERK1/2, and certain downstream ERK substrates.  Cell lines dependent on the activation of Tyr kinase mitogen receptor targets of the resorcylic acid lactones were unusually sensitive toward hypothemycin and showed the expected inhibition of kinase phosphorylation due to inhibition of the mitogen receptors and/or MEK1/2 and ERK1/2.  Among cells without mitogen receptor targets, those harboring an ERK pathway-activating B-RAF V600E mutation were selectively and potently inhibited by hypothemycin.  Hypothemycin also prevented stimulated activation of the p38 cascade through inhibition of the Cys-contg. targets MEK3/6 and TGF-β-activated kinase 1 and of the JNK/SAPK (c-Jun N-terminal kinase/stress-activated protein kinase) cascade through inhibition of MEK4/7.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraww22qbwEYLVg90H21EOLACvtfcHk0lhFWCg0t71FtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XivFWhsr0%253D&md5=6a4be819f2c2a5a601e5c9cb75faf433</span></div><a href="/servlet/linkout?suffix=cit207&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0600445103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0600445103%26sid%3Dliteratum%253Aachs%26aulast%3DSchirmer%26aufirst%3DA.%26aulast%3DKennedy%26aufirst%3DJ.%26aulast%3DMurli%26aufirst%3DS.%26aulast%3DReid%26aufirst%3DR.%26aulast%3DSanti%26aufirst%3DD.%2BV.%26atitle%3DTargeted%2520covalent%2520inactivation%2520of%2520protein%2520kinases%2520by%2520resorcylic%2520acid%2520lactone%2520polyketides%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2006%26volume%3D103%26spage%3D4234%26epage%3D4239%26doi%3D10.1073%2Fpnas.0600445103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref208"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref208'); return false;" data-citation="" class="refNumLink">208</a></strong><div class="NLM_citation" id="cit208"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nishino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choy, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gushwa, N. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oses-Prieto, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koupparis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burlingame, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renslo, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKerrow, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taunton, J.</span></span> <span> </span><span class="NLM_article-title">Hypothemycin, a fungal natural product, identifies therapeutic targets in <i>Trypanosoma brucei</i> [corrected]</span>. <i>eLife</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">e00712</span>, <span class="refDoi"> DOI: 10.7554/eLife.00712</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.7554%2FeLife.00712" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=23853713" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtlWkuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2013&pages=e00712&author=M.+Nishinoauthor=J.+W.+Choyauthor=N.+N.+Gushwaauthor=J.+A.+Oses-Prietoauthor=K.+Koupparisauthor=A.+L.+Burlingameauthor=A.+R.+Rensloauthor=J.+H.+McKerrowauthor=J.+Taunton&title=Hypothemycin%2C+a+fungal+natural+product%2C+identifies+therapeutic+targets+in+Trypanosoma+brucei+%5Bcorrected%5D&doi=10.7554%2FeLife.00712"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit208R"><div class="casContent"><span class="casTitleNuber">208</span><div class="casTitle"><span class="NLM_cas:atitle">Hypothemycin, a fungal natural product, identifies therapeutic targets in Trypanosoma brucei</span></div><div class="casAuthors">Nishino, Mari; Choy, Jonathan W.; Gushwa, Nathan N.; Oses-Prieto, Juan A.; Koupparis, Kyriacos; Burlingame, Alma L.; Renslo, Adam R.; McKerrow, James H.; Taunton, Jack</div><div class="citationInfo"><span class="NLM_cas:title">eLife</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">e00712/1-e00712/15</span>CODEN:
                <span class="NLM_cas:coden">ELIFA8</span>;
        ISSN:<span class="NLM_cas:issn">2050-084X</span>.
    
            (<span class="NLM_cas:orgname">eLife Sciences Publications Ltd.</span>)
        </div><div class="casAbstract">Protein kinases are potentially attractive therapeutic targets for neglected parasitic diseases, including African trypanosomiasis caused by the protozoan, Trypanosoma brucei.  How to prioritize T. brucei kinases and quantify their intracellular engagement by small-mol. inhibitors remain unsolved problems.  Here, we combine chemoproteomics and RNA interference to interrogate trypanosome kinases bearing a Cys-Asp-Xaa-Gly motif (CDXG kinases).  We discovered that hypothemycin, a fungal polyketide previously shown to covalently inactivate a subset of human CDXG kinases, kills T. brucei in culture and in infected mice.  Quant. chemoproteomic anal. with a hypothemycin-based probe revealed the relative sensitivity of endogenous CDXG kinases, including TbGSK3short and a previously uncharacterized kinase, TbCLK1.  RNAi-mediated knockdown demonstrated that both kinases are essential, but only TbCLK1 is fully engaged by cytotoxic concns. of hypothemycin in intact cells.  Our study identifies TbCLK1 as a therapeutic target for African trypanosomiasis and establishes a new chemoproteomic tool for interrogating CDXG kinases in their native context.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXltBVaNyBJrVg90H21EOLACvtfcHk0lhFWCg0t71FtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtlWkuw%253D%253D&md5=c48f8af3298177d671f4b3495f264223</span></div><a href="/servlet/linkout?suffix=cit208&amp;dbid=16384&amp;doi=10.7554%2FeLife.00712&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7554%252FeLife.00712%26sid%3Dliteratum%253Aachs%26aulast%3DNishino%26aufirst%3DM.%26aulast%3DChoy%26aufirst%3DJ.%2BW.%26aulast%3DGushwa%26aufirst%3DN.%2BN.%26aulast%3DOses-Prieto%26aufirst%3DJ.%2BA.%26aulast%3DKoupparis%26aufirst%3DK.%26aulast%3DBurlingame%26aufirst%3DA.%2BL.%26aulast%3DRenslo%26aufirst%3DA.%2BR.%26aulast%3DMcKerrow%26aufirst%3DJ.%2BH.%26aulast%3DTaunton%26aufirst%3DJ.%26atitle%3DHypothemycin%252C%2520a%2520fungal%2520natural%2520product%252C%2520identifies%2520therapeutic%2520targets%2520in%2520Trypanosoma%2520brucei%2520%255Bcorrected%255D%26jtitle%3DeLife%26date%3D2013%26volume%3D2%26spage%3De00712%26doi%3D10.7554%2FeLife.00712" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref209"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref209'); return false;" data-citation="" class="refNumLink">209</a></strong><div class="NLM_citation" id="cit209"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nickel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serwa, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaschani, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ninck, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zweerink, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tate, E. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaiser, M.</span></span> <span> </span><span class="NLM_article-title">Chemoproteomic evaluation of the polyacetylene callyspongynic acid</span>. <i>Chem. - Eur. J.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">10721</span>– <span class="NLM_lpage">10728</span>, <span class="refDoi"> DOI: 10.1002/chem.201500934</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1002%2Fchem.201500934" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=26079733" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpvFWntr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=10721-10728&author=S.+Nickelauthor=R.+A.+Serwaauthor=F.+Kaschaniauthor=S.+Ninckauthor=S.+Zweerinkauthor=E.+W.+Tateauthor=M.+Kaiser&title=Chemoproteomic+evaluation+of+the+polyacetylene+callyspongynic+acid&doi=10.1002%2Fchem.201500934"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit209R"><div class="casContent"><span class="casTitleNuber">209</span><div class="casTitle"><span class="NLM_cas:atitle">Chemoproteomic Evaluation of the Polyacetylene Callyspongynic Acid</span></div><div class="casAuthors">Nickel, Sabrina; Serwa, Remigiusz A.; Kaschani, Farnusch; Ninck, Sabrina; Zweerink, Susanne; Tate, Edward W.; Kaiser, Markus</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry - A European Journal</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">10721-10728</span>CODEN:
                <span class="NLM_cas:coden">CEUJED</span>;
        ISSN:<span class="NLM_cas:issn">0947-6539</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Polyacetylenes are a class of alkyne-contg. natural products.  Although potent bioactivities and thus possible applications as chem. probes have already been reported for some polyacetylenes, insights into the biol. activities or mol. mode of action are still rather limited in most cases.  To overcome this limitation, we describe the application of the polyacetylene callyspongynic acid in the development of an exptl. roadmap for characterizing potential protein targets of alkyne-contg. natural products.  To this end, we undertook the first chem. synthesis of callyspongynic acid.  We then used in situ chem. proteomics methods to demonstrate extensive callyspongynic acid-mediated chem. tagging of endoplasmic reticulum-assocd. lipid-metabolizing and modifying enzymes.  We anticipate that an elucidation of protein targets of natural products may serve as an effective guide to the development of subsequent biol. assays that aim to identify chem. phenotypes and bioactivities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9Ojlvw2Lq2bVg90H21EOLACvtfcHk0ljcIndgKrXdFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpvFWntr4%253D&md5=8335ad39e825ebe7e4b71e0a0d0029ab</span></div><a href="/servlet/linkout?suffix=cit209&amp;dbid=16384&amp;doi=10.1002%2Fchem.201500934&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fchem.201500934%26sid%3Dliteratum%253Aachs%26aulast%3DNickel%26aufirst%3DS.%26aulast%3DSerwa%26aufirst%3DR.%2BA.%26aulast%3DKaschani%26aufirst%3DF.%26aulast%3DNinck%26aufirst%3DS.%26aulast%3DZweerink%26aufirst%3DS.%26aulast%3DTate%26aufirst%3DE.%2BW.%26aulast%3DKaiser%26aufirst%3DM.%26atitle%3DChemoproteomic%2520evaluation%2520of%2520the%2520polyacetylene%2520callyspongynic%2520acid%26jtitle%3DChem.%2520-%2520Eur.%2520J.%26date%3D2015%26volume%3D21%26spage%3D10721%26epage%3D10728%26doi%3D10.1002%2Fchem.201500934" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref210"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref210'); return false;" data-citation="" class="refNumLink">210</a></strong><div class="NLM_citation" id="cit210"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mileni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beidler, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, J. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKinney, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weerapana, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadagopan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liimatta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazerwith, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stiff, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamtekar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhattacharya, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swaney, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Becelaere, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span> <span> </span><span class="NLM_article-title">Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">411</span>– <span class="NLM_lpage">420</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2009.02.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1016%2Fj.chembiol.2009.02.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=19389627" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD1MXltVCms7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2009&pages=411-420&author=K.+Ahnauthor=D.+S.+Johnsonauthor=M.+Mileniauthor=D.+Beidlerauthor=J.+Z.+Longauthor=M.+K.+McKinneyauthor=E.+Weerapanaauthor=N.+Sadagopanauthor=M.+Liimattaauthor=S.+E.+Smithauthor=S.+Lazerwithauthor=C.+Stiffauthor=S.+Kamtekarauthor=K.+Bhattacharyaauthor=Y.+Zhangauthor=S.+Swaneyauthor=K.+Van+Becelaereauthor=R.+C.+Stevensauthor=B.+F.+Cravatt&title=Discovery+and+characterization+of+a+highly+selective+FAAH+inhibitor+that+reduces+inflammatory+pain&doi=10.1016%2Fj.chembiol.2009.02.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit210R"><div class="casContent"><span class="casTitleNuber">210</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Characterization of a Highly Selective FAAH Inhibitor that Reduces Inflammatory Pain</span></div><div class="casAuthors">Ahn, Kay; Johnson, Douglas S.; Mileni, Mauro; Beidler, David; Long, Jonathan Z.; McKinney, Michele K.; Weerapana, Eranthie; Sadagopan, Nalini; Liimatta, Marya; Smith, Sarah E.; Lazerwith, Scott; Stiff, Cory; Kamtekar, Satwik; Bhattacharya, Keshab; Zhang, Yanhua; Swaney, Stephen; Van Becelaere, Keri; Stevens, Raymond C.; Cravatt, Benjamin F.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">411-420</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Summary: Endocannabinoids are lipid signaling mols. that regulate a wide range of mammalian behaviors, including pain, inflammation, and cognitive/emotional state.  The endocannabinoid anandamide is principally degraded by the integral membrane enzyme fatty acid amide hydrolase (FAAH), and there is currently much interest in developing FAAH inhibitors to augment endocannabinoid signaling in vivo.  Here, we report the discovery and detailed characterization of a highly efficacious and selective FAAH inhibitor, PF-3845.  Mechanistic and structural studies confirm that PF-3845 is a covalent inhibitor that carbamylates FAAH's serine nucleophile.  PF-3845 selectively inhibits FAAH in vivo, as detd. by activity-based protein profiling; raises brain anandamide levels for up to 24 h; and produces significant cannabinoid receptor-dependent redns. in inflammatory pain.  These data thus designate PF-3845 as a valuable pharmacol. tool for in vivo characterization of the endocannabinoid system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWANdntofbhbVg90H21EOLACvtfcHk0ljcIndgKrXdFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXltVCms7w%253D&md5=c418dbdf626109415af7001db5a7cb93</span></div><a href="/servlet/linkout?suffix=cit210&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2009.02.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2009.02.013%26sid%3Dliteratum%253Aachs%26aulast%3DAhn%26aufirst%3DK.%26aulast%3DJohnson%26aufirst%3DD.%2BS.%26aulast%3DMileni%26aufirst%3DM.%26aulast%3DBeidler%26aufirst%3DD.%26aulast%3DLong%26aufirst%3DJ.%2BZ.%26aulast%3DMcKinney%26aufirst%3DM.%2BK.%26aulast%3DWeerapana%26aufirst%3DE.%26aulast%3DSadagopan%26aufirst%3DN.%26aulast%3DLiimatta%26aufirst%3DM.%26aulast%3DSmith%26aufirst%3DS.%2BE.%26aulast%3DLazerwith%26aufirst%3DS.%26aulast%3DStiff%26aufirst%3DC.%26aulast%3DKamtekar%26aufirst%3DS.%26aulast%3DBhattacharya%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DSwaney%26aufirst%3DS.%26aulast%3DVan%2BBecelaere%26aufirst%3DK.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26atitle%3DDiscovery%2520and%2520characterization%2520of%2520a%2520highly%2520selective%2520FAAH%2520inhibitor%2520that%2520reduces%2520inflammatory%2520pain%26jtitle%3DChem.%2520Biol.%26date%3D2009%26volume%3D16%26spage%3D411%26epage%3D420%26doi%3D10.1016%2Fj.chembiol.2009.02.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref211"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref211'); return false;" data-citation="" class="refNumLink">211</a></strong><div class="NLM_citation" id="cit211"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Naik, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Won, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ban, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhattarai, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.</span></span> <span> </span><span class="NLM_article-title">Synthesis and structure-activity relationship study of chemical probes as hypoxia induced factor-1alpha/malate dehydrogenase 2 inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">9522</span>– <span class="NLM_lpage">9538</span>, <span class="refDoi"> DOI: 10.1021/jm501241g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501241g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVelurrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=9522-9538&author=R.+Naikauthor=M.+Wonauthor=H.+S.+Banauthor=D.+Bhattaraiauthor=X.+Xuauthor=Y.+Eoauthor=Y.+S.+Hongauthor=S.+Singhauthor=Y.+Choiauthor=H.+C.+Ahnauthor=K.+Lee&title=Synthesis+and+structure-activity+relationship+study+of+chemical+probes+as+hypoxia+induced+factor-1alpha%2Fmalate+dehydrogenase+2+inhibitors&doi=10.1021%2Fjm501241g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit211R"><div class="casContent"><span class="casTitleNuber">211</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Structure-Activity Relationship Study of Chemical Probes as Hypoxia Induced Factor-1α/Malate Dehydrogenase 2 Inhibitors</span></div><div class="casAuthors">Naik, Ravi; Won, Misun; Ban, Hyun Seung; Bhattarai, Deepak; Xu, Xuezhen; Eo, Yumi; Hong, Ye Seul; Singh, Sarbjit; Choi, Yongseok; Ahn, Hee-Chul; Lee, Kyeong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">9522-9538</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A structure-activity relationship study of hypoxia inducible factor-1α inhibitor 3-aminobenzoic acid-based chem. probes, which were previously identified to bind to mitochondrial malate dehydrogenase 2, was performed to provide a better understanding of the pharmacol. effects of LW6 and its relation to hypoxia inducible factor-1α (HIF-1α) and malate dehydrogenase 2 (MDH2).  A variety of multifunctional probes including the benzophenone or the trifluoromethyl diazirine for photoaffinity labeling and click reaction were prepd. and evaluated for their biol. activity using a cell-based HRE-luciferase assay as well as a MDH2 assay in human colorectal cancer HCT116 cells.  Among them, the diazirine probe I showed strong inhibitory activity against both HIF-1α and MDH2.  Significantly, the inhibitory effect of the probes on HIF-1α activity was consistent with that of the MDH2 enzyme assay, which was further confirmed by the effect on in vitro binding activity to recombinant human MDH2, oxygen consumption, ATP prodn., and AMP activated protein kinase (AMPK) activation.  Competitive binding modes of LW6 and probe I to MDH2 were also demonstrated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSeg3MyMk_rLVg90H21EOLACvtfcHk0ljcIndgKrXdFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVelurrN&md5=4ca2511030541f1257a79edd60301e83</span></div><a href="/servlet/linkout?suffix=cit211&amp;dbid=16384&amp;doi=10.1021%2Fjm501241g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501241g%26sid%3Dliteratum%253Aachs%26aulast%3DNaik%26aufirst%3DR.%26aulast%3DWon%26aufirst%3DM.%26aulast%3DBan%26aufirst%3DH.%2BS.%26aulast%3DBhattarai%26aufirst%3DD.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DEo%26aufirst%3DY.%26aulast%3DHong%26aufirst%3DY.%2BS.%26aulast%3DSingh%26aufirst%3DS.%26aulast%3DChoi%26aufirst%3DY.%26aulast%3DAhn%26aufirst%3DH.%2BC.%26aulast%3DLee%26aufirst%3DK.%26atitle%3DSynthesis%2520and%2520structure-activity%2520relationship%2520study%2520of%2520chemical%2520probes%2520as%2520hypoxia%2520induced%2520factor-1alpha%252Fmalate%2520dehydrogenase%25202%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D9522%26epage%3D9538%26doi%3D10.1021%2Fjm501241g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref212"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref212'); return false;" data-citation="" class="refNumLink">212</a></strong><div class="NLM_citation" id="cit212"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maity, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yim, C.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jadhav, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verhassel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuomela, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solin, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grönroos, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Virta, P.</span></span> <span> </span><span class="NLM_article-title">Synthesis of an alkyne-modified bleomycin disaccharide precursor, conversion to a <sup>18</sup>F-labeled radiotracer, and preliminary in vivo-PET imaging studies</span>. <i>Eur. J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>2019</i></span>,  <span class="NLM_fpage">156</span>– <span class="NLM_lpage">163</span>, <span class="refDoi"> DOI: 10.1002/ejoc.201801488</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1002%2Fejoc.201801488" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVenu7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2019&publication_year=2019&pages=156-163&author=S.+K.+Maityauthor=C.-B.+Yimauthor=S.+Jadhavauthor=A.+Verhasselauthor=J.+Tuomelaauthor=O.+Solinauthor=T.+J.+Gr%C3%B6nroosauthor=P.+Virta&title=Synthesis+of+an+alkyne-modified+bleomycin+disaccharide+precursor%2C+conversion+to+a+18F-labeled+radiotracer%2C+and+preliminary+in+vivo-PET+imaging+studies&doi=10.1002%2Fejoc.201801488"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit212R"><div class="casContent"><span class="casTitleNuber">212</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of an Alkyne-Modified Bleomycin Disaccharide Precursor, Conversion to a 18F-Labeled Radiotracer, and Preliminary in vivo-PET Imaging Studies</span></div><div class="casAuthors">Maity, Sajal K.; Yim, Cheng-Bin; Jadhav, Satish; Verhassel, Alejandra; Tuomela, Johanna; Solin, Olof; Groenroos, Tove J.; Virta, Pasi</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">2019</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">156-163</span>CODEN:
                <span class="NLM_cas:coden">EJOCFK</span>;
        ISSN:<span class="NLM_cas:issn">1099-0690</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The bleomycins (BLMs) are known antitumor antibiotics composed of the tumoricidal and tumor seeking domains.  The peptide structure of BLMs is responsible for the cytotoxicity by selective oxidative cleavage of DNA (and RNA), while the tumor cell selectivity and internalization resides in the disaccharide moiety (i.e. BLM disaccharide).  This has prompted researchers to utilize BLM disaccharide and its derivs. as constituents for the selective recognition of tumor cells, which may find further applications as new tumor imaging tools or drug delivery vehicles.  In the present study a high yielding synthesis of an alkyne modified BLM disaccharide precursor that may be used as a useful agent for the click conjugation, its conversion to a 18F-labeled radiotracer, and preliminary in vivo PET imaging studies of the tracer with breast cancer (MCF-7) xenograft mouse models are described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8fm_nLU5pB7Vg90H21EOLACvtfcHk0lhifDC9Y9eAwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVenu7rL&md5=0ca0384621af4642ee09ce4959b987ad</span></div><a href="/servlet/linkout?suffix=cit212&amp;dbid=16384&amp;doi=10.1002%2Fejoc.201801488&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fejoc.201801488%26sid%3Dliteratum%253Aachs%26aulast%3DMaity%26aufirst%3DS.%2BK.%26aulast%3DYim%26aufirst%3DC.-B.%26aulast%3DJadhav%26aufirst%3DS.%26aulast%3DVerhassel%26aufirst%3DA.%26aulast%3DTuomela%26aufirst%3DJ.%26aulast%3DSolin%26aufirst%3DO.%26aulast%3DGr%25C3%25B6nroos%26aufirst%3DT.%2BJ.%26aulast%3DVirta%26aufirst%3DP.%26atitle%3DSynthesis%2520of%2520an%2520alkyne-modified%2520bleomycin%2520disaccharide%2520precursor%252C%2520conversion%2520to%2520a%252018F-labeled%2520radiotracer%252C%2520and%2520preliminary%2520in%2520vivo-PET%2520imaging%2520studies%26jtitle%3DEur.%2520J.%2520Org.%2520Chem.%26date%3D2019%26volume%3D2019%26spage%3D156%26epage%3D163%26doi%3D10.1002%2Fejoc.201801488" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref213"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref213'); return false;" data-citation="" class="refNumLink">213</a></strong><div class="NLM_citation" id="cit213"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kazandjian, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzman, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blumenthal, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mushti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Libeg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keegan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazdur, R.</span></span> <span> </span><span class="NLM_article-title">FDA Approval summary: Nivolumab for the treatment of metastatic non-small cell lung cancer with progression on or after platinum-based chemotherapy</span>. <i>Oncologist</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">634</span>– <span class="NLM_lpage">642</span>, <span class="refDoi"> DOI: 10.1634/theoncologist.2015-0507</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1634%2Ftheoncologist.2015-0507" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=26984449" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFGntbfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2016&pages=634-642&author=D.+Kazandjianauthor=D.+L.+Suzmanauthor=G.+Blumenthalauthor=S.+Mushtiauthor=K.+Heauthor=M.+Libegauthor=P.+Keeganauthor=R.+Pazdur&title=FDA+Approval+summary%3A+Nivolumab+for+the+treatment+of+metastatic+non-small+cell+lung+cancer+with+progression+on+or+after+platinum-based+chemotherapy&doi=10.1634%2Ftheoncologist.2015-0507"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit213R"><div class="casContent"><span class="casTitleNuber">213</span><div class="casTitle"><span class="NLM_cas:atitle">FDA approval summary: nivolumab for the treatment of metastatic non-small cell lung cancer with progression on or after platinum-based chemotherapy</span></div><div class="casAuthors">Kazandjian, Dickran; Suzman, Daniel L.; Blumenthal, Gideon; Mushti, Sirisha; He, Kun; Libeg, Meredith; Keegan, Patricia; Pazdur, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Oncologist</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">634-642</span>CODEN:
                <span class="NLM_cas:coden">OCOLF6</span>;
        ISSN:<span class="NLM_cas:issn">1083-7159</span>.
    
            (<span class="NLM_cas:orgname">AlphaMed Press</span>)
        </div><div class="casAbstract">On Oct. 9, 2015, the U.S.  Food and Drug Administration expanded the nivolumab metastatic non-small cell lung cancer (NSCLC) indication to include patients with nonsquamous NSCLC after a 3.25-mo review timeline.  Approval was based on demonstration of an improvement in overall survival (OS) in an international, multicenter, open-label, randomized trial comparing nivolumab to docetaxel in patients with metastatic nonsquamous NSCLC with progression on or after platinum-based chemotherapy.  The CheckMate 057 trial enrolled 582 patients who were randomized (1:1) to receive nivolumab or docetaxel.  Nivolumab demonstrated improved OS compared with docetaxel at the prespecified interim anal. with a hazard ratio (HR) of 0.73 (p = .0015), and a median OS of 12.2 mo (95% CI: 9.7-15.0 mo) in patients treated with nivolumab compared with 9.4 mo (95% CI: 8.0-10.7 mo) in patients treated with docetaxel.  A statistically significant improvement in objective response rate (ORR) was also obsd., with an ORR of 19% (95% CI: 15%-24%) in the nivolumab arm and 12% (95% CI: 9%-17%) in the docetaxel arm.  The median duration of response was 17 mo in the nivolumab arm and 6 mo in the docetaxel arm.  Progression-free survival was not statistically different between arms.  A prespecified retrospective subgroup anal. suggested that patients with programmed cell death ligand 1-neg. tumors treated with nivolumab had similar OS to those treated with docetaxel.  The toxicity profile of nivolumab was consistent with the known immune-mediated adverse event profile except for 1 case of grade 5 limbic encephalitis, which led to a postmarketing requirement study to better characterize immune-mediated encephalitis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8ZYyuBD8U8bVg90H21EOLACvtfcHk0lhifDC9Y9eAwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFGntbfE&md5=eee78dd8d34877e911dbea9bc3eb9873</span></div><a href="/servlet/linkout?suffix=cit213&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.2015-0507&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.2015-0507%26sid%3Dliteratum%253Aachs%26aulast%3DKazandjian%26aufirst%3DD.%26aulast%3DSuzman%26aufirst%3DD.%2BL.%26aulast%3DBlumenthal%26aufirst%3DG.%26aulast%3DMushti%26aufirst%3DS.%26aulast%3DHe%26aufirst%3DK.%26aulast%3DLibeg%26aufirst%3DM.%26aulast%3DKeegan%26aufirst%3DP.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DFDA%2520Approval%2520summary%253A%2520Nivolumab%2520for%2520the%2520treatment%2520of%2520metastatic%2520non-small%2520cell%2520lung%2520cancer%2520with%2520progression%2520on%2520or%2520after%2520platinum-based%2520chemotherapy%26jtitle%3DOncologist%26date%3D2016%26volume%3D21%26spage%3D634%26epage%3D642%26doi%3D10.1634%2Ftheoncologist.2015-0507" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref214"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref214'); return false;" data-citation="" class="refNumLink">214</a></strong><div class="NLM_citation" id="cit214"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Herbst, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baas, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felip, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Gracia, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molina, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arvis, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majem, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidler, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Castro, G.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrido, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubiniecki, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shentu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Im, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolled-Filhart, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garon, E. B.</span></span> <span> </span><span class="NLM_article-title">Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>387</i></span>,  <span class="NLM_fpage">1540</span>– <span class="NLM_lpage">1550</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(15)01281-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1016%2FS0140-6736%2815%2901281-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=26712084" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVGrtLzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=387&publication_year=2016&pages=1540-1550&author=R.+S.+Herbstauthor=P.+Baasauthor=D.+W.+Kimauthor=E.+Felipauthor=J.+L.+Perez-Graciaauthor=J.+Y.+Hanauthor=J.+Molinaauthor=J.+H.+Kimauthor=C.+D.+Arvisauthor=M.+J.+Ahnauthor=M.+Majemauthor=M.+J.+Fidlerauthor=G.+de+Castroauthor=M.+Garridoauthor=G.+M.+Lubinieckiauthor=Y.+Shentuauthor=E.+Imauthor=M.+Dolled-Filhartauthor=E.+B.+Garon&title=Pembrolizumab+versus+docetaxel+for+previously+treated%2C+PD-L1-positive%2C+advanced+non-small-cell+lung+cancer+%28KEYNOTE-010%29%3A+a+randomised+controlled+trial&doi=10.1016%2FS0140-6736%2815%2901281-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit214R"><div class="casContent"><span class="casTitleNuber">214</span><div class="casTitle"><span class="NLM_cas:atitle">Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial</span></div><div class="casAuthors">Herbst, Roy S.; Baas, Paul; Kim, Dong-Wan; Felip, Enriqueta; Perez-Gracia, Jose L.; Han, Ji-Youn; Molina, Julian; Kim, Joo-Hang; Arvis, Catherine Dubos; Ahn, Myung-Ju; Majem, Margarita; Fidler, Mary J.; de Castro, Gilberto Jr; Garrido, Marcelo; Lubiniecki, Gregory M.; Shentu, Yue; Im, Ellie; Dolled-Filhart, Marisa; Garon, Edward B.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">387</span>
        (<span class="NLM_cas:issue">10027</span>),
    <span class="NLM_cas:pages">1540-1550</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Despite recent advances in the treatment of advanced non-small-cell lung cancer, there remains a need for effective treatments for progressive disease.  We assessed the efficacy of pembrolizumab for patients with previously treated, PD-L1-pos., advanced non-small-cell lung cancer.  We did this randomised, open-label, phase 2/3 study at 202 academic medical centers in 24 countries.  Patients with previously treated non-small-cell lung cancer with PD-L1 expression on at least 1% of tumor cells were randomly assigned (1:1:1) in blocks of six per stratum with an interactive voice-response system to receive pembrolizumab 2 mg/kg, pembrolizumab 10 mg/kg, or docetaxel 75 mg/m2 every 3 wk.  The primary endpoints were overall survival and progression-free survival both in the total population and in patients with PD-L1 expression on at least 50% of tumor cells.  We used a threshold for significance of p<0·00825 (one-sided) for the anal. of overall survival and a threshold of p<0·001 for progression-free survival.  This trial is registered at ClinicalTrials.gov, no. NCT01905657.  Between Aug 28, 2013, and Feb 27, 2015, we enrolled 1034 patients: 345 allocated to pembrolizumab 2 mg/kg, 346 allocated to pembrolizumab 10 mg/kg, and 343 allocated to docetaxel.  By Sept 30, 2015, 521 patients had died.  In the total population, median overall survival was 10·4 mo with pembrolizumab 2 mg/kg, 12·7 mo with pembrolizumab 10 mg/kg, and 8·5 mo with docetaxel.  Overall survival was significantly longer for pembrolizumab 2 mg/kg vs. docetaxel (hazard ratio [HR] 0·71, 95% CI 0·58-0·88; p=0·0008) and for pembrolizumab 10 mg/kg vs. docetaxel (0·61, 0·49-0·75; p<0·0001).  Median progression-free survival was 3·9 mo with pembrolizumab 2 mg/kg, 4·0 mo with pembrolizumab 10 mg/kg, and 4·0 mo with docetaxel, with no significant difference for pembrolizumab 2 mg/kg vs. docetaxel (0·88, 0·74-1·05; p=0·07) or for pembrolizumab 10 mg/kg vs. docetaxel (HR 0·79, 95% CI 0·66-0·94; p=0·004).  Among patients with at least 50% of tumor cells expressing PD-L1, overall survival was significantly longer with pembrolizumab 2 mg/kg than with docetaxel (median 14·9 mo vs 8·2 mo; HR 0·54, 95% CI 0·38-0·77; p=0·0002) and with pembrolizumab 10 mg/kg than with docetaxel (17·3 mo vs 8·2 mo; 0·50, 0·36-0·70; p<0·0001).  Likewise, for this patient population, progression-free survival was significantly longer with pembrolizumab 2 mg/kg than with docetaxel (median 5·0 mo vs 4·1 mo; HR 0·59, 95% CI 0·44-0·78; p=0·0001) and with pembrolizumab 10 mg/kg than with docetaxel (5·2 mo vs 4·1 mo; 0·59, 0·45-0·78; p<0·0001).  Grade 3-5 treatment-related adverse events were less common with pembrolizumab than with docetaxel (43 [13%] of 339 patients given 2 mg/kg, 55 [16%] of 343 given 10 mg/kg, and 109 [35%] of 309 given docetaxel).  Pembrolizumab prolongs overall survival and has a favorable benefit-to-risk profile in patients with previously treated, PD-L1-pos., advanced non-small-cell lung cancer.  These data establish pembrolizumab as a new treatment option for this population and validate the use of PD-L1 selection.Merck & Co.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnxRttuwvktbVg90H21EOLACvtfcHk0lh37lgqsWXAhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVGrtLzI&md5=333bd6a558ec0f3716e15a2a96b2c02f</span></div><a href="/servlet/linkout?suffix=cit214&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2815%2901281-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252815%252901281-7%26sid%3Dliteratum%253Aachs%26aulast%3DHerbst%26aufirst%3DR.%2BS.%26aulast%3DBaas%26aufirst%3DP.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DPerez-Gracia%26aufirst%3DJ.%2BL.%26aulast%3DHan%26aufirst%3DJ.%2BY.%26aulast%3DMolina%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DJ.%2BH.%26aulast%3DArvis%26aufirst%3DC.%2BD.%26aulast%3DAhn%26aufirst%3DM.%2BJ.%26aulast%3DMajem%26aufirst%3DM.%26aulast%3DFidler%26aufirst%3DM.%2BJ.%26aulast%3Dde%2BCastro%26aufirst%3DG.%26aulast%3DGarrido%26aufirst%3DM.%26aulast%3DLubiniecki%26aufirst%3DG.%2BM.%26aulast%3DShentu%26aufirst%3DY.%26aulast%3DIm%26aufirst%3DE.%26aulast%3DDolled-Filhart%26aufirst%3DM.%26aulast%3DGaron%26aufirst%3DE.%2BB.%26atitle%3DPembrolizumab%2520versus%2520docetaxel%2520for%2520previously%2520treated%252C%2520PD-L1-positive%252C%2520advanced%2520non-small-cell%2520lung%2520cancer%2520%2528KEYNOTE-010%2529%253A%2520a%2520randomised%2520controlled%2520trial%26jtitle%3DLancet%26date%3D2016%26volume%3D387%26spage%3D1540%26epage%3D1550%26doi%3D10.1016%2FS0140-6736%2815%2901281-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref215"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref215'); return false;" data-citation="" class="refNumLink">215</a></strong><div class="NLM_citation" id="cit215"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Donnelly, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipovsek, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gokemeijer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lafont, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pena, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kukral, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dischino, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chow, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adelakun, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonacorsi, S. J.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, W.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biologic evaluation of a novel (18)F-labeled adnectin as a PET radioligand for imaging PD-L1 expression</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">529</span>– <span class="NLM_lpage">535</span>, <span class="refDoi"> DOI: 10.2967/jnumed.117.199596</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.2967%2Fjnumed.117.199596" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=29025984" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFylu77L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2018&pages=529-535&author=D.+J.+Donnellyauthor=R.+A.+Smithauthor=P.+Morinauthor=D.+Lipovsekauthor=J.+Gokemeijerauthor=D.+Cohenauthor=V.+Lafontauthor=T.+Tranauthor=E.+L.+Coleauthor=M.+Wrightauthor=J.+Kimauthor=A.+Penaauthor=D.+Kukralauthor=D.+D.+Dischinoauthor=P.+Chowauthor=J.+Ganauthor=O.+Adelakunauthor=X.+T.+Wangauthor=K.+Caoauthor=D.+Leungauthor=S.+J.+Bonacorsiauthor=W.+Hayes&title=Synthesis+and+biologic+evaluation+of+a+novel+%2818%29F-labeled+adnectin+as+a+PET+radioligand+for+imaging+PD-L1+expression&doi=10.2967%2Fjnumed.117.199596"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit215R"><div class="casContent"><span class="casTitleNuber">215</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biologic evaluation of a novel 18F-labeled adnectin as a PET radioligand for imaging PD-L1 expression</span></div><div class="casAuthors">Donnelly, David J.; Smith, R. Adam; Morin, Paul; Lipovsek, Dasa; Gokemeijer, Jochem; Cohen, Daniel; Lafont, Virginie; Tran, Tritin; Cole, Erin L.; Wright, Martin; Kim, Joonyoung; Pena, Adrienne; Kukral, Daniel; Dischino, Douglas D.; Chow, Patrick; Gan, Jinping; Adelakun, Olufemi; Wang, Xi-Tao; Cao, Kai; Leung, David; Bonacorsi, Samuel J.; Hayes, Wendy</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">529-535</span>CODEN:
                <span class="NLM_cas:coden">JNMEAQ</span>;
        ISSN:<span class="NLM_cas:issn">1535-5667</span>.
    
            (<span class="NLM_cas:orgname">Society of Nuclear Medicine and Molecular Imaging</span>)
        </div><div class="casAbstract">The programmed death protein (PD-1) and its ligand (PD-L1) play crit. roles in a checkpoint pathway cancer cells exploit to evade the immune system.  A same-day PET imaging agent for measuring PD-L1 status in primary and metastatic lesions could be important for optimizing drug therapy.  Herein, we have evaluated the tumor targeting of an anti-PD-L1 adnectin after 18F-fluorine labeling.  Methods: An anti-PD-L1 adnectin was labeled with 18F in 2 steps.  This synthesis featured fluorination of a novel prosthetic group, followed by a copper-free click conjugation to a modified adnectin to generate 18F-BMS-986192. 18F-BMS-986192 was evaluated in tumors using in vitro autoradiog. and PET with mice bearing bilateral PD-L1-neg. (PD-L1(-)) and PD-L1-pos. (PD-L1(1)) s.c. tumors. 18F-BMS-986192 was evaluated for distribution, binding, and radiation dosimetry in a healthy cynomolgus monkey.  Results: 18F-BMS-986192 bound to human and cynomolgus PD-L1 with a dissocn. const. of less than 35 pM, as measured by surface plasmon resonance.  This adnectin was labeled with 18F to yield a PET radioligand for assessing PD-L1 expression in vivo. 18F-BMS-986192 bound to tumor tissues as a function of PD-L1 expression detd. by immunohistochem.  Radioligand binding was blocked in a dose-dependent manner.  In vivo PET imaging clearly visualized PD-L1 expression in mice implanted with PD-L1(1), L2987 xenograft tumors.  Two hours after dosing, a 3.5-fold-higher uptake (2.41 ± 0.29 vs. 0.82 ± 0.11 percentage injected dose per g, P < 0.0001) was obsd. in L2987 than in control HT-29 (PD-L1(-)) tumors.  Coadministration of 3 mg/kg ADX_5322_A02 anti-PD-L1 adnectin reduced tumor uptake at 2 h after injection by approx. 70%, whereas HT-29 uptake remained unchanged, demonstrating PD-L1-specific binding.  Biodistribution in a nonhuman primate showed binding in the PD-L1-rich spleen, with rapid blood clearance through the kidneys and bladder.  Binding in the PD-L1(1) spleen was reduced by coadministration of BMS-986192.  Dosimetry ests. indicate that the kidney is the dose-limiting organ, with an estd. human absorbed dose of 2.20E-01 mSv/MBq.  Conclusion: 18FBMS-986192 demonstrated the feasibility of noninvasively imaging the PD-L1 status of tumors by small-animal PET studies.  Clin. studies with 18F-BMS-986192 are under way to measure PD-L1 expression in human tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzn6Jua02bzLVg90H21EOLACvtfcHk0lh37lgqsWXAhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFylu77L&md5=2621cf749657192a080d3707d09455e8</span></div><a href="/servlet/linkout?suffix=cit215&amp;dbid=16384&amp;doi=10.2967%2Fjnumed.117.199596&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2967%252Fjnumed.117.199596%26sid%3Dliteratum%253Aachs%26aulast%3DDonnelly%26aufirst%3DD.%2BJ.%26aulast%3DSmith%26aufirst%3DR.%2BA.%26aulast%3DMorin%26aufirst%3DP.%26aulast%3DLipovsek%26aufirst%3DD.%26aulast%3DGokemeijer%26aufirst%3DJ.%26aulast%3DCohen%26aufirst%3DD.%26aulast%3DLafont%26aufirst%3DV.%26aulast%3DTran%26aufirst%3DT.%26aulast%3DCole%26aufirst%3DE.%2BL.%26aulast%3DWright%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DPena%26aufirst%3DA.%26aulast%3DKukral%26aufirst%3DD.%26aulast%3DDischino%26aufirst%3DD.%2BD.%26aulast%3DChow%26aufirst%3DP.%26aulast%3DGan%26aufirst%3DJ.%26aulast%3DAdelakun%26aufirst%3DO.%26aulast%3DWang%26aufirst%3DX.%2BT.%26aulast%3DCao%26aufirst%3DK.%26aulast%3DLeung%26aufirst%3DD.%26aulast%3DBonacorsi%26aufirst%3DS.%2BJ.%26aulast%3DHayes%26aufirst%3DW.%26atitle%3DSynthesis%2520and%2520biologic%2520evaluation%2520of%2520a%2520novel%2520%252818%2529F-labeled%2520adnectin%2520as%2520a%2520PET%2520radioligand%2520for%2520imaging%2520PD-L1%2520expression%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2018%26volume%3D59%26spage%3D529%26epage%3D535%26doi%3D10.2967%2Fjnumed.117.199596" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref216"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref216'); return false;" data-citation="" class="refNumLink">216</a></strong><div class="NLM_citation" id="cit216"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoleru, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salic, A.</span></span> <span> </span><span class="NLM_article-title">Imaging protein synthesis in cells and tissues with an alkyne analog of puromycin</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">413</span>– <span class="NLM_lpage">418</span>, <span class="refDoi"> DOI: 10.1073/pnas.1111561108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1073%2Fpnas.1111561108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=22160674" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1ensrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2012&pages=413-418&author=J.+Liuauthor=Y.+Xuauthor=D.+Stoleruauthor=A.+Salic&title=Imaging+protein+synthesis+in+cells+and+tissues+with+an+alkyne+analog+of+puromycin&doi=10.1073%2Fpnas.1111561108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit216R"><div class="casContent"><span class="casTitleNuber">216</span><div class="casTitle"><span class="NLM_cas:atitle">Imaging protein synthesis in cells and tissues with an alkyne analog of puromycin</span></div><div class="casAuthors">Liu, Jing; Xu, Yangqing; Stoleru, Dan; Salic, Adrian</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">413-418, S413/1-S413/5</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Synthesis of many proteins is tightly controlled at the level of translation, and plays an essential role in fundamental processes such as cell growth-and proliferation, signaling, differentiation, or death.  Methods that allow imaging and identification of nascent proteins are crit. for dissecting regulation of translation, both spatially and temporally, particularly in whole organisms.  We introduce a simple and robust chem. method to image and affinity-purify nascent proteins in cells and in animals, based on an alkyne analog of puromycin, O-propargyl-puromycin (OP-puro).  OP-puro forms covalent conjugates with nascent polypeptide chains, which are rapidly turned over by the proteasome and can be visualized or captured by copper(l)-catalyzed azide-alkyne cycloaddn.  Unlike methionine analogs, OP-puro does not require methionine-free conditions and, uniquely, can be used to label and assay nascent proteins in whole organisms.  This strategy should have broad applicability for imaging protein synthesis and for identifying proteins synthesized under various physiol. and pathol. conditions in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTwcNZbUrncbVg90H21EOLACvtfcHk0lh37lgqsWXAhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1ensrY%253D&md5=4fae8dd7f5894f12dfa0b550d40d65bb</span></div><a href="/servlet/linkout?suffix=cit216&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1111561108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1111561108%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DStoleru%26aufirst%3DD.%26aulast%3DSalic%26aufirst%3DA.%26atitle%3DImaging%2520protein%2520synthesis%2520in%2520cells%2520and%2520tissues%2520with%2520an%2520alkyne%2520analog%2520of%2520puromycin%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2012%26volume%3D109%26spage%3D413%26epage%3D418%26doi%3D10.1073%2Fpnas.1111561108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref217"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref217'); return false;" data-citation="" class="refNumLink">217</a></strong><div class="NLM_citation" id="cit217"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bosc, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakhlal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deprez, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deprez-Poulain, R.</span></span> <span> </span><span class="NLM_article-title">Kinetic target-guided synthesis in drug discovery and chemical biology: A comprehensive facts and figures survey</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">381</span>– <span class="NLM_lpage">404</span>, <span class="refDoi"> DOI: 10.4155/fmc-2015-0007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.4155%2Ffmc-2015-0007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=26877247" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC28XksFCgtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=381-404&author=D.+Boscauthor=J.+Jakhlalauthor=B.+Deprezauthor=R.+Deprez-Poulain&title=Kinetic+target-guided+synthesis+in+drug+discovery+and+chemical+biology%3A+A+comprehensive+facts+and+figures+survey&doi=10.4155%2Ffmc-2015-0007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit217R"><div class="casContent"><span class="casTitleNuber">217</span><div class="casTitle"><span class="NLM_cas:atitle">Kinetic target-guided synthesis in drug discovery and chemical biology: a comprehensive facts and figures survey</span></div><div class="casAuthors">Bosc, Damien; Jakhlal, Jouda; Deprez, Benoit; Deprez-Poulain, Rebecca</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">381-404</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">For the last 15 years, kinetic target-guided syntheses, including in situ click chem., have been used as alternative methods to find ligands to therapeutically relevant proteins.  In this review, a comprehensive survey of biol. targets used in kinetic target-guided synthesis covers historical and recent examples.  The chem. reactions employed and practical aspects, including controls, library sizes and product detection, are presented.  A particular focus is on the reagents and warhead selection and design with a crit. overview of the challenges encountered.  As protein supply remains a key success factor, it appears that increased efforts should be taken toward miniaturization in order to expand the scope of this strategy and qualify it as a fully fledged drug discovery tool.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8Rt7hXE5irrVg90H21EOLACvtfcHk0ljSHZ9cIMYdOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XksFCgtrw%253D&md5=6f4a3603979d3862590e1bb5207d3458</span></div><a href="/servlet/linkout?suffix=cit217&amp;dbid=16384&amp;doi=10.4155%2Ffmc-2015-0007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc-2015-0007%26sid%3Dliteratum%253Aachs%26aulast%3DBosc%26aufirst%3DD.%26aulast%3DJakhlal%26aufirst%3DJ.%26aulast%3DDeprez%26aufirst%3DB.%26aulast%3DDeprez-Poulain%26aufirst%3DR.%26atitle%3DKinetic%2520target-guided%2520synthesis%2520in%2520drug%2520discovery%2520and%2520chemical%2520biology%253A%2520A%2520comprehensive%2520facts%2520and%2520figures%2520survey%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2016%26volume%3D8%26spage%3D381%26epage%3D404%26doi%3D10.4155%2Ffmc-2015-0007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref218"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref218'); return false;" data-citation="" class="refNumLink">218</a></strong><div class="NLM_citation" id="cit218"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Antti, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellstedt, M.</span></span> <span> </span><span class="NLM_article-title">Cell-based kinetic target-guided synthesis of an enzyme inhibitor</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">351</span>– <span class="NLM_lpage">353</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00535</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00535" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjvFansr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=351-353&author=H.+Anttiauthor=M.+Sellstedt&title=Cell-based+kinetic+target-guided+synthesis+of+an+enzyme+inhibitor&doi=10.1021%2Facsmedchemlett.7b00535"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit218R"><div class="casContent"><span class="casTitleNuber">218</span><div class="casTitle"><span class="NLM_cas:atitle">Cell-Based Kinetic Target-Guided Synthesis of an Enzyme Inhibitor</span></div><div class="casAuthors">Antti, Henrik; Sellstedt, Magnus</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">351-353</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Finding a new drug candidate for a selected target is an expensive and time-consuming process.  Target guided-synthesis, or in situ click chem., is a concept where the drug target is used to template the formation of its own inhibitors from reactive building blocks.  This could simplify the identification of drug candidates.  However, with the exception of one example of an RNA-target, target-guided synthesis has always employed purified targets.  This limits the no. of targets that can be screened by the method.  By applying methods from the field of metabolomics, we demonstrate that target-guided synthesis with protein targets also can be performed directly in cell-based systems.  These methods offer new possibilities to conduct screening for drug candidates of difficult protein targets in cellular environments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsLDGNYh5NN7Vg90H21EOLACvtfcHk0ljSHZ9cIMYdOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjvFansr8%253D&md5=117e4a2748228d419128f2d2046c2e35</span></div><a href="/servlet/linkout?suffix=cit218&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00535&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00535%26sid%3Dliteratum%253Aachs%26aulast%3DAntti%26aufirst%3DH.%26aulast%3DSellstedt%26aufirst%3DM.%26atitle%3DCell-based%2520kinetic%2520target-guided%2520synthesis%2520of%2520an%2520enzyme%2520inhibitor%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D9%26spage%3D351%26epage%3D353%26doi%3D10.1021%2Facsmedchemlett.7b00535" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref219"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref219'); return false;" data-citation="" class="refNumLink">219</a></strong><div class="NLM_citation" id="cit219"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oueis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renard, P. Y.</span></span> <span> </span><span class="NLM_article-title">New insights into the kinetic target-guided synthesis of protein ligands</span>. <i>Chem. Commun. (Cambridge, U. K.)</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">12158</span>– <span class="NLM_lpage">12169</span>, <span class="refDoi"> DOI: 10.1039/C5CC04183J</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1039%2FC5CC04183J" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=26144842" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFWgtbbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2015&pages=12158-12169&author=E.+Oueisauthor=C.+Sabotauthor=P.+Y.+Renard&title=New+insights+into+the+kinetic+target-guided+synthesis+of+protein+ligands&doi=10.1039%2FC5CC04183J"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit219R"><div class="casContent"><span class="casTitleNuber">219</span><div class="casTitle"><span class="NLM_cas:atitle">New insights into the kinetic target-guided synthesis of protein ligands</span></div><div class="casAuthors">Oueis, Emilia; Sabot, Cyrille; Renard, Pierre-Yves</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">61</span>),
    <span class="NLM_cas:pages">12158-12169</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  The kinetic target-guided synthesis (KTGS) strategy is an unconventional discovery approach that takes advantage of the presence of the biol. target itself in order to irreversibly assemble the best inhibitors from an array of building blocks.  This strategy has grown over the last two decades notably after the introduction of the in situ click chem. concept by Sharpless and colleagues in the early 2000s based on the use of the Huisgen cycloaddn. between terminal alkynes and azides.  KTGS is a captivating area of research offering an unprecedented and powerful strategy to probe the macromol. complexity and dynamics of biol. targets.  After a brief introduction listing all chem. ligation reactions reported to date in KTGS, this review focuses on the last five years' progress to expand the repertoire of the click or "click-like" tool box targeting proteins, as well as to overcome limitations arising in particular from false negatives, i.e. potent ligands that are not formed, or formed in undetectable trace amts.  Furthermore, we wish to analyze the new twists and novelties described in some of these applications in order to better understand the conditions that govern this strategy and the extent to which it can be developed and generalized for a more efficient process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3mdKSqL3JKLVg90H21EOLACvtfcHk0ljSHZ9cIMYdOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFWgtbbE&md5=76af69545c88c006feb0fe7a544b3805</span></div><a href="/servlet/linkout?suffix=cit219&amp;dbid=16384&amp;doi=10.1039%2FC5CC04183J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5CC04183J%26sid%3Dliteratum%253Aachs%26aulast%3DOueis%26aufirst%3DE.%26aulast%3DSabot%26aufirst%3DC.%26aulast%3DRenard%26aufirst%3DP.%2BY.%26atitle%3DNew%2520insights%2520into%2520the%2520kinetic%2520target-guided%2520synthesis%2520of%2520protein%2520ligands%26jtitle%3DChem.%2520Commun.%2520%2528Cambridge%252C%2520U.%2520K.%2529%26date%3D2015%26volume%3D51%26spage%3D12158%26epage%3D12169%26doi%3D10.1039%2FC5CC04183J" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref220"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref220'); return false;" data-citation="" class="refNumLink">220</a></strong><div class="NLM_citation" id="cit220"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marakovic, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinko, G.</span></span> <span> </span><span class="NLM_article-title">The lock is the key: Development of novel drugs through receptor based combinatorial chemistry</span>. <i>Acta Chim. Slov.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">15</span>– <span class="NLM_lpage">39</span>, <span class="refDoi"> DOI: 10.17344/acsi.2016.3134</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.17344%2Facsi.2016.3134" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=28380234" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1eksbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2017&pages=15-39&author=N.+Marakovicauthor=G.+Sinko&title=The+lock+is+the+key%3A+Development+of+novel+drugs+through+receptor+based+combinatorial+chemistry&doi=10.17344%2Facsi.2016.3134"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit220R"><div class="casContent"><span class="casTitleNuber">220</span><div class="casTitle"><span class="NLM_cas:atitle">The lock is the key: development of novel drugs through receptor based combinatorial chemistry</span></div><div class="casAuthors">Marakovic, Nikola; Sinko, Goran</div><div class="citationInfo"><span class="NLM_cas:title">Acta Chimica Slovenica</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">15-39</span>CODEN:
                <span class="NLM_cas:coden">ACSLE7</span>;
        ISSN:<span class="NLM_cas:issn">1318-0207</span>.
    
            (<span class="NLM_cas:orgname">Slovenian Chemical Society</span>)
        </div><div class="casAbstract">Modem drug discovery is mainly based on the de novo synthesis of a large no. of compds. with a diversity of chem. functionalities.  Though the introduction of combinatorial chem. enabled the prepn. of large libraries of compds. from so-called building blocks, the problem of successfully identifying leads remains.  The introduction of a dynamic combinatorial chem. method served as a step forward due to the involvement of biol. rnacromo- lecuIar targets (receptors) in the synthesis of high affinity products.  The major breakthrough was a synthetic method in which building blocks are irreversibly combined due to the presence of a receptor.  Here we present various receptor-ba- sed combinatorial chem. approaches.  Huisgen's cycloaddn. (1,3-dipolar cycloaddn. of azides and alkynes) forms stabile 1,2,3-triazoles with very high receptor affinity that can reach femtomolar levels, as the case with acetylc- holinesterase inhibitors shows.  Huisgen's cycloaddn. can be applied to various receptors including acetyleholineste- rase, acetylcholine binding protein, carbonic anhydrase-II, serine/threonine-protein kinase and minor groove of DNA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphjiJtd7rV3bVg90H21EOLACvtfcHk0ljSHZ9cIMYdOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1eksbvI&md5=13627591d772ccfe0e8dea1febc49427</span></div><a href="/servlet/linkout?suffix=cit220&amp;dbid=16384&amp;doi=10.17344%2Facsi.2016.3134&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.17344%252Facsi.2016.3134%26sid%3Dliteratum%253Aachs%26aulast%3DMarakovic%26aufirst%3DN.%26aulast%3DSinko%26aufirst%3DG.%26atitle%3DThe%2520lock%2520is%2520the%2520key%253A%2520Development%2520of%2520novel%2520drugs%2520through%2520receptor%2520based%2520combinatorial%2520chemistry%26jtitle%3DActa%2520Chim.%2520Slov.%26date%3D2017%26volume%3D64%26spage%3D15%26epage%3D39%26doi%3D10.17344%2Facsi.2016.3134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref221"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref221'); return false;" data-citation="" class="refNumLink">221</a></strong><div class="NLM_citation" id="cit221"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gregson, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masterson, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pillow, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raab, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis Phillips, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunzner-Toste, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Safina, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohri, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darwish, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozak, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dela Cruz-Chuh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flygare, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, P. W.</span></span> <span> </span><span class="NLM_article-title">Pyrrolobenzodiazepine dimer antibody-drug conjugates: Synthesis and evaluation of noncleavable drug-linkers</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">9490</span>– <span class="NLM_lpage">9507</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00736</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00736" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslOns7%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=9490-9507&author=S.+J.+Gregsonauthor=L.+A.+Mastersonauthor=B.+Weiauthor=T.+H.+Pillowauthor=S.+D.+Spencerauthor=G.+D.+Kangauthor=S.+F.+Yuauthor=H.+Raabauthor=J.+Lauauthor=G.+Liauthor=G.+D.+Lewis+Phillipsauthor=J.+Gunzner-Tosteauthor=B.+S.+Safinaauthor=R.+Ohriauthor=M.+Darwishauthor=K.+R.+Kozakauthor=J.+Dela+Cruz-Chuhauthor=A.+Polsonauthor=J.+A.+Flygareauthor=P.+W.+Howard&title=Pyrrolobenzodiazepine+dimer+antibody-drug+conjugates%3A+Synthesis+and+evaluation+of+noncleavable+drug-linkers&doi=10.1021%2Facs.jmedchem.7b00736"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit221R"><div class="casContent"><span class="casTitleNuber">221</span><div class="casTitle"><span class="NLM_cas:atitle">Pyrrolobenzodiazepine Dimer Antibody-Drug Conjugates: Synthesis and Evaluation of Noncleavable Drug-Linkers</span></div><div class="casAuthors">Gregson, Stephen J.; Masterson, Luke A.; Wei, Binqing; Pillow, Thomas H.; Spencer, Susan D.; Kang, Gyoung-Dong; Yu, Shang-Fan; Raab, Helga; Lau, Jeffrey; Li, Guangmin; Lewis Phillips, Gail D.; Gunzner-Toste, Janet; Safina, Brian S.; Ohri, Rachana; Darwish, Martine; Kozak, Katherine R.; dela Cruz-Chuh, Josefa; Polson, Andrew; Flygare, John A.; Howard, Philip W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">9490-9507</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Three rationally designed pyrrolobenzodiazepine (PBD) drug-linkers have been synthesized via intermediate, (11S,11'S,11aS,11'aS)-10,10'-bis(1,1-dimethylethyl) (11S,11aS,11'S,11a'S)-di-tert-Bu 8,8'-[(5-iodo-1,3-phenylene)bis(methyleneoxy)]bis[2,3,11,11a-tetrahydro-7-methoxy-2-methylene-5-oxo-11-[(tetrahydro-2H-pyran-2-yl)oxy]-1H-pyrrolo[2,1-c][1,4]benzodiazepine-10(5H)-carboxylate [1630094-65-3](19) for use in antibody-drug conjugates (ADCs).  They lack a cleavable trigger in the linker and consist of a maleimide for cysteine antibody conjugation, a hydrophilic spacer, and either an alkyne, triazole, or piperazine link to the PBD.  In vitro IC50 values were 11-48 ng/mL in HER2 3+ SK-BR-3 and KPL-4 (triazole conjugate, inactive) for the anti-HER2 ADCs (HER2 0 MCF7, all inactive) and 0.10-1.73 μg/mL (triazole conjugate, inactive) in CD22 3+ BJAB and WSU-DLCL2 for anti-CD22 ADCs (CD22 0 Jurkat, all inactive at low doses).  In vivo antitumor efficacy for the anti-HER2 ADCs in Founder 5 was obsd. with tumor stasis at 0.5-1 mg/kg, 1 mg/kg, and 3-6 mg/kg for three conjugates, resp.  Tumor stasis at 2 mg/kg was obsd. for anti-CD22 alkyne conjugate in WSU-DLCL2.  In summary, noncleavable PBD-ADCs exhibit potent activity, particularly in HER2 models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeLqWakvWPDLVg90H21EOLACvtfcHk0likE1ClJVvn5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslOns7%252FF&md5=99e06646a68d1395711428540c61884f</span></div><a href="/servlet/linkout?suffix=cit221&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00736%26sid%3Dliteratum%253Aachs%26aulast%3DGregson%26aufirst%3DS.%2BJ.%26aulast%3DMasterson%26aufirst%3DL.%2BA.%26aulast%3DWei%26aufirst%3DB.%26aulast%3DPillow%26aufirst%3DT.%2BH.%26aulast%3DSpencer%26aufirst%3DS.%2BD.%26aulast%3DKang%26aufirst%3DG.%2BD.%26aulast%3DYu%26aufirst%3DS.%2BF.%26aulast%3DRaab%26aufirst%3DH.%26aulast%3DLau%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DLewis%2BPhillips%26aufirst%3DG.%2BD.%26aulast%3DGunzner-Toste%26aufirst%3DJ.%26aulast%3DSafina%26aufirst%3DB.%2BS.%26aulast%3DOhri%26aufirst%3DR.%26aulast%3DDarwish%26aufirst%3DM.%26aulast%3DKozak%26aufirst%3DK.%2BR.%26aulast%3DDela%2BCruz-Chuh%26aufirst%3DJ.%26aulast%3DPolson%26aufirst%3DA.%26aulast%3DFlygare%26aufirst%3DJ.%2BA.%26aulast%3DHoward%26aufirst%3DP.%2BW.%26atitle%3DPyrrolobenzodiazepine%2520dimer%2520antibody-drug%2520conjugates%253A%2520Synthesis%2520and%2520evaluation%2520of%2520noncleavable%2520drug-linkers%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D9490%26epage%3D9507%26doi%3D10.1021%2Facs.jmedchem.7b00736" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref222"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref222'); return false;" data-citation="" class="refNumLink">222</a></strong><div class="NLM_citation" id="cit222"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boons, G. J.</span></span> <span> </span><span class="NLM_article-title">Preparation of well-defined antibody-drug conjugates through glycan remodeling and strain-promoted azide-alkyne cycloadditions</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">7179</span>– <span class="NLM_lpage">7182</span>, <span class="refDoi"> DOI: 10.1002/anie.201402606</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1002%2Fanie.201402606" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC2cXos1aks7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2014&pages=7179-7182&author=X.+Liauthor=T.+Fangauthor=G.+J.+Boons&title=Preparation+of+well-defined+antibody-drug+conjugates+through+glycan+remodeling+and+strain-promoted+azide-alkyne+cycloadditions&doi=10.1002%2Fanie.201402606"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit222R"><div class="casContent"><span class="casTitleNuber">222</span><div class="casTitle"><span class="NLM_cas:atitle">Preparation of well-defined antibody-drug conjugates through glycan remodeling and strain-promoted azide-alkyne cycloadditions</span></div><div class="casAuthors">Li, Xiuru; Fang, Tao; Boons, Geert-Jan</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">28</span>),
    <span class="NLM_cas:pages">7179-7182</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Antibody-drug conjugates hold considerable promise as anticancer agents, however, producing them remains a challenge and there is a need for mild, broadly applicable, site-specific conjugation methods that yield homogenous products.  It was envisaged that enzymic remodeling of the oligosaccharides of an antibody would enable the introduction of reactive groups that can be exploited for the site-specific attachment of cytotoxic drugs.  This is based on the observation that glycosyltransferases often tolerate chem. modifications in their sugar nucleotide substrates, thus allowing the installation of reactive functionalities.  An azide was incorporated because this functional group is virtually absent in biol. systems and can be reacted by strain-promoted alkyne-azide cycloaddn.  This method, which does not require genetic engineering, was used to produce an anti-CD22 antibody modified with doxorubicin to selectively target and kill lymphoma cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6LFIucRfbx7Vg90H21EOLACvtfcHk0likE1ClJVvn5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXos1aks7w%253D&md5=d59a17169fb0891a63e88960285c4f55</span></div><a href="/servlet/linkout?suffix=cit222&amp;dbid=16384&amp;doi=10.1002%2Fanie.201402606&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201402606%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%26aulast%3DFang%26aufirst%3DT.%26aulast%3DBoons%26aufirst%3DG.%2BJ.%26atitle%3DPreparation%2520of%2520well-defined%2520antibody-drug%2520conjugates%2520through%2520glycan%2520remodeling%2520and%2520strain-promoted%2520azide-alkyne%2520cycloadditions%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2014%26volume%3D53%26spage%3D7179%26epage%3D7182%26doi%3D10.1002%2Fanie.201402606" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref223"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref223'); return false;" data-citation="" class="refNumLink">223</a></strong><div class="NLM_citation" id="cit223"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, D. Y.</span></span> <span> </span><span class="NLM_article-title">Processes for constructing homogeneous antibody drug conjugates</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">852</span>– <span class="NLM_lpage">866</span>, <span class="refDoi"> DOI: 10.1021/acs.oprd.6b00067</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.oprd.6b00067" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC28XmtVGmsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2016&pages=852-866&author=D.+Y.+Jackson&title=Processes+for+constructing+homogeneous+antibody+drug+conjugates&doi=10.1021%2Facs.oprd.6b00067"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit223R"><div class="casContent"><span class="casTitleNuber">223</span><div class="casTitle"><span class="NLM_cas:atitle">Processes for Constructing Homogeneous Antibody Drug Conjugates</span></div><div class="casAuthors">Jackson, David Y.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">852-866</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Antibody drug conjugates (ADCs) are synthesized by conjugating a cytotoxic drug or "payload" to a monoclonal antibody.  The payloads are conjugated using amino or sulfhydryl specific linkers that react with lysines or cysteines on the antibody surface.  A typical antibody contains over 60 lysines and up to 12 cysteines as potential conjugation sites.  The desired DAR (drugs/antibody ratio) depends on a no. of different factors and ranges from two to eight drugs/antibody.  The discrepancy between the no. of potential conjugation sites and the desired DAR, combined with use of conventional conjugation methods that are not site-specific, results in heterogeneous ADCs that vary in both DAR and conjugation sites.  Heterogeneous ADCs contain significant fractions with suboptimal DARs that are known to possess undesired pharmacol. properties.  As a result, new methods for synthesizing homogeneous ADCs have been developed in order to increase their potential as therapeutic agents.  This article will review recently reported processes for prepg. ADCs with improved homogeneity.  The advantages and potential limitations of each process are discussed, with emphasis on efficiency, quality, and in vivo efficacy relative to similar heterogeneous ADCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXoa73dqwCyrVg90H21EOLACvtfcHk0likE1ClJVvn5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmtVGmsbo%253D&md5=4bd838112b5dd262ab6531ec9dc22bd9</span></div><a href="/servlet/linkout?suffix=cit223&amp;dbid=16384&amp;doi=10.1021%2Facs.oprd.6b00067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.oprd.6b00067%26sid%3Dliteratum%253Aachs%26aulast%3DJackson%26aufirst%3DD.%2BY.%26atitle%3DProcesses%2520for%2520constructing%2520homogeneous%2520antibody%2520drug%2520conjugates%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2016%26volume%3D20%26spage%3D852%26epage%3D866%26doi%3D10.1021%2Facs.oprd.6b00067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref224"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref224'); return false;" data-citation="" class="refNumLink">224</a></strong><div class="NLM_citation" id="cit224"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walsh, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omarjee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galloway, W. R. J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwan, T. T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sore, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyvönen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spring, D. R.</span></span> <span> </span><span class="NLM_article-title">A general approach for the site-selective modification of native proteins, enabling the generation of stable and functional antibody–drug conjugates</span>. <i>Chem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">694</span>– <span class="NLM_lpage">700</span>, <span class="refDoi"> DOI: 10.1039/C8SC04645J</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1039%2FC8SC04645J" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=30774870" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFCgsLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=694-700&author=S.+J.+Walshauthor=S.+Omarjeeauthor=W.+R.+J.+D.+Gallowayauthor=T.+T.+L.+Kwanauthor=H.+F.+Soreauthor=J.+S.+Parkerauthor=M.+Hyv%C3%B6nenauthor=J.+S.+Carrollauthor=D.+R.+Spring&title=A+general+approach+for+the+site-selective+modification+of+native+proteins%2C+enabling+the+generation+of+stable+and+functional+antibody%E2%80%93drug+conjugates&doi=10.1039%2FC8SC04645J"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit224R"><div class="casContent"><span class="casTitleNuber">224</span><div class="casTitle"><span class="NLM_cas:atitle">A general approach for the site-selective modification of native proteins, enabling the generation of stable and functional antibody-drug conjugates</span></div><div class="casAuthors">Walsh, Stephen J.; Omarjee, Soleilmane; Galloway, Warren R. J. D.; Kwan, Terence T.-L.; Sore, Hannah F.; Parker, Jeremy S.; Hyvonen, Marko; Carroll, Jason S.; Spring, David R.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Science</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">694-700</span>CODEN:
                <span class="NLM_cas:coden">CSHCCN</span>;
        ISSN:<span class="NLM_cas:issn">2041-6520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Antibody-drug conjugates (ADCs) are a class of targeted therapeutics that utilize the specificity of antibodies to selectively deliver highly potent cytotoxins to target cells.  Although recent years have witnessed significant interest in ADCs, problems remain with the std. linkage chemistries used for cytotoxin-antibody bioconjugation.  These typically (1) generate unstable constructs, which may lead to premature cytotoxin release, (2) often give a wide variance in drug-antibody ratios (DAR) and (3) have poor control of attachment location on the antibody, resulting in a variable pharmacokinetic profile.  Herein, we report a novel divinylpyrimidine (DVP) linker platform for selective bioconjugation via covalent re-bridging of reduced disulfide bonds on native antibodies.  Model studies using the non-engineered trastuzumab antibody validate the utility of this linker platform for the generic generation of highly plasma-stable and functional antibody constructs that incorporate variable biol. relevant payloads (including cytotoxins) in an efficient and site-selective manner with precise control over DAR.  DVP linkers were also used to efficiently re-bridge both monomeric and dimeric protein systems, demonstrating their potential utility for general protein modification, protein stabilization or the development of other protein-conjugate therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6Z6QWcC1VerVg90H21EOLACvtfcHk0lg6BMs2eq-_zg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFCgsLvN&md5=ffa84327d4af248ad3fa2a058f05e9cb</span></div><a href="/servlet/linkout?suffix=cit224&amp;dbid=16384&amp;doi=10.1039%2FC8SC04645J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC8SC04645J%26sid%3Dliteratum%253Aachs%26aulast%3DWalsh%26aufirst%3DS.%2BJ.%26aulast%3DOmarjee%26aufirst%3DS.%26aulast%3DGalloway%26aufirst%3DW.%2BR.%2BJ.%2BD.%26aulast%3DKwan%26aufirst%3DT.%2BT.%2BL.%26aulast%3DSore%26aufirst%3DH.%2BF.%26aulast%3DParker%26aufirst%3DJ.%2BS.%26aulast%3DHyv%25C3%25B6nen%26aufirst%3DM.%26aulast%3DCarroll%26aufirst%3DJ.%2BS.%26aulast%3DSpring%26aufirst%3DD.%2BR.%26atitle%3DA%2520general%2520approach%2520for%2520the%2520site-selective%2520modification%2520of%2520native%2520proteins%252C%2520enabling%2520the%2520generation%2520of%2520stable%2520and%2520functional%2520antibody%25E2%2580%2593drug%2520conjugates%26jtitle%3DChem.%2520Sci.%26date%3D2019%26volume%3D10%26spage%3D694%26epage%3D700%26doi%3D10.1039%2FC8SC04645J" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref225"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref225'); return false;" data-citation="" class="refNumLink">225</a></strong><div class="NLM_citation" id="cit225"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tsuchikama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, Z.</span></span> <span> </span><span class="NLM_article-title">Antibody-drug conjugates: recent advances in conjugation and linker chemistries</span>. <i>Protein Cell</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">33</span>– <span class="NLM_lpage">46</span>, <span class="refDoi"> DOI: 10.1007/s13238-016-0323-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1007%2Fs13238-016-0323-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=27743348" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslSlsrjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=33-46&author=K.+Tsuchikamaauthor=Z.+An&title=Antibody-drug+conjugates%3A+recent+advances+in+conjugation+and+linker+chemistries&doi=10.1007%2Fs13238-016-0323-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit225R"><div class="casContent"><span class="casTitleNuber">225</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody-drug conjugates: recent advances in conjugation and linker chemistries</span></div><div class="casAuthors">Tsuchikama, Kyoji; An, Zhiqiang</div><div class="citationInfo"><span class="NLM_cas:title">Protein & Cell</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">33-46</span>CODEN:
                <span class="NLM_cas:coden">PCREFB</span>;
        ISSN:<span class="NLM_cas:issn">1674-800X</span>.
    
            (<span class="NLM_cas:orgname">Higher Education Press</span>)
        </div><div class="casAbstract">The antibody-drug conjugate (ADC), a humanized or human monoclonal antibody conjugated with highly cytotoxic small mols. (payloads) through chem. linkers, is a novel therapeutic format and has great potential to make a paradigm shift in cancer chemotherapy.  This new antibody-based mol. platform enables selective delivery of a potent cytotoxic payload to target cancer cells, resulting in improved efficacy, reduced systemic toxicity, and preferable pharmacokinetics (PK)/pharmacodynamics (PD) and biodistribution compared to traditional chemotherapy.  Boosted by the successes of FDA-approved Adcetris and Kadcyla, this drug class has been rapidly growing along with about 60 ADCs currently in clin. trials.  In this article, we briefly review mol. aspects of each component (the antibody, payload, and linker) of ADCs, and then mainly discuss traditional and new technologies of the conjugation and linker chemistries for successful construction of clin. effective ADCs.  Current efforts in the conjugation and linker chemistries will provide greater insights into mol. design and strategies for clin. effective ADCs from medicinal chem. and pharmacol. standpoints.  The development of site-specific conjugation methodologies for constructing homogeneous ADCs is an esp. promising path to improving ADC design, which will open the way for novel cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQM6rnMshPgrVg90H21EOLACvtfcHk0lg6BMs2eq-_zg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslSlsrjJ&md5=774905d4270dfdbf53456f7ef6e2b7b6</span></div><a href="/servlet/linkout?suffix=cit225&amp;dbid=16384&amp;doi=10.1007%2Fs13238-016-0323-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13238-016-0323-0%26sid%3Dliteratum%253Aachs%26aulast%3DTsuchikama%26aufirst%3DK.%26aulast%3DAn%26aufirst%3DZ.%26atitle%3DAntibody-drug%2520conjugates%253A%2520recent%2520advances%2520in%2520conjugation%2520and%2520linker%2520chemistries%26jtitle%3DProtein%2520Cell%26date%3D2018%26volume%3D9%26spage%3D33%26epage%3D46%26doi%3D10.1007%2Fs13238-016-0323-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146'],'ref147':['cit147'],'ref148':['cit148'],'ref149':['cit149'],'ref150':['cit150'],'ref151':['cit151'],'ref152':['cit152'],'ref153':['cit153'],'ref154':['cit154'],'ref155':['cit155'],'ref156':['cit156'],'ref157':['cit157'],'ref158':['cit158'],'ref159':['cit159'],'ref160':['cit160'],'ref161':['cit161'],'ref162':['cit162'],'ref163':['cit163'],'ref164':['cit164'],'ref165':['cit165'],'ref166':['cit166'],'ref167':['cit167'],'ref168':['cit168'],'ref169':['cit169'],'ref170':['cit170'],'ref171':['cit171'],'ref172':['cit172'],'ref173':['cit173'],'ref174':['cit174'],'ref175':['cit175'],'ref176':['cit176'],'ref177':['cit177'],'ref178':['cit178'],'ref179':['cit179'],'ref180':['cit180'],'ref181':['cit181'],'ref182':['cit182'],'ref183':['cit183'],'ref184':['cit184'],'ref185':['cit185'],'ref186':['cit186'],'ref187':['cit187'],'ref188':['cit188'],'ref189':['cit189'],'ref190':['cit190'],'ref191':['cit191'],'ref192':['cit192'],'ref193':['cit193'],'ref194':['cit194'],'ref195':['cit195'],'ref196':['cit196'],'ref197':['cit197'],'ref198':['cit198'],'ref199':['cit199'],'ref200':['cit200'],'ref201':['cit201'],'ref202':['cit202'],'ref203':['cit203'],'ref204':['cit204'],'ref205':['cit205'],'ref206':['cit206'],'ref207':['cit207'],'ref208':['cit208'],'ref209':['cit209'],'ref210':['cit210'],'ref211':['cit211'],'ref212':['cit212'],'ref213':['cit213'],'ref214':['cit214'],'ref215':['cit215'],'ref216':['cit216'],'ref217':['cit217'],'ref218':['cit218'],'ref219':['cit219'],'ref220':['cit220'],'ref221':['cit221'],'ref222':['cit222'],'ref223':['cit223'],'ref224':['cit224'],'ref225':['cit225']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 15 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Lucio Litti, Stefano Trivini, Davide Ferraro, <span class="NLM_string-name hlFld-ContribAuthor">Javier Reguera</span>. </span><span class="cited-content_cbyCitation_article-title">3D Printed Microfluidic Device for Magnetic Trapping and SERS Quantitative Evaluation of Environmental and Biomedical Analytes. </span><span class="cited-content_cbyCitation_journal-name">ACS Applied Materials & Interfaces</span><span> <strong>2021,</strong> <em>13 </em>
                                    (29)
                                     , 34752-34761. <a href="https://doi.org/10.1021/acsami.1c09771" title="DOI URL">https://doi.org/10.1021/acsami.1c09771</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsami.1c09771&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsami.1c09771%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Applied%2520Materials%2520%2526%2520Interfaces%26atitle%3D3D%252BPrinted%252BMicrofluidic%252BDevice%252Bfor%252BMagnetic%252BTrapping%252Band%252BSERS%252BQuantitative%252BEvaluation%252Bof%252BEnvironmental%252Band%252BBiomedical%252BAnalytes%26aulast%3DLitti%26aufirst%3DLucio%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D27052021%26date%3D05072021%26date%3D14072021%26volume%3D13%26issue%3D29%26spage%3D34752%26epage%3D34761" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Tamara Halkina, Jaclyn L. Henderson, Edward Y. Lin, Martin K. Himmelbauer, J. Howard Jones, Marta Nevalainen, Jun Feng, Kristopher King, Michael Rooney, Joshua L. Johnson, Douglas J. Marcotte, Jayanth V. Chodaparambil, P. Rajesh Kumar, Thomas A. Patterson, Paramasivam Murugan, Eli Schuman, LaiYee Wong, Thomas Hesson, Sarah Lamore, Channa Bao, Michael Calhoun, Hannah Certo, Brenda Amaral, Gregory M. Dillon, Rab Gilfillan, <span class="NLM_string-name hlFld-ContribAuthor">Felix Gonzalez-Lopez de Turiso</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Potent and Brain-Penetrant Tau Tubulin Kinase 1 (TTBK1) Inhibitors that Lower Tau Phosphorylation In Vivo. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (9)
                                     , 6358-6380. <a href="https://doi.org/10.1021/acs.jmedchem.1c00382" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00382</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00382&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00382%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BPotent%252Band%252BBrain-Penetrant%252BTau%252BTubulin%252BKinase%252B1%252B%252528TTBK1%252529%252BInhibitors%252Bthat%252BLower%252BTau%252BPhosphorylation%252BIn%252BVivo%26aulast%3DHalkina%26aufirst%3DTamara%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D02032021%26date%3D04052021%26volume%3D64%26issue%3D9%26spage%3D6358%26epage%3D6380" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Nicholas L. Yan, Diogo Santos-Martins, Reji Nair, Alan Chu, Ian A. Wilson, Kristen A. Johnson, Stefano Forli, Gareth J. Morgan, H. Michael Petrassi, <span class="NLM_string-name hlFld-ContribAuthor">Jeffery W. Kelly</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Potent Coumarin-Based Kinetic Stabilizers of Amyloidogenic Immunoglobulin Light Chains Using Structure-Based Design. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (9)
                                     , 6273-6299. <a href="https://doi.org/10.1021/acs.jmedchem.1c00339" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00339</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00339&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00339%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BPotent%252BCoumarin-Based%252BKinetic%252BStabilizers%252Bof%252BAmyloidogenic%252BImmunoglobulin%252BLight%252BChains%252BUsing%252BStructure-Based%252BDesign%26aulast%3DYan%26aufirst%3DNicholas%2BL.%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D23022021%26date%3D03052021%26volume%3D64%26issue%3D9%26spage%3D6273%26epage%3D6299" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Elma Mons, Robbert Q. Kim, Bjorn R. van Doodewaerd, Peter A. van Veelen, Monique P. C. Mulder, <span class="NLM_string-name hlFld-ContribAuthor">Huib Ovaa</span>. </span><span class="cited-content_cbyCitation_article-title">Exploring the Versatility of the Covalent Thiol–Alkyne Reaction with Substituted Propargyl Warheads: A Deciding Role for the Cysteine Protease. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2021,</strong> <em>143 </em>
                                    (17)
                                     , 6423-6433. <a href="https://doi.org/10.1021/jacs.0c10513" title="DOI URL">https://doi.org/10.1021/jacs.0c10513</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.0c10513&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.0c10513%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DExploring%252Bthe%252BVersatility%252Bof%252Bthe%252BCovalent%252BThiol%2525E2%252580%252593Alkyne%252BReaction%252Bwith%252BSubstituted%252BPropargyl%252BWarheads%25253A%252BA%252BDeciding%252BRole%252Bfor%252Bthe%252BCysteine%252BProtease%26aulast%3DMons%26aufirst%3DElma%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D02102020%26date%3D22042021%26volume%3D143%26issue%3D17%26spage%3D6423%26epage%3D6433" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Corie M. McHale, Lucas J. Karas, Xiqu Wang, Judy I. Wu, <span class="NLM_string-name hlFld-ContribAuthor">Ognjen Š. Miljanić</span>. </span><span class="cited-content_cbyCitation_article-title">Cyclobenzoin Esters as Hosts for Thin Guests. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2021,</strong> <em>23 </em>
                                    (6)
                                     , 2253-2257. <a href="https://doi.org/10.1021/acs.orglett.1c00383" title="DOI URL">https://doi.org/10.1021/acs.orglett.1c00383</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.1c00383&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.1c00383%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DCyclobenzoin%252BEsters%252Bas%252BHosts%252Bfor%252BThin%252BGuests%26aulast%3DMcHale%26aufirst%3DCorie%2BM.%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D01022021%26date%3D26022021%26volume%3D23%26issue%3D6%26spage%3D2253%26epage%3D2257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Luca Capaldo, <span class="NLM_string-name hlFld-ContribAuthor">Davide Ravelli</span>. </span><span class="cited-content_cbyCitation_article-title">Decatungstate as Direct Hydrogen Atom Transfer Photocatalyst for SOMOphilic Alkynylation. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2021,</strong> <em>23 </em>
                                    (6)
                                     , 2243-2247. <a href="https://doi.org/10.1021/acs.orglett.1c00381" title="DOI URL">https://doi.org/10.1021/acs.orglett.1c00381</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.1c00381&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.1c00381%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DDecatungstate%252Bas%252BDirect%252BHydrogen%252BAtom%252BTransfer%252BPhotocatalyst%252Bfor%252BSOMOphilic%252BAlkynylation%26aulast%3DCapaldo%26aufirst%3DLuca%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D01022021%26date%3D03032021%26volume%3D23%26issue%3D6%26spage%3D2243%26epage%3D2247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Kenji Mishiro, Mitsuki Nomura, Taniyuki Furuyama, <span class="NLM_string-name hlFld-ContribAuthor">Munetaka Kunishima</span>. </span><span class="cited-content_cbyCitation_article-title">Efficiency Enhancement of a Photocatalytic Decarbonylation of an Aminocyclopropenone by Benzothiophene Substitution. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2021,</strong> <em>86 </em>
                                    (4)
                                     , 3625-3636. <a href="https://doi.org/10.1021/acs.joc.0c02997" title="DOI URL">https://doi.org/10.1021/acs.joc.0c02997</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.0c02997&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.0c02997%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DEfficiency%252BEnhancement%252Bof%252Ba%252BPhotocatalytic%252BDecarbonylation%252Bof%252Ban%252BAminocyclopropenone%252Bby%252BBenzothiophene%252BSubstitution%26aulast%3DMishiro%26aufirst%3DKenji%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D22122020%26date%3D08022021%26volume%3D86%26issue%3D4%26spage%3D3625%26epage%3D3636" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Upul K. Bandarage, Alex M. Aronov, Jingrong Cao, Jon H. Come, Kevin M. Cottrell, Robert J. Davies, Simon Giroux, Marc Jacobs, Sudipta Mahajan, David Messersmith, Cameron S. Moody, Rebecca Swett, <span class="NLM_string-name hlFld-ContribAuthor">Jinwang Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a Novel Series of Potent and Selective Alkynylthiazole-Derived PI3Kγ Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>12 </em>
                                    (1)
                                     , 129-135. <a href="https://doi.org/10.1021/acsmedchemlett.0c00573" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.0c00573</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.0c00573&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.0c00573%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252Ba%252BNovel%252BSeries%252Bof%252BPotent%252Band%252BSelective%252BAlkynylthiazole-Derived%252BPI3K%2525CE%2525B3%252BInhibitors%26aulast%3DBandarage%26aufirst%3DUpul%2BK.%26date%3D2021%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D28102020%26date%3D11122020%26date%3D18122020%26volume%3D12%26issue%3D1%26spage%3D129%26epage%3D135" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Iraj  Behroz</span>, <span class="hlFld-ContribAuthor ">Leonardo  Kleebauer</span>, <span class="hlFld-ContribAuthor ">Kay  Hommernick</span>, <span class="hlFld-ContribAuthor ">Maria  Seidel</span>, <span class="hlFld-ContribAuthor ">Stefan  Grätz</span>, <span class="hlFld-ContribAuthor ">Andi  Mainz</span>, <span class="hlFld-ContribAuthor ">John B.  Weston</span>, <span class="hlFld-ContribAuthor ">Roderich D.  Süssmuth</span>. </span><span class="cited-content_cbyCitation_article-title">Acetylenic Replacement of Albicidin's Methacrylamide Residue Circumvents Detrimental
              E
              /
              Z
              Photoisomerization and Preserves Antibacterial Activity. </span><span class="cited-content_cbyCitation_journal-name">Chemistry – A European Journal</span><span> <strong>2021,</strong> <em>27 </em>
                                    (35)
                                     , 9077-9086. <a href="https://doi.org/10.1002/chem.202100523" title="DOI URL">https://doi.org/10.1002/chem.202100523</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/chem.202100523&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fchem.202100523%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520%25E2%2580%2593%2520A%2520European%2520Journal%26atitle%3DAcetylenic%252BReplacement%252Bof%252BAlbicidin%252527s%252BMethacrylamide%252BResidue%252BCircumvents%252BDetrimental%252BE%252B%25252F%252BZ%252BPhotoisomerization%252Band%252BPreserves%252BAntibacterial%252BActivity%26aulast%3DBehroz%26aufirst%3DIraj%26date%3D2021%26date%3D2021%26volume%3D27%26issue%3D35%26spage%3D9077%26epage%3D9086" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wen-Wen  Zhang</span>, <span class="hlFld-ContribAuthor ">Bi-Jie  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Iridium-catalyzed enantioselective hydroalkynylation via alkene isomerization. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron Letters</span><span> <strong>2021,</strong> <em>73 </em>, 153108. <a href="https://doi.org/10.1016/j.tetlet.2021.153108" title="DOI URL">https://doi.org/10.1016/j.tetlet.2021.153108</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tetlet.2021.153108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tetlet.2021.153108%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%2520Letters%26atitle%3DIridium-catalyzed%252Benantioselective%252Bhydroalkynylation%252Bvia%252Balkene%252Bisomerization%26aulast%3DZhang%26aufirst%3DWen-Wen%26date%3D2021%26volume%3D73%26spage%3D153108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hiroaki  Ohno</span>, <span class="hlFld-ContribAuthor ">Shinsuke  Inuki</span>. </span><span class="cited-content_cbyCitation_article-title">Nonbiomimetic total synthesis of indole alkaloids using alkyne-based strategies. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2021,</strong> <em>19 </em>
                                    (16)
                                     , 3551-3568. <a href="https://doi.org/10.1039/D0OB02577A" title="DOI URL">https://doi.org/10.1039/D0OB02577A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0OB02577A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0OB02577A%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DNonbiomimetic%252Btotal%252Bsynthesis%252Bof%252Bindole%252Balkaloids%252Busing%252Balkyne-based%252Bstrategies%26aulast%3DOhno%26aufirst%3DHiroaki%26date%3D2021%26date%3D2021%26volume%3D19%26issue%3D16%26spage%3D3551%26epage%3D3568" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rita  Fuerst</span>, <span class="hlFld-ContribAuthor ">Rolf  Breinbauer</span>. </span><span class="cited-content_cbyCitation_article-title">Activity‐Based Protein Profiling (ABPP) of Oxidoreductases. </span><span class="cited-content_cbyCitation_journal-name">ChemBioChem</span><span> <strong>2021,</strong> <em>22 </em>
                                    (4)
                                     , 630-638. <a href="https://doi.org/10.1002/cbic.202000542" title="DOI URL">https://doi.org/10.1002/cbic.202000542</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cbic.202000542&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcbic.202000542%26sid%3Dliteratum%253Aachs%26jtitle%3DChemBioChem%26atitle%3DActivity%2525E2%252580%252590Based%252BProtein%252BProfiling%252B%252528ABPP%252529%252Bof%252BOxidoreductases%26aulast%3DFuerst%26aufirst%3DRita%26date%3D2021%26date%3D2020%26volume%3D22%26issue%3D4%26spage%3D630%26epage%3D638" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Elwira  Chrobak</span>, <span class="hlFld-ContribAuthor ">Maria  Jastrzębska</span>, <span class="hlFld-ContribAuthor ">Ewa  Bębenek</span>, <span class="hlFld-ContribAuthor ">Monika  Kadela-Tomanek</span>, <span class="hlFld-ContribAuthor ">Krzysztof  Marciniec</span>, <span class="hlFld-ContribAuthor ">Małgorzata  Latocha</span>, <span class="hlFld-ContribAuthor ">Roman  Wrzalik</span>, <span class="hlFld-ContribAuthor ">Joachim  Kusz</span>, <span class="hlFld-ContribAuthor ">Stanisław  Boryczka</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular Structure, In Vitro Anticancer Study and Molecular Docking of New Phosphate Derivatives of Betulin. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2021,</strong> <em>26 </em>
                                    (3)
                                     , 737. <a href="https://doi.org/10.3390/molecules26030737" title="DOI URL">https://doi.org/10.3390/molecules26030737</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules26030737&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules26030737%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DMolecular%252BStructure%25252C%252BIn%252BVitro%252BAnticancer%252BStudy%252Band%252BMolecular%252BDocking%252Bof%252BNew%252BPhosphate%252BDerivatives%252Bof%252BBetulin%26aulast%3DChrobak%26aufirst%3DElwira%26date%3D2021%26date%3D2021%26volume%3D26%26issue%3D3%26spage%3D737" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Danhua  Ge</span>, <span class="hlFld-ContribAuthor ">Xin  Wang</span>, <span class="hlFld-ContribAuthor ">Xue-Qiang  Chu</span>. </span><span class="cited-content_cbyCitation_article-title">SOMOphilic alkynylation using acetylenic sulfones as functional reagents. </span><span class="cited-content_cbyCitation_journal-name">Organic Chemistry Frontiers</span><span> <strong>2021,</strong> <em>63 </em><a href="https://doi.org/10.1039/D1QO00798J" title="DOI URL">https://doi.org/10.1039/D1QO00798J</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D1QO00798J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD1QO00798J%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Chemistry%2520Frontiers%26atitle%3DSOMOphilic%252Balkynylation%252Busing%252Bacetylenic%252Bsulfones%252Bas%252Bfunctional%252Breagents%26aulast%3DGe%26aufirst%3DDanhua%26date%3D2021%26date%3D2021%26volume%3D63" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaolin  Peng</span>, <span class="hlFld-ContribAuthor ">Jun  Xu</span>, <span class="hlFld-ContribAuthor ">Tingting  Li</span>, <span class="hlFld-ContribAuthor ">Yonggui Robin  Chi</span>, <span class="hlFld-ContribAuthor ">Zhichao  Jin</span>. </span><span class="cited-content_cbyCitation_article-title">Chemo-selective cross reaction of two enals
              via
              carbene-catalyzed dual activation. </span><span class="cited-content_cbyCitation_journal-name">Chemical Science</span><span> <strong>2020,</strong> <em>11 </em>
                                    (46)
                                     , 12533-12539. <a href="https://doi.org/10.1039/D0SC03297B" title="DOI URL">https://doi.org/10.1039/D0SC03297B</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0SC03297B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0SC03297B%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Science%26atitle%3DChemo-selective%252Bcross%252Breaction%252Bof%252Btwo%252Benals%252Bvia%252Bcarbene-catalyzed%252Bdual%252Bactivation%26aulast%3DPeng%26aufirst%3DXiaolin%26date%3D2020%26date%3D2020%26volume%3D11%26issue%3D46%26spage%3D12533%26epage%3D12539" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0084.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0084.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures and in vitro potency of Mtb PknA/PknB inhibitors <b>1</b> and <b>2</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structures and EGFR2 kinase inhibitory activity of <b>3</b> and <b>4</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Structures, in vitro potency, and in vivo PK properties of troponin activators <b>5</b>–<b>8</b>. AC, concentration that increases native ATPas function by 40%; <i>F</i><sub>u</sub>, fraction unbound; ND, not determined.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Structures and in vitro potency of cyanoenone Michael acceptors <b>9</b>–<b>12</b>. <sup><i>a</i></sup>Average of three independent experiments. <sup><i>b</i></sup>Concentration required to double the specificity of NAD(P)H quinone dehydrogenase 1 (NQ01).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Structures and DENV-4 NS5 polymerase inhibitory activity of <b>13</b>–<b>16</b>. ITC, isothermal calorimetry; SPR, surface plasmon resonance.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Structures and PI3K inhibitory potency of <b>17</b>–<b>19</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Structures and anti-HIV activity of <b>20</b>–<b>22</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Structure and anti-HIV activity of <b>23</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Structures and GPR40 agonist activity of <b>24</b> and <b>25</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Structures, in vitro potency, and PK property of anti-MRSA agents <b>26</b> and <b>27</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Structures and anti-<i>C. difficile</i> activity of <b>28</b> and <b>29</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Structures and in vitro profile of BACE1 inhibitors <b>30</b>–<b>36</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0013.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Structures and cytotoxic data of compounds <b>37</b>–<b>39</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0014.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Structures and in vitro potency of p53–HDM2 interaction disruptors <b>40</b> and <b>41</b>. <sup><i>a</i></sup>ThermoFluor screening assay; <sup><i>b</i></sup>fluorescence polarization peptide displacement assay.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0015.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Structures and in vitro activity of D<sub>2</sub>/D<sub>3</sub> full agonist <b>42</b> and D<sub>2</sub> partial/D<sub>3</sub> full agonist <b>43</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0016.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Structures and cytotoxic data of compounds <b>44</b>–<b>46</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0017.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Structures of CysLT<sub>1</sub> and CysLT<sub>2</sub> receptor antagonists <b>47</b>–<b>49</b> and their in vitro potency and permeability data.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0018.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Structures of bis-Michael acceptors <b>50</b>–<b>52</b> and their in vitro potency.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig19" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0019.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Structures and the mPTPB inhibitory activity of <b>53</b> and <b>54</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig20" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0020.jpeg" id="rightTab-gr20" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. Structures and in vitro potency of CaSR antagonists <b>55</b> and <b>56</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig21" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0021.jpeg" id="rightTab-gr21" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21. Structures of compounds <b>57</b>–<b>59</b> and HDAC8-inhibitory activity of <b>57</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig22" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0022.jpeg" id="rightTab-gr22" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22. Structures and activity of mGluR5 antagonists <b>60</b>–<b>64</b>. <sup><i>a</i></sup>[<sup>3</sup>H]-M-MPEP binding displacement in rat membranes.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig23" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Figure 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0023.jpeg" id="rightTab-gr23" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 23. Structures of DCN1–UBE2M interaction inhibitors <b>65</b>–<b>68</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig23"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig24" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Figure 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0024.jpeg" id="rightTab-gr24" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 24. Structures and DPP-4 inhibitory activity of <b>69</b>–<b>71</b>. <sup><i>a</i></sup>hERG current remaining at tested concentration of 1 μM.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig24"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig25" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Figure 25</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0025.jpeg" id="rightTab-gr25" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 25. Structures of <b>72</b> and <b>73</b> with B-Raf inhibitory activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig25"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig26" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Figure 26</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0026.jpeg" id="rightTab-gr26" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 26. Structures, in vitro potency (<b>74</b> and <b>75</b>), serum protein binding, and clearance data of CRTH2 receptor antagonist <b>76</b>. KHSA, human serum albumin binding constant.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig26"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig27" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Figure 27</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0027.jpeg" id="rightTab-gr27" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 27. Structures of <b>77</b> and <b>78</b> with TACE inhibitory activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig27"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig28" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Figure 28</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0028.jpeg" id="rightTab-gr28" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 28. Structures and LSD1 inhibitory potency of <b>79</b> and <b>80</b>. A covalent complex of <b>79</b> with LSD1 cofactor FAD is also shown.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig28"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig29" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Figure 29</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0029.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0029.jpeg" id="rightTab-gr29" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 29. Structures of <b>81</b> and <b>82</b> with DAGLα and ABHD6 inhibitory activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig29"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig30" data-index="30" class="article__inlineFigure"><h2 class="fig-label">Figure 30</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0030.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0030.jpeg" id="rightTab-gr30" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 30. Structures of human rhinovirus 3C protease inhibitors <b>83</b> and <b>84</b> and their in vitro potency and DMPK profile.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0030.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig30"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig31" data-index="31" class="article__inlineFigure"><h2 class="fig-label">Figure 31</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0031.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0031.jpeg" id="rightTab-gr31" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 31. Structures, in vitro potency and <i>C</i><sub>max</sub> data of poliovirus plaque inhibitors <b>85</b> and <b>86</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0031.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig31"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig32" data-index="32" class="article__inlineFigure"><h2 class="fig-label">Figure 32</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0032.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0032.jpeg" id="rightTab-gr32" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 32. Structures, in vitro UDPGT rate, and PK profile of 5-lipoxygenase inhibitors <b>87</b>–<b>90</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0032.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig32"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig33" data-index="33" class="article__inlineFigure"><h2 class="fig-label">Figure 33</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0033.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0033.jpeg" id="rightTab-gr33" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 33. Structures of the alkyne-containing steroidal drugs <b>91</b>–<b>96</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0033.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig33"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig34" data-index="34" class="article__inlineFigure"><h2 class="fig-label">Figure 34</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0034.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0034.jpeg" id="rightTab-gr34" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 34. Structures and CYP1B1/CYP1A1 inhibitory activity of <b>97</b> and <b>98</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0034.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig34"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig35" data-index="35" class="article__inlineFigure"><h2 class="fig-label">Figure 35</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0035.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0035.jpeg" id="rightTab-gr35" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 35. Structures, in vitro activity, and microsomal stability profile of GK-GKRP disrupters <b>99</b>–<b>101</b>. <sup><i>a</i></sup>AS, hGK-hGKRP AlphaScreen. <sup><i>b</i></sup>mGK, mouse GK translation assay. <sup><i>c</i></sup>In vitro microsomal stability measurements.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0035.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig35"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig36" data-index="36" class="article__inlineFigure"><h2 class="fig-label">Figure 36</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0036.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0036.jpeg" id="rightTab-gr36" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 36. Structures, in vitro activity, and microsomal stability profile of ghrelin inverse agonists <b>102</b>–<b>105</b>. <sup><i>a</i></sup>Inositol phosphate accumulation assay.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0036.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig36"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig37" data-index="37" class="article__inlineFigure"><h2 class="fig-label">Figure 37</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0037.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0037.jpeg" id="rightTab-gr37" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 37. Structures of DPP-4 inhibitors <b>106</b>–<b>108</b> and in vitro potency.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0037.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig37"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig38" data-index="38" class="article__inlineFigure"><h2 class="fig-label">Figure 38</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0038.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0038.jpeg" id="rightTab-gr38" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 38. Structures of <b>109</b> and <b>110</b> with KCNQ channel agonist activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0038.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig38"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig39" data-index="39" class="article__inlineFigure"><h2 class="fig-label">Figure 39</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0039.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0039.jpeg" id="rightTab-gr39" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 39. Structures of ERAP1/ERAP2/IRAP inhibitors <b>111</b> and <b>112</b> with in vitro potency data.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0039.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig39"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig40" data-index="40" class="article__inlineFigure"><h2 class="fig-label">Figure 40</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0040.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0040.jpeg" id="rightTab-gr40" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 40. Structures of <b>113</b>–<b>115</b> with Bcr-Abl kinase inhibitory activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0040.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig40"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig41" data-index="41" class="article__inlineFigure"><h2 class="fig-label">Figure 41</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0041.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0041.jpeg" id="rightTab-gr41" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 41. Structure and KIT inhibitory activity of <b>116</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0041.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig41"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig42" data-index="42" class="article__inlineFigure"><h2 class="fig-label">Figure 42</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0042.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0042.jpeg" id="rightTab-gr42" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 42. Structure and MELK inhibitory activity of <b>117</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0042.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig42"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig43" data-index="43" class="article__inlineFigure"><h2 class="fig-label">Figure 43</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0043.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0043.jpeg" id="rightTab-gr43" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 43. Structures and activity of Hsp90 inhibitors <b>118</b> and <b>119</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0043.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig43"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig44" data-index="44" class="article__inlineFigure"><h2 class="fig-label">Figure 44</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0044.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0044.jpeg" id="rightTab-gr44" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 44. Structure and in vitro potency of LpxC inhibitor <b>120</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0044.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig44"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig45" data-index="45" class="article__inlineFigure"><h2 class="fig-label">Figure 45</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0045.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0045.jpeg" id="rightTab-gr45" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 45. Structures of LpxC inhibitors <b>121</b>–<b>123</b> and in vitro potency.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0045.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig45"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig46" data-index="46" class="article__inlineFigure"><h2 class="fig-label">Figure 46</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0046.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0046.jpeg" id="rightTab-gr46" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 46. Structure and in vitro potency of Smac mimetic dimer <b>124</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0046.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig46"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig47" data-index="47" class="article__inlineFigure"><h2 class="fig-label">Figure 47</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0047.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0047.jpeg" id="rightTab-gr47" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 47. Structures of tretinoin (<b>125</b>) and tazarotene (<b>126</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0047.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig47"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig48" data-index="48" class="article__inlineFigure"><h2 class="fig-label">Figure 48</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0048.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0048.jpeg" id="rightTab-gr48" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 48. Structures of BTK inhibitors <b>127</b>–<b>129</b> and covalent mechanism of action.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0048.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig48"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig49" data-index="49" class="article__inlineFigure"><h2 class="fig-label">Figure 49</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0049.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0049.jpeg" id="rightTab-gr49" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 49. Structure and covalent mechanism of Nek2 kinase inhibitor <b>130</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0049.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig49"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig50" data-index="50" class="article__inlineFigure"><h2 class="fig-label">Figure 50</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0050.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0050.jpeg" id="rightTab-gr50" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 50. Structure and covalent mechanism of p97 inhibitor <b>131</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0050.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig50"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig51" data-index="51" class="article__inlineFigure"><h2 class="fig-label">Figure 51</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0051.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0051.jpeg" id="rightTab-gr51" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 51. Structure and covalent mechanism of EGFR kinase inhibitor <b>132</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0051.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig51"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig52" data-index="52" class="article__inlineFigure"><h2 class="fig-label">Figure 52</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0052.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0052.jpeg" id="rightTab-gr52" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 52. (A) DUB-mediated cleavage of the ubiquitin isopeptide bond. Isopeptide amide carbon activated by oxyanion hole residues is nucleophilically attacked by the thiolate anion. (B) Active site-directed covalent inhibitor undergoes similar type of reaction to inhibit DUB in an irreversible manner. (C) Increasing steric bulk at the propargyl unit leads to decreased reactivity toward cysteine.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0052.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig52"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig53" data-index="53" class="article__inlineFigure"><h2 class="fig-label">Figure 53</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0053.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0053.jpeg" id="rightTab-gr53" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 53. Structures of reversible covalent inhibitor <b>133</b> and irreversible inhibitor <b>134</b> and its covalent mechanism of action.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0053.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig53"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig54" data-index="54" class="article__inlineFigure"><h2 class="fig-label">Figure 54</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0054.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0054.jpeg" id="rightTab-gr54" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 54. Structure and the covalent mechanism of DHPDHase inhibitor <b>135</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0054.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig54"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig55" data-index="55" class="article__inlineFigure"><h2 class="fig-label">Figure 55</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0055.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0055.jpeg" id="rightTab-gr55" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 55. Structure and covalent mechanism of LSD1 inhibitor <b>136</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0055.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig55"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig56" data-index="56" class="article__inlineFigure"><h2 class="fig-label">Figure 56</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0056.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0056.jpeg" id="rightTab-gr56" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 56. Structures and covalent mechanism of MAO-B inhibitors <b>137</b>–<b>139</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0056.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig56"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig57" data-index="57" class="article__inlineFigure"><h2 class="fig-label">Figure 57</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0057.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0057.jpeg" id="rightTab-gr57" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 57. Structures of multifunctional anti-AD compounds <b>140</b>–<b>148</b>. ee, <i>Electrophorus electricus</i>; eq, equine; hr, human recombinant.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0057.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig57"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig58" data-index="58" class="article__inlineFigure"><h2 class="fig-label">Figure 58</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0058.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0058.jpeg" id="rightTab-gr58" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 58. Structures of natural product <b>149</b> and its semisynthetic derivative <b>150</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0058.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig58"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig59" data-index="59" class="article__inlineFigure"><h2 class="fig-label">Figure 59</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0059.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0059.jpeg" id="rightTab-gr59" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 59. Examples of natural products <b>151</b>–<b>155</b> and associated in vitro potency.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0059.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig59"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig60" data-index="60" class="article__inlineFigure"><h2 class="fig-label">Figure 60</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0060.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0060.jpeg" id="rightTab-gr60" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 60. Structure and covalent mechanism of <b>156</b> (calicheamicin).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0060.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig60"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig61" data-index="61" class="article__inlineFigure"><h2 class="fig-label">Figure 61</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0061.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0061.jpeg" id="rightTab-gr61" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 61. Structure and covalent mechanism of dynemicin A (<b>157</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0061.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig61"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig62" data-index="62" class="article__inlineFigure"><h2 class="fig-label">Figure 62</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0062.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0062.jpeg" id="rightTab-gr62" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 62. Structures of <b>158</b> (inotuzumab ozogamicin) and <b>159</b> (gemtuzumab ozogamicin).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0062.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig62"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig63" data-index="63" class="article__inlineFigure"><h2 class="fig-label">Figure 63</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0063.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0063.jpeg" id="rightTab-gr63" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 63. Structures and mechanism of inactivation of CYP450 by acetylene-containing steroids <b>91</b>, <b>93</b>, <b>96</b>, and <b>160</b> and MAO-B inhibitor <b>137</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0063.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig63"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig64" data-index="64" class="article__inlineFigure"><h2 class="fig-label">Figure 64</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0064.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0064.jpeg" id="rightTab-gr64" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 64. Structures of mGluR5 PAMs <b>161</b> and <b>162</b> and the mechanism of conjugation of <b>161</b> with GSH.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0064.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig64"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig65" data-index="65" class="article__inlineFigure"><h2 class="fig-label">Figure 65</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0065.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0065.jpeg" id="rightTab-gr65" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 65. Structure and rat-specific mechanism of inactivation of GSH by <b>163</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0065.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig65"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig66" data-index="66" class="article__inlineFigure"><h2 class="fig-label">Figure 66</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0066.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0066.jpeg" id="rightTab-gr66" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 66. Structure and mechanism of time-dependent inhibition of CYP3A4 by <b>4</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0066.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig66"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig67" data-index="67" class="article__inlineFigure"><h2 class="fig-label">Figure 67</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0067.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0067.jpeg" id="rightTab-gr67" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 67. Schematic representation of the concept of ABPP. ABP reacts with target proteins and tagged with fluorescent azides via CuAAC and subsequent trypsinization and detection by LC-MS/MS.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0067.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig67"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig68" data-index="68" class="article__inlineFigure"><h2 class="fig-label">Figure 68</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0068.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0068.jpeg" id="rightTab-gr68" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 68. Structures of <b>164</b> (<span class="smallcaps smallerCapital">d</span>-lactate) and <b>165</b> (dipeptide) probes and the corresponding click products with 6-FAM-azide. THPTA, Tris(3-hydroxypropyltriazolylmethyl)amine.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0068.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig68"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig69" data-index="69" class="article__inlineFigure"><h2 class="fig-label">Figure 69</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0069.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0069.jpeg" id="rightTab-gr69" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 69. Structure of NPC1-targeted compound <b>166</b> and its covalent bonding to the target protein. The covalent complexes are tagged via CuAAC using Alexa-fluor 488-azide for in gel detection.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0069.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig69"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig70" data-index="70" class="article__inlineFigure"><h2 class="fig-label">Figure 70</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0070.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0070.jpeg" id="rightTab-gr70" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 70. Structures of <b>167</b> and <b>167</b>-derived ABP (<b>168</b>) and elucidation of alkylated target proteins by CuAAC click chemistry with a trifunctional tag. TCEP, Tris(2-carboxyethyl)phosphine; TBTA, Tris[(1-benzyl-1<i>H</i>-1,2,3-triazol-4-yl)methyl]amine.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0070.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig70"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig71" data-index="71" class="article__inlineFigure"><h2 class="fig-label">Figure 71</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0071.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0071.jpeg" id="rightTab-gr71" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 71. Structures of HDAC inhibitor (<b>169</b>) and <b>169</b>-derived alkyne-containing photo-cross-linking probe (<b>170</b>). Alkylated proteins are tagged via CuAAC with a trifunctional rhodamine-biotin-azide for subsequent detection.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0071.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig71"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig72" data-index="72" class="article__inlineFigure"><h2 class="fig-label">Figure 72</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0072.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0072.jpeg" id="rightTab-gr72" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 72. Structure of clickable TG2 inhibitor <b>171</b> and labeling and visualization of catalytically active TG2.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0072.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig72"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig73" data-index="73" class="article__inlineFigure"><h2 class="fig-label">Figure 73</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0073.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0073.jpeg" id="rightTab-gr73" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 73. Structure of the alkyne probe (<b>172</b>) and detection of alkylated CYP450s via CuAAC reaction with rhodamine-azide.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0073.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig73"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig74" data-index="74" class="article__inlineFigure"><h2 class="fig-label">Figure 74</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0074.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0074.jpeg" id="rightTab-gr74" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 74. Structures of <b>173</b> and <b>173</b>-derived alkyne affinity probe (<b>174</b>) and subsequent in gel visualization of bound target proteins by CuAAC reaction with rhodamine-azide or biotin-azide. TAMRA-azide, tetramethylrhodamine-azide.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0074.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig74"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig75" data-index="75" class="article__inlineFigure"><h2 class="fig-label">Figure 75</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0075.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0075.jpeg" id="rightTab-gr75" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 75. Structure of the alkyne probe <b>150</b> and subsequent detection of labeling events using CuAAC reaction with Alexa-Fluor 488-azide.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0075.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig75"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig76" data-index="76" class="article__inlineFigure"><h2 class="fig-label">Figure 76</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0076.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0076.jpeg" id="rightTab-gr76" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 76. Structure of a polyalkyne probe <b>175</b> and subsequent in gel and proteome LC-MS/MS analyses via CuAAC reaction with Tb-azide.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0076.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig76"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig77" data-index="77" class="article__inlineFigure"><h2 class="fig-label">Figure 77</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0077.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0077.jpeg" id="rightTab-gr77" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 77. Structures of FAAH inhibitor <b>176</b> and <b>176</b>-derived alkyne probe (<b>177</b>). <b>177</b> allowed for in gel analysis of the target proteins using CuAAC reaction with rhodamine-azide.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0077.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig77"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig78" data-index="78" class="article__inlineFigure"><h2 class="fig-label">Figure 78</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0078.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0078.jpeg" id="rightTab-gr78" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 78. Structure of <b>178</b> featuring photoactivatable diazirine probe and a terminal alkyne handle. Alkylated target proteins were subsequently detected using CuAAC reaction with Cy3-azide.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0078.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig78"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig79" data-index="79" class="article__inlineFigure"><h2 class="fig-label">Figure 79</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0079.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0079.jpeg" id="rightTab-gr79" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 79. Structures of clickable <b>179</b> and clicked PET imaging agent <b>180</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0079.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig79"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig80" data-index="80" class="article__inlineFigure"><h2 class="fig-label">Figure 80</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0080.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0080.jpeg" id="rightTab-gr80" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 80. Structure and synthesis of clicked PET imaging agent <b>181</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0080.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig80"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig81" data-index="81" class="article__inlineFigure"><h2 class="fig-label">Figure 81</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0081.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0081.jpeg" id="rightTab-gr81" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 81. Structures of puromycin <b>182</b> and its clickable handle <b>183</b> and mechanism of formation of fluorescently labeled click product.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0081.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig81"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig82" data-index="82" class="article__inlineFigure"><h2 class="fig-label">Figure 82</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0082.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0082.jpeg" id="rightTab-gr82" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 82. (A) Schematic representation of target-guided synthesis of lead compounds. (B) Example of cell-based KTGS.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0082.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig82"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig83" data-index="83" class="article__inlineFigure"><h2 class="fig-label">Figure 83</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/medium/jm9b01617_0083.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0083.jpeg" id="rightTab-gr83" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 83. Structure of the pyrrolobenzodiazepine dimer <b>187</b> and the corresponding alkyne-/triazole-based anti-HER2 or anti-CD22 cysteine-containing antibodies <b>188</b> and <b>189</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.9b01617/20200604/images/large/jm9b01617_0083.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01617&amp;id=fig83"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i99">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_25634" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_25634" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 225 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ervin, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gronert, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barlow, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilles, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bierbaum, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DePuy, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lineberger, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellison, G. B.</span></span> <span> </span><span class="NLM_article-title">Bond strengths of ethylene and acetylene</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>112</i></span>,  <span class="NLM_fpage">5750</span>– <span class="NLM_lpage">5759</span>, <span class="refDoi"> DOI: 10.1021/ja00171a013</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja00171a013" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADyaK3cXkslOls7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=1990&pages=5750-5759&author=K.+M.+Ervinauthor=S.+Gronertauthor=S.+E.+Barlowauthor=M.+K.+Gillesauthor=A.+G.+Harrisonauthor=V.+M.+Bierbaumauthor=C.+H.+DePuyauthor=W.+C.+Linebergerauthor=G.+B.+Ellison&title=Bond+strengths+of+ethylene+and+acetylene&doi=10.1021%2Fja00171a013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Bond strengths of ethylene and acetylene</span></div><div class="casAuthors">Ervin, Kent M.; Gronert, Scott; Barlow, S. E.; Gilles, Mary K.; Harrison, Alex G.; Bierbaum, Veronica M.; DePuy, Charles H.; Lineberger, W. C.; Ellison, G. Barney</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5750-9</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    </div><div class="casAbstract">Neg. ion photoelectron spectroscopy and gas-phase proton transfer kinetics were employed to det. the CH bond dissocn. energies of acetylene, ethylene, and vinyl radical: D0(HCC-H) = 131.3 ± 0.7 kcal mol-1, D0(CH2CH-H) = 109.7 ± 0.8 kcal mol-1, and D0(CH2C-H) = 81.0 ± 3.5 kcal mol-1.  The strengths of each of the other CH and CC bonds in acetylene and ethylene and their fragments were derived.  The energy required to isomerize acetylene to vinylidene was also detd.  Proton transfer kinetics in a flowing after glow/selected-ion flow tube app. were used to refine the acidities of ethylene, acetylene, and vinyl.  The gas-phase acidity of acetylene was tied to values for HF.  The electron affinities of ethynyl, vinyl, and vinylidene radicals were detd. by photoelectron spectroscopy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9WztXNlowjbVg90H21EOLACvtfcHk0lhhEE7TDVM03A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXkslOls7Y%253D&md5=7fedf13049014cd6bb88bfc7eb0667ed</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1021%2Fja00171a013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja00171a013%26sid%3Dliteratum%253Aachs%26aulast%3DErvin%26aufirst%3DK.%2BM.%26aulast%3DGronert%26aufirst%3DS.%26aulast%3DBarlow%26aufirst%3DS.%2BE.%26aulast%3DGilles%26aufirst%3DM.%2BK.%26aulast%3DHarrison%26aufirst%3DA.%2BG.%26aulast%3DBierbaum%26aufirst%3DV.%2BM.%26aulast%3DDePuy%26aufirst%3DC.%2BH.%26aulast%3DLineberger%26aufirst%3DW.%2BC.%26aulast%3DEllison%26aufirst%3DG.%2BB.%26atitle%3DBond%2520strengths%2520of%2520ethylene%2520and%2520acetylene%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1990%26volume%3D112%26spage%3D5750%26epage%3D5759%26doi%3D10.1021%2Fja00171a013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blanksby, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellison, G. B.</span></span> <span> </span><span class="NLM_article-title">Bond dissociation energies of organic molecules</span>. <i>Acc. Chem. Res.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">255</span>– <span class="NLM_lpage">263</span>, <span class="refDoi"> DOI: 10.1021/ar020230d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ar020230d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmt1OqsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2003&pages=255-263&author=S.+J.+Blanksbyauthor=G.+B.+Ellison&title=Bond+dissociation+energies+of+organic+molecules&doi=10.1021%2Far020230d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Bond Dissociation Energies of Organic Molecules</span></div><div class="casAuthors">Blanksby, Stephen J.; Ellison, G. Barney</div><div class="citationInfo"><span class="NLM_cas:title">Accounts of Chemical Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">255-263</span>CODEN:
                <span class="NLM_cas:coden">ACHRE4</span>;
        ISSN:<span class="NLM_cas:issn">0001-4842</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  In this Account the authors have compiled a list of reliable bond energies that are based on a set of critically evaluated expts.  A brief description of the three most important exptl. techniques for measuring bond energies is provided.  The authors demonstrate how these exptl. data can be applied to yield the heats of formation of org. radicals and the bond enthalpies of more than 100 representative org. mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1Gd4XRKVyrbVg90H21EOLACvtfcHk0lhhEE7TDVM03A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmt1OqsA%253D%253D&md5=e313bd3c3a7809b70baa32c83e70d135</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1021%2Far020230d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Far020230d%26sid%3Dliteratum%253Aachs%26aulast%3DBlanksby%26aufirst%3DS.%2BJ.%26aulast%3DEllison%26aufirst%3DG.%2BB.%26atitle%3DBond%2520dissociation%2520energies%2520of%2520organic%2520molecules%26jtitle%3DAcc.%2520Chem.%2520Res.%26date%3D2003%26volume%3D36%26spage%3D255%26epage%3D263%26doi%3D10.1021%2Far020230d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bent, H. A.</span></span> <span> </span><span class="NLM_article-title">Distribution of atomic s character in molecules and its chemical implications</span>. <i>J. Chem. Educ.</i> <span class="NLM_year" style="font-weight: bold;">1960</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">616</span>, <span class="refDoi"> DOI: 10.1021/ed037p616</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ed037p616" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADyaF3MXhtVeitLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1960&pages=616&author=H.+A.+Bent&title=Distribution+of+atomic+s+character+in+molecules+and+its+chemical+implications&doi=10.1021%2Fed037p616"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Distribution of atomic s character in molecules and its chemical implication</span></div><div class="casAuthors">Bent, Henry A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Education</span>
        (<span class="NLM_cas:date">1960</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">616-24</span>CODEN:
                <span class="NLM_cas:coden">JCEDA8</span>;
        ISSN:<span class="NLM_cas:issn">0021-9584</span>.
    </div><div class="casAbstract">Classification of s character in mols. according to sp, sp2, and sp3 bonding permits prediction of bond lengths, bond angles, relative electronegativity, and basicity of valence.  Deviation from these simple hybrid bonds is explained by use of a quantum-mech. model, which also explains a mechanism for the inductive effect, carbonium ion rearrangements, energetics of addn. to multiple bonds, interaction within the CO group, and the structure of CO2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqC5PcB2Z1JeLVg90H21EOLACvtfcHk0lg5stB2G8kDGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF3MXhtVeitLw%253D&md5=771fd607741b33ac004c8ab5af17eda5</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1021%2Fed037p616&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fed037p616%26sid%3Dliteratum%253Aachs%26aulast%3DBent%26aufirst%3DH.%2BA.%26atitle%3DDistribution%2520of%2520atomic%2520s%2520character%2520in%2520molecules%2520and%2520its%2520chemical%2520implications%26jtitle%3DJ.%2520Chem.%2520Educ.%26date%3D1960%26volume%3D37%26spage%3D616%26doi%3D10.1021%2Fed037p616" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W. G.</span></span> <span> </span><span class="NLM_article-title">The vinyl carbanion1</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">1959</span>,  <span class="NLM_volume"><i>81</i></span>,  <span class="NLM_fpage">6313</span>– <span class="NLM_lpage">6319</span>, <span class="refDoi"> DOI: 10.1021/ja01532a050</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja01532a050" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADyaF3MXht12gug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=1959&pages=6313-6319&author=S.+I.+Millerauthor=W.+G.+Lee&title=The+vinyl+carbanion1&doi=10.1021%2Fja01532a050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">The vinyl carbanion</span></div><div class="casAuthors">Miller, Sidney I.; Lee, Warren G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">1959</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">6313-19</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    </div><div class="casAbstract">A kinetic and mechanistic study of H-D exchange and elimination reactions of 1,2-dihalo-ethenes was made in order to est. pK values and cis-trans isomerization energy barriers.  (CDBr2)2 (I), b0.04 56°, n25D 1.6331 (prepd. by bromination of DC:CD), was debrominated with Zn to a cis-trans mixt. of BrDC:CDBr (II), which was fractionated to yield pure cis-II, n25D 1.5365 (CA 45, 9984d).  The rates of dehydrobromination of cis-II and cis-HBrC: CBrH (III) in various concns. of halides and MeONa in MeOH at 24.8-35.4° were measured and no isotope effect was observed, kH/kD = 1.03.  The rates of MeO-catalyzed exchange of II with MeOH were followed by infrared analysis by using the C-D band at 45 μ.  If extinction coeffs. for C-D and C-H bands were equal, k = 3.3 × 10-3 l./mole sec. at 26° (mean).  Several alkenes, which were treated with basic D2O, with no exchange taking place at 210° during 2-6 days in the presence of tert-BuOK, were Me acrylate, maleic anhydride, Et cinnamate, Me chloromaleate, cis- and trans-stilbene, 1,1-diphenylethylene, and triphenylethylene.  For alkenes which exchanged with D2O, approx. 1-2M in NaOMe, resp., were given compd., temp., time in hrs., CC-D/CC-H, energy of activation for the dehydrobromination reaction in kcal./mole: trans-III, 25, 65, 0.24, 33.4; cis-III, 25, 45, 0.26, 28.1; trans-HCCl:CHCl (trans-IV), 3, 48, 0.03, 29.0; cis-IV, 70, 20, 1, 35.1; trans-CHI:CHI (V), 55, 20, 1, 35.8; cis-CHI: CHI, 25, 88, <0.05, 2.47; BrHC:CBr, 25, 2, 0.13, -; PhCH:CHBr, 110, 144, 0.06, -.  Exchange rates of 5 dihaloethers decreased in the order cis-IV ∼ cis-III > trans-IV > trans-II > trans-V.  Bromides isomerized during the exchange reaction to a greater extent than chlorides.  Yield of V was >95% in a single equilibration run.  A mechanism involving a vinyl anion intermediate in the key steps for both elimination and exchange reaction was suggested.  By use of the abs. rate theory the acidity of the alkenes was estd., thus the pKa of cis-III and cis-IV were, resp., 33.6 and ∼34 at most, whereas the pKa of the resp. trans isomers were 1-2 units higher.  Stability of vinyl anions was discussed in terms of the cistrans isomerization energy barrier.  A kinetic analysis of the elimination was proposed, assuming a steady state vinyl ion concn., with H-D exchange, H-H exchange, isomerization, and HX elimination as competing reactions.  Apparently similar systems eliminate by different paths and 1-, 2-, or 3-step mechanisms must be considered for each specific case.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoW6JzVz6DMzrVg90H21EOLACvtfcHk0lg5stB2G8kDGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF3MXht12gug%253D%253D&md5=43a7c615b70403a419e5e2335404f0aa</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1021%2Fja01532a050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja01532a050%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DS.%2BI.%26aulast%3DLee%26aufirst%3DW.%2BG.%26atitle%3DThe%2520vinyl%2520carbanion1%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1959%26volume%3D81%26spage%3D6313%26epage%3D6319%26doi%3D10.1021%2Fja01532a050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lenz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boeckler, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gmeiner, P.</span></span> <span> </span><span class="NLM_article-title">Fancy bioisosteres: Synthesis, SAR, and pharmacological investigations of novel nonaromatic dopamine D<sub>3</sub> receptor ligands</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">4434</span>– <span class="NLM_lpage">4442</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2005.04.047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1016%2Fj.bmc.2005.04.047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=15908220" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlt1Sktbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2005&pages=4434-4442&author=C.+Lenzauthor=F.+Boecklerauthor=H.+Hubnerauthor=P.+Gmeiner&title=Fancy+bioisosteres%3A+Synthesis%2C+SAR%2C+and+pharmacological+investigations+of+novel+nonaromatic+dopamine+D3+receptor+ligands&doi=10.1016%2Fj.bmc.2005.04.047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Fancy bioisosteres: Synthesis, SAR, and pharmacological investigations of novel nonaromatic dopamine D3 receptor ligands</span></div><div class="casAuthors">Lenz, Carola; Boeckler, Frank; Huebner, Harald; Gmeiner, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4434-4442</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Structural variations of the lead compd. FAUC 88 led to dopaminergic enynes with an extended π-system when Pd-catalyzed cross coupling reactions were employed for the key reaction steps.  The dienyne (I) displayed substantial affinity for the dopamine receptor subtype D3 and remarkable selectivity over D4.  Compared to FAUC 88, the novel fancy bioisostere I displayed reduced ligand efficacy.  DFT-based conformational anal. of the test compd. I, including the calcn. of diagnostic magnetic shielding properties and their comparison with exptl. derived NMR data, indicated a clear energetic preference for the s-trans geometry of the diene substructure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqu1n-sAJR8QbVg90H21EOLACvtfcHk0lg5stB2G8kDGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlt1Sktbs%253D&md5=24f78ad6908b4c927206cf6efa150afb</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2005.04.047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2005.04.047%26sid%3Dliteratum%253Aachs%26aulast%3DLenz%26aufirst%3DC.%26aulast%3DBoeckler%26aufirst%3DF.%26aulast%3DHubner%26aufirst%3DH.%26aulast%3DGmeiner%26aufirst%3DP.%26atitle%3DFancy%2520bioisosteres%253A%2520Synthesis%252C%2520SAR%252C%2520and%2520pharmacological%2520investigations%2520of%2520novel%2520nonaromatic%2520dopamine%2520D3%2520receptor%2520ligands%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2005%26volume%3D13%26spage%3D4434%26epage%3D4442%26doi%3D10.1016%2Fj.bmc.2005.04.047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lenz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haubmann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boeckler, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gmeiner, P.</span></span> <span> </span><span class="NLM_article-title">Fancy bioisosteres: Synthesis and dopaminergic properties of the endiyne FAUC 88 as a novel non-aromatic D<sub>3</sub> agonist</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">185</span>– <span class="NLM_lpage">191</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2004.09.044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1016%2Fj.bmc.2004.09.044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=15582463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A280%3ADC%252BD2M%252FitFKrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2005&pages=185-191&author=C.+Lenzauthor=C.+Haubmannauthor=H.+Hubnerauthor=F.+Boecklerauthor=P.+Gmeiner&title=Fancy+bioisosteres%3A+Synthesis+and+dopaminergic+properties+of+the+endiyne+FAUC+88+as+a+novel+non-aromatic+D3+agonist&doi=10.1016%2Fj.bmc.2004.09.044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Fancy bioisosteres: synthesis and dopaminergic properties of the endiyne FAUC 88 as a novel non-aromatic D3 agonist</span></div><div class="casAuthors">Lenz Carola; Haubmann Christian; Hubner Harald; Boeckler Frank; Gmeiner Peter</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & medicinal chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">185-91</span>
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    </div><div class="casAbstract">Enlargement of the pi-electronic system of the non-aromatic D3 agonist FAUC 73 led to dopaminergic endiynes of type 1 being synthesized via the bromovinyl triflate 7a as a key intermediate when palladium catalyzed coupling reactions were exploited for the introduction of the (aza)alkyne substituents.  As the first neuroreceptor active endiyne, FAUC 88 (1c) displayed high and selective dopamine D3 receptor affinity (K(ihigh) = 3.2 nM) and substantial ligand efficacy (72%, EC(50) = 2.5 nM).  Similarities between molecular electrostatic potentials induced by the catechol subunit of the genuine neurotransmitter and those of its non-aromatic endiyne bioisostere are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRyHvFP5rn5GbHHuJhbyicZfW6udTcc2ebnMpncaddeKbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2M%252FitFKrtg%253D%253D&md5=107537fb22eec1736c001d91b7041d9a</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2004.09.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2004.09.044%26sid%3Dliteratum%253Aachs%26aulast%3DLenz%26aufirst%3DC.%26aulast%3DHaubmann%26aufirst%3DC.%26aulast%3DHubner%26aufirst%3DH.%26aulast%3DBoeckler%26aufirst%3DF.%26aulast%3DGmeiner%26aufirst%3DP.%26atitle%3DFancy%2520bioisosteres%253A%2520Synthesis%2520and%2520dopaminergic%2520properties%2520of%2520the%2520endiyne%2520FAUC%252088%2520as%2520a%2520novel%2520non-aromatic%2520D3%2520agonist%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2005%26volume%3D13%26spage%3D185%26epage%3D191%26doi%3D10.1016%2Fj.bmc.2004.09.044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Voronin, V. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ledovskaya, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogachenkov, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodygin, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ananikov, V. P.</span></span> <span> </span><span class="NLM_article-title">Acetylene in organic synthesis: Recent progress and new uses</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">2442</span>, <span class="refDoi"> DOI: 10.3390/molecules23102442</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.3390%2Fmolecules23102442" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2018&pages=2442&author=V.+V.+Voroninauthor=M.+S.+Ledovskayaauthor=A.+S.+Bogachenkovauthor=K.+S.+Rodyginauthor=V.+P.+Ananikov&title=Acetylene+in+organic+synthesis%3A+Recent+progress+and+new+uses&doi=10.3390%2Fmolecules23102442"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.3390%2Fmolecules23102442&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules23102442%26sid%3Dliteratum%253Aachs%26aulast%3DVoronin%26aufirst%3DV.%2BV.%26aulast%3DLedovskaya%26aufirst%3DM.%2BS.%26aulast%3DBogachenkov%26aufirst%3DA.%2BS.%26aulast%3DRodygin%26aufirst%3DK.%2BS.%26aulast%3DAnanikov%26aufirst%3DV.%2BP.%26atitle%3DAcetylene%2520in%2520organic%2520synthesis%253A%2520Recent%2520progress%2520and%2520new%2520uses%26jtitle%3DMolecules%26date%3D2018%26volume%3D23%26spage%3D2442%26doi%3D10.3390%2Fmolecules23102442" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kolb, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharpless, K. B.</span></span> <span> </span><span class="NLM_article-title">The growing impact of click chemistry on drug discovery</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1128</span>– <span class="NLM_lpage">1137</span>, <span class="refDoi"> DOI: 10.1016/S1359-6446(03)02933-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1016%2FS1359-6446%2803%2902933-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=14678739" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpvVWkuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2003&pages=1128-1137&author=H.+C.+Kolbauthor=K.+B.+Sharpless&title=The+growing+impact+of+click+chemistry+on+drug+discovery&doi=10.1016%2FS1359-6446%2803%2902933-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">The growing impact of click chemistry on drug discovery</span></div><div class="casAuthors">Kolb, Hartmuth C.; Sharpless, K. Barry</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">1128-1137</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Click chem. is a modular approach that uses only the most practical and reliable chem. transformations.  Its applications are increasingly found in all aspects of drug discovery, ranging from lead finding through combinatorial chem. and target-templated in situ chem., to proteomics and DNA research, using bioconjugation reactions.  The copper-(I)-catalyzed 1,2,3-triazole formation from azides and terminal acetylenes is a particularly powerful linking reaction, due to its high degree of dependability, complete specificity, and the bio-compatibility of the reactants.  The triazole products are more than just passive linkers; they readily assoc. with biol. targets, through hydrogen bonding and dipole interactions.  Click chem., a modular approach based on highly reliable chem. transformations, is being applied in all aspects of drug discovery, ranging from lead finding to proteomics and DNA research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqEB1hjIBNhbVg90H21EOLACvtfcHk0lhq6NI5yZf_tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpvVWkuro%253D&md5=f0042f3a8f153d1c1192533d90699d19</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2803%2902933-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252803%252902933-7%26sid%3Dliteratum%253Aachs%26aulast%3DKolb%26aufirst%3DH.%2BC.%26aulast%3DSharpless%26aufirst%3DK.%2BB.%26atitle%3DThe%2520growing%2520impact%2520of%2520click%2520chemistry%2520on%2520drug%2520discovery%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2003%26volume%3D8%26spage%3D1128%26epage%3D1137%26doi%3D10.1016%2FS1359-6446%2803%2902933-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tron, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirali, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billington, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canonico, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorba, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genazzani, A. A.</span></span> <span> </span><span class="NLM_article-title">Click chemistry reactions in medicinal chemistry: applications of the 1,3-dipolar cycloaddition between azides and alkynes</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">278</span>– <span class="NLM_lpage">308</span>, <span class="refDoi"> DOI: 10.1002/med.20107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1002%2Fmed.20107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=17763363" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjsVerurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2008&pages=278-308&author=G.+C.+Tronauthor=T.+Piraliauthor=R.+A.+Billingtonauthor=P.+L.+Canonicoauthor=G.+Sorbaauthor=A.+A.+Genazzani&title=Click+chemistry+reactions+in+medicinal+chemistry%3A+applications+of+the+1%2C3-dipolar+cycloaddition+between+azides+and+alkynes&doi=10.1002%2Fmed.20107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Click chemistry reactions in medicinal chemistry: applications of the 1,3-dipolar cycloaddition between azides and alkynes</span></div><div class="casAuthors">Tron, Gian Cesare; Pirali, Tracey; Billington, Richard A.; Canonico, Pier Luigi; Sorba, Giovanni; Genazzani, Armando A.</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">278-308</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  In recent years, there has been an ever-increasing need for rapid reactions that meet the three main criteria of an ideal synthesis: efficiency, versatility, and selectivity.  Such reactions would allow medicinal chem. to keep pace with the multitude of information derived from modern biol. screening techniques.  The present review describes one of these reactions, the 1,3-dipolar cycloaddn. ("click-reaction") between azides and alkynes catalyzed by copper (I) salts.  The simplicity of this reaction and the ease of purifn. of the resulting products have opened new opportunities in generating vast arrays of compds. with biol. potential.  The present review will outline the accomplishments of this strategy achieved so far and outline some of medicinal chem. applications in which click-chem. might be relevant in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbqDBrdkhYXrVg90H21EOLACvtfcHk0lhq6NI5yZf_tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjsVerurg%253D&md5=ef565fc46c50047a6181e85711cb5c37</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1002%2Fmed.20107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.20107%26sid%3Dliteratum%253Aachs%26aulast%3DTron%26aufirst%3DG.%2BC.%26aulast%3DPirali%26aufirst%3DT.%26aulast%3DBillington%26aufirst%3DR.%2BA.%26aulast%3DCanonico%26aufirst%3DP.%2BL.%26aulast%3DSorba%26aufirst%3DG.%26aulast%3DGenazzani%26aufirst%3DA.%2BA.%26atitle%3DClick%2520chemistry%2520reactions%2520in%2520medicinal%2520chemistry%253A%2520applications%2520of%2520the%25201%252C3-dipolar%2520cycloaddition%2520between%2520azides%2520and%2520alkynes%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2008%26volume%3D28%26spage%3D278%26epage%3D308%26doi%3D10.1002%2Fmed.20107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aneja, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaiken, I.</span></span> <span> </span><span class="NLM_article-title">Click chemistry in peptide-based drug design</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">9797</span>– <span class="NLM_lpage">9817</span>, <span class="refDoi"> DOI: 10.3390/molecules18089797</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.3390%2Fmolecules18089797" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=23959192" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlKlsrbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2013&pages=9797-9817&author=H.+Liauthor=R.+Anejaauthor=I.+Chaiken&title=Click+chemistry+in+peptide-based+drug+design&doi=10.3390%2Fmolecules18089797"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Click chemistry in peptide-based drug design</span></div><div class="casAuthors">Li, Huiyuan; Aneja, Rachna; Chaiken, Irwin</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">9797-9817</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Click chem. is an efficient and chemoselective synthetic method for coupling mol. fragments under mild reaction conditions.  Since the advent in 2001 of methods to improve stereochem. conservation, the click chem. approach has been broadly used to construct diverse chemotypes in both chem. and biol. fields.  In this review, we discuss the application of click chem. in peptide-based drug design.  We highlight how triazoles formed by click reactions have been used for mimicking peptide and disulfide bonds, building secondary structural components of peptides, linking functional groups together, and bioconjugation.  The progress made in this field opens the way for synthetic approaches to convert peptides with promising functional leads into structure-minimized and more stable forms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoo3QhPT6JMbrVg90H21EOLACvtfcHk0lhq6NI5yZf_tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlKlsrbN&md5=cc7cfed7b6249b9ce98a7051def886ee</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.3390%2Fmolecules18089797&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules18089797%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DH.%26aulast%3DAneja%26aufirst%3DR.%26aulast%3DChaiken%26aufirst%3DI.%26atitle%3DClick%2520chemistry%2520in%2520peptide-based%2520drug%2520design%26jtitle%3DMolecules%26date%3D2013%26volume%3D18%26spage%3D9797%26epage%3D9817%26doi%3D10.3390%2Fmolecules18089797" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kolb, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finn, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharpless, K. B.</span></span> <span> </span><span class="NLM_article-title">Click chemistry: Diverse chemical function from a few good reactions</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">2004</span>– <span class="NLM_lpage">2021</span>, <span class="refDoi"> DOI: 10.1002/1521-3773(20010601)40:11<2004::AID-ANIE2004>3.0.CO;2-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1002%2F1521-3773%2820010601%2940%3A11%3C2004%3A%3AAID-ANIE2004%3E3.0.CO%3B2-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=11433435" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD3MXksVOis78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2001&pages=2004-2021&author=H.+C.+Kolbauthor=M.+G.+Finnauthor=K.+B.+Sharpless&title=Click+chemistry%3A+Diverse+chemical+function+from+a+few+good+reactions&doi=10.1002%2F1521-3773%2820010601%2940%3A11%3C2004%3A%3AAID-ANIE2004%3E3.0.CO%3B2-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Click chemistry: diverse chemical function from a few good reactions</span></div><div class="casAuthors">Kolb, Hartmuth C.; Finn, M. G.; Sharpless, K. Barry</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2004-2021</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH</span>)
        </div><div class="casAbstract">Review with > 88 refs.  Examn. of nature's favorite mols. reveals a striking preference for making carbon-heteroatom bonds over carbon-carbon bonds - surely no surprise given that carbon dioxide is nature's starting material and that most reactions are performed in water.  Nucleic acids, proteins, and polysaccharides are condensation polymers of small subunits stitched together by carbon-heteroatom bonds.  Even the 35 or so building blocks from which these crucial mols. are made each contain, at most, six contiguous C-C bonds, except for the three arom. amino acids.  Taking a cue from nature's approach, the development of a set of powerful, highly reliable, and selective reactions for the rapid synthesis of useful new compds. and combinatorial libraries through heteroatom links (C-X-C), an approach called "click chem." is addressed.  Click chem. is at once defined, enabled, and constrained by a handful of nearly perfect "spring-loaded" reactions.  The stringent criteria for a process to earn click chem. status are described along with examples of the mol. frameworks that are easily made using this spartan, but powerful, synthetic strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptrjo9nxXNRrVg90H21EOLACvtfcHk0lic6jRozNWf7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXksVOis78%253D&md5=61c28b416c42c87821bc8a5bc2fdec36</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1002%2F1521-3773%2820010601%2940%3A11%3C2004%3A%3AAID-ANIE2004%3E3.0.CO%3B2-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F1521-3773%252820010601%252940%253A11%253C2004%253A%253AAID-ANIE2004%253E3.0.CO%253B2-5%26sid%3Dliteratum%253Aachs%26aulast%3DKolb%26aufirst%3DH.%2BC.%26aulast%3DFinn%26aufirst%3DM.%2BG.%26aulast%3DSharpless%26aufirst%3DK.%2BB.%26atitle%3DClick%2520chemistry%253A%2520Diverse%2520chemical%2520function%2520from%2520a%2520few%2520good%2520reactions%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2001%26volume%3D40%26spage%3D2004%26epage%3D2021%26doi%3D10.1002%2F1521-3773%2820010601%2940%3A11%3C2004%3A%3AAID-ANIE2004%3E3.0.CO%3B2-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harper, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fullerton, S. E.</span></span> <span> </span><span class="NLM_article-title">Ethynyl and styryl compounds of the prodine type</span>. <i>J. Med. Pharm. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1961</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">297</span>– <span class="NLM_lpage">316</span>, <span class="refDoi"> DOI: 10.1021/jm50018a005</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm50018a005" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADyaF38XitlWk" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=1961&pages=297-316&author=N.+J.+Harperauthor=S.+E.+Fullerton&title=Ethynyl+and+styryl+compounds+of+the+prodine+type&doi=10.1021%2Fjm50018a005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Ethynyl and styryl compounds of the prodine type</span></div><div class="casAuthors">Harper, N. J.; Fullerton, S. E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal & Pharmaceutical Chemistry</span>
        (<span class="NLM_cas:date">1961</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">297-316</span>CODEN:
                <span class="NLM_cas:coden">JMPCAS</span>;
        ISSN:<span class="NLM_cas:issn">0095-9065</span>.
    </div><div class="casAbstract">N-Substituted 4-acetylenic-4-piperidinols and their acyloxy esters were synthesized.  N-Phenethyl-4-phenylethynyl-4-piperidinol was reduced to the 4-styryland 4-phenethyl analogs.  The compds. were assessed for analgesic activity to evaluate the effect of replacing the 4phenyl group in analgesics of the prodine type by an ethynyl or substituted ethynyl group.  The compds. were tested by the hot-plate and tail-pinch methods on mice, and although some of the compds. showed central nervous system activity, it was unlikely that they were true morphine-like analgesics.  Me2CO-free acetylene was bubbled through a suspension of sodamide (from 4.1 g. Na) in 750 ml. liquid NH3 contg. a trace of Fe(NO3)3 4 hrs. at -25°.  A soln. of 30.3 g.  N-phenethyl-4-piperidone in 150 ml. Et2O was added dropwise over 1 hr., the passage of acetylene through the soln. continued 6 hrs. more (with 25 ml. Et2C being added every 2 hrs.), 7.5 g. NH4Cl was added in small portions, followed by 50 ml. concd. NH4OH and 100 g. crushed ice.  The mixt. allowed to stand at room temp. overnight, extd. with 3 150-ml. portions CHCl3, the exts. extd. with 3 100- ml. portions dil. HCl, the acid soln. washed with Et2O, made alk. with NH4OH, extd. with 3 100-ml. portions CHCl3, the combined exts. evapd. to dryness, and the residue recrystd. from C6H6-petr. ether (40:60) gave N-phenethyl-4-ethynyl-4-piperidinol, m. 96.5-7.5°.  Also prepd. were:  N-phenethyl-3-methyl-4-phenylethynyl-4-piperidinol, m. 144.5°; N-methyl-3-methyl-4-phenylethynyl-4-piperidinol, m. 144.5°; N-phenethyl-3-methyl-4-chloro-4-phenylethynylpiperidone-HCl, m. 199°.  A soln. of 3.5 g. N-phenethyl- 4-phenylethynyl-4-piperidinol in 50 ml. tetrahydrofuran was added to a suspension of 0.4 g. LiAlH4 in 77 ml. tetrahydrofuran during 0.5 hr., the mixt. refluxed 3 hrs., cooled, the product decompd. with damp tetrahydrofuran, filtered, evapd., and crystd. from C6H6 to give trans-N-phenethyl-4styryl-4-piperidinol, isomer A, m. 127.5°.  Also prepd. were:  N-phenethyl-3-methyl-4-phenylethynyl-4-piperidinol, m. 111-2°; N-methyl-3-methyl-4-phenylethynyl-4piperidinol, isomer A, m. 159.5°; isomer B, m. 130.5°; N-phenethyl-4-acetoxy-4-phenethylpiperidine-HCl, m. 241°; N-phenethyl-4-styryl-1,2,5,6-tetrahydropyridineHCl, m. 252-4° (decompn.); trans-N-phenethyl-4-acetoxy-4-styrylpiperidine-HCl, isomer A, m. 247.5-9.5°; cis-N-phenethyl-4-acetoxy-4-styrylpiperidine-HCl, isomer B, m. 190.5-1.5°; N-phenethyl-3-methyl-4-piperidone, m. 111-12°; N-phenethyl-4-bromoethynyl-4-piperidinol-HCl, m. 192.5-5.5° (decompn.); N-phenethyl-4-cyano-4-piperidinol, m. 93°; N-phenethyl-4-acetoxy-4-cyanopiperidine-HCl, m. 258.5°; N-phenethyl-4-cyano-4-propionyloxypiperidine-HCl, m. 245°; N-phenethyl-4-carboxy-4-piperidinol-HCl, m. 176.5°.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2x4wtLUaPy7Vg90H21EOLACvtfcHk0lic6jRozNWf7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF38XitlWk&md5=0537af38e9d24425eb6b6eb502b3f953</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fjm50018a005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm50018a005%26sid%3Dliteratum%253Aachs%26aulast%3DHarper%26aufirst%3DN.%2BJ.%26aulast%3DFullerton%26aufirst%3DS.%2BE.%26atitle%3DEthynyl%2520and%2520styryl%2520compounds%2520of%2520the%2520prodine%2520type%26jtitle%3DJ.%2520Med.%2520Pharm.%2520Chem.%26date%3D1961%26volume%3D4%26spage%3D297%26epage%3D316%26doi%3D10.1021%2Fjm50018a005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Easton, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dillard, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henderson, F. G.</span></span> <span> </span><span class="NLM_article-title">Acetylenic amines. III. The haloethynyl derivatives</span>. <i>J. Med. Pharm. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1962</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">780</span>– <span class="NLM_lpage">784</span>, <span class="refDoi"> DOI: 10.1021/jm01239a011</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm01239a011" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADyaF38Xks1ylu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1962&pages=780-784&author=C.+W.+Ryanauthor=N.+R.+Eastonauthor=R.+D.+Dillardauthor=F.+G.+Henderson&title=Acetylenic+amines.+III.+The+haloethynyl+derivatives&doi=10.1021%2Fjm01239a011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Acetylenic amines. III. The haloethynyl derivatives</span></div><div class="casAuthors">Ryan, C. W.; Easton, Nelson E.; Dillard, Robert D.; Henderson, Francis G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal & Pharmaceutical Chemistry</span>
        (<span class="NLM_cas:date">1962</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">780-4</span>CODEN:
                <span class="NLM_cas:coden">JMPCAS</span>;
        ISSN:<span class="NLM_cas:issn">0095-9065</span>.
    </div><div class="casAbstract">A series of 15 haloethynyl analogs of acetylenic amines were prepd.  The bromo compds. were more potent than the chloro compds., and the most potent compd., 3-tert-butylamino-3-methyl-1-bromo-1-butyne-HCl, was about as potent as the nonhalogenated analog in tests on hypertensive rats.  Na (2.5 g.) was added to 300 ml. liquid NH3 contg. a trace of Fe(NO3)3, 13.9 g. 3-(tert-butylamino)-3-methyl-1-butyne was added dropwise, the soln. stirred 1 hr. 250 ml. dry Et2O added, the mixt. warmed to release the NH3, then refluxed 1 hr.  The soln. was cooled, 20 g. p-toluenesulfonyl chloride in 150 ml. dry Et2O added over 5 min., the mixt. refluxed with stirring 2 hrs., allowed to stand overnight, 200 ml. H2O added cautiously, the org. layer sepd., dried, and concd. in vacuo, the residue distd. at 45-50° and 9 mm., and then redistd. to give 7 g. oil, b10 55°, n25D 1.4510.  This oil was mixed with excess HCl-EtOH, and the salt recrystd. from EtOAc to give 3.5 g. 3-(tert-butylamino)-1-chloro-3-methyl1-butyne-HCl.  A soln. of 30 g. 3-ethylamino-3-methyl-1-butyne, 15 g. ethylene oxide, and 500 ml. EtOH was stirred 14 hrs. at room temp., then refluxed 2 hrs., cooled, 10% HCl-EtOH added until acidic to litmus, the solvent removed in vacuo, the residue dissolved in H2O, made alk. to litmus with 50% NaOH, extd. with Et2O, the org. layer sepd., dried and distd. to give 9.5 g. 3-(2-hydroxydiethylamino)-3-methyl-1-butyne, bl0 89-90°, n25D 1.4529.  3-(2-Hydroxydiethylamino)-3-methyl-1-butyne-HCl (38.1 g.) in 100 ml. CHCl3 was mixed with 40 ml. dihydropyran and 5 drops H2SO4, stirred 4 hrs., 100 ml. 20% NaOH added, the org. layer sepd., dried, concd. on a steam bath, and the residue distd. to give 44.2 g. 3-methyl-3-[2-(2-tetrahydropyranoxy)diethylamino]-1-butyne, b1 82°, n25D 1.4652.  Prepd. similarly were: 1-chloro-3-(2-hydroxydiethylamino)3-methyl-1-butyne, b1 73-5°, n25D 1.4793-1.4800; 3-tert-butylamino-3-methyl-1-bromo-1-butyne, m. 41-2°; 1-bromoethynyl-1-(tert-butylamino)cyclohexane-HCl,in. 232-4°.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkm5tOzbQkibVg90H21EOLACvtfcHk0lic6jRozNWf7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF38Xks1ylu7o%253D&md5=9994c910f1e1e9441d0610699e070af7</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Fjm01239a011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm01239a011%26sid%3Dliteratum%253Aachs%26aulast%3DRyan%26aufirst%3DC.%2BW.%26aulast%3DEaston%26aufirst%3DN.%2BR.%26aulast%3DDillard%26aufirst%3DR.%2BD.%26aulast%3DHenderson%26aufirst%3DF.%2BG.%26atitle%3DAcetylenic%2520amines.%2520III.%2520The%2520haloethynyl%2520derivatives%26jtitle%3DJ.%2520Med.%2520Pharm.%2520Chem.%26date%3D1962%26volume%3D5%26spage%3D780%26epage%3D784%26doi%3D10.1021%2Fjm01239a011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neumeyer, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cannon, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckley, J. P.</span></span> <span> </span><span class="NLM_article-title">Synthesis and hypotensive activity of unsymmetrically substituted acetylenic bis-quaternary ammonium compounds and certain of their reduction products</span>. <i>J. Med. Pharm. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1962</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">784</span>– <span class="NLM_lpage">792</span>, <span class="refDoi"> DOI: 10.1021/jm01239a012</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm01239a012" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADyaF38XkslaitLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1962&pages=784-792&author=J.+L.+Neumeyerauthor=J.+G.+Cannonauthor=J.+P.+Buckley&title=Synthesis+and+hypotensive+activity+of+unsymmetrically+substituted+acetylenic+bis-quaternary+ammonium+compounds+and+certain+of+their+reduction+products&doi=10.1021%2Fjm01239a012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and hypotensive activity of unsymmetrically substituted acetylenic bisquaternary ammonium compounds and certain of their reduction products</span></div><div class="casAuthors">Neumeyer, John L.; Cannon, Joseph G.; Buckley, Joseph P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal & Pharmaceutical Chemistry</span>
        (<span class="NLM_cas:date">1962</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">784-92</span>CODEN:
                <span class="NLM_cas:coden">JMPCAS</span>;
        ISSN:<span class="NLM_cas:issn">0095-9065</span>.
    </div><div class="casAbstract">Twelve acetylenic bisquaternary compds. derived from quinoline were prepd. as a part of a structure-activity study of steric requirements for ganglionic blockade.  The compds. were screened for hypotensive activity in anesthetized normotensive rats and dogs, and the results were consistent with Gill's concept of the significance of interquaternary distance in ganglionic blockade (CA 53, 15347c).  Several of the compds. were reduced stereospecifically to the cis- and trans-olefins, and further to alkanes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNDhSydYROMbVg90H21EOLACvtfcHk0lgRhNaZydSikw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF38XkslaitLo%253D&md5=dc147ca2244a39a2d711cb12bcabb058</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Fjm01239a012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm01239a012%26sid%3Dliteratum%253Aachs%26aulast%3DNeumeyer%26aufirst%3DJ.%2BL.%26aulast%3DCannon%26aufirst%3DJ.%2BG.%26aulast%3DBuckley%26aufirst%3DJ.%2BP.%26atitle%3DSynthesis%2520and%2520hypotensive%2520activity%2520of%2520unsymmetrically%2520substituted%2520acetylenic%2520bis-quaternary%2520ammonium%2520compounds%2520and%2520certain%2520of%2520their%2520reduction%2520products%26jtitle%3DJ.%2520Med.%2520Pharm.%2520Chem.%26date%3D1962%26volume%3D5%26spage%3D784%26epage%3D792%26doi%3D10.1021%2Fjm01239a012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerman, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ariëns, E. J.</span></span> <span> </span><span class="NLM_article-title">1-Ethynylphenethylamine1</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1966</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">469</span>– <span class="NLM_lpage">470</span>, <span class="refDoi"> DOI: 10.1021/jm00322a004</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00322a004" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADyaF28Xkt1Snu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1966&pages=469-470&author=A.+Burgerauthor=S.+E.+Zimmermanauthor=E.+J.+Ari%C3%ABns&title=1-Ethynylphenethylamine1&doi=10.1021%2Fjm00322a004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">1-Ethynylphenethylamine</span></div><div class="casAuthors">Burger, Alfred; Zimmerman, Stuart E.; Ariens, E. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1966</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">469-70</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">The synthesis of 1-ethynylphenethylamine (I) is described.  I appears to protect phenethylamine from biol. deamination and reveals its central nervous system activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxFHzvdMquErVg90H21EOLACvtfcHk0lgRhNaZydSikw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF28Xkt1Snu7s%253D&md5=8537b90608dcf466d933145671a4cb31</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fjm00322a004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00322a004%26sid%3Dliteratum%253Aachs%26aulast%3DBurger%26aufirst%3DA.%26aulast%3DZimmerman%26aufirst%3DS.%2BE.%26aulast%3DAri%25C3%25ABns%26aufirst%3DE.%2BJ.%26atitle%3D1-Ethynylphenethylamine1%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1966%26volume%3D9%26spage%3D469%26epage%3D470%26doi%3D10.1021%2Fjm00322a004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Christiansen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urban, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merten, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liebscher, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlsen, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamacher, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spinrath, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bond, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewke, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ullrich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kassack, M. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kostenis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulven, T.</span></span> <span> </span><span class="NLM_article-title">Discovery of potent and selective agonists for the free fatty acid receptor 1 (FFA(1)/GPR40), a potential target for the treatment of type II diabetes</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">7061</span>– <span class="NLM_lpage">7064</span>, <span class="refDoi"> DOI: 10.1021/jm8010178</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm8010178" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht12qt73J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=7061-7064&author=E.+Christiansenauthor=C.+Urbanauthor=N.+Mertenauthor=K.+Liebscherauthor=K.+K.+Karlsenauthor=A.+Hamacherauthor=A.+Spinrathauthor=A.+D.+Bondauthor=C.+Drewkeauthor=S.+Ullrichauthor=M.+U.+Kassackauthor=E.+Kostenisauthor=T.+Ulven&title=Discovery+of+potent+and+selective+agonists+for+the+free+fatty+acid+receptor+1+%28FFA%281%29%2FGPR40%29%2C+a+potential+target+for+the+treatment+of+type+II+diabetes&doi=10.1021%2Fjm8010178"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Potent and Selective Agonists for the Free Fatty Acid Receptor 1 (FFA1/GPR40), a Potential Target for the Treatment of Type II Diabetes</span></div><div class="casAuthors">Christiansen, Elisabeth; Urban, Christian; Merten, Nicole; Liebscher, Kathrin; Karlsen, Kasper K.; Hamacher, Alexandra; Spinrath, Andreas; Bond, Andrew D.; Drewke, Christel; Ullrich, Susanne; Kassack, Matthias U.; Kostenis, Evi; Ulven, Trond</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">7061-7064</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of 4-phenethynyldihydrocinnamic acid agonists of the free fatty acid receptor 1 (FFA1) has been discovered and explored.  The preferred compd. 20 (TUG-424, EC50 = 32 nM) significantly increased glucose-stimulated insulin secretion at 100 nM and may serve to explore the role of FFA1 in metabolic diseases such as diabetes or obesity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBq5qOnlccv7Vg90H21EOLACvtfcHk0lgRhNaZydSikw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht12qt73J&md5=b097bb659bc0b5adbbd6c8757f820214</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fjm8010178&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8010178%26sid%3Dliteratum%253Aachs%26aulast%3DChristiansen%26aufirst%3DE.%26aulast%3DUrban%26aufirst%3DC.%26aulast%3DMerten%26aufirst%3DN.%26aulast%3DLiebscher%26aufirst%3DK.%26aulast%3DKarlsen%26aufirst%3DK.%2BK.%26aulast%3DHamacher%26aufirst%3DA.%26aulast%3DSpinrath%26aufirst%3DA.%26aulast%3DBond%26aufirst%3DA.%2BD.%26aulast%3DDrewke%26aufirst%3DC.%26aulast%3DUllrich%26aufirst%3DS.%26aulast%3DKassack%26aufirst%3DM.%2BU.%26aulast%3DKostenis%26aufirst%3DE.%26aulast%3DUlven%26aufirst%3DT.%26atitle%3DDiscovery%2520of%2520potent%2520and%2520selective%2520agonists%2520for%2520the%2520free%2520fatty%2520acid%2520receptor%25201%2520%2528FFA%25281%2529%252FGPR40%2529%252C%2520a%2520potential%2520target%2520for%2520the%2520treatment%2520of%2520type%2520II%2520diabetes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D7061%26epage%3D7064%26doi%3D10.1021%2Fjm8010178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Christiansen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urban, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grundmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Due-Hansen, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagesaether, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ullrich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kostenis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kassack, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulven, T.</span></span> <span> </span><span class="NLM_article-title">Identification of a potent and selective free fatty acid receptor 1 (FFA1/GPR40) agonist with favorable physicochemical and in vitro ADME properties</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">6691</span>– <span class="NLM_lpage">6703</span>, <span class="refDoi"> DOI: 10.1021/jm2005699</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2005699" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFKrs7%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6691-6703&author=E.+Christiansenauthor=C.+Urbanauthor=M.+Grundmannauthor=M.+E.+Due-Hansenauthor=E.+Hagesaetherauthor=J.+Schmidtauthor=L.+Pardoauthor=S.+Ullrichauthor=E.+Kostenisauthor=M.+Kassackauthor=T.+Ulven&title=Identification+of+a+potent+and+selective+free+fatty+acid+receptor+1+%28FFA1%2FGPR40%29+agonist+with+favorable+physicochemical+and+in+vitro+ADME+properties&doi=10.1021%2Fjm2005699"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a Potent and Selective Free Fatty Acid Receptor 1 (FFA1/GPR40) Agonist with Favorable Physicochemical and in Vitro ADME Properties</span></div><div class="casAuthors">Christiansen, Elisabeth; Urban, Christian; Grundmann, Manuel; Due-Hansen, Maria E.; Hagesaether, Ellen; Schmidt, Johannes; Pardo, Leonardo; Ullrich, Susanne; Kostenis, Evi; Kassack, Matthias; Ulven, Trond</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">6691-6703</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The free fatty acid receptor 1 (FFA1, also known as GPR40) enhances glucose-stimulated insulin secretion from pancreatic β-cells and is recognized as an interesting new target for treatment of type 2 diabetes.  Several series of selective FFA1 agonists are already known.  Most of these are derived from free fatty acids (FFAs) or glitazones and are relatively lipophilic.  Aiming for the development of potent, selective, and less lipophilic FFA1 agonists, the terminal Ph of a known compd. series was replaced by nitrogen contg. heterocycles.  This resulted in the identification of 37, a selective FFA1 agonist with potent activity on recombinant human FFA1 receptors and on the rat insulinoma cell line INS-1E, optimal lipophilicity, and excellent in vitro permeability and metabolic stability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojEP11kF9rsLVg90H21EOLACvtfcHk0lgRhNaZydSikw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFKrs7%252FE&md5=e21df7c246c56e61708c3937c272350e</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm2005699&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2005699%26sid%3Dliteratum%253Aachs%26aulast%3DChristiansen%26aufirst%3DE.%26aulast%3DUrban%26aufirst%3DC.%26aulast%3DGrundmann%26aufirst%3DM.%26aulast%3DDue-Hansen%26aufirst%3DM.%2BE.%26aulast%3DHagesaether%26aufirst%3DE.%26aulast%3DSchmidt%26aufirst%3DJ.%26aulast%3DPardo%26aufirst%3DL.%26aulast%3DUllrich%26aufirst%3DS.%26aulast%3DKostenis%26aufirst%3DE.%26aulast%3DKassack%26aufirst%3DM.%26aulast%3DUlven%26aufirst%3DT.%26atitle%3DIdentification%2520of%2520a%2520potent%2520and%2520selective%2520free%2520fatty%2520acid%2520receptor%25201%2520%2528FFA1%252FGPR40%2529%2520agonist%2520with%2520favorable%2520physicochemical%2520and%2520in%2520vitro%2520ADME%2520properties%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6691%26epage%3D6703%26doi%3D10.1021%2Fjm2005699" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christiansen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urban, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudson, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stocker, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Due-Hansen, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wargent, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimpukade, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almeida, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ejsing, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cawthorne, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kassack, M. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milligan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulven, T.</span></span> <span> </span><span class="NLM_article-title">Discovery of a potent free fatty acid 1 receptor agonist with low lipophilicity, low polar surface area, and robust in vivo efficacy</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">2841</span>– <span class="NLM_lpage">2846</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01962</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01962" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC28XjsFaqsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=2841-2846&author=S.+V.+Hansenauthor=E.+Christiansenauthor=C.+Urbanauthor=B.+D.+Hudsonauthor=C.+J.+Stockerauthor=M.+E.+Due-Hansenauthor=E.+T.+Wargentauthor=B.+Shimpukadeauthor=R.+Almeidaauthor=C.+S.+Ejsingauthor=M.+A.+Cawthorneauthor=M.+U.+Kassackauthor=G.+Milliganauthor=T.+Ulven&title=Discovery+of+a+potent+free+fatty+acid+1+receptor+agonist+with+low+lipophilicity%2C+low+polar+surface+area%2C+and+robust+in+vivo+efficacy&doi=10.1021%2Facs.jmedchem.5b01962"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent Free Fatty Acid 1 Receptor Agonist with Low Lipophilicity, Low Polar Surface Area, and Robust in Vivo Efficacy</span></div><div class="casAuthors">Hansen, Steffen V. F.; Christiansen, Elisabeth; Urban, Christian; Hudson, Brian D.; Stocker, Claire J.; Due-Hansen, Maria E.; Wargent, Ed T.; Shimpukade, Bharat; Almeida, Reinaldo; Ejsing, Christer S.; Cawthorne, Michael A.; Kassack, Matthias U.; Milligan, Graeme; Ulven, Trond</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2841-2846</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The free fatty acid receptor 1 (FFA1 or GPR40) is established as an interesting potential target for treatment of type 2 diabetes.  However, to obtain optimal ligands, it may be necessary to limit both lipophilicity and polar surface area, translating to a need for small compds.  We here describe the identification of 24, a potent FFA1 agonist with low lipophilicity and very high ligand efficiency that exhibit robust glucose lowering effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzSC_3c__9I7Vg90H21EOLACvtfcHk0liPz_fMjmHyhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjsFaqsLg%253D&md5=fd45247c6b2bb272cc23b84cb97391d9</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01962&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01962%26sid%3Dliteratum%253Aachs%26aulast%3DHansen%26aufirst%3DS.%2BV.%26aulast%3DChristiansen%26aufirst%3DE.%26aulast%3DUrban%26aufirst%3DC.%26aulast%3DHudson%26aufirst%3DB.%2BD.%26aulast%3DStocker%26aufirst%3DC.%2BJ.%26aulast%3DDue-Hansen%26aufirst%3DM.%2BE.%26aulast%3DWargent%26aufirst%3DE.%2BT.%26aulast%3DShimpukade%26aufirst%3DB.%26aulast%3DAlmeida%26aufirst%3DR.%26aulast%3DEjsing%26aufirst%3DC.%2BS.%26aulast%3DCawthorne%26aufirst%3DM.%2BA.%26aulast%3DKassack%26aufirst%3DM.%2BU.%26aulast%3DMilligan%26aufirst%3DG.%26aulast%3DUlven%26aufirst%3DT.%26atitle%3DDiscovery%2520of%2520a%2520potent%2520free%2520fatty%2520acid%25201%2520receptor%2520agonist%2520with%2520low%2520lipophilicity%252C%2520low%2520polar%2520surface%2520area%252C%2520and%2520robust%2520in%2520vivo%2520efficacy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D2841%26epage%3D2846%26doi%3D10.1021%2Facs.jmedchem.5b01962" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vranesic, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ofner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flor, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bilbe, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouhelal, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desrayaud, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McAllister, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhn, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasparini, F.</span></span> <span> </span><span class="NLM_article-title">AFQ056/mavoglurant, a novel clinically effective mGluR5 antagonist: identification, SAR and pharmacological characterization</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">5790</span>– <span class="NLM_lpage">5803</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2014.09.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1016%2Fj.bmc.2014.09.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=25316499" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslGns7bJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=5790-5803&author=I.+Vranesicauthor=S.+Ofnerauthor=P.+J.+Florauthor=G.+Bilbeauthor=R.+Bouhelalauthor=A.+Enzauthor=S.+Desrayaudauthor=K.+McAllisterauthor=R.+Kuhnauthor=F.+Gasparini&title=AFQ056%2Fmavoglurant%2C+a+novel+clinically+effective+mGluR5+antagonist%3A+identification%2C+SAR+and+pharmacological+characterization&doi=10.1016%2Fj.bmc.2014.09.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">AFQ056/mavoglurant, a novel clinically effective mGluR5 antagonist: Identification, SAR and pharmacological characterization</span></div><div class="casAuthors">Vranesic, Ivo; Ofner, Silvio; Flor, Peter Josef; Bilbe, Graeme; Bouhelal, Rochdi; Enz, Albert; Desrayaud, Sandrine; McAllister, Kevin; Kuhn, Rainer; Gasparini, Fabrizio</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5790-5803</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Here we describe the identification, structure-activity relation and the initial pharmacol. characterization of AFQ056/mavoglurant, a structurally novel, non-competitive mGlu5 receptor antagonist.  AFQ056/mavoglurant was identified by chem. derivatization of a lead compd. discovered in a HTS campaign.  In vitro, AFQ056/mavoglurant had an IC50 of 30 nM in a functional assay with human mGluR5 and was selective over the other mGluR subtypes, iGluRs and a panel of 238 CNS relevant receptors, transporter or enzymes.  In vivo, AFQ056/mavoglurant showed an improved pharmacokinetic profile in rat and efficacy in the stress-induced hyperthermia test in mice as compared to the prototypic mGluR5 antagonist MPEP.  The efficacy of AFQ056/mavoglurant in humans has been assessed in L-dopa induced dyskinesia in Parkinson's disease and Fragile X syndrome in proof of principle clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomfnTAWNW_RbVg90H21EOLACvtfcHk0liPz_fMjmHyhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslGns7bJ&md5=a34ab6585a186730f2fbf09d8c97180c</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2014.09.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2014.09.033%26sid%3Dliteratum%253Aachs%26aulast%3DVranesic%26aufirst%3DI.%26aulast%3DOfner%26aufirst%3DS.%26aulast%3DFlor%26aufirst%3DP.%2BJ.%26aulast%3DBilbe%26aufirst%3DG.%26aulast%3DBouhelal%26aufirst%3DR.%26aulast%3DEnz%26aufirst%3DA.%26aulast%3DDesrayaud%26aufirst%3DS.%26aulast%3DMcAllister%26aufirst%3DK.%26aulast%3DKuhn%26aufirst%3DR.%26aulast%3DGasparini%26aufirst%3DF.%26atitle%3DAFQ056%252Fmavoglurant%252C%2520a%2520novel%2520clinically%2520effective%2520mGluR5%2520antagonist%253A%2520identification%252C%2520SAR%2520and%2520pharmacological%2520characterization%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2014%26volume%3D22%26spage%3D5790%26epage%3D5803%26doi%3D10.1016%2Fj.bmc.2014.09.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balakrishnan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sivarao, D. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Easton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulianello, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanumegowda, U. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matchett, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattson, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santone, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senapati, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shields, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simutis, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westphal, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whiterock, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bronson, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macor, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degnan, A. P.</span></span> <span> </span><span class="NLM_article-title">Discovery and preclinical evaluation of BMS-955829, a potent positive allosteric modulator of mGluR5</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">289</span>– <span class="NLM_lpage">293</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00450</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00450" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVaqsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=289-293&author=F.+Yangauthor=L.+B.+Snyderauthor=A.+Balakrishnanauthor=J.+M.+Brownauthor=D.+V.+Sivaraoauthor=A.+Eastonauthor=A.+Fernandesauthor=M.+Gulianelloauthor=U.+M.+Hanumegowdaauthor=H.+Huangauthor=Y.+Huangauthor=K.+M.+Jonesauthor=Y.+W.+Liauthor=M.+Matchettauthor=G.+Mattsonauthor=R.+Millerauthor=K.+S.+Santoneauthor=A.+Senapatiauthor=E.+E.+Shieldsauthor=F.+J.+Simutisauthor=R.+Westphalauthor=V.+J.+Whiterockauthor=J.+J.+Bronsonauthor=J.+E.+Macorauthor=A.+P.+Degnan&title=Discovery+and+preclinical+evaluation+of+BMS-955829%2C+a+potent+positive+allosteric+modulator+of+mGluR5&doi=10.1021%2Facsmedchemlett.5b00450"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Preclinical Evaluation of BMS-955829, a Potent Positive Allosteric Modulator of mGluR5</span></div><div class="casAuthors">Yang, Fukang; Snyder, Lawrence B.; Balakrishnan, Anand; Brown, Jeffrey M.; Sivarao, Digavalli V.; Easton, Amy; Fernandes, Alda; Gulianello, Michael; Hanumegowda, Umesh M.; Huang, Hong; Huang, Yanling; Jones, Kelli M.; Li, Yu-Wen; Matchett, Michele; Mattson, Gail; Miller, Regina; Santone, Kenneth S.; Senapati, Arun; Shields, Eric E.; Simutis, Frank J.; Westphal, Ryan; Whiterock, Valerie J.; Bronson, Joanne J.; Macor, John E.; Degnan, Andrew P.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">289-293</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Pos. allosteric modulators (PAMs) of the metabotropic glutamate receptor subtype 5 (mGluR5) are of interest due to their potential therapeutic utility in schizophrenia and other cognitive disorders.  Herein we describe the discovery and optimization of a novel oxazolidinone-based chemotype to identify BMS-955829 (4), a compd. with high functional PAM potency, excellent mGluR5 binding affinity, low glutamate fold shift, and high selectivity for the mGluR5 subtype.  The low fold shift and absence of agonist activity proved crit. in the identification of a mol. with an acceptable preclin. safety profile.  Despite its low fold shift, 4 retained efficacy in set shifting and novel object recognition models in rodents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeCsDWyDOvK7Vg90H21EOLACvtfcHk0lhsURQnmobQgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVaqsA%253D%253D&md5=07f54ebf4e79aa16bd51823b81897975</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00450&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00450%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DF.%26aulast%3DSnyder%26aufirst%3DL.%2BB.%26aulast%3DBalakrishnan%26aufirst%3DA.%26aulast%3DBrown%26aufirst%3DJ.%2BM.%26aulast%3DSivarao%26aufirst%3DD.%2BV.%26aulast%3DEaston%26aufirst%3DA.%26aulast%3DFernandes%26aufirst%3DA.%26aulast%3DGulianello%26aufirst%3DM.%26aulast%3DHanumegowda%26aufirst%3DU.%2BM.%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DJones%26aufirst%3DK.%2BM.%26aulast%3DLi%26aufirst%3DY.%2BW.%26aulast%3DMatchett%26aufirst%3DM.%26aulast%3DMattson%26aufirst%3DG.%26aulast%3DMiller%26aufirst%3DR.%26aulast%3DSantone%26aufirst%3DK.%2BS.%26aulast%3DSenapati%26aufirst%3DA.%26aulast%3DShields%26aufirst%3DE.%2BE.%26aulast%3DSimutis%26aufirst%3DF.%2BJ.%26aulast%3DWestphal%26aufirst%3DR.%26aulast%3DWhiterock%26aufirst%3DV.%2BJ.%26aulast%3DBronson%26aufirst%3DJ.%2BJ.%26aulast%3DMacor%26aufirst%3DJ.%2BE.%26aulast%3DDegnan%26aufirst%3DA.%2BP.%26atitle%3DDiscovery%2520and%2520preclinical%2520evaluation%2520of%2520BMS-955829%252C%2520a%2520potent%2520positive%2520allosteric%2520modulator%2520of%2520mGluR5%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D289%26epage%3D293%26doi%3D10.1021%2Facsmedchemlett.5b00450" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Turlington, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noetzel, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chun, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gogliotti, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregory, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinson, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rook, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gogi, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bridges, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniels, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niswender, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meiler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conn, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindsley, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stauffer, S. R.</span></span> <span> </span><span class="NLM_article-title">Exploration of allosteric agonism structure-activity relationships within an acetylene series of metabotropic glutamate receptor 5 (mGlu5) positive allosteric modulators (PAMs): discovery of 5-((3-fluorophenyl)ethynyl)-N-(3-methyloxetan-3-yl)picolinamide (ML254)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">7976</span>– <span class="NLM_lpage">7996</span>, <span class="refDoi"> DOI: 10.1021/jm401028t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401028t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVynsr7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=7976-7996&author=M.+Turlingtonauthor=M.+J.+Noetzelauthor=A.+Chunauthor=Y.+Zhouauthor=R.+D.+Gogliottiauthor=E.+D.+Nguyenauthor=K.+J.+Gregoryauthor=P.+N.+Vinsonauthor=J.+M.+Rookauthor=K.+K.+Gogiauthor=Z.+Xiangauthor=T.+M.+Bridgesauthor=J.+S.+Danielsauthor=C.+Jonesauthor=C.+M.+Niswenderauthor=J.+Meilerauthor=P.+J.+Connauthor=C.+W.+Lindsleyauthor=S.+R.+Stauffer&title=Exploration+of+allosteric+agonism+structure-activity+relationships+within+an+acetylene+series+of+metabotropic+glutamate+receptor+5+%28mGlu5%29+positive+allosteric+modulators+%28PAMs%29%3A+discovery+of+5-%28%283-fluorophenyl%29ethynyl%29-N-%283-methyloxetan-3-yl%29picolinamide+%28ML254%29&doi=10.1021%2Fjm401028t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Exploration of Allosteric Agonism Structure-Activity Relationships within an Acetylene Series of Metabotropic Glutamate Receptor 5 (mGlu5) Positive Allosteric Modulators (PAMs): Discovery of 5((3-Fluorophenyl)ethynyl)N(3-methyloxetan-3-yl)picolinamide (ML254)</span></div><div class="casAuthors">Turlington, Mark; Noetzel, Meredith J.; Chun, Aspen; Zhou, Ya; Gogliotti, Rocco D.; Nguyen, Elizabeth D.; Gregory, Karen J.; Vinson, Paige N.; Rook, Jerri M.; Gogi, Kiran K.; Xiang, Zixiu; Bridges, Thomas M.; Daniels, J. Scott; Jones, Carrie; Niswender, Colleen M.; Meiler, Jens; Conn, P. Jeffrey; Lindsley, Craig W.; Stauffer, Shaun R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7976-7996</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Pos. allosteric modulators (PAMs) of metabotropic glutamate receptor 5 (mGlu5) represent a promising therapeutic strategy for the treatment of schizophrenia.  Both allosteric agonism and high glutamate fold-shift have been implicated in the neurotoxic profile of some mGlu5 PAMs; however, these hypotheses remain to be adequately addressed.  To develop tool compds. to probe these hypotheses, the structure-activity relationship of allosteric agonism was examd. within an acetylenic series of mGlu5 PAMs exhibiting allosteric agonism in addn. to pos. allosteric modulation (ago-PAMs).  PAM 38t, a low glutamate fold-shift allosteric ligand (max. fold-shift ∼3.0), was selected as a potent PAM with no agonism in the in vitro system used for compd. characterization and in two native electrophysiol. systems using rat hippocampal slices.  PAM 38t (ML254) will be useful to probe the relative contribution of cooperativity and allosteric agonism to the adverse effect liability and neurotoxicity assocd. with this class of mGlu5 PAMs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnDUnm1DOpl7Vg90H21EOLACvtfcHk0lhsURQnmobQgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVynsr7K&md5=6cde52e3bce520515109ee638054230a</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjm401028t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401028t%26sid%3Dliteratum%253Aachs%26aulast%3DTurlington%26aufirst%3DM.%26aulast%3DNoetzel%26aufirst%3DM.%2BJ.%26aulast%3DChun%26aufirst%3DA.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DGogliotti%26aufirst%3DR.%2BD.%26aulast%3DNguyen%26aufirst%3DE.%2BD.%26aulast%3DGregory%26aufirst%3DK.%2BJ.%26aulast%3DVinson%26aufirst%3DP.%2BN.%26aulast%3DRook%26aufirst%3DJ.%2BM.%26aulast%3DGogi%26aufirst%3DK.%2BK.%26aulast%3DXiang%26aufirst%3DZ.%26aulast%3DBridges%26aufirst%3DT.%2BM.%26aulast%3DDaniels%26aufirst%3DJ.%2BS.%26aulast%3DJones%26aufirst%3DC.%26aulast%3DNiswender%26aufirst%3DC.%2BM.%26aulast%3DMeiler%26aufirst%3DJ.%26aulast%3DConn%26aufirst%3DP.%2BJ.%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26aulast%3DStauffer%26aufirst%3DS.%2BR.%26atitle%3DExploration%2520of%2520allosteric%2520agonism%2520structure-activity%2520relationships%2520within%2520an%2520acetylene%2520series%2520of%2520metabotropic%2520glutamate%2520receptor%25205%2520%2528mGlu5%2529%2520positive%2520allosteric%2520modulators%2520%2528PAMs%2529%253A%2520discovery%2520of%25205-%2528%25283-fluorophenyl%2529ethynyl%2529-N-%25283-methyloxetan-3-yl%2529picolinamide%2520%2528ML254%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D7976%26epage%3D7996%26doi%3D10.1021%2Fjm401028t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guengerich, F. P.</span></span> <span> </span><span class="NLM_article-title">Oxidation of 17 alpha-ethynylestradiol by human liver cytochrome P-450</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">500</span>– <span class="NLM_lpage">508</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=3285175" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADyaL1cXktFOitLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=1988&pages=500-508&author=F.+P.+Guengerich&title=Oxidation+of+17+alpha-ethynylestradiol+by+human+liver+cytochrome+P-450"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Oxidation of 17α-ethynylestradiol by human liver cytochrome P-450</span></div><div class="casAuthors">Guengerich, F. Peter</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">500-8</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    </div><div class="casAbstract">Previous work had demonstrated increased metab. (2-hydroxylation) of 17α-ethynylestradiol in individuals using rifampicin.  Evidence is presented for the involvement of a specific form of human cytochrome P 450, termed P-450NF, in this phenomenon.  Although purified P-450NF has only relatively low catalytic 17α-ethynylestradiol 2-hydroxylase activity, antibodies raised to P-450NF specifically inhibited >90% of the activity in liver microsomes which had either high or low catalytic activity.  When different liver samples were compared, rates of microsomal 17α-ethynylestradiol 2-hydroxylation were highly correlated with amts. of immunochem. measured P-450NF or rates of nifedipine oxidn., a characteristic activity of P-450NF.  Prior incubation of human liver microsomes with NADPH and troleandomycin resulted in decreased 17α-ethynylestradiol 2-hydroxylation.  In addn., 17α-ethynylestradiol appears to be a mechanism-based inhibitor in human liver microsomes, as shown by the loss of both spectrally detectable cytochrome P 450 and 17α-ethynylestradiol 2-hydroxylase activity during incubation in the presence of NADPH.  Addnl. expts. did not show any evidence for the involvement of a no. of other human cytochrome P 450 enzymes in 17α-ethynylestradiol 2-hydroxylation (i.e., P-450DB, P-450PA, P-450MP, P-450j).  Apparently, P-450NF is the major enzyme involved in 17α-ethynylestradiol oxidn. and drugs and hormones which influence the expression and activity of this enzyme can influence the efficacy and side effects of this compd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLHe0Mmm83l7Vg90H21EOLACvtfcHk0lhsURQnmobQgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXktFOitLY%253D&md5=f46c7608ed02490b5779a0bfbd0669a1</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGuengerich%26aufirst%3DF.%2BP.%26atitle%3DOxidation%2520of%252017%2520alpha-ethynylestradiol%2520by%2520human%2520liver%2520cytochrome%2520P-450%26jtitle%3DMol.%2520Pharmacol.%26date%3D1988%26volume%3D33%26spage%3D500%26epage%3D508" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">White, I. N.</span></span> <span> </span><span class="NLM_article-title">Metabolic activation of acetylenic substituents to derivatives in the rat causing the loss of hepatic cytochrome P-450 and haem</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">1978</span>,  <span class="NLM_volume"><i>174</i></span>,  <span class="NLM_fpage">853</span>– <span class="NLM_lpage">861</span>, <span class="refDoi"> DOI: 10.1042/bj1740853</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1042%2Fbj1740853" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=728091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADyaE1MXhvVSlsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=174&publication_year=1978&pages=853-861&author=I.+N.+White&title=Metabolic+activation+of+acetylenic+substituents+to+derivatives+in+the+rat+causing+the+loss+of+hepatic+cytochrome+P-450+and+haem&doi=10.1042%2Fbj1740853"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic activation of acetylenic substituents to derivatives in the rat causing the loss of hepatic cytochrome P-450 and heme</span></div><div class="casAuthors">White, Ian N. H.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">1978</span>),
    <span class="NLM_cas:volume">174</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">853-61</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    </div><div class="casAbstract">2,2-Dipropargylacetamide  [69977-32-8], danazol  [17230-88-5] in doses of 3.0 μg, and acetylene  [74-86-2] in a 4:1 vol. acetylene/O mixt. when administered to rats in vivo caused decreased concns. of the hepatic microsomal cytochrome P 450  [9035-51-2] and heme  [14875-96-8].  The enzyme responsible for the activation of the acetylenic substituent, and hence loss of P-450 showed characteristics typical of microsomal mixed-function oxidases.  When rats were dosed with 17α-ethynyl-17β-hydroxyandrost-4-en-3-one  [434-03-7] (1 mmol/kg) the pattern of green pigments extd. from the liver 4 h after dosing was different from that in rats given vinyltestosterone  [1235-98-9].  The green pigments extd. from livers of rats 4 h after administration of acetylene-substituted compds. (1 mmol/kg) had variable Rf values on thin-layer chromatog. on silica gel.  The no. and distribution of green pigments was characteristic of each compd. given.  After incubation of acetylene-14C in vitro with microsomal prepns. from phenobarbitone-pretreated rats, and a NADPH-generating system, no significant covalent binding to microsomal protein was detected over 30 min incubation, although under similar conditions, there was significant loss of P 450.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGSWdIZrqzjrVg90H21EOLACvtfcHk0ljs_kPkNdDFOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE1MXhvVSlsrY%253D&md5=e87cb97e88b470440b5bb3b74983f946</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1042%2Fbj1740853&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252Fbj1740853%26sid%3Dliteratum%253Aachs%26aulast%3DWhite%26aufirst%3DI.%2BN.%26atitle%3DMetabolic%2520activation%2520of%2520acetylenic%2520substituents%2520to%2520derivatives%2520in%2520the%2520rat%2520causing%2520the%2520loss%2520of%2520hepatic%2520cytochrome%2520P-450%2520and%2520haem%26jtitle%3DBiochem.%2520J.%26date%3D1978%26volume%3D174%26spage%3D853%26epage%3D861%26doi%3D10.1042%2Fbj1740853" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollenberg, P. F.</span></span> <span> </span><span class="NLM_article-title">Inactivation of cytochrome P4502B1 by the monoamine oxidase inhibitors R-(−)-deprenyl and clorgyline</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">669</span>– <span class="NLM_lpage">675</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=8781784" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADyaK28Xjs1Crt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=1996&pages=669-675&author=U.+Sharmaauthor=E.+S.+Robertsauthor=P.+F.+Hollenberg&title=Inactivation+of+cytochrome+P4502B1+by+the+monoamine+oxidase+inhibitors+R-%28%E2%88%92%29-deprenyl+and+clorgyline"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Inactivation of cytochrome P4502B1 by the monoamine oxidase inhibitors R-(-)-deprenyl and clorgyline</span></div><div class="casAuthors">Sharma, Uma; Roberts, Elizabeth S.; Hollenberg, Paul F.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">669-675</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">The monoamine oxidase inhibitors R-(-)-deprenyl and clorgyline inactivated the 7-ethoxy-4-trifluoromethylcoumarin O-deethylase activity of purified cytochrome P 4502B1 in a reconstituted system contg. P 4502B1, NADPH-cytochrome P 450 oxidoreductase, and L-α-phosphatidylcholine dilauroyl as the lipid.  The inactivation was time- and concn.-dependent.  The inactivation required NADPH, demonstrated satn. kinetics, and no lag time for inactivation was obsd.  The inactivation was not affected by the presence of an excess exogenous nucleophile, such as glutathione.  Deprenyl exhibited a KI (concn. of inactivator required for half-maximal inactivation) of 1.05 μM, and clorgyline had a KI of 1.5 μM.  The max. rate of inactivation of the enzyme at satg. levels of inactivator was 0.23 min-1 for deprenyl and 0.28 min-1 for clorgyline.  The partition ratio for deprenyl and clorgyline was between 2 and 3.  Studies on the isoenzyme specificity of these compds. in microsomes from rats pretreated with specific inducers demonstrate that the inactivation was relatively specific for the major phenobarbital-inducible isoenzyme, P 4502B1, because significant inactivation of P 4501A1 and P 4502E1 was not obsd.  When the purified P 4502B1 in the reconstituted system was incubated with either inactivator in the presence of NADPH, there was approx. a 60-70% loss in spectrally detectable P 450 over 5 min at a 1:21 ratio of P 450 to inactivator.  However, at this ratio of enzyme to inactivator, there was >90% loss of the O-deethylase activity.  This loss in enzyme activity was irreversible, and the protein did not regain activity after dialysis or extensive washing to remove excess inactivator.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYr8hu-oz-C7Vg90H21EOLACvtfcHk0ljs_kPkNdDFOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xjs1Crt7Y%253D&md5=e401e911e5e29cbfdf531e6bdb07776e</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DU.%26aulast%3DRoberts%26aufirst%3DE.%2BS.%26aulast%3DHollenberg%26aufirst%3DP.%2BF.%26atitle%3DInactivation%2520of%2520cytochrome%2520P4502B1%2520by%2520the%2520monoamine%2520oxidase%2520inhibitors%2520R-%2528%25E2%2588%2592%2529-deprenyl%2520and%2520clorgyline%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D1996%26volume%3D24%26spage%3D669%26epage%3D675" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woolf, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollenberg, P. F.</span></span> <span> </span><span class="NLM_article-title">Mechanism-based inactivation of cytochrome P-450–3A4 by mifepristone (RU486)</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>288</i></span>,  <span class="NLM_fpage">791</span>– <span class="NLM_lpage">797</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=9918590" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADyaK1MXpvFOlsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=288&publication_year=1999&pages=791-797&author=K.+Heauthor=T.+F.+Woolfauthor=P.+F.+Hollenberg&title=Mechanism-based+inactivation+of+cytochrome+P-450%E2%80%933A4+by+mifepristone+%28RU486%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism-based inactivation of cytochrome P-450-3A4 by mifepristone (RU486)</span></div><div class="casAuthors">He, Kan; Woolf, Thomas F.; Hollenberg, Paul F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">288</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">791-797</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Mifepristone (RU486), an 11β-substituted nor-steroid contg. a 17α-1-propynyl group used clin. as an antiprogestin agent for medical abortions, was demonstrated to be a selective mechanism-based inactivator of human cytochrome P 450-3A4 (CYP-3A4).  The loss of testosterone 6β-hydroxylation activity was time- and concn.-dependent as well as requiring metab. of mifepristone in a purified CYP-3A4 reconstituted system.  The inactivation exhibited pseudofirst-order kinetics.  The values for KI and kinactivation were 4.7 μM and 0.089 min-1, resp.  The reduced-CO spectrum of CYP-3A4 was decreased by 76%, whereas approx. 81% of the activity was lost following incubation with mifepristone in the reconstituted system in the presence of NADPH.  However, the Soret peak of the inactivated CYP-3A4 was slightly increased.  High-performance liq. chromatog. anal. of the incubation mixt. showed that the peak contg. the heme dissocd. from the inactivated CYP3A4 was almost identical with that seen for the -NADPH control.  Covalent binding of [3H]mifepristone to apoCYP3A4 was demonstrated by SDS-PAGE and high-pressure liq. chromatog. analyses of the reconstituted system contg. CYP-3A4, NADPH-CYP reductase, cytochrome b5 and lipids in the presence of NADPH.  The stoichiometry was detd. to be approx. 1 mol of mifepristone bound per 1 mol of CYP-3A4 inactivated.  Therefore, the mechanism of inactivation of CYP-34A by mifepristone involves irreversible modification of the apoprotein at the enzyme active site instead of being the result of heme adduct formation or heme fragmentation.  Mifepristone exhibits selectivity for CYP-3A4 as evidenced by the fact that it did not show mechanism-based inactivation of CYPs 1A, 2B, 2D6, and 2E1, although a competitive inhibition of CYP 2B1 and 2D6 was obsd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1tJZHJLfOOLVg90H21EOLACvtfcHk0ljs_kPkNdDFOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXpvFOlsA%253D%253D&md5=b445578c15b3828b36da08f32b9fe46c</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DK.%26aulast%3DWoolf%26aufirst%3DT.%2BF.%26aulast%3DHollenberg%26aufirst%3DP.%2BF.%26atitle%3DMechanism-based%2520inactivation%2520of%2520cytochrome%2520P-450%25E2%2580%25933A4%2520by%2520mifepristone%2520%2528RU486%2529%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1999%26volume%3D288%26spage%3D791%26epage%3D797" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chan, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sui, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortiz de Montellano, P. R.</span></span> <span> </span><span class="NLM_article-title">Determinants of protein modification versus heme alkylation: inactivation of cytochrome P450 1A1 by 1-ethynylpyrene and phenylacetylene</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">38</span>– <span class="NLM_lpage">45</span>, <span class="refDoi"> DOI: 10.1021/tx00031a006</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx00031a006" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADyaK3sXltlOhtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1993&pages=38-45&author=W.+K.+Chanauthor=Z.+Suiauthor=P.+R.+Ortiz+de+Montellano&title=Determinants+of+protein+modification+versus+heme+alkylation%3A+inactivation+of+cytochrome+P450+1A1+by+1-ethynylpyrene+and+phenylacetylene&doi=10.1021%2Ftx00031a006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Determinants of protein modification versus heme alkylation:  inactivation of cytochrome P450 1A1 by 1-ethynylpyrene and phenylacetylene</span></div><div class="casAuthors">Chan, William K.; Sui, Zhihua; Ortiz de Montellano, Paul R.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">38-45</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    </div><div class="casAbstract">The authors have investigated the cytochrome P 4501A1-catalyzed oxidn. of 1-ethynylpyrene (1-EP) (I) and phenylacetylene (PA).  Cytochrome P 4501A1 in microsomes from β-naphthoflavone-induced rats is inactivated in a time- and NADPH-dependent manner by 1-EP and PA.  Parallel loss of the heme chromophore is obsd. with PA but not with 1-EP, although partial heme chromophore loss is obsd. when the purified, reconstituted enzyme is inactivated by either agent.  Product anal. shows that 1-EP and PA are oxidized to, resp., (1'-pyrenyl)acetic and phenylacetic acids.  In contrast to the inactivation of cytochrome P 4502B1 by PA, no isotope effect is obsd. on enzyme inactivation or metabolite formation when the acetylenic hydrogen is replaced by deuterium in either 1-EP or PA.  Inactivation of cytochrome P 4501A1 by 1-EP results in covalent binding of 0.8-0.9 equiv (relative to total cytochrome P 450 content) of the inhibitor to the microsomal protein.  The results demonstrate that a single isoenzyme can be inactivated, depending on the structure of the arylacetylene, by heme or protein alkylation.  Spectroscopic binding consts. (Ks) show that 1-EP binds to the enzyme with >2000 times greater affinity that PA.  This large difference in binding affinity is a probable factor in the heme vs. protein specificity of the inactivation reaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwxYo06ht8UbVg90H21EOLACvtfcHk0ljs_kPkNdDFOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXltlOhtw%253D%253D&md5=31bdb5ab23048a75b7feaadb0c03a196</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Ftx00031a006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx00031a006%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DW.%2BK.%26aulast%3DSui%26aufirst%3DZ.%26aulast%3DOrtiz%2Bde%2BMontellano%26aufirst%3DP.%2BR.%26atitle%3DDeterminants%2520of%2520protein%2520modification%2520versus%2520heme%2520alkylation%253A%2520inactivation%2520of%2520cytochrome%2520P450%25201A1%2520by%25201-ethynylpyrene%2520and%2520phenylacetylene%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D1993%26volume%3D6%26spage%3D38%26epage%3D45%26doi%3D10.1021%2Ftx00031a006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhuo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degnan, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shu, Y. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, B. M.</span></span> <span> </span><span class="NLM_article-title">Identification of glutathione conjugates of acetylene-containing positive allosteric modulators of metabotropic glutamate receptor subtype 5</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">578</span>– <span class="NLM_lpage">589</span>, <span class="refDoi"> DOI: 10.1124/dmd.114.061879</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1124%2Fdmd.114.061879" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=25633841" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC2MXkvFSjsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2015&pages=578-589&author=X.+Zhuoauthor=X.+S.+Huangauthor=A.+P.+Degnanauthor=L.+B.+Snyderauthor=F.+Yangauthor=H.+Huangauthor=Y.+Z.+Shuauthor=B.+M.+Johnson&title=Identification+of+glutathione+conjugates+of+acetylene-containing+positive+allosteric+modulators+of+metabotropic+glutamate+receptor+subtype+5&doi=10.1124%2Fdmd.114.061879"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of glutathione conjugates of acetylene-containing positive allosteric modulators of metabotropic glutamate receptor subtype 5</span></div><div class="casAuthors">Zhuo, Xiaoliang; Huang, Xiaohua Stella; Degnan, Andrew P.; Snyder, Lawrence B.; Yang, Fukang; Huang, Hong; Shu, Yue-Zhong; Johnson, Benjamin M.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">578-589</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A recent medicinal chem. campaign to identify pos. allosteric modulators (PAMs) of metabotropic glutamate receptor subtype 5 (mGluR5) led to the discovery of potent compds. featuring an oxazolidinone structural core flanked by biaryl acetylene and haloaryl moieties.  However, biotransformation studies of some of these mGluR5 PAMs demonstrated the formation of glutathione (GSH) conjugates.  The conjugates in question were formed independently of NADPH as the main products in liver microsomes and liver cytosol (rat and human) and exhibited masses that were 307 u greater than their resp. substrates, indicating the involvement of a reductive step in the formation of these metabolites.  To further characterize the relevant metabolic sequences, GSH conjugates of (4R,5R)-5-(3-fluorophenyl)-4-(5-(pyrazin-2-ylethynyl)pyridin-3-yl)oxazolidin-2-one and (4R,5R)-5-(4-fluorophenyl)-4-(6-((3-fluoropyridin-2-yl)ethynyl) pyridin-2-yl)oxazolidin-2-one were biosynthesized and isolated.  Subsequent anal. by NMR showed that GSH had reacted with the acetylene carbon atoms of these mGluR5 PAMs, suggesting a conjugate addn. mechanism and implicating cytosolic and microsomal GSH S-transferases (GSTs) in catalysis.  Interestingly, five closely related mGluR5 PAMs were not similarly prone to the formation of GSH conjugates in vitro.  These compds. also featured acetylenes, but were flanked by either Ph or cyclohexyl rings, which indicated that the formation of GSH conjugates was influenced by proximal functional groups that modulated the electron d. of the triple bond and/or differences in enzyme-substrate specificity.  These results informed an ongoing drug-discovery effort to identify mGluR5 PAMs with drug-like properties and a low risk of reactivity with endogenous thiols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIHBHWhrex97Vg90H21EOLACvtfcHk0lh-xstfMcmF8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXkvFSjsbY%253D&md5=fca55e910eac73eebdf2e67242b13718</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1124%2Fdmd.114.061879&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.114.061879%26sid%3Dliteratum%253Aachs%26aulast%3DZhuo%26aufirst%3DX.%26aulast%3DHuang%26aufirst%3DX.%2BS.%26aulast%3DDegnan%26aufirst%3DA.%2BP.%26aulast%3DSnyder%26aufirst%3DL.%2BB.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DShu%26aufirst%3DY.%2BZ.%26aulast%3DJohnson%26aufirst%3DB.%2BM.%26atitle%3DIdentification%2520of%2520glutathione%2520conjugates%2520of%2520acetylene-containing%2520positive%2520allosteric%2520modulators%2520of%2520metabotropic%2520glutamate%2520receptor%2520subtype%25205%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2015%26volume%3D43%26spage%3D578%26epage%3D589%26doi%3D10.1124%2Fdmd.114.061879" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bouska, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodfellow, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, G. W.</span></span> <span> </span><span class="NLM_article-title">Improving the in vivo duration of 5-lipoxygenase inhibitors: application of an in vitro glucuronosyltransferase assay</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1032</span>– <span class="NLM_lpage">1038</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=9311617" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADyaK2sXmt1Wqsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=1997&pages=1032-1038&author=J.+J.+Bouskaauthor=R.+L.+Bellauthor=C.+L.+Goodfellowauthor=A.+O.+Stewartauthor=C.+D.+Brooksauthor=G.+W.+Carter&title=Improving+the+in+vivo+duration+of+5-lipoxygenase+inhibitors%3A+application+of+an+in+vitro+glucuronosyltransferase+assay"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Improving the in vivo duration of 5-lipoxygenase inhibitors: application of an in vitro glucuronosyltransferase assay</span></div><div class="casAuthors">Bouska, Jennifer J.; Bell, Randy L.; Goodfellow, Carole L.; Stewart, Andrew O.; Brooks, Clint D. W.; Carter, George W.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1032-1038</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">An in vitro glucuronidation assay was used to optimize a series of N-hydroxyurea-contg. 5-lipoxygenase inhibitors for metabolic stability.  The glucuronidation of these compds. in cynomolgus monkey microsomes followed Michaelis-Menten kinetics allowing calcn. of Vmax and KM.  The Vmax values ranged from 0.02 to 7.9 nmol/min/mg microsomal protein, a 400-fold difference, whereas KM ranged from 204 to 2500 μM, only a 12-fold difference.  In vitro intrinsic clearance values (CLint) were calcd. for 18 compds. tested in the kinetic assay and compared with the in vivo plasma clearance (CLp) calcd. from i.v. studies done in cynomolgus monkeys.  These initial results suggested a relation between the in vitro CLint and in vivo duration as defined by CLp.  A more rapid in vitro assay was developed in a 96-well format using a single concn. of substrate (100 μM) from which a glucuronidation rate was calcd.  The results from this assay for 40 compds. correlated with in vivo plasma clearance (r = 0.57).  This more efficient assay was used to test more than 100 compds. and develop structure-metab. relationships based on metabolic stability and improved duration.  The culmination of this effort contributed to the discovery of ABT-761, a 5-lipoxygenase inhibitor with in vivo duration in monkey improved 40-fold over the first generation inhibitor.  Further studies performed in human liver microsomes demonstrated a similar trend that was corroborated by the 8-fold increase in duration after oral dosing in humans obsd. with ABT-761.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKusP0a0dCmbVg90H21EOLACvtfcHk0lh-xstfMcmF8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXmt1Wqsbg%253D&md5=1779014c9842d5927a96e5ea3e4503fb</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBouska%26aufirst%3DJ.%2BJ.%26aulast%3DBell%26aufirst%3DR.%2BL.%26aulast%3DGoodfellow%26aufirst%3DC.%2BL.%26aulast%3DStewart%26aufirst%3DA.%2BO.%26aulast%3DBrooks%26aufirst%3DC.%2BD.%26aulast%3DCarter%26aufirst%3DG.%2BW.%26atitle%3DImproving%2520the%2520in%2520vivo%2520duration%2520of%25205-lipoxygenase%2520inhibitors%253A%2520application%2520of%2520an%2520in%2520vitro%2520glucuronosyltransferase%2520assay%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D1997%26volume%3D25%26spage%3D1032%26epage%3D1038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sonogashira, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tohda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagihara, N.</span></span> <span> </span><span class="NLM_article-title">A convenient synthesis of acetylenes: catalytic substitutions of acetylenic hydrogen with bromoalkenes, iodoarenes and bromopyridines</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">1975</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">4467</span>– <span class="NLM_lpage">4470</span>, <span class="refDoi"> DOI: 10.1016/S0040-4039(00)91094-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1016%2FS0040-4039%2800%2991094-3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1975&pages=4467-4470&author=K.+Sonogashiraauthor=Y.+Tohdaauthor=N.+Hagihara&title=A+convenient+synthesis+of+acetylenes%3A+catalytic+substitutions+of+acetylenic+hydrogen+with+bromoalkenes%2C+iodoarenes+and+bromopyridines&doi=10.1016%2FS0040-4039%2800%2991094-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2FS0040-4039%2800%2991094-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4039%252800%252991094-3%26sid%3Dliteratum%253Aachs%26aulast%3DSonogashira%26aufirst%3DK.%26aulast%3DTohda%26aufirst%3DY.%26aulast%3DHagihara%26aufirst%3DN.%26atitle%3DA%2520convenient%2520synthesis%2520of%2520acetylenes%253A%2520catalytic%2520substitutions%2520of%2520acetylenic%2520hydrogen%2520with%2520bromoalkenes%252C%2520iodoarenes%2520and%2520bromopyridines%26jtitle%3DTetrahedron%2520Lett.%26date%3D1975%26volume%3D16%26spage%3D4467%26epage%3D4470%26doi%3D10.1016%2FS0040-4039%2800%2991094-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hinze, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaffe, H. H.</span></span> <span> </span><span class="NLM_article-title">Electronegativity. I. Orbital electronegativity of neutral atoms</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">1962</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">540</span>– <span class="NLM_lpage">546</span>, <span class="refDoi"> DOI: 10.1021/ja00863a008</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja00863a008" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADyaF38XktF2qtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=1962&pages=540-546&author=J.+Hinzeauthor=H.+H.+Jaffe&title=Electronegativity.+I.+Orbital+electronegativity+of+neutral+atoms&doi=10.1021%2Fja00863a008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Electronegativity. I. Orbital electronegativity of neutral atoms</span></div><div class="casAuthors">Hinze, Juergen; Jaffe, H. H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">1962</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">540-6</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    </div><div class="casAbstract">The electronegativity of atoms is considered to change with the electron configuration found in the mol. environment.  The energy difference (P) between the ground state and various valence stages of atoms in the first 2 periods of the periodic table are calcd. by using a variation of Slater's treatment.  Combination of these energies with the ionization potentials (Ig) and electron affinities (Eg) of the ground state gives the electronegativities of the valence state (v), according to Mulliken's definition X = Iv + Ev, where Iv = Ig + P+ + P0 and Ev = Eg  = P0 - P-.  Both the promotion energies and electronegativities (X) are tabulated and compared with Pauling's electronegativities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQilfyJSUQhLVg90H21EOLACvtfcHk0lh-xstfMcmF8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF38XktF2qtbo%253D&md5=c46b83f7910959d390c0d49d225b61e6</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fja00863a008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja00863a008%26sid%3Dliteratum%253Aachs%26aulast%3DHinze%26aufirst%3DJ.%26aulast%3DJaffe%26aufirst%3DH.%2BH.%26atitle%3DElectronegativity.%2520I.%2520Orbital%2520electronegativity%2520of%2520neutral%2520atoms%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1962%26volume%3D84%26spage%3D540%26epage%3D546%26doi%3D10.1021%2Fja00863a008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Av-Gay, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Everett, M.</span></span> <span> </span><span class="NLM_article-title">The eukaryotic-like Ser/Thr protein kinases of <i>Mycobacterium tuberculosis</i></span>. <i>Trends Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">238</span>– <span class="NLM_lpage">244</span>, <span class="refDoi"> DOI: 10.1016/S0966-842X(00)01734-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1016%2FS0966-842X%2800%2901734-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10785641" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A280%3ADC%252BD3czpt1aitw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2000&pages=238-244&author=Y.+Av-Gayauthor=M.+Everett&title=The+eukaryotic-like+Ser%2FThr+protein+kinases+of+Mycobacterium+tuberculosis&doi=10.1016%2FS0966-842X%2800%2901734-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">The eukaryotic-like Ser/Thr protein kinases of Mycobacterium tuberculosis</span></div><div class="casAuthors">Av-Gay Y; Everett M</div><div class="citationInfo"><span class="NLM_cas:title">Trends in microbiology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">238-44</span>
        ISSN:<span class="NLM_cas:issn">0966-842X</span>.
    </div><div class="casAbstract">In bacteria, extracellular signals are generally transduced into cellular responses via a two-component system.  However, genome sequence data have now revealed the presence of 'eukaryotic-like' protein kinases and phosphatases.  Mycobacterium tuberculosis appears to be unique among bacteria in that its genome contains 11 members of a newly identified protein kinase family.  These M. tuberculosis eukaryotic-like protein kinases could be key regulators of metabolic processes, including transcription, cell development and interactions with host cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTm1x1DQVChQZPlX7E30qdzfW6udTcc2eaiwh3EOtZQ3bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3czpt1aitw%253D%253D&md5=9b872125492821512af6d68cc7c3e56b</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2FS0966-842X%2800%2901734-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0966-842X%252800%252901734-0%26sid%3Dliteratum%253Aachs%26aulast%3DAv-Gay%26aufirst%3DY.%26aulast%3DEverett%26aufirst%3DM.%26atitle%3DThe%2520eukaryotic-like%2520Ser%252FThr%2520protein%2520kinases%2520of%2520Mycobacterium%2520tuberculosis%26jtitle%3DTrends%2520Microbiol.%26date%3D2000%26volume%3D8%26spage%3D238%26epage%3D244%26doi%3D10.1016%2FS0966-842X%2800%2901734-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saint-Joanis, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barilone, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gicquel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alzari, P. M.</span></span> <span> </span><span class="NLM_article-title">The Ser/Thr protein kinase PknB is essential for sustaining mycobacterial growth</span>. <i>J. Bacteriol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>188</i></span>,  <span class="NLM_fpage">7778</span>– <span class="NLM_lpage">7784</span>, <span class="refDoi"> DOI: 10.1128/JB.00963-06</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1128%2FJB.00963-06" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=16980473" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1ahsb%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=188&publication_year=2006&pages=7778-7784&author=P.+Fernandezauthor=B.+Saint-Joanisauthor=N.+Bariloneauthor=M.+Jacksonauthor=B.+Gicquelauthor=S.+T.+Coleauthor=P.+M.+Alzari&title=The+Ser%2FThr+protein+kinase+PknB+is+essential+for+sustaining+mycobacterial+growth&doi=10.1128%2FJB.00963-06"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">The Ser/Thr protein kinase PknB is essential for sustaining mycobacterial growth</span></div><div class="casAuthors">Fernandez, Pablo; Saint-Joanis, Brigitte; Barilone, Nathalie; Jackson, Mary; Gicquel, Brigitte; Cole, Stewart T.; Alzari, Pedro M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Bacteriology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">188</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">7778-7784</span>CODEN:
                <span class="NLM_cas:coden">JOBAAY</span>;
        ISSN:<span class="NLM_cas:issn">0021-9193</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The receptor-like protein kinase PknB from Mycobacterium tuberculosis is encoded by the distal gene in a highly conserved operon, present in all actinobacteria, that may control cell shape and cell division.  Genes coding for a PknB-like protein kinase are also found in many more distantly related gram-pos. bacteria.  Here, we report that the pknB gene can be disrupted by allelic replacement in M. tuberculosis and the saprophyte Mycobacterium smegmatis only in the presence of a second functional copy of the gene.  We also demonstrate that eukaryotic Ser/Thr protein kinase inhibitors, which inactivate PknB in vitro with a 50% inhibitory concn. in the submicromolar range, are able to kill M. tuberculosis H37Rv, M. smegmatis Mc2155, and Mycobacterium aurum A+ with MICs in the micromolar range.  Furthermore, significantly higher concns. of these compds. are required to inhibit growth of M. smegmatis strains overexpressing PknB, suggesting that this protein kinase is the mol. target.  These findings demonstrate that the Ser/Thr protein kinase PknB is essential for sustaining mycobacterial growth and support the development of protein kinase inhibitors as new potential antituberculosis drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpe6ARQk75TCLVg90H21EOLACvtfcHk0liC58jUaMqQcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1ahsb%252FM&md5=83cfb5336c75a7708be9f12420d9ede6</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1128%2FJB.00963-06&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJB.00963-06%26sid%3Dliteratum%253Aachs%26aulast%3DFernandez%26aufirst%3DP.%26aulast%3DSaint-Joanis%26aufirst%3DB.%26aulast%3DBarilone%26aufirst%3DN.%26aulast%3DJackson%26aufirst%3DM.%26aulast%3DGicquel%26aufirst%3DB.%26aulast%3DCole%26aufirst%3DS.%2BT.%26aulast%3DAlzari%26aufirst%3DP.%2BM.%26atitle%3DThe%2520Ser%252FThr%2520protein%2520kinase%2520PknB%2520is%2520essential%2520for%2520sustaining%2520mycobacterial%2520growth%26jtitle%3DJ.%2520Bacteriol.%26date%3D2006%26volume%3D188%26spage%3D7778%26epage%3D7784%26doi%3D10.1128%2FJB.00963-06" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bemis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanzelka, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuccola, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wynn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moody, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locher, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennani, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomson, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muh, U.</span></span> <span> </span><span class="NLM_article-title">Mtb PKNA/PKNB dual inhibition provides selectivity advantages for inhibitor design to minimize host kinase interactions</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1224</span>– <span class="NLM_lpage">1229</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00239</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00239" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVOit7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1224-1229&author=T.+Wangauthor=G.+Bemisauthor=B.+Hanzelkaauthor=H.+Zuccolaauthor=M.+Wynnauthor=C.+S.+Moodyauthor=J.+Greenauthor=C.+Locherauthor=A.+Liuauthor=H.+Gaoauthor=Y.+Xuauthor=S.+Wangauthor=J.+Wangauthor=Y.+L.+Bennaniauthor=J.+A.+Thomsonauthor=U.+Muh&title=Mtb+PKNA%2FPKNB+dual+inhibition+provides+selectivity+advantages+for+inhibitor+design+to+minimize+host+kinase+interactions&doi=10.1021%2Facsmedchemlett.7b00239"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Mtb PKNA/PKNB Dual Inhibition Provides Selectivity Advantages for Inhibitor Design To Minimize Host Kinase Interactions</span></div><div class="casAuthors">Wang, Tiansheng; Bemis, Guy; Hanzelka, Brian; Zuccola, Harmon; Wynn, Michael; Moody, Cameron Stuver; Green, Jeremy; Locher, Christopher; Liu, Aixiang; Gao, Hongwu; Xu, Yuzhou; Wang, Shaohui; Wang, Jie; Bennani, Youssef L.; Thomson, John A.; Muh, Ute</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1224-1229</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Drug resistant tuberculosis (TB) infections are on the rise and antibiotics that inhibit Mycobacterium tuberculosis through a novel mechanism could be an important component of evolving TB therapy.  Protein kinase A (PknA) and protein kinase B (PknB) are both essential serine-threonine kinases in M. tuberculosis.  Given the extensive knowledge base in kinase inhibition, these enzymes present an interesting opportunity for antimycobacterial drug discovery.  This study focused on targeting both PknA and PknB while improving the selectivity window over related mammalian kinases.  Compds. achieved potent inhibition (Ki ≈ 5 nM) of both PknA and PknB.  A binding pocket unique to mycobacterial kinases was identified.  Substitutions that filled this pocket resulted in a 100-fold differential against a broad selection of mammalian kinases.  Reducing lipophilicity improved antimycobacterial activity with the most potent compds. achieving min. inhibitory concns. ranging from 3 to 5 μM (1-2 μg/mL) against the H37Ra isolate of M. tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo14ZnkMwzQ0LVg90H21EOLACvtfcHk0liC58jUaMqQcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVOit7%252FM&md5=aebc570badb168bf80d5b3a921a48847</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00239&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00239%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DT.%26aulast%3DBemis%26aufirst%3DG.%26aulast%3DHanzelka%26aufirst%3DB.%26aulast%3DZuccola%26aufirst%3DH.%26aulast%3DWynn%26aufirst%3DM.%26aulast%3DMoody%26aufirst%3DC.%2BS.%26aulast%3DGreen%26aufirst%3DJ.%26aulast%3DLocher%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DA.%26aulast%3DGao%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DBennani%26aufirst%3DY.%2BL.%26aulast%3DThomson%26aufirst%3DJ.%2BA.%26aulast%3DMuh%26aufirst%3DU.%26atitle%3DMtb%2520PKNA%252FPKNB%2520dual%2520inhibition%2520provides%2520selectivity%2520advantages%2520for%2520inhibitor%2520design%2520to%2520minimize%2520host%2520kinase%2520interactions%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26spage%3D1224%26epage%3D1229%26doi%3D10.1021%2Facsmedchemlett.7b00239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wilcken, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lange, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joerger, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boeckler, F. M.</span></span> <span> </span><span class="NLM_article-title">Principles and applications of halogen bonding in medicinal chemistry and chemical biology</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">1363</span>– <span class="NLM_lpage">1388</span>, <span class="refDoi"> DOI: 10.1021/jm3012068</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3012068" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1GrurfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=1363-1388&author=R.+Wilckenauthor=M.+O.+Zimmermannauthor=A.+Langeauthor=A.+C.+Joergerauthor=F.+M.+Boeckler&title=Principles+and+applications+of+halogen+bonding+in+medicinal+chemistry+and+chemical+biology&doi=10.1021%2Fjm3012068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Principles and Applications of Halogen Bonding in Medicinal Chemistry and Chemical Biology</span></div><div class="casAuthors">Wilcken, Rainer; Zimmermann, Markus O.; Lange, Andreas; Joerger, Andreas C.; Boeckler, Frank M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1363-1388</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Halogen bonding has been known in material science for decades, but until recently, halogen bonds in protein-ligand interactions were largely the result of serendipitous discovery rather than rational design.  In this Perspective, we provide insights into the phenomenon of halogen bonding, with special focus on its role in drug discovery.  We summarize the theor. background defining its strength and directionality, provide a systematic anal. of its occurrence and interaction geometries in protein-ligand complexes, and give recent examples where halogen bonding has been successfully harnessed for lead identification and optimization.  In light of these data, we discuss the potential and limitations of exploiting halogen bonds for mol. recognition and rational drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjholHfNZ9kbVg90H21EOLACvtfcHk0lgJqmyqXeByiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1GrurfJ&md5=81ba024e4427fac3e7af0a4cd330909c</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fjm3012068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3012068%26sid%3Dliteratum%253Aachs%26aulast%3DWilcken%26aufirst%3DR.%26aulast%3DZimmermann%26aufirst%3DM.%2BO.%26aulast%3DLange%26aufirst%3DA.%26aulast%3DJoerger%26aufirst%3DA.%2BC.%26aulast%3DBoeckler%26aufirst%3DF.%2BM.%26atitle%3DPrinciples%2520and%2520applications%2520of%2520halogen%2520bonding%2520in%2520medicinal%2520chemistry%2520and%2520chemical%2520biology%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D1363%26epage%3D1388%26doi%3D10.1021%2Fjm3012068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boggon, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greulich, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span> <span> </span><span class="NLM_article-title">Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">217</span>– <span class="NLM_lpage">227</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2006.12.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1016%2Fj.ccr.2006.12.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=17349580" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjsVymtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2007&pages=217-227&author=C.+H.+Yunauthor=T.+J.+Boggonauthor=Y.+Liauthor=M.+S.+Wooauthor=H.+Greulichauthor=M.+Meyersonauthor=M.+J.+Eck&title=Structures+of+lung+cancer-derived+EGFR+mutants+and+inhibitor+complexes%3A+mechanism+of+activation+and+insights+into+differential+inhibitor+sensitivity&doi=10.1016%2Fj.ccr.2006.12.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity</span></div><div class="casAuthors">Yun, Cai-Hong; Boggon, Titus J.; Li, Yiqun; Woo, Michele S.; Greulich, Heidi; Meyerson, Matthew; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">217-227</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Mutations in the EGFR kinase are a cause of non-small-cell lung cancer.  To understand their mechanism of activation and effects on drug binding, we studied the kinetics of the L858R and G719S mutants and detd. their crystal structures with inhibitors including gefitinib, AEE788, and a staurosporine.  We find that the mutations activate the kinase by disrupting autoinhibitory interactions, and that they accelerate catalysis as much as 50-fold in vitro.  Structures of inhibitors in complex with both wild-type and mutant kinases reveal similar binding modes for gefitinib and AEE788, but a marked rotation of the staurosporine in the G719S mutant.  Strikingly, direct binding measurements show that gefitinib binds 20-fold more tightly to the L858R mutant than to the wild-type enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoogeLQ1CuEnLVg90H21EOLACvtfcHk0lgJqmyqXeByiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjsVymtL4%253D&md5=6bc3223df84d829d9cb2bb00fd88ca29</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2006.12.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2006.12.017%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWoo%26aufirst%3DM.%2BS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DStructures%2520of%2520lung%2520cancer-derived%2520EGFR%2520mutants%2520and%2520inhibitor%2520complexes%253A%2520mechanism%2520of%2520activation%2520and%2520insights%2520into%2520differential%2520inhibitor%2520sensitivity%26jtitle%3DCancer%2520Cell%26date%3D2007%26volume%3D11%26spage%3D217%26epage%3D227%26doi%3D10.1016%2Fj.ccr.2006.12.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wilcken, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutherford, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fersht, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joerger, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boeckler, F. M.</span></span> <span> </span><span class="NLM_article-title">Experimental and theoretical evaluation of the ethynyl moiety as a halogen bioisostere</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">2725</span>– <span class="NLM_lpage">2732</span>, <span class="refDoi"> DOI: 10.1021/acschembio.5b00515</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.5b00515" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFWns7zF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=2725-2732&author=R.+Wilckenauthor=M.+O.+Zimmermannauthor=M.+R.+Bauerauthor=T.+J.+Rutherfordauthor=A.+R.+Fershtauthor=A.+C.+Joergerauthor=F.+M.+Boeckler&title=Experimental+and+theoretical+evaluation+of+the+ethynyl+moiety+as+a+halogen+bioisostere&doi=10.1021%2Facschembio.5b00515"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Experimental and Theoretical Evaluation of the Ethynyl Moiety as a Halogen Bioisostere</span></div><div class="casAuthors">Wilcken, Rainer; Zimmermann, Markus O.; Bauer, Matthias R.; Rutherford, Trevor J.; Fersht, Alan R.; Joerger, Andreas C.; Boeckler, Frank M.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2725-2732</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bioisosteric replacements are widely used in medicinal chem. to improve physicochem. and ADME properties of mols. while retaining or improving affinity.  Here, using the p53 cancer mutant Y220C as a test case, we investigate both computationally and exptl. whether an ethynyl moiety is a suitable bioisostere to replace iodine in ligands that form halogen bonds with the protein backbone.  This bioisosteric transformation is synthetically feasible via Sonogashira cross-coupling.  In our test case of a particularly strong halogen bond, replacement of the iodine with an ethynyl group resulted in a 13-fold affinity loss.  High-resoln. crystal structures of the two analogs in complex with the p53-Y220C mutant enabled us to correlate the different affinities with particular features of the binding site and subtle changes in ligand binding mode.  In addn., using QM calcns. and analyzing the PDB, we provide general guidelines for identifying cases where such a transformation is likely to improve ligand recognition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoK-zRhwdTYQbVg90H21EOLACvtfcHk0lgJqmyqXeByiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFWns7zF&md5=7525e863f79e26f7dbe18ad45fde39e6</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Facschembio.5b00515&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.5b00515%26sid%3Dliteratum%253Aachs%26aulast%3DWilcken%26aufirst%3DR.%26aulast%3DZimmermann%26aufirst%3DM.%2BO.%26aulast%3DBauer%26aufirst%3DM.%2BR.%26aulast%3DRutherford%26aufirst%3DT.%2BJ.%26aulast%3DFersht%26aufirst%3DA.%2BR.%26aulast%3DJoerger%26aufirst%3DA.%2BC.%26aulast%3DBoeckler%26aufirst%3DF.%2BM.%26atitle%3DExperimental%2520and%2520theoretical%2520evaluation%2520of%2520the%2520ethynyl%2520moiety%2520as%2520a%2520halogen%2520bioisostere%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2015%26volume%3D10%26spage%3D2725%26epage%3D2732%26doi%3D10.1021%2Facschembio.5b00515" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemmon, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radhakrishnan, R.</span></span> <span> </span><span class="NLM_article-title">Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>448</i></span>,  <span class="NLM_fpage">417</span>– <span class="NLM_lpage">423</span>, <span class="refDoi"> DOI: 10.1042/BJ20121513</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1042%2FBJ20121513" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=23101586" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhslelt7zK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=448&publication_year=2012&pages=417-423&author=J.+H.+Parkauthor=Y.+Liuauthor=M.+A.+Lemmonauthor=R.+Radhakrishnan&title=Erlotinib+binds+both+inactive+and+active+conformations+of+the+EGFR+tyrosine+kinase+domain&doi=10.1042%2FBJ20121513"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain</span></div><div class="casAuthors">Park, Jin H.; Liu, Yingting; Lemmon, Mark A.; Radhakrishnan, Ravi</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">448</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">417-423</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">Erlotinib and gefitinib, tyrosine kinase inhibitors used to block EGFR (epidermal growth factor receptor) signalling in cancer, are thought to bind only the active conformation of the EGFR-TKD (tyrosine kinase domain).  Through parallel computational and crystallog. studies, we show in the present study that erlotinib also binds the inactive EGFR-TKD conformation, which may have significant implications for its use in EGFR-mutated cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprbzRYtaWcm7Vg90H21EOLACvtfcHk0lgJqmyqXeByiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhslelt7zK&md5=170e0fe51a413edfbc15d4357ba6877b</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1042%2FBJ20121513&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20121513%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DJ.%2BH.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLemmon%26aufirst%3DM.%2BA.%26aulast%3DRadhakrishnan%26aufirst%3DR.%26atitle%3DErlotinib%2520binds%2520both%2520inactive%2520and%2520active%2520conformations%2520of%2520the%2520EGFR%2520tyrosine%2520kinase%2520domain%26jtitle%3DBiochem.%2520J.%26date%3D2012%26volume%3D448%26spage%3D417%26epage%3D423%26doi%3D10.1042%2FBJ20121513" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gomes, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potter, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szczesna-Cordary, D.</span></span> <span> </span><span class="NLM_article-title">The role of troponins in muscle contraction</span>. <i>IUBMB Life</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">323</span>– <span class="NLM_lpage">333</span>, <span class="refDoi"> DOI: 10.1080/15216540216037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1080%2F15216540216037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=12665242" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD3sXitVagsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2002&pages=323-333&author=A.+V.+Gomesauthor=J.+D.+Potterauthor=D.+Szczesna-Cordary&title=The+role+of+troponins+in+muscle+contraction&doi=10.1080%2F15216540216037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">The Role of Troponins in Muscle Contraction</span></div><div class="casAuthors">Gomes, Aldrin V.; Potter, James D.; Szczesna-Cordary, Danuta</div><div class="citationInfo"><span class="NLM_cas:title">IUBMB Life</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">323-333</span>CODEN:
                <span class="NLM_cas:coden">IULIF8</span>;
        ISSN:<span class="NLM_cas:issn">1521-6543</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis, Inc.</span>)
        </div><div class="casAbstract">A review.  Troponin (Tn) is the sarcomeric Ca2+ regulator for striated (skeletal and cardiac) muscle contraction.  On binding Ca2+ Tn transmits information via structural changes throughout the actin-tropomyosin filaments, activating myosin ATPase activity and muscle contraction.  Although the Tn-mediated regulation of striated muscle contraction is now well understood, the role of different Tn isoforms in these processes is the subject of intensive investigations.  This review addresses the physiol. significance of the multiple Tn isoforms in skeletal and cardiac muscles as well as their role in the regulation of contraction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosVGCwqDg7ibVg90H21EOLACvtfcHk0liqBid49T8krg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXitVagsLk%253D&md5=aa86ee82bce082c9fe20b9b31a16bbda</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1080%2F15216540216037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F15216540216037%26sid%3Dliteratum%253Aachs%26aulast%3DGomes%26aufirst%3DA.%2BV.%26aulast%3DPotter%26aufirst%3DJ.%2BD.%26aulast%3DSzczesna-Cordary%26aufirst%3DD.%26atitle%3DThe%2520role%2520of%2520troponins%2520in%2520muscle%2520contraction%26jtitle%3DIUBMB%2520Life%26date%3D2002%26volume%3D54%26spage%3D323%26epage%3D333%26doi%3D10.1080%2F15216540216037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rowland, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shneider, N. A.</span></span> <span> </span><span class="NLM_article-title">Amyotrophic lateral sclerosis</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>344</i></span>,  <span class="NLM_fpage">1688</span>– <span class="NLM_lpage">1700</span>, <span class="refDoi"> DOI: 10.1056/NEJM200105313442207</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1056%2FNEJM200105313442207" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=11386269" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD3MXkslWjtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=344&publication_year=2001&pages=1688-1700&author=L.+P.+Rowlandauthor=N.+A.+Shneider&title=Amyotrophic+lateral+sclerosis&doi=10.1056%2FNEJM200105313442207"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Amyotrophic lateral sclerosis</span></div><div class="casAuthors">Rowland, Lewis P.; Shneider, Neil A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">344</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">1688-1700</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review, with 148 refs., discusses the definition and the diagnosis of amyotrophic lateral sclerosis.  It also covers the environmental causes, pathogenesis, and therapy of the disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJH5K1VPSzK7Vg90H21EOLACvtfcHk0liqBid49T8krg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXkslWjtbo%253D&md5=085da8625919cb55acaf8834d3450fed</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1056%2FNEJM200105313442207&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM200105313442207%26sid%3Dliteratum%253Aachs%26aulast%3DRowland%26aufirst%3DL.%2BP.%26aulast%3DShneider%26aufirst%3DN.%2BA.%26atitle%3DAmyotrophic%2520lateral%2520sclerosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2001%26volume%3D344%26spage%3D1688%26epage%3D1700%26doi%3D10.1056%2FNEJM200105313442207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kolb, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kissel, J. T.</span></span> <span> </span><span class="NLM_article-title">Spinal muscular atrophy: a timely review</span>. <i>Arch. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">979</span>– <span class="NLM_lpage">984</span>, <span class="refDoi"> DOI: 10.1001/archneurol.2011.74</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1001%2Farchneurol.2011.74" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=21482919" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A280%3ADC%252BC3MjksVKjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2011&pages=979-984&author=S.+J.+Kolbauthor=J.+T.+Kissel&title=Spinal+muscular+atrophy%3A+a+timely+review&doi=10.1001%2Farchneurol.2011.74"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Spinal muscular atrophy: a timely review</span></div><div class="casAuthors">Kolb Stephen J; Kissel John T</div><div class="citationInfo"><span class="NLM_cas:title">Archives of neurology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">979-84</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Spinal muscular atrophy (SMA) is a neurodegenerative disease characterized by loss of motor neurons in the anterior horn of the spinal cord and resultant weakness.  The most common form of SMA, accounting for 95% of cases, is autosomal recessive proximal SMA associated with mutations in the survival of motor neurons (SMN1) gene.  Relentless progress during the past 15 years in the understanding of the molecular genetics and pathophysiology of SMA has resulted in a unique opportunity for rational, effective therapeutic trials.  The goal of SMA therapy is to increase the expression levels of the SMN protein in the correct cells at the right time.  With this target in sight, investigators can now effectively screen potential therapies in vitro, test them in accurate, reliable animal models, move promising agents forward to clinical trials, and accurately diagnose patients at an early or presymptomatic stage of disease.  A major challenge for the SMA community will be to prioritize and develop the most promising therapies in an efficient, timely, and safe manner with the guidance of the appropriate regulatory agencies.  This review will take a historical perspective to highlight important milestones on the road to developing effective therapies for SMA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQy90kBbekgJf69nzq6467DfW6udTcc2eb4tuRapjK-Abntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MjksVKjsA%253D%253D&md5=0dca2120de923052563b6d2f3905a87d</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1001%2Farchneurol.2011.74&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Farchneurol.2011.74%26sid%3Dliteratum%253Aachs%26aulast%3DKolb%26aufirst%3DS.%2BJ.%26aulast%3DKissel%26aufirst%3DJ.%2BT.%26atitle%3DSpinal%2520muscular%2520atrophy%253A%2520a%2520timely%2520review%26jtitle%3DArch.%2520Neurol.%26date%3D2011%26volume%3D68%26spage%3D979%26epage%3D984%26doi%3D10.1001%2Farchneurol.2011.74" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Collibee, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergnes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muci, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Browne, W. F. t.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinken, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suehiro, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawas, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marquez, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomlinson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwee, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaletzky, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malik, F. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgans, D. J.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, B. P.</span></span> <span> </span><span class="NLM_article-title">Discovery of tirasemtiv, the first direct fast skeletal muscle troponin activator</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">354</span>– <span class="NLM_lpage">358</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00546</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00546" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC1cXis1Kqurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=354-358&author=S.+E.+Collibeeauthor=G.+Bergnesauthor=A.+Muciauthor=W.+F.+t.+Browneauthor=M.+Garardauthor=A.+C.+Hinkenauthor=A.+J.+Russellauthor=I.+Suehiroauthor=J.+Hartmanauthor=R.+Kawasauthor=P.+P.+Luauthor=K.+H.+Leeauthor=D.+Marquezauthor=M.+Tomlinsonauthor=D.+Xuauthor=A.+Kennedyauthor=D.+Hweeauthor=J.+Schaletzkyauthor=K.+Leungauthor=F.+I.+Malikauthor=D.+J.+Morgansauthor=B.+P.+Morgan&title=Discovery+of+tirasemtiv%2C+the+first+direct+fast+skeletal+muscle+troponin+activator&doi=10.1021%2Facsmedchemlett.7b00546"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Tirasemtiv, the First Direct Fast Skeletal Muscle Troponin Activator</span></div><div class="casAuthors">Collibee, Scott E.; Bergnes, Gustave; Muci, Alexander; Browne, William F.; Garard, Marc; Hinken, Aaron C.; Russell, Alan J.; Suehiro, Ion; Hartman, James; Kawas, Raja; Lu, Pu-Ping; Lee, Kenneth H.; Marquez, David; Tomlinson, Matthew; Xu, Donghong; Kennedy, Adam; Hwee, Darren; Schaletzky, Julia; Leung, Kwan; Malik, Fady I.; Morgans, David J.; Morgan, Bradley P.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">354-358</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The identification and optimization of the first activators of fast skeletal muscle are reported.  Compd. I was identified from high-throughput screening (HTS) and subsequently found to improve muscle function via interaction with the troponin complex.  Optimization of I for potency, metabolic stability and phys. properties led to the discovery of tirasemtiv (25), which has been extensively characterized in clin. trials for the treatment of ALS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOmgscBIzySrVg90H21EOLACvtfcHk0lgF2vVO5EVk1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXis1Kqurg%253D&md5=33b2fba4224554b6a4c7309aaaa67c25</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00546&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00546%26sid%3Dliteratum%253Aachs%26aulast%3DCollibee%26aufirst%3DS.%2BE.%26aulast%3DBergnes%26aufirst%3DG.%26aulast%3DMuci%26aufirst%3DA.%26aulast%3DBrowne%26aufirst%3DW.%2BF.%2Bt.%26aulast%3DGarard%26aufirst%3DM.%26aulast%3DHinken%26aufirst%3DA.%2BC.%26aulast%3DRussell%26aufirst%3DA.%2BJ.%26aulast%3DSuehiro%26aufirst%3DI.%26aulast%3DHartman%26aufirst%3DJ.%26aulast%3DKawas%26aufirst%3DR.%26aulast%3DLu%26aufirst%3DP.%2BP.%26aulast%3DLee%26aufirst%3DK.%2BH.%26aulast%3DMarquez%26aufirst%3DD.%26aulast%3DTomlinson%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DD.%26aulast%3DKennedy%26aufirst%3DA.%26aulast%3DHwee%26aufirst%3DD.%26aulast%3DSchaletzky%26aufirst%3DJ.%26aulast%3DLeung%26aufirst%3DK.%26aulast%3DMalik%26aufirst%3DF.%2BI.%26aulast%3DMorgans%26aufirst%3DD.%2BJ.%26aulast%3DMorgan%26aufirst%3DB.%2BP.%26atitle%3DDiscovery%2520of%2520tirasemtiv%252C%2520the%2520first%2520direct%2520fast%2520skeletal%2520muscle%2520troponin%2520activator%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D9%26spage%3D354%26epage%3D358%26doi%3D10.1021%2Facsmedchemlett.7b00546" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vijayakumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoltz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolff, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malik, F. I.</span></span> <span> </span><span class="NLM_article-title">CK-2127107 amplifies skeletal muscle response to nerve activation in humans</span>. <i>Muscle Nerve</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">729</span>– <span class="NLM_lpage">734</span>, <span class="refDoi"> DOI: 10.1002/mus.26017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1002%2Fmus.26017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=29150952" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotlyhsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2018&pages=729-734&author=J.+A.+Andrewsauthor=T.+M.+Millerauthor=V.+Vijayakumarauthor=R.+Stoltzauthor=J.+K.+Jamesauthor=L.+Mengauthor=A.+A.+Wolffauthor=F.+I.+Malik&title=CK-2127107+amplifies+skeletal+muscle+response+to+nerve+activation+in+humans&doi=10.1002%2Fmus.26017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">CK-2127107 amplifies skeletal muscle response to nerve activation in humans</span></div><div class="casAuthors">Andrews, Jinsy A.; Miller, Timothy M.; Vijayakumar, Vipin; Stoltz, Randall; James, Joyce K.; Meng, Lisa; Wolff, Andrew A.; Malik, Fady I.</div><div class="citationInfo"><span class="NLM_cas:title">Muscle & Nerve</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">729-734</span>CODEN:
                <span class="NLM_cas:coden">MUNEDE</span>;
        ISSN:<span class="NLM_cas:issn">0148-639X</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Three studies evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics of CK-2127107 (CK-107), a next-generation fast skeletal muscle troponin activator (FSTA), in healthy participants.  We tested the hypothesis that CK-107 would amplify the force-frequency response of muscle in humans.  To assess the force-frequency response, participants received single doses of CK-107 and placebo in a randomized, double-blind, 4-period, crossover study.  The force-frequency response of foot dorsiflexion following stimulation of the deep fibular nerve to activate the tibialis anterior muscle was assessed.  CK-107 significantly increased tibialis anterior muscle response with increasing dose and plasma concn. in a frequency-dependent manner; the largest increase in peak force was ∼60% at 10 Hz.  CK-107 appears more potent and produced larger increases in force than tirasemtiv-a first-generation FSTA-in a similar pharmacodynamic study, thereby supporting its development for improvement of muscle function of patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqH8rDODhoS47Vg90H21EOLACvtfcHk0lgF2vVO5EVk1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotlyhsrc%253D&md5=cceb7e42894750c3a2657a0381076417</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1002%2Fmus.26017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmus.26017%26sid%3Dliteratum%253Aachs%26aulast%3DAndrews%26aufirst%3DJ.%2BA.%26aulast%3DMiller%26aufirst%3DT.%2BM.%26aulast%3DVijayakumar%26aufirst%3DV.%26aulast%3DStoltz%26aufirst%3DR.%26aulast%3DJames%26aufirst%3DJ.%2BK.%26aulast%3DMeng%26aufirst%3DL.%26aulast%3DWolff%26aufirst%3DA.%2BA.%26aulast%3DMalik%26aufirst%3DF.%2BI.%26atitle%3DCK-2127107%2520amplifies%2520skeletal%2520muscle%2520response%2520to%2520nerve%2520activation%2520in%2520humans%26jtitle%3DMuscle%2520Nerve%26date%3D2018%26volume%3D57%26spage%3D729%26epage%3D734%26doi%3D10.1002%2Fmus.26017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santosh Laxmi, Y. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">David, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinkova-Kostova, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiavoni, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trevino, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bumeister, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ojima, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wigley, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bliska, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mierke, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honda, T.</span></span> <span> </span><span class="NLM_article-title">Synthesis, chemical reactivity as Michael acceptors, and biological potency of monocyclic cyanoenones, novel and highly potent anti-inflammatory and cytoprotective agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">4837</span>– <span class="NLM_lpage">4846</span>, <span class="refDoi"> DOI: 10.1021/jm3003922</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3003922" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC38XmtFWju78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=4837-4846&author=S.+Zhengauthor=Y.+R.+Santosh+Laxmiauthor=E.+Davidauthor=A.+T.+Dinkova-Kostovaauthor=K.+H.+Shiavoniauthor=Y.+Renauthor=Y.+Zhengauthor=I.+Trevinoauthor=R.+Bumeisterauthor=I.+Ojimaauthor=W.+C.+Wigleyauthor=J.+B.+Bliskaauthor=D.+F.+Mierkeauthor=T.+Honda&title=Synthesis%2C+chemical+reactivity+as+Michael+acceptors%2C+and+biological+potency+of+monocyclic+cyanoenones%2C+novel+and+highly+potent+anti-inflammatory+and+cytoprotective+agents&doi=10.1021%2Fjm3003922"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, Chemical Reactivity as Michael Acceptors, and Biological Potency of Monocyclic Cyanoenones, Novel and Highly Potent Anti-inflammatory and Cytoprotective Agents</span></div><div class="casAuthors">Zheng, Suqing; Santosh Laxmi, Y. R.; David, Emilie; Dinkova-Kostova, Albena T.; Shiavoni, Katherine H.; Ren, Yanqing; Zheng, Ying; Trevino, Isaac; Bumeister, Ronald; Ojima, Iwao; Wigley, W. Christian; Bliska, James B.; Mierke, Dale F.; Honda, Tadashi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4837-4846</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Novel monocyclic cyanoenones examd. to date display unique features regarding chem. reactivity as Michael acceptors and biol. potency.  Remarkably, in some biol. assays, the simple structure is more potent than pentacyclic triterpenoids (e.g., CDDO and bardoxolone methyl) and tricycles (e.g., TBE-31).  Among monocyclic cyanoenones, 1 (I) is a highly reactive Michael acceptor with thiol nucleophiles.  Furthermore, an important feature of 1 is that its Michael addn. is reversible.  For the inhibition of NO prodn., 1 shows the highest potency.  Notably, its potency is about three times higher than CDDO, whose Me ester (bardoxolone methyl) is presently in phase III clin. trials.  For the induction of NQO1, 1 also demonstrated the highest potency.  These results suggest that the reactivity of these Michael acceptors is closely related to their biol. potency.  Interestingly, in LPS-stimulated macrophages, 1 causes apoptosis and inhibits secretion of TNF-α and IL-1β with potencies that are higher than those of bardoxolone Me and TBE-31.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9JECzJnGhn7Vg90H21EOLACvtfcHk0lgF2vVO5EVk1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmtFWju78%253D&md5=c821917bc8e0da1143c02c58cbc6dae6</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Fjm3003922&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3003922%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DS.%26aulast%3DSantosh%2BLaxmi%26aufirst%3DY.%2BR.%26aulast%3DDavid%26aufirst%3DE.%26aulast%3DDinkova-Kostova%26aufirst%3DA.%2BT.%26aulast%3DShiavoni%26aufirst%3DK.%2BH.%26aulast%3DRen%26aufirst%3DY.%26aulast%3DZheng%26aufirst%3DY.%26aulast%3DTrevino%26aufirst%3DI.%26aulast%3DBumeister%26aufirst%3DR.%26aulast%3DOjima%26aufirst%3DI.%26aulast%3DWigley%26aufirst%3DW.%2BC.%26aulast%3DBliska%26aufirst%3DJ.%2BB.%26aulast%3DMierke%26aufirst%3DD.%2BF.%26aulast%3DHonda%26aufirst%3DT.%26atitle%3DSynthesis%252C%2520chemical%2520reactivity%2520as%2520Michael%2520acceptors%252C%2520and%2520biological%2520potency%2520of%2520monocyclic%2520cyanoenones%252C%2520novel%2520and%2520highly%2520potent%2520anti-inflammatory%2520and%2520cytoprotective%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D4837%26epage%3D4846%26doi%3D10.1021%2Fjm3003922" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yokokawa, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noble, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tania, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunziker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karuna, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manjunatha, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P. W.</span></span> <span> </span><span class="NLM_article-title">Discovery of potent non-nucleoside inhibitors of Dengue viral RNA-dependent RNA polymerase from a fragment hit using structure-based drug design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">3935</span>– <span class="NLM_lpage">3952</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00143</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00143" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC28Xkt1Cmsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=3935-3952&author=F.+Yokokawaauthor=S.+Nilarauthor=C.+G.+Nobleauthor=S.+P.+Limauthor=R.+Raoauthor=S.+Taniaauthor=G.+Wangauthor=G.+Leeauthor=J.+Hunzikerauthor=R.+Karunaauthor=U.+Manjunathaauthor=P.+Y.+Shiauthor=P.+W.+Smith&title=Discovery+of+potent+non-nucleoside+inhibitors+of+Dengue+viral+RNA-dependent+RNA+polymerase+from+a+fragment+hit+using+structure-based+drug+design&doi=10.1021%2Facs.jmedchem.6b00143"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Potent Non-Nucleoside Inhibitors of Dengue Viral RNA-Dependent RNA Polymerase from a Fragment Hit Using Structure-Based Drug Design</span></div><div class="casAuthors">Yokokawa, Fumiaki; Nilar, Shahul; Noble, Christian G.; Lim, Siew Pheng; Rao, Ranga; Tania, Stefani; Wang, Gang; Lee, Gladys; Hunziker, Jurg; Karuna, Ratna; Manjunatha, Ujjini; Shi, Pei-Yong; Smith, Paul W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3935-3952</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery and optimization of non-nucleoside dengue viral RNA-dependent-RNA polymerase (RdRp) inhibitors are described.  An X-ray-based fragment screen of Novartis' fragment collection resulted in the identification of a biphenyl acetic acid fragment 3, which bound in the palm subdomain of RdRp.  Subsequent optimization of the fragment hit 3, relying on structure-based design, resulted in a >1000-fold improvement in potency in vitro and acquired antidengue activity against all four serotypes with low micromolar EC50 in cell-based assays.  The lead candidate 27 interacts with a novel binding pocket in the palm subdomain of the RdRp and exerts a promising activity against all clin. relevant dengue serotypes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpRKw1WHPPP7Vg90H21EOLACvtfcHk0liNjnNMfZVYVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xkt1Cmsb4%253D&md5=93c41f9b5b01dc1ea8c91b6e0a6ef2ea</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00143&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00143%26sid%3Dliteratum%253Aachs%26aulast%3DYokokawa%26aufirst%3DF.%26aulast%3DNilar%26aufirst%3DS.%26aulast%3DNoble%26aufirst%3DC.%2BG.%26aulast%3DLim%26aufirst%3DS.%2BP.%26aulast%3DRao%26aufirst%3DR.%26aulast%3DTania%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DLee%26aufirst%3DG.%26aulast%3DHunziker%26aufirst%3DJ.%26aulast%3DKaruna%26aufirst%3DR.%26aulast%3DManjunatha%26aufirst%3DU.%26aulast%3DShi%26aufirst%3DP.%2BY.%26aulast%3DSmith%26aufirst%3DP.%2BW.%26atitle%3DDiscovery%2520of%2520potent%2520non-nucleoside%2520inhibitors%2520of%2520Dengue%2520viral%2520RNA-dependent%2520RNA%2520polymerase%2520from%2520a%2520fragment%2520hit%2520using%2520structure-based%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D3935%26epage%3D3952%26doi%3D10.1021%2Facs.jmedchem.6b00143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Irie-Sasaki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliveira-dos-Santos, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanford, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolon, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakeham, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Itie, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouchard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozieradzki, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joza, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mak, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohashi, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penninger, J. M.</span></span> <span> </span><span class="NLM_article-title">Function of PI3Kgamma in thymocyte development, T cell activation, and neutrophil migration</span>. <i>Science (Washington, DC, U. S.)</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>287</i></span>,  <span class="NLM_fpage">1040</span>– <span class="NLM_lpage">1046</span>, <span class="refDoi"> DOI: 10.1126/science.287.5455.1040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1126%2Fscience.287.5455.1040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10669416" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhtFyqtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=287&publication_year=2000&pages=1040-1046&author=T.+Sasakiauthor=J.+Irie-Sasakiauthor=R.+G.+Jonesauthor=A.+J.+Oliveira-dos-Santosauthor=W.+L.+Stanfordauthor=B.+Bolonauthor=A.+Wakehamauthor=A.+Itieauthor=D.+Bouchardauthor=I.+Kozieradzkiauthor=N.+Jozaauthor=T.+W.+Makauthor=P.+S.+Ohashiauthor=A.+Suzukiauthor=J.+M.+Penninger&title=Function+of+PI3Kgamma+in+thymocyte+development%2C+T+cell+activation%2C+and+neutrophil+migration&doi=10.1126%2Fscience.287.5455.1040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Function of PI3Kγ in thymocyte development, T cell activation, and neutrophil migration</span></div><div class="casAuthors">Sasaki, Takehiko; Irie-Sasaki, Unko; Jones, Russell G.; Oliveira-do-Santos, Antonio J.; Stanford, William L.; Bolon, Brad; Wakeham, Andrew; Itie, Annick; Bouchard, Dennis; Kozieradzki, Ivona; Joza, Nicholas; Mak, Tak W.; Ohashi, Pamela S.; Suzuki, Akira; Penninger, Josef M.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">287</span>
        (<span class="NLM_cas:issue">5455</span>),
    <span class="NLM_cas:pages">1040-1046</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Phosphoinositide 3-kinases (PI3Ks) regulate fundamental cellular responses such as proliferation, apoptosis, cell motility, and adhesion.  Viable gene-targeted mice lacking the p110 catalytic subunit of PI3Kγ were generated.  The authors show that PI3Kγ controls thymocyte survival and activation of mature T cells but has no role in the development or function of B cells.  PI3Kγ-deficient neutrophils exhibited severe defects in migration and respiratory burst in response to heterotrimeric GTP-binding protein (G protein)-coupled receptor (GPCR) agonists and chemotactic agents.  P13Kγ links GPCR stimulation to the formation of phosphatidylinositol 3,4,5-triphosphate and the activation of protein kinase B, ribosomal protein S6 kinase, and extracellular signal-regulated kinases 1 and 2.  Thus, P13Kγ regulates thymocyte development, T cell activation, neutrophil migration, and the oxidative burst.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6G1gpy-GhpbVg90H21EOLACvtfcHk0liNjnNMfZVYVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhtFyqtb4%253D&md5=53c44ac104f8eb423a727eb3d09364a5</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1126%2Fscience.287.5455.1040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.287.5455.1040%26sid%3Dliteratum%253Aachs%26aulast%3DSasaki%26aufirst%3DT.%26aulast%3DIrie-Sasaki%26aufirst%3DJ.%26aulast%3DJones%26aufirst%3DR.%2BG.%26aulast%3DOliveira-dos-Santos%26aufirst%3DA.%2BJ.%26aulast%3DStanford%26aufirst%3DW.%2BL.%26aulast%3DBolon%26aufirst%3DB.%26aulast%3DWakeham%26aufirst%3DA.%26aulast%3DItie%26aufirst%3DA.%26aulast%3DBouchard%26aufirst%3DD.%26aulast%3DKozieradzki%26aufirst%3DI.%26aulast%3DJoza%26aufirst%3DN.%26aulast%3DMak%26aufirst%3DT.%2BW.%26aulast%3DOhashi%26aufirst%3DP.%2BS.%26aulast%3DSuzuki%26aufirst%3DA.%26aulast%3DPenninger%26aufirst%3DJ.%2BM.%26atitle%3DFunction%2520of%2520PI3Kgamma%2520in%2520thymocyte%2520development%252C%2520T%2520cell%2520activation%252C%2520and%2520neutrophil%2520migration%26jtitle%3DScience%2520%2528Washington%252C%2520DC%252C%2520U.%2520S.%2529%26date%3D2000%26volume%3D287%26spage%3D1040%26epage%3D1046%26doi%3D10.1126%2Fscience.287.5455.1040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Evans, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lescarbeau, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nair, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grenier, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pradeilles, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glenadel, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tibbitts, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowley, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiNitto, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brophy, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Hearn, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkler, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Hearn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoyt, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soglia, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pink, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proctor, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palombella, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tremblay, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castro, A. C.</span></span> <span> </span><span class="NLM_article-title">Discovery of a selective phosphoinositide-3-kinase (PI3K)-gamma inhibitor (IPI-549) as an immuno-oncology clinical candidate</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">862</span>– <span class="NLM_lpage">867</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.6b00238</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00238" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1aju7vO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=862-867&author=C.+A.+Evansauthor=T.+Liuauthor=A.+Lescarbeauauthor=S.+J.+Nairauthor=L.+Grenierauthor=J.+A.+Pradeillesauthor=Q.+Glenadelauthor=T.+Tibbittsauthor=A.+M.+Rowleyauthor=J.+P.+DiNittoauthor=E.+E.+Brophyauthor=E.+L.+O%E2%80%99Hearnauthor=J.+A.+Aliauthor=D.+G.+Winklerauthor=S.+I.+Goldsteinauthor=P.+O%E2%80%99Hearnauthor=C.+M.+Martinauthor=J.+G.+Hoytauthor=J.+R.+Sogliaauthor=C.+Cheungauthor=M.+M.+Pinkauthor=J.+L.+Proctorauthor=V.+J.+Palombellaauthor=M.+R.+Tremblayauthor=A.+C.+Castro&title=Discovery+of+a+selective+phosphoinositide-3-kinase+%28PI3K%29-gamma+inhibitor+%28IPI-549%29+as+an+immuno-oncology+clinical+candidate&doi=10.1021%2Facsmedchemlett.6b00238"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Selective Phosphoinositide-3-Kinase (PI3K)-γ Inhibitor (IPI-549) as an Immuno-Oncology Clinical Candidate</span></div><div class="casAuthors">Evans, Catherine A.; Liu, Tao; Lescarbeau, Andre; Nair, Somarajan J.; Grenier, Louis; Pradeilles, Johan A.; Glenadel, Quentin; Tibbitts, Thomas; Rowley, Ann M.; DiNitto, Jonathan P.; Brophy, Erin E.; OHearn, Erin L.; Ali, Janid A.; Winkler, David G.; Goldstein, Stanley I.; OHearn, Patrick; Martin, Christian M.; Hoyt, Jennifer G.; Soglia, John R.; Cheung, Culver; Pink, Melissa M.; Proctor, Jennifer L.; Palombella, Vito J.; Tremblay, Martin R.; Castro, Alfredo C.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">862-867</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Optimization of isoquinolinone PI3K inhibitors led to the discovery of a potent inhibitor of PI3K-γ (IPI-549) with >100-fold selectivity over other lipid and protein kinases.  IPI-549 demonstrates favorable pharmacokinetic properties and robust inhibition of PI3K-γ mediated neutrophil migration in vivo and is currently in Phase 1 clin. evaluation in subjects with advanced solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrc4njNatEdTbVg90H21EOLACvtfcHk0liNjnNMfZVYVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1aju7vO&md5=9850bb40b0727512d0ca844264c2ec8a</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00238%26sid%3Dliteratum%253Aachs%26aulast%3DEvans%26aufirst%3DC.%2BA.%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DLescarbeau%26aufirst%3DA.%26aulast%3DNair%26aufirst%3DS.%2BJ.%26aulast%3DGrenier%26aufirst%3DL.%26aulast%3DPradeilles%26aufirst%3DJ.%2BA.%26aulast%3DGlenadel%26aufirst%3DQ.%26aulast%3DTibbitts%26aufirst%3DT.%26aulast%3DRowley%26aufirst%3DA.%2BM.%26aulast%3DDiNitto%26aufirst%3DJ.%2BP.%26aulast%3DBrophy%26aufirst%3DE.%2BE.%26aulast%3DO%25E2%2580%2599Hearn%26aufirst%3DE.%2BL.%26aulast%3DAli%26aufirst%3DJ.%2BA.%26aulast%3DWinkler%26aufirst%3DD.%2BG.%26aulast%3DGoldstein%26aufirst%3DS.%2BI.%26aulast%3DO%25E2%2580%2599Hearn%26aufirst%3DP.%26aulast%3DMartin%26aufirst%3DC.%2BM.%26aulast%3DHoyt%26aufirst%3DJ.%2BG.%26aulast%3DSoglia%26aufirst%3DJ.%2BR.%26aulast%3DCheung%26aufirst%3DC.%26aulast%3DPink%26aufirst%3DM.%2BM.%26aulast%3DProctor%26aufirst%3DJ.%2BL.%26aulast%3DPalombella%26aufirst%3DV.%2BJ.%26aulast%3DTremblay%26aufirst%3DM.%2BR.%26aulast%3DCastro%26aufirst%3DA.%2BC.%26atitle%3DDiscovery%2520of%2520a%2520selective%2520phosphoinositide-3-kinase%2520%2528PI3K%2529-gamma%2520inhibitor%2520%2528IPI-549%2529%2520as%2520an%2520immuno-oncology%2520clinical%2520candidate%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D862%26epage%3D867%26doi%3D10.1021%2Facsmedchemlett.6b00238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haraguchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumamoto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baba, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y. C.</span></span> <span> </span><span class="NLM_article-title">4′-Ethynylstavudine (4′-Ed4T) has potent anti-HIV-1 activity with reduced toxicity and shows a unique activity profile against drug-resistant mutants</span>. <i>Antiviral Chem. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">217</span>– <span class="NLM_lpage">221</span>, <span class="refDoi"> DOI: 10.1177/095632020501600402</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1177%2F095632020501600402" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=16130520" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpvVKnsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2005&pages=217-221&author=H.+Tanakaauthor=K.+Haraguchiauthor=H.+Kumamotoauthor=M.+Babaauthor=Y.+C.+Cheng&title=4%E2%80%B2-Ethynylstavudine+%284%E2%80%B2-Ed4T%29+has+potent+anti-HIV-1+activity+with+reduced+toxicity+and+shows+a+unique+activity+profile+against+drug-resistant+mutants&doi=10.1177%2F095632020501600402"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">4'-Ethynylstavudine (4'-Ed4T) has potent anti-HIV-1 activity with reduced toxicity and shows a unique activity profile against drug-resistant mutants</span></div><div class="casAuthors">Tanaka, Hiromichi; Haraguchi, Kazuhiro; Kumamoto, Hiroki; Baba, Masanori; Cheng, Yung-Chi</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Chemistry & Chemotherapy</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">217-221</span>CODEN:
                <span class="NLM_cas:coden">ACCHEH</span>;
        ISSN:<span class="NLM_cas:issn">0956-3202</span>.
    
            (<span class="NLM_cas:orgname">International Medical Press</span>)
        </div><div class="casAbstract">A nucleoside analog 4'-ethynylstavudine (4'-Ed4T) was recently synthesized during chem. studies directed towards the development of a new route to 4'-carbon-substituted nucleosides.  This compd. was more anti-HIV-1 active than the parent compd. stavudine (d4T) and much less toxic to various cells and also to mitochondrial DNA synthesis.  It became apparent that 4'-Ed4T is a better substrate for human thymidine kinase than d4t, and very much more resistant to catabolism by thymidine phosphorylase.  The study of 4'-Ed4T against various drug-resistant HIV-1 mutants has disclosed its unique activity profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolQCaaea0lurVg90H21EOLACvtfcHk0lh2v6E84vSaQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpvVKnsLk%253D&md5=0d0ff69b964bc0d1cc1876020ce295ad</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1177%2F095632020501600402&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F095632020501600402%26sid%3Dliteratum%253Aachs%26aulast%3DTanaka%26aufirst%3DH.%26aulast%3DHaraguchi%26aufirst%3DK.%26aulast%3DKumamoto%26aufirst%3DH.%26aulast%3DBaba%26aufirst%3DM.%26aulast%3DCheng%26aufirst%3DY.%2BC.%26atitle%3D4%25E2%2580%25B2-Ethynylstavudine%2520%25284%25E2%2580%25B2-Ed4T%2529%2520has%2520potent%2520anti-HIV-1%2520activity%2520with%2520reduced%2520toxicity%2520and%2520shows%2520a%2520unique%2520activity%2520profile%2520against%2520drug-resistant%2520mutants%26jtitle%3DAntiviral%2520Chem.%2520Chemother.%26date%3D2005%26volume%3D16%26spage%3D217%26epage%3D221%26doi%3D10.1177%2F095632020501600402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kawamoto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kodama, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarafianos, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakagami, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohgo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitano, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashida, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayakawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakata, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsuya, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuoka, M.</span></span> <span> </span><span class="NLM_article-title">2′-Deoxy-4′-C-ethynyl-2-halo-adenosines active against drug-resistant human immunodeficiency virus type 1 variants</span>. <i>Int. J. Biochem. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">2410</span>– <span class="NLM_lpage">2420</span>, <span class="refDoi"> DOI: 10.1016/j.biocel.2008.04.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1016%2Fj.biocel.2008.04.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=18487070" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpsVaguro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2008&pages=2410-2420&author=A.+Kawamotoauthor=E.+Kodamaauthor=S.+G.+Sarafianosauthor=Y.+Sakagamiauthor=S.+Kohgoauthor=K.+Kitanoauthor=N.+Ashidaauthor=Y.+Iwaiauthor=H.+Hayakawaauthor=H.+Nakataauthor=H.+Mitsuyaauthor=E.+Arnoldauthor=M.+Matsuoka&title=2%E2%80%B2-Deoxy-4%E2%80%B2-C-ethynyl-2-halo-adenosines+active+against+drug-resistant+human+immunodeficiency+virus+type+1+variants&doi=10.1016%2Fj.biocel.2008.04.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">2'-Deoxy-4'-C-ethynyl-2-halo-adenosines active against drug-resistant human immunodeficiency virus type 1 variants</span></div><div class="casAuthors">Kawamoto, Atsushi; Kodama, Eiichi; Sarafianos, Stefan G.; Sakagami, Yasuko; Kohgo, Satoru; Kitano, Kenji; Ashida, Noriyuki; Iwai, Yuko; Hayakawa, Hiroyuki; Nakata, Hirotomo; Mitsuya, Hiroaki; Arnold, Eddy; Matsuoka, Masao</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Biochemistry & Cell Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2410-2420</span>CODEN:
                <span class="NLM_cas:coden">IJBBFU</span>;
        ISSN:<span class="NLM_cas:issn">1357-2725</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">One of the formidable challenges in therapy of infections by human immunodeficiency virus (HIV) is the emergence of drug-resistant variants that attenuate the efficacy of highly active antiretroviral therapy (HAART).  We have recently introduced 4'-ethynyl-nucleoside analogs as nucleoside reverse transcriptase inhibitors (NRTIs) that could be developed as therapeutics for treatment of HIV infections.  In this study, we present 2'-deoxy-4'-C-ethynyl-2-fluoroadenosine (EFdA), a second generation 4'-ethynyl inhibitor that exerted highly potent activity against wild-type HIV-1 (EC50 ∼ 0.07 nM).  EFdA retains potency toward many HIV-1 resistant strains, including the multi-drug resistant clone HIV-1A62V/V75I/F77L/F116Y/q151M.  The selectivity index of EFdA (cytotoxicity/inhibitory activity) is more favorable than all approved NRTIs used in HIV therapy.  Furthermore, EFdA efficiently inhibited clin. isolates from patients heavily treated with multiple anti-HIV-1 drugs.  EFdA appears to be primarily phosphorylated by the cellular 2'-deoxycytidine kinase (dCK) because: (a) the antiviral activity of EFdA was reduced by the addn. of dC, which competes nucleosides phosphorylated by the dCK pathway, (b) the antiviral activity of EFdA was significantly reduced in dCK-deficient HT-1080/Ara-Cr cells, but restored after dCK transduction.  Further, unlike other dA analogs, EFdA is completely resistant to degrdn. by adenosine deaminase.  Moderate decrease in susceptibility to EFdA is conferred by a combination of three RT mutations (I142V, T165R, and M184V) that result in a significant decrease of viral fitness.  Mol. modeling anal. suggests that the M184V/I substitutions may reduce anti-HIV activity of EFdA through steric hindrance between its 4'-ethynyl moiety and the V/I184 β-branched side chains.  The present data suggest that EFdA, is a promising candidate for developing as a therapeutic agent for the treatment of individuals harboring multi-drug resistant HIV variants.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1x9Q0xUpKX7Vg90H21EOLACvtfcHk0lh2v6E84vSaQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpsVaguro%253D&md5=69039c735ae8e2f42c73c085f5ba87a3</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2Fj.biocel.2008.04.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biocel.2008.04.007%26sid%3Dliteratum%253Aachs%26aulast%3DKawamoto%26aufirst%3DA.%26aulast%3DKodama%26aufirst%3DE.%26aulast%3DSarafianos%26aufirst%3DS.%2BG.%26aulast%3DSakagami%26aufirst%3DY.%26aulast%3DKohgo%26aufirst%3DS.%26aulast%3DKitano%26aufirst%3DK.%26aulast%3DAshida%26aufirst%3DN.%26aulast%3DIwai%26aufirst%3DY.%26aulast%3DHayakawa%26aufirst%3DH.%26aulast%3DNakata%26aufirst%3DH.%26aulast%3DMitsuya%26aufirst%3DH.%26aulast%3DArnold%26aufirst%3DE.%26aulast%3DMatsuoka%26aufirst%3DM.%26atitle%3D2%25E2%2580%25B2-Deoxy-4%25E2%2580%25B2-C-ethynyl-2-halo-adenosines%2520active%2520against%2520drug-resistant%2520human%2520immunodeficiency%2520virus%2520type%25201%2520variants%26jtitle%3DInt.%2520J.%2520Biochem.%2520Cell%2520Biol.%26date%3D2008%26volume%3D40%26spage%3D2410%26epage%3D2420%26doi%3D10.1016%2Fj.biocel.2008.04.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Michailidis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchand, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kodama, E. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuoka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirby, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawani, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagy, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashida, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsuya, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parniak, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarafianos, S. G.</span></span> <span> </span><span class="NLM_article-title">Mechanism of inhibition of HIV-1 reverse transcriptase by 4′-Ethynyl-2-fluoro-2′-deoxyadenosine triphosphate, a translocation-defective reverse transcriptase inhibitor</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>284</i></span>,  <span class="NLM_fpage">35681</span>– <span class="NLM_lpage">35691</span>, <span class="refDoi"> DOI: 10.1074/jbc.M109.036616</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1074%2Fjbc.M109.036616" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=19837673" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFCqurfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=284&publication_year=2009&pages=35681-35691&author=E.+Michailidisauthor=B.+Marchandauthor=E.+N.+Kodamaauthor=K.+Singhauthor=M.+Matsuokaauthor=K.+A.+Kirbyauthor=E.+M.+Ryanauthor=A.+M.+Sawaniauthor=E.+Nagyauthor=N.+Ashidaauthor=H.+Mitsuyaauthor=M.+A.+Parniakauthor=S.+G.+Sarafianos&title=Mechanism+of+inhibition+of+HIV-1+reverse+transcriptase+by+4%E2%80%B2-Ethynyl-2-fluoro-2%E2%80%B2-deoxyadenosine+triphosphate%2C+a+translocation-defective+reverse+transcriptase+inhibitor&doi=10.1074%2Fjbc.M109.036616"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of Inhibition of HIV-1 Reverse Transcriptase by 4'-Ethynyl-2-fluoro-2'-deoxyadenosine Triphosphate, a Translocation-defective Reverse Transcriptase Inhibitor</span></div><div class="casAuthors">Michailidis, Eleftherios; Marchand, Bruno; Kodama, Eiichi N.; Singh, Kamlendra; Matsuoka, Masao; Kirby, Karen A.; Ryan, Emily M.; Sawani, Ali M.; Nagy, Eva; Ashida, Noriyuki; Mitsuya, Hiroaki; Parniak, Michael A.; Sarafianos, Stefan G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">284</span>
        (<span class="NLM_cas:issue">51</span>),
    <span class="NLM_cas:pages">35681-35691</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Nucleoside reverse transcriptase inhibitors (NRTIs) are employed in first line therapies for the treatment of human immunodeficiency virus (HIV) infection.  They generally lack a 3'-hydroxyl group, and thus when incorporated into the nascent DNA they prevent further elongation.  The authors show that 4'-ethynyl-2-fluoro-2'-deoxyadenosine (EFdA), a nucleoside analog that retains a 3'-hydroxyl moiety, inhibited HIV-1 replication in activated peripheral blood mononuclear cells with an EC50 of 0.05 nM, a potency several orders of magnitude better than any of the current clin. used NRTIs.  This exceptional antiviral activity stems in part from a mechanism of action that is different from approved NRTIs.  Reverse transcriptase (RT) can use EFdA-5'-triphosphate (EFdA-TP) as a substrate more efficiently than the natural substrate, dATP.  Importantly, despite the presence of a 3'-hydroxyl, the incorporated EFdA monophosphate (EFdA-MP) acted mainly as a de facto terminator of further RT-catalyzed DNA synthesis because of the difficulty of RT translocation on the nucleic acid primer possessing 3'-terminal EFdA-MP.  EFdA-TP is thus a translocation-defective RT inhibitor (TDRTI).  This diminished translocation kept the primer 3'-terminal EFdA-MP ideally located to undergo phosphorolytic excision.  However, net phosphorolysis was not substantially increased, because of the apparently facile reincorporation of the newly excised EFdA-TP.  The authors' mol. modeling studies suggest that the 4'-ethynyl fits into a hydrophobic pocket defined by RT residues Ala 114, Tyr-115, Phe 160, and Met 184 and the aliph. chain of Asp 185.  These interactions, which contribute to both enhanced RT utilization of EFdA-TP and difficulty in the translocation of 3'-terminal EFdA-MP primers, underlie the mechanism of action of this potent antiviral nucleoside.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSzybzRvJFz7Vg90H21EOLACvtfcHk0lh2v6E84vSaQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFCqurfI&md5=af4d7c768df0bc42d8a058bd7fd7e993</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M109.036616&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M109.036616%26sid%3Dliteratum%253Aachs%26aulast%3DMichailidis%26aufirst%3DE.%26aulast%3DMarchand%26aufirst%3DB.%26aulast%3DKodama%26aufirst%3DE.%2BN.%26aulast%3DSingh%26aufirst%3DK.%26aulast%3DMatsuoka%26aufirst%3DM.%26aulast%3DKirby%26aufirst%3DK.%2BA.%26aulast%3DRyan%26aufirst%3DE.%2BM.%26aulast%3DSawani%26aufirst%3DA.%2BM.%26aulast%3DNagy%26aufirst%3DE.%26aulast%3DAshida%26aufirst%3DN.%26aulast%3DMitsuya%26aufirst%3DH.%26aulast%3DParniak%26aufirst%3DM.%2BA.%26aulast%3DSarafianos%26aufirst%3DS.%2BG.%26atitle%3DMechanism%2520of%2520inhibition%2520of%2520HIV-1%2520reverse%2520transcriptase%2520by%25204%25E2%2580%25B2-Ethynyl-2-fluoro-2%25E2%2580%25B2-deoxyadenosine%2520triphosphate%252C%2520a%2520translocation-defective%2520reverse%2520transcriptase%2520inhibitor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2009%26volume%3D284%26spage%3D35681%26epage%3D35691%26doi%3D10.1074%2Fjbc.M109.036616" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ohrui, H.</span></span> <span> </span><span class="NLM_article-title">2′-Deoxy-4′-C-ethynyl-2-fluoroadenosine, a nucleoside reverse transcriptase inhibitor, is highly potent against all human immunodeficiency viruses type 1 and has low toxicity</span>. <i>Chem. Rec.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">133</span>– <span class="NLM_lpage">143</span>, <span class="refDoi"> DOI: 10.1002/tcr.20078</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1002%2Ftcr.20078" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=16795005" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD28XntVChsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=133-143&author=H.+Ohrui&title=2%E2%80%B2-Deoxy-4%E2%80%B2-C-ethynyl-2-fluoroadenosine%2C+a+nucleoside+reverse+transcriptase+inhibitor%2C+is+highly+potent+against+all+human+immunodeficiency+viruses+type+1+and+has+low+toxicity&doi=10.1002%2Ftcr.20078"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">2'-deoxy-4'-C-ethynyl-2-fluoroadenosine, a nucleoside reverse transcriptase inhibitor, is highly potent against all human immunodeficiency viruses type 1 and has low toxicity</span></div><div class="casAuthors">Ohrui, Hiroshi</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Record</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">133-143</span>CODEN:
                <span class="NLM_cas:coden">CRHEAK</span>;
        ISSN:<span class="NLM_cas:issn">1527-8999</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">This review presents an idea to use 4'-C-substituted-2'-deoxynucleoside derivs. based on a working hypothesis to solve the problems of existing acquired immune deficiency syndrome chemotherapy (highly active antiretroviral therapy).  Subsequent studies have successfully proved the validity of the idea and resulted in the development of 2'-deoxy-4'-C-ethynyl-2-fluoroadenosine, a nucleoside reverse transcriptase inhibitor, which is highly potent to all human immunodeficiency viruses type 1 (HIV-1s) including multidrug-resistant HIV-1 and has a low toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdvdl4XojO6bVg90H21EOLACvtfcHk0lgU_r5g8FAiHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XntVChsL0%253D&md5=088b34c005c70f95a5b72eb5f6cdba69</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1002%2Ftcr.20078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Ftcr.20078%26sid%3Dliteratum%253Aachs%26aulast%3DOhrui%26aufirst%3DH.%26atitle%3D2%25E2%2580%25B2-Deoxy-4%25E2%2580%25B2-C-ethynyl-2-fluoroadenosine%252C%2520a%2520nucleoside%2520reverse%2520transcriptase%2520inhibitor%252C%2520is%2520highly%2520potent%2520against%2520all%2520human%2520immunodeficiency%2520viruses%2520type%25201%2520and%2520has%2520low%2520toxicity%26jtitle%3DChem.%2520Rec.%26date%3D2006%26volume%3D6%26spage%3D133%26epage%3D143%26doi%3D10.1002%2Ftcr.20078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Salie, Z. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirby, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michailidis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchand, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rohan, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kodama, E. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsuya, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parniak, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarafianos, S. G.</span></span> <span> </span><span class="NLM_article-title">Structural basis of HIV inhibition by translocation-defective RT inhibitor 4′-ethynyl-2-fluoro-2′-deoxyadenosine (EFdA)</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">9274</span>– <span class="NLM_lpage">9279</span>, <span class="refDoi"> DOI: 10.1073/pnas.1605223113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1073%2Fpnas.1605223113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=27489345" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1ygt73K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2016&pages=9274-9279&author=Z.+L.+Salieauthor=K.+A.+Kirbyauthor=E.+Michailidisauthor=B.+Marchandauthor=K.+Singhauthor=L.+C.+Rohanauthor=E.+N.+Kodamaauthor=H.+Mitsuyaauthor=M.+A.+Parniakauthor=S.+G.+Sarafianos&title=Structural+basis+of+HIV+inhibition+by+translocation-defective+RT+inhibitor+4%E2%80%B2-ethynyl-2-fluoro-2%E2%80%B2-deoxyadenosine+%28EFdA%29&doi=10.1073%2Fpnas.1605223113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis of HIV inhibition by translocation-defective RT inhibitor 4'-ethynyl-2-fluoro-2'-deoxyadenosine (EFdA)</span></div><div class="casAuthors">Salie, Zhe Li; Kirby, Karen A.; Michailidis, Eleftherios; Marchand, Bruno; Singh, Kamalendra; Rohan, Lisa C.; Kodama, Eiichi N.; Mitsuya, Hiroaki; Parniak, Michael A.; Sarafianos, Stefan G.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">9274-9279</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">4'-Ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) is the most potent nucleoside analog inhibitor of HIV reverse transcriptase (RT).  It retains a 3'-OH yet acts as a chain-terminating agent by diminishing translocation from the pretranslocation nucleotide-binding site (N site) to the posttranslocation primer-binding site (P site).  Also, facile misincorporation of EFdA-monophosphate (MP) results in difficult-to-extend mismatched primers.  To understand the high potency and unusual inhibition mechanism of EFdA, we solved RT crystal structures (resolns. from 2.4 to 2.9 Å) that include inhibition intermediates (i) before inhibitor incorporation (catalytic complex, RT/DNA/EFdA-triphosphate), (ii) after incorporation of EFdA-MP followed by dT-MP (RT/DNAEFdA-MPSUP°P/SUP°buldT-MPSUP°N/SUP°), or (iii) after incorporation of two EFdA-MPs (RT/DNAEFdA-MPSUP°P/SUP°bulEFdA-MPSUP°N/SUP°); (iv) the latter was also solved with EFdA-MP mismatched at the N site (RT/DNAEFdA-MPSUP°P/SUP°bulEFdA-MPtSUP°N/SUP°).  We report that the inhibition mechanism and potency of EFdA stem from interactions of its 4'-ethynyl at a previously unexploited conserved hydrophobic pocket in the polymerase active site.  The high resoln. of the catalytic complex structure revealed a network of ordered water mols. at the polymerase active site that stabilize enzyme interactions with nucleotide and DNA substrates.  Finally, decreased translocation results from favorable interactions of primer-terminating EFdA-MP at the pretranslocation site and unfavorable posttranslocation interactions that lead to obsd. localized primer distortions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-6y_9SBl-hbVg90H21EOLACvtfcHk0lgU_r5g8FAiHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1ygt73K&md5=f3668fe0d312877907006a44549d1520</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1605223113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1605223113%26sid%3Dliteratum%253Aachs%26aulast%3DSalie%26aufirst%3DZ.%2BL.%26aulast%3DKirby%26aufirst%3DK.%2BA.%26aulast%3DMichailidis%26aufirst%3DE.%26aulast%3DMarchand%26aufirst%3DB.%26aulast%3DSingh%26aufirst%3DK.%26aulast%3DRohan%26aufirst%3DL.%2BC.%26aulast%3DKodama%26aufirst%3DE.%2BN.%26aulast%3DMitsuya%26aufirst%3DH.%26aulast%3DParniak%26aufirst%3DM.%2BA.%26aulast%3DSarafianos%26aufirst%3DS.%2BG.%26atitle%3DStructural%2520basis%2520of%2520HIV%2520inhibition%2520by%2520translocation-defective%2520RT%2520inhibitor%25204%25E2%2580%25B2-ethynyl-2-fluoro-2%25E2%2580%25B2-deoxyadenosine%2520%2528EFdA%2529%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2016%26volume%3D113%26spage%3D9274%26epage%3D9279%26doi%3D10.1073%2Fpnas.1605223113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Itoh, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawamata, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujii, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukusumi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosoya, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uejima, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maruyama, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satoh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okubo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kizawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komatsu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumura, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noguchi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinohara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinuma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujisawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujino, M.</span></span> <span> </span><span class="NLM_article-title">Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>422</i></span>,  <span class="NLM_fpage">173</span>– <span class="NLM_lpage">176</span>, <span class="refDoi"> DOI: 10.1038/nature01478</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1038%2Fnature01478" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=12629551" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhvFKgs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=422&publication_year=2003&pages=173-176&author=Y.+Itohauthor=Y.+Kawamataauthor=M.+Haradaauthor=M.+Kobayashiauthor=R.+Fujiiauthor=S.+Fukusumiauthor=K.+Ogiauthor=M.+Hosoyaauthor=Y.+Tanakaauthor=H.+Uejimaauthor=H.+Tanakaauthor=M.+Maruyamaauthor=R.+Satohauthor=S.+Okuboauthor=H.+Kizawaauthor=H.+Komatsuauthor=F.+Matsumuraauthor=Y.+Noguchiauthor=T.+Shinoharaauthor=S.+Hinumaauthor=Y.+Fujisawaauthor=M.+Fujino&title=Free+fatty+acids+regulate+insulin+secretion+from+pancreatic+beta+cells+through+GPR40&doi=10.1038%2Fnature01478"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Free fatty acids regulate insulin secretion from pancreatic β cells through GPR40</span></div><div class="casAuthors">Itoh, Yasuaki; Kawamata, Yuji; Harada, Masataka; Kobayashi, Makoto; Fujii, Ryo; Fukusumi, Shoji; Ogi, Kazuhiro; Hosoya, Masaki; Tanaka, Yasuhiro; Uejima, Hiroshi; Tanaka, Hideyuki; Maruyama, Minoru; Satoh, Rie; Okubo, Shoichi; Kizawa, Hideki; Komatsu, Hidetoshi; Matsumura, Fumika; Noguchi, Yuko; Shinohara, Tokuyuki; Hinuma, Shuji; Fujisawa, Yukio; Fujino, Masahiko</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">422</span>
        (<span class="NLM_cas:issue">6928</span>),
    <span class="NLM_cas:pages">173-176</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Diabetes, a disease in which carbohydrate and lipid metab. are regulated improperly by insulin, is a serious worldwide health issue.  Insulin is secreted from pancreatic β cells in response to elevated plasma glucose, with various factors modifying its secretion.  Free fatty acids (FFAs) provide an important energy source as nutrients, and they also act as signaling mols. in various cellular processes, including insulin secretion.  Although FFAs are thought to promote insulin secretion in an acute phase, this mechanism is not clearly understood.  A G-protein-coupled receptor, GPR40, which is abundantly expressed in the pancreas, functions as a receptor for long-chain FFAs.  Furthermore, the authors show that long-chain FFAs amplify glucose-stimulated insulin secretion from pancreatic β cells by activating GPR40.  The authors' results indicate that GPR40 agonists and/or antagonists show potential for the development of new anti-diabetic drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5Y9oes-9VG7Vg90H21EOLACvtfcHk0lgU_r5g8FAiHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhvFKgs7w%253D&md5=96af869fb87b235a482ad6c0c42db5e3</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1038%2Fnature01478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature01478%26sid%3Dliteratum%253Aachs%26aulast%3DItoh%26aufirst%3DY.%26aulast%3DKawamata%26aufirst%3DY.%26aulast%3DHarada%26aufirst%3DM.%26aulast%3DKobayashi%26aufirst%3DM.%26aulast%3DFujii%26aufirst%3DR.%26aulast%3DFukusumi%26aufirst%3DS.%26aulast%3DOgi%26aufirst%3DK.%26aulast%3DHosoya%26aufirst%3DM.%26aulast%3DTanaka%26aufirst%3DY.%26aulast%3DUejima%26aufirst%3DH.%26aulast%3DTanaka%26aufirst%3DH.%26aulast%3DMaruyama%26aufirst%3DM.%26aulast%3DSatoh%26aufirst%3DR.%26aulast%3DOkubo%26aufirst%3DS.%26aulast%3DKizawa%26aufirst%3DH.%26aulast%3DKomatsu%26aufirst%3DH.%26aulast%3DMatsumura%26aufirst%3DF.%26aulast%3DNoguchi%26aufirst%3DY.%26aulast%3DShinohara%26aufirst%3DT.%26aulast%3DHinuma%26aufirst%3DS.%26aulast%3DFujisawa%26aufirst%3DY.%26aulast%3DFujino%26aufirst%3DM.%26atitle%3DFree%2520fatty%2520acids%2520regulate%2520insulin%2520secretion%2520from%2520pancreatic%2520beta%2520cells%2520through%2520GPR40%26jtitle%3DNature%26date%3D2003%26volume%3D422%26spage%3D173%26epage%3D176%26doi%3D10.1038%2Fnature01478" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, Y. Q.</span></span> <span> </span><span class="NLM_article-title">Discovery of potent and orally bioavailable GPR40 full agonists bearing thiophen-2-ylpropanoic acid scaffold</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">2697</span>– <span class="NLM_lpage">2717</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01357</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01357" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC2sXktVagu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=2697-2717&author=H.+Liauthor=Q.+Huangauthor=C.+Chenauthor=B.+Xuauthor=H.+Y.+Wangauthor=Y.+Q.+Long&title=Discovery+of+potent+and+orally+bioavailable+GPR40+full+agonists+bearing+thiophen-2-ylpropanoic+acid+scaffold&doi=10.1021%2Facs.jmedchem.6b01357"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Potent and Orally Bioavailable GPR40 Full Agonists Bearing Thiophen-2-ylpropanoic Acid Scaffold</span></div><div class="casAuthors">Li, He; Huang, Qi; Chen, Cheng; Xu, Bin; Wang, He-Yao; Long, Ya-Qiu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2697-2717</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The free fatty acid receptor GPR40 is predominantly expressed in pancreatic β-cells and enhances insulin secretion in a glucose dependent manner.  Therefore, GPR40 agonists are possible novel insulin secretagogues with reduced or no risk of hypoglycemia for the treatment of type 2 diabetes mellitus (T2DM).  Chem. and structurally diverse GPR40 agonists with high safety are pursued for the clin. development of GPR40-based pharmacotherapeutics.  Herein we report our design and discovery of a new chemotype of GPR40 agonists free of the typical phenylpropanoic acid scaffold.  The thiophen-2-ylpropanoic acid contg. GPR40 modulators functioned as full agonists with high-efficacy response (Emax) and reduced lipophilicity.  Significantly, the lead compd. in this series, (R)-7k, exhibited more potent in vitro glucose-stimulated insulin secretion and in vivo glucose-lowering effects (10 mg/kg, po) than the GPR40 partial agonist TAK-875, which was once in phase III clin. trials, and high selectivity over the relevant receptors GPR120 and PPARγ.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqsvYiEpKif7Vg90H21EOLACvtfcHk0ljyInoNaHKuBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXktVagu7w%253D&md5=d766a3a56c2a5b22a2b48591ecb7d27e</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01357&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01357%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DXu%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DH.%2BY.%26aulast%3DLong%26aufirst%3DY.%2BQ.%26atitle%3DDiscovery%2520of%2520potent%2520and%2520orally%2520bioavailable%2520GPR40%2520full%2520agonists%2520bearing%2520thiophen-2-ylpropanoic%2520acid%2520scaffold%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D2697%26epage%3D2717%26doi%3D10.1021%2Facs.jmedchem.6b01357" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bouley, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bastian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lastochkin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suckow, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroeder, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolter, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mobashery, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, M.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationship for the 4(3<i>H</i>)-quinazolinone antibacterials</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">5011</span>– <span class="NLM_lpage">5021</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00372</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00372" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC28XmtF2lsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=5011-5021&author=R.+Bouleyauthor=D.+Dingauthor=Z.+Pengauthor=M.+Bastianauthor=E.+Lastochkinauthor=W.+Songauthor=M.+A.+Suckowauthor=V.+A.+Schroederauthor=W.+R.+Wolterauthor=S.+Mobasheryauthor=M.+Chang&title=Structure-activity+relationship+for+the+4%283H%29-quinazolinone+antibacterials&doi=10.1021%2Facs.jmedchem.6b00372"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity Relationship for the 4(3H)-Quinazolinone Antibacterials</span></div><div class="casAuthors">Bouley, Renee; Ding, Derong; Peng, Zhihong; Bastian, Maria; Lastochkin, Elena; Song, Wei; Suckow, Mark A.; Schroeder, Valerie A.; Wolter, William R.; Mobashery, Shahriar; Chang, Mayland</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">5011-5021</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We recently reported on the discovery of a novel antibacterial (2) with a 4(3H)-quinazolinone core.  This discovery was made by in silico screening of 1.2 million compds. for binding to a penicillin-binding protein and the subsequent demonstration of antibacterial activity against Staphylococcus aureus.  The first structure-activity relationship for this antibacterial scaffold is explored in this report with evaluation of 77 variants of the structural class.  Eleven promising compds. were further evaluated for in vitro toxicity, pharmacokinetics, and efficacy in a mouse peritonitis model of infection, which led to the discovery of compd. 27.  This new quinazolinone has potent activity against methicillin-resistant (MRSA) strains, low clearance, oral bioavailability and shows efficacy in a mouse neutropenic thigh infection model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoES54kEeDf6bVg90H21EOLACvtfcHk0ljyInoNaHKuBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmtF2lsr4%253D&md5=9287f7924141b19a517b3ec04d723eff</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00372&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00372%26sid%3Dliteratum%253Aachs%26aulast%3DBouley%26aufirst%3DR.%26aulast%3DDing%26aufirst%3DD.%26aulast%3DPeng%26aufirst%3DZ.%26aulast%3DBastian%26aufirst%3DM.%26aulast%3DLastochkin%26aufirst%3DE.%26aulast%3DSong%26aufirst%3DW.%26aulast%3DSuckow%26aufirst%3DM.%2BA.%26aulast%3DSchroeder%26aufirst%3DV.%2BA.%26aulast%3DWolter%26aufirst%3DW.%2BR.%26aulast%3DMobashery%26aufirst%3DS.%26aulast%3DChang%26aufirst%3DM.%26atitle%3DStructure-activity%2520relationship%2520for%2520the%25204%25283H%2529-quinazolinone%2520antibacterials%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D5011%26epage%3D5021%26doi%3D10.1021%2Facs.jmedchem.6b00372" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">AbdelKhalek, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abutaleb, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velagapudi, U. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoganathan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seleem, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talele, T. T.</span></span> <span> </span><span class="NLM_article-title">Chemical space exploration around thieno[3,2-d]pyrimidin-4(3<i>H</i>)-one scaffold led to a novel class of highly active <i>Clostridium difficile</i> inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">9772</span>– <span class="NLM_lpage">9791</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01198</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01198" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFSru7fJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=9772-9791&author=X.+Shaoauthor=A.+AbdelKhalekauthor=N.+S.+Abutalebauthor=U.+K.+Velagapudiauthor=S.+Yoganathanauthor=M.+N.+Seleemauthor=T.+T.+Talele&title=Chemical+space+exploration+around+thieno%5B3%2C2-d%5Dpyrimidin-4%283H%29-one+scaffold+led+to+a+novel+class+of+highly+active+Clostridium+difficile+inhibitors&doi=10.1021%2Facs.jmedchem.9b01198"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical Space Exploration around Thieno[3,2-d]pyrimidin-4(3H)-one Scaffold Led to a Novel Class of Highly Active Clostridium difficile Inhibitors</span></div><div class="casAuthors">Shao, Xuwei; AbdelKhalek, Ahmed; Abutaleb, Nader S.; Velagapudi, Uday Kiran; Yoganathan, Sabesan; Seleem, Mohamed N.; Talele, Tanaji T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">9772-9791</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Clostridium difficile infection (CDI) is the leading cause of health care-assocd. infection in the United States.  Therefore, development of novel treatments for CDI is a high priority.  Toward this goal, the authors began in vitro screening of a structurally diverse inhouse library of 67 compds. against two pathogenic C. difficile strains (ATCC BAA 1870 and ATCC 43255), which yielded a hit compd., 2-methyl-8-nitroquinazolin-4(3H)-one with moderate potency (MIC = 312/156 μM).  Optimization of the hit compd. gave lead compd. 2-methyl-7-nitrothieno[3,2-d]pyrimidin-4(3H)-one with improved potency (MIC = 19/38 μM), selectivity over normal gut microflora, CC50s >606 μM against mammalian cell lines, and acceptable stability in simulated gastric and intestinal fluid.  Further optimization of the lead compd. at C2-, N3-, C4- and C7-positions resulted in a library of >50 compds. with MICs ranging from 3-800 μM against clin. isolates of C. difficile.  Compd. 8f, (E)-2-(4-fluorostyryl)-7-nitrothieno(3,2-d)pyrimidin-4(3H)-one [2380003-26-7] (MIC = 3/6 μM) was identified as a promising lead for further optimization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZXT-bOec4IbVg90H21EOLACvtfcHk0ljyInoNaHKuBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFSru7fJ&md5=7f6b5ef5fdc67ec804c24018a6e7bd9c</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01198&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01198%26sid%3Dliteratum%253Aachs%26aulast%3DShao%26aufirst%3DX.%26aulast%3DAbdelKhalek%26aufirst%3DA.%26aulast%3DAbutaleb%26aufirst%3DN.%2BS.%26aulast%3DVelagapudi%26aufirst%3DU.%2BK.%26aulast%3DYoganathan%26aufirst%3DS.%26aulast%3DSeleem%26aufirst%3DM.%2BN.%26aulast%3DTalele%26aufirst%3DT.%2BT.%26atitle%3DChemical%2520space%2520exploration%2520around%2520thieno%255B3%252C2-d%255Dpyrimidin-4%25283H%2529-one%2520scaffold%2520led%2520to%2520a%2520novel%2520class%2520of%2520highly%2520active%2520Clostridium%2520difficile%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D9772%26epage%3D9791%26doi%3D10.1021%2Facs.jmedchem.9b01198" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Swahn, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolmodin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlstrom, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Berg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soderman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holenz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindstrom, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sundstrom, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turek, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kihlstrom, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slivo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pyring, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rotticci, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohberg, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kers, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Kieseritzky, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsson, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eketjall, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Georgievska, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeppsson, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falting, J.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of beta-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors with in vivo brain reduction of beta-amyloid peptides</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">9346</span>– <span class="NLM_lpage">9361</span>, <span class="refDoi"> DOI: 10.1021/jm3009025</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3009025" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1OmtL%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=9346-9361&author=B.+M.+Swahnauthor=K.+Kolmodinauthor=S.+Karlstromauthor=S.+von+Bergauthor=P.+Sodermanauthor=J.+Holenzauthor=S.+Bergauthor=J.+Lindstromauthor=M.+Sundstromauthor=D.+Turekauthor=J.+Kihlstromauthor=C.+Slivoauthor=L.+Anderssonauthor=D.+Pyringauthor=D.+Rotticciauthor=L.+Ohbergauthor=A.+Kersauthor=K.+Bogarauthor=F.+von+Kieseritzkyauthor=M.+Berghauthor=L.+L.+Olssonauthor=J.+Jansonauthor=S.+Eketjallauthor=B.+Georgievskaauthor=F.+Jeppssonauthor=J.+Falting&title=Design+and+synthesis+of+beta-site+amyloid+precursor+protein+cleaving+enzyme+%28BACE1%29+inhibitors+with+in+vivo+brain+reduction+of+beta-amyloid+peptides&doi=10.1021%2Fjm3009025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of β-Site Amyloid Precursor Protein Cleaving Enzyme (BACE1) Inhibitors with in Vivo Brain Reduction of β-Amyloid Peptides</span></div><div class="casAuthors">Swahn, Britt-Marie; Kolmodin, Karin; Karlstroem, Sofia; von Berg, Stefan; Soederman, Peter; Holenz, Joerg; Berg, Stefan; Lindstroem, Johan; Sundstroem, Marie; Turek, Dominika; Kihlstroem, Jacob; Slivo, Can; Andersson, Lars; Pyring, David; Rotticci, Didier; Oehberg, Liselotte; Kers, Annika; Bogar, Krisztian; Bergh, Margareta; Olsson, Lise-Lotte; Janson, Juliette; Eketjaell, Susanna; Georgievska, Biljana; Jeppsson, Fredrik; Faelting, Johanna</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">9346-9361</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The evaluation of a series of aminoisoindoles as β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors and the discovery of a clin. candidate drug for Alzheimer's disease, (S)-32 (I, AZD3839), are described.  The improvement in permeability properties by the introduction of fluorine adjacent to the amidine moiety, resulting in in vivo brain redn. of Aβ40, is discussed.  Due to the basic nature of these compds., they displayed affinity for the human ether-a-go-go related gene (hERG) ion channel.  Different ways to reduce hERG inhibition and increase hERG margins for this series are described, culminating in (S)-16 (II) and (R)-41 (III) showing large in vitro margins with BACE1 cell IC50 values of 8.6 and 0.16 nM, resp., and hERG IC50 values of 16 and 2.8 μM, resp.  Several compds. were advanced into pharmacodynamic studies and demonstrated significant redn. of β-amyloid peptides in mouse brain following oral dosing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGox062OT8a6ubVg90H21EOLACvtfcHk0liC2Arq_x3pZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1OmtL%252FM&md5=da7685d90f56449caa77b6e6393e0a7d</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1021%2Fjm3009025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3009025%26sid%3Dliteratum%253Aachs%26aulast%3DSwahn%26aufirst%3DB.%2BM.%26aulast%3DKolmodin%26aufirst%3DK.%26aulast%3DKarlstrom%26aufirst%3DS.%26aulast%3Dvon%2BBerg%26aufirst%3DS.%26aulast%3DSoderman%26aufirst%3DP.%26aulast%3DHolenz%26aufirst%3DJ.%26aulast%3DBerg%26aufirst%3DS.%26aulast%3DLindstrom%26aufirst%3DJ.%26aulast%3DSundstrom%26aufirst%3DM.%26aulast%3DTurek%26aufirst%3DD.%26aulast%3DKihlstrom%26aufirst%3DJ.%26aulast%3DSlivo%26aufirst%3DC.%26aulast%3DAndersson%26aufirst%3DL.%26aulast%3DPyring%26aufirst%3DD.%26aulast%3DRotticci%26aufirst%3DD.%26aulast%3DOhberg%26aufirst%3DL.%26aulast%3DKers%26aufirst%3DA.%26aulast%3DBogar%26aufirst%3DK.%26aulast%3Dvon%2BKieseritzky%26aufirst%3DF.%26aulast%3DBergh%26aufirst%3DM.%26aulast%3DOlsson%26aufirst%3DL.%2BL.%26aulast%3DJanson%26aufirst%3DJ.%26aulast%3DEketjall%26aufirst%3DS.%26aulast%3DGeorgievska%26aufirst%3DB.%26aulast%3DJeppsson%26aufirst%3DF.%26aulast%3DFalting%26aufirst%3DJ.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520beta-site%2520amyloid%2520precursor%2520protein%2520cleaving%2520enzyme%2520%2528BACE1%2529%2520inhibitors%2520with%2520in%2520vivo%2520brain%2520reduction%2520of%2520beta-amyloid%2520peptides%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D9346%26epage%3D9361%26doi%3D10.1021%2Fjm3009025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cumming, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misiaszek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durkin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iserloh, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strickland, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voigt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuvelkar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyde, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Favreau, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czarniecki, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenlee, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKittrick, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stamford, A. W.</span></span> <span> </span><span class="NLM_article-title">Structure based design of iminohydantoin BACE1 inhibitors: identification of an orally available, centrally active BACE1 inhibitor</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">2444</span>– <span class="NLM_lpage">2449</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.02.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1016%2Fj.bmcl.2012.02.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=22390835" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjt1ektbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=2444-2449&author=J.+N.+Cummingauthor=E.+M.+Smithauthor=L.+Wangauthor=J.+Misiaszekauthor=J.+Durkinauthor=J.+Panauthor=U.+Iserlohauthor=Y.+Wuauthor=Z.+Zhuauthor=C.+Stricklandauthor=J.+Voigtauthor=X.+Chenauthor=M.+E.+Kennedyauthor=R.+Kuvelkarauthor=L.+A.+Hydeauthor=K.+Coxauthor=L.+Favreauauthor=M.+F.+Czarnieckiauthor=W.+J.+Greenleeauthor=B.+A.+McKittrickauthor=E.+M.+Parkerauthor=A.+W.+Stamford&title=Structure+based+design+of+iminohydantoin+BACE1+inhibitors%3A+identification+of+an+orally+available%2C+centrally+active+BACE1+inhibitor&doi=10.1016%2Fj.bmcl.2012.02.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Structure based design of iminohydantoin BACE1 inhibitors: Identification of an orally available, centrally active BACE1 inhibitor</span></div><div class="casAuthors">Cumming, Jared N.; Smith, Elizabeth M.; Wang, Lingyan; Misiaszek, Jeffrey; Durkin, James; Pan, Jianping; Iserloh, Ulrich; Wu, Yusheng; Zhu, Zhaoning; Strickland, Corey; Voigt, Johannes; Chen, Xia; Kennedy, Matthew E.; Kuvelkar, Reshma; Hyde, Lynn A.; Cox, Kathleen; Favreau, Leonard; Czarniecki, Michael F.; Greenlee, William J.; McKittrick, Brian A.; Parker, Eric M.; Stamford, Andrew W.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2444-2449</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">From an initial lead 2-imino-1-methyl-4,4-diphenyl-5-imidazolidinone, a structure-based design approach led to identification of the novel, high-affinity iminohydantoin BACE1 inhibitor I that lowers CNS-derived Aβ following oral administration to rats.  SAR development in the S3 and F' subsites of BACE1 for this series, the synthetic approaches employed in this effort, and in vivo data for I are reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3tWBE09QKNLVg90H21EOLACvtfcHk0liC2Arq_x3pZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjt1ektbY%253D&md5=783b6cb9a6d9608ff5e9dc4f5d634397</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.02.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.02.013%26sid%3Dliteratum%253Aachs%26aulast%3DCumming%26aufirst%3DJ.%2BN.%26aulast%3DSmith%26aufirst%3DE.%2BM.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DMisiaszek%26aufirst%3DJ.%26aulast%3DDurkin%26aufirst%3DJ.%26aulast%3DPan%26aufirst%3DJ.%26aulast%3DIserloh%26aufirst%3DU.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DStrickland%26aufirst%3DC.%26aulast%3DVoigt%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DKennedy%26aufirst%3DM.%2BE.%26aulast%3DKuvelkar%26aufirst%3DR.%26aulast%3DHyde%26aufirst%3DL.%2BA.%26aulast%3DCox%26aufirst%3DK.%26aulast%3DFavreau%26aufirst%3DL.%26aulast%3DCzarniecki%26aufirst%3DM.%2BF.%26aulast%3DGreenlee%26aufirst%3DW.%2BJ.%26aulast%3DMcKittrick%26aufirst%3DB.%2BA.%26aulast%3DParker%26aufirst%3DE.%2BM.%26aulast%3DStamford%26aufirst%3DA.%2BW.%26atitle%3DStructure%2520based%2520design%2520of%2520iminohydantoin%2520BACE1%2520inhibitors%253A%2520identification%2520of%2520an%2520orally%2520available%252C%2520centrally%2520active%2520BACE1%2520inhibitor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D2444%26epage%3D2449%26doi%3D10.1016%2Fj.bmcl.2012.02.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stamford, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tadesse, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misiaszek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cumming, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKittrick, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strickland, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orth, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voigt, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuvelkar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodgson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyde, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Favreau, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenlee, W. J.</span></span> <span> </span><span class="NLM_article-title">Discovery of an orally available, brain penetrant BACE1 inhibitor that affords robust CNS Abeta reduction</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">897</span>– <span class="NLM_lpage">902</span>, <span class="refDoi"> DOI: 10.1021/ml3001165</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml3001165" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVWhtLvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=897-902&author=A.+W.+Stamfordauthor=J.+D.+Scottauthor=S.+W.+Liauthor=S.+Babuauthor=D.+Tadesseauthor=R.+Hunterauthor=Y.+Wuauthor=J.+Misiaszekauthor=J.+N.+Cummingauthor=E.+J.+Gilbertauthor=C.+Huangauthor=B.+A.+McKittrickauthor=L.+Hongauthor=T.+Guoauthor=Z.+Zhuauthor=C.+Stricklandauthor=P.+Orthauthor=J.+H.+Voigtauthor=M.+E.+Kennedyauthor=X.+Chenauthor=R.+Kuvelkarauthor=R.+Hodgsonauthor=L.+A.+Hydeauthor=K.+Coxauthor=L.+Favreauauthor=E.+M.+Parkerauthor=W.+J.+Greenlee&title=Discovery+of+an+orally+available%2C+brain+penetrant+BACE1+inhibitor+that+affords+robust+CNS+Abeta+reduction&doi=10.1021%2Fml3001165"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of an Orally Available, Brain Penetrant BACE1 Inhibitor That Affords Robust CNS Aβ Reduction</span></div><div class="casAuthors">Stamford, Andrew W.; Scott, Jack D.; Li, Sarah W.; Babu, Suresh; Tadesse, Dawit; Hunter, Rachael; Wu, Yusheng; Misiaszek, Jeffrey; Cumming, Jared N.; Gilbert, Eric J.; Huang, Chunli; McKittrick, Brian A.; Hong, Liwu; Guo, Tao; Zhu, Zhaoning; Strickland, Corey; Orth, Peter; Voigt, Johannes H.; Kennedy, Matthew E.; Chen, Xia; Kuvelkar, Reshma; Hodgson, Robert; Hyde, Lynn A.; Cox, Kathleen; Favreau, Leonard; Parker, Eric M.; Greenlee, William J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">897-902</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of BACE1 to prevent brain Aβ peptide formation is a potential disease-modifying approach to the treatment of Alzheimer's disease.  Despite over a decade of drug discovery efforts, the identification of brain-penetrant BACE1 inhibitors that substantially lower CNS Aβ levels following systemic administration remains challenging.  In this report we describe structure-based optimization of a series of brain-penetrant BACE1 inhibitors derived from an iminopyrimidinone scaffold.  Application of structure-based design in tandem with control of physicochem. properties culminated in the discovery of compd. 16, which potently reduced cortex and CSF Aβ40 levels when administered orally to rats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplHonEJedFZbVg90H21EOLACvtfcHk0lj5P6ySWEAx4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVWhtLvL&md5=8f743636119e48ed25d0f8c97d963440</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1021%2Fml3001165&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml3001165%26sid%3Dliteratum%253Aachs%26aulast%3DStamford%26aufirst%3DA.%2BW.%26aulast%3DScott%26aufirst%3DJ.%2BD.%26aulast%3DLi%26aufirst%3DS.%2BW.%26aulast%3DBabu%26aufirst%3DS.%26aulast%3DTadesse%26aufirst%3DD.%26aulast%3DHunter%26aufirst%3DR.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DMisiaszek%26aufirst%3DJ.%26aulast%3DCumming%26aufirst%3DJ.%2BN.%26aulast%3DGilbert%26aufirst%3DE.%2BJ.%26aulast%3DHuang%26aufirst%3DC.%26aulast%3DMcKittrick%26aufirst%3DB.%2BA.%26aulast%3DHong%26aufirst%3DL.%26aulast%3DGuo%26aufirst%3DT.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DStrickland%26aufirst%3DC.%26aulast%3DOrth%26aufirst%3DP.%26aulast%3DVoigt%26aufirst%3DJ.%2BH.%26aulast%3DKennedy%26aufirst%3DM.%2BE.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DKuvelkar%26aufirst%3DR.%26aulast%3DHodgson%26aufirst%3DR.%26aulast%3DHyde%26aufirst%3DL.%2BA.%26aulast%3DCox%26aufirst%3DK.%26aulast%3DFavreau%26aufirst%3DL.%26aulast%3DParker%26aufirst%3DE.%2BM.%26aulast%3DGreenlee%26aufirst%3DW.%2BJ.%26atitle%3DDiscovery%2520of%2520an%2520orally%2520available%252C%2520brain%2520penetrant%2520BACE1%2520inhibitor%2520that%2520affords%2520robust%2520CNS%2520Abeta%2520reduction%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D3%26spage%3D897%26epage%3D902%26doi%3D10.1021%2Fml3001165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Amdouni, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Driowya, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furstoss, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubois, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dufies, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zerhouni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orange, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacas-Gervais, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bougrin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auberger, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benhida, R.</span></span> <span> </span><span class="NLM_article-title">In vitro and in vivo evaluation of fully substituted (5-(3-ethoxy-3-oxopropynyl)-4-(ethoxycarbonyl)-1,2,3-triazolyl-glycosides as original nucleoside analogues to circumvent resistance in myeloid malignancies</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1523</span>– <span class="NLM_lpage">1533</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01803</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01803" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1Wis7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=1523-1533&author=H.+Amdouniauthor=G.+Robertauthor=M.+Driowyaauthor=N.+Furstossauthor=C.+Metierauthor=A.+Duboisauthor=M.+Dufiesauthor=M.+Zerhouniauthor=F.+Orangeauthor=S.+Lacas-Gervaisauthor=K.+Bougrinauthor=A.+R.+Martinauthor=P.+Aubergerauthor=R.+Benhida&title=In+vitro+and+in+vivo+evaluation+of+fully+substituted+%285-%283-ethoxy-3-oxopropynyl%29-4-%28ethoxycarbonyl%29-1%2C2%2C3-triazolyl-glycosides+as+original+nucleoside+analogues+to+circumvent+resistance+in+myeloid+malignancies&doi=10.1021%2Facs.jmedchem.6b01803"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">In Vitro and in Vivo Evaluation of Fully Substituted (5-(3-Ethoxy-3-oxopropynyl)-4-(ethoxycarbonyl)-1,2,3-triazolyl-glycosides as Original Nucleoside Analogues to Circumvent Resistance in Myeloid Malignancies</span></div><div class="casAuthors">Amdouni, Hella; Robert, Guillaume; Driowya, Mohsine; Furstoss, Nathan; Metier, Camille; Dubois, Alix; Dufies, Maeva; Zerhouni, Marwa; Orange, Francois; Lacas-Gervais, Sandra; Bougrin, Khalid; Martin, Anthony R.; Auberger, Patrick; Benhida, Rachid</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1523-1533</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of nucleoside analogs, e.g. I, bearing a 1,4,5-tri-substituted-1,2,3-triazole aglycon was synthesized using a straightforward click/electrophilic addn. or click/oxidative coupling tandem procedures.  SAR anal., using cell culture assays, led to the discovery of a series of compds. belonging to the 5-alkynyl-1,2,3-triazole family that exhibits potent antileukemic effects on several hematol. malignancies including chronic myeloid leukemia (CML) and myelodysplastic syndromes (MDS) either sensitive or resistant to their resp. therapy.  Compd. I also proved efficient in vivo on mice xenografted with SKM1-R MDS cell line.  Addnl., some insights in its mode of action revealed that this compd. can induce cell death by caspase and autophagy induction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTyWFgIEL5lbVg90H21EOLACvtfcHk0lj5P6ySWEAx4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1Wis7Y%253D&md5=ff14c875c43a6f56897d356d48c4a6e9</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01803&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01803%26sid%3Dliteratum%253Aachs%26aulast%3DAmdouni%26aufirst%3DH.%26aulast%3DRobert%26aufirst%3DG.%26aulast%3DDriowya%26aufirst%3DM.%26aulast%3DFurstoss%26aufirst%3DN.%26aulast%3DMetier%26aufirst%3DC.%26aulast%3DDubois%26aufirst%3DA.%26aulast%3DDufies%26aufirst%3DM.%26aulast%3DZerhouni%26aufirst%3DM.%26aulast%3DOrange%26aufirst%3DF.%26aulast%3DLacas-Gervais%26aufirst%3DS.%26aulast%3DBougrin%26aufirst%3DK.%26aulast%3DMartin%26aufirst%3DA.%2BR.%26aulast%3DAuberger%26aufirst%3DP.%26aulast%3DBenhida%26aufirst%3DR.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520evaluation%2520of%2520fully%2520substituted%2520%25285-%25283-ethoxy-3-oxopropynyl%2529-4-%2528ethoxycarbonyl%2529-1%252C2%252C3-triazolyl-glycosides%2520as%2520original%2520nucleoside%2520analogues%2520to%2520circumvent%2520resistance%2520in%2520myeloid%2520malignancies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D1523%26epage%3D1533%26doi%3D10.1021%2Facs.jmedchem.6b01803" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robert, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ben Sahra, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puissant, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colosetti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belhacene, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gounon, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bost, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassuto, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auberger, P.</span></span> <span> </span><span class="NLM_article-title">Acadesine kills chronic myelogenous leukemia (CML) cells through PKC-dependent induction of autophagic cell death</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">e7889</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0007889</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1371%2Fjournal.pone.0007889" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=19924252" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2009&pages=e7889&author=G.+Robertauthor=I.+Ben+Sahraauthor=A.+Puissantauthor=P.+Colosettiauthor=N.+Belhaceneauthor=P.+Gounonauthor=P.+Hofmanauthor=F.+Bostauthor=J.+P.+Cassutoauthor=P.+Auberger&title=Acadesine+kills+chronic+myelogenous+leukemia+%28CML%29+cells+through+PKC-dependent+induction+of+autophagic+cell+death&doi=10.1371%2Fjournal.pone.0007889"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0007889&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0007889%26sid%3Dliteratum%253Aachs%26aulast%3DRobert%26aufirst%3DG.%26aulast%3DBen%2BSahra%26aufirst%3DI.%26aulast%3DPuissant%26aufirst%3DA.%26aulast%3DColosetti%26aufirst%3DP.%26aulast%3DBelhacene%26aufirst%3DN.%26aulast%3DGounon%26aufirst%3DP.%26aulast%3DHofman%26aufirst%3DP.%26aulast%3DBost%26aufirst%3DF.%26aulast%3DCassuto%26aufirst%3DJ.%2BP.%26aulast%3DAuberger%26aufirst%3DP.%26atitle%3DAcadesine%2520kills%2520chronic%2520myelogenous%2520leukemia%2520%2528CML%2529%2520cells%2520through%2520PKC-dependent%2520induction%2520of%2520autophagic%2520cell%2520death%26jtitle%3DPLoS%2520One%26date%3D2009%26volume%3D4%26spage%3De7889%26doi%3D10.1371%2Fjournal.pone.0007889" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Echeverria, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chene, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blommers, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furet, P.</span></span> <span> </span><span class="NLM_article-title">Discovery of potent antagonists of the interaction between human double minute 2 and tumor suppressor p53</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">3205</span>– <span class="NLM_lpage">3208</span>, <span class="refDoi"> DOI: 10.1021/jm990966p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm990966p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD3cXltlOruro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=3205-3208&author=C.+Garcia-Echeverriaauthor=P.+Cheneauthor=M.+J.+Blommersauthor=P.+Furet&title=Discovery+of+potent+antagonists+of+the+interaction+between+human+double+minute+2+and+tumor+suppressor+p53&doi=10.1021%2Fjm990966p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Potent Antagonists of the Interaction between Human Double Minute 2 and Tumor Suppressor p53</span></div><div class="casAuthors">Garcia-Echeverria, Carlos; Chene, Patrick; Blommers, Marcel J. J.; Furet, Pascal</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">3205-3208</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">As part of a drug discovery program to identify antagonists of the p53/hdm2 (human double minute 2) protein-protein interaction, the authors have attempted to det. the amino acid specificities of hdm2's binding pockets to establish a pharmacophore model for this protein-protein interaction.  This work has resulted in the identification of highly potent peptide antagonists.  Structural information has been exploited to increase the hdm2-binding affinity of short peptide motifs derived from the N-terminal domain of the human wild-type p53 protein.  Combining conformational constraints as selected by mol. modeling with functional groups that are able to establish addnl. electrostatic and van der Waals interactions with the hdm2 protein, the authors have been able to increase the hdm2-binding affinity of the authors initial peptide 1700-fold.  Particularly interesting is the increase in binding affinity obtained by replacing tryptophan with 6-chlorotryptophan (IC50 = 314 nM vs. IC50 = 5 nM, 63-fold).  The new interactions identified and exptl. confirmed in this work could be directly applied to the optimization of nonpeptidic leads or incorporated into the "de novo" design of antagonists of the p53/hdm2 protein-protein interaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpOq3ikfGqz7Vg90H21EOLACvtfcHk0lj5P6ySWEAx4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXltlOruro%253D&md5=b921adfdd6a5c85510276a6446e600a8</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1021%2Fjm990966p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm990966p%26sid%3Dliteratum%253Aachs%26aulast%3DGarcia-Echeverria%26aufirst%3DC.%26aulast%3DChene%26aufirst%3DP.%26aulast%3DBlommers%26aufirst%3DM.%2BJ.%26aulast%3DFuret%26aufirst%3DP.%26atitle%3DDiscovery%2520of%2520potent%2520antagonists%2520of%2520the%2520interaction%2520between%2520human%2520double%2520minute%25202%2520and%2520tumor%2520suppressor%2520p53%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D3205%26epage%3D3208%26doi%3D10.1021%2Fjm990966p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parks, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lafrance, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calvo, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milkiewicz, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lattanze, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramachandren, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carver, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrella, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cummings, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maguire, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grasberger, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, T.</span></span> <span> </span><span class="NLM_article-title">1,4-Benzodiazepine-2,5-diones as small molecule antagonists of the HDM2-p53 interaction: discovery and SAR</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">765</span>– <span class="NLM_lpage">770</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2004.11.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1016%2Fj.bmcl.2004.11.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=15664854" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD2MXnsVOjsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=765-770&author=D.+J.+Parksauthor=L.+V.+Lafranceauthor=R.+R.+Calvoauthor=K.+L.+Milkiewiczauthor=V.+Guptaauthor=J.+Lattanzeauthor=K.+Ramachandrenauthor=T.+E.+Carverauthor=E.+C.+Petrellaauthor=M.+D.+Cummingsauthor=D.+Maguireauthor=B.+L.+Grasbergerauthor=T.+Lu&title=1%2C4-Benzodiazepine-2%2C5-diones+as+small+molecule+antagonists+of+the+HDM2-p53+interaction%3A+discovery+and+SAR&doi=10.1016%2Fj.bmcl.2004.11.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">1,4-Benzodiazepine-2,5-diones as small molecule antagonists of the HDM2-p53 interaction: discovery and SAR</span></div><div class="casAuthors">Parks, Daniel J.; LaFrance, Louis V.; Calvo, Raul R.; Milkiewicz, Karen L.; Gupta, Varsha; Lattanze, Jennifer; Ramachandren, Kannan; Carver, Theodore E.; Petrella, Eugene C.; Cummings, Maxwell D.; Maguire, Diane; Grasberger, Bruce L.; Lu, Tianbao</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">765-770</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A library of 1,4-benzodiazepine-2,5-diones, e.g., I, was screened for binding to the p53-binding domain of HDM2 using Thermofluor, a miniaturized thermal denaturation assay.  The hits obtained were shown to bind to HDM2 in the p53-binding pocket using a fluorescence polarization (FP) peptide displacement assay.  The potency of the series was optimized, leading to sub-micromolar antagonists of the p53-HDM2 interaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_zZ37DwJB07Vg90H21EOLACvtfcHk0livCpOUVotZ3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXnsVOjsg%253D%253D&md5=2c6cbe6faecdf2313130f4c6a868be7c</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2004.11.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2004.11.009%26sid%3Dliteratum%253Aachs%26aulast%3DParks%26aufirst%3DD.%2BJ.%26aulast%3DLafrance%26aufirst%3DL.%2BV.%26aulast%3DCalvo%26aufirst%3DR.%2BR.%26aulast%3DMilkiewicz%26aufirst%3DK.%2BL.%26aulast%3DGupta%26aufirst%3DV.%26aulast%3DLattanze%26aufirst%3DJ.%26aulast%3DRamachandren%26aufirst%3DK.%26aulast%3DCarver%26aufirst%3DT.%2BE.%26aulast%3DPetrella%26aufirst%3DE.%2BC.%26aulast%3DCummings%26aufirst%3DM.%2BD.%26aulast%3DMaguire%26aufirst%3DD.%26aulast%3DGrasberger%26aufirst%3DB.%2BL.%26aulast%3DLu%26aufirst%3DT.%26atitle%3D1%252C4-Benzodiazepine-2%252C5-diones%2520as%2520small%2520molecule%2520antagonists%2520of%2520the%2520HDM2-p53%2520interaction%253A%2520discovery%2520and%2520SAR%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2005%26volume%3D15%26spage%3D765%26epage%3D770%26doi%3D10.1016%2Fj.bmcl.2004.11.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Das, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vedachalam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonio, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reith, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutta, A. K.</span></span> <span> </span><span class="NLM_article-title">Development of a highly potent D<sub>2</sub>/D<sub>3</sub> agonist and a partial agonist from structure-activity relationship study of <i>N</i>(6)-(2-(4-(1<i>H</i>-indol-5-yl)piperazin-1-yl)ethyl)-<i>N</i>(6)-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine analogues: Implication in the treatment of Parkinson’s disease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">9179</span>– <span class="NLM_lpage">9195</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01031</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01031" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVWnsb3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=9179-9195&author=B.+Dasauthor=S.+Vedachalamauthor=D.+Luoauthor=T.+Antonioauthor=M.+E.+Reithauthor=A.+K.+Dutta&title=Development+of+a+highly+potent+D2%2FD3+agonist+and+a+partial+agonist+from+structure-activity+relationship+study+of+N%286%29-%282-%284-%281H-indol-5-yl%29piperazin-1-yl%29ethyl%29-N%286%29-propyl-4%2C5%2C6%2C7-tetrahydrobenzo%5Bd%5Dthiazole-2%2C6-diamine+analogues%3A+Implication+in+the+treatment+of+Parkinson%E2%80%99s+disease&doi=10.1021%2Facs.jmedchem.5b01031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a Highly Potent D2/D3 Agonist and a Partial Agonist from Structure-Activity Relationship Study of N6-(2-(4-(1H-Indol-5-yl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine Analogues: Implication in the Treatment of Parkinson's Disease</span></div><div class="casAuthors">Das, Banibrata; Vedachalam, Seenuvasan; Luo, Dan; Antonio, Tamara; Reith, Maarten E. A.; Dutta, Aloke K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">9179-9195</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The structure-activity relationship studies with N6-(2-(4-(1H-indol-5-yl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine derivs. led to development of a lead compd. I which exhibited very high affinity (Ki, D2 = 16.4 nM, D3 = 1.15 nM) and full agonist activity (EC50 (GTPγS); D2 = 3.23 and D3 = 1.41 nM) at both D2 and D3 receptors.  A partial agonist mol. II (EC50 (GTPγS); D2 = 21.6 (Emax = 27%) and D3 = 10.9 nM) was also identified.  In a Parkinson's disease (PD) animal model, I was highly efficacious in reversing hypolocomotion in reserpinized rats with a long duration of action, indicating its potential as an anti-PD drug.  Compd. II was also able to elevate locomotor activity in the above PD animal model significantly, implying its potential application in PD therapy.  Furthermore, I was shown to be neuroprotective in protecting neuronal PC12 from toxicity of 6-OHDA.  This report, therefore, underpins the notion that a multifunctional drug like I might have the potential not only to ameliorate motor dysfunction in PD patients but also to modify disease progression by protecting DA neurons from progressive degeneration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3VvEVudaNt7Vg90H21EOLACvtfcHk0livCpOUVotZ3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVWnsb3F&md5=a9f9d11a85cb0fb0150899403dba4fd7</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01031%26sid%3Dliteratum%253Aachs%26aulast%3DDas%26aufirst%3DB.%26aulast%3DVedachalam%26aufirst%3DS.%26aulast%3DLuo%26aufirst%3DD.%26aulast%3DAntonio%26aufirst%3DT.%26aulast%3DReith%26aufirst%3DM.%2BE.%26aulast%3DDutta%26aufirst%3DA.%2BK.%26atitle%3DDevelopment%2520of%2520a%2520highly%2520potent%2520D2%252FD3%2520agonist%2520and%2520a%2520partial%2520agonist%2520from%2520structure-activity%2520relationship%2520study%2520of%2520N%25286%2529-%25282-%25284-%25281H-indol-5-yl%2529piperazin-1-yl%2529ethyl%2529-N%25286%2529-propyl-4%252C5%252C6%252C7-tetrahydrobenzo%255Bd%255Dthiazole-2%252C6-diamine%2520analogues%253A%2520Implication%2520in%2520the%2520treatment%2520of%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D9179%26epage%3D9195%26doi%3D10.1021%2Facs.jmedchem.5b01031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aridoss, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hermanson, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bleeker, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, C.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationship (SAR) study of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4<i>H</i>-chromene-3-carboxylate (CXL017) and the potential of the lead against multidrug resistance in cancer treatment</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">5566</span>– <span class="NLM_lpage">5581</span>, <span class="refDoi"> DOI: 10.1021/jm300515q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300515q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC38XmvFWrurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=5566-5581&author=G.+Aridossauthor=B.+Zhouauthor=D.+L.+Hermansonauthor=N.+P.+Bleekerauthor=C.+Xing&title=Structure-activity+relationship+%28SAR%29+study+of+ethyl+2-amino-6-%283%2C5-dimethoxyphenyl%29-4-%282-ethoxy-2-oxoethyl%29-4H-chromene-3-carboxylate+%28CXL017%29+and+the+potential+of+the+lead+against+multidrug+resistance+in+cancer+treatment&doi=10.1021%2Fjm300515q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-activity relationship (SAR) study of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and the potential of the lead against multidrug resistance in cancer treatment</span></div><div class="casAuthors">Aridoss, Gopalakrishnan; Zhou, Bo; Hermanson, David L.; Bleeker, Nicholas P.; Xing, Chengguo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5566-5581</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Multidrug resistance (MDR) against std. therapies poses a serious challenge in cancer treatment, and there is a clin. need for new anticancer agents that would selectively target MDR malignancies.  Our previous studies have identified a 4H-chromene system, CXL017 as an example, that can preferentially kill MDR cancer cells.  To further improve its potency, we have performed detailed structure-activity relationship (SAR) studies at the 3, 4, and 6 positions of the 4H-chromene system.  The results reveal that the 3 and 4 positions prefer rigid and hydrophobic functional groups while the 6 position prefers a meta or para-substituted aryl functional group and the substituent should be small and hydrophilic.  We have also identified and characterized nine MDR cancer cells that acquire MDR through different mechanisms and demonstrated the scope of our new lead, (I), to selectively target different MDR cancers, which holds promise to help manage MDR in cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUJiRF64HIhrVg90H21EOLACvtfcHk0livCpOUVotZ3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmvFWrurs%253D&md5=d3de8ff2f8decb159a3872d076c84920</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1021%2Fjm300515q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300515q%26sid%3Dliteratum%253Aachs%26aulast%3DAridoss%26aufirst%3DG.%26aulast%3DZhou%26aufirst%3DB.%26aulast%3DHermanson%26aufirst%3DD.%2BL.%26aulast%3DBleeker%26aufirst%3DN.%2BP.%26aulast%3DXing%26aufirst%3DC.%26atitle%3DStructure-activity%2520relationship%2520%2528SAR%2529%2520study%2520of%2520ethyl%25202-amino-6-%25283%252C5-dimethoxyphenyl%2529-4-%25282-ethoxy-2-oxoethyl%2529-4H-chromene-3-carboxylate%2520%2528CXL017%2529%2520and%2520the%2520potential%2520of%2520the%2520lead%2520against%2520multidrug%2520resistance%2520in%2520cancer%2520treatment%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D5566%26epage%3D5581%26doi%3D10.1021%2Fjm300515q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heise, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Dowd, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figueroa, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawyer, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Im, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stocco, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellefeuille, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abramovitz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, D. L.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clements, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coulombe, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neill, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metters, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, J. F.</span></span> <span> </span><span class="NLM_article-title">Characterization of the human cysteinyl leukotriene 2 receptor</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>275</i></span>,  <span class="NLM_fpage">30531</span>– <span class="NLM_lpage">30536</span>, <span class="refDoi"> DOI: 10.1074/jbc.M003490200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1074%2Fjbc.M003490200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10851239" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD3cXnt1agt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=275&publication_year=2000&pages=30531-30536&author=C.+E.+Heiseauthor=B.+F.+O%E2%80%99Dowdauthor=D.+J.+Figueroaauthor=N.+Sawyerauthor=T.+Nguyenauthor=D.+S.+Imauthor=R.+Stoccoauthor=J.+N.+Bellefeuilleauthor=M.+Abramovitzauthor=R.+Chengauthor=D.+L.+Williamsauthor=Z.+Zengauthor=Q.+Liuauthor=L.+Maauthor=M.+K.+Clementsauthor=N.+Coulombeauthor=Y.+Liuauthor=C.+P.+Austinauthor=S.+R.+Georgeauthor=G.+P.+O%E2%80%99Neillauthor=K.+M.+Mettersauthor=K.+R.+Lynchauthor=J.+F.+Evans&title=Characterization+of+the+human+cysteinyl+leukotriene+2+receptor&doi=10.1074%2Fjbc.M003490200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of the human cysteinyl leukotriene 2 receptor</span></div><div class="casAuthors">Heise, Christopher E.; O'Dowd, Brian F.; Figueroa, David J.; Sawyer, Nicole; Nguyen, Tuan; Im, Dong-Soon; Stocco, Rino; Bellefeuille, Julie N.; Abramovitz, Mark; Cheng, Regina; Williams, David L., Jr.; Zeng, Zhizhen; Liu, Qingyun; Ma, Lei; Clements, Michelle K.; Coulombe, Nathalie; Liu, Yuan; Austin, Christopher P.; George, Susan R.; O'Neill, Gary P.; Metters, Kathleen M.; Lynch, Kevin R.; Evans, Jilly F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">275</span>
        (<span class="NLM_cas:issue">39</span>),
    <span class="NLM_cas:pages">30531-30536</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The contractile and inflammatory actions of the cysteinyl leukotrienes (CysLTs), LTC4, LTD4, and LTE4, are thought to be mediated through at least two distinct but related CysLT G protein-coupled receptors.  The human CysLT1 receptor has been recently cloned and characterized.  We describe here the cloning and characterization of the second cysteinyl leukotriene receptor, CysLT2, a 346-amino acid protein with 38% amino acid identity to the CysLT1 receptor.  The recombinant human CysLT2 receptor was expressed in Xenopus oocytes and HEK293T cells and shown to couple to elevation of intracellular calcium when activated by LTC4, LTD4, or LTE4.  Analyses of radiolabeled LTD4 binding to the recombinant CysLT2 receptor demonstrated high affinity binding and a rank order of potency for competition of LTC4 = LTD4 » LTE4.  In contrast to the dual CysLT1/CysLT2 antagonist, BAY u9773, the CysLT1 receptor-selective antagonists MK-571, montelukast, zafirlukast, and pranlukast exhibited low potency in competition for LTD4 binding and as antagonists of CysLT2 receptor signaling.  CysLT2 receptor mRNA was detected in lung macrophages and airway smooth muscle, cardiac Purkinje cells, adrenal medulla cells, peripheral blood leukocytes, and brain, and the receptor gene was mapped to chromosome 13q14, a region linked to atopic asthma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNARzHAjs1wLVg90H21EOLACvtfcHk0ljFritRMnpazw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXnt1agt74%253D&md5=a3c128d90e193664c2180e3029d8b96d</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M003490200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M003490200%26sid%3Dliteratum%253Aachs%26aulast%3DHeise%26aufirst%3DC.%2BE.%26aulast%3DO%25E2%2580%2599Dowd%26aufirst%3DB.%2BF.%26aulast%3DFigueroa%26aufirst%3DD.%2BJ.%26aulast%3DSawyer%26aufirst%3DN.%26aulast%3DNguyen%26aufirst%3DT.%26aulast%3DIm%26aufirst%3DD.%2BS.%26aulast%3DStocco%26aufirst%3DR.%26aulast%3DBellefeuille%26aufirst%3DJ.%2BN.%26aulast%3DAbramovitz%26aufirst%3DM.%26aulast%3DCheng%26aufirst%3DR.%26aulast%3DWilliams%26aufirst%3DD.%2BL.%26aulast%3DZeng%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DMa%26aufirst%3DL.%26aulast%3DClements%26aufirst%3DM.%2BK.%26aulast%3DCoulombe%26aufirst%3DN.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DAustin%26aufirst%3DC.%2BP.%26aulast%3DGeorge%26aufirst%3DS.%2BR.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DG.%2BP.%26aulast%3DMetters%26aufirst%3DK.%2BM.%26aulast%3DLynch%26aufirst%3DK.%2BR.%26aulast%3DEvans%26aufirst%3DJ.%2BF.%26atitle%3DCharacterization%2520of%2520the%2520human%2520cysteinyl%2520leukotriene%25202%2520receptor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2000%26volume%3D275%26spage%3D30531%26epage%3D30536%26doi%3D10.1074%2Fjbc.M003490200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Figueroa, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borish, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baramki, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philip, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, J. F.</span></span> <span> </span><span class="NLM_article-title">Expression of cysteinyl leukotriene synthetic and signalling proteins in inflammatory cells in active seasonal allergic rhinitis</span>. <i>Clin. Exp. Allergy</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">1380</span>– <span class="NLM_lpage">1388</span>, <span class="refDoi"> DOI: 10.1046/j.1365-2222.2003.01786.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1046%2Fj.1365-2222.2003.01786.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=14519144" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD3sXptVCjt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2003&pages=1380-1388&author=D.+J.+Figueroaauthor=L.+Borishauthor=D.+Baramkiauthor=G.+Philipauthor=C.+P.+Austinauthor=J.+F.+Evans&title=Expression+of+cysteinyl+leukotriene+synthetic+and+signalling+proteins+in+inflammatory+cells+in+active+seasonal+allergic+rhinitis&doi=10.1046%2Fj.1365-2222.2003.01786.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of cysteinyl leukotriene synthetic and signalling proteins in inflammatory cells in active seasonal allergic rhinitis</span></div><div class="casAuthors">Figueroa, D. J.; Borish, L.; Baramki, D.; Philip, G.; Austin, C. P.; Evans, J. F.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and Experimental Allergy</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1380-1388</span>CODEN:
                <span class="NLM_cas:coden">CLEAEN</span>;
        ISSN:<span class="NLM_cas:issn">0954-7894</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Cysteinyl leukotrienes (CysLTs) are bioactive lipids that have been shown to contribute to allergic and inflammatory diseases.  Eosinophils and mast cells have the capacity to produce large amts. of CysLTs after allergic or non-allergic stimulation.  Mol. identification of both the synthetic and signaling proteins in the CysLT pathway allows the investigation of expression of the CysLT enzymes and receptors in active allergic rhinitis.  The authors examd. the expression of the proteins involved in the synthesis of CysLTs and the cysteinyl leukotriene-1 (CysLT1) and cysteinyl leukotriene-2 (CysLT2) receptors in inflammatory cells from patients with active seasonal allergic rhinitis.  Nasal lavage samples were obtained from patients during active seasonal allergic rhinitis.  Specific cellular immunocytochem. techniques were used to detect the cysteinyl leukotriene synthetic proteins, namely 5-lipoxygenase (5-LO), 5-lipoxygenase-activating protein (FLAP), and leukotriene C4 synthase (LTC4S).  In situ hybridization and immunocytochem. techniques were used to identify the mRNA and proteins for the CysLT1 and CysLT2 receptors.  5-LO, FLAP, and LTC4S, and the CysLT1 and CysLT2 receptors were expressed in the majority of eosinophils and in subsets of mast cells and mononuclear cells.  5-LO, FLAP, and the CysLT1 receptor, but not LTC4S or the CysLT2 receptor, were expressed in a subset of nasal neutrophils.  The study thus demonstrates the presence of CysLT pathway proteins in key allergic and inflammatory cells from the upper airway of patients with active seasonal allergic rhinitis.  These data highlight the potential of CysLT-modifying agents to treat both upper and lower airway symptoms in patients suffering from allergic rhinitis and asthma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpm-YdA-xBKwbVg90H21EOLACvtfcHk0ljFritRMnpazw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXptVCjt7w%253D&md5=d0957d7e8082e022542f234ed7e77f3c</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1046%2Fj.1365-2222.2003.01786.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1365-2222.2003.01786.x%26sid%3Dliteratum%253Aachs%26aulast%3DFigueroa%26aufirst%3DD.%2BJ.%26aulast%3DBorish%26aufirst%3DL.%26aulast%3DBaramki%26aufirst%3DD.%26aulast%3DPhilip%26aufirst%3DG.%26aulast%3DAustin%26aufirst%3DC.%2BP.%26aulast%3DEvans%26aufirst%3DJ.%2BF.%26atitle%3DExpression%2520of%2520cysteinyl%2520leukotriene%2520synthetic%2520and%2520signalling%2520proteins%2520in%2520inflammatory%2520cells%2520in%2520active%2520seasonal%2520allergic%2520rhinitis%26jtitle%3DClin.%2520Exp.%2520Allergy%26date%3D2003%26volume%3D33%26spage%3D1380%26epage%3D1388%26doi%3D10.1046%2Fj.1365-2222.2003.01786.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Itadani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yashiro, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aratani, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekiguchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinoshita, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriguchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohta, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishida, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tajima, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hisaichi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ima, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueda, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egashira, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekioka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadode, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yonetomi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakao, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nomura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitamine, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nabe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imagawa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakayama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeuchi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohmoto, K.</span></span> <span> </span><span class="NLM_article-title">Discovery of gemilukast (ONO-6950), a dual CysLT1 and CysLT2 antagonist as a therapeutic agent for asthma</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">6093</span>– <span class="NLM_lpage">6113</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00741</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00741" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFejt7fO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=6093-6113&author=S.+Itadaniauthor=K.+Yashiroauthor=Y.+Arataniauthor=T.+Sekiguchiauthor=A.+Kinoshitaauthor=H.+Moriguchiauthor=N.+Ohtaauthor=S.+Takahashiauthor=A.+Ishidaauthor=Y.+Tajimaauthor=K.+Hisaichiauthor=M.+Imaauthor=J.+Uedaauthor=H.+Egashiraauthor=T.+Sekiokaauthor=M.+Kadodeauthor=Y.+Yonetomiauthor=T.+Nakaoauthor=A.+Inoueauthor=H.+Nomuraauthor=T.+Kitamineauthor=M.+Fujitaauthor=T.+Nabeauthor=Y.+Yamauraauthor=N.+Matsumuraauthor=A.+Imagawaauthor=Y.+Nakayamaauthor=J.+Takeuchiauthor=K.+Ohmoto&title=Discovery+of+gemilukast+%28ONO-6950%29%2C+a+dual+CysLT1+and+CysLT2+antagonist+as+a+therapeutic+agent+for+asthma&doi=10.1021%2Facs.jmedchem.5b00741"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Gemilukast (ONO-6950), a Dual CysLT1 and CysLT2 Antagonist As a Therapeutic Agent for Asthma</span></div><div class="casAuthors">Itadani, Satoshi; Yashiro, Kentaro; Aratani, Yoshiyuki; Sekiguchi, Tetsuya; Kinoshita, Atsushi; Moriguchi, Hideki; Ohta, Nobukazu; Takahashi, Shinya; Ishida, Akiharu; Tajima, Yohei; Hisaichi, Katsuya; Ima, Masaki; Ueda, Junya; Egashira, Hiromu; Sekioka, Tomohiko; Kadode, Michiaki; Yonetomi, Yasuo; Nakao, Takafumi; Inoue, Atsuto; Nomura, Hiroaki; Kitamine, Tetsuya; Fujita, Manabu; Nabe, Takeshi; Yamaura, Yoshiyuki; Matsumura, Naoya; Imagawa, Akira; Nakayama, Yoshisuke; Takeuchi, Jun; Ohmoto, Kazuyuki</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6093-6113</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">An orally active dual CysLT1 and CysLT2 antagonist possessing a distinctive structure which consists of triple bond and dicarboxylic acid moieties is described.  Gemilukast I (ONO-6950) was generated via isomerization of the core indole and the incorporation of a triple bond into a lead compd.  Gemilukast exhibited antagonist activities with IC50 values of 1.7 and 25 nM against human CysLT1 and human CysLT2, resp., and potent efficacy at an oral dose of 0.1 mg/kg given 24 h before LTD4 challenge in a CysLT1-dependent guinea pig asthmatic model.  In addn., gemilukast dose-dependently reduced LTC4-induced bronchoconstriction in both CysLT1- and CysLT2-dependent guinea pig asthmatic models, and it reduced antigen-induced constriction of isolated human bronchi.  Gemilukast is currently being evaluated in phase II trials for the treatment of asthma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFLZ2Xl1uTMLVg90H21EOLACvtfcHk0ljFritRMnpazw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFejt7fO&md5=038a9b0d067394f1398b57f6bf440afe</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00741&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00741%26sid%3Dliteratum%253Aachs%26aulast%3DItadani%26aufirst%3DS.%26aulast%3DYashiro%26aufirst%3DK.%26aulast%3DAratani%26aufirst%3DY.%26aulast%3DSekiguchi%26aufirst%3DT.%26aulast%3DKinoshita%26aufirst%3DA.%26aulast%3DMoriguchi%26aufirst%3DH.%26aulast%3DOhta%26aufirst%3DN.%26aulast%3DTakahashi%26aufirst%3DS.%26aulast%3DIshida%26aufirst%3DA.%26aulast%3DTajima%26aufirst%3DY.%26aulast%3DHisaichi%26aufirst%3DK.%26aulast%3DIma%26aufirst%3DM.%26aulast%3DUeda%26aufirst%3DJ.%26aulast%3DEgashira%26aufirst%3DH.%26aulast%3DSekioka%26aufirst%3DT.%26aulast%3DKadode%26aufirst%3DM.%26aulast%3DYonetomi%26aufirst%3DY.%26aulast%3DNakao%26aufirst%3DT.%26aulast%3DInoue%26aufirst%3DA.%26aulast%3DNomura%26aufirst%3DH.%26aulast%3DKitamine%26aufirst%3DT.%26aulast%3DFujita%26aufirst%3DM.%26aulast%3DNabe%26aufirst%3DT.%26aulast%3DYamaura%26aufirst%3DY.%26aulast%3DMatsumura%26aufirst%3DN.%26aulast%3DImagawa%26aufirst%3DA.%26aulast%3DNakayama%26aufirst%3DY.%26aulast%3DTakeuchi%26aufirst%3DJ.%26aulast%3DOhmoto%26aufirst%3DK.%26atitle%3DDiscovery%2520of%2520gemilukast%2520%2528ONO-6950%2529%252C%2520a%2520dual%2520CysLT1%2520and%2520CysLT2%2520antagonist%2520as%2520a%2520therapeutic%2520agent%2520for%2520asthma%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D6093%26epage%3D6113%26doi%3D10.1021%2Facs.jmedchem.5b00741" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Motohashi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, M.</span></span> <span> </span><span class="NLM_article-title">Toward clinical application of the Keap1-Nrf2 pathway</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">340</span>– <span class="NLM_lpage">346</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2013.04.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1016%2Fj.tips.2013.04.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=23664668" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnsVylu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2013&pages=340-346&author=T.+Suzukiauthor=H.+Motohashiauthor=M.+Yamamoto&title=Toward+clinical+application+of+the+Keap1-Nrf2+pathway&doi=10.1016%2Fj.tips.2013.04.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Toward clinical application of the Keap1-Nrf2 pathway</span></div><div class="casAuthors">Suzuki, Takafumi; Motohashi, Hozumi; Yamamoto, Masayuki</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">340-346</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The Keap1-Nrf2 pathway plays a crucial role in detg. the sensitivity of cells to chem. and/or oxidative insults by regulating the basal and inducible expression of detoxification and antioxidant enzymes, ABC transporters, and other stress response enzymes and/or proteins.  Increasing attention has been focused on the roles that the Keap1-Nrf2 pathway plays in the protection of our body against drug toxicity and stress-induced diseases.  Simultaneously, Nrf2 has been recognized to promote oncogenesis and resistance to chemotherapeutic drugs.  Cancer cells hijack Nrf2 activity to support their malignant growth and thus Nrf2 has emerged as a therapeutic target.  Translational studies of the Keap1-Nrf2 system, from mechanistic understanding to clin. applications, are now important to improve human health.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3LyyVFE7CB7Vg90H21EOLACvtfcHk0lir5chz4188bQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnsVylu7s%253D&md5=5834bbcb887101cbd4231e384e0580b6</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2013.04.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2013.04.005%26sid%3Dliteratum%253Aachs%26aulast%3DSuzuki%26aufirst%3DT.%26aulast%3DMotohashi%26aufirst%3DH.%26aulast%3DYamamoto%26aufirst%3DM.%26atitle%3DToward%2520clinical%2520application%2520of%2520the%2520Keap1-Nrf2%2520pathway%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2013%26volume%3D34%26spage%3D340%26epage%3D346%26doi%3D10.1016%2Fj.tips.2013.04.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deny, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traboulsi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantin, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsault, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richter, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belanger, G.</span></span> <span> </span><span class="NLM_article-title">Bis-Michael acceptors as novel probes to study the Keap1/Nrf2/ARE pathway</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">9431</span>– <span class="NLM_lpage">9442</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01132</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01132" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFyntrbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=9431-9442&author=L.+J.+Denyauthor=H.+Traboulsiauthor=A.+M.+Cantinauthor=E.+Marsaultauthor=M.+V.+Richterauthor=G.+Belanger&title=Bis-Michael+acceptors+as+novel+probes+to+study+the+Keap1%2FNrf2%2FARE+pathway&doi=10.1021%2Facs.jmedchem.6b01132"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Bis-Michael Acceptors as Novel Probes to Study the Keap1/Nrf2/ARE Pathway</span></div><div class="casAuthors">Deny, Ludovic J.; Traboulsi, Hussein; Cantin, Andre M.; Marsault, Eric; Richter, Martin V.; Belanger, Guillaume</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">9431-9442</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Nuclear factor erythroid 2-related factor 2 (Nrf2) is a master regulator that promotes the transcription of cytoprotective genes in response to oxidative/electrophilic stress.  Various Michael-type compds. were designed and synthesized and their potency to activate the Keap1/Nrf2/ARE pathway was evaluated.  Compds. bearing two Michael-type acceptors proved to be the most active.  Tether length and rigidity between the acceptors was crucial.  This study will help to understand how this feature disrupts the interaction between Keap1 and Nrf2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9W1p2xZ8QDLVg90H21EOLACvtfcHk0lir5chz4188bQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFyntrbK&md5=f70adbe3ebaef7bac1d9ed91778bd723</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01132&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01132%26sid%3Dliteratum%253Aachs%26aulast%3DDeny%26aufirst%3DL.%2BJ.%26aulast%3DTraboulsi%26aufirst%3DH.%26aulast%3DCantin%26aufirst%3DA.%2BM.%26aulast%3DMarsault%26aufirst%3DE.%26aulast%3DRichter%26aufirst%3DM.%2BV.%26aulast%3DBelanger%26aufirst%3DG.%26atitle%3DBis-Michael%2520acceptors%2520as%2520novel%2520probes%2520to%2520study%2520the%2520Keap1%252FNrf2%252FARE%2520pathway%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D9431%26epage%3D9442%26doi%3D10.1021%2Facs.jmedchem.6b01132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shakila, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khera, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koul, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naseema, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayanan, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paramasivan, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramanathan, V. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyagi, A. K.</span></span> <span> </span><span class="NLM_article-title">Disruption of mptpB impairs the ability of <i>Mycobacterium tuberculosis</i> to survive in guinea pigs</span>. <i>Mol. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">751</span>– <span class="NLM_lpage">762</span>, <span class="refDoi"> DOI: 10.1046/j.1365-2958.2003.03712.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1046%2Fj.1365-2958.2003.03712.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=14617138" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD3sXptVyrsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2003&pages=751-762&author=R.+Singhauthor=V.+Raoauthor=H.+Shakilaauthor=R.+Guptaauthor=A.+Kheraauthor=N.+Dharauthor=A.+Singhauthor=A.+Koulauthor=Y.+Singhauthor=M.+Naseemaauthor=P.+R.+Narayananauthor=C.+N.+Paramasivanauthor=V.+D.+Ramanathanauthor=A.+K.+Tyagi&title=Disruption+of+mptpB+impairs+the+ability+of+Mycobacterium+tuberculosis+to+survive+in+guinea+pigs&doi=10.1046%2Fj.1365-2958.2003.03712.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Disruption of mptpB impairs the ability of Mycobacterium tuberculosis to survive in guinea pigs</span></div><div class="casAuthors">Singh, Ramandeep; Rao, Vivek; Shakila, H.; Gupta, Radhika; Khera, Aparna; Dhar, Neeraj; Singh, Amit; Koul, Anil; Singh, Yogendra; Naseema, M.; Narayanan, P. R.; Paramasivan, C. N.; Ramanathan, V. D.; Tyagi, Anil K.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Microbiology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">751-762</span>CODEN:
                <span class="NLM_cas:coden">MOMIEE</span>;
        ISSN:<span class="NLM_cas:issn">0950-382X</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Protein tyrosine kinases and tyrosine phosphatases from several bacterial pathogens have been shown to act as virulence factors by modulating the phosphorylation and dephosphorylation of host proteins.  The identification and characterization of two tyrosine phosphatases, namely MptpA and MptpB, from M. tuberculosis has been reported earlier.  MptpB is secreted by M. tuberculosis into extracellular milieu and exhibits a pH optimum of 5.6, similar to the pH of the lysosomal compartment of the cell.  To det. the role of MptpB in the pathogenesis of M. tuberculosis, we constructed a mptpB mutant strain by homologous recombination and compared the ability of parent and the mutant strain to survive intracellularly.  We show that disruption of the mptpB gene impairs the ability of the mutant strain to survive in activated macrophages and guinea pigs but not in resting macrophages, suggesting the importance of its role in the host-pathogen interaction.  Infection of guinea pigs with the mutant strain resulted in a 70-fold redn. in the bacillary load of spleens in infected animals as compared with the bacillary load in animals infected with the parental strain.  Upon reintroduction of the mptpB gene into the mutant strain, the complemented strain was able to establish infection and survive in guinea pigs at rates comparable to the parental strain.  These observations demonstrate a role of MptpB in the pathogenesis of M. tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqna7lf5deGyLVg90H21EOLACvtfcHk0lir5chz4188bQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXptVyrsbg%253D&md5=88d8f01f758712bb90bf974bf7bf0662</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1046%2Fj.1365-2958.2003.03712.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1365-2958.2003.03712.x%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DR.%26aulast%3DRao%26aufirst%3DV.%26aulast%3DShakila%26aufirst%3DH.%26aulast%3DGupta%26aufirst%3DR.%26aulast%3DKhera%26aufirst%3DA.%26aulast%3DDhar%26aufirst%3DN.%26aulast%3DSingh%26aufirst%3DA.%26aulast%3DKoul%26aufirst%3DA.%26aulast%3DSingh%26aufirst%3DY.%26aulast%3DNaseema%26aufirst%3DM.%26aulast%3DNarayanan%26aufirst%3DP.%2BR.%26aulast%3DParamasivan%26aufirst%3DC.%2BN.%26aulast%3DRamanathan%26aufirst%3DV.%2BD.%26aulast%3DTyagi%26aufirst%3DA.%2BK.%26atitle%3DDisruption%2520of%2520mptpB%2520impairs%2520the%2520ability%2520of%2520Mycobacterium%2520tuberculosis%2520to%2520survive%2520in%2520guinea%2520pigs%26jtitle%3DMol.%2520Microbiol.%26date%3D2003%26volume%3D50%26spage%3D751%26epage%3D762%26doi%3D10.1046%2Fj.1365-2958.2003.03712.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franzblau, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z. Y.</span></span> <span> </span><span class="NLM_article-title">Targeting mycobacterium protein tyrosine phosphatase B for antituberculosis agents</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">4573</span>– <span class="NLM_lpage">4578</span>, <span class="refDoi"> DOI: 10.1073/pnas.0909133107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1073%2Fpnas.0909133107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=20167798" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjs1emur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=4573-4578&author=B.+Zhouauthor=Y.+Heauthor=X.+Zhangauthor=J.+Xuauthor=Y.+Luoauthor=Y.+Wangauthor=S.+G.+Franzblauauthor=Z.+Yangauthor=R.+J.+Chanauthor=Y.+Liuauthor=J.+Zhengauthor=Z.+Y.+Zhang&title=Targeting+mycobacterium+protein+tyrosine+phosphatase+B+for+antituberculosis+agents&doi=10.1073%2Fpnas.0909133107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting mycobacterium protein tyrosine phosphatase B for antituberculosis agents</span></div><div class="casAuthors">Zhou, Bo; He, Yantao; Zhang, Xian; Xu, Jie; Luo, Yong; Wang, Yuehong; Franzblau, Scott G.; Yang, Zhenyun; Chan, Rebecca J.; Liu, Yan; Zheng, Jianyu; Zhang, Zhong-Yin</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4573-4578, S4573/1-S4573/27</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Protein tyrosine phosphatases are often exploited and subverted by pathogenic bacteria to cause human diseases.  The tyrosine phosphatase mPTPB from Mycobacterium tuberculosis is an essential virulence factor that is secreted by the bacterium into the cytoplasm of macrophages, where it mediates mycobacterial survival in the host.  Consequently, there is considerable interest in understanding the mechanism by which mPTPB evades the host immune responses, and in developing potent and selective mPTPB inhibitors as unique antituberculosis (antiTB) agents.  We uncovered that mPTPB subverts the innate immune responses by blocking the ERK1/2 and p38 mediated IL-6 prodn. and promoting host cell survival by activating the Akt pathway.  We identified a potent and selective mPTPB inhibitor I-A09 with highly efficacious cellular activity, from a combinatorial library of bidentate benzofuran salicylic acid derivs. assembled by click chem.  We demonstrated that inhibition of mPTPB with I-A09 in macrophages reverses the altered host immune responses induced by the bacterial phosphatase and prevents TB growth in host cells.  The results provide the necessary proof-of-principle data to support the notion that specific inhibitors of the mPTPB may serve as effective antiTB therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqm8ZG4dVudgrVg90H21EOLACvtfcHk0lhvWfgXBm0i-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjs1emur4%253D&md5=2d4d319b03d7a7268d8b348e0f7eaf7c</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0909133107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0909133107%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DB.%26aulast%3DHe%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DFranzblau%26aufirst%3DS.%2BG.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DChan%26aufirst%3DR.%2BJ.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DZheng%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DZ.%2BY.%26atitle%3DTargeting%2520mycobacterium%2520protein%2520tyrosine%2520phosphatase%2520B%2520for%2520antituberculosis%2520agents%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2010%26volume%3D107%26spage%3D4573%26epage%3D4578%26doi%3D10.1073%2Fpnas.0909133107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Z. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunawan, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z. Y.</span></span> <span> </span><span class="NLM_article-title">Discovery and evaluation of novel inhibitors of mycobacterium protein tyrosine phosphatase B from the 6-Hydroxy-benzofuran-5-carboxylic acid scaffold</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">832</span>– <span class="NLM_lpage">842</span>, <span class="refDoi"> DOI: 10.1021/jm301781p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301781p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC3sXms1Oguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=832-842&author=Y.+Heauthor=J.+Xuauthor=Z.+H.+Yuauthor=A.+M.+Gunawanauthor=L.+Wuauthor=L.+Wangauthor=Z.+Y.+Zhang&title=Discovery+and+evaluation+of+novel+inhibitors+of+mycobacterium+protein+tyrosine+phosphatase+B+from+the+6-Hydroxy-benzofuran-5-carboxylic+acid+scaffold&doi=10.1021%2Fjm301781p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Evaluation of Novel Inhibitors of Mycobacterium Protein Tyrosine Phosphatase B from the 6-Hydroxy-benzofuran-5-carboxylic Acid Scaffold</span></div><div class="casAuthors">He, Yantao; Xu, Jie; Yu, Zhi-Hong; Gunawan, Andrea M.; Wu, Li; Wang, Lina; Zhang, Zhong-Yin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">832-842</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Mycobacterium tuberculosis (Mtb) protein tyrosine phosphatase B (mPTPB) is a virulence factor secreted by the pathogen and mediates mycobacterial survival in macrophages by targeting host cell immune responses.  Consequently, mPTPB represents an exciting new target to combat tuberculosis (TB) infection.  We describe a medicinal chem. oriented approach that transforms a benzofuran salicylic acid scaffold into a highly potent (IC50 = 38 nM) and selective mPTPB inhibitor (>50 fold against a large panel of PTPs).  Importantly, the inhibitor is capable of reversing the altered host immune responses induced by the bacterial phosphatase and restoring the macrophage's full capacity to secrete IL-6 and undergo apoptosis in response to interferon-γ stimulation, validating the concept that chem. inhibition of mPTPB may be therapeutically useful for novel TB treatment.  The study further demonstrates that bicyclic salicylic acid pharmacophores can be used to deliver PTP inhibitors with high potency, selectivity, and cellular efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPqxb8o40oqrVg90H21EOLACvtfcHk0lhvWfgXBm0i-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXms1Oguw%253D%253D&md5=c9492d72c21adb7be4e74eb2f5d5860a</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1021%2Fjm301781p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301781p%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DZ.%2BH.%26aulast%3DGunawan%26aufirst%3DA.%2BM.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DZ.%2BY.%26atitle%3DDiscovery%2520and%2520evaluation%2520of%2520novel%2520inhibitors%2520of%2520mycobacterium%2520protein%2520tyrosine%2520phosphatase%2520B%2520from%2520the%25206-Hydroxy-benzofuran-5-carboxylic%2520acid%2520scaffold%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D832%26epage%3D842%26doi%3D10.1021%2Fjm301781p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, E. M.</span></span> <span> </span><span class="NLM_article-title">The calcium-sensing receptor: physiology, pathophysiology and CaR-based therapeutics</span>. <i>Subcell. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">139</span>– <span class="NLM_lpage">167</span>, <span class="refDoi"> DOI: 10.1007/978-1-4020-6191-2_6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1007%2F978-1-4020-6191-2_6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=18193637" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A280%3ADC%252BD1c%252FktVahtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2007&pages=139-167&author=E.+M.+Brown&title=The+calcium-sensing+receptor%3A+physiology%2C+pathophysiology+and+CaR-based+therapeutics&doi=10.1007%2F978-1-4020-6191-2_6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">The calcium-sensing receptor: physiology, pathophysiology and CaR-based therapeutics</span></div><div class="casAuthors">Brown E M</div><div class="citationInfo"><span class="NLM_cas:title">Sub-cellular biochemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">139-67</span>
        ISSN:<span class="NLM_cas:issn">0306-0225</span>.
    </div><div class="casAbstract">The extracellular calcium (Ca(o)2+)-sensing receptor (CaR) enables the parathyroid glands and other CaR-expressing cells to sense alterations in the level of Ca(o)2+ and to respond with changes in function that are directed at normalizing the blood calcium concentration.  In addition to the parathyroid gland, the kidney is a key site for Ca(o)2(+)-sensing that enables it to make physiologically relevant alterations in divalent cation and water metabolism.  Several disorders of Ca(o)2(+)-sensing arise from inherited or acquired abnormalities that "reset" the serum calcium concentration upward or downward.  Inactivating mutations produce a benign form of hypercalcemia when present in the heterozygous state, termed Familial Hypocalciuric Hypercalcemia (FHH), while homozygous mutations produce a much more severe hypercalcemic disorder resulting from marked hyperparathyroidism, called Neonatal Severe Hyperparathyroidism (NSHPT).  Activating mutations cause a hypocalcemic syndrome of varying severity, termed autosomal dominant hypocalcemia or hypoparathyroidism.  Inactivating or activating antibodies directed at the CaR produce the expected hyper- or hypocalcemic syndromes, respectively. "Calcimimetic" CaR activators and "calcilytic" CaR antagonists have been developed.  The calcimimetics are currently in use for controlling severe hyperparathyroidism in patients receiving dialysis treatment for end stage renal disease or with parathyroid cancer.  Calcilytics are being evaluated as a means of inducing a "pulse" in the circulating parathyroid hormone (PTH) concentration, which would mimic that resulting from injection of PTH, an established anabolic form of treatment for osteoporosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR8IqdjdhC4Am52AMpI4GK2fW6udTcc2eZNJcIgWgqx-7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c%252FktVahtQ%253D%253D&md5=efb4412b5755168f5433ee1f034cd934</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1007%2F978-1-4020-6191-2_6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-4020-6191-2_6%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DE.%2BM.%26atitle%3DThe%2520calcium-sensing%2520receptor%253A%2520physiology%252C%2520pathophysiology%2520and%2520CaR-based%2520therapeutics%26jtitle%3DSubcell.%2520Biochem.%26date%3D2007%26volume%3D45%26spage%3D139%26epage%3D167%26doi%3D10.1007%2F978-1-4020-6191-2_6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Steddon, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, J.</span></span> <span> </span><span class="NLM_article-title">Calcimimetics and calcilytics--fooling the calcium receptor</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>365</i></span>,  <span class="NLM_fpage">2237</span>– <span class="NLM_lpage">2239</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(05)66782-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1016%2FS0140-6736%2805%2966782-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=15978932" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlsFCrsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=365&publication_year=2005&pages=2237-2239&author=S.+J.+Steddonauthor=J.+Cunningham&title=Calcimimetics+and+calcilytics%2D%2Dfooling+the+calcium+receptor&doi=10.1016%2FS0140-6736%2805%2966782-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Calcimimetics and calcilytics-fooling the calcium receptor</span></div><div class="casAuthors">Steddon, Simon J.; Cunningham, John</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">365</span>
        (<span class="NLM_cas:issue">9478</span>),
    <span class="NLM_cas:pages">2237-2239</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Context: Just a decade after the the calcium-sensing receptor (CaR) was identified, pharmacol. manipulation of the CaR is about to enter routine practice.  For hyperparathyroid states, calcimimetics, which increase activation of the CaR, have been licensed in Europe and the USA.  Calcilytics, which decrease CaR function and increase secretion of parathyroid hormone (PTH), might allow the anabolic effects of PTH on bone to be harnessed for the prevention and treatment of osteoporosis.  Starting point: In a multicentre randomised double-blind placebo-controlled study, Munro Peacock and colleagues recently confirmed the efficacy of the oral calcimimetic cinacalcet for achieving long-term redns. in serum calcium and PTH concns. in primary hyperparathyroidism (J Clin Endocrinol Metab 2005; 90:135-41).  The arrival of a non-surgical option for this common disorder is important.  What next: Study in primary and uremic secondary hyperparathyroidism will indicate whether the efficacy of calcimimetic agents extends into the longer term.  The extracellular relation between the CaR and its ligands and the intracellular signalling cascades that modify PTH gene transcription and secretion need further study.  Drugs acting on the CaR might treat other disorders of bone remodelling, including osteoporosis.  CaR expression in tissues beyond those involved in mineral ion homoeostasis should remain an important focus of research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrK4dlbwzx3XLVg90H21EOLACvtfcHk0lgD2zdQJyGSFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlsFCrsrY%253D&md5=2fbb8130dc410d3f438037e09c5e22cd</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2805%2966782-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252805%252966782-7%26sid%3Dliteratum%253Aachs%26aulast%3DSteddon%26aufirst%3DS.%2BJ.%26aulast%3DCunningham%26aufirst%3DJ.%26atitle%3DCalcimimetics%2520and%2520calcilytics--fooling%2520the%2520calcium%2520receptor%26jtitle%3DLancet%26date%3D2005%26volume%3D365%26spage%3D2237%26epage%3D2239%26doi%3D10.1016%2FS0140-6736%2805%2966782-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Widler, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altmann, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beerli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breitenstein, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouhelal, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buhl, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamse, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerspacher, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halleux, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">John, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehmann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalb, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kneissel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Missbach, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, I. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reidemeister, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renaud, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taillardat, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tommasi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiler, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seuwen, K.</span></span> <span> </span><span class="NLM_article-title">1-Alkyl-4-phenyl-6-alkoxy-1<i>H</i>-quinazolin-2-ones: A novel series of potent calcium-sensing receptor antagonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">2250</span>– <span class="NLM_lpage">2263</span>, <span class="refDoi"> DOI: 10.1021/jm901811v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901811v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhvF2ksrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2250-2263&author=L.+Widlerauthor=E.+Altmannauthor=R.+Beerliauthor=W.+Breitensteinauthor=R.+Bouhelalauthor=T.+Buhlauthor=R.+Gamseauthor=M.+Gerspacherauthor=C.+Halleuxauthor=M.+R.+Johnauthor=H.+Lehmannauthor=O.+Kalbauthor=M.+Kneisselauthor=M.+Missbachauthor=I.+R.+Mullerauthor=S.+Reidemeisterauthor=J.+Renaudauthor=A.+Taillardatauthor=R.+Tommasiauthor=S.+Weilerauthor=R.+M.+Wolfauthor=K.+Seuwen&title=1-Alkyl-4-phenyl-6-alkoxy-1H-quinazolin-2-ones%3A+A+novel+series+of+potent+calcium-sensing+receptor+antagonists&doi=10.1021%2Fjm901811v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">1-Alkyl-4-phenyl-6-alkoxy-1H-quinazolin-2-ones: A Novel Series of Potent Calcium-Sensing Receptor Antagonists</span></div><div class="casAuthors">Widler, Leo; Altmann, Eva; Beerli, Rene; Breitenstein, Werner; Bouhelal, Rochdi; Buhl, Thomas; Gamse, Rainer; Gerspacher, Marc; Halleux, Christine; John, Markus R.; Lehmann, Hansjoerg; Kalb, Oskar; Kneissel, Michaela; Missbach, Martin; Muller, Irene R.; Reidemeister, Sibylle; Renaud, Johanne; Taillardat, Agnes; Tommasi, Ruben; Weiler, Sven; Wolf, Romain M.; Seuwen, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2250-2263</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Parathyroid hormone (PTH) is an effective bone anabolic agent.  However, only when administered by daily s.c. injections exposure of short duration is achieved, a prerequisite for an anabolic response.  Instead of applying exogenous PTH, mobilization of endogenous stores of the hormone can be envisaged.  The secretion of PTH stored in the parathyroid glands is mediated by a calcium sensing receptor (CaSR) a GPCR localized at the cell surface.  Antagonists of CaSR (calcilytics) mimic a state of hypocalcemia and stimulate PTH release to the bloodstream.  Screening of the internal compd. collection for inhibition of CaSR signaling function afforded 2a (I).  In vitro potency could be improved > 1000 fold by optimization of its chem. structure.  The binding mode of our compds. was predicted based on mol. modeling and confirmed by testing with mutated receptors.  While the compds. readily induced PTH release after iv application a special formulation was needed for oral activity.  The required profile was achieved by using microemulsions.  Excellent PK/PD correlation was found in rats and dogs.  High levels of PTH were reached in plasma within minutes which reverted to baseline in about 1-2 h in both species.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodQxVma9P28LVg90H21EOLACvtfcHk0lgD2zdQJyGSFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhvF2ksrY%253D&md5=5828ea47ee9160c5b1a63221f95dae1d</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1021%2Fjm901811v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901811v%26sid%3Dliteratum%253Aachs%26aulast%3DWidler%26aufirst%3DL.%26aulast%3DAltmann%26aufirst%3DE.%26aulast%3DBeerli%26aufirst%3DR.%26aulast%3DBreitenstein%26aufirst%3DW.%26aulast%3DBouhelal%26aufirst%3DR.%26aulast%3DBuhl%26aufirst%3DT.%26aulast%3DGamse%26aufirst%3DR.%26aulast%3DGerspacher%26aufirst%3DM.%26aulast%3DHalleux%26aufirst%3DC.%26aulast%3DJohn%26aufirst%3DM.%2BR.%26aulast%3DLehmann%26aufirst%3DH.%26aulast%3DKalb%26aufirst%3DO.%26aulast%3DKneissel%26aufirst%3DM.%26aulast%3DMissbach%26aufirst%3DM.%26aulast%3DMuller%26aufirst%3DI.%2BR.%26aulast%3DReidemeister%26aufirst%3DS.%26aulast%3DRenaud%26aufirst%3DJ.%26aulast%3DTaillardat%26aufirst%3DA.%26aulast%3DTommasi%26aufirst%3DR.%26aulast%3DWeiler%26aufirst%3DS.%26aulast%3DWolf%26aufirst%3DR.%2BM.%26aulast%3DSeuwen%26aufirst%3DK.%26atitle%3D1-Alkyl-4-phenyl-6-alkoxy-1H-quinazolin-2-ones%253A%2520A%2520novel%2520series%2520of%2520potent%2520calcium-sensing%2520receptor%2520antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2250%26epage%3D2263%26doi%3D10.1021%2Fjm901811v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ingham, O. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paranal, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Escobar, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yueh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porco, J. A.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beeler, A. B.</span></span> <span> </span><span class="NLM_article-title">Development of a potent and selective HDAC8 inhibitor</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">929</span>– <span class="NLM_lpage">932</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.6b00239</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00239" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVeksbbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=929-932&author=O.+J.+Inghamauthor=R.+M.+Paranalauthor=W.+B.+Smithauthor=R.+A.+Escobarauthor=H.+Yuehauthor=T.+Snyderauthor=J.+A.+Porcoauthor=J.+E.+Bradnerauthor=A.+B.+Beeler&title=Development+of+a+potent+and+selective+HDAC8+inhibitor&doi=10.1021%2Facsmedchemlett.6b00239"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a Potent and Selective HDAC8 Inhibitor</span></div><div class="casAuthors">Ingham, Oscar J.; Paranal, Ronald M.; Smith, William B.; Escobar, Randolph A.; Yueh, Han; Snyder, Tracy; Porco, John A.; Bradner, James E.; Beeler, Aaron B.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">929-932</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel, isoform-selective inhibitor of histone deacetylase 8 (HDAC8) has been discovered by the repurposing of a diverse compd. collection.  Medicinal chem. optimization led to the identification of a highly potent (0.8 nM) and selective inhibitor I of HDAC8.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKF0r_7S2dWLVg90H21EOLACvtfcHk0li91ZqC9kkL3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVeksbbP&md5=69ab76f942dfc6a6b7801b90f48aa619</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00239&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00239%26sid%3Dliteratum%253Aachs%26aulast%3DIngham%26aufirst%3DO.%2BJ.%26aulast%3DParanal%26aufirst%3DR.%2BM.%26aulast%3DSmith%26aufirst%3DW.%2BB.%26aulast%3DEscobar%26aufirst%3DR.%2BA.%26aulast%3DYueh%26aufirst%3DH.%26aulast%3DSnyder%26aufirst%3DT.%26aulast%3DPorco%26aufirst%3DJ.%2BA.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DBeeler%26aufirst%3DA.%2BB.%26atitle%3DDevelopment%2520of%2520a%2520potent%2520and%2520selective%2520HDAC8%2520inhibitor%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D929%26epage%3D932%26doi%3D10.1021%2Facsmedchemlett.6b00239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gasparini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bilbe, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez-Mancilla, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spooren, W.</span></span> <span> </span><span class="NLM_article-title">mGluR5 antagonists: discovery, characterization and drug development</span>. <i>Curr. Opin. Drug Discovery Dev.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">655</span>– <span class="NLM_lpage">665</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=18729017" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtV2rt7nO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2008&pages=655-665&author=F.+Gaspariniauthor=G.+Bilbeauthor=B.+Gomez-Mancillaauthor=W.+Spooren&title=mGluR5+antagonists%3A+discovery%2C+characterization+and+drug+development"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">mGluR5 antagonists: discovery, characterization and drug development</span></div><div class="casAuthors">Gasparini, Fabrizio; Bilbe, Graeme; Gomez-Mancilla, Baltazar; Spooren, Will</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Drug Discovery & Development</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">655-665</span>CODEN:
                <span class="NLM_cas:coden">CODDFF</span>;
        ISSN:<span class="NLM_cas:issn">1367-6733</span>.
    
            (<span class="NLM_cas:orgname">Thomson Scientific</span>)
        </div><div class="casAbstract">A review.  Disturbances of glutamate-mediated neurotransmission have been implicated in a broad range of nervous system disorders.  Numerous attempts to correct nervous system dysfunction by pharmacol. intervention at glutamate receptors have been made, and some of the approaches have achieved a high level of preclin. validation.  However, in a no. of cases involving agents acting as blockers of the ionotropic glutamate receptors, clin. success could not be achieved, mostly because of the lack of a therapeutic window.  The identification of the metabotropic glutamate receptor (mGluR) family and their modulatory role in the control of neurotransmission provided a new means to alter glutamatergic transmission.  Furthermore, selective agents acting as allosteric antagonists at the mGluR5 subtype have demonstrated therapeutic potential.  The identification and characterization of mGluR5 antagonists and recent progress in clin. development are summarized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGox2OH93uxCzbVg90H21EOLACvtfcHk0lhDorbofKyJhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtV2rt7nO&md5=cce30e9f299498315c4d2799f43bf4e3</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGasparini%26aufirst%3DF.%26aulast%3DBilbe%26aufirst%3DG.%26aulast%3DGomez-Mancilla%26aufirst%3DB.%26aulast%3DSpooren%26aufirst%3DW.%26atitle%3DmGluR5%2520antagonists%253A%2520discovery%252C%2520characterization%2520and%2520drug%2520development%26jtitle%3DCurr.%2520Opin.%2520Drug%2520Discovery%2520Dev.%26date%3D2008%26volume%3D11%26spage%3D655%26epage%3D665" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sarkaria, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O-Charoenrat, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talbot, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ngai, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maghami, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yonekawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghossein, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoffel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramanathan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, B.</span></span> <span> </span><span class="NLM_article-title">Squamous cell carcinoma related oncogene/DCUN1D1 is highly conserved and activated by amplification in squamous cell carcinomas</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">9437</span>– <span class="NLM_lpage">9444</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-06-2074</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1158%2F0008-5472.CAN-06-2074" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=17018598" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVamsrjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=9437-9444&author=I.+Sarkariaauthor=P.+O-Charoenratauthor=S.+G.+Talbotauthor=P.+G.+Reddyauthor=I.+Ngaiauthor=E.+Maghamiauthor=K.+N.+Patelauthor=B.+Leeauthor=Y.+Yonekawaauthor=M.+Dudasauthor=A.+Kaufmanauthor=R.+Ryanauthor=R.+Ghosseinauthor=P.+H.+Raoauthor=A.+Stoffelauthor=Y.+Ramanathanauthor=B.+Singh&title=Squamous+cell+carcinoma+related+oncogene%2FDCUN1D1+is+highly+conserved+and+activated+by+amplification+in+squamous+cell+carcinomas&doi=10.1158%2F0008-5472.CAN-06-2074"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Squamous Cell Carcinoma Related Oncogene/DCUN1D1 Is Highly Conserved and Activated by Amplification in Squamous Cell Carcinomas</span></div><div class="casAuthors">Sarkaria, Inderpal; O-charoenrat, Pornchai; Talbot, Simon G.; Reddy, Pabbathi G.; Ngai, Ivan; Maghami, Ellie; Patel, Kepal N.; Lee, Benjamin; Yonekawa, Yoshihiro; Dudas, Maria; Kaufman, Andrew; Ryan, Russell; Ghossein, Ronald; Rao, Pulivarthi H.; Stoffel, Archontoula; Ramanathan, Y.; Singh, Bhuvanesh</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">9437-9444</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Chromosomal amplification at 3q is common to multiple human cancers, but has a specific predilection for squamous cell carcinomas (SCC) of mucosal origin.  We identified and characterized a novel oncogene, SCC-related oncogene (SCCRO), which is amplified along the 3q26.3 region in human SCC.  Amplification and overexpression of SCCRO in these tumors correlate with poor clin. outcome.  The importance of SCCRO amplification in malignant transformation is established by the apoptotic response to short hairpin RNA against SCCRO, exclusively in cancer cell lines carrying SCCRO amplification.  The oncogenic potential of SCCRO is underscored by its ability to transform fibroblasts (NIH-3T3 cells) in vitro and in vivo.  We show that SCCRO regulates Gli1-a key regulator of the hedgehog (HH) pathway.  Collectively, these data suggest that SCCRO is a novel component of the HH signaling pathway involved in the malignant transformation of squamous cell lineage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzTIFIhphYXrVg90H21EOLACvtfcHk0lhWPFDT0cdh1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVamsrjE&md5=359faefb6b6305279f3df1ec54a544f7</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-06-2074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-06-2074%26sid%3Dliteratum%253Aachs%26aulast%3DSarkaria%26aufirst%3DI.%26aulast%3DO-Charoenrat%26aufirst%3DP.%26aulast%3DTalbot%26aufirst%3DS.%2BG.%26aulast%3DReddy%26aufirst%3DP.%2BG.%26aulast%3DNgai%26aufirst%3DI.%26aulast%3DMaghami%26aufirst%3DE.%26aulast%3DPatel%26aufirst%3DK.%2BN.%26aulast%3DLee%26aufirst%3DB.%26aulast%3DYonekawa%26aufirst%3DY.%26aulast%3DDudas%26aufirst%3DM.%26aulast%3DKaufman%26aufirst%3DA.%26aulast%3DRyan%26aufirst%3DR.%26aulast%3DGhossein%26aufirst%3DR.%26aulast%3DRao%26aufirst%3DP.%2BH.%26aulast%3DStoffel%26aufirst%3DA.%26aulast%3DRamanathan%26aufirst%3DY.%26aulast%3DSingh%26aufirst%3DB.%26atitle%3DSquamous%2520cell%2520carcinoma%2520related%2520oncogene%252FDCUN1D1%2520is%2520highly%2520conserved%2520and%2520activated%2520by%2520amplification%2520in%2520squamous%2520cell%2520carcinomas%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D9437%26epage%3D9444%26doi%3D10.1158%2F0008-5472.CAN-06-2074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Salas, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chinnaswamy, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Layton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuckey, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">A potent small-molecule inhibitor of the DCN1-UBC12 interaction that selectively blocks cullin 3 neddylation</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1150</span>, <span class="refDoi"> DOI: 10.1038/s41467-017-01243-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1038%2Fs41467-017-01243-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=29074978" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A280%3ADC%252BC1M7kvFOquw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1150&author=H.+Zhouauthor=J.+Luauthor=L.+Liuauthor=D.+Bernardauthor=C.+Y.+Yangauthor=E.+Fernandez-Salasauthor=K.+Chinnaswamyauthor=S.+Laytonauthor=J.+Stuckeyauthor=Q.+Yuauthor=W.+Zhouauthor=Z.+Panauthor=Y.+Sunauthor=S.+Wang&title=A+potent+small-molecule+inhibitor+of+the+DCN1-UBC12+interaction+that+selectively+blocks+cullin+3+neddylation&doi=10.1038%2Fs41467-017-01243-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">A potent small-molecule inhibitor of the DCN1-UBC12 interaction that selectively blocks cullin 3 neddylation</span></div><div class="casAuthors">Zhou Haibin; Lu Jianfeng; Liu Liu; Bernard Denzil; Yang Chao-Yie; Wang Shaomeng; Fernandez-Salas Ester; Chinnaswamy Krishnapriya; Layton Stephanie; Stuckey Jeanne; Yu Qing; Sun Yi; Zhou Weihua; Sun Yi; Pan Zhenqiang; Wang Shaomeng; Wang Shaomeng</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1150</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The Cullin-RING E3 ubiquitin ligases (CRLs) regulate homeostasis of ~20% of cellular proteins and their activation require neddylation of their cullin subunit.  Cullin neddylation is modulated by a scaffolding DCN protein through interactions with both the cullin protein and an E2 enzyme such as UBC12.  Here we report the development of DI-591 as a high-affinity, cell-permeable small-molecule inhibitor of the DCN1-UBC12 interaction.  DI-591 binds to purified recombinant human DCN1 and DCN2 proteins with K i values of 10-12 nM, and disrupts the DCN1-UBC12 interaction in cells.  Treatment with DI-591 selectively converts cellular cullin 3 into an un-neddylated inactive form with no or minimum effect on other cullin members.  Our data firmly establish a previously unrecognized specific role of the DCN1-UBC12 interaction for cellular neddylation of cullin 3.  DI-591 is an excellent probe compound to investigate the role of the cullin 3 CRL ligase in biological processes and human diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTn87oIyDIsYOxsqfvU0ziafW6udTcc2ea5AqRKH024tLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M7kvFOquw%253D%253D&md5=47a713f31bcad6e0b45196cb3f1c8766</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1038%2Fs41467-017-01243-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-017-01243-7%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DBernard%26aufirst%3DD.%26aulast%3DYang%26aufirst%3DC.%2BY.%26aulast%3DFernandez-Salas%26aufirst%3DE.%26aulast%3DChinnaswamy%26aufirst%3DK.%26aulast%3DLayton%26aufirst%3DS.%26aulast%3DStuckey%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DQ.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DPan%26aufirst%3DZ.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DA%2520potent%2520small-molecule%2520inhibitor%2520of%2520the%2520DCN1-UBC12%2520interaction%2520that%2520selectively%2520blocks%2520cullin%25203%2520neddylation%26jtitle%3DNat.%2520Commun.%26date%3D2017%26volume%3D8%26spage%3D1150%26doi%3D10.1038%2Fs41467-017-01243-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span> <span> </span><span class="NLM_article-title">Potent 5-cyano-6-phenyl-pyrimidin-based derivatives targeting DCN1–UBE2M interaction</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">5382</span>– <span class="NLM_lpage">5403</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00003</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00003" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVOntrzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=5382-5403&author=W.+Zhouauthor=L.+Maauthor=L.+Dingauthor=Q.+Guoauthor=Z.+Heauthor=J.+Yangauthor=H.+Qiaoauthor=L.+Liauthor=J.+Yangauthor=S.+Yuauthor=L.+Zhaoauthor=S.+Wangauthor=H.-M.+Liuauthor=Z.+Suoauthor=W.+Zhao&title=Potent+5-cyano-6-phenyl-pyrimidin-based+derivatives+targeting+DCN1%E2%80%93UBE2M+interaction&doi=10.1021%2Facs.jmedchem.9b00003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Potent 5-Cyano-6-phenyl-pyrimidin-Based Derivatives Targeting DCN1-UBE2M Interaction</span></div><div class="casAuthors">Zhou, Wenjuan; Ma, Liying; Ding, Lina; Guo, Qian; He, Zhangxu; Yang, Jing; Qiao, Hui; Li, Lingyu; Yang, Jie; Yu, Shimin; Zhao, Lili; Wang, Shaomeng; Liu, Hong-Min; Suo, Zhenhe; Zhao, Wen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5382-5403</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Neddylation of the Cullin-RING E3 ligases (CRLs) regulates the homeostasis of approx. 20% of cellular proteins.  Defective in cullin neddylation 1 (DCN1), as a co-E3 ligase, interacts with UBE2M to enhance the activation of CRLs, and this interaction is emerging as a therapeutic target for human diseases.  Here, we present a series of pyrimidin-based small mol. inhibitors targeting DCN1-UBE2M interaction.  After finding a novel inhibitor DC-1 with IC50 = 1.2 μM, we performed a series of chem. optimizations, which finally led to the discovery of a potent thiazole contg. 5-cyano-6-phenylpyrimidin-based inhibitor DC-2 (IC50 = 15 nM).  Next, using protein and cellular thermal shift assays, coimmunopptn., mol. docking, and site-specific mutation expts., we further proved that DC-2 specifically inhibited the interaction of UBE2M and DCN1 at mol. and cellular levels, resulting in the decrease of cullin3 neddylation and accumulation of its substrate, NRF2.  Our findings indicate that DC-2 may serve as a novel lead compd. for specific derivs. targeting DCN1-UBE2M interaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqFJ-HvcKxn7Vg90H21EOLACvtfcHk0lhWPFDT0cdh1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVOntrzI&md5=b0b7b00a80e377905d1532b4e2c5992b</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00003%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DMa%26aufirst%3DL.%26aulast%3DDing%26aufirst%3DL.%26aulast%3DGuo%26aufirst%3DQ.%26aulast%3DHe%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DQiao%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DH.-M.%26aulast%3DSuo%26aufirst%3DZ.%26aulast%3DZhao%26aufirst%3DW.%26atitle%3DPotent%25205-cyano-6-phenyl-pyrimidin-based%2520derivatives%2520targeting%2520DCN1%25E2%2580%2593UBE2M%2520interaction%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D5382%26epage%3D5403%26doi%3D10.1021%2Facs.jmedchem.9b00003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eckhardt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langkopf, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mark, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tadayyon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nar, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfrengle, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guth, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lotz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sieger, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuchs, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Himmelsbach, F.</span></span> <span> </span><span class="NLM_article-title">8-(3-(<i>R</i>)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-yl-methyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">6450</span>– <span class="NLM_lpage">6453</span>, <span class="refDoi"> DOI: 10.1021/jm701280z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm701280z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlyqs7vJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=6450-6453&author=M.+Eckhardtauthor=E.+Langkopfauthor=M.+Markauthor=M.+Tadayyonauthor=L.+Thomasauthor=H.+Narauthor=W.+Pfrengleauthor=B.+Guthauthor=R.+Lotzauthor=P.+Siegerauthor=H.+Fuchsauthor=F.+Himmelsbach&title=8-%283-%28R%29-aminopiperidin-1-yl%29-7-but-2-ynyl-3-methyl-1-%284-methyl-quinazolin-2-yl-methyl%29-3%2C7-dihydropurine-2%2C6-dione+%28BI+1356%29%2C+a+highly+potent%2C+selective%2C+long-acting%2C+and+orally+bioavailable+DPP-4+inhibitor+for+the+treatment+of+type+2+diabetes&doi=10.1021%2Fjm701280z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">8-(3-(R)-Aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a Highly Potent, Selective, Long-Acting, and Orally Bioavailable DPP-4 Inhibitor for the Treatment of Type 2 Diabetes</span></div><div class="casAuthors">Eckhardt, Matthias; Langkopf, Elke; Mark, Michael; Tadayyon, Moh; Thomas, Leo; Nar, Herbert; Pfrengle, Waldemar; Guth, Brian; Lotz, Ralf; Sieger, Peter; Fuchs, Holger; Himmelsbach, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">6450-6453</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new chem. class of potent DPP-4 inhibitors structurally derived from the xanthine scaffold for the treatment of type 2 diabetes has been discovered and evaluated.  Systematic structural variations have led to 1 (BI 1356, I), a highly potent, selective, long-acting, and orally active DPP-4 inhibitor that shows considerable blood glucose lowering in different animal species.  1 Is currently undergoing clin. phase IIb trials and holds the potential for once-daily treatment of type 2 diabetics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVyDZtAZGjgLVg90H21EOLACvtfcHk0lhdAo3GSXvwNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlyqs7vJ&md5=442ec88b800d899cc7a1f1528e1af4fa</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1021%2Fjm701280z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701280z%26sid%3Dliteratum%253Aachs%26aulast%3DEckhardt%26aufirst%3DM.%26aulast%3DLangkopf%26aufirst%3DE.%26aulast%3DMark%26aufirst%3DM.%26aulast%3DTadayyon%26aufirst%3DM.%26aulast%3DThomas%26aufirst%3DL.%26aulast%3DNar%26aufirst%3DH.%26aulast%3DPfrengle%26aufirst%3DW.%26aulast%3DGuth%26aufirst%3DB.%26aulast%3DLotz%26aufirst%3DR.%26aulast%3DSieger%26aufirst%3DP.%26aulast%3DFuchs%26aufirst%3DH.%26aulast%3DHimmelsbach%26aufirst%3DF.%26atitle%3D8-%25283-%2528R%2529-aminopiperidin-1-yl%2529-7-but-2-ynyl-3-methyl-1-%25284-methyl-quinazolin-2-yl-methyl%2529-3%252C7-dihydropurine-2%252C6-dione%2520%2528BI%25201356%2529%252C%2520a%2520highly%2520potent%252C%2520selective%252C%2520long-acting%252C%2520and%2520orally%2520bioavailable%2520DPP-4%2520inhibitor%2520for%2520the%2520treatment%2520of%2520type%25202%2520diabetes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D6450%26epage%3D6453%26doi%3D10.1021%2Fjm701280z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dhillon, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rath, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolch, W.</span></span> <span> </span><span class="NLM_article-title">MAP kinase signalling pathways in cancer</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">3279</span>– <span class="NLM_lpage">3290</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1210421</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1038%2Fsj.onc.1210421" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=17496922" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlt1WktLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=3279-3290&author=A.+S.+Dhillonauthor=S.+Haganauthor=O.+Rathauthor=W.+Kolch&title=MAP+kinase+signalling+pathways+in+cancer&doi=10.1038%2Fsj.onc.1210421"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">MAP kinase signaling pathways in cancer</span></div><div class="casAuthors">Dhillon, A. S.; Hagan, S.; Rath, O.; Kolch, W.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">3279-3290</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Cancer can be perceived as a disease of communication between and within cells.  The aberrations are pleiotropic, but mitogen-activated protein kinase (MAPK) pathways feature prominently.  Here, we discuss recent findings and hypotheses on the role of MAPK pathways in cancer.  Cancerous mutations in MAPK pathways are frequently mostly affecting Ras and B-Raf in the extracellular signal-regulated kinase pathway.  Stress-activated pathways, such as Jun N-terminal kinase and p38, largely seem to counteract malignant transformation.  The balance and integration between these signals may widely vary in different tumors, but are important for the outcome and the sensitivity to drug therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2AJjwZsw0PbVg90H21EOLACvtfcHk0lhdAo3GSXvwNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlt1WktLc%253D&md5=510709dcee2bbe62c7d48dbd8f270130</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1210421&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1210421%26sid%3Dliteratum%253Aachs%26aulast%3DDhillon%26aufirst%3DA.%2BS.%26aulast%3DHagan%26aufirst%3DS.%26aulast%3DRath%26aufirst%3DO.%26aulast%3DKolch%26aufirst%3DW.%26atitle%3DMAP%2520kinase%2520signalling%2520pathways%2520in%2520cancer%26jtitle%3DOncogene%26date%3D2007%26volume%3D26%26spage%3D3279%26epage%3D3290%26doi%3D10.1038%2Fsj.onc.1210421" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarkowski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baccarini, M.</span></span> <span> </span><span class="NLM_article-title">Raf kinases in cancer-roles and therapeutic opportunities</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">3477</span>– <span class="NLM_lpage">3488</span>, <span class="refDoi"> DOI: 10.1038/onc.2011.160</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1038%2Fonc.2011.160" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=21577205" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtV2hsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2011&pages=3477-3488&author=G.+Maurerauthor=B.+Tarkowskiauthor=M.+Baccarini&title=Raf+kinases+in+cancer-roles+and+therapeutic+opportunities&doi=10.1038%2Fonc.2011.160"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Raf kinases in cancer - roles and therapeutic opportunities</span></div><div class="casAuthors">Maurer, G.; Tarkowski, B.; Baccarini, M.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">3477-3488</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Raf are conserved, ubiquitous serine/protein kinases discovered as the cellular elements hijacked by transforming retroviruses.  The 3 mammalian RAF proteins (A, B and CRAF) can be activated by the human oncogene RAS, downstream from which they exert both kinase-dependent and kinase-independent, tumor-promoting functions.  The kinase-dependent functions are mediated chiefly by the MEK/ERK pathway, whose activation is assocd. with proliferation in a broad range of human tumors.  Almost 10 years ago, activating BRAF mutations were discovered in a subset of human tumors, and in the past year treatment with small-mol. RAF inhibitors has yielded unprecedented response rates in melanoma patients.  Thus, Raf qualifies as an excellent mol. target for anticancer therapy.  This review focuses on the role of BRAF and CRAF in different aspects of carcinogenesis, on the success of mol. therapies targeting Raf and the challenges they present.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnwcV59PKy5bVg90H21EOLACvtfcHk0lhdAo3GSXvwNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtV2hsrk%253D&md5=b2e37c1cd3a97d3dceedf5ec3e965f2e</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1038%2Fonc.2011.160&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2011.160%26sid%3Dliteratum%253Aachs%26aulast%3DMaurer%26aufirst%3DG.%26aulast%3DTarkowski%26aufirst%3DB.%26aulast%3DBaccarini%26aufirst%3DM.%26atitle%3DRaf%2520kinases%2520in%2520cancer-roles%2520and%2520therapeutic%2520opportunities%26jtitle%3DOncogene%26date%3D2011%26volume%3D30%26spage%3D3477%26epage%3D3488%26doi%3D10.1038%2Fonc.2011.160" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bollag, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirth, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spevak, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habets, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burton, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shellooe, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marimuthu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artis, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higgins, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Andrea, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koehler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stumm, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grippo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puzanov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McArthur, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaherty, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nathanson, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolop, K.</span></span> <span> </span><span class="NLM_article-title">Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>467</i></span>,  <span class="NLM_fpage">596</span>– <span class="NLM_lpage">599</span>, <span class="refDoi"> DOI: 10.1038/nature09454</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1038%2Fnature09454" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=20823850" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1ajtbfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=467&publication_year=2010&pages=596-599&author=G.+Bollagauthor=P.+Hirthauthor=J.+Tsaiauthor=J.+Zhangauthor=P.+N.+Ibrahimauthor=H.+Choauthor=W.+Spevakauthor=C.+Zhangauthor=Y.+Zhangauthor=G.+Habetsauthor=E.+A.+Burtonauthor=B.+Wongauthor=G.+Tsangauthor=B.+L.+Westauthor=B.+Powellauthor=R.+Shellooeauthor=A.+Marimuthuauthor=H.+Nguyenauthor=K.+Y.+Zhangauthor=D.+R.+Artisauthor=J.+Schlessingerauthor=F.+Suauthor=B.+Higginsauthor=R.+Iyerauthor=K.+D%E2%80%99Andreaauthor=A.+Koehlerauthor=M.+Stummauthor=P.+S.+Linauthor=R.+J.+Leeauthor=J.+Grippoauthor=I.+Puzanovauthor=K.+B.+Kimauthor=A.+Ribasauthor=G.+A.+McArthurauthor=J.+A.+Sosmanauthor=P.+B.+Chapmanauthor=K.+T.+Flahertyauthor=X.+Xuauthor=K.+L.+Nathansonauthor=K.+Nolop&title=Clinical+efficacy+of+a+RAF+inhibitor+needs+broad+target+blockade+in+BRAF-mutant+melanoma&doi=10.1038%2Fnature09454"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma</span></div><div class="casAuthors">Bollag, Gideon; Hirth, Peter; Tsai, James; Zhang, Jiazhong; Ibrahim, Prabha N.; Cho, Hanna; Spevak, Wayne; Zhang, Chao; Zhang, Ying; Habets, Gaston; Burton, Elizabeth A.; Wong, Bernice; Tsang, Garson; West, Brian L.; Powell, Ben; Shellooe, Rafe; Marimuthu, Adhirai; Nguyen, Hoa; Zhang, Kam Y. J.; Artis, Dean R.; Schlessinger, Joseph; Su, Fei; Higgins, Brian; Iyer, Raman; D'Andrea, Kurt; Koehler, Astrid; Stumm, Michael; Lin, Paul S.; Lee, Richard J.; Grippo, Joseph; Puzanov, Igor; Kim, Kevin B.; Ribas, Antoni; McArthur, Grant A.; Sosman, Jeffrey A.; Chapman, Paul B.; Flaherty, Keith T.; Xu, Xiaowei; Nathanson, Katherine L.; Nolop, Keith</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">467</span>
        (<span class="NLM_cas:issue">7315</span>),
    <span class="NLM_cas:pages">596-599</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">B-RAF is the most frequently mutated protein kinase in human cancers.  The finding that oncogenic mutations in BRAF are common in melanoma, followed by the demonstration that these tumors are dependent on the RAF/MEK/ERK pathway, offered hope that inhibition of B-RAF kinase activity could benefit melanoma patients.  Herein, we describe the structure-guided discovery of PLX4032 (RG7204), a potent inhibitor of oncogenic B-RAF kinase activity.  Preclin. expts. demonstrated that PLX4032 selectively blocked the RAF/MEK/ERK pathway in BRAF mutant cells and caused regression of BRAF mutant xenografts.  Toxicol. studies confirmed a wide safety margin consistent with the high degree of selectivity, enabling Phase 1 clin. trials using a cryst. formulation of PLX4032 (ref. 5).  In a subset of melanoma patients, pathway inhibition was monitored in paired biopsy specimens collected before treatment initiation and following 2 wk of treatment.  This anal. revealed substantial inhibition of ERK phosphorylation, yet clin. evaluation did not show tumor regressions.  At higher drug exposures afforded by a new amorphous drug formulation, greater than 80% inhibition of ERK phosphorylation in the tumors of patients correlated with clin. response.  Indeed, the Phase 1 clin. data revealed a remarkably high 81% response rate in metastatic melanoma patients treated at an oral dose of 960 mg twice daily.  These data demonstrate that BRAF-mutant melanomas are highly dependent on B-RAF kinase activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpYwlns1EfcLVg90H21EOLACvtfcHk0lhfdOoy6JvRHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1ajtbfK&md5=8a26d0ab41970f39a109ddafff2f17b4</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1038%2Fnature09454&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature09454%26sid%3Dliteratum%253Aachs%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DHirth%26aufirst%3DP.%26aulast%3DTsai%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DIbrahim%26aufirst%3DP.%2BN.%26aulast%3DCho%26aufirst%3DH.%26aulast%3DSpevak%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHabets%26aufirst%3DG.%26aulast%3DBurton%26aufirst%3DE.%2BA.%26aulast%3DWong%26aufirst%3DB.%26aulast%3DTsang%26aufirst%3DG.%26aulast%3DWest%26aufirst%3DB.%2BL.%26aulast%3DPowell%26aufirst%3DB.%26aulast%3DShellooe%26aufirst%3DR.%26aulast%3DMarimuthu%26aufirst%3DA.%26aulast%3DNguyen%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DK.%2BY.%26aulast%3DArtis%26aufirst%3DD.%2BR.%26aulast%3DSchlessinger%26aufirst%3DJ.%26aulast%3DSu%26aufirst%3DF.%26aulast%3DHiggins%26aufirst%3DB.%26aulast%3DIyer%26aufirst%3DR.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DK.%26aulast%3DKoehler%26aufirst%3DA.%26aulast%3DStumm%26aufirst%3DM.%26aulast%3DLin%26aufirst%3DP.%2BS.%26aulast%3DLee%26aufirst%3DR.%2BJ.%26aulast%3DGrippo%26aufirst%3DJ.%26aulast%3DPuzanov%26aufirst%3DI.%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DChapman%26aufirst%3DP.%2BB.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DNathanson%26aufirst%3DK.%2BL.%26aulast%3DNolop%26aufirst%3DK.%26atitle%3DClinical%2520efficacy%2520of%2520a%2520RAF%2520inhibitor%2520needs%2520broad%2520target%2520blockade%2520in%2520BRAF-mutant%2520melanoma%26jtitle%3DNature%26date%3D2010%26volume%3D467%26spage%3D596%26epage%3D599%26doi%3D10.1038%2Fnature09454" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lito, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solit, D. B.</span></span> <span> </span><span class="NLM_article-title">Tumor adaptation and resistance to RAF inhibitors</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1401</span>– <span class="NLM_lpage">1409</span>, <span class="refDoi"> DOI: 10.1038/nm.3392</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1038%2Fnm.3392" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=24202393" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslCntbvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=1401-1409&author=P.+Litoauthor=N.+Rosenauthor=D.+B.+Solit&title=Tumor+adaptation+and+resistance+to+RAF+inhibitors&doi=10.1038%2Fnm.3392"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Tumor adaptation and resistance to RAF inhibitors</span></div><div class="casAuthors">Lito, Piro; Rosen, Neal; Solit, David B.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1401-1409</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  RAF kinase inhibitors have substantial therapeutic effects in patients with BRAF-mutant melanoma.  However, only rarely do tumors regress completely, and the therapeutic effects are often temporary.  Several mechanisms of resistance to RAF inhibitors have been proposed.  The majority of these cause ERK signaling to become insensitive to treatment with RAF inhibitors by increasing the amt. of RAF dimers in cells, whereas others bypass the dependence of the tumor on mutant RAF.  One motivation for studying mechanisms of drug resistance is that such efforts may suggest new therapeutic targets or rational combination strategies that delay or prevent the emergence of drug-resistant clones.  Here, we review the current model of RAF inhibitor resistance with a focus on the implications of this model on ongoing lab. and clin. efforts to develop more effective therapeutic strategies for patients with BRAF-mutant tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpApldbPW5lXLVg90H21EOLACvtfcHk0lhfdOoy6JvRHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslCntbvN&md5=32718ee0a8ea50be5d6412ce0086cf3d</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1038%2Fnm.3392&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3392%26sid%3Dliteratum%253Aachs%26aulast%3DLito%26aufirst%3DP.%26aulast%3DRosen%26aufirst%3DN.%26aulast%3DSolit%26aufirst%3DD.%2BB.%26atitle%3DTumor%2520adaptation%2520and%2520resistance%2520to%2520RAF%2520inhibitors%26jtitle%3DNat.%2520Med.%26date%3D2013%26volume%3D19%26spage%3D1401%26epage%3D1409%26doi%3D10.1038%2Fnm.3392" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhuang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taghipouran, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smaill, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span> <span> </span><span class="NLM_article-title"><i>N</i>-(3-Ethynyl-2,4-difluorophenyl)sulfonamide derivatives as selective Raf inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">543</span>– <span class="NLM_lpage">547</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00039</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00039" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC2MXksl2hsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=543-547&author=Y.+Liauthor=H.+Chengauthor=Z.+Zhangauthor=X.+Zhuangauthor=J.+Luoauthor=H.+Longauthor=Y.+Zhouauthor=Y.+Xuauthor=R.+Taghipouranauthor=D.+Liauthor=A.+Pattersonauthor=J.+Smaillauthor=Z.+Tuauthor=D.+Wuauthor=X.+Renauthor=K.+Ding&title=N-%283-Ethynyl-2%2C4-difluorophenyl%29sulfonamide+derivatives+as+selective+Raf+inhibitors&doi=10.1021%2Facsmedchemlett.5b00039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">N-(3-Ethynyl-2,4-difluorophenyl)sulfonamide Derivatives as Selective Raf Inhibitors</span></div><div class="casAuthors">Li, Yingjun; Cheng, Huimin; Zhang, Zhang; Zhuang, Xiaoxi; Luo, Jinfeng; Long, Huoyou; Zhou, Yang; Xu, Yong; Taghipouran, Rana; Li, Dan; Patterson, Adam; Smaill, Jeff; Tu, Zhengchao; Wu, Donghai; Ren, Xiaomei; Ding, Ke</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">543-547</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of N-(3-ethynyl-2,4-difluorophenyl)sulfonamides were identified as new selective Raf inhibitors.  The compds. potently inhibit B-RafV600E with low nanomolar IC50 values and exhibit excellent target specificity in a selectivity profiling investigation against 468 kinases.  They strongly suppress proliferation of a panel of human cancer cell lines and patient-derived melanoma cells with B-RafV600E mutation while being significantly less potent to the cells with B-RafWT.  The compds. also display favorable pharmacokinetic properties with a preferred example (3s) demonstrating significant in vivo antitumor efficacy in a xenograft mouse model of B-RafV600E mutated Colo205 human colorectal cancer cells, supporting it as a promising lead compd. for further anticancer drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4y5H_m-zXlLVg90H21EOLACvtfcHk0lhfdOoy6JvRHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXksl2hsbc%253D&md5=ea0fd2bf798161ff95853daf9518ae31</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00039%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DZhuang%26aufirst%3DX.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DLong%26aufirst%3DH.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DTaghipouran%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DPatterson%26aufirst%3DA.%26aulast%3DSmaill%26aufirst%3DJ.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DD.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DN-%25283-Ethynyl-2%252C4-difluorophenyl%2529sulfonamide%2520derivatives%2520as%2520selective%2520Raf%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26spage%3D543%26epage%3D547%26doi%3D10.1021%2Facsmedchemlett.5b00039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pettipher, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansel, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armer, R.</span></span> <span> </span><span class="NLM_article-title">Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">313</span>– <span class="NLM_lpage">325</span>, <span class="refDoi"> DOI: 10.1038/nrd2266</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1038%2Fnrd2266" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=17396136" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjs1SisL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=313-325&author=R.+Pettipherauthor=T.+T.+Hanselauthor=R.+Armer&title=Antagonism+of+the+prostaglandin+D2+receptors+DP1+and+CRTH2+as+an+approach+to+treat+allergic+diseases&doi=10.1038%2Fnrd2266"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases</span></div><div class="casAuthors">Pettipher, Roy; Hansel, Trevor T.; Armer, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">313-325</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Immunol. activation of mast cells is an important trigger in the cascade of inflammatory events leading to the manifestation of allergic diseases.  Pharmacol. studies using the recently discovered DP1 and CRTH2 antagonists combined with genetic anal. support the view that these receptors have a pivotal role in mediating aspects of allergic diseases that are resistant to current therapy.  This Review focuses on the emerging roles that DP1 and CRTH2 (also known as DP2) have in acute and chronic aspects of allergic diseases and proposes that, rather than having opposing actions, these receptors have complementary roles in the initiation and maintenance of the allergy state.  We also discuss recent progress in the discovery and development of selective antagonists of these receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBjHJH6cAZgbVg90H21EOLACvtfcHk0ljv3_oWcl_6SQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjs1SisL0%253D&md5=270421c9fa796738b0a27331ef448ea0</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1038%2Fnrd2266&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2266%26sid%3Dliteratum%253Aachs%26aulast%3DPettipher%26aufirst%3DR.%26aulast%3DHansel%26aufirst%3DT.%2BT.%26aulast%3DArmer%26aufirst%3DR.%26atitle%3DAntagonism%2520of%2520the%2520prostaglandin%2520D2%2520receptors%2520DP1%2520and%2520CRTH2%2520as%2520an%2520approach%2520to%2520treat%2520allergic%2520diseases%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26spage%3D313%26epage%3D325%26doi%3D10.1038%2Fnrd2266" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crosignani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pretre, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorand-Lebrun, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraboulet, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seenisamy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Augustine, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Missotten, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humbert, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cleva, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abla, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daff, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schott, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgat-Charvillon, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivron, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamernig, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arrighi, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaudet, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerli, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juillard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, Z.</span></span> <span> </span><span class="NLM_article-title">Discovery of potent, selective, and orally bioavailable alkynylphenoxyacetic acid CRTH2 (DP2) receptor antagonists for the treatment of allergic inflammatory diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">7299</span>– <span class="NLM_lpage">7317</span>, <span class="refDoi"> DOI: 10.1021/jm200866y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200866y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1GitLrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7299-7317&author=S.+Crosignaniauthor=A.+Pretreauthor=C.+Jorand-Lebrunauthor=G.+Frabouletauthor=J.+Seenisamyauthor=J.+K.+Augustineauthor=M.+Missottenauthor=Y.+Humbertauthor=C.+Clevaauthor=N.+Ablaauthor=H.+Daffauthor=O.+Schottauthor=M.+Schneiderauthor=F.+Burgat-Charvillonauthor=D.+Rivronauthor=I.+Hamernigauthor=J.+F.+Arrighiauthor=M.+Gaudetauthor=S.+C.+Zimmerliauthor=P.+Juillardauthor=Z.+Johnson&title=Discovery+of+potent%2C+selective%2C+and+orally+bioavailable+alkynylphenoxyacetic+acid+CRTH2+%28DP2%29+receptor+antagonists+for+the+treatment+of+allergic+inflammatory+diseases&doi=10.1021%2Fjm200866y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Potent, Selective, and Orally Bioavailable Alkynylphenoxyacetic Acid CRTH2 (DP2) Receptor Antagonists for the Treatment of Allergic Inflammatory Diseases</span></div><div class="casAuthors">Crosignani, Stefano; Pretre, Adeline; Jorand-Lebrun, Catherine; Fraboulet, Gaele; Seenisamy, Jeyaprakashnarayanan; Augustine, John Kallikat; Missotten, Marc; Humbert, Yves; Cleva, Christophe; Abla, Nada; Daff, Hamina; Schott, Olivier; Schneider, Manfred; Burgat-Charvillon, Fabienne; Rivron, Delphine; Hamernig, Ingrid; Arrighi, Jean-Francois; Gaudet, Marilene; Zimmerli, Simone C.; Juillard, Pierre; Johnson, Zoe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7299-7317</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">New phenoxyacetic acid antagonists of CRTH2 are described.  Following the discovery of a hit compd., I, by a focused screening, high protein binding was identified as its main weakness.  Optimization aimed at reducing serum protein binding led to the identification of several compds. that showed not only excellent affinities for the receptor (41 compds. with Ki < 10 nM) but also excellent potencies in a human whole blood assay (IC50 < 100 nM; PGD2-induced eosinophil shape change).  Addnl. optimization of the pharmacokinetic characteristics led to the identification of several compds. suitable for in vivo testing.  Of these, II (R1 = n-Pr, R2 = Me; R1 = n-Pr, R2 = F) were tested in two different pharmacol. models (acute FITC-mediated contact hypersensitivity and ovalbumin-induced eosinophilia models) and found to be active after oral dosing (10 and 30 mg/kg).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryieXI4i54w7Vg90H21EOLACvtfcHk0ljv3_oWcl_6SQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1GitLrK&md5=348d6859d00f830d881599aab91e48bd</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1021%2Fjm200866y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200866y%26sid%3Dliteratum%253Aachs%26aulast%3DCrosignani%26aufirst%3DS.%26aulast%3DPretre%26aufirst%3DA.%26aulast%3DJorand-Lebrun%26aufirst%3DC.%26aulast%3DFraboulet%26aufirst%3DG.%26aulast%3DSeenisamy%26aufirst%3DJ.%26aulast%3DAugustine%26aufirst%3DJ.%2BK.%26aulast%3DMissotten%26aufirst%3DM.%26aulast%3DHumbert%26aufirst%3DY.%26aulast%3DCleva%26aufirst%3DC.%26aulast%3DAbla%26aufirst%3DN.%26aulast%3DDaff%26aufirst%3DH.%26aulast%3DSchott%26aufirst%3DO.%26aulast%3DSchneider%26aufirst%3DM.%26aulast%3DBurgat-Charvillon%26aufirst%3DF.%26aulast%3DRivron%26aufirst%3DD.%26aulast%3DHamernig%26aufirst%3DI.%26aulast%3DArrighi%26aufirst%3DJ.%2BF.%26aulast%3DGaudet%26aufirst%3DM.%26aulast%3DZimmerli%26aufirst%3DS.%2BC.%26aulast%3DJuillard%26aufirst%3DP.%26aulast%3DJohnson%26aufirst%3DZ.%26atitle%3DDiscovery%2520of%2520potent%252C%2520selective%252C%2520and%2520orally%2520bioavailable%2520alkynylphenoxyacetic%2520acid%2520CRTH2%2520%2528DP2%2529%2520receptor%2520antagonists%2520for%2520the%2520treatment%2520of%2520allergic%2520inflammatory%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D7299%26epage%3D7317%26doi%3D10.1021%2Fjm200866y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cerretti, D. P.</span></span> <span> </span><span class="NLM_article-title">Characterization of the tumour necrosis factor alpha-converting enzyme, TACE/ADAM17</span>. <i>Biochem. Soc. Trans.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">219</span>– <span class="NLM_lpage">223</span>, <span class="refDoi"> DOI: 10.1042/bst0270219</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1042%2Fbst0270219" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10093737" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADyaK1MXhsValurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1999&pages=219-223&author=D.+P.+Cerretti&title=Characterization+of+the+tumour+necrosis+factor+alpha-converting+enzyme%2C+TACE%2FADAM17&doi=10.1042%2Fbst0270219"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of the tumor necrosis factor α-converting enzyme, TACE/ADAM17</span></div><div class="casAuthors">Cerretti, D. P.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Society Transactions</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">219-223</span>CODEN:
                <span class="NLM_cas:coden">BCSTB5</span>;
        ISSN:<span class="NLM_cas:issn">0300-5127</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">TNF-α is a trimeric type II transmembrane protein with its N-terminus inside the cell and its C-terminus outside the cell.  A specific proteinase or TNF-α-converting enzyme (TACE) is responsible for the cleavage or shedding of the precursor protein (pro-TNF-α) from the membrane surface.  To characterize TACE we searched for cells that produced large quantities of shed TNF-α.  We found that the human monocytic cell line THP-1 met this criterion.  Our findings have demonstrated that a single proteinase TACE/ADAM17 is required for the shedding of TNF-α from T cells and myeloid cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVWiKYnfWkzLVg90H21EOLACvtfcHk0ljv3_oWcl_6SQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXhsValurw%253D&md5=4e7f18bc489a082ae2de77d8e9be3131</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1042%2Fbst0270219&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252Fbst0270219%26sid%3Dliteratum%253Aachs%26aulast%3DCerretti%26aufirst%3DD.%2BP.%26atitle%3DCharacterization%2520of%2520the%2520tumour%2520necrosis%2520factor%2520alpha-converting%2520enzyme%252C%2520TACE%252FADAM17%26jtitle%3DBiochem.%2520Soc.%2520Trans.%26date%3D1999%26volume%3D27%26spage%3D219%26epage%3D223%26doi%3D10.1042%2Fbst0270219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shankar, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavey, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosinski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizvi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feltz, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piwinski, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosner, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shih, N. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siddiqui, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orth, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Umland, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundell, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozlowski, J. A.</span></span> <span> </span><span class="NLM_article-title">Biaryl substituted hydantoin compounds as TACE inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">5286</span>– <span class="NLM_lpage">5289</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.06.134</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1016%2Fj.bmcl.2010.06.134" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=20663669" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVehtr3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=5286-5289&author=W.+Yuauthor=L.+Tongauthor=S.+H.+Kimauthor=M.+K.+Wongauthor=L.+Chenauthor=D.+Y.+Yangauthor=B.+B.+Shankarauthor=B.+J.+Laveyauthor=G.+Zhouauthor=A.+Kosinskiauthor=R.+Rizviauthor=D.+Liauthor=R.+J.+Feltzauthor=J.+J.+Piwinskiauthor=K.+E.+Rosnerauthor=N.+Y.+Shihauthor=M.+A.+Siddiquiauthor=Z.+Guoauthor=P.+Orthauthor=H.+Shahauthor=J.+Sunauthor=S.+Umlandauthor=D.+J.+Lundellauthor=X.+Niuauthor=J.+A.+Kozlowski&title=Biaryl+substituted+hydantoin+compounds+as+TACE+inhibitors&doi=10.1016%2Fj.bmcl.2010.06.134"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Biaryl substituted hydantoin compounds as TACE inhibitors</span></div><div class="casAuthors">Yu, Wensheng; Tong, Ling; Kim, Seong Heon; Wong, Michael K. C.; Chen, Lei; Yang, De-Yi; Shankar, Bandarpalle B.; Lavey, Brian J.; Zhou, Guowei; Kosinski, Aneta; Rizvi, Razia; Li, Dansu; Feltz, Robert J.; Piwinski, John J.; Rosner, Kristin E.; Shih, Neng-Yang; Siddiqui, M. Arshad; Guo, Zhuyan; Orth, Peter; Shah, Himanshu; Sun, Jing; Umland, Shelby; Lundell, Daniel J.; Niu, Xiaoda; Kozlowski, Joseph A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5286-5289</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We disclose further optimization of hydantoin TNF-α convertase enzyme (TACE) inhibitors.  SAR with respect to the non-prime region of TACE active site was explored.  A series of biaryl substituted hydantoin compds. was shown to have sub-nanomolar K i, good rat PK, and good selectivity vs. MMP-1, -2, -3, -7, -9, and -13.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMqDvlftR2sbVg90H21EOLACvtfcHk0lg4TmEw-eRviA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVehtr3I&md5=085e9aeb4fb958b2c91d7cf3ffa7cbe7</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.06.134&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.06.134%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DW.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DWong%26aufirst%3DM.%2BK.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DD.%2BY.%26aulast%3DShankar%26aufirst%3DB.%2BB.%26aulast%3DLavey%26aufirst%3DB.%2BJ.%26aulast%3DZhou%26aufirst%3DG.%26aulast%3DKosinski%26aufirst%3DA.%26aulast%3DRizvi%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DFeltz%26aufirst%3DR.%2BJ.%26aulast%3DPiwinski%26aufirst%3DJ.%2BJ.%26aulast%3DRosner%26aufirst%3DK.%2BE.%26aulast%3DShih%26aufirst%3DN.%2BY.%26aulast%3DSiddiqui%26aufirst%3DM.%2BA.%26aulast%3DGuo%26aufirst%3DZ.%26aulast%3DOrth%26aufirst%3DP.%26aulast%3DShah%26aufirst%3DH.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DUmland%26aufirst%3DS.%26aulast%3DLundell%26aufirst%3DD.%2BJ.%26aulast%3DNiu%26aufirst%3DX.%26aulast%3DKozlowski%26aufirst%3DJ.%2BA.%26atitle%3DBiaryl%2520substituted%2520hydantoin%2520compounds%2520as%2520TACE%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D5286%26epage%3D5289%26doi%3D10.1016%2Fj.bmcl.2010.06.134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Girijavallabhan, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feltz, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Firmansjah, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozlowski, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavey, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosinski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piwinski, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popovici-Muller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizvi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosner, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shankar, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shih, N. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siddiqui, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orth, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madison, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundell, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Umland, S.</span></span> <span> </span><span class="NLM_article-title">Novel TNF-alpha converting enzyme (TACE) inhibitors as potential treatment for inflammatory diseases</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">7283</span>– <span class="NLM_lpage">7287</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.10.081</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1016%2Fj.bmcl.2010.10.081" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=21106451" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVKjtb7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=7283-7287&author=V.+M.+Girijavallabhanauthor=L.+Chenauthor=C.+Daiauthor=R.+J.+Feltzauthor=L.+Firmansjahauthor=D.+Liauthor=S.+H.+Kimauthor=J.+A.+Kozlowskiauthor=B.+J.+Laveyauthor=A.+Kosinskiauthor=J.+J.+Piwinskiauthor=J.+Popovici-Mullerauthor=R.+Rizviauthor=K.+E.+Rosnerauthor=B.+B.+Shankarauthor=N.+Y.+Shihauthor=M.+A.+Siddiquiauthor=L.+Tongauthor=M.+K.+Wongauthor=D.+Y.+Yangauthor=L.+Yangauthor=W.+Yuauthor=G.+Zhouauthor=Z.+Guoauthor=P.+Orthauthor=V.+Madisonauthor=H.+Bianauthor=D.+Lundellauthor=X.+Niuauthor=H.+Shahauthor=J.+Sunauthor=S.+Umland&title=Novel+TNF-alpha+converting+enzyme+%28TACE%29+inhibitors+as+potential+treatment+for+inflammatory+diseases&doi=10.1016%2Fj.bmcl.2010.10.081"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Novel TNF-α converting enzyme (TACE) inhibitors as potential treatment for inflammatory diseases</span></div><div class="casAuthors">Girijavallabhan, Vinay M.; Chen, Lei; Dai, Chaoyang; Feltz, Robert J.; Firmansjah, Luke; Li, Dansu; Kim, Seong Heon; Kozlowski, Joseph A.; Lavey, Brian J.; Kosinski, Aneta; Piwinski, John J.; Popovici-Muller, Janeta; Rizvi, Razia; Rosner, Kristin E.; Shankar, Banderpalle B.; Shih, Neng-Yang; Siddiqui, M. Arshad; Tong, Ling; Wong, Michael K. C.; Yang, De-yi; Yang, Liping; Yu, Wensheng; Zhou, Guowei; Guo, Zhuyan; Orth, Peter; Madison, Vincent; Bian, Hong; Lundell, Daniel; Niu, Xiaoda; Shah, Himanshu; Sun, Jing; Umland, Shelby</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7283-7287</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Our research on hydantoin based TNF-α converting enzyme (TACE) inhibitors has led to an acetylene contg. series that demonstrates sub-nanomolar potency (K i) as well as excellent activity in human whole blood.  These studies led to the discovery of highly potent TACE inhibitors such as 37 (I) with good DMPK profiles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZMVt5qIgU-7Vg90H21EOLACvtfcHk0lg4TmEw-eRviA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVKjtb7P&md5=f885b195abe9ce531bf1f5dde1f8b89f</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.10.081&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.10.081%26sid%3Dliteratum%253Aachs%26aulast%3DGirijavallabhan%26aufirst%3DV.%2BM.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DDai%26aufirst%3DC.%26aulast%3DFeltz%26aufirst%3DR.%2BJ.%26aulast%3DFirmansjah%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DKozlowski%26aufirst%3DJ.%2BA.%26aulast%3DLavey%26aufirst%3DB.%2BJ.%26aulast%3DKosinski%26aufirst%3DA.%26aulast%3DPiwinski%26aufirst%3DJ.%2BJ.%26aulast%3DPopovici-Muller%26aufirst%3DJ.%26aulast%3DRizvi%26aufirst%3DR.%26aulast%3DRosner%26aufirst%3DK.%2BE.%26aulast%3DShankar%26aufirst%3DB.%2BB.%26aulast%3DShih%26aufirst%3DN.%2BY.%26aulast%3DSiddiqui%26aufirst%3DM.%2BA.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DWong%26aufirst%3DM.%2BK.%26aulast%3DYang%26aufirst%3DD.%2BY.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DYu%26aufirst%3DW.%26aulast%3DZhou%26aufirst%3DG.%26aulast%3DGuo%26aufirst%3DZ.%26aulast%3DOrth%26aufirst%3DP.%26aulast%3DMadison%26aufirst%3DV.%26aulast%3DBian%26aufirst%3DH.%26aulast%3DLundell%26aufirst%3DD.%26aulast%3DNiu%26aufirst%3DX.%26aulast%3DShah%26aufirst%3DH.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DUmland%26aufirst%3DS.%26atitle%3DNovel%2520TNF-alpha%2520converting%2520enzyme%2520%2528TACE%2529%2520inhibitors%2520as%2520potential%2520treatment%2520for%2520inflammatory%2520diseases%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D7283%26epage%3D7287%26doi%3D10.1016%2Fj.bmcl.2010.10.081" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyata, N.</span></span> <span> </span><span class="NLM_article-title">Lysine demethylases inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">8236</span>– <span class="NLM_lpage">8250</span>, <span class="refDoi"> DOI: 10.1021/jm201048w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201048w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1OrtrnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=8236-8250&author=T.+Suzukiauthor=N.+Miyata&title=Lysine+demethylases+inhibitors&doi=10.1021%2Fjm201048w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Lysine Demethylases Inhibitors</span></div><div class="casAuthors">Suzuki, Takayoshi; Miyata, Naoki</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8236-8250</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review, on the use of lysine demethylases inhibitors in therapy of various diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplp9MjSdvnn7Vg90H21EOLACvtfcHk0lg4TmEw-eRviA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1OrtrnF&md5=194d4bbc2e52672f5d5f019de0bb760c</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1021%2Fjm201048w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201048w%26sid%3Dliteratum%253Aachs%26aulast%3DSuzuki%26aufirst%3DT.%26aulast%3DMiyata%26aufirst%3DN.%26atitle%3DLysine%2520demethylases%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D8236%26epage%3D8250%26doi%3D10.1021%2Fjm201048w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, L. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H. M.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and structure-activity relationship of novel LSD1 inhibitors based on pyrimidine-thiourea hybrids as potent, orally active antitumor agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">1705</span>– <span class="NLM_lpage">1716</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00037</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00037" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlyksbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=1705-1716&author=L.+Y.+Maauthor=Y.+C.+Zhengauthor=S.+Q.+Wangauthor=B.+Wangauthor=Z.+R.+Wangauthor=L.+P.+Pangauthor=M.+Zhangauthor=J.+W.+Wangauthor=L.+Dingauthor=J.+Liauthor=C.+Wangauthor=B.+Huauthor=Y.+Liuauthor=X.+D.+Zhangauthor=J.+J.+Wangauthor=Z.+J.+Wangauthor=W.+Zhaoauthor=H.+M.+Liu&title=Design%2C+synthesis%2C+and+structure-activity+relationship+of+novel+LSD1+inhibitors+based+on+pyrimidine-thiourea+hybrids+as+potent%2C+orally+active+antitumor+agents&doi=10.1021%2Facs.jmedchem.5b00037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Structure-Activity Relationship of Novel LSD1 Inhibitors Based on Pyrimidine-Thiourea Hybrids As Potent, Orally Active Antitumor Agents</span></div><div class="casAuthors">Ma, Li-Ying; Zheng, Yi-Chao; Wang, Sai-Qi; Wang, Bo; Wang, Zhi-Ru; Pang, Lu-Ping; Zhang, Miao; Wang, Jun-Wei; Ding, Lina; Li, Juan; Wang, Cong; Hu, Biao; Liu, Ying; Zhang, Xiao-Dan; Wang, Jia-Jia; Wang, Zhi-Jian; Zhao, Wen; Liu, Hong-Min</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1705-1716</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Histone lysine specific demethylase 1 (LSD1) was reported to be overexpressed in several human cancers and recognized as a promising anticancer drug target.  In the current study, we designed and synthesized a novel series of pyrimidine-thiourea hybrids and evaluated their potential LSD1 inhibitory effect.  One of the compds., 6b, contg. a terminal alkyne appendage, was shown to be the most potent and selective LSD1 inhibitor in vitro and exhibited strong cytotoxicity against LSD1 overexpressed gastric cancer cells.  Compd. 6b also showed marked inhibition of cell migration and invasion as well as significant in vivo tumor suppressing and antimetastasis role, without significant side effects by oral administration.  Our findings indicate that the pyrimidine-thiourea-based LSD1 inactivator may serve as a leading compd. targeting LSD1 overexpressed cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpy8SIAhdqGGbVg90H21EOLACvtfcHk0lg5K3XcqtPzhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlyksbw%253D&md5=7256792e23b75e5f26bac47dfa773b11</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00037%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DL.%2BY.%26aulast%3DZheng%26aufirst%3DY.%2BC.%26aulast%3DWang%26aufirst%3DS.%2BQ.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DZ.%2BR.%26aulast%3DPang%26aufirst%3DL.%2BP.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DJ.%2BW.%26aulast%3DDing%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DHu%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DX.%2BD.%26aulast%3DWang%26aufirst%3DJ.%2BJ.%26aulast%3DWang%26aufirst%3DZ.%2BJ.%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DH.%2BM.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520structure-activity%2520relationship%2520of%2520novel%2520LSD1%2520inhibitors%2520based%2520on%2520pyrimidine-thiourea%2520hybrids%2520as%2520potent%252C%2520orally%2520active%2520antitumor%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D1705%26epage%3D1716%26doi%3D10.1021%2Facs.jmedchem.5b00037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Szewczuk, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Culhane, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majumdar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, P. A.</span></span> <span> </span><span class="NLM_article-title">Mechanistic analysis of a suicide inactivator of histone demethylase LSD1</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">6892</span>– <span class="NLM_lpage">6902</span>, <span class="refDoi"> DOI: 10.1021/bi700414b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi700414b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlsVSgt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2007&pages=6892-6902&author=L.+M.+Szewczukauthor=J.+C.+Culhaneauthor=M.+Yangauthor=A.+Majumdarauthor=H.+Yuauthor=P.+A.+Cole&title=Mechanistic+analysis+of+a+suicide+inactivator+of+histone+demethylase+LSD1&doi=10.1021%2Fbi700414b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanistic Analysis of a Suicide Inactivator of Histone Demethylase LSD1</span></div><div class="casAuthors">Szewczuk, Lawrence M.; Culhane, Jeffrey C.; Yang, Maojun; Majumdar, Ananya; Yu, Hongtao; Cole, Philip A.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">6892-6902</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Lysine-specific demethylase 1 (LSD1) is a transcriptional repressor and a flavin-dependent amine oxidase that is responsible for the removal of Me from lysine 4 of histone H3.  In this study, we characterize the mechanism and scope of LSD1 inhibition by a propargylamine-derivatized histone H3 substrate (1).  Unlike aziridinyl and cyclopropylamine-derivatized histone H3 peptide substrate analogs, compd. 1 appears to covalently modify and irreversibly inactivate LSD1 with high potency.  Accompanying this inactivation is a spectroscopic change, which shifts the absorbance max. to 392 nm.  Spectral changes assocd. with the 1-LSD1 complex and reactivity to decreased pH and sodium borohydride treatment were suggestive of a structure involving a flavin-linked inhibitor conjugate between N5 of the flavin and the terminal carbon of the inhibitor.  Using a 13C-labeled inhibitor, NMR anal. of the 1-flavin conjugate was consistent with this structural assignment.  Kinetic anal. of the spectroscopic shift induced by 1 showed that the flavin adduct formed in a reaction with kinetic consts. similar to those of the LSD1 inactivation process.  Taken together, these data support a mechanism of LSD1 inactivation by 1 involving amine oxidn. followed by Michael addn. to the propargylic imine.  We further examd. the potential for a biotinylated analog of 1 (1-Btn) to be used as a tool in affinity pulldown expts.  Using 1-Btn, it was feasible to selectively pull down spiked and endogenous LSD1 from HeLa cell nuclear exts., setting the stage for activity-based demethylase proteomics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2nUlBCS3LG7Vg90H21EOLACvtfcHk0lg5K3XcqtPzhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlsVSgt7Y%253D&md5=97eaa358443717b9f5b1214b4aebe807</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1021%2Fbi700414b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi700414b%26sid%3Dliteratum%253Aachs%26aulast%3DSzewczuk%26aufirst%3DL.%2BM.%26aulast%3DCulhane%26aufirst%3DJ.%2BC.%26aulast%3DYang%26aufirst%3DM.%26aulast%3DMajumdar%26aufirst%3DA.%26aulast%3DYu%26aufirst%3DH.%26aulast%3DCole%26aufirst%3DP.%2BA.%26atitle%3DMechanistic%2520analysis%2520of%2520a%2520suicide%2520inactivator%2520of%2520histone%2520demethylase%2520LSD1%26jtitle%3DBiochemistry%26date%3D2007%26volume%3D46%26spage%3D6892%26epage%3D6902%26doi%3D10.1021%2Fbi700414b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bisogno, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howell, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minassi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cascio, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ligresti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matias, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiano-Moriello, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paul, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gangadharan, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hobbs, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Marzo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doherty, P.</span></span> <span> </span><span class="NLM_article-title">Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain</span>. <i>J. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>163</i></span>,  <span class="NLM_fpage">463</span>– <span class="NLM_lpage">468</span>, <span class="refDoi"> DOI: 10.1083/jcb.200305129</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1083%2Fjcb.200305129" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=14610053" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD3sXovFCnur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2003&pages=463-468&author=T.+Bisognoauthor=F.+Howellauthor=G.+Williamsauthor=A.+Minassiauthor=M.+G.+Cascioauthor=A.+Ligrestiauthor=I.+Matiasauthor=A.+Schiano-Morielloauthor=P.+Paulauthor=E.+J.+Williamsauthor=U.+Gangadharanauthor=C.+Hobbsauthor=V.+Di+Marzoauthor=P.+Doherty&title=Cloning+of+the+first+sn1-DAG+lipases+points+to+the+spatial+and+temporal+regulation+of+endocannabinoid+signaling+in+the+brain&doi=10.1083%2Fjcb.200305129"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain</span></div><div class="casAuthors">Bisogno, Tiziana; Howell, Fiona; Williams, Gareth; Minassi, Alberto; Grazia Cascio, Maria; Ligresti, Alessia; Matias, Isabel; Schiano-Moriello, Aniello; Paul, Praveen; Williams, Emma-Jane; Gangadharan, Uma; Hobbs, Carl; Di Marzo, Vincenzo; Doherty, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Biology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">463-468</span>CODEN:
                <span class="NLM_cas:coden">JCLBA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9525</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Diacylglycerol (DAG) lipase activity is required for axonal growth during development and for retrograde synaptic signaling at mature synapses.  This enzyme synthesizes the endocannabinoid 2-arachidonoyl-glycerol (2-AG), and the CB1 cannabinoid receptor is also required for the above responses.  We now report on the cloning and enzymic characterization of the first specific sn-1 DAG lipases.  Two closely related genes have been identified and their expression in cells correlated with 2-AG biosynthesis and release.  The expression of both enzymes changes from axonal tracts in the embryo to dendritic fields in the adult, and this correlates with the developmental change in requirement for 2-AG synthesis from the pre- to the postsynaptic compartment.  This switch provides a possible explanation for a fundamental change in endocannabinoid function during brain development.  Identification of these enzymes may offer new therapeutic opportunities for a wide range of disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolsTG3YamCQ7Vg90H21EOLACvtfcHk0lg5K3XcqtPzhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXovFCnur8%253D&md5=37bfbb4e29da593151e155d4c9d22cfa</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1083%2Fjcb.200305129&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.200305129%26sid%3Dliteratum%253Aachs%26aulast%3DBisogno%26aufirst%3DT.%26aulast%3DHowell%26aufirst%3DF.%26aulast%3DWilliams%26aufirst%3DG.%26aulast%3DMinassi%26aufirst%3DA.%26aulast%3DCascio%26aufirst%3DM.%2BG.%26aulast%3DLigresti%26aufirst%3DA.%26aulast%3DMatias%26aufirst%3DI.%26aulast%3DSchiano-Moriello%26aufirst%3DA.%26aulast%3DPaul%26aufirst%3DP.%26aulast%3DWilliams%26aufirst%3DE.%2BJ.%26aulast%3DGangadharan%26aufirst%3DU.%26aulast%3DHobbs%26aufirst%3DC.%26aulast%3DDi%2BMarzo%26aufirst%3DV.%26aulast%3DDoherty%26aufirst%3DP.%26atitle%3DCloning%2520of%2520the%2520first%2520sn1-DAG%2520lipases%2520points%2520to%2520the%2520spatial%2520and%2520temporal%2520regulation%2520of%2520endocannabinoid%2520signaling%2520in%2520the%2520brain%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D2003%26volume%3D163%26spage%3D463%26epage%3D468%26doi%3D10.1083%2Fjcb.200305129" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sugiura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sukagawa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakane, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinoda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Itoh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waku, K.</span></span> <span> </span><span class="NLM_article-title">2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>215</i></span>,  <span class="NLM_fpage">89</span>– <span class="NLM_lpage">97</span>, <span class="refDoi"> DOI: 10.1006/bbrc.1995.2437</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1006%2Fbbrc.1995.2437" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=7575630" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADyaK2MXosVyqtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=215&publication_year=1995&pages=89-97&author=T.+Sugiuraauthor=S.+Kondoauthor=A.+Sukagawaauthor=S.+Nakaneauthor=A.+Shinodaauthor=K.+Itohauthor=A.+Yamashitaauthor=K.+Waku&title=2-Arachidonoylglycerol%3A+a+possible+endogenous+cannabinoid+receptor+ligand+in+brain&doi=10.1006%2Fbbrc.1995.2437"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain</span></div><div class="casAuthors">Sugiura, Takayuki; Kondo, Sachiko; Sukagawa, Akihiro; Nakane, Shinji; Shinoda, Akira; Itoh, Koyoko; Yamashita, Atsushi; Waku, Keizo</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">215</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">89-97</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Academic</span>)
        </div><div class="casAbstract">The effects of anandamide, 2-arachidonoylglycerol and related compds. on the specific binding of a radiolabeled cannabinoid receptor ligand, [3H]CP55940, to synaptosomal membranes were examines.  Anandamide, an endogenous cannabinoid receptor ligand, reduced the specific binding of [3H]CP55940 to synaptosomal membranes in a dose-dependent manner: the Ki value was 89 nM.  2-Arachidonoylglycerol was also shown to bind appreciably to the cannabinoid receptor in competitive inhibition expts.  The apparent binding affinity was markedly increased when the binding assay was carried out in the presence of the esterase inhibitor DFP or at 0°C.  Free arachidonic acid and N-palmitoylethanolamine were almost inactive in terms of binding to the cannabinoid receptor in synaptosomal membranes.  2-Arachidonoylglycerol may be an endogenous cannabinoid receptor ligand in the brain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGob2R5xY8ybgbVg90H21EOLACvtfcHk0lj5KwzYu4JEbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXosVyqtLk%253D&md5=faac2eccf862d0e27808349932440009</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1006%2Fbbrc.1995.2437&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fbbrc.1995.2437%26sid%3Dliteratum%253Aachs%26aulast%3DSugiura%26aufirst%3DT.%26aulast%3DKondo%26aufirst%3DS.%26aulast%3DSukagawa%26aufirst%3DA.%26aulast%3DNakane%26aufirst%3DS.%26aulast%3DShinoda%26aufirst%3DA.%26aulast%3DItoh%26aufirst%3DK.%26aulast%3DYamashita%26aufirst%3DA.%26aulast%3DWaku%26aufirst%3DK.%26atitle%3D2-Arachidonoylglycerol%253A%2520a%2520possible%2520endogenous%2520cannabinoid%2520receptor%2520ligand%2520in%2520brain%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D1995%26volume%3D215%26spage%3D89%26epage%3D97%26doi%3D10.1006%2Fbbrc.1995.2437" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kooijman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van den
Nieuwendijk, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogasawara, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Wel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Dalen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baggelaar, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janssen, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van den Berg, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">den Dulk, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overkleeft, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rensen, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Stelt, M.</span></span> <span> </span><span class="NLM_article-title">Triazole ureas act as diacylglycerol lipase inhibitors and prevent fasting-induced refeeding</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">428</span>– <span class="NLM_lpage">440</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01482</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01482" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVGitbrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=428-440&author=H.+Dengauthor=S.+Kooijmanauthor=A.+M.+van+den%0ANieuwendijkauthor=D.+Ogasawaraauthor=T.+van+der+Welauthor=F.+van+Dalenauthor=M.+P.+Baggelaarauthor=F.+J.+Janssenauthor=R.+J.+van+den+Bergauthor=H.+den+Dulkauthor=B.+F.+Cravattauthor=H.+S.+Overkleeftauthor=P.+C.+Rensenauthor=M.+van+der+Stelt&title=Triazole+ureas+act+as+diacylglycerol+lipase+inhibitors+and+prevent+fasting-induced+refeeding&doi=10.1021%2Facs.jmedchem.6b01482"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Triazole Ureas Act as Diacylglycerol Lipase Inhibitors and Prevent Fasting-Induced Refeeding</span></div><div class="casAuthors">Deng, Hui; Kooijman, Sander; van den Nieuwendijk, Adrianus M. C. H.; Ogasawara, Daisuke; van der Wel, Tom; van Dalen, Floris; Baggelaar, Marc P.; Janssen, Freek J.; van den Berg, Richard J. B. H. N.; den Dulk, Hans; Cravatt, Benjamin F.; Overkleeft, Herman S.; Rensen, Patrick C. N.; van der Stelt, Mario</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">428-440</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Triazole ureas constitute a versatile class of irreversible inhibitors that target serine hydrolases in both cells and animal models.  We have previously reported that triazole ureas can act as selective and CNS-active inhibitors for diacylglycerol lipases (DAGLs), enzymes responsible for the biosynthesis of 2-arachidonoyl glycerol (2-AG) that activates cannabinoid CB1 receptor.  Here, we report the enantio- and diastereoselective synthesis and structure-activity relationship studies.  We found that 2,4-substituted triazole ureas with a biphenylmethanol group provided the most optimal scaffold.  Introduction of a chiral ether substituent on the 5-position of the piperidine ring provided ultrapotent inhibitor I (DH376) with picomolar activity.  Compd. I temporarily reduces fasting-induced refeeding of mice, thereby emulating the effect of cannabinoid CB1-receptor inverse agonists.  This was mirrored by II (DO34) but also by the neg. control compd. III (DO53) (which does not inhibit DAGL), which indicates the triazole ureas may affect the energy balance in mice through multiple mol. targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp70FEOiinaZrVg90H21EOLACvtfcHk0lj5KwzYu4JEbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVGitbrF&md5=94d1ccb26a0d76fbc5c2e5d59b579c0c</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01482&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01482%26sid%3Dliteratum%253Aachs%26aulast%3DDeng%26aufirst%3DH.%26aulast%3DKooijman%26aufirst%3DS.%26aulast%3Dvan%2Bden%2BNieuwendijk%26aufirst%3DA.%2BM.%26aulast%3DOgasawara%26aufirst%3DD.%26aulast%3Dvan%2Bder%2BWel%26aufirst%3DT.%26aulast%3Dvan%2BDalen%26aufirst%3DF.%26aulast%3DBaggelaar%26aufirst%3DM.%2BP.%26aulast%3DJanssen%26aufirst%3DF.%2BJ.%26aulast%3Dvan%2Bden%2BBerg%26aufirst%3DR.%2BJ.%26aulast%3Dden%2BDulk%26aufirst%3DH.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26aulast%3DOverkleeft%26aufirst%3DH.%2BS.%26aulast%3DRensen%26aufirst%3DP.%2BC.%26aulast%3Dvan%2Bder%2BStelt%26aufirst%3DM.%26atitle%3DTriazole%2520ureas%2520act%2520as%2520diacylglycerol%2520lipase%2520inhibitors%2520and%2520prevent%2520fasting-induced%2520refeeding%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D428%26epage%3D440%26doi%3D10.1021%2Facs.jmedchem.6b01482" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dragovich, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prins, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hua, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luu, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakata, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maldonado, F. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuntland, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuhrman, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zalman, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patick, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, E. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borer, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nayyar, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moran, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rejto, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guzman, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dovalsantos, E. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohajeri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liese, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosa, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batugo, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gleeson, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meador, J. W.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferre, R. A.</span></span> <span> </span><span class="NLM_article-title">Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 8. Pharmacological optimization of orally bioavailable 2-pyridone-containing peptidomimetics</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">4572</span>– <span class="NLM_lpage">4285</span>, <span class="refDoi"> DOI: 10.1021/jm030166l</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm030166l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD3sXot1Ojs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=4572-4285&author=P.+S.+Dragovichauthor=T.+J.+Prinsauthor=R.+Zhouauthor=T.+O.+Johnsonauthor=Y.+Huaauthor=H.+T.+Luuauthor=S.+K.+Sakataauthor=E.+L.+Brownauthor=F.+C.+Maldonadoauthor=T.+Tuntlandauthor=C.+A.+Leeauthor=S.+A.+Fuhrmanauthor=L.+S.+Zalmanauthor=A.+K.+Patickauthor=D.+A.+Matthewsauthor=E.+Y.+Wuauthor=M.+Guoauthor=B.+C.+Borerauthor=N.+K.+Nayyarauthor=T.+Moranauthor=L.+Chenauthor=P.+A.+Rejtoauthor=P.+W.+Roseauthor=M.+C.+Guzmanauthor=E.+Z.+Dovalsantosauthor=S.+Leeauthor=K.+McGeeauthor=M.+Mohajeriauthor=A.+Lieseauthor=J.+Taoauthor=M.+B.+Kosaauthor=B.+Liuauthor=M.+R.+Batugoauthor=J.+P.+Gleesonauthor=Z.+P.+Wuauthor=J.+Liuauthor=J.+W.+Meadorauthor=R.+A.+Ferre&title=Structure-based+design%2C+synthesis%2C+and+biological+evaluation+of+irreversible+human+rhinovirus+3C+protease+inhibitors.+8.+Pharmacological+optimization+of+orally+bioavailable+2-pyridone-containing+peptidomimetics&doi=10.1021%2Fjm030166l"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 8. Pharmacological optimization of orally bioavailable 2-pyridone-containing peptidomimetics</span></div><div class="casAuthors">Dragovich, Peter S.; Prins, Thomas J.; Zhou, Ru; Johnson, Theodore O.; Hua, Ye; Luu, Hiep T.; Sakata, Sylvie K.; Brown, Edward L.; Maldonado, Fausto C.; Tuntland, Tove; Lee, Caroline A.; Fuhrman, Shella A.; Zalman, Leora S.; Patick, Amy K.; Matthews, David A.; Wu, Ellen Y.; Guo, Ming; Borer, Bennett C.; Nayyar, Naresh K.; Moran, Terence; Chen, Lijian; Rejto, Paul A.; Rose, Peter W.; Guzman, Mark C.; Dovalsantos, Elena Z.; Lee, Steven; McGee, Kevin; Mohajeri, Michael; Liese, Andreas; Tao, Junhua; Kosa, Maha B.; Liu, Bo; Batugo, Minerva R.; Gleeson, Jean-Paul R.; Wu, Zhen Ping; Liu, Jia; Meador, James W., III; Ferre, Rose Ann</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">4572-4585</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The optimization of the pharmacokinetic performance of various 2-pyridone-contg. human rhinovirus (HRV) 3C protease (3CP) inhibitors following oral administration to either beagle dogs or CM-monkeys is described.  The mols. described in this work are composed of a 2-pyridone-contg. peptidomimetic binding determinant and an α,β-unsatd. ester Michael acceptor moiety which forms an irreversible covalent adduct with the active site cysteine residue of the 3C enzyme.  Modification of the ester contained within these compds. is detailed along with alteration of the P2 substituent present in the peptidomimetic portion of the inhibitors.  The pharmacokinetics of several inhibitors in both dogs and monkeys are described (7 h plasma concns. after oral administration) along with their human plasma stabilities, stabilities in incubations with human, dog, and monkey microsomes and hepatocytes, Caco-2 permeabilities, and aq. solubilities.  Compds. contg. an α,β-unsatd. Et ester fragment and either an Et or propargyl P2 moiety displayed the most promising combination of 3C enzyme inhibition (kobs/[I] 170 000-223 000 M-1 s-1), antiviral activity (EC50 = 0.047-0.058 μM, mean vs. seven HRV serotypes), and pharmacokinetics following oral administration (7 h dog plasma levels = 0.248-0.682 μM; 7 h CM-monkey plasma levels = 0.057-0.896 μM).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGom7ef81WRYlrVg90H21EOLACvtfcHk0lim9k71TAOj5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXot1Ojs78%253D&md5=c4b964698cce3c97c107076f24692056</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1021%2Fjm030166l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030166l%26sid%3Dliteratum%253Aachs%26aulast%3DDragovich%26aufirst%3DP.%2BS.%26aulast%3DPrins%26aufirst%3DT.%2BJ.%26aulast%3DZhou%26aufirst%3DR.%26aulast%3DJohnson%26aufirst%3DT.%2BO.%26aulast%3DHua%26aufirst%3DY.%26aulast%3DLuu%26aufirst%3DH.%2BT.%26aulast%3DSakata%26aufirst%3DS.%2BK.%26aulast%3DBrown%26aufirst%3DE.%2BL.%26aulast%3DMaldonado%26aufirst%3DF.%2BC.%26aulast%3DTuntland%26aufirst%3DT.%26aulast%3DLee%26aufirst%3DC.%2BA.%26aulast%3DFuhrman%26aufirst%3DS.%2BA.%26aulast%3DZalman%26aufirst%3DL.%2BS.%26aulast%3DPatick%26aufirst%3DA.%2BK.%26aulast%3DMatthews%26aufirst%3DD.%2BA.%26aulast%3DWu%26aufirst%3DE.%2BY.%26aulast%3DGuo%26aufirst%3DM.%26aulast%3DBorer%26aufirst%3DB.%2BC.%26aulast%3DNayyar%26aufirst%3DN.%2BK.%26aulast%3DMoran%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DRejto%26aufirst%3DP.%2BA.%26aulast%3DRose%26aufirst%3DP.%2BW.%26aulast%3DGuzman%26aufirst%3DM.%2BC.%26aulast%3DDovalsantos%26aufirst%3DE.%2BZ.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DMcGee%26aufirst%3DK.%26aulast%3DMohajeri%26aufirst%3DM.%26aulast%3DLiese%26aufirst%3DA.%26aulast%3DTao%26aufirst%3DJ.%26aulast%3DKosa%26aufirst%3DM.%2BB.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DBatugo%26aufirst%3DM.%2BR.%26aulast%3DGleeson%26aufirst%3DJ.%2BP.%26aulast%3DWu%26aufirst%3DZ.%2BP.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DMeador%26aufirst%3DJ.%2BW.%26aulast%3DFerre%26aufirst%3DR.%2BA.%26atitle%3DStructure-based%2520design%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520irreversible%2520human%2520rhinovirus%25203C%2520protease%2520inhibitors.%25208.%2520Pharmacological%2520optimization%2520of%2520orally%2520bioavailable%25202-pyridone-containing%2520peptidomimetics%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D4572%26epage%3D4285%26doi%3D10.1021%2Fjm030166l" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Victor, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campanale, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinz, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shipley, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vance, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spitzer, W. A.</span></span> <span> </span><span class="NLM_article-title">Synthesis, antiviral activity, and biological properties of vinylacetylene analogs of enviroxime</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">1511</span>– <span class="NLM_lpage">1518</span>, <span class="refDoi"> DOI: 10.1021/jm960718i</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm960718i" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADyaK2sXis1ahtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1997&pages=1511-1518&author=F.+Victorauthor=T.+J.+Brownauthor=K.+Campanaleauthor=B.+A.+Heinzauthor=L.+A.+Shipleyauthor=K.+S.+Suauthor=J.+Tangauthor=L.+M.+Vanceauthor=W.+A.+Spitzer&title=Synthesis%2C+antiviral+activity%2C+and+biological+properties+of+vinylacetylene+analogs+of+enviroxime&doi=10.1021%2Fjm960718i"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, Antiviral Activity, and Biological Properties of Vinylacetylene Analogs of Enviroxime</span></div><div class="casAuthors">Victor, Frantz; Brown, Thomas J.; Campanale, Kristina; Heinz, Beverly A.; Shipley, Lisa A.; Su, Kenneth S.; Tang, Joseph; Vance, Lori M.; Spitzer, Wayne A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1511-1518</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of vinylacetylene analogs of Enviroxime was synthesized.  The new compds. are potent inhibitors of poliovirus in tissue culture.  Cross-sensitivity with enviroxime-derived mutants shows that the new compds. have the same mechanism of action as enviroxime, which involves the viral 3A protein.  In studies with Rhesus monkeys, the p-fluoro deriv. was unique in providing oral bioavailability.  Metab. studies using hepatic microsomes suggest that this procedure would be a useful in vitro method for selecting the appropriate animal model for testing oral absorption.  The p-fluoro deriv. was efficacious by oral administration in treating a Coxsackie A21 infection in CD-1 mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpk0XGBilSt-rVg90H21EOLACvtfcHk0lim9k71TAOj5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXis1ahtbw%253D&md5=0dec8942b9a94455e1c79fa41acc5b59</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1021%2Fjm960718i&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm960718i%26sid%3Dliteratum%253Aachs%26aulast%3DVictor%26aufirst%3DF.%26aulast%3DBrown%26aufirst%3DT.%2BJ.%26aulast%3DCampanale%26aufirst%3DK.%26aulast%3DHeinz%26aufirst%3DB.%2BA.%26aulast%3DShipley%26aufirst%3DL.%2BA.%26aulast%3DSu%26aufirst%3DK.%2BS.%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DVance%26aufirst%3DL.%2BM.%26aulast%3DSpitzer%26aufirst%3DW.%2BA.%26atitle%3DSynthesis%252C%2520antiviral%2520activity%252C%2520and%2520biological%2520properties%2520of%2520vinylacetylene%2520analogs%2520of%2520enviroxime%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1997%26volume%3D40%26spage%3D1511%26epage%3D1518%26doi%3D10.1021%2Fjm960718i" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, M. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conney, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, B. T.</span></span> <span> </span><span class="NLM_article-title">Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome P450 isoforms</span>. <i>Endocrinology</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>144</i></span>,  <span class="NLM_fpage">3382</span>– <span class="NLM_lpage">3398</span>, <span class="refDoi"> DOI: 10.1210/en.2003-0192</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1210%2Fen.2003-0192" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=12865317" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD3sXlslGjsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=2003&pages=3382-3398&author=A.+J.+Leeauthor=M.+X.+Caiauthor=P.+E.+Thomasauthor=A.+H.+Conneyauthor=B.+T.+Zhu&title=Characterization+of+the+oxidative+metabolites+of+17beta-estradiol+and+estrone+formed+by+15+selectively+expressed+human+cytochrome+P450+isoforms&doi=10.1210%2Fen.2003-0192"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of the oxidative metabolites of 17β-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms</span></div><div class="casAuthors">Lee, Anthony J.; Cai, May Xiaoxin; Thomas, Paul E.; Conney, Allan H.; Zhu, Bao Ting</div><div class="citationInfo"><span class="NLM_cas:title">Endocrinology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">144</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3382-3398</span>CODEN:
                <span class="NLM_cas:coden">ENDOAO</span>;
        ISSN:<span class="NLM_cas:issn">0013-7227</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">We systematically characterized the oxidative metabolites of 17β-estradiol and estrone formed by 15 human cytochrome P 450 (CYP) isoforms.  CYP1A1 had high activity for 17β-estradiol 2-hydroxylation, followed by 15α-, 6α-, 4-, and 7α-hydroxylation.  However, when estrone was the substrate, CYP1A1 formed more 4-hydroxyestrone than 15α- or 6α-hydroxyestrone, with 2-hydroxyestrone as the major metabolite.  CYP1A2 had the highest activity for the 2-hydroxylation of both 17β-estradiol and estrone, although it also had considerable activity for their 4-hydroxylation (9-13% of 2-hydroxylation).  CYP1B1 mainly catalyzed the formation of catechol estrogens, with 4-hydroxyestrogens predominant.  CYP2A6, 2B6, 2C8, 2C9, 2C19, and 2D6 each showed a varying degree of low catalytic activity for estrogen 2-hydroxylation, whereas CYP2C18 and CYP2E1 did not show any detectable estrogen-hydroxylating activity.  CYP3A4 had strong activity for the formation of 2-hydroxyestradiol, followed by 4-hydroxyestradiol and an unknown polar metabolite, and small amts. of 16α- and 16β-hydroxyestrogens were also formed.  The ratio of 4- to 2-hydroxylation of 17β-estradiol or estrone with CYP3A4 was 0.22 or 0.51, resp.  CYP3A5 had similar catalytic activity for the formation of 2- and 4-hydroxyestrogens.  Notably, CYP3A5 had an unusually high ratio of 4- to 2-hydroxylation of 17β-estradiol or estrone (0.53 or 1.26, resp.).  CYP3A4 and 3A5 also catalyzed the formation of nonpolar estrogen metabolite peaks (chromatog. less polar than estrone).  CYP3A7 had a distinct catalytic activity for the 16α-hydroxylation of estrone, but not 17β-estradiol.  CYP4A11 had little catalytic activity for the metab. of 17β-estradiol and estrone.  In conclusion, many human CYP isoforms are involved in the oxidative metab. of 17β-estradiol and estrone, with a varying degree of catalytic activity and distinct regioselectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5q2Y1i5eYsrVg90H21EOLACvtfcHk0lim9k71TAOj5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXlslGjsb0%253D&md5=dc77411de262647d6fcf0c28c27d66e7</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1210%2Fen.2003-0192&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fen.2003-0192%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DA.%2BJ.%26aulast%3DCai%26aufirst%3DM.%2BX.%26aulast%3DThomas%26aufirst%3DP.%2BE.%26aulast%3DConney%26aufirst%3DA.%2BH.%26aulast%3DZhu%26aufirst%3DB.%2BT.%26atitle%3DCharacterization%2520of%2520the%2520oxidative%2520metabolites%2520of%252017beta-estradiol%2520and%2520estrone%2520formed%2520by%252015%2520selectively%2520expressed%2520human%2520cytochrome%2520P450%2520isoforms%26jtitle%3DEndocrinology%26date%3D2003%26volume%3D144%26spage%3D3382%26epage%3D3398%26doi%3D10.1210%2Fen.2003-0192" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McKinney, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cawley, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerwick, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunnington, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambrus, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willis, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLeod, M. D.</span></span> <span> </span><span class="NLM_article-title">The metabolism of anabolic-androgenic steroids in the greyhound</span>. <i>Bioanalysis</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">769</span>– <span class="NLM_lpage">781</span>, <span class="refDoi"> DOI: 10.4155/bio.13.40</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.4155%2Fbio.13.40" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=23534422" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC3sXks1Gitrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&pages=769-781&author=A.+R.+McKinneyauthor=A.+T.+Cawleyauthor=E.+B.+Youngauthor=C.+M.+Kerwickauthor=K.+Cunningtonauthor=R.+T.+Stewartauthor=J.+I.+Ambrusauthor=A.+C.+Willisauthor=M.+D.+McLeod&title=The+metabolism+of+anabolic-androgenic+steroids+in+the+greyhound&doi=10.4155%2Fbio.13.40"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">The metabolism of anabolic-androgenic steroids in the greyhound</span></div><div class="casAuthors">McKinney, Andrew R.; Cawley, Adam T.; Young, E. Bruce; Kerwick, Carmel M.; Cunnington, Karen; Stewart, Rhiannon T.; Ambrus, Joseph I.; Willis, Anthony C.; McLeod, Malcolm D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioanalysis</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">769-781</span>CODEN:
                <span class="NLM_cas:coden">BIOAB4</span>;
        ISSN:<span class="NLM_cas:issn">1757-6180</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">Background: Effective control of the use of anabolic-androgenic steroids (AASs) in animal sports is essential in order to ensure both animal welfare and integrity.  In order to better police their use in Australian and New Zealand greyhound racing, thorough metabolic studies have been carried out on a range of registered human and veterinary AASs available in the region.  Results: Canine metabolic data are presented for the AASs boldenone, danazol, ethylestrenol, mesterolone, methandriol, nandrolone and norethandrolone.  The principal Phase I metabolic processes obsd. were the redn. of A-ring unsaturations and/or 3-ketones with either 3α,5β- or 3β,5α-stereochem., the oxidn. of secondary 17β-hydroxyl groups and 16α-hydroxylation.  The Phase II β-glucuronylation of sterol metabolites was extensive.  Conclusion: The presented data have enabled the effective anal. of AASs and their metabolites in competition greyhound urine samples.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrL0M_uDTI-iLVg90H21EOLACvtfcHk0lhcwGuxz6Ddjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXks1Gitrc%253D&md5=b6d3508a2074b8e928491aeb73910075</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.4155%2Fbio.13.40&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Fbio.13.40%26sid%3Dliteratum%253Aachs%26aulast%3DMcKinney%26aufirst%3DA.%2BR.%26aulast%3DCawley%26aufirst%3DA.%2BT.%26aulast%3DYoung%26aufirst%3DE.%2BB.%26aulast%3DKerwick%26aufirst%3DC.%2BM.%26aulast%3DCunnington%26aufirst%3DK.%26aulast%3DStewart%26aufirst%3DR.%2BT.%26aulast%3DAmbrus%26aufirst%3DJ.%2BI.%26aulast%3DWillis%26aufirst%3DA.%2BC.%26aulast%3DMcLeod%26aufirst%3DM.%2BD.%26atitle%3DThe%2520metabolism%2520of%2520anabolic-androgenic%2520steroids%2520in%2520the%2520greyhound%26jtitle%3DBioanalysis%26date%3D2013%26volume%3D5%26spage%3D769%26epage%3D781%26doi%3D10.4155%2Fbio.13.40" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rochat, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morsman, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, G. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figg, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLeod, H. L.</span></span> <span> </span><span class="NLM_article-title">Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation?</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>296</i></span>,  <span class="NLM_fpage">537</span>– <span class="NLM_lpage">541</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=11160641" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD3MXoslejtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=296&publication_year=2001&pages=537-541&author=B.+Rochatauthor=J.+M.+Morsmanauthor=G.+I.+Murrayauthor=W.+D.+Figgauthor=H.+L.+McLeod&title=Human+CYP1B1+and+anticancer+agent+metabolism%3A+mechanism+for+tumor-specific+drug+inactivation%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation?</span></div><div class="casAuthors">Rochat, Bertrand; Morsman, Janine M.; Murray, Graeme I.; Figg, William D.; Mcleod, Howard L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">296</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">537-541</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The cytochrome P 450 1B1 (CYP1B1) is involved in the metab. of procarcinogens and xenobiotics.  Human CYP1B1 protein has been detected in a variety of tumors but is not detected in adjacent normal tissues or in liver.  This suggests that CYP1B1 could biotransform anticancer agents specifically in the target cells.  The interaction between CYP1B1 and 12 commonly used anticancer drugs was screened using an ethoxyresorufin deethylase assay.  Four agents were competitive inhibitors of CYP1B1 activity: flutamide (Ki = 1.0 μM), paclitaxel (Ki = 31.6 μM), mitoxantrone (Ki = 11.6 μM), and docetaxel (Ki = 28.0 μM).  Doxorubicin (Ki = 2.6 μM) and daunomycin (Ki = 2.1 μM) were mixed inhibitors, while tamoxifen was a noncompetitive inhibitor (Ki = 5.0 μM).  Vinblastine, vincristine, 5-fluorouracil, etoposide, and cyclophosphamide did not inhibit CYP1B1 activity.  In vitro incubations with flutamide and CYP1B1 produced a metabolite consistent with 2-hydroxyflutamide.  Comparison of kinetic parameters (Km, Ki, Vmax) for flutamide 2-hydroxylation by CYP1B1, CYP1A1, and CYP1A2 indicate that CYP1B1 could play a major role for flutamide biotransformation in tumors.  The results obtained indicate that several anticancer agents inhibit CYP1B1 activity.  Drug inactivation by CYP1B1 may represent a novel mechanism of resistance, influencing the clin. outcome of chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbcNluZYN4frVg90H21EOLACvtfcHk0lhcwGuxz6Ddjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXoslejtQ%253D%253D&md5=868705be020cddfc48ca2577ecf66265</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRochat%26aufirst%3DB.%26aulast%3DMorsman%26aufirst%3DJ.%2BM.%26aulast%3DMurray%26aufirst%3DG.%2BI.%26aulast%3DFigg%26aufirst%3DW.%2BD.%26aulast%3DMcLeod%26aufirst%3DH.%2BL.%26atitle%3DHuman%2520CYP1B1%2520and%2520anticancer%2520agent%2520metabolism%253A%2520mechanism%2520for%2520tumor-specific%2520drug%2520inactivation%253F%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2001%26volume%3D296%26spage%3D537%26epage%3D541" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murray, G. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McFadyen, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKay, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenlee, W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melvin, W. T.</span></span> <span> </span><span class="NLM_article-title">Tumor-specific expression of cytochrome P450 CYP1B1</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">3026</span>– <span class="NLM_lpage">3031</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=9230218" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADyaK2sXkslOkurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=1997&pages=3026-3031&author=G.+I.+Murrayauthor=M.+C.+Taylorauthor=M.+C.+McFadyenauthor=J.+A.+McKayauthor=W.+F.+Greenleeauthor=M.+D.+Burkeauthor=W.+T.+Melvin&title=Tumor-specific+expression+of+cytochrome+P450+CYP1B1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Tumor-specific expression of cytochrome P450 CYP1B1</span></div><div class="casAuthors">Murray, Graeme I.; Taylor, Martin C.; Mcfadyen, Morag C. E.; Mckay, Judith A.; Greenlee, William F.; Burke, M. Danny; Melvin, William T.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">3026-3031</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Cytochrome P 450 CYP1B1 is a recently cloned dioxin-inducible form of the cytochrome P 450 family of xenobiotic metabolizing enzymes.  An antibody raised against a peptide specific for CYP1B1 was found to recognize CYP1B1 expressed in human lymphoblastoid cells but not to recognize other forms of cytochrome P 450, particularly CYP1A1 and CYP1A2.  Using this antibody, the cellular distribution and localization of CYP1B1 were investigated by immunohistochem. in a range of malignant tumors and corresponding normal tissues.  CYP1B1 was found to be expressed at a high frequency in a wide range of human cancers of different histogenetic types, including cancers of the breast, colon, lung, esophagus, skin, lymph node, brain, and testis.  There was no detectable immunostaining for CYP1B1 in normal tissues.  These results provide the basis for the development of novel methods of cancer diagnosis based on the identification of CYP1B1 in tumor cells and the development of anticancer drugs that are selectively activated in tumors by CYP1B1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlIpk-3D25VLVg90H21EOLACvtfcHk0lhcwGuxz6Ddjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXkslOkurg%253D&md5=bf8fe72b748a4e920d71ad37d91e6a22</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMurray%26aufirst%3DG.%2BI.%26aulast%3DTaylor%26aufirst%3DM.%2BC.%26aulast%3DMcFadyen%26aufirst%3DM.%2BC.%26aulast%3DMcKay%26aufirst%3DJ.%2BA.%26aulast%3DGreenlee%26aufirst%3DW.%2BF.%26aulast%3DBurke%26aufirst%3DM.%2BD.%26aulast%3DMelvin%26aufirst%3DW.%2BT.%26atitle%3DTumor-specific%2520expression%2520of%2520cytochrome%2520P450%2520CYP1B1%26jtitle%3DCancer%2520Res.%26date%3D1997%26volume%3D57%26spage%3D3026%26epage%3D3031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dutour, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes-Benitez, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maltais, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poirier, D.</span></span> <span> </span><span class="NLM_article-title">Targeting cytochrome P450 (CYP) 1B1 enzyme with four series of A-ring substituted estrane derivatives: Design, synthesis, inhibitory activity, and selectivity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">9229</span>– <span class="NLM_lpage">9245</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00907</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00907" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslaitLrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=9229-9245&author=R.+Dutourauthor=J.+Royauthor=F.+Cortes-Benitezauthor=R.+Maltaisauthor=D.+Poirier&title=Targeting+cytochrome+P450+%28CYP%29+1B1+enzyme+with+four+series+of+A-ring+substituted+estrane+derivatives%3A+Design%2C+synthesis%2C+inhibitory+activity%2C+and+selectivity&doi=10.1021%2Facs.jmedchem.8b00907"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Cytochrome P450 (CYP) 1B1 Enzyme with Four Series of A-Ring Substituted Estrane Derivatives: Design, Synthesis, Inhibitory Activity, and Selectivity</span></div><div class="casAuthors">Dutour, Raphael; Roy, Jenny; Cortes-Benitez, Francisco; Maltais, Rene; Poirier, Donald</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">9229-9245</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cytochrome P 450 (CYP) 1B1 is involved in the bioactivation of procarcinogens and drug resistance.  To obtain selective CYP1B1 inhibitors over CYP1A1, we synthesized four series of estrane derivs.: (1) 12 estrone (E1)- and 17β-estradiol (E2)-derivs. bearing a 3- or a 4-pyridinyl core at C2, C3, or C4, (2) eight estrane derivs. with different sulfur groups at C3, (3) 19 E1- and E2-derivs. bearing distinct aryls at C2, and (4) five D-ring derivs.  E2-derivs. were more active than oxidized E1-analogs, thus highlighting the key role of 17β-OH for interaction with CYP1B1.  2-(4-Fluorophenyl)-E2 was the best CYP1B1 inhibitor (IC50 = 0.24 μM), with a selectivity index (SI) of 20 over CYP1A1.  Furthermore, the addn. of a C17α-ethynyl group as D-ring modification improved the selectivity index to 25 with only a slight loss of activity (IC50 = 0.37 μM).  Our docking results showed that these compds. fit better into the CYP1B1 binding site than that of CYP1A1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeOdA_fcjr77Vg90H21EOLACvtfcHk0lhcwGuxz6Ddjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslaitLrP&md5=3b962485950d1a34001e34a45aa37c8d</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00907&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00907%26sid%3Dliteratum%253Aachs%26aulast%3DDutour%26aufirst%3DR.%26aulast%3DRoy%26aufirst%3DJ.%26aulast%3DCortes-Benitez%26aufirst%3DF.%26aulast%3DMaltais%26aufirst%3DR.%26aulast%3DPoirier%26aufirst%3DD.%26atitle%3DTargeting%2520cytochrome%2520P450%2520%2528CYP%2529%25201B1%2520enzyme%2520with%2520four%2520series%2520of%2520A-ring%2520substituted%2520estrane%2520derivatives%253A%2520Design%252C%2520synthesis%252C%2520inhibitory%2520activity%252C%2520and%2520selectivity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D9229%26epage%3D9245%26doi%3D10.1021%2Facs.jmedchem.8b00907" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matschinsky, F. M.</span></span> <span> </span><span class="NLM_article-title">GKAs for diabetes therapy: why no clinically useful drug after two decades of trying?</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">90</span>– <span class="NLM_lpage">99</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2012.11.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1016%2Fj.tips.2012.11.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=23305809" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC3sXltVCguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2013&pages=90-99&author=F.+M.+Matschinsky&title=GKAs+for+diabetes+therapy%3A+why+no+clinically+useful+drug+after+two+decades+of+trying%3F&doi=10.1016%2Fj.tips.2012.11.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">GKAs for diabetes therapy: why no clinically useful drug after two decades of trying?</span></div><div class="casAuthors">Matschinsky, Franz M.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">90-99</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Results of basic biochem. and physiol. research, strongly endorsed by findings in human pathophysiol. and genetics, had characterized the glucose phosphorylating enzyme glucokinase as a crit. player in normal glucose homeostasis, diabetes mellitus, and hyperinsulinemic hypoglycemia, and identified the enzyme as a promising new drug target.  R&D initiated in the early 1990s and directed at this target discovered glucokinase activators (GKAs) as a new class of potentially antidiabetic drugs.  GKAs were characterized as nonessential allosteric activators that increase glucose affinity and Vmax of the enzyme, thus stimulating glucose metab. in glucokinase expressing tissue, of foremost functional significance in the insulin producing pancreatic beta cells and the liver.  The results of preclin. testing of GKAs by many pharmaceutical companies demonstrated uniformly high hypoglycemic efficacy in normal and diabetic animals.  GKAs were also highly effective in Phase I trials in patients with type 2 diabetes mellitus (T2DM).  However, results of a recent Phase II trial were less encouraging because patients developed hyperlipidemia and vascular hypertension, and the drug lost efficacy within several months.  This outcome is prompting a reappraisal of the GKA strategy.  In this opinion article, the 'pros and cons' of the strategy to use these compds. in diabetes management are critically reexamd. and suggestions are made that might facilitate progress of GKA R&D that could still result in a novel antidiabetic medicine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5MvSwP_8RcLVg90H21EOLACvtfcHk0ljtWJVdh12FPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXltVCguw%253D%253D&md5=d118756d0cdb6de4478e18862ba71c20</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2012.11.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2012.11.007%26sid%3Dliteratum%253Aachs%26aulast%3DMatschinsky%26aufirst%3DF.%2BM.%26atitle%3DGKAs%2520for%2520diabetes%2520therapy%253A%2520why%2520no%2520clinically%2520useful%2520drug%2520after%2520two%2520decades%2520of%2520trying%253F%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2013%26volume%3D34%26spage%3D90%26epage%3D99%26doi%3D10.1016%2Fj.tips.2012.11.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">St. Jean, D. J.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashton, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartberger, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chmait, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cupples, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galbreath, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helmering, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, F. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunz, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michelsen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pennington, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poon, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reid, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sivits, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stec, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tadesse, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamayo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fotsch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lloyd, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hale, C.</span></span> <span> </span><span class="NLM_article-title">Small molecule disruptors of the glucokinase-glucokinase regulatory protein interaction: 2. Leveraging structure-based drug design to identify analogues with improved pharmacokinetic profiles</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">325</span>– <span class="NLM_lpage">338</span>, <span class="refDoi"> DOI: 10.1021/jm4016747</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4016747" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkvFKitw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=325-338&author=D.+J.+St.+Jeanauthor=K.+S.+Ashtonauthor=M.+D.+Bartbergerauthor=J.+Chenauthor=S.+Chmaitauthor=R.+Cupplesauthor=E.+Galbreathauthor=J.+Helmeringauthor=F.+T.+Hongauthor=S.+R.+Jordanauthor=L.+Liuauthor=R.+K.+Kunzauthor=K.+Michelsenauthor=N.+Nishimuraauthor=L.+D.+Penningtonauthor=S.+F.+Poonauthor=D.+Reidauthor=G.+Sivitsauthor=M.+M.+Stecauthor=S.+Tadesseauthor=N.+Tamayoauthor=G.+Vanauthor=K.+C.+Yangauthor=J.+Zhangauthor=M.+H.+Normanauthor=C.+Fotschauthor=D.+J.+Lloydauthor=C.+Hale&title=Small+molecule+disruptors+of+the+glucokinase-glucokinase+regulatory+protein+interaction%3A+2.+Leveraging+structure-based+drug+design+to+identify+analogues+with+improved+pharmacokinetic+profiles&doi=10.1021%2Fjm4016747"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Disruptors of the Glucokinase-Glucokinase Regulatory Protein Interaction: 2. Leveraging Structure-Based Drug Design to Identify Analogues with Improved Pharmacokinetic Profiles</span></div><div class="casAuthors">St. Jean, David J., Jr.; Ashton, Kate S.; Bartberger, Michael D.; Chen, Jie; Chmait, Samer; Cupples, Rod; Galbreath, Elizabeth; Helmering, Joan; Hong, Fang-Tsao; Jordan, Steven R.; Liu, Longbin; Kunz, Roxanne K.; Michelsen, Klaus; Nishimura, Nobuko; Pennington, Lewis D.; Poon, Steve F.; Reid, Darren; Sivits, Glenn; Stec, Markian M.; Tadesse, Seifu; Tamayo, Nuria; Van, Gwyneth; Yang, Kevin C.; Zhang, Jiandong; Norman, Mark H.; Fotsch, Christopher; Lloyd, David J.; Hale, Clarence</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">325-338</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In the previous report, we described the discovery and optimization of novel small mol. disruptors of the GK-GKRP interaction culminating in the identification of I (AMG-1694).  Although this analog possessed excellent in vitro potency and was a useful tool compd. in initial proof-of-concept expts., high metabolic turnover limited its advancement.  Guided by a combination of metabolite identification and structure-based design, we have successfully discovered a potent and metabolically stable GK-GKRP disruptor, II (AMG-3969).  When administered to db/db mice, this compd. demonstrated a robust pharmacodynamic response (GK translocation) as well as statistically significant dose-dependent redns. in fed blood glucose levels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPdKFACRrkebVg90H21EOLACvtfcHk0ljtWJVdh12FPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkvFKitw%253D%253D&md5=aebfcbc169a9fbd443badcff47b2b90f</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1021%2Fjm4016747&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4016747%26sid%3Dliteratum%253Aachs%26aulast%3DSt.%2BJean%26aufirst%3DD.%2BJ.%26aulast%3DAshton%26aufirst%3DK.%2BS.%26aulast%3DBartberger%26aufirst%3DM.%2BD.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DChmait%26aufirst%3DS.%26aulast%3DCupples%26aufirst%3DR.%26aulast%3DGalbreath%26aufirst%3DE.%26aulast%3DHelmering%26aufirst%3DJ.%26aulast%3DHong%26aufirst%3DF.%2BT.%26aulast%3DJordan%26aufirst%3DS.%2BR.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DKunz%26aufirst%3DR.%2BK.%26aulast%3DMichelsen%26aufirst%3DK.%26aulast%3DNishimura%26aufirst%3DN.%26aulast%3DPennington%26aufirst%3DL.%2BD.%26aulast%3DPoon%26aufirst%3DS.%2BF.%26aulast%3DReid%26aufirst%3DD.%26aulast%3DSivits%26aufirst%3DG.%26aulast%3DStec%26aufirst%3DM.%2BM.%26aulast%3DTadesse%26aufirst%3DS.%26aulast%3DTamayo%26aufirst%3DN.%26aulast%3DVan%26aufirst%3DG.%26aulast%3DYang%26aufirst%3DK.%2BC.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DNorman%26aufirst%3DM.%2BH.%26aulast%3DFotsch%26aufirst%3DC.%26aulast%3DLloyd%26aufirst%3DD.%2BJ.%26aulast%3DHale%26aufirst%3DC.%26atitle%3DSmall%2520molecule%2520disruptors%2520of%2520the%2520glucokinase-glucokinase%2520regulatory%2520protein%2520interaction%253A%25202.%2520Leveraging%2520structure-based%2520drug%2520design%2520to%2520identify%2520analogues%2520with%2520improved%2520pharmacokinetic%2520profiles%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D325%26epage%3D338%26doi%3D10.1021%2Fjm4016747" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, K. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhattacharya, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loomis, A. K.</span></span> <span> </span><span class="NLM_article-title">Small molecule ghrelin receptor inverse agonists and antagonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">8671</span>– <span class="NLM_lpage">8691</span>, <span class="refDoi"> DOI: 10.1021/jm5003183</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5003183" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFyiur3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=8671-8691&author=K.+O.+Cameronauthor=S.+K.+Bhattacharyaauthor=A.+K.+Loomis&title=Small+molecule+ghrelin+receptor+inverse+agonists+and+antagonists&doi=10.1021%2Fjm5003183"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Ghrelin Receptor Inverse Agonists and Antagonists</span></div><div class="casAuthors">Cameron, Kimberly O.; Bhattacharya, Samit K.; Loomis, A. Katrina</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">8671-8691</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Ghrelin is an endogenous peptide hormone secreted primarily by the stomach and is involved in a no. of physiol. processes including growth hormone secretion, food intake, as well as energy and glucose homeostasis.  The physiol. actions of ghrelin are mediated through the growth hormone secretagogue receptor 1a (ghrelin receptor), a peptidic G-protein-coupled receptor.  This target has attracted much interest, as agents that block ghrelin's actions on its receptor are anticipated to be pharmaceutical interventions for a no. of diseases.  This review provides an overview of ghrelin biol. with a focus on metabolic diseases and summarizes recent medicinal chem. programs aimed at delivering small mol. ghrelin receptor antagonists and inverse agonists to the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohKCJaGbnZerVg90H21EOLACvtfcHk0ljtWJVdh12FPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFyiur3P&md5=06ce0cd0c75db752aaa984fd2723aaed</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1021%2Fjm5003183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5003183%26sid%3Dliteratum%253Aachs%26aulast%3DCameron%26aufirst%3DK.%2BO.%26aulast%3DBhattacharya%26aufirst%3DS.%2BK.%26aulast%3DLoomis%26aufirst%3DA.%2BK.%26atitle%3DSmall%2520molecule%2520ghrelin%2520receptor%2520inverse%2520agonists%2520and%2520antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D8671%26epage%3D8691%26doi%3D10.1021%2Fjm5003183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Daina, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giuliano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pietra, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guainazzi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia Rubio, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoete, V.</span></span> <span> </span><span class="NLM_article-title">Rational design, synthesis, and pharmacological characterization of novel Ghrelin receptor inverse agonists as potential treatment against obesity-related metabolic diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">11039</span>– <span class="NLM_lpage">11060</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00794</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00794" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVantLfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=11039-11060&author=A.+Dainaauthor=C.+Giulianoauthor=C.+Pietraauthor=J.+Wangauthor=Y.+Chiauthor=Z.+Zouauthor=F.+Liauthor=Z.+Yanauthor=Y.+Zhouauthor=A.+Guainazziauthor=S.+Garcia+Rubioauthor=V.+Zoete&title=Rational+design%2C+synthesis%2C+and+pharmacological+characterization+of+novel+Ghrelin+receptor+inverse+agonists+as+potential+treatment+against+obesity-related+metabolic+diseases&doi=10.1021%2Facs.jmedchem.8b00794"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Design, Synthesis, and Pharmacological Characterization of Novel Ghrelin Receptor Inverse Agonists as Potential Treatment against Obesity-Related Metabolic Diseases</span></div><div class="casAuthors">Daina, Antoine; Giuliano, Claudio; Pietra, Claudio; Wang, Junbo; Chi, Yushi; Zou, Zack; Li, Fugang; Yan, Zhonghua; Zhou, Yifan; Guainazzi, Angelo; Garcia Rubio, Silvina; Zoete, Vincent</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">11039-11060</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new chemotype of ghrelin inverse agonists was discovered through chimeric design based on mol. scaffolds known as growth-hormone secretagogue receptor (GHSR) modulators but with divergent pharmacodynamic and pharmacokinetic properties.  The structure-activities/properties exploration led to compd. I, which displayed potent human GHSR antagonism and inverse agonism in cellular assays (IC50 = 68 nM, EC50 = 29 nM), moderate oral bioavailability, and notable brain penetration in rat (F = 27%, B/P ratio = 1.9).  First in vivo studies demonstrated effective redn. of food intake after oral or parenteral administration to mouse (78% at 1 h and 38% at 8 h, resp.).  Further preclin. studies are needed to evaluate the most suited mode of administration with the aim of promoting a first central-acting ghrelin inverse agonist mol. to development, which would represent a significant step toward therapeutic agents to treat metabolic disorders related to obesity, such as type 2 diabetes mellitus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQ1xJll3Qu0LVg90H21EOLACvtfcHk0lhZqjntafoQiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVantLfI&md5=83f3dd140db3f999eeed0158a5dcc9f6</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00794&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00794%26sid%3Dliteratum%253Aachs%26aulast%3DDaina%26aufirst%3DA.%26aulast%3DGiuliano%26aufirst%3DC.%26aulast%3DPietra%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DChi%26aufirst%3DY.%26aulast%3DZou%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DYan%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DGuainazzi%26aufirst%3DA.%26aulast%3DGarcia%2BRubio%26aufirst%3DS.%26aulast%3DZoete%26aufirst%3DV.%26atitle%3DRational%2520design%252C%2520synthesis%252C%2520and%2520pharmacological%2520characterization%2520of%2520novel%2520Ghrelin%2520receptor%2520inverse%2520agonists%2520as%2520potential%2520treatment%2520against%2520obesity-related%2520metabolic%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D11039%26epage%3D11060%26doi%3D10.1021%2Facs.jmedchem.8b00794" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Madar, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopecka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pireh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiedeman, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Djuric, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Von Geldern, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fickes, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhagavatula, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittenberger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richards, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longenecker, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubben, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballaron, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stashko, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zinker, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mika, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beno, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kempf-Grote, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polakowski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segreti, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinhart, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fryer, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sham, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trevillyan, J. M.</span></span> <span> </span><span class="NLM_article-title">Discovery of 2-[4-{{2-(2<i>S</i>,5<i>R</i>)-2-cyano-5-ethynyl-1-pyrrolidinyl]-2-oxoethyl]amino]- 4-methyl-1-piperidinyl]-4-pyridinecarboxylic acid (ABT-279): A very potent, selective, effective, and well-tolerated inhibitor of dipeptidyl peptidase-IV, useful for the treatment of diabetes</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">6416</span>– <span class="NLM_lpage">6420</span>, <span class="refDoi"> DOI: 10.1021/jm060777o</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060777o" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD28XpvVGmurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=6416-6420&author=D.+J.+Madarauthor=H.+Kopeckaauthor=D.+Pirehauthor=H.+Yongauthor=Z.+Peiauthor=X.+Liauthor=P.+E.+Wiedemanauthor=S.+W.+Djuricauthor=T.+W.+Von+Geldernauthor=M.+G.+Fickesauthor=L.+Bhagavatulaauthor=T.+McDermottauthor=S.+Wittenbergerauthor=S.+J.+Richardsauthor=K.+L.+Longeneckerauthor=K.+D.+Stewartauthor=T.+H.+Lubbenauthor=S.+J.+Ballaronauthor=M.+A.+Stashkoauthor=M.+A.+Longauthor=H.+Wellsauthor=B.+A.+Zinkerauthor=A.+K.+Mikaauthor=D.+W.+Benoauthor=A.+J.+Kempf-Groteauthor=J.+Polakowskiauthor=J.+Segretiauthor=G.+A.+Reinhartauthor=R.+M.+Fryerauthor=H.+L.+Shamauthor=J.+M.+Trevillyan&title=Discovery+of+2-%5B4-%7B%7B2-%282S%2C5R%29-2-cyano-5-ethynyl-1-pyrrolidinyl%5D-2-oxoethyl%5Damino%5D-+4-methyl-1-piperidinyl%5D-4-pyridinecarboxylic+acid+%28ABT-279%29%3A+A+very+potent%2C+selective%2C+effective%2C+and+well-tolerated+inhibitor+of+dipeptidyl+peptidase-IV%2C+useful+for+the+treatment+of+diabetes&doi=10.1021%2Fjm060777o"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 2-[4-{{2-(2S,5R)-2-Cyano-5-ethynyl-1-pyrrolidinyl]-2-oxoethyl]amino]- 4-methyl-1-piperidinyl]-4-pyridinecarboxylic Acid (ABT-279): A Very Potent, Selective, Effective, and Well-Tolerated Inhibitor of Dipeptidyl Peptidase-IV, Useful for the Treatment of Diabetes</span></div><div class="casAuthors">Madar, David J.; Kopecka, Hana; Pireh, Daisy; Yong, Hong; Pei, Zhonghua; Li, Xiaofeng; Wiedeman, Paul E.; Djuric, Stevan W.; Von Geldern, Thomas W.; Fickes, Michael G.; Bhagavatula, Lakshmi; McDermott, Todd; Wittenberger, Steven; Richards, Steven J.; Longenecker, Kenton L.; Stewart, Kent D.; Lubben, Thomas H.; Ballaron, Stephen J.; Stashko, Michael A.; Long, Michelle A.; Wells, Heidi; Zinker, Bradley A.; Mika, Amanda K.; Beno, David W. A.; Kempf-Grote, Anita J.; Polakowski, James; Segreti, Jason; Reinhart, Glenn A.; Fryer, Ryan M.; Sham, Hing L.; Trevillyan, James M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6416-6420</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dipeptidyl peptidase-IV (DPP-IV) inhibitors are poised to be the next major drug class for the treatment of type 2 diabetes.  Structure-activity studies of substitutions at the C5 position of the 2-cyanopyrrolidide warhead led to the discovery of potent inhibitors of DPP-IV that lack activity against DPP8 and DPP9.  Further modification led to an extremely potent (KiDPP-IV = 1.0 nM) and selective (KiDPP8 > 30 μM; KiDPP9 > 30 μM) clin. candidate, ABT-279 (I), that is orally available, efficacious, and remarkably safe in preclin. safety studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqpkr5QItgArVg90H21EOLACvtfcHk0lhZqjntafoQiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XpvVGmurc%253D&md5=e4b070b39f0be7367cb8949b8e85c40b</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1021%2Fjm060777o&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060777o%26sid%3Dliteratum%253Aachs%26aulast%3DMadar%26aufirst%3DD.%2BJ.%26aulast%3DKopecka%26aufirst%3DH.%26aulast%3DPireh%26aufirst%3DD.%26aulast%3DYong%26aufirst%3DH.%26aulast%3DPei%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DWiedeman%26aufirst%3DP.%2BE.%26aulast%3DDjuric%26aufirst%3DS.%2BW.%26aulast%3DVon%2BGeldern%26aufirst%3DT.%2BW.%26aulast%3DFickes%26aufirst%3DM.%2BG.%26aulast%3DBhagavatula%26aufirst%3DL.%26aulast%3DMcDermott%26aufirst%3DT.%26aulast%3DWittenberger%26aufirst%3DS.%26aulast%3DRichards%26aufirst%3DS.%2BJ.%26aulast%3DLongenecker%26aufirst%3DK.%2BL.%26aulast%3DStewart%26aufirst%3DK.%2BD.%26aulast%3DLubben%26aufirst%3DT.%2BH.%26aulast%3DBallaron%26aufirst%3DS.%2BJ.%26aulast%3DStashko%26aufirst%3DM.%2BA.%26aulast%3DLong%26aufirst%3DM.%2BA.%26aulast%3DWells%26aufirst%3DH.%26aulast%3DZinker%26aufirst%3DB.%2BA.%26aulast%3DMika%26aufirst%3DA.%2BK.%26aulast%3DBeno%26aufirst%3DD.%2BW.%26aulast%3DKempf-Grote%26aufirst%3DA.%2BJ.%26aulast%3DPolakowski%26aufirst%3DJ.%26aulast%3DSegreti%26aufirst%3DJ.%26aulast%3DReinhart%26aufirst%3DG.%2BA.%26aulast%3DFryer%26aufirst%3DR.%2BM.%26aulast%3DSham%26aufirst%3DH.%2BL.%26aulast%3DTrevillyan%26aufirst%3DJ.%2BM.%26atitle%3DDiscovery%2520of%25202-%255B4-%257B%257B2-%25282S%252C5R%2529-2-cyano-5-ethynyl-1-pyrrolidinyl%255D-2-oxoethyl%255Damino%255D-%25204-methyl-1-piperidinyl%255D-4-pyridinecarboxylic%2520acid%2520%2528ABT-279%2529%253A%2520A%2520very%2520potent%252C%2520selective%252C%2520effective%252C%2520and%2520well-tolerated%2520inhibitor%2520of%2520dipeptidyl%2520peptidase-IV%252C%2520useful%2520for%2520the%2520treatment%2520of%2520diabetes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D6416%26epage%3D6420%26doi%3D10.1021%2Fjm060777o" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haick, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byron, K. L.</span></span> <span> </span><span class="NLM_article-title">Novel treatment strategies for smooth muscle disorders: Targeting Kv7 potassium channels</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>165</i></span>,  <span class="NLM_fpage">14</span>– <span class="NLM_lpage">25</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2016.05.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1016%2Fj.pharmthera.2016.05.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=27179745" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC28XnvFOisLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=165&publication_year=2016&pages=14-25&author=J.+M.+Haickauthor=K.+L.+Byron&title=Novel+treatment+strategies+for+smooth+muscle+disorders%3A+Targeting+Kv7+potassium+channels&doi=10.1016%2Fj.pharmthera.2016.05.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Novel treatment strategies for smooth muscle disorders: Targeting Kv7 potassium channels</span></div><div class="casAuthors">Haick, Jennifer M.; Byron, Kenneth L.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">165</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">14-25</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Smooth muscle cells provide crucial contractile functions in visceral, vascular, and lung tissues.  The contractile state of smooth muscle is largely detd. by their elec. excitability, which is in turn influenced by the activity of potassium channels.  The activity of potassium channels sustains smooth muscle cell membrane hyperpolarization, reducing cellular excitability and thereby promoting smooth muscle relaxation.  Research over the past decade has indicated an important role for Kv7 (KCNQ) voltage-gated potassium channels in the regulation of the excitability of smooth muscle cells.  Expression of multiple Kv7 channel subtypes has been demonstrated in smooth muscle cells from viscera (gastrointestinal, bladder, myometrial), from the systemic and pulmonary vasculature, and from the airways of the lung, from multiple species, including humans.  A no. of clin. used drugs, some of which were developed to target Kv7 channels in other tissues, have been found to exert robust effects on smooth muscle Kv7 channels.  Functional studies have indicated that Kv7 channel activators and inhibitors have the ability to relax and contact smooth muscle prepns., resp., suggesting a wide range of novel applications for the pharmacol. tool set.  This review summarizes recent findings regarding the physiol. functions of Kv7 channels in smooth muscle, and highlights potential therapeutic applications based on pharmacol. targeting of smooth muscle Kv7 channels throughout the body.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxEjwlNnlcTbVg90H21EOLACvtfcHk0ljxY7--vozNZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnvFOisLw%253D&md5=d85c0b5cd6f22a65fb9c10a41fef579e</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2016.05.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2016.05.002%26sid%3Dliteratum%253Aachs%26aulast%3DHaick%26aufirst%3DJ.%2BM.%26aulast%3DByron%26aufirst%3DK.%2BL.%26atitle%3DNovel%2520treatment%2520strategies%2520for%2520smooth%2520muscle%2520disorders%253A%2520Targeting%2520Kv7%2520potassium%2520channels%26jtitle%3DPharmacol.%2520Ther.%26date%3D2016%26volume%3D165%26spage%3D14%26epage%3D25%26doi%3D10.1016%2Fj.pharmthera.2016.05.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiao, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, H. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Z. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nan, F. J.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel retigabine derivatives as potent KCNQ4 and KCNQ5 channel agonists with improved specificity</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">27</span>– <span class="NLM_lpage">33</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.8b00315</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.8b00315" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFKiurvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=27-33&author=L.+Wangauthor=G.+H.+Qiaoauthor=H.+N.+Huauthor=Z.+B.+Gaoauthor=F.+J.+Nan&title=Discovery+of+novel+retigabine+derivatives+as+potent+KCNQ4+and+KCNQ5+channel+agonists+with+improved+specificity&doi=10.1021%2Facsmedchemlett.8b00315"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel Retigabine Derivatives as Potent KCNQ4 and KCNQ5 Channel Agonists with Improved Specificity</span></div><div class="casAuthors">Wang, Lei; Qiao, Guan-Hua; Hu, Hai-Ning; Gao, Zhao-Bing; Nan, Fa-Jun</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-33</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Recent research suggests that KCNQ isoforms, particularly the KCNQ4 and KCNQ5 subtypes expressed in smooth muscle cells, are involved in both establishing and maintaining resting membrane potentials and regulating smooth muscle contractility.  Retigabine (RTG) is a first-in-class antiepileptic drug that potentiates neuronal KCNQ potassium channels, but poor subtype selectivity limits its further application as a pharmacol. tool.  In this study, we improved the subtype specificity of retigabine by altering the N-1/3 substituents and discovered several compds. that show better selectivity for KCNQ4 and KCNQ5 channels.  Among these compds., 10g is highly selective for KCNQ4 and KCNQ5 channels without potentiating KCNQ1 and KCNQ2 channels.  These results are an advance in the exploration of small mol. modifiers that selectively activate different KCNQ isoforms.  The developed compds. could also serve as new pharmacol. tools for elucidating the function of KCNQ channels natively expressed in various tissues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrv-ER_THotFbVg90H21EOLACvtfcHk0ljxY7--vozNZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFKiurvJ&md5=ae805b9756783970a0e721a3c232c1fd</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.8b00315&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.8b00315%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DL.%26aulast%3DQiao%26aufirst%3DG.%2BH.%26aulast%3DHu%26aufirst%3DH.%2BN.%26aulast%3DGao%26aufirst%3DZ.%2BB.%26aulast%3DNan%26aufirst%3DF.%2BJ.%26atitle%3DDiscovery%2520of%2520novel%2520retigabine%2520derivatives%2520as%2520potent%2520KCNQ4%2520and%2520KCNQ5%2520channel%2520agonists%2520with%2520improved%2520specificity%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26spage%3D27%26epage%3D33%26doi%3D10.1021%2Facsmedchemlett.8b00315" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tsujimoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hattori, A.</span></span> <span> </span><span class="NLM_article-title">The oxytocinase subfamily of M1 aminopeptidases</span>. <i>Biochim. Biophys. Acta, Proteins Proteomics</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>1751</i></span>,  <span class="NLM_fpage">9</span>– <span class="NLM_lpage">18</span>, <span class="refDoi"> DOI: 10.1016/j.bbapap.2004.09.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1016%2Fj.bbapap.2004.09.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=16054015" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmvVWlsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1751&publication_year=2005&pages=9-18&author=M.+Tsujimotoauthor=A.+Hattori&title=The+oxytocinase+subfamily+of+M1+aminopeptidases&doi=10.1016%2Fj.bbapap.2004.09.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">The oxytocinase subfamily of M1 aminopeptidases</span></div><div class="casAuthors">Tsujimoto, Masafumi; Hattori, Akira</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Proteins and Proteomics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">1751</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">9-18</span>CODEN:
                <span class="NLM_cas:coden">BBAPBW</span>;
        ISSN:<span class="NLM_cas:issn">1570-9639</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Placental leucine aminopeptidase (P-LAP), adipocyte-derived leucine aminopeptidase (A-LAP) and leukocyte-derived aminopeptidase (L-RAP) belong to one distinct group of the M1 family of aminopeptidases, which has been termed the "oxytocinase subfamily".  They share HEXXH(X)18E Zn-binding and GAMEN motifs essential for the enzymic activities.  Intracellular localization is the characteristic feature of the subfamily members.  While P-LAP is translocated from intracellular vesicles to plasma membrane in a stimulus-dependent manner, both A-LAP and L-RAP are retained in the endoplasmic reticulum.  They contain sequences necessary for the specific localization in the cell.  It has become evident that the subfamily members play important roles in the maintenance of homeostasis including maintenance of normal pregnancy, memory retention, blood pressure regulation, and antigen presentation.  Here, the current situation of this newly identified subfamily is summarized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrghl94CnfL-LVg90H21EOLACvtfcHk0ljxY7--vozNZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmvVWlsro%253D&md5=26ccab0ed3f952b827d8ab956100e121</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1016%2Fj.bbapap.2004.09.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbapap.2004.09.011%26sid%3Dliteratum%253Aachs%26aulast%3DTsujimoto%26aufirst%3DM.%26aulast%3DHattori%26aufirst%3DA.%26atitle%3DThe%2520oxytocinase%2520subfamily%2520of%2520M1%2520aminopeptidases%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Proteins%2520Proteomics%26date%3D2005%26volume%3D1751%26spage%3D9%26epage%3D18%26doi%3D10.1016%2Fj.bbapap.2004.09.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weimershaus, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evnouchidou, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saveanu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Endert, P.</span></span> <span> </span><span class="NLM_article-title">Peptidases trimming MHC class I ligands</span>. <i>Curr. Opin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">90</span>– <span class="NLM_lpage">96</span>, <span class="refDoi"> DOI: 10.1016/j.coi.2012.10.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1016%2Fj.coi.2012.10.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=23089230" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFCksLzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2013&pages=90-96&author=M.+Weimershausauthor=I.+Evnouchidouauthor=L.+Saveanuauthor=P.+van+Endert&title=Peptidases+trimming+MHC+class+I+ligands&doi=10.1016%2Fj.coi.2012.10.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Peptidases trimming MHC class I ligands</span></div><div class="casAuthors">Weimershaus, Mirjana; Evnouchidou, Irini; Saveanu, Loredana; van Endert, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Immunology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">90-96</span>CODEN:
                <span class="NLM_cas:coden">COPIEL</span>;
        ISSN:<span class="NLM_cas:issn">0952-7915</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Peptides presented by MHC class I mols. are typically produced through antigen degrdn. by the proteasome followed by trimming by exopeptidases.  According to recent results, these include both aminopeptidases and carboxypeptidases in the cytosol and the endoplasmic reticulum.  While cytosolic peptidases have a net neutral or destructive effect on MHC ligands, endoplasmic reticulum aminopeptidases are required for efficient class I loading and have a strong effect on the repertoire of peptide/MHC complexes.  Cells lacking these enzymes can be eliminated both by NK cells and by CD8+ T cells recognizing complexes formed between an MHC class Ib mol. and a conserved peptide.  Cross-presented peptides derived from internalized antigens can be processed by insulin-regulated aminopeptidase, the only endosomal trimming peptidase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTTuHIi5zkQrVg90H21EOLACvtfcHk0ljxY7--vozNZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFCksLzL&md5=dbed24e460af7509ad6a8c9ac453de5b</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1016%2Fj.coi.2012.10.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coi.2012.10.001%26sid%3Dliteratum%253Aachs%26aulast%3DWeimershaus%26aufirst%3DM.%26aulast%3DEvnouchidou%26aufirst%3DI.%26aulast%3DSaveanu%26aufirst%3DL.%26aulast%3Dvan%2BEndert%26aufirst%3DP.%26atitle%3DPeptidases%2520trimming%2520MHC%2520class%2520I%2520ligands%26jtitle%3DCurr.%2520Opin.%2520Immunol.%26date%3D2013%26volume%3D25%26spage%3D90%26epage%3D96%26doi%3D10.1016%2Fj.coi.2012.10.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saveanu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weimershaus, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guermonprez, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Firat, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davoust, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kratzer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niedermann, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Endert, P.</span></span> <span> </span><span class="NLM_article-title">IRAP identifies an endosomal compartment required for MHC class I cross-presentation</span>. <i>Science (Washington, DC, U. S.)</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>325</i></span>,  <span class="NLM_fpage">213</span>– <span class="NLM_lpage">217</span>, <span class="refDoi"> DOI: 10.1126/science.1172845</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1126%2Fscience.1172845" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=19498108" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD1MXos1Srtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=325&publication_year=2009&pages=213-217&author=L.+Saveanuauthor=O.+Carrollauthor=M.+Weimershausauthor=P.+Guermonprezauthor=E.+Firatauthor=V.+Lindoauthor=F.+Greerauthor=J.+Davoustauthor=R.+Kratzerauthor=S.+R.+Kellerauthor=G.+Niedermannauthor=P.+van+Endert&title=IRAP+identifies+an+endosomal+compartment+required+for+MHC+class+I+cross-presentation&doi=10.1126%2Fscience.1172845"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">IRAP Identifies an Endosomal Compartment Required for MHC Class I Cross-Presentation</span></div><div class="casAuthors">Saveanu, Loredana; Carroll, Oliver; Weimershaus, Mirjana; Guermonprez, Pierre; Firat, Elke; Lindo, Vivian; Greer, Fiona; Davoust, Jean; Kratzer, Roland; Keller, Susanna R.; Niedermann, Gabriele; van Endert, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">325</span>
        (<span class="NLM_cas:issue">5937</span>),
    <span class="NLM_cas:pages">213-217</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Major histocompatibility complex (MHC) class I mols. present peptides, produced through cytosolic proteasomal degrdn. of cellular proteins, to cytotoxic T lymphocytes.  In dendritic cells, the peptides can also be derived from internalized antigens through a process known as cross-presentation.  The cellular compartments involved in cross-presentation remain poorly defined.  The authors found a role for peptide trimming by insulin-regulated aminopeptidase (IRAP) in cross-presentation.  In human dendritic cells, IRAP was localized to a Rab14+ endosomal storage compartment in which it interacted with MHC class I mols.  IRAP deficiency compromised cross-presentation in vitro and in vivo but did not affect endogenous presentation.  The authors propose the existence of two pathways for proteasome-dependent cross-presentation in which final peptide trimming involves IRAP in endosomes and involves the related aminopeptidases in the endoplasmic reticulum.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGot6ZHOya1cBrVg90H21EOLACvtfcHk0lh7Da4BOmiglg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXos1Srtbo%253D&md5=563afe447cf31123b55c9da2d5c8b12f</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1126%2Fscience.1172845&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1172845%26sid%3Dliteratum%253Aachs%26aulast%3DSaveanu%26aufirst%3DL.%26aulast%3DCarroll%26aufirst%3DO.%26aulast%3DWeimershaus%26aufirst%3DM.%26aulast%3DGuermonprez%26aufirst%3DP.%26aulast%3DFirat%26aufirst%3DE.%26aulast%3DLindo%26aufirst%3DV.%26aulast%3DGreer%26aufirst%3DF.%26aulast%3DDavoust%26aufirst%3DJ.%26aulast%3DKratzer%26aufirst%3DR.%26aulast%3DKeller%26aufirst%3DS.%2BR.%26aulast%3DNiedermann%26aufirst%3DG.%26aulast%3Dvan%2BEndert%26aufirst%3DP.%26atitle%3DIRAP%2520identifies%2520an%2520endosomal%2520compartment%2520required%2520for%2520MHC%2520class%2520I%2520cross-presentation%26jtitle%3DScience%2520%2528Washington%252C%2520DC%252C%2520U.%2520S.%2529%26date%3D2009%26volume%3D325%26spage%3D213%26epage%3D217%26doi%3D10.1126%2Fscience.1172845" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stratikos, E.</span></span> <span> </span><span class="NLM_article-title">Regulating adaptive immune responses using small molecule modulators of aminopeptidases that process antigenic peptides</span>. <i>Curr. Opin. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">7</span>, <span class="refDoi"> DOI: 10.1016/j.cbpa.2014.08.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1016%2Fj.cbpa.2014.08.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=25173825" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVOmtr%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2014&pages=1-7&author=E.+Stratikos&title=Regulating+adaptive+immune+responses+using+small+molecule+modulators+of+aminopeptidases+that+process+antigenic+peptides&doi=10.1016%2Fj.cbpa.2014.08.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Regulating adaptive immune responses using small molecule modulators of aminopeptidases that process antigenic peptides</span></div><div class="casAuthors">Stratikos, Efstratios</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-7</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Antigenic peptide processing by intracellular aminopeptidases has emerged recently as an important pathway that regulates adaptive immune responses.  Pathogens and cancer can manipulate the activity of key enzymes of this pathway to promote immune evasion.  Furthermore, the activity of these enzymes is naturally variable due to polymorphic variation, contributing to predisposition to disease, most notably autoimmunity.  Here, we review recent findings that suggest that the pharmacol. regulation of the activity of these aminopeptidases constitutes a valid approach for regulating human immune responses.  We furthermore review the state of the art in chem. tools for inhibiting these enzymes and how these tools can be useful for the development of innovative therapeutic approaches for a variety of diseases including cancer, viral infections and autoimmunity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmdJYdWyF8GLVg90H21EOLACvtfcHk0lh7Da4BOmiglg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVOmtr%252FM&md5=7b375d25108c1620a29380cc2b6c41f2</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2014.08.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2014.08.007%26sid%3Dliteratum%253Aachs%26aulast%3DStratikos%26aufirst%3DE.%26atitle%3DRegulating%2520adaptive%2520immune%2520responses%2520using%2520small%2520molecule%2520modulators%2520of%2520aminopeptidases%2520that%2520process%2520antigenic%2520peptides%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2014%26volume%3D23%26spage%3D1%26epage%3D7%26doi%3D10.1016%2Fj.cbpa.2014.08.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kokkala, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mpakali, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mauvais, F. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papakyriakou, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daskalaki, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petropoulou, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kavvalou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papathanasopoulou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agrotis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fonsou, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Endert, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stratikos, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Georgiadis, D.</span></span> <span> </span><span class="NLM_article-title">Optimization and structure-activity relationships of phosphinic pseudotripeptide inhibitors of aminopeptidases that generate antigenic peptides</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">9107</span>– <span class="NLM_lpage">9123</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01031</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01031" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVyqtbzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=9107-9123&author=P.+Kokkalaauthor=A.+Mpakaliauthor=F.+X.+Mauvaisauthor=A.+Papakyriakouauthor=I.+Daskalakiauthor=I.+Petropoulouauthor=S.+Kavvalouauthor=M.+Papathanasopoulouauthor=S.+Agrotisauthor=T.+M.+Fonsouauthor=P.+van+Endertauthor=E.+Stratikosauthor=D.+Georgiadis&title=Optimization+and+structure-activity+relationships+of+phosphinic+pseudotripeptide+inhibitors+of+aminopeptidases+that+generate+antigenic+peptides&doi=10.1021%2Facs.jmedchem.6b01031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization and Structure-Activity Relationships of Phosphinic Pseudotripeptide Inhibitors of Aminopeptidases That Generate Antigenic Peptides</span></div><div class="casAuthors">Kokkala, Paraskevi; Mpakali, Anastasia; Mauvais, Francois-Xavier; Papakyriakou, Athanasios; Daskalaki, Ira; Petropoulou, Ioanna; Kavvalou, Sofia; Papathanasopoulou, Mirto; Agrotis, Stefanos; Fonsou, Theodora-Markisia; van Endert, Peter; Stratikos, Efstratios; Georgiadis, Dimitris</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">9107-9123</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The oxytocinase subfamily of M1 aminopeptidases, consisting of ER aminopeptidase 1 (ERAP1), ER aminopeptidase 2 (ERAP2) and insulin-regulated aminopeptidase (IRAP), plays crit. roles in the generation of antigenic peptides and indirectly regulates human adaptive immune responses.  The authors have previously demonstrated that phosphinic pseudotripeptides can constitute potent inhibitors of this group of enzymes.  In this study, the authors used synthetic methodologies able to furnish a series of stereochem. defined phosphinic pseudotripeptides and demonstrate that side-chains at P1 and P2 positions are crit. determinants in driving potency and selectivity.  The authors identified low nanomolar inhibitors of ERAP2 and IRAP that display selectivity of more than 2 and 3 orders of magnitude, resp.  Cellular anal. demonstrated that one of the compds. that is a selective IRAP inhibitor can reduce IRAP-dependent but not ERAP1-dependent cross-presentation by dendritic cells with nanomolar efficacy.  The results encourage further preclin. development of phosphinic pseudotripeptides as regulators of adaptive immune responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0t6PN8VuuXrVg90H21EOLACvtfcHk0lh7Da4BOmiglg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVyqtbzF&md5=6353903037762758d64a48c5b1529f20</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01031%26sid%3Dliteratum%253Aachs%26aulast%3DKokkala%26aufirst%3DP.%26aulast%3DMpakali%26aufirst%3DA.%26aulast%3DMauvais%26aufirst%3DF.%2BX.%26aulast%3DPapakyriakou%26aufirst%3DA.%26aulast%3DDaskalaki%26aufirst%3DI.%26aulast%3DPetropoulou%26aufirst%3DI.%26aulast%3DKavvalou%26aufirst%3DS.%26aulast%3DPapathanasopoulou%26aufirst%3DM.%26aulast%3DAgrotis%26aufirst%3DS.%26aulast%3DFonsou%26aufirst%3DT.%2BM.%26aulast%3Dvan%2BEndert%26aufirst%3DP.%26aulast%3DStratikos%26aufirst%3DE.%26aulast%3DGeorgiadis%26aufirst%3DD.%26atitle%3DOptimization%2520and%2520structure-activity%2520relationships%2520of%2520phosphinic%2520pseudotripeptide%2520inhibitors%2520of%2520aminopeptidases%2520that%2520generate%2520antigenic%2520peptides%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D9107%26epage%3D9123%26doi%3D10.1021%2Facs.jmedchem.6b01031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Giastas, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowland, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stratikos, E.</span></span> <span> </span><span class="NLM_article-title">High-resolution crystal structure of endoplasmic reticulum aminopeptidase 1 with bound phosphinic transition-state analogue inhibitor</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">708</span>– <span class="NLM_lpage">713</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00002</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00002" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjtVGmsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=708-713&author=P.+Giastasauthor=M.+Neuauthor=P.+Rowlandauthor=E.+Stratikos&title=High-resolution+crystal+structure+of+endoplasmic+reticulum+aminopeptidase+1+with+bound+phosphinic+transition-state+analogue+inhibitor&doi=10.1021%2Facsmedchemlett.9b00002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">High-resolution crystal structure of endoplasmic reticulum aminopeptidase 1 with bound phosphinic transition-state analogue inhibitor</span></div><div class="casAuthors">Giastas, Petros; Neu, Margarete; Rowland, Paul; Stratikos, Efstratios</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">708-713</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Endoplasmic reticulum aminopeptidase 1 (ERAP1) is an intracellular enzyme that helps generate peptides presented by Major Histocompatibility Complex Class I (MHC class I) mols. and is an emerging target for immunotherapy applications.  Despite almost two decades of research on ERAP1, lack of high-resoln. crystal structures has hampered drug-development efforts.  By optimizing the protein construct, we obtained a high-resoln. (1.60 Å) crystal structure of the closed-conformation of ERAP1 with a potent phosphinic pseudopeptide inhibitor bound in its active site.  The structure provides key insight on the mechanism of inhibition as well as selectivity toward homologous enzymes and allows detailed mapping of the internal cavity of the enzyme that accommodates peptide-substrates.  Bis-tris propane and malic acid mols., found bound in pockets in the internal cavity, reveal potential druggable secondary binding sites.  The ability to obtain high-resoln. crystal structures of ERAP1 removes a major bottleneck in the development of compds. that regulate its activity and will greatly accelerate drug-discovery efforts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTY0rTge63ZLVg90H21EOLACvtfcHk0li3GchSSj2P5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjtVGmsLo%253D&md5=b6e4b207eb7723944f709389e9ff4bed</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00002%26sid%3Dliteratum%253Aachs%26aulast%3DGiastas%26aufirst%3DP.%26aulast%3DNeu%26aufirst%3DM.%26aulast%3DRowland%26aufirst%3DP.%26aulast%3DStratikos%26aufirst%3DE.%26atitle%3DHigh-resolution%2520crystal%2520structure%2520of%2520endoplasmic%2520reticulum%2520aminopeptidase%25201%2520with%2520bound%2520phosphinic%2520transition-state%2520analogue%2520inhibitor%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26spage%3D708%26epage%3D713%26doi%3D10.1021%2Facsmedchemlett.9b00002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kurzrock, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Druker, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talpaz, M.</span></span> <span> </span><span class="NLM_article-title">Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics</span>. <i>Ann. Intern. Med.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>138</i></span>,  <span class="NLM_fpage">819</span>– <span class="NLM_lpage">830</span>, <span class="refDoi"> DOI: 10.7326/0003-4819-138-10-200305200-00010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.7326%2F0003-4819-138-10-200305200-00010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=12755554" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD3sXktl2ht70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=2003&pages=819-830&author=R.+Kurzrockauthor=H.+M.+Kantarjianauthor=B.+J.+Drukerauthor=M.+Talpaz&title=Philadelphia+chromosome-positive+leukemias%3A+from+basic+mechanisms+to+molecular+therapeutics&doi=10.7326%2F0003-4819-138-10-200305200-00010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Philadelphia chromosome-positive leukemias: From basic mechanisms to molecular therapeutics</span></div><div class="casAuthors">Kurzrock, Razelle; Kantarjian, Hagop M.; Druker, Brian J.; Talpaz, Moshe</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Internal Medicine</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">138</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">819-830</span>CODEN:
                <span class="NLM_cas:coden">AIMEAS</span>;
        ISSN:<span class="NLM_cas:issn">0003-4819</span>.
    
            (<span class="NLM_cas:orgname">American College of Physicians-American Society of Internal Medicine</span>)
        </div><div class="casAbstract">A review.  The Philadelphia chromosome translocation (t(9;22)) results in the mol. juxtaposition of 2 genes, BCR and ABL, to form an aberrant BCR-ABL gene on chromosome 22.  BCR-ABL is crit. to the pathogenesis of chronic myelogenous leukemia and a subset of acute leukemias.  The chimeric Bcr-Abl protein has constitutively elevated tyrosine phosphokinase activity.  This abnormal enzymic activation is crit. to the oncogenic potential of Bcr-Abl.  Initially, protein kinases were thought to be poor therapeutic targets because of their ubiquitous nature and crucial role in many normal physiol. processes.  However, the advent of imatinib mesylate (Gleevec, Novartis Pharmaceuticals, Basel, Switzerland), formerly known as ST1571 and CGP57148B, demonstrated that designer kinase inhibitors could be specific.  This agent has shown striking activity in chronic myelogenous leukemia.  It also inhibits phosphorylation of Kit (stem-cell factor receptor) and platelet-derived growth factor receptor.  In addn., it has shown similar impressive responses, with little host toxicity, in gastrointestinal stromal tumors, which harbor activating Kit mutations, and in tumors with activated platelet-derived growth factor receptor.  The studies of imatinib mesylate provide proof-of-principle for using aberrant kinases as a therapeutic target and are a model for the promise of mol. therapeutics.  This paper reviews the current knowledge on the function of Bcr-Abl and its normal counterparts (Bcr and Abl), as well as the impact of this knowledge on the development of a remarkably successful targeted therapy approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3h7VvjEn5vrVg90H21EOLACvtfcHk0li3GchSSj2P5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXktl2ht70%253D&md5=ac97d62f6cfcc51f268d6cea1dcf1d22</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.7326%2F0003-4819-138-10-200305200-00010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7326%252F0003-4819-138-10-200305200-00010%26sid%3Dliteratum%253Aachs%26aulast%3DKurzrock%26aufirst%3DR.%26aulast%3DKantarjian%26aufirst%3DH.%2BM.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DTalpaz%26aufirst%3DM.%26atitle%3DPhiladelphia%2520chromosome-positive%2520leukemias%253A%2520from%2520basic%2520mechanisms%2520to%2520molecular%2520therapeutics%26jtitle%3DAnn.%2520Intern.%2520Med.%26date%3D2003%26volume%3D138%26spage%3D819%26epage%3D830%26doi%3D10.7326%2F0003-4819-138-10-200305200-00010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Capdeville, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchdunger, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matter, A.</span></span> <span> </span><span class="NLM_article-title">Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">493</span>– <span class="NLM_lpage">502</span>, <span class="refDoi"> DOI: 10.1038/nrd839</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1038%2Fnrd839" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=12120256" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD38XkvFKlurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=493-502&author=R.+Capdevilleauthor=E.+Buchdungerauthor=J.+Zimmermannauthor=A.+Matter&title=Glivec+%28STI571%2C+imatinib%29%2C+a+rationally+developed%2C+targeted+anticancer+drug&doi=10.1038%2Fnrd839"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug</span></div><div class="casAuthors">Capdeville, Renaud; Buchdunger, Elisabeth; Zimmermann, Juerg; Matter, Alex</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">493-502</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In the early 1980s, it became apparent that the work of pioneers such as Robert Weinberg, Mariano Barbacid and many others in identifying cancer-causing genes in humans was opening the door to a new era in anticancer research.  Motivated by this, and by dissatisfaction with the limited efficacy and tolerability of available anticancer modalities, a drug discovery program was initiated with the aim of rationally developing targeted anticancer therapies.  Here, we describe how this program led to the discovery and continuing development of Glivec (Gleevec in the United States), the first selective tyrosine-kinase inhibitor to be approved for the treatment of a cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeI0HV4de6ObVg90H21EOLACvtfcHk0li3GchSSj2P5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkvFKlurY%253D&md5=c8f6b7a66f74b64f0dedb5e641097acc</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1038%2Fnrd839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd839%26sid%3Dliteratum%253Aachs%26aulast%3DCapdeville%26aufirst%3DR.%26aulast%3DBuchdunger%26aufirst%3DE.%26aulast%3DZimmermann%26aufirst%3DJ.%26aulast%3DMatter%26aufirst%3DA.%26atitle%3DGlivec%2520%2528STI571%252C%2520imatinib%2529%252C%2520a%2520rationally%2520developed%252C%2520targeted%2520anticancer%2520drug%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2002%26volume%3D1%26spage%3D493%26epage%3D502%26doi%3D10.1038%2Fnrd839" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malinoski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prakash, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span> <span> </span><span class="NLM_article-title">Development of alkyne-containing pyrazolopyrimidines to overcome drug resistance of Bcr-Abl kinase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">9228</span>– <span class="NLM_lpage">9237</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01125</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01125" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVaht7vL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=9228-9237&author=X.+Liuauthor=A.+Kungauthor=B.+Malinoskiauthor=G.+K.+Prakashauthor=C.+Zhang&title=Development+of+alkyne-containing+pyrazolopyrimidines+to+overcome+drug+resistance+of+Bcr-Abl+kinase&doi=10.1021%2Facs.jmedchem.5b01125"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Alkyne-Containing Pyrazolopyrimidines To Overcome Drug Resistance of Bcr-Abl Kinase</span></div><div class="casAuthors">Liu, Xu; Kung, Alvin; Malinoski, Brock; Prakash, G. K. Surya; Zhang, Chao</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">9228-9237</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Despite the success of imatinib at inhibiting Bcr-Abl and treating chronic myelogenous leukemia (CML), resistance to the therapy occurs over time in patients.  In particular, the resistance to imatinib caused by the gatekeeper mutation T315I in Bcr-Abl remains a challenge in the clinic.  Inspired by the successful development of ponatinib to curb drug resistance, we hypothesize that the incorporation of an alkyne linker in other heterocyclic scaffolds can also achieve potent inhibition of Bcr-AblT315I by allowing for simultaneous occupancy of both the active site and the allosteric pocket in the Abl kinase domain.  Herein, we describe the design, synthesis, and characterization of a series of alkyne-contg. pyrazolopyrimidines as Bcr-Abl inhibitors.  Our results demonstrate that some alkyne-contg. pyrazolopyrimidines potently inhibit not only AblT315I in vitro but also Bcr-AblT315I in cells.  These pyrazolopyrimidines can serve as lead compds. for future development of novel targeted therapy to overcome drug resistance of CML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvCwLSMJhHxLVg90H21EOLACvtfcHk0li3GchSSj2P5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVaht7vL&md5=adfdddc095b76175f04f8ace9f51b847</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01125%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DKung%26aufirst%3DA.%26aulast%3DMalinoski%26aufirst%3DB.%26aulast%3DPrakash%26aufirst%3DG.%2BK.%26aulast%3DZhang%26aufirst%3DC.%26atitle%3DDevelopment%2520of%2520alkyne-containing%2520pyrazolopyrimidines%2520to%2520overcome%2520drug%2520resistance%2520of%2520Bcr-Abl%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D9228%26epage%3D9237%26doi%3D10.1021%2Facs.jmedchem.5b01125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metcalf, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sundaramoorthi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banda, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lentini, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keats, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wardwell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ning, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snodgrass, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broudy, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russian, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Commodore, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narasimhan, N. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohemmad, Q. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iuliucci, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivera, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalgarno, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawyer, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clackson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shakespeare, W. C.</span></span> <span> </span><span class="NLM_article-title">Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-<i>N</i>-{4-[(4-methylpiperazin-1-y l)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">4701</span>– <span class="NLM_lpage">4719</span>, <span class="refDoi"> DOI: 10.1021/jm100395q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100395q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmslels7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=4701-4719&author=W.+S.+Huangauthor=C.+A.+Metcalfauthor=R.+Sundaramoorthiauthor=Y.+Wangauthor=D.+Zouauthor=R.+M.+Thomasauthor=X.+Zhuauthor=L.+Caiauthor=D.+Wenauthor=S.+Liuauthor=J.+Romeroauthor=J.+Qiauthor=I.+Chenauthor=G.+Bandaauthor=S.+P.+Lentiniauthor=S.+Dasauthor=Q.+Xuauthor=J.+Keatsauthor=F.+Wangauthor=S.+Wardwellauthor=Y.+Ningauthor=J.+T.+Snodgrassauthor=M.+I.+Broudyauthor=K.+Russianauthor=T.+Zhouauthor=L.+Commodoreauthor=N.+I.+Narasimhanauthor=Q.+K.+Mohemmadauthor=J.+Iuliucciauthor=V.+M.+Riveraauthor=D.+C.+Dalgarnoauthor=T.+K.+Sawyerauthor=T.+Clacksonauthor=W.+C.+Shakespeare&title=Discovery+of+3-%5B2-%28imidazo%5B1%2C2-b%5Dpyridazin-3-yl%29ethynyl%5D-4-methyl-N-%7B4-%5B%284-methylpiperazin-1-y+l%29methyl%5D-3-%28trifluoromethyl%29phenyl%7Dbenzamide+%28AP24534%29%2C+a+potent%2C+orally+active+pan-inhibitor+of+breakpoint+cluster+region-abelson+%28BCR-ABL%29+kinase+including+the+T315I+gatekeeper+mutant&doi=10.1021%2Fjm100395q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 3-[2-(Imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-[4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl]benzamide (AP24534), a Potent, Orally Active Pan-Inhibitor of Breakpoint Cluster Region-Abelson (BCR-ABL) Kinase Including the T315I Gatekeeper Mutant</span></div><div class="casAuthors">Huang, Wei-Sheng; Metcalf, Chester A.; Sundaramoorthi, Raji; Wang, Yihan; Zou, Dong; Thomas, R. Mathew; Zhu, Xiaotian; Cai, Lisi; Wen, David; Liu, Shuangying; Romero, Jan; Qi, Jiwei; Chen, Ingrid; Banda, Geetha; Lentini, Scott P.; Das, Sasmita; Xu, Qihong; Keats, Jeff; Wang, Frank; Wardwell, Scott; Ning, Yaoyu; Snodgrass, Joseph T.; Broudy, Marc I.; Russian, Karin; Zhou, Tianjun; Commodore, Lois; Narasimhan, Narayana I.; Mohemmad, Qurish K.; Iuliucci, John; Rivera, Victor M.; Dalgarno, David C.; Sawyer, Tomi K.; Clackson, Tim; Shakespeare, William C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4701-4719</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In the treatment of chronic myeloid leukemia (CML) with BCR-ABL kinase inhibitors, the T315I gatekeeper mutant has emerged as resistant to all currently approved agents.  This report describes the structure-guided design of a novel series of potent pan-inhibitors of BCR-ABL, including the T315I mutation.  A key structural feature is the carbon-carbon triple bond linker which skirts the increased bulk of Ile315 side chain.  Extensive SAR studies led to the discovery of development candidate benzamide I (AP24534), which inhibited the kinase activity of both native BCR-ABL and the T315I mutant with low nM IC50s, and potently inhibited proliferation of corresponding Ba/F3-derived cell lines.  Daily oral administration of I significantly prolonged survival of mice injected i.v. with BCR-ABLT315I expressing Ba/F3 cells.  These data, coupled with a favorable ADME profile, support the potential of I to be an effective treatment for CML, including patients refractory to all currently approved therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoci2zVFUazgLVg90H21EOLACvtfcHk0ljwJdCoyCedxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmslels7s%253D&md5=0dcd7b4ff31164b1d9883e897b7058ff</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1021%2Fjm100395q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100395q%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DW.%2BS.%26aulast%3DMetcalf%26aufirst%3DC.%2BA.%26aulast%3DSundaramoorthi%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZou%26aufirst%3DD.%26aulast%3DThomas%26aufirst%3DR.%2BM.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DCai%26aufirst%3DL.%26aulast%3DWen%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DRomero%26aufirst%3DJ.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DI.%26aulast%3DBanda%26aufirst%3DG.%26aulast%3DLentini%26aufirst%3DS.%2BP.%26aulast%3DDas%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DKeats%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DWardwell%26aufirst%3DS.%26aulast%3DNing%26aufirst%3DY.%26aulast%3DSnodgrass%26aufirst%3DJ.%2BT.%26aulast%3DBroudy%26aufirst%3DM.%2BI.%26aulast%3DRussian%26aufirst%3DK.%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DCommodore%26aufirst%3DL.%26aulast%3DNarasimhan%26aufirst%3DN.%2BI.%26aulast%3DMohemmad%26aufirst%3DQ.%2BK.%26aulast%3DIuliucci%26aufirst%3DJ.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26aulast%3DDalgarno%26aufirst%3DD.%2BC.%26aulast%3DSawyer%26aufirst%3DT.%2BK.%26aulast%3DClackson%26aufirst%3DT.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26atitle%3DDiscovery%2520of%25203-%255B2-%2528imidazo%255B1%252C2-b%255Dpyridazin-3-yl%2529ethynyl%255D-4-methyl-N-%257B4-%255B%25284-methylpiperazin-1-y%2520l%2529methyl%255D-3-%2528trifluoromethyl%2529phenyl%257Dbenzamide%2520%2528AP24534%2529%252C%2520a%2520potent%252C%2520orally%2520active%2520pan-inhibitor%2520of%2520breakpoint%2520cluster%2520region-abelson%2520%2528BCR-ABL%2529%2520kinase%2520including%2520the%2520T315I%2520gatekeeper%2520mutant%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D4701%26epage%3D4719%26doi%3D10.1021%2Fjm100395q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kaitsiotou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keul, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardick, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muhlenberg, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ketzer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehrt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krull, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medda, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giordanetto, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauh, D.</span></span> <span> </span><span class="NLM_article-title">Inhibitors to overcome secondary mutations in the stem cell factor receptor KIT</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">8801</span>– <span class="NLM_lpage">8815</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00841</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00841" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1amtLrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=8801-8815&author=H.+Kaitsiotouauthor=M.+Keulauthor=J.+Hardickauthor=T.+Muhlenbergauthor=J.+Ketzerauthor=C.+Ehrtauthor=J.+Krullauthor=F.+Meddaauthor=O.+Kochauthor=F.+Giordanettoauthor=S.+Bauerauthor=D.+Rauh&title=Inhibitors+to+overcome+secondary+mutations+in+the+stem+cell+factor+receptor+KIT&doi=10.1021%2Facs.jmedchem.7b00841"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors to Overcome Secondary Mutations in the Stem Cell Factor Receptor KIT</span></div><div class="casAuthors">Kaitsiotou, Helena; Keul, Marina; Hardick, Julia; Muehlenberg, Thomas; Ketzer, Julia; Ehrt, Christiane; Kruell, Jasmin; Medda, Federico; Koch, Oliver; Giordanetto, Fabrizio; Bauer, Sebastian; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">8801-8815</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In modern cancer therapy, the use of small org. mols. against receptor tyrosine kinases (RTKs) has been shown to be a valuable strategy.  The assocn. of cancer cells with dysregulated signaling pathways linked to RTKs represents a key element in targeted cancer therapies.  The tyrosine kinase mast/stem cell growth factor receptor KIT is an example of a clin. relevant RTK.  KIT is targeted for cancer therapy in gastrointestinal stromal tumors (GISTs) and chronic myelogenous leukemia (CML).  However, acquired resistance mutations within the catalytic domain decrease the efficacy of this strategy and are the most common cause of failed therapy.  Here, we present the structure-based design and synthesis of novel type II kinase inhibitors to overcome these mutations in KIT.  Biochem. and cellular studies revealed promising mols. for the inhibition of mutated KIT.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-lJTbHOMKKbVg90H21EOLACvtfcHk0ljwJdCoyCedxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1amtLrE&md5=27459cff0dbf5dad390dea330458c201</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00841&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00841%26sid%3Dliteratum%253Aachs%26aulast%3DKaitsiotou%26aufirst%3DH.%26aulast%3DKeul%26aufirst%3DM.%26aulast%3DHardick%26aufirst%3DJ.%26aulast%3DMuhlenberg%26aufirst%3DT.%26aulast%3DKetzer%26aufirst%3DJ.%26aulast%3DEhrt%26aufirst%3DC.%26aulast%3DKrull%26aufirst%3DJ.%26aulast%3DMedda%26aufirst%3DF.%26aulast%3DKoch%26aufirst%3DO.%26aulast%3DGiordanetto%26aufirst%3DF.%26aulast%3DBauer%26aufirst%3DS.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DInhibitors%2520to%2520overcome%2520secondary%2520mutations%2520in%2520the%2520stem%2520cell%2520factor%2520receptor%2520KIT%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D8801%26epage%3D8815%26doi%3D10.1021%2Facs.jmedchem.7b00841" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gray, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jubb, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hogue, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowd, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kljavin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frantz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koeppen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Sauvage, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, D. P.</span></span> <span> </span><span class="NLM_article-title">Maternal embryonic leucine zipper kinase/murine protein serine-threonine kinase 38 is a promising therapeutic target for multiple cancers</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">9751</span>– <span class="NLM_lpage">9761</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-04-4531</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1158%2F0008-5472.CAN-04-4531" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=16266996" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFKktL7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=9751-9761&author=D.+Grayauthor=A.+M.+Jubbauthor=D.+Hogueauthor=P.+Dowdauthor=N.+Kljavinauthor=S.+Yiauthor=W.+Baiauthor=G.+Frantzauthor=Z.+Zhangauthor=H.+Koeppenauthor=F.+J.+de+Sauvageauthor=D.+P.+Davis&title=Maternal+embryonic+leucine+zipper+kinase%2Fmurine+protein+serine-threonine+kinase+38+is+a+promising+therapeutic+target+for+multiple+cancers&doi=10.1158%2F0008-5472.CAN-04-4531"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Maternal embryonic leucine zipper kinase/murine protein serine-threonine kinase 38 is a promising therapeutic target for multiple cancers</span></div><div class="casAuthors">Gray, Daniel; Jubb, Adrian M.; Hogue, Deborah; Dowd, Patrick; Kljavin, Noelyn; Yi, Sothy; Bai, Wei; Frantz, Gretchen; Zhang, Zemin; Koeppen, Hartmut; de Sauvage, Frederic J.; Davis, David P.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">9751-9761</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">To identify genes that could serve as targets for novel cancer therapeutics, we used a bioinformatic anal. of microarray data comparing gene expression between normal and tumor-derived primary human tissues.  From this approach, we have found that maternal embryonic leucine zipper kinase (Melk), a member of the AMP serine/threonine kinase family, exhibits multiple features consistent with the potential utility of this gene as an anticancer target.  An oligonucleotide microarray anal. of multiple human tumor samples and cell lines suggests that Melk expression is frequently elevated in cancer relative to normal tissues, a pattern confirmed by quant. reverse transcription-PCR and Western blotting of selected primary tumor samples.  In situ hybridization localized Melk expression to malignant epithelial cells in 96%, 23%, and 13% of colorectal, lung, and ovarian tissue tumor samples, resp.  Expression of this gene is also elevated in spontaneous tumors derived from the ApcMin and Apc1638N murine models of intestinal tumorigenesis.  To begin addressing whether Melk is relevant for tumorigenesis, RNA interference-mediated silencing within human and murine tumor cell lines was done.  We show that Melk knockdown decreases proliferation and anchorage-independent growth in vitro as well as tumor growth in a xenograft model.  Together, these results suggest that Melk may provide a growth advantage for neoplastic cells and, therefore, inactivation may be therapeutically beneficial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_9K-J3ofrbrVg90H21EOLACvtfcHk0ljAQWNiHDAjmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFKktL7F&md5=9d923595fbdf3b522d22c1329ba634c9</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-04-4531&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-04-4531%26sid%3Dliteratum%253Aachs%26aulast%3DGray%26aufirst%3DD.%26aulast%3DJubb%26aufirst%3DA.%2BM.%26aulast%3DHogue%26aufirst%3DD.%26aulast%3DDowd%26aufirst%3DP.%26aulast%3DKljavin%26aufirst%3DN.%26aulast%3DYi%26aufirst%3DS.%26aulast%3DBai%26aufirst%3DW.%26aulast%3DFrantz%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DKoeppen%26aufirst%3DH.%26aulast%3Dde%2BSauvage%26aufirst%3DF.%2BJ.%26aulast%3DDavis%26aufirst%3DD.%2BP.%26atitle%3DMaternal%2520embryonic%2520leucine%2520zipper%2520kinase%252Fmurine%2520protein%2520serine-threonine%2520kinase%252038%2520is%2520a%2520promising%2520therapeutic%2520target%2520for%2520multiple%2520cancers%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26spage%3D9751%26epage%3D9761%26doi%3D10.1158%2F0008-5472.CAN-04-4531" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adelinet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berdini, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beke, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brehmer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coyle, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frederickson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freyne, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilissen, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamlett, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meerpoel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mevellec, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMenamin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasquier, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rees, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linders, J. T.</span></span> <span> </span><span class="NLM_article-title">Structure-based design of type II inhibitors applied to maternal embryonic leucine zipper kinase</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">36</span>, <span class="refDoi"> DOI: 10.1021/ml5001273</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml5001273" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC2cXos1WltL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=31-36&author=C.+N.+Johnsonauthor=C.+Adelinetauthor=V.+Berdiniauthor=L.+Bekeauthor=P.+Bonnetauthor=D.+Brehmerauthor=F.+Caloauthor=J.+E.+Coyleauthor=P.+J.+Dayauthor=M.+Fredericksonauthor=E.+J.+Freyneauthor=R.+A.+Gilissenauthor=C.+C.+Hamlettauthor=S.+Howardauthor=L.+Meerpoelauthor=L.+Mevellecauthor=R.+McMenaminauthor=E.+Pasquierauthor=S.+Patelauthor=D.+C.+Reesauthor=J.+T.+Linders&title=Structure-based+design+of+type+II+inhibitors+applied+to+maternal+embryonic+leucine+zipper+kinase&doi=10.1021%2Fml5001273"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Design of Type II Inhibitors Applied to Maternal Embryonic Leucine Zipper Kinase</span></div><div class="casAuthors">Johnson, Christopher N.; Adelinet, Christophe; Berdini, Valerio; Beke, Lijs; Bonnet, Pascal; Brehmer, Dirk; Calo, Frederick; Coyle, Joseph E.; Day, Phillip J.; Frederickson, Martyn; Freyne, Eddy J. E.; Gilissen, Ron A. H. J.; Hamlett, Christopher C. F.; Howard, Steven; Meerpoel, Lieven; Mevellec, Laurence; McMenamin, Rachel; Pasquier, Elisabeth; Patel, Sahil; Rees, David C.; Linders, Joannes T. M.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">31-36</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel Type II kinase inhibitor chemotype has been identified for maternal embryonic leucine zipper kinase (MELK) using structure-based ligand design.  The strategy involved structural characterization of an induced DFG-out pocket by protein-ligand X-ray crystallog. and incorporation of a slender linkage capable of bypassing a large gate-keeper residue, thus enabling design of mols. accessing both hinge and induced pocket regions.  Optimization of an initial hit led to the identification of a low-nanomolar, cell-penetrant Type II inhibitor suitable for use as a chem. probe for MELK.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWmY300FJpQ7Vg90H21EOLACvtfcHk0ljAQWNiHDAjmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXos1WltL8%253D&md5=35e87bcfe134c8373da3dc57c3c4e6c5</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1021%2Fml5001273&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml5001273%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DC.%2BN.%26aulast%3DAdelinet%26aufirst%3DC.%26aulast%3DBerdini%26aufirst%3DV.%26aulast%3DBeke%26aufirst%3DL.%26aulast%3DBonnet%26aufirst%3DP.%26aulast%3DBrehmer%26aufirst%3DD.%26aulast%3DCalo%26aufirst%3DF.%26aulast%3DCoyle%26aufirst%3DJ.%2BE.%26aulast%3DDay%26aufirst%3DP.%2BJ.%26aulast%3DFrederickson%26aufirst%3DM.%26aulast%3DFreyne%26aufirst%3DE.%2BJ.%26aulast%3DGilissen%26aufirst%3DR.%2BA.%26aulast%3DHamlett%26aufirst%3DC.%2BC.%26aulast%3DHoward%26aufirst%3DS.%26aulast%3DMeerpoel%26aufirst%3DL.%26aulast%3DMevellec%26aufirst%3DL.%26aulast%3DMcMenamin%26aufirst%3DR.%26aulast%3DPasquier%26aufirst%3DE.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DRees%26aufirst%3DD.%2BC.%26aulast%3DLinders%26aufirst%3DJ.%2BT.%26atitle%3DStructure-based%2520design%2520of%2520type%2520II%2520inhibitors%2520applied%2520to%2520maternal%2520embryonic%2520leucine%2520zipper%2520kinase%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26spage%3D31%26epage%3D36%26doi%3D10.1021%2Fml5001273" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neckers, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Workman, P.</span></span> <span> </span><span class="NLM_article-title">Hsp90 molecular chaperone inhibitors: are we there yet?</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">64</span>– <span class="NLM_lpage">76</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-11-1000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1158%2F1078-0432.CCR-11-1000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=22215907" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvFWmsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=64-76&author=L.+Neckersauthor=P.+Workman&title=Hsp90+molecular+chaperone+inhibitors%3A+are+we+there+yet%3F&doi=10.1158%2F1078-0432.CCR-11-1000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Hsp90 Molecular Chaperone Inhibitors: Are We There Yet?</span></div><div class="casAuthors">Neckers, Len; Workman, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">64-76</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Heat shock protein (Hsp) 90 is an ATP-dependent mol. chaperone that is exploited by malignant cells to support activated oncoproteins, including many cancer-assocd. kinases and transcription factors, and it is essential for oncogenic transformation.  Originally viewed with skepticism, Hsp90 inhibitors are now being actively pursued by the pharmaceutical industry, with 17 agents having entered clin. trials.  Investigators established Hsp90's druggability using the natural products geldanamycin and radicicol, which mimic the unusual ATP structure adopted in the chaperone's N-terminal nucleotide-binding pocket and cause potent and selective blockade of ATP binding/hydrolysis, inhibit chaperone function, deplete oncogenic clients, and show antitumor activity.  Preclin. data obtained with these natural products have heightened interest in Hsp90 as a drug target, and 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) has shown clin. activity (as defined by Response Evaluation Criteria in Solid Tumors) in HER2+ breast cancer.  Many optimized synthetic, small-mol. Hsp90 inhibitors from diverse chemotypes are now in clin. trials.  Here, we review the discovery and development of Hsp90 inhibitors and assess their potential.  There has been significant learning from studies of the basic biol. of Hsp90, as well as translational drug development involving this chaperone, enhanced by the use of Hsp90 inhibitors as chem. probes.  Success will likely lie in treating cancers that are addicted to particular driver oncogene products (e.g., HER2, ALK, EGFR, and BRAF) that are sensitive Hsp90 clients, as well as malignancies (esp. multiple myeloma) in which buffering of proteotoxic stress is crit. for survival.  We discuss approaches for enhancing the effectiveness of Hsp90 inhibitors and highlight new chaperone and stress-response pathway targets, including HSF1 and Hsp70.  Clin Cancer Res; 18(1); 64-76.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfICmNu1IWFbVg90H21EOLACvtfcHk0lhlqODHHMFKew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvFWmsw%253D%253D&md5=f67c3c11b5847e3866c91af2a16a63b8</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-1000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-1000%26sid%3Dliteratum%253Aachs%26aulast%3DNeckers%26aufirst%3DL.%26aulast%3DWorkman%26aufirst%3DP.%26atitle%3DHsp90%2520molecular%2520chaperone%2520inhibitors%253A%2520are%2520we%2520there%2520yet%253F%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D64%26epage%3D76%26doi%3D10.1158%2F1078-0432.CCR-11-1000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kasibhatla, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biamonte, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Busch, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karjian, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sensintaffar, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lough, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brekken, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundgren, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grecko, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timony, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ran, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansfield, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fritz, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulm, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boehm, M. F.</span></span> <span> </span><span class="NLM_article-title">Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">2767</span>– <span class="NLM_lpage">2778</span>, <span class="refDoi"> DOI: 10.1021/jm050752+</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm050752%2B" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltVWqtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=2767-2778&author=S.+R.+Kasibhatlaauthor=K.+Hongauthor=M.+A.+Biamonteauthor=D.+J.+Buschauthor=P.+L.+Karjianauthor=J.+L.+Sensintaffarauthor=A.+Kamalauthor=R.+E.+Loughauthor=J.+Brekkenauthor=K.+Lundgrenauthor=R.+Greckoauthor=G.+A.+Timonyauthor=Y.+Ranauthor=R.+Mansfieldauthor=L.+C.+Fritzauthor=E.+Ulmauthor=F.+J.+Burrowsauthor=M.+F.+Boehm&title=Rationally+designed+high-affinity+2-amino-6-halopurine+heat+shock+protein+90+inhibitors+that+exhibit+potent+antitumor+activity&doi=10.1021%2Fjm050752%2B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Rationally Designed High-Affinity 2-Amino-6-halopurine Heat Shock Protein 90 Inhibitors That Exhibit Potent Antitumor Activity</span></div><div class="casAuthors">Kasibhatla, Srinivas R.; Hong, Kevin; Biamonte, Marco A.; Busch, David J.; Karjian, Patricia L.; Sensintaffar, John L.; Kamal, Adeela; Lough, Rachel E.; Brekken, John; Lundgren, Karen; Grecko, Roy; Timony, Gregg A.; Ran, Yingqing; Mansfield, Robert; Fritz, Lawrence C.; Ulm, Edgar; Burrows, Francis J.; Boehm, Marcus F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2767-2778</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Heat shock protein 90 (Hsp90) is a mol. chaperone protein implicated in stabilizing the conformation and maintaining the function of many cell-signaling proteins.  Many oncogenic proteins are more dependent on Hsp90 in maintaining their conformation, stability, and maturation than their normal counterparts.  Furthermore, recent data show that Hsp90 exists in an activated form in malignant cells but in a latent inactive form in normal tissues, suggesting that inhibitors selective for the activated form could provide a high therapeutic index.  Hence, Hsp90 is emerging as an exciting new target for the treatment of cancer.  We now report on a novel series of 2-amino-6-halopurine Hsp90 inhibitors exemplified by 2-amino-6-chloro-9-(4-iodo-3,5-dimethylpyridin-2-ylmethyl)purine (30).  These highly potent inhibitors (IC50 of 30 = 0.009 μM in a HER-2 degrdn. assay) also display excellent antiproliferative activity against various tumor cell lines (IC50 of 30 = 0.03 μM in MCF7 cells).  Moreover, this class of inhibitors shows higher affinity for the activated form of Hsp90 compared to our earlier 8-sulfanylpurine Hsp90 inhibitor series.  When administered orally to mice, these compds. exhibited potent tumor growth inhibition (>80%) in an N87 xenograft model, similar to that obsd. with 17-allylamino-17-desmethoxygeldanamycin (17-AAG), which is a compd. currently in phase I/II clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiBDUeN7k4z7Vg90H21EOLACvtfcHk0lhlqODHHMFKew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltVWqtLY%253D&md5=4d339610f0865ba089df631decae91f4</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1021%2Fjm050752%2B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050752%252B%26sid%3Dliteratum%253Aachs%26aulast%3DKasibhatla%26aufirst%3DS.%2BR.%26aulast%3DHong%26aufirst%3DK.%26aulast%3DBiamonte%26aufirst%3DM.%2BA.%26aulast%3DBusch%26aufirst%3DD.%2BJ.%26aulast%3DKarjian%26aufirst%3DP.%2BL.%26aulast%3DSensintaffar%26aufirst%3DJ.%2BL.%26aulast%3DKamal%26aufirst%3DA.%26aulast%3DLough%26aufirst%3DR.%2BE.%26aulast%3DBrekken%26aufirst%3DJ.%26aulast%3DLundgren%26aufirst%3DK.%26aulast%3DGrecko%26aufirst%3DR.%26aulast%3DTimony%26aufirst%3DG.%2BA.%26aulast%3DRan%26aufirst%3DY.%26aulast%3DMansfield%26aufirst%3DR.%26aulast%3DFritz%26aufirst%3DL.%2BC.%26aulast%3DUlm%26aufirst%3DE.%26aulast%3DBurrows%26aufirst%3DF.%2BJ.%26aulast%3DBoehm%26aufirst%3DM.%2BF.%26atitle%3DRationally%2520designed%2520high-affinity%25202-amino-6-halopurine%2520heat%2520shock%2520protein%252090%2520inhibitors%2520that%2520exhibit%2520potent%2520antitumor%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D2767%26epage%3D2778%26doi%3D10.1021%2Fjm050752%2B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van de Water, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamer, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weichert, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandoval, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasibhatla, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boehm, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundgren, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timple, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lough, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibanez, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boykin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kehry, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harning, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambrose, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bixler, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunah, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snodgrass-Belt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arndt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enyedy, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKenzie, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biamonte, M. A.</span></span> <span> </span><span class="NLM_article-title">EC144 is a potent inhibitor of the heat shock protein 90</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">7786</span>– <span class="NLM_lpage">7795</span>, <span class="refDoi"> DOI: 10.1021/jm300810x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300810x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht12it7%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=7786-7795&author=J.+Shiauthor=R.+Van+de+Waterauthor=K.+Hongauthor=R.+B.+Lamerauthor=K.+W.+Weichertauthor=C.+M.+Sandovalauthor=S.+R.+Kasibhatlaauthor=M.+F.+Boehmauthor=J.+Chaoauthor=K.+Lundgrenauthor=N.+Timpleauthor=R.+Loughauthor=G.+Ibanezauthor=C.+Boykinauthor=F.+J.+Burrowsauthor=M.+R.+Kehryauthor=T.+J.+Yunauthor=E.+K.+Harningauthor=C.+Ambroseauthor=J.+Thompsonauthor=S.+A.+Bixlerauthor=A.+Dunahauthor=P.+Snodgrass-Beltauthor=J.+Arndtauthor=I.+J.+Enyedyauthor=P.+Liauthor=V.+S.+Hongauthor=A.+McKenzieauthor=M.+A.+Biamonte&title=EC144+is+a+potent+inhibitor+of+the+heat+shock+protein+90&doi=10.1021%2Fjm300810x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">EC144 Is a Potent Inhibitor of the Heat Shock Protein 90</span></div><div class="casAuthors">Shi, Jiandong; Van de Water, Ryan; Hong, Kevin; Lamer, Ryan B.; Weichert, Kenneth W.; Sandoval, Cristina M.; Kasibhatla, Srinivas R.; Boehm, Marcus F.; Chao, Jianhua; Lundgren, Karen; Timple, Noelito; Lough, Rachel; Ibanez, Gerardo; Boykin, Christina; Burrows, Francis J.; Kehry, Marilyn R.; Yun, Theodore J.; Harning, Erin K.; Ambrose, Christine; Thompson, Jeffrey; Bixler, Sarah A.; Dunah, Anthone; Snodgrass-Belt, Pamela; Arndt, Joseph; Enyedy, Istvan J.; Li, Ping; Hong, Victor S.; McKenzie, Andres; Biamonte, Marco A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7786-7795</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Alkyne 5-(2-amino-4-chloro-7-((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methylpent-4-yn-2-ol (EC144), is a second generation inhibitor of heat shock protein 90 (Hsp90) and is substantially more potent in vitro and in vivo than the first generation inhibitor (BIIB021) that completed phase II clin. trials.  Alkyne (EC144) is more potent than (BIIB021) in an Hsp90α binding assay (IC50 = 1.1 vs. 5.1 nM) as well as in its ability to degrade Her-2 in MCF-7 cells (EC50 = 14 vs. 38 nM).  In a mouse model of gastric tumors (N87), (EC144) stops tumor growth at 5 mg/kg and causes partial tumor regressions at 10 mg/kg (po, qd×5).  Under the same conditions, (BIIB021) stops tumor growth only at 120 mg/kg, and does not induce partial regressions.  Thus, alkyne (EC144) is approx. 20-fold more efficacious than (BIIB021) in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLRtKyDCD2OLVg90H21EOLACvtfcHk0lhQMU8lzn1OVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht12it7%252FE&md5=201153ad61f71af267f1e1ba2ca7c2e7</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1021%2Fjm300810x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300810x%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DVan%2Bde%2BWater%26aufirst%3DR.%26aulast%3DHong%26aufirst%3DK.%26aulast%3DLamer%26aufirst%3DR.%2BB.%26aulast%3DWeichert%26aufirst%3DK.%2BW.%26aulast%3DSandoval%26aufirst%3DC.%2BM.%26aulast%3DKasibhatla%26aufirst%3DS.%2BR.%26aulast%3DBoehm%26aufirst%3DM.%2BF.%26aulast%3DChao%26aufirst%3DJ.%26aulast%3DLundgren%26aufirst%3DK.%26aulast%3DTimple%26aufirst%3DN.%26aulast%3DLough%26aufirst%3DR.%26aulast%3DIbanez%26aufirst%3DG.%26aulast%3DBoykin%26aufirst%3DC.%26aulast%3DBurrows%26aufirst%3DF.%2BJ.%26aulast%3DKehry%26aufirst%3DM.%2BR.%26aulast%3DYun%26aufirst%3DT.%2BJ.%26aulast%3DHarning%26aufirst%3DE.%2BK.%26aulast%3DAmbrose%26aufirst%3DC.%26aulast%3DThompson%26aufirst%3DJ.%26aulast%3DBixler%26aufirst%3DS.%2BA.%26aulast%3DDunah%26aufirst%3DA.%26aulast%3DSnodgrass-Belt%26aufirst%3DP.%26aulast%3DArndt%26aufirst%3DJ.%26aulast%3DEnyedy%26aufirst%3DI.%2BJ.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DHong%26aufirst%3DV.%2BS.%26aulast%3DMcKenzie%26aufirst%3DA.%26aulast%3DBiamonte%26aufirst%3DM.%2BA.%26atitle%3DEC144%2520is%2520a%2520potent%2520inhibitor%2520of%2520the%2520heat%2520shock%2520protein%252090%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D7786%26epage%3D7795%26doi%3D10.1021%2Fjm300810x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mdluli, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witte, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kline, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barb, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erwin, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansfield, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McClerren, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirrung, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tumey, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warrener, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raetz, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stover, C. K.</span></span> <span> </span><span class="NLM_article-title">Molecular validation of LpxC as an antibacterial drug target in <i>Pseudomonas aeruginosa</i></span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">2178</span>– <span class="NLM_lpage">2184</span>, <span class="refDoi"> DOI: 10.1128/AAC.00140-06</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1128%2FAAC.00140-06" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=16723580" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD28XlsVOiu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2006&pages=2178-2184&author=K.+E.+Mdluliauthor=P.+R.+Witteauthor=T.+Klineauthor=A.+W.+Barbauthor=A.+L.+Erwinauthor=B.+E.+Mansfieldauthor=A.+L.+McClerrenauthor=M.+C.+Pirrungauthor=L.+N.+Tumeyauthor=P.+Warrenerauthor=C.+R.+Raetzauthor=C.+K.+Stover&title=Molecular+validation+of+LpxC+as+an+antibacterial+drug+target+in+Pseudomonas+aeruginosa&doi=10.1128%2FAAC.00140-06"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular validation of LpxC as an antibacterial drug target in Pseudomonas aeruginosa</span></div><div class="casAuthors">Mdluli, Khisimuzi E.; Witte, Pamela R.; Kline, Toni; Barb, Adam W.; Erwin, Alice L.; Mansfield, Bryce E.; McClerren, Amanda L.; Pirrung, Michael C.; Tumey, L. Nathan; Warrener, Paul; Raetz, Christian R. H.; Stover, C. Kendall</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2178-2184</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">LpxC [UDP-3-O-(R-3-hydroxymyristoyl)-GlcNAc deacetylase] is a metalloamidase that catalyzes the first committed step in the biosynthesis of the lipid A component of lipopolysaccharide.  A previous study identified a series of synthetic LpxC-inhibitory mols. that were bactericidal for Escherichia coli.  These mols. did not inhibit the growth of Pseudomonas aeruginosa and were therefore not developed further as antibacterial drugs.  The inactivity of the LpxC inhibitors for P. aeruginosa raised the possibility that LpxC activity might not be essential for all gram-neg. bacteria.  By placing the lpxC gene of P. aeruginosa under tight control of an arabinose-inducible promoter, we demonstrated the essentiality of LpxC activity for P. aeruginosa.  It was found that compd. L-161,240, the most potent inhibitor from the previous study, was active against a P. aeruginosa construct in which the endogenous lpxC gene was inactivated and in which LpxC activity was supplied by the lpxC gene from E. coli.  Conversely, an E. coli construct in which growth was dependent on the P. aeruginosa lpxC gene was resistant to the compd.  The differential activities of L-161,240 against the two bacterial species are thus the result primarily of greater potency toward the E. coli enzyme rather than of differences in the intrinsic resistance of the bacteria toward antibacterial compds. due to permeability or efflux.  These data validate P. aeruginosa LpxC as a target for novel antibiotic drugs and should help direct the design of inhibitors against clin. important gram-neg. bacteria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr72k931w5vjbVg90H21EOLACvtfcHk0lhjpUKs3EM-yw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlsVOiu74%253D&md5=2fa9711c5bcbea239092f23d3c70e87b</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1128%2FAAC.00140-06&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00140-06%26sid%3Dliteratum%253Aachs%26aulast%3DMdluli%26aufirst%3DK.%2BE.%26aulast%3DWitte%26aufirst%3DP.%2BR.%26aulast%3DKline%26aufirst%3DT.%26aulast%3DBarb%26aufirst%3DA.%2BW.%26aulast%3DErwin%26aufirst%3DA.%2BL.%26aulast%3DMansfield%26aufirst%3DB.%2BE.%26aulast%3DMcClerren%26aufirst%3DA.%2BL.%26aulast%3DPirrung%26aufirst%3DM.%2BC.%26aulast%3DTumey%26aufirst%3DL.%2BN.%26aulast%3DWarrener%26aufirst%3DP.%26aulast%3DRaetz%26aufirst%3DC.%2BR.%26aulast%3DStover%26aufirst%3DC.%2BK.%26atitle%3DMolecular%2520validation%2520of%2520LpxC%2520as%2520an%2520antibacterial%2520drug%2520target%2520in%2520Pseudomonas%2520aeruginosa%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2006%26volume%3D50%26spage%3D2178%26epage%3D2184%26doi%3D10.1128%2FAAC.00140-06" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Piizzi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patnaik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wattanasin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenoir, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nunez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerrigan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKenney, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osborne, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanieri, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bojkovic, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dzink-Fox, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lilly, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sprague, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranjitkar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glick, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamann, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tommasi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dean, C. R.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and properties of a potent inhibitor of <i>Pseudomonas aeruginosa</i> deacetylase LpxC</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">5002</span>– <span class="NLM_lpage">5014</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00377</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00377" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC2sXos1SgsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=5002-5014&author=G.+Piizziauthor=D.+T.+Parkerauthor=Y.+Pengauthor=M.+Doblerauthor=A.+Patnaikauthor=S.+Wattanasinauthor=E.+Liuauthor=F.+Lenoirauthor=J.+Nunezauthor=J.+Kerriganauthor=D.+McKenneyauthor=C.+Osborneauthor=D.+Yuauthor=L.+Lanieriauthor=J.+Bojkovicauthor=J.+Dzink-Foxauthor=M.+D.+Lillyauthor=E.+R.+Spragueauthor=Y.+Luauthor=H.+Wangauthor=S.+Ranjitkarauthor=L.+Xieauthor=B.+Wangauthor=M.+Glickauthor=L.+G.+Hamannauthor=R.+Tommasiauthor=X.+Yangauthor=C.+R.+Dean&title=Design%2C+synthesis%2C+and+properties+of+a+potent+inhibitor+of+Pseudomonas+aeruginosa+deacetylase+LpxC&doi=10.1021%2Facs.jmedchem.7b00377"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Properties of a Potent Inhibitor of Pseudomonas aeruginosa Deacetylase LpxC</span></div><div class="casAuthors">Piizzi, Grazia; Parker, David T.; Peng, Yunshan; Dobler, Markus; Patnaik, Anup; Wattanasin, Som; Liu, Eugene; Lenoir, Francois; Nunez, Jill; Kerrigan, John; McKenney, David; Osborne, Colin; Yu, Donghui; Lanieri, Leanne; Bojkovic, Jade; Dzink-Fox, JoAnn; Lilly, Maria-Dawn; Sprague, Elizabeth R.; Lu, Yipin; Wang, Hongming; Ranjitkar, Srijan; Xie, Lili; Wang, Bing; Glick, Meir; Hamann, Lawrence G.; Tommasi, Ruben; Yang, Xia; Dean, Charles R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5002-5014</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Over the past several decades, the frequency of antibacterial resistance in hospitals, including multidrug resistance (MDR) and its assocn. with serious infectious diseases, has increased at alarming rates.  Pseudomonas aeruginosa is a leading cause of nosocomial infections, and resistance to virtually all approved antibacterial agents is emerging in this pathogen.  To address the need for new agents to treat MDR P. aeruginosa, we focused on inhibiting the first committed step in the biosynthesis of lipid A, the deacetylation of uridyldiphospho-3-O-(R-hydroxydecanoyl)-N-acetylglucosamine by the enzyme LpxC.  We approached this through the design, synthesis, and biol. evaluation of novel hydroxamic acid LpxC inhibitors, exemplified by I, where cytotoxicity against mammalian cell lines was reduced, soly. and plasma-protein binding were improved while retaining potent anti-pseudomonal activity in vitro and in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodbG9H5F_ITrVg90H21EOLACvtfcHk0lhjpUKs3EM-yw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXos1SgsLk%253D&md5=ea3fc92a1b15ffed9edd3702395a2b35</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00377&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00377%26sid%3Dliteratum%253Aachs%26aulast%3DPiizzi%26aufirst%3DG.%26aulast%3DParker%26aufirst%3DD.%2BT.%26aulast%3DPeng%26aufirst%3DY.%26aulast%3DDobler%26aufirst%3DM.%26aulast%3DPatnaik%26aufirst%3DA.%26aulast%3DWattanasin%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DE.%26aulast%3DLenoir%26aufirst%3DF.%26aulast%3DNunez%26aufirst%3DJ.%26aulast%3DKerrigan%26aufirst%3DJ.%26aulast%3DMcKenney%26aufirst%3DD.%26aulast%3DOsborne%26aufirst%3DC.%26aulast%3DYu%26aufirst%3DD.%26aulast%3DLanieri%26aufirst%3DL.%26aulast%3DBojkovic%26aufirst%3DJ.%26aulast%3DDzink-Fox%26aufirst%3DJ.%26aulast%3DLilly%26aufirst%3DM.%2BD.%26aulast%3DSprague%26aufirst%3DE.%2BR.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DRanjitkar%26aufirst%3DS.%26aulast%3DXie%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DGlick%26aufirst%3DM.%26aulast%3DHamann%26aufirst%3DL.%2BG.%26aulast%3DTommasi%26aufirst%3DR.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DDean%26aufirst%3DC.%2BR.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520properties%2520of%2520a%2520potent%2520inhibitor%2520of%2520Pseudomonas%2520aeruginosa%2520deacetylase%2520LpxC%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D5002%26epage%3D5014%26doi%3D10.1021%2Facs.jmedchem.7b00377" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lapointe, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madera, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simmons, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yifru, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tjandra, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karur, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rico, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bojkovic, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uehara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellamacina, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKenney, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonn, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osborne, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benton, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDowell, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, Z. K.</span></span> <span> </span><span class="NLM_article-title">Application of virtual screening to the identification of new LpxC inhibitor chemotypes, oxazolidinone and isoxazoline</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">9360</span>– <span class="NLM_lpage">9370</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01287</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01287" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslaqtrvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=9360-9370&author=P.+S.+Leeauthor=G.+Lapointeauthor=A.+M.+Maderaauthor=R.+L.+Simmonsauthor=W.+Xuauthor=A.+Yifruauthor=M.+Tjandraauthor=S.+Karurauthor=A.+Ricoauthor=K.+Thompsonauthor=J.+Bojkovicauthor=L.+Xieauthor=K.+Ueharaauthor=A.+Liuauthor=W.+Shuauthor=C.+Bellamacinaauthor=D.+McKenneyauthor=L.+Morrisauthor=G.+R.+Tonnauthor=C.+Osborneauthor=B.+M.+Bentonauthor=L.+McDowellauthor=J.+Fuauthor=Z.+K.+Sweeney&title=Application+of+virtual+screening+to+the+identification+of+new+LpxC+inhibitor+chemotypes%2C+oxazolidinone+and+isoxazoline&doi=10.1021%2Facs.jmedchem.8b01287"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Application of Virtual Screening to the Identification of New LpxC Inhibitor Chemotypes, Oxazolidinone and Isoxazoline</span></div><div class="casAuthors">Lee, Patrick S.; Lapointe, Guillaume; Madera, Ann Marie; Simmons, Robert L.; Xu, Wenjian; Yifru, Aregahegn; Tjandra, Meiliana; Karur, Subramanian; Rico, Alice; Thompson, Katherine; Bojkovic, Jade; Xie, Lili; Uehara, Kyoko; Liu, Amy; Shu, Wei; Bellamacina, Cornelia; McKenney, David; Morris, Laura; Tonn, George R.; Osborne, Colin; Benton, Bret M.; McDowell, Laura; Fu, Jiping; Sweeney, Zachary K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">9360-9370</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This report summarizes the identification and synthesis of novel LpxC inhibitors aided by computational methods that leveraged numerous crystal structures.  This effort led to the identification of oxazolidinone and isoxazoline inhibitors with potent in vitro activity against P. aeruginosa and other Gram-neg. bacteria.  Representative compd. 13f demonstrated efficacy against P. aeruginosa in a mouse neutropenic thigh infection model.  The antibacterial activity against K. pneumoniae could be potentiated by Gram-pos. antibiotics rifampicin (RIF) and vancomycin (VAN) in both in vitro and in vivo models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphGwLR2DR7VrVg90H21EOLACvtfcHk0lj1dLwhZZpYVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslaqtrvF&md5=73c59bf77a4a9ea5c993d7f935955307</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01287&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01287%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DP.%2BS.%26aulast%3DLapointe%26aufirst%3DG.%26aulast%3DMadera%26aufirst%3DA.%2BM.%26aulast%3DSimmons%26aufirst%3DR.%2BL.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DYifru%26aufirst%3DA.%26aulast%3DTjandra%26aufirst%3DM.%26aulast%3DKarur%26aufirst%3DS.%26aulast%3DRico%26aufirst%3DA.%26aulast%3DThompson%26aufirst%3DK.%26aulast%3DBojkovic%26aufirst%3DJ.%26aulast%3DXie%26aufirst%3DL.%26aulast%3DUehara%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DA.%26aulast%3DShu%26aufirst%3DW.%26aulast%3DBellamacina%26aufirst%3DC.%26aulast%3DMcKenney%26aufirst%3DD.%26aulast%3DMorris%26aufirst%3DL.%26aulast%3DTonn%26aufirst%3DG.%2BR.%26aulast%3DOsborne%26aufirst%3DC.%26aulast%3DBenton%26aufirst%3DB.%2BM.%26aulast%3DMcDowell%26aufirst%3DL.%26aulast%3DFu%26aufirst%3DJ.%26aulast%3DSweeney%26aufirst%3DZ.%2BK.%26atitle%3DApplication%2520of%2520virtual%2520screening%2520to%2520the%2520identification%2520of%2520new%2520LpxC%2520inhibitor%2520chemotypes%252C%2520oxazolidinone%2520and%2520isoxazoline%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D9360%26epage%3D9370%26doi%3D10.1021%2Facs.jmedchem.8b01287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kyin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span> <span> </span><span class="NLM_article-title">Structural and biochemical basis of apoptotic activation by Smac/DIABLO</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>406</i></span>,  <span class="NLM_fpage">855</span>– <span class="NLM_lpage">862</span>, <span class="refDoi"> DOI: 10.1038/35022514</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1038%2F35022514" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10972280" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmsVCrsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=406&publication_year=2000&pages=855-862&author=J.+Chaiauthor=C.+Duauthor=J.+W.+Wuauthor=S.+Kyinauthor=X.+Wangauthor=Y.+Shi&title=Structural+and+biochemical+basis+of+apoptotic+activation+by+Smac%2FDIABLO&doi=10.1038%2F35022514"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and biochemical basis of apoptotic activation by Smac/DIABLO</span></div><div class="casAuthors">Chai, Jijie; Du, Chunying; Wu, Jia-Wei; Kyin, Saw; Wang, Xiaodong; Shi, Yigong</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">406</span>
        (<span class="NLM_cas:issue">6798</span>),
    <span class="NLM_cas:pages">855-862</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Apoptosis (programmed cell death), an essential process in the development and homeostasis of metazoans, is carried out by caspases.  The mitochondrial protein Smac/DIABLO performs a crit. function in apoptosis by eliminating the inhibitory effect of IAPs (inhibitor of apoptosis proteins) on caspases.  Here we show that Smac/DIABLO promotes not only the proteolytic activation of procaspase-3 but also the enzymic activity of mature caspase-3, both of which depend upon its ability to interact phys. with IAPs.  The crystal structure of Smac/DIABLO at 2.2Å resoln. reveals that it homodimerizes through an extensive hydrophobic interface.  Missense mutations inactivating this dimeric interface significantly compromise the function of Smac/DIABLO.  As in the Drosophila proteins Reaper, Grim and Hid, the amino-terminal amino acids of Smac/DIABLO are indispensable for its function, and a seven-residue peptide derived from the amino terminus promotes procaspase-3 activation in vitro.  These results establish an evolutionarily conserved structural and biochem. basis for the activation of apoptosis by Smac/DIABLO.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQ4zPSamJORbVg90H21EOLACvtfcHk0lj1dLwhZZpYVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmsVCrsLk%253D&md5=e3e65405a679b11556fa875b7c5dc9fa</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1038%2F35022514&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35022514%26sid%3Dliteratum%253Aachs%26aulast%3DChai%26aufirst%3DJ.%26aulast%3DDu%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DJ.%2BW.%26aulast%3DKyin%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DShi%26aufirst%3DY.%26atitle%3DStructural%2520and%2520biochemical%2520basis%2520of%2520apoptotic%2520activation%2520by%2520Smac%252FDIABLO%26jtitle%3DNature%26date%3D2000%26volume%3D406%26spage%3D855%26epage%3D862%26doi%3D10.1038%2F35022514" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hennessy, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adam, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aquila, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castriotta, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hattersley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hird, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huntington, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamhi, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laing, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacIntyre, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omer, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oza, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Repik, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rooney, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saeh, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sha, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasbinder, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitston, D.</span></span> <span> </span><span class="NLM_article-title">Discovery of a novel class of dimeric Smac mimetics as potent IAP antagonists resulting in a clinical candidate for the treatment of cancer (AZD5582)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">9897</span>– <span class="NLM_lpage">9919</span>, <span class="refDoi"> DOI: 10.1021/jm401075x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401075x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFWltrjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=9897-9919&author=E.+J.+Hennessyauthor=A.+Adamauthor=B.+M.+Aquilaauthor=L.+M.+Castriottaauthor=D.+Cookauthor=M.+Hattersleyauthor=A.+W.+Hirdauthor=C.+Huntingtonauthor=V.+M.+Kamhiauthor=N.+M.+Laingauthor=D.+Liauthor=T.+MacIntyreauthor=C.+A.+Omerauthor=V.+Ozaauthor=T.+Pattersonauthor=G.+Repikauthor=M.+T.+Rooneyauthor=J.+C.+Saehauthor=L.+Shaauthor=M.+M.+Vasbinderauthor=H.+Wangauthor=D.+Whitston&title=Discovery+of+a+novel+class+of+dimeric+Smac+mimetics+as+potent+IAP+antagonists+resulting+in+a+clinical+candidate+for+the+treatment+of+cancer+%28AZD5582%29&doi=10.1021%2Fjm401075x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Novel Class of Dimeric Smac Mimetics as Potent IAP Antagonists Resulting in a Clinical Candidate for the Treatment of Cancer (AZD5582)</span></div><div class="casAuthors">Hennessy, Edward J.; Adam, Ammar; Aquila, Brian M.; Castriotta, Lillian M.; Cook, Donald; Hattersley, Maureen; Hird, Alexander W.; Huntington, Christopher; Kamhi, Victor M.; Laing, Naomi M.; Li, Danyang; MacIntyre, Terry; Omer, Charles A.; Oza, Vibha; Patterson, Troy; Repik, Galina; Rooney, Michael T.; Saeh, Jamal C.; Sha, Li; Vasbinder, Melissa M.; Wang, Haiyun; Whitston, David</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">9897-9919</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of dimeric compds. based on the AVPI motif of Smac (second mitochondrial activator of caspases) were designed and prepd. as antagonists of the inhibitor of apoptosis proteins (IAPs).  Optimization of cellular potency, phys. properties, and pharmacokinetic parameters led to the identification of compd. 14 (AZD5582), which binds potently to the BIR3 domains of cIAP1, cIAP2, and XIAP (IC50 = 15, 21, and 15 nM, resp.).  This compd. causes cIAP1 degrdn. and induces apoptosis in the MDA-MB-231 breast cancer cell line at subnanomolar concns. in vitro.  When administered i.v. to MDA-MB-231 xenograft-bearing mice, 14 results in cIAP1 degrdn. and caspase-3 cleavage within tumor cells and causes substantial tumor regressions following two weekly doses of 3.0 mg/kg.  Antiproliferative effects are obsd. with 14 in only a small subset of the over 200 cancer cell lines examd., consistent with other published IAP inhibitors.  As a result of its in vitro and in vivo profile, 14 was nominated as a candidate for clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppmeDH06Y5lLVg90H21EOLACvtfcHk0lj1dLwhZZpYVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFWltrjM&md5=9b4a5f7b89ebf74737d86c86acdf9c77</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1021%2Fjm401075x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401075x%26sid%3Dliteratum%253Aachs%26aulast%3DHennessy%26aufirst%3DE.%2BJ.%26aulast%3DAdam%26aufirst%3DA.%26aulast%3DAquila%26aufirst%3DB.%2BM.%26aulast%3DCastriotta%26aufirst%3DL.%2BM.%26aulast%3DCook%26aufirst%3DD.%26aulast%3DHattersley%26aufirst%3DM.%26aulast%3DHird%26aufirst%3DA.%2BW.%26aulast%3DHuntington%26aufirst%3DC.%26aulast%3DKamhi%26aufirst%3DV.%2BM.%26aulast%3DLaing%26aufirst%3DN.%2BM.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DMacIntyre%26aufirst%3DT.%26aulast%3DOmer%26aufirst%3DC.%2BA.%26aulast%3DOza%26aufirst%3DV.%26aulast%3DPatterson%26aufirst%3DT.%26aulast%3DRepik%26aufirst%3DG.%26aulast%3DRooney%26aufirst%3DM.%2BT.%26aulast%3DSaeh%26aufirst%3DJ.%2BC.%26aulast%3DSha%26aufirst%3DL.%26aulast%3DVasbinder%26aufirst%3DM.%2BM.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DWhitston%26aufirst%3DD.%26atitle%3DDiscovery%2520of%2520a%2520novel%2520class%2520of%2520dimeric%2520Smac%2520mimetics%2520as%2520potent%2520IAP%2520antagonists%2520resulting%2520in%2520a%2520clinical%2520candidate%2520for%2520the%2520treatment%2520of%2520cancer%2520%2528AZD5582%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D9897%26epage%3D9919%26doi%3D10.1021%2Fjm401075x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chandraratna, R. A.</span></span> <span> </span><span class="NLM_article-title">Tazarotene: the first receptor-selective topical retinoid for the treatment of psoriasis</span>. <i>J. Am. Acad. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">S12</span>– <span class="NLM_lpage">17</span>, <span class="refDoi"> DOI: 10.1016/S0190-9622(97)80395-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1016%2FS0190-9622%2897%2980395-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=9270551" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1997&pages=S12-17&author=R.+A.+Chandraratna&title=Tazarotene%3A+the+first+receptor-selective+topical+retinoid+for+the+treatment+of+psoriasis&doi=10.1016%2FS0190-9622%2897%2980395-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1016%2FS0190-9622%2897%2980395-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0190-9622%252897%252980395-7%26sid%3Dliteratum%253Aachs%26aulast%3DChandraratna%26aufirst%3DR.%2BA.%26atitle%3DTazarotene%253A%2520the%2520first%2520receptor-selective%2520topical%2520retinoid%2520for%2520the%2520treatment%2520of%2520psoriasis%26jtitle%3DJ.%2520Am.%2520Acad.%2520Dermatol.%26date%3D1997%26volume%3D37%26spage%3DS12%26epage%3D17%26doi%3D10.1016%2FS0190-9622%2897%2980395-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Talele, T. T.</span></span> <span> </span><span class="NLM_article-title">Natural-products-inspired use of the <i>gem</i>-dimethyl group in medicinal chemistry</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">2166</span>– <span class="NLM_lpage">2210</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00315</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00315" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtl2lsLjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=2166-2210&author=T.+T.+Talele&title=Natural-products-inspired+use+of+the+gem-dimethyl+group+in+medicinal+chemistry&doi=10.1021%2Facs.jmedchem.7b00315"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Natural-Products-Inspired Use of the gem-Dimethyl Group in Medicinal Chemistry</span></div><div class="casAuthors">Talele, Tanaji T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2166-2210</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The gem-di-Me moiety is a structural feature frequently found in many natural products of clin. interest, including, but not limited to, taxanes, epothilones, statins, retinoids, di-/triterpenes, noviose deoxysugar, and antibiotics derived from β-lactams, macrolides, and aminocoumarins.  Inspired by this time-tested moiety, medicinal chemists have widely explored its use in developing bioactive mols. because of the possibility to (1) increase target engagement, potency, and selectivity through van der Waals interactions and entropically favorable restriction to a bioactive conformation, (2) mitigate toxicity, (3) obtain superior DMPK profile, (4) modulate the pKa of nearby functionality, (5) induce symmetry into a monomethyl substituted chiral center, and (6) apply the Thorpe-Ingold conformational effect in an o-hydroxydihydrocinnamic acid based prodrug design.  The aim of this Perspective is to illustrate how medicinal chemists have elegantly employed the gem-di-Me group to obtain clin. useful drugs and to provide synthetic methods to install a gem-di-Me group.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdrXsWHYSwO7Vg90H21EOLACvtfcHk0lhRKC4RONi96w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtl2lsLjE&md5=dcb844c4655081b8a38f75696ea2723d</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00315&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00315%26sid%3Dliteratum%253Aachs%26aulast%3DTalele%26aufirst%3DT.%2BT.%26atitle%3DNatural-products-inspired%2520use%2520of%2520the%2520gem-dimethyl%2520group%2520in%2520medicinal%2520chemistry%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D2166%26epage%3D2210%26doi%3D10.1021%2Facs.jmedchem.7b00315" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gehringer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, S. A.</span></span> <span> </span><span class="NLM_article-title">Emerging and re-emerging warheads for targeted covalent inhibitors: Applications in medicinal chemistry and chemical biology</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">5673</span>– <span class="NLM_lpage">5724</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01153</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01153" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFKiur%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=5673-5724&author=M.+Gehringerauthor=S.+A.+Laufer&title=Emerging+and+re-emerging+warheads+for+targeted+covalent+inhibitors%3A+Applications+in+medicinal+chemistry+and+chemical+biology&doi=10.1021%2Facs.jmedchem.8b01153"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging and Re-Emerging Warheads for Targeted Covalent Inhibitors: Applications in Medicinal Chemistry and Chemical Biology</span></div><div class="casAuthors">Gehringer, Matthias; Laufer, Stefan A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5673-5724</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Targeted covalent inhibitors (TCIs) are designed to bind poorly conserved amino acids by means of reactive groups, the so-called warheads.  Currently, targeting noncatalytic cysteine residues with acrylamides and other α,β-unsatd. carbonyl compds. is the predominant strategy in TCI development.  The recent ascent of covalent drugs has stimulated considerable efforts to characterize alternative warheads for the covalent-reversible and irreversible engagement of noncatalytic cysteine residues as well as other amino acids.  This Perspective article provides an overview of warheads-beyond α,β-unsatd. amides-recently used in the design of targeted covalent ligands.  Promising reactive groups that have not yet demonstrated their utility in TCI development are also highlighted.  Special emphasis is placed on the discussion of reactivity and of case studies illustrating applications in medicinal chem. and chem. biol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDhc4PWV293LVg90H21EOLACvtfcHk0lhRKC4RONi96w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFKiur%252FL&md5=4623733558ff99aadebfc13950b816ad</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01153%26sid%3Dliteratum%253Aachs%26aulast%3DGehringer%26aufirst%3DM.%26aulast%3DLaufer%26aufirst%3DS.%2BA.%26atitle%3DEmerging%2520and%2520re-emerging%2520warheads%2520for%2520targeted%2520covalent%2520inhibitors%253A%2520Applications%2520in%2520medicinal%2520chemistry%2520and%2520chemical%2520biology%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D5673%26epage%3D5724%26doi%3D10.1021%2Facs.jmedchem.8b01153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barf, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Covey, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izumi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van de Kar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulrajani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Lith, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Hoek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Zwart, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mittag, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demont, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verkaik, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krantz, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulrich, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaptein, A.</span></span> <span> </span><span class="NLM_article-title">Acalabrutinib (ACP-196): A covalent Bruton Tyrosine Kinase inhibitor with a differentiated selectivity and in vivo potency profile</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>363</i></span>,  <span class="NLM_fpage">240</span>– <span class="NLM_lpage">252</span>, <span class="refDoi"> DOI: 10.1124/jpet.117.242909</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1124%2Fjpet.117.242909" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=28882879" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtleltrnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2017&pages=240-252&author=T.+Barfauthor=T.+Coveyauthor=R.+Izumiauthor=B.+van+de+Karauthor=M.+Gulrajaniauthor=B.+van+Lithauthor=M.+van+Hoekauthor=E.+de+Zwartauthor=D.+Mittagauthor=D.+Demontauthor=S.+Verkaikauthor=F.+Krantzauthor=P.+G.+Pearsonauthor=R.+Ulrichauthor=A.+Kaptein&title=Acalabrutinib+%28ACP-196%29%3A+A+covalent+Bruton+Tyrosine+Kinase+inhibitor+with+a+differentiated+selectivity+and+in+vivo+potency+profile&doi=10.1124%2Fjpet.117.242909"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Acalabrutinib (ACP-196): a covalent Bruton tyrosine kinase inhibitor with a differentiated selectivity and in vivo potency profile</span></div><div class="casAuthors">Barf, Tjeerd; Covey, Todd; Izumi, Raquel; van de Kar, Bas; Gulrajani, Michael; van Lith, Bart; van Hoek, Maaike; de Zwart, Edwin; Mittag, Diana; Demont, Dennis; Verkaik, Saskia; Krantz, Fanny; Pearson, Paul G.; Ulrich, Roger; Kaptein, Allard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">240-252</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Several small-mol. Bruton tyrosine kinase (BTK) inhibitors are in development for B cell malignancies and autoimmune disorders, each characterized by distinct potency and selectivity patterns.  Herein we describe the pharmacol. characterization of BTK inhibitor acalabrutinib [compd. 1, ACP-196 (4-[8- amino-3-[(2S)-1-but-2-ynoylpyrrolidin-2-yl]imidazo[1,5-a]pyrazin1-yl]-N-(2-pyridyl)benzamide)].  Acalabrutinib possesses a reactive butynamide group that binds covalently to Cys481 in BTK.  Relative to the other BTK inhibitors described here, the reduced intrinsic reactivity of acalabrutinib helps to limit inhibition of off-target kinases having cysteine-mediated covalent binding potential.  Acalabrutinib demonstrated higher biochem. and cellular selectivity than ibrutinib and spebrutinib (compds. 2 and 3, resp.).  Importantly, off-target kinases, such as epidermal growth factor receptor (EGFR) and interleukin 2-inducible T cell kinase (ITK), were not inhibited.  Detn. of the inhibitory potential of anti-IgM-induced CD69 expression in human peripheral blood mononuclear cells and whole blood demonstrated that acalabrutinib is a potent functional BTK inhibitor.  In vivo evaluation in mice revealed that acalabrutinib is more potent than ibrutinib and spebrutinib.  Preclin. and clin. studies showed that the level and duration of BTK occupancy correlates with in vivo efficacy.  Evaluation of the pharmacokinetic properties of acalabrutinib in healthy adult volunteers demonstrated rapid absorption and fast elimination.  In these healthy individuals, a single oral dose of 100 mg showed approx. 99% median target coverage at 3 and 12 h and around 90% at 24 h in peripheral B cells.  In conclusion, acalabrutinib is a BTK inhibitor with key pharmacol. differentiators vs. ibrutinib and spebrutinib and is currently being evaluated in clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGol9xhDmwvup7Vg90H21EOLACvtfcHk0lhRKC4RONi96w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtleltrnO&md5=73cbd3a87396abbf8cb20e4361f96f64</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1124%2Fjpet.117.242909&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.117.242909%26sid%3Dliteratum%253Aachs%26aulast%3DBarf%26aufirst%3DT.%26aulast%3DCovey%26aufirst%3DT.%26aulast%3DIzumi%26aufirst%3DR.%26aulast%3Dvan%2Bde%2BKar%26aufirst%3DB.%26aulast%3DGulrajani%26aufirst%3DM.%26aulast%3Dvan%2BLith%26aufirst%3DB.%26aulast%3Dvan%2BHoek%26aufirst%3DM.%26aulast%3Dde%2BZwart%26aufirst%3DE.%26aulast%3DMittag%26aufirst%3DD.%26aulast%3DDemont%26aufirst%3DD.%26aulast%3DVerkaik%26aufirst%3DS.%26aulast%3DKrantz%26aufirst%3DF.%26aulast%3DPearson%26aufirst%3DP.%2BG.%26aulast%3DUlrich%26aufirst%3DR.%26aulast%3DKaptein%26aufirst%3DA.%26atitle%3DAcalabrutinib%2520%2528ACP-196%2529%253A%2520A%2520covalent%2520Bruton%2520Tyrosine%2520Kinase%2520inhibitor%2520with%2520a%2520differentiated%2520selectivity%2520and%2520in%2520vivo%2520potency%2520profile%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2017%26volume%3D363%26spage%3D240%26epage%3D252%26doi%3D10.1124%2Fjpet.117.242909" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walter, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rule, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyer, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cazin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quittet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchinson, C. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffy, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birkett, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamieson, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Courtenay-Luck, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshizawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharpe, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohno, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cartron, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morschhauser, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fegan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salles, G.</span></span> <span> </span><span class="NLM_article-title">A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">411</span>– <span class="NLM_lpage">419</span>, <span class="refDoi"> DOI: 10.1182/blood-2015-08-664086</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1182%2Fblood-2015-08-664086" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=26542378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Cis7zO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2016&pages=411-419&author=H.+S.+Walterauthor=S.+A.+Ruleauthor=M.+J.+Dyerauthor=L.+Karlinauthor=C.+Jonesauthor=B.+Cazinauthor=P.+Quittetauthor=N.+Shahauthor=C.+V.+Hutchinsonauthor=H.+Hondaauthor=K.+Duffyauthor=J.+Birkettauthor=V.+Jamiesonauthor=N.+Courtenay-Luckauthor=T.+Yoshizawaauthor=J.+Sharpeauthor=T.+Ohnoauthor=S.+Abeauthor=A.+Nishimuraauthor=G.+Cartronauthor=F.+Morschhauserauthor=C.+Feganauthor=G.+Salles&title=A+phase+1+clinical+trial+of+the+selective+BTK+inhibitor+ONO%2FGS-4059+in+relapsed+and+refractory+mature+B-cell+malignancies&doi=10.1182%2Fblood-2015-08-664086"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies</span></div><div class="casAuthors">Walter, Harriet S.; Rule, Simon A.; Dyer, Martin J. S.; Karlin, Lionel; Jones, Ceri; Cazin, Bruno; Quittet, Philippe; Shah, Nimish; Hutchinson, Claire V.; Honda, Hideyuki; Duffy, Kevin; Birkett, Joseph; Jamieson, Virginia; Courtenay-Luck, Nigel; Yoshizawa, Toshio; Sharpe, John; Ohno, Tomoya; Abe, Shinichiro; Nishimura, Akihisa; Cartron, Guillaume; Morschhauser, Franck; Fegan, Christopher; Salles, Gilles</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">411-419</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">We report the results of a multicenter phase 1 dose-escalation study of the selective Bruton tyrosine kinase (BTK) inhibitor ONO/GS-4059 in 90 patients with relapsed/refractory B-cell malignancies.  There were 9 dose-escalation cohorts ranging from 20 mg to 600 mg once daily with twice-daily regimens of 240 mg and 300 mg.  Twenty-four of 25 evaluable chronic lymphocytic leukemia (CLL) patients (96%) responded to ONO/GS-4059, with a median treatment duration of 80 wk; 21 CLL patients remain on treatment.  Lymph node responses were rapid and assocd. with a concurrent lymphocytosis.  Eleven of 12 evaluable patients with mantle cell lymphoma (92%) responded (median treatment duration, 40 wk).  Eleven of 31 non-germinal center B-cell diffuse large B-cell lymphoma patients (35%) responded but median treatment duration was 12 wk due to development of progressive disease.  ONO/GS-4059 was very well tolerated with 75% of adverse events (AEs) being Common Toxicity Criteria for Adverse Events version 4.0 grade 1 or grade 2.  Grade 3/4 AEs were mainly hematol. and recovered spontaneously during therapy.  One CLL patient experienced a grade 3 treatment-related bleeding event (spontaneous muscle hematoma) but no clin. significant diarrhea, cardiac dysrhythmias, or arthralgia were obsd.  No maximal tolerated dose (MTD) was reached in the CLL cohort.  In the non-Hodgkin lymphoma cohort, 4 patients developed a dose-limiting toxicity, yielding an MTD of 480 mg once daily.  ONO/GS-4059 has significant activity in relapsed/refractory B-cell malignancies without major drug-related toxicity.  The selectivity of ONO/GS-4059 should confer advantages in combination therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZFfZyaWsIdbVg90H21EOLACvtfcHk0ljTkP0SkWFkBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Cis7zO&md5=f12cd01520c82ddd2067f2b329bd38a9</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1182%2Fblood-2015-08-664086&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2015-08-664086%26sid%3Dliteratum%253Aachs%26aulast%3DWalter%26aufirst%3DH.%2BS.%26aulast%3DRule%26aufirst%3DS.%2BA.%26aulast%3DDyer%26aufirst%3DM.%2BJ.%26aulast%3DKarlin%26aufirst%3DL.%26aulast%3DJones%26aufirst%3DC.%26aulast%3DCazin%26aufirst%3DB.%26aulast%3DQuittet%26aufirst%3DP.%26aulast%3DShah%26aufirst%3DN.%26aulast%3DHutchinson%26aufirst%3DC.%2BV.%26aulast%3DHonda%26aufirst%3DH.%26aulast%3DDuffy%26aufirst%3DK.%26aulast%3DBirkett%26aufirst%3DJ.%26aulast%3DJamieson%26aufirst%3DV.%26aulast%3DCourtenay-Luck%26aufirst%3DN.%26aulast%3DYoshizawa%26aufirst%3DT.%26aulast%3DSharpe%26aufirst%3DJ.%26aulast%3DOhno%26aufirst%3DT.%26aulast%3DAbe%26aufirst%3DS.%26aulast%3DNishimura%26aufirst%3DA.%26aulast%3DCartron%26aufirst%3DG.%26aulast%3DMorschhauser%26aufirst%3DF.%26aulast%3DFegan%26aufirst%3DC.%26aulast%3DSalles%26aufirst%3DG.%26atitle%3DA%2520phase%25201%2520clinical%2520trial%2520of%2520the%2520selective%2520BTK%2520inhibitor%2520ONO%252FGS-4059%2520in%2520relapsed%2520and%2520refractory%2520mature%2520B-cell%2520malignancies%26jtitle%3DBlood%26date%3D2016%26volume%3D127%26spage%3D411%26epage%3D419%26doi%3D10.1182%2Fblood-2015-08-664086" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watterson, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaudoin
Bertrand, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batt, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pattoli, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skala, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obermeier, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vickery, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elzinga, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Discenza, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Arienzo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillooly, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulicicchio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heimrich, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruan, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westhouse, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catlett, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhry, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galella, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tebben, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pokross, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rampulla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allentoff, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallace, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salter-Cid, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macor, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tino, J. A.</span></span> <span> </span><span class="NLM_article-title">Discovery of branebrutinib (BMS-986195): A strategy for identifying a highly potent and selective covalent inhibitor providing rapid in vivo inactivation of Bruton’s tyrosine kinase (BTK)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">3228</span>– <span class="NLM_lpage">3250</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00167</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00167" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC1MXls1aks7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=3228-3250&author=S.+H.+Wattersonauthor=Q.+Liuauthor=M.+Beaudoin%0ABertrandauthor=D.+G.+Battauthor=L.+Liauthor=M.+A.+Pattoliauthor=S.+Skalaauthor=L.+Chengauthor=M.+T.+Obermeierauthor=R.+Mooreauthor=Z.+Yangauthor=R.+Vickeryauthor=P.+A.+Elzingaauthor=L.+Discenzaauthor=C.+D%E2%80%99Arienzoauthor=K.+M.+Gilloolyauthor=T.+L.+Taylorauthor=C.+Pulicicchioauthor=Y.+Zhangauthor=E.+Heimrichauthor=K.+W.+McIntyreauthor=Q.+Ruanauthor=R.+A.+Westhouseauthor=I.+M.+Catlettauthor=N.+Zhengauthor=C.+Chaudhryauthor=J.+Daiauthor=M.+A.+Galellaauthor=A.+J.+Tebbenauthor=M.+Pokrossauthor=J.+Liauthor=R.+Zhaoauthor=D.+Smithauthor=R.+Rampullaauthor=A.+Allentoffauthor=M.+A.+Wallaceauthor=A.+Mathurauthor=L.+Salter-Cidauthor=J.+E.+Macorauthor=P.+H.+Carterauthor=A.+Furaauthor=J.+R.+Burkeauthor=J.+A.+Tino&title=Discovery+of+branebrutinib+%28BMS-986195%29%3A+A+strategy+for+identifying+a+highly+potent+and+selective+covalent+inhibitor+providing+rapid+in+vivo+inactivation+of+Bruton%E2%80%99s+tyrosine+kinase+%28BTK%29&doi=10.1021%2Facs.jmedchem.9b00167"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton's Tyrosine Kinase (BTK)</span></div><div class="casAuthors">Watterson, Scott H.; Liu, Qingjie; Beaudoin Bertrand, Myra; Batt, Douglas G.; Li, Ling; Pattoli, Mark A.; Skala, Stacey; Cheng, Lihong; Obermeier, Mary T.; Moore, Robin; Yang, Zheng; Vickery, Rodney; Elzinga, Paul A.; Discenza, Lorell; D'Arienzo, Celia; Gillooly, Kathleen M.; Taylor, Tracy L.; Pulicicchio, Claudine; Zhang, Yifan; Heimrich, Elizabeth; McIntyre, Kim W.; Ruan, Qian; Westhouse, Richard A.; Catlett, Ian M.; Zheng, Naiyu; Chaudhry, Charu; Dai, Jun; Galella, Michael A.; Tebben, Andrew J.; Pokross, Matt; Li, Jianqing; Zhao, Rulin; Smith, Daniel; Rampulla, Richard; Allentoff, Alban; Wallace, Michael A.; Mathur, Arvind; Salter-Cid, Luisa; Macor, John E.; Carter, Percy H.; Fura, Aberra; Burke, James R.; Tino, Joseph A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3228-3250</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (BTK), a non-receptor tyrosine kinase, is a member of the Tec family of kinases and is essential for B cell receptor (BCR) mediated signaling.  BTK also plays a crit. role in the downstream signaling pathways for the Fcγ receptor in monocytes, the Fcε receptor in granulocytes, and the RANK receptor in osteoclasts.  As a result, pharmacol. inhibition of BTK is anticipated to provide an effective strategy for the clin. treatment of autoimmune diseases such as rheumatoid arthritis and lupus.  This article will outline the evolution of our strategy to identify a covalent, irreversible inhibitor of BTK that has the intrinsic potency, selectivity, and pharmacokinetic properties necessary to provide a rapid rate of inactivation systemically following a very low dose.  With excellent in vivo efficacy and a very desirable tolerability profile, 5a (branebrutinib, BMS-986195) has advanced into clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGr5oQEoebirVg90H21EOLACvtfcHk0ljTkP0SkWFkBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXls1aks7w%253D&md5=2d521ec7c06d503f940cb44d381af58d</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00167%26sid%3Dliteratum%253Aachs%26aulast%3DWatterson%26aufirst%3DS.%2BH.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DBeaudoin%2BBertrand%26aufirst%3DM.%26aulast%3DBatt%26aufirst%3DD.%2BG.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DPattoli%26aufirst%3DM.%2BA.%26aulast%3DSkala%26aufirst%3DS.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DObermeier%26aufirst%3DM.%2BT.%26aulast%3DMoore%26aufirst%3DR.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DVickery%26aufirst%3DR.%26aulast%3DElzinga%26aufirst%3DP.%2BA.%26aulast%3DDiscenza%26aufirst%3DL.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%26aulast%3DGillooly%26aufirst%3DK.%2BM.%26aulast%3DTaylor%26aufirst%3DT.%2BL.%26aulast%3DPulicicchio%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHeimrich%26aufirst%3DE.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DRuan%26aufirst%3DQ.%26aulast%3DWesthouse%26aufirst%3DR.%2BA.%26aulast%3DCatlett%26aufirst%3DI.%2BM.%26aulast%3DZheng%26aufirst%3DN.%26aulast%3DChaudhry%26aufirst%3DC.%26aulast%3DDai%26aufirst%3DJ.%26aulast%3DGalella%26aufirst%3DM.%2BA.%26aulast%3DTebben%26aufirst%3DA.%2BJ.%26aulast%3DPokross%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DR.%26aulast%3DSmith%26aufirst%3DD.%26aulast%3DRampulla%26aufirst%3DR.%26aulast%3DAllentoff%26aufirst%3DA.%26aulast%3DWallace%26aufirst%3DM.%2BA.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DSalter-Cid%26aufirst%3DL.%26aulast%3DMacor%26aufirst%3DJ.%2BE.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DFura%26aufirst%3DA.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26aulast%3DTino%26aufirst%3DJ.%2BA.%26atitle%3DDiscovery%2520of%2520branebrutinib%2520%2528BMS-986195%2529%253A%2520A%2520strategy%2520for%2520identifying%2520a%2520highly%2520potent%2520and%2520selective%2520covalent%2520inhibitor%2520providing%2520rapid%2520in%2520vivo%2520inactivation%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528BTK%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D3228%26epage%3D3250%26doi%3D10.1021%2Facs.jmedchem.9b00167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hayward, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faragher, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pillai, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagan, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fry, A. M.</span></span> <span> </span><span class="NLM_article-title">The centrosomal kinase Nek2 displays elevated levels of protein expression in human breast cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">7370</span>– <span class="NLM_lpage">7376</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-04-0960</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1158%2F0008-5472.CAN-04-0960" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=15492258" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD2cXosFyntLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=7370-7376&author=D.+G.+Haywardauthor=R.+B.+Clarkeauthor=A.+J.+Faragherauthor=M.+R.+Pillaiauthor=I.+M.+Haganauthor=A.+M.+Fry&title=The+centrosomal+kinase+Nek2+displays+elevated+levels+of+protein+expression+in+human+breast+cancer&doi=10.1158%2F0008-5472.CAN-04-0960"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">The Centrosomal Kinase Nek2 Displays Elevated Levels of Protein Expression in Human Breast Cancer</span></div><div class="casAuthors">Hayward, Daniel G.; Clarke, Robert B.; Faragher, Alison J.; Pillai, Meenu R.; Hagan, Iain M.; Fry, Andrew M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7370-7376</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Aneuploidy and chromosome instability are common abnormalities in human cancer.  Loss of control over mitotic progression, multipolar spindle formation, and cytokinesis defects are all likely to contribute to these phenotypes.  Nek2 is a cell cycle-regulated protein kinase with maximal activity at the onset of mitosis that localizes to the centrosome.  Functional studies have implicated Nek2 in regulation of centrosome sepn. and spindle formation.  Here, the authors present the first study of the protein expression levels of the Nek2 kinase in human cancer cell lines and primary tumors.  Nek2 protein is elevated 2- to 5-fold in cell lines derived from a range of human tumors including those of cervical, ovarian, breast, prostate, and leukemic origin.  Most importantly, by immunohistochem., the authors find that Nek2 protein is significantly up-regulated in preinvasive in situ ductal carcinomas of the breast as well as in invasive breast carcinomas.  Finally, by ectopic expression of Nek2A in immortalized HBL100 breast epithelial cells, the authors show that increased Nek2 protein leads to accumulation of multinucleated cells with supernumerary centrosomes.  These data highlight the Nek2 kinase as novel potential target for chemotherapeutic intervention in breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4ko1rEDu8fbVg90H21EOLACvtfcHk0lhLN8Tw5ZKENw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXosFyntLc%253D&md5=10b8d50fa1025dd8013fced43532e4c2</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-04-0960&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-04-0960%26sid%3Dliteratum%253Aachs%26aulast%3DHayward%26aufirst%3DD.%2BG.%26aulast%3DClarke%26aufirst%3DR.%2BB.%26aulast%3DFaragher%26aufirst%3DA.%2BJ.%26aulast%3DPillai%26aufirst%3DM.%2BR.%26aulast%3DHagan%26aufirst%3DI.%2BM.%26aulast%3DFry%26aufirst%3DA.%2BM.%26atitle%3DThe%2520centrosomal%2520kinase%2520Nek2%2520displays%2520elevated%2520levels%2520of%2520protein%2520expression%2520in%2520human%2520breast%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26spage%3D7370%26epage%3D7376%26doi%3D10.1158%2F0008-5472.CAN-04-0960" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andreasson, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dictor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jerkeman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berglund, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sundstrom, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linderoth, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenquist, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borrebaeck, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ek, S.</span></span> <span> </span><span class="NLM_article-title">Identification of molecular targets associated with transformed diffuse large B cell lymphoma using highly purified tumor cells</span>. <i>Am. J. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">803</span>– <span class="NLM_lpage">808</span>, <span class="refDoi"> DOI: 10.1002/ajh.21549</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1002%2Fajh.21549" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=19844990" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjslOmsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2009&pages=803-808&author=U.+Andreassonauthor=M.+Dictorauthor=M.+Jerkemanauthor=M.+Berglundauthor=C.+Sundstromauthor=J.+Linderothauthor=R.+Rosenquistauthor=C.+A.+Borrebaeckauthor=S.+Ek&title=Identification+of+molecular+targets+associated+with+transformed+diffuse+large+B+cell+lymphoma+using+highly+purified+tumor+cells&doi=10.1002%2Fajh.21549"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of molecular targets associated with transformed diffuse large B cell lymphoma using highly purified tumor cells</span></div><div class="casAuthors">Andreasson, Ulrika; Dictor, Michael; Jerkeman, Mats; Berglund, Mattias; Sundstroem, Christer; Linderoth, Johan; Rosenquist, Richard; Borrebaeck, Carl A. K.; Ek, Sara</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Hematology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">803-808</span>CODEN:
                <span class="NLM_cas:coden">AJHEDD</span>;
        ISSN:<span class="NLM_cas:issn">0361-8609</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Follicular lymphoma (FL) frequently transforms into the more aggressive diffuse large B cell lymphoma (DLBCL-tr), but no protein biomarkers have been identified for predictive or early diagnosis.  Gene expression analyses have identified genes changing on transformation but have failed to be reproducible in different studies, reflecting the heterogeneity within the tumor tissue and between tumor samples.  Gene expression analyses on Affymetrix Human Genome U133 Plus 2.0 arrays were performed, using flow cytometry sorted tumor cells derived from FL and transformed DLBCL.  To identify mol. targets assocd. with the transformation, subsequent immunohistochem. (IHC) analyses of the corresponding proteins were performed.  Using highly purified cells, this study identified 163 genes, which were significantly deregulated during the transformation in a majority of cases.  Among the upregulated transcripts, 13 genes were selected for validation using IHC, based on the availability of com. antibodies, and galectin-3 and NEK2 proteins specifically identify DLBCL-tr, when compared with FL.  We demonstrate that by purifying tumor cells through cell sorting, thereby reducing the heterogeneity due to infiltrating cells, it was possible to identify distinct differences between tumor entities rather than variations due to cellular compn.  Galectin-3 and NEK2 both identified a subgroup of DLBCL-tr, and the function of these protein markers also suggests a biol. role in the transformation process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpprkSM8SoOcrVg90H21EOLACvtfcHk0lhLN8Tw5ZKENw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjslOmsA%253D%253D&md5=8e1a1cb183a5a11a28efdf011c8bb52f</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1002%2Fajh.21549&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fajh.21549%26sid%3Dliteratum%253Aachs%26aulast%3DAndreasson%26aufirst%3DU.%26aulast%3DDictor%26aufirst%3DM.%26aulast%3DJerkeman%26aufirst%3DM.%26aulast%3DBerglund%26aufirst%3DM.%26aulast%3DSundstrom%26aufirst%3DC.%26aulast%3DLinderoth%26aufirst%3DJ.%26aulast%3DRosenquist%26aufirst%3DR.%26aulast%3DBorrebaeck%26aufirst%3DC.%2BA.%26aulast%3DEk%26aufirst%3DS.%26atitle%3DIdentification%2520of%2520molecular%2520targets%2520associated%2520with%2520transformed%2520diffuse%2520large%2520B%2520cell%2520lymphoma%2520using%2520highly%2520purified%2520tumor%2520cells%26jtitle%3DAm.%2520J.%2520Hematol.%26date%3D2009%26volume%3D84%26spage%3D803%26epage%3D808%26doi%3D10.1002%2Fajh.21549" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Henise, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taunton, J.</span></span> <span> </span><span class="NLM_article-title">Irreversible Nek2 kinase inhibitors with cellular activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">4133</span>– <span class="NLM_lpage">4146</span>, <span class="refDoi"> DOI: 10.1021/jm200222m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200222m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmslGlsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=4133-4146&author=J.+C.+Heniseauthor=J.+Taunton&title=Irreversible+Nek2+kinase+inhibitors+with+cellular+activity&doi=10.1021%2Fjm200222m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Irreversible Nek2 Kinase Inhibitors with Cellular Activity</span></div><div class="casAuthors">Henise, Jeffrey C.; Taunton, Jack</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4133-4146</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A structure-based approach was used to design irreversible, cysteine-targeted inhibitors of the human centrosomal kinase, Nek2.  Potent inhibition of Nek2 kinase activity in biochem. and cell-based assays required a noncatalytic cysteine residue (Cys22), located near the glycine-rich loop in a subset of human kinases.  Elaboration of an oxindole scaffold led to our most selective compd., oxindole propynamide 16 (JH295).  Propynamide 16 irreversibly inhibited cellular Nek2 without affecting the mitotic kinases, Cdk1, Aurora B, or Plk1.  Moreover, 16 did not perturb bipolar spindle assembly or the spindle assembly checkpoint.  To our knowledge, 16 is the first small mol. shown to inactivate Nek2 kinase activity in cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpq8mOvaT5BPbVg90H21EOLACvtfcHk0lhLN8Tw5ZKENw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmslGlsb4%253D&md5=35277e74fc346501e4847bba6586f9d0</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1021%2Fjm200222m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200222m%26sid%3Dliteratum%253Aachs%26aulast%3DHenise%26aufirst%3DJ.%2BC.%26aulast%3DTaunton%26aufirst%3DJ.%26atitle%3DIrreversible%2520Nek2%2520kinase%2520inhibitors%2520with%2520cellular%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D4133%26epage%3D4146%26doi%3D10.1021%2Fjm200222m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Moigne, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Djakovic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valle, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiss von
Soly, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madriaga, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soriano, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menon, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kampmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weissman, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aftab, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yakes, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shawver, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wustrow, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolfe, M.</span></span> <span> </span><span class="NLM_article-title">Targeting the AAA ATPase p97 as an approach to treat cancer through disruption of protein homeostasis</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">653</span>– <span class="NLM_lpage">665</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2015.10.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1016%2Fj.ccell.2015.10.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=26555175" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVSksr%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2015&pages=653-665&author=D.+J.+Andersonauthor=R.+Le+Moigneauthor=S.+Djakovicauthor=B.+Kumarauthor=J.+Riceauthor=S.+Wongauthor=J.+Wangauthor=B.+Yaoauthor=E.+Valleauthor=S.+Kiss+von%0ASolyauthor=A.+Madriagaauthor=F.+Sorianoauthor=M.+K.+Menonauthor=Z.+Y.+Wuauthor=M.+Kampmannauthor=Y.+Chenauthor=J.+S.+Weissmanauthor=B.+T.+Aftabauthor=F.+M.+Yakesauthor=L.+Shawverauthor=H.+J.+Zhouauthor=D.+Wustrowauthor=M.+Rolfe&title=Targeting+the+AAA+ATPase+p97+as+an+approach+to+treat+cancer+through+disruption+of+protein+homeostasis&doi=10.1016%2Fj.ccell.2015.10.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the AAA ATPase p97 as an Approach to Treat Cancer through Disruption of Protein Homeostasis</span></div><div class="casAuthors">Anderson, Daniel J.; Le Moigne, Ronan; Djakovic, Stevan; Kumar, Brajesh; Rice, Julie; Wong, Steve; Wang, Jinhai; Yao, Bing; Valle, Eduardo; Kiss von Soly, Szerenke; Madriaga, Antonett; Soriano, Ferdie; Menon, Mary-Kamala; Wu, Zhi Yong; Kampmann, Martin; Chen, Yuwen; Weissman, Jonathan S.; Aftab, Blake T.; Yakes, F. Michael; Shawver, Laura; Zhou, Han-Jie; Wustrow, David; Rolfe, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">653-665</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">P97 is a AAA-ATPase with multiple cellular functions, one of which is crit. regulation of protein homeostasis pathways.  We describe the characterization of CB-5083, a potent, selective, and orally bioavailable inhibitor of p97.  Treatment of tumor cells with CB-5083 leads to accumulation of poly-ubiquitinated proteins, retention of endoplasmic reticulum-assocd. degrdn. (ERAD) substrates, and generation of irresolvable proteotoxic stress, leading to activation of the apoptotic arm of the unfolded protein response.  In xenograft models, CB-5083 causes modulation of key p97-related pathways, induces apoptosis, and has antitumor activity in a broad range of both hematol. and solid tumor models.  Mol. determinants of CB-5083 activity include expression of genes in the ERAD pathway, providing a potential strategy for patient selection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7c4WXhvOlYLVg90H21EOLACvtfcHk0lji-RE02Z9aXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVSksr%252FN&md5=662df92598397deba1586e8993f2bb7a</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2015.10.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2015.10.002%26sid%3Dliteratum%253Aachs%26aulast%3DAnderson%26aufirst%3DD.%2BJ.%26aulast%3DLe%2BMoigne%26aufirst%3DR.%26aulast%3DDjakovic%26aufirst%3DS.%26aulast%3DKumar%26aufirst%3DB.%26aulast%3DRice%26aufirst%3DJ.%26aulast%3DWong%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DYao%26aufirst%3DB.%26aulast%3DValle%26aufirst%3DE.%26aulast%3DKiss%2Bvon%2BSoly%26aufirst%3DS.%26aulast%3DMadriaga%26aufirst%3DA.%26aulast%3DSoriano%26aufirst%3DF.%26aulast%3DMenon%26aufirst%3DM.%2BK.%26aulast%3DWu%26aufirst%3DZ.%2BY.%26aulast%3DKampmann%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DWeissman%26aufirst%3DJ.%2BS.%26aulast%3DAftab%26aufirst%3DB.%2BT.%26aulast%3DYakes%26aufirst%3DF.%2BM.%26aulast%3DShawver%26aufirst%3DL.%26aulast%3DZhou%26aufirst%3DH.%2BJ.%26aulast%3DWustrow%26aufirst%3DD.%26aulast%3DRolfe%26aufirst%3DM.%26atitle%3DTargeting%2520the%2520AAA%2520ATPase%2520p97%2520as%2520an%2520approach%2520to%2520treat%2520cancer%2520through%2520disruption%2520of%2520protein%2520homeostasis%26jtitle%3DCancer%2520Cell%26date%3D2015%26volume%3D28%26spage%3D653%26epage%3D665%26doi%3D10.1016%2Fj.ccell.2015.10.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Djakovic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valle, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soriano, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menon, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madriaga, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiss von
Soly, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parlati, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yakes, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shawver, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Moigne, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolfe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wustrow, D.</span></span> <span> </span><span class="NLM_article-title">Discovery of a first-in-class, potent, selective, and orally bioavailable inhibitor of the p97 AAA ATPase (CB-5083)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">9480</span>– <span class="NLM_lpage">9497</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01346</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01346" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVahtL3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=9480-9497&author=H.+J.+Zhouauthor=J.+Wangauthor=B.+Yaoauthor=S.+Wongauthor=S.+Djakovicauthor=B.+Kumarauthor=J.+Riceauthor=E.+Valleauthor=F.+Sorianoauthor=M.+K.+Menonauthor=A.+Madriagaauthor=S.+Kiss+von%0ASolyauthor=A.+Kumarauthor=F.+Parlatiauthor=F.+M.+Yakesauthor=L.+Shawverauthor=R.+Le+Moigneauthor=D.+J.+Andersonauthor=M.+Rolfeauthor=D.+Wustrow&title=Discovery+of+a+first-in-class%2C+potent%2C+selective%2C+and+orally+bioavailable+inhibitor+of+the+p97+AAA+ATPase+%28CB-5083%29&doi=10.1021%2Facs.jmedchem.5b01346"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a First-in-Class, Potent, Selective, and Orally Bioavailable Inhibitor of the p97 AAA ATPase (CB-5083)</span></div><div class="casAuthors">Zhou, Han-Jie; Wang, Jinhai; Yao, Bing; Wong, Steve; Djakovic, Stevan; Kumar, Brajesh; Rice, Julie; Valle, Eduardo; Soriano, Ferdie; Menon, Mary-Kamala; Madriaga, Antonett; Kiss von Soly, Szerenke; Kumar, Abhinav; Parlati, Francesco; Yakes, F. Michael; Shawver, Laura; Le Moigne, Ronan; Anderson, Daniel J.; Rolfe, Mark; Wustrow, David</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">9480-9497</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The AAA-ATPase p97 plays vital roles in mechanisms of protein homeostasis, including ubiquitin-proteasome system (UPS) mediated protein degrdn., endoplasmic reticulum-assocd. degrdn. (ERAD), and autophagy.  Herein we describe our lead optimization efforts focused on in vitro potency, ADME, and pharmaceutical properties that led to the discovery of a potent, ATP-competitive, D2-selective, and orally bioavailable p97 inhibitor 71, CB-5083 (I).  Treatment of tumor cells with 71 leads to significant accumulation of markers assocd. with inhibition of UPS and ERAD functions, which induces irresolvable proteotoxic stress and cell death.  In tumor bearing mice, oral administration of 71 causes rapid accumulation of markers of the unfolded protein response (UPR) and subsequently induces apoptosis leading to sustained antitumor activity in in vivo xenograft models of both solid and hematol. tumors. 71 has been taken into phase 1 clin. trials in patients with multiple myeloma and solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGok_KA_ARhOyLVg90H21EOLACvtfcHk0lji-RE02Z9aXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVahtL3K&md5=9e124f8653d0b9ea7f0eba5f4b2a4412</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01346&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01346%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DH.%2BJ.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DYao%26aufirst%3DB.%26aulast%3DWong%26aufirst%3DS.%26aulast%3DDjakovic%26aufirst%3DS.%26aulast%3DKumar%26aufirst%3DB.%26aulast%3DRice%26aufirst%3DJ.%26aulast%3DValle%26aufirst%3DE.%26aulast%3DSoriano%26aufirst%3DF.%26aulast%3DMenon%26aufirst%3DM.%2BK.%26aulast%3DMadriaga%26aufirst%3DA.%26aulast%3DKiss%2Bvon%2BSoly%26aufirst%3DS.%26aulast%3DKumar%26aufirst%3DA.%26aulast%3DParlati%26aufirst%3DF.%26aulast%3DYakes%26aufirst%3DF.%2BM.%26aulast%3DShawver%26aufirst%3DL.%26aulast%3DLe%2BMoigne%26aufirst%3DR.%26aulast%3DAnderson%26aufirst%3DD.%2BJ.%26aulast%3DRolfe%26aufirst%3DM.%26aulast%3DWustrow%26aufirst%3DD.%26atitle%3DDiscovery%2520of%2520a%2520first-in-class%252C%2520potent%252C%2520selective%252C%2520and%2520orally%2520bioavailable%2520inhibitor%2520of%2520the%2520p97%2520AAA%2520ATPase%2520%2528CB-5083%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D9480%26epage%3D9497%26doi%3D10.1021%2Facs.jmedchem.5b01346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ding, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span> <span> </span><span class="NLM_article-title">Discovery of irreversible p97 inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">2814</span>– <span class="NLM_lpage">2829</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00144</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00144" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjvFyjs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=2814-2829&author=R.+Dingauthor=T.+Zhangauthor=D.+J.+Wilsonauthor=J.+Xieauthor=J.+Williamsauthor=Y.+Xuauthor=Y.+Yeauthor=L.+Chen&title=Discovery+of+irreversible+p97+inhibitors&doi=10.1021%2Facs.jmedchem.9b00144"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Irreversible p97 Inhibitors</span></div><div class="casAuthors">Ding, Rui; Zhang, Ting; Wilson, Daniel J.; Xie, Jiashu; Williams, Jessica; Xu, Yue; Ye, Yihong; Chen, Liqiang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2814-2829</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibitors of human p97 (also known as valosin-contg. protein) have been actively pursued because of their potential therapeutic applications in cancer and other diseases.  However, covalent and irreversible p97 inhibitors have not been well explored.  Herein, we report our design, synthesis, and biol. evaluation of covalent and irreversible inhibitors of p97.  Among an amide and a reverse amide series we synthesized, we have identified a p97 inhibitor whose functional irreversibility has been established both in vitro and in cells.  Also importantly, mass spectrometry reveals three potential cysteine residues labeled by this compd., and mutagenesis together with computer modeling suggests Cys522 as a major site, which when modified, could compromise the function of p97.  Taken together, this new inhibitor may provide a template for designing more potent p97 inhibitors with covalent and irreversible characteristics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrL1fyf_-hDOLVg90H21EOLACvtfcHk0lji-RE02Z9aXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjvFyjs74%253D&md5=313f9befff986d93967d4c1e9d631517</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00144&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00144%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DWilson%26aufirst%3DD.%2BJ.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DWilliams%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DYe%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DL.%26atitle%3DDiscovery%2520of%2520irreversible%2520p97%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D2814%26epage%3D2829%26doi%3D10.1021%2Facs.jmedchem.9b00144" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wood, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shewchuk, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brignola, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brashear, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caferro, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickerson, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickson, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donaldson, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaul, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassell, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keith, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrov, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reno, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusnak, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tadepalli, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulrich, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanderwall, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waterson, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uehling, D. E.</span></span> <span> </span><span class="NLM_article-title">6-Ethynylthieno[3,2-d]- and 6-ethynylthieno[2,3-d]pyrimidin-4-anilines as tunable covalent modifiers of ErbB kinases</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">2773</span>– <span class="NLM_lpage">2778</span>, <span class="refDoi"> DOI: 10.1073/pnas.0708281105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1073%2Fpnas.0708281105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=18287036" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjtVSjtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=2773-2778&author=E.+R.+Woodauthor=L.+M.+Shewchukauthor=B.+Ellisauthor=P.+Brignolaauthor=R.+L.+Brashearauthor=T.+R.+Caferroauthor=S.+H.+Dickersonauthor=H.+D.+Dicksonauthor=K.+H.+Donaldsonauthor=M.+Gaulauthor=R.+J.+Griffinauthor=A.+M.+Hassellauthor=B.+Keithauthor=R.+Mullinauthor=K.+G.+Petrovauthor=M.+J.+Renoauthor=D.+W.+Rusnakauthor=S.+M.+Tadepalliauthor=J.+C.+Ulrichauthor=C.+D.+Wagnerauthor=D.+E.+Vanderwallauthor=A.+G.+Watersonauthor=J.+D.+Williamsauthor=W.+L.+Whiteauthor=D.+E.+Uehling&title=6-Ethynylthieno%5B3%2C2-d%5D-+and+6-ethynylthieno%5B2%2C3-d%5Dpyrimidin-4-anilines+as+tunable+covalent+modifiers+of+ErbB+kinases&doi=10.1073%2Fpnas.0708281105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">6-Ethynylthieno[3,2-d]- and 6-ethynylthieno[2,3-d]pyrimidin-4-anilines as tunable covalent modifiers of ErbB kinases</span></div><div class="casAuthors">Wood, Edgar R.; Shewchuk, Lisa M.; Ellis, Byron; Brignola, Perry; Brashear, Ronald L.; Caferro, Thomas R.; Dickerson, Scott H.; Dickson, Hamilton D.; Donaldson, Kelly H.; Gaule, Michael; Griffin, Robert J.; Hassell, Anne M.; Keith, Barry; Mullin, Robert; Petrov, Kimberly G.; Reno, Michael J.; Rusnak, David W.; Tadepalli, Sarva M.; Ulrich, John C.; Wagner, Craig D.; Vanderwall, Dana E.; Waterson, Alex G.; Williams, Jon D.; White, Wendy L.; Uehling, David E.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2773-2778</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Anal. of the x-ray crystal structure of mono-substituted acetylenic thienopyrimidine 6 complexed with the ErbB family enzyme ErbB-4 revealed a covalent bond between the terminal carbon of the acetylene moiety and the sulfhydryl group of Cys-803 at the solvent interface.  The identification of this covalent adduct suggested that acetylenic thienopyrimidine 6 and related analogs might also be capable of forming an analogous covalent adduct with EGFR, which has a conserved cysteine (797) near the ATP binding pocket.  To test this hypothesis, we treated a truncated, catalytically competent form of EGFR (678-1020) with a structurally related propargylic amine (8).  An investigation of the resulting complex by mass spectrometry revealed the formation of a covalent complex of thienopyrimidine 8 with Cys-797 of EGFR.  This finding enabled us to readily assess the irreversibility of various inhibitors and also facilitated a structure-activity relation understanding of the covalent modifying potential and biol. activity of a series of acetylenic thienopyrimidine compds. with potent antitumor activity.  Several ErbB family enzyme and cell potent 6-ethynyl thienopyrimidine kinase inhibitors were found to form covalent adducts with EGFR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNoM38Ky48ELVg90H21EOLACvtfcHk0lgD4XELtcfsWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjtVSjtbw%253D&md5=fbfeeff1f03e8f7fb2c9e228231ff92e</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0708281105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0708281105%26sid%3Dliteratum%253Aachs%26aulast%3DWood%26aufirst%3DE.%2BR.%26aulast%3DShewchuk%26aufirst%3DL.%2BM.%26aulast%3DEllis%26aufirst%3DB.%26aulast%3DBrignola%26aufirst%3DP.%26aulast%3DBrashear%26aufirst%3DR.%2BL.%26aulast%3DCaferro%26aufirst%3DT.%2BR.%26aulast%3DDickerson%26aufirst%3DS.%2BH.%26aulast%3DDickson%26aufirst%3DH.%2BD.%26aulast%3DDonaldson%26aufirst%3DK.%2BH.%26aulast%3DGaul%26aufirst%3DM.%26aulast%3DGriffin%26aufirst%3DR.%2BJ.%26aulast%3DHassell%26aufirst%3DA.%2BM.%26aulast%3DKeith%26aufirst%3DB.%26aulast%3DMullin%26aufirst%3DR.%26aulast%3DPetrov%26aufirst%3DK.%2BG.%26aulast%3DReno%26aufirst%3DM.%2BJ.%26aulast%3DRusnak%26aufirst%3DD.%2BW.%26aulast%3DTadepalli%26aufirst%3DS.%2BM.%26aulast%3DUlrich%26aufirst%3DJ.%2BC.%26aulast%3DWagner%26aufirst%3DC.%2BD.%26aulast%3DVanderwall%26aufirst%3DD.%2BE.%26aulast%3DWaterson%26aufirst%3DA.%2BG.%26aulast%3DWilliams%26aufirst%3DJ.%2BD.%26aulast%3DWhite%26aufirst%3DW.%2BL.%26aulast%3DUehling%26aufirst%3DD.%2BE.%26atitle%3D6-Ethynylthieno%255B3%252C2-d%255D-%2520and%25206-ethynylthieno%255B2%252C3-d%255Dpyrimidin-4-anilines%2520as%2520tunable%2520covalent%2520modifiers%2520of%2520ErbB%2520kinases%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26spage%3D2773%26epage%3D2778%26doi%3D10.1073%2Fpnas.0708281105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arkona, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rademann, J.</span></span> <span> </span><span class="NLM_article-title">Propargyl amides as irreversible inhibitors of cysteine proteases--a lesson on the biological reactivity of alkynes</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">8210</span>– <span class="NLM_lpage">8212</span>, <span class="refDoi"> DOI: 10.1002/anie.201303544</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1002%2Fanie.201303544" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpvVeqtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2013&pages=8210-8212&author=C.+Arkonaauthor=J.+Rademann&title=Propargyl+amides+as+irreversible+inhibitors+of+cysteine+proteases%2D%2Da+lesson+on+the+biological+reactivity+of+alkynes&doi=10.1002%2Fanie.201303544"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Propargyl Amides as Irreversible Inhibitors of Cysteine Proteases-A Lesson on the Biological Reactivity of Alkynes</span></div><div class="casAuthors">Arkona, Christoph; Rademann, Joerg</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">8210-8212</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Ubiquitin like proteins are transferred to target proteins and bound by means of isopeptide bonds in an ATP driven enzymic transfer reaction with thioester intermediates.  Modified target proteins are often driven towards degrdn.  De-ubiquitinating enzymes (DUB) are capable of hydrolyzing the isopeptide bonds thereby reliberating ubiquitin-like proteins and target proteins.  This review discusses the role of DUBs in health and disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppalwwtDnPW7Vg90H21EOLACvtfcHk0lgD4XELtcfsWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpvVeqtb0%253D&md5=18ee2b226627f5bf11f4ac54ff365884</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1002%2Fanie.201303544&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201303544%26sid%3Dliteratum%253Aachs%26aulast%3DArkona%26aufirst%3DC.%26aulast%3DRademann%26aufirst%3DJ.%26atitle%3DPropargyl%2520amides%2520as%2520irreversible%2520inhibitors%2520of%2520cysteine%2520proteases--a%2520lesson%2520on%2520the%2520biological%2520reactivity%2520of%2520alkynes%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2013%26volume%3D52%26spage%3D8210%26epage%3D8212%26doi%3D10.1002%2Fanie.201303544" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ekkebus, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Kasteren, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulathu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scholten, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berlin, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geurink, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Jong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goerdayal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neefjes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heck, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komander, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ovaa, H.</span></span> <span> </span><span class="NLM_article-title">On terminal alkynes that can react with active-site cysteine nucleophiles in proteases</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>135</i></span>,  <span class="NLM_fpage">2867</span>– <span class="NLM_lpage">2870</span>, <span class="refDoi"> DOI: 10.1021/ja309802n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja309802n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC3sXit1Sqtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=135&publication_year=2013&pages=2867-2870&author=R.+Ekkebusauthor=S.+I.+van+Kasterenauthor=Y.+Kulathuauthor=A.+Scholtenauthor=I.+Berlinauthor=P.+P.+Geurinkauthor=A.+de+Jongauthor=S.+Goerdayalauthor=J.+Neefjesauthor=A.+J.+Heckauthor=D.+Komanderauthor=H.+Ovaa&title=On+terminal+alkynes+that+can+react+with+active-site+cysteine+nucleophiles+in+proteases&doi=10.1021%2Fja309802n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">On Terminal Alkynes That Can React with Active-Site Cysteine Nucleophiles in Proteases</span></div><div class="casAuthors">Ekkebus, Reggy; van Kasteren, Sander I.; Kulathu, Yogesh; Scholten, Arjen; Berlin, Ilana; Geurink, Paul P.; de Jong, Annemieke; Goerdayal, Soenita; Neefjes, Jacques; Heck, Albert J. R.; Komander, David; Ovaa, Huib</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">135</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2867-2870</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Active-site directed probes are powerful in studies of enzymic function.  We report an active-site directed probe based on a warhead so far considered unreactive.  By replacing the C-terminal carboxylate of ubiquitin (Ub) with an alkyne functionality, a selective reaction with the active-site cysteine residue of deubiquitinating enzymes (DUBs) was obsd.  The resulting product was shown to be a quaternary vinyl thioether, as detd. by X-ray crystallog.  Proteomic anal. of proteins bound to an immobilized Ub alkyne probe confirmed the selectivity toward deubiquitinating enzymes.  The obsd. reactivity is not just restricted to propargylated Ub, as highlighted by the selective reaction between caspase-1 (interleukin converting enzyme) and a propargylated peptide derived from IL-1β, a caspase-1 substrate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtg0tt7PzZcbVg90H21EOLACvtfcHk0lgD4XELtcfsWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXit1Sqtbc%253D&md5=d0f813975b6dae3de723facd0b78e47f</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1021%2Fja309802n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja309802n%26sid%3Dliteratum%253Aachs%26aulast%3DEkkebus%26aufirst%3DR.%26aulast%3Dvan%2BKasteren%26aufirst%3DS.%2BI.%26aulast%3DKulathu%26aufirst%3DY.%26aulast%3DScholten%26aufirst%3DA.%26aulast%3DBerlin%26aufirst%3DI.%26aulast%3DGeurink%26aufirst%3DP.%2BP.%26aulast%3Dde%2BJong%26aufirst%3DA.%26aulast%3DGoerdayal%26aufirst%3DS.%26aulast%3DNeefjes%26aufirst%3DJ.%26aulast%3DHeck%26aufirst%3DA.%2BJ.%26aulast%3DKomander%26aufirst%3DD.%26aulast%3DOvaa%26aufirst%3DH.%26atitle%3DOn%2520terminal%2520alkynes%2520that%2520can%2520react%2520with%2520active-site%2520cysteine%2520nucleophiles%2520in%2520proteases%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2013%26volume%3D135%26spage%3D2867%26epage%3D2870%26doi%3D10.1021%2Fja309802n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Turk, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoka, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasiljeva, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renko, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turk, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turk, D.</span></span> <span> </span><span class="NLM_article-title">Cysteine cathepsins: from structure, function and regulation to new frontiers</span>. <i>Biochim. Biophys. Acta, Proteins Proteomics</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>1824</i></span>,  <span class="NLM_fpage">68</span>– <span class="NLM_lpage">88</span>, <span class="refDoi"> DOI: 10.1016/j.bbapap.2011.10.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1016%2Fj.bbapap.2011.10.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=22024571" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFOns7rI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1824&publication_year=2012&pages=68-88&author=V.+Turkauthor=V.+Stokaauthor=O.+Vasiljevaauthor=M.+Renkoauthor=T.+Sunauthor=B.+Turkauthor=D.+Turk&title=Cysteine+cathepsins%3A+from+structure%2C+function+and+regulation+to+new+frontiers&doi=10.1016%2Fj.bbapap.2011.10.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Cysteine cathepsins: From structure, function and regulation to new frontiers</span></div><div class="casAuthors">Turk, Vito; Stoka, Veronika; Vasiljeva, Olga; Renko, Miha; Sun, Tao; Turk, Boris; Turk, Dusan</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Proteins and Proteomics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">1824</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">68-88</span>CODEN:
                <span class="NLM_cas:coden">BBAPBW</span>;
        ISSN:<span class="NLM_cas:issn">1570-9639</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B. V.</span>)
        </div><div class="casAbstract">A review.  It is more than 50 years since the lysosome was discovered.  Since then its hydrolytic machinery, including proteases and other hydrolases, has been fairly well identified and characterized.  Among these are the cysteine cathepsins, members of the family of papain-like cysteine proteases.  They have unique reactive-site properties and an uneven tissue-specific expression pattern.  In living organisms, their activity is a delicate balance of expression, targeting, zymogen activation, inhibition by protein inhibitors and degrdn.  The specificity of their substrate binding sites, small-mol. inhibitor repertoire and crystal structures are providing new tools for research and development.  Their unique reactive-site properties have made it possible to confine the targets simply by the use of appropriate reactive groups.  The epoxysuccinyls still dominate the field, but now nitriles seem to be the most appropriate "warhead".  The view of cysteine cathepsins as lysosomal proteases is changing as there is now clear evidence of their localization in other cellular compartments.  Besides being involved in protein turnover, they build an important part of endosomal antigen presentation.  Together with the growing no. of non-endosomal roles of cysteine cathepsins is growing also the knowledge of their involvement in diseases such as cancer and rheumatoid arthritis, among others.  Finally, cysteine cathepsins are important regulators and signaling mols. of an unimaginable no. of biol. processes.  The current challenge is to identify their endogenous substrates, in order to gain an insight into the mechanisms of substrate degrdn. and processing.  In this review, some of the remarkable advances that have taken place in the past decade are presented.  This article is part of a Special Issue entitled: Proteolysis 50 years after the discovery of lysosome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUEZ0u2P21D7Vg90H21EOLACvtfcHk0lgqUs3Jcp4__w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFOns7rI&md5=8615c1f0205d66b0fad932d6ff874390</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1016%2Fj.bbapap.2011.10.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbapap.2011.10.002%26sid%3Dliteratum%253Aachs%26aulast%3DTurk%26aufirst%3DV.%26aulast%3DStoka%26aufirst%3DV.%26aulast%3DVasiljeva%26aufirst%3DO.%26aulast%3DRenko%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DT.%26aulast%3DTurk%26aufirst%3DB.%26aulast%3DTurk%26aufirst%3DD.%26atitle%3DCysteine%2520cathepsins%253A%2520from%2520structure%252C%2520function%2520and%2520regulation%2520to%2520new%2520frontiers%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Proteins%2520Proteomics%26date%3D2012%26volume%3D1824%26spage%3D68%26epage%3D88%26doi%3D10.1016%2Fj.bbapap.2011.10.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mons, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansen, I. D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loboda, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Doodewaerd, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hermans, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verdoes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Boeckel, C. A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Veelen, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turk, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turk, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ovaa, H.</span></span> <span> </span><span class="NLM_article-title">The alkyne moiety as a latent electrophile in irreversible covalent small molecule inhibitors of cathepsin K</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>141</i></span>,  <span class="NLM_fpage">3507</span>– <span class="NLM_lpage">3514</span>, <span class="refDoi"> DOI: 10.1021/jacs.8b11027</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.8b11027" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFKjtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2019&pages=3507-3514&author=E.+Monsauthor=I.+D.+C.+Jansenauthor=J.+Lobodaauthor=B.+R.+van+Doodewaerdauthor=J.+Hermansauthor=M.+Verdoesauthor=C.+A.+A.+van+Boeckelauthor=P.+A.+van+Veelenauthor=B.+Turkauthor=D.+Turkauthor=H.+Ovaa&title=The+alkyne+moiety+as+a+latent+electrophile+in+irreversible+covalent+small+molecule+inhibitors+of+cathepsin+K&doi=10.1021%2Fjacs.8b11027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">The Alkyne Moiety as a Latent Electrophile in Irreversible Covalent Small Molecule Inhibitors of Cathepsin K</span></div><div class="casAuthors">Mons, Elma; Jansen, Ineke D. C.; Loboda, Jure; van Doodewaerd, Bjorn R.; Hermans, Jill; Verdoes, Martijn; van Boeckel, Constant A. A.; van Veelen, Peter A.; Turk, Boris; Turk, Dusan; Ovaa, Huib</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3507-3514</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Irreversible covalent inhibitors can have a beneficial pharmacokinetic/pharmacodynamics profile but are still often avoided due to the risk of indiscriminate covalent reactivity and the resulting adverse effects.  To overcome this potential liability, we introduced an alkyne moiety as a latent electrophile into small mol. inhibitors of cathepsin K (CatK).  Alkyne-based inhibitors do not show indiscriminate thiol reactivity but potently inhibit CatK protease activity by formation of an irreversible covalent bond with the catalytic cysteine residue, confirmed by crystal structure anal.  The rate of covalent bond formation (kinact) does not correlate with electrophilicity of the alkyne moiety, indicative of a proximity-driven reactivity.  Inhibition of CatK-mediated bone resorption is validated in human osteoclasts.  Together, this work illustrates the potential of alkynes as latent electrophiles in small mol. inhibitors, enabling the development of irreversible covalent inhibitors with an improved safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzdP4Hy1PKPrVg90H21EOLACvtfcHk0lgqUs3Jcp4__w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFKjtbY%253D&md5=3a18718aa722a8d46c5be1cf07dd077b</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1021%2Fjacs.8b11027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.8b11027%26sid%3Dliteratum%253Aachs%26aulast%3DMons%26aufirst%3DE.%26aulast%3DJansen%26aufirst%3DI.%2BD.%2BC.%26aulast%3DLoboda%26aufirst%3DJ.%26aulast%3Dvan%2BDoodewaerd%26aufirst%3DB.%2BR.%26aulast%3DHermans%26aufirst%3DJ.%26aulast%3DVerdoes%26aufirst%3DM.%26aulast%3Dvan%2BBoeckel%26aufirst%3DC.%2BA.%2BA.%26aulast%3Dvan%2BVeelen%26aufirst%3DP.%2BA.%26aulast%3DTurk%26aufirst%3DB.%26aulast%3DTurk%26aufirst%3DD.%26aulast%3DOvaa%26aufirst%3DH.%26atitle%3DThe%2520alkyne%2520moiety%2520as%2520a%2520latent%2520electrophile%2520in%2520irreversible%2520covalent%2520small%2520molecule%2520inhibitors%2520of%2520cathepsin%2520K%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2019%26volume%3D141%26spage%3D3507%26epage%3D3514%26doi%3D10.1021%2Fjacs.8b11027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Porter, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chestnut, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merrill, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spector, T.</span></span> <span> </span><span class="NLM_article-title">Mechanism-based inactivation of dihydropyrimidine dehydrogenase by 5-ethynyluracil</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>267</i></span>,  <span class="NLM_fpage">5236</span>– <span class="NLM_lpage">5242</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1544906" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADyaK38XitFSju7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=267&publication_year=1992&pages=5236-5242&author=D.+J.+Porterauthor=W.+G.+Chestnutauthor=B.+M.+Merrillauthor=T.+Spector&title=Mechanism-based+inactivation+of+dihydropyrimidine+dehydrogenase+by+5-ethynyluracil"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism-based inactivation of dihydropyrimidine dehydrogenase by 5-ethynyluracil</span></div><div class="casAuthors">Porter, David J. T.; Chestnut, William G.; Merrill, Barbara M.; Spector, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">267</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">5236-42</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">Uracil analogs with appropriate substituents at the 5-position inactivated dihydropyrimidine dehydrogenase (I).  The efficiency of these inactivators was highly dependent on the size of the 5-substituent.  For example, 5-ethynyluracil (II) inactivated I with an efficiency (kinact/Ki) that was 500-fold greater than that for 5-propynyluracil.  II inactivated I by initially forming a reversible complex with a Ki of 1.6 μM.  This initial complex yielded inactivated enzyme with a rate const. of 20 min-1 (kinact).  Thymine competitively decreased the apparent rate const. for inactivation of I by II.  The absorbance spectrum of II-inactivated I was different from that of reduced enzyme.  These optical changes were correlated with the loss of enzymic activity.  II inactivated I with a stoichiometry of 0.9 mol of inactivator per mol of active site.  I inactivated with [2-14C]II retained all of the radiolabel after denaturation in 8M urea, but lost radiolabel under acidic conditions.  These results suggested that inactivation was due to covalent modification of an amino acid residue and not due to modification of a noncovalently bound prosthetic group.  A radiolabeled peptide was isolated from a tryptic digest of the enzyme inactivated with [2-14C]II.  The sequence of this peptide was Lys-Ala-Glu-Ala-Ser-Gly-Ala-Y-Ala-Leu-Glu-Leu-Asn-Leu-Ser-X-Pro-His-Gly-Met-Gly-Glu-Arg, where X and Y were unidentified amino acids.  Since the radiolabel was lost from the peptide during the 1st cycle on the amino acid sequenator, the position of the radiolabeled amino acid was not detd.  The amino acid residue designated by X was identified as Cys from previous work with I inactivated with 5-iodouracil.  In contrast to II, 5-cyanouracil was a reversible inactivator of I.  5-Cyanouracil-inactivated I slowly regained activity (t1/2 = 1.8 min) after diln. into the std. assay.  I isolated from rat, mouse, and human liver had similar sensitivities to inactivation by 5-alkynyluracils.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7Yb9-u9vspbVg90H21EOLACvtfcHk0lgqUs3Jcp4__w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XitFSju7c%253D&md5=993e74947279ca25da52d60149ff8473</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPorter%26aufirst%3DD.%2BJ.%26aulast%3DChestnut%26aufirst%3DW.%2BG.%26aulast%3DMerrill%26aufirst%3DB.%2BM.%26aulast%3DSpector%26aufirst%3DT.%26atitle%3DMechanism-based%2520inactivation%2520of%2520dihydropyrimidine%2520dehydrogenase%2520by%25205-ethynyluracil%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1992%26volume%3D267%26spage%3D5236%26epage%3D5242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Metzger, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wissmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunther, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buettner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schule, R.</span></span> <span> </span><span class="NLM_article-title">LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>437</i></span>,  <span class="NLM_fpage">436</span>– <span class="NLM_lpage">439</span>, <span class="refDoi"> DOI: 10.1038/nature04020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1038%2Fnature04020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=16079795" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpvFOrtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=437&publication_year=2005&pages=436-439&author=E.+Metzgerauthor=M.+Wissmannauthor=N.+Yinauthor=J.+M.+Mullerauthor=R.+Schneiderauthor=A.+H.+Petersauthor=T.+Guntherauthor=R.+Buettnerauthor=R.+Schule&title=LSD1+demethylates+repressive+histone+marks+to+promote+androgen-receptor-dependent+transcription&doi=10.1038%2Fnature04020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription</span></div><div class="casAuthors">Metzger, Eric; Wissmann, Melanie; Yin, Na; Mueller, Judith M.; Schneider, Robert; Peters, Antoine H. F. M.; Guenther, Thomas; Buettner, Reinhard; Schuele, Roland</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">437</span>
        (<span class="NLM_cas:issue">7057</span>),
    <span class="NLM_cas:pages">436-439</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Gene regulation in eukaryotes requires the coordinate interaction of chromatin-modulating proteins with specific transcription factors such as the androgen receptor.  Gene activation and repression is specifically regulated by histone methylation status at distinct lysine residues.  Here the authors show that lysine-specific demethylase 1 (LSD1; also known as BHC110) co-localizes with the androgen receptor in normal human prostate and prostate tumor.  LSD1 interacts with androgen receptor in vitro and in vivo, and stimulates androgen-receptor-dependent transcription.  Conversely, knockdown of LSD1 protein levels abrogates androgen-induced transcriptional activation and cell proliferation.  Chromatin immunopptn. analyses demonstrate that androgen receptor and LSD1 form chromatin-assocd. complexes in a ligand-dependent manner.  LSD1 relieves repressive histone marks by demethylation of histone H3 at lysine 9 (H3-K9), thereby leading to de-repression of androgen receptor target genes.  Furthermore, the authors identify pargyline as an inhibitor of LSD1.  Pargyline blocks demethylation of H3-K9 by LSD1 and consequently androgen-receptor-dependent transcription.  Thus, modulation of LSD1 activity offers a new strategy to regulate androgen receptor functions.  Here, the authors link demethylation of a repressive histone mark with androgen-receptor-dependent gene activation, thus providing a mechanism by which demethylases control specific gene expression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgFgaYIdjiFbVg90H21EOLACvtfcHk0ljEnSl0UrSPFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpvFOrtL4%253D&md5=6cac1e6f6c21a80f59de27796cc9ee22</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1038%2Fnature04020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature04020%26sid%3Dliteratum%253Aachs%26aulast%3DMetzger%26aufirst%3DE.%26aulast%3DWissmann%26aufirst%3DM.%26aulast%3DYin%26aufirst%3DN.%26aulast%3DMuller%26aufirst%3DJ.%2BM.%26aulast%3DSchneider%26aufirst%3DR.%26aulast%3DPeters%26aufirst%3DA.%2BH.%26aulast%3DGunther%26aufirst%3DT.%26aulast%3DBuettner%26aufirst%3DR.%26aulast%3DSchule%26aufirst%3DR.%26atitle%3DLSD1%2520demethylates%2520repressive%2520histone%2520marks%2520to%2520promote%2520androgen-receptor-dependent%2520transcription%26jtitle%3DNature%26date%3D2005%26volume%3D437%26spage%3D436%26epage%3D439%26doi%3D10.1038%2Fnature04020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref152"><div class="reference"><strong class="refLabel"><a href="#ref152" class="rightTabRefNumLink">152</a></strong><div class="NLM_citation" id="rightTab-cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hauser, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlino, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pippel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulz-Fincke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metzger, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yiu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schule, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sippl, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, M.</span></span> <span> </span><span class="NLM_article-title">Nonpeptidic propargylamines as inhibitors of lysine specific demethylase 1 (LSD1) with cellular activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">7334</span>– <span class="NLM_lpage">7342</span>, <span class="refDoi"> DOI: 10.1021/jm400792m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400792m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlSjurnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=7334-7342&author=M.+L.+Schmittauthor=A.+T.+Hauserauthor=L.+Carlinoauthor=M.+Pippelauthor=J.+Schulz-Finckeauthor=E.+Metzgerauthor=D.+Willmannauthor=T.+Yiuauthor=M.+Bartonauthor=R.+Schuleauthor=W.+Sipplauthor=M.+Jung&title=Nonpeptidic+propargylamines+as+inhibitors+of+lysine+specific+demethylase+1+%28LSD1%29+with+cellular+activity&doi=10.1021%2Fjm400792m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Nonpeptidic Propargylamines as Inhibitors of Lysine Specific Demethylase 1 (LSD1) with Cellular Activity</span></div><div class="casAuthors">Schmitt, Martin L.; Hauser, Alexander-Thomas; Carlino, Luca; Pippel, Martin; Schulz-Fincke, Johannes; Metzger, Eric; Willmann, Dominica; Yiu, Teresa; Barton, Michelle; Schuele, Roland; Sippl, Wolfgang; Jung, Manfred</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">7334-7342</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Lysine demethylases play an important role in epigenetic regulation and thus in the development of diseases like cancer or neurodegenerative disorders.  As the lysine specific demethylase 1 (LSD1/KDM1) has been strongly connected to androgen and estrogen dependent gene expression, it serves as a promising target for the therapy of hormone dependent cancer.  Here, we report on the discovery of new small mol. inhibitors of LSD1 contg. a propargylamine warhead, starting out from lysine contg. substrate analogs.  On the basis of these substrate mimicking inhibitors, we were able to increase potency by a combination of similarity-based virtual screening and subsequent synthetic optimization resulting in more druglike LSD1 inhibitors that led to histone hypermethylation in breast cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRGRr4rUPfsLVg90H21EOLACvtfcHk0ljEnSl0UrSPFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlSjurnO&md5=d4de914dec37f011a7b9488ec539a395</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1021%2Fjm400792m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400792m%26sid%3Dliteratum%253Aachs%26aulast%3DSchmitt%26aufirst%3DM.%2BL.%26aulast%3DHauser%26aufirst%3DA.%2BT.%26aulast%3DCarlino%26aufirst%3DL.%26aulast%3DPippel%26aufirst%3DM.%26aulast%3DSchulz-Fincke%26aufirst%3DJ.%26aulast%3DMetzger%26aufirst%3DE.%26aulast%3DWillmann%26aufirst%3DD.%26aulast%3DYiu%26aufirst%3DT.%26aulast%3DBarton%26aufirst%3DM.%26aulast%3DSchule%26aufirst%3DR.%26aulast%3DSippl%26aufirst%3DW.%26aulast%3DJung%26aufirst%3DM.%26atitle%3DNonpeptidic%2520propargylamines%2520as%2520inhibitors%2520of%2520lysine%2520specific%2520demethylase%25201%2520%2528LSD1%2529%2520with%2520cellular%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D7334%26epage%3D7342%26doi%3D10.1021%2Fjm400792m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref153"><div class="reference"><strong class="refLabel"><a href="#ref153" class="rightTabRefNumLink">153</a></strong><div class="NLM_citation" id="rightTab-cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Potashman, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duggan, M. E.</span></span> <span> </span><span class="NLM_article-title">Covalent modifiers: an orthogonal approach to drug design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">1231</span>– <span class="NLM_lpage">1246</span>, <span class="refDoi"> DOI: 10.1021/jm8008597</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm8008597" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1Sltbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=1231-1246&author=M.+H.+Potashmanauthor=M.+E.+Duggan&title=Covalent+modifiers%3A+an+orthogonal+approach+to+drug+design&doi=10.1021%2Fjm8008597"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent Modifiers: An Orthogonal Approach to Drug Design</span></div><div class="casAuthors">Potashman, Michele H.; Duggan, Mark E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1231-1246</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  In this article we review a variety of examples in which therapeutic targets are covalently bound by small-mol. drugs or by compds. in advanced clin. development.  The covalent interactions can be either reversible or irreversible, depending on the reaction partners.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6BO6g9_F717Vg90H21EOLACvtfcHk0ljEnSl0UrSPFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1Sltbw%253D&md5=f8380d5a1cdd8638ad2a1e0405d25267</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1021%2Fjm8008597&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8008597%26sid%3Dliteratum%253Aachs%26aulast%3DPotashman%26aufirst%3DM.%2BH.%26aulast%3DDuggan%26aufirst%3DM.%2BE.%26atitle%3DCovalent%2520modifiers%253A%2520an%2520orthogonal%2520approach%2520to%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D1231%26epage%3D1246%26doi%3D10.1021%2Fjm8008597" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref154"><div class="reference"><strong class="refLabel"><a href="#ref154" class="rightTabRefNumLink">154</a></strong><div class="NLM_citation" id="rightTab-cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gaweska, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzpatrick, P. F.</span></span> <span> </span><span class="NLM_article-title">Structures and mechanism of the monoamine oxidase family</span>. <i>Biomol. Concepts</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">365</span>– <span class="NLM_lpage">377</span>, <span class="refDoi"> DOI: 10.1515/BMC.2011.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1515%2FBMC.2011.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=22022344" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFejtrrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=365-377&author=H.+Gaweskaauthor=P.+F.+Fitzpatrick&title=Structures+and+mechanism+of+the+monoamine+oxidase+family&doi=10.1515%2FBMC.2011.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Structures and mechanism of the monoamine oxidase family</span></div><div class="casAuthors">Gaweska, Helena; Fitzpatrick, Paul F.</div><div class="citationInfo"><span class="NLM_cas:title">Biomolecular Concepts</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">365-377</span>CODEN:
                <span class="NLM_cas:coden">BCIOB8</span>;
        ISSN:<span class="NLM_cas:issn">1868-5021</span>.
    
            (<span class="NLM_cas:orgname">Walter de Gruyter GmbH & Co. KG</span>)
        </div><div class="casAbstract">A review.  Members of the monoamine oxidase family of flavoproteins catalyze the oxidn. of primary and secondary amines, polyamines, amino acids, and methylated lysine side chains in proteins.  The enzymes have similar overall structures, with conserved FAD (FAD)-binding domains and varied substrate-binding sites.  Multiple mechanisms have been proposed for the catalytic reactions of these enzymes.  The present review compares the structures of different members of the family and the various mechanistic proposals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoI1ElkC8rKEbVg90H21EOLACvtfcHk0ljEnSl0UrSPFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFejtrrM&md5=8674c4f01d7ad790037ee46d2e39dfd1</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1515%2FBMC.2011.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1515%252FBMC.2011.030%26sid%3Dliteratum%253Aachs%26aulast%3DGaweska%26aufirst%3DH.%26aulast%3DFitzpatrick%26aufirst%3DP.%2BF.%26atitle%3DStructures%2520and%2520mechanism%2520of%2520the%2520monoamine%2520oxidase%2520family%26jtitle%3DBiomol.%2520Concepts%26date%3D2011%26volume%3D2%26spage%3D365%26epage%3D377%26doi%3D10.1515%2FBMC.2011.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref155"><div class="reference"><strong class="refLabel"><a href="#ref155" class="rightTabRefNumLink">155</a></strong><div class="NLM_citation" id="rightTab-cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pisani, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonetti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolotti, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefanachi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campagna, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carotti, A.</span></span> <span> </span><span class="NLM_article-title">Targeting monoamine oxidases with multipotent ligands: an emerging strategy in the search of new drugs against neurodegenerative diseases</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">4568</span>– <span class="NLM_lpage">4587</span>, <span class="refDoi"> DOI: 10.2174/092986711797379302</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.2174%2F092986711797379302" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=21864289" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlyitb7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=4568-4587&author=L.+Pisaniauthor=M.+Cattoauthor=F.+Leonettiauthor=O.+Nicolottiauthor=A.+Stefanachiauthor=F.+Campagnaauthor=A.+Carotti&title=Targeting+monoamine+oxidases+with+multipotent+ligands%3A+an+emerging+strategy+in+the+search+of+new+drugs+against+neurodegenerative+diseases&doi=10.2174%2F092986711797379302"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting monoamine oxidases with multipotent ligands: an emerging strategy in the search of new drugs against neurodegenerative diseases</span></div><div class="casAuthors">Pisani, L.; Catto, M.; Leonetti, F.; Nicolotti, O.; Stefanachi, A.; Campagna, F.; Carotti, A.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">4568-4587</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The socioeconomic burden of multi-factorial pathologies, such as neurodegenerative diseases (NDs), is enormous worldwide.  Unfortunately, no proven disease-modifying therapy is available yet and in most cases (e.g., Alzheimer's and Parkinson's disease) the approved drugs exert only palliative and symptomatic effects.  Nowadays, an emerging strategy for the discovery of disease-modifying drugs is based on the multi-target directed ligand (MTDL) design, an innovative shift from the traditional approach one-drug-one-target to the more ambitious one-drug-more-targets goal.  Herein, we review the discovery strategy, the mechanism of action and the biopharmacol. evaluation of multipotent ligands exhibiting monoamine oxidase (MAO) inhibition as the core activity with a potential for the treatment of NDs.  In particular, MAO inhibitors exhibiting addnl. acetylcholinesterase (AChE) or nitric oxide synthase (NOS) inhibition, or ion chelation/antioxidant-radical scavenging/anti-inflammatory/A2A receptor antagonist/APP processing modulating activities have been thoroughly examd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4N8fMdFNcwrVg90H21EOLACvtfcHk0lhvt2oATXQ5qw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlyitb7O&md5=2463da84a1da0142e353ff9d3a354fe6</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.2174%2F092986711797379302&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986711797379302%26sid%3Dliteratum%253Aachs%26aulast%3DPisani%26aufirst%3DL.%26aulast%3DCatto%26aufirst%3DM.%26aulast%3DLeonetti%26aufirst%3DF.%26aulast%3DNicolotti%26aufirst%3DO.%26aulast%3DStefanachi%26aufirst%3DA.%26aulast%3DCampagna%26aufirst%3DF.%26aulast%3DCarotti%26aufirst%3DA.%26atitle%3DTargeting%2520monoamine%2520oxidases%2520with%2520multipotent%2520ligands%253A%2520an%2520emerging%2520strategy%2520in%2520the%2520search%2520of%2520new%2520drugs%2520against%2520neurodegenerative%2520diseases%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2011%26volume%3D18%26spage%3D4568%26epage%3D4587%26doi%3D10.2174%2F092986711797379302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref156"><div class="reference"><strong class="refLabel"><a href="#ref156" class="rightTabRefNumLink">156</a></strong><div class="NLM_citation" id="rightTab-cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Querfurth, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaFerla, F. M.</span></span> <span> </span><span class="NLM_article-title">Alzheimer’s disease</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>362</i></span>,  <span class="NLM_fpage">329</span>– <span class="NLM_lpage">344</span>, <span class="refDoi"> DOI: 10.1056/NEJMra0909142</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1056%2FNEJMra0909142" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=20107219" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1aqt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=362&publication_year=2010&pages=329-344&author=H.+W.+Querfurthauthor=F.+M.+LaFerla&title=Alzheimer%E2%80%99s+disease&doi=10.1056%2FNEJMra0909142"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Alzheimer's disease</span></div><div class="casAuthors">Querfurth, Henry W.; LaFerla, Frank M.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">362</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">329-344</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review.  The role of β-amyloid peptide in spontaneous self-aggregation in brain in Alzheimer's disease is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPeniV_Jn6orVg90H21EOLACvtfcHk0lhvt2oATXQ5qw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1aqt7s%253D&md5=c116f6a6b8fed9af9f5282cc4b755c70</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1056%2FNEJMra0909142&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra0909142%26sid%3Dliteratum%253Aachs%26aulast%3DQuerfurth%26aufirst%3DH.%2BW.%26aulast%3DLaFerla%26aufirst%3DF.%2BM.%26atitle%3DAlzheimer%25E2%2580%2599s%2520disease%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D362%26spage%3D329%26epage%3D344%26doi%3D10.1056%2FNEJMra0909142" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref157"><div class="reference"><strong class="refLabel"><a href="#ref157" class="rightTabRefNumLink">157</a></strong><div class="NLM_citation" id="rightTab-cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Finberg, J. P.</span></span> <span> </span><span class="NLM_article-title">Update on the pharmacology of selective inhibitors of MAO-A and MAO-B: focus on modulation of CNS monoamine neurotransmitter release</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>143</i></span>,  <span class="NLM_fpage">133</span>– <span class="NLM_lpage">152</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2014.02.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1016%2Fj.pharmthera.2014.02.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=24607445" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkslGht7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=143&publication_year=2014&pages=133-152&author=J.+P.+Finberg&title=Update+on+the+pharmacology+of+selective+inhibitors+of+MAO-A+and+MAO-B%3A+focus+on+modulation+of+CNS+monoamine+neurotransmitter+release&doi=10.1016%2Fj.pharmthera.2014.02.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Update on the pharmacology of selective inhibitors of MAO-A and MAO-B: Focus on modulation of CNS monoamine neurotransmitter release</span></div><div class="casAuthors">Finberg, John P. M.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">143</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">133-152</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Inhibitors of monoamine oxidase (MAO) were initially used in medicine following the discovery of their antidepressant action.  Subsequently their ability to potentiate the effects of an indirectly-acting sympathomimetic amine such as tyramine was discovered, leading to their limitation in clin. use, except for cases of treatment-resistant depression.  More recently, the understanding that: a) potentiation of indirectly-acting sympathomimetic amines is caused by inhibitors of MAO-A but not by inhibitors of MAO-B, and b) that reversible inhibitors of MAO-A cause minimal tyramine potentiation, has led to their re-introduction to clin. use for treatment of depression (reversible MAO-A inhibitors and new dose form MAO-B inhibitor) and treatment of Parkinson's disease (MAO-B inhibitors).  The profound neuroprotective properties of propargyl-based inhibitors of MAO-B in preclin. expts. have drawn attention to the possibility of employing these drugs for their neuroprotective effect in neurodegenerative diseases, and have raised the question of the involvement of the MAO-mediated reaction as a source of reactive free radicals.  Despite the long-standing history of MAO inhibitors in medicine, the way in which they affect neuronal release of monoamine neurotransmitters is still poorly understood.  In recent years, the detailed chem. structure of MAO-B and MAO-A has become available, providing new possibilities for synthesis of mechanism-based inhibitors.  This review describes the latest advances in understanding the way in which MAO inhibitors affect the release of the monoamine neurotransmitters dopamine, noradrenaline and serotonin (5-HT) in the CNS, with an accent on the importance of these effects for the clin. actions of the drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSGMvtQ1Ca5bVg90H21EOLACvtfcHk0lhvt2oATXQ5qw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkslGht7o%253D&md5=0f31959bad34842d4aaaba7b8162e5b8</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2014.02.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2014.02.010%26sid%3Dliteratum%253Aachs%26aulast%3DFinberg%26aufirst%3DJ.%2BP.%26atitle%3DUpdate%2520on%2520the%2520pharmacology%2520of%2520selective%2520inhibitors%2520of%2520MAO-A%2520and%2520MAO-B%253A%2520focus%2520on%2520modulation%2520of%2520CNS%2520monoamine%2520neurotransmitter%2520release%26jtitle%3DPharmacol.%2520Ther.%26date%3D2014%26volume%3D143%26spage%3D133%26epage%3D152%26doi%3D10.1016%2Fj.pharmthera.2014.02.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref158"><div class="reference"><strong class="refLabel"><a href="#ref158" class="rightTabRefNumLink">158</a></strong><div class="NLM_citation" id="rightTab-cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Storr, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orvig, C.</span></span> <span> </span><span class="NLM_article-title">Design of targeting ligands in medicinal inorganic chemistry</span>. <i>Chem. Soc. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">534</span>– <span class="NLM_lpage">544</span>, <span class="refDoi"> DOI: 10.1039/b514859f</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1039%2Fb514859f" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=16729147" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD28XkvFOitLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2006&pages=534-544&author=T.+Storrauthor=K.+H.+Thompsonauthor=C.+Orvig&title=Design+of+targeting+ligands+in+medicinal+inorganic+chemistry&doi=10.1039%2Fb514859f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Design of targeting ligands in medicinal inorganic chemistry</span></div><div class="casAuthors">Storr, Tim; Thompson, Katherine H.; Orvig, Chris</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Society Reviews</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">534-544</span>CODEN:
                <span class="NLM_cas:coden">CSRVBR</span>;
        ISSN:<span class="NLM_cas:issn">0306-0012</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  This tutorial review will highlight recent advances in medicinal inorg. chem. pertaining to the use of multifunctional ligands for enhanced effect.  Ligands that adequately bind metal ions and also include specific targeting features are gaining in popularity due to their ability to enhance the efficacy of less complicated metal-based agents.  Moving beyond the traditional view of ligands modifying reactivity, stabilizing specific oxidn. states, and contributing to substitution inertness, the authors will discuss recent work involving metal complexes with multifunctional ligands that target specific tissues, membrane receptors, or endogenous mols., including enzymes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRgMqYlFgDWLVg90H21EOLACvtfcHk0lg35rlWGknSvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XkvFOitLs%253D&md5=71fdda23c9be3857c8415114c7c12b50</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1039%2Fb514859f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fb514859f%26sid%3Dliteratum%253Aachs%26aulast%3DStorr%26aufirst%3DT.%26aulast%3DThompson%26aufirst%3DK.%2BH.%26aulast%3DOrvig%26aufirst%3DC.%26atitle%3DDesign%2520of%2520targeting%2520ligands%2520in%2520medicinal%2520inorganic%2520chemistry%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2006%26volume%3D35%26spage%3D534%26epage%3D544%26doi%3D10.1039%2Fb514859f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref159"><div class="reference"><strong class="refLabel"><a href="#ref159" class="rightTabRefNumLink">159</a></strong><div class="NLM_citation" id="rightTab-cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gella, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durany, N.</span></span> <span> </span><span class="NLM_article-title">Oxidative stress in Alzheimer disease</span>. <i>Cell Adh. Migr.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">88</span>– <span class="NLM_lpage">93</span>, <span class="refDoi"> DOI: 10.4161/cam.3.1.7402</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.4161%2Fcam.3.1.7402" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=19372765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A280%3ADC%252BC3cvps1ajsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2009&pages=88-93&author=A.+Gellaauthor=N.+Durany&title=Oxidative+stress+in+Alzheimer+disease&doi=10.4161%2Fcam.3.1.7402"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">Oxidative stress in Alzheimer disease</span></div><div class="casAuthors">Gella Alejandro; Durany Nuria</div><div class="citationInfo"><span class="NLM_cas:title">Cell adhesion & migration</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">88-93</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Alzheimer disease (AD) is a progressive dementia affecting a large proportion of the aging population.  The histopathological changes in AD include neuronal cell death, formation of amyloid plaques and neurofibrillary tangles.  There is also evidence that brain tissue in patients with AD is exposed to oxidative stress (e.g., protein oxidation, lipid oxidation, DNA oxidation and glycoxidation) during the course of the disease.  Advanced glycation endproducts (AGEs) are present in amyloid plaques in AD, and its extracellular accumulation may be caused by an accelerated oxidation of glycated proteins.  AGEs participate in neuronal death causing direct (chemical) and indirect (cellular) free radical production and consequently increase oxidative stress.  The development of drugs for the treatment of AD that breaks the vicious cycles of oxidative stress and neurodegeneration offer new opportunities.  These approaches include AGE-inhibitors, antioxidants and anti-inflammatory substances, which prevent free radical production.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTWN_iAi3-0DO3MPKNEWB5RfW6udTcc2eYt54TUnNjVRLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cvps1ajsw%253D%253D&md5=13d55d79537d8763d44759703e13e023</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.4161%2Fcam.3.1.7402&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcam.3.1.7402%26sid%3Dliteratum%253Aachs%26aulast%3DGella%26aufirst%3DA.%26aulast%3DDurany%26aufirst%3DN.%26atitle%3DOxidative%2520stress%2520in%2520Alzheimer%2520disease%26jtitle%3DCell%2520Adh.%2520Migr.%26date%3D2009%26volume%3D3%26spage%3D88%26epage%3D93%26doi%3D10.4161%2Fcam.3.1.7402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref160"><div class="reference"><strong class="refLabel"><a href="#ref160" class="rightTabRefNumLink">160</a></strong><div class="NLM_citation" id="rightTab-cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hardy, J.</span></span> <span> </span><span class="NLM_article-title">The amyloid hypothesis for Alzheimer’s disease: a critical reappraisal</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">1129</span>– <span class="NLM_lpage">1134</span>, <span class="refDoi"> DOI: 10.1111/j.1471-4159.2009.06181.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1111%2Fj.1471-4159.2009.06181.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=19457065" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpsFOmu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2009&pages=1129-1134&author=J.+Hardy&title=The+amyloid+hypothesis+for+Alzheimer%E2%80%99s+disease%3A+a+critical+reappraisal&doi=10.1111%2Fj.1471-4159.2009.06181.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">The amyloid hypothesis for Alzheimer's disease: a critical reappraisal</span></div><div class="casAuthors">Hardy, John</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1129-1134</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  The amyloid hypothesis has been the basis for most work on the pathogenesis of Alzheimer's disease.  Recent clin. trials based on this hypothesis have been inconclusive.  In this article I review the current status of the hypothesis and suggest that a major scientific need is to understand the normal function of amyloid-β precursor protein (APP) and think how this may relate to the cell death in the disease process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvUSGTA_5CwbVg90H21EOLACvtfcHk0lg35rlWGknSvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpsFOmu70%253D&md5=b33ac5bdb5b02548736b5d7cbc83325c</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1111%2Fj.1471-4159.2009.06181.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1471-4159.2009.06181.x%26sid%3Dliteratum%253Aachs%26aulast%3DHardy%26aufirst%3DJ.%26atitle%3DThe%2520amyloid%2520hypothesis%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%253A%2520a%2520critical%2520reappraisal%26jtitle%3DJ.%2520Neurochem.%26date%3D2009%26volume%3D110%26spage%3D1129%26epage%3D1134%26doi%3D10.1111%2Fj.1471-4159.2009.06181.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref161"><div class="reference"><strong class="refLabel"><a href="#ref161" class="rightTabRefNumLink">161</a></strong><div class="NLM_citation" id="rightTab-cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Calissano, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matrone, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amadoro, G.</span></span> <span> </span><span class="NLM_article-title">Apoptosis and in vitro Alzheimer disease neuronal models</span>. <i>Commun. Integr. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">163</span>– <span class="NLM_lpage">169</span>, <span class="refDoi"> DOI: 10.4161/cib.7704</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.4161%2Fcib.7704" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=19513272" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1Ojs7zK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2009&pages=163-169&author=P.+Calissanoauthor=C.+Matroneauthor=G.+Amadoro&title=Apoptosis+and+in+vitro+Alzheimer+disease+neuronal+models&doi=10.4161%2Fcib.7704"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Apoptosis and in vitro Alzheimer's disease neuronal models</span></div><div class="casAuthors">Calissano, P.; Matrone, C.; Amadoro, G.</div><div class="citationInfo"><span class="NLM_cas:title">Communicative & Integrative Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">163-169</span>CODEN:
                <span class="NLM_cas:coden">CIBOBQ</span>;
        ISSN:<span class="NLM_cas:issn">1942-0889</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">A review.  Alzheimer disease (AD) is a human neurodegenerative disease characterized by co-existence of extracellular senile plaques (SP) and neurofibrillary tangles (NFT) assocd. with an extensive neuronal loss, primarily in the cerebral cortex and hippocampus.  Several studies suggest that caspase(s)-mediated neuronal death occurs in cellular and animal AD models as well as in human brains of affected patients, although an etiol. role of apoptosis in such neurodegenerative disorder is still debated.  This review summarizes the exptl. evidences corroborating the possible involvement of apoptosis in AD pathogenesis and discusses the usefulness of ad hoc devised in vitro approaches to study how caspase(s), amyloidogenic processing and tau metab. might reciprocally interact leading to neuronal death.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsZQ_pSt_Hc7Vg90H21EOLACvtfcHk0lg35rlWGknSvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1Ojs7zK&md5=90cbf25854989a8908b49c0faeee1cf0</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.4161%2Fcib.7704&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcib.7704%26sid%3Dliteratum%253Aachs%26aulast%3DCalissano%26aufirst%3DP.%26aulast%3DMatrone%26aufirst%3DC.%26aulast%3DAmadoro%26aufirst%3DG.%26atitle%3DApoptosis%2520and%2520in%2520vitro%2520Alzheimer%2520disease%2520neuronal%2520models%26jtitle%3DCommun.%2520Integr.%2520Biol.%26date%3D2009%26volume%3D2%26spage%3D163%26epage%3D169%26doi%3D10.4161%2Fcib.7704" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref162"><div class="reference"><strong class="refLabel"><a href="#ref162" class="rightTabRefNumLink">162</a></strong><div class="NLM_citation" id="rightTab-cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Domingues, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">da Cruz, E. S. O. A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henriques, A. G.</span></span> <span> </span><span class="NLM_article-title">Impact of cytokines and chemokines on Alzheimer’s disease neuropathological hallmarks</span>. <i>Curr. Alzheimer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">870</span>– <span class="NLM_lpage">882</span>, <span class="refDoi"> DOI: 10.2174/1567205014666170317113606</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.2174%2F1567205014666170317113606" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=28317487" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1Okur7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2017&pages=870-882&author=C.+Dominguesauthor=E.+S.+O.+A.+B.+da+Cruzauthor=A.+G.+Henriques&title=Impact+of+cytokines+and+chemokines+on+Alzheimer%E2%80%99s+disease+neuropathological+hallmarks&doi=10.2174%2F1567205014666170317113606"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of Cytokines and Chemokines on Alzheimer's Disease Neuropathological Hallmarks</span></div><div class="casAuthors">Domingues, Catarina; da Cruz e Silva, Odete A. B.; Henriques, Ana Gabriela</div><div class="citationInfo"><span class="NLM_cas:title">Current Alzheimer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">870-882</span>CODEN:
                <span class="NLM_cas:coden">CARUBY</span>;
        ISSN:<span class="NLM_cas:issn">1567-2050</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Alzheimer's disease (AD) is the most common neurodegenerative disorder, neuropathol. characterized by aggregates of β-amyloid peptides, which deposit as senile plaques, and of TAU protein, which forms neurofibrillary tangles.  It is now widely accepted that neuroinflammation is implicated in AD pathogenesis.  Indeed, inflammatory mediators, such as cytokines and chemokines (chemotactic cytokines) can impact on the Alzheimer's amyloid precursor protein by affecting its expression levels and amyloidogenic processing and/or β -amyloid aggregation.  Addnl., cytokines and chemokines can influence kinases' activities, leading to abnormal TAU phosphorylation.  To date there is no cure for AD, but several therapeutic strategies have been directed to prevent neuroinflammation.  Anti-inflammatory, but also anti-amyloidogenic compds., such as flavonoids were shown to favorably modulate some pathol. events assocd. with neurodegeneration.  This review focuses on the role of cytokines and chemokines in AD-assocd. pathologies, and summarizes the potential anti-inflammatory therapeutic approaches aimed at preventing or slowing down disease progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWGEmdgXfysLVg90H21EOLACvtfcHk0linOjFjzW1BQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1Okur7M&md5=860ab9a2701a805b519aaf4ee802e48f</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.2174%2F1567205014666170317113606&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1567205014666170317113606%26sid%3Dliteratum%253Aachs%26aulast%3DDomingues%26aufirst%3DC.%26aulast%3Dda%2BCruz%26aufirst%3DE.%2BS.%2BO.%2BA.%2BB.%26aulast%3DHenriques%26aufirst%3DA.%2BG.%26atitle%3DImpact%2520of%2520cytokines%2520and%2520chemokines%2520on%2520Alzheimer%25E2%2580%2599s%2520disease%2520neuropathological%2520hallmarks%26jtitle%3DCurr.%2520Alzheimer%2520Res.%26date%3D2017%26volume%3D14%26spage%3D870%26epage%3D882%26doi%3D10.2174%2F1567205014666170317113606" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref163"><div class="reference"><strong class="refLabel"><a href="#ref163" class="rightTabRefNumLink">163</a></strong><div class="NLM_citation" id="rightTab-cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rahman, A.</span></span> <span> </span><span class="NLM_article-title">The role of adenosine in Alzheimer’s disease</span>. <i>Curr. Neuropharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">207</span>– <span class="NLM_lpage">216</span>, <span class="refDoi"> DOI: 10.2174/157015909789152119</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.2174%2F157015909789152119" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=20190962" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVSksrnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2009&pages=207-216&author=A.+Rahman&title=The+role+of+adenosine+in+Alzheimer%E2%80%99s+disease&doi=10.2174%2F157015909789152119"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">The role of adenosine in Alzheimer's disease</span></div><div class="casAuthors">Rahman, Anisur</div><div class="citationInfo"><span class="NLM_cas:title">Current Neuropharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">207-216</span>CODEN:
                <span class="NLM_cas:coden">CNUEAN</span>;
        ISSN:<span class="NLM_cas:issn">1875-6190</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Alzheimer's disease (AD) is a neurodegenerative disorder of the central nervous system manifested by cognitive and memory deterioration, a variety of neuropsychiatric symptoms, behavioral disturbances, and progressive impairment of daily life activities.  Current pharmacotherapies are restricted to symptomatic interventions but do not prevent progressive neuronal degeneration.  Therefore, new therapeutic strategies are needed to intervene with these progressive pathol. processes.  In the past several years adenosine, a ubiquitously released purine ribonucleoside, has become important for its neuromodulating capability and its emerging pos. exptl. effects in neurodegenerative diseases.  Recent research suggests that adenosine receptors play important roles in the modulation of cognitive function.  The present paper attempts to review published reports and data from different studies showing the evidence of a relationship between adenosinergic function and AD-related cognitive deficits.  Epidemiol. studies have found an assocn. between coffee (a nonselective adenosine receptor antagonist) consumption and improved cognitive function in AD patients and in the elderly.  Long-term administration of caffeine in transgenic animal models showed a reduced amyloid burden in brain with better cognitive performance.  Antagonists of adenosine A2A receptors mimic these beneficial effects of caffeine on cognitive function.  Neuronal cell cultures with amyloid beta in the presence of an A2A receptor antagonist completely prevented amyloid beta-induced neurotoxicity.  These findings suggest that the adenosinergic system constitutes a new therapeutic target for AD, and caffeine and A2A receptor antagonists may have promise to manage cognitive dysfunction in AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrV5y-6o7HJKbVg90H21EOLACvtfcHk0linOjFjzW1BQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVSksrnP&md5=91646b591f011f244b07654acea2741c</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.2174%2F157015909789152119&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F157015909789152119%26sid%3Dliteratum%253Aachs%26aulast%3DRahman%26aufirst%3DA.%26atitle%3DThe%2520role%2520of%2520adenosine%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DCurr.%2520Neuropharmacol.%26date%3D2009%26volume%3D7%26spage%3D207%26epage%3D216%26doi%3D10.2174%2F157015909789152119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref164"><div class="reference"><strong class="refLabel"><a href="#ref164" class="rightTabRefNumLink">164</a></strong><div class="NLM_citation" id="rightTab-cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carrillo, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minami, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitani, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maruyama, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naoi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Youdim, M. B.</span></span> <span> </span><span class="NLM_article-title">Enhancing effect of rasagiline on superoxide dismutase and catalase activities in the dopaminergic system in the rat</span>. <i>Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">577</span>– <span class="NLM_lpage">585</span>, <span class="refDoi"> DOI: 10.1016/S0024-3205(00)00643-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1016%2FS0024-3205%2800%2900643-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10993123" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD3cXksVKjurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2000&pages=577-585&author=M.+C.+Carrilloauthor=C.+Minamiauthor=K.+Kitaniauthor=W.+Maruyamaauthor=K.+Ohashiauthor=T.+Yamamotoauthor=M.+Naoiauthor=S.+Kanaiauthor=M.+B.+Youdim&title=Enhancing+effect+of+rasagiline+on+superoxide+dismutase+and+catalase+activities+in+the+dopaminergic+system+in+the+rat&doi=10.1016%2FS0024-3205%2800%2900643-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">Enhancing effect of rasagiline on superoxide dismutase and catalase activities in the dopaminergic system in the rat</span></div><div class="casAuthors">Carrillo, M. C.; Minami, C.; Kitani, K.; Maruyama, W.; Ohashi, K.; Yamamoto, T.; Naoi, M.; Kanai, S.; Youdim, M. B. H.</div><div class="citationInfo"><span class="NLM_cas:title">Life Sciences</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">577-585</span>CODEN:
                <span class="NLM_cas:coden">LIFSAK</span>;
        ISSN:<span class="NLM_cas:issn">0024-3205</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">Rasagiline [N-propargyl-1(R)-aminoindan] is a selective irreversible MAO-B inhibitor as is (-)deprenyl.  The effect of the drug on antioxidant enzyme activities on dopaminergic tissue was examd. in male F-344 rats (8.5-mo-old).  Two exptl. groups were infused s.c. with rasagiline saline solns. by means of osmotic mini pumpus implanted s.c. in the back of the rats.  Control animals were also similarly implanted with saline filled mini-pumps.  Three-and-one-half weeks later, animals were sacrificed and selected tissue samples removed from brain, kidney and heart.  Two doses of rasagiline (0.5 mg/kg/day, 1.0 mg/kg/day, both for 3.5 wk) significantly increased catalase activities about 2-fold in substantia nigra and striatum but not in hippocampus.  Interestingly, in both renal cortex and medulla, catalase (CAT) activities were significantly increased.  Both Mn- and Cu,Zn-superoxide dismutase (SOD) activities were increased 2 to 4 fold in substantia nigra, striatum and renal cortex and heart.  Several groups, including our own have reported an extension of survival of deprenyl-treated animals of different species.  Although the mechanism(s) of the life extension by deprenyl remains unresolved, it would be interesting to investigate the effect of rasagiline on the survival of animals, since deprenyl also was shown to increase antioxidant enzyme activities in brain dopaminergic regions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3sp8TlppOL7Vg90H21EOLACvtfcHk0linOjFjzW1BQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXksVKjurg%253D&md5=8e0b602a42ddf81f039b732fbf1d76b1</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1016%2FS0024-3205%2800%2900643-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0024-3205%252800%252900643-3%26sid%3Dliteratum%253Aachs%26aulast%3DCarrillo%26aufirst%3DM.%2BC.%26aulast%3DMinami%26aufirst%3DC.%26aulast%3DKitani%26aufirst%3DK.%26aulast%3DMaruyama%26aufirst%3DW.%26aulast%3DOhashi%26aufirst%3DK.%26aulast%3DYamamoto%26aufirst%3DT.%26aulast%3DNaoi%26aufirst%3DM.%26aulast%3DKanai%26aufirst%3DS.%26aulast%3DYoudim%26aufirst%3DM.%2BB.%26atitle%3DEnhancing%2520effect%2520of%2520rasagiline%2520on%2520superoxide%2520dismutase%2520and%2520catalase%2520activities%2520in%2520the%2520dopaminergic%2520system%2520in%2520the%2520rat%26jtitle%3DLife%2520Sci.%26date%3D2000%26volume%3D67%26spage%3D577%26epage%3D585%26doi%3D10.1016%2FS0024-3205%2800%2900643-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref165"><div class="reference"><strong class="refLabel"><a href="#ref165" class="rightTabRefNumLink">165</a></strong><div class="NLM_citation" id="rightTab-cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Youdim, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstock, M.</span></span> <span> </span><span class="NLM_article-title">Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(<i>N</i>-propargyl-(3<i>R</i>)aminoindan-5-yl)-ethyl methyl carbamate]</span>. <i>Cell. Mol. Neurobiol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">555</span>– <span class="NLM_lpage">573</span>, <span class="refDoi"> DOI: 10.1023/A:1015131516649</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1023%2FA%3A1015131516649" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=12043833" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A280%3ADC%252BD38zgt12ksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2001&pages=555-573&author=M.+B.+Youdimauthor=M.+Weinstock&title=Molecular+basis+of+neuroprotective+activities+of+rasagiline+and+the+anti-Alzheimer+drug+TV3326+%5B%28N-propargyl-%283R%29aminoindan-5-yl%29-ethyl+methyl+carbamate%5D&doi=10.1023%2FA%3A1015131516649"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate]</span></div><div class="casAuthors">Youdim M B; Weinstock M</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and molecular neurobiology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">555-73</span>
        ISSN:<span class="NLM_cas:issn">0272-4340</span>.
    </div><div class="casAbstract">Rasagiline (N-propargyl-1-(R)-aminoindan) is a selective, irreversible monoamine oxidase B (MAO B) inhibitor which has been developed as an anti-Parkinson drug.  In controlled monotherapy and as adjunct to L-dopa it has shown anti-Parkinson activity.  In cell culture (PC-12 and neuroblastoma SH-SY5Y cells) it exhibits neuroprotective and anti-apoptotic activity against several neurotoxins (SIN-1, MPTP, 6-hydroxydopamine and N-methyl-(R)-salsolinol) and ischemia.  In vivo, it reduces the sequelae of traumatic brain injury in mice and speeds their recovery.  The neuroprotective activity of rasagaline does not result from MAO B inhibition, since its S-enantiomer, TVP1022, which has 1000-fold weaker MAO inhibitory activity, exhibits similar neuroprotective properties.  Introduction of a carbamate moiety into the rasagiline molecule to confer cholinesterase inhibitory activity for the treatment of Alzheimer's disease, resulted in compounds TV3326 [(N-Propargyl-(3R)Aminoindan-5-YL)-Ethyl Methyl Carbamate] and its S-enantiomer TV3279 [(N-Propargyl-(3S)Aminoindan-5-YL)-Ethyl Methyl Carbamate], which retain the neuroprotective activities of rasagiline and TVP1022.  They also antagonize scopolamine-induced impairments in spatial memory.  In addition, TV3326 exhibits brain-selective MAO A and B inhibitory activity after chronic administration and has antidepressant-like activity in the forced swim test.  This is associated with an increase in brain levels of serotonin.  The anti-apoptotic activity of these propargylamine-containing derivatives may be related to their ability to delay the opening of voltage-dependent anion channels (VDAC), which are part of the mitochondrial permeability transition pore.  The propargylamine moiety is responsible for the increase in the mitochondrial family of Bcl-2 proteins, prevention in the fall in mitochondrial membrane potential, prevention of the activation of caspase 3, and of translocation of glyceraldehyde-3-phosphate dehydrogenase from the cytoplasm to the nucleus.  The latter processes are closely associated with neurotoxin-induced apoptosis.  Rasagiline interacts with and prevents the binding of PKI 1195 to the pro-apoptotic peripheral benzodiazepine receptor, which together with Bcl-2, hexokinase, porin, and adenine nucleotide translocator constitutes part of the VDAC.  Furthermore, rasagiline, TV3326 and TV3279 are able to influence the processing of amyloid precursor protein by activation of alpha-secretase and increasing the release of soluble alpha APP in rat PC-12 and human neuroblastoma SH-SY5Y cells and in rat and mice cortex and hippocampus.  This process has been shown to involve the upregulation of PKC and MAP kinase.  It is quite likely that the induction of Bcl-2 and activation of PKC by rasagiline and TV3326 is closely linked to the anti-apoptotic action of these drugs and their ability to process APP by activation of alpha-secretase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQR3CdWC5jGOz0SWnHPWbmmfW6udTcc2eaK5RkmbtQl7bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD38zgt12ksQ%253D%253D&md5=0909d8e1af5f7cbdcd55ad7d48ebfc15</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1023%2FA%3A1015131516649&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1015131516649%26sid%3Dliteratum%253Aachs%26aulast%3DYoudim%26aufirst%3DM.%2BB.%26aulast%3DWeinstock%26aufirst%3DM.%26atitle%3DMolecular%2520basis%2520of%2520neuroprotective%2520activities%2520of%2520rasagiline%2520and%2520the%2520anti-Alzheimer%2520drug%2520TV3326%2520%255B%2528N-propargyl-%25283R%2529aminoindan-5-yl%2529-ethyl%2520methyl%2520carbamate%255D%26jtitle%3DCell.%2520Mol.%2520Neurobiol.%26date%3D2001%26volume%3D21%26spage%3D555%26epage%3D573%26doi%3D10.1023%2FA%3A1015131516649" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref166"><div class="reference"><strong class="refLabel"><a href="#ref166" class="rightTabRefNumLink">166</a></strong><div class="NLM_citation" id="rightTab-cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perez, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marco, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Alvarez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unzeta, M.</span></span> <span> </span><span class="NLM_article-title">Relevance of benzyloxy group in 2-indolyl methylamines in the selective MAO-B inhibition</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">869</span>– <span class="NLM_lpage">876</span>, <span class="refDoi"> DOI: 10.1038/sj.bjp.0702600</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1038%2Fsj.bjp.0702600" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10433493" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADyaK1MXktlOmsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=1999&pages=869-876&author=V.+Perezauthor=J.+L.+Marcoauthor=E.+Fernandez-Alvarezauthor=M.+Unzeta&title=Relevance+of+benzyloxy+group+in+2-indolyl+methylamines+in+the+selective+MAO-B+inhibition&doi=10.1038%2Fsj.bjp.0702600"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">Relevance of benzyloxy group in 2-indolyl methylamines in the selective MAO-B inhibition</span></div><div class="casAuthors">Perez, Virgili; Marco, Jose Luis; Fernandez-Alvarez, Eldiberto; Unzeta, Mercedes</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">869-876</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Stockton Press</span>)
        </div><div class="casAbstract">Previous studies with indolyl derivs. as monoamine oxidase (MAO) inhibitors have shown the relevance of the indole structure for recognition by the active site of this enzyme.  We now report a new series of mols. with structural features which det. the selectivity of MAO inhibition.  A benzyloxy group attached at position 5 of the indole ring is crit. for this selective behavior.  Amongst all of these benzyloxy-indolyl methylamines, N-(2-propynyl)-2-(5-benzyloxyindol)methylamine FA-73 was the most potent MAO-B "suicide" inhibitor studied.  The Ki values for MAO-A and MAO-B were 800±60 and 0.75±0.15 nM, resp.  These data represent a selectivity value of 1066 for MAO-B, being 48 times more selective than L-deprenyl (Ki values of 376±0.032 and 16.8±0.1 nM for MAO A and MAO-B, resp.).  The IC50 values for dopamine uptake in striatal synaptosomal fractions from rats were 150±8 μM for FA-73 and 68±10 μM for L-deprenyl whereas in human caudate tissue the IC50 values were 0.36±0.015 μM for FA-73 and 0.10±0.007 μM for L-deprenyl.  Moreover, mouse brain MAO-B activity was 90% ex vivo inhibited by both compds. 1 h after 4 mg kg-1 administration, MAO-A activity was not affected.  These novel mols. should provide a better understanding of the active site of monoamine oxidase and could be the starting point for the design of further selective, non-amphetamine-like MAO-B inhibitors with therapeutic potential for the treatment of neurol. disorders, such as parkinsonism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoynmDOjiKQgbVg90H21EOLACvtfcHk0ljsrSNi6KWZfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXktlOmsrw%253D&md5=756c3b6564fe28ee128fdcf06b730f6c</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0702600&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0702600%26sid%3Dliteratum%253Aachs%26aulast%3DPerez%26aufirst%3DV.%26aulast%3DMarco%26aufirst%3DJ.%2BL.%26aulast%3DFernandez-Alvarez%26aufirst%3DE.%26aulast%3DUnzeta%26aufirst%3DM.%26atitle%3DRelevance%2520of%2520benzyloxy%2520group%2520in%25202-indolyl%2520methylamines%2520in%2520the%2520selective%2520MAO-B%2520inhibition%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D1999%26volume%3D127%26spage%3D869%26epage%3D876%26doi%3D10.1038%2Fsj.bjp.0702600" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref167"><div class="reference"><strong class="refLabel"><a href="#ref167" class="rightTabRefNumLink">167</a></strong><div class="NLM_citation" id="rightTab-cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bolea, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juarez-Jimenez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Los Rios, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chioua, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pouplana, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luque, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unzeta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marco-Contelles, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samadi, A.</span></span> <span> </span><span class="NLM_article-title">Synthesis, biological evaluation, and molecular modeling of donepezil and <i>N</i>-[(5-(benzyloxy)-1-methyl-1<i>H</i>-indol-2-yl)methyl]-<i>N</i>-methylprop-2-yn-1-amine hybrids as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer’s disease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">8251</span>– <span class="NLM_lpage">8270</span>, <span class="refDoi"> DOI: 10.1021/jm200853t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200853t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlGktrrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=8251-8270&author=I.+Boleaauthor=J.+Juarez-Jimenezauthor=C.+de+Los+Riosauthor=M.+Chiouaauthor=R.+Pouplanaauthor=F.+J.+Luqueauthor=M.+Unzetaauthor=J.+Marco-Contellesauthor=A.+Samadi&title=Synthesis%2C+biological+evaluation%2C+and+molecular+modeling+of+donepezil+and+N-%5B%285-%28benzyloxy%29-1-methyl-1H-indol-2-yl%29methyl%5D-N-methylprop-2-yn-1-amine+hybrids+as+new+multipotent+cholinesterase%2Fmonoamine+oxidase+inhibitors+for+the+treatment+of+Alzheimer%E2%80%99s+disease&doi=10.1021%2Fjm200853t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, biological evaluation, and molecular modeling of donepezil and N-[(5-(benzyloxy)-1-methyl-1H-indol-2-yl)methyl]-N-methylprop-2-yn-1-amine hybrids as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease</span></div><div class="casAuthors">Bolea, Irene; Juarez-Jimenez, Jordi; de los Rios, Cristobal; Chioua, Mourad; Pouplana, Ramon; Luque, F. Javier; Unzeta, Mercedes; Marco-Contelles, Jose; Samadi, Abdelouahid</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8251-8270</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new family of multitarget mols. able to interact with acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), as well as with monoamino oxidase (MAO) A and B, has been synthesized.  Novel compds. (3-9) (I) (X = N, Y = CH, n = 0, 1, 2, 3; X = CH, Y = N, n = 1, 2; X = Y = N, n = 2) have been designed using a conjunctive approach that combines the benzylpiperidine moiety of the AChE inhibitor donepezil (II) and the indolyl propargylamino moiety of the MAO inhibitor N-[(5-benzyloxy-1-methyl-1H-indol-2-yl)methyl]-N-methylprop-2-yn-1-amine (III), connected through an oligomethylene linker.  The most promising hybrid I ( X =N, Y = CH, n =2) is a potent inhibitor of both MAO-A (IC50 = 5.2 ± 1.1 nM) and MAO-B (IC50 = 43 ± 8.0 nM) and is a moderately potent inhibitor of AChE (IC50 = 0.35 ± 0.01 μM) and BuChE (IC50 = 0.46 ± 0.06 μM).  Moreover, mol. modeling and kinetic studies support the dual binding site to AChE, which explains the inhibitory effect exerted on Aβ aggregation.  Overall, the results suggest that the new compds. are promising multitarget drug candidates with potential impact for Alzheimer's disease therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHRdbLgOyA0LVg90H21EOLACvtfcHk0ljsrSNi6KWZfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlGktrrP&md5=c82c849b5db4315744c4b9b9554b6b30</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1021%2Fjm200853t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200853t%26sid%3Dliteratum%253Aachs%26aulast%3DBolea%26aufirst%3DI.%26aulast%3DJuarez-Jimenez%26aufirst%3DJ.%26aulast%3Dde%2BLos%2BRios%26aufirst%3DC.%26aulast%3DChioua%26aufirst%3DM.%26aulast%3DPouplana%26aufirst%3DR.%26aulast%3DLuque%26aufirst%3DF.%2BJ.%26aulast%3DUnzeta%26aufirst%3DM.%26aulast%3DMarco-Contelles%26aufirst%3DJ.%26aulast%3DSamadi%26aufirst%3DA.%26atitle%3DSynthesis%252C%2520biological%2520evaluation%252C%2520and%2520molecular%2520modeling%2520of%2520donepezil%2520and%2520N-%255B%25285-%2528benzyloxy%2529-1-methyl-1H-indol-2-yl%2529methyl%255D-N-methylprop-2-yn-1-amine%2520hybrids%2520as%2520new%2520multipotent%2520cholinesterase%252Fmonoamine%2520oxidase%2520inhibitors%2520for%2520the%2520treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D8251%26epage%3D8270%26doi%3D10.1021%2Fjm200853t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref168"><div class="reference"><strong class="refLabel"><a href="#ref168" class="rightTabRefNumLink">168</a></strong><div class="NLM_citation" id="rightTab-cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sterling, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herzig, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goren, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finkelstein, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lerner, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldenberg, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miskolczi, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molnar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rantal, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamas, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toth, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zagyva, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zekany, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavian, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gross, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Razin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krais, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chorev, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Youdim, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstock, M.</span></span> <span> </span><span class="NLM_article-title">Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer’s disease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">5260</span>– <span class="NLM_lpage">5279</span>, <span class="refDoi"> DOI: 10.1021/jm020120c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm020120c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD38XotVymsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=5260-5279&author=J.+Sterlingauthor=Y.+Herzigauthor=T.+Gorenauthor=N.+Finkelsteinauthor=D.+Lernerauthor=W.+Goldenbergauthor=I.+Miskolcziauthor=S.+Molnarauthor=F.+Rantalauthor=T.+Tamasauthor=G.+Tothauthor=A.+Zagyvaauthor=A.+Zekanyauthor=G.+Lavianauthor=A.+Grossauthor=R.+Friedmanauthor=M.+Razinauthor=W.+Huangauthor=B.+Kraisauthor=M.+Chorevauthor=M.+B.+Youdimauthor=M.+Weinstock&title=Novel+dual+inhibitors+of+AChE+and+MAO+derived+from+hydroxy+aminoindan+and+phenethylamine+as+potential+treatment+for+Alzheimer%E2%80%99s+disease&doi=10.1021%2Fjm020120c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Dual Inhibitors of AChE and MAO Derived from Hydroxy Aminoindan and Phenethylamine as Potential Treatment for Alzheimer's Disease</span></div><div class="casAuthors">Sterling, Jeffrey; Herzig, Yaacov; Goren, Tamar; Finkelstein, Nina; Lerner, David; Goldenberg, Willy; Miskolczi, Istvan; Molnar, Sandor; Rantal, Ferenc; Tamas, Tivadar; Toth, Gyorgy; Zagyva, Adela; Zekany, Andras; Lavian, Gila; Gross, Aviva; Friedman, Rachel; Razin, Michal; Huang, Wei; Krais, Boris; Chorev, Michael; Youdim, Moussa B.; Weinstock, Marta</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">5260-5279</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Carbamate derivs. of N-propargylaminoindanes (Series I) and N-propargylphenethylamines (Series II) were synthesized via multistep procedures from the corresponding hydroxy precursors.  The resp. rasagiline- and selegiline-related series were designed to combine inhibitory activities of both acetylcholine esterase (AChE) and monoamine oxidase (MAO) by virtue of their carbamoyl and propargylamine pharmacophores.  Each compd. was tested for these activities in vitro in order to find mols. with similar potencies against each enzyme.  Compds. with such dual AChE and MAO inhibitory activities are expected to have potential for the treatment of Alzheimer's disease.  The obsd. SAR also offers insight into the requirements of the active sites on these enzymes.  A carbamate moiety was found to be essential for AChE inhibition, which was absent in the corresponding hydroxy precursors.  The propargyl group caused 2-70-fold decrease in AChE inhibitory activity (depending on the position of the carbamoyl group) of Series I, but had little or no effect in Series II.  Thus, the 6- and 7-carbamyloxyphenyls in Series I were either equipotent to, or slightly (2- to 5-fold) less active as AChE inhibitors than, the corresponding compds. in Series II, while the 4-carbamyloxyphenyls were more potent.  The presence of the carbamate moiety in 6- and 7-carbamyloxyphenyls of Series I, considerably decreased MAO-A and -B inhibitory activity, compared to that of the parent hydroxy analogs, while the opposite was true for Series II.  Thus, the 6- and 7-carbamyloxyphenyls in Series I were 2-3 orders of magnitude weaker MAO inhibitors while the 4- carbamyloxyphenyls were equipotent with the corresponding compds. in Series II.  In both series, N-methylation of the propargylamine enhanced the MAO (A and B equally) inhibitory activities and decreased the AChE inhibitory activity.  Two candidates belonging to the indan and tetralin ring systems (HCl salts of I and II) and one phenethylamine (mesylate salt of III) were identified as possible leads for further development based on the following criteria: (a) comparable AChE and MAO-B inhibitory activities, (b) good to moderate AChE inhibitory activity, and (c) lack of strong MAO-A selectivity.  However, it is likely that these compds. will be metabolized to the corresponding phenols, with inhibitory activities against AChE and/or MAO-A or -B, different from those of the parent carbamates.  Thus, the apparent enzyme inhibition will be a result of the combined inhibition of all of these individual metabolites.  The results of our ongoing in vivo screening programs will be published elsewhere.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0RScteajUEbVg90H21EOLACvtfcHk0ljX4LxEoOwGCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XotVymsLg%253D&md5=62136a48889ce0fe28a76aa70e577eb9</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1021%2Fjm020120c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020120c%26sid%3Dliteratum%253Aachs%26aulast%3DSterling%26aufirst%3DJ.%26aulast%3DHerzig%26aufirst%3DY.%26aulast%3DGoren%26aufirst%3DT.%26aulast%3DFinkelstein%26aufirst%3DN.%26aulast%3DLerner%26aufirst%3DD.%26aulast%3DGoldenberg%26aufirst%3DW.%26aulast%3DMiskolczi%26aufirst%3DI.%26aulast%3DMolnar%26aufirst%3DS.%26aulast%3DRantal%26aufirst%3DF.%26aulast%3DTamas%26aufirst%3DT.%26aulast%3DToth%26aufirst%3DG.%26aulast%3DZagyva%26aufirst%3DA.%26aulast%3DZekany%26aufirst%3DA.%26aulast%3DLavian%26aufirst%3DG.%26aulast%3DGross%26aufirst%3DA.%26aulast%3DFriedman%26aufirst%3DR.%26aulast%3DRazin%26aufirst%3DM.%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DKrais%26aufirst%3DB.%26aulast%3DChorev%26aufirst%3DM.%26aulast%3DYoudim%26aufirst%3DM.%2BB.%26aulast%3DWeinstock%26aufirst%3DM.%26atitle%3DNovel%2520dual%2520inhibitors%2520of%2520AChE%2520and%2520MAO%2520derived%2520from%2520hydroxy%2520aminoindan%2520and%2520phenethylamine%2520as%2520potential%2520treatment%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D5260%26epage%3D5279%26doi%3D10.1021%2Fjm020120c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref169"><div class="reference"><strong class="refLabel"><a href="#ref169" class="rightTabRefNumLink">169</a></strong><div class="NLM_citation" id="rightTab-cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yogev-Falach, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bar-Am, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amit, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinreb, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Youdim, M. B.</span></span> <span> </span><span class="NLM_article-title">A multifunctional, neuroprotective drug, ladostigil (TV3326), regulates holo-APP translation and processing</span>. <i>FASEB J.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">2177</span>– <span class="NLM_lpage">2179</span>, <span class="refDoi"> DOI: 10.1096/fj.05-4910fje</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1096%2Ffj.05-4910fje" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=16935943" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVyrurvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2006&pages=2177-2179&author=M.+Yogev-Falachauthor=O.+Bar-Amauthor=T.+Amitauthor=O.+Weinrebauthor=M.+B.+Youdim&title=A+multifunctional%2C+neuroprotective+drug%2C+ladostigil+%28TV3326%29%2C+regulates+holo-APP+translation+and+processing&doi=10.1096%2Ffj.05-4910fje"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">A multifunctional, neuroprotective drug, ladostigil (TV3326), regulates holo-APP translation and processing</span></div><div class="casAuthors">Yogev-Falach, Merav; Bar-Am, Orit; Amit, Tamar; Weinreb, Orly; Youdim, Moussa B. H.</div><div class="citationInfo"><span class="NLM_cas:title">FASEB Journal</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2177-2179</span>CODEN:
                <span class="NLM_cas:coden">FAJOEC</span>;
        ISSN:<span class="NLM_cas:issn">0892-6638</span>.
    
            (<span class="NLM_cas:orgname">Federation of American Societies for Experimental Biology</span>)
        </div><div class="casAbstract">The recent therapeutic approach in which drug candidates are designed to possess diverse pharmacol. properties and act on multiple targets has stimulated the development of the bifunctional drug ladostigil (TV3326) [(N-propargyl-(3R) aminoindan-5-yl)-Et Me carbamate].  Ladostigil combines the neuroprotective effects of the antiparkinson drug rasagiline, a selective monoamine oxidase (MAO)-B inhibitor, with the cholinesterase (ChE) inhibitory activity of rivastigmine in a single mol., as a potential treatment for Alzheimer's disease (AD) and Lewy Body disease.  Here, we assessed the dual effects of lodostigil in terms of the mol. mechanism of neuroprotection and amyloid precursor protein (APP) regulation/processing by using an apoptotic model of neuroblastoma SK-N-SH cells.  Ladostigil dose-dependently decreased cell death via inhibition of the cleavage and prevention of caspase-3 activation (IC50=1.05 μM) through a mechanism related to regulation of the Bcl-2 family proteins, which resulted in reduced levels of Bad and Bax and induced levels of Bcl-2 gene and protein expression.  We have also followed APP regulation/processing and found that ladostigil markedly decreased apoptotic-induced levels of holo-APP protein without altering APP mRNA levels, suggesting a posttranscriptional mechanism.  In addn., the drug-elevated phosphorylated protein kinase C (pPKC) levels and stimulated the release of the nonamyloidogenic ot-secretase proteolytic pathway.  Similar to ladostigil, its S-isomer, TV3279, which is a ChE inhibitor but lacks MAO inhibitory activity, exerted neuroprotective properties and regulated APP processing, indicating that these effects are independent of MAO inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEeVwmkmV5FrVg90H21EOLACvtfcHk0ljX4LxEoOwGCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVyrurvJ&md5=98af5388c49c4d1a4cf7b56752367fc6</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1096%2Ffj.05-4910fje&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1096%252Ffj.05-4910fje%26sid%3Dliteratum%253Aachs%26aulast%3DYogev-Falach%26aufirst%3DM.%26aulast%3DBar-Am%26aufirst%3DO.%26aulast%3DAmit%26aufirst%3DT.%26aulast%3DWeinreb%26aufirst%3DO.%26aulast%3DYoudim%26aufirst%3DM.%2BB.%26atitle%3DA%2520multifunctional%252C%2520neuroprotective%2520drug%252C%2520ladostigil%2520%2528TV3326%2529%252C%2520regulates%2520holo-APP%2520translation%2520and%2520processing%26jtitle%3DFASEB%2520J.%26date%3D2006%26volume%3D20%26spage%3D2177%26epage%3D2179%26doi%3D10.1096%2Ffj.05-4910fje" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref170"><div class="reference"><strong class="refLabel"><a href="#ref170" class="rightTabRefNumLink">170</a></strong><div class="NLM_citation" id="rightTab-cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Denya, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malan, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enogieru, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omoruyi, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekpo, O. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapp, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zindo, F. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joubert, J.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and evaluation of indole derivatives as multifunctional agents against Alzheimer’s disease</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">357</span>– <span class="NLM_lpage">370</span>, <span class="refDoi"> DOI: 10.1039/C7MD00569E</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1039%2FC7MD00569E" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=30108930" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC1cXovFSnuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=357-370&author=I.+Denyaauthor=S.+F.+Malanauthor=A.+B.+Enogieruauthor=S.+I.+Omoruyiauthor=O.+E.+Ekpoauthor=E.+Kappauthor=F.+T.+Zindoauthor=J.+Joubert&title=Design%2C+synthesis+and+evaluation+of+indole+derivatives+as+multifunctional+agents+against+Alzheimer%E2%80%99s+disease&doi=10.1039%2FC7MD00569E"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit170R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and evaluation of indole derivatives as multifunctional agents against Alzheimer's disease</span></div><div class="casAuthors">Denya, Ireen; Malan, Sarel F.; Enogieru, Adaze B.; Omoruyi, Sylvester I.; Ekpo, Okobi E.; Kapp, Erika; Zindo, Frank T.; Joubert, Jacques</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">357-370</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A series of indole derivs. was designed and synthesized to improve on activity and circumvent pharmacokinetic limitations experienced with the structurally related compd., ladostigil.  The compds. consisted of a propargylamine moiety (a known MAO inhibitor and neuroprotector) at the N1 position and a ChE inhibiting diethyl-carbamate/urea moiety at the 5 or 6 position of the indole ring.  In order to prevent or slow down the in vivo hydrolysis and deactivation assocd. with the carbamate function of ladostigil, a urea moeity was incorporated into selected compds. to obtain more metabolically stable structures.  The majority of the synthesized compds. showed improved MAO-A inhibitory activity compared to ladostigil.  The compds. possessing the propargylamine moiety showed good MAO-B inhibitory activity with 6 and 8 portraying IC50 values between 14-20 fold better than ladostigil.  The ChE assay results indicated that the compds. have non-selective inhibitory activities on eeAChE and eqBuChE regardless of the type or position of substitution (IC50: 2-5 μM).  MAO-A and MAO-B docking results showed that the propargylamine moiety was positioned in close proximity to the FAD cofactor suggesting that the good inhibitory activity may be attributed to the propargylamine moiety and irreversible inhibition as confirmed in the reversibility studies.  Docking results also indicated that the compds. have interactions with important amino acids in the AChE and BuChE catalytic sites.  Compd. 6 was the most potent multifunctional agent showing better inhibitory activity than ladostigil in vitro on all enzymes tested (hMAO-A IC50 = 4.31 μM, hMAO-B IC50 = 2.62 μM, eeAChE IC50 = 3.70 μM, eqBuChE IC50 = 2.82 μM).  Chem. stability tests confirmed the diethyl-urea contg. compd. 6 to be more stable than its diethyl-carbamate contg. counterpart compd. 8.  Compd. 6 also exerted significant neuroprotection (52.62% at 1 μM) against MPP+ insult to SH-SY5Y neural cells and has good in silico predicted ADMET properties.  The favorable neuronal enzyme inhibitory activity, likely improved pharmacokinetic properties in vivo and the potent neuroprotective ability of compd. 6 make it a promising compd. for further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJKcedPibrbbVg90H21EOLACvtfcHk0ljX4LxEoOwGCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXovFSnuw%253D%253D&md5=81fd9574c036f0ad3923170e5a7c206c</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1039%2FC7MD00569E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC7MD00569E%26sid%3Dliteratum%253Aachs%26aulast%3DDenya%26aufirst%3DI.%26aulast%3DMalan%26aufirst%3DS.%2BF.%26aulast%3DEnogieru%26aufirst%3DA.%2BB.%26aulast%3DOmoruyi%26aufirst%3DS.%2BI.%26aulast%3DEkpo%26aufirst%3DO.%2BE.%26aulast%3DKapp%26aufirst%3DE.%26aulast%3DZindo%26aufirst%3DF.%2BT.%26aulast%3DJoubert%26aufirst%3DJ.%26atitle%3DDesign%252C%2520synthesis%2520and%2520evaluation%2520of%2520indole%2520derivatives%2520as%2520multifunctional%2520agents%2520against%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DMedChemComm%26date%3D2018%26volume%3D9%26spage%3D357%26epage%3D370%26doi%3D10.1039%2FC7MD00569E" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref171"><div class="reference"><strong class="refLabel"><a href="#ref171" class="rightTabRefNumLink">171</a></strong><div class="NLM_citation" id="rightTab-cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span> <span> </span><span class="NLM_article-title">A novel series of tacrine-selegiline hybrids with cholinesterase and monoamine oxidase inhibition activities for the treatment of Alzheimer’s disease</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">745</span>– <span class="NLM_lpage">753</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2013.01.039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1016%2Fj.ejmech.2013.01.039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=23454517" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlslWgu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2013&pages=745-753&author=C.+Luauthor=Q.+Zhouauthor=J.+Yanauthor=Z.+Duauthor=L.+Huangauthor=X.+Li&title=A+novel+series+of+tacrine-selegiline+hybrids+with+cholinesterase+and+monoamine+oxidase+inhibition+activities+for+the+treatment+of+Alzheimer%E2%80%99s+disease&doi=10.1016%2Fj.ejmech.2013.01.039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">A novel series of tacrine-selegiline hybrids with cholinesterase and monoamine oxidase inhibition activities for the treatment of Alzheimer's disease</span></div><div class="casAuthors">Lu, Chuanjun; Zhou, Qi; Yan, Jun; Du, Zhiyun; Huang, Ling; Li, Xingshu</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">745-753</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A novel series of tacrine-selegiline hybrids was synthesized and evaluated for application as inhibitors of cholinesterase (AChE/BuChE) and monoamine oxidase (MAO-A/B).  The results demonstrate that most of the synthesized compds. exhibit high inhibitory activity.  Among these compds., compd. I provided a good balance of activity towards all targets (with IC50 values of 22.6 nM, 9.37 nM, 0.3724 μM, and 0.1810 μM for AChE, BuChE, MAO-A and MAO-B, resp.).  These results indicated that I has the potential to be a multi-functional candidate for Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB-OnHqpBtBrVg90H21EOLACvtfcHk0ljNG-X_CHhDmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlslWgu7g%253D&md5=9e0cfdecbe4e8a2890482f8b32cbf4a4</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2013.01.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2013.01.039%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DC.%26aulast%3DZhou%26aufirst%3DQ.%26aulast%3DYan%26aufirst%3DJ.%26aulast%3DDu%26aufirst%3DZ.%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DX.%26atitle%3DA%2520novel%2520series%2520of%2520tacrine-selegiline%2520hybrids%2520with%2520cholinesterase%2520and%2520monoamine%2520oxidase%2520inhibition%2520activities%2520for%2520the%2520treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2013%26volume%3D62%26spage%3D745%26epage%3D753%26doi%3D10.1016%2Fj.ejmech.2013.01.039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref172"><div class="reference"><strong class="refLabel"><a href="#ref172" class="rightTabRefNumLink">172</a></strong><div class="NLM_citation" id="rightTab-cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esteban, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ojima, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bautista-Aguilera, O. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inokuchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moraleda, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iriepa, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samadi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Youdim, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soriano, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrero, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez Fernandez, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Murillo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marco-Contelles, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unzeta, M.</span></span> <span> </span><span class="NLM_article-title">Donepezil + propargylamine + 8-hydroxyquinoline hybrids as new multifunctional metal-chelators, ChE and MAO inhibitors for the potential treatment of Alzheimer’s disease</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">543</span>– <span class="NLM_lpage">561</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2014.04.078</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1016%2Fj.ejmech.2014.04.078" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=24813882" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC2cXovVensL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2014&pages=543-561&author=L.+Wangauthor=G.+Estebanauthor=M.+Ojimaauthor=O.+M.+Bautista-Aguileraauthor=T.+Inokuchiauthor=I.+Moraledaauthor=I.+Iriepaauthor=A.+Samadiauthor=M.+B.+Youdimauthor=A.+Romeroauthor=E.+Sorianoauthor=R.+Herreroauthor=A.+P.+Fernandez+Fernandezauthor=R.+Martinez-Murilloauthor=J.+Marco-Contellesauthor=M.+Unzeta&title=Donepezil+%2B+propargylamine+%2B+8-hydroxyquinoline+hybrids+as+new+multifunctional+metal-chelators%2C+ChE+and+MAO+inhibitors+for+the+potential+treatment+of+Alzheimer%E2%80%99s+disease&doi=10.1016%2Fj.ejmech.2014.04.078"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Donepezil + propargylamine + 8-hydroxyquinoline hybrids as new multifunctional metal-chelators, ChE and MAO inhibitors for the potential treatment of Alzheimer's disease</span></div><div class="casAuthors">Wang, Li; Esteban, Gerard; Ojima, Masaki; Bautista-Aguilera, Oscar M.; Inokuchi, Tsutomu; Moraleda, Ignacio; Iriepa, Isabel; Samadi, Abdelouahid; Youdim, Moussa B. H.; Romero, Alejandro; Soriano, Elena; Herrero, Raquel; Fernandez Fernandez, Ana Patricia; Ricardo-Martinez-Murillo; Marco-Contelles, Jose; Unzeta, Mercedes</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">543-561</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The synthesis, biochem. evaluation, ADMET, toxicity and mol. modeling of novel multi-target-directed Donepezil + Propargylamine + 8-Hydroxyquinoline (DPH) hybrids for the potential prevention and treatment of Alzheimer's disease is described.  The most interesting deriv. was racemic α-aminotrile4-(1-benzylpiperidin-4-yl)-2-(((8-hydroxyquinolin-5-yl)methyl)(prop-2-yn-1-yl)amino) butanenitrile (DPH6) [MAO A (IC50 = 6.2±0.7 μM); MAO B (IC50 = 10.2±0.9 μM); AChE (IC50 = 1.8±0.1 μM); BuChE (IC50 = 1.6±0.25 μM)], an irreversible MAO A/B inhibitor and mixed-type AChE inhibitor with metal-chelating properties.  According to docking studies, both DPH6 enantiomers interact simultaneously with the catalytic and peripheral site of EeAChE through a linker of appropriate length, supporting the obsd. mixed-type AChE inhibition.  Both enantiomers exhibited a relatively similar position of both hydroxyquinoline and benzyl moieties with the rest of the mol. easily accommodated in the relatively large cavity of MAO A.  For MAO B, the quinoline system was hosted at the cavity entrance, whereas for MAO A this system occupied the substrate cavity.  In this disposition the quinoline moiety interacted directly with the FAD arom. ring.  Very similar binding affinity values were also obsd. for both enantiomers with ChE and MAO enzymes.  DPH derivs. exhibited moderate to good ADMET properties and brain penetration capacity for CNS activity.  DPH6 was less toxic than donepezil at high concns.; while at low concns. both displayed a similar cell viability profile.  Finally, in a passive avoidance task, the antiamnesic effect of DPH6 was tested on mice with exptl. induced amnesia.  DPH6 was capable to significantly decrease scopolamine-induced learning deficits in healthy adult mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphrIxeM4RW2rVg90H21EOLACvtfcHk0ljNG-X_CHhDmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXovVensL8%253D&md5=2e1f262b4002653cbac7a6dafabe3548</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.04.078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.04.078%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DL.%26aulast%3DEsteban%26aufirst%3DG.%26aulast%3DOjima%26aufirst%3DM.%26aulast%3DBautista-Aguilera%26aufirst%3DO.%2BM.%26aulast%3DInokuchi%26aufirst%3DT.%26aulast%3DMoraleda%26aufirst%3DI.%26aulast%3DIriepa%26aufirst%3DI.%26aulast%3DSamadi%26aufirst%3DA.%26aulast%3DYoudim%26aufirst%3DM.%2BB.%26aulast%3DRomero%26aufirst%3DA.%26aulast%3DSoriano%26aufirst%3DE.%26aulast%3DHerrero%26aufirst%3DR.%26aulast%3DFernandez%2BFernandez%26aufirst%3DA.%2BP.%26aulast%3DMartinez-Murillo%26aufirst%3DR.%26aulast%3DMarco-Contelles%26aufirst%3DJ.%26aulast%3DUnzeta%26aufirst%3DM.%26atitle%3DDonepezil%2520%252B%2520propargylamine%2520%252B%25208-hydroxyquinoline%2520hybrids%2520as%2520new%2520multifunctional%2520metal-chelators%252C%2520ChE%2520and%2520MAO%2520inhibitors%2520for%2520the%2520potential%2520treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2014%26volume%3D80%26spage%3D543%26epage%3D561%26doi%3D10.1016%2Fj.ejmech.2014.04.078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref173"><div class="reference"><strong class="refLabel"><a href="#ref173" class="rightTabRefNumLink">173</a></strong><div class="NLM_citation" id="rightTab-cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esteban, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brogi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shionoya, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campiani, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unzeta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inokuchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marco-Contelles, J.</span></span> <span> </span><span class="NLM_article-title">Donepezil-like multifunctional agents: Design, synthesis, molecular modeling and biological evaluation</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>121</i></span>,  <span class="NLM_fpage">864</span>– <span class="NLM_lpage">879</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2015.10.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1016%2Fj.ejmech.2015.10.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=26471320" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1GktL%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2016&pages=864-879&author=M.+Y.+Wuauthor=G.+Estebanauthor=S.+Brogiauthor=M.+Shionoyaauthor=L.+Wangauthor=G.+Campianiauthor=M.+Unzetaauthor=T.+Inokuchiauthor=S.+Butiniauthor=J.+Marco-Contelles&title=Donepezil-like+multifunctional+agents%3A+Design%2C+synthesis%2C+molecular+modeling+and+biological+evaluation&doi=10.1016%2Fj.ejmech.2015.10.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">Donepezil-like multifunctional agents: Design, synthesis, molecular modeling and biological evaluation</span></div><div class="casAuthors">Wu, Ming-Yu; Esteban, Gerard; Brogi, Simone; Shionoya, Masahi; Wang, Li; Campiani, Giuseppe; Unzeta, Mercedes; Inokuchi, Tsutomu; Butini, Stefania; Marco-Contelles, Jose</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">864-879</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Currently available drugs against Alzheimer's disease (AD) are only able to ameliorate the disease symptoms resulting in a moderate improvement in memory and cognitive function without any efficacy in preventing and inhibiting the progression of the pathol.  In an effort to obtain disease-modifying anti-Alzheimer's drugs (DMAADs) following the multifactorial nature of AD, we have recently developed multifunctional compds.  We herein describe the design, synthesis, mol. modeling and biol. evaluation of a new series of donepezil-related compds. possessing metal chelating properties, and being capable of targeting different enzymic systems related to AD (cholinesterases, ChEs, and monoamine oxidase A, MAO-A).  Among this set of analogs compd. I showed excellent ChEs inhibition potency and a selective MAO-A inhibition (vs MAO-B) coupled to strong complexing properties for zinc and copper ions, both known to be involved in the progression of AD.  Moreover, I exhibited moderate antioxidant properties as found by in vitro assessment.  This compd. represents a novel donepezil-hydroxyquinoline hybrid with DMAAD profile paving the way to the development of a novel class of drugs potentially able to treat AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCOvmO6AroXrVg90H21EOLACvtfcHk0ljNG-X_CHhDmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1GktL%252FM&md5=7bf3ba2586578a39287a0aacbbe3f672</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.10.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.10.001%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DM.%2BY.%26aulast%3DEsteban%26aufirst%3DG.%26aulast%3DBrogi%26aufirst%3DS.%26aulast%3DShionoya%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DCampiani%26aufirst%3DG.%26aulast%3DUnzeta%26aufirst%3DM.%26aulast%3DInokuchi%26aufirst%3DT.%26aulast%3DButini%26aufirst%3DS.%26aulast%3DMarco-Contelles%26aufirst%3DJ.%26atitle%3DDonepezil-like%2520multifunctional%2520agents%253A%2520Design%252C%2520synthesis%252C%2520molecular%2520modeling%2520and%2520biological%2520evaluation%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D121%26spage%3D864%26epage%3D879%26doi%3D10.1016%2Fj.ejmech.2015.10.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref174"><div class="reference"><strong class="refLabel"><a href="#ref174" class="rightTabRefNumLink">174</a></strong><div class="NLM_citation" id="rightTab-cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bautista-Aguilera, O. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esteban, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chioua, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolic, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agbaba, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moraleda, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iriepa, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soriano, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samadi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unzeta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marco-Contelles, J.</span></span> <span> </span><span class="NLM_article-title">Multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer’s disease: design, synthesis, biochemical evaluation, ADMET, molecular modeling, and QSAR analysis of novel donepezil-pyridyl hybrids</span>. <i>Drug Des., Dev. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1893</span>– <span class="NLM_lpage">1910</span>, <span class="refDoi"> DOI: 10.2147/DDDT.S69258</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.2147%2FDDDT.S69258" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=25378907" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A280%3ADC%252BC2M3ms1alug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2014&pages=1893-1910&author=O.+M.+Bautista-Aguileraauthor=G.+Estebanauthor=M.+Chiouaauthor=K.+Nikolicauthor=D.+Agbabaauthor=I.+Moraledaauthor=I.+Iriepaauthor=E.+Sorianoauthor=A.+Samadiauthor=M.+Unzetaauthor=J.+Marco-Contelles&title=Multipotent+cholinesterase%2Fmonoamine+oxidase+inhibitors+for+the+treatment+of+Alzheimer%E2%80%99s+disease%3A+design%2C+synthesis%2C+biochemical+evaluation%2C+ADMET%2C+molecular+modeling%2C+and+QSAR+analysis+of+novel+donepezil-pyridyl+hybrids&doi=10.2147%2FDDDT.S69258"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">Multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease: design, synthesis, biochemical evaluation, ADMET, molecular modeling, and QSAR analysis of novel donepezil-pyridyl hybrids</span></div><div class="casAuthors">Bautista-Aguilera Oscar M; Chioua Mourad; Samadi Abdelouahid; Marco-Contelles Jose; Esteban Gerard; Unzeta Mercedes; Nikolic Katarina; Agbaba Danica; Moraleda Ignacio; Iriepa Isabel; Soriano Elena</div><div class="citationInfo"><span class="NLM_cas:title">Drug design, development and therapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1893-910</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The design, synthesis, and biochemical evaluation of donepezil-pyridyl hybrids (DPHs) as multipotent cholinesterase (ChE) and monoamine oxidase (MAO) inhibitors for the potential treatment of Alzheimer's disease (AD) is reported.  The 3D-quantitative structure-activity relationship study was used to define 3D-pharmacophores for inhibition of MAO A/B, acetylcholinesterase (AChE), and butyrylcholinesterase (BuChE) enzymes and to design DPHs as novel multi-target drug candidates with potential impact in the therapy of AD.  DPH14 (Electrophorus electricus AChE [EeAChE]: half maximal inhibitory concentration [IC50] =1.1±0.3 nM; equine butyrylcholinesterase [eqBuChE]: IC50 =600±80 nM) was 318-fold more potent for the inhibition of AChE, and 1.3-fold less potent for the inhibition of BuChE than the reference compound ASS234.  DPH14 is a potent human recombinant BuChE (hBuChE) inhibitor, in the same range as DPH12 or DPH16, but 13.1-fold less potent than DPH15 for the inhibition of human recombinant AChE (hAChE).  Compared with donepezil, DPH14 is almost equipotent for the inhibition of hAChE, and 8.8-fold more potent for hBuChE.  Concerning human monoamine oxidase (hMAO) A inhibition, only DPH9 and 5 proved active, compound DPH9 being the most potent (IC50 [MAO A] =5,700±2,100 nM).  For hMAO B, only DPHs 13 and 14 were moderate inhibitors, and compound DPH14 was the most potent (IC50 [MAO B] =3,950±940 nM).  Molecular modeling of inhibitor DPH14 within EeAChE showed a binding mode with an extended conformation, interacting simultaneously with both catalytic and peripheral sites of EeAChE thanks to a linker of appropriate length.  Absortion, distribution, metabolism, excretion and toxicity analysis showed that structures lacking phenyl-substituent show better druglikeness profiles; in particular, DPHs13-15 showed the most suitable absortion, distribution, metabolism, excretion and toxicity properties.  Novel donepezil-pyridyl hybrid DPH14 is a potent, moderately selective hAChE and selective irreversible hMAO B inhibitor which might be considered as a promising compound for further development for the treatment of AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSpLMbTfemCUrFU0A1HOshhfW6udTcc2eYq3rEJMmdVnbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M3ms1alug%253D%253D&md5=3b3ba418a994f9a5aa796dc3710260a0</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S69258&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S69258%26sid%3Dliteratum%253Aachs%26aulast%3DBautista-Aguilera%26aufirst%3DO.%2BM.%26aulast%3DEsteban%26aufirst%3DG.%26aulast%3DChioua%26aufirst%3DM.%26aulast%3DNikolic%26aufirst%3DK.%26aulast%3DAgbaba%26aufirst%3DD.%26aulast%3DMoraleda%26aufirst%3DI.%26aulast%3DIriepa%26aufirst%3DI.%26aulast%3DSoriano%26aufirst%3DE.%26aulast%3DSamadi%26aufirst%3DA.%26aulast%3DUnzeta%26aufirst%3DM.%26aulast%3DMarco-Contelles%26aufirst%3DJ.%26atitle%3DMultipotent%2520cholinesterase%252Fmonoamine%2520oxidase%2520inhibitors%2520for%2520the%2520treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%253A%2520design%252C%2520synthesis%252C%2520biochemical%2520evaluation%252C%2520ADMET%252C%2520molecular%2520modeling%252C%2520and%2520QSAR%2520analysis%2520of%2520novel%2520donepezil-pyridyl%2520hybrids%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2014%26volume%3D8%26spage%3D1893%26epage%3D1910%26doi%3D10.2147%2FDDDT.S69258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref175"><div class="reference"><strong class="refLabel"><a href="#ref175" class="rightTabRefNumLink">175</a></strong><div class="NLM_citation" id="rightTab-cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koch, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akkari, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunschweiger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borrmann, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlenk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuppers, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kose, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radjainia, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hockemeyer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drabczynska, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiec-Kononowicz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, C. E.</span></span> <span> </span><span class="NLM_article-title">1,3-Dialkyl-substituted tetrahydropyrimido[1,2-f]purine-2,4-diones as multiple target drugs for the potential treatment of neurodegenerative diseases</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">7435</span>– <span class="NLM_lpage">7452</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2013.09.044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1016%2Fj.bmc.2013.09.044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=24139167" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1CrsbfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=7435-7452&author=P.+Kochauthor=R.+Akkariauthor=A.+Brunschweigerauthor=T.+Borrmannauthor=M.+Schlenkauthor=P.+Kuppersauthor=M.+Koseauthor=H.+Radjainiaauthor=J.+Hockemeyerauthor=A.+Drabczynskaauthor=K.+Kiec-Kononowiczauthor=C.+E.+Muller&title=1%2C3-Dialkyl-substituted+tetrahydropyrimido%5B1%2C2-f%5Dpurine-2%2C4-diones+as+multiple+target+drugs+for+the+potential+treatment+of+neurodegenerative+diseases&doi=10.1016%2Fj.bmc.2013.09.044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">1,3-Dialkyl-substituted tetrahydropyrimido[1,2-f]purine-2,4-diones as multiple target drugs for the potential treatment of neurodegenerative diseases</span></div><div class="casAuthors">Koch, Pierre; Akkari, Rhalid; Brunschweiger, Andreas; Borrmann, Thomas; Schlenk, Miriam; Kueppers, Petra; Koese, Meryem; Radjainia, Hamid; Hockemeyer, Joerg; Drabczynska, Anna; Kiec-Kononowicz, Katarzyna; Mueller, Christa E.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">7435-7452</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Adenosine receptors and monoamine oxidases are drug targets for neurodegenerative diseases such as Parkinson's and Alzheimer's disease.  In the present study the authors prepd. a library of 55 mostly novel tetrahydropyrimido[2,1-f]purinediones I [R1 = Me, Et, n-Pr, CH≡CCH2; R2 = Me, Et, n-Pr; R3 = PhCH2, 4-FC6H4, 2-thienyl, etc.].  A synthetic strategy to obtain 3-propargyl-substituted tetrahydropyrimido[2,1-f]purinedione derivs. was developed.  The new compds. were evaluated for their interaction with all four adenosine receptor subtypes and for their ability to inhibit monoamine oxidases (MAO).  Introduction of mono- or di-chloro-substituted Ph, benzyl or phenethyl residues at N9 of the 1,3-di-Me series led to the discovery of a novel class of potent MAO-B inhibitors, the most potent compd. being I [R1 = Me; R2 = Me; R3 = 3,4-Cl2C6H3CH2] 9-(3,4-dichlorobenzyl)-1,3-dimethyl-6,7,8,9-tetrahydropyrimido[1,2-f]purine-2,4(1H,3H)-dione (IC50 human MAO-B: 0.0629 μM), which displayed high selectivity vs. the other investigated targets.  Potent dually active A1/A2A adenosine receptor antagonists were identified, for example, 9-benzyl-1-methyl-3-propargyl-6,7,8,9-tetrahydropyrimido[1,2-f]purine-2,4(1H,3H)dione I [R1 = CH≡CCH2; R2 = Me; R3 = PhCH2] (Ki, human receptors, A1: 0.249 μM, A2A: 0.253 μM).  Several compds. showed triple-target inhibition, the best compd. being I [R1 = CH≡CCH2; R2 = Me; R3 = 3-MeOC6H4CH2] (KiA1: 0.605 μM, KiA2A: 0.417 μM, IC50 MAO-B: 1.80 μM).  Compds. inhibiting several different targets involved in neurodegeneration may exhibit additive or even synergistic effects in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPERWbTreIyLVg90H21EOLACvtfcHk0ljJzQklcl7LQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1CrsbfK&md5=27b1f8581d9f8c96d80d93a1117e6008</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2013.09.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2013.09.044%26sid%3Dliteratum%253Aachs%26aulast%3DKoch%26aufirst%3DP.%26aulast%3DAkkari%26aufirst%3DR.%26aulast%3DBrunschweiger%26aufirst%3DA.%26aulast%3DBorrmann%26aufirst%3DT.%26aulast%3DSchlenk%26aufirst%3DM.%26aulast%3DKuppers%26aufirst%3DP.%26aulast%3DKose%26aufirst%3DM.%26aulast%3DRadjainia%26aufirst%3DH.%26aulast%3DHockemeyer%26aufirst%3DJ.%26aulast%3DDrabczynska%26aufirst%3DA.%26aulast%3DKiec-Kononowicz%26aufirst%3DK.%26aulast%3DMuller%26aufirst%3DC.%2BE.%26atitle%3D1%252C3-Dialkyl-substituted%2520tetrahydropyrimido%255B1%252C2-f%255Dpurine-2%252C4-diones%2520as%2520multiple%2520target%2520drugs%2520for%2520the%2520potential%2520treatment%2520of%2520neurodegenerative%2520diseases%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2013%26volume%3D21%26spage%3D7435%26epage%3D7452%26doi%3D10.1016%2Fj.bmc.2013.09.044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref176"><div class="reference"><strong class="refLabel"><a href="#ref176" class="rightTabRefNumLink">176</a></strong><div class="NLM_citation" id="rightTab-cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Siddiq, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dembitsky, V.</span></span> <span> </span><span class="NLM_article-title">Acetylenic anticancer agents</span>. <i>Anti-Cancer Agents Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">132</span>– <span class="NLM_lpage">170</span>, <span class="refDoi"> DOI: 10.2174/187152008783497073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.2174%2F187152008783497073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=18288919" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsFOmsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=132-170&author=A.+Siddiqauthor=V.+Dembitsky&title=Acetylenic+anticancer+agents&doi=10.2174%2F187152008783497073"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">Acetylenic anticancer agents</span></div><div class="casAuthors">Siddiq, A.; Dembitsky, V.</div><div class="citationInfo"><span class="NLM_cas:title">Anti-Cancer Agents in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">132-170</span>CODEN:
                <span class="NLM_cas:coden">AAMCE4</span>;
        ISSN:<span class="NLM_cas:issn">1871-5206</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  This review is a comprehensive survey of acetylenic anticancer agents obtained from living organisms.  Acetylenic metabolites belong to a class of mols. contg. triple bond(s).  They are found in plants, fungi, microorganisms, and marine invertebrates.  Although acetylenes are common as components of terrestrial plants, fungi, and bacteria, it is only within the last 30 years that biol. active polyacetylenes having unusual structural features have been reported from plants, cyanobacteria, algae, invertebrates, and other sources.  Naturally occurring aquatic acetylenes are of particular interest since many of them display important biol. activities and possess antitumor, antibacterial, antimicrobial, antifungal, phototoxic, HIV inhibitory, and immunosuppressive properties.  There is no doubt that they are of great interest, esp. for the medicinal chem., and/or pharmaceutical industries.  This review presents structures and describes cytotoxic activities of more than 300 acetylenic metabolites isolated from living organisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrw4lcEs6Xy9bVg90H21EOLACvtfcHk0ljJzQklcl7LQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsFOmsb4%253D&md5=6bbede7c9a964ff699d1b560411b19cf</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.2174%2F187152008783497073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F187152008783497073%26sid%3Dliteratum%253Aachs%26aulast%3DSiddiq%26aufirst%3DA.%26aulast%3DDembitsky%26aufirst%3DV.%26atitle%3DAcetylenic%2520anticancer%2520agents%26jtitle%3DAnti-Cancer%2520Agents%2520Med.%2520Chem.%26date%3D2008%26volume%3D8%26spage%3D132%26epage%3D170%26doi%3D10.2174%2F187152008783497073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref177"><div class="reference"><strong class="refLabel"><a href="#ref177" class="rightTabRefNumLink">177</a></strong><div class="NLM_citation" id="rightTab-cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kinashi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O̅take, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yonehara, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, Y.</span></span> <span> </span><span class="NLM_article-title">The structure of salinomycin, a new member of the polyether antibiotics</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">1973</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">4955</span>– <span class="NLM_lpage">4958</span>, <span class="refDoi"> DOI: 10.1016/S0040-4039(01)87382-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1016%2FS0040-4039%2801%2987382-2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1973&pages=4955-4958&author=H.+Kinashiauthor=N.+O%CC%85takeauthor=H.+Yoneharaauthor=S.+Satoauthor=Y.+Saito&title=The+structure+of+salinomycin%2C+a+new+member+of+the+polyether+antibiotics&doi=10.1016%2FS0040-4039%2801%2987382-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1016%2FS0040-4039%2801%2987382-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4039%252801%252987382-2%26sid%3Dliteratum%253Aachs%26aulast%3DKinashi%26aufirst%3DH.%26aulast%3DO%25CC%2585take%26aufirst%3DN.%26aulast%3DYonehara%26aufirst%3DH.%26aulast%3DSato%26aufirst%3DS.%26aulast%3DSaito%26aufirst%3DY.%26atitle%3DThe%2520structure%2520of%2520salinomycin%252C%2520a%2520new%2520member%2520of%2520the%2520polyether%2520antibiotics%26jtitle%3DTetrahedron%2520Lett.%26date%3D1973%26volume%3D14%26spage%3D4955%26epage%3D4958%26doi%3D10.1016%2FS0040-4039%2801%2987382-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref178"><div class="reference"><strong class="refLabel"><a href="#ref178" class="rightTabRefNumLink">178</a></strong><div class="NLM_citation" id="rightTab-cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mai, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hienzsch, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caneque, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wicinski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cabaud, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leroy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">David, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acevedo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ginestier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birnbaum, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charafe-Jauffret, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Codogno, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehrpour, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, R.</span></span> <span> </span><span class="NLM_article-title">Salinomycin kills cancer stem cells by sequestering iron in lysosomes</span>. <i>Nat. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1025</span>– <span class="NLM_lpage">1033</span>, <span class="refDoi"> DOI: 10.1038/nchem.2778</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1038%2Fnchem.2778" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=28937680" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnslKku7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2017&pages=1025-1033&author=T.+T.+Maiauthor=A.+Hamaiauthor=A.+Hienzschauthor=T.+Canequeauthor=S.+Mullerauthor=J.+Wicinskiauthor=O.+Cabaudauthor=C.+Leroyauthor=A.+Davidauthor=V.+Acevedoauthor=A.+Ryoauthor=C.+Ginestierauthor=D.+Birnbaumauthor=E.+Charafe-Jauffretauthor=P.+Codognoauthor=M.+Mehrpourauthor=R.+Rodriguez&title=Salinomycin+kills+cancer+stem+cells+by+sequestering+iron+in+lysosomes&doi=10.1038%2Fnchem.2778"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">Salinomycin kills cancer stem cells by sequestering iron in lysosomes</span></div><div class="casAuthors">Mai, Trang Thi; Hamai, Ahmed; Hienzsch, Antje; Caneque, Tatiana; Muller, Sebastian; Wicinski, Julien; Cabaud, Olivier; Leroy, Christine; David, Amandine; Acevedo, Veronica; Ryo, Akihide; Ginestier, Christophe; Birnbaum, Daniel; Charafe-Jauffret, Emmanuelle; Codogno, Patrice; Mehrpour, Maryam; Rodriguez, Raphael</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1025-1033</span>CODEN:
                <span class="NLM_cas:coden">NCAHBB</span>;
        ISSN:<span class="NLM_cas:issn">1755-4330</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Cancer stem cells (CSCs) represent a subset of cells within tumors that exhibit self-renewal properties and the capacity to seed tumors.  CSCs are typically refractory to conventional treatments and have been assocd. to metastasis and relapse.  Salinomycin operates as a selective agent against CSCs through mechanisms that remain elusive.  Here, the authors provide evidence that a synthetic deriv. of salinomycin, which the authors named ironomycin (AM5), exhibits a more potent and selective activity against breast CSCs in vitro and in vivo, by accumulating and sequestering iron in lysosomes.  In response to the ensuing cytoplasmic depletion of iron, cells triggered the degrdn. of ferritin in lysosomes, leading to further iron loading in this organelle.  Iron-mediated prodn. of reactive oxygen species promoted lysosomal membrane permeabilization, activating a cell death pathway consistent with ferroptosis.  These findings reveal the prevalence of iron homeostasis in breast CSCs, pointing towards iron and iron-mediated processes as potential targets against these cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHPwn6HNYghLVg90H21EOLACvtfcHk0ljg2XecbITVhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnslKku7Y%253D&md5=41218199375748b92d4b2478f0cb6086</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1038%2Fnchem.2778&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchem.2778%26sid%3Dliteratum%253Aachs%26aulast%3DMai%26aufirst%3DT.%2BT.%26aulast%3DHamai%26aufirst%3DA.%26aulast%3DHienzsch%26aufirst%3DA.%26aulast%3DCaneque%26aufirst%3DT.%26aulast%3DMuller%26aufirst%3DS.%26aulast%3DWicinski%26aufirst%3DJ.%26aulast%3DCabaud%26aufirst%3DO.%26aulast%3DLeroy%26aufirst%3DC.%26aulast%3DDavid%26aufirst%3DA.%26aulast%3DAcevedo%26aufirst%3DV.%26aulast%3DRyo%26aufirst%3DA.%26aulast%3DGinestier%26aufirst%3DC.%26aulast%3DBirnbaum%26aufirst%3DD.%26aulast%3DCharafe-Jauffret%26aufirst%3DE.%26aulast%3DCodogno%26aufirst%3DP.%26aulast%3DMehrpour%26aufirst%3DM.%26aulast%3DRodriguez%26aufirst%3DR.%26atitle%3DSalinomycin%2520kills%2520cancer%2520stem%2520cells%2520by%2520sequestering%2520iron%2520in%2520lysosomes%26jtitle%3DNat.%2520Chem.%26date%3D2017%26volume%3D9%26spage%3D1025%26epage%3D1033%26doi%3D10.1038%2Fnchem.2778" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref179"><div class="reference"><strong class="refLabel"><a href="#ref179" class="rightTabRefNumLink">179</a></strong><div class="NLM_citation" id="rightTab-cit179"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hitora, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takada, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okada, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ise, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsunaga, S.</span></span> <span> </span><span class="NLM_article-title">(−)-Duryne and its homologues, cytotoxic acetylenes from a marine sponge Petrosia sp</span>. <i>J. Nat. Prod.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">1262</span>– <span class="NLM_lpage">1267</span>, <span class="refDoi"> DOI: 10.1021/np200271n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/np200271n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlsVyhs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2011&pages=1262-1267&author=Y.+Hitoraauthor=K.+Takadaauthor=S.+Okadaauthor=Y.+Iseauthor=S.+Matsunaga&title=%28%E2%88%92%29-Duryne+and+its+homologues%2C+cytotoxic+acetylenes+from+a+marine+sponge+Petrosia+sp&doi=10.1021%2Fnp200271n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">(-)-Duryne and Its Homologues, Cytotoxic Acetylenes from a Marine Sponge Petrosia sp.</span></div><div class="casAuthors">Hitora, Yuki; Takada, Kentaro; Okada, Shigeru; Ise, Yuji; Matsunaga, Shigeki</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Natural Products</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1262-1267</span>CODEN:
                <span class="NLM_cas:coden">JNPRDF</span>;
        ISSN:<span class="NLM_cas:issn">0163-3864</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society-American Society of Pharmacognosy</span>)
        </div><div class="casAbstract">Six linear acetylenes, (-)-duryne (I) and (-)-durynes B-F, were isolated from the marine sponge Petrosia sp.  Their structures were elucidated by NMR and tandem FABMS analyses.  The positions of the olefinic bonds were confirmed by ozonolysis expts., and the abs. configurations were detd. by the modified Mosher's method.  I was found to be the enantiomer of duryne, a previously reported sponge metabolite.  All 6 compds. show cytotoxicity against HeLa cells with IC50 values between 0.08 and 0.50 μM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_M5WONe43lrVg90H21EOLACvtfcHk0ljg2XecbITVhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlsVyhs74%253D&md5=6b28fe2cede33296d5f15cb822280fd0</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1021%2Fnp200271n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fnp200271n%26sid%3Dliteratum%253Aachs%26aulast%3DHitora%26aufirst%3DY.%26aulast%3DTakada%26aufirst%3DK.%26aulast%3DOkada%26aufirst%3DS.%26aulast%3DIse%26aufirst%3DY.%26aulast%3DMatsunaga%26aufirst%3DS.%26atitle%3D%2528%25E2%2588%2592%2529-Duryne%2520and%2520its%2520homologues%252C%2520cytotoxic%2520acetylenes%2520from%2520a%2520marine%2520sponge%2520Petrosia%2520sp%26jtitle%3DJ.%2520Nat.%2520Prod.%26date%3D2011%26volume%3D74%26spage%3D1262%26epage%3D1267%26doi%3D10.1021%2Fnp200271n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref180"><div class="reference"><strong class="refLabel"><a href="#ref180" class="rightTabRefNumLink">180</a></strong><div class="NLM_citation" id="rightTab-cit180"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vesely, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Della
Togna, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerwick, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kyle, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linington, R. G.</span></span> <span> </span><span class="NLM_article-title">Almiramides A-C: Discovery and development of a new class of leishmaniasis lead compounds</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">4187</span>– <span class="NLM_lpage">4197</span>, <span class="refDoi"> DOI: 10.1021/jm100265s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100265s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlsFeqtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=4187-4197&author=L.+M.+Sanchezauthor=D.+Lopezauthor=B.+A.+Veselyauthor=G.+Della%0ATognaauthor=W.+H.+Gerwickauthor=D.+E.+Kyleauthor=R.+G.+Linington&title=Almiramides+A-C%3A+Discovery+and+development+of+a+new+class+of+leishmaniasis+lead+compounds&doi=10.1021%2Fjm100265s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">Almiramides A-C: Discovery and development of a new class of Leishmaniasis lead compounds</span></div><div class="casAuthors">Sanchez, Laura M.; Lopez, Dioxelis; Vesely, Brian A.; Della Togna, Gina; Gerwick, William H.; Kyle, Dennis E.; Linington, Roger G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4187-4197</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Leishmaniasis is a debilitating disease caused by protozoan parasites of the genus Leishmania, which affects an estd. 12 million people worldwide.  The discovery of new lead compds. for leishmaniasis is therefore a pressing concern for global health programs.  The org. ext. of a Panamanian collection of the marine cyanobacterium Lyngbya majuscula showed strong in vitro activity in two complementary screens against the tropical parasite Leishmania donovani, the causative agent of visceral leishmaniasis.  Chromatog. sepn. of this complex mixt. led to the isolation of the highly N-methylated linear lipopeptides, almiramides A-C.  Comparison with the biol. activities of a no. of related metabolites and semisynthetic derivs. revealed key features required for activity and afforded one new compd. (I) with superior in vitro activity.  Subsequent synthesis of a library of simplified analogs led to the discovery of several compds. with improved therapeutic indexes to the natural products.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonVhootp7ISLVg90H21EOLACvtfcHk0ljg2XecbITVhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlsFeqtr8%253D&md5=ea573cd8d849d3418b46a7641b7bb381</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1021%2Fjm100265s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100265s%26sid%3Dliteratum%253Aachs%26aulast%3DSanchez%26aufirst%3DL.%2BM.%26aulast%3DLopez%26aufirst%3DD.%26aulast%3DVesely%26aufirst%3DB.%2BA.%26aulast%3DDella%2BTogna%26aufirst%3DG.%26aulast%3DGerwick%26aufirst%3DW.%2BH.%26aulast%3DKyle%26aufirst%3DD.%2BE.%26aulast%3DLinington%26aufirst%3DR.%2BG.%26atitle%3DAlmiramides%2520A-C%253A%2520Discovery%2520and%2520development%2520of%2520a%2520new%2520class%2520of%2520leishmaniasis%2520lead%2520compounds%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D4187%26epage%3D4197%26doi%3D10.1021%2Fjm100265s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref181"><div class="reference"><strong class="refLabel"><a href="#ref181" class="rightTabRefNumLink">181</a></strong><div class="NLM_citation" id="rightTab-cit181"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iwasaki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohno, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sumimoto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suenaga, K.</span></span> <span> </span><span class="NLM_article-title">Kurahyne, an acetylene-containing lipopeptide from a marine cyanobacterial assemblage of Lyngbya sp</span>. <i>RSC Adv.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">12840</span>– <span class="NLM_lpage">12843</span>, <span class="refDoi"> DOI: 10.1039/C4RA00132J</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1039%2FC4RA00132J" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjslGgsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=12840-12843&author=A.+Iwasakiauthor=O.+Ohnoauthor=S.+Sumimotoauthor=S.+Sudaauthor=K.+Suenaga&title=Kurahyne%2C+an+acetylene-containing+lipopeptide+from+a+marine+cyanobacterial+assemblage+of+Lyngbya+sp&doi=10.1039%2FC4RA00132J"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit181R"><div class="casContent"><span class="casTitleNuber">181</span><div class="casTitle"><span class="NLM_cas:atitle">Kurahyne, an acetylene-containing lipopeptide from a marine cyanobacterial assemblage of Lyngbya sp.</span></div><div class="casAuthors">Iwasaki, Arihiro; Ohno, Osamu; Sumimoto, Shinpei; Suda, Shoichiro; Suenaga, Kiyotake</div><div class="citationInfo"><span class="NLM_cas:title">RSC Advances</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">12840-12843</span>CODEN:
                <span class="NLM_cas:coden">RSCACL</span>;
        ISSN:<span class="NLM_cas:issn">2046-2069</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Kurahyne, a new acetylene-contg. lipopeptide, was isolated from a cyanobacterial assemblage that mostly consisted of Lyngbya sp.  Its structure was elucidated by spectroscopic analyses and chiral HPLC analyses of hydrolysis products.  Kurahyne inhibited the growth of human cancer cells and induced apoptosis in HeLa cells, and it seemed to localize in mitochondria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolH4kEzvcjR7Vg90H21EOLACvtfcHk0lgZP2MDlBcB_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjslGgsb8%253D&md5=d474abf9e6d5063a088ee5de94a504c6</span></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.1039%2FC4RA00132J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC4RA00132J%26sid%3Dliteratum%253Aachs%26aulast%3DIwasaki%26aufirst%3DA.%26aulast%3DOhno%26aufirst%3DO.%26aulast%3DSumimoto%26aufirst%3DS.%26aulast%3DSuda%26aufirst%3DS.%26aulast%3DSuenaga%26aufirst%3DK.%26atitle%3DKurahyne%252C%2520an%2520acetylene-containing%2520lipopeptide%2520from%2520a%2520marine%2520cyanobacterial%2520assemblage%2520of%2520Lyngbya%2520sp%26jtitle%3DRSC%2520Adv.%26date%3D2014%26volume%3D4%26spage%3D12840%26epage%3D12843%26doi%3D10.1039%2FC4RA00132J" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref182"><div class="reference"><strong class="refLabel"><a href="#ref182" class="rightTabRefNumLink">182</a></strong><div class="NLM_citation" id="rightTab-cit182"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Simmons, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engene, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urena, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, L. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortega-Barria, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerwick, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerwick, W. H.</span></span> <span> </span><span class="NLM_article-title">Viridamides A and B, lipodepsipeptides with antiprotozoal activity from the marine cyanobacterium <i>Oscillatoria nigro-viridis</i></span>. <i>J. Nat. Prod.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">1544</span>– <span class="NLM_lpage">1550</span>, <span class="refDoi"> DOI: 10.1021/np800110e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/np800110e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A280%3ADC%252BD1cnivFChsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2008&pages=1544-1550&author=T.+L.+Simmonsauthor=N.+Engeneauthor=L.+D.+Urenaauthor=L.+I.+Romeroauthor=E.+Ortega-Barriaauthor=L.+Gerwickauthor=W.+H.+Gerwick&title=Viridamides+A+and+B%2C+lipodepsipeptides+with+antiprotozoal+activity+from+the+marine+cyanobacterium+Oscillatoria+nigro-viridis&doi=10.1021%2Fnp800110e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit182R"><div class="casContent"><span class="casTitleNuber">182</span><div class="casTitle"><span class="NLM_cas:atitle">Viridamides A and B, lipodepsipeptides with antiprotozoal activity from the marine cyanobacterium Oscillatoria nigro-viridis</span></div><div class="casAuthors">Simmons T Luke; Engene Niclas; Urena Luis David; Romero Luz I; Ortega-Barria Eduardo; Gerwick Lena; Gerwick William H</div><div class="citationInfo"><span class="NLM_cas:title">Journal of natural products</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1544-50</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Parallel chemical and phylogenetic investigation of a marine cyanobacterium from Panama led to the isolation of two new PKS-NRPS-derived compounds, viridamides A and B.  Their structures were determined by NMR and mass spectroscopic methods, and the absolute configurations assigned by Marfey's method and chiral HPLC analysis.  In addition to six standard, N-methylated amino and hydroxy acids, these metabolites contained the structurally novel 5-methoxydec-9-ynoic acid moiety and an unusual proline methyl ester terminus.  Morphologically, this cyanobacterium was identified as Oscillatoria nigro-viridis, and its 16S rDNA sequence is reported here for the first time.  Phylogenetic analysis of these sequence data has identified O. nigro-viridis strain OSC3L to be closely related to two other marine cyanobacterial genera, Trichodesmium and Blennothrix.  Viridamide A showed antitrypanosomal activity with an IC50 of 1.1 microM and antileishmanial activity with an IC50 of 1.5 microM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQDGAOZde4J9iCEBeYuoi7AfW6udTcc2eZ1iDnspJjR97ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cnivFChsw%253D%253D&md5=dcddca72c89105ce99fa0abc73c17bf7</span></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.1021%2Fnp800110e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fnp800110e%26sid%3Dliteratum%253Aachs%26aulast%3DSimmons%26aufirst%3DT.%2BL.%26aulast%3DEngene%26aufirst%3DN.%26aulast%3DUrena%26aufirst%3DL.%2BD.%26aulast%3DRomero%26aufirst%3DL.%2BI.%26aulast%3DOrtega-Barria%26aufirst%3DE.%26aulast%3DGerwick%26aufirst%3DL.%26aulast%3DGerwick%26aufirst%3DW.%2BH.%26atitle%3DViridamides%2520A%2520and%2520B%252C%2520lipodepsipeptides%2520with%2520antiprotozoal%2520activity%2520from%2520the%2520marine%2520cyanobacterium%2520Oscillatoria%2520nigro-viridis%26jtitle%3DJ.%2520Nat.%2520Prod.%26date%3D2008%26volume%3D71%26spage%3D1544%26epage%3D1550%26doi%3D10.1021%2Fnp800110e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref183"><div class="reference"><strong class="refLabel"><a href="#ref183" class="rightTabRefNumLink">183</a></strong><div class="NLM_citation" id="rightTab-cit183"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vining, O. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Videau, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serrill, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, J. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerwick, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proteau, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishmael, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McPhail, K. L.</span></span> <span> </span><span class="NLM_article-title">Depsipeptide companeramides from a Panamanian marine cyanobacterium associated with the coibamide producer</span>. <i>J. Nat. Prod.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">413</span>– <span class="NLM_lpage">420</span>, <span class="refDoi"> DOI: 10.1021/np5007907</span> </span><div class="citationLinks">[<a href="/doi/10.1021/np5007907" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC2MXltVWktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2015&pages=413-420&author=O.+B.+Viningauthor=R.+A.+Medinaauthor=E.+A.+Mitchellauthor=P.+Videauauthor=D.+Liauthor=J.+D.+Serrillauthor=J.+X.+Kellyauthor=W.+H.+Gerwickauthor=P.+J.+Proteauauthor=J.+E.+Ishmaelauthor=K.+L.+McPhail&title=Depsipeptide+companeramides+from+a+Panamanian+marine+cyanobacterium+associated+with+the+coibamide+producer&doi=10.1021%2Fnp5007907"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit183R"><div class="casContent"><span class="casTitleNuber">183</span><div class="casTitle"><span class="NLM_cas:atitle">Depsipeptide companeramides from a Panamanian marine cyanobacterium associated with the coibamide producer</span></div><div class="casAuthors">Vining, Oliver B.; Medina, Rebecca A.; Mitchell, Edward A.; Videau, Patrick; Li, Dong; Serrill, Jeffrey D.; Kelly, Jane X.; Gerwick, William H.; Proteau, Philip J.; Ishmael, Jane E.; McPhail, Kerry L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Natural Products</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">413-420</span>CODEN:
                <span class="NLM_cas:coden">JNPRDF</span>;
        ISSN:<span class="NLM_cas:issn">0163-3864</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society-American Society of Pharmacognosy</span>)
        </div><div class="casAbstract">Two new cyclic depsipeptides, companeramides A (I) and B (II), have been isolated from the phylogenetically characterized cyanobacterial collection that yielded the previously reported cancer cell toxin coibamide A (collected from Coiba Island, Panama).  The planar structures of the companeramides, which contain 3-amino-2-methyl-7-octynoic acid (Amoya), hydroxy isovaleric acid (Hiva), and eight α-amino acid units, were established by NMR spectroscopy and mass spectrometry.  The abs. configuration of each companeramide was assigned using a combination of Marfey's methodol. and chiral-phase HPLC anal. of complete and partial hydrolysis products compared to com. and synthesized stds.  Companeramides A (1) and B (2) showed high nanomolar in vitro antiplasmodial activity but were not overtly cytotoxic to four human cancer cell lines at the doses tested.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocYIfQRHhNFbVg90H21EOLACvtfcHk0lgZP2MDlBcB_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXltVWktg%253D%253D&md5=10073c7ff72892615a5f6340adc936eb</span></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.1021%2Fnp5007907&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fnp5007907%26sid%3Dliteratum%253Aachs%26aulast%3DVining%26aufirst%3DO.%2BB.%26aulast%3DMedina%26aufirst%3DR.%2BA.%26aulast%3DMitchell%26aufirst%3DE.%2BA.%26aulast%3DVideau%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DSerrill%26aufirst%3DJ.%2BD.%26aulast%3DKelly%26aufirst%3DJ.%2BX.%26aulast%3DGerwick%26aufirst%3DW.%2BH.%26aulast%3DProteau%26aufirst%3DP.%2BJ.%26aulast%3DIshmael%26aufirst%3DJ.%2BE.%26aulast%3DMcPhail%26aufirst%3DK.%2BL.%26atitle%3DDepsipeptide%2520companeramides%2520from%2520a%2520Panamanian%2520marine%2520cyanobacterium%2520associated%2520with%2520the%2520coibamide%2520producer%26jtitle%3DJ.%2520Nat.%2520Prod.%26date%3D2015%26volume%3D78%26spage%3D413%26epage%3D420%26doi%3D10.1021%2Fnp5007907" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref184"><div class="reference"><strong class="refLabel"><a href="#ref184" class="rightTabRefNumLink">184</a></strong><div class="NLM_citation" id="rightTab-cit184"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chai, Q. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, B. N.</span></span> <span> </span><span class="NLM_article-title">Alkynyl-containing peptides of marine origin: A review</span>. <i>Mar. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">216</span>, <span class="refDoi"> DOI: 10.3390/md14110216</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.3390%2Fmd14110216" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC1cXptVagtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2016&pages=216&author=Q.+Y.+Chaiauthor=Z.+Yangauthor=H.+W.+Linauthor=B.+N.+Han&title=Alkynyl-containing+peptides+of+marine+origin%3A+A+review&doi=10.3390%2Fmd14110216"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit184R"><div class="casContent"><span class="casTitleNuber">184</span><div class="casTitle"><span class="NLM_cas:atitle">Alkynyl-containing peptides of marine origin: A review</span></div><div class="casAuthors">Chai, Qiu-Ye; Yang, Zhen; Lin, Hou-Wen; Han, Bing-Nan</div><div class="citationInfo"><span class="NLM_cas:title">Marine Drugs</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">216/1-216/18</span>CODEN:
                <span class="NLM_cas:coden">MDARE6</span>;
        ISSN:<span class="NLM_cas:issn">1660-3397</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Since the 1990s, a no. of terminal alkynyl residue-contg. cyclic/acyclic peptides have been identified from marine organisms, esp. cyanobacteria and marine mollusks.  This review has presented 66 peptides, which covers over 90% marine peptides with terminal alkynyl fatty acyl units.  In fact, more than 90% of these peptides described in the literature are of cyanobacterial origin.  Interestingly, all the linear peptides featured with terminal alkyne were solely discovered from marine cyanobacteria.  The objective of this article is to provide an overview on the types, structural characterization of these unusual terminal alkynyl fatty acyl units, as well as the sources and biol. functions of their composed peptides.  Many of these peptides have a variety of biol. activities, including antitumor, antibacterial, antimalarial, etc.  Further, we have also discussed the evident biosynthetic origin responsible for formation of terminal alkynes of natural PKS (polyketide synthase)/NRPS (nonribosome peptide synthetase) hybrids.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJ4rgRFnei-7Vg90H21EOLACvtfcHk0lgZP2MDlBcB_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXptVagtg%253D%253D&md5=cca7c110ea5e062ed565580f016df27c</span></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.3390%2Fmd14110216&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmd14110216%26sid%3Dliteratum%253Aachs%26aulast%3DChai%26aufirst%3DQ.%2BY.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DLin%26aufirst%3DH.%2BW.%26aulast%3DHan%26aufirst%3DB.%2BN.%26atitle%3DAlkynyl-containing%2520peptides%2520of%2520marine%2520origin%253A%2520A%2520review%26jtitle%3DMar.%2520Drugs%26date%3D2016%26volume%3D14%26spage%3D216%26doi%3D10.3390%2Fmd14110216" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref185"><div class="reference"><strong class="refLabel"><a href="#ref185" class="rightTabRefNumLink">185</a></strong><div class="NLM_citation" id="rightTab-cit185"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunne, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morton, G. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borders, D. B.</span></span> <span> </span><span class="NLM_article-title">Calichemicins, a novel family of antitumor antibiotics. 1. Chemistry and partial structure of calichemicin.gamma.1I</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">3464</span>– <span class="NLM_lpage">3466</span>, <span class="refDoi"> DOI: 10.1021/ja00245a050</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja00245a050" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADyaL2sXkt1elsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=1987&pages=3464-3466&author=M.+D.+Leeauthor=T.+S.+Dunneauthor=M.+M.+Siegelauthor=C.+C.+Changauthor=G.+O.+Mortonauthor=D.+B.+Borders&title=Calichemicins%2C+a+novel+family+of+antitumor+antibiotics.+1.+Chemistry+and+partial+structure+of+calichemicin.gamma.1I&doi=10.1021%2Fja00245a050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit185R"><div class="casContent"><span class="casTitleNuber">185</span><div class="casTitle"><span class="NLM_cas:atitle">Calichemicins, a novel family of antitumor antibiotics.  1.  Chemistry and partial structure of calichemicin γ1I</span></div><div class="casAuthors">Lee, May D.; Dunne, Theresa S.; Siegel, Marshall M.; Chang, Conway C.; Morton, George O.; Borders, Donald B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3464-6</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    </div><div class="casAbstract">The calichemicins, produced by Micromonospora echinospora ssp.. calichensis, represent a novel class of extremely potent antitumor antibiotics.  Degrdn. and derivatization studies were carried out on calichemicin γ1I (I; C55H74IN3O21S4), the major component of the calichemicin complex, and provided information for a partial structure proposal.  These studies showed calichemicin γ1I to contain 3-O-methyl-α-L-rhamnopyranoside, a pentasubstituted benzoate, a novel thioglycoside, an unusual hydroxyaminoglycoside, an ethylaminoglycoside, and an aglycon (C18H17NO5S3).  The connectivity and the substitution patterns of these structural units were elucidated by two-dimensional NMR techniques, high-resoln. FABMS (fast-atom-bombardment mass spectra), and x-ray crystallog. of degrdn. products.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlVcIXyoXokbVg90H21EOLACvtfcHk0lh6qFBGBLFiag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXkt1elsb0%253D&md5=dc21e6bfd8f6bef5774439d7c3e93c0f</span></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=10.1021%2Fja00245a050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja00245a050%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DM.%2BD.%26aulast%3DDunne%26aufirst%3DT.%2BS.%26aulast%3DSiegel%26aufirst%3DM.%2BM.%26aulast%3DChang%26aufirst%3DC.%2BC.%26aulast%3DMorton%26aufirst%3DG.%2BO.%26aulast%3DBorders%26aufirst%3DD.%2BB.%26atitle%3DCalichemicins%252C%2520a%2520novel%2520family%2520of%2520antitumor%2520antibiotics.%25201.%2520Chemistry%2520and%2520partial%2520structure%2520of%2520calichemicin.gamma.1I%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1987%26volume%3D109%26spage%3D3464%26epage%3D3466%26doi%3D10.1021%2Fja00245a050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref186"><div class="reference"><strong class="refLabel"><a href="#ref186" class="rightTabRefNumLink">186</a></strong><div class="NLM_citation" id="rightTab-cit186"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nicolaou, K. C.</span></span> <span> </span><span class="NLM_article-title">The battle of calicheamicin γ</span>. <i>Angew. Chem., Int. Ed. Engl.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">1377</span>– <span class="NLM_lpage">1385</span>, <span class="refDoi"> DOI: 10.1002/anie.199313773</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1002%2Fanie.199313773" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=1993&pages=1377-1385&author=K.+C.+Nicolaou&title=The+battle+of+calicheamicin+%CE%B3&doi=10.1002%2Fanie.199313773"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=10.1002%2Fanie.199313773&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.199313773%26sid%3Dliteratum%253Aachs%26aulast%3DNicolaou%26aufirst%3DK.%2BC.%26atitle%3DThe%2520battle%2520of%2520calicheamicin%2520%25CE%25B3%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%2520Engl.%26date%3D1993%26volume%3D32%26spage%3D1377%26epage%3D1385%26doi%3D10.1002%2Fanie.199313773" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref187"><div class="reference"><strong class="refLabel"><a href="#ref187" class="rightTabRefNumLink">187</a></strong><div class="NLM_citation" id="rightTab-cit187"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bergman, R. G.</span></span> <span> </span><span class="NLM_article-title">Reactive 1,4-dehydroaromatics</span>. <i>Acc. Chem. Res.</i> <span class="NLM_year" style="font-weight: bold;">1973</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">25</span>– <span class="NLM_lpage">31</span>, <span class="refDoi"> DOI: 10.1021/ar50061a004</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ar50061a004" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADyaE3sXntFWktw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1973&pages=25-31&author=R.+G.+Bergman&title=Reactive+1%2C4-dehydroaromatics&doi=10.1021%2Far50061a004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit187R"><div class="casContent"><span class="casTitleNuber">187</span><div class="casTitle"><span class="NLM_cas:atitle">Reactive 1,4-dehydroaromatics</span></div><div class="casAuthors">Bergman, Robert G.</div><div class="citationInfo"><span class="NLM_cas:title">Accounts of Chemical Research</span>
        (<span class="NLM_cas:date">1973</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">25-31</span>CODEN:
                <span class="NLM_cas:coden">ACHRE4</span>;
        ISSN:<span class="NLM_cas:issn">0001-4842</span>.
    </div><div class="casAbstract">A review with 44 ref. and some new data.  The synthesis and chemistry of dehydroarom. mols. is discussed.  Evidence is presented for the generation of 1,4-dehydrobenzene as a transient intermediate in the thermal rearrangement of cis-1,5-hexadiyn-3-ene.  Pyrolysis of the diacetylene labeled with D in the acetylenic positions results in scrambling of D between the vinyl and acetylenic positions.  Trapping experiments provide evidence that this rearrangement proceeds through 1,4-dehydrobenzene, which apparently has a 1,4-benzenediyl structure:  pyrolysis of cis-1,5-hexadiyne-3-ene in hydrocarbon soln. gives benzene, in CCl4 gives p-C6H4Cl2, and in MeOH leads to PhCH2OH but no anisole.  1,4-Dehydroaromatics having 7 rather than 6 carbons are discussed.  Pyrolysis of cis- and trans-1,2-diethynylcyclopropane leads to bicyclo[3.2.0]hepta-1,4,6-triene.  The mechanism of this reaction is discussed and evidence for the formation of the bicycloheptatrienyl anion on treatment of the triene with strong base is presented.  Finally, the synthesis and some chemistry of 3,6-dehydrooxepin (3-oxabicyclo[3.2.0]hepta-1,4,6-triene) is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpW-wcqQofoSLVg90H21EOLACvtfcHk0lh6qFBGBLFiag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE3sXntFWktw%253D%253D&md5=8fe8a9163b905b76db270de291b3ebe1</span></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=10.1021%2Far50061a004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Far50061a004%26sid%3Dliteratum%253Aachs%26aulast%3DBergman%26aufirst%3DR.%2BG.%26atitle%3DReactive%25201%252C4-dehydroaromatics%26jtitle%3DAcc.%2520Chem.%2520Res.%26date%3D1973%26volume%3D6%26spage%3D25%26epage%3D31%26doi%3D10.1021%2Far50061a004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref188"><div class="reference"><strong class="refLabel"><a href="#ref188" class="rightTabRefNumLink">188</a></strong><div class="NLM_citation" id="rightTab-cit188"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kraka, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cremer, D.</span></span> <span> </span><span class="NLM_article-title">Computer design of anticancer drugs. A new enediyne warhead</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>122</i></span>,  <span class="NLM_fpage">8245</span>– <span class="NLM_lpage">8264</span>, <span class="refDoi"> DOI: 10.1021/ja001017k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja001017k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD3cXls1OktrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2000&pages=8245-8264&author=E.+Krakaauthor=D.+Cremer&title=Computer+design+of+anticancer+drugs.+A+new+enediyne+warhead&doi=10.1021%2Fja001017k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit188R"><div class="casContent"><span class="casTitleNuber">188</span><div class="casTitle"><span class="NLM_cas:atitle">Computer design of anticancer drugs. a new enediyne warhead</span></div><div class="casAuthors">Kraka, Elfi; Cremer, Dieter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">8245-8264</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Seven criteria are developed and discussed that lead to the design of a new enediyne anticancer drug, which should have low toxicity but high biol. selectivity and activity when attacking the DNA of tumor cells.  These criteria concern (among others) the thermodn. and kinetic stability of the species involved in the reaction of an enediyne, the biradical character and H-abstraction ability of the intermediate biradical generated in a Bergman reaction of the enediyne, and the basicity of the enediyne and its assocd. biradical.  Thirteen different heteroenediynes were investigated with the help of B3LYP/6-31G(d,p) calcns. to find a suitable candidate for a new enediyne anticancer drug, which fulfills the seven criteria.  These calcns. included the detn. of reaction profiles for Bergman and retro-Bergman reactions, the calcn. of singlet-triplet splittings of biradicals formed from enediynes, and the prediction of pKa values.  Results were tested by using a larger basis set (6-311+G(3df,3pd)), another functional (BLYP), and coupled cluster methods such as CCSD(T) and the Brueckner orbitals-based BD(T) method.  The best candidate for a new enediyne anticancer drug is an N,C-dialkynyl aldimine incorporated into a cyclodecaene ring.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvrqtsKh3_DLVg90H21EOLACvtfcHk0lh6qFBGBLFiag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXls1OktrY%253D&md5=c93596dcf27b7f50554d436268405996</span></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=10.1021%2Fja001017k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja001017k%26sid%3Dliteratum%253Aachs%26aulast%3DKraka%26aufirst%3DE.%26aulast%3DCremer%26aufirst%3DD.%26atitle%3DComputer%2520design%2520of%2520anticancer%2520drugs.%2520A%2520new%2520enediyne%2520warhead%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2000%26volume%3D122%26spage%3D8245%26epage%3D8264%26doi%3D10.1021%2Fja001017k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref189"><div class="reference"><strong class="refLabel"><a href="#ref189" class="rightTabRefNumLink">189</a></strong><div class="NLM_citation" id="rightTab-cit189"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Konishi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohkuma, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuno, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamei, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawaguchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">VanDuyne, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clardy, J.</span></span> <span> </span><span class="NLM_article-title">Dynemicin A, a novel antibiotic with the anthraquinone and 1,5-diyn-3-ene subunit</span>. <i>J. Antibiot.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">1449</span>– <span class="NLM_lpage">1452</span>, <span class="refDoi"> DOI: 10.7164/antibiotics.42.1449</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.7164%2Fantibiotics.42.1449" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=2793600" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADyaK3cXjtlSgsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1989&pages=1449-1452&author=M.+Konishiauthor=H.+Ohkumaauthor=K.+Matsumotoauthor=T.+Tsunoauthor=H.+Kameiauthor=T.+Miyakiauthor=T.+Okiauthor=H.+Kawaguchiauthor=G.+D.+VanDuyneauthor=J.+Clardy&title=Dynemicin+A%2C+a+novel+antibiotic+with+the+anthraquinone+and+1%2C5-diyn-3-ene+subunit&doi=10.7164%2Fantibiotics.42.1449"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit189R"><div class="casContent"><span class="casTitleNuber">189</span><div class="casTitle"><span class="NLM_cas:atitle">Dynemicin A, a novel antibiotic with the anthraquinone and 1,5-diyn-3-ene subunit</span></div><div class="casAuthors">Konishi, Masataka; Ohkuma, Hiroaki; Matsumoto, Kiyoshi; Tsuno, Takashi; Kamei, Hideo; Miyaki, Takeo; Oki, Toshikazu; Kawaguchi, Hiroshi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antibiotics</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1449-52</span>CODEN:
                <span class="NLM_cas:coden">JANTAJ</span>;
        ISSN:<span class="NLM_cas:issn">0021-8820</span>.
    </div><div class="casAbstract">Dynemicin A (I) was isolated from the culture broth of Micromonospora species and its structure was detd.  It was esp. active against gram-pos. bacteria and prolonged the life span of mice inoculated with P388 leukemia.  Treating I with acetic acid anhydride yielded a triacetyl deriv. of I which was 2-5-fold as potent as I against all microbes tested.  In addn. both compds. displayed significant activity against P388 leukemia and 316 melanoma in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6sU283EH0HbVg90H21EOLACvtfcHk0lhYHDX0ueyvYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXjtlSgsw%253D%253D&md5=48845123f3f9273cb43fb87bb3f55604</span></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=10.7164%2Fantibiotics.42.1449&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7164%252Fantibiotics.42.1449%26sid%3Dliteratum%253Aachs%26aulast%3DKonishi%26aufirst%3DM.%26aulast%3DOhkuma%26aufirst%3DH.%26aulast%3DMatsumoto%26aufirst%3DK.%26aulast%3DTsuno%26aufirst%3DT.%26aulast%3DKamei%26aufirst%3DH.%26aulast%3DMiyaki%26aufirst%3DT.%26aulast%3DOki%26aufirst%3DT.%26aulast%3DKawaguchi%26aufirst%3DH.%26aulast%3DVanDuyne%26aufirst%3DG.%2BD.%26aulast%3DClardy%26aufirst%3DJ.%26atitle%3DDynemicin%2520A%252C%2520a%2520novel%2520antibiotic%2520with%2520the%2520anthraquinone%2520and%25201%252C5-diyn-3-ene%2520subunit%26jtitle%3DJ.%2520Antibiot.%26date%3D1989%26volume%3D42%26spage%3D1449%26epage%3D1452%26doi%3D10.7164%2Fantibiotics.42.1449" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref190"><div class="reference"><strong class="refLabel"><a href="#ref190" class="rightTabRefNumLink">190</a></strong><div class="NLM_citation" id="rightTab-cit190"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sugiura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiraki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konishi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oki, T.</span></span> <span> </span><span class="NLM_article-title">DNA intercalation and cleavage of an antitumor antibiotic dynemicin that contains anthracycline and enediyne cores</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">3831</span>– <span class="NLM_lpage">3835</span>, <span class="refDoi"> DOI: 10.1073/pnas.87.10.3831</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1073%2Fpnas.87.10.3831" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=2339123" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADyaK3cXksFaitbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=1990&pages=3831-3835&author=Y.+Sugiuraauthor=T.+Shirakiauthor=M.+Konishiauthor=T.+Oki&title=DNA+intercalation+and+cleavage+of+an+antitumor+antibiotic+dynemicin+that+contains+anthracycline+and+enediyne+cores&doi=10.1073%2Fpnas.87.10.3831"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit190R"><div class="casContent"><span class="casTitleNuber">190</span><div class="casTitle"><span class="NLM_cas:atitle">DNA intercalation and cleavage of an antitumor antibiotic dynemicin that contains anthracycline and enediyne cores</span></div><div class="casAuthors">Sugiura, Yukio; Shiraki, Takashi; Konishi, Masataka; Oki, Toshikazu</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3831-5</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">Dynemicin is a hybrid contg. anthraquinone and enediyne cores, which contribute to binding and cleavage of DNA, resp.  DNA strand scission by the antitumor antibiotic is enhanced by the addn. of NADPH or thiol compds.  The preferential cutting site of dynemicin is on the 3' side of purine bases (i.e., 5'-GC, -GT, and -AG) and is clearly different from the cutting sites of esperamicin and calicheamicin.  The double-stranded and the stem regions of single-stranded DNAs are preferentially cleaved by dynemicin.  Therefore, dynemicin may be a useful reagent for probing secondary structures of DNA.  Pretreatment of DNA with Adriamycin and actinomycin D alters the cutting mode of dynemicin.  Dynemicin-mediated DNA breakage is strongly inhibited by pretreatment of the DNA with distamycin A and anthramycin, suggesting that dynemicin interacts with the minor groove of the DNA helix.  Intercalation of the anthraquinone core into the DNA followed by the attack of the Ph diradical formed from the enediyne core is considered as a possible mechanism of action of dynemicin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIbvMr4_V1SrVg90H21EOLACvtfcHk0lhYHDX0ueyvYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXksFaitbw%253D&md5=5fb86c3df813ba5d8f33944000458106</span></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=10.1073%2Fpnas.87.10.3831&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.87.10.3831%26sid%3Dliteratum%253Aachs%26aulast%3DSugiura%26aufirst%3DY.%26aulast%3DShiraki%26aufirst%3DT.%26aulast%3DKonishi%26aufirst%3DM.%26aulast%3DOki%26aufirst%3DT.%26atitle%3DDNA%2520intercalation%2520and%2520cleavage%2520of%2520an%2520antitumor%2520antibiotic%2520dynemicin%2520that%2520contains%2520anthracycline%2520and%2520enediyne%2520cores%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1990%26volume%3D87%26spage%3D3831%26epage%3D3835%26doi%3D10.1073%2Fpnas.87.10.3831" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref191"><div class="reference"><strong class="refLabel"><a href="#ref191" class="rightTabRefNumLink">191</a></strong><div class="NLM_citation" id="rightTab-cit191"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chari, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widdison, W. C.</span></span> <span> </span><span class="NLM_article-title">Antibody-drug conjugates: an emerging concept in cancer therapy</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">3796</span>– <span class="NLM_lpage">3827</span>, <span class="refDoi"> DOI: 10.1002/anie.201307628</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1002%2Fanie.201307628" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtVGmsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2014&pages=3796-3827&author=R.+V.+Chariauthor=M.+L.+Millerauthor=W.+C.+Widdison&title=Antibody-drug+conjugates%3A+an+emerging+concept+in+cancer+therapy&doi=10.1002%2Fanie.201307628"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit191R"><div class="casContent"><span class="casTitleNuber">191</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody-Drug Conjugates: An Emerging Concept in Cancer Therapy</span></div><div class="casAuthors">Chari, Ravi V. J.; Miller, Michael L.; Widdison, Wayne C.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3796-3827</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Traditional cancer chemotherapy is often accompanied by systemic toxicity to the patient.  Monoclonal antibodies against antigens on cancer cells offer an alternative tumor-selective treatment approach.  However, most monoclonal antibodies are not sufficiently potent to be therapeutically active on their own.  Antibody-drug conjugates (ADCs) use antibodies to deliver a potent cytotoxic compd. selectively to tumor cells, thus improving the therapeutic index of chemotherapeutic agents.  The recent approval of two ADCs, brentuximab vedotin and ado-trastuzumab emtansine, for cancer treatment has spurred tremendous research interest in this field.  This Review touches upon the early efforts in the field, and describes how the lessons learned from the first-generation ADCs have led to improvements in every aspect of this technol., i.e., the antibody, the cytotoxic compd., and the linker connecting them, leading to the current successes.  The design of ADCs currently in clin. development, and results from mechanistic studies and preclin. and clin. evaluation are discussed.  Emerging technologies that seek to further advance this exciting area of research are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4T2rhmji6DLVg90H21EOLACvtfcHk0lhYHDX0ueyvYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtVGmsr0%253D&md5=fbfb2f843f516654ea7c0eb98949604c</span></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=10.1002%2Fanie.201307628&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201307628%26sid%3Dliteratum%253Aachs%26aulast%3DChari%26aufirst%3DR.%2BV.%26aulast%3DMiller%26aufirst%3DM.%2BL.%26aulast%3DWiddison%26aufirst%3DW.%2BC.%26atitle%3DAntibody-drug%2520conjugates%253A%2520an%2520emerging%2520concept%2520in%2520cancer%2520therapy%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2014%26volume%3D53%26spage%3D3796%26epage%3D3827%26doi%3D10.1002%2Fanie.201307628" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref192"><div class="reference"><strong class="refLabel"><a href="#ref192" class="rightTabRefNumLink">192</a></strong><div class="NLM_citation" id="rightTab-cit192"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fontana, R. J.</span></span> <span> </span><span class="NLM_article-title">Acute liver failure due to drugs</span>. <i>Semin. Liver Dis.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">175</span>– <span class="NLM_lpage">187</span>, <span class="refDoi"> DOI: 10.1055/s-2008-1073117</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1055%2Fs-2008-1073117" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=18452117" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmsV2mu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2008&pages=175-187&author=R.+J.+Fontana&title=Acute+liver+failure+due+to+drugs&doi=10.1055%2Fs-2008-1073117"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit192R"><div class="casContent"><span class="casTitleNuber">192</span><div class="casTitle"><span class="NLM_cas:atitle">Acute liver failure due to drugs</span></div><div class="casAuthors">Fontana, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Liver Disease</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">175-187</span>CODEN:
                <span class="NLM_cas:coden">SLDIEE</span>;
        ISSN:<span class="NLM_cas:issn">0272-8087</span>.
    
            (<span class="NLM_cas:orgname">Thieme Medical Publishers, Inc.</span>)
        </div><div class="casAbstract">A review.  Acetaminophen overdose and idiosyncratic drug-induced liver injury (DILI) are the most commonly identified causes of acute liver failure (ALF) in the United States.  Suspected acetaminophen hepatotoxicity can be effectively treated with N-acetylcysteine but still an estd. 500 patients die each year.  Product labeling changes, dispensing restrictions, and reformulation of acetaminophen contg. narcotic analgesics have been proposed to reduce the rising incidence of this preventable form of dose-dependent liver injury.  In contrast, idiosyncratic DILI is not preventable due to our lack of understanding of host susceptibility and outcome factors.  Patients with ALF due to DILI are difficult to diagnose and have a low likelihood of spontaneous recovery.  Patients with severe idiosyncratic DILI should be urgently referred to a transplant center as there are no established medical treatments beyond drug discontinuation.  Investigation of host variability in metabolic, regeneration, and immunol. pathways may provide insights into the mol. basis of DILI as well as improved diagnostic and prognostic biomarkers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq51HyI4BlEa7Vg90H21EOLACvtfcHk0lj4G1Hv1CP05Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmsV2mu7Y%253D&md5=fc960892169cc9aed8be5f062982abab</span></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=10.1055%2Fs-2008-1073117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-2008-1073117%26sid%3Dliteratum%253Aachs%26aulast%3DFontana%26aufirst%3DR.%2BJ.%26atitle%3DAcute%2520liver%2520failure%2520due%2520to%2520drugs%26jtitle%3DSemin.%2520Liver%2520Dis.%26date%3D2008%26volume%3D28%26spage%3D175%26epage%3D187%26doi%3D10.1055%2Fs-2008-1073117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref193"><div class="reference"><strong class="refLabel"><a href="#ref193" class="rightTabRefNumLink">193</a></strong><div class="NLM_citation" id="rightTab-cit193"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mutlib, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nemeth, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gan, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christ, D. D.</span></span> <span> </span><span class="NLM_article-title">Liquid chromatography/mass spectrometry and high-field nuclear magnetic resonance characterization of novel mixed diconjugates of the non-nucleoside human immunodeficiency virus-1 reverse transcriptase inhibitor, efavirenz</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">1045</span>– <span class="NLM_lpage">1056</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10460805" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADyaK1MXlslCqsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1999&pages=1045-1056&author=A.+E.+Mutlibauthor=H.+Chenauthor=G.+Nemethauthor=L.+S.+Ganauthor=D.+D.+Christ&title=Liquid+chromatography%2Fmass+spectrometry+and+high-field+nuclear+magnetic+resonance+characterization+of+novel+mixed+diconjugates+of+the+non-nucleoside+human+immunodeficiency+virus-1+reverse+transcriptase+inhibitor%2C+efavirenz"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit193R"><div class="casContent"><span class="casTitleNuber">193</span><div class="casTitle"><span class="NLM_cas:atitle">Liquid chromatography/mass spectrometry and high-field nuclear magnetic resonance characterization of novel mixed diconjugates of the non-nucleoside human immunodeficiency virus-1 reverse transcriptase inhibitor, efavirenz</span></div><div class="casAuthors">Mutlib, A. E.; Chen, H.; Nemeth, G.; Gan, L.-S.; Christ, D. D.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1045-1056</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Efavirenz (Sustiva) is a potent and specific inhibitor of the HIV-1 reverse transcriptase and is approved for the treatment of HIV infection.  The metab. of efavirenz in different species has been described previously.  Efavirenz is primarily metabolized in rats to the glucuronide conjugate of 8-OH efavirenz.  Electrospray ionization-liq. chromatog./mass spectrometry analyses of bile samples from rats dosed with either efavirenz or with 8-OH efavirenz revealed three polar metabolites, M9, M12, and M13, with pseudomol. ions [M-H]- at m/z 733, 602, and 749, resp.  The characteristic mass spectral fragmentation patterns obtained for metabolites M9 and M13 suggested that these were glutathione-sulfate diconjugates, and the presence of a glutathione moiety in metabolite M9 was confirmed by liq. chromatog./NMR (NMR) anal. of bile exts.  Metabolite M12 was characterized by liq. chromatog./mass spectrometry as a glucuronide-sulfate diconjugate.  Unambiguous structures of M9, M12, and M13 were obtained from one-dimensional proton and carbon NMR as well as proton-proton (correlated spectroscopy, two-dimensional shift correlation), proton-carbon heteronuclear multiple quantum correlation, and long-range proton-carbon (heteronuclear multiple bond correlation) correlated two-dimensional NMR analyses of metabolites isolated from rat bile.  The mass spectral and NMR analyses of M10, which was isolated from rat urine, suggested a cysteinylglycine-sulfate diconjugate.  The isolation of these polar metabolites for further characterization by NMR was aided by mass spectral analyses of HPLC fractions and solid phase extn. exts. during the isolation steps.  The complete characterization of these novel diconjugates demonstrates that further phase II metab. of polar conjugates such as sulfates could take place in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3NZjMK6OUK7Vg90H21EOLACvtfcHk0lj4G1Hv1CP05Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXlslCqsrs%253D&md5=0d71b01f85990a6222ccae185aa848e0</span></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMutlib%26aufirst%3DA.%2BE.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DNemeth%26aufirst%3DG.%26aulast%3DGan%26aufirst%3DL.%2BS.%26aulast%3DChrist%26aufirst%3DD.%2BD.%26atitle%3DLiquid%2520chromatography%252Fmass%2520spectrometry%2520and%2520high-field%2520nuclear%2520magnetic%2520resonance%2520characterization%2520of%2520novel%2520mixed%2520diconjugates%2520of%2520the%2520non-nucleoside%2520human%2520immunodeficiency%2520virus-1%2520reverse%2520transcriptase%2520inhibitor%252C%2520efavirenz%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D1999%26volume%3D27%26spage%3D1045%26epage%3D1056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref194"><div class="reference"><strong class="refLabel"><a href="#ref194" class="rightTabRefNumLink">194</a></strong><div class="NLM_citation" id="rightTab-cit194"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mutlib, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerson, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meunier, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haley, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gan, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gemzik, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christ, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krahn, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markwalder, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seitz, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miwa, G. T.</span></span> <span> </span><span class="NLM_article-title">The species-dependent metabolism of efavirenz produces a nephrotoxic glutathione conjugate in rats</span>. <i>Toxicol. Appl. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>169</i></span>,  <span class="NLM_fpage">102</span>– <span class="NLM_lpage">113</span>, <span class="refDoi"> DOI: 10.1006/taap.2000.9055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1006%2Ftaap.2000.9055" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=11076702" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD3cXnvFyrt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=169&publication_year=2000&pages=102-113&author=A.+E.+Mutlibauthor=R.+J.+Gersonauthor=P.+C.+Meunierauthor=P.+J.+Haleyauthor=H.+Chenauthor=L.+S.+Ganauthor=M.+H.+Daviesauthor=B.+Gemzikauthor=D.+D.+Christauthor=D.+F.+Krahnauthor=J.+A.+Markwalderauthor=S.+P.+Seitzauthor=R.+T.+Robertsonauthor=G.+T.+Miwa&title=The+species-dependent+metabolism+of+efavirenz+produces+a+nephrotoxic+glutathione+conjugate+in+rats&doi=10.1006%2Ftaap.2000.9055"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit194R"><div class="casContent"><span class="casTitleNuber">194</span><div class="casTitle"><span class="NLM_cas:atitle">The Species-Dependent Metabolism of Efavirenz Produces a Nephrotoxic Glutathione Conjugate in Rats</span></div><div class="casAuthors">Mutlib, Abdul E.; Gerson, Ronald J.; Meunier, Paul C.; Haley, Patrick J.; Chen, Hao; Gan, Lawrence S.; Davies, Marc H.; Gemzik, Brian; Christ, David D.; Krahn, David F.; Markwalder, Jay A.; Seitz, Steven P.; Robertson, Richard T.; Miwa, Gerald T.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology and Applied Pharmacology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">169</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">102-113</span>CODEN:
                <span class="NLM_cas:coden">TXAPA9</span>;
        ISSN:<span class="NLM_cas:issn">0041-008X</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">Efavirenz, a potent nonnucleoside reverse transcriptase inhibitor widely prescribed for the treatment of HIV infection, produces renal tubular epithelial cell necrosis in rats but not in cynomolgus monkeys or humans.  This species selectivity in nephrotoxicity could result from differences in the prodn. or processing of reactive metabolites, or both.  A detailed comparison of the metabolites produced by rats, monkeys, and humans revealed that rats produce a unique glutathione adduct.  The mechanism of formation and role of this glutathione adduct in the renal toxicity were investigated using both chem. and biochem. probes.  Efavirenz was labeled at the methine position on the cyclopropyl ring with the stable isotope deuterium, effectively reducing the formation of the cyclopropanol metabolite, an obligate precursor to the glutathione adduct.  This substitution markedly reduced both the incidence and severity of nephrotoxicity as measured histol.  Further processing of this glutathione adduct was also important in producing the lesion and was demonstrated by inhibiting γ-glutamyltranspeptidase with acivicin pretreatment (10 mg/kg, IV) prior to dosing with efavirenz.  Again, both the incidence and severity of the nephrotoxicity were reduced, such that four of nine rats given acivicin were without detectable lesions.  These studies provide compelling evidence that a species-specific formation of glutathione conjugate(s) from efavirenz is involved in producing nephrotoxicity in rats.  Mechanisms are proposed for the formation of reactive metabolites that could be responsible for the renal toxicity obsd. in rats.  (c) 2000 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtZ2yUYxMePrVg90H21EOLACvtfcHk0lj4G1Hv1CP05Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXnvFyrt7Y%253D&md5=13f8d2f66902fef25d827b2f492f88ce</span></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=10.1006%2Ftaap.2000.9055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Ftaap.2000.9055%26sid%3Dliteratum%253Aachs%26aulast%3DMutlib%26aufirst%3DA.%2BE.%26aulast%3DGerson%26aufirst%3DR.%2BJ.%26aulast%3DMeunier%26aufirst%3DP.%2BC.%26aulast%3DHaley%26aufirst%3DP.%2BJ.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DGan%26aufirst%3DL.%2BS.%26aulast%3DDavies%26aufirst%3DM.%2BH.%26aulast%3DGemzik%26aufirst%3DB.%26aulast%3DChrist%26aufirst%3DD.%2BD.%26aulast%3DKrahn%26aufirst%3DD.%2BF.%26aulast%3DMarkwalder%26aufirst%3DJ.%2BA.%26aulast%3DSeitz%26aufirst%3DS.%2BP.%26aulast%3DRobertson%26aufirst%3DR.%2BT.%26aulast%3DMiwa%26aufirst%3DG.%2BT.%26atitle%3DThe%2520species-dependent%2520metabolism%2520of%2520efavirenz%2520produces%2520a%2520nephrotoxic%2520glutathione%2520conjugate%2520in%2520rats%26jtitle%3DToxicol.%2520Appl.%2520Pharmacol.%26date%3D2000%26volume%3D169%26spage%3D102%26epage%3D113%26doi%3D10.1006%2Ftaap.2000.9055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref195"><div class="reference"><strong class="refLabel"><a href="#ref195" class="rightTabRefNumLink">195</a></strong><div class="NLM_citation" id="rightTab-cit195"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamenecka, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, M. D.</span></span> <span> </span><span class="NLM_article-title">Cytochrome P450-mediated bioactivation of the epidermal growth factor receptor inhibitor erlotinib to a reactive electrophile</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">1238</span>– <span class="NLM_lpage">1245</span>, <span class="refDoi"> DOI: 10.1124/dmd.109.030361</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1124%2Fdmd.109.030361" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=20382753" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC3cXos1Kltr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2010&pages=1238-1245&author=X.+Liauthor=T.+M.+Kameneckaauthor=M.+D.+Cameron&title=Cytochrome+P450-mediated+bioactivation+of+the+epidermal+growth+factor+receptor+inhibitor+erlotinib+to+a+reactive+electrophile&doi=10.1124%2Fdmd.109.030361"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit195R"><div class="casContent"><span class="casTitleNuber">195</span><div class="casTitle"><span class="NLM_cas:atitle">Cytochrome P450-mediated bioactivation of the epidermal growth factor receptor inhibitor erlotinib to a reactive electrophile</span></div><div class="casAuthors">Li, Xiaohai; Kamenecka, Theodore M.; Cameron, Michael D.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1238-1245</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (ERL) is approved for treatment of non-small-cell lung cancer.  Numerous reports of ERL-assocd. toxicities are consistent with immune-mediated toxicity, including drug-induced hepatitis, interstitial lung disease, Stevens-Johnson syndrome, and toxic epidermal necrolysis.  Although the mechanism of toxicity has not been established, we present evidence that reactive intermediates are formed during the metab. of ERL, which can covalently conjugate to the cysteine group of the peptide-mimetic GSH.  Seven ERL-GSH conjugates were identified in incubations with hepatic microsomes.  Cytochrome P 450-dependent adducts are proposed to be formed via reactive epoxide and electrophilic quinone-imine intermediates.  In incubations of human liver microsomes, intestinal microsomes, pulmonary microsomes, and recombinant P450s, CYP3A4 was the primary enzyme responsible for the bioactivation of ERL; however, CYP1A1, CYP1A2, CYP3A5, and CYP2D6 were capable of catalyzing the bioactivation as well.  During the metab. of ERL, CYP3A4 and CYP3A5 are irreversibly inactivated by ERL in a time- and concn.-dependent manner.  Inactivation was not dependent on oxidn. of the ERL alkyne group to form a reactive oxirene or ketene, as shown by synthesizing analogs where the alkyne was replaced with a cyano group.  CYP1A1, CYP1A2, and CYP2D6 were not inactivated despite catalyzing the formation of ERL-GSH adducts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-JZKcu0DZAbVg90H21EOLACvtfcHk0lj4G1Hv1CP05Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXos1Kltr8%253D&md5=281dd1ded9b88b66451f03532fafc6e7</span></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=10.1124%2Fdmd.109.030361&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.109.030361%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%26aulast%3DKamenecka%26aufirst%3DT.%2BM.%26aulast%3DCameron%26aufirst%3DM.%2BD.%26atitle%3DCytochrome%2520P450-mediated%2520bioactivation%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520inhibitor%2520erlotinib%2520to%2520a%2520reactive%2520electrophile%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2010%26volume%3D38%26spage%3D1238%26epage%3D1245%26doi%3D10.1124%2Fdmd.109.030361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref196"><div class="reference"><strong class="refLabel"><a href="#ref196" class="rightTabRefNumLink">196</a></strong><div class="NLM_citation" id="rightTab-cit196"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, J.</span></span> <span> </span><span class="NLM_article-title">Identification of ketene-reactive intermediate of erlotinib possibly responsible for inactivation of P450 enzymes</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">442</span>– <span class="NLM_lpage">450</span>, <span class="refDoi"> DOI: 10.1124/dmd.117.079327</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1124%2Fdmd.117.079327" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=29352069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpsV2kt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2018&pages=442-450&author=H.+Zhaoauthor=S.+Liauthor=Z.+Yangauthor=Y.+Pengauthor=X.+Chenauthor=J.+Zheng&title=Identification+of+ketene-reactive+intermediate+of+erlotinib+possibly+responsible+for+inactivation+of+P450+enzymes&doi=10.1124%2Fdmd.117.079327"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit196R"><div class="casContent"><span class="casTitleNuber">196</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of ketene-reactive intermediate of erlotinib possibly responsible for inactivation of P450 enzymes</span></div><div class="casAuthors">Zhao, Huimin; Li, Siyuan; Yang, Zixin; Peng, Ying; Chen, Xiaohui; Zheng, Jiang</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">442-450</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Erlotinib (ELT), a tyrosine kinase inhibitor, is widely used for the treatment of nonsmall cell lung cancer in clinic.  Unfortunately, severe drug-induced liver injury and other adverse effects occurred during the treatment.  Meanwhile, ELT has been reported to be a mechanism-based inactivator of cytochrome P 450(CYPs) 3A4 and 3A5.  The objectives of this study were to identify ketene intermediate of ELT and investigate the assocn. of the acetylenic bioactivation with the enzyme inactivation caused by ELT.  A ketene intermediate was detected in human microsomal incubations of ELT, using 4-bromobenzylamine as a trapping agent.  CYPs 3A4 and 3A5 mainly contributed to the bioactivation of ELT.  Microsomal incubation study showed that the ketene intermediate covalently modified the enzyme protein at lysine residues and destroyed the structure of heme.  The vinyl and Et analogs of ELT showed minor enzyme inhibitory effect (less than 20%), whereas ELT inactivated more than 60% of the enzyme.  The present study provided a novel bioactivation pathway of ELT and facilitated the understanding of the mechanisms of ELT-induced mechanism-based enzyme inactivation and liver injury.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrK0gSOxk31P7Vg90H21EOLACvtfcHk0liWou-b5qvnaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpsV2kt7k%253D&md5=8baff6e76338898db2e01114265d4f95</span></div><a href="/servlet/linkout?suffix=cit196&amp;dbid=16384&amp;doi=10.1124%2Fdmd.117.079327&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.117.079327%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DPeng%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DZheng%26aufirst%3DJ.%26atitle%3DIdentification%2520of%2520ketene-reactive%2520intermediate%2520of%2520erlotinib%2520possibly%2520responsible%2520for%2520inactivation%2520of%2520P450%2520enzymes%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2018%26volume%3D46%26spage%3D442%26epage%3D450%26doi%3D10.1124%2Fdmd.117.079327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref197"><div class="reference"><strong class="refLabel"><a href="#ref197" class="rightTabRefNumLink">197</a></strong><div class="NLM_citation" id="rightTab-cit197"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bugg, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutka-Malen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arthur, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Courvalin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walsh, C. T.</span></span> <span> </span><span class="NLM_article-title">Identification of vancomycin resistance protein VanA as a D-alanine:D-alanine ligase of altered substrate specificity</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">2017</span>– <span class="NLM_lpage">2021</span>, <span class="refDoi"> DOI: 10.1021/bi00222a002</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi00222a002" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADyaK3MXpslWlug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=1991&pages=2017-2021&author=T.+D.+Buggauthor=S.+Dutka-Malenauthor=M.+Arthurauthor=P.+Courvalinauthor=C.+T.+Walsh&title=Identification+of+vancomycin+resistance+protein+VanA+as+a+D-alanine%3AD-alanine+ligase+of+altered+substrate+specificity&doi=10.1021%2Fbi00222a002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit197R"><div class="casContent"><span class="casTitleNuber">197</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of vancomycin resistance protein VanA as a D-alanine:D-alanine ligase of altered substrate specificity</span></div><div class="casAuthors">Bugg, Timothy D. H.; Dutka-Malen, Sylvie; Arthur, Michel; Courvalin, Patrice; Walsh, Christopher T.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2017-21</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    </div><div class="casAbstract">High-level glycopeptide resistance in Enterococcus faecium BM4147 is mediated by a 38-kDa protein VanA, whose amino acid sequence is related to Gram-neg. D-alanyl-D-alanine synthetase (I).  The purifn. of VanA is reported and it is demonstrated that it has I activity but has substantially modified substrate specificity, compared with I from Gram-neg. bacteria.  VanA preferentially condenses D-alanine with D-methionine or D-phenylalanine, raising the possibility that its cellular role is to synthesize a modified cell-wall component, which is subsequently not recognized by vancomycin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoE6W_5B3bKILVg90H21EOLACvtfcHk0liWou-b5qvnaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXpslWlug%253D%253D&md5=c4266c9c43d4aa5d3c983e3c95ee8529</span></div><a href="/servlet/linkout?suffix=cit197&amp;dbid=16384&amp;doi=10.1021%2Fbi00222a002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi00222a002%26sid%3Dliteratum%253Aachs%26aulast%3DBugg%26aufirst%3DT.%2BD.%26aulast%3DDutka-Malen%26aufirst%3DS.%26aulast%3DArthur%26aufirst%3DM.%26aulast%3DCourvalin%26aufirst%3DP.%26aulast%3DWalsh%26aufirst%3DC.%2BT.%26atitle%3DIdentification%2520of%2520vancomycin%2520resistance%2520protein%2520VanA%2520as%2520a%2520D-alanine%253AD-alanine%2520ligase%2520of%2520altered%2520substrate%2520specificity%26jtitle%3DBiochemistry%26date%3D1991%26volume%3D30%26spage%3D2017%26epage%3D2021%26doi%3D10.1021%2Fbi00222a002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref198"><div class="reference"><strong class="refLabel"><a href="#ref198" class="rightTabRefNumLink">198</a></strong><div class="NLM_citation" id="rightTab-cit198"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arthur, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molinas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bugg, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walsh, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Courvalin, P.</span></span> <span> </span><span class="NLM_article-title">Evidence for in vivo incorporation of D-lactate into peptidoglycan precursors of vancomycin-resistant enterococci</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">867</span>– <span class="NLM_lpage">869</span>, <span class="refDoi"> DOI: 10.1128/AAC.36.4.867</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1128%2FAAC.36.4.867" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1503450" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADyaK38XitFWjtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1992&pages=867-869&author=M.+Arthurauthor=C.+Molinasauthor=T.+D.+Buggauthor=G.+D.+Wrightauthor=C.+T.+Walshauthor=P.+Courvalin&title=Evidence+for+in+vivo+incorporation+of+D-lactate+into+peptidoglycan+precursors+of+vancomycin-resistant+enterococci&doi=10.1128%2FAAC.36.4.867"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit198R"><div class="casContent"><span class="casTitleNuber">198</span><div class="casTitle"><span class="NLM_cas:atitle">Evidence for in vivo incorporation of D-lactate into peptidoglycan precursors of vancomycin-resistant enterococci</span></div><div class="casAuthors">Arthur, Michel; Molinas, Catherine; Bugg, Timothy D. H.; Wright, Gerard D.; Walsh, Christopher T.; Courvalin, Patrice</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">867-9</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    </div><div class="casAbstract">The VanA ligase encoded by the vancomycin resistance plasmid pIP816 of Enterococcus faecium BM4147 condenses D-alanine with various D-2-hydroxy and D-2-amino acids in vitro.  D-Lactate added to the culture medium restored the vancomycin resistance of a strain that does not produce the VanH dehydrogenase and therefore appears to be a substrate of VanA in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPd65bkEY0p7Vg90H21EOLACvtfcHk0liWou-b5qvnaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XitFWjtrk%253D&md5=5c71e639085a7265af95f0eccc42fdc0</span></div><a href="/servlet/linkout?suffix=cit198&amp;dbid=16384&amp;doi=10.1128%2FAAC.36.4.867&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.36.4.867%26sid%3Dliteratum%253Aachs%26aulast%3DArthur%26aufirst%3DM.%26aulast%3DMolinas%26aufirst%3DC.%26aulast%3DBugg%26aufirst%3DT.%2BD.%26aulast%3DWright%26aufirst%3DG.%2BD.%26aulast%3DWalsh%26aufirst%3DC.%2BT.%26aulast%3DCourvalin%26aufirst%3DP.%26atitle%3DEvidence%2520for%2520in%2520vivo%2520incorporation%2520of%2520D-lactate%2520into%2520peptidoglycan%2520precursors%2520of%2520vancomycin-resistant%2520enterococci%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1992%26volume%3D36%26spage%3D867%26epage%3D869%26doi%3D10.1128%2FAAC.36.4.867" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref199"><div class="reference"><strong class="refLabel"><a href="#ref199" class="rightTabRefNumLink">199</a></strong><div class="NLM_citation" id="rightTab-cit199"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pidgeon, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pires, M. M.</span></span> <span> </span><span class="NLM_article-title">Cell wall remodeling by a synthetic analog reveals metabolic adaptation in vancomycin resistant Enterococci</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1913</span>– <span class="NLM_lpage">1918</span>, <span class="refDoi"> DOI: 10.1021/acschembio.7b00412</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.7b00412" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC2sXptFels7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=1913-1918&author=S.+E.+Pidgeonauthor=M.+M.+Pires&title=Cell+wall+remodeling+by+a+synthetic+analog+reveals+metabolic+adaptation+in+vancomycin+resistant+Enterococci&doi=10.1021%2Facschembio.7b00412"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit199R"><div class="casContent"><span class="casTitleNuber">199</span><div class="casTitle"><span class="NLM_cas:atitle">Cell Wall Remodeling by a Synthetic Analog Reveals Metabolic Adaptation in Vancomycin Resistant Enterococci</span></div><div class="casAuthors">Pidgeon, Sean E.; Pires, Marcos M.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1913-1918</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Drug-resistant bacterial infections threaten to overburden our healthcare system and disrupt modern medicine.  A large class of potent antibiotics, including vancomycin, operate by interfering with bacterial cell wall biosynthesis.  Vancomycin-resistant Enterococci (VRE) evade the blockage of cell wall biosynthesis by altering cell wall precursors, rendering them drug insensitive.  Herein, we reveal the phenotypic plasticity and cell wall remodeling of VRE in response to vancomycin in live bacterial cells via a metabolic probe.  A synthetic cell wall analog was designed and constructed to monitor cell wall structural alterations.  Our results demonstrate that the biosynthetic pathway for vancomycin-resistant precursors can be hijacked by synthetic analogs to track the kinetics of phenotype induction.  In addn., we leveraged this probe to interrogate the response of VRE cells to vancomycin analogs and a series of cell wall-targeted antibiotics.  Finally, we describe a proof-of-principle strategy to visually inspect drug resistance induction.  Based on our findings, we anticipate that our metabolic probe will play an important role in further elucidating the interplay among the enzymes involved in the VRE biosynthetic rewiring.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrupp-jjQmcB7Vg90H21EOLACvtfcHk0li8vj4s8nzQtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXptFels7c%253D&md5=21a7864cf48856ac03af543d25dec50a</span></div><a href="/servlet/linkout?suffix=cit199&amp;dbid=16384&amp;doi=10.1021%2Facschembio.7b00412&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.7b00412%26sid%3Dliteratum%253Aachs%26aulast%3DPidgeon%26aufirst%3DS.%2BE.%26aulast%3DPires%26aufirst%3DM.%2BM.%26atitle%3DCell%2520wall%2520remodeling%2520by%2520a%2520synthetic%2520analog%2520reveals%2520metabolic%2520adaptation%2520in%2520vancomycin%2520resistant%2520Enterococci%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2017%26volume%3D12%26spage%3D1913%26epage%3D1918%26doi%3D10.1021%2Facschembio.7b00412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref200"><div class="reference"><strong class="refLabel"><a href="#ref200" class="rightTabRefNumLink">200</a></strong><div class="NLM_citation" id="rightTab-cit200"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pidgeon, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pires, M. M.</span></span> <span> </span><span class="NLM_article-title">Vancomycin-dependent response in live drug-resistant bacteria by metabolic labeling</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">8839</span>– <span class="NLM_lpage">8843</span>, <span class="refDoi"> DOI: 10.1002/anie.201704851</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1002%2Fanie.201704851" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVCrtrfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2017&pages=8839-8843&author=S.+E.+Pidgeonauthor=M.+M.+Pires&title=Vancomycin-dependent+response+in+live+drug-resistant+bacteria+by+metabolic+labeling&doi=10.1002%2Fanie.201704851"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit200R"><div class="casContent"><span class="casTitleNuber">200</span><div class="casTitle"><span class="NLM_cas:atitle">Vancomycin-Dependent Response in Live Drug-Resistant Bacteria by Metabolic Labeling</span></div><div class="casAuthors">Pidgeon, Sean E.; Pires, Marcos M.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">8839-8843</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The surge in drug-resistant bacterial infections threatens to overburden healthcare systems worldwide.  Bacterial cell walls are essential to bacteria, thus making them unique targets for the development of antibiotics.  We describe a cellular reporter to directly monitor the phenotypic switch in drug-resistant bacteria with temporal resoln.  Vancomycin-resistant enterococci (VRE) escape the bactericidal action of vancomycin by chem. modifying their cell-wall precursors.  A synthetic cell-wall analog was developed to hijack the biosynthetic rewiring of drug-resistant cells in response to antibiotics.  Our study provides the first in vivo VanX reporter agent that responds to cell-wall alteration in drug-resistant bacteria.  Cellular reporters that reveal mechanisms related to antibiotic resistance can potentially have a significant impact on the fundamental understanding of cellular adaptation to antibiotics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobKUDAIhEpObVg90H21EOLACvtfcHk0li8vj4s8nzQtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVCrtrfF&md5=d11b3fbcb2e2df1ecf5e4db6436984ee</span></div><a href="/servlet/linkout?suffix=cit200&amp;dbid=16384&amp;doi=10.1002%2Fanie.201704851&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201704851%26sid%3Dliteratum%253Aachs%26aulast%3DPidgeon%26aufirst%3DS.%2BE.%26aulast%3DPires%26aufirst%3DM.%2BM.%26atitle%3DVancomycin-dependent%2520response%2520in%2520live%2520drug-resistant%2520bacteria%2520by%2520metabolic%2520labeling%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2017%26volume%3D56%26spage%3D8839%26epage%3D8843%26doi%3D10.1002%2Fanie.201704851" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref201"><div class="reference"><strong class="refLabel"><a href="#ref201" class="rightTabRefNumLink">201</a></strong><div class="NLM_citation" id="rightTab-cit201"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cote, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gholamreza, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misasi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruchez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, J.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Ebola virus infection: Identification of niemann-pick C1 as the target by optimization of a chemical probe</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">239</span>– <span class="NLM_lpage">243</span>, <span class="refDoi"> DOI: 10.1021/ml300370k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml300370k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVCjurfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=239-243&author=K.+Leeauthor=T.+Renauthor=M.+Coteauthor=B.+Gholamrezaauthor=J.+Misasiauthor=A.+Bruchezauthor=J.+Cunningham&title=Inhibition+of+Ebola+virus+infection%3A+Identification+of+niemann-pick+C1+as+the+target+by+optimization+of+a+chemical+probe&doi=10.1021%2Fml300370k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit201R"><div class="casContent"><span class="casTitleNuber">201</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Ebola Virus Infection: Identification of Niemann-Pick C1 as the Target by Optimization of a Chemical Probe</span></div><div class="casAuthors">Lee, Kyungae; Ren, Tao; Cote, Marceline; Gholamreza, Berahman; Misasi, John; Bruchez, Anna; Cunningham, James</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">239-243</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A high-throughput screen identified adamantane dipeptide 1 as an inhibitor of Ebola virus (EboV) infection.  Hit-to-lead optimization to det. the structure-activity relationship (SAR) identified the more potent EboV inhibitor (I) and a photoaffinity labeling agent (II).  These antiviral compds. were employed to identify the target as Niemann-Pick C1 (NPC1), a host protein that binds the EboV glycoprotein and is essential for infection.  These studies establish NPC1 as a promising target for antiviral therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSQ3UVP3tK47Vg90H21EOLACvtfcHk0li8vj4s8nzQtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVCjurfO&md5=b4d0829f290d3d785f3595f335ad6609</span></div><a href="/servlet/linkout?suffix=cit201&amp;dbid=16384&amp;doi=10.1021%2Fml300370k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml300370k%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DK.%26aulast%3DRen%26aufirst%3DT.%26aulast%3DCote%26aufirst%3DM.%26aulast%3DGholamreza%26aufirst%3DB.%26aulast%3DMisasi%26aufirst%3DJ.%26aulast%3DBruchez%26aufirst%3DA.%26aulast%3DCunningham%26aufirst%3DJ.%26atitle%3DInhibition%2520of%2520Ebola%2520virus%2520infection%253A%2520Identification%2520of%2520niemann-pick%2520C1%2520as%2520the%2520target%2520by%2520optimization%2520of%2520a%2520chemical%2520probe%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26spage%3D239%26epage%3D243%26doi%3D10.1021%2Fml300370k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref202"><div class="reference"><strong class="refLabel"><a href="#ref202" class="rightTabRefNumLink">202</a></strong><div class="NLM_citation" id="rightTab-cit202"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ismail, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barton, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phanchana, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charoensutthivarakul, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemingway, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biagini, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neill, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, S. A.</span></span> <span> </span><span class="NLM_article-title">Artemisinin activity-based probes identify multiple molecular targets within the asexual stage of the malaria parasites Plasmodium falciparum 3D7</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">2080</span>– <span class="NLM_lpage">2085</span>, <span class="refDoi"> DOI: 10.1073/pnas.1600459113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1073%2Fpnas.1600459113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=26858419" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC28Xit12ktb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2016&pages=2080-2085&author=H.+M.+Ismailauthor=V.+Bartonauthor=M.+Phanchanaauthor=S.+Charoensutthivarakulauthor=M.+H.+Wongauthor=J.+Hemingwayauthor=G.+A.+Biaginiauthor=P.+M.+O%E2%80%99Neillauthor=S.+A.+Ward&title=Artemisinin+activity-based+probes+identify+multiple+molecular+targets+within+the+asexual+stage+of+the+malaria+parasites+Plasmodium+falciparum+3D7&doi=10.1073%2Fpnas.1600459113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit202R"><div class="casContent"><span class="casTitleNuber">202</span><div class="casTitle"><span class="NLM_cas:atitle">Artemisinin activity-based probes identify multiple molecular targets within the asexual stage of the malaria parasites Plasmodium falciparum 3D7</span></div><div class="casAuthors">Ismail, Hanafy M.; Barton, Victoria; Phanchana, Matthew; Charoensutthivarakul, Sitthivut; Wong, Michael H. L.; Hemingway, Janet; Biagini, Giancarlo A.; O'Neill, Paul M.; Ward, Stephen A.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2080-2085</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The artemisinin (ART)-based antimalarials have contributed significantly to reducing global malaria deaths over the past decade, but the authors still do not know how they kill parasites.  To gain greater insight into the potential mechanisms of ART drug action, the authors developed a suite of ART activity-based protein profiling probes to identify parasite protein drug targets in situ.  Probes were designed to retain biol. activity and alkylate the mol. target(s) of Plasmodium falciparum 3D7 parasites in situ.  Proteins tagged with the ART probe can then be isolated using click chem. before identification by liq. chromatog.-MS/MS.  Using these probes, the authors define an ART proteome that shows alkylated targets in the glycolytic, Hb degrdn., antioxidant defense, and protein synthesis pathways, processes essential for parasite survival.  This work reveals the pleiotropic nature of the biol. functions targeted by this important class of antimalarial drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqe38he4JorxrVg90H21EOLACvtfcHk0lhTfkL5a9C3yw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xit12ktb8%253D&md5=50a46614e45c5e2e7c819675679ec4a1</span></div><a href="/servlet/linkout?suffix=cit202&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1600459113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1600459113%26sid%3Dliteratum%253Aachs%26aulast%3DIsmail%26aufirst%3DH.%2BM.%26aulast%3DBarton%26aufirst%3DV.%26aulast%3DPhanchana%26aufirst%3DM.%26aulast%3DCharoensutthivarakul%26aufirst%3DS.%26aulast%3DWong%26aufirst%3DM.%2BH.%26aulast%3DHemingway%26aufirst%3DJ.%26aulast%3DBiagini%26aufirst%3DG.%2BA.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DP.%2BM.%26aulast%3DWard%26aufirst%3DS.%2BA.%26atitle%3DArtemisinin%2520activity-based%2520probes%2520identify%2520multiple%2520molecular%2520targets%2520within%2520the%2520asexual%2520stage%2520of%2520the%2520malaria%2520parasites%2520Plasmodium%2520falciparum%25203D7%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2016%26volume%3D113%26spage%3D2080%26epage%3D2085%26doi%3D10.1073%2Fpnas.1600459113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref203"><div class="reference"><strong class="refLabel"><a href="#ref203" class="rightTabRefNumLink">203</a></strong><div class="NLM_citation" id="rightTab-cit203"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Salisbury, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span> <span> </span><span class="NLM_article-title">Optimization of activity-based probes for proteomic profiling of histone deacetylase complexes</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>130</i></span>,  <span class="NLM_fpage">2184</span>– <span class="NLM_lpage">2194</span>, <span class="refDoi"> DOI: 10.1021/ja074138u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja074138u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD1cXps1KksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2008&pages=2184-2194&author=C.+M.+Salisburyauthor=B.+F.+Cravatt&title=Optimization+of+activity-based+probes+for+proteomic+profiling+of+histone+deacetylase+complexes&doi=10.1021%2Fja074138u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit203R"><div class="casContent"><span class="casTitleNuber">203</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of Activity-Based Probes for Proteomic Profiling of Histone Deacetylase Complexes</span></div><div class="casAuthors">Salisbury, Cleo M.; Cravatt, Benjamin F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2184-2194</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) are key enzymic regulators of the epigenome and serve as promising targets for anticancer therapeutics.  Recently, we developed a photoreactive "clickable" probe, SAHA-BPyne, to report on HDAC activity and complex formation in native biol. systems.  Here, we investigate the selectivity, sensitivity, and inhibitory properties of SAHA-BPyne and related potential activity-based probes for HDACs.  While we identified several probes that are potent HDAC inhibitors and label HDAC complex components in native proteomic prepns., SAHA-BPyne was markedly superior for profiling HDAC activities in live cells.  Interestingly, the enhanced performance of SAHA-BPyne as an in situ activity-based probe could not be solely ascribed to potency in HDAC binding, implying that other features of the mol. were key to efficient active site-directed labeling in living systems.  Finally, we demonstrate the value of in situ profiling of HDACs by comparing the activity and expression of HDAC1 in cancer cells treated with the cytotoxic agent parthenolide.  These results underscore the utility of activity-based protein profiling for studying HDAC function and may provide insight for the future development of click chem.-based photoreactive probes for the in situ anal. of addnl. enzyme activities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqq74n9E1na_LVg90H21EOLACvtfcHk0lhTfkL5a9C3yw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXps1KksQ%253D%253D&md5=19155ee3a2771bab4c9b16a5de68c7ad</span></div><a href="/servlet/linkout?suffix=cit203&amp;dbid=16384&amp;doi=10.1021%2Fja074138u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja074138u%26sid%3Dliteratum%253Aachs%26aulast%3DSalisbury%26aufirst%3DC.%2BM.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26atitle%3DOptimization%2520of%2520activity-based%2520probes%2520for%2520proteomic%2520profiling%2520of%2520histone%2520deacetylase%2520complexes%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2008%26volume%3D130%26spage%3D2184%26epage%3D2194%26doi%3D10.1021%2Fja074138u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref204"><div class="reference"><strong class="refLabel"><a href="#ref204" class="rightTabRefNumLink">204</a></strong><div class="NLM_citation" id="rightTab-cit204"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weerapana, E.</span></span> <span> </span><span class="NLM_article-title">Applications of copper-catalyzed click chemistry in activity-based protein profiling</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1378</span>– <span class="NLM_lpage">1393</span>, <span class="refDoi"> DOI: 10.3390/molecules19021378</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.3390%2Fmolecules19021378" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=24473203" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkvVClsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2014&pages=1378-1393&author=J.+Martellauthor=E.+Weerapana&title=Applications+of+copper-catalyzed+click+chemistry+in+activity-based+protein+profiling&doi=10.3390%2Fmolecules19021378"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit204R"><div class="casContent"><span class="casTitleNuber">204</span><div class="casTitle"><span class="NLM_cas:atitle">Applications of copper-catalyzed click chemistry in activity-based protein profiling</span></div><div class="casAuthors">Martell, Julianne; Weerapana, Eranthie</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">1378-1393, 16 pp.</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Activity-based protein profiling (ABPP) is a chem. proteomic technique that enables the interrogation of protein activity directly within complex proteomes.  Given the dominant role of posttranslational modifications in regulating protein function in vivo, ABPP provides a direct readout of activity that is not attained through traditional proteomic methods.  ABPP relies on the design of covalent binding probes that either target a specific enzyme or a class of enzymes with related function.  These covalent warheads are coupled to either fluorophores or biotin groups for visualization and enrichment of these active proteins.  The advent of bioorthogonal chemistries, in particular, the copper (I)-catalyzed azide-alkyne cycloaddn. (CuAAC), has benefitted the field of ABPP by achieving the following: (1) replacing bulky reporter groups with smaller alkyne or azide groups to promote cell permeability; (2) adding modularity to the system such that a single probe can be diversified with a variety of reporter groups without the need to develop new synthetic routes; and (3) enabling the conjugation of complex linkers to facilitate quant. proteomic analyses.  Here, we summarize recent examples of CuAAC in ABPP that serve to illustrate the contribution of bioorthogonal chem. to advancing discoveries in this field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqH5hQZJXhe7bVg90H21EOLACvtfcHk0lhTfkL5a9C3yw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkvVClsbY%253D&md5=1f306b2cb93635295832e63b555a6df0</span></div><a href="/servlet/linkout?suffix=cit204&amp;dbid=16384&amp;doi=10.3390%2Fmolecules19021378&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules19021378%26sid%3Dliteratum%253Aachs%26aulast%3DMartell%26aufirst%3DJ.%26aulast%3DWeerapana%26aufirst%3DE.%26atitle%3DApplications%2520of%2520copper-catalyzed%2520click%2520chemistry%2520in%2520activity-based%2520protein%2520profiling%26jtitle%3DMolecules%26date%3D2014%26volume%3D19%26spage%3D1378%26epage%3D1393%26doi%3D10.3390%2Fmolecules19021378" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref205"><div class="reference"><strong class="refLabel"><a href="#ref205" class="rightTabRefNumLink">205</a></strong><div class="NLM_citation" id="rightTab-cit205"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dafik, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khosla, C.</span></span> <span> </span><span class="NLM_article-title">Dihydroisoxazole analogs for labeling and visualization of catalytically active transglutaminase 2</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">58</span>– <span class="NLM_lpage">66</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2010.11.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1016%2Fj.chembiol.2010.11.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=21276939" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlars7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=58-66&author=L.+Dafikauthor=C.+Khosla&title=Dihydroisoxazole+analogs+for+labeling+and+visualization+of+catalytically+active+transglutaminase+2&doi=10.1016%2Fj.chembiol.2010.11.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit205R"><div class="casContent"><span class="casTitleNuber">205</span><div class="casTitle"><span class="NLM_cas:atitle">Dihydroisoxazole Analogs for Labeling and Visualization of Catalytically Active Transglutaminase 2</span></div><div class="casAuthors">Dafik, Laila; Khosla, Chaitan</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">58-66</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">We report the synthesis and preliminary characterization of "clickable" inhibitors of human transglutaminase 2 (TG2).  These inhibitors possess the 3-halo-4,5-dihydroisoxazole warhead along with bioorthogonal groups such as azide or alkyne moieties that enable subsequent covalent modification with fluorophores.  Their mechanism for inhibition of TG2 is based on halide displacement, resulting in the formation of a stable imino thioether.  Inhibition assays against recombinant human TG2 revealed that some of the clickable inhibitors prepd. in this study have comparable specificity as benchmark dihydroisoxazole inhibitors reported earlier.  At low micromolar concns. they completely inhibited transiently activated TG2 in a WI-38 fibroblast scratch assay and could subsequently be used to visualize the active enzyme in situ.  The potential use of these inhibitors to probe the role of TG2 in celiac sprue as well as other diseases is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpa5iAwD6WvG7Vg90H21EOLACvtfcHk0lhTfkL5a9C3yw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlars7c%253D&md5=686bfe203bff64029fc001c48ef83e8a</span></div><a href="/servlet/linkout?suffix=cit205&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2010.11.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2010.11.004%26sid%3Dliteratum%253Aachs%26aulast%3DDafik%26aufirst%3DL.%26aulast%3DKhosla%26aufirst%3DC.%26atitle%3DDihydroisoxazole%2520analogs%2520for%2520labeling%2520and%2520visualization%2520of%2520catalytically%2520active%2520transglutaminase%25202%26jtitle%3DChem.%2520Biol.%26date%3D2011%26volume%3D18%26spage%3D58%26epage%3D66%26doi%3D10.1016%2Fj.chembiol.2010.11.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref206"><div class="reference"><strong class="refLabel"><a href="#ref206" class="rightTabRefNumLink">206</a></strong><div class="NLM_citation" id="rightTab-cit206"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wright, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span> <span> </span><span class="NLM_article-title">A suite of activity-based probes for human cytochrome P450 enzymes</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">10692</span>– <span class="NLM_lpage">10700</span>, <span class="refDoi"> DOI: 10.1021/ja9037609</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja9037609" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD1MXot1ejsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2009&pages=10692-10700&author=A.+T.+Wrightauthor=J.+D.+Songauthor=B.+F.+Cravatt&title=A+suite+of+activity-based+probes+for+human+cytochrome+P450+enzymes&doi=10.1021%2Fja9037609"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit206R"><div class="casContent"><span class="casTitleNuber">206</span><div class="casTitle"><span class="NLM_cas:atitle">A Suite of Activity-Based Probes for Human Cytochrome P450 Enzymes</span></div><div class="casAuthors">Wright, Aaron T.; Song, Joongyu D.; Cravatt, Benjamin F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">10692-10700</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cytochrome P 450 enzymes regulate a variety of endogenous signaling mols. and play central roles in the metab. of xenobiotics and drugs.  We recently showed that an aryl alkyne serves as an effective activity-based probe for profiling mouse liver microsomal P450s in vitro and in vivo.  However, individual P450s display distinct substrate and inhibitor specificities, indicating that multiple probe structures may be required to achieve comprehensive coverage of this large and diverse enzyme family.  Here, we have synthesized a suite of P 450-directed, activity-based protein profiling (ABPP) probes that contain: (1) varied chem. architectures validated as mechanism-based inhibitors of the P 450 enzyme family, and (2) terminal alkyne groups for click chem. conjugation of reporter tags.  This set of probes was screened against a wide cross-section of human P450s, leading to the discovery of an optimal set of probes that provide broad coverage of this enzyme family.  We used these probes to profile the effects on P 450 activity of aromatase inhibitors in current clin. use for the treatment of breast cancer.  We describe the surprising discovery that one of these aromatase inhibitors, anastrozole, significantly increases probe-labeling of P 450 1A2, indicative of a heterotypic cooperativity effect on a central P 450 isoenzyme involved in metabolizing numerous drugs and xenobiotics.  The results presented herein greatly expand the suite of ABPP probes for profiling P450s and illuminate new applications for these tools to understand P 450-drug interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPSCo5wcvBLrVg90H21EOLACvtfcHk0lhsAW5KAGTOLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXot1ejsbY%253D&md5=73f0ebac489c8df2ad9cc184819f2e43</span></div><a href="/servlet/linkout?suffix=cit206&amp;dbid=16384&amp;doi=10.1021%2Fja9037609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja9037609%26sid%3Dliteratum%253Aachs%26aulast%3DWright%26aufirst%3DA.%2BT.%26aulast%3DSong%26aufirst%3DJ.%2BD.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26atitle%3DA%2520suite%2520of%2520activity-based%2520probes%2520for%2520human%2520cytochrome%2520P450%2520enzymes%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2009%26volume%3D131%26spage%3D10692%26epage%3D10700%26doi%3D10.1021%2Fja9037609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref207"><div class="reference"><strong class="refLabel"><a href="#ref207" class="rightTabRefNumLink">207</a></strong><div class="NLM_citation" id="rightTab-cit207"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schirmer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reid, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santi, D. V.</span></span> <span> </span><span class="NLM_article-title">Targeted covalent inactivation of protein kinases by resorcylic acid lactone polyketides</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">4234</span>– <span class="NLM_lpage">4239</span>, <span class="refDoi"> DOI: 10.1073/pnas.0600445103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1073%2Fpnas.0600445103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=16537514" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD28XivFWhsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2006&pages=4234-4239&author=A.+Schirmerauthor=J.+Kennedyauthor=S.+Murliauthor=R.+Reidauthor=D.+V.+Santi&title=Targeted+covalent+inactivation+of+protein+kinases+by+resorcylic+acid+lactone+polyketides&doi=10.1073%2Fpnas.0600445103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit207R"><div class="casContent"><span class="casTitleNuber">207</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted covalent inactivation of protein kinases by resorcylic acid lactone polyketides</span></div><div class="casAuthors">Schirmer, Andreas; Kennedy, Jonathan; Murli, Sumati; Reid, Ralph; Santi, Daniel V.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4234-4239</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Resorcylic acid lactones contg. a cis-enone are susceptible to Michael addn. reactions and are potent inhibitors of several protein kinases.  A structural-bioinformatics anal. identified a conserved Cys residue in the ATP-binding site of the kinases reported to be inhibited by cis-enone resorcylic acid lactones but absent in those that are not.  Mining of the kinome database revealed that a subset of some 46 kinases contained this Cys residue.  Screening a panel of 124 kinases with the resorcylic acid lactone hypothemycin showed that 18 of 19 targets contg. the conserved Cys were inhibited.  Kinetic analyses showed time-dependent inhibition, a hallmark of covalent inactivation, and biochem. studies of the interaction of extracellular signal-regulated kinase (ERK)2 with hypothemycin confirmed covalent adduct formation.  Resorcylic acid lactones are unique among kinase inhibitors in that they target mitogen-activated protein (MAP) kinase pathways at four levels: mitogen receptors, MAP kinase kinase (MEK)1/2 and ERK1/2, and certain downstream ERK substrates.  Cell lines dependent on the activation of Tyr kinase mitogen receptor targets of the resorcylic acid lactones were unusually sensitive toward hypothemycin and showed the expected inhibition of kinase phosphorylation due to inhibition of the mitogen receptors and/or MEK1/2 and ERK1/2.  Among cells without mitogen receptor targets, those harboring an ERK pathway-activating B-RAF V600E mutation were selectively and potently inhibited by hypothemycin.  Hypothemycin also prevented stimulated activation of the p38 cascade through inhibition of the Cys-contg. targets MEK3/6 and TGF-β-activated kinase 1 and of the JNK/SAPK (c-Jun N-terminal kinase/stress-activated protein kinase) cascade through inhibition of MEK4/7.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraww22qbwEYLVg90H21EOLACvtfcHk0lhsAW5KAGTOLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XivFWhsr0%253D&md5=6a4be819f2c2a5a601e5c9cb75faf433</span></div><a href="/servlet/linkout?suffix=cit207&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0600445103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0600445103%26sid%3Dliteratum%253Aachs%26aulast%3DSchirmer%26aufirst%3DA.%26aulast%3DKennedy%26aufirst%3DJ.%26aulast%3DMurli%26aufirst%3DS.%26aulast%3DReid%26aufirst%3DR.%26aulast%3DSanti%26aufirst%3DD.%2BV.%26atitle%3DTargeted%2520covalent%2520inactivation%2520of%2520protein%2520kinases%2520by%2520resorcylic%2520acid%2520lactone%2520polyketides%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2006%26volume%3D103%26spage%3D4234%26epage%3D4239%26doi%3D10.1073%2Fpnas.0600445103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref208"><div class="reference"><strong class="refLabel"><a href="#ref208" class="rightTabRefNumLink">208</a></strong><div class="NLM_citation" id="rightTab-cit208"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nishino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choy, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gushwa, N. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oses-Prieto, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koupparis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burlingame, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renslo, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKerrow, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taunton, J.</span></span> <span> </span><span class="NLM_article-title">Hypothemycin, a fungal natural product, identifies therapeutic targets in <i>Trypanosoma brucei</i> [corrected]</span>. <i>eLife</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">e00712</span>, <span class="refDoi"> DOI: 10.7554/eLife.00712</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.7554%2FeLife.00712" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=23853713" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtlWkuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2013&pages=e00712&author=M.+Nishinoauthor=J.+W.+Choyauthor=N.+N.+Gushwaauthor=J.+A.+Oses-Prietoauthor=K.+Koupparisauthor=A.+L.+Burlingameauthor=A.+R.+Rensloauthor=J.+H.+McKerrowauthor=J.+Taunton&title=Hypothemycin%2C+a+fungal+natural+product%2C+identifies+therapeutic+targets+in+Trypanosoma+brucei+%5Bcorrected%5D&doi=10.7554%2FeLife.00712"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit208R"><div class="casContent"><span class="casTitleNuber">208</span><div class="casTitle"><span class="NLM_cas:atitle">Hypothemycin, a fungal natural product, identifies therapeutic targets in Trypanosoma brucei</span></div><div class="casAuthors">Nishino, Mari; Choy, Jonathan W.; Gushwa, Nathan N.; Oses-Prieto, Juan A.; Koupparis, Kyriacos; Burlingame, Alma L.; Renslo, Adam R.; McKerrow, James H.; Taunton, Jack</div><div class="citationInfo"><span class="NLM_cas:title">eLife</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">e00712/1-e00712/15</span>CODEN:
                <span class="NLM_cas:coden">ELIFA8</span>;
        ISSN:<span class="NLM_cas:issn">2050-084X</span>.
    
            (<span class="NLM_cas:orgname">eLife Sciences Publications Ltd.</span>)
        </div><div class="casAbstract">Protein kinases are potentially attractive therapeutic targets for neglected parasitic diseases, including African trypanosomiasis caused by the protozoan, Trypanosoma brucei.  How to prioritize T. brucei kinases and quantify their intracellular engagement by small-mol. inhibitors remain unsolved problems.  Here, we combine chemoproteomics and RNA interference to interrogate trypanosome kinases bearing a Cys-Asp-Xaa-Gly motif (CDXG kinases).  We discovered that hypothemycin, a fungal polyketide previously shown to covalently inactivate a subset of human CDXG kinases, kills T. brucei in culture and in infected mice.  Quant. chemoproteomic anal. with a hypothemycin-based probe revealed the relative sensitivity of endogenous CDXG kinases, including TbGSK3short and a previously uncharacterized kinase, TbCLK1.  RNAi-mediated knockdown demonstrated that both kinases are essential, but only TbCLK1 is fully engaged by cytotoxic concns. of hypothemycin in intact cells.  Our study identifies TbCLK1 as a therapeutic target for African trypanosomiasis and establishes a new chemoproteomic tool for interrogating CDXG kinases in their native context.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXltBVaNyBJrVg90H21EOLACvtfcHk0lhsAW5KAGTOLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtlWkuw%253D%253D&md5=c48f8af3298177d671f4b3495f264223</span></div><a href="/servlet/linkout?suffix=cit208&amp;dbid=16384&amp;doi=10.7554%2FeLife.00712&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7554%252FeLife.00712%26sid%3Dliteratum%253Aachs%26aulast%3DNishino%26aufirst%3DM.%26aulast%3DChoy%26aufirst%3DJ.%2BW.%26aulast%3DGushwa%26aufirst%3DN.%2BN.%26aulast%3DOses-Prieto%26aufirst%3DJ.%2BA.%26aulast%3DKoupparis%26aufirst%3DK.%26aulast%3DBurlingame%26aufirst%3DA.%2BL.%26aulast%3DRenslo%26aufirst%3DA.%2BR.%26aulast%3DMcKerrow%26aufirst%3DJ.%2BH.%26aulast%3DTaunton%26aufirst%3DJ.%26atitle%3DHypothemycin%252C%2520a%2520fungal%2520natural%2520product%252C%2520identifies%2520therapeutic%2520targets%2520in%2520Trypanosoma%2520brucei%2520%255Bcorrected%255D%26jtitle%3DeLife%26date%3D2013%26volume%3D2%26spage%3De00712%26doi%3D10.7554%2FeLife.00712" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref209"><div class="reference"><strong class="refLabel"><a href="#ref209" class="rightTabRefNumLink">209</a></strong><div class="NLM_citation" id="rightTab-cit209"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nickel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serwa, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaschani, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ninck, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zweerink, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tate, E. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaiser, M.</span></span> <span> </span><span class="NLM_article-title">Chemoproteomic evaluation of the polyacetylene callyspongynic acid</span>. <i>Chem. - Eur. J.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">10721</span>– <span class="NLM_lpage">10728</span>, <span class="refDoi"> DOI: 10.1002/chem.201500934</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1002%2Fchem.201500934" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=26079733" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpvFWntr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=10721-10728&author=S.+Nickelauthor=R.+A.+Serwaauthor=F.+Kaschaniauthor=S.+Ninckauthor=S.+Zweerinkauthor=E.+W.+Tateauthor=M.+Kaiser&title=Chemoproteomic+evaluation+of+the+polyacetylene+callyspongynic+acid&doi=10.1002%2Fchem.201500934"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit209R"><div class="casContent"><span class="casTitleNuber">209</span><div class="casTitle"><span class="NLM_cas:atitle">Chemoproteomic Evaluation of the Polyacetylene Callyspongynic Acid</span></div><div class="casAuthors">Nickel, Sabrina; Serwa, Remigiusz A.; Kaschani, Farnusch; Ninck, Sabrina; Zweerink, Susanne; Tate, Edward W.; Kaiser, Markus</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry - A European Journal</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">10721-10728</span>CODEN:
                <span class="NLM_cas:coden">CEUJED</span>;
        ISSN:<span class="NLM_cas:issn">0947-6539</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Polyacetylenes are a class of alkyne-contg. natural products.  Although potent bioactivities and thus possible applications as chem. probes have already been reported for some polyacetylenes, insights into the biol. activities or mol. mode of action are still rather limited in most cases.  To overcome this limitation, we describe the application of the polyacetylene callyspongynic acid in the development of an exptl. roadmap for characterizing potential protein targets of alkyne-contg. natural products.  To this end, we undertook the first chem. synthesis of callyspongynic acid.  We then used in situ chem. proteomics methods to demonstrate extensive callyspongynic acid-mediated chem. tagging of endoplasmic reticulum-assocd. lipid-metabolizing and modifying enzymes.  We anticipate that an elucidation of protein targets of natural products may serve as an effective guide to the development of subsequent biol. assays that aim to identify chem. phenotypes and bioactivities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9Ojlvw2Lq2bVg90H21EOLACvtfcHk0liOAhJT0utLlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpvFWntr4%253D&md5=8335ad39e825ebe7e4b71e0a0d0029ab</span></div><a href="/servlet/linkout?suffix=cit209&amp;dbid=16384&amp;doi=10.1002%2Fchem.201500934&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fchem.201500934%26sid%3Dliteratum%253Aachs%26aulast%3DNickel%26aufirst%3DS.%26aulast%3DSerwa%26aufirst%3DR.%2BA.%26aulast%3DKaschani%26aufirst%3DF.%26aulast%3DNinck%26aufirst%3DS.%26aulast%3DZweerink%26aufirst%3DS.%26aulast%3DTate%26aufirst%3DE.%2BW.%26aulast%3DKaiser%26aufirst%3DM.%26atitle%3DChemoproteomic%2520evaluation%2520of%2520the%2520polyacetylene%2520callyspongynic%2520acid%26jtitle%3DChem.%2520-%2520Eur.%2520J.%26date%3D2015%26volume%3D21%26spage%3D10721%26epage%3D10728%26doi%3D10.1002%2Fchem.201500934" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref210"><div class="reference"><strong class="refLabel"><a href="#ref210" class="rightTabRefNumLink">210</a></strong><div class="NLM_citation" id="rightTab-cit210"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mileni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beidler, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, J. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKinney, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weerapana, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadagopan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liimatta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazerwith, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stiff, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamtekar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhattacharya, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swaney, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Becelaere, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span> <span> </span><span class="NLM_article-title">Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">411</span>– <span class="NLM_lpage">420</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2009.02.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1016%2Fj.chembiol.2009.02.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=19389627" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BD1MXltVCms7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2009&pages=411-420&author=K.+Ahnauthor=D.+S.+Johnsonauthor=M.+Mileniauthor=D.+Beidlerauthor=J.+Z.+Longauthor=M.+K.+McKinneyauthor=E.+Weerapanaauthor=N.+Sadagopanauthor=M.+Liimattaauthor=S.+E.+Smithauthor=S.+Lazerwithauthor=C.+Stiffauthor=S.+Kamtekarauthor=K.+Bhattacharyaauthor=Y.+Zhangauthor=S.+Swaneyauthor=K.+Van+Becelaereauthor=R.+C.+Stevensauthor=B.+F.+Cravatt&title=Discovery+and+characterization+of+a+highly+selective+FAAH+inhibitor+that+reduces+inflammatory+pain&doi=10.1016%2Fj.chembiol.2009.02.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit210R"><div class="casContent"><span class="casTitleNuber">210</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Characterization of a Highly Selective FAAH Inhibitor that Reduces Inflammatory Pain</span></div><div class="casAuthors">Ahn, Kay; Johnson, Douglas S.; Mileni, Mauro; Beidler, David; Long, Jonathan Z.; McKinney, Michele K.; Weerapana, Eranthie; Sadagopan, Nalini; Liimatta, Marya; Smith, Sarah E.; Lazerwith, Scott; Stiff, Cory; Kamtekar, Satwik; Bhattacharya, Keshab; Zhang, Yanhua; Swaney, Stephen; Van Becelaere, Keri; Stevens, Raymond C.; Cravatt, Benjamin F.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">411-420</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Summary: Endocannabinoids are lipid signaling mols. that regulate a wide range of mammalian behaviors, including pain, inflammation, and cognitive/emotional state.  The endocannabinoid anandamide is principally degraded by the integral membrane enzyme fatty acid amide hydrolase (FAAH), and there is currently much interest in developing FAAH inhibitors to augment endocannabinoid signaling in vivo.  Here, we report the discovery and detailed characterization of a highly efficacious and selective FAAH inhibitor, PF-3845.  Mechanistic and structural studies confirm that PF-3845 is a covalent inhibitor that carbamylates FAAH's serine nucleophile.  PF-3845 selectively inhibits FAAH in vivo, as detd. by activity-based protein profiling; raises brain anandamide levels for up to 24 h; and produces significant cannabinoid receptor-dependent redns. in inflammatory pain.  These data thus designate PF-3845 as a valuable pharmacol. tool for in vivo characterization of the endocannabinoid system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWANdntofbhbVg90H21EOLACvtfcHk0liOAhJT0utLlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXltVCms7w%253D&md5=c418dbdf626109415af7001db5a7cb93</span></div><a href="/servlet/linkout?suffix=cit210&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2009.02.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2009.02.013%26sid%3Dliteratum%253Aachs%26aulast%3DAhn%26aufirst%3DK.%26aulast%3DJohnson%26aufirst%3DD.%2BS.%26aulast%3DMileni%26aufirst%3DM.%26aulast%3DBeidler%26aufirst%3DD.%26aulast%3DLong%26aufirst%3DJ.%2BZ.%26aulast%3DMcKinney%26aufirst%3DM.%2BK.%26aulast%3DWeerapana%26aufirst%3DE.%26aulast%3DSadagopan%26aufirst%3DN.%26aulast%3DLiimatta%26aufirst%3DM.%26aulast%3DSmith%26aufirst%3DS.%2BE.%26aulast%3DLazerwith%26aufirst%3DS.%26aulast%3DStiff%26aufirst%3DC.%26aulast%3DKamtekar%26aufirst%3DS.%26aulast%3DBhattacharya%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DSwaney%26aufirst%3DS.%26aulast%3DVan%2BBecelaere%26aufirst%3DK.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26atitle%3DDiscovery%2520and%2520characterization%2520of%2520a%2520highly%2520selective%2520FAAH%2520inhibitor%2520that%2520reduces%2520inflammatory%2520pain%26jtitle%3DChem.%2520Biol.%26date%3D2009%26volume%3D16%26spage%3D411%26epage%3D420%26doi%3D10.1016%2Fj.chembiol.2009.02.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref211"><div class="reference"><strong class="refLabel"><a href="#ref211" class="rightTabRefNumLink">211</a></strong><div class="NLM_citation" id="rightTab-cit211"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Naik, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Won, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ban, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhattarai, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.</span></span> <span> </span><span class="NLM_article-title">Synthesis and structure-activity relationship study of chemical probes as hypoxia induced factor-1alpha/malate dehydrogenase 2 inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">9522</span>– <span class="NLM_lpage">9538</span>, <span class="refDoi"> DOI: 10.1021/jm501241g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501241g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVelurrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=9522-9538&author=R.+Naikauthor=M.+Wonauthor=H.+S.+Banauthor=D.+Bhattaraiauthor=X.+Xuauthor=Y.+Eoauthor=Y.+S.+Hongauthor=S.+Singhauthor=Y.+Choiauthor=H.+C.+Ahnauthor=K.+Lee&title=Synthesis+and+structure-activity+relationship+study+of+chemical+probes+as+hypoxia+induced+factor-1alpha%2Fmalate+dehydrogenase+2+inhibitors&doi=10.1021%2Fjm501241g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit211R"><div class="casContent"><span class="casTitleNuber">211</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Structure-Activity Relationship Study of Chemical Probes as Hypoxia Induced Factor-1α/Malate Dehydrogenase 2 Inhibitors</span></div><div class="casAuthors">Naik, Ravi; Won, Misun; Ban, Hyun Seung; Bhattarai, Deepak; Xu, Xuezhen; Eo, Yumi; Hong, Ye Seul; Singh, Sarbjit; Choi, Yongseok; Ahn, Hee-Chul; Lee, Kyeong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">9522-9538</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A structure-activity relationship study of hypoxia inducible factor-1α inhibitor 3-aminobenzoic acid-based chem. probes, which were previously identified to bind to mitochondrial malate dehydrogenase 2, was performed to provide a better understanding of the pharmacol. effects of LW6 and its relation to hypoxia inducible factor-1α (HIF-1α) and malate dehydrogenase 2 (MDH2).  A variety of multifunctional probes including the benzophenone or the trifluoromethyl diazirine for photoaffinity labeling and click reaction were prepd. and evaluated for their biol. activity using a cell-based HRE-luciferase assay as well as a MDH2 assay in human colorectal cancer HCT116 cells.  Among them, the diazirine probe I showed strong inhibitory activity against both HIF-1α and MDH2.  Significantly, the inhibitory effect of the probes on HIF-1α activity was consistent with that of the MDH2 enzyme assay, which was further confirmed by the effect on in vitro binding activity to recombinant human MDH2, oxygen consumption, ATP prodn., and AMP activated protein kinase (AMPK) activation.  Competitive binding modes of LW6 and probe I to MDH2 were also demonstrated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSeg3MyMk_rLVg90H21EOLACvtfcHk0liOAhJT0utLlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVelurrN&md5=4ca2511030541f1257a79edd60301e83</span></div><a href="/servlet/linkout?suffix=cit211&amp;dbid=16384&amp;doi=10.1021%2Fjm501241g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501241g%26sid%3Dliteratum%253Aachs%26aulast%3DNaik%26aufirst%3DR.%26aulast%3DWon%26aufirst%3DM.%26aulast%3DBan%26aufirst%3DH.%2BS.%26aulast%3DBhattarai%26aufirst%3DD.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DEo%26aufirst%3DY.%26aulast%3DHong%26aufirst%3DY.%2BS.%26aulast%3DSingh%26aufirst%3DS.%26aulast%3DChoi%26aufirst%3DY.%26aulast%3DAhn%26aufirst%3DH.%2BC.%26aulast%3DLee%26aufirst%3DK.%26atitle%3DSynthesis%2520and%2520structure-activity%2520relationship%2520study%2520of%2520chemical%2520probes%2520as%2520hypoxia%2520induced%2520factor-1alpha%252Fmalate%2520dehydrogenase%25202%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D9522%26epage%3D9538%26doi%3D10.1021%2Fjm501241g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref212"><div class="reference"><strong class="refLabel"><a href="#ref212" class="rightTabRefNumLink">212</a></strong><div class="NLM_citation" id="rightTab-cit212"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maity, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yim, C.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jadhav, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verhassel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuomela, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solin, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grönroos, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Virta, P.</span></span> <span> </span><span class="NLM_article-title">Synthesis of an alkyne-modified bleomycin disaccharide precursor, conversion to a <sup>18</sup>F-labeled radiotracer, and preliminary in vivo-PET imaging studies</span>. <i>Eur. J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>2019</i></span>,  <span class="NLM_fpage">156</span>– <span class="NLM_lpage">163</span>, <span class="refDoi"> DOI: 10.1002/ejoc.201801488</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1002%2Fejoc.201801488" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVenu7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2019&publication_year=2019&pages=156-163&author=S.+K.+Maityauthor=C.-B.+Yimauthor=S.+Jadhavauthor=A.+Verhasselauthor=J.+Tuomelaauthor=O.+Solinauthor=T.+J.+Gr%C3%B6nroosauthor=P.+Virta&title=Synthesis+of+an+alkyne-modified+bleomycin+disaccharide+precursor%2C+conversion+to+a+18F-labeled+radiotracer%2C+and+preliminary+in+vivo-PET+imaging+studies&doi=10.1002%2Fejoc.201801488"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit212R"><div class="casContent"><span class="casTitleNuber">212</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of an Alkyne-Modified Bleomycin Disaccharide Precursor, Conversion to a 18F-Labeled Radiotracer, and Preliminary in vivo-PET Imaging Studies</span></div><div class="casAuthors">Maity, Sajal K.; Yim, Cheng-Bin; Jadhav, Satish; Verhassel, Alejandra; Tuomela, Johanna; Solin, Olof; Groenroos, Tove J.; Virta, Pasi</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">2019</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">156-163</span>CODEN:
                <span class="NLM_cas:coden">EJOCFK</span>;
        ISSN:<span class="NLM_cas:issn">1099-0690</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The bleomycins (BLMs) are known antitumor antibiotics composed of the tumoricidal and tumor seeking domains.  The peptide structure of BLMs is responsible for the cytotoxicity by selective oxidative cleavage of DNA (and RNA), while the tumor cell selectivity and internalization resides in the disaccharide moiety (i.e. BLM disaccharide).  This has prompted researchers to utilize BLM disaccharide and its derivs. as constituents for the selective recognition of tumor cells, which may find further applications as new tumor imaging tools or drug delivery vehicles.  In the present study a high yielding synthesis of an alkyne modified BLM disaccharide precursor that may be used as a useful agent for the click conjugation, its conversion to a 18F-labeled radiotracer, and preliminary in vivo PET imaging studies of the tracer with breast cancer (MCF-7) xenograft mouse models are described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8fm_nLU5pB7Vg90H21EOLACvtfcHk0lhJWMHCi8HTrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVenu7rL&md5=0ca0384621af4642ee09ce4959b987ad</span></div><a href="/servlet/linkout?suffix=cit212&amp;dbid=16384&amp;doi=10.1002%2Fejoc.201801488&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fejoc.201801488%26sid%3Dliteratum%253Aachs%26aulast%3DMaity%26aufirst%3DS.%2BK.%26aulast%3DYim%26aufirst%3DC.-B.%26aulast%3DJadhav%26aufirst%3DS.%26aulast%3DVerhassel%26aufirst%3DA.%26aulast%3DTuomela%26aufirst%3DJ.%26aulast%3DSolin%26aufirst%3DO.%26aulast%3DGr%25C3%25B6nroos%26aufirst%3DT.%2BJ.%26aulast%3DVirta%26aufirst%3DP.%26atitle%3DSynthesis%2520of%2520an%2520alkyne-modified%2520bleomycin%2520disaccharide%2520precursor%252C%2520conversion%2520to%2520a%252018F-labeled%2520radiotracer%252C%2520and%2520preliminary%2520in%2520vivo-PET%2520imaging%2520studies%26jtitle%3DEur.%2520J.%2520Org.%2520Chem.%26date%3D2019%26volume%3D2019%26spage%3D156%26epage%3D163%26doi%3D10.1002%2Fejoc.201801488" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref213"><div class="reference"><strong class="refLabel"><a href="#ref213" class="rightTabRefNumLink">213</a></strong><div class="NLM_citation" id="rightTab-cit213"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kazandjian, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzman, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blumenthal, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mushti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Libeg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keegan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazdur, R.</span></span> <span> </span><span class="NLM_article-title">FDA Approval summary: Nivolumab for the treatment of metastatic non-small cell lung cancer with progression on or after platinum-based chemotherapy</span>. <i>Oncologist</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">634</span>– <span class="NLM_lpage">642</span>, <span class="refDoi"> DOI: 10.1634/theoncologist.2015-0507</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1634%2Ftheoncologist.2015-0507" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=26984449" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFGntbfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2016&pages=634-642&author=D.+Kazandjianauthor=D.+L.+Suzmanauthor=G.+Blumenthalauthor=S.+Mushtiauthor=K.+Heauthor=M.+Libegauthor=P.+Keeganauthor=R.+Pazdur&title=FDA+Approval+summary%3A+Nivolumab+for+the+treatment+of+metastatic+non-small+cell+lung+cancer+with+progression+on+or+after+platinum-based+chemotherapy&doi=10.1634%2Ftheoncologist.2015-0507"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit213R"><div class="casContent"><span class="casTitleNuber">213</span><div class="casTitle"><span class="NLM_cas:atitle">FDA approval summary: nivolumab for the treatment of metastatic non-small cell lung cancer with progression on or after platinum-based chemotherapy</span></div><div class="casAuthors">Kazandjian, Dickran; Suzman, Daniel L.; Blumenthal, Gideon; Mushti, Sirisha; He, Kun; Libeg, Meredith; Keegan, Patricia; Pazdur, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Oncologist</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">634-642</span>CODEN:
                <span class="NLM_cas:coden">OCOLF6</span>;
        ISSN:<span class="NLM_cas:issn">1083-7159</span>.
    
            (<span class="NLM_cas:orgname">AlphaMed Press</span>)
        </div><div class="casAbstract">On Oct. 9, 2015, the U.S.  Food and Drug Administration expanded the nivolumab metastatic non-small cell lung cancer (NSCLC) indication to include patients with nonsquamous NSCLC after a 3.25-mo review timeline.  Approval was based on demonstration of an improvement in overall survival (OS) in an international, multicenter, open-label, randomized trial comparing nivolumab to docetaxel in patients with metastatic nonsquamous NSCLC with progression on or after platinum-based chemotherapy.  The CheckMate 057 trial enrolled 582 patients who were randomized (1:1) to receive nivolumab or docetaxel.  Nivolumab demonstrated improved OS compared with docetaxel at the prespecified interim anal. with a hazard ratio (HR) of 0.73 (p = .0015), and a median OS of 12.2 mo (95% CI: 9.7-15.0 mo) in patients treated with nivolumab compared with 9.4 mo (95% CI: 8.0-10.7 mo) in patients treated with docetaxel.  A statistically significant improvement in objective response rate (ORR) was also obsd., with an ORR of 19% (95% CI: 15%-24%) in the nivolumab arm and 12% (95% CI: 9%-17%) in the docetaxel arm.  The median duration of response was 17 mo in the nivolumab arm and 6 mo in the docetaxel arm.  Progression-free survival was not statistically different between arms.  A prespecified retrospective subgroup anal. suggested that patients with programmed cell death ligand 1-neg. tumors treated with nivolumab had similar OS to those treated with docetaxel.  The toxicity profile of nivolumab was consistent with the known immune-mediated adverse event profile except for 1 case of grade 5 limbic encephalitis, which led to a postmarketing requirement study to better characterize immune-mediated encephalitis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8ZYyuBD8U8bVg90H21EOLACvtfcHk0lhJWMHCi8HTrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFGntbfE&md5=eee78dd8d34877e911dbea9bc3eb9873</span></div><a href="/servlet/linkout?suffix=cit213&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.2015-0507&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.2015-0507%26sid%3Dliteratum%253Aachs%26aulast%3DKazandjian%26aufirst%3DD.%26aulast%3DSuzman%26aufirst%3DD.%2BL.%26aulast%3DBlumenthal%26aufirst%3DG.%26aulast%3DMushti%26aufirst%3DS.%26aulast%3DHe%26aufirst%3DK.%26aulast%3DLibeg%26aufirst%3DM.%26aulast%3DKeegan%26aufirst%3DP.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DFDA%2520Approval%2520summary%253A%2520Nivolumab%2520for%2520the%2520treatment%2520of%2520metastatic%2520non-small%2520cell%2520lung%2520cancer%2520with%2520progression%2520on%2520or%2520after%2520platinum-based%2520chemotherapy%26jtitle%3DOncologist%26date%3D2016%26volume%3D21%26spage%3D634%26epage%3D642%26doi%3D10.1634%2Ftheoncologist.2015-0507" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref214"><div class="reference"><strong class="refLabel"><a href="#ref214" class="rightTabRefNumLink">214</a></strong><div class="NLM_citation" id="rightTab-cit214"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Herbst, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baas, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felip, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Gracia, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molina, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arvis, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majem, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidler, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Castro, G.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrido, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubiniecki, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shentu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Im, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolled-Filhart, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garon, E. B.</span></span> <span> </span><span class="NLM_article-title">Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>387</i></span>,  <span class="NLM_fpage">1540</span>– <span class="NLM_lpage">1550</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(15)01281-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1016%2FS0140-6736%2815%2901281-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=26712084" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVGrtLzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=387&publication_year=2016&pages=1540-1550&author=R.+S.+Herbstauthor=P.+Baasauthor=D.+W.+Kimauthor=E.+Felipauthor=J.+L.+Perez-Graciaauthor=J.+Y.+Hanauthor=J.+Molinaauthor=J.+H.+Kimauthor=C.+D.+Arvisauthor=M.+J.+Ahnauthor=M.+Majemauthor=M.+J.+Fidlerauthor=G.+de+Castroauthor=M.+Garridoauthor=G.+M.+Lubinieckiauthor=Y.+Shentuauthor=E.+Imauthor=M.+Dolled-Filhartauthor=E.+B.+Garon&title=Pembrolizumab+versus+docetaxel+for+previously+treated%2C+PD-L1-positive%2C+advanced+non-small-cell+lung+cancer+%28KEYNOTE-010%29%3A+a+randomised+controlled+trial&doi=10.1016%2FS0140-6736%2815%2901281-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit214R"><div class="casContent"><span class="casTitleNuber">214</span><div class="casTitle"><span class="NLM_cas:atitle">Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial</span></div><div class="casAuthors">Herbst, Roy S.; Baas, Paul; Kim, Dong-Wan; Felip, Enriqueta; Perez-Gracia, Jose L.; Han, Ji-Youn; Molina, Julian; Kim, Joo-Hang; Arvis, Catherine Dubos; Ahn, Myung-Ju; Majem, Margarita; Fidler, Mary J.; de Castro, Gilberto Jr; Garrido, Marcelo; Lubiniecki, Gregory M.; Shentu, Yue; Im, Ellie; Dolled-Filhart, Marisa; Garon, Edward B.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">387</span>
        (<span class="NLM_cas:issue">10027</span>),
    <span class="NLM_cas:pages">1540-1550</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Despite recent advances in the treatment of advanced non-small-cell lung cancer, there remains a need for effective treatments for progressive disease.  We assessed the efficacy of pembrolizumab for patients with previously treated, PD-L1-pos., advanced non-small-cell lung cancer.  We did this randomised, open-label, phase 2/3 study at 202 academic medical centers in 24 countries.  Patients with previously treated non-small-cell lung cancer with PD-L1 expression on at least 1% of tumor cells were randomly assigned (1:1:1) in blocks of six per stratum with an interactive voice-response system to receive pembrolizumab 2 mg/kg, pembrolizumab 10 mg/kg, or docetaxel 75 mg/m2 every 3 wk.  The primary endpoints were overall survival and progression-free survival both in the total population and in patients with PD-L1 expression on at least 50% of tumor cells.  We used a threshold for significance of p<0·00825 (one-sided) for the anal. of overall survival and a threshold of p<0·001 for progression-free survival.  This trial is registered at ClinicalTrials.gov, no. NCT01905657.  Between Aug 28, 2013, and Feb 27, 2015, we enrolled 1034 patients: 345 allocated to pembrolizumab 2 mg/kg, 346 allocated to pembrolizumab 10 mg/kg, and 343 allocated to docetaxel.  By Sept 30, 2015, 521 patients had died.  In the total population, median overall survival was 10·4 mo with pembrolizumab 2 mg/kg, 12·7 mo with pembrolizumab 10 mg/kg, and 8·5 mo with docetaxel.  Overall survival was significantly longer for pembrolizumab 2 mg/kg vs. docetaxel (hazard ratio [HR] 0·71, 95% CI 0·58-0·88; p=0·0008) and for pembrolizumab 10 mg/kg vs. docetaxel (0·61, 0·49-0·75; p<0·0001).  Median progression-free survival was 3·9 mo with pembrolizumab 2 mg/kg, 4·0 mo with pembrolizumab 10 mg/kg, and 4·0 mo with docetaxel, with no significant difference for pembrolizumab 2 mg/kg vs. docetaxel (0·88, 0·74-1·05; p=0·07) or for pembrolizumab 10 mg/kg vs. docetaxel (HR 0·79, 95% CI 0·66-0·94; p=0·004).  Among patients with at least 50% of tumor cells expressing PD-L1, overall survival was significantly longer with pembrolizumab 2 mg/kg than with docetaxel (median 14·9 mo vs 8·2 mo; HR 0·54, 95% CI 0·38-0·77; p=0·0002) and with pembrolizumab 10 mg/kg than with docetaxel (17·3 mo vs 8·2 mo; 0·50, 0·36-0·70; p<0·0001).  Likewise, for this patient population, progression-free survival was significantly longer with pembrolizumab 2 mg/kg than with docetaxel (median 5·0 mo vs 4·1 mo; HR 0·59, 95% CI 0·44-0·78; p=0·0001) and with pembrolizumab 10 mg/kg than with docetaxel (5·2 mo vs 4·1 mo; 0·59, 0·45-0·78; p<0·0001).  Grade 3-5 treatment-related adverse events were less common with pembrolizumab than with docetaxel (43 [13%] of 339 patients given 2 mg/kg, 55 [16%] of 343 given 10 mg/kg, and 109 [35%] of 309 given docetaxel).  Pembrolizumab prolongs overall survival and has a favorable benefit-to-risk profile in patients with previously treated, PD-L1-pos., advanced non-small-cell lung cancer.  These data establish pembrolizumab as a new treatment option for this population and validate the use of PD-L1 selection.Merck & Co.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnxRttuwvktbVg90H21EOLACvtfcHk0lhJWMHCi8HTrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVGrtLzI&md5=333bd6a558ec0f3716e15a2a96b2c02f</span></div><a href="/servlet/linkout?suffix=cit214&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2815%2901281-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252815%252901281-7%26sid%3Dliteratum%253Aachs%26aulast%3DHerbst%26aufirst%3DR.%2BS.%26aulast%3DBaas%26aufirst%3DP.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DPerez-Gracia%26aufirst%3DJ.%2BL.%26aulast%3DHan%26aufirst%3DJ.%2BY.%26aulast%3DMolina%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DJ.%2BH.%26aulast%3DArvis%26aufirst%3DC.%2BD.%26aulast%3DAhn%26aufirst%3DM.%2BJ.%26aulast%3DMajem%26aufirst%3DM.%26aulast%3DFidler%26aufirst%3DM.%2BJ.%26aulast%3Dde%2BCastro%26aufirst%3DG.%26aulast%3DGarrido%26aufirst%3DM.%26aulast%3DLubiniecki%26aufirst%3DG.%2BM.%26aulast%3DShentu%26aufirst%3DY.%26aulast%3DIm%26aufirst%3DE.%26aulast%3DDolled-Filhart%26aufirst%3DM.%26aulast%3DGaron%26aufirst%3DE.%2BB.%26atitle%3DPembrolizumab%2520versus%2520docetaxel%2520for%2520previously%2520treated%252C%2520PD-L1-positive%252C%2520advanced%2520non-small-cell%2520lung%2520cancer%2520%2528KEYNOTE-010%2529%253A%2520a%2520randomised%2520controlled%2520trial%26jtitle%3DLancet%26date%3D2016%26volume%3D387%26spage%3D1540%26epage%3D1550%26doi%3D10.1016%2FS0140-6736%2815%2901281-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref215"><div class="reference"><strong class="refLabel"><a href="#ref215" class="rightTabRefNumLink">215</a></strong><div class="NLM_citation" id="rightTab-cit215"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Donnelly, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipovsek, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gokemeijer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lafont, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pena, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kukral, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dischino, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chow, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adelakun, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonacorsi, S. J.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, W.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biologic evaluation of a novel (18)F-labeled adnectin as a PET radioligand for imaging PD-L1 expression</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">529</span>– <span class="NLM_lpage">535</span>, <span class="refDoi"> DOI: 10.2967/jnumed.117.199596</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.2967%2Fjnumed.117.199596" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=29025984" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFylu77L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2018&pages=529-535&author=D.+J.+Donnellyauthor=R.+A.+Smithauthor=P.+Morinauthor=D.+Lipovsekauthor=J.+Gokemeijerauthor=D.+Cohenauthor=V.+Lafontauthor=T.+Tranauthor=E.+L.+Coleauthor=M.+Wrightauthor=J.+Kimauthor=A.+Penaauthor=D.+Kukralauthor=D.+D.+Dischinoauthor=P.+Chowauthor=J.+Ganauthor=O.+Adelakunauthor=X.+T.+Wangauthor=K.+Caoauthor=D.+Leungauthor=S.+J.+Bonacorsiauthor=W.+Hayes&title=Synthesis+and+biologic+evaluation+of+a+novel+%2818%29F-labeled+adnectin+as+a+PET+radioligand+for+imaging+PD-L1+expression&doi=10.2967%2Fjnumed.117.199596"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit215R"><div class="casContent"><span class="casTitleNuber">215</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biologic evaluation of a novel 18F-labeled adnectin as a PET radioligand for imaging PD-L1 expression</span></div><div class="casAuthors">Donnelly, David J.; Smith, R. Adam; Morin, Paul; Lipovsek, Dasa; Gokemeijer, Jochem; Cohen, Daniel; Lafont, Virginie; Tran, Tritin; Cole, Erin L.; Wright, Martin; Kim, Joonyoung; Pena, Adrienne; Kukral, Daniel; Dischino, Douglas D.; Chow, Patrick; Gan, Jinping; Adelakun, Olufemi; Wang, Xi-Tao; Cao, Kai; Leung, David; Bonacorsi, Samuel J.; Hayes, Wendy</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">529-535</span>CODEN:
                <span class="NLM_cas:coden">JNMEAQ</span>;
        ISSN:<span class="NLM_cas:issn">1535-5667</span>.
    
            (<span class="NLM_cas:orgname">Society of Nuclear Medicine and Molecular Imaging</span>)
        </div><div class="casAbstract">The programmed death protein (PD-1) and its ligand (PD-L1) play crit. roles in a checkpoint pathway cancer cells exploit to evade the immune system.  A same-day PET imaging agent for measuring PD-L1 status in primary and metastatic lesions could be important for optimizing drug therapy.  Herein, we have evaluated the tumor targeting of an anti-PD-L1 adnectin after 18F-fluorine labeling.  Methods: An anti-PD-L1 adnectin was labeled with 18F in 2 steps.  This synthesis featured fluorination of a novel prosthetic group, followed by a copper-free click conjugation to a modified adnectin to generate 18F-BMS-986192. 18F-BMS-986192 was evaluated in tumors using in vitro autoradiog. and PET with mice bearing bilateral PD-L1-neg. (PD-L1(-)) and PD-L1-pos. (PD-L1(1)) s.c. tumors. 18F-BMS-986192 was evaluated for distribution, binding, and radiation dosimetry in a healthy cynomolgus monkey.  Results: 18F-BMS-986192 bound to human and cynomolgus PD-L1 with a dissocn. const. of less than 35 pM, as measured by surface plasmon resonance.  This adnectin was labeled with 18F to yield a PET radioligand for assessing PD-L1 expression in vivo. 18F-BMS-986192 bound to tumor tissues as a function of PD-L1 expression detd. by immunohistochem.  Radioligand binding was blocked in a dose-dependent manner.  In vivo PET imaging clearly visualized PD-L1 expression in mice implanted with PD-L1(1), L2987 xenograft tumors.  Two hours after dosing, a 3.5-fold-higher uptake (2.41 ± 0.29 vs. 0.82 ± 0.11 percentage injected dose per g, P < 0.0001) was obsd. in L2987 than in control HT-29 (PD-L1(-)) tumors.  Coadministration of 3 mg/kg ADX_5322_A02 anti-PD-L1 adnectin reduced tumor uptake at 2 h after injection by approx. 70%, whereas HT-29 uptake remained unchanged, demonstrating PD-L1-specific binding.  Biodistribution in a nonhuman primate showed binding in the PD-L1-rich spleen, with rapid blood clearance through the kidneys and bladder.  Binding in the PD-L1(1) spleen was reduced by coadministration of BMS-986192.  Dosimetry ests. indicate that the kidney is the dose-limiting organ, with an estd. human absorbed dose of 2.20E-01 mSv/MBq.  Conclusion: 18FBMS-986192 demonstrated the feasibility of noninvasively imaging the PD-L1 status of tumors by small-animal PET studies.  Clin. studies with 18F-BMS-986192 are under way to measure PD-L1 expression in human tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzn6Jua02bzLVg90H21EOLACvtfcHk0ljc6C1aYNeDYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFylu77L&md5=2621cf749657192a080d3707d09455e8</span></div><a href="/servlet/linkout?suffix=cit215&amp;dbid=16384&amp;doi=10.2967%2Fjnumed.117.199596&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2967%252Fjnumed.117.199596%26sid%3Dliteratum%253Aachs%26aulast%3DDonnelly%26aufirst%3DD.%2BJ.%26aulast%3DSmith%26aufirst%3DR.%2BA.%26aulast%3DMorin%26aufirst%3DP.%26aulast%3DLipovsek%26aufirst%3DD.%26aulast%3DGokemeijer%26aufirst%3DJ.%26aulast%3DCohen%26aufirst%3DD.%26aulast%3DLafont%26aufirst%3DV.%26aulast%3DTran%26aufirst%3DT.%26aulast%3DCole%26aufirst%3DE.%2BL.%26aulast%3DWright%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DPena%26aufirst%3DA.%26aulast%3DKukral%26aufirst%3DD.%26aulast%3DDischino%26aufirst%3DD.%2BD.%26aulast%3DChow%26aufirst%3DP.%26aulast%3DGan%26aufirst%3DJ.%26aulast%3DAdelakun%26aufirst%3DO.%26aulast%3DWang%26aufirst%3DX.%2BT.%26aulast%3DCao%26aufirst%3DK.%26aulast%3DLeung%26aufirst%3DD.%26aulast%3DBonacorsi%26aufirst%3DS.%2BJ.%26aulast%3DHayes%26aufirst%3DW.%26atitle%3DSynthesis%2520and%2520biologic%2520evaluation%2520of%2520a%2520novel%2520%252818%2529F-labeled%2520adnectin%2520as%2520a%2520PET%2520radioligand%2520for%2520imaging%2520PD-L1%2520expression%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2018%26volume%3D59%26spage%3D529%26epage%3D535%26doi%3D10.2967%2Fjnumed.117.199596" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref216"><div class="reference"><strong class="refLabel"><a href="#ref216" class="rightTabRefNumLink">216</a></strong><div class="NLM_citation" id="rightTab-cit216"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoleru, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salic, A.</span></span> <span> </span><span class="NLM_article-title">Imaging protein synthesis in cells and tissues with an alkyne analog of puromycin</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">413</span>– <span class="NLM_lpage">418</span>, <span class="refDoi"> DOI: 10.1073/pnas.1111561108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1073%2Fpnas.1111561108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=22160674" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1ensrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2012&pages=413-418&author=J.+Liuauthor=Y.+Xuauthor=D.+Stoleruauthor=A.+Salic&title=Imaging+protein+synthesis+in+cells+and+tissues+with+an+alkyne+analog+of+puromycin&doi=10.1073%2Fpnas.1111561108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit216R"><div class="casContent"><span class="casTitleNuber">216</span><div class="casTitle"><span class="NLM_cas:atitle">Imaging protein synthesis in cells and tissues with an alkyne analog of puromycin</span></div><div class="casAuthors">Liu, Jing; Xu, Yangqing; Stoleru, Dan; Salic, Adrian</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">413-418, S413/1-S413/5</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Synthesis of many proteins is tightly controlled at the level of translation, and plays an essential role in fundamental processes such as cell growth-and proliferation, signaling, differentiation, or death.  Methods that allow imaging and identification of nascent proteins are crit. for dissecting regulation of translation, both spatially and temporally, particularly in whole organisms.  We introduce a simple and robust chem. method to image and affinity-purify nascent proteins in cells and in animals, based on an alkyne analog of puromycin, O-propargyl-puromycin (OP-puro).  OP-puro forms covalent conjugates with nascent polypeptide chains, which are rapidly turned over by the proteasome and can be visualized or captured by copper(l)-catalyzed azide-alkyne cycloaddn.  Unlike methionine analogs, OP-puro does not require methionine-free conditions and, uniquely, can be used to label and assay nascent proteins in whole organisms.  This strategy should have broad applicability for imaging protein synthesis and for identifying proteins synthesized under various physiol. and pathol. conditions in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTwcNZbUrncbVg90H21EOLACvtfcHk0ljc6C1aYNeDYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1ensrY%253D&md5=4fae8dd7f5894f12dfa0b550d40d65bb</span></div><a href="/servlet/linkout?suffix=cit216&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1111561108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1111561108%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DStoleru%26aufirst%3DD.%26aulast%3DSalic%26aufirst%3DA.%26atitle%3DImaging%2520protein%2520synthesis%2520in%2520cells%2520and%2520tissues%2520with%2520an%2520alkyne%2520analog%2520of%2520puromycin%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2012%26volume%3D109%26spage%3D413%26epage%3D418%26doi%3D10.1073%2Fpnas.1111561108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref217"><div class="reference"><strong class="refLabel"><a href="#ref217" class="rightTabRefNumLink">217</a></strong><div class="NLM_citation" id="rightTab-cit217"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bosc, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakhlal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deprez, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deprez-Poulain, R.</span></span> <span> </span><span class="NLM_article-title">Kinetic target-guided synthesis in drug discovery and chemical biology: A comprehensive facts and figures survey</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">381</span>– <span class="NLM_lpage">404</span>, <span class="refDoi"> DOI: 10.4155/fmc-2015-0007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.4155%2Ffmc-2015-0007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=26877247" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC28XksFCgtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=381-404&author=D.+Boscauthor=J.+Jakhlalauthor=B.+Deprezauthor=R.+Deprez-Poulain&title=Kinetic+target-guided+synthesis+in+drug+discovery+and+chemical+biology%3A+A+comprehensive+facts+and+figures+survey&doi=10.4155%2Ffmc-2015-0007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit217R"><div class="casContent"><span class="casTitleNuber">217</span><div class="casTitle"><span class="NLM_cas:atitle">Kinetic target-guided synthesis in drug discovery and chemical biology: a comprehensive facts and figures survey</span></div><div class="casAuthors">Bosc, Damien; Jakhlal, Jouda; Deprez, Benoit; Deprez-Poulain, Rebecca</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">381-404</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">For the last 15 years, kinetic target-guided syntheses, including in situ click chem., have been used as alternative methods to find ligands to therapeutically relevant proteins.  In this review, a comprehensive survey of biol. targets used in kinetic target-guided synthesis covers historical and recent examples.  The chem. reactions employed and practical aspects, including controls, library sizes and product detection, are presented.  A particular focus is on the reagents and warhead selection and design with a crit. overview of the challenges encountered.  As protein supply remains a key success factor, it appears that increased efforts should be taken toward miniaturization in order to expand the scope of this strategy and qualify it as a fully fledged drug discovery tool.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8Rt7hXE5irrVg90H21EOLACvtfcHk0ljc6C1aYNeDYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XksFCgtrw%253D&md5=6f4a3603979d3862590e1bb5207d3458</span></div><a href="/servlet/linkout?suffix=cit217&amp;dbid=16384&amp;doi=10.4155%2Ffmc-2015-0007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc-2015-0007%26sid%3Dliteratum%253Aachs%26aulast%3DBosc%26aufirst%3DD.%26aulast%3DJakhlal%26aufirst%3DJ.%26aulast%3DDeprez%26aufirst%3DB.%26aulast%3DDeprez-Poulain%26aufirst%3DR.%26atitle%3DKinetic%2520target-guided%2520synthesis%2520in%2520drug%2520discovery%2520and%2520chemical%2520biology%253A%2520A%2520comprehensive%2520facts%2520and%2520figures%2520survey%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2016%26volume%3D8%26spage%3D381%26epage%3D404%26doi%3D10.4155%2Ffmc-2015-0007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref218"><div class="reference"><strong class="refLabel"><a href="#ref218" class="rightTabRefNumLink">218</a></strong><div class="NLM_citation" id="rightTab-cit218"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Antti, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellstedt, M.</span></span> <span> </span><span class="NLM_article-title">Cell-based kinetic target-guided synthesis of an enzyme inhibitor</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">351</span>– <span class="NLM_lpage">353</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00535</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00535" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjvFansr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=351-353&author=H.+Anttiauthor=M.+Sellstedt&title=Cell-based+kinetic+target-guided+synthesis+of+an+enzyme+inhibitor&doi=10.1021%2Facsmedchemlett.7b00535"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit218R"><div class="casContent"><span class="casTitleNuber">218</span><div class="casTitle"><span class="NLM_cas:atitle">Cell-Based Kinetic Target-Guided Synthesis of an Enzyme Inhibitor</span></div><div class="casAuthors">Antti, Henrik; Sellstedt, Magnus</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">351-353</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Finding a new drug candidate for a selected target is an expensive and time-consuming process.  Target guided-synthesis, or in situ click chem., is a concept where the drug target is used to template the formation of its own inhibitors from reactive building blocks.  This could simplify the identification of drug candidates.  However, with the exception of one example of an RNA-target, target-guided synthesis has always employed purified targets.  This limits the no. of targets that can be screened by the method.  By applying methods from the field of metabolomics, we demonstrate that target-guided synthesis with protein targets also can be performed directly in cell-based systems.  These methods offer new possibilities to conduct screening for drug candidates of difficult protein targets in cellular environments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsLDGNYh5NN7Vg90H21EOLACvtfcHk0ligMvuCbX2E2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjvFansr8%253D&md5=117e4a2748228d419128f2d2046c2e35</span></div><a href="/servlet/linkout?suffix=cit218&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00535&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00535%26sid%3Dliteratum%253Aachs%26aulast%3DAntti%26aufirst%3DH.%26aulast%3DSellstedt%26aufirst%3DM.%26atitle%3DCell-based%2520kinetic%2520target-guided%2520synthesis%2520of%2520an%2520enzyme%2520inhibitor%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D9%26spage%3D351%26epage%3D353%26doi%3D10.1021%2Facsmedchemlett.7b00535" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref219"><div class="reference"><strong class="refLabel"><a href="#ref219" class="rightTabRefNumLink">219</a></strong><div class="NLM_citation" id="rightTab-cit219"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oueis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renard, P. Y.</span></span> <span> </span><span class="NLM_article-title">New insights into the kinetic target-guided synthesis of protein ligands</span>. <i>Chem. Commun. (Cambridge, U. K.)</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">12158</span>– <span class="NLM_lpage">12169</span>, <span class="refDoi"> DOI: 10.1039/C5CC04183J</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1039%2FC5CC04183J" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=26144842" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFWgtbbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2015&pages=12158-12169&author=E.+Oueisauthor=C.+Sabotauthor=P.+Y.+Renard&title=New+insights+into+the+kinetic+target-guided+synthesis+of+protein+ligands&doi=10.1039%2FC5CC04183J"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit219R"><div class="casContent"><span class="casTitleNuber">219</span><div class="casTitle"><span class="NLM_cas:atitle">New insights into the kinetic target-guided synthesis of protein ligands</span></div><div class="casAuthors">Oueis, Emilia; Sabot, Cyrille; Renard, Pierre-Yves</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">61</span>),
    <span class="NLM_cas:pages">12158-12169</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  The kinetic target-guided synthesis (KTGS) strategy is an unconventional discovery approach that takes advantage of the presence of the biol. target itself in order to irreversibly assemble the best inhibitors from an array of building blocks.  This strategy has grown over the last two decades notably after the introduction of the in situ click chem. concept by Sharpless and colleagues in the early 2000s based on the use of the Huisgen cycloaddn. between terminal alkynes and azides.  KTGS is a captivating area of research offering an unprecedented and powerful strategy to probe the macromol. complexity and dynamics of biol. targets.  After a brief introduction listing all chem. ligation reactions reported to date in KTGS, this review focuses on the last five years' progress to expand the repertoire of the click or "click-like" tool box targeting proteins, as well as to overcome limitations arising in particular from false negatives, i.e. potent ligands that are not formed, or formed in undetectable trace amts.  Furthermore, we wish to analyze the new twists and novelties described in some of these applications in order to better understand the conditions that govern this strategy and the extent to which it can be developed and generalized for a more efficient process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3mdKSqL3JKLVg90H21EOLACvtfcHk0ligMvuCbX2E2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFWgtbbE&md5=76af69545c88c006feb0fe7a544b3805</span></div><a href="/servlet/linkout?suffix=cit219&amp;dbid=16384&amp;doi=10.1039%2FC5CC04183J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5CC04183J%26sid%3Dliteratum%253Aachs%26aulast%3DOueis%26aufirst%3DE.%26aulast%3DSabot%26aufirst%3DC.%26aulast%3DRenard%26aufirst%3DP.%2BY.%26atitle%3DNew%2520insights%2520into%2520the%2520kinetic%2520target-guided%2520synthesis%2520of%2520protein%2520ligands%26jtitle%3DChem.%2520Commun.%2520%2528Cambridge%252C%2520U.%2520K.%2529%26date%3D2015%26volume%3D51%26spage%3D12158%26epage%3D12169%26doi%3D10.1039%2FC5CC04183J" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref220"><div class="reference"><strong class="refLabel"><a href="#ref220" class="rightTabRefNumLink">220</a></strong><div class="NLM_citation" id="rightTab-cit220"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marakovic, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinko, G.</span></span> <span> </span><span class="NLM_article-title">The lock is the key: Development of novel drugs through receptor based combinatorial chemistry</span>. <i>Acta Chim. Slov.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">15</span>– <span class="NLM_lpage">39</span>, <span class="refDoi"> DOI: 10.17344/acsi.2016.3134</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.17344%2Facsi.2016.3134" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=28380234" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1eksbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2017&pages=15-39&author=N.+Marakovicauthor=G.+Sinko&title=The+lock+is+the+key%3A+Development+of+novel+drugs+through+receptor+based+combinatorial+chemistry&doi=10.17344%2Facsi.2016.3134"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit220R"><div class="casContent"><span class="casTitleNuber">220</span><div class="casTitle"><span class="NLM_cas:atitle">The lock is the key: development of novel drugs through receptor based combinatorial chemistry</span></div><div class="casAuthors">Marakovic, Nikola; Sinko, Goran</div><div class="citationInfo"><span class="NLM_cas:title">Acta Chimica Slovenica</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">15-39</span>CODEN:
                <span class="NLM_cas:coden">ACSLE7</span>;
        ISSN:<span class="NLM_cas:issn">1318-0207</span>.
    
            (<span class="NLM_cas:orgname">Slovenian Chemical Society</span>)
        </div><div class="casAbstract">Modem drug discovery is mainly based on the de novo synthesis of a large no. of compds. with a diversity of chem. functionalities.  Though the introduction of combinatorial chem. enabled the prepn. of large libraries of compds. from so-called building blocks, the problem of successfully identifying leads remains.  The introduction of a dynamic combinatorial chem. method served as a step forward due to the involvement of biol. rnacromo- lecuIar targets (receptors) in the synthesis of high affinity products.  The major breakthrough was a synthetic method in which building blocks are irreversibly combined due to the presence of a receptor.  Here we present various receptor-ba- sed combinatorial chem. approaches.  Huisgen's cycloaddn. (1,3-dipolar cycloaddn. of azides and alkynes) forms stabile 1,2,3-triazoles with very high receptor affinity that can reach femtomolar levels, as the case with acetylc- holinesterase inhibitors shows.  Huisgen's cycloaddn. can be applied to various receptors including acetyleholineste- rase, acetylcholine binding protein, carbonic anhydrase-II, serine/threonine-protein kinase and minor groove of DNA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphjiJtd7rV3bVg90H21EOLACvtfcHk0ligMvuCbX2E2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1eksbvI&md5=13627591d772ccfe0e8dea1febc49427</span></div><a href="/servlet/linkout?suffix=cit220&amp;dbid=16384&amp;doi=10.17344%2Facsi.2016.3134&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.17344%252Facsi.2016.3134%26sid%3Dliteratum%253Aachs%26aulast%3DMarakovic%26aufirst%3DN.%26aulast%3DSinko%26aufirst%3DG.%26atitle%3DThe%2520lock%2520is%2520the%2520key%253A%2520Development%2520of%2520novel%2520drugs%2520through%2520receptor%2520based%2520combinatorial%2520chemistry%26jtitle%3DActa%2520Chim.%2520Slov.%26date%3D2017%26volume%3D64%26spage%3D15%26epage%3D39%26doi%3D10.17344%2Facsi.2016.3134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref221"><div class="reference"><strong class="refLabel"><a href="#ref221" class="rightTabRefNumLink">221</a></strong><div class="NLM_citation" id="rightTab-cit221"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gregson, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masterson, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pillow, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raab, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis Phillips, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunzner-Toste, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Safina, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohri, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darwish, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozak, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dela Cruz-Chuh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flygare, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, P. W.</span></span> <span> </span><span class="NLM_article-title">Pyrrolobenzodiazepine dimer antibody-drug conjugates: Synthesis and evaluation of noncleavable drug-linkers</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">9490</span>– <span class="NLM_lpage">9507</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00736</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00736" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslOns7%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=9490-9507&author=S.+J.+Gregsonauthor=L.+A.+Mastersonauthor=B.+Weiauthor=T.+H.+Pillowauthor=S.+D.+Spencerauthor=G.+D.+Kangauthor=S.+F.+Yuauthor=H.+Raabauthor=J.+Lauauthor=G.+Liauthor=G.+D.+Lewis+Phillipsauthor=J.+Gunzner-Tosteauthor=B.+S.+Safinaauthor=R.+Ohriauthor=M.+Darwishauthor=K.+R.+Kozakauthor=J.+Dela+Cruz-Chuhauthor=A.+Polsonauthor=J.+A.+Flygareauthor=P.+W.+Howard&title=Pyrrolobenzodiazepine+dimer+antibody-drug+conjugates%3A+Synthesis+and+evaluation+of+noncleavable+drug-linkers&doi=10.1021%2Facs.jmedchem.7b00736"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit221R"><div class="casContent"><span class="casTitleNuber">221</span><div class="casTitle"><span class="NLM_cas:atitle">Pyrrolobenzodiazepine Dimer Antibody-Drug Conjugates: Synthesis and Evaluation of Noncleavable Drug-Linkers</span></div><div class="casAuthors">Gregson, Stephen J.; Masterson, Luke A.; Wei, Binqing; Pillow, Thomas H.; Spencer, Susan D.; Kang, Gyoung-Dong; Yu, Shang-Fan; Raab, Helga; Lau, Jeffrey; Li, Guangmin; Lewis Phillips, Gail D.; Gunzner-Toste, Janet; Safina, Brian S.; Ohri, Rachana; Darwish, Martine; Kozak, Katherine R.; dela Cruz-Chuh, Josefa; Polson, Andrew; Flygare, John A.; Howard, Philip W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">9490-9507</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Three rationally designed pyrrolobenzodiazepine (PBD) drug-linkers have been synthesized via intermediate, (11S,11'S,11aS,11'aS)-10,10'-bis(1,1-dimethylethyl) (11S,11aS,11'S,11a'S)-di-tert-Bu 8,8'-[(5-iodo-1,3-phenylene)bis(methyleneoxy)]bis[2,3,11,11a-tetrahydro-7-methoxy-2-methylene-5-oxo-11-[(tetrahydro-2H-pyran-2-yl)oxy]-1H-pyrrolo[2,1-c][1,4]benzodiazepine-10(5H)-carboxylate [1630094-65-3](19) for use in antibody-drug conjugates (ADCs).  They lack a cleavable trigger in the linker and consist of a maleimide for cysteine antibody conjugation, a hydrophilic spacer, and either an alkyne, triazole, or piperazine link to the PBD.  In vitro IC50 values were 11-48 ng/mL in HER2 3+ SK-BR-3 and KPL-4 (triazole conjugate, inactive) for the anti-HER2 ADCs (HER2 0 MCF7, all inactive) and 0.10-1.73 μg/mL (triazole conjugate, inactive) in CD22 3+ BJAB and WSU-DLCL2 for anti-CD22 ADCs (CD22 0 Jurkat, all inactive at low doses).  In vivo antitumor efficacy for the anti-HER2 ADCs in Founder 5 was obsd. with tumor stasis at 0.5-1 mg/kg, 1 mg/kg, and 3-6 mg/kg for three conjugates, resp.  Tumor stasis at 2 mg/kg was obsd. for anti-CD22 alkyne conjugate in WSU-DLCL2.  In summary, noncleavable PBD-ADCs exhibit potent activity, particularly in HER2 models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeLqWakvWPDLVg90H21EOLACvtfcHk0lgJ5IU93bO94w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslOns7%252FF&md5=99e06646a68d1395711428540c61884f</span></div><a href="/servlet/linkout?suffix=cit221&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00736%26sid%3Dliteratum%253Aachs%26aulast%3DGregson%26aufirst%3DS.%2BJ.%26aulast%3DMasterson%26aufirst%3DL.%2BA.%26aulast%3DWei%26aufirst%3DB.%26aulast%3DPillow%26aufirst%3DT.%2BH.%26aulast%3DSpencer%26aufirst%3DS.%2BD.%26aulast%3DKang%26aufirst%3DG.%2BD.%26aulast%3DYu%26aufirst%3DS.%2BF.%26aulast%3DRaab%26aufirst%3DH.%26aulast%3DLau%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DLewis%2BPhillips%26aufirst%3DG.%2BD.%26aulast%3DGunzner-Toste%26aufirst%3DJ.%26aulast%3DSafina%26aufirst%3DB.%2BS.%26aulast%3DOhri%26aufirst%3DR.%26aulast%3DDarwish%26aufirst%3DM.%26aulast%3DKozak%26aufirst%3DK.%2BR.%26aulast%3DDela%2BCruz-Chuh%26aufirst%3DJ.%26aulast%3DPolson%26aufirst%3DA.%26aulast%3DFlygare%26aufirst%3DJ.%2BA.%26aulast%3DHoward%26aufirst%3DP.%2BW.%26atitle%3DPyrrolobenzodiazepine%2520dimer%2520antibody-drug%2520conjugates%253A%2520Synthesis%2520and%2520evaluation%2520of%2520noncleavable%2520drug-linkers%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D9490%26epage%3D9507%26doi%3D10.1021%2Facs.jmedchem.7b00736" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref222"><div class="reference"><strong class="refLabel"><a href="#ref222" class="rightTabRefNumLink">222</a></strong><div class="NLM_citation" id="rightTab-cit222"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boons, G. J.</span></span> <span> </span><span class="NLM_article-title">Preparation of well-defined antibody-drug conjugates through glycan remodeling and strain-promoted azide-alkyne cycloadditions</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">7179</span>– <span class="NLM_lpage">7182</span>, <span class="refDoi"> DOI: 10.1002/anie.201402606</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1002%2Fanie.201402606" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC2cXos1aks7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2014&pages=7179-7182&author=X.+Liauthor=T.+Fangauthor=G.+J.+Boons&title=Preparation+of+well-defined+antibody-drug+conjugates+through+glycan+remodeling+and+strain-promoted+azide-alkyne+cycloadditions&doi=10.1002%2Fanie.201402606"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit222R"><div class="casContent"><span class="casTitleNuber">222</span><div class="casTitle"><span class="NLM_cas:atitle">Preparation of well-defined antibody-drug conjugates through glycan remodeling and strain-promoted azide-alkyne cycloadditions</span></div><div class="casAuthors">Li, Xiuru; Fang, Tao; Boons, Geert-Jan</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">28</span>),
    <span class="NLM_cas:pages">7179-7182</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Antibody-drug conjugates hold considerable promise as anticancer agents, however, producing them remains a challenge and there is a need for mild, broadly applicable, site-specific conjugation methods that yield homogenous products.  It was envisaged that enzymic remodeling of the oligosaccharides of an antibody would enable the introduction of reactive groups that can be exploited for the site-specific attachment of cytotoxic drugs.  This is based on the observation that glycosyltransferases often tolerate chem. modifications in their sugar nucleotide substrates, thus allowing the installation of reactive functionalities.  An azide was incorporated because this functional group is virtually absent in biol. systems and can be reacted by strain-promoted alkyne-azide cycloaddn.  This method, which does not require genetic engineering, was used to produce an anti-CD22 antibody modified with doxorubicin to selectively target and kill lymphoma cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6LFIucRfbx7Vg90H21EOLACvtfcHk0lgJ5IU93bO94w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXos1aks7w%253D&md5=d59a17169fb0891a63e88960285c4f55</span></div><a href="/servlet/linkout?suffix=cit222&amp;dbid=16384&amp;doi=10.1002%2Fanie.201402606&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201402606%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%26aulast%3DFang%26aufirst%3DT.%26aulast%3DBoons%26aufirst%3DG.%2BJ.%26atitle%3DPreparation%2520of%2520well-defined%2520antibody-drug%2520conjugates%2520through%2520glycan%2520remodeling%2520and%2520strain-promoted%2520azide-alkyne%2520cycloadditions%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2014%26volume%3D53%26spage%3D7179%26epage%3D7182%26doi%3D10.1002%2Fanie.201402606" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref223"><div class="reference"><strong class="refLabel"><a href="#ref223" class="rightTabRefNumLink">223</a></strong><div class="NLM_citation" id="rightTab-cit223"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, D. Y.</span></span> <span> </span><span class="NLM_article-title">Processes for constructing homogeneous antibody drug conjugates</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">852</span>– <span class="NLM_lpage">866</span>, <span class="refDoi"> DOI: 10.1021/acs.oprd.6b00067</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.oprd.6b00067" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC28XmtVGmsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2016&pages=852-866&author=D.+Y.+Jackson&title=Processes+for+constructing+homogeneous+antibody+drug+conjugates&doi=10.1021%2Facs.oprd.6b00067"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit223R"><div class="casContent"><span class="casTitleNuber">223</span><div class="casTitle"><span class="NLM_cas:atitle">Processes for Constructing Homogeneous Antibody Drug Conjugates</span></div><div class="casAuthors">Jackson, David Y.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">852-866</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Antibody drug conjugates (ADCs) are synthesized by conjugating a cytotoxic drug or "payload" to a monoclonal antibody.  The payloads are conjugated using amino or sulfhydryl specific linkers that react with lysines or cysteines on the antibody surface.  A typical antibody contains over 60 lysines and up to 12 cysteines as potential conjugation sites.  The desired DAR (drugs/antibody ratio) depends on a no. of different factors and ranges from two to eight drugs/antibody.  The discrepancy between the no. of potential conjugation sites and the desired DAR, combined with use of conventional conjugation methods that are not site-specific, results in heterogeneous ADCs that vary in both DAR and conjugation sites.  Heterogeneous ADCs contain significant fractions with suboptimal DARs that are known to possess undesired pharmacol. properties.  As a result, new methods for synthesizing homogeneous ADCs have been developed in order to increase their potential as therapeutic agents.  This article will review recently reported processes for prepg. ADCs with improved homogeneity.  The advantages and potential limitations of each process are discussed, with emphasis on efficiency, quality, and in vivo efficacy relative to similar heterogeneous ADCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXoa73dqwCyrVg90H21EOLACvtfcHk0lgJ5IU93bO94w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmtVGmsbo%253D&md5=4bd838112b5dd262ab6531ec9dc22bd9</span></div><a href="/servlet/linkout?suffix=cit223&amp;dbid=16384&amp;doi=10.1021%2Facs.oprd.6b00067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.oprd.6b00067%26sid%3Dliteratum%253Aachs%26aulast%3DJackson%26aufirst%3DD.%2BY.%26atitle%3DProcesses%2520for%2520constructing%2520homogeneous%2520antibody%2520drug%2520conjugates%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2016%26volume%3D20%26spage%3D852%26epage%3D866%26doi%3D10.1021%2Facs.oprd.6b00067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref224"><div class="reference"><strong class="refLabel"><a href="#ref224" class="rightTabRefNumLink">224</a></strong><div class="NLM_citation" id="rightTab-cit224"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walsh, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omarjee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galloway, W. R. J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwan, T. T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sore, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyvönen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spring, D. R.</span></span> <span> </span><span class="NLM_article-title">A general approach for the site-selective modification of native proteins, enabling the generation of stable and functional antibody–drug conjugates</span>. <i>Chem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">694</span>– <span class="NLM_lpage">700</span>, <span class="refDoi"> DOI: 10.1039/C8SC04645J</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1039%2FC8SC04645J" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=30774870" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFCgsLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=694-700&author=S.+J.+Walshauthor=S.+Omarjeeauthor=W.+R.+J.+D.+Gallowayauthor=T.+T.+L.+Kwanauthor=H.+F.+Soreauthor=J.+S.+Parkerauthor=M.+Hyv%C3%B6nenauthor=J.+S.+Carrollauthor=D.+R.+Spring&title=A+general+approach+for+the+site-selective+modification+of+native+proteins%2C+enabling+the+generation+of+stable+and+functional+antibody%E2%80%93drug+conjugates&doi=10.1039%2FC8SC04645J"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit224R"><div class="casContent"><span class="casTitleNuber">224</span><div class="casTitle"><span class="NLM_cas:atitle">A general approach for the site-selective modification of native proteins, enabling the generation of stable and functional antibody-drug conjugates</span></div><div class="casAuthors">Walsh, Stephen J.; Omarjee, Soleilmane; Galloway, Warren R. J. D.; Kwan, Terence T.-L.; Sore, Hannah F.; Parker, Jeremy S.; Hyvonen, Marko; Carroll, Jason S.; Spring, David R.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Science</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">694-700</span>CODEN:
                <span class="NLM_cas:coden">CSHCCN</span>;
        ISSN:<span class="NLM_cas:issn">2041-6520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Antibody-drug conjugates (ADCs) are a class of targeted therapeutics that utilize the specificity of antibodies to selectively deliver highly potent cytotoxins to target cells.  Although recent years have witnessed significant interest in ADCs, problems remain with the std. linkage chemistries used for cytotoxin-antibody bioconjugation.  These typically (1) generate unstable constructs, which may lead to premature cytotoxin release, (2) often give a wide variance in drug-antibody ratios (DAR) and (3) have poor control of attachment location on the antibody, resulting in a variable pharmacokinetic profile.  Herein, we report a novel divinylpyrimidine (DVP) linker platform for selective bioconjugation via covalent re-bridging of reduced disulfide bonds on native antibodies.  Model studies using the non-engineered trastuzumab antibody validate the utility of this linker platform for the generic generation of highly plasma-stable and functional antibody constructs that incorporate variable biol. relevant payloads (including cytotoxins) in an efficient and site-selective manner with precise control over DAR.  DVP linkers were also used to efficiently re-bridge both monomeric and dimeric protein systems, demonstrating their potential utility for general protein modification, protein stabilization or the development of other protein-conjugate therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6Z6QWcC1VerVg90H21EOLACvtfcHk0lgJ5IU93bO94w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFCgsLvN&md5=ffa84327d4af248ad3fa2a058f05e9cb</span></div><a href="/servlet/linkout?suffix=cit224&amp;dbid=16384&amp;doi=10.1039%2FC8SC04645J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC8SC04645J%26sid%3Dliteratum%253Aachs%26aulast%3DWalsh%26aufirst%3DS.%2BJ.%26aulast%3DOmarjee%26aufirst%3DS.%26aulast%3DGalloway%26aufirst%3DW.%2BR.%2BJ.%2BD.%26aulast%3DKwan%26aufirst%3DT.%2BT.%2BL.%26aulast%3DSore%26aufirst%3DH.%2BF.%26aulast%3DParker%26aufirst%3DJ.%2BS.%26aulast%3DHyv%25C3%25B6nen%26aufirst%3DM.%26aulast%3DCarroll%26aufirst%3DJ.%2BS.%26aulast%3DSpring%26aufirst%3DD.%2BR.%26atitle%3DA%2520general%2520approach%2520for%2520the%2520site-selective%2520modification%2520of%2520native%2520proteins%252C%2520enabling%2520the%2520generation%2520of%2520stable%2520and%2520functional%2520antibody%25E2%2580%2593drug%2520conjugates%26jtitle%3DChem.%2520Sci.%26date%3D2019%26volume%3D10%26spage%3D694%26epage%3D700%26doi%3D10.1039%2FC8SC04645J" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref225"><div class="reference"><strong class="refLabel"><a href="#ref225" class="rightTabRefNumLink">225</a></strong><div class="NLM_citation" id="rightTab-cit225"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tsuchikama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, Z.</span></span> <span> </span><span class="NLM_article-title">Antibody-drug conjugates: recent advances in conjugation and linker chemistries</span>. <i>Protein Cell</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">33</span>– <span class="NLM_lpage">46</span>, <span class="refDoi"> DOI: 10.1007/s13238-016-0323-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=10.1007%2Fs13238-016-0323-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=27743348" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslSlsrjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=33-46&author=K.+Tsuchikamaauthor=Z.+An&title=Antibody-drug+conjugates%3A+recent+advances+in+conjugation+and+linker+chemistries&doi=10.1007%2Fs13238-016-0323-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit225R"><div class="casContent"><span class="casTitleNuber">225</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody-drug conjugates: recent advances in conjugation and linker chemistries</span></div><div class="casAuthors">Tsuchikama, Kyoji; An, Zhiqiang</div><div class="citationInfo"><span class="NLM_cas:title">Protein & Cell</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">33-46</span>CODEN:
                <span class="NLM_cas:coden">PCREFB</span>;
        ISSN:<span class="NLM_cas:issn">1674-800X</span>.
    
            (<span class="NLM_cas:orgname">Higher Education Press</span>)
        </div><div class="casAbstract">The antibody-drug conjugate (ADC), a humanized or human monoclonal antibody conjugated with highly cytotoxic small mols. (payloads) through chem. linkers, is a novel therapeutic format and has great potential to make a paradigm shift in cancer chemotherapy.  This new antibody-based mol. platform enables selective delivery of a potent cytotoxic payload to target cancer cells, resulting in improved efficacy, reduced systemic toxicity, and preferable pharmacokinetics (PK)/pharmacodynamics (PD) and biodistribution compared to traditional chemotherapy.  Boosted by the successes of FDA-approved Adcetris and Kadcyla, this drug class has been rapidly growing along with about 60 ADCs currently in clin. trials.  In this article, we briefly review mol. aspects of each component (the antibody, payload, and linker) of ADCs, and then mainly discuss traditional and new technologies of the conjugation and linker chemistries for successful construction of clin. effective ADCs.  Current efforts in the conjugation and linker chemistries will provide greater insights into mol. design and strategies for clin. effective ADCs from medicinal chem. and pharmacol. standpoints.  The development of site-specific conjugation methodologies for constructing homogeneous ADCs is an esp. promising path to improving ADC design, which will open the way for novel cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQM6rnMshPgrVg90H21EOLACvtfcHk0li6vSERX-dZFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslSlsrjJ&md5=774905d4270dfdbf53456f7ef6e2b7b6</span></div><a href="/servlet/linkout?suffix=cit225&amp;dbid=16384&amp;doi=10.1007%2Fs13238-016-0323-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13238-016-0323-0%26sid%3Dliteratum%253Aachs%26aulast%3DTsuchikama%26aufirst%3DK.%26aulast%3DAn%26aufirst%3DZ.%26atitle%3DAntibody-drug%2520conjugates%253A%2520recent%2520advances%2520in%2520conjugation%2520and%2520linker%2520chemistries%26jtitle%3DProtein%2520Cell%26date%3D2018%26volume%3D9%26spage%3D33%26epage%3D46%26doi%3D10.1007%2Fs13238-016-0323-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b01617&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b01617%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-11" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b01617" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                6MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677aa2b16c6c3db2","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
